-DOCSTART- -X- -X- O

Torsade NNP NNP O
de IN IN O
pointes NNS NNS O
ventricular NN NN O
tachycardia NNS NNS O
during IN IN O
low JJ JJ O
dose NN NN O
intermittent NN NN O
dobutamine NN NN B-CHEM
treatment NN NN O
in IN IN O
a DT DT O
patient NN NN O
with IN IN O
dilated JJ JJ O
cardiomyopathy NN NN O
and CC CC O
congestive JJ JJ O
heart NN NN O
failure NN NN O
. . . O

The DT DT O
authors NNS NNS O
describe VBP VBP O
the DT DT O
case NN NN O
of IN IN O
a DT DT O
56 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
woman NN NN O
with IN IN O
chronic JJ JJ O
, , , O
severe JJ JJ O
heart NN NN O
failure NN NN O
secondary JJ JJ O
to TO TO O
dilated JJ JJ O
cardiomyopathy NN NN O
and CC CC O
absence NN NN O
of IN IN O
significant JJ JJ O
ventricular NN NN O
arrhythmias NNS NNS O
who WP WP O
developed VBD VBD O
QT NNP NNP O
prolongation NN NN O
and CC CC O
torsade VB VB O
de IN IN O
pointes NNS NNS O
ventricular NN NN O
tachycardia NNS NNS O
during IN IN O
one CD CD O
cycle NN NN O
of IN IN O
intermittent JJ JJ O
low JJ JJ O
dose NN NN O
( ( ( O
2 CD CD O
. . . O
5 CD CD O
mcg NN NN O
/ NN NN O
kg NN NN O
per IN IN O
min NN NN O
) ) ) O
dobutamine NN NN B-CHEM
. . . O

This DT DT O
report NN NN O
of IN IN O
torsade NN NN O
de IN IN O
pointes NNS NNS O
ventricular NN NN O
tachycardia NNS NNS O
during IN IN O
intermittent NN NN O
dobutamine NN NN B-CHEM
supports VBZ VBZ O
the DT DT O
hypothesis NNS NNS O
that IN IN O
unpredictable JJ JJ O
fatal JJ JJ O
arrhythmias NNS NNS O
may MD MD O
occur VB VB O
even RB RB O
with IN IN O
low JJ JJ O
doses NNS NNS O
and CC CC O
in IN IN O
patients NNS NNS O
with IN IN O
no DT DT O
history NN NN O
of IN IN O
significant JJ JJ O
rhythm NN NN O
disturbances NNS NNS O
. . . O

The DT DT O
mechanisms NNS NNS O
of IN IN O
proarrhythmic JJ JJ O
effects NNS NNS O
of IN IN O
Dubutamine NNP NNP B-CHEM
are VBP VBP O
discussed VBN VBN O
. . . O

Positive JJ JJ O
skin NN NN O
tests NNS NNS O
in IN IN O
late JJ JJ O
reactions NNS NNS O
to TO TO O
radiographic JJ JJ O
contrast NN NN B-CHEM
media NNS NNS I-CHEM
. . . O

In IN IN O
the DT DT O
last JJ JJ O
few JJ JJ O
years NNS NNS O
delayed VBD VBD O
reactions NNS NNS O
several JJ JJ O
hours NNS NNS O
after IN IN O
the DT DT O
injection NN NN O
of IN IN O
radiographic JJ JJ O
and CC CC O
contrast NN NN B-CHEM
materials NNS NNS I-CHEM
( ( ( O
PRC NNP NNP B-CHEM
) ) ) O
have VBP VBP O
been VBN VBN O
described VBN VBN O
with IN IN O
increasing VBG VBG O
frequency NN NN O
. . . O

The DT DT O
authors NNS NNS O
report VBP VBP O
two CD CD O
observations NNS NNS O
on IN IN O
patients NNS NNS O
with IN IN O
delayed VBN VBN O
reactions NNS NNS O
in IN IN O
whom WP WP O
intradermoreactions NNS NNS O
( ( ( O
IDR NNP NNP O
) ) ) O
and CC CC O
patch NN NN O
tests NNS NNS O
to TO TO O
a DT DT O
series NN NN O
of IN IN O
ionic JJ JJ O
and CC CC O
non NN NN O
ionic JJ JJ O
PRC NNP NNP B-CHEM
were VBD VBD O
studied VBN VBN O
. . . O

After IN IN O
angiography NN NN O
by IN IN O
the DT DT O
venous JJ JJ O
route NN NN O
in IN IN O
patient NN NN O
n NN NN O
degree NN NN O
1 CD CD O
a DT DT O
biphasic JJ JJ O
reaction NN NN O
with IN IN O
an DT DT O
immediate JJ JJ O
reaction NN NN O
( ( ( O
dyspnea NN NN O
, , , O
loss NN NN O
of IN IN O
consciousness NN NN O
) ) ) O
and CC CC O
delayed VBN VBN O
macro JJ JJ O
- - - O
papular JJ JJ O
rash NN NN O
appeared VBD VBD O
, , , O
whilst NN NN O
patient NN NN O
n NN NN O
degree NN NN O
2 CD CD O
developed VBD VBD O
a DT DT O
generalised JJ JJ O
sensation NN NN O
of IN IN O
heat NN NN O
, , , O
persistent JJ JJ O
pain NN NN O
at IN IN O
the DT DT O
site NN NN O
of IN IN O
injection NN NN O
immediately RB RB O
and CC CC O
a DT DT O
generalised JJ JJ O
macro NN NN O
- - - O
papular JJ JJ O
reaction NN NN O
after IN IN O
24 CD CD O
hours NNS NNS O
. . . O

The DT DT O
skin NN NN O
tests NNS NNS O
revealed VBD VBD O
positive JJ JJ O
delayed JJ JJ O
reactions NNS NNS O
of IN IN O
24 CD CD O
hours NNS NNS O
and CC CC O
48 CD CD O
hours NNS NNS O
by IN IN O
IDR NNP NNP O
and CC CC O
patch NN NN O
tests NNS NNS O
to TO TO O
only RB RB O
some DT DT O
PRC NNP NNP B-CHEM
with IN IN O
common JJ JJ O
chains NNS NNS O
in IN IN O
their PRP$ PRP$ O
structures NNS NNS O
. . . O

The DT DT O
positive JJ JJ O
skin NN NN O
tests NNS NNS O
are VBP VBP O
in IN IN O
favour NN NN O
of IN IN O
immunological JJ JJ O
reactions NNS NNS O
and CC CC O
may MD MD O
help VB VB O
in IN IN O
diagnosis NN NN O
of IN IN O
allergy NN NN O
in IN IN O
the DT DT O
patients NNS NNS O
. . . O

Risk NN NN O
of IN IN O
transient NN NN O
hyperammonemic JJ JJ O
encephalopathy NN NN O
in IN IN O
cancer NN NN O
patients NNS NNS O
who WP WP O
received VBD VBD O
continuous JJ JJ O
infusion NN NN O
of IN IN O
5 CD CD B-CHEM
- : : I-CHEM
fluorouracil NN NN I-CHEM
with IN IN O
the DT DT O
complication NN NN O
of IN IN O
dehydration NN NN O
and CC CC O
infection NN NN O
. . . O

From IN IN O
1986 CD CD O
to TO TO O
1998 CD CD O
, , , O
29 CD CD O
cancer NN NN O
patients NNS NNS O
who WP WP O
had VBD VBD O
32 CD CD O
episodes NNS NNS O
of IN IN O
transient JJ JJ O
hyperammonemic JJ JJ O
encephalopathy NN NN O
related VBN VBN O
to TO TO O
continuous JJ JJ O
infusion NN NN O
of IN IN O
5 CD CD B-CHEM
- : : I-CHEM
fluorouracil NN NN I-CHEM
( ( ( O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
) ) ) O
were VBD VBD O
identified VBN VBN O
. . . O

None NN NN O
of IN IN O
the DT DT O
patients NNS NNS O
had VBD VBD O
decompensated VBN VBN O
liver NN NN O
disease NN NN O
. . . O

Onset NNP NNP O
of IN IN O
hyperammonemic JJ JJ O
encephalopathy NN NN O
varied VBD VBD O
from IN IN O
0 CD CD O
. . . O
5 CD CD O
to TO TO O
5 CD CD O
days NNS NNS O
( ( ( O
mean VB VB O
: : : O
2 CD CD O
. . . O
6 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
3 CD CD O
days NNS NNS O
) ) ) O
after IN IN O
the DT DT O
initiation NN NN O
of IN IN O
chemotherapy NN NN O
. . . O

Plasma NNP NNP O
ammonium NN NN B-CHEM
level NN NN O
ranged VBN VBN O
from IN IN O
248 CD CD O
to TO TO O
2387 CD CD O
microg NN NN O
% NN NN O
( ( ( O
mean VB VB O
: : : O
626 CD CD O
+ NN NN O
/ NN NN O
- : : O
431 CD CD O
microg CD CD O
% NN NN O
) ) ) O
. . . O

Among IN IN O
the DT DT O
32 CD CD O
episodes NNS NNS O
, , , O
26 CD CD O
( ( ( O
81 CD CD O
% NN NN O
) ) ) O
had VBD VBD O
various JJ JJ O
degrees NNS NNS O
of IN IN O
azotemia NN NN O
, , , O
18 CD CD O
( ( ( O
56 CD CD O
% NN NN O
) ) ) O
occurred VBD VBD O
during IN IN O
bacterial JJ JJ O
infections NNS NNS O
and CC CC O
14 CD CD O
( ( ( O
44 CD CD O
% NN NN O
) ) ) O
without IN IN O
infection NN NN O
occurred VBD VBD O
during IN IN O
periods NNS NNS O
of IN IN O
dehydration NN NN O
. . . O

Higher JJR JJR O
plasma NN NN O
ammonium NN NN B-CHEM
levels NNS NNS O
and CC CC O
more JJR JJR O
rapid JJ JJ O
onset NN NN O
of IN IN O
hyperammonemia NN NN O
were VBD VBD O
seen VBN VBN O
in IN IN O
18 CD CD O
patients NNS NNS O
with IN IN O
bacterial JJ JJ O
infections NNS NNS O
( ( ( O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
003 CD CD O
and CC CC O
0 CD CD O
. . . O
0006 CD CD O
, , , O
respectively RB RB O
) ) ) O
and CC CC O
in IN IN O
nine CD CD O
patients NNS NNS O
receiving VBG VBG O
high JJ JJ O
daily JJ JJ O
doses NNS NNS O
( ( ( O
2600 CD CD O
or CC CC O
1800 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
) ) ) O
of IN IN O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
( ( ( O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
0001 CD CD O
and CC CC O
< NN NN O
0 CD CD O
. . . O
0001 CD CD O
, , , O
respectively RB RB O
) ) ) O
. . . O

In IN IN O
25 CD CD O
out IN IN O
of IN IN O
32 CD CD O
episodes NNS NNS O
( ( ( O
78 CD CD O
% NN NN O
) ) ) O
, , , O
plasma NN NN O
ammonium NN NN B-CHEM
levels NNS NNS O
and CC CC O
mental JJ JJ O
status NN NN O
returned VBD VBD O
to TO TO O
normal JJ JJ O
within IN IN O
2 CD CD O
days NNS NNS O
after IN IN O
adequate JJ JJ O
management NN NN O
. . . O

In IN IN O
conclusion NN NN O
, , , O
hyperammonemic JJ JJ O
encephalopathy NN NN O
can MD MD O
occur VB VB O
in IN IN O
patients NNS NNS O
receiving VBG VBG O
continuous JJ JJ O
infusion NN NN O
of IN IN O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
. . . O

Azotemia NNP NNP O
, , , O
body NN NN O
fluid JJ JJ O
insufficiency NN NN O
and CC CC O
bacterial JJ JJ O
infections NNS NNS O
were VBD VBD O
frequently RB RB O
found VBN VBN O
in IN IN O
these DT DT O
patients NNS NNS O
. . . O

It PRP PRP O
is VBZ VBZ O
therefore RB RB O
important JJ JJ O
to TO TO O
recognize VB VB O
this DT DT O
condition NN NN O
in IN IN O
patients NNS NNS O
receiving VBG VBG O
continuous JJ JJ O
infusion NN NN O
of IN IN O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
. . . O

The DT DT O
effects NNS NNS O
of IN IN O
quinine NN NN B-CHEM
and CC CC O
4 CD CD B-CHEM
- : : I-CHEM
aminopyridine NN NN I-CHEM
on IN IN O
conditioned VBN VBN O
place NN NN O
preference NN NN O
and CC CC O
changes NNS NNS O
in IN IN O
motor NN NN O
activity NN NN O
induced VBN VBN O
by IN IN O
morphine NN NN B-CHEM
in IN IN O
rats NNS NNS O
. . . O

1 CD CD O
. . . O

The DT DT O
effects NNS NNS O
of IN IN O
two CD CD O
unselective JJ JJ O
potassium NN NN B-CHEM
( ( ( O
K NNP NNP B-CHEM
( ( ( O
+ NN NN O
) ) ) O
- : : O
) ) ) O
channel NN NN O
blockers NNS NNS O
, , , O
quinine NN NN B-CHEM
( ( ( O
12 CD CD O
. . . O
5 CD CD O
, , , O
25 CD CD O
and CC CC O
50 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
and CC CC O
4 CD CD B-CHEM
- : : I-CHEM
aminopyridine NN NN I-CHEM
( ( ( O
1 CD CD O
and CC CC O
2 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
, , , O
on IN IN O
conditioned VBN VBN O
place NN NN O
preference NN NN O
and CC CC O
biphasic JJ JJ O
changes NNS NNS O
in IN IN O
motor NN NN O
activity NN NN O
induced VBN VBN O
by IN IN O
morphine NN NN B-CHEM
( ( ( O
10 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
were VBD VBD O
tested VBN VBN O
in IN IN O
Wistar NNP NNP O
rats NNS NNS O
. . . O

Quinine NNP NNP B-CHEM
is VBZ VBZ O
known VBN VBN O
to TO TO O
block VB VB O
voltage NN NN O
- : : O
, , , O
calcium NN NN B-CHEM
- - - O
and CC CC O
ATP NNP NNP B-CHEM
- : : O
sensitive JJ JJ O
K NNP NNP B-CHEM
( ( ( O
+ NN NN O
) ) ) O
- : : O
channels NNS NNS O
while IN IN O
4 CD CD B-CHEM
- : : I-CHEM
aminopyridine NN NN I-CHEM
is VBZ VBZ O
known VBN VBN O
to TO TO O
block VB VB O
voltage NN NN O
- - - O
sensitive JJ JJ O
K NNP NNP B-CHEM
( ( ( O
+ NN NN O
) ) ) O
- : : O
channels NNS NNS O
. . . O

2 CD CD O
. . . O

In IN IN O
the DT DT O
counterbalanced JJ JJ O
method NN NN O
, , , O
quinine NN NN B-CHEM
attenuated VBN VBN O
morphine NN NN B-CHEM
- - - O
induced JJ JJ O
place NN NN O
preference NN NN O
, , , O
whereas IN IN O
4 CD CD B-CHEM
- : : I-CHEM
aminopyridine NN NN I-CHEM
was VBD VBD O
ineffective JJ JJ O
. . . O

In IN IN O
the DT DT O
motor NN NN O
activity NN NN O
test NN NN O
measured VBN VBN O
with IN IN O
an DT DT O
Animex NNP NNP O
- - - O
activity NN NN O
meter NN NN O
neither DT DT O
of IN IN O
the DT DT O
K NNP NNP B-CHEM
( ( ( O
+ NN NN O
) ) ) O
- : : O
channel NN NN O
blockers NNS NNS O
affected VBN VBN O
morphine NN NN B-CHEM
- - - O
induced JJ JJ O
hypoactivity NN NN O
, , , O
but CC CC O
both DT DT O
K NNP NNP B-CHEM
( ( ( O
+ NN NN O
) ) ) O
- : : O
channel NN NN O
blockers NNS NNS O
prevented VBN VBN O
morphine NN NN B-CHEM
- - - O
induced JJ JJ O
secondary JJ JJ O
hyperactivity NN NN O
. . . O

3 CD CD O
. . . O

These DT DT O
results NNS NNS O
suggest VBP VBP O
the DT DT O
involvement NN NN O
of IN IN O
quinine NN NN B-CHEM
- - - O
sensitive JJ JJ O
but CC CC O
not RB RB O
4 CD CD B-CHEM
- : : I-CHEM
aminopyridine NN NN I-CHEM
- - - O
sensitive JJ JJ O
K NNP NNP B-CHEM
( ( ( O
+ NN NN O
) ) ) O
- : : O
channels NNS NNS O
in IN IN O
morphine NN NN B-CHEM
reward NN NN O
. . . O

It PRP PRP O
is VBZ VBZ O
also RB RB O
suggested VBN VBN O
that IN IN O
the DT DT O
blockade NN NN O
of IN IN O
K NNP NNP B-CHEM
( ( ( O
+ NN NN O
) ) ) O
- : : O
channels NNS NNS O
sensitive JJ JJ O
to TO TO O
these DT DT O
blockers NNS NNS O
is VBZ VBZ O
not RB RB O
sufficient JJ JJ O
to TO TO O
prevent VB VB O
morphine NN NN B-CHEM
- : : O
induced JJ JJ O
hypoactivity NN NN O
whereas IN IN O
morphine NN NN B-CHEM
- - - O
induced JJ JJ O
hyperactivity NN NN O
seems VBZ VBZ O
to TO TO O
be VB VB O
connected VBN VBN O
to TO TO O
both DT DT O
quinine NN NN B-CHEM
- : : O
and CC CC O
4 CD CD B-CHEM
- : : I-CHEM
aminopyridine NN NN I-CHEM
- - - O
sensitive JJ JJ O
K NNP NNP B-CHEM
( ( ( O
+ NN NN O
) ) ) O
- : : O
channels NNS NNS O
. . . O

Nociceptin NNP NNP B-CHEM
/ NN NN O
orphanin NN NN B-CHEM
FQ NNP NNP I-CHEM
and CC CC O
nocistatin NN NN B-CHEM
on IN IN O
learning VBG VBG O
and CC CC O
memory NN NN O
impairment NN NN O
induced VBN VBN O
by IN IN O
scopolamine NN NN B-CHEM
in IN IN O
mice NN NN O
. . . O

1 CD CD O
. . . O

Nociceptin NNP NNP B-CHEM
, , , O
also RB RB O
known VBN VBN O
as IN IN O
orphanin NN NN B-CHEM
FQ NNP NNP I-CHEM
, , , O
is VBZ VBZ O
an DT DT O
endogenous JJ JJ O
ligand NN NN O
for IN IN O
the DT DT O
orphan JJ JJ O
opioid NN NN O
receptor NN NN O
- - - O
like IN IN O
receptor NN NN O
1 CD CD O
( ( ( O
ORL1 NNP NNP O
) ) ) O
and CC CC O
involves VBZ VBZ O
in IN IN O
various JJ JJ O
functions NNS NNS O
in IN IN O
the DT DT O
central JJ JJ O
nervous JJ JJ O
system NN NN O
( ( ( O
CNS NNP NNP O
) ) ) O
. . . O

On IN IN O
the DT DT O
other JJ JJ O
hand NN NN O
, , , O
nocistatin NN NN B-CHEM
is VBZ VBZ O
recently RB RB O
isolated VBN VBN O
from IN IN O
the DT DT O
same JJ JJ O
precursor NN NN O
as IN IN O
nociceptin NN NN B-CHEM
and CC CC O
blocks NNS NNS O
nociceptin NN NN B-CHEM
- : : O
induced JJ JJ O
allodynia NN NN O
and CC CC O
hyperalgesia NN NN O
. . . O

2 CD CD O
. . . O

Although IN IN O
ORL1 NNP NNP O
receptors NNS NNS O
which WDT WDT O
display VBP VBP O
a DT DT O
high JJ JJ O
degree NN NN O
of IN IN O
sequence NN NN O
homology NN NN O
with IN IN O
classical JJ JJ O
opioid NN NN O
receptors NNS NNS O
are VBP VBP O
abundant JJ JJ O
in IN IN O
the DT DT O
hippocampus NN NN O
, , , O
little JJ JJ O
is VBZ VBZ O
known VBN VBN O
regarding VBG VBG O
their PRP$ PRP$ O
role NN NN O
in IN IN O
learning VBG VBG O
and CC CC O
memory NN NN O
. . . O

3 CD CD O
. . . O

The DT DT O
present JJ JJ O
study NN NN O
was VBD VBD O
designed VBN VBN O
to TO TO O
investigate VB VB O
whether IN IN O
nociceptin NN NN B-CHEM
/ NN NN O
orphanin NN NN B-CHEM
FQ NNP NNP I-CHEM
and CC CC O
nocistatin NN NN B-CHEM
could MD MD O
modulate VB VB O
impairment NN NN O
of IN IN O
learning VBG VBG O
and CC CC O
memory NN NN O
induced VBN VBN O
by IN IN O
scopolamine NN NN B-CHEM
, , , O
a DT DT O
muscarinic JJ JJ O
cholinergic JJ JJ O
receptor NN NN O
antagonist NN NN O
, , , O
using VBG VBG O
spontaneous JJ JJ O
alternation NN NN O
of IN IN O
Y NNP NNP O
- : : O
maze NN NN O
and CC CC O
step NN NN O
- - - O
down RP RP O
type NN NN O
passive JJ JJ O
avoidance NN NN O
tasks NNS NNS O
in IN IN O
mice NN NN O
. . . O

4 CD CD O
. . . O

While IN IN O
nocistatin NN NN B-CHEM
( ( ( O
0 CD CD O
. . . O
5 CD CD O
- : : O
5 CD CD O
. . . O
0 CD CD O
nmol NN NN O
mouse NN NN O
- : : O
1 CD CD O
, , , O
i NNP NNP O
. . . O
c SYM SYM O
. . . O
v NN NN O
. . . O
) ) ) O
administered VBD VBD O
30 CD CD O
min NN NN O
before IN IN O
spontaneous JJ JJ O
alternation NN NN O
performance NN NN O
or CC CC O
the DT DT O
training NN NN O
session NN NN O
of IN IN O
the DT DT O
passive JJ JJ O
avoidance NN NN O
task NN NN O
, , , O
had VBD VBD O
no DT DT O
effect NN NN O
on IN IN O
spontaneous JJ JJ O
alternation NN NN O
or CC CC O
passive JJ JJ O
avoidance NN NN O
behaviours NNS NNS O
, , , O
a DT DT O
lower JJR JJR O
per IN IN O
cent NN NN O
alternation NN NN O
and CC CC O
shorter JJR JJR O
median JJ JJ O
step NN NN O
- - - O
down RB RB O
latency NN NN O
in IN IN O
the DT DT O
retention NN NN O
test NN NN O
were VBD VBD O
obtained VBN VBN O
in IN IN O
nociceptin NN NN B-CHEM
( ( ( O
1 CD CD O
. . . O
5 CD CD O
and CC CC O
/ NN NN O
or CC CC O
5 CD CD O
. . . O
0 CD CD O
nmol NN NN O
mouse NN NN O
- : : O
1 CD CD O
, , , O
i NNP NNP O
. . . O
c SYM SYM O
. . . O
v NN NN O
. . . O
) ) ) O
- : : O
treated VBN VBN O
normal JJ JJ O
mice NN NN O
. . . O

5 CD CD O
. . . O

Administration NNP NNP O
of IN IN O
nocistatin NN NN B-CHEM
( ( ( O
1 CD CD O
. . . O
5 CD CD O
and CC CC O
/ NN NN O
or CC CC O
5 CD CD O
. . . O
0 CD CD O
nmol NN NN O
mouse NN NN O
- : : O
1 CD CD O
, , , O
i NNP NNP O
. . . O
c SYM SYM O
. . . O
v NN NN O
. . . O
) ) ) O
30 CD CD O
min NN NN O
before IN IN O
spontaneous JJ JJ O
alternation NN NN O
performance NN NN O
or CC CC O
the DT DT O
training NN NN O
session NN NN O
of IN IN O
the DT DT O
passive JJ JJ O
avoidance NN NN O
task NN NN O
, , , O
attenuated VBD VBD O
the DT DT O
scopolamine NN NN B-CHEM
- - - O
induced JJ JJ O
impairment NN NN O
of IN IN O
spontaneous JJ JJ O
alternation NN NN O
and CC CC O
passive JJ JJ O
avoidance NN NN O
behaviours NNS NNS O
. . . O

6 CD CD O
. . . O

These DT DT O
results NNS NNS O
indicated VBD VBD O
that IN IN O
nocistatin NN NN B-CHEM
, , , O
a DT DT O
new JJ JJ O
biologically RB RB O
active JJ JJ O
peptide NN NN O
, , , O
ameliorates VBZ VBZ O
impairments NNS NNS O
of IN IN O
spontaneous JJ JJ O
alternation NN NN O
and CC CC O
passive JJ JJ O
avoidance NN NN O
induced VBN VBN O
by IN IN O
scopolamine NN NN B-CHEM
, , , O
and CC CC O
suggested VBD VBD O
that IN IN O
these DT DT O
peptides NNS NNS O
play VBP VBP O
opposite JJ JJ O
roles NNS NNS O
in IN IN O
learning VBG VBG O
and CC CC O
memory NN NN O
. . . O

Meloxicam NNP NNP B-CHEM
- : : O
induced JJ JJ O
liver NN NN O
toxicity NN NN O
. . . O

We PRP PRP O
report VBP VBP O
the DT DT O
case NN NN O
of IN IN O
a DT DT O
female JJ JJ O
patient NN NN O
with IN IN O
rheumatoid NN NN O
arthritis NN NN O
who WP WP O
developed VBD VBD O
acute JJ JJ O
cytolytic JJ JJ O
hepatitis NN NN O
due JJ JJ O
to TO TO O
meloxicam NN NN B-CHEM
. . . O

Recently RB RB O
introduced VBN VBN O
in IN IN O
Belgium NNP NNP O
, , , O
meloxicam NN NN B-CHEM
is VBZ VBZ O
the DT DT O
first JJ JJ O
nonsteroidal NN NN O
antiinflammatory NN NN O
drug NN NN O
with IN IN O
selective JJ JJ O
action NN NN O
on IN IN O
the DT DT O
inducible JJ JJ O
form NN NN O
of IN IN O
cyclooxygenase NN NN O
2 CD CD O
. . . O

The DT DT O
acute JJ JJ O
cytolytic JJ JJ O
hepatitis NN NN O
occurred VBD VBD O
rapidly RB RB O
after IN IN O
meloxicam NN NN B-CHEM
administration NN NN O
and CC CC O
was VBD VBD O
associated VBN VBN O
with IN IN O
the DT DT O
development NN NN O
of IN IN O
antinuclear NN NN O
antibodies NNS NNS O
suggesting VBG VBG O
a DT DT O
hypersensitivity NN NN O
mechanism NN NN O
. . . O

This DT DT O
first JJ JJ O
case NN NN O
of IN IN O
meloxicam NN NN B-CHEM
related VBN VBN O
liver NN NN O
toxicity NN NN O
demonstrates VBZ VBZ O
the DT DT O
potential NN NN O
of IN IN O
this DT DT O
drug NN NN O
to TO TO O
induce VB VB O
hepatic JJ JJ O
damage NN NN O
. . . O

Induction NNP NNP O
of IN IN O
apoptosis NNS NNS O
by IN IN O
remoxipride NN NN B-CHEM
metabolites NNS NNS O
in IN IN O
HL60 NNP NNP O
and CC CC O
CD34 NNP NNP O
+ NN NN O
/ NN NN O
CD19 NNP NNP O
- : : O
human JJ JJ O
bone NN NN O
marrow NN NN O
progenitor NN NN O
cells NNS NNS O
: : : O
potential JJ JJ O
relevance NN NN O
to TO TO O
remoxipride VB VB B-CHEM
- - - O
induced JJ JJ O
aplastic JJ JJ O
anemia NN NN O
. . . O

The DT DT O
antipsychotic JJ JJ O
agent NN NN O
, , , O
remoxipride NN NN B-CHEM
[ NN NN O
( ( ( B-CHEM
S NNP NNP I-CHEM
) ) ) I-CHEM
- : : I-CHEM
( ( ( I-CHEM
- : : I-CHEM
) ) ) I-CHEM
- : : I-CHEM
3 CD CD I-CHEM
- : : I-CHEM
bromo NN NN I-CHEM
- - - I-CHEM
N NNP NNP I-CHEM
- : : I-CHEM
[ NN NN I-CHEM
( ( ( I-CHEM
1 CD CD I-CHEM
- : : I-CHEM
ethyl NN NN I-CHEM
- : : I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
pyrrolidinyl NN NN I-CHEM
) ) ) I-CHEM
methyl NN NN I-CHEM
] NN NN I-CHEM
- : : I-CHEM
2 CD CD I-CHEM
, , , I-CHEM
6 CD CD I-CHEM
- : : I-CHEM
dimethoxybenz NN NN I-CHEM
amide NN NN I-CHEM
] NN NN O
has VBZ VBZ O
been VBN VBN O
associated VBN VBN O
with IN IN O
acquired JJ JJ O
aplastic JJ JJ O
anemia NN NN O
. . . O

We PRP PRP O
have VBP VBP O
examined VBN VBN O
the DT DT O
ability NN NN O
of IN IN O
remoxipride NN NN B-CHEM
, , , O
three CD CD O
pyrrolidine NN NN B-CHEM
ring NN NN O
metabolites NNS NNS O
and CC CC O
five CD CD O
aromatic JJ JJ O
ring NN NN O
metabolites NNS NNS O
of IN IN O
the DT DT O
parent NN NN O
compound NN NN O
to TO TO O
induce VB VB O
apoptosis NN NN O
in IN IN O
HL60 NNP NNP O
cells NNS NNS O
and CC CC O
human JJ JJ O
bone NN NN O
marrow NN NN O
progenitor NN NN O
( ( ( O
HBMP NNP NNP O
) ) ) O
cells NNS NNS O
. . . O

Cells NNS NNS O
were VBD VBD O
treated VBN VBN O
for IN IN O
0 CD CD O
- : : O
24 CD CD O
h NN NN O
with IN IN O
each DT DT O
compound NN NN O
( ( ( O
0 CD CD O
- : : O
200 CD CD O
microM NN NN O
) ) ) O
. . . O

Apoptosis NNP NNP O
was VBD VBD O
assessed VBN VBN O
by IN IN O
fluorescence NN NN O
microscopy NN NN O
in IN IN O
Hoechst NNP NNP B-CHEM
33342 CD CD I-CHEM
- : : O
and CC CC O
propidium NN NN B-CHEM
iodide NN NN I-CHEM
stained JJ JJ O
cell NN NN O
samples NNS NNS O
. . . O

Results NNS NNS O
were VBD VBD O
confirmed VBN VBN O
by IN IN O
determination NN NN O
of IN IN O
internucleosomal NN NN O
DNA NNP NNP O
fragmentation NN NN O
using VBG VBG O
gel NN NN O
electrophoresis NN NN O
for IN IN O
HL60 NNP NNP O
cell NN NN O
samples NNS NNS O
and CC CC O
terminal NN NN O
deoxynucleotidyl NN NN O
transferase NN NN O
assay NN NN O
in IN IN O
HBMP NNP NNP O
cells NNS NNS O
. . . O

The DT DT O
catechol NN NN B-CHEM
and CC CC O
hydroquinone NN NN B-CHEM
metabolites NNS NNS O
, , , O
NCQ436 NNP NNP B-CHEM
and CC CC O
NCQ344 NNP NNP B-CHEM
, , , O
induced JJ JJ O
apoptosis NN NN O
in IN IN O
HL60 NNP NNP O
and CC CC O
HBMP NNP NNP O
cells NNS NNS O
in IN IN O
a DT DT O
time NN NN O
- : : O
and CC CC O
concentration NN NN O
dependent JJ JJ O
manner NN NN O
, , , O
while IN IN O
the DT DT O
phenols NNS NNS B-CHEM
, , , O
NCR181 NNP NNP O
, , , O
FLA873 NNP NNP O
, , , O
and CC CC O
FLA797 NNP NNP B-CHEM
, , , O
and CC CC O
the DT DT O
derivatives NNS NNS O
formed VBN VBN O
by IN IN O
oxidation NN NN O
of IN IN O
the DT DT O
pyrrolidine NN NN B-CHEM
ring NN NN O
, , , O
FLA838 NNP NNP O
, , , O
NCM001 NNP NNP O
, , , O
and CC CC O
NCL118 NNP NNP O
, , , O
had VBD VBD O
no DT DT O
effect NN NN O
. . . O

No DT DT O
necrosis NN NN O
was VBD VBD O
observed VBN VBN O
in IN IN O
cells NNS NNS O
treated VBN VBN O
with IN IN O
NCQ436 NNP NNP B-CHEM
but CC CC O
NCQ344 NNP NNP B-CHEM
had VBD VBD O
a DT DT O
biphasic JJ JJ O
effect NN NN O
in IN IN O
both DT DT O
cell NN NN O
types NNS NNS O
, , , O
inducing VBG VBG O
apoptosis NN NN O
at IN IN O
lower JJR JJR O
concentrations NNS NNS O
and CC CC O
necrosis NN NN O
at IN IN O
higher JJR JJR O
concentrations NNS NNS O
. . . O

These DT DT O
data NNS NNS O
show VBP VBP O
that IN IN O
the DT DT O
catechol NN NN B-CHEM
and CC CC O
hydroquinone NN NN B-CHEM
metabolites NNS NNS O
of IN IN O
remoxipride NN NN B-CHEM
have VBP VBP O
direct JJ JJ O
toxic JJ JJ O
effects NNS NNS O
in IN IN O
HL60 NNP NNP O
and CC CC O
HBMP NNP NNP O
cells NNS NNS O
, , , O
leading VBG VBG O
to TO TO O
apoptosis NN NN O
, , , O
while IN IN O
the DT DT O
phenol NN NN B-CHEM
metabolites NNS NNS O
were VBD VBD O
inactive JJ JJ O
. . . O

Similarly RB RB O
, , , O
benzene NN NN B-CHEM
- - - O
derived VBN VBN O
catechol NN NN B-CHEM
and CC CC O
hydroquinone NN NN B-CHEM
, , , O
but CC CC O
not RB RB O
phenol VB VB B-CHEM
, , , O
induce VB VB O
apoptosis NN NN O
in IN IN O
HBMP NNP NNP O
cells NNS NNS O
[ NN NN O
Moran NNP NNP O
et CC CC O
al NN NN O
. . . O
, , , O
Mol NNP NNP O
. . . O
Pharmacol NNP NNP O
. . . O
, , , O
50 CD CD O
( ( ( O
1996 CD CD O
) ) ) O
610 CD CD O
- : : O
615 CD CD O
] NN NN O
. . . O

We PRP PRP O
propose VBP VBP O
that IN IN O
remoxipride NN NN B-CHEM
and CC CC O
benzene NN NN B-CHEM
may MD MD O
induce VB VB O
aplastic JJ JJ O
anemia NN NN O
via IN IN O
production NN NN O
of IN IN O
similar JJ JJ O
reactive JJ JJ O
metabolites NNS NNS O
and CC CC O
that IN IN O
the DT DT O
ability NN NN O
of IN IN O
NCQ436 NNP NNP B-CHEM
and CC CC O
NCQ344 NNP NNP B-CHEM
to TO TO O
induce VB VB O
apoptosis NN NN O
in IN IN O
HBMP NNP NNP O
cells NNS NNS O
may MD MD O
contribute VB VB O
to TO TO O
the DT DT O
mechanism NN NN O
underlying VBG VBG O
acquired VBN VBN O
aplastic JJ JJ O
anemia NN NN O
that WDT WDT O
has VBZ VBZ O
been VBN VBN O
associated VBN VBN O
with IN IN O
remoxipride NN NN B-CHEM
. . . O

Synthesis NNP NNP O
and CC CC O
preliminary JJ JJ O
pharmacological JJ JJ O
investigations NNS NNS O
of IN IN O
1 CD CD B-CHEM
- : : I-CHEM
( ( ( I-CHEM
1 CD CD I-CHEM
, , , I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
dihydro NN NN I-CHEM
- : : I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
acenaphthylenyl NN NN I-CHEM
) ) ) I-CHEM
piperazine NN NN I-CHEM
derivatives NNS NNS O
as IN IN O
potential JJ JJ O
atypical JJ JJ O
antipsychotic JJ JJ O
agents NNS NNS O
in IN IN O
mice NN NN O
. . . O

In IN IN O
research NN NN O
towards IN IN O
the DT DT O
development NN NN O
of IN IN O
new JJ JJ O
atypical JJ JJ O
antipsychotic JJ JJ O
agents NNS NNS O
, , , O
one CD CD O
strategy NN NN O
is VBZ VBZ O
that IN IN O
the DT DT O
dopaminergic JJ JJ O
system NN NN O
can MD MD O
be VB VB O
modulated VBN VBN O
through IN IN O
manipulation NN NN O
of IN IN O
the DT DT O
serotonergic JJ JJ O
system NN NN O
. . . O

The DT DT O
synthesis NN NN O
and CC CC O
preliminary JJ JJ O
pharmacological JJ JJ O
evaluation NN NN O
of IN IN O
a DT DT O
series NN NN O
of IN IN O
potential JJ JJ O
atypical JJ JJ O
antipsychotic JJ JJ O
agents NNS NNS O
based VBN VBN O
on IN IN O
the DT DT O
structure NN NN O
of IN IN O
1 CD CD B-CHEM
- : : I-CHEM
( ( ( I-CHEM
1 CD CD I-CHEM
, , , I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
dihydro NN NN I-CHEM
- : : I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
acenaphthylenyl NN NN I-CHEM
) ) ) I-CHEM
piperazine NN NN I-CHEM
( ( ( O
7 CD CD O
) ) ) O
is VBZ VBZ O
described VBN VBN O
. . . O

Compound NNP NNP O
7e CD CD O
, , , O
5 CD CD B-CHEM
- : : I-CHEM
{ ( ( I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
[ NN NN I-CHEM
4 CD CD I-CHEM
- : : I-CHEM
( ( ( I-CHEM
1 CD CD I-CHEM
, , , I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
dihydro NN NN I-CHEM
- : : I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
acenaphthylenyl NN NN I-CHEM
) ) ) I-CHEM
piperazinyl NN NN I-CHEM
] NN NN I-CHEM
ethyl NN NN I-CHEM
} ) ) I-CHEM
- : : I-CHEM
2 CD CD I-CHEM
, , , I-CHEM
3 CD CD I-CHEM
- : : I-CHEM
dihy NN NN I-CHEM
dro NN NN I-CHEM
- : : I-CHEM
1H CD CD I-CHEM
- : : I-CHEM
indol NN NN I-CHEM
- : : I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
one CD CD I-CHEM
, , , O
from IN IN O
this DT DT O
series NN NN O
showed VBD VBD O
significant JJ JJ O
affinities NNS NNS O
at IN IN O
the DT DT O
5 CD CD O
- : : O
HT1A NNP NNP O
and CC CC O
5 CD CD O
- : : O
HT2A NNP NNP O
receptors NNS NNS O
and CC CC O
moderate JJ JJ O
affinity NN NN O
at IN IN O
the DT DT O
D2 NN NN O
receptor NN NN O
. . . O

7e CD CD O
exhibits VBZ VBZ O
a DT DT O
high JJ JJ O
reversal NN NN O
of IN IN O
catalepsy NN NN O
induced VBN VBN O
by IN IN O
haloperidol NN NN B-CHEM
indicating VBG VBG O
its PRP$ PRP$ O
atypical JJ JJ O
antipsychotic JJ JJ O
nature NN NN O
. . . O

Sub NNP NNP O
- : : O
chronic JJ JJ O
inhibition NN NN O
of IN IN O
nitric JJ JJ B-CHEM
- - - I-CHEM
oxide NN NN I-CHEM
synthesis NN NN O
modifies NNS NNS O
haloperidol NN NN B-CHEM
- : : O
induced JJ JJ O
catalepsy NN NN O
and CC CC O
the DT DT O
number NN NN O
of IN IN O
NADPH NNP NNP B-CHEM
- : : O
diaphorase VB VB O
neurons NNS NNS O
in IN IN O
mice NN NN O
. . . O

RATIONALE NNP NNP O
: : : O
NG NNP NNP B-CHEM
- - - I-CHEM
nitro NN NN I-CHEM
- - - I-CHEM
L NNP NNP I-CHEM
- : : I-CHEM
arginine NN NN I-CHEM
( ( ( O
L NNP NNP B-CHEM
- - - I-CHEM
NOARG NNP NNP I-CHEM
) ) ) O
, , , O
an DT DT O
inhibitor NN NN O
of IN IN O
nitric JJ JJ B-CHEM
- - - I-CHEM
oxide NN NN I-CHEM
synthase NN NN O
( ( ( O
NOS NNP NNP O
) ) ) O
, , , O
induces NNS NNS O
catalepsy NN NN O
in IN IN O
mice NN NN O
. . . O

This DT DT O
effect NN NN O
undergoes NNS NNS O
rapid JJ JJ O
tolerance NN NN O
, , , O
showing VBG VBG O
a DT DT O
significant JJ JJ O
decrease NN NN O
after IN IN O
2 CD CD O
days NNS NNS O
of IN IN O
sub NN NN O
- - - O
chronic JJ JJ O
L NNP NNP B-CHEM
- : : I-CHEM
NOARG NNP NNP I-CHEM
treatment NN NN O
. . . O

Nitric NNP NNP B-CHEM
oxide NN NN I-CHEM
( ( ( O
NO NNP NNP B-CHEM
) ) ) O
has VBZ VBZ O
been VBN VBN O
shown VBN VBN O
to TO TO O
influence VB VB O
dopaminergic JJ JJ O
neurotransmission NN NN O
in IN IN O
the DT DT O
striatum NN NN O
. . . O

Neuroleptic NNP NNP O
drugs NNS NNS O
such JJ JJ O
as IN IN O
haloperidol NN NN B-CHEM
, , , O
which WDT WDT O
block NN NN O
dopamine NN NN B-CHEM
receptors NNS NNS O
, , , O
also RB RB O
cause VB VB O
catalepsy NN NN O
in IN IN O
rodents NNS NNS O
. . . O

OBJECTIVES NNP NNP O
: : : O
To TO TO O
investigate VB VB O
the DT DT O
effects NNS NNS O
of IN IN O
subchronic JJ JJ O
L NNP NNP B-CHEM
- : : I-CHEM
NOARG NNP NNP I-CHEM
treatment NN NN O
in IN IN O
haloperidol NN NN B-CHEM
- - - O
induced JJ JJ O
catalepsy NN NN O
and CC CC O
the DT DT O
number NN NN O
of IN IN O
NOS NNP NNP O
neurons NNS NNS O
in IN IN O
areas NNS NNS O
related VBN VBN O
to TO TO O
motor NN NN O
control NN NN O
. . . O

METHODS NNP NNP O
: : : O
Male NNP NNP O
albino NN NN O
Swiss NNP NNP O
mice NN NN O
were VBD VBD O
treated VBN VBN O
sub NN NN O
- : : O
chronically RB RB O
( ( ( O
twice RB RB O
a DT DT O
day NN NN O
for IN IN O
4 CD CD O
days NNS NNS O
) ) ) O
with IN IN O
L NNP NNP B-CHEM
- : : I-CHEM
NOARG NNP NNP I-CHEM
( ( ( O
40 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
or CC CC O
haloperidol NN NN B-CHEM
( ( ( O
1 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
. . . O

Catalepsy NNP NNP O
was VBD VBD O
evaluated VBN VBN O
at IN IN O
the DT DT O
beginning NN NN O
and CC CC O
the DT DT O
end NN NN O
of IN IN O
the DT DT O
treatments NNS NNS O
. . . O

Reduced NNP NNP O
nicotinamide NN NN B-CHEM
adenine NN NN I-CHEM
dinucleotide NN NN I-CHEM
phosphate NN NN I-CHEM
- : : O
diaphorase NN NN O
( ( ( O
NADPH NNP NNP B-CHEM
- - - O
d SYM SYM O
) ) ) O
histochemistry NN NN O
was VBD VBD O
also RB RB O
employed VBN VBN O
to TO TO O
visualize VB VB O
NOS NNP NNP O
as IN IN O
an DT DT O
index NN NN O
of IN IN O
enzyme NN NN O
expression NN NN O
in IN IN O
mice NNS NNS O
brain NN NN O
regions NNS NNS O
related VBN VBN O
to TO TO O
motor NN NN O
control NN NN O
. . . O

RESULTS NNS NNS O
: : : O
L NNP NNP B-CHEM
- - - I-CHEM
NOARG NNP NNP I-CHEM
sub NN NN O
- : : O
chronic JJ JJ O
administration NN NN O
produced VBD VBD O
tolerance NN NN O
of IN IN O
L NNP NNP B-CHEM
- : : I-CHEM
NOARG NNP NNP I-CHEM
and CC CC O
of IN IN O
haloperidol NN NN B-CHEM
- - - O
induced JJ JJ O
catalepsy NN NN O
. . . O

It PRP PRP O
also RB RB O
induced VBD VBD O
an DT DT O
increase NN NN O
in IN IN O
the DT DT O
number NN NN O
of IN IN O
NADPH NNP NNP B-CHEM
- : : O
d SYM SYM O
- : : O
positive JJ JJ O
cells NNS NNS O
in IN IN O
the DT DT O
dorsal NN NN O
part NN NN O
of IN IN O
the DT DT O
caudate NN NN O
and CC CC O
accumbens NNS NNS O
nuclei RB RB O
compared VBN VBN O
with IN IN O
haloperidol NN NN B-CHEM
and CC CC O
in IN IN O
the DT DT O
pedunculopontine NN NN O
tegmental NN NN O
nucleus NN NN O
compared VBN VBN O
with IN IN O
saline NN NN O
. . . O

In IN IN O
contrast NN NN O
, , , O
there EX EX O
was VBD VBD O
a DT DT O
decrease NN NN O
in IN IN O
NADPH NNP NNP B-CHEM
- : : O
d SYM SYM O
neuron NN NN O
number NN NN O
in IN IN O
the DT DT O
substantia NN NN O
nigra NN NN O
, , , O
pars NNS NNS O
compacta NN NN O
in IN IN O
both DT DT O
haloperidol NN NN B-CHEM
- - - O
treated VBN VBN O
and CC CC O
L NNP NNP B-CHEM
- : : I-CHEM
NOARG NNP NNP I-CHEM
- - - O
treated JJ JJ O
animals NNS NNS O
. . . O

CONCLUSIONS NNP NNP O
: : : O
The DT DT O
results NNS NNS O
give VBP VBP O
further JJ JJ O
support NN NN O
to TO TO O
the DT DT O
hypothesis NNS NNS O
that IN IN O
NO DT DT B-CHEM
plays VBZ VBZ O
a DT DT O
role NN NN O
in IN IN O
motor NN NN O
behavior NN NN O
control NN NN O
and CC CC O
suggest VB VB O
that IN IN O
it PRP PRP O
may MD MD O
take VB VB O
part NN NN O
in IN IN O
the DT DT O
synaptic JJ JJ O
changes NNS NNS O
produced VBN VBN O
by IN IN O
antipsychotic JJ JJ O
treatment NN NN O
. . . O

Prolonged NNP NNP O
left VBD VBD O
ventricular NN NN O
dysfunction NN NN O
occurs VBZ VBZ O
in IN IN O
patients NNS NNS O
with IN IN O
coronary JJ JJ O
artery NN NN O
disease NN NN O
after IN IN O
both DT DT O
dobutamine NN NN B-CHEM
and CC CC O
exercise NN NN O
induced VBD VBD O
myocardial JJ JJ O
ischaemia NN NN O
. . . O

OBJECTIVE NNP NNP O
: : : O
To TO TO O
determine VB VB O
whether IN IN O
pharmacological JJ JJ O
stress NN NN O
leads VBZ VBZ O
to TO TO O
prolonged JJ JJ O
but CC CC O
reversible JJ JJ O
left VBD VBD O
ventricular NN NN O
dysfunction NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
coronary JJ JJ O
artery NN NN O
disease NN NN O
, , , O
similar JJ JJ O
to TO TO O
that DT DT O
seen VBN VBN O
after IN IN O
exercise NN NN O
. . . O

DESIGN NNP NNP O
: : : O
A DT DT O
randomised JJ JJ O
crossover NN NN O
study NN NN O
of IN IN O
recovery NN NN O
time NN NN O
of IN IN O
systolic JJ JJ O
and CC CC O
diastolic JJ JJ O
left VBD VBD O
ventricular NN NN O
function NN NN O
after IN IN O
exercise NN NN O
and CC CC O
dobutamine NN NN B-CHEM
induced JJ JJ O
ischaemia NN NN O
. . . O

SUBJECTS NNP NNP O
: : : O
10 CD CD O
patients NNS NNS O
with IN IN O
stable JJ JJ O
angina NN NN O
, , , O
angiographically RB RB O
proven VBN VBN O
coronary JJ JJ O
artery NN NN O
disease NN NN O
, , , O
and CC CC O
normal JJ JJ O
left VBD VBD O
ventricular NN NN O
function NN NN O
. . . O

INTERVENTIONS NNP NNP O
: : : O
Treadmill NNP NNP O
exercise NN NN O
and CC CC O
dobutamine NN NN B-CHEM
stress NN NN O
were VBD VBD O
performed VBN VBN O
on IN IN O
different JJ JJ O
days NNS NNS O
. . . O

Quantitative NNP NNP O
assessment NN NN O
of IN IN O
systolic JJ JJ O
and CC CC O
diastolic JJ JJ O
left VBD VBD O
ventricular NN NN O
function NN NN O
was VBD VBD O
performed VBN VBN O
using VBG VBG O
transthoracic NN NN O
echocardiography NN NN O
at IN IN O
baseline NN NN O
and CC CC O
at IN IN O
regular JJ JJ O
intervals NNS NNS O
after IN IN O
each DT DT O
test NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Both DT DT O
forms NNS NNS O
of IN IN O
stress NN NN O
led VBN VBN O
to TO TO O
prolonged JJ JJ O
but CC CC O
reversible JJ JJ O
systolic JJ JJ O
and CC CC O
diastolic JJ JJ O
dysfunction NN NN O
. . . O

There EX EX O
was VBD VBD O
no DT DT O
difference NN NN O
in IN IN O
the DT DT O
maximum NN NN O
double JJ JJ O
product NN NN O
( ( ( O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
53 CD CD O
) ) ) O
or CC CC O
ST NNP NNP O
depression NN NN O
( ( ( O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
63 CD CD O
) ) ) O
with IN IN O
either DT DT O
form NN NN O
of IN IN O
stress NN NN O
. . . O

After IN IN O
exercise NN NN O
, , , O
ejection NN NN O
fraction NN NN O
was VBD VBD O
reduced VBN VBN O
at IN IN O
15 CD CD O
and CC CC O
30 CD CD O
minutes NNS NNS O
compared VBN VBN O
with IN IN O
baseline NN NN O
( ( ( O
mean NN NN O
( ( ( O
SEM NNP NNP O
) ) ) O
, , , O
- - - O
5 CD CD O
. . . O
6 CD CD O
( ( ( O
1 CD CD O
. . . O
5 CD CD O
) ) ) O
% NN NN O
, , , O
p NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
; : : O
and CC CC O
- : : O
6 CD CD O
. . . O
1 CD CD O
( ( ( O
2 CD CD O
. . . O
2 CD CD O
) ) ) O
% NN NN O
, , , O
p NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
, , , O
and CC CC O
at IN IN O
30 CD CD O
and CC CC O
45 CD CD O
minutes NNS NNS O
after IN IN O
dobutamine NN NN B-CHEM
( ( ( O
- : : O
10 CD CD O
. . . O
8 CD CD O
( ( ( O
1 CD CD O
. . . O
8 CD CD O
) ) ) O
% NN NN O
and CC CC O
- - - O
5 CD CD O
. . . O
5 CD CD O
( ( ( O
1 CD CD O
. . . O
8 CD CD O
) ) ) O
% NN NN O
, , , O
both DT DT O
p NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
. . . O

Regional NNP NNP O
analysis NN NN O
showed VBD VBD O
a DT DT O
reduction NN NN O
in IN IN O
the DT DT O
worst JJS JJS O
affected VBN VBN O
segment NN NN O
15 CD CD O
and CC CC O
30 CD CD O
minutes NNS NNS O
after IN IN O
exercise NN NN O
( ( ( O
- : : O
27 CD CD O
. . . O
9 CD CD O
( ( ( O
7 CD CD O
. . . O
2 CD CD O
) ) ) O
% NN NN O
and CC CC O
- - - O
28 CD CD O
. . . O
6 CD CD O
( ( ( O
5 CD CD O
. . . O
7 CD CD O
) ) ) O
% NN NN O
, , , O
both DT DT O
p NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
, , , O
and CC CC O
at IN IN O
30 CD CD O
minutes NNS NNS O
after IN IN O
dobutamine NN NN B-CHEM
( ( ( O
- : : O
32 CD CD O
( ( ( O
5 CD CD O
. . . O
3 CD CD O
) ) ) O
% NN NN O
, , , O
p NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
. . . O

The DT DT O
isovolumic JJ JJ O
relaxation NN NN O
period NN NN O
was VBD VBD O
prolonged JJ JJ O
45 CD CD O
minutes NNS NNS O
after IN IN O
each DT DT O
form NN NN O
of IN IN O
stress NN NN O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

CONCLUSIONS NNP NNP O
: : : O
In IN IN O
patients NNS NNS O
with IN IN O
coronary JJ JJ O
artery NN NN O
disease NN NN O
, , , O
dobutamine NN NN B-CHEM
induced VBN VBN O
ischaemia NN NN O
results NNS NNS O
in IN IN O
prolonged JJ JJ O
reversible NN NN O
left VBD VBD O
ventricular NN NN O
dysfunction NN NN O
, , , O
presumed VBN VBN O
to TO TO O
be VB VB O
myocardial JJ JJ O
stunning NN NN O
, , , O
similar JJ JJ O
to TO TO O
that DT DT O
seen VBN VBN O
after IN IN O
exercise NN NN O
. . . O

Dobutamine NNP NNP B-CHEM
induced VBD VBD O
ischaemia NN NN O
could MD MD O
therefore RB RB O
be VB VB O
used VBN VBN O
to TO TO O
study VB VB O
the DT DT O
pathophysiology NN NN O
of IN IN O
this DT DT O
phenomenon NN NN O
further RB RB O
in IN IN O
patients NNS NNS O
with IN IN O
coronary JJ JJ O
artery NN NN O
disease NN NN O
. . . O

Anorexigens NNP NNP O
and CC CC O
pulmonary JJ JJ O
hypertension NN NN O
in IN IN O
the DT DT O
United NNP NNP O
States NNPS NNPS O
: : : O
results NNS NNS O
from IN IN O
the DT DT O
surveillance NN NN O
of IN IN O
North NNP NNP O
American NNP NNP O
pulmonary JJ JJ O
hypertension NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
The DT DT O
use NN NN O
of IN IN O
appetite NN NN O
suppressants NNS NNS O
in IN IN O
Europe NNP NNP O
has VBZ VBZ O
been VBN VBN O
associated VBN VBN O
with IN IN O
the DT DT O
development NN NN O
of IN IN O
primary JJ JJ O
pulmonary JJ JJ O
hypertension NN NN O
( ( ( O
PPH NNP NNP O
) ) ) O
. . . O

Recently RB RB O
, , , O
fenfluramine NN NN B-CHEM
appetite NN NN O
suppressants NNS NNS O
became VBD VBD O
widely RB RB O
used VBN VBN O
in IN IN O
the DT DT O
United NNP NNP O
States NNPS NNPS O
but CC CC O
were VBD VBD O
withdrawn VBN VBN O
in IN IN O
September NNP NNP O
1997 CD CD O
because IN IN O
of IN IN O
concerns NNS NNS O
over IN IN O
adverse JJ JJ O
effects NNS NNS O
. . . O

MATERIALS NNS NNS O
AND CC CC O
METHODS NNP NNP O
: : : O
We PRP PRP O
conducted VBD VBD O
a DT DT O
prospective JJ JJ O
surveillance NN NN O
study NN NN O
on IN IN O
patients NNS NNS O
diagnosed VBN VBN O
with IN IN O
pulmonary JJ JJ O
hypertension NN NN O
at IN IN O
12 CD CD O
large JJ JJ O
referral NN NN O
centers NNS NNS O
in IN IN O
North NNP NNP O
America NNP NNP O
. . . O

Data NNP NNP O
collected VBN VBN O
on IN IN O
patients NNS NNS O
seen VBN VBN O
from IN IN O
September NNP NNP O
1 CD CD O
, , , O
1996 CD CD O
, , , O
to TO TO O
December NNP NNP O
31 CD CD O
, , , O
1997 CD CD O
, , , O
included VBD VBD O
the DT DT O
cause NN NN O
of IN IN O
the DT DT O
pulmonary JJ JJ O
hypertension NN NN O
and CC CC O
its PRP$ PRP$ O
severity NN NN O
. . . O

Patients NNS NNS O
with IN IN O
no DT DT O
identifiable JJ JJ O
cause NN NN O
of IN IN O
pulmonary JJ JJ O
hypertension NN NN O
were VBD VBD O
classed VBN VBN O
as IN IN O
PPH NNP NNP O
. . . O

A DT DT O
history NN NN O
of IN IN O
drug NN NN O
exposure NN NN O
also RB RB O
was VBD VBD O
taken VBN VBN O
with IN IN O
special JJ JJ O
attention NN NN O
on IN IN O
the DT DT O
use NN NN O
of IN IN O
antidepressants NNS NNS O
, , , O
anorexigens NNS NNS O
, , , O
and CC CC O
amphetamines NNS NNS B-CHEM
. . . O

RESULTS NNS NNS O
: : : O
Five CD CD O
hundred CD CD O
seventy NN NN O
- - - O
nine CD CD O
patients NNS NNS O
were VBD VBD O
studied VBN VBN O
, , , O
205 CD CD O
with IN IN O
PPH NNP NNP O
and CC CC O
374 CD CD O
with IN IN O
pulmonary JJ JJ O
hypertension NN NN O
from IN IN O
other JJ JJ O
causes NNS NNS O
( ( ( O
secondary JJ JJ O
pulmonary JJ JJ O
hypertension NN NN O
[ NN NN O
SPH NNP NNP O
] NN NN O
) ) ) O
. . . O

The DT DT O
use NN NN O
of IN IN O
anorexigens NNS NNS O
was VBD VBD O
common JJ JJ O
in IN IN O
both DT DT O
groups NNS NNS O
. . . O

However RB RB O
, , , O
of IN IN O
the DT DT O
medications NNS NNS O
surveyed VBD VBD O
, , , O
only RB RB O
the DT DT O
fenfluramines NNS NNS B-CHEM
had VBD VBD O
a DT DT O
significant JJ JJ O
preferential JJ JJ O
association NN NN O
with IN IN O
PPH NNP NNP O
as IN IN O
compared VBN VBN O
with IN IN O
SPH NNP NNP O
( ( ( O
adjusted VBN VBN O
odds NNS NNS O
ratio NN NN O
for IN IN O
use NN NN O
> NN NN O
6 CD CD O
months NNS NNS O
, , , O
7 CD CD O
. . . O
5 CD CD O
; : : O
95 CD CD O
% NN NN O
confidence NN NN O
interval NN NN O
, , , O
1 CD CD O
. . . O
7 CD CD O
to TO TO O
32 CD CD O
. . . O
4 CD CD O
) ) ) O
. . . O

The DT DT O
association NN NN O
was VBD VBD O
stronger JJR JJR O
with IN IN O
longer JJR JJR O
duration NN NN O
of IN IN O
use NN NN O
when WRB WRB O
compared VBN VBN O
to TO TO O
shorter JJR JJR O
duration NN NN O
of IN IN O
use NN NN O
and CC CC O
was VBD VBD O
more RBR RBR O
pronounced JJ JJ O
in IN IN O
recent JJ JJ O
users NNS NNS O
than IN IN O
in IN IN O
remote JJ JJ O
users NNS NNS O
. . . O

An DT DT O
unexpectedly RB RB O
high JJ JJ O
( ( ( O
11 CD CD O
. . . O
4 CD CD O
% NN NN O
) ) ) O
number NN NN O
of IN IN O
patients NNS NNS O
with IN IN O
SPH NNP NNP O
had VBD VBD O
used VBN VBN O
anorexigens NNS NNS O
. . . O

CONCLUSION NNP NNP O
: : : O
The DT DT O
magnitude NN NN O
of IN IN O
the DT DT O
association NN NN O
with IN IN O
PPH NNP NNP O
, , , O
the DT DT O
increase NN NN O
of IN IN O
association NN NN O
with IN IN O
increasing VBG VBG O
duration NN NN O
of IN IN O
use NN NN O
, , , O
and CC CC O
the DT DT O
specificity NN NN O
for IN IN O
fenfluramines NNS NNS B-CHEM
are VBP VBP O
consistent JJ JJ O
with IN IN O
previous JJ JJ O
studies NNS NNS O
indicating VBG VBG O
that DT DT O
fenfluramines NNS NNS B-CHEM
are VBP VBP O
causally RB RB O
related VBN VBN O
to TO TO O
PPH NNP NNP O
. . . O

The DT DT O
high JJ JJ O
prevalence NN NN O
of IN IN O
anorexigen NN NN O
use NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
SPH NNP NNP O
also RB RB O
raises VBZ VBZ O
the DT DT O
possibility NN NN O
that IN IN O
these DT DT O
drugs NNS NNS O
precipitate NN NN O
pulmonary JJ JJ O
hypertension NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
underlying VBG VBG O
conditions NNS NNS O
associated VBN VBN O
with IN IN O
SPH NNP NNP O
. . . O

Clinical NNP NNP O
aspects NNS NNS O
of IN IN O
heparin NN NN B-CHEM
- - - O
induced JJ JJ O
thrombocytopenia NN NN O
and CC CC O
thrombosis NNS NNS O
and CC CC O
other JJ JJ O
side NN NN O
effects NNS NNS O
of IN IN O
heparin NN NN B-CHEM
therapy NN NN O
. . . O

Heparin NNP NNP B-CHEM
, , , O
first JJ JJ O
used VBN VBN O
to TO TO O
prevent VB VB O
the DT DT O
clotting NN NN O
of IN IN O
blood NN NN O
in IN IN O
vitro NN NN O
, , , O
has VBZ VBZ O
been VBN VBN O
clinically RB RB O
used VBN VBN O
to TO TO O
treat VB VB O
thrombosis NNS NNS O
for IN IN O
more JJR JJR O
than IN IN O
50 CD CD O
years NNS NNS O
. . . O

Although IN IN O
several JJ JJ O
new JJ JJ O
anticoagulant JJ JJ O
drugs NNS NNS O
are VBP VBP O
in IN IN O
development NN NN O
, , , O
heparin NN NN B-CHEM
remains VBZ VBZ O
the DT DT O
anticoagulant NN NN O
of IN IN O
choice NN NN O
to TO TO O
treat VB VB O
acute JJ JJ O
thrombotic JJ JJ O
episodes NNS NNS O
. . . O

The DT DT O
clinical JJ JJ O
effects NNS NNS O
of IN IN O
heparin NN NN B-CHEM
are VBP VBP O
meritorious JJ JJ O
, , , O
but CC CC O
side NN NN O
effects NNS NNS O
do VBP VBP O
exist VB VB O
. . . O

Bleeding NNP NNP O
is VBZ VBZ O
the DT DT O
primary JJ JJ O
untoward JJ JJ O
effect NN NN O
of IN IN O
heparin NN NN B-CHEM
. . . O

Major NNP NNP O
bleeding NN NN O
is VBZ VBZ O
of IN IN O
primary JJ JJ O
concern NN NN O
in IN IN O
patients NNS NNS O
receiving VBG VBG O
heparin NN NN B-CHEM
therapy NN NN O
. . . O

However RB RB O
, , , O
additional JJ JJ O
important JJ JJ O
untoward JJ JJ O
effects NNS NNS O
of IN IN O
heparin NN NN B-CHEM
therapy NN NN O
include VBP VBP O
heparin NN NN B-CHEM
- - - O
induced JJ JJ O
thrombocytopenia NN NN O
, , , O
heparin NN NN B-CHEM
- - - O
associated VBN VBN O
osteoporosis NN NN O
, , , O
eosinophilia NN NN O
, , , O
skin NN NN O
reactions NNS NNS O
, , , O
allergic JJ JJ O
reactions NNS NNS O
other JJ JJ O
than IN IN O
thrombocytopenia NN NN O
, , , O
alopecia NN NN O
, , , O
transaminasemia NN NN O
, , , O
hyperkalemia NN NN O
, , , O
hypoaldosteronism NN NN O
, , , O
and CC CC O
priapism NN NN O
. . . O

These DT DT O
side NN NN O
effects NNS NNS O
are VBP VBP O
relatively RB RB O
rare JJ JJ O
in IN IN O
a DT DT O
given VBN VBN O
individual JJ JJ O
, , , O
but CC CC O
given VBN VBN O
the DT DT O
extremely RB RB O
widespread JJ JJ O
use NN NN O
of IN IN O
heparin NN NN B-CHEM
, , , O
some DT DT O
are VBP VBP O
quite RB RB O
common JJ JJ O
, , , O
particularly RB RB O
HITT NNP NNP O
and CC CC O
osteoporosis NN NN O
. . . O

Although IN IN O
reasonable JJ JJ O
incidences NNS NNS O
of IN IN O
many JJ JJ O
of IN IN O
these DT DT O
side NN NN O
effects NNS NNS O
can MD MD O
be VB VB O
" '' '' O
softly RB RB O
" '' '' O
deduced VBN VBN O
from IN IN O
current JJ JJ O
reports NNS NNS O
dealing VBG VBG O
with IN IN O
unfractionated JJ JJ O
heparin NN NN B-CHEM
, , , O
at IN IN O
present JJ JJ O
the DT DT O
incidences NNS NNS O
of IN IN O
these DT DT O
side NN NN O
effects NNS NNS O
with IN IN O
newer JJR JJR O
low JJ JJ O
molecular JJ JJ O
weight NN NN O
heparins NNS NNS B-CHEM
appear VBP VBP O
to TO TO O
be VB VB O
much RB RB O
less RBR RBR O
common JJ JJ O
. . . O

However RB RB O
, , , O
only RB RB O
longer RB RB O
experience NN NN O
will MD MD O
more RBR RBR O
clearly RB RB O
define VB VB O
the DT DT O
incidence NN NN O
of IN IN O
each DT DT O
side NN NN O
effect NN NN O
with IN IN O
low JJ JJ O
molecular JJ JJ O
weight NN NN O
preparations NNS NNS O
. . . O

A DT DT O
case NN NN O
of IN IN O
bilateral JJ JJ O
optic JJ JJ O
neuropathy NN NN O
in IN IN O
a DT DT O
patient NN NN O
on IN IN O
tacrolimus NN NN B-CHEM
( ( ( O
FK506 NNP NNP B-CHEM
) ) ) O
therapy NN NN O
after IN IN O
liver NN NN O
transplantation NN NN O
. . . O

PURPOSE NNP NNP O
: : : O
To TO TO O
report VB VB O
a DT DT O
case NN NN O
of IN IN O
bilateral JJ JJ O
optic JJ JJ O
neuropathy NN NN O
in IN IN O
a DT DT O
patient NN NN O
receiving VBG VBG O
tacrolimus NN NN B-CHEM
( ( ( O
FK NNP NNP B-CHEM
506 CD CD I-CHEM
, , , O
Prograf NNP NNP O
; : : O
Fujisawa NNP NNP O
USA NNP NNP O
, , , O
Inc NNP NNP O
, , , O
Deerfield NNP NNP O
, , , O
Illinois NNP NNP O
) ) ) O
for IN IN O
immunosuppression NN NN O
after IN IN O
orthotropic JJ JJ O
liver NN NN O
transplantation NN NN O
. . . O

METHOD NNP NNP O
: : : O
Case NN NN O
report NN NN O
. . . O

In IN IN O
a DT DT O
58 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
man NN NN O
receiving VBG VBG O
tacrolimus NN NN B-CHEM
after IN IN O
orthotropic JJ JJ O
liver NN NN O
transplantation NN NN O
, , , O
serial NN NN O
neuro NN NN O
- : : O
ophthalmologic JJ JJ O
examinations NNS NNS O
and CC CC O
laboratory NN NN O
studies NNS NNS O
were VBD VBD O
performed VBN VBN O
. . . O

RESULTS NNS NNS O
: : : O
The DT DT O
patient NN NN O
had VBD VBD O
episodic JJ JJ O
deterioration NN NN O
of IN IN O
vision NN NN O
in IN IN O
both DT DT O
eyes NNS NNS O
, , , O
with IN IN O
clinical JJ JJ O
features NNS NNS O
resembling VBG VBG O
ischemic JJ JJ O
optic JJ JJ O
neuropathies NNS NNS O
. . . O

Deterioration NNP NNP O
of IN IN O
vision NN NN O
occurred VBD VBD O
despite IN IN O
discontinuation NN NN O
of IN IN O
the DT DT O
tacrolimus NN NN B-CHEM
. . . O

CONCLUSION NNP NNP O
: : : O
Tacrolimus NNP NNP B-CHEM
and CC CC O
other JJ JJ O
immunosuppressive JJ JJ O
agents NNS NNS O
may MD MD O
be VB VB O
associated VBN VBN O
with IN IN O
optic JJ JJ O
nerve NN NN O
toxicity NN NN O
. . . O

Hypercalcemia NNP NNP O
, , , O
arrhythmia NN NN O
, , , O
and CC CC O
mood NN NN O
stabilizers NNS NNS O
. . . O

Recent JJ JJ O
findings NNS NNS O
in IN IN O
a DT DT O
bipolar JJ JJ O
patient NN NN O
receiving VBG VBG O
maintenance NN NN O
lithium NN NN B-CHEM
therapy NN NN O
who WP WP O
developed VBD VBD O
hypercalcemia NN NN O
and CC CC O
severe JJ JJ O
bradyarrhythmia NN NN O
prompted VBD VBD O
the DT DT O
authors NNS NNS O
to TO TO O
conduct VB VB O
a DT DT O
retrospective NN NN O
study NN NN O
of IN IN O
bipolar NN NN O
patients NNS NNS O
with IN IN O
lithium NN NN B-CHEM
- - - O
associated VBN VBN O
hypercalcemia NN NN O
. . . O

A DT DT O
printout NN NN O
of IN IN O
all DT DT O
cases NNS NNS O
of IN IN O
hypercalcemia NN NN O
that WDT WDT O
presented VBD VBD O
during IN IN O
a DT DT O
1 CD CD O
- : : O
year NN NN O
period NN NN O
was VBD VBD O
generated VBN VBN O
. . . O

After IN IN O
eliminating VBG VBG O
spurious JJ JJ O
hypercalcemias NN NN O
or CC CC O
those DT DT O
associated VBN VBN O
with IN IN O
intravenous JJ JJ O
fluids NNS NNS O
, , , O
the DT DT O
authors NNS NNS O
identified VBD VBD O
18 CD CD O
non NN NN O
- : : O
lithium NN NN B-CHEM
- - - O
treated VBN VBN O
patients NNS NNS O
with IN IN O
hypercalcemias NN NN O
related VBN VBN O
to TO TO O
malignancies NNS NNS O
and CC CC O
other JJ JJ O
medical JJ JJ O
conditions NNS NNS O
( ( ( O
group NN NN O
A DT DT O
) ) ) O
and CC CC O
12 CD CD O
patients NNS NNS O
with IN IN O
lithium NN NN B-CHEM
- - - O
associated VBN VBN O
hypercalcemia NN NN O
( ( ( O
group NN NN O
B NNP NNP O
) ) ) O
. . . O

Patients NNS NNS O
in IN IN O
group NN NN O
B NNP NNP O
were VBD VBD O
not RB RB O
comparable JJ JJ O
to TO TO O
those DT DT O
in IN IN O
group NN NN O
A DT DT O
, , , O
as IN IN O
the DT DT O
latter NN NN O
were VBD VBD O
medically RB RB O
compromised VBN VBN O
and CC CC O
were VBD VBD O
receiving VBG VBG O
multiple JJ JJ O
pharmacotherapies NNS NNS O
. . . O

Thus RB RB O
, , , O
two CD CD O
control NN NN O
groups NNS NNS O
were VBD VBD O
generated VBN VBN O
: : : O
group NN NN O
C1 NNP NNP O
, , , O
which WDT WDT O
included VBD VBD O
age NN NN O
- : : O
and CC CC O
sex NN NN O
- - - O
comparable JJ JJ O
lithium NN NN B-CHEM
- - - O
treated VBN VBN O
bipolar JJ JJ O
normocalcemic JJ JJ O
patients NNS NNS O
, , , O
and CC CC O
group NN NN O
C2 NNP NNP O
, , , O
which WDT WDT O
included VBD VBD O
bipolar JJ JJ O
normocalcemic JJ JJ O
patients NNS NNS O
treated VBN VBN O
with IN IN O
anticonvulsant JJ JJ O
mood NN NN O
stabilizers NNS NNS O
. . . O

The DT DT O
electrocardiographic JJ JJ O
( ( ( O
ECG NNP NNP O
) ) ) O
findings NNS NNS O
for IN IN O
patients NNS NNS O
in IN IN O
group NN NN O
B NNP NNP O
were VBD VBD O
compared VBN VBN O
with IN IN O
those DT DT O
of IN IN O
patients NNS NNS O
in IN IN O
groups NNS NNS O
C1 NNP NNP O
and CC CC O
C2 NNP NNP O
. . . O

It PRP PRP O
was VBD VBD O
found VBN VBN O
that IN IN O
these DT DT O
groups NNS NNS O
did VBD VBD O
not RB RB O
differ VB VB O
in IN IN O
their PRP$ PRP$ O
overall JJ JJ O
frequency NN NN O
of IN IN O
ECG NNP NNP O
abnormalities NNS NNS O
; : : O
however RB RB O
, , , O
there EX EX O
were VBD VBD O
significant JJ JJ O
differences NNS NNS O
in IN IN O
the DT DT O
frequency NN NN O
of IN IN O
conduction NN NN O
defects NNS NNS O
. . . O

Patients NNS NNS O
with IN IN O
hypercalcemia NN NN O
resulting VBG VBG O
from IN IN O
medical JJ JJ O
diseases NNS NNS O
and CC CC O
bipolar NN NN O
patients NNS NNS O
with IN IN O
lithium NN NN B-CHEM
- - - O
associated VBN VBN O
hypercalcemia NN NN O
had VBD VBD O
significantly RB RB O
higher JJR JJR O
frequencies NNS NNS O
of IN IN O
conduction NN NN O
defects NNS NNS O
. . . O

Patients NNS NNS O
in IN IN O
group NN NN O
A DT DT O
had VBD VBD O
significant JJ JJ O
mortality NN NN O
at IN IN O
2 CD CD O
- : : O
year NN NN O
follow VB VB O
- : : O
up RP RP O
( ( ( O
28 CD CD O
% NN NN O
) ) ) O
, , , O
in IN IN O
contrast NN NN O
to TO TO O
zero CD CD O
mortality NN NN O
in IN IN O
the DT DT O
other JJ JJ O
three CD CD O
groups NNS NNS O
. . . O

The DT DT O
clinical JJ JJ O
implications NNS NNS O
of IN IN O
these DT DT O
findings NNS NNS O
are VBP VBP O
discussed VBN VBN O
. . . O

Attenuation NNP NNP O
of IN IN O
nephrotoxicity NN NN O
by IN IN O
a DT DT O
novel NN NN O
lipid NN NN O
nanosphere NN NN O
( ( ( O
NS NNP NNP O
- - - O
718 CD CD O
) ) ) O
incorporating VBG VBG O
amphotericin NN NN B-CHEM
B NNP NNP I-CHEM
. . . O

NS NNP NNP O
- : : O
718 CD CD O
, , , O
a DT DT O
lipid NN NN O
nanosphere RB RB O
incorporating VBG VBG O
amphotericin NN NN B-CHEM
B NNP NNP I-CHEM
, , , O
is VBZ VBZ O
effective JJ JJ O
against IN IN O
pathogenic JJ JJ O
fungi NN NN O
and CC CC O
has VBZ VBZ O
low JJ JJ O
toxicity NN NN O
. . . O

We PRP PRP O
compared VBD VBD O
the DT DT O
toxicity NN NN O
of IN IN O
NS NNP NNP O
- : : O
718 CD CD O
with IN IN O
that DT DT O
of IN IN O
Fungizone NNP NNP B-CHEM
( ( ( O
amphotericin NN NN B-CHEM
B NNP NNP I-CHEM
- - - I-CHEM
sodium NN NN I-CHEM
deoxycholate NN NN I-CHEM
; : : O
D NNP NNP B-CHEM
- - - I-CHEM
AmB NNP NNP I-CHEM
) ) ) O
in IN IN O
vitro NN NN O
using VBG VBG O
renal JJ JJ O
cell NN NN O
cultures NNS NNS O
and CC CC O
in IN IN O
vivo NN NN O
by IN IN O
biochemical JJ JJ O
analysis NN NN O
, , , O
histopathological JJ JJ O
study NN NN O
of IN IN O
the DT DT O
kidney NN NN O
and CC CC O
pharmacokinetic JJ JJ O
study NN NN O
of IN IN O
amphotericin NN NN B-CHEM
B NNP NNP I-CHEM
following VBG VBG O
intravenous JJ JJ O
infusion NN NN O
of IN IN O
the DT DT O
formulation NN NN O
in IN IN O
rats NNS NNS O
. . . O

Incubation NNP NNP O
with IN IN O
NS NNP NNP O
- : : O
718 CD CD O
resulted VBD VBD O
in IN IN O
significantly RB RB O
less JJR JJR O
damage NN NN O
of IN IN O
cultured JJ JJ O
human JJ JJ O
renal NN NN O
proximal NN NN O
tubular NN NN O
epithelial NN NN O
cells NNS NNS O
compared VBN VBN O
with IN IN O
D NNP NNP B-CHEM
- : : I-CHEM
AmB NNP NNP I-CHEM
. . . O

Serum NNP NNP O
blood NN NN O
urea NN NN B-CHEM
and CC CC O
creatinine NN NN B-CHEM
concentrations NNS NNS O
increased VBN VBN O
significantly RB RB O
in IN IN O
rats NNS NNS O
given VBN VBN O
an DT DT O
iv NN NN O
infusion NN NN O
of IN IN O
D NNP NNP B-CHEM
- : : I-CHEM
AmB NNP NNP I-CHEM
3 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
but CC CC O
not RB RB O
in IN IN O
those DT DT O
given VBN VBN O
the DT DT O
same JJ JJ O
dose NN NN O
of IN IN O
NS NNP NNP O
- : : O
718 CD CD O
. . . O

Histopathological NNP NNP O
examination NN NN O
of IN IN O
the DT DT O
kidney NN NN O
showed VBD VBD O
tubular JJ JJ O
necrosis NNS NNS O
in IN IN O
D NNP NNP B-CHEM
- - - I-CHEM
AmB NNP NNP I-CHEM
- - - O
treated JJ JJ O
rats NNS NNS O
but CC CC O
no DT DT O
change NN NN O
in IN IN O
NS NNP NNP O
- : : O
718 CD CD O
- : : O
treated JJ JJ O
rats NNS NNS O
. . . O

Amphotericin NNP NNP B-CHEM
B NNP NNP I-CHEM
concentrations NNS NNS O
in IN IN O
the DT DT O
kidney NN NN O
in IN IN O
NS NNP NNP O
- : : O
718 CD CD O
- : : O
treated JJ JJ O
rats NNS NNS O
were VBD VBD O
higher JJR JJR O
than IN IN O
those DT DT O
in IN IN O
D NNP NNP B-CHEM
- - - I-CHEM
AmB NNP NNP I-CHEM
- - - O
treated JJ JJ O
rats NNS NNS O
. . . O

Our PRP$ PRP$ O
in IN IN O
vitro NN NN O
and CC CC O
in IN IN O
vivo NN NN O
results NNS NNS O
suggest VBP VBP O
that DT DT O
incorporation NN NN O
of IN IN O
amphotericin NN NN B-CHEM
B NNP NNP I-CHEM
into IN IN O
lipid NN NN O
nanospheres NNS NNS O
of IN IN O
NS NNP NNP O
- : : O
718 CD CD O
attenuates VBZ VBZ O
the DT DT O
nephrotoxicity NN NN O
of IN IN O
amphotericin NN NN B-CHEM
B NNP NNP I-CHEM
. . . O

Patterns NNS NNS O
of IN IN O
sulfadiazine NN NN B-CHEM
acute JJ JJ O
nephrotoxicity NN NN O
. . . O

Sulfadiazine NNP NNP B-CHEM
acute JJ JJ O
nephrotoxicity NN NN O
is VBZ VBZ O
reviving VBG VBG O
specially RB RB O
because IN IN O
of IN IN O
its PRP$ PRP$ O
use NN NN O
in IN IN O
toxoplasmosis NN NN O
in IN IN O
HIV NNP NNP O
- - - O
positive JJ JJ O
patients NNS NNS O
. . . O

We PRP PRP O
report VBP VBP O
4 CD CD O
cases NNS NNS O
, , , O
one CD CD O
of IN IN O
them PRP PRP O
in IN IN O
a DT DT O
previously RB RB O
healthy JJ JJ O
person NN NN O
. . . O

Under IN IN O
treatment NN NN O
with IN IN O
sulfadiazine NN NN B-CHEM
they PRP PRP O
developed VBD VBD O
oliguria RB RB O
, , , O
abdominal JJ JJ O
pain NN NN O
, , , O
renal JJ JJ O
failure NN NN O
and CC CC O
showed VBD VBD O
multiple JJ JJ O
radiolucent NN NN O
renal JJ JJ O
calculi NN NN O
in IN IN O
echography NN NN O
. . . O

All DT DT O
patients NNS NNS O
recovered VBD VBD O
their PRP$ PRP$ O
previous JJ JJ O
normal JJ JJ O
renal JJ JJ O
function NN NN O
after IN IN O
adequate JJ JJ O
hydration NN NN O
and CC CC O
alcalinization NN NN O
. . . O

A DT DT O
nephrostomy NN NN O
tube NN NN O
had VBD VBD O
to TO TO O
be VB VB O
placed VBN VBN O
in IN IN O
one CD CD O
of IN IN O
the DT DT O
patients NNS NNS O
for IN IN O
ureteral JJ JJ O
lithiasis NN NN O
in IN IN O
a DT DT O
single JJ JJ O
functional JJ JJ O
kidney NN NN O
. . . O

None NN NN O
of IN IN O
them PRP PRP O
needed VBD VBD O
dialysis NN NN O
or CC CC O
a DT DT O
renal JJ JJ O
biopsy NN NN O
because IN IN O
of IN IN O
a DT DT O
typical JJ JJ O
benign NN NN O
course NN NN O
. . . O

Treatment NN NN O
with IN IN O
sulfadiazine NN NN B-CHEM
requires VBZ VBZ O
exquisite JJ JJ O
control NN NN O
of IN IN O
renal JJ JJ O
function NN NN O
, , , O
an DT DT O
increase NN NN O
in IN IN O
water NN NN O
ingestion NN NN O
and CC CC O
possibly RB RB O
the DT DT O
alcalinization NN NN O
of IN IN O
the DT DT O
urine NN NN O
. . . O

We PRP PRP O
communicate VBP VBP O
a DT DT O
case NN NN O
in IN IN O
a DT DT O
previously RB RB O
healthy JJ JJ O
person NN NN O
, , , O
a DT DT O
fact NN NN O
not RB RB O
found VBD VBD O
in IN IN O
the DT DT O
recent JJ JJ O
literature NN NN O
. . . O

Probably RB RB O
many JJ JJ O
more JJR JJR O
cases NNS NNS O
are VBP VBP O
not RB RB O
detected VBN VBN O
. . . O

We PRP PRP O
think VBP VBP O
that IN IN O
a DT DT O
prospective JJ JJ O
study NN NN O
would MD MD O
be VB VB O
useful JJ JJ O
. . . O

Downbeat NNP NNP O
nystagmus NN NN O
associated VBN VBN O
with IN IN O
intravenous JJ JJ O
patient NN NN O
- - - O
controlled JJ JJ O
administration NN NN O
of IN IN O
morphine NN NN B-CHEM
. . . O

IMPLICATIONS NNP NNP O
: : : O
This DT DT O
case NN NN O
documents VBZ VBZ O
a DT DT O
patient NN NN O
who WP WP O
developed VBD VBD O
dizziness JJ JJ O
with IN IN O
downbeating VBG VBG O
nystagmus NN NN O
while IN IN O
receiving VBG VBG O
a DT DT O
relatively RB RB O
large JJ JJ O
dose NN NN O
of IN IN O
IV NNP NNP O
patient NN NN O
- : : O
controlled JJ JJ O
analgesia NN NN O
morphine NN NN B-CHEM
. . . O

Although IN IN O
there EX EX O
have VBP VBP O
been VBN VBN O
case NN NN O
reports NNS NNS O
of IN IN O
epidural JJ JJ O
morphine NN NN B-CHEM
with IN IN O
these DT DT O
symptoms NNS NNS O
and CC CC O
signs NNS NNS O
, , , O
this DT DT O
has VBZ VBZ O
not RB RB O
been VBN VBN O
previously RB RB O
documented VBN VBN O
with IN IN O
IV NNP NNP O
or CC CC O
patient NN NN O
- - - O
controlled JJ JJ O
analgesia NN NN O
morphine NN NN B-CHEM
. . . O

Hemodynamic NNP NNP O
and CC CC O
antiadrenergic JJ JJ O
effects NNS NNS O
of IN IN O
dronedarone NN NN B-CHEM
and CC CC O
amiodarone NN NN B-CHEM
in IN IN O
animals NNS NNS O
with IN IN O
a DT DT O
healed JJ JJ O
myocardial NN NN O
infarction NN NN O
. . . O

The DT DT O
hemodynamic JJ JJ O
and CC CC O
antiadrenergic JJ JJ O
effects NNS NNS O
of IN IN O
dronedarone NN NN B-CHEM
, , , O
a DT DT O
noniodinated JJ JJ O
compound NN NN O
structurally RB RB O
related VBN VBN O
to TO TO O
amiodarone NN NN B-CHEM
, , , O
were VBD VBD O
compared VBN VBN O
with IN IN O
those DT DT O
of IN IN O
amiodarone NN NN B-CHEM
after IN IN O
prolonged JJ JJ O
oral JJ JJ O
administration NN NN O
, , , O
both DT DT O
at IN IN O
rest NN NN O
and CC CC O
during IN IN O
sympathetic JJ JJ O
stimulation NN NN O
in IN IN O
conscious JJ JJ O
dogs NNS NNS O
with IN IN O
a DT DT O
healed JJ JJ O
myocardial NN NN O
infarction NN NN O
. . . O

All DT DT O
dogs NNS NNS O
( ( ( O
n NN NN O
= SYM SYM O
6 CD CD O
) ) ) O
randomly NN NN O
received VBD VBD O
orally RB RB O
dronedarone NN NN B-CHEM
( ( ( O
10 CD CD O
and CC CC O
30 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
, , , O
amiodarone NN NN B-CHEM
( ( ( O
10 CD CD O
and CC CC O
30 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
, , , O
and CC CC O
placebo NN NN O
twice RB RB O
daily JJ JJ O
for IN IN O
7 CD CD O
days NNS NNS O
, , , O
with IN IN O
a DT DT O
3 CD CD O
- : : O
week NN NN O
washout NN NN O
between IN IN O
consecutive JJ JJ O
treatments NNS NNS O
. . . O

Heart NNP NNP O
rate NN NN O
( ( ( O
HR NNP NNP O
) ) ) O
, , , O
mean VB VB O
arterial JJ JJ O
pressure NN NN O
( ( ( O
MBP NNP NNP O
) ) ) O
, , , O
positive JJ JJ O
rate NN NN O
of IN IN O
increase NN NN O
of IN IN O
left VBD VBD O
ventricular NN NN O
pressure NN NN O
( ( ( O
+ NN NN O
LVdP NNP NNP O
/ NN NN O
dt NN NN O
) ) ) O
, , , O
echocardiographically RB RB O
assessed VBN VBN O
left VBD VBD O
ventricular NN NN O
ejection NN NN O
fraction NN NN O
( ( ( O
LVEF NNP NNP O
) ) ) O
, , , O
and CC CC O
fractional JJ JJ O
shortening NN NN O
( ( ( O
FS NNP NNP O
) ) ) O
, , , O
as RB RB O
well RB RB O
as IN IN O
chronotropic NN NN O
response NN NN O
to TO TO O
isoproterenol NN NN B-CHEM
and CC CC O
exercise NN NN O
- - - O
induced JJ JJ O
sympathetic JJ JJ O
stimulation NN NN O
were VBD VBD O
evaluated VBN VBN O
under IN IN O
baseline NN NN O
and CC CC O
posttreatment NN NN O
conditions NNS NNS O
. . . O

Resting NNP NNP O
values NNS NNS O
of IN IN O
LVEF NNP NNP O
, , , O
FS NNP NNP O
, , , O
+ NN NN O
LVdP NNP NNP O
/ NN NN O
dt NN NN O
, , , O
and CC CC O
MBP NNP NNP O
remained VBD VBD O
unchanged JJ JJ O
whatever WDT WDT O
the DT DT O
drug NN NN O
and CC CC O
the DT DT O
dosing VBG VBG O
regimen NNS NNS O
, , , O
whereas IN IN O
resting VBG VBG O
HR NNP NNP O
was VBD VBD O
significantly RB RB O
and CC CC O
dose VB VB O
- : : O
dependently RB RB O
lowered VBD VBD O
after IN IN O
dronedarone NN NN B-CHEM
and CC CC O
to TO TO O
a DT DT O
lesser NN NN O
extent NN NN O
after IN IN O
amiodarone NN NN B-CHEM
. . . O

Both DT DT O
dronedarone NN NN B-CHEM
and CC CC O
amiodarone NN NN B-CHEM
significantly RB RB O
reduced VBD VBD O
the DT DT O
exercise NN NN O
- - - O
induced JJ JJ O
tachycardia NN NN O
and CC CC O
, , , O
at IN IN O
the DT DT O
highest JJS JJS O
dose NN NN O
, , , O
decreased VBD VBD O
the DT DT O
isoproterenol NN NN B-CHEM
- - - O
induced JJ JJ O
tachycardia NN NN O
. . . O

Thus RB RB O
, , , O
dronedarone NN NN B-CHEM
and CC CC O
amiodarone NN NN B-CHEM
displayed VBD VBD O
a DT DT O
similar JJ JJ O
level NN NN O
of IN IN O
antiadrenergic JJ JJ O
effect NN NN O
and CC CC O
did VBD VBD O
not RB RB O
impair VB VB O
the DT DT O
resting VBG VBG O
left VBN VBN O
ventricular NN NN O
function NN NN O
. . . O

Consequently RB RB O
, , , O
dronedarone NN NN B-CHEM
might MD MD O
be VB VB O
particularly RB RB O
suitable JJ JJ O
for IN IN O
the DT DT O
treatment NN NN O
and CC CC O
prevention NN NN O
of IN IN O
various JJ JJ O
clinical JJ JJ O
arrhythmias NNS NNS O
, , , O
without IN IN O
compromising VBG VBG O
the DT DT O
left NN NN O
ventricular NN NN O
function NN NN O
. . . O

Phase NN NN O
2 CD CD O
trial NN NN O
of IN IN O
liposomal NN NN O
doxorubicin NN NN B-CHEM
( ( ( O
40 CD CD O
mg NN NN O
/ NN NN O
m NN NN O
( ( ( O
2 CD CD O
) ) ) O
) ) ) O
in IN IN O
platinum NN NN B-CHEM
/ NN NN O
paclitaxel NN NN B-CHEM
- : : O
refractory NN NN O
ovarian NN NN O
and CC CC O
fallopian JJ JJ O
tube NN NN O
cancers NNS NNS O
and CC CC O
primary JJ JJ O
carcinoma NN NN O
of IN IN O
the DT DT O
peritoneum NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
Several JJ JJ O
studies NNS NNS O
have VBP VBP O
demonstrated VBN VBN O
liposomal NN NN O
doxorubicin NN NN B-CHEM
( ( ( O
Doxil NNP NNP B-CHEM
) ) ) O
to TO TO O
be VB VB O
an DT DT O
active JJ JJ O
antineoplastic JJ JJ O
agent NN NN O
in IN IN O
platinum NN NN B-CHEM
- - - O
resistant JJ JJ O
ovarian JJ JJ O
cancer NN NN O
, , , O
with IN IN O
dose NN NN O
limiting VBG VBG O
toxicity NN NN O
of IN IN O
the DT DT O
standard JJ JJ O
dosing VBG VBG O
regimen NNS NNS O
( ( ( O
50 CD CD O
mg NN NN O
/ NN NN O
m NN NN O
( ( ( O
2 CD CD O
) ) ) O
q NN NN O
4 CD CD O
weeks NNS NNS O
) ) ) O
being VBG VBG O
severe JJ JJ O
erythrodysesthesia NN NN O
( ( ( O
" '' '' O
hand NN NN O
- - - O
foot NN NN O
syndrome NN NN O
" '' '' O
) ) ) O
and CC CC O
stomatitis NNS NNS O
. . . O

We PRP PRP O
wished VBD VBD O
to TO TO O
develop VB VB O
a DT DT O
more RBR RBR O
tolerable JJ JJ O
liposomal NN NN O
doxorubicin NN NN B-CHEM
treatment NN NN O
regimen NNS NNS O
and CC CC O
document VB VB O
its PRP$ PRP$ O
level NN NN O
of IN IN O
activity NN NN O
in IN IN O
a DT DT O
well RB RB O
- - - O
defined VBN VBN O
patient NN NN O
population NN NN O
with IN IN O
platinum NN NN B-CHEM
/ NN NN O
paclitaxel NN NN B-CHEM
- : : O
refractory NN NN O
disease NN NN O
. . . O

METHODS NNP NNP O
AND CC CC O
MATERIALS NNS NNS O
: : : O
Patients NNS NNS O
with IN IN O
ovarian NN NN O
or CC CC O
fallopian JJ JJ O
tube NN NN O
cancers NNS NNS O
or CC CC O
primary JJ JJ O
peritoneal NN NN O
carcinoma NN NN O
with IN IN O
platinum NN NN B-CHEM
/ NN NN O
paclitaxel NN NN B-CHEM
- : : O
refractory NN NN O
disease NN NN O
( ( ( O
stable JJ JJ O
or CC CC O
progressive JJ JJ O
disease NN NN O
following VBG VBG O
treatment NN NN O
with IN IN O
these DT DT O
agents NNS NNS O
or CC CC O
previous JJ JJ O
objective NN NN O
response NN NN O
< NN NN O
3 CD CD O
months NNS NNS O
in IN IN O
duration NN NN O
) ) ) O
were VBD VBD O
treated VBN VBN O
with IN IN O
liposomal NN NN O
doxorubicin NN NN B-CHEM
at IN IN O
a DT DT O
dose NN NN O
of IN IN O
40 CD CD O
mg NN NN O
/ NN NN O
m NN NN O
( ( ( O
2 CD CD O
) ) ) O
q NN NN O
4 CD CD O
weeks NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
A DT DT O
total NN NN O
of IN IN O
49 CD CD O
patients NNS NNS O
( ( ( O
median JJ JJ O
age NN NN O
: : : O
60 CD CD O
; : : O
range NN NN O
41 CD CD O
- : : O
81 CD CD O
) ) ) O
entered VBD VBD O
this DT DT O
phase NN NN O
2 CD CD O
trial NN NN O
. . . O

The DT DT O
median JJ JJ O
number NN NN O
of IN IN O
prior JJ JJ O
regimens NNS NNS O
was VBD VBD O
2 CD CD O
( ( ( O
range NN NN O
: : : O
1 CD CD O
- : : O
6 CD CD O
) ) ) O
. . . O

Six CD CD O
( ( ( O
12 CD CD O
% NN NN O
) ) ) O
and CC CC O
4 CD CD O
( ( ( O
8 CD CD O
% NN NN O
) ) ) O
patients NNS NNS O
experienced VBN VBN O
grade NN NN O
2 CD CD O
hand NN NN O
- : : O
foot NN NN O
syndrome NN NN O
and CC CC O
stomatitis NNS NNS O
, , , O
respectively RB RB O
( ( ( O
no DT DT O
episodes NNS NNS O
of IN IN O
grade NN NN O
3 CD CD O
) ) ) O
. . . O

One CD CD O
patient NN NN O
developed VBN VBN O
grade NN NN O
3 CD CD O
diarrhea NN NN O
requiring VBG VBG O
hospitalization NN NN O
for IN IN O
hydration NN NN O
. . . O

Six CD CD O
( ( ( O
12 CD CD O
% NN NN O
) ) ) O
individuals NNS NNS O
required VBN VBN O
dose JJ JJ O
reductions NNS NNS O
. . . O

The DT DT O
median JJ JJ O
number NN NN O
of IN IN O
courses NNS NNS O
of IN IN O
liposomal NN NN O
doxorubicin NN NN B-CHEM
administered VBN VBN O
on IN IN O
this DT DT O
protocol NN NN O
was VBD VBD O
2 CD CD O
( ( ( O
range NN NN O
: : : O
1 CD CD O
- : : O
12 CD CD O
) ) ) O
. . . O

Four CD CD O
of IN IN O
44 CD CD O
patients NNS NNS O
( ( ( O
9 CD CD O
% NN NN O
) ) ) O
evaluable JJ JJ O
for IN IN O
response NN NN O
exhibited VBN VBN O
objective NN NN O
and CC CC O
subjective JJ JJ O
evidence NN NN O
of IN IN O
an DT DT O
antineoplastic JJ JJ O
effect NN NN O
of IN IN O
therapy NN NN O
. . . O

CONCLUSION NNP NNP O
: : : O
This DT DT O
modified VBN VBN O
liposomal NN NN O
doxorubicin NN NN B-CHEM
regimen NN NN O
results NNS NNS O
in IN IN O
less JJR JJR O
toxicity NN NN O
( ( ( O
stomatitis NNS NNS O
, , , O
hand NN NN O
- - - O
foot NN NN O
syndrome NN NN O
) ) ) O
than IN IN O
the DT DT O
standard JJ JJ O
FDA NNP NNP O
- : : O
approved VBD VBD O
dose NN NN O
schedule NN NN O
. . . O

Definite NNP NNP O
, , , O
although IN IN O
limited JJ JJ O
, , , O
antineoplastic JJ JJ O
activity NN NN O
is VBZ VBZ O
observed VBN VBN O
in IN IN O
patients NNS NNS O
with IN IN O
well RB RB O
- : : O
defined VBN VBN O
platinum NN NN B-CHEM
- : : O
and CC CC O
paclitaxel NN NN B-CHEM
- - - O
refractory NN NN O
ovarian JJ JJ O
cancer NN NN O
. . . O

Efficacy NNP NNP O
of IN IN O
olanzapine NN NN B-CHEM
in IN IN O
acute JJ JJ O
bipolar NN NN O
mania NN NN O
: : : O
a DT DT O
double JJ JJ O
- - - O
blind JJ JJ O
, , , O
placebo NN NN O
- - - O
controlled JJ JJ O
study NN NN O
. . . O

The DT DT O
Olanzipine NNP NNP B-CHEM
HGGW NNP NNP O
Study NNP NNP O
Group NNP NNP O
. . . O

BACKGROUND NNP NNP O
: : : O
We PRP PRP O
compared VBD VBD O
the DT DT O
efficacy NN NN O
and CC CC O
safety NN NN O
of IN IN O
olanzapine NN NN B-CHEM
vs NNS NNS O
placebo NN NN O
for IN IN O
the DT DT O
treatment NN NN O
of IN IN O
acute JJ JJ O
bipolar NN NN O
mania NN NN O
. . . O

METHODS NNP NNP O
: : : O
Four CD CD O
- - - O
week NN NN O
, , , O
randomized VBD VBD O
, , , O
double JJ JJ O
- - - O
blind JJ JJ O
, , , O
parallel JJ JJ O
study NN NN O
. . . O

A DT DT O
total NN NN O
of IN IN O
115 CD CD O
patients NNS NNS O
with IN IN O
a DT DT O
DSM NNP NNP O
- - - O
IV NNP NNP O
diagnosis NN NN O
of IN IN O
bipolar JJ JJ O
disorder NN NN O
, , , O
manic JJ JJ O
or CC CC O
mixed JJ JJ O
, , , O
were VBD VBD O
randomized VBN VBN O
to TO TO O
olanzapine VB VB B-CHEM
, , , O
5 CD CD O
to TO TO O
20 CD CD O
mg NN NN O
/ NN NN O
d SYM SYM O
( ( ( O
n NN NN O
= SYM SYM O
55 CD CD O
) ) ) O
, , , O
or CC CC O
placebo NN NN O
( ( ( O
n NN NN O
= SYM SYM O
60 CD CD O
) ) ) O
. . . O

The DT DT O
primary JJ JJ O
efficacy NN NN O
measure NN NN O
was VBD VBD O
the DT DT O
Young NNP NNP O
- - - O
Mania NNP NNP O
Rating NNP NNP O
Scale NNP NNP O
( ( ( O
Y NNP NNP O
- - - O
MRS NNP NNP O
) ) ) O
total JJ JJ O
score NN NN O
. . . O

Response NNP NNP O
and CC CC O
euthymia NN NN O
were VBD VBD O
defined VBN VBN O
, , , O
a DT DT O
priori NN NN O
, , , O
as IN IN O
at IN IN O
least JJS JJS O
a DT DT O
50 CD CD O
% NN NN O
improvement NN NN O
from IN IN O
baseline NN NN O
to TO TO O
end VB VB O
point NN NN O
and CC CC O
as IN IN O
a DT DT O
score NN NN O
of IN IN O
no DT DT O
less JJR JJR O
than IN IN O
12 CD CD O
at IN IN O
end NN NN O
point NN NN O
in IN IN O
the DT DT O
Y NNP NNP O
- - - O
MRS NNP NNP O
total JJ JJ O
score NN NN O
, , , O
respectively RB RB O
. . . O

Safety NNP NNP O
was VBD VBD O
assessed VBN VBN O
using VBG VBG O
adverse JJ JJ O
events NNS NNS O
, , , O
Extrapyramidal NNP NNP O
Symptom NNP NNP O
( ( ( O
EPS NNP NNP O
) ) ) O
rating VBG VBG O
scales NNS NNS O
, , , O
laboratory NN NN O
values NNS NNS O
, , , O
electrocardiograms NNS NNS O
, , , O
vital JJ JJ O
signs NNS NNS O
, , , O
and CC CC O
weight NN NN O
change NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Olanzapine NNP NNP B-CHEM
- - - O
treated VBN VBN O
patients NNS NNS O
demonstrated VBD VBD O
a DT DT O
statistically RB RB O
significant JJ JJ O
greater JJR JJR O
mean NN NN O
( ( ( O
+ NN NN O
/ NN NN O
- - - O
SD NNP NNP O
) ) ) O
improvement NN NN O
in IN IN O
Y NNP NNP O
- : : O
MRS NNP NNP O
total JJ JJ O
score NN NN O
than IN IN O
placebo NN NN O
- - - O
treated VBN VBN O
patients NNS NNS O
( ( ( O
- : : O
14 CD CD O
. . . O
8 CD CD O
+ NN NN O
/ NN NN O
- : : O
12 CD CD O
. . . O
5 CD CD O
and CC CC O
- : : O
8 CD CD O
. . . O
1 CD CD O
+ NN NN O
/ NN NN O
- : : O
12 CD CD O
. . . O
7 CD CD O
, , , O
respectively RB RB O
; : : O
P NN NN O
< NN NN O
. . . O
001 CD CD O
) ) ) O
, , , O
which WDT WDT O
was VBD VBD O
evident JJ JJ O
at IN IN O
the DT DT O
first JJ JJ O
postbaseline NN NN O
observation NN NN O
1 CD CD O
week NN NN O
after IN IN O
randomization NN NN O
and CC CC O
was VBD VBD O
maintained VBN VBN O
throughout IN IN O
the DT DT O
study NN NN O
( ( ( O
last JJ JJ O
observation NN NN O
carried VBD VBD O
forward RB RB O
) ) ) O
. . . O

Olanzapine NNP NNP B-CHEM
- - - O
treated VBN VBN O
patients NNS NNS O
demonstrated VBD VBD O
a DT DT O
higher JJR JJR O
rate NN NN O
of IN IN O
response NN NN O
( ( ( O
65 CD CD O
% NN NN O
vs NNS NNS O
43 CD CD O
% NN NN O
, , , O
respectively RB RB O
; : : O
P NN NN O
= SYM SYM O
. . . O
02 CD CD O
) ) ) O
and CC CC O
euthymia NN NN O
( ( ( O
61 CD CD O
% NN NN O
vs NNS NNS O
36 CD CD O
% NN NN O
, , , O
respectively RB RB O
; : : O
P NN NN O
= SYM SYM O
. . . O
01 CD CD O
) ) ) O
than IN IN O
placebo NN NN O
- - - O
treated VBN VBN O
patients NNS NNS O
. . . O

There EX EX O
were VBD VBD O
no DT DT O
statistically RB RB O
significant JJ JJ O
differences NNS NNS O
in IN IN O
EPSs NNP NNP O
between IN IN O
groups NNS NNS O
. . . O

However RB RB O
, , , O
olanzapine JJ JJ B-CHEM
- - - O
treated VBN VBN O
patients NNS NNS O
had VBD VBD O
a DT DT O
statistically RB RB O
significant JJ JJ O
greater JJR JJR O
mean NN NN O
( ( ( O
+ NN NN O
/ NN NN O
- - - O
SD NNP NNP O
) ) ) O
weight NN NN O
gain NN NN O
than IN IN O
placebo NN NN O
- - - O
treated VBN VBN O
patients NNS NNS O
( ( ( O
2 CD CD O
. . . O
1 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
. . . O
8 CD CD O
vs NNS NNS O
0 CD CD O
. . . O
45 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
. . . O
3 CD CD O
kg NN NN O
, , , O
respectively RB RB O
) ) ) O
and CC CC O
also RB RB O
experienced VBN VBN O
more RBR RBR O
treatment NN NN O
- - - O
emergent NN NN O
somnolence NN NN O
( ( ( O
21 CD CD O
patients NNS NNS O
[ NN NN O
38 CD CD O
. . . O
2 CD CD O
% NN NN O
] NN NN O
vs NN NN O
5 CD CD O
[ NN NN O
8 CD CD O
. . . O
3 CD CD O
% NN NN O
] NN NN O
, , , O
respectively RB RB O
) ) ) O
. . . O

CONCLUSION NNP NNP O
: : : O
Olanzapine NNP NNP B-CHEM
demonstrated VBD VBD O
greater JJR JJR O
efficacy NN NN O
than IN IN O
placebo NN NN O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
acute JJ JJ O
bipolar NN NN O
mania NN NN O
and CC CC O
was VBD VBD O
generally RB RB O
well RB RB O
tolerated VBN VBN O
. . . O

The DT DT O
effect NN NN O
of IN IN O
pupil NN NN O
dilation NN NN O
with IN IN O
tropicamide NN NN B-CHEM
on IN IN O
vision NN NN O
and CC CC O
driving VBG VBG O
simulator NN NN O
performance NN NN O
. . . O

PURPOSE NNP NNP O
: : : O
To TO TO O
assess VB VB O
the DT DT O
effect NN NN O
of IN IN O
pupil NN NN O
dilation NN NN O
on IN IN O
vision NN NN O
and CC CC O
driving VBG VBG O
ability NN NN O
. . . O

METHODS NNP NNP O
: : : O
A DT DT O
series NN NN O
of IN IN O
tests NNS NNS O
on IN IN O
various JJ JJ O
parameters NNS NNS O
of IN IN O
visual JJ JJ O
function NN NN O
and CC CC O
driving VBG VBG O
simulator NN NN O
performance NN NN O
were VBD VBD O
performed VBN VBN O
on IN IN O
12 CD CD O
healthy JJ JJ O
drivers NNS NNS O
, , , O
before IN IN O
and CC CC O
after IN IN O
pupil NN NN O
dilation NN NN O
using VBG VBG O
guttae NN NN O
tropicamide NN NN B-CHEM
1 CD CD O
% NN NN O
. . . O

A DT DT O
driving VBG VBG O
simulator NN NN O
( ( ( O
Transport NNP NNP O
Research NNP NNP O
Laboratory NNP NNP O
) ) ) O
was VBD VBD O
used VBN VBN O
to TO TO O
measure VB VB O
reaction NN NN O
time NN NN O
( ( ( O
RT NNP NNP O
) ) ) O
, , , O
speed NN NN O
maintenance NN NN O
and CC CC O
steering VBG VBG O
accuracy NN NN O
. . . O

Tests NNP NNP O
of IN IN O
basic JJ JJ O
visual JJ JJ O
function NN NN O
included VBN VBN O
high JJ JJ O
- - - O
and CC CC O
low JJ JJ O
- - - O
contrast NN NN O
visual JJ JJ O
acuity NN NN O
( ( ( O
HCVA NNP NNP O
and CC CC O
LCVA NNP NNP O
) ) ) O
, , , O
Pelli NNP NNP O
- : : O
Robson NNP NNP O
contrast NN NN O
threshold NN NN O
( ( ( O
CT NNP NNP O
) ) ) O
and CC CC O
Goldmann NNP NNP O
perimetry NN NN O
( ( ( O
FIELDS NNP NNP O
) ) ) O
. . . O

Useful NNP NNP O
Field NNP NNP O
of IN IN O
View NNP NNP O
( ( ( O
UFOV NNP NNP O
- - - O
- - - O
a DT DT O
test NN NN O
of IN IN O
visual JJ JJ O
attention NN NN O
) ) ) O
was VBD VBD O
also RB RB O
undertaken VBN VBN O
. . . O

The DT DT O
mean NN NN O
differences NNS NNS O
in IN IN O
the DT DT O
pre NN NN O
- - - O
and CC CC O
post NN NN O
- - - O
dilatation NN NN O
measurements NNS NNS O
were VBD VBD O
tested VBN VBN O
for IN IN O
statistical JJ JJ O
significance NN NN O
at IN IN O
the DT DT O
95 CD CD O
% NN NN O
level NN NN O
using VBG VBG O
one CD CD O
- - - O
tail NN NN O
paired VBN VBN O
t NN NN O
- - - O
tests NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
Pupillary NNP NNP O
dilation NN NN O
resulted VBD VBD O
in IN IN O
a DT DT O
statistically RB RB O
significant JJ JJ O
deterioration NN NN O
in IN IN O
CT NNP NNP O
and CC CC O
HCVA NNP NNP O
only RB RB O
. . . O

Five CD CD O
of IN IN O
12 CD CD O
drivers NNS NNS O
also RB RB O
exhibited VBN VBN O
deterioration NN NN O
in IN IN O
LCVA NNP NNP O
, , , O
CT NNP NNP O
and CC CC O
RT NNP NNP O
. . . O

Little NNP NNP O
evidence NN NN O
emerged VBD VBD O
for IN IN O
deterioration NN NN O
in IN IN O
FIELDS NNP NNP O
and CC CC O
UFOV NNP NNP O
. . . O

Also RB RB O
, , , O
7 CD CD O
of IN IN O
12 CD CD O
drivers NNS NNS O
appeared VBD VBD O
to TO TO O
adjust VB VB O
their PRP$ PRP$ O
driving VBG VBG O
behaviour NN NN O
by IN IN O
reducing VBG VBG O
their PRP$ PRP$ O
speed NN NN O
on IN IN O
the DT DT O
driving VBG VBG O
simulator NN NN O
, , , O
leading VBG VBG O
to TO TO O
improved VBN VBN O
steering VBG VBG O
accuracy NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Pupillary NNP NNP O
dilation NN NN O
may MD MD O
lead VB VB O
to TO TO O
a DT DT O
decrease NN NN O
in IN IN O
vision NN NN O
and CC CC O
daylight NN NN O
driving VBG VBG O
performance NN NN O
in IN IN O
young JJ JJ O
people NNS NNS O
. . . O

A DT DT O
larger JJR JJR O
study NN NN O
, , , O
including VBG VBG O
a DT DT O
broader JJR JJR O
spectrum NN NN O
of IN IN O
subjects NNS NNS O
, , , O
is VBZ VBZ O
warranted VBN VBN O
before IN IN O
guidelines NNS NNS O
can MD MD O
be VB VB O
recommended VBN VBN O
. . . O

A DT DT O
case NN NN O
of IN IN O
isotretinoin NN NN O
embryopathy NN NN O
with IN IN O
bilateral JJ JJ O
anotia NN NN O
and CC CC O
Taussig NNP NNP O
- : : O
Bing NNP NNP O
malformation NN NN O
. . . O

We PRP PRP O
report VBP VBP O
a DT DT O
newborn JJ JJ O
infant NN NN O
with IN IN O
multiple JJ JJ O
congenital JJ JJ O
anomalies NNS NNS O
( ( ( O
anotia NN NN O
and CC CC O
Taussig NNP NNP O
- : : O
Bing NNP NNP O
malformation NN NN O
) ) ) O
due JJ JJ O
to TO TO O
exposure VB VB O
to TO TO O
isotretinoin VB VB B-CHEM
within IN IN O
the DT DT O
first JJ JJ O
trimester NN NN O
. . . O

In IN IN O
this DT DT O
paper NN NN O
we PRP PRP O
aim VBP VBP O
to TO TO O
draw VB VB O
to TO TO O
the DT DT O
fact NN NN O
that DT DT O
caution NN NN O
is VBZ VBZ O
needed VBN VBN O
when WRB WRB O
prescribing VBG VBG O
vitamin NN NN B-CHEM
A DT DT I-CHEM
- - - O
containing VBG VBG O
drugs NNS NNS O
to TO TO O
women NNS NNS O
of IN IN O
childbearing VBG VBG O
years NNS NNS O
. . . O

Effect NN NN O
of IN IN O
methoxamine NN NN B-CHEM
on IN IN O
maximum NN NN O
urethral JJ JJ O
pressure NN NN O
in IN IN O
women NNS NNS O
with IN IN O
genuine JJ JJ O
stress NN NN O
incontinence NN NN O
: : : O
a DT DT O
placebo NN NN O
- - - O
controlled VBN VBN O
, , , O
double JJ JJ O
- - - O
blind JJ JJ O
crossover NN NN O
study NN NN O
. . . O

The DT DT O
aim NN NN O
of IN IN O
the DT DT O
study NN NN O
was VBD VBD O
to TO TO O
evaluate VB VB O
the DT DT O
potential JJ JJ O
role NN NN O
for IN IN O
a DT DT O
selective JJ JJ O
alpha1 NN NN O
- - - O
adrenoceptor NN NN O
agonist NN NN O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
urinary JJ JJ O
stress NN NN O
incontinence NN NN O
. . . O

A DT DT O
randomised VBN VBN O
, , , O
double JJ JJ O
- - - O
blind JJ JJ O
, , , O
placebo NN NN O
- - - O
controlled JJ JJ O
, , , O
crossover NN NN O
study NN NN O
design NN NN O
was VBD VBD O
employed VBN VBN O
. . . O

Half NNP NNP O
log NN NN O
incremental JJ JJ O
doses NNS NNS O
of IN IN O
intravenous JJ JJ O
methoxamine NN NN B-CHEM
or CC CC O
placebo NN NN O
( ( ( O
saline NN NN O
) ) ) O
were VBD VBD O
administered VBN VBN O
to TO TO O
a DT DT O
group NN NN O
of IN IN O
women NNS NNS O
with IN IN O
genuine JJ JJ O
stress NN NN O
incontinence NN NN O
while IN IN O
measuring VBG VBG O
maximum NN NN O
urethral JJ JJ O
pressure NN NN O
( ( ( O
MUP NNP NNP O
) ) ) O
, , , O
blood NN NN O
pressure NN NN O
, , , O
heart NN NN O
rate NN NN O
, , , O
and CC CC O
symptomatic JJ JJ O
side NN NN O
effects NNS NNS O
. . . O

Methoxamine NNP NNP B-CHEM
evoked VBD VBD O
non NN NN O
- : : O
significant JJ JJ O
increases NNS NNS O
in IN IN O
MUP NNP NNP O
and CC CC O
diastolic JJ JJ O
blood NN NN O
pressure NN NN O
but CC CC O
caused VBD VBD O
a DT DT O
significant JJ JJ O
rise NN NN O
in IN IN O
systolic JJ JJ O
blood NN NN O
pressure NN NN O
and CC CC O
significant JJ JJ O
fall NN NN O
in IN IN O
heart NN NN O
rate NN NN O
at IN IN O
maximum NN NN O
dosage NN NN O
. . . O

Systemic NNP NNP O
side NN NN O
effects NNS NNS O
including VBG VBG O
piloerection NN NN O
, , , O
headache NN NN O
, , , O
and CC CC O
cold JJ JJ O
extremities NNS NNS O
were VBD VBD O
experienced VBN VBN O
in IN IN O
all DT DT O
subjects NNS NNS O
. . . O

The DT DT O
results NNS NNS O
indicate VBP VBP O
that IN IN O
the DT DT O
clinical JJ JJ O
usefulness NN NN O
of IN IN O
direct JJ JJ O
, , , O
peripherally RB RB O
acting VBG VBG O
sub NN NN O
- - - O
type NN NN O
- - - O
selective JJ JJ O
alpha1 NN NN O
- - - O
adrenoceptor NN NN O
agonists NNS NNS O
in IN IN O
the DT DT O
medical JJ JJ O
treatment NN NN O
of IN IN O
stress NN NN O
incontinence NN NN O
may MD MD O
be VB VB O
limited JJ JJ O
by IN IN O
associated VBN VBN O
piloerection NN NN O
and CC CC O
cardiovascular JJ JJ O
side NN NN O
effects NNS NNS O
. . . O

Hyperglycemic NNP NNP O
effect NN NN O
of IN IN O
amino JJ JJ B-CHEM
compounds NNS NNS O
structurally RB RB O
related VBN VBN O
to TO TO O
caproate VB VB B-CHEM
in IN IN O
rats NNS NNS O
. . . O

The DT DT O
chronic JJ JJ O
feeding NN NN O
of IN IN O
small JJ JJ O
amounts NNS NNS O
( ( ( O
0 CD CD O
. . . O
3 CD CD O
- : : O
3 CD CD O
% NN NN O
of IN IN O
diet NN NN O
weight NN NN O
) ) ) O
of IN IN O
certain JJ JJ O
amino JJ JJ B-CHEM
derivatives NNS NNS O
of IN IN O
caproate NN NN B-CHEM
resulted VBD VBD O
in IN IN O
hyperglycemia NN NN O
, , , O
an DT DT O
elevated VBD VBD O
glucose NN NN B-CHEM
tolerance NN NN O
curve NN NN O
and CC CC O
, , , O
occasionally RB RB O
, , , O
glucosuria NN NN O
. . . O

Effective NNP NNP O
compounds NNS NNS O
included VBD VBD O
norleucine NN NN B-CHEM
, , , O
norvaline NN NN B-CHEM
, , , O
glutamate NN NN B-CHEM
, , , O
epsilon NN NN B-CHEM
- - - I-CHEM
aminocaproate NN NN I-CHEM
, , , O
methionine NN NN B-CHEM
, , , O
and CC CC O
leucine NN NN B-CHEM
. . . O

Toleration NNP NNP O
of IN IN O
high JJ JJ O
doses NNS NNS O
of IN IN O
angiotensin NN NN B-CHEM
- - - I-CHEM
converting VBG VBG I-CHEM
enzyme NN NN I-CHEM
inhibitors NNS NNS I-CHEM
in IN IN O
patients NNS NNS O
with IN IN O
chronic JJ JJ O
heart NN NN O
failure NN NN O
: : : O
results NNS NNS O
from IN IN O
the DT DT O
ATLAS NNP NNP O
trial NN NN O
. . . O

The DT DT O
Assessment NNP NNP O
of IN IN O
Treatment NN NN O
with IN IN O
Lisinopril NNP NNP B-CHEM
and CC CC O
Survival NNP NNP O
. . . O

BACKGROUND NNP NNP O
: : : O
Treatment NN NN O
with IN IN O
angiotensin NN NN B-CHEM
- - - I-CHEM
converting VBG VBG I-CHEM
enzyme NN NN I-CHEM
( ( ( I-CHEM
ACE NNP NNP I-CHEM
) ) ) I-CHEM
inhibitors NNS NNS I-CHEM
reduces VBZ VBZ O
mortality NN NN O
and CC CC O
morbidity NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
chronic JJ JJ O
heart NN NN O
failure NN NN O
( ( ( O
CHF NNP NNP O
) ) ) O
, , , O
but CC CC O
most RBS RBS O
affected VBN VBN O
patients NNS NNS O
are VBP VBP O
not RB RB O
receiving VBG VBG O
these DT DT O
agents NNS NNS O
or CC CC O
are VBP VBP O
being VBG VBG O
treated VBN VBN O
with IN IN O
doses NNS NNS O
lower JJR JJR O
than IN IN O
those DT DT O
found VBN VBN O
to TO TO O
be VB VB O
efficacious JJ JJ O
in IN IN O
trials NNS NNS O
, , , O
primarily RB RB O
because IN IN O
of IN IN O
concerns NNS NNS O
about IN IN O
the DT DT O
safety NN NN O
and CC CC O
tolerability NN NN O
of IN IN O
these DT DT O
agents NNS NNS O
, , , O
especially RB RB O
at IN IN O
the DT DT O
recommended JJ JJ O
doses NNS NNS O
. . . O

The DT DT O
present JJ JJ O
study NN NN O
examines VBZ VBZ O
the DT DT O
safety NN NN O
and CC CC O
tolerability NN NN O
of IN IN O
high JJ JJ O
- - - O
compared VBN VBN O
with IN IN O
low JJ JJ O
- - - O
dose NN NN O
lisinopril NN NN B-CHEM
in IN IN O
CHF NNP NNP O
. . . O

METHODS NNP NNP O
: : : O
The DT DT O
Assessment NNP NNP O
of IN IN O
Lisinopril NNP NNP B-CHEM
and CC CC O
Survival NNP NNP O
study NN NN O
was VBD VBD O
a DT DT O
multicenter NN NN O
, , , O
randomized JJ JJ O
, , , O
double JJ JJ O
- - - O
blind JJ JJ O
trial NN NN O
in IN IN O
which WDT WDT O
patients NNS NNS O
with IN IN O
or CC CC O
without IN IN O
previous JJ JJ O
ACE NNP NNP B-CHEM
inhibitor NN NN I-CHEM
treatment NN NN O
were VBD VBD O
stabilized VBN VBN O
receiving VBG VBG O
medium NN NN O
- - - O
dose NN NN O
lisinopril NN NN B-CHEM
( ( ( O
12 CD CD O
. . . O
5 CD CD O
or CC CC O
15 CD CD O
. . . O
0 CD CD O
mg NN NN O
once RB RB O
daily JJ JJ O
[ NN NN O
OD NNP NNP O
] NN NN O
) ) ) O
for IN IN O
2 CD CD O
to TO TO O
4 CD CD O
weeks NNS NNS O
and CC CC O
then RB RB O
randomized JJ JJ O
to TO TO O
high JJ JJ O
- - - O
( ( ( O
35 CD CD O
. . . O
0 CD CD O
or CC CC O
32 CD CD O
. . . O
5 CD CD O
mg NN NN O
OD NNP NNP O
) ) ) O
or CC CC O
low JJ JJ O
- - - O
dose NN NN O
( ( ( O
5 CD CD O
. . . O
0 CD CD O
or CC CC O
2 CD CD O
. . . O
5 CD CD O
mg NN NN O
OD NNP NNP O
) ) ) O
groups NNS NNS O
. . . O

Patients NNS NNS O
with IN IN O
New NNP NNP O
York NNP NNP O
Heart NNP NNP O
Association NNP NNP O
classes NNS NNS O
II NNP NNP O
to TO TO O
IV NNP NNP O
CHF NNP NNP O
and CC CC O
left VBD VBD O
ventricular JJ JJ O
ejection NN NN O
fractions NNS NNS O
of IN IN O
no DT DT O
greater JJR JJR O
than IN IN O
0 CD CD O
. . . O
30 CD CD O
( ( ( O
n NN NN O
= SYM SYM O
3164 CD CD O
) ) ) O
were VBD VBD O
randomized VBN VBN O
and CC CC O
followed VBN VBN O
up RP RP O
for IN IN O
a DT DT O
median NN NN O
of IN IN O
46 CD CD O
months NNS NNS O
. . . O

We PRP PRP O
examined VBD VBD O
the DT DT O
occurrence NN NN O
of IN IN O
adverse JJ JJ O
events NNS NNS O
and CC CC O
the DT DT O
need NN NN O
for IN IN O
discontinuation NN NN O
and CC CC O
dose NN NN O
reduction NN NN O
during IN IN O
treatment NN NN O
, , , O
with IN IN O
a DT DT O
focus NN NN O
on IN IN O
hypotension NN NN O
and CC CC O
renal JJ JJ O
dysfunction NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Of IN IN O
405 CD CD O
patients NNS NNS O
not RB RB O
previously RB RB O
receiving VBG VBG O
an DT DT O
ACE NNP NNP B-CHEM
inhibitor NN NN I-CHEM
, , , O
doses NNS NNS O
in IN IN O
only RB RB O
4 CD CD O
. . . O
2 CD CD O
% NN NN O
could MD MD O
not RB RB O
be VB VB O
titrated VBN VBN O
to TO TO O
the DT DT O
medium NN NN O
doses NNS NNS O
required VBN VBN O
for IN IN O
randomization NN NN O
because IN IN O
of IN IN O
symptoms NNS NNS O
possibly RB RB O
related VBN VBN O
to TO TO O
hypotension NN NN O
( ( ( O
2 CD CD O
. . . O
0 CD CD O
% NN NN O
) ) ) O
or CC CC O
because IN IN O
of IN IN O
renal JJ JJ O
dysfunction NN NN O
or CC CC O
hyperkalemia NN NN O
( ( ( O
2 CD CD O
. . . O
3 CD CD O
% NN NN O
) ) ) O
. . . O

Doses NNP NNP O
in IN IN O
more JJR JJR O
than IN IN O
90 CD CD O
% NN NN O
of IN IN O
randomized JJ JJ O
patients NNS NNS O
in IN IN O
the DT DT O
high JJ JJ O
- - - O
and CC CC O
low JJ JJ O
- - - O
dose NN NN O
groups NNS NNS O
were VBD VBD O
titrated VBN VBN O
to TO TO O
their PRP$ PRP$ O
assigned JJ JJ O
target NN NN O
, , , O
and CC CC O
the DT DT O
mean JJ JJ O
doses NNS NNS O
of IN IN O
blinded JJ JJ O
medication NN NN O
in IN IN O
both DT DT O
groups NNS NNS O
remained VBD VBD O
similar JJ JJ O
throughout IN IN O
the DT DT O
study NN NN O
. . . O

Withdrawals NNP NNP O
occurred VBD VBD O
in IN IN O
27 CD CD O
. . . O
1 CD CD O
% NN NN O
of IN IN O
the DT DT O
high JJ JJ O
- - - O
and CC CC O
30 CD CD O
. . . O
7 CD CD O
% NN NN O
of IN IN O
the DT DT O
low JJ JJ O
- - - O
dose NN NN O
groups NNS NNS O
. . . O

Subgroups NNP NNP O
presumed VBD VBD O
to TO TO O
be VB VB O
at IN IN O
higher JJR JJR O
risk NN NN O
for IN IN O
ACE NNP NNP B-CHEM
inhibitor NN NN I-CHEM
intolerance NN NN O
( ( ( O
blood NN NN O
pressure NN NN O
, , , O
< NN NN O
120 CD CD O
mm NN NN O
Hg NNP NNP O
; : : O
creatinine NN NN B-CHEM
, , , O
> NN NN O
or CC CC O
= SYM SYM O
132 CD CD O
. . . O
6 CD CD O
micromol NN NN O
/ NN NN O
L NNP NNP O
[ NN NN O
> NN NN O
or CC CC O
= SYM SYM O
1 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
dL NN NN O
] NN NN O
; : : O
age NN NN O
, , , O
> NN NN O
or CC CC O
= SYM SYM O
70 CD CD O
years NNS NNS O
; : : O
and CC CC O
patients NNS NNS O
with IN IN O
diabetes NN NN O
) ) ) O
generally RB RB O
tolerated VBN VBN O
the DT DT O
high JJ JJ O
- - - O
dose NN NN O
strategy NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
These DT DT O
findings NNS NNS O
demonstrate VBP VBP O
that IN IN O
ACE NNP NNP B-CHEM
inhibitor NN NN I-CHEM
therapy NN NN O
in IN IN O
most JJS JJS O
patients NNS NNS O
with IN IN O
CHF NNP NNP O
can MD MD O
be VB VB O
successfully RB RB O
titrated VBN VBN O
to TO TO O
and CC CC O
maintained VBN VBN O
at IN IN O
high JJ JJ O
doses NNS NNS O
, , , O
and CC CC O
that IN IN O
more RBR RBR O
aggressive JJ JJ O
use NN NN O
of IN IN O
these DT DT O
agents NNS NNS O
is VBZ VBZ O
warranted VBN VBN O
. . . O

Cocaine NNP NNP B-CHEM
, , , O
ethanol NN NN B-CHEM
, , , O
and CC CC O
cocaethylene NN NN B-CHEM
cardiotoxity NN NN O
in IN IN O
an DT DT O
animal NN NN O
model NN NN O
of IN IN O
cocaine NN NN O
and CC CC O
ethanol NN NN O
abuse NN NN O
. . . O

OBJECTIVES NNP NNP O
: : : O
Simultaneous NNP NNP O
abuse NN NN O
of IN IN O
cocaine NN NN O
and CC CC O
ethanol NN NN O
affects VBZ VBZ O
12 CD CD O
million CD CD O
Americans NNPS NNPS O
annually RB RB O
. . . O

In IN IN O
combination NN NN O
, , , O
these DT DT O
substances NNS NNS O
are VBP VBP O
substantially RB RB O
more RBR RBR O
toxic JJ JJ O
than IN IN O
either DT DT O
drug NN NN O
alone RB RB O
. . . O

Their PRP$ PRP$ O
combined JJ JJ O
cardiac JJ JJ O
toxicity NN NN O
may MD MD O
be VB VB O
due JJ JJ O
to TO TO O
independent JJ JJ O
effects NNS NNS O
of IN IN O
each DT DT O
drug NN NN O
; : : O
however RB RB O
, , , O
they PRP PRP O
may MD MD O
also RB RB O
be VB VB O
due JJ JJ O
to TO TO O
cocaethylene VB VB B-CHEM
( ( ( O
CE NNP NNP B-CHEM
) ) ) O
, , , O
a DT DT O
cocaine NN NN B-CHEM
metabolite NN NN O
formed VBD VBD O
only RB RB O
in IN IN O
the DT DT O
presence NN NN O
of IN IN O
ethanol NN NN B-CHEM
. . . O

The DT DT O
purpose NN NN O
of IN IN O
this DT DT O
study NN NN O
was VBD VBD O
to TO TO O
delineate VB VB O
the DT DT O
role NN NN O
of IN IN O
CE NNP NNP B-CHEM
in IN IN O
the DT DT O
combined JJ JJ O
cardiotoxicity NN NN O
of IN IN O
cocaine NN NN B-CHEM
and CC CC O
ethanol NN NN B-CHEM
in IN IN O
a DT DT O
model NN NN O
simulating VBG VBG O
their PRP$ PRP$ O
abuse NN NN O
. . . O

METHODS NNP NNP O
: : : O
Twenty CD CD O
- - - O
three CD CD O
dogs NNS NNS O
were VBD VBD O
randomized VBN VBN O
to TO TO O
receive VB VB O
either CC CC O
1 CD CD O
) ) ) O
three CD CD O
intravenous JJ JJ O
( ( ( O
IV NNP NNP O
) ) ) O
boluses NNS NNS O
of IN IN O
cocaine NN NN B-CHEM
7 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
with IN IN O
ethanol NN NN B-CHEM
( ( ( O
1 CD CD O
g SYM SYM O
/ NN NN O
kg NN NN O
) ) ) O
as IN IN O
an DT DT O
IV NNP NNP O
infusion NN NN O
( ( ( O
C NNP NNP O
+ NN NN O
E NNP NNP O
, , , O
n NN NN O
= SYM SYM O
8 CD CD O
) ) ) O
, , , O
2 CD CD O
) ) ) O
three CD CD O
cocaine NN NN B-CHEM
boluses NNS NNS O
only RB RB O
( ( ( O
C NNP NNP O
, , , O
n NN NN O
= SYM SYM O
6 CD CD O
) ) ) O
, , , O
3 CD CD O
) ) ) O
ethanol NN NN B-CHEM
infusion NN NN O
only RB RB O
( ( ( O
E NNP NNP O
, , , O
n NN NN O
= SYM SYM O
5 CD CD O
) ) ) O
, , , O
or CC CC O
4 CD CD O
) ) ) O
placebo NN NN O
boluses NNS NNS O
and CC CC O
infusion NN NN O
( ( ( O
n NN NN O
= SYM SYM O
4 CD CD O
) ) ) O
. . . O

Hemodynamic NNP NNP O
measurements NNS NNS O
, , , O
electrocardiograms NNS NNS O
, , , O
and CC CC O
serum NN NN O
drug NN NN O
concentrations NNS NNS O
were VBD VBD O
obtained VBN VBN O
at IN IN O
baseline NN NN O
, , , O
and CC CC O
then RB RB O
at IN IN O
fixed VBN VBN O
time NN NN O
intervals NNS NNS O
after IN IN O
each DT DT O
drug NN NN O
was VBD VBD O
administered VBN VBN O
. . . O

RESULTS NNS NNS O
: : : O
Two CD CD O
of IN IN O
eight CD CD O
dogs NNS NNS O
in IN IN O
the DT DT O
C NNP NNP O
+ NN NN O
E NNP NNP O
group NN NN O
experienced VBN VBN O
cardiovascular JJ JJ O
collapse NN NN O
. . . O

The DT DT O
most RBS RBS O
dramatic JJ JJ O
hemodynamic JJ JJ O
changes NNS NNS O
occurred VBD VBD O
after IN IN O
each DT DT O
cocaine NN NN B-CHEM
bolus NN NN O
in IN IN O
the DT DT O
C NNP NNP O
+ NN NN O
E NNP NNP O
and CC CC O
C NNP NNP O
only RB RB O
groups NNS NNS O
; : : O
however RB RB O
, , , O
persistent JJ JJ O
hemodynamic JJ JJ O
changes NNS NNS O
occurred VBD VBD O
in IN IN O
the DT DT O
C NNP NNP O
+ NN NN O
E NNP NNP O
group NN NN O
. . . O

Peak NNP NNP O
CE NNP NNP B-CHEM
levels NNS NNS O
were VBD VBD O
associated VBN VBN O
with IN IN O
a DT DT O
45 CD CD O
% NN NN O
( ( ( O
SD NNP NNP O
+ NN NN O
/ NN NN O
- : : O
22 CD CD O
% NN NN O
, , , O
95 CD CD O
% NN NN O
CI NNP NNP O
= SYM SYM O
22 CD CD O
% NN NN O
to TO TO O
69 CD CD O
% NN NN O
) ) ) O
decrease NN NN O
in IN IN O
cardiac JJ JJ O
output NN NN O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
, , , O
a DT DT O
56 CD CD O
% NN NN O
( ( ( O
SD NNP NNP O
+ NN NN O
/ NN NN O
- : : O
23 CD CD O
% NN NN O
, , , O
95 CD CD O
% NN NN O
CI NNP NNP O
= SYM SYM O
32 CD CD O
% NN NN O
to TO TO O
80 CD CD O
% NN NN O
) ) ) O
decrease NN NN O
in IN IN O
dP NN NN O
/ NN NN O
dt NN NN O
( ( ( O
max NN NN O
) ) ) O
( ( ( O
p NN NN O
< NN NN O
. . . O
006 CD CD O
) ) ) O
, , , O
and CC CC O
a DT DT O
23 CD CD O
% NN NN O
( ( ( O
SD NNP NNP O
+ NN NN O
/ NN NN O
- : : O
15 CD CD O
% NN NN O
, , , O
95 CD CD O
% NN NN O
CI NNP NNP O
= SYM SYM O
7 CD CD O
% NN NN O
to TO TO O
49 CD CD O
% NN NN O
) ) ) O
decrease NN NN O
in IN IN O
SVO NNP NNP O
( ( ( O
2 CD CD O
) ) ) O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
025 CD CD O
) ) ) O
. . . O

Ventricular NNP NNP O
arrhythmias NNS NNS O
were VBD VBD O
primarily RB RB O
observed VBN VBN O
in IN IN O
the DT DT O
C NNP NNP O
+ NN NN O
E NNP NNP O
group NN NN O
, , , O
in IN IN O
which WDT WDT O
four CD CD O
of IN IN O
eight CD CD O
dogs NNS NNS O
experienced VBN VBN O
ventricular NN NN O
tachycardia NNS NNS O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Cocaine NNP NNP B-CHEM
and CC CC O
ethanol NN NN B-CHEM
in IN IN O
combination NN NN O
were VBD VBD O
more RBR RBR O
toxic JJ JJ O
than IN IN O
either DT DT O
substance NN NN O
alone RB RB O
. . . O

Co NNP NNP O
- - - O
administration NN NN O
resulted VBD VBD O
in IN IN O
prolonged JJ JJ O
cardiac NN NN O
toxicity NN NN O
and CC CC O
was VBD VBD O
dysrhythmogenic JJ JJ O
. . . O

Peak NNP NNP O
serum NN NN O
cocaethylene NN NN B-CHEM
concentrations NNS NNS O
were VBD VBD O
associated VBN VBN O
with IN IN O
prolonged JJ JJ O
myocardial NN NN O
depression NN NN O
. . . O

Worsening NNP NNP O
of IN IN O
Parkinsonism NNP NNP O
after IN IN O
the DT DT O
use NN NN O
of IN IN O
veralipride NN NN B-CHEM
for IN IN O
treatment NN NN O
of IN IN O
menopause NN NN O
: : : O
case NN NN O
report NN NN O
. . . O

We PRP PRP O
describe VBP VBP O
a DT DT O
female JJ JJ O
patient NN NN O
with IN IN O
stable JJ JJ O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
who WP WP O
has VBZ VBZ O
shown VBN VBN O
a DT DT O
marked VBN VBN O
worsening NN NN O
of IN IN O
her PRP$ PRP$ O
motor NN NN O
functions NNS NNS O
following VBG VBG O
therapy NN NN O
of IN IN O
menopause NN NN O
related VBN VBN O
symptoms NNS NNS O
with IN IN O
veralipride NN NN B-CHEM
, , , O
as RB RB O
well RB RB O
as IN IN O
the DT DT O
improvement NN NN O
of IN IN O
her PRP$ PRP$ O
symptoms NNS NNS O
back RB RB O
to TO TO O
baseline VB VB O
after IN IN O
discontinuation NN NN O
of IN IN O
the DT DT O
drug NN NN O
. . . O

We PRP PRP O
emphasize VBP VBP O
the DT DT O
anti JJ JJ O
- : : O
dopaminergic JJ JJ O
effect NN NN O
of IN IN O
veralipride NN NN B-CHEM
. . . O

Viracept NNP NNP B-CHEM
and CC CC O
irregular JJ JJ O
heartbeat NN NN O
warning NN NN O
. . . O

A DT DT O
group NN NN O
of IN IN O
doctors NNS NNS O
in IN IN O
Boston NNP NNP O
warn NN NN O
that IN IN O
the DT DT O
protease NN NN O
inhibitor NN NN O
Viracept NNP NNP B-CHEM
may MD MD O
cause VB VB O
an DT DT O
irregular JJ JJ O
heart NN NN O
beat NN NN O
, , , O
known VBN VBN O
as IN IN O
bradycardia NN NN O
, , , O
in IN IN O
people NNS NNS O
with IN IN O
HIV NNP NNP O
. . . O

Bradycardia NNP NNP O
occurred VBD VBD O
in IN IN O
a DT DT O
45 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
male JJ JJ O
patient NN NN O
who WP WP O
was VBD VBD O
Viracept NNP NNP B-CHEM
in IN IN O
combination NN NN O
with IN IN O
other JJ JJ O
anti JJ JJ O
- : : O
HIV NNP NNP O
drugs NNS NNS O
. . . O

The DT DT O
symptoms NNS NNS O
ceased VBN VBN O
after IN IN O
switching VBG VBG O
to TO TO O
another DT DT O
drug NN NN O
combination NN NN O
. . . O

Frequency NNP NNP O
of IN IN O
appearance NN NN O
of IN IN O
myeloperoxidase NN NN O
- - - O
antineutrophil NN NN O
cytoplasmic JJ JJ O
antibody NN NN O
( ( ( O
MPO NNP NNP O
- - - O
ANCA NNP NNP O
) ) ) O
in IN IN O
Graves NNP NNP O
' POS POS O
disease NN NN O
patients NNS NNS O
treated VBN VBN O
with IN IN O
propylthiouracil NN NN B-CHEM
and CC CC O
the DT DT O
relationship NN NN O
between IN IN O
MPO NNP NNP O
- : : O
ANCA NNP NNP O
and CC CC O
clinical JJ JJ O
manifestations NNS NNS O
. . . O

OBJECTIVE NNP NNP O
: : : O
Myeloperoxidase NNP NNP O
antineutrophil NN NN O
cytoplasmic JJ JJ O
antibody NN NN O
( ( ( O
MPO NNP NNP O
- - - O
ANCA NNP NNP O
) ) ) O
- : : O
positive JJ JJ O
vasculitis NN NN O
has VBZ VBZ O
been VBN VBN O
reported VBN VBN O
in IN IN O
patients NNS NNS O
with IN IN O
Graves NNP NNP O
' POS POS O
disease NN NN O
who WP WP O
were VBD VBD O
treated VBN VBN O
with IN IN O
propylthiouracil NN NN B-CHEM
( ( ( O
PTU NNP NNP B-CHEM
) ) ) O
. . . O

The DT DT O
appearance NN NN O
of IN IN O
MPO NNP NNP O
- : : O
ANCA NNP NNP O
in IN IN O
these DT DT O
cases NNS NNS O
was VBD VBD O
suspected VBN VBN O
of IN IN O
being VBG VBG O
related VBN VBN O
to TO TO O
PTU NNP NNP B-CHEM
because IN IN O
the DT DT O
titres NNS NNS O
of IN IN O
MPO NNP NNP O
- : : O
ANCA NNP NNP O
decreased VBD VBD O
when WRB WRB O
PTU NNP NNP B-CHEM
was VBD VBD O
stopped VBN VBN O
. . . O

Nevertheless RB RB O
, , , O
there EX EX O
have VBP VBP O
been VBN VBN O
no DT DT O
studies NNS NNS O
on IN IN O
the DT DT O
temporal JJ JJ O
relationship NN NN O
between IN IN O
the DT DT O
appearance NN NN O
of IN IN O
MPO NNP NNP O
- : : O
ANCA NNP NNP O
and CC CC O
vasculitis NN NN O
during IN IN O
PTU NNP NNP B-CHEM
therapy NN NN O
, , , O
or CC CC O
on IN IN O
the DT DT O
incidence NN NN O
of IN IN O
MPO NNP NNP O
- : : O
ANCA NNP NNP O
in IN IN O
untreated JJ JJ O
Graves NNP NNP O
' POS POS O
disease NN NN O
patients NNS NNS O
. . . O

Therefore RB RB O
, , , O
we PRP PRP O
sought VBD VBD O
to TO TO O
address VB VB O
these DT DT O
parameters NNS NNS O
in IN IN O
patients NNS NNS O
with IN IN O
Graves NNP NNP O
' POS POS O
disease NN NN O
. . . O

PATIENTS NNS NNS O
: : : O
We PRP PRP O
investigated VBD VBD O
102 CD CD O
untreated JJ JJ O
patients NNS NNS O
with IN IN O
hyperthyroidism NN NN O
due JJ JJ O
to TO TO O
Graves NNP NNP O
' POS POS O
disease NN NN O
for IN IN O
the DT DT O
presence NN NN O
of IN IN O
MPO NNP NNP O
- : : O
ANCA NNP NNP O
, , , O
and CC CC O
for IN IN O
the DT DT O
development NN NN O
vasculitis NN NN O
after IN IN O
starting VBG VBG O
PTU NNP NNP B-CHEM
therapy NN NN O
. . . O

Twenty CD CD O
- - - O
nine CD CD O
of IN IN O
them PRP PRP O
were VBD VBD O
later RB RB O
excluded VBN VBN O
because IN IN O
of IN IN O
adverse JJ JJ O
effects NNS NNS O
of IN IN O
PTU NNP NNP B-CHEM
or CC CC O
because IN IN O
the DT DT O
observation NN NN O
period NN NN O
was VBD VBD O
less JJR JJR O
than IN IN O
3 CD CD O
months NNS NNS O
. . . O

The DT DT O
remaining VBG VBG O
73 CD CD O
patients NNS NNS O
( ( ( O
55 CD CD O
women NNS NNS O
and CC CC O
18 CD CD O
men NNS NNS O
) ) ) O
, , , O
all DT DT O
of IN IN O
whom WP WP O
were VBD VBD O
examined VBN VBN O
for IN IN O
more JJR JJR O
than IN IN O
3 CD CD O
months NNS NNS O
, , , O
were VBD VBD O
adopted VBN VBN O
as IN IN O
the DT DT O
subjects NNS NNS O
of IN IN O
the DT DT O
investigation NN NN O
. . . O

The DT DT O
median JJ JJ O
observation NN NN O
period NN NN O
was VBD VBD O
23 CD CD O
. . . O
6 CD CD O
months NNS NNS O
( ( ( O
range NN NN O
: : : O
3 CD CD O
- : : O
37 CD CD O
months NNS NNS O
) ) ) O
. . . O

MEASUREMENTS NNP NNP O
: : : O
MPO NNP NNP O
- - - O
ANCA NNP NNP O
was VBD VBD O
measured VBN VBN O
at IN IN O
intervals NNS NNS O
of IN IN O
2 CD CD O
- : : O
6 CD CD O
months NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
Before IN IN O
treatment NN NN O
, , , O
the DT DT O
MPO NNP NNP O
- - - O
ANCA NNP NNP O
titres NNS NNS O
of IN IN O
all DT DT O
102 CD CD O
untreated JJ JJ O
Graves NNP NNP O
' POS POS O
disease NN NN O
patients NNS NNS O
were VBD VBD O
within IN IN O
the DT DT O
reference NN NN O
range NN NN O
( ( ( O
below IN IN O
10 CD CD O
U NNP NNP O
/ NN NN O
ml NN NN O
) ) ) O
. . . O

Three CD CD O
( ( ( O
4 CD CD O
. . . O
1 CD CD O
% NN NN O
) ) ) O
of IN IN O
the DT DT O
73 CD CD O
patients NNS NNS O
were VBD VBD O
positive JJ JJ O
for IN IN O
MPO NNP NNP O
- : : O
ANCA NNP NNP O
at IN IN O
13 CD CD O
, , , O
16 CD CD O
and CC CC O
17 CD CD O
months NNS NNS O
, , , O
respectively RB RB O
, , , O
after IN IN O
the DT DT O
start NN NN O
of IN IN O
PTU NNP NNP B-CHEM
therapy NN NN O
. . . O

In IN IN O
two CD CD O
of IN IN O
them PRP PRP O
, , , O
the DT DT O
MPO NNP NNP O
- - - O
ANCA NNP NNP O
titres NNS NNS O
transiently RB RB O
increased VBN VBN O
to TO TO O
12 CD CD O
. . . O
8 CD CD O
and CC CC O
15 CD CD O
. . . O
0 CD CD O
U NNP NNP O
/ NN NN O
ml NN NN O
, , , O
respectively RB RB O
, , , O
despite IN IN O
continued VBD VBD O
PTU NNP NNP B-CHEM
therapy NN NN O
, , , O
but CC CC O
no DT DT O
vasculitic JJ JJ O
disorders NNS NNS O
developed VBD VBD O
. . . O

In IN IN O
the DT DT O
third JJ JJ O
patient NN NN O
, , , O
the DT DT O
MPO NNP NNP O
- - - O
ANCA NNP NNP O
titre NNS NNS O
increased VBN VBN O
to TO TO O
204 CD CD O
U NNP NNP O
/ NN NN O
ml NN NN O
and CC CC O
she PRP PRP O
developed VBD VBD O
a DT DT O
higher JJR JJR O
fever NN NN O
, , , O
oral JJ JJ O
ulcers NNS NNS O
and CC CC O
polyarthralgia NN NN O
, , , O
but CC CC O
the DT DT O
symptoms NNS NNS O
resolved VBD VBD O
2 CD CD O
weeks NNS NNS O
after IN IN O
stopping VBG VBG O
PTU NNP NNP B-CHEM
therapy NN NN O
, , , O
and CC CC O
the DT DT O
MPO NNP NNP O
- - - O
ANCA NNP NNP O
titre NN NN O
decreased VBD VBD O
to TO TO O
20 CD CD O
. . . O
7 CD CD O
U NNP NNP O
/ NN NN O
ml NN NN O
by IN IN O
4 CD CD O
months NNS NNS O
after IN IN O
discontinuing VBG VBG O
PTU NNP NNP B-CHEM
. . . O

CONCLUSIONS NNP NNP O
: : : O
PTU NNP NNP B-CHEM
therapy NN NN O
may MD MD O
be VB VB O
related VBN VBN O
to TO TO O
the DT DT O
appearance NN NN O
of IN IN O
MPO NNP NNP O
- : : O
ANCA NNP NNP O
, , , O
but CC CC O
MPO NNP NNP O
- : : O
ANCA NNP NNP O
does VBZ VBZ O
not RB RB O
appear VB VB O
to TO TO O
be VB VB O
closely RB RB O
related VBN VBN O
to TO TO O
vasculitis NNS NNS O
. . . O

Prevalence NNP NNP O
of IN IN O
heart NN NN O
disease NN NN O
in IN IN O
asymptomatic JJ JJ O
chronic JJ JJ O
cocaine NN NN B-CHEM
users NNS NNS O
. . . O

To TO TO O
determine VB VB O
the DT DT O
prevalence NN NN O
of IN IN O
heart NN NN O
disease NN NN O
in IN IN O
outpatient JJ JJ O
young JJ JJ O
asymptomatic JJ JJ O
chronic JJ JJ O
cocaine NN NN B-CHEM
users NNS NNS O
, , , O
35 CD CD O
cocaine NN NN B-CHEM
users NNS NNS O
and CC CC O
32 CD CD O
age NN NN O
- : : O
matched JJ JJ O
controls NNS NNS O
underwent JJ JJ O
resting NN NN O
and CC CC O
exercise NN NN O
electrocardiography NN NN O
( ( ( O
ECG NNP NNP O
) ) ) O
and CC CC O
Doppler NNP NNP O
echocardiography NN NN O
. . . O

Findings NNS NNS O
consistent JJ JJ O
with IN IN O
coronary JJ JJ O
artery NN NN O
disease NN NN O
were VBD VBD O
detected VBN VBN O
in IN IN O
12 CD CD O
( ( ( O
34 CD CD O
% NN NN O
) ) ) O
patients NNS NNS O
and CC CC O
3 CD CD O
( ( ( O
9 CD CD O
% NN NN O
) ) ) O
controls NNS NNS O
( ( ( O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
. . . O

Decreased NNP NNP O
left VBD VBD O
ventricular NN NN O
systolic JJ JJ O
function NN NN O
was VBD VBD O
demonstrated VBN VBN O
in IN IN O
5 CD CD O
( ( ( O
14 CD CD O
% NN NN O
) ) ) O
patients NNS NNS O
, , , O
but CC CC O
in IN IN O
none NN NN O
of IN IN O
the DT DT O
controls NNS NNS O
( ( ( O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
055 CD CD O
) ) ) O
. . . O

Finally RB RB O
, , , O
resting VBG VBG O
and CC CC O
peak NN NN O
exercise NN NN O
abnormal NN NN O
left VBD VBD O
ventricular NN NN O
filling VBG VBG O
was VBD VBD O
detected VBN VBN O
in IN IN O
38 CD CD O
and CC CC O
35 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
as IN IN O
compared VBN VBN O
to TO TO O
19 CD CD O
and CC CC O
9 CD CD O
% NN NN O
of IN IN O
controls NNS NNS O
, , , O
respectively RB RB O
( ( ( O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
11 CD CD O
and CC CC O
0 CD CD O
. . . O
02 CD CD O
, , , O
respectively RB RB O
) ) ) O
. . . O

We PRP PRP O
conclude VBP VBP O
that IN IN O
coronary JJ JJ O
artery NN NN O
or CC CC O
myocardial NN NN O
disease NN NN O
is VBZ VBZ O
common JJ JJ O
( ( ( O
38 CD CD O
% NN NN O
) ) ) O
in IN IN O
young JJ JJ O
asymptomatic JJ JJ O
chronic JJ JJ O
cocaine NN NN B-CHEM
users NNS NNS O
. . . O

Therefore RB RB O
, , , O
screening VBG VBG O
ECG NNP NNP O
and CC CC O
echocardiography NN NN O
may MD MD O
be VB VB O
warranted VBN VBN O
in IN IN O
these DT DT O
patients NNS NNS O
. . . O

Cardioprotective NNP NNP O
effects NNS NNS O
of IN IN O
Picrorrhiza NNP NNP O
kurroa NN NN O
against IN IN O
isoproterenol NN NN B-CHEM
- - - O
induced JJ JJ O
myocardial NN NN O
stress NN NN O
in IN IN O
rats NNS NNS O
. . . O

The DT DT O
cardioprotective JJ JJ O
effect NN NN O
of IN IN O
the DT DT O
ethanol NN NN B-CHEM
extract NN NN O
of IN IN O
Picrorrhiza NNP NNP O
kurroa NN NN O
rhizomes NNS NNS O
and CC CC O
roots NNS NNS O
( ( ( O
PK NNP NNP O
) ) ) O
on IN IN O
isoproterenol NN NN B-CHEM
- : : O
induced JJ JJ O
myocardial NN NN O
infarction NN NN O
in IN IN O
rats NNS NNS O
with IN IN O
respect NN NN O
to TO TO O
lipid VB VB O
metabolism NN NN O
in IN IN O
serum NN NN O
and CC CC O
heart NN NN O
tissue NN NN O
has VBZ VBZ O
been VBN VBN O
investigated VBN VBN O
. . . O

Oral NNP NNP O
pre NN NN O
- : : O
treatment NN NN O
with IN IN O
PK NNP NNP O
( ( ( O
80 CD CD O
mg NN NN O
kg NN NN O
( ( ( O
- : : O
1 CD CD O
) ) ) O
day NN NN O
( ( ( O
- : : O
1 CD CD O
) ) ) O
for IN IN O
15 CD CD O
days NNS NNS O
) ) ) O
significantly RB RB O
prevented VBD VBD O
the DT DT O
isoproterenol NN NN B-CHEM
- - - O
induced JJ JJ O
myocardial NN NN O
infarction NN NN O
and CC CC O
maintained VBD VBD O
the DT DT O
rats NNS NNS O
at IN IN O
near IN IN O
normal JJ JJ O
status NN NN O
. . . O

Phase NN NN O
2 CD CD O
early JJ JJ O
afterdepolarization NN NN O
as IN IN O
a DT DT O
trigger NN NN O
of IN IN O
polymorphic JJ JJ O
ventricular NN NN O
tachycardia NNS NNS O
in IN IN O
acquired VBN VBN O
long JJ JJ O
- - - O
QT NNP NNP O
syndrome NN NN O
: : : O
direct JJ JJ O
evidence NN NN O
from IN IN O
intracellular JJ JJ O
recordings NNS NNS O
in IN IN O
the DT DT O
intact NN NN O
left VBD VBD O
ventricular JJ JJ O
wall NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
This DT DT O
study NN NN O
examined VBD VBD O
the DT DT O
role NN NN O
of IN IN O
phase NN NN O
2 CD CD O
early JJ JJ O
afterdepolarization NN NN O
( ( ( O
EAD NNP NNP O
) ) ) O
in IN IN O
producing VBG VBG O
a DT DT O
trigger NN NN O
to TO TO O
initiate VB VB O
torsade NN NN O
de IN IN O
pointes NNS NNS O
( ( ( O
TdP NNP NNP O
) ) ) O
with IN IN O
QT NNP NNP O
prolongation NN NN O
induced VBN VBN O
by IN IN O
dl NN NN O
- : : O
sotalol NN NN B-CHEM
and CC CC O
azimilide NN NN B-CHEM
. . . O

The DT DT O
contribution NN NN O
of IN IN O
transmural JJ JJ O
dispersion NN NN O
of IN IN O
repolarization NN NN O
( ( ( O
TDR NNP NNP O
) ) ) O
to TO TO O
transmural JJ JJ O
propagation NN NN O
of IN IN O
EAD NNP NNP O
and CC CC O
the DT DT O
maintenance NN NN O
of IN IN O
TdP NNP NNP O
was VBD VBD O
also RB RB O
evaluated VBN VBN O
. . . O

METHODS NNP NNP O
AND CC CC O
RESULTS NNS NNS O
: : : O
Transmembrane NNP NNP O
action NN NN O
potentials NNS NNS O
from IN IN O
epicardium NN NN O
, , , O
midmyocardium NN NN O
, , , O
and CC CC O
endocardium NN NN O
were VBD VBD O
recorded VBN VBN O
simultaneously RB RB O
, , , O
together RB RB O
with IN IN O
a DT DT O
transmural JJ JJ O
ECG NNP NNP O
, , , O
in IN IN O
arterially RB RB O
perfused VBN VBN O
canine NN NN O
and CC CC O
rabbit NN NN O
left VBD VBD O
ventricular JJ JJ O
preparations NNS NNS O
. . . O

dl NN NN O
- : : O
Sotalol NNP NNP B-CHEM
preferentially RB RB O
prolonged JJ JJ O
action NN NN O
potential JJ JJ O
duration NN NN O
( ( ( O
APD NNP NNP O
) ) ) O
in IN IN O
M NNP NNP O
cells NNS NNS O
dose RB RB O
- : : O
dependently RB RB O
( ( ( O
1 CD CD O
to TO TO O
100 CD CD O
micromol NN NN O
/ NN NN O
L NNP NNP O
) ) ) O
, , , O
leading VBG VBG O
to TO TO O
QT NNP NNP O
prolongation NN NN O
and CC CC O
an DT DT O
increase NN NN O
in IN IN O
TDR NNP NNP O
. . . O

Azimilide NNP NNP B-CHEM
, , , O
however RB RB O
, , , O
significantly RB RB O
prolonged JJ JJ O
APD NNP NNP O
and CC CC O
QT NNP NNP O
interval NN NN O
at IN IN O
concentrations NNS NNS O
from IN IN O
0 CD CD O
. . . O
1 CD CD O
to TO TO O
10 CD CD O
micromol NN NN O
/ NN NN O
L NNP NNP O
but CC CC O
shortened VBD VBD O
them PRP PRP O
at IN IN O
30 CD CD O
micromol NN NN O
/ NN NN O
L NNP NNP O
. . . O

Unlike IN IN O
dl NN NN O
- - - O
sotalol NN NN B-CHEM
, , , O
azimilide IN IN B-CHEM
( ( ( O
> NN NN O
3 CD CD O
micromol NN NN O
/ NN NN O
L NNP NNP O
) ) ) O
increased VBN VBN O
epicardial JJ JJ O
APD NNP NNP O
markedly RB RB O
, , , O
causing VBG VBG O
a DT DT O
diminished JJ JJ O
TDR NNP NNP O
. . . O

Although IN IN O
both DT DT O
dl NN NN O
- - - O
sotalol NN NN B-CHEM
and CC CC O
azimilide NN NN B-CHEM
rarely RB RB O
induced VBD VBD O
EADs NNP NNP O
in IN IN O
canine NN NN O
left VBD VBD O
ventricles NNS NNS O
, , , O
they PRP PRP O
produced VBD VBD O
frequent JJ JJ O
EADs NNP NNP O
in IN IN O
rabbits NNS NNS O
, , , O
in IN IN O
which WDT WDT O
more RBR RBR O
pronounced JJ JJ O
QT NNP NNP O
prolongation NN NN O
was VBD VBD O
seen VBN VBN O
. . . O

An DT DT O
increase NN NN O
in IN IN O
TDR NNP NNP O
by IN IN O
dl NN NN O
- - - O
sotalol NN NN B-CHEM
facilitated VBD VBD O
transmural JJ JJ O
propagation NN NN O
of IN IN O
EADs NNP NNP O
that WDT WDT O
initiated JJ JJ O
multiple JJ JJ O
episodes NNS NNS O
of IN IN O
spontaneous JJ JJ O
TdP NNP NNP O
in IN IN O
3 CD CD O
of IN IN O
6 CD CD O
rabbit NN NN O
left VBD VBD O
ventricles NNS NNS O
. . . O

Of IN IN O
note NN NN O
, , , O
although IN IN O
azimilide NN NN B-CHEM
( ( ( O
3 CD CD O
to TO TO O
10 CD CD O
micromol NN NN O
/ NN NN O
L NNP NNP O
) ) ) O
increased VBN VBN O
APD NNP NNP O
more JJR JJR O
than IN IN O
dl NN NN O
- - - O
sotalol NN NN B-CHEM
, , , O
its PRP$ PRP$ O
EADs NNP NNP O
often RB RB O
failed VBD VBD O
to TO TO O
propagate VB VB O
transmurally RB RB O
, , , O
probably RB RB O
because IN IN O
of IN IN O
a DT DT O
diminished JJ JJ O
TDR NNP NNP O
. . . O

CONCLUSIONS NNP NNP O
: : : O
This DT DT O
study NN NN O
provides VBZ VBZ O
the DT DT O
first JJ JJ O
direct JJ JJ O
evidence NN NN O
from IN IN O
intracellular JJ JJ O
action NN NN O
potential JJ JJ O
recordings NNS NNS O
that WDT WDT O
phase NN NN O
2 CD CD O
EAD NNP NNP O
can MD MD O
be VB VB O
generated VBN VBN O
from IN IN O
intact JJ JJ O
ventricular JJ JJ O
wall NN NN O
and CC CC O
produce VB VB O
a DT DT O
trigger NN NN O
to TO TO O
initiate VB VB O
the DT DT O
onset NN NN O
of IN IN O
TdP NNP NNP O
under IN IN O
QT NNP NNP O
prolongation NN NN O
. . . O

A DT DT O
pilot NN NN O
study NN NN O
to TO TO O
assess VB VB O
the DT DT O
safety NN NN O
of IN IN O
dobutamine NN NN B-CHEM
stress NN NN O
echocardiography NN NN O
in IN IN O
the DT DT O
emergency NN NN O
department NN NN O
evaluation NN NN O
of IN IN O
cocaine NN NN B-CHEM
- - - O
associated JJ JJ O
chest NN NN O
pain NN NN O
. . . O

STUDY NNP NNP O
OBJECTIVE NNP NNP O
: : : O
Chest NN NN O
pain NN NN O
in IN IN O
the DT DT O
setting VBG VBG O
of IN IN O
cocaine NN NN B-CHEM
use NN NN O
poses VBZ VBZ O
a DT DT O
diagnostic JJ JJ O
dilemma NN NN O
. . . O

Dobutamine NNP NNP B-CHEM
stress NN NN O
echocardiography NN NN O
( ( ( O
DSE NNP NNP O
) ) ) O
is VBZ VBZ O
a DT DT O
widely RB RB O
available JJ JJ O
and CC CC O
sensitive JJ JJ O
test NN NN O
for IN IN O
evaluating VBG VBG O
cardiac NN NN O
ischemia NN NN O
. . . O

Because IN IN O
of IN IN O
the DT DT O
theoretical JJ JJ O
concern NN NN O
regarding VBG VBG O
administration NN NN O
of IN IN O
dobutamine NN NN B-CHEM
in IN IN O
the DT DT O
setting VBG VBG O
of IN IN O
cocaine NN NN B-CHEM
use NN NN O
, , , O
we PRP PRP O
conducted VBD VBD O
a DT DT O
pilot NN NN O
study NN NN O
to TO TO O
assess VB VB O
the DT DT O
safety NN NN O
of IN IN O
DSE NNP NNP O
in IN IN O
emergency NN NN O
department NN NN O
patients NNS NNS O
with IN IN O
cocaine NN NN B-CHEM
- - - O
associated JJ JJ O
chest NN NN O
pain NN NN O
. . . O

METHODS NNP NNP O
: : : O
A DT DT O
prospective JJ JJ O
case NN NN O
series NN NN O
was VBD VBD O
conducted VBN VBN O
in IN IN O
the DT DT O
intensive JJ JJ O
diagnostic JJ JJ O
and CC CC O
treatment NN NN O
unit NN NN O
in IN IN O
the DT DT O
ED NNP NNP O
of IN IN O
an DT DT O
urban JJ JJ O
tertiary JJ JJ O
- - - O
care NN NN O
teaching NN NN O
hospital NN NN O
. . . O

Patients NNS NNS O
were VBD VBD O
eligible JJ JJ O
for IN IN O
DSE NNP NNP O
if IN IN O
they PRP PRP O
had VBD VBD O
used VBN VBN O
cocaine NN NN B-CHEM
within IN IN O
24 CD CD O
hours NNS NNS O
preceding VBG VBG O
the DT DT O
onset NN NN O
of IN IN O
chest NN NN O
pain NN NN O
and CC CC O
had VBD VBD O
a DT DT O
normal JJ JJ O
ECG NNP NNP O
and CC CC O
tropinin NN NN O
I PRP PRP O
level VBP VBP O
. . . O

Patients NNS NNS O
exhibiting VBG VBG O
signs NNS NNS O
of IN IN O
continuing VBG VBG O
cocaine NN NN B-CHEM
toxicity NN NN O
were VBD VBD O
excluded VBN VBN O
from IN IN O
the DT DT O
study NN NN O
. . . O

All DT DT O
patients NNS NNS O
were VBD VBD O
admitted VBN VBN O
to TO TO O
the DT DT O
hospital NN NN O
for IN IN O
serial NN NN O
testing NN NN O
after IN IN O
the DT DT O
DSE NNP NNP O
testing NN NN O
in IN IN O
the DT DT O
intensive JJ JJ O
diagnostic JJ JJ O
and CC CC O
treatment NN NN O
unit NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Twenty CD CD O
- - - O
four CD CD O
patients NNS NNS O
were VBD VBD O
enrolled VBN VBN O
. . . O

Two CD CD O
patients NNS NNS O
had VBD VBD O
inadequate JJ JJ O
resting NN NN O
images NNS NNS O
, , , O
one CD CD O
DSE NNP NNP O
was VBD VBD O
terminated VBN VBN O
because IN IN O
of IN IN O
inferior JJ JJ O
hypokinesis NN NN O
, , , O
another DT DT O
DSE NNP NNP O
was VBD VBD O
terminated VBN VBN O
because IN IN O
of IN IN O
a DT DT O
rate NN NN O
- - - O
related VBN VBN O
atrial JJ JJ O
conduction NN NN O
deficit NN NN O
, , , O
and CC CC O
1 CD CD O
patient NN NN O
did VBD VBD O
not RB RB O
reach VB VB O
the DT DT O
target NN NN O
heart NN NN O
rate NN NN O
. . . O

Thus RB RB O
, , , O
19 CD CD O
patients NNS NNS O
completed VBD VBD O
a DT DT O
DSE NNP NNP O
and CC CC O
reached VBD VBD O
their PRP$ PRP$ O
target NN NN O
heart NN NN O
rates NNS NNS O
. . . O

None NN NN O
of IN IN O
the DT DT O
patients NNS NNS O
experienced VBN VBN O
signs NNS NNS O
of IN IN O
exaggerated JJ JJ O
adrenergic JJ JJ O
response NN NN O
, , , O
which WDT WDT O
was VBD VBD O
defined VBN VBN O
as IN IN O
a DT DT O
systolic JJ JJ O
blood NN NN O
pressure NN NN O
of IN IN O
greater JJR JJR O
than IN IN O
200 CD CD O
mm NN NN O
Hg NNP NNP O
or CC CC O
the DT DT O
occurrence NN NN O
of IN IN O
tachydysrhythmias NN NN O
( ( ( O
excluding VBG VBG O
sinus NN NN O
tachycardia NNS NNS O
) ) ) O
. . . O

Further RB RB O
suggesting VBG VBG O
lack NN NN O
of IN IN O
exaggerated JJ JJ O
adrenergic JJ JJ O
response NN NN O
, , , O
13 CD CD O
( ( ( O
65 CD CD O
% NN NN O
) ) ) O
of IN IN O
20 CD CD O
patients NNS NNS O
required VBN VBN O
supplemental JJ JJ O
atropine NN NN B-CHEM
to TO TO O
reach VB VB O
their PRP$ PRP$ O
target NN NN O
heart NN NN O
rates NNS NNS O
. . . O

CONCLUSION NNP NNP O
: : : O
No DT DT O
exaggerated JJ JJ O
adrenergic JJ JJ O
response NN NN O
was VBD VBD O
detected VBN VBN O
when WRB WRB O
dobutamine NN NN B-CHEM
was VBD VBD O
administered VBN VBN O
to TO TO O
patients NNS NNS O
with IN IN O
cocaine NN NN B-CHEM
- - - O
related JJ JJ O
chest NN NN O
pain NN NN O
. . . O

Prenatal NNP NNP O
cocaine NN NN B-CHEM
exposure NN NN O
and CC CC O
cranial JJ JJ O
sonographic JJ JJ O
findings NNS NNS O
in IN IN O
preterm NN NN O
infants NNS NNS O
. . . O

PURPOSE NNP NNP O
: : : O
Prenatal NNP NNP O
cocaine NN NN B-CHEM
exposure NN NN O
has VBZ VBZ O
been VBN VBN O
linked VBN VBN O
with IN IN O
subependymal JJ JJ O
hemorrhage NN NN O
and CC CC O
the DT DT O
formation NN NN O
of IN IN O
cysts NNS NNS O
that WDT WDT O
are VBP VBP O
detectable JJ JJ O
on IN IN O
cranial JJ JJ O
sonography NN NN O
in IN IN O
neonates NNS NNS O
born VBN VBN O
at IN IN O
term NN NN O
. . . O

We PRP PRP O
sought VBD VBD O
to TO TO O
determine VB VB O
if IN IN O
prenatal JJ JJ O
cocaine NN NN B-CHEM
exposure NN NN O
increases NNS NNS O
the DT DT O
incidence NN NN O
of IN IN O
subependymal JJ JJ O
cysts NNS NNS O
in IN IN O
preterm NN NN O
infants NNS NNS O
. . . O

METHODS NNP NNP O
: : : O
We PRP PRP O
retrospectively RB RB O
reviewed VBD VBD O
the DT DT O
medical JJ JJ O
records NNS NNS O
and CC CC O
cranial JJ JJ O
sonograms NNS NNS O
obtained VBN VBN O
during IN IN O
a DT DT O
1 CD CD O
- : : O
year NN NN O
period NN NN O
on IN IN O
122 CD CD O
premature NN NN O
( ( ( O
< NN NN O
36 CD CD O
weeks NNS NNS O
of IN IN O
gestation NN NN O
) ) ) O
infants NNS NNS O
. . . O

Infants NNP NNP O
were VBD VBD O
categorized VBN VBN O
into IN IN O
1 CD CD O
of IN IN O
2 CD CD O
groups NNS NNS O
: : : O
those DT DT O
exposed VBN VBN O
to TO TO O
cocaine NN NN B-CHEM
and CC CC O
those DT DT O
not RB RB O
exposed VBN VBN O
to TO TO O
cocaine NN NN B-CHEM
. . . O

Infants NNP NNP O
were VBD VBD O
assigned VBN VBN O
to TO TO O
the DT DT O
cocaine NN NN B-CHEM
- - - O
exposed VBN VBN O
group NN NN O
if IN IN O
there EX EX O
was VBD VBD O
a DT DT O
maternal JJ JJ O
history NN NN O
of IN IN O
cocaine NN NN O
abuse NN NN O
during IN IN O
pregnancy NN NN O
or CC CC O
if IN IN O
maternal JJ JJ O
or CC CC O
neonatal JJ JJ O
urine NN NN O
toxicology NN NN O
results NNS NNS O
were VBD VBD O
positive JJ JJ O
at IN IN O
the DT DT O
time NN NN O
of IN IN O
delivery NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Five CD CD O
of IN IN O
the DT DT O
122 CD CD O
infants NNS NNS O
were VBD VBD O
excluded VBN VBN O
from IN IN O
the DT DT O
study NN NN O
because IN IN O
of IN IN O
insufficient JJ JJ O
medical JJ JJ O
and CC CC O
drug NN NN O
histories NNS NNS O
. . . O

The DT DT O
incidence NN NN O
of IN IN O
subependymal JJ JJ O
cysts NNS NNS O
in IN IN O
the DT DT O
117 CD CD O
remaining VBG VBG O
infants NNS NNS O
was VBD VBD O
14 CD CD O
% NN NN O
( ( ( O
16 CD CD O
of IN IN O
117 CD CD O
) ) ) O
. . . O

The DT DT O
incidence NN NN O
of IN IN O
subependymal JJ JJ O
cysts NNS NNS O
in IN IN O
infants NNS NNS O
exposed VBN VBN O
to TO TO O
cocaine NN NN B-CHEM
prenatally RB RB O
was VBD VBD O
44 CD CD O
% NN NN O
( ( ( O
8 CD CD O
of IN IN O
18 CD CD O
) ) ) O
compared VBN VBN O
with IN IN O
8 CD CD O
% NN NN O
( ( ( O
8 CD CD O
of IN IN O
99 CD CD O
) ) ) O
in IN IN O
the DT DT O
unexposed JJ JJ O
group NN NN O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
. . . O

CONCLUSIONS NNP NNP O
: : : O
We PRP PRP O
found VBD VBD O
an DT DT O
increased JJ JJ O
incidence NN NN O
of IN IN O
subependymal NN NN O
cyst NN NN O
formation NN NN O
in IN IN O
preterm NN NN O
infants NNS NNS O
who WP WP O
were VBD VBD O
exposed VBN VBN O
to TO TO O
cocaine VB VB B-CHEM
prenatally RB RB O
. . . O

This DT DT O
result NN NN O
is VBZ VBZ O
consistent JJ JJ O
with IN IN O
results NNS NNS O
of IN IN O
similar JJ JJ O
studies NNS NNS O
in IN IN O
term NN NN O
infants NNS NNS O
. . . O

Thalidomide NNP NNP B-CHEM
neuropathy NN NN O
in IN IN O
patients NNS NNS O
treated VBN VBN O
for IN IN O
metastatic JJ JJ O
prostate NN NN O
cancer NN NN O
. . . O

We PRP PRP O
prospectively RB RB O
evaluated VBD VBD O
thalidomide IN IN B-CHEM
- : : O
induced VBN VBN O
neuropathy NN NN O
using VBG VBG O
electrodiagnostic JJ JJ O
studies NNS NNS O
. . . O

Sixty NNP NNP O
- : : O
seven CD CD O
men NNS NNS O
with IN IN O
metastatic JJ JJ O
androgen NN NN B-CHEM
- - - O
independent JJ JJ O
prostate NN NN O
cancer NN NN O
in IN IN O
an DT DT O
open JJ JJ O
- - - O
label NN NN O
trial NN NN O
of IN IN O
oral JJ JJ O
thalidomide NN NN B-CHEM
underwent JJ JJ O
neurologic JJ JJ O
examinations NNS NNS O
and CC CC O
nerve NN NN O
conduction NN NN O
studies NNS NNS O
( ( ( O
NCS NNP NNP O
) ) ) O
prior RB RB O
to TO TO O
and CC CC O
at IN IN O
3 CD CD O
- : : O
month NN NN O
intervals NNS NNS O
during IN IN O
treatment NN NN O
. . . O

NCS NNP NNP O
included VBD VBD O
recording NN NN O
of IN IN O
sensory JJ JJ O
nerve NN NN O
action NN NN O
potentials NNS NNS O
( ( ( O
SNAPs NNP NNP O
) ) ) O
from IN IN O
median NN NN O
, , , O
radial NN NN O
, , , O
ulnar NN NN O
, , , O
and CC CC O
sural JJ JJ O
nerves NNS NNS O
. . . O

SNAP NNP NNP O
amplitudes NNS NNS O
for IN IN O
each DT DT O
nerve NN NN O
were VBD VBD O
expressed VBN VBN O
as IN IN O
the DT DT O
percentage NN NN O
of IN IN O
its PRP$ PRP$ O
baseline NN NN O
, , , O
and CC CC O
the DT DT O
mean NN NN O
of IN IN O
the DT DT O
four CD CD O
was VBD VBD O
termed VBN VBN O
the DT DT O
SNAP NNP NNP O
index NN NN O
. . . O

A DT DT O
40 CD CD O
% NN NN O
decline NN NN O
in IN IN O
the DT DT O
SNAP NNP NNP O
index NN NN O
was VBD VBD O
considered VBN VBN O
clinically RB RB O
significant JJ JJ O
. . . O

Thalidomide NNP NNP B-CHEM
was VBD VBD O
discontinued VBN VBN O
in IN IN O
55 CD CD O
patients NNS NNS O
for IN IN O
lack NN NN O
of IN IN O
therapeutic JJ JJ O
response NN NN O
. . . O

Of IN IN O
67 CD CD O
patients NNS NNS O
initially RB RB O
enrolled VBN VBN O
, , , O
24 CD CD O
remained VBD VBD O
on IN IN O
thalidomide NN NN B-CHEM
for IN IN O
3 CD CD O
months NNS NNS O
, , , O
8 CD CD O
remained VBD VBD O
at IN IN O
6 CD CD O
months NNS NNS O
, , , O
and CC CC O
3 CD CD O
remained VBD VBD O
at IN IN O
9 CD CD O
months NNS NNS O
. . . O

Six CD CD O
patients NNS NNS O
developed VBN VBN O
neuropathy NN NN O
. . . O

Clinical NNP NNP O
symptoms NNS NNS O
and CC CC O
a DT DT O
decline NN NN O
in IN IN O
the DT DT O
SNAP NNP NNP O
index NN NN O
occurred VBD VBD O
concurrently RB RB O
. . . O

Older JJR JJR O
age NN NN O
and CC CC O
cumulative JJ JJ O
dose NN NN O
were VBD VBD O
possible JJ JJ O
contributing JJ JJ O
factors NNS NNS O
. . . O

Neuropathy NNP NNP O
may MD MD O
thus RB RB O
be VB VB O
a DT DT O
common JJ JJ O
complication NN NN O
of IN IN O
thalidomide NN NN B-CHEM
in IN IN O
older JJR JJR O
patients NNS NNS O
. . . O

The DT DT O
SNAP NNP NNP O
index NN NN O
can MD MD O
be VB VB O
used VBN VBN O
to TO TO O
monitor VB VB O
peripheral JJ JJ O
neuropathy NN NN O
, , , O
but CC CC O
not RB RB O
for IN IN O
early JJ JJ O
detection NN NN O
. . . O

Overexpression NNP NNP O
of IN IN O
copper NN NN B-CHEM
/ NN NN O
zinc NN NN B-CHEM
- - - O
superoxide NN NN B-CHEM
dismutase NN NN O
protects NNS NNS O
from IN IN O
kanamycin NN NN B-CHEM
- - - O
induced JJ JJ O
hearing NN NN O
loss NN NN O
. . . O

The DT DT O
participation NN NN O
of IN IN O
reactive JJ JJ O
oxygen NN NN B-CHEM
species NNS NNS O
in IN IN O
aminoglycoside NN NN B-CHEM
- - - O
induced JJ JJ O
ototoxicity NN NN O
has VBZ VBZ O
been VBN VBN O
deduced VBN VBN O
from IN IN O
observations NNS NNS O
that WDT WDT O
aminoglycoside NN NN B-CHEM
- - - O
iron NN NN B-CHEM
complexes NNS NNS O
catalyze NN NN O
the DT DT O
formation NN NN O
of IN IN O
superoxide NN NN B-CHEM
radicals NNS NNS O
in IN IN O
vitro NN NN O
and CC CC O
that IN IN O
antioxidants NNS NNS O
attenuate VBP VBP O
ototoxicity NN NN O
in IN IN O
vivo NN NN O
. . . O

We PRP PRP O
therefore RB RB O
hypothesized VBD VBD O
that DT DT O
overexpression NN NN O
of IN IN O
Cu NNP NNP B-CHEM
/ NN NN O
Zn NNP NNP B-CHEM
- - - O
superoxide NN NN B-CHEM
dismutase NN NN O
( ( ( O
h NN NN O
- - - O
SOD1 NNP NNP O
) ) ) O
should MD MD O
protect VB VB O
transgenic JJ JJ O
mice NNS NNS O
from IN IN O
ototoxicity NN NN O
. . . O

Immunocytochemistry NNP NNP O
confirmed VBD VBD O
expression NN NN O
of IN IN O
h NN NN O
- - - O
SOD1 NNP NNP O
in IN IN O
inner JJ JJ O
ear NN NN O
tissues NNS NNS O
of IN IN O
transgenic JJ JJ O
C57BL NNP NNP O
/ NN NN O
6 CD CD O
- : : O
TgN NNP NNP O
[ NN NN O
SOD1 NNP NNP O
] NN NN O
3Cje CD CD O
mice NN NN O
. . . O

Transgenic NNP NNP O
and CC CC O
nontransgenic JJ JJ O
littermates NNS NNS O
received VBD VBD O
kanamycin NN NN B-CHEM
( ( ( O
400 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
body NN NN O
weight NN NN O
/ NN NN O
day NN NN O
) ) ) O
for IN IN O
10 CD CD O
days NNS NNS O
beginning VBG VBG O
on IN IN O
day NN NN O
10 CD CD O
after IN IN O
birth NN NN O
. . . O

Auditory NNP NNP O
thresholds NNS NNS O
were VBD VBD O
tested VBN VBN O
by IN IN O
evoked JJ JJ O
auditory NN NN O
brain NN NN O
stem NN NN O
responses NNS NNS O
at IN IN O
1 CD CD O
month NN NN O
after IN IN O
birth NN NN O
. . . O

In IN IN O
nontransgenic JJ JJ O
animals NNS NNS O
, , , O
the DT DT O
threshold NN NN O
in IN IN O
the DT DT O
kanamycin NN NN B-CHEM
- - - O
treated JJ JJ O
group NN NN O
was VBD VBD O
45 CD CD O
- : : O
50 CD CD O
dB NN NN O
higher JJR JJR O
than IN IN O
in IN IN O
saline NN NN O
- - - O
injected JJ JJ O
controls NNS NNS O
. . . O

In IN IN O
the DT DT O
transgenic JJ JJ O
group NN NN O
, , , O
kanamycin NN NN B-CHEM
increased VBD VBD O
the DT DT O
threshold NN NN O
by IN IN O
only RB RB O
15 CD CD O
dB NN NN O
over IN IN O
the DT DT O
respective JJ JJ O
controls NNS NNS O
. . . O

The DT DT O
effects NNS NNS O
were VBD VBD O
similar JJ JJ O
at IN IN O
12 CD CD O
and CC CC O
24 CD CD O
kHz NN NN O
. . . O

The DT DT O
protection NN NN O
by IN IN O
overexpression NN NN O
of IN IN O
superoxide NN NN B-CHEM
dismutase NN NN O
supports VBZ VBZ O
the DT DT O
hypothesis NNS NNS O
that IN IN O
oxidant JJ JJ O
stress NN NN O
plays VBZ VBZ O
a DT DT O
significant JJ JJ O
role NN NN O
in IN IN O
aminoglycoside NN NN B-CHEM
- - - O
induced JJ JJ O
ototoxicity NN NN O
. . . O

The DT DT O
results NNS NNS O
also RB RB O
suggest VBP VBP O
transgenic JJ JJ O
animals NNS NNS O
as IN IN O
suitable JJ JJ O
models NNS NNS O
to TO TO O
investigate VB VB O
the DT DT O
underlying VBG VBG O
mechanisms NNS NNS O
and CC CC O
possible JJ JJ O
strategies NNS NNS O
for IN IN O
prevention NN NN O
. . . O

Fatty NNP NNP O
liver NN NN O
induced VBN VBN O
by IN IN O
tetracycline NN NN B-CHEM
in IN IN O
the DT DT O
rat NN NN O
. . . O

Dose NNP NNP O
- : : O
response NN NN O
relationships NNS NNS O
and CC CC O
effect NN NN O
of IN IN O
sex NN NN O
. . . O

Dose NNP NNP O
- : : O
response NN NN O
relationships NNS NNS O
, , , O
biochemical JJ JJ O
mechanisms NNS NNS O
, , , O
and CC CC O
sex NN NN O
differences NNS NNS O
in IN IN O
the DT DT O
experimental JJ JJ O
fatty NN NN O
liver NN NN O
induced VBN VBN O
by IN IN O
tetracycline NN NN B-CHEM
were VBD VBD O
studied VBN VBN O
in IN IN O
the DT DT O
intact JJ JJ O
rat NN NN O
and CC CC O
with IN IN O
the DT DT O
isolated VBN VBN O
perfused VBN VBN O
rat NN NN O
liver NN NN O
in IN IN O
vitro NN NN O
. . . O

In IN IN O
the DT DT O
intact JJ JJ O
male JJ JJ O
and CC CC O
female JJ JJ O
rat NN NN O
, , , O
no DT DT O
direct JJ JJ O
relationship NN NN O
was VBD VBD O
observed VBN VBN O
between IN IN O
dose NN NN O
of IN IN O
tetracycline NN NN B-CHEM
and CC CC O
hepatic JJ JJ O
accumulation NN NN O
of IN IN O
triglyceride NN NN B-CHEM
. . . O

With IN IN O
provision NN NN O
of IN IN O
adequate JJ JJ O
oleic JJ JJ B-CHEM
acid NN NN I-CHEM
as IN IN O
a DT DT O
substrate NN NN O
for IN IN O
the DT DT O
isolated VBN VBN O
perfused JJ JJ O
liver NN NN O
, , , O
a DT DT O
direct JJ JJ O
relationship NN NN O
was VBD VBD O
observed VBN VBN O
between IN IN O
dose NN NN O
of IN IN O
tetracycline NN NN B-CHEM
and CC CC O
both DT DT O
accumulation NN NN O
of IN IN O
triglyceride NN NN B-CHEM
in IN IN O
the DT DT O
liver NN NN O
and CC CC O
depression NN NN O
of IN IN O
output NN NN O
of IN IN O
triglyceride NN NN B-CHEM
by IN IN O
livers NNS NNS O
from IN IN O
male JJ JJ O
and CC CC O
female JJ JJ O
rats NNS NNS O
. . . O

Marked NNP NNP O
differences NNS NNS O
were VBD VBD O
observed VBN VBN O
between IN IN O
female JJ JJ O
and CC CC O
male JJ JJ O
rats NNS NNS O
with IN IN O
regard NN NN O
to TO TO O
base VB VB O
line NN NN O
( ( ( O
control NN NN O
) ) ) O
hepatic JJ JJ O
concentration NN NN O
of IN IN O
triglyceride NN NN B-CHEM
and CC CC O
output NN NN O
of IN IN O
triglyceride NN NN B-CHEM
. . . O

Accumulation NNP NNP O
of IN IN O
hepatic JJ JJ O
triglyceride NN NN B-CHEM
, , , O
as IN IN O
a DT DT O
per IN IN O
cent NN NN O
of IN IN O
control NN NN O
values NNS NNS O
, , , O
in IN IN O
response NN NN O
to TO TO O
graded JJ JJ O
doses NNS NNS O
of IN IN O
tetracycline NN NN B-CHEM
, , , O
did VBD VBD O
not RB RB O
differ VB VB O
significantly RB RB O
between IN IN O
male JJ JJ O
, , , O
female JJ JJ O
and CC CC O
pregnant JJ JJ O
rat NN NN O
livers NNS NNS O
. . . O

However RB RB O
, , , O
livers NNS NNS O
from IN IN O
female JJ JJ O
, , , O
and CC CC O
especially RB RB O
pregnant JJ JJ O
female JJ JJ O
rats NNS NNS O
, , , O
were VBD VBD O
strikingly RB RB O
resistant JJ JJ O
to TO TO O
the DT DT O
effects NNS NNS O
of IN IN O
tetracycline NN NN B-CHEM
on IN IN O
depression NN NN O
of IN IN O
output NN NN O
of IN IN O
triglyceride NN NN B-CHEM
under IN IN O
these DT DT O
experimental JJ JJ O
conditions NNS NNS O
. . . O

These DT DT O
differences NNS NNS O
between IN IN O
the DT DT O
sexes NNS NNS O
could MD MD O
not RB RB O
be VB VB O
related VBN VBN O
to TO TO O
altered JJ JJ O
disposition NN NN O
of IN IN O
tetracycline NN NN B-CHEM
or CC CC O
altered VBN VBN O
uptake NN NN O
of IN IN O
oleic JJ JJ B-CHEM
acid NN NN I-CHEM
. . . O

Depressed NNP NNP O
hepatic JJ JJ O
secretion NN NN O
of IN IN O
triglyceride NN NN B-CHEM
accounted VBD VBD O
only RB RB O
for IN IN O
30 CD CD O
to TO TO O
50 CD CD O
% NN NN O
of IN IN O
accumulated VBN VBN O
hepatic JJ JJ O
triglyceride NN NN B-CHEM
, , , O
indicating VBG VBG O
that IN IN O
additional JJ JJ O
mechanisms NNS NNS O
must MD MD O
be VB VB O
involved VBN VBN O
in IN IN O
the DT DT O
production NN NN O
of IN IN O
the DT DT O
triglyceride NN NN B-CHEM
- - - O
rich JJ JJ O
fatty RB RB O
liver NN NN O
in IN IN O
response NN NN O
to TO TO O
tetracycline NN NN B-CHEM
. . . O

Prednisone NNP NNP B-CHEM
induces NNS NNS O
anxiety NN NN O
and CC CC O
glial JJ JJ O
cerebral JJ JJ O
changes NNS NNS O
in IN IN O
rats NNS NNS O
. . . O

OBJECTIVE NNP NNP O
: : : O
To TO TO O
assess VB VB O
whether IN IN O
prednisone NN NN B-CHEM
( ( ( O
PDN NNP NNP B-CHEM
) ) ) O
produces NNS NNS O
anxiety NN NN O
and CC CC O
/ NN NN O
or CC CC O
cerebral JJ JJ O
glial NN NN O
changes NNS NNS O
in IN IN O
rats NNS NNS O
. . . O

METHODS NNP NNP O
: : : O
Male NNP NNP O
Wistar NNP NNP O
rats NNS NNS O
were VBD VBD O
studied VBN VBN O
and CC CC O
3 CD CD O
groups NNS NNS O
were VBD VBD O
formed VBN VBN O
( ( ( O
8 CD CD O
rats NNS NNS O
per IN IN O
group NN NN O
) ) ) O
. . . O

The DT DT O
moderate JJ JJ O
- - - O
dose NN NN O
group NN NN O
received VBD VBD O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
PDN NNP NNP B-CHEM
released VBD VBD O
from IN IN O
a DT DT O
subcutaneous JJ JJ O
implant NN NN O
. . . O

In IN IN O
the DT DT O
high JJ JJ O
- - - O
dose NN NN O
group NN NN O
, , , O
implants NNS NNS O
containing VBG VBG O
PDN NNP NNP B-CHEM
equivalent NN NN O
to TO TO O
60 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
were VBD VBD O
applied VBN VBN O
. . . O

In IN IN O
the DT DT O
control NN NN O
group NN NN O
implants NNS NNS O
contained VBD VBD O
no DT DT O
PDN NNP NNP B-CHEM
. . . O

Anxiety NNP NNP O
was VBD VBD O
assessed VBN VBN O
using VBG VBG O
an DT DT O
open JJ JJ O
field NN NN O
and CC CC O
elevated VBD VBD O
plus CC CC O
- : : O
maze NN NN O
devices NNS NNS O
. . . O

The DT DT O
number NN NN O
of IN IN O
cells NNS NNS O
and CC CC O
cytoplasmic JJ JJ O
transformation NN NN O
of IN IN O
astrocytes NNS NNS O
and CC CC O
microglia NN NN O
cells NNS NNS O
were VBD VBD O
assessed VBN VBN O
by IN IN O
immunohistochemical JJ JJ O
analyses NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
Anxiety NNP NNP O
was VBD VBD O
documented VBN VBN O
in IN IN O
both DT DT O
groups NNS NNS O
of IN IN O
PDN NNP NNP B-CHEM
treated VBD VBD O
rats NNS NNS O
compared VBN VBN O
with IN IN O
controls NNS NNS O
. . . O

The DT DT O
magnitude NN NN O
of IN IN O
transformation NN NN O
of IN IN O
the DT DT O
microglia NN NN O
assessed VBN VBN O
by IN IN O
the DT DT O
number NN NN O
of IN IN O
intersections NNS NNS O
was VBD VBD O
significantly RB RB O
higher JJR JJR O
in IN IN O
the DT DT O
PDN NNP NNP B-CHEM
groups NNS NNS O
than IN IN O
in IN IN O
controls NNS NNS O
in IN IN O
the DT DT O
prefrontal NN NN O
cortex NN NN O
( ( ( O
moderate JJ JJ O
- - - O
dose NN NN O
, , , O
24 CD CD O
. . . O
1 CD CD O
; : : O
high JJ JJ O
- - - O
dose NN NN O
, , , O
23 CD CD O
. . . O
6 CD CD O
; : : O
controls NNS NNS O
18 CD CD O
. . . O
7 CD CD O
; : : O
p NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
and CC CC O
striatum NN NN O
( ( ( O
moderate JJ JJ O
- : : O
dose NN NN O
25 CD CD O
. . . O
6 CD CD O
; : : O
high JJ JJ O
- - - O
dose NN NN O
26 CD CD O
. . . O
3 CD CD O
; : : O
controls NNS NNS O
18 CD CD O
. . . O
9 CD CD O
; : : O
p NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
, , , O
but CC CC O
not RB RB O
in IN IN O
hippocampus NN NN O
. . . O

The DT DT O
number NN NN O
of IN IN O
stained JJ JJ O
microglia NN NN O
cells NNS NNS O
was VBD VBD O
significantly RB RB O
higher JJR JJR O
in IN IN O
the DT DT O
PDN NNP NNP B-CHEM
treated VBN VBN O
groups NNS NNS O
in IN IN O
the DT DT O
prefrontal NN NN O
cortex NN NN O
than IN IN O
in IN IN O
controls NNS NNS O
( ( ( O
moderate JJ JJ O
- - - O
dose NN NN O
, , , O
29 CD CD O
. . . O
1 CD CD O
; : : O
high JJ JJ O
- - - O
dose NN NN O
, , , O
28 CD CD O
. . . O
4 CD CD O
; : : O
control NN NN O
, , , O
17 CD CD O
. . . O
7 CD CD O
cells NNS NNS O
per IN IN O
field NN NN O
; : : O
p NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
. . . O

Stained NNP NNP O
microglia NN NN O
cells NNS NNS O
were VBD VBD O
significantly RB RB O
more RBR RBR O
numerous JJ JJ O
striatum NN NN O
and CC CC O
hippocampus NN NN O
in IN IN O
the DT DT O
high JJ JJ O
- - - O
dose NN NN O
group NN NN O
compared VBN VBN O
to TO TO O
controls NNS NNS O
. . . O

CONCLUSION NNP NNP O
: : : O
Subacute NNP NNP O
exposure NN NN O
to TO TO O
PDN NNP NNP B-CHEM
induced VBD VBD O
anxiety NN NN O
and CC CC O
reactivity NN NN O
of IN IN O
microglia NN NN O
. . . O

The DT DT O
relevance NN NN O
of IN IN O
these DT DT O
features NNS NNS O
for IN IN O
patients NNS NNS O
using VBG VBG O
PDN NNP NNP B-CHEM
remains VBZ VBZ O
to TO TO O
be VB VB O
elucidated VBN VBN O
. . . O

Phase NNP NNP O
II NNP NNP O
study NN NN O
of IN IN O
carboplatin NN NN B-CHEM
and CC CC O
liposomal NN NN O
doxorubicin NN NN B-CHEM
in IN IN O
patients NNS NNS O
with IN IN O
recurrent JJ JJ O
squamous JJ JJ O
cell NN NN O
carcinoma NN NN O
of IN IN O
the DT DT O
cervix NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
The DT DT O
activity NN NN O
of IN IN O
the DT DT O
combination NN NN O
of IN IN O
carboplatin NN NN B-CHEM
and CC CC O
liposomal NN NN O
doxorubicin NN NN B-CHEM
was VBD VBD O
tested VBN VBN O
in IN IN O
a DT DT O
Phase NNP NNP O
II NNP NNP O
study NN NN O
of IN IN O
patients NNS NNS O
with IN IN O
recurrent JJ JJ O
cervical JJ JJ O
carcinoma NN NN O
. . . O

METHODS NNP NNP O
: : : O
The DT DT O
combination NN NN O
of IN IN O
carboplatin NN NN B-CHEM
( ( ( O
area NN NN O
under IN IN O
the DT DT O
concentration NN NN O
curve NN NN O
[ NN NN O
AUC NNP NNP O
] NN NN O
, , , O
5 CD CD O
) ) ) O
and CC CC O
liposomal JJ JJ O
doxorubicin NN NN B-CHEM
( ( ( O
Doxil NNP NNP B-CHEM
; : : O
starting VBG VBG O
dose NN NN O
, , , O
40 CD CD O
mg NN NN O
/ NN NN O
m NN NN O
( ( ( O
2 CD CD O
) ) ) O
) ) ) O
was VBD VBD O
administered VBN VBN O
intravenously RB RB O
every DT DT O
28 CD CD O
days NNS NNS O
to TO TO O
37 CD CD O
patients NNS NNS O
with IN IN O
recurrent JJ JJ O
squamous JJ JJ O
cell NN NN O
cervical JJ JJ O
carcinoma NN NN O
to TO TO O
determine VB VB O
antitumor NN NN O
activity NN NN O
and CC CC O
toxicity NN NN O
profile NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Twenty CD CD O
- - - O
nine CD CD O
patients NNS NNS O
were VBD VBD O
assessable JJ JJ O
for IN IN O
response NN NN O
, , , O
and CC CC O
35 CD CD O
patients NNS NNS O
were VBD VBD O
assessable JJ JJ O
for IN IN O
toxicity NN NN O
. . . O

The DT DT O
overall JJ JJ O
response NN NN O
rate NN NN O
was VBD VBD O
38 CD CD O
% NN NN O
, , , O
the DT DT O
median JJ JJ O
time NN NN O
to TO TO O
response NN NN O
was VBD VBD O
10 CD CD O
weeks NNS NNS O
, , , O
the DT DT O
median JJ JJ O
duration NN NN O
of IN IN O
response NN NN O
was VBD VBD O
26 CD CD O
weeks NNS NNS O
, , , O
and CC CC O
the DT DT O
median NN NN O
survival NN NN O
was VBD VBD O
37 CD CD O
weeks NNS NNS O
. . . O

The DT DT O
main JJ JJ O
toxic JJ JJ O
effect NN NN O
was VBD VBD O
myelosuppression NN NN O
, , , O
with IN IN O
Grade NNP NNP O
3 CD CD O
and CC CC O
4 CD CD O
neutropenia NN NN O
in IN IN O
16 CD CD O
patients NNS NNS O
, , , O
anemia NN NN O
in IN IN O
12 CD CD O
patients NNS NNS O
, , , O
thrombocytopenia NN NN O
in IN IN O
11 CD CD O
patients NNS NNS O
, , , O
and CC CC O
neutropenic JJ JJ O
fever NN NN O
in IN IN O
3 CD CD O
patients NNS NNS O
. . . O

Four CD CD O
patients NNS NNS O
had VBD VBD O
five CD CD O
infusion NN NN O
- - - O
related VBN VBN O
reactions NNS NNS O
during IN IN O
the DT DT O
infusion NN NN O
of IN IN O
liposomal NN NN O
doxorubicin NN NN B-CHEM
, , , O
leading VBG VBG O
to TO TO O
treatment NN NN O
discontinuation NN NN O
in IN IN O
three CD CD O
patients NNS NNS O
. . . O

Grade NNP NNP O
> NN NN O
or CC CC O
= SYM SYM O
2 CD CD O
nonhematologic JJ JJ O
toxicity NN NN O
included VBD VBD O
nausea NN NN O
in IN IN O
17 CD CD O
patients NNS NNS O
, , , O
emesis NN NN O
in IN IN O
14 CD CD O
patients NNS NNS O
, , , O
fatigue NN NN O
in IN IN O
9 CD CD O
patients NNS NNS O
, , , O
mucositis NNS NNS O
and CC CC O
/ NN NN O
or CC CC O
stomatitis NN NN O
in IN IN O
8 CD CD O
patients NNS NNS O
, , , O
constipation NN NN O
in IN IN O
6 CD CD O
patients NNS NNS O
, , , O
weight NN NN O
loss NN NN O
in IN IN O
5 CD CD O
patients NNS NNS O
, , , O
hand NN NN O
- - - O
foot NN NN O
syndrome NN NN O
in IN IN O
2 CD CD O
patients NNS NNS O
, , , O
and CC CC O
skin NN NN O
reactions NNS NNS O
in IN IN O
3 CD CD O
patients NNS NNS O
. . . O

CONCLUSIONS NNP NNP O
: : : O
The DT DT O
combination NN NN O
of IN IN O
carboplatin NN NN B-CHEM
and CC CC O
liposomal NN NN O
doxorubicin NN NN B-CHEM
has VBZ VBZ O
modest JJ JJ O
activity NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
recurrent JJ JJ O
cervical JJ JJ O
carcinoma NN NN O
. . . O

Antimicrobial NNP NNP O
- : : O
induced JJ JJ O
mania NN NN O
( ( ( O
antibiomania NN NN O
) ) ) O
: : : O
a DT DT O
review NN NN O
of IN IN O
spontaneous JJ JJ O
reports NNS NNS O
. . . O

The DT DT O
authors NNS NNS O
reviewed VBD VBD O
reported VBD VBD O
cases NNS NNS O
of IN IN O
antibiotic JJ JJ O
- - - O
induced JJ JJ O
manic NN NN O
episodes NNS NNS O
by IN IN O
means NNS NNS O
of IN IN O
a DT DT O
MEDLINE NNP NNP O
and CC CC O
PsychLit NNP NNP O
search NN NN O
for IN IN O
reports NNS NNS O
of IN IN O
antibiotic JJ JJ O
- - - O
induced JJ JJ O
mania NN NN O
. . . O

Unpublished NNP NNP O
reports NNS NNS O
were VBD VBD O
requested VBN VBN O
from IN IN O
the DT DT O
World NNP NNP O
Health NNP NNP O
Organization NNP NNP O
( ( ( O
WHO WP WP O
) ) ) O
and CC CC O
the DT DT O
Food NNP NNP O
and CC CC O
Drug NN NN O
Administration NNP NNP O
( ( ( O
FDA NNP NNP O
) ) ) O
. . . O

Twenty CD CD O
- : : O
one CD CD O
reports NNS NNS O
of IN IN O
antimicrobial JJ JJ O
- - - O
induced JJ JJ O
mania NN NN O
were VBD VBD O
found VBN VBN O
in IN IN O
the DT DT O
literature NN NN O
. . . O

There EX EX O
were VBD VBD O
6 CD CD O
cases NNS NNS O
implicating VBG VBG O
clarithromycin NN NN B-CHEM
, , , O
13 CD CD O
implicating VBG VBG O
isoniazid NN NN B-CHEM
, , , O
and CC CC O
1 CD CD O
case NN NN O
each DT DT O
implicating VBG VBG O
erythromycin NN NN B-CHEM
and CC CC O
amoxicillin NN NN B-CHEM
. . . O

The DT DT O
WHO WP WP O
reported VBD VBD O
82 CD CD O
cases NNS NNS O
. . . O

Of IN IN O
these DT DT O
, , , O
clarithromycin NN NN B-CHEM
was VBD VBD O
implicated VBN VBN O
in IN IN O
23 CD CD O
( ( ( O
27 CD CD O
. . . O
6 CD CD O
% NN NN O
) ) ) O
cases NNS NNS O
, , , O
ciprofloxacin NN NN B-CHEM
in IN IN O
12 CD CD O
( ( ( O
14 CD CD O
. . . O
4 CD CD O
% NN NN O
) ) ) O
cases NNS NNS O
, , , O
and CC CC O
ofloxacin NN NN B-CHEM
in IN IN O
10 CD CD O
( ( ( O
12 CD CD O
% NN NN O
) ) ) O
cases NNS NNS O
. . . O

Cotrimoxazole NNP NNP B-CHEM
, , , O
metronidazole NN NN B-CHEM
, , , O
and CC CC O
erythromycin NN NN B-CHEM
were VBD VBD O
involved VBN VBN O
in IN IN O
15 CD CD O
reported VBD VBD O
manic JJ JJ O
episodes NNS NNS O
. . . O

Cases NNS NNS O
reported VBN VBN O
by IN IN O
the DT DT O
FDA NNP NNP O
showed VBD VBD O
clarithromycin NN NN B-CHEM
and CC CC O
ciprofloxacin NN NN B-CHEM
to TO TO O
be VB VB O
the DT DT O
most RBS RBS O
frequently RB RB O
associated VBN VBN O
with IN IN O
the DT DT O
development NN NN O
of IN IN O
mania NN NN O
. . . O

Statistical NNP NNP O
analysis NN NN O
of IN IN O
the DT DT O
data NNS NNS O
would MD MD O
not RB RB O
have VB VB O
demonstrated VBN VBN O
a DT DT O
significant JJ JJ O
statistical JJ JJ O
correlative JJ JJ O
risk NN NN O
and CC CC O
was VBD VBD O
therefore RB RB O
not RB RB O
undertaken VBN VBN O
. . . O

Patients NNS NNS O
have VBP VBP O
an DT DT O
increased VBN VBN O
risk NN NN O
of IN IN O
developing VBG VBG O
mania NN NN O
while IN IN O
being VBG VBG O
treated VBN VBN O
with IN IN O
antimicrobials NNS NNS O
. . . O

Although IN IN O
this DT DT O
is VBZ VBZ O
not RB RB O
a DT DT O
statistically RB RB O
significant JJ JJ O
risk NN NN O
, , , O
physicians NNS NNS O
must MD MD O
be VB VB O
aware JJ JJ O
of IN IN O
the DT DT O
effect NN NN O
and CC CC O
reversibility NN NN O
. . . O

Further RB RB O
research NN NN O
clearly RB RB O
is VBZ VBZ O
required VBN VBN O
to TO TO O
determine VB VB O
the DT DT O
incidence NN NN O
of IN IN O
antimicrobial JJ JJ O
- - - O
induced JJ JJ O
mania NN NN O
, , , O
the DT DT O
relative JJ JJ O
risk NN NN O
factors NNS NNS O
of IN IN O
developing VBG VBG O
an DT DT O
antimicrobial JJ JJ O
- - - O
induced JJ JJ O
manic JJ JJ O
episode NN NN O
among IN IN O
various JJ JJ O
demographic JJ JJ O
populations NNS NNS O
, , , O
and CC CC O
the DT DT O
incidence NN NN O
of IN IN O
patients NNS NNS O
who WP WP O
continue VBP VBP O
to TO TO O
have VB VB O
persistent JJ JJ O
affective JJ JJ O
disorders NNS NNS O
once RB RB O
the DT DT O
initial JJ JJ O
episode NN NN O
, , , O
which WDT WDT O
occurs VBZ VBZ O
while IN IN O
the DT DT O
patient NN NN O
is VBZ VBZ O
taking VBG VBG O
antibiotics NNS NNS O
, , , O
subsides NNS NNS O
. . . O

The DT DT O
authors NNS NNS O
elected VBD VBD O
to TO TO O
name VB VB O
this DT DT O
syndrome NN NN O
" '' '' O
antibiomania NN NN O
. . . O
" '' '' O

Levodopa NNP NNP B-CHEM
- : : O
induced JJ JJ O
ocular NN NN O
dyskinesias NN NN O
in IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
. . . O

Levodopa NNP NNP B-CHEM
- : : O
induced JJ JJ O
ocular NN NN O
dyskinesias NNS NNS O
are VBP VBP O
very RB RB O
uncommon JJ JJ O
. . . O

Usually RB RB O
they PRP PRP O
occur VBP VBP O
simultaneously RB RB O
with IN IN O
limb NN NN O
peak NN NN O
- : : O
dose NN NN O
choreatic JJ JJ O
dyskinesias NN NN O
. . . O

We PRP PRP O
report VBP VBP O
on IN IN O
a DT DT O
patient NN NN O
with IN IN O
leftward NN NN O
and CC CC O
upward JJ JJ O
deviations NNS NNS O
of IN IN O
gaze VBP VBP O
during IN IN O
the DT DT O
peak NN NN O
effect NN NN O
of IN IN O
levodopa NN NN B-CHEM
, , , O
and CC CC O
hypothesize NN NN O
that IN IN O
a DT DT O
severe JJ JJ O
dopaminergic JJ JJ O
denervation NN NN O
in IN IN O
the DT DT O
caudate NN NN O
nucleus NN NN O
is VBZ VBZ O
needed VBN VBN O
for IN IN O
the DT DT O
appearance NN NN O
of IN IN O
these DT DT O
levodopa NN NN B-CHEM
- - - O
induce NN NN O
ocular JJ JJ O
dyskinesias NN NN O
. . . O

A DT DT O
comparison NN NN O
of IN IN O
glyceryl NN NN B-CHEM
trinitrate NN NN I-CHEM
with IN IN O
diclofenac NN NN B-CHEM
for IN IN O
the DT DT O
treatment NN NN O
of IN IN O
primary JJ JJ O
dysmenorrhea NN NN O
: : : O
an DT DT O
open JJ JJ O
, , , O
randomized JJ JJ O
, , , O
cross JJ JJ O
- - - O
over IN IN O
trial NN NN O
. . . O

Primary JJ JJ O
dysmenorrhea NN NN O
is VBZ VBZ O
a DT DT O
syndrome NN NN O
characterized VBN VBN O
by IN IN O
painful JJ JJ O
uterine NN NN O
contractility NN NN O
caused VBN VBN O
by IN IN O
a DT DT O
hypersecretion NN NN O
of IN IN O
endometrial JJ JJ O
prostaglandins NNS NNS B-CHEM
; : : O
non NN NN O
- : : O
steroidal NN NN O
anti NN NN O
- : : O
inflammatory JJ JJ O
drugs NNS NNS O
are VBP VBP O
the DT DT O
first JJ JJ O
choice NN NN O
for IN IN O
its PRP$ PRP$ O
treatment NN NN O
. . . O

However RB RB O
, , , O
in IN IN O
vivo NN NN O
and CC CC O
in IN IN O
vitro NN NN O
studies NNS NNS O
have VBP VBP O
demonstrated VBN VBN O
that IN IN O
myometrial JJ JJ O
cells NNS NNS O
are VBP VBP O
also RB RB O
targets NNS NNS O
of IN IN O
the DT DT O
relaxant JJ JJ O
effects NNS NNS O
of IN IN O
nitric JJ JJ B-CHEM
oxide NN NN I-CHEM
( ( ( O
NO DT DT B-CHEM
) ) ) O
. . . O

The DT DT O
aim NN NN O
of IN IN O
the DT DT O
present JJ JJ O
study NN NN O
was VBD VBD O
to TO TO O
determine VB VB O
the DT DT O
efficacy NN NN O
of IN IN O
glyceryl NN NN B-CHEM
trinitrate NN NN I-CHEM
( ( ( O
GTN NNP NNP B-CHEM
) ) ) O
, , , O
an DT DT O
NO NNP NNP B-CHEM
donor NN NN O
, , , O
in IN IN O
the DT DT O
resolution NN NN O
of IN IN O
primary JJ JJ O
dysmenorrhea NN NN O
in IN IN O
comparison NN NN O
with IN IN O
diclofenac NN NN B-CHEM
( ( ( O
DCF NNP NNP B-CHEM
) ) ) O
. . . O

A DT DT O
total NN NN O
of IN IN O
24 CD CD O
patients NNS NNS O
with IN IN O
the DT DT O
diagnosis NN NN O
of IN IN O
severe JJ JJ O
primary JJ JJ O
dysmenorrhea NN NN O
were VBD VBD O
studied VBN VBN O
during IN IN O
two CD CD O
consecutive JJ JJ O
menstrual JJ JJ O
cycles NNS NNS O
. . . O

In IN IN O
an DT DT O
open JJ JJ O
, , , O
cross JJ JJ O
- - - O
over IN IN O
, , , O
controlled JJ JJ O
design NN NN O
, , , O
patients NNS NNS O
were VBD VBD O
randomized VBN VBN O
to TO TO O
receive VB VB O
either CC CC O
DCF NNP NNP B-CHEM
per IN IN O
os NN NN O
or CC CC O
GTN NNP NNP B-CHEM
patches VBZ VBZ O
the DT DT O
first JJ JJ O
days NNS NNS O
of IN IN O
menses NNS NNS O
, , , O
when WRB WRB O
menstrual JJ JJ O
cramps NNS NNS O
became VBD VBD O
unendurable JJ JJ O
. . . O

In IN IN O
the DT DT O
subsequent JJ JJ O
cycle NN NN O
the DT DT O
other JJ JJ O
treatment NN NN O
was VBD VBD O
used VBN VBN O
. . . O

Patients NNS NNS O
received VBD VBD O
up IN IN O
to TO TO O
3 CD CD O
doses NNS NNS O
/ NN NN O
day NN NN O
of IN IN O
50 CD CD O
mg NN NN O
DCF NNP NNP B-CHEM
or CC CC O
2 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
24 CD CD O
h NN NN O
transdermal NN NN O
GTN NNP NNP B-CHEM
for IN IN O
the DT DT O
first JJ JJ O
3 CD CD O
days NNS NNS O
of IN IN O
the DT DT O
cycle NN NN O
, , , O
according VBG VBG O
to TO TO O
their PRP$ PRP$ O
needs NNS NNS O
. . . O

The DT DT O
participants NNS NNS O
recorded VBN VBN O
menstrual JJ JJ O
symptoms NNS NNS O
and CC CC O
possible JJ JJ O
side NN NN O
- : : O
effects NNS NNS O
at IN IN O
different JJ JJ O
times NNS NNS O
( ( ( O
0 CD CD O
, , , O
30 CD CD O
, , , O
60 CD CD O
, , , O
120 CD CD O
minutes NNS NNS O
) ) ) O
after IN IN O
the DT DT O
first JJ JJ O
dose NN NN O
of IN IN O
medication NN NN O
on IN IN O
the DT DT O
first JJ JJ O
day NN NN O
of IN IN O
the DT DT O
cycle NN NN O
, , , O
with IN IN O
both DT DT O
drugs NNS NNS O
. . . O

The DT DT O
difference NN NN O
in IN IN O
pain NN NN O
intensity NN NN O
score NN NN O
( ( ( O
DPI NNP NNP O
) ) ) O
was VBD VBD O
the DT DT O
main JJ JJ O
outcome NN NN O
variable JJ JJ O
. . . O

Both DT DT O
treatments NNS NNS O
significantly RB RB O
reduced VBN VBN O
DPI NNP NNP O
by IN IN O
the DT DT O
30th CD CD O
minute NN NN O
( ( ( O
GTN NNP NNP B-CHEM
, , , O
- - - O
12 CD CD O
. . . O
8 CD CD O
+ NN NN O
/ NN NN O
- : : O
17 CD CD O
. . . O
9 CD CD O
; : : O
DCF NNP NNP B-CHEM
, , , O
- - - O
18 CD CD O
. . . O
9 CD CD O
+ NN NN O
/ NN NN O
- : : O
16 CD CD O
. . . O
6 CD CD O
) ) ) O
. . . O

However RB RB O
, , , O
DCF NNP NNP B-CHEM
continued VBD VBD O
to TO TO O
be VB VB O
effective JJ JJ O
in IN IN O
reducing VBG VBG O
pelvic JJ JJ O
pain NN NN O
for IN IN O
two CD CD O
hours NNS NNS O
, , , O
whereas IN IN O
GTN NNP NNP B-CHEM
scores NNS NNS O
remained VBD VBD O
more JJR JJR O
or CC CC O
less RBR RBR O
stable JJ JJ O
after IN IN O
30 CD CD O
min NN NN O
and CC CC O
significantly RB RB O
higher JJR JJR O
than IN IN O
those DT DT O
for IN IN O
DFC NNP NNP O
( ( ( O
after IN IN O
one CD CD O
hour NN NN O
: : : O
GTN NNP NNP B-CHEM
, , , O
- - - O
12 CD CD O
. . . O
8 CD CD O
+ NN NN O
/ NN NN O
- : : O
17 CD CD O
. . . O
9 CD CD O
; : : O
DFC NNP NNP O
, , , O
- - - O
18 CD CD O
. . . O
9 CD CD O
+ NN NN O
/ NN NN O
- : : O
16 CD CD O
. . . O
6 CD CD O
and CC CC O
after IN IN O
two CD CD O
hours NNS NNS O
: : : O
GTN NNP NNP B-CHEM
, , , O
- - - O
23 CD CD O
. . . O
7 CD CD O
+ NN NN O
/ NN NN O
- : : O
20 CD CD O
. . . O
5 CD CD O
; : : O
DFC NNP NNP O
, , , O
- - - O
59 CD CD O
. . . O
7 CD CD O
+ NN NN O
/ NN NN O
- : : O
17 CD CD O
. . . O
9 CD CD O
, , , O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
0001 CD CD O
) ) ) O
. . . O

Low NNP NNP O
back RB RB O
pain NN NN O
was VBD VBD O
also RB RB O
relieved VBN VBN O
by IN IN O
both DT DT O
drugs NNS NNS O
. . . O

Headache NNP NNP O
was VBD VBD O
significantly RB RB O
increased VBN VBN O
by IN IN O
GTN NNP NNP B-CHEM
but CC CC O
not RB RB O
by IN IN O
DCF NNP NNP B-CHEM
. . . O

Eight CD CD O
patients NNS NNS O
stopped VBD VBD O
using VBG VBG O
GTN NNP NNP B-CHEM
because IN IN O
headache NN NN O
- - - O
- - - O
attributed VBN VBN O
to TO TO O
its PRP$ PRP$ O
use NN NN O
- - - O
- - - O
became VBD VBD O
intolerable JJ JJ O
. . . O

These DT DT O
findings NNS NNS O
indicate VBP VBP O
that IN IN O
GTN NNP NNP B-CHEM
has VBZ VBZ O
a DT DT O
reduced VBN VBN O
efficacy NN NN O
and CC CC O
tolerability NN NN O
by IN IN O
comparison NN NN O
with IN IN O
DCF NNP NNP B-CHEM
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
primary JJ JJ O
dysmenorrhea NN NN O
. . . O

Temocapril NNP NNP B-CHEM
, , , O
a DT DT O
long JJ JJ O
- - - O
acting VBG VBG O
non NN NN O
- - - O
SH NNP NNP O
group NN NN O
angiotensin NN NN B-CHEM
converting VBG VBG O
enzyme NN NN O
inhibitor NN NN O
, , , O
modulates NNS NNS O
glomerular JJ JJ O
injury NN NN O
in IN IN O
chronic JJ JJ O
puromycin NN NN B-CHEM
aminonucleoside NN NN I-CHEM
nephrosis NN NN O
. . . O

The DT DT O
purpose NN NN O
of IN IN O
the DT DT O
present JJ JJ O
study NN NN O
was VBD VBD O
to TO TO O
determine VB VB O
whether IN IN O
chronic JJ JJ O
administration NN NN O
of IN IN O
temocapril NN NN B-CHEM
, , , O
a DT DT O
long JJ JJ O
- - - O
acting VBG VBG O
non NN NN O
- - - O
SH NNP NNP O
group NN NN O
angiotensin NN NN B-CHEM
converting VBG VBG O
enzyme NN NN O
( ( ( O
ACE NNP NNP O
) ) ) O
inhibitor NN NN O
, , , O
reduced VBD VBD O
proteinuria NN NN O
, , , O
inhibited JJ JJ O
glomerular NN NN O
hypertrophy NN NN O
and CC CC O
prevented VBD VBD O
glomerulosclerosis NN NN O
in IN IN O
chronic JJ JJ O
puromycin NN NN B-CHEM
aminonucleoside NN NN I-CHEM
( ( ( O
PAN NNP NNP B-CHEM
) ) ) O
- : : O
induced JJ JJ O
nephrotic JJ JJ O
rats NNS NNS O
. . . O

Nephrosis NNP NNP O
was VBD VBD O
induced VBN VBN O
by IN IN O
injection NN NN O
of IN IN O
PAN NNP NNP B-CHEM
( ( ( O
15mg CD CD O
/ NN NN O
100g CD CD O
body NN NN O
weight NN NN O
) ) ) O
in IN IN O
male JJ JJ O
Sprague NNP NNP O
- : : O
Dawley NNP NNP O
( ( ( O
SD NNP NNP O
) ) ) O
rats NNS NNS O
. . . O

Four CD CD O
groups NNS NNS O
were VBD VBD O
used VBN VBN O
, , , O
i NNP NNP O
) ) ) O
the DT DT O
PAN NNP NNP B-CHEM
group NN NN O
( ( ( O
14 CD CD O
) ) ) O
, , , O
ii NN NN O
) ) ) O
PAN NNP NNP B-CHEM
/ NN NN O
temocapril NN NN B-CHEM
( ( ( O
13 CD CD O
) ) ) O
, , , O
iii NN NN O
) ) ) O
temocapril NN NN B-CHEM
( ( ( O
14 CD CD O
) ) ) O
and CC CC O
iv NN NN O
) ) ) O
untreated JJ JJ O
controls NNS NNS O
( ( ( O
15 CD CD O
) ) ) O
. . . O

Temocapril NNP NNP B-CHEM
( ( ( O
8 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
) ) ) O
was VBD VBD O
administered VBN VBN O
to TO TO O
the DT DT O
rats NNS NNS O
which WDT WDT O
were VBD VBD O
killed VBN VBN O
at IN IN O
weeks NNS NNS O
4 CD CD O
, , , O
14 CD CD O
or CC CC O
20 CD CD O
. . . O

At IN IN O
each DT DT O
time NN NN O
point NN NN O
, , , O
systolic JJ JJ O
blood NN NN O
pressure NN NN O
( ( ( O
BP NNP NNP O
) ) ) O
, , , O
urinary JJ JJ O
protein NN NN O
excretion NN NN O
and CC CC O
renal JJ JJ O
histopathological JJ JJ O
findings NNS NNS O
were VBD VBD O
evaluated VBN VBN O
, , , O
and CC CC O
morphometric JJ JJ O
image NN NN O
analysis NN NN O
was VBD VBD O
done VBN VBN O
. . . O

Systolic NNP NNP O
BP NNP NNP O
in IN IN O
the DT DT O
PAN NNP NNP B-CHEM
group NN NN O
was VBD VBD O
significantly RB RB O
high JJ JJ O
at IN IN O
4 CD CD O
, , , O
14 CD CD O
and CC CC O
20 CD CD O
weeks NNS NNS O
, , , O
but CC CC O
was VBD VBD O
normal JJ JJ O
in IN IN O
the DT DT O
PAN NNP NNP B-CHEM
/ NN NN O
temocapril NN NN B-CHEM
group NN NN O
. . . O

Urinary NNP NNP O
protein NN NN O
excretion NN NN O
in IN IN O
the DT DT O
PAN NNP NNP B-CHEM
group NN NN O
increased VBD VBD O
significantly RB RB O
, , , O
peaking VBG VBG O
at IN IN O
8 CD CD O
days NNS NNS O
, , , O
then RB RB O
decreased VBD VBD O
at IN IN O
4 CD CD O
weeks NNS NNS O
, , , O
but CC CC O
rose VBD VBD O
again RB RB O
significantly RB RB O
at IN IN O
14 CD CD O
and CC CC O
20 CD CD O
weeks NNS NNS O
. . . O

Temocapril NNP NNP B-CHEM
did VBD VBD O
not RB RB O
attenuate VB VB O
proteinuria NN NN O
at IN IN O
8 CD CD O
days NNS NNS O
, , , O
but CC CC O
it PRP PRP O
did VBD VBD O
markedly RB RB O
lower JJR JJR O
it PRP PRP O
from IN IN O
weeks NNS NNS O
4 CD CD O
to TO TO O
20 CD CD O
. . . O

The DT DT O
glomerulosclerosis NN NN O
index NN NN O
( ( ( O
GSI NNP NNP O
) ) ) O
was VBD VBD O
6 CD CD O
. . . O
21 CD CD O
% NN NN O
at IN IN O
4 CD CD O
weeks NNS NNS O
and CC CC O
respectively RB RB O
25 CD CD O
. . . O
35 CD CD O
% NN NN O
and CC CC O
30 CD CD O
. . . O
49 CD CD O
% NN NN O
at IN IN O
14 CD CD O
and CC CC O
20 CD CD O
weeks NNS NNS O
in IN IN O
the DT DT O
PAN NNP NNP B-CHEM
group NN NN O
. . . O

There EX EX O
was VBD VBD O
a DT DT O
significant JJ JJ O
correlation NN NN O
between IN IN O
urinary JJ JJ O
protein NN NN O
excretion NN NN O
and CC CC O
GSI NNP NNP O
( ( ( O
r LS LS O
= SYM SYM O
0 CD CD O
. . . O
808 CD CD O
, , , O
p NN NN O
< NN NN O
0 CD CD O
. . . O
0001 CD CD O
) ) ) O
. . . O

The DT DT O
ratio NN NN O
of IN IN O
glomerular NN NN O
tuft NN NN O
area NN NN O
to TO TO O
the DT DT O
area NN NN O
of IN IN O
Bowman NNP NNP O
' POS POS O
s VBZ VBZ O
capsules NNS NNS O
( ( ( O
GT NNP NNP O
/ NN NN O
BC NNP NNP O
) ) ) O
in IN IN O
the DT DT O
PAN NNP NNP B-CHEM
group NN NN O
was VBD VBD O
significantly RB RB O
increased VBN VBN O
, , , O
but CC CC O
it PRP PRP O
was VBD VBD O
significantly RB RB O
lower JJR JJR O
in IN IN O
the DT DT O
PAN NNP NNP B-CHEM
/ NN NN O
temocapril NN NN B-CHEM
group NN NN O
. . . O

It PRP PRP O
appears VBZ VBZ O
that IN IN O
temocapril NN NN B-CHEM
was VBD VBD O
effective JJ JJ O
in IN IN O
retarding VBG VBG O
renal JJ JJ O
progression NN NN O
and CC CC O
protected VBN VBN O
renal JJ JJ O
function NN NN O
in IN IN O
PAN NNP NNP B-CHEM
neprotic JJ JJ O
rats NNS NNS O
. . . O

Pulmonary NNP NNP O
hypertension NN NN O
after IN IN O
ibuprofen NN NN B-CHEM
prophylaxis NN NN O
in IN IN O
very RB RB O
preterm JJ JJ O
infants NNS NNS O
. . . O

We PRP PRP O
report VBP VBP O
three CD CD O
cases NNS NNS O
of IN IN O
severe JJ JJ O
hypoxaemia NN NN O
after IN IN O
ibuprofen NN NN B-CHEM
administration NN NN O
during IN IN O
a DT DT O
randomised JJ JJ O
controlled VBN VBN O
trial NN NN O
of IN IN O
prophylactic JJ JJ O
treatment NN NN O
of IN IN O
patent NN NN O
ductus NN NN O
arteriosus NN NN O
with IN IN O
ibuprofen NN NN B-CHEM
in IN IN O
premature JJ JJ O
infants NNS NNS O
born VBN VBN O
at IN IN O
less JJR JJR O
than IN IN O
28 CD CD O
weeks NNS NNS O
of IN IN O
gestation NN NN O
. . . O

Echocardiography NNP NNP O
showed VBD VBD O
severely RB RB O
decreased VBN VBN O
pulmonary JJ JJ O
blood NN NN O
flow NN NN O
. . . O

Hypoxaemia NNP NNP O
resolved VBD VBD O
quickly RB RB O
on IN IN O
inhaled JJ JJ O
nitric JJ JJ B-CHEM
oxide NN NN I-CHEM
therapy NN NN O
. . . O

We PRP PRP O
suggest VBP VBP O
that IN IN O
investigators NNS NNS O
involved VBN VBN O
in IN IN O
similar JJ JJ O
trials NNS NNS O
pay VBP VBP O
close VB VB O
attention NN NN O
to TO TO O
pulmonary VB VB O
pressure NN NN O
if IN IN O
hypoxaemia NN NN O
occurs VBZ VBZ O
after IN IN O
prophylactic JJ JJ O
administration NN NN O
of IN IN O
ibuprofen NN NN B-CHEM
. . . O

Hyponatremia NNP NNP O
and CC CC O
syndrome NN NN O
of IN IN O
inappropriate JJ JJ O
anti NN NN O
- : : O
diuretic JJ JJ O
hormone NN NN O
reported VBD VBD O
with IN IN O
the DT DT O
use NN NN O
of IN IN O
Vincristine NNP NNP B-CHEM
: : : O
an DT DT O
over IN IN O
- - - O
representation NN NN O
of IN IN O
Asians NNP NNP O
? . . O

PURPOSE NNP NNP O
: : : O
This DT DT O
retrospective NN NN O
study NN NN O
used VBD VBD O
a DT DT O
pharmaceutical JJ JJ O
company NN NN O
' '' '' O
s VBZ VBZ O
global JJ JJ O
safety NN NN O
database NN NN O
to TO TO O
determine VB VB O
the DT DT O
reporting VBG VBG O
rate NN NN O
of IN IN O
hyponatremia NN NN O
and CC CC O
/ NN NN O
or CC CC O
syndrome NN NN O
of IN IN O
inappropriate JJ JJ O
secretion NN NN O
of IN IN O
anti JJ JJ O
- : : O
diuretic JJ JJ O
hormone NN NN O
( ( ( O
SIADH NNP NNP O
) ) ) O
among IN IN O
vincristine NN NN B-CHEM
- - - O
treated VBN VBN O
patients NNS NNS O
and CC CC O
to TO TO O
explore VB VB O
the DT DT O
possibility NN NN O
of IN IN O
at IN IN O
- - - O
risk NN NN O
population NN NN O
subgroups NNS NNS O
. . . O

METHOD NNP NNP O
: : : O
We PRP PRP O
searched VBD VBD O
the DT DT O
Eli NNP NNP O
Lilly NNP NNP O
and CC CC O
Company NNP NNP O
' POS POS O
s VBZ VBZ O
computerized JJ JJ O
adverse JJ JJ O
event NN NN O
database NN NN O
for IN IN O
all DT DT O
reported VBN VBN O
cases NNS NNS O
of IN IN O
hyponatremia NN NN O
and CC CC O
/ NN NN O
or CC CC O
SIADH NNP NNP O
as IN IN O
of IN IN O
1 CD CD O
November NNP NNP O
1999 CD CD O
that WDT WDT O
had VBD VBD O
been VBN VBN O
reported VBN VBN O
during IN IN O
the DT DT O
use NN NN O
of IN IN O
vincristine NN NN B-CHEM
. . . O

RESULTS NNS NNS O
: : : O
A DT DT O
total NN NN O
of IN IN O
76 CD CD O
cases NNS NNS O
of IN IN O
hyponatremia NN NN O
and CC CC O
/ NN NN O
or CC CC O
SIADH NNP NNP O
associated VBN VBN O
with IN IN O
vincristine NN NN B-CHEM
use NN NN O
were VBD VBD O
identified VBN VBN O
. . . O

The DT DT O
overall JJ JJ O
reporting NN NN O
rate NN NN O
was VBD VBD O
estimated VBN VBN O
to TO TO O
be VB VB O
1 CD CD O
. . . O
3 CD CD O
/ NN NN O
100 CD CD O
, , , O
000 CD CD O
treated VBN VBN O
patients NNS NNS O
. . . O

The DT DT O
average JJ JJ O
age NN NN O
of IN IN O
patients NNS NNS O
was VBD VBD O
35 CD CD O
. . . O
6 CD CD O
+ NN NN O
/ NN NN O
- : : O
28 CD CD O
. . . O
3 CD CD O
years NNS NNS O
, , , O
and CC CC O
62 CD CD O
% NN NN O
were VBD VBD O
males NNS NNS O
. . . O

Approximately RB RB O
75 CD CD O
% NN NN O
of IN IN O
the DT DT O
patients NNS NNS O
were VBD VBD O
receiving VBG VBG O
treatment NN NN O
for IN IN O
leukemia NN NN O
or CC CC O
lymphoma NN NN O
. . . O

Among IN IN O
the DT DT O
39 CD CD O
reports NNS NNS O
that WDT WDT O
included VBD VBD O
information NN NN O
on IN IN O
race NN NN O
, , , O
the DT DT O
racial JJ JJ O
distribution NN NN O
was VBD VBD O
: : : O
1 CD CD O
Black NNP NNP O
, , , O
3 CD CD O
Caucasian NNP NNP O
, , , O
and CC CC O
35 CD CD O
Asian NNP NNP O
. . . O

CONCLUSION NNP NNP O
: : : O
Our PRP$ PRP$ O
data NNS NNS O
suggest VBP VBP O
that IN IN O
Asian NNP NNP O
patients NNS NNS O
may MD MD O
be VB VB O
at IN IN O
increased VBN VBN O
risk NN NN O
of IN IN O
hyponatremia NN NN O
and CC CC O
/ NN NN O
or CC CC O
SIADH NNP NNP O
associated VBN VBN O
with IN IN O
vincristine NN NN B-CHEM
use NN NN O
. . . O

Although IN IN O
the DT DT O
overall JJ JJ O
reported VBD VBD O
rate NN NN O
of IN IN O
SIADH NNP NNP O
associated VBN VBN O
with IN IN O
vincristine NN NN B-CHEM
is VBZ VBZ O
very RB RB O
low JJ JJ O
, , , O
physicians NNS NNS O
caring VBG VBG O
for IN IN O
Asian JJ JJ O
oncology NN NN O
patients NNS NNS O
should MD MD O
be VB VB O
aware JJ JJ O
of IN IN O
this DT DT O
potential JJ JJ O
serious JJ JJ O
but CC CC O
reversible JJ JJ O
adverse JJ JJ O
event NN NN O
. . . O

Delayed NNP NNP O
toxicity NN NN O
of IN IN O
cyclophosphamide NN NN B-CHEM
on IN IN O
the DT DT O
bladder NN NN O
of IN IN O
DBA NNP NNP O
/ NN NN O
2 CD CD O
and CC CC O
C57BL NNP NNP O
/ NN NN O
6 CD CD O
female JJ JJ O
mouse NN NN O
. . . O

The DT DT O
present JJ JJ O
study NN NN O
describes VBZ VBZ O
the DT DT O
delayed JJ JJ O
development NN NN O
of IN IN O
a DT DT O
severe JJ JJ O
bladder NN NN O
pathology NN NN O
in IN IN O
a DT DT O
susceptible JJ JJ O
strain NN NN O
of IN IN O
mice NN NN O
( ( ( O
DBA NNP NNP O
/ NN NN O
2 CD CD O
) ) ) O
but CC CC O
not RB RB O
in IN IN O
a DT DT O
resistant JJ JJ O
strain NN NN O
( ( ( O
C57BL NNP NNP O
/ NN NN O
6 CD CD O
) ) ) O
when WRB WRB O
both DT DT O
were VBD VBD O
treated VBN VBN O
with IN IN O
a DT DT O
single JJ JJ O
300 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
dose NN NN O
of IN IN O
cyclophosphamide NN NN B-CHEM
( ( ( O
CY NNP NNP B-CHEM
) ) ) O
. . . O

Inbred NNP NNP O
DBA NNP NNP O
/ NN NN O
2 CD CD O
and CC CC O
C57BL NNP NNP O
/ NN NN O
6 CD CD O
female JJ JJ O
mice NN NN O
were VBD VBD O
injected VBN VBN O
with IN IN O
CY NNP NNP B-CHEM
, , , O
and CC CC O
the DT DT O
effect NN NN O
of IN IN O
the DT DT O
drug NN NN O
on IN IN O
the DT DT O
bladder NN NN O
was VBD VBD O
assessed VBN VBN O
during IN IN O
100 CD CD O
days NNS NNS O
by IN IN O
light JJ JJ O
microscopy NN NN O
using VBG VBG O
different JJ JJ O
staining NN NN O
procedures NNS NNS O
, , , O
and CC CC O
after IN IN O
30 CD CD O
days NNS NNS O
by IN IN O
conventional JJ JJ O
electron NN NN O
microscopy NN NN O
. . . O

Early RB RB O
CY NNP NNP B-CHEM
toxicity NN NN O
caused VBD VBD O
a DT DT O
typical JJ JJ O
haemorrhagic JJ JJ O
cystitis NNS NNS O
in IN IN O
both DT DT O
strains NNS NNS O
that WDT WDT O
was VBD VBD O
completely RB RB O
repaired VBN VBN O
in IN IN O
about IN IN O
7 CD CD O
- : : O
10 CD CD O
days NNS NNS O
. . . O

After IN IN O
30 CD CD O
days NNS NNS O
of IN IN O
CY NNP NNP B-CHEM
injection NN NN O
ulcerous JJ JJ O
and CC CC O
non NN NN O
- - - O
ulcerous JJ JJ O
forms NNS NNS O
of IN IN O
chronic JJ JJ O
cystitis NNS NNS O
appeared VBD VBD O
in IN IN O
86 CD CD O
% NN NN O
of IN IN O
DBA NNP NNP O
/ NN NN O
2 CD CD O
mice NN NN O
but CC CC O
only RB RB O
in IN IN O
4 CD CD O
% NN NN O
of IN IN O
C57BL NNP NNP O
/ NN NN O
6 CD CD O
mice NN NN O
. . . O

Delayed JJ JJ O
cystitis NNS NNS O
was VBD VBD O
characterized VBN VBN O
by IN IN O
infiltration NN NN O
and CC CC O
transepithelial JJ JJ O
passage NN NN O
into IN IN O
the DT DT O
lumen NNS NNS O
of IN IN O
inflammatory JJ JJ O
cells NNS NNS O
and CC CC O
by IN IN O
frequent JJ JJ O
exfoliation NN NN O
of IN IN O
the DT DT O
urothelium NN NN O
. . . O

Mast NNP NNP O
cells NNS NNS O
appeared VBD VBD O
in IN IN O
the DT DT O
connective JJ JJ O
and CC CC O
muscular JJ JJ O
layers NNS NNS O
of IN IN O
the DT DT O
bladder NN NN O
at IN IN O
a DT DT O
much RB RB O
higher JJR JJR O
number NN NN O
in IN IN O
DBA NNP NNP O
/ NN NN O
2 CD CD O
mice NN NN O
than IN IN O
in IN IN O
C57BL NNP NNP O
/ NN NN O
6 CD CD O
mice NN NN O
or CC CC O
untreated JJ JJ O
controls NNS NNS O
. . . O

Electron NNP NNP O
microscopy NN NN O
disclosed VBD VBD O
the DT DT O
absence NN NN O
of IN IN O
the DT DT O
typical JJ JJ O
discoidal NN NN O
vesicles NNS NNS O
normally RB RB O
present JJ JJ O
in IN IN O
the DT DT O
cytoplasm NN NN O
of IN IN O
surface NN NN O
cells NNS NNS O
. . . O

Instead RB RB O
, , , O
numerous JJ JJ O
abnormal JJ JJ O
vesicles NNS NNS O
containing VBG VBG O
one CD CD O
or CC CC O
several JJ JJ O
dark JJ JJ O
granules NNS NNS O
were VBD VBD O
observed VBN VBN O
in IN IN O
the DT DT O
cytoplasm NN NN O
of IN IN O
cells NNS NNS O
from IN IN O
all PDT PDT O
the DT DT O
epithelial NN NN O
layers NNS NNS O
. . . O

Delayed JJ JJ O
cystitis NNS NNS O
still RB RB O
persisted VBD VBD O
in IN IN O
DBA NNP NNP O
/ NN NN O
2 CD CD O
mice NN NN O
100 CD CD O
days NNS NNS O
after IN IN O
treatment NN NN O
. . . O

These DT DT O
results NNS NNS O
indicate VBP VBP O
that IN IN O
delayed JJ JJ O
toxicity NN NN O
of IN IN O
CY NNP NNP B-CHEM
in IN IN O
female JJ JJ O
DBA NNP NNP O
/ NN NN O
2 CD CD O
mice NN NN O
causes NNS NNS O
a DT DT O
bladder NN NN O
pathology NN NN O
that WDT WDT O
is VBZ VBZ O
not RB RB O
observed VBN VBN O
in IN IN O
C57BL NNP NNP O
/ NN NN O
6 CD CD O
mice NN NN O
. . . O

This DT DT O
pathology NN NN O
resembles VBZ VBZ O
interstitial JJ JJ O
cystitis NNS NNS O
in IN IN O
humans NNS NNS O
and CC CC O
could MD MD O
perhaps RB RB O
be VB VB O
used VBN VBN O
as IN IN O
an DT DT O
animal NN NN O
model NN NN O
for IN IN O
studies NNS NNS O
on IN IN O
the DT DT O
disease NN NN O
. . . O

High NNP NNP O
- : : O
dose NN NN O
5 CD CD B-CHEM
- : : I-CHEM
fluorouracil NN NN I-CHEM
/ NN NN O
folinic JJ JJ B-CHEM
acid NN NN I-CHEM
in IN IN O
combination NN NN O
with IN IN O
three CD CD O
- - - O
weekly JJ JJ O
mitomycin NN NN B-CHEM
C NNP NNP I-CHEM
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
advanced VBD VBD O
gastric JJ JJ O
cancer NN NN O
. . . O

A DT DT O
phase NN NN O
II NNP NNP O
study NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
The DT DT O
24 CD CD O
- : : O
hour NN NN O
continuous JJ JJ O
infusion NN NN O
of IN IN O
5 CD CD B-CHEM
- : : I-CHEM
fluorouracil NN NN I-CHEM
( ( ( O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
) ) ) O
and CC CC O
folinic JJ JJ B-CHEM
acid NN NN I-CHEM
( ( ( O
FA NNP NNP B-CHEM
) ) ) O
as IN IN O
part NN NN O
of IN IN O
several JJ JJ O
new JJ JJ O
multidrug NN NN O
chemotherapy NN NN O
regimens NNS NNS O
in IN IN O
advanced JJ JJ O
gastric JJ JJ O
cancer NN NN O
( ( ( O
AGC NNP NNP O
) ) ) O
has VBZ VBZ O
shown VBN VBN O
to TO TO O
be VB VB O
effective JJ JJ O
, , , O
with IN IN O
low JJ JJ O
toxicity NN NN O
. . . O

In IN IN O
a DT DT O
previous JJ JJ O
phase NN NN O
II NNP NNP O
study NN NN O
with IN IN O
3 CD CD O
- : : O
weekly JJ JJ O
bolus NN NN O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
, , , O
FA NNP NNP B-CHEM
and CC CC O
mitomycin NN NN B-CHEM
C NNP NNP I-CHEM
( ( ( O
MMC NNP NNP B-CHEM
) ) ) O
we PRP PRP O
found VBD VBD O
a DT DT O
low JJ JJ O
toxicity NN NN O
rate NN NN O
and CC CC O
response NN NN O
rates NNS NNS O
comparable JJ JJ O
to TO TO O
those DT DT O
of IN IN O
regimens NNS NNS O
such JJ JJ O
as IN IN O
ELF NNP NNP O
, , , O
FAM NNP NNP O
or CC CC O
FAMTX NNP NNP O
, , , O
and CC CC O
a DT DT O
promising JJ JJ O
median NN NN O
overall JJ JJ O
survival NN NN O
. . . O

In IN IN O
order NN NN O
to TO TO O
improve VB VB O
this DT DT O
MMC NNP NNP B-CHEM
- : : O
dependent NN NN O
schedule NN NN O
we PRP PRP O
initiated VBD VBD O
a DT DT O
phase NN NN O
II NNP NNP O
study NN NN O
with IN IN O
high JJ JJ O
- - - O
dose NN NN O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
/ NN NN O
FA NNP NNP B-CHEM
and CC CC O
3 CD CD O
- : : O
weekly JJ JJ O
bolus NN NN O
MMC NNP NNP B-CHEM
. . . O

PATIENTS NNS NNS O
AND CC CC O
METHODS NNP NNP O
: : : O
From IN IN O
February NNP NNP O
, , , O
1998 CD CD O
to TO TO O
September NNP NNP O
, , , O
2000 CD CD O
we PRP PRP O
recruited VBD VBD O
33 CD CD O
patients NNS NNS O
with IN IN O
AGC NNP NNP O
to TO TO O
receive VB VB O
weekly JJ JJ O
24 CD CD O
- : : O
hour NN NN O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
2 CD CD O
, , , O
600 CD CD O
mg NN NN O
/ NN NN O
m NN NN O
( ( ( O
2 CD CD O
) ) ) O
preceded VBN VBN O
by IN IN O
2 CD CD O
- : : O
hour NN NN O
FA NNP NNP B-CHEM
500 CD CD O
mg NN NN O
/ NN NN O
m NN NN O
( ( ( O
2 CD CD O
) ) ) O
for IN IN O
6 CD CD O
weeks NNS NNS O
, , , O
followed VBN VBN O
by IN IN O
a DT DT O
2 CD CD O
- : : O
week NN NN O
rest NN NN O
period NN NN O
. . . O

Bolus NNP NNP O
MMC NNP NNP B-CHEM
10 CD CD O
mg NN NN O
/ NN NN O
m NN NN O
( ( ( O
2 CD CD O
) ) ) O
was VBD VBD O
added VBN VBN O
in IN IN O
3 CD CD O
- : : O
weekly JJ JJ O
intervals NNS NNS O
. . . O

Treatment NN NN O
given VBN VBN O
on IN IN O
an DT DT O
outpatient JJ JJ O
basis NN NN O
, , , O
using VBG VBG O
portable JJ JJ O
pump NN NN O
systems NNS NNS O
, , , O
was VBD VBD O
repeated VBN VBN O
on IN IN O
day NN NN O
57 CD CD O
. . . O

Patients NNS NNS O
' POS POS O
characteristics NNS NNS O
were VBD VBD O
: : : O
male JJ JJ O
/ NN NN O
female NN NN O
ratio NN NN O
20 CD CD O
/ NN NN O
13 CD CD O
; : : O
median JJ JJ O
age NN NN O
57 CD CD O
( ( ( O
27 CD CD O
- : : O
75 CD CD O
) ) ) O
years NNS NNS O
; : : O
median NN NN O
WHO WP WP O
status NN NN O
1 CD CD O
( ( ( O
0 CD CD O
- : : O
2 CD CD O
) ) ) O
. . . O

18 CD CD O
patients NNS NNS O
had VBD VBD O
a DT DT O
primary JJ JJ O
AGC NNP NNP O
, , , O
and CC CC O
15 CD CD O
showed VBD VBD O
a DT DT O
relapsed JJ JJ O
AGC NNP NNP O
. . . O

Median NNP NNP O
follow VB VB O
- - - O
up RP RP O
was VBD VBD O
11 CD CD O
. . . O
8 CD CD O
months NNS NNS O
( ( ( O
range NN NN O
of IN IN O
those DT DT O
surviving VBG VBG O
: : : O
2 CD CD O
. . . O
7 CD CD O
- : : O
11 CD CD O
. . . O
8 CD CD O
months NNS NNS O
) ) ) O
. . . O

RESULTS NNS NNS O
: : : O
32 CD CD O
patients NNS NNS O
were VBD VBD O
evaluable JJ JJ O
for IN IN O
response NN NN O
- - - O
complete JJ JJ O
remission NN NN O
9 CD CD O
. . . O
1 CD CD O
% NN NN O
( ( ( O
n NN NN O
= SYM SYM O
3 CD CD O
) ) ) O
, , , O
partial JJ JJ O
remission NN NN O
45 CD CD O
. . . O
5 CD CD O
% NN NN O
( ( ( O
n NN NN O
= SYM SYM O
15 CD CD O
) ) ) O
, , , O
no DT DT O
change NN NN O
27 CD CD O
. . . O
3 CD CD O
% NN NN O
( ( ( O
n NN NN O
= SYM SYM O
9 CD CD O
) ) ) O
, , , O
progressive JJ JJ O
disease NN NN O
15 CD CD O
. . . O
1 CD CD O
% NN NN O
( ( ( O
n NN NN O
= SYM SYM O
5 CD CD O
) ) ) O
. . . O

Median NNP NNP O
overall JJ JJ O
survival NN NN O
time NN NN O
was VBD VBD O
10 CD CD O
. . . O
2 CD CD O
months NNS NNS O
[ NN NN O
95 CD CD O
% NN NN O
confidence NN NN O
interval NN NN O
( ( ( O
CI NNP NNP O
) ) ) O
: : : O
8 CD CD O
. . . O
7 CD CD O
- : : O
11 CD CD O
. . . O
6 CD CD O
] NN NN O
, , , O
and CC CC O
median JJ JJ O
progression NN NN O
- - - O
free JJ JJ O
survival NN NN O
time NN NN O
was VBD VBD O
7 CD CD O
. . . O
6 CD CD O
months NNS NNS O
( ( ( O
95 CD CD O
% NN NN O
CI NNP NNP O
: : : O
4 CD CD O
. . . O
4 CD CD O
- : : O
10 CD CD O
. . . O
9 CD CD O
) ) ) O
. . . O

The DT DT O
worst JJS JJS O
toxicities NNS NNS O
( ( ( O
% NN NN O
) ) ) O
observed VBD VBD O
were VBD VBD O
( ( ( O
CTC NNP NNP O
- : : O
NCI NNP NNP O
1 CD CD O
/ NN NN O
2 CD CD O
/ NN NN O
3 CD CD O
) ) ) O
: : : O
leukopenia NN NN O
45 CD CD O
. . . O
5 CD CD O
/ NN NN O
18 CD CD O
. . . O
2 CD CD O
/ NN NN O
6 CD CD O
. . . O
1 CD CD O
, , , O
thrombocytopenia NN NN O
33 CD CD O
. . . O
3 CD CD O
/ NN NN O
9 CD CD O
. . . O
1 CD CD O
/ NN NN O
6 CD CD O
. . . O
1 CD CD O
, , , O
vomitus NN NN O
24 CD CD O
. . . O
2 CD CD O
/ NN NN O
9 CD CD O
. . . O
1 CD CD O
/ NN NN O
0 CD CD O
, , , O
diarrhea NN NN O
36 CD CD O
. . . O
4 CD CD O
/ NN NN O
6 CD CD O
. . . O
1 CD CD O
/ NN NN O
3 CD CD O
. . . O
0 CD CD O
, , , O
stomatitis NN NN O
18 CD CD O
. . . O
2 CD CD O
/ NN NN O
9 CD CD O
. . . O
1 CD CD O
/ NN NN O
0 CD CD O
, , , O
hand NN NN O
- - - O
foot NN NN O
syndrome NN NN O
12 CD CD O
. . . O
1 CD CD O
/ NN NN O
0 CD CD O
/ NN NN O
0 CD CD O
. . . O

Two CD CD O
patients NNS NNS O
developed VBN VBN O
hemolytic JJ JJ O
- - - O
uremic JJ JJ O
syndrome NN NN O
( ( ( O
HUS NNP NNP O
) ) ) O
. . . O

CONCLUSIONS NNP NNP O
: : : O
High JJ JJ O
- - - O
dose NN NN O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
/ NN NN O
FA NNP NNP B-CHEM
/ NN NN O
MMC NNP NNP B-CHEM
is VBZ VBZ O
an DT DT O
effective JJ JJ O
and CC CC O
well RB RB O
- - - O
tolerated JJ JJ O
outpatient NN NN O
regimen NNS NNS O
for IN IN O
AGC NNP NNP O
( ( ( O
objective NN NN O
response NN NN O
rate NN NN O
54 CD CD O
. . . O
6 CD CD O
% NN NN O
) ) ) O
. . . O

It PRP PRP O
may MD MD O
serve VB VB O
as IN IN O
an DT DT O
alternative NN NN O
to TO TO O
cisplatin VB VB B-CHEM
- : : O
containing VBG VBG O
regimens NNS NNS O
; : : O
however RB RB O
, , , O
it PRP PRP O
has VBZ VBZ O
to TO TO O
be VB VB O
considered VBN VBN O
that IN IN O
possibly RB RB O
HUS NNP NNP O
may MD MD O
occur VB VB O
. . . O

Persistent NNP NNP O
sterile JJ JJ O
leukocyturia NN NN O
is VBZ VBZ O
associated VBN VBN O
with IN IN O
impaired JJ JJ O
renal JJ JJ O
function NN NN O
in IN IN O
human JJ JJ O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 CD CD O
- : : O
infected JJ JJ O
children NNS NNS O
treated VBN VBN O
with IN IN O
indinavir NN NN B-CHEM
. . . O

BACKGROUND NNP NNP O
: : : O
Prolonged NNP NNP O
administration NN NN O
of IN IN O
indinavir NN NN B-CHEM
is VBZ VBZ O
associated VBN VBN O
with IN IN O
the DT DT O
occurrence NN NN O
of IN IN O
a DT DT O
variety NN NN O
of IN IN O
renal JJ JJ O
complications NNS NNS O
in IN IN O
adults NNS NNS O
. . . O

These DT DT O
well RB RB O
- - - O
documented VBN VBN O
side NN NN O
effects NNS NNS O
have VBP VBP O
restricted VBN VBN O
the DT DT O
use NN NN O
of IN IN O
this DT DT O
potent JJ JJ O
protease NN NN O
inhibitor NN NN O
in IN IN O
children NNS NNS O
. . . O

DESIGN NNP NNP O
: : : O
A DT DT O
prospective JJ JJ O
study NN NN O
to TO TO O
monitor VB VB O
indinavir NN NN B-CHEM
- - - O
related VBN VBN O
nephrotoxicity NN NN O
in IN IN O
a DT DT O
cohort NN NN O
of IN IN O
30 CD CD O
human JJ JJ O
immunodeficiency NN NN O
virus NN NN O
type NN NN O
1 CD CD O
- : : O
infected JJ JJ O
children NNS NNS O
treated VBN VBN O
with IN IN O
indinavir NN NN B-CHEM
. . . O

METHODS NNP NNP O
: : : O
Urinary NNP NNP O
pH NN NN O
, , , O
albumin NN NN O
, , , O
creatinine NN NN B-CHEM
, , , O
the DT DT O
presence NN NN O
of IN IN O
erythrocytes NNS NNS O
, , , O
leukocytes NNS NNS O
, , , O
bacteria NNS NNS O
and CC CC O
crystals NNS NNS O
, , , O
and CC CC O
culture NN NN O
were VBD VBD O
analyzed VBN VBN O
every DT DT O
3 CD CD O
months NNS NNS O
for IN IN O
96 CD CD O
weeks NNS NNS O
. . . O

Serum NNP NNP O
creatinine NN NN B-CHEM
levels NNS NNS O
were VBD VBD O
routinely RB RB O
determined VBN VBN O
at IN IN O
the DT DT O
same JJ JJ O
time NN NN O
points NNS NNS O
. . . O

Steady JJ JJ O
- : : O
state NN NN O
pharmacokinetics NNS NNS O
of IN IN O
indinavir NN NN B-CHEM
were VBD VBD O
done VBN VBN O
at IN IN O
week NN NN O
4 CD CD O
after IN IN O
the DT DT O
initiation NN NN O
of IN IN O
indinavir NN NN B-CHEM
. . . O

RESULTS NNS NNS O
: : : O
The DT DT O
cumulative JJ JJ O
incidence NN NN O
of IN IN O
persistent JJ JJ O
sterile JJ JJ O
leukocyturia NN NN O
( ( ( O
> NN NN O
or CC CC O
= SYM SYM O
75 CD CD O
cells NNS NNS O
/ NN NN O
micro JJ JJ O
L NNP NNP O
in IN IN O
at IN IN O
least JJS JJS O
2 CD CD O
consecutive JJ JJ O
visits NNS NNS O
) ) ) O
after IN IN O
96 CD CD O
weeks NNS NNS O
was VBD VBD O
53 CD CD O
% NN NN O
. . . O

Persistent NNP NNP O
sterile JJ JJ O
leukocyturia NN NN O
was VBD VBD O
frequently RB RB O
associated VBN VBN O
with IN IN O
a DT DT O
mild JJ JJ O
increase NN NN O
in IN IN O
the DT DT O
urine NN NN O
albumin NN NN O
/ NN NN O
creatinine NN NN B-CHEM
ratio NN NN O
and CC CC O
by IN IN O
microscopic JJ JJ O
hematuria NN NN O
. . . O

The DT DT O
cumulative JJ JJ O
incidence NN NN O
of IN IN O
serum NN NN O
creatinine NN NN B-CHEM
levels NNS NNS O
> NN NN O
50 CD CD O
% NN NN O
above IN IN O
normal NN NN O
was VBD VBD O
33 CD CD O
% NN NN O
after IN IN O
96 CD CD O
weeks NNS NNS O
. . . O

Children NNP NNP O
with IN IN O
persistent JJ JJ O
sterile JJ JJ O
leukocyturia NN NN O
more RBR RBR O
frequently RB RB O
had VBD VBD O
serum NN NN O
creatinine NN NN B-CHEM
levels NNS NNS O
of IN IN O
50 CD CD O
% NN NN O
above IN IN O
normal JJ JJ O
than IN IN O
those DT DT O
children NNS NNS O
without IN IN O
persistent JJ JJ O
sterile JJ JJ O
leukocyturia NN NN O
. . . O

In IN IN O
children NNS NNS O
younger JJR JJR O
than IN IN O
5 CD CD O
. . . O
6 CD CD O
years NNS NNS O
, , , O
persistent JJ JJ O
sterile JJ JJ O
leukocyturia NNS NNS O
was VBD VBD O
significantly RB RB O
more RBR RBR O
frequent JJ JJ O
than IN IN O
in IN IN O
older JJR JJR O
children NNS NNS O
. . . O

A DT DT O
higher JJR JJR O
cumulative JJ JJ O
incidence NN NN O
of IN IN O
persistent JJ JJ O
leukocyturia NN NN O
was VBD VBD O
found VBN VBN O
in IN IN O
children NNS NNS O
with IN IN O
an DT DT O
area NN NN O
under IN IN O
the DT DT O
curve NN NN O
> NN NN O
19 CD CD O
mg NN NN O
/ NN NN O
L NNP NNP O
x SYM SYM O
h NN NN O
or CC CC O
a DT DT O
peak JJ JJ O
serum NN NN O
level NN NN O
of IN IN O
indinavir NN NN B-CHEM
> NN NN O
12 CD CD O
mg NN NN O
/ NN NN O
L NNP NNP O
. . . O

In IN IN O
4 CD CD O
children NNS NNS O
, , , O
indinavir NN NN B-CHEM
was VBD VBD O
discontinued VBN VBN O
because IN IN O
of IN IN O
nephrotoxicity NN NN O
. . . O

Subsequently RB RB O
, , , O
the DT DT O
serum NN NN O
creatinine NN NN B-CHEM
levels NNS NNS O
decreased VBD VBD O
, , , O
the DT DT O
urine NN NN O
albumin NN NN O
/ NN NN O
creatinine NN NN B-CHEM
ratios NN NN O
returned VBD VBD O
to TO TO O
zero CD CD O
, , , O
and CC CC O
the DT DT O
leukocyturia NN NN O
disappeared VBD VBD O
within IN IN O
3 CD CD O
months NNS NNS O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Children NNP NNP O
treated VBN VBN O
with IN IN O
indinavir NN NN B-CHEM
have VBP VBP O
a DT DT O
high JJ JJ O
cumulative JJ JJ O
incidence NN NN O
of IN IN O
persistent JJ JJ O
sterile JJ JJ O
leukocyturia NN NN O
. . . O

Children NNP NNP O
with IN IN O
persistent JJ JJ O
sterile JJ JJ O
leukocyturia NN NN O
more RBR RBR O
frequently RB RB O
had VBD VBD O
an DT DT O
increase NN NN O
in IN IN O
serum NN NN O
creatinine NN NN B-CHEM
levels NNS NNS O
of IN IN O
> NN NN O
50 CD CD O
% NN NN O
above IN IN O
normal JJ JJ O
. . . O

Younger NNP NNP O
children NNS NNS O
have VBP VBP O
an DT DT O
additional JJ JJ O
risk NN NN O
for IN IN O
renal JJ JJ O
complications NNS NNS O
. . . O

The DT DT O
impairment NN NN O
of IN IN O
the DT DT O
renal JJ JJ O
function NN NN O
in IN IN O
these DT DT O
children NNS NNS O
occurred VBD VBD O
in IN IN O
the DT DT O
absence NN NN O
of IN IN O
clinical JJ JJ O
symptoms NNS NNS O
of IN IN O
nephrolithiasis NN NN O
. . . O

Indinavir NNP NNP B-CHEM
- - - O
associated JJ JJ O
nephrotoxicity NN NN O
must MD MD O
be VB VB O
monitored VBN VBN O
closely RB RB O
, , , O
especially RB RB O
in IN IN O
children NNS NNS O
with IN IN O
risk NN NN O
factors NNS NNS O
such JJ JJ O
as IN IN O
persistent JJ JJ O
sterile JJ JJ O
leukocyturia NNS NNS O
, , , O
age NN NN O
< NN NN O
5 CD CD O
. . . O
6 CD CD O
years NNS NNS O
, , , O
an DT DT O
area NN NN O
under IN IN O
the DT DT O
curve NN NN O
of IN IN O
indinavir NN NN B-CHEM
> NN NN O
19 CD CD O
mg NN NN O
/ NN NN O
L NNP NNP O
x SYM SYM O
h NN NN O
, , , O
and CC CC O
a DT DT O
C NNP NNP O
( ( ( O
max NN NN O
) ) ) O
> NN NN O
12 CD CD O
mg NN NN O
/ NN NN O
L NNP NNP O
. . . O

Utility NNP NNP O
of IN IN O
troponin NN NN O
I PRP PRP O
in IN IN O
patients NNS NNS O
with IN IN O
cocaine NN NN B-CHEM
- - - O
associated JJ JJ O
chest NN NN O
pain NN NN O
. . . O

Baseline NNP NNP O
electrocardiogram NN NN O
abnormalities NNS NNS O
and CC CC O
market NN NN O
elevations NNS NNS O
not RB RB O
associated VBN VBN O
with IN IN O
myocardial NN NN O
necrosis NN NN O
make NN NN O
accurate JJ JJ O
diagnosis NN NN O
of IN IN O
myocardial NN NN O
infarction NN NN O
( ( ( O
MI NNP NNP O
) ) ) O
difficult JJ JJ O
in IN IN O
patients NNS NNS O
with IN IN O
cocaine NN NN B-CHEM
- - - O
associated JJ JJ O
chest NN NN O
pain NN NN O
. . . O

Troponin NNP NNP O
sampling VBG VBG O
may MD MD O
offer VB VB O
greater JJR JJR O
diagnostic JJ JJ O
utility NN NN O
in IN IN O
these DT DT O
patients NNS NNS O
. . . O

OBJECTIVE NNP NNP O
: : : O
To TO TO O
assess VB VB O
outcomes NNS NNS O
based VBN VBN O
on IN IN O
troponin NN NN O
positivity NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
cocaine NN NN B-CHEM
chest NN NN O
pain NN NN O
admitted VBN VBN O
for IN IN O
exclusion NN NN O
of IN IN O
MI NNP NNP O
. . . O

METHODS NNP NNP O
: : : O
Outcomes NNP NNP O
were VBD VBD O
examined VBN VBN O
in IN IN O
patients NNS NNS O
admitted VBN VBN O
for IN IN O
possible JJ JJ O
MI NNP NNP O
after IN IN O
cocaine NN NN B-CHEM
use NN NN O
. . . O

All DT DT O
patients NNS NNS O
underwent VBD VBD O
a DT DT O
rapid JJ JJ O
rule NN NN O
- : : O
in IN IN O
protocol NN NN O
that WDT WDT O
included VBD VBD O
serial JJ JJ O
sampling NN NN O
of IN IN O
creatine NN NN B-CHEM
kinase NN NN O
( ( ( O
CK NNP NNP O
) ) ) O
, , , O
CK NNP NNP O
- : : O
MB NNP NNP O
, , , O
and CC CC O
cardiac JJ JJ O
troponin NN NN O
I PRP PRP O
( ( ( O
cTnI NN NN O
) ) ) O
over IN IN O
eight CD CD O
hours NNS NNS O
. . . O

Outcomes NNP NNP O
included VBD VBD O
CK NNP NNP O
- : : O
MB NNP NNP O
MI NNP NNP O
( ( ( O
CK NNP NNP O
- : : O
MB NNP NNP O
> NN NN O
or CC CC O
= SYM SYM O
8 CD CD O
ng NN NN O
/ NN NN O
mL NN NN O
with IN IN O
a DT DT O
relative JJ JJ O
index NN NN O
[ NN NN O
( ( ( O
CK NNP NNP O
- : : O
MB NNP NNP O
x SYM SYM O
100 CD CD O
) ) ) O
/ NN NN O
total JJ JJ O
CK NNP NNP O
] NN NN O
> NN NN O
or CC CC O
= SYM SYM O
4 CD CD O
, , , O
cardiac JJ JJ O
death NN NN O
, , , O
and CC CC O
significant JJ JJ O
coronary JJ JJ O
disease NN NN O
( ( ( O
> NN NN O
or CC CC O
= SYM SYM O
50 CD CD O
% NN NN O
) ) ) O
. . . O

RESULTS NNS NNS O
: : : O
Of IN IN O
the DT DT O
246 CD CD O
admitted VBN VBN O
patients NNS NNS O
, , , O
34 CD CD O
( ( ( O
14 CD CD O
% NN NN O
) ) ) O
met VBD VBD O
CK NNP NNP O
- : : O
MB NNP NNP O
criteria NNS NNS O
for IN IN O
MI NNP NNP O
and CC CC O
38 CD CD O
( ( ( O
16 CD CD O
% NN NN O
) ) ) O
had VBD VBD O
cTnI VBN VBN O
elevations NNS NNS O
. . . O

Angiography NNP NNP O
was VBD VBD O
performed VBN VBN O
in IN IN O
29 CD CD O
of IN IN O
38 CD CD O
patients NNS NNS O
who WP WP O
were VBD VBD O
cTnI NN NN O
- - - O
positive JJ JJ O
, , , O
with IN IN O
significant JJ JJ O
disease NN NN O
present JJ JJ O
in IN IN O
25 CD CD O
( ( ( O
86 CD CD O
% NN NN O
) ) ) O
. . . O

Three CD CD O
of IN IN O
the DT DT O
four CD CD O
patients NNS NNS O
without IN IN O
significant JJ JJ O
disease NN NN O
who WP WP O
had VBD VBD O
cTnI NN NN O
elevations NNS NNS O
met VBD VBD O
CK NNP NNP O
- : : O
MB NNP NNP O
criteria NNS NNS O
for IN IN O
MI NNP NNP O
, , , O
and CC CC O
the DT DT O
other JJ JJ O
had VBD VBD O
a DT DT O
peak NN NN O
CK NNP NNP O
- : : O
MB NNP NNP O
level NN NN O
of IN IN O
13 CD CD O
ng NN NN O
/ NN NN O
mL NN NN O
. . . O

Sensitivities NNP NNP O
, , , O
specificities NNS NNS O
, , , O
and CC CC O
positive JJ JJ O
and CC CC O
negative JJ JJ O
likelihood NN NN O
ratios NNS NNS O
for IN IN O
predicting VBG VBG O
cardiac JJ JJ O
death NN NN O
or CC CC O
significant JJ JJ O
disease NN NN O
were VBD VBD O
high JJ JJ O
for IN IN O
both DT DT O
CK NNP NNP O
- : : O
MB NNP NNP O
MI NNP NNP O
and CC CC O
cTnI NN NN O
and CC CC O
were VBD VBD O
not RB RB O
significantly RB RB O
different JJ JJ O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Most JJS JJS O
patients NNS NNS O
with IN IN O
cTnI NN NN O
elevations NNS NNS O
meet VBP VBP O
CK NNP NNP O
- : : O
MB NNP NNP O
criteria NNS NNS O
for IN IN O
MI NNP NNP O
, , , O
as RB RB O
well RB RB O
as IN IN O
have VBP VBP O
a DT DT O
high JJ JJ O
incidence NN NN O
of IN IN O
underlying VBG VBG O
significant JJ JJ O
disease NN NN O
. . . O

Troponin NNP NNP O
appears VBZ VBZ O
to TO TO O
have VB VB O
an DT DT O
equivalent NN NN O
diagnostic JJ JJ O
accuracy NN NN O
compared VBN VBN O
with IN IN O
CK NNP NNP O
- : : O
MB NNP NNP O
for IN IN O
diagnosing VBG VBG O
necrosis NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
cocaine NN NN B-CHEM
- - - O
associated JJ JJ O
chest NN NN O
pain NN NN O
and CC CC O
suspected VBD VBD O
MI NNP NNP O
. . . O

Acute JJ JJ O
interstitial JJ JJ O
nephritis NNS NNS O
due JJ JJ O
to TO TO O
nicergoline NN NN B-CHEM
( ( ( O
Sermion NNP NNP B-CHEM
) ) ) O
. . . O

We PRP PRP O
report VBP VBP O
a DT DT O
case NN NN O
of IN IN O
acute JJ JJ O
interstitial JJ JJ O
nephritis NN NN O
( ( ( O
AIN NNP NNP O
) ) ) O
due JJ JJ O
to TO TO O
nicergoline NN NN B-CHEM
( ( ( O
Sermion NNP NNP B-CHEM
) ) ) O
. . . O

A DT DT O
50 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
patient NN NN O
admitted VBN VBN O
to TO TO O
our PRP$ PRP$ O
hospital NN NN O
for IN IN O
fever NN NN O
and CC CC O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
. . . O

Before IN IN O
admission NN NN O
, , , O
he PRP PRP O
had VBD VBD O
been VBN VBN O
taking VBG VBG O
nicergoline NN NN B-CHEM
and CC CC O
bendazac NN NN B-CHEM
lysine NN NN I-CHEM
due JJ JJ O
to TO TO O
retinal JJ JJ O
vein NN NN O
occlusion NN NN O
at IN IN O
ophthalmologic JJ JJ O
department NN NN O
. . . O

Thereafter NNP NNP O
, , , O
he PRP PRP O
experienced VBD VBD O
intermittent JJ JJ O
fever NN NN O
and CC CC O
skin NN NN O
rash NN NN O
. . . O

On IN IN O
admission NN NN O
, , , O
clinical JJ JJ O
symptoms NNS NNS O
( ( ( O
i NNP NNP O
. . . O
e SYM SYM O
. . . O
arthralgia NN NN O
and CC CC O
fever NN NN O
) ) ) O
and CC CC O
laboratory NN NN O
findings NNS NNS O
( ( ( O
i NNP NNP O
. . . O
e SYM SYM O
. . . O
eosinophilia NN NN O
and CC CC O
renal JJ JJ O
failure NN NN O
) ) ) O
suggested VBD VBD O
AIN NNP NNP O
, , , O
and CC CC O
which WDT WDT O
was VBD VBD O
confirmed VBN VBN O
by IN IN O
pathologic JJ JJ O
findings NNS NNS O
on IN IN O
renal JJ JJ O
biopsy NN NN O
. . . O

A DT DT O
lymphocyte NN NN O
transformation NN NN O
test NN NN O
demonstrated VBD VBD O
a DT DT O
positive JJ JJ O
result NN NN O
against IN IN O
nicergoline NN NN B-CHEM
. . . O

Treatment NN NN O
was VBD VBD O
consisted VBN VBN O
of IN IN O
withdrawal NN NN O
of IN IN O
nicergoline NN NN B-CHEM
and CC CC O
intravenous JJ JJ O
methylprednisolone NN NN B-CHEM
, , , O
and CC CC O
his PRP$ PRP$ O
renal JJ JJ O
function NN NN O
was VBD VBD O
completely RB RB O
recovered VBN VBN O
. . . O

To TO TO O
our PRP$ PRP$ O
knowledge NN NN O
, , , O
this DT DT O
is VBZ VBZ O
the DT DT O
first JJ JJ O
report NN NN O
of IN IN O
nicergoline NN NN B-CHEM
- - - O
associated VBN VBN O
AIN NNP NNP O
. . . O

Neuroleptic NNP NNP O
malignant NN NN O
syndrome NN NN O
complicated VBN VBN O
by IN IN O
massive JJ JJ O
intestinal JJ JJ O
bleeding NN NN O
in IN IN O
a DT DT O
patient NN NN O
with IN IN O
chronic JJ JJ O
renal JJ JJ O
failure NN NN O
. . . O

A DT DT O
patient NN NN O
with IN IN O
chronic JJ JJ O
renal JJ JJ O
failure NN NN O
( ( ( O
CRF NNP NNP O
) ) ) O
developed VBN VBN O
neuroleptic JJ JJ O
malignant NN NN O
syndrome NN NN O
( ( ( O
NMS NNP NNP O
) ) ) O
after IN IN O
administration NN NN O
of IN IN O
risperidone NN NN B-CHEM
and CC CC O
levomepromazine NN NN B-CHEM
. . . O

In IN IN O
addition NN NN O
to TO TO O
the DT DT O
typical JJ JJ O
symptoms NNS NNS O
of IN IN O
NMS NNP NNP O
, , , O
massive JJ JJ O
intestinal JJ JJ O
bleeding NN NN O
was VBD VBD O
observed VBN VBN O
during IN IN O
the DT DT O
episode NN NN O
. . . O

This DT DT O
report NN NN O
suggests VBZ VBZ O
that IN IN O
NMS NNP NNP O
in IN IN O
a DT DT O
patient NN NN O
with IN IN O
CRF NNP NNP O
may MD MD O
be VB VB O
complicated VBN VBN O
by IN IN O
intestinal JJ JJ O
bleeding NN NN O
and CC CC O
needs VBZ VBZ O
special JJ JJ O
caution NN NN O
for IN IN O
this DT DT O
complication NN NN O
. . . O

Blood NNP NNP O
brain NN NN O
barrier NN NN O
in IN IN O
right NN NN O
- - - O
and CC CC O
left VBD VBD O
- : : O
pawed JJ JJ O
female JJ JJ O
rats NNS NNS O
assessed VBN VBN O
by IN IN O
a DT DT O
new JJ JJ O
staining VBG VBG O
method NN NN O
. . . O

The DT DT O
asymmetrical JJ JJ O
breakdown NN NN O
of IN IN O
the DT DT O
blood NN NN O
- - - O
brain NN NN O
barrier NN NN O
( ( ( O
BBB NNP NNP O
) ) ) O
was VBD VBD O
studied VBN VBN O
in IN IN O
female JJ JJ O
rats NNS NNS O
. . . O

Paw NNP NNP O
preference NN NN O
was VBD VBD O
assessed VBN VBN O
by IN IN O
a DT DT O
food NN NN O
reaching VBG VBG O
test NN NN O
. . . O

Adrenaline NNP NNP B-CHEM
- : : O
induced JJ JJ O
hypertension NN NN O
was VBD VBD O
used VBN VBN O
to TO TO O
destroy VB VB O
the DT DT O
BBB NNP NNP O
, , , O
which WDT WDT O
was VBD VBD O
evaluated VBN VBN O
using VBG VBG O
triphenyltetrazolium NN NN B-CHEM
( ( ( O
TTC NNP NNP B-CHEM
) ) ) O
staining VBG VBG O
of IN IN O
the DT DT O
brain NN NN O
slices NNS NNS O
just RB RB O
after IN IN O
giving VBG VBG O
adrenaline NN NN B-CHEM
for IN IN O
30 CD CD O
s VBZ VBZ O
. . . O

In IN IN O
normal JJ JJ O
rats NNS NNS O
, , , O
the DT DT O
whole JJ JJ O
brain NN NN O
sections NNS NNS O
exhibited VBN VBN O
complete JJ JJ O
staining VBG VBG O
with IN IN O
TTC NNP NNP B-CHEM
. . . O

After IN IN O
adrenaline NN NN B-CHEM
infusion NN NN O
for IN IN O
30 CD CD O
s VBZ VBZ O
, , , O
there EX EX O
were VBD VBD O
large JJ JJ O
unstained JJ JJ O
areas NNS NNS O
in IN IN O
the DT DT O
left NN NN O
brain NN NN O
in IN IN O
right NN NN O
- - - O
pawed JJ JJ O
animals NNS NNS O
, , , O
and CC CC O
vice NN NN O
versa NN NN O
in IN IN O
left VBD VBD O
- - - O
pawed JJ JJ O
animals NNS NNS O
. . . O

Similar JJ JJ O
results NNS NNS O
were VBD VBD O
obtained VBN VBN O
in IN IN O
seizure NN NN O
- - - O
induced JJ JJ O
breakdown NN NN O
of IN IN O
BBB NNP NNP O
. . . O

These DT DT O
results NNS NNS O
were VBD VBD O
explained VBN VBN O
by IN IN O
an DT DT O
asymmetric JJ JJ O
cerebral JJ JJ O
blood NN NN O
flow NN NN O
depending VBG VBG O
upon IN IN O
the DT DT O
paw NN NN O
preference NN NN O
in IN IN O
rats NNS NNS O
. . . O

It PRP PRP O
was VBD VBD O
suggested VBN VBN O
that IN IN O
this DT DT O
new JJ JJ O
method NN NN O
and CC CC O
the DT DT O
results NNS NNS O
are VBP VBP O
consistent JJ JJ O
with IN IN O
contralateral JJ JJ O
motor NN NN O
control NN NN O
that WDT WDT O
may MD MD O
be VB VB O
important JJ JJ O
in IN IN O
determining VBG VBG O
the DT DT O
dominant JJ JJ O
cerebral JJ JJ O
hemisphere NN NN O
in IN IN O
animals NNS NNS O
. . . O

Carvedilol NNP NNP B-CHEM
protects VBZ VBZ O
against IN IN O
doxorubicin NN NN B-CHEM
- - - O
induced JJ JJ O
mitochondrial NN NN O
cardiomyopathy NN NN O
. . . O

Several JJ JJ O
cytopathic JJ JJ O
mechanisms NNS NNS O
have VBP VBP O
been VBN VBN O
suggested VBN VBN O
to TO TO O
mediate VB VB O
the DT DT O
dose NN NN O
- - - O
limiting VBG VBG O
cumulative JJ JJ O
and CC CC O
irreversible JJ JJ O
cardiomyopathy NN NN O
caused VBN VBN O
by IN IN O
doxorubicin NN NN B-CHEM
. . . O

Recent JJ JJ O
evidence NN NN O
indicates VBZ VBZ O
that IN IN O
oxidative JJ JJ O
stress NN NN O
and CC CC O
mitochondrial JJ JJ O
dysfunction NN NN O
are VBP VBP O
key JJ JJ O
factors NNS NNS O
in IN IN O
the DT DT O
pathogenic JJ JJ O
process NN NN O
. . . O

The DT DT O
objective NN NN O
of IN IN O
this DT DT O
investigation NN NN O
was VBD VBD O
to TO TO O
test VB VB O
the DT DT O
hypothesis NNS NNS O
that WDT WDT O
carvedilol NN NN B-CHEM
, , , O
a DT DT O
nonselective JJ JJ O
beta NN NN O
- - - O
adrenergic JJ JJ O
receptor NN NN O
antagonist NN NN O
with IN IN O
potent JJ JJ O
antioxidant JJ JJ O
properties NNS NNS O
, , , O
protects VBZ VBZ O
against IN IN O
the DT DT O
cardiac NN NN O
and CC CC O
hepatic JJ JJ O
mitochondrial NN NN O
bioenergetic JJ JJ O
dysfunction NN NN O
associated VBN VBN O
with IN IN O
subchronic JJ JJ O
doxorubicin NN NN B-CHEM
toxicity NN NN O
. . . O

Heart NNP NNP O
and CC CC O
liver NN NN O
mitochondria NN NN O
were VBD VBD O
isolated VBN VBN O
from IN IN O
rats NNS NNS O
treated VBN VBN O
for IN IN O
7 CD CD O
weeks NNS NNS O
with IN IN O
doxorubicin NN NN B-CHEM
( ( ( O
2 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
sc NN NN O
/ NN NN O
week NN NN O
) ) ) O
, , , O
carvedilol NN NN B-CHEM
( ( ( O
1 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
ip NNP NNP O
/ NN NN O
week NN NN O
) ) ) O
, , , O
or CC CC O
the DT DT O
combination NN NN O
of IN IN O
the DT DT O
two CD CD O
drugs NNS NNS O
. . . O

Heart NNP NNP O
mitochondria NN NN O
isolated VBN VBN O
from IN IN O
doxorubicin NN NN B-CHEM
- - - O
treated VBN VBN O
rats NNS NNS O
exhibited VBN VBN O
depressed VBN VBN O
rates NNS NNS O
for IN IN O
state NN NN O
3 CD CD O
respiration NN NN O
( ( ( O
336 CD CD O
+ NN NN O
/ NN NN O
- : : O
26 CD CD O
versus CC CC O
425 CD CD O
+ NN NN O
/ NN NN O
- : : O
53 CD CD O
natom NN NN O
O NNP NNP O
/ NN NN O
min NN NN O
/ NN NN O
mg NN NN O
protein NN NN O
) ) ) O
and CC CC O
a DT DT O
lower JJR JJR O
respiratory NN NN O
control NN NN O
ratio NN NN O
( ( ( O
RCR NNP NNP O
) ) ) O
( ( ( O
4 CD CD O
. . . O
3 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
6 CD CD O
versus CC CC O
5 CD CD O
. . . O
8 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
4 CD CD O
) ) ) O
compared VBN VBN O
with IN IN O
cardiac JJ JJ O
mitochondria NN NN O
isolated VBN VBN O
from IN IN O
saline NN NN O
- - - O
treated VBN VBN O
rats NNS NNS O
. . . O

Mitochondrial NNP NNP O
calcium NN NN B-CHEM
- : : O
loading NN NN O
capacity NN NN O
and CC CC O
the DT DT O
activity NN NN O
of IN IN O
NADH NNP NNP O
- : : O
dehydrogenase NN NN O
were VBD VBD O
also RB RB O
suppressed VBN VBN O
in IN IN O
cardiac JJ JJ O
mitochondria NN NN O
from IN IN O
doxorubicin NN NN B-CHEM
- - - O
treated VBN VBN O
rats NNS NNS O
. . . O

Doxorubicin NNP NNP B-CHEM
treatment NN NN O
also RB RB O
caused VBD VBD O
a DT DT O
decrease NN NN O
in IN IN O
RCR NNP NNP O
for IN IN O
liver NN NN O
mitochondria NN NN O
( ( ( O
3 CD CD O
. . . O
9 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
9 CD CD O
versus CC CC O
5 CD CD O
. . . O
6 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
7 CD CD O
for IN IN O
control NN NN O
rats NNS NNS O
) ) ) O
and CC CC O
inhibition NN NN O
of IN IN O
hepatic JJ JJ O
cytochrome NN NN O
oxidase NN NN O
activity NN NN O
. . . O

Coadministration NNP NNP O
of IN IN O
carvedilol NN NN B-CHEM
decreased VBD VBD O
the DT DT O
extent NN NN O
of IN IN O
cellular JJ JJ O
vacuolization NN NN O
in IN IN O
cardiac JJ JJ O
myocytes NNS NNS O
and CC CC O
prevented VBD VBD O
the DT DT O
inhibitory JJ JJ O
effect NN NN O
of IN IN O
doxorubicin NN NN B-CHEM
on IN IN O
mitochondrial JJ JJ O
respiration NN NN O
in IN IN O
both DT DT O
heart NN NN O
and CC CC O
liver NN NN O
. . . O

Carvedilol NNP NNP B-CHEM
also RB RB O
prevented VBD VBD O
the DT DT O
decrease NN NN O
in IN IN O
mitochondrial NN NN O
Ca NNP NNP B-CHEM
( ( ( O
2 CD CD O
+ NN NN O
) ) ) O
loading NN NN O
capacity NN NN O
and CC CC O
the DT DT O
inhibition NN NN O
of IN IN O
the DT DT O
respiratory JJ JJ O
complexes NNS NNS O
of IN IN O
heart NN NN O
mitochondria NN NN O
caused VBN VBN O
by IN IN O
doxorubicin NN NN B-CHEM
. . . O

Carvedilol NNP NNP B-CHEM
by IN IN O
itself PRP PRP O
did VBD VBD O
not RB RB O
affect VB VB O
any DT DT O
of IN IN O
the DT DT O
parameters NNS NNS O
measured VBN VBN O
for IN IN O
heart NN NN O
or CC CC O
liver NN NN O
mitochondria NN NN O
. . . O

It PRP PRP O
is VBZ VBZ O
concluded VBN VBN O
that IN IN O
this DT DT O
protection NN NN O
by IN IN O
carvedilol NN NN B-CHEM
against IN IN O
both DT DT O
the DT DT O
structural JJ JJ O
and CC CC O
functional JJ JJ O
cardiac NN NN O
tissue NN NN O
damage NN NN O
may MD MD O
afford VB VB O
significant JJ JJ O
clinical JJ JJ O
advantage NN NN O
in IN IN O
minimizing VBG VBG O
the DT DT O
dose NN NN O
- - - O
limiting VBG VBG O
mitochondrial JJ JJ O
dysfunction NN NN O
and CC CC O
cardiomyopathy NN NN O
that WDT WDT O
accompanies NNS NNS O
long JJ JJ O
- - - O
term NN NN O
doxorubicin NN NN B-CHEM
therapy NN NN O
in IN IN O
cancer NN NN O
patients NNS NNS O
. . . O

Cocaine NNP NNP B-CHEM
- : : O
induced JJ JJ O
hyperactivity NN NN O
is VBZ VBZ O
more RBR RBR O
influenced JJ JJ O
by IN IN O
adenosine NN NN B-CHEM
receptor NN NN O
agonists NNS NNS O
than IN IN O
amphetamine NN NN B-CHEM
- - - O
induced JJ JJ O
hyperactivity NN NN O
. . . O

The DT DT O
influence NN NN O
of IN IN O
adenosine NN NN B-CHEM
receptor NN NN O
agonists NNS NNS O
and CC CC O
antagonists NNS NNS O
on IN IN O
cocaine NN NN B-CHEM
- : : O
and CC CC O
amphetamine JJ JJ B-CHEM
- - - O
induced JJ JJ O
hyperactivity NN NN O
was VBD VBD O
examined VBN VBN O
in IN IN O
mice NN NN O
. . . O

All DT DT O
adenosine VBP VBP B-CHEM
receptor NN NN O
agonists NNS NNS O
significantly RB RB O
decreased VBD VBD O
the DT DT O
locomotor NN NN O
activity NN NN O
in IN IN O
mice NN NN O
, , , O
and CC CC O
the DT DT O
effects NNS NNS O
were VBD VBD O
dose JJ JJ O
- - - O
dependent NN NN O
. . . O

It PRP PRP O
seems VBZ VBZ O
that IN IN O
adenosine NN NN B-CHEM
A1 NNP NNP O
and CC CC O
A2 NNP NNP O
receptors NNS NNS O
might MD MD O
be VB VB O
involved VBN VBN O
in IN IN O
this DT DT O
reaction NN NN O
. . . O

Moreover RB RB O
, , , O
all DT DT O
adenosine NN NN B-CHEM
receptor NN NN O
agonists NNS NNS O
: : : O
2 CD CD B-CHEM
- : : I-CHEM
p NN NN I-CHEM
- : : I-CHEM
( ( ( I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
carboxyethyl NN NN I-CHEM
) ) ) I-CHEM
phenethylamino NN NN I-CHEM
- : : I-CHEM
5 CD CD I-CHEM
' POS POS I-CHEM
- : : I-CHEM
N NNP NNP I-CHEM
- : : I-CHEM
ethylcarboxamidoadenosine NN NN I-CHEM
( ( ( O
CGS NNP NNP B-CHEM
21680 CD CD I-CHEM
) ) ) O
, , , O
A2A NNP NNP O
receptor NN NN O
agonist NN NN O
, , , O
N6 NNP NNP B-CHEM
- : : I-CHEM
cyclopentyladenosine NN NN I-CHEM
( ( ( O
CPA NNP NNP B-CHEM
) ) ) O
, , , O
A1 NNP NNP O
receptor NN NN O
agonist NN NN O
, , , O
and CC CC O
5 CD CD B-CHEM
' POS POS I-CHEM
- : : I-CHEM
N NNP NNP I-CHEM
- : : I-CHEM
ethylcarboxamidoadenosine NN NN I-CHEM
( ( ( O
NECA NNP NNP B-CHEM
) ) ) O
, , , O
A2 NNP NNP O
/ NN NN O
A1 NNP NNP O
receptor NN NN O
agonist NN NN O
significantly RB RB O
and CC CC O
dose VB VB O
- : : O
dependently RB RB O
decreased VBN VBN O
cocaine NN NN B-CHEM
- - - O
induced JJ JJ O
locomotor NN NN O
activity NN NN O
. . . O

CPA NNP NNP B-CHEM
reduced VBD VBD O
cocaine NN NN B-CHEM
action NN NN O
at IN IN O
the DT DT O
doses NNS NNS O
which WDT WDT O
, , , O
given VBN VBN O
alone RB RB O
, , , O
did VBD VBD O
not RB RB O
influence VB VB O
motility NN NN O
, , , O
while IN IN O
CGS NNP NNP B-CHEM
21680 CD CD I-CHEM
and CC CC O
NECA NNP NNP B-CHEM
decreased VBD VBD O
the DT DT O
action NN NN O
of IN IN O
cocaine NN NN B-CHEM
at IN IN O
the DT DT O
doses NNS NNS O
which WDT WDT O
, , , O
given VBN VBN O
alone RB RB O
, , , O
decreased VBD VBD O
locomotor NN NN O
activity NN NN O
in IN IN O
animals NNS NNS O
. . . O

These DT DT O
results NNS NNS O
suggest VBP VBP O
the DT DT O
involvement NN NN O
of IN IN O
both DT DT O
adenosine NN NN B-CHEM
receptors NNS NNS O
in IN IN O
the DT DT O
action NN NN O
of IN IN O
cocaine NN NN B-CHEM
although IN IN O
agonists NNS NNS O
of IN IN O
A1 NNP NNP O
receptors NNS NNS O
seem VBP VBP O
to TO TO O
have VB VB O
stronger JJR JJR O
influence NN NN O
on IN IN O
it PRP PRP O
. . . O

The DT DT O
selective JJ JJ O
blockade NN NN O
of IN IN O
A2 NNP NNP O
adenosine NN NN B-CHEM
receptor NN NN O
by IN IN O
DMPX NNP NNP B-CHEM
( ( ( O
3 CD CD B-CHEM
, , , I-CHEM
7 CD CD I-CHEM
- : : I-CHEM
dimethyl NN NN I-CHEM
- : : I-CHEM
1 CD CD I-CHEM
- : : I-CHEM
propargylxanthine NN NN I-CHEM
) ) ) O
significantly RB RB O
enhanced VBN VBN O
cocaine NN NN B-CHEM
- - - O
induced JJ JJ O
locomotor NN NN O
activity NN NN O
of IN IN O
animals NNS NNS O
. . . O

Caffeine NNP NNP B-CHEM
had VBD VBD O
similar JJ JJ O
action NN NN O
but CC CC O
the DT DT O
effect NN NN O
was VBD VBD O
not RB RB O
significant JJ JJ O
. . . O

CPT NNP NNP B-CHEM
( ( ( O
8 CD CD B-CHEM
- : : I-CHEM
cyclopentyltheophylline NN NN I-CHEM
) ) ) O
- : : O
- - - O
A1 NNP NNP O
receptor NN NN O
antagonist NN NN O
, , , O
did VBD VBD O
not RB RB O
show VB VB O
any DT DT O
influence NN NN O
in IN IN O
this DT DT O
test NN NN O
. . . O

Similarly RB RB O
, , , O
all DT DT O
adenosine NN NN B-CHEM
receptor NN NN O
agonists NNS NNS O
decreased VBD VBD O
amphetamine JJ JJ B-CHEM
- : : O
induced JJ JJ O
hyperactivity NN NN O
, , , O
but CC CC O
at IN IN O
the DT DT O
higher JJR JJR O
doses NNS NNS O
than IN IN O
those DT DT O
which WDT WDT O
were VBD VBD O
active JJ JJ O
in IN IN O
cocaine NN NN B-CHEM
- - - O
induced JJ JJ O
hyperactivity NN NN O
. . . O

The DT DT O
selective JJ JJ O
blockade NN NN O
of IN IN O
A2 NNP NNP O
adenosine NN NN B-CHEM
receptors NNS NNS O
( ( ( O
DMPX NNP NNP B-CHEM
) ) ) O
and CC CC O
non NN NN O
- - - O
selective JJ JJ O
blockade NN NN O
of IN IN O
adenosine NN NN B-CHEM
receptors NNS NNS O
( ( ( O
caffeine NN NN B-CHEM
) ) ) O
significantly RB RB O
increased VBD VBD O
the DT DT O
action NN NN O
of IN IN O
amphetamine NN NN B-CHEM
in IN IN O
the DT DT O
locomotor NN NN O
activity NN NN O
test NN NN O
. . . O

Our PRP$ PRP$ O
results NNS NNS O
have VBP VBP O
shown VBN VBN O
that IN IN O
all DT DT O
adenosine NN NN B-CHEM
receptor NN NN O
agonists NNS NNS O
( ( ( O
A1 NNP NNP O
and CC CC O
A2 NNP NNP O
) ) ) O
reduce VB VB O
cocaine NN NN B-CHEM
- : : O
and CC CC O
amphetamine JJ JJ B-CHEM
- - - O
induced JJ JJ O
locomotor NN NN O
activity NN NN O
and CC CC O
indicate VB VB O
that IN IN O
cocaine NN NN B-CHEM
- : : O
induced JJ JJ O
hyperactivity NN NN O
is VBZ VBZ O
more RBR RBR O
influenced JJ JJ O
by IN IN O
adenosine NN NN B-CHEM
receptor NN NN O
agonists NNS NNS O
( ( ( O
particularly RB RB O
A1 NNP NNP O
receptors NNS NNS O
) ) ) O
than IN IN O
amphetamine NN NN B-CHEM
- - - O
induced JJ JJ O
hyperactivity NN NN O
. . . O

Amiodarone NNP NNP B-CHEM
and CC CC O
the DT DT O
risk NN NN O
of IN IN O
bradyarrhythmia NN NN O
requiring VBG VBG O
permanent JJ JJ O
pacemaker NN NN O
in IN IN O
elderly JJ JJ O
patients NNS NNS O
with IN IN O
atrial JJ JJ O
fibrillation NN NN O
and CC CC O
prior RB RB O
myocardial NN NN O
infarction NN NN O
. . . O

OBJECTIVES NNP NNP O
: : : O
The DT DT O
aim NN NN O
of IN IN O
this DT DT O
study NN NN O
was VBD VBD O
to TO TO O
determine VB VB O
whether IN IN O
the DT DT O
use NN NN O
of IN IN O
amiodarone NN NN B-CHEM
in IN IN O
patients NNS NNS O
with IN IN O
atrial JJ JJ O
fibrillation NN NN O
( ( ( O
AF NNP NNP O
) ) ) O
increases NNS NNS O
the DT DT O
risk NN NN O
of IN IN O
bradyarrhythmia NN NN O
requiring VBG VBG O
a DT DT O
permanent JJ JJ O
pacemaker NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
Reports NNS NNS O
of IN IN O
severe JJ JJ O
bradyarrhythmia NN NN O
during IN IN O
amiodarone NN NN B-CHEM
therapy NN NN O
are VBP VBP O
infrequent JJ JJ O
and CC CC O
limited JJ JJ O
to TO TO O
studies NNS NNS O
assessing VBG VBG O
the DT DT O
therapy NN NN O
' '' '' O
s VBZ VBZ O
use NN NN O
in IN IN O
the DT DT O
management NN NN O
of IN IN O
patients NNS NNS O
with IN IN O
ventricular NN NN O
arrhythmias NNS NNS O
. . . O

METHODS NNP NNP O
: : : O
A DT DT O
study NN NN O
cohort NN NN O
of IN IN O
8 CD CD O
, , , O
770 CD CD O
patients NNS NNS O
age NN NN O
> NN NN O
or CC CC O
= SYM SYM O
65 CD CD O
years NNS NNS O
with IN IN O
a DT DT O
new JJ JJ O
diagnosis NN NN O
of IN IN O
AF NNP NNP O
was VBD VBD O
identified VBN VBN O
from IN IN O
a DT DT O
provincewide NN NN O
database NN NN O
of IN IN O
Quebec NNP NNP O
residents NNS NNS O
with IN IN O
a DT DT O
myocardial NN NN O
infarction NN NN O
( ( ( O
MI NNP NNP O
) ) ) O
between IN IN O
1991 CD CD O
and CC CC O
1999 CD CD O
. . . O

Using VBG VBG O
a DT DT O
nested JJ JJ O
case NN NN O
- - - O
control NN NN O
design NN NN O
, , , O
477 CD CD O
cases NNS NNS O
of IN IN O
bradyarrhythmia NN NN O
requiring VBG VBG O
a DT DT O
permanent JJ JJ O
pacemaker NN NN O
were VBD VBD O
matched VBN VBN O
( ( ( O
1 CD CD O
: : : O
4 CD CD O
) ) ) O
to TO TO O
1 CD CD O
, , , O
908 CD CD O
controls NNS NNS O
. . . O

Multivariable NNP NNP O
logistic JJ JJ O
regression NN NN O
was VBD VBD O
used VBN VBN O
to TO TO O
estimate VB VB O
the DT DT O
odds NNS NNS O
ratio NN NN O
( ( ( O
OR CC CC O
) ) ) O
of IN IN O
pacemaker NN NN O
insertion NN NN O
associated VBN VBN O
with IN IN O
amiodarone NN NN B-CHEM
use NN NN O
, , , O
controlling VBG VBG O
for IN IN O
baseline NN NN O
risk NN NN O
factors NNS NNS O
and CC CC O
exposure NN NN O
to TO TO O
sotalol VB VB B-CHEM
, , , O
Class NNP NNP O
I PRP PRP O
antiarrhythmic JJ JJ O
agents NNS NNS O
, , , O
beta NN NN O
- - - O
blockers NNS NNS O
, , , O
calcium NN NN B-CHEM
channel NN NN O
blockers NNS NNS O
, , , O
and CC CC O
digoxin NN NN B-CHEM
. . . O

RESULTS NNS NNS O
: : : O
amiodarone NN NN B-CHEM
use NN NN O
was VBD VBD O
associated VBN VBN O
with IN IN O
an DT DT O
increased JJ JJ O
risk NN NN O
of IN IN O
pacemaker NN NN O
insertion NN NN O
( ( ( O
OR CC CC O
: : : O
2 CD CD O
. . . O
14 CD CD O
, , , O
95 CD CD O
% NN NN O
confidence NN NN O
interval NN NN O
[ NN NN O
CI NNP NNP O
] NN NN O
: : : O
1 CD CD O
. . . O
30 CD CD O
to TO TO O
3 CD CD O
. . . O
54 CD CD O
) ) ) O
. . . O

This DT DT O
effect NN NN O
was VBD VBD O
modified VBN VBN O
by IN IN O
gender NN NN O
, , , O
with IN IN O
a DT DT O
greater JJR JJR O
risk NN NN O
in IN IN O
women NNS NNS O
versus CC CC O
men NNS NNS O
( ( ( O
OR CC CC O
: : : O
3 CD CD O
. . . O
86 CD CD O
, , , O
95 CD CD O
% NN NN O
CI NNP NNP O
: : : O
1 CD CD O
. . . O
70 CD CD O
to TO TO O
8 CD CD O
. . . O
75 CD CD O
vs NNS NNS O
. . . O
OR CC CC O
: : : O
1 CD CD O
. . . O
52 CD CD O
, , , O
95 CD CD O
% NN NN O
CI NNP NNP O
: : : O
0 CD CD O
. . . O
80 CD CD O
to TO TO O
2 CD CD O
. . . O
89 CD CD O
) ) ) O
. . . O

Digoxin NNP NNP B-CHEM
was VBD VBD O
the DT DT O
only RB RB O
other JJ JJ O
medication NN NN O
associated VBN VBN O
with IN IN O
an DT DT O
increased JJ JJ O
risk NN NN O
of IN IN O
pacemaker NN NN O
insertion NN NN O
( ( ( O
OR CC CC O
: : : O
1 CD CD O
. . . O
78 CD CD O
, , , O
95 CD CD O
% NN NN O
CI NNP NNP O
: : : O
1 CD CD O
. . . O
37 CD CD O
to TO TO O
2 CD CD O
. . . O
31 CD CD O
) ) ) O
. . . O

CONCLUSIONS NNP NNP O
: : : O
This DT DT O
study NN NN O
suggests VBZ VBZ O
that IN IN O
the DT DT O
use NN NN O
of IN IN O
amiodarone NN NN B-CHEM
in IN IN O
elderly JJ JJ O
patients NNS NNS O
with IN IN O
AF NNP NNP O
and CC CC O
a DT DT O
previous JJ JJ O
MI NNP NNP O
increases NNS NNS O
the DT DT O
risk NN NN O
of IN IN O
bradyarrhythmia NN NN O
requiring VBG VBG O
a DT DT O
permanent JJ JJ O
pacemaker NN NN O
. . . O

The DT DT O
finding NN NN O
of IN IN O
an DT DT O
augmented JJ JJ O
risk NN NN O
of IN IN O
pacemaker NN NN O
insertion NN NN O
in IN IN O
elderly JJ JJ O
women NNS NNS O
receiving VBG VBG O
amiodarone NN NN B-CHEM
requires VBZ VBZ O
further JJ JJ O
investigation NN NN O
. . . O

Indomethacin NNP NNP B-CHEM
- : : O
induced JJ JJ O
morphologic JJ JJ O
changes NNS NNS O
in IN IN O
the DT DT O
rat NN NN O
urinary JJ JJ O
bladder NN NN O
epithelium NN NN O
. . . O

OBJECTIVES NNP NNP O
: : : O
To TO TO O
evaluate VB VB O
the DT DT O
morphologic JJ JJ O
changes NNS NNS O
in IN IN O
rat NN NN O
urothelium NN NN O
induced VBN VBN O
by IN IN O
indomethacin NN NN B-CHEM
. . . O

Nonsteroidal NNP NNP O
anti JJ JJ O
- : : O
inflammatory JJ JJ O
drug NN NN O
- - - O
induced JJ JJ O
cystitis NN NN O
is VBZ VBZ O
a DT DT O
poorly RB RB O
recognized VBN VBN O
and CC CC O
under IN IN O
- - - O
reported JJ JJ O
condition NN NN O
. . . O

In IN IN O
addition NN NN O
to TO TO O
tiaprofenic JJ JJ B-CHEM
acid NN NN I-CHEM
, , , O
indomethacin NN NN B-CHEM
has VBZ VBZ O
been VBN VBN O
reported VBN VBN O
to TO TO O
be VB VB O
associated VBN VBN O
with IN IN O
this DT DT O
condition NN NN O
. . . O

METHODS NNP NNP O
: : : O
Three CD CD O
groups NNS NNS O
were VBD VBD O
established VBN VBN O
: : : O
a DT DT O
control NN NN O
group NN NN O
( ( ( O
n NN NN O
= SYM SYM O
10 CD CD O
) ) ) O
, , , O
a DT DT O
high JJ JJ O
- - - O
dose NN NN O
group NN NN O
( ( ( O
n NN NN O
= SYM SYM O
10 CD CD O
) ) ) O
, , , O
treated VBN VBN O
with IN IN O
one CD CD O
intraperitoneal JJ JJ O
injection NN NN O
of IN IN O
indomethacin NN NN B-CHEM
20 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
and CC CC O
a DT DT O
therapeutic JJ JJ O
dose NN NN O
group NN NN O
( ( ( O
n NN NN O
= SYM SYM O
10 CD CD O
) ) ) O
in IN IN O
which WDT WDT O
oral JJ JJ O
indomethacin NN NN B-CHEM
was VBD VBD O
administered VBN VBN O
3 CD CD O
. . . O
25 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
body NN NN O
weight NN NN O
daily JJ JJ O
for IN IN O
3 CD CD O
weeks NNS NNS O
. . . O

The DT DT O
animals NNS NNS O
were VBD VBD O
then RB RB O
killed VBN VBN O
and CC CC O
the DT DT O
bladders NNS NNS O
removed VBD VBD O
for IN IN O
light JJ JJ O
and CC CC O
electron NN NN O
microscopic NN NN O
studies NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
The DT DT O
light JJ JJ O
microscopic NN NN O
findings NNS NNS O
showed VBD VBD O
some DT DT O
focal JJ JJ O
epithelial NN NN O
degeneration NN NN O
that WDT WDT O
was VBD VBD O
more RBR RBR O
prominent JJ JJ O
in IN IN O
the DT DT O
high JJ JJ O
- - - O
dose NN NN O
group NN NN O
. . . O

When WRB WRB O
compared VBN VBN O
with IN IN O
the DT DT O
control NN NN O
group NN NN O
, , , O
both DT DT O
indomethacin NN NN B-CHEM
groups NNS NNS O
revealed VBD VBD O
statistically RB RB O
increased VBN VBN O
numbers NNS NNS O
of IN IN O
mast NN NN O
cells NNS NNS O
in IN IN O
the DT DT O
mucosa NN NN O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
0001 CD CD O
) ) ) O
and CC CC O
penetration NN NN O
of IN IN O
lanthanum NN NN B-CHEM
nitrate NN NN I-CHEM
through IN IN O
intercellular JJ JJ O
areas NNS NNS O
of IN IN O
the DT DT O
epithelium NN NN O
. . . O

Furthermore RB RB O
, , , O
the DT DT O
difference NN NN O
in IN IN O
mast NN NN O
cell NN NN O
counts VBZ VBZ O
between IN IN O
the DT DT O
high JJ JJ O
and CC CC O
therapeutic JJ JJ O
dose NN NN O
groups NNS NNS O
was VBD VBD O
also RB RB O
statistically RB RB O
significant JJ JJ O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
0001 CD CD O
) ) ) O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Indomethacin NNP NNP B-CHEM
resulted VBD VBD O
in IN IN O
histopathologic NN NN O
findings NNS NNS O
typical JJ JJ O
of IN IN O
interstitial JJ JJ O
cystitis NNS NNS O
, , , O
such JJ JJ O
as IN IN O
leaky JJ JJ O
bladder NN NN O
epithelium NN NN O
and CC CC O
mucosal NN NN O
mastocytosis NN NN O
. . . O

The DT DT O
true JJ JJ O
incidence NN NN O
of IN IN O
nonsteroidal NN NN O
anti NN NN O
- : : O
inflammatory JJ JJ O
drug NN NN O
- - - O
induced JJ JJ O
cystitis NN NN O
in IN IN O
humans NNS NNS O
must MD MD O
be VB VB O
clarified VBN VBN O
by IN IN O
prospective JJ JJ O
clinical JJ JJ O
trials NNS NNS O
. . . O

An DT DT O
open JJ JJ O
- - - O
label NN NN O
phase NN NN O
II NNP NNP O
study NN NN O
of IN IN O
low JJ JJ O
- - - O
dose NN NN O
thalidomide NN NN B-CHEM
in IN IN O
androgen NN NN B-CHEM
- - - O
independent JJ JJ O
prostate NN NN O
cancer NN NN O
. . . O

The DT DT O
antiangiogenic JJ JJ O
effects NNS NNS O
of IN IN O
thalidomide NN NN B-CHEM
have VBP VBP O
been VBN VBN O
assessed VBN VBN O
in IN IN O
clinical JJ JJ O
trials NNS NNS O
in IN IN O
patients NNS NNS O
with IN IN O
various JJ JJ O
solid JJ JJ O
and CC CC O
haematological JJ JJ O
malignancies NNS NNS O
. . . O

Thalidomide NNP NNP B-CHEM
blocks NNS NNS O
the DT DT O
activity NN NN O
of IN IN O
angiogenic JJ JJ O
agents NNS NNS O
including VBG VBG O
bFGF NN NN O
, , , O
VEGF NNP NNP O
and CC CC O
IL NNP NNP O
- : : O
6 CD CD O
. . . O

We PRP PRP O
undertook VBP VBP O
an DT DT O
open JJ JJ O
- - - O
label NN NN O
study NN NN O
using VBG VBG O
thalidomide NN NN B-CHEM
100 CD CD O
mg NN NN O
once RB RB O
daily RB RB O
for IN IN O
up IN IN O
to TO TO O
6 CD CD O
months NNS NNS O
in IN IN O
20 CD CD O
men NNS NNS O
with IN IN O
androgen NN NN B-CHEM
- - - O
independent JJ JJ O
prostate NN NN O
cancer NN NN O
. . . O

The DT DT O
mean JJ JJ O
time NN NN O
of IN IN O
study NN NN O
was VBD VBD O
109 CD CD O
days NNS NNS O
( ( ( O
median NN NN O
107 CD CD O
, , , O
range NN NN O
4 CD CD O
- : : O
184 CD CD O
days NNS NNS O
) ) ) O
. . . O

Patients NNS NNS O
underwent JJ JJ O
regular JJ JJ O
measurement NN NN O
of IN IN O
prostate NN NN O
- - - O
specific JJ JJ O
antigen NN NN O
( ( ( O
PSA NNP NNP O
) ) ) O
, , , O
urea NN NN B-CHEM
and CC CC O
electrolytes NNS NNS O
, , , O
serum NN NN O
bFGF NN NN O
and CC CC O
VEGF NNP NNP O
. . . O

Three CD CD O
men NNS NNS O
( ( ( O
15 CD CD O
% NN NN O
) ) ) O
showed VBD VBD O
a DT DT O
decline NN NN O
in IN IN O
serum NN NN O
PSA NNP NNP O
of IN IN O
at IN IN O
least JJS JJS O
50 CD CD O
% NN NN O
, , , O
sustained VBD VBD O
throughout IN IN O
treatment NN NN O
. . . O

Of IN IN O
16 CD CD O
men NNS NNS O
treated VBN VBN O
for IN IN O
at IN IN O
least JJS JJS O
2 CD CD O
months NNS NNS O
, , , O
six CD CD O
( ( ( O
37 CD CD O
. . . O
5 CD CD O
% NN NN O
) ) ) O
showed VBD VBD O
a DT DT O
fall NN NN O
in IN IN O
absolute JJ JJ O
PSA NNP NNP O
by IN IN O
a DT DT O
median NN NN O
of IN IN O
48 CD CD O
% NN NN O
. . . O

Increasing NNP NNP O
levels NNS NNS O
of IN IN O
serum NN NN O
bFGF NN NN O
and CC CC O
VEGF NNP NNP O
were VBD VBD O
associated VBN VBN O
with IN IN O
progressive JJ JJ O
disease NN NN O
; : : O
five CD CD O
of IN IN O
six CD CD O
men NNS NNS O
who WP WP O
demonstrated VBD VBD O
a DT DT O
fall NN NN O
in IN IN O
PSA NNP NNP O
also RB RB O
showed VBD VBD O
a DT DT O
decline NN NN O
in IN IN O
bFGF NN NN O
and CC CC O
VEGF NNP NNP O
levels NNS NNS O
, , , O
and CC CC O
three CD CD O
of IN IN O
four CD CD O
men NNS NNS O
with IN IN O
a DT DT O
rising VBG VBG O
PSA NNP NNP O
showed VBD VBD O
an DT DT O
increase NN NN O
in IN IN O
both DT DT O
growth NN NN O
factors NNS NNS O
. . . O

Adverse NNP NNP O
effects NNS NNS O
included VBD VBD O
constipation NN NN O
, , , O
morning NN NN O
drowsiness NN NN O
, , , O
dizziness NN NN O
and CC CC O
rash NN NN O
, , , O
and CC CC O
resulted VBD VBD O
in IN IN O
withdrawal NN NN O
from IN IN O
the DT DT O
study NN NN O
by IN IN O
three CD CD O
men NNS NNS O
. . . O

Evidence NN NN O
of IN IN O
peripheral JJ JJ O
sensory NN NN O
neuropathy NN NN O
was VBD VBD O
found VBN VBN O
in IN IN O
nine CD CD O
of IN IN O
13 CD CD O
men NNS NNS O
before IN IN O
treatment NN NN O
. . . O

In IN IN O
the DT DT O
seven CD CD O
men NNS NNS O
who WP WP O
completed VBD VBD O
six CD CD O
months NNS NNS O
on IN IN O
thalidomide NN NN B-CHEM
, , , O
subclinical JJ JJ O
evidence NN NN O
of IN IN O
peripheral JJ JJ O
neuropathy NN NN O
was VBD VBD O
found VBN VBN O
in IN IN O
four CD CD O
before IN IN O
treatment NN NN O
, , , O
but CC CC O
in IN IN O
all DT DT O
seven CD CD O
at IN IN O
repeat NN NN O
testing NN NN O
. . . O

The DT DT O
findings NNS NNS O
indicate VBP VBP O
that IN IN O
thalidomide NN NN B-CHEM
may MD MD O
be VB VB O
an DT DT O
option NN NN O
for IN IN O
patients NNS NNS O
who WP WP O
have VBP VBP O
failed VBN VBN O
other JJ JJ O
forms NNS NNS O
of IN IN O
therapy NN NN O
, , , O
provided VBD VBD O
close VB VB O
follow VB VB O
- - - O
up RP RP O
is VBZ VBZ O
maintained VBN VBN O
for IN IN O
development NN NN O
of IN IN O
peripheral JJ JJ O
neuropathy NN NN O
. . . O

Central NNP NNP O
nervous JJ JJ O
system NN NN O
toxicity NN NN O
following VBG VBG O
the DT DT O
administration NN NN O
of IN IN O
levobupivacaine NN NN B-CHEM
for IN IN O
lumbar NN NN O
plexus NN NN O
block NN NN O
: : : O
A DT DT O
report NN NN O
of IN IN O
two CD CD O
cases NNS NNS O
. . . O

BACKGROUND NNP NNP O
AND CC CC O
OBJECTIVES NNP NNP O
: : : O
Central NNP NNP O
nervous JJ JJ O
system NN NN O
and CC CC O
cardiac JJ JJ O
toxicity NN NN O
following VBG VBG O
the DT DT O
administration NN NN O
of IN IN O
local JJ JJ O
anesthetics NNS NNS O
is VBZ VBZ O
a DT DT O
recognized JJ JJ O
complication NN NN O
of IN IN O
regional JJ JJ O
anesthesia NN NN O
. . . O

Levobupivacaine NNP NNP B-CHEM
, , , O
the DT DT O
pure NN NN O
S NNP NNP O
( ( ( O
- : : O
) ) ) O
enantiomer NN NN O
of IN IN O
bupivacaine NN NN B-CHEM
, , , O
was VBD VBD O
developed VBN VBN O
to TO TO O
improve VB VB O
the DT DT O
cardiac NN NN O
safety NN NN O
profile NN NN O
of IN IN O
bupivacaine NN NN B-CHEM
. . . O

We PRP PRP O
describe VBP VBP O
2 CD CD O
cases NNS NNS O
of IN IN O
grand JJ JJ O
mal NN NN O
seizures NNS NNS O
following VBG VBG O
accidental NN NN O
intravascular JJ JJ O
injection NN NN O
of IN IN O
levobupivacaine NN NN B-CHEM
. . . O

CASE NN NN O
REPORT NNP NNP O
: : : O
Two CD CD O
patients NNS NNS O
presenting VBG VBG O
for IN IN O
elective JJ JJ O
orthopedic JJ JJ O
surgery NN NN O
of IN IN O
the DT DT O
lower JJR JJR O
limb NN NN O
underwent JJ JJ O
blockade NN NN O
of IN IN O
the DT DT O
lumbar NN NN O
plexus NN NN O
via IN IN O
the DT DT O
posterior NN NN O
approach NN NN O
. . . O

Immediately RB RB O
after IN IN O
the DT DT O
administration NN NN O
of IN IN O
levobupivacaine NN NN B-CHEM
0 CD CD O
. . . O
5 CD CD O
% NN NN O
with IN IN O
epinephrine NN NN B-CHEM
2 CD CD O
. . . O
5 CD CD O
microgram NN NN O
/ NN NN O
mL NN NN O
, , , O
the DT DT O
patients NNS NNS O
developed VBN VBN O
grand JJ JJ O
mal JJ JJ O
seizures NNS NNS O
, , , O
despite IN IN O
negative JJ JJ O
aspiration NN NN O
for IN IN O
blood NN NN O
and CC CC O
no DT DT O
clinical JJ JJ O
signs NNS NNS O
of IN IN O
intravenous JJ JJ O
epinephrine NN NN B-CHEM
administration NN NN O
. . . O

The DT DT O
seizures NNS NNS O
were VBD VBD O
successfully RB RB O
treated VBN VBN O
with IN IN O
sodium NN NN B-CHEM
thiopental NN NN I-CHEM
in IN IN O
addition NN NN O
to TO TO O
succinylcholine VB VB B-CHEM
in IN IN O
1 CD CD O
patient NN NN O
. . . O

Neither DT DT O
patient NN NN O
developed VBN VBN O
signs NNS NNS O
of IN IN O
cardiovascular JJ JJ O
toxicity NN NN O
. . . O

Both DT DT O
patients NNS NNS O
were VBD VBD O
treated VBN VBN O
preoperatively RB RB O
with IN IN O
beta NN NN O
- - - O
adrenergic JJ JJ O
antagonist NN NN O
medications NNS NNS O
, , , O
which WDT WDT O
may MD MD O
have VB VB O
masked VBN VBN O
the DT DT O
cardiovascular JJ JJ O
signs NNS NNS O
of IN IN O
the DT DT O
unintentional JJ JJ O
intravascular JJ JJ O
administration NN NN O
of IN IN O
levobupivacaine NN NN B-CHEM
with IN IN O
epinephrine NN NN B-CHEM
. . . O

CONCLUSIONS NNP NNP O
: : : O
Although IN IN O
levobupivacaine NN NN B-CHEM
may MD MD O
have VB VB O
a DT DT O
safer JJR JJR O
cardiac JJ JJ O
toxicity NN NN O
profile NN NN O
than IN IN O
racemic JJ JJ O
bupivacaine NN NN B-CHEM
, , , O
if IN IN O
adequate JJ JJ O
amounts NNS NNS O
of IN IN O
levobupivacaine NN NN B-CHEM
reach NN NN O
the DT DT O
circulation NN NN O
, , , O
it PRP PRP O
will MD MD O
result VB VB O
in IN IN O
convulsions NNS NNS O
. . . O

Plasma NNP NNP O
concentrations NNS NNS O
sufficient JJ JJ O
to TO TO O
result VB VB O
in IN IN O
central JJ JJ O
nervous JJ JJ O
system NN NN O
toxicity NN NN O
did VBD VBD O
not RB RB O
produce VB VB O
manifestations NNS NNS O
of IN IN O
cardiac JJ JJ O
toxicity NN NN O
in IN IN O
these DT DT O
2 CD CD O
patients NNS NNS O
. . . O

Amiodarone NNP NNP B-CHEM
- - - O
induced JJ JJ O
torsade NN NN O
de IN IN O
pointes NNS NNS O
during IN IN O
bladder NN NN O
irrigation NN NN O
: : : O
an DT DT O
unusual JJ JJ O
presentation NN NN O
- - - O
- - - O
a DT DT O
case NN NN O
report NN NN O
. . . O

The DT DT O
authors NNS NNS O
present JJ JJ O
a DT DT O
case NN NN O
of IN IN O
early JJ JJ O
( ( ( O
within IN IN O
4 CD CD O
days NNS NNS O
) ) ) O
development NN NN O
of IN IN O
torsade NN NN O
de IN IN O
pointes NNS NNS O
( ( ( O
TdP NNP NNP O
) ) ) O
associated VBN VBN O
with IN IN O
oral JJ JJ O
amiodarone NN NN B-CHEM
therapy NN NN O
. . . O

Consistent JJ JJ O
with IN IN O
other JJ JJ O
reports NNS NNS O
this DT DT O
case NN NN O
of IN IN O
TdP NNP NNP O
occurred VBD VBD O
in IN IN O
the DT DT O
context NN NN O
of IN IN O
multiple JJ JJ O
exacerbating VBG VBG O
factors NNS NNS O
including VBG VBG O
hypokalemia NN NN O
and CC CC O
digoxin NN NN B-CHEM
excess NN NN O
. . . O

Transient NNP NNP O
prolongation NN NN O
of IN IN O
the DT DT O
QT NNP NNP O
during IN IN O
bladder NN NN O
irrigation NN NN O
prompted VBD VBD O
the DT DT O
episode NN NN O
of IN IN O
TdP NNP NNP O
. . . O

It PRP PRP O
is VBZ VBZ O
well RB RB O
known VBN VBN O
that IN IN O
bradycardia NN NN O
exacerbates NNS NNS O
acquired VBN VBN O
TdP NNP NNP O
. . . O

The DT DT O
authors NNS NNS O
speculate VBP VBP O
that IN IN O
the DT DT O
increased VBN VBN O
vagal NN NN O
tone NN NN O
during IN IN O
bladder NN NN O
irrigation NN NN O
, , , O
a DT DT O
vagal JJ JJ O
maneuver NN NN O
, , , O
in IN IN O
the DT DT O
context NN NN O
of IN IN O
amiodarone NN NN B-CHEM
therapy NN NN O
resulted VBD VBD O
in IN IN O
amiodarone NN NN B-CHEM
- - - O
induced JJ JJ O
proarrhythmia NN NN O
. . . O

In IN IN O
the DT DT O
absence NN NN O
of IN IN O
amiodarone NN NN B-CHEM
therapy NN NN O
, , , O
a DT DT O
second JJ JJ O
bladder NN NN O
irrigation NN NN O
did VBD VBD O
not RB RB O
induce VB VB O
TdP NNP NNP O
despite IN IN O
hypokalemia NN NN O
and CC CC O
hypomagnesemia NN NN O
. . . O

Anaesthetic NNP NNP O
complications NNS NNS O
associated VBN VBN O
with IN IN O
myotonia NN NN O
congenita NN NN O
: : : O
case NN NN O
study NN NN O
and CC CC O
comparison NN NN O
with IN IN O
other JJ JJ O
myotonic JJ JJ O
disorders NNS NNS O
. . . O

Myotonia NNP NNP O
congenita NN NN O
( ( ( O
MC NNP NNP O
) ) ) O
is VBZ VBZ O
caused VBN VBN O
by IN IN O
a DT DT O
defect NN NN O
in IN IN O
the DT DT O
skeletal JJ JJ O
muscle NN NN O
chloride NN NN B-CHEM
channel NN NN O
function NN NN O
, , , O
which WDT WDT O
may MD MD O
cause VB VB O
sustained JJ JJ O
membrane NN NN O
depolarisation NN NN O
. . . O

We PRP PRP O
describe VBP VBP O
a DT DT O
previously RB RB O
healthy JJ JJ O
32 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
woman NN NN O
who WP WP O
developed VBD VBD O
a DT DT O
life NN NN O
- - - O
threatening VBG VBG O
muscle NN NN O
spasm NN NN O
and CC CC O
secondary JJ JJ O
ventilation NN NN O
difficulties NNS NNS O
following VBG VBG O
a DT DT O
preoperative JJ JJ O
injection NN NN O
of IN IN O
suxamethonium NN NN B-CHEM
. . . O

The DT DT O
muscle NN NN O
spasms NNS NNS O
disappeared VBD VBD O
spontaneously RB RB O
and CC CC O
the DT DT O
surgery NN NN O
proceeded VBD VBD O
without IN IN O
further JJ JJ O
problems NNS NNS O
. . . O

When WRB WRB O
subsequently RB RB O
questioned VBD VBD O
, , , O
she PRP PRP O
reported VBD VBD O
minor JJ JJ O
symptoms NNS NNS O
suggesting VBG VBG O
a DT DT O
myotonic JJ JJ O
condition NN NN O
. . . O

Myotonia NNP NNP O
was VBD VBD O
found VBN VBN O
on IN IN O
clinical JJ JJ O
examination NN NN O
and CC CC O
EMG NNP NNP O
. . . O

The DT DT O
diagnosis NN NN O
MC NNP NNP O
was VBD VBD O
confirmed VBN VBN O
genetically RB RB O
. . . O

Neither DT DT O
the DT DT O
patient NN NN O
nor CC CC O
the DT DT O
anaesthetist NN NN O
were VBD VBD O
aware JJ JJ O
of IN IN O
the DT DT O
diagnosis NN NN O
before IN IN O
this DT DT O
potentially RB RB O
lethal JJ JJ O
complication NN NN O
occurred VBD VBD O
. . . O

We PRP PRP O
give VBP VBP O
a DT DT O
brief JJ JJ O
overview NN NN O
of IN IN O
ion NN NN O
channel NN NN O
disorders NNS NNS O
including VBG VBG O
malignant NN NN O
hyperthermia NN NN O
and CC CC O
their PRP$ PRP$ O
anaesthetic JJ JJ O
considerations NNS NNS O
. . . O

Respiratory NNP NNP O
pattern NN NN O
in IN IN O
a DT DT O
rat NN NN O
model NN NN O
of IN IN O
epilepsy NN NN O
. . . O

PURPOSE NNP NNP O
: : : O
Apnea NNP NNP O
is VBZ VBZ O
known VBN VBN O
to TO TO O
occur VB VB O
during IN IN O
seizures NNS NNS O
, , , O
but CC CC O
systematic JJ JJ O
studies NNS NNS O
of IN IN O
ictal JJ JJ O
respiratory NN NN O
changes NNS NNS O
in IN IN O
adults NNS NNS O
are VBP VBP O
few JJ JJ O
. . . O

Data NNP NNP O
regarding VBG VBG O
respiratory JJ JJ O
pattern NN NN O
defects NNS NNS O
during IN IN O
interictal JJ JJ O
periods NNS NNS O
also RB RB O
are VBP VBP O
scarce JJ JJ O
. . . O

Here RB RB O
we PRP PRP O
sought VBD VBD O
to TO TO O
generate VB VB O
information NN NN O
with IN IN O
regard NN NN O
to TO TO O
the DT DT O
interictal JJ JJ O
period NN NN O
in IN IN O
animals NNS NNS O
with IN IN O
pilocarpine NN NN B-CHEM
- - - O
induced JJ JJ O
epilepsy NN NN O
. . . O

METHODS NNP NNP O
: : : O
Twelve NNP NNP O
rats NNS NNS O
( ( ( O
six CD CD O
chronically RB RB O
epileptic JJ JJ O
animals NNS NNS O
and CC CC O
six CD CD O
controls NNS NNS O
) ) ) O
were VBD VBD O
anesthetized VBN VBN O
, , , O
given VBN VBN O
tracheotomies NNS NNS O
, , , O
and CC CC O
subjected VBD VBD O
to TO TO O
hyperventilation NN NN O
or CC CC O
hypoventilation NN NN O
conditions NNS NNS O
. . . O

Breathing NNP NNP O
movements NNS NNS O
caused VBD VBD O
changes NNS NNS O
in IN IN O
thoracic NN NN O
volume NN NN O
and CC CC O
forced VBN VBN O
air NN NN O
to TO TO O
flow VB VB O
tidally RB RB O
through IN IN O
a DT DT O
pneumotachograph NN NN O
. . . O

This DT DT O
flow NN NN O
was VBD VBD O
measured VBN VBN O
by IN IN O
using VBG VBG O
a DT DT O
differential JJ JJ O
pressure NN NN O
transducer NN NN O
, , , O
passed VBN VBN O
through IN IN O
a DT DT O
polygraph NN NN O
, , , O
and CC CC O
from IN IN O
this DT DT O
to TO TO O
a DT DT O
computer NN NN O
with IN IN O
custom NN NN O
software NN NN O
that WDT WDT O
derived VBD VBD O
ventilation NN NN O
( ( ( O
VE NNP NNP O
) ) ) O
, , , O
tidal NN NN O
volume NN NN O
( ( ( O
VT NNP NNP O
) ) ) O
, , , O
inspiratory JJ JJ O
time NN NN O
( ( ( O
TI NNP NNP O
) ) ) O
, , , O
expiratory JJ JJ O
time NN NN O
( ( ( O
TE NNP NNP O
) ) ) O
, , , O
breathing VBG VBG O
frequency NN NN O
( ( ( O
f SYM SYM O
) ) ) O
, , , O
and CC CC O
mean VB VB O
inspiratory NN NN O
flow NN NN O
( ( ( O
VT NNP NNP O
/ NN NN O
TI NNP NNP O
) ) ) O
on IN IN O
a DT DT O
breath NN NN O
- - - O
by IN IN O
- - - O
breath NN NN O
basis NN NN O
. . . O

RESULTS NNS NNS O
: : : O
The DT DT O
hyperventilation NN NN O
maneuver NN NN O
caused VBD VBD O
a DT DT O
decrease NN NN O
in IN IN O
spontaneous JJ JJ O
ventilation NN NN O
in IN IN O
pilocarpine NN NN B-CHEM
- - - O
treated VBN VBN O
and CC CC O
control NN NN O
rats NNS NNS O
. . . O

Although IN IN O
VE NNP NNP O
had VBD VBD O
a DT DT O
similar JJ JJ O
decrease NN NN O
in IN IN O
both DT DT O
groups NNS NNS O
, , , O
in IN IN O
the DT DT O
epileptic JJ JJ O
group NN NN O
, , , O
the DT DT O
decrease NN NN O
in IN IN O
VE NNP NNP O
was VBD VBD O
due JJ JJ O
to TO TO O
a DT DT O
significant JJ JJ O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
increase NN NN O
in IN IN O
TE NNP NNP O
peak NN NN O
in IN IN O
relation NN NN O
to TO TO O
that DT DT O
of IN IN O
the DT DT O
control NN NN O
animals NNS NNS O
. . . O

The DT DT O
hypoventilation NN NN O
maneuver NN NN O
led VBN VBN O
to TO TO O
an DT DT O
increase NN NN O
in IN IN O
the DT DT O
arterial JJ JJ O
Paco2 NNP NNP O
, , , O
followed VBN VBN O
by IN IN O
an DT DT O
increase NN NN O
in IN IN O
VE NNP NNP O
. . . O

In IN IN O
the DT DT O
epileptic JJ JJ O
group NN NN O
, , , O
the DT DT O
increase NN NN O
in IN IN O
VE NNP NNP O
was VBD VBD O
mediated VBN VBN O
by IN IN O
a DT DT O
significant JJ JJ O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
decrease NN NN O
in IN IN O
TE NNP NNP O
peak NN NN O
compared VBN VBN O
with IN IN O
the DT DT O
control NN NN O
group NN NN O
. . . O

Systemic NNP NNP O
application NN NN O
of IN IN O
KCN NNP NNP O
, , , O
to TO TO O
evaluate VB VB O
the DT DT O
effects NNS NNS O
of IN IN O
peripheral JJ JJ O
chemoreception NN NN O
activation NN NN O
on IN IN O
ventilation NN NN O
, , , O
led VBN VBN O
to TO TO O
a DT DT O
similar JJ JJ O
increase NN NN O
in IN IN O
VE NNP NNP O
for IN IN O
both DT DT O
groups NNS NNS O
. . . O

CONCLUSIONS NNP NNP O
: : : O
The DT DT O
data NNS NNS O
indicate VBP VBP O
that IN IN O
pilocarpine NN NN B-CHEM
- - - O
treated JJ JJ O
animals NNS NNS O
have VBP VBP O
an DT DT O
altered VBN VBN O
ability NN NN O
to TO TO O
react VB VB O
to TO TO O
( ( ( O
or CC CC O
compensate NN NN O
for IN IN O
) ) ) O
blood NN NN O
gas NN NN O
changes NNS NNS O
with IN IN O
changes NNS NNS O
in IN IN O
ventilation NN NN O
and CC CC O
suggest VB VB O
that IN IN O
it PRP PRP O
is VBZ VBZ O
centrally RB RB O
determined VBN VBN O
. . . O

We PRP PRP O
speculate VBP VBP O
on IN IN O
the DT DT O
possible JJ JJ O
relation NN NN O
of IN IN O
the DT DT O
current JJ JJ O
findings NNS NNS O
on IN IN O
treating VBG VBG O
different JJ JJ O
epilepsy NN NN O
- - - O
associated VBN VBN O
conditions NNS NNS O
. . . O

Fatal NNP NNP O
myeloencephalopathy NN NN O
due JJ JJ O
to TO TO O
intrathecal JJ JJ O
vincristine NN NN B-CHEM
administration NN NN O
. . . O

Vincristine NNP NNP B-CHEM
was VBD VBD O
accidentally RB RB O
given VBN VBN O
intrathecally RB RB O
to TO TO O
a DT DT O
child NN NN O
with IN IN O
leukaemia NN NN O
, , , O
producing VBG VBG O
sensory JJ JJ O
and CC CC O
motor NN NN O
dysfunction NN NN O
followed VBN VBN O
by IN IN O
encephalopathy JJ JJ O
and CC CC O
death NN NN O
. . . O

Separate JJ JJ O
times NNS NNS O
for IN IN O
administering VBG VBG O
vincristine NN NN B-CHEM
and CC CC O
intrathecal JJ JJ O
therapy NN NN O
is VBZ VBZ O
recommended VBN VBN O
. . . O

Progesterone NNP NNP B-CHEM
potentiation NN NN O
of IN IN O
bupivacaine NN NN B-CHEM
arrhythmogenicity NN NN O
in IN IN O
pentobarbital JJ JJ B-CHEM
- - - O
anesthetized JJ JJ O
rats NNS NNS O
and CC CC O
beating VBG VBG O
rat NN NN O
heart NN NN O
cell NN NN O
cultures NNS NNS O
. . . O

The DT DT O
effects NNS NNS O
of IN IN O
progesterone NN NN B-CHEM
treatment NN NN O
on IN IN O
bupivacaine NN NN B-CHEM
arrhythmogenicity NN NN O
in IN IN O
beating NN NN O
rat NN NN O
heart NN NN O
myocyte NN NN O
cultures NNS NNS O
and CC CC O
on IN IN O
anesthetized JJ JJ O
rats NNS NNS O
were VBD VBD O
determined VBN VBN O
. . . O

After IN IN O
determining VBG VBG O
the DT DT O
bupivacaine NN NN B-CHEM
AD50 NNP NNP O
( ( ( O
the DT DT O
concentration NN NN O
of IN IN O
bupivacaine NN NN B-CHEM
that WDT WDT O
caused VBD VBD O
50 CD CD O
% NN NN O
of IN IN O
all DT DT O
beating VBG VBG O
rat NN NN O
heart NN NN O
myocyte NN NN O
cultures NNS NNS O
to TO TO O
become VB VB O
arrhythmic JJ JJ O
) ) ) O
, , , O
we PRP PRP O
determined VBD VBD O
the DT DT O
effect NN NN O
of IN IN O
1 CD CD O
- : : O
hour NN NN O
progesterone NN NN B-CHEM
HCl NNP NNP B-CHEM
exposure NN NN O
on IN IN O
myocyte NN NN O
contractile NN NN O
rhythm NN NN O
. . . O

Each DT DT O
concentration NN NN O
of IN IN O
progesterone NN NN B-CHEM
( ( ( O
6 CD CD O
. . . O
25 CD CD O
, , , O
12 CD CD O
. . . O
5 CD CD O
, , , O
25 CD CD O
, , , O
and CC CC O
50 CD CD O
micrograms NNS NNS O
/ NN NN O
ml NN NN O
) ) ) O
caused VBD VBD O
a DT DT O
significant JJ JJ O
and CC CC O
concentration NN NN O
- - - O
dependent JJ JJ O
reduction NN NN O
in IN IN O
the DT DT O
AD50 NNP NNP O
for IN IN O
bupivacaine NN NN B-CHEM
. . . O

Estradiol NNP NNP B-CHEM
treatment NN NN O
also RB RB O
increased VBD VBD O
the DT DT O
arrhythmogenicity NN NN O
of IN IN O
bupivacaine NN NN B-CHEM
in IN IN O
myocyte NN NN O
cultures NNS NNS O
, , , O
but CC CC O
was VBD VBD O
only RB RB O
one CD CD O
fourth JJ JJ O
as RB RB O
potent NN NN O
as IN IN O
progesterone NN NN B-CHEM
. . . O

Neither DT DT O
progesterone NN NN B-CHEM
nor CC CC O
estradiol NN NN B-CHEM
effects NNS NNS O
on IN IN O
bupivacaine NN NN B-CHEM
arrhythmogenicity NN NN O
were VBD VBD O
potentiated VBN VBN O
by IN IN O
epinephrine NN NN B-CHEM
. . . O

Chronic NNP NNP O
progesterone NN NN B-CHEM
pretreatment NN NN O
( ( ( O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
for IN IN O
21 CD CD O
days NNS NNS O
) ) ) O
caused VBD VBD O
a DT DT O
significant JJ JJ O
increase NN NN O
in IN IN O
bupivacaine NN NN B-CHEM
arrhythmogenicity NN NN O
in IN IN O
intact JJ JJ O
pentobarbital JJ JJ B-CHEM
- - - O
anesthetized JJ JJ O
rats NNS NNS O
. . . O

There EX EX O
was VBD VBD O
a DT DT O
significant JJ JJ O
decrease NN NN O
in IN IN O
the DT DT O
time NN NN O
to TO TO O
onset NN NN O
of IN IN O
arrhythmia NN NN O
as IN IN O
compared VBN VBN O
with IN IN O
control NN NN O
nonprogesterone NN NN O
- - - O
treated VBN VBN O
rats NNS NNS O
( ( ( O
6 CD CD O
. . . O
2 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
3 CD CD O
vs NNS NNS O
. . . O
30 CD CD O
. . . O
8 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
. . . O
5 CD CD O
min NN NN O
, , , O
mean NN NN O
+ NN NN O
/ NN NN O
- - - O
SE NNP NNP O
) ) ) O
. . . O

The DT DT O
results NNS NNS O
of IN IN O
this DT DT O
study NN NN O
indicate VBP VBP O
that IN IN O
progesterone NN NN B-CHEM
can MD MD O
potentiate VB VB O
bupivacaine NN NN B-CHEM
arrhythmogenicity NN NN O
both DT DT O
in IN IN O
vivo NN NN O
and CC CC O
in IN IN O
vitro NN NN O
. . . O

Potentiation NNP NNP O
of IN IN O
bupivacaine NN NN B-CHEM
arrhythmia NN NN O
in IN IN O
myocyte NN NN O
cultures NNS NNS O
suggests VBZ VBZ O
that IN IN O
this DT DT O
effect NN NN O
is VBZ VBZ O
at IN IN O
least JJS JJS O
partly RB RB O
mediated VBN VBN O
at IN IN O
the DT DT O
myocyte NN NN O
level NN NN O
. . . O

Increased NNP NNP O
serum NN NN O
soluble JJ JJ O
Fas NNP NNP O
in IN IN O
patients NNS NNS O
with IN IN O
acute JJ JJ O
liver NN NN O
failure NN NN O
due JJ JJ O
to TO TO O
paracetamol VB VB B-CHEM
overdose NN NN O
. . . O

BACKGROUND NNP NNP O
/ NN NN O
AIMS NNP NNP O
: : : O
Experimental NNP NNP O
studies NNS NNS O
have VBP VBP O
suggested VBN VBN O
that IN IN O
apoptosis NN NN O
via IN IN O
the DT DT O
Fas NNP NNP O
/ NN NN O
Fas NNP NNP O
Ligand NNP NNP O
signaling VBG VBG O
system NN NN O
may MD MD O
play VB VB O
an DT DT O
important JJ JJ O
role NN NN O
in IN IN O
the DT DT O
development NN NN O
of IN IN O
acute JJ JJ O
liver NN NN O
failure NN NN O
. . . O

The DT DT O
aim NN NN O
of IN IN O
the DT DT O
study NN NN O
was VBD VBD O
to TO TO O
investigate VB VB O
the DT DT O
soluble JJ JJ O
form NN NN O
of IN IN O
Fas NNP NNP O
in IN IN O
patients NNS NNS O
with IN IN O
acute JJ JJ O
liver NN NN O
failure NN NN O
. . . O

METHODOLOGY NNP NNP O
: : : O
Serum NNP NNP O
levels NNS NNS O
of IN IN O
sFas NN NN O
( ( ( O
soluble JJ JJ O
Fas NNP NNP O
) ) ) O
were VBD VBD O
measured VBN VBN O
by IN IN O
ELISA NNP NNP O
in IN IN O
24 CD CD O
patients NNS NNS O
with IN IN O
acute JJ JJ O
liver NN NN O
failure NN NN O
and CC CC O
10 CD CD O
normal JJ JJ O
control NN NN O
subjects NNS NNS O
. . . O

Serum NNP NNP O
levels NNS NNS O
of IN IN O
tumor NN NN O
necrosis NN NN O
factor NN NN O
- : : O
alpha NN NN O
and CC CC O
interferon NN NN O
- - - O
gamma NN NN O
were VBD VBD O
also RB RB O
determined VBN VBN O
by IN IN O
ELISA NNP NNP O
. . . O

RESULTS NNS NNS O
: : : O
Serum NNP NNP O
sFas NN NN O
was VBD VBD O
significantly RB RB O
increased VBN VBN O
in IN IN O
patients NNS NNS O
with IN IN O
acute JJ JJ O
liver NN NN O
failure NN NN O
( ( ( O
median NN NN O
, , , O
26 CD CD O
. . . O
8 CD CD O
U NNP NNP O
/ NN NN O
mL NN NN O
; : : O
range NN NN O
, , , O
6 CD CD O
. . . O
9 CD CD O
- : : O
52 CD CD O
. . . O
7 CD CD O
U NNP NNP O
/ NN NN O
mL NN NN O
) ) ) O
compared VBN VBN O
to TO TO O
the DT DT O
normal JJ JJ O
controls NNS NNS O
( ( ( O
median NN NN O
, , , O
8 CD CD O
. . . O
6 CD CD O
U NNP NNP O
/ NN NN O
mL NN NN O
; : : O
range NN NN O
, , , O
6 CD CD O
. . . O
5 CD CD O
- : : O
12 CD CD O
. . . O
0 CD CD O
U NNP NNP O
/ NN NN O
mL NN NN O
, , , O
P NN NN O
< NN NN O
0 CD CD O
. . . O
0001 CD CD O
) ) ) O
. . . O

Levels NNS NNS O
were VBD VBD O
significantly RB RB O
greater JJR JJR O
in IN IN O
patients NNS NNS O
with IN IN O
acute JJ JJ O
liver NN NN O
failure NN NN O
due JJ JJ O
to TO TO O
paracetamol NN NN B-CHEM
overdose NN NN O
( ( ( O
median NN NN O
, , , O
28 CD CD O
. . . O
7 CD CD O
U NNP NNP O
/ NN NN O
mL NN NN O
; : : O
range NN NN O
, , , O
12 CD CD O
. . . O
8 CD CD O
- : : O
52 CD CD O
. . . O
7 CD CD O
U NNP NNP O
/ NN NN O
mL NN NN O
, , , O
n NN NN O
= SYM SYM O
17 CD CD O
) ) ) O
than IN IN O
those DT DT O
due JJ JJ O
to TO TO O
non NN NN O
- - - O
A DT DT O
to TO TO O
E NNP NNP O
hepatitis NN NN O
( ( ( O
median NN NN O
, , , O
12 CD CD O
. . . O
5 CD CD O
U NNP NNP O
/ NN NN O
mL NN NN O
; : : O
range NN NN O
, , , O
6 CD CD O
. . . O
9 CD CD O
- : : O
46 CD CD O
. . . O
0 CD CD O
U NNP NNP O
/ NN NN O
mL NN NN O
, , , O
n NN NN O
= SYM SYM O
7 CD CD O
, , , O
P NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
. . . O

There EX EX O
was VBD VBD O
no DT DT O
relationship NN NN O
of IN IN O
sFas NN NN O
to TO TO O
eventual VB VB O
outcome NN NN O
in IN IN O
the DT DT O
patients NNS NNS O
. . . O

A DT DT O
significant JJ JJ O
correlation NN NN O
was VBD VBD O
observed VBN VBN O
between IN IN O
serum NN NN O
sFas NN NN O
levels NNS NNS O
and CC CC O
aspartate NN NN B-CHEM
aminotransferase NN NN O
( ( ( O
r LS LS O
= SYM SYM O
0 CD CD O
. . . O
613 CD CD O
, , , O
P NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
. . . O

CONCLUSIONS NNP NNP O
: : : O
The DT DT O
increased JJ JJ O
concentration NN NN O
of IN IN O
sFas NN NN O
in IN IN O
serum NN NN O
of IN IN O
patients NNS NNS O
with IN IN O
acute JJ JJ O
liver NN NN O
failure NN NN O
may MD MD O
reflect VB VB O
activation NN NN O
of IN IN O
Fas NNP NNP O
- - - O
mediated JJ JJ O
apoptosis NN NN O
in IN IN O
the DT DT O
liver NN NN O
and CC CC O
this DT DT O
together RB RB O
with IN IN O
increased VBN VBN O
tumor NN NN O
necrosis NN NN O
factor NN NN O
- : : O
alpha NN NN O
may MD MD O
be VB VB O
an DT DT O
important JJ JJ O
factor NN NN O
in IN IN O
liver NN NN O
cell NN NN O
loss NN NN O
. . . O

Bilateral NNP NNP O
subthalamic JJ JJ O
nucleus NN NN O
stimulation NN NN O
for IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
. . . O

High NNP NNP O
frequency NN NN O
stimulation NN NN O
of IN IN O
the DT DT O
subthalamic JJ JJ O
nucleus NN NN O
( ( ( O
STN NNP NNP O
) ) ) O
is VBZ VBZ O
known VBN VBN O
to TO TO O
ameliorate VB VB O
the DT DT O
signs NNS NNS O
and CC CC O
symptoms NNS NNS O
of IN IN O
advanced JJ JJ O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
. . . O

AIM NNP NNP O
: : : O
We PRP PRP O
studied VBD VBD O
the DT DT O
effect NN NN O
of IN IN O
high JJ JJ O
frequency NN NN O
STN NNP NNP O
stimulation NN NN O
in IN IN O
23 CD CD O
patients NNS NNS O
. . . O

METHOD NNP NNP O
: : : O
Twenty CD CD O
- - - O
three CD CD O
patients NNS NNS O
suffering VBG VBG O
from IN IN O
severe JJ JJ O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
( ( ( O
Stages NNP NNP O
III NNP NNP O
- : : O
V NNP NNP O
on IN IN O
Hoehn NNP NNP O
and CC CC O
Yahr NNP NNP O
scale NN NN O
) ) ) O
and CC CC O
, , , O
particularly RB RB O
bradykinesia NN NN O
, , , O
rigidity NN NN O
, , , O
and CC CC O
levodopa NN NN B-CHEM
- - - O
induced JJ JJ O
dyskinesias NN NN O
underwent JJ JJ O
bilateral JJ JJ O
implantation NN NN O
of IN IN O
electrodes NNS NNS O
in IN IN O
the DT DT O
STN NNP NNP O
. . . O

Preoperative NNP NNP O
and CC CC O
postoperative JJ JJ O
assessments NNS NNS O
of IN IN O
these DT DT O
patients NNS NNS O
at IN IN O
1 CD CD O
, , , O
3 CD CD O
, , , O
6 CD CD O
and CC CC O
12 CD CD O
months NNS NNS O
follow VB VB O
- - - O
up RP RP O
, , , O
in IN IN O
" '' '' O
on IN IN O
" '' '' O
and CC CC O
" '' '' O
off IN IN O
" '' '' O
drug NN NN O
conditions NNS NNS O
, , , O
was VBD VBD O
carried VBN VBN O
out IN IN O
using VBG VBG O
Unified NNP NNP O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
Disease NNP NNP O
Rating NNP NNP O
Scale NNP NNP O
, , , O
Hoehn NNP NNP O
and CC CC O
Yahr NNP NNP O
staging VBG VBG O
, , , O
England NNP NNP O
activities NNS NNS O
of IN IN O
daily JJ JJ O
living NN NN O
score NN NN O
and CC CC O
video NN NN O
recordings NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
After IN IN O
one CD CD O
year NN NN O
of IN IN O
electrical JJ JJ O
stimulation NN NN O
of IN IN O
the DT DT O
STN NNP NNP O
, , , O
the DT DT O
patients NNS NNS O
' POS POS O
scores NNS NNS O
for IN IN O
activities NNS NNS O
of IN IN O
daily JJ JJ O
living NN NN O
and CC CC O
motor NN NN O
examination NN NN O
scores NNS NNS O
( ( ( O
Unified NNP NNP O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
Disease NNP NNP O
Rating NNP NNP O
Scale NNP NNP O
parts NNS NNS O
II NNP NNP O
and CC CC O
III NNP NNP O
) ) ) O
off RP RP O
medication NN NN O
improved VBN VBN O
by IN IN O
62 CD CD O
% NN NN O
and CC CC O
61 CD CD O
% NN NN O
respectively RB RB O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
0005 CD CD O
) ) ) O
. . . O

The DT DT O
subscores NNS NNS O
for IN IN O
the DT DT O
akinesia NN NN O
, , , O
rigidity NN NN O
, , , O
tremor NN NN O
and CC CC O
gait NN NN O
also RB RB O
improved VBD VBD O
. . . O

( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
0005 CD CD O
) ) ) O
. . . O

The DT DT O
average JJ JJ O
levodopa NN NN B-CHEM
dose NN NN O
decreased VBD VBD O
from IN IN O
813 CD CD O
mg NN NN O
to TO TO O
359 CD CD O
mg NN NN O
. . . O

The DT DT O
cognitive JJ JJ O
functions NNS NNS O
remained VBD VBD O
unchanged JJ JJ O
. . . O

Two CD CD O
patients NNS NNS O
developed VBN VBN O
device NN NN O
- - - O
related VBN VBN O
complications NNS NNS O
and CC CC O
two CD CD O
patients NNS NNS O
experienced VBN VBN O
abnormal JJ JJ O
weight NN NN O
gain NN NN O
. . . O

CONCLUSION NNP NNP O
: : : O
Bilateral NNP NNP O
subthalamic JJ JJ O
nucleus NN NN O
stimulation NN NN O
is VBZ VBZ O
an DT DT O
effective JJ JJ O
treatment NN NN O
for IN IN O
advanced JJ JJ O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
. . . O

It PRP PRP O
reduces VBZ VBZ O
the DT DT O
severity NN NN O
of IN IN O
" '' '' O
off IN IN O
" '' '' O
phase NN NN O
symptoms NNS NNS O
, , , O
improves VBZ VBZ O
the DT DT O
axial JJ JJ O
symptoms NNS NNS O
and CC CC O
reduces NNS NNS O
levodopa NN NN B-CHEM
requirements NNS NNS O
. . . O

The DT DT O
reduction NN NN O
in IN IN O
the DT DT O
levodopa NN NN B-CHEM
dose NN NN O
is VBZ VBZ O
useful JJ JJ O
in IN IN O
controlling VBG VBG O
drug NN NN O
- - - O
induced JJ JJ O
dyskinesias NN NN O
. . . O

Acute JJ JJ O
renal JJ JJ O
failure NN NN O
occurring VBG VBG O
during IN IN O
intravenous JJ JJ O
desferrioxamine NN NN B-CHEM
therapy NN NN O
: : : O
recovery NN NN O
after IN IN O
haemodialysis NN NN O
. . . O

A DT DT O
patient NN NN O
with IN IN O
transfusion NN NN O
- - - O
dependent JJ JJ O
thalassemia NN NN O
was VBD VBD O
undergoing VBG VBG O
home NN NN O
intravenous JJ JJ O
desferrioxamine NN NN B-CHEM
( ( ( O
DFX NNP NNP B-CHEM
) ) ) O
treatment NN NN O
by IN IN O
means NNS NNS O
of IN IN O
a DT DT O
totally RB RB O
implanted JJ JJ O
system NN NN O
because IN IN O
of IN IN O
his PRP$ PRP$ O
poor JJ JJ O
compliance NN NN O
with IN IN O
the DT DT O
nightly RB RB O
subcutaneous JJ JJ O
therapy NN NN O
. . . O

Due NNP NNP O
to TO TO O
an DT DT O
accidental NN NN O
malfunctioning NN NN O
of IN IN O
the DT DT O
infusion NN NN O
pump NN NN O
, , , O
the DT DT O
patient NN NN O
was VBD VBD O
inadvertently RB RB O
administered VBN VBN O
a DT DT O
toxic JJ JJ O
dosage NN NN O
of IN IN O
the DT DT O
drug NN NN O
which WDT WDT O
caused VBD VBD O
renal JJ JJ O
insufficiency NN NN O
. . . O

Given VBN VBN O
the DT DT O
progressive JJ JJ O
deterioration NN NN O
of IN IN O
the DT DT O
symptoms NNS NNS O
and CC CC O
of IN IN O
the DT DT O
laboratory NN NN O
values NNS NNS O
, , , O
despite IN IN O
adequate JJ JJ O
medical JJ JJ O
treatment NN NN O
, , , O
a DT DT O
decision NN NN O
was VBD VBD O
made VBN VBN O
to TO TO O
introduce VB VB O
haemodialytical JJ JJ O
therapy NN NN O
in IN IN O
order NN NN O
to TO TO O
remove VB VB O
the DT DT O
drug NN NN O
and CC CC O
therapy NN NN O
reduce VB VB O
the DT DT O
nephrotoxicity NN NN O
. . . O

From IN IN O
the DT DT O
results NNS NNS O
obtained VBN VBN O
, , , O
haemodialysis NN NN O
can MD MD O
therefore RB RB O
be VB VB O
suggested VBN VBN O
as IN IN O
a DT DT O
useful JJ JJ O
therapy NN NN O
in IN IN O
rare JJ JJ O
cases NNS NNS O
of IN IN O
progressive JJ JJ O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
caused VBN VBN O
by IN IN O
desferrioxamine NN NN B-CHEM
. . . O

Ocular NNP NNP O
motility NN NN O
changes NNS NNS O
after IN IN O
subtenon NN NN O
carboplatin NN NN B-CHEM
chemotherapy NN NN O
for IN IN O
retinoblastoma NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
Focal NNP NNP O
subtenon NN NN O
carboplatin NN NN B-CHEM
injections NNS NNS O
have VBP VBP O
recently RB RB O
been VBN VBN O
used VBN VBN O
as IN IN O
a DT DT O
presumably RB RB O
toxicity NN NN O
- - - O
free JJ JJ O
adjunct NN NN O
to TO TO O
systemic JJ JJ O
chemotherapy NN NN O
for IN IN O
intraocular JJ JJ O
retinoblastoma NN NN O
. . . O

OBJECTIVE NNP NNP O
: : : O
To TO TO O
report VB VB O
our PRP$ PRP$ O
clinical JJ JJ O
experience NN NN O
with IN IN O
abnormal JJ JJ O
ocular NN NN O
motility NN NN O
in IN IN O
patients NNS NNS O
treated VBN VBN O
with IN IN O
subtenon NN NN O
carboplatin NN NN B-CHEM
chemotherapy NN NN O
. . . O

METHODS NNP NNP O
: : : O
We PRP PRP O
noted VBD VBD O
abnormal JJ JJ O
ocular NN NN O
motility NN NN O
in IN IN O
10 CD CD O
consecutive JJ JJ O
patients NNS NNS O
with IN IN O
retinoblastoma NN NN O
who WP WP O
had VBD VBD O
received VBN VBN O
subtenon NN NN O
carboplatin NN NN B-CHEM
. . . O

During IN IN O
ocular JJ JJ O
manipulation NN NN O
under IN IN O
general JJ JJ O
anesthesia NN NN O
, , , O
we PRP PRP O
assessed VBD VBD O
their PRP$ PRP$ O
eyes NNS NNS O
by IN IN O
forced JJ JJ O
duction NN NN O
testing NN NN O
, , , O
comparing VBG VBG O
ocular JJ JJ O
motility NN NN O
after IN IN O
tumor NN NN O
control NN NN O
with IN IN O
ocular JJ JJ O
motility NN NN O
at IN IN O
diagnosis NN NN O
. . . O

Eyes NNS NNS O
subsequently RB RB O
enucleated VBN VBN O
because IN IN O
of IN IN O
treatment NN NN O
failure NN NN O
( ( ( O
n NN NN O
= SYM SYM O
4 CD CD O
) ) ) O
were VBD VBD O
examined VBN VBN O
histologically RB RB O
. . . O

RESULTS NNS NNS O
: : : O
Limitation NNP NNP O
of IN IN O
ocular JJ JJ O
motility NN NN O
was VBD VBD O
detected VBN VBN O
in IN IN O
all DT DT O
12 CD CD O
eyes NNS NNS O
of IN IN O
10 CD CD O
patients NNS NNS O
treated VBN VBN O
for IN IN O
intraocular JJ JJ O
retinoblastoma NN NN O
with IN IN O
1 CD CD O
to TO TO O
6 CD CD O
injections NNS NNS O
of IN IN O
subtenon NN NN O
carboplatin NN NN B-CHEM
as IN IN O
part NN NN O
of IN IN O
multimodality NN NN O
therapy NN NN O
. . . O

Histopathological NNP NNP O
examination NN NN O
revealed VBD VBD O
many JJ JJ O
lipophages NNS NNS O
in IN IN O
the DT DT O
periorbital JJ JJ O
fat NN NN O
surrounding VBG VBG O
the DT DT O
optic JJ JJ O
nerve NN NN O
in IN IN O
1 CD CD O
eye NN NN O
, , , O
indicative JJ JJ O
of IN IN O
phagocytosis NN NN O
of IN IN O
previously RB RB O
existing VBG VBG O
fat JJ JJ O
cells NNS NNS O
and CC CC O
suggesting VBG VBG O
prior RB RB O
fat JJ JJ O
necrosis NN NN O
. . . O

The DT DT O
enucleations NNS NNS O
were VBD VBD O
technically RB RB O
difficult JJ JJ O
and CC CC O
hazardous JJ JJ O
for IN IN O
globe NN NN O
rupture NN NN O
because IN IN O
of IN IN O
extensive JJ JJ O
orbital JJ JJ O
soft JJ JJ O
tissue NN NN O
adhesions NNS NNS O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Subtenon NNP NNP O
carboplatin NN NN B-CHEM
chemotherapy NN NN O
is VBZ VBZ O
associated VBN VBN O
with IN IN O
significant JJ JJ O
fibrosis NNS NNS O
of IN IN O
orbital JJ JJ O
soft JJ JJ O
tissues NNS NNS O
, , , O
leading VBG VBG O
to TO TO O
mechanical JJ JJ O
restriction NN NN O
of IN IN O
eye NN NN O
movements NNS NNS O
and CC CC O
making VBG VBG O
subsequent JJ JJ O
enucleation NN NN O
difficult JJ JJ O
. . . O

Subtenon NNP NNP O
carboplatin NN NN B-CHEM
is VBZ VBZ O
not RB RB O
free JJ JJ O
of IN IN O
toxicity NN NN O
, , , O
and CC CC O
its PRP$ PRP$ O
use NN NN O
is VBZ VBZ O
best JJS JJS O
restricted VBN VBN O
to TO TO O
specific JJ JJ O
indications NNS NNS O
. . . O

Ethambutol NNP NNP B-CHEM
and CC CC O
optic JJ JJ O
neuropathy NN NN O
. . . O

PURPOSE NNP NNP O
: : : O
To TO TO O
demonstrate VB VB O
the DT DT O
association NN NN O
between IN IN O
ethambutol NN NN B-CHEM
and CC CC O
optic JJ JJ O
neuropathy NN NN O
. . . O

METHOD NNP NNP O
: : : O
Thirteen NNP NNP O
patients NNS NNS O
who WP WP O
developed VBD VBD O
optic JJ JJ O
neuropathy NN NN O
after IN IN O
being VBG VBG O
treated VBN VBN O
with IN IN O
ethambutol NN NN B-CHEM
for IN IN O
tuberculosis NN NN O
of IN IN O
the DT DT O
lung NN NN O
or CC CC O
lymph NN NN O
node NN NN O
at IN IN O
Siriraj NNP NNP O
Hospital NNP NNP O
between IN IN O
1997 CD CD O
and CC CC O
2001 CD CD O
were VBD VBD O
retrospectively RB RB O
reviewed VBN VBN O
. . . O

The DT DT O
clinical JJ JJ O
characteristics NNS NNS O
and CC CC O
initial JJ JJ O
and CC CC O
final JJ JJ O
visual JJ JJ O
acuity NN NN O
were VBD VBD O
analyzed VBN VBN O
to TO TO O
determine VB VB O
visual JJ JJ O
outcome NN NN O
. . . O

RESULTS NNS NNS O
: : : O
All DT DT O
patients NNS NNS O
had VBD VBD O
optic JJ JJ O
neuropathy NN NN O
between IN IN O
1 CD CD O
to TO TO O
6 CD CD O
months NNS NNS O
( ( ( O
mean NN NN O
= SYM SYM O
2 CD CD O
. . . O
9 CD CD O
months NNS NNS O
) ) ) O
after IN IN O
starting VBG VBG O
ethambutol NN NN B-CHEM
therapy NN NN O
at IN IN O
a DT DT O
dosage NN NN O
ranging VBG VBG O
from IN IN O
13 CD CD O
to TO TO O
20 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
( ( ( O
mean VB VB O
= SYM SYM O
17 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
) ) ) O
. . . O

Seven CD CD O
( ( ( O
54 CD CD O
% NN NN O
) ) ) O
of IN IN O
the DT DT O
13 CD CD O
patients NNS NNS O
experienced VBN VBN O
visual JJ JJ O
recovery NN NN O
after IN IN O
stopping VBG VBG O
the DT DT O
drug NN NN O
. . . O

Of IN IN O
6 CD CD O
patients NNS NNS O
with IN IN O
irreversible JJ JJ O
visual JJ JJ O
impairment NN NN O
, , , O
4 CD CD O
patients NNS NNS O
had VBD VBD O
diabetes NNS NNS O
mellitus NN NN O
, , , O
glaucoma NN NN O
and CC CC O
a DT DT O
history NN NN O
of IN IN O
heavy JJ JJ O
smoking NN NN O
. . . O

CONCLUSION NNP NNP O
: : : O
Early JJ JJ O
recognition NN NN O
of IN IN O
optic JJ JJ O
neuropathy NN NN O
should MD MD O
be VB VB O
considered VBN VBN O
in IN IN O
patients NNS NNS O
with IN IN O
ethambutol NN NN B-CHEM
therapy NN NN O
. . . O

A DT DT O
low JJ JJ O
dose NN NN O
and CC CC O
prompt VB VB O
discontinuation NN NN O
of IN IN O
the DT DT O
drug NN NN O
is VBZ VBZ O
recommended VBN VBN O
particularly RB RB O
in IN IN O
individuals NNS NNS O
with IN IN O
diabetes NN NN O
mellitus NN NN O
, , , O
glaucoma NN NN O
or CC CC O
who WP WP O
are VBP VBP O
heavy JJ JJ O
smokers NNS NNS O
. . . O

Treatment NN NN O
of IN IN O
compensatory NN NN O
gustatory NN NN O
hyperhidrosis NN NN O
with IN IN O
topical JJ JJ O
glycopyrrolate NN NN B-CHEM
. . . O

Gustatory NNP NNP O
hyperhidrosis NN NN O
is VBZ VBZ O
facial JJ JJ O
sweating VBG VBG O
usually RB RB O
associated VBN VBN O
with IN IN O
the DT DT O
eating VBG VBG O
of IN IN O
hot JJ JJ O
spicy NN NN O
food NN NN O
or CC CC O
even RB RB O
smelling VBG VBG O
this DT DT O
food NN NN O
. . . O

Current NNP NNP O
options NNS NNS O
of IN IN O
treatment NN NN O
include VBP VBP O
oral JJ JJ O
anticholinergic JJ JJ O
drugs NNS NNS O
, , , O
the DT DT O
topical JJ JJ O
application NN NN O
of IN IN O
anticholinergics NNS NNS O
or CC CC O
aluminum NN NN B-CHEM
chloride NN NN I-CHEM
, , , O
and CC CC O
the DT DT O
injection NN NN O
of IN IN O
botulinum NN NN O
toxin NN NN O
. . . O

Thirteen NNP NNP O
patients NNS NNS O
have VBP VBP O
been VBN VBN O
treated VBN VBN O
to TO TO O
date NN NN O
with IN IN O
1 CD CD O
. . . O
5 CD CD O
% NN NN O
or CC CC O
2 CD CD O
% NN NN O
topical JJ JJ O
glycopyrrolate NN NN B-CHEM
. . . O

All DT DT O
patients NNS NNS O
had VBD VBD O
gustatory JJ JJ O
hyperhidrosis NN NN O
, , , O
which WDT WDT O
interfered VBD VBD O
with IN IN O
their PRP$ PRP$ O
social JJ JJ O
activities NNS NNS O
, , , O
after IN IN O
transthroacic NN NN O
endoscopic NN NN O
sympathectomy NN NN O
, , , O
and CC CC O
which WDT WDT O
was VBD VBD O
associated VBN VBN O
with IN IN O
compensatory JJ JJ O
focal JJ JJ O
hyperhidrosis NN NN O
. . . O

After IN IN O
applying VBG VBG O
topical JJ JJ O
glycopyrrolate NN NN B-CHEM
, , , O
the DT DT O
subjective JJ JJ O
effect NN NN O
was VBD VBD O
excellent JJ JJ O
( ( ( O
no DT DT O
sweating VBG VBG O
after IN IN O
eating VBG VBG O
hot JJ JJ O
spicy NN NN O
food NN NN O
) ) ) O
in IN IN O
10 CD CD O
patients NNS NNS O
( ( ( O
77 CD CD O
% NN NN O
) ) ) O
, , , O
and CC CC O
fair JJ JJ O
( ( ( O
clearly RB RB O
reduced VBN VBN O
sweating VBG VBG O
) ) ) O
in IN IN O
3 CD CD O
patients NNS NNS O
( ( ( O
23 CD CD O
% NN NN O
) ) ) O
. . . O

All DT DT O
had VBD VBD O
reported VBN VBN O
incidents NNS NNS O
of IN IN O
being VBG VBG O
very RB RB O
embarrassed JJ JJ O
whilst NN NN O
eating VBG VBG O
hot JJ JJ O
spicy NN NN O
foods NNS NNS O
. . . O

Adverse NNP NNP O
effects NNS NNS O
included VBD VBD O
a DT DT O
mildly RB RB O
dry JJ JJ O
mouth NN NN O
and CC CC O
a DT DT O
sore NN NN O
throat NN NN O
in IN IN O
2 CD CD O
patients NNS NNS O
( ( ( O
2 CD CD O
% NN NN O
glycopyrrolate NN NN B-CHEM
) ) ) O
, , , O
a DT DT O
light JJ JJ O
headache NN NN O
in IN IN O
1 CD CD O
patient NN NN O
( ( ( O
1 CD CD O
. . . O
5 CD CD O
% NN NN O
glycopyrrolate NN NN B-CHEM
) ) ) O
. . . O

The DT DT O
topical JJ JJ O
application NN NN O
of IN IN O
a DT DT O
glycopyrrolate NN NN B-CHEM
pad NN NN O
appeared VBD VBD O
to TO TO O
be VB VB O
safe JJ JJ O
, , , O
efficacious JJ JJ O
, , , O
well RB RB O
tolerated VBN VBN O
, , , O
and CC CC O
a DT DT O
convenient JJ JJ O
method NN NN O
of IN IN O
treatment NN NN O
for IN IN O
moderate NN NN O
to TO TO O
severe JJ JJ O
symptoms NNS NNS O
of IN IN O
gustatory NN NN O
hyperhidrosis NN NN O
in IN IN O
post NN NN O
transthoracic NN NN O
endoscopic NN NN O
sympathectomy NN NN O
or CC CC O
sympathicotomy NN NN O
patients NNS NNS O
, , , O
with IN IN O
few JJ JJ O
side NN NN O
effects NNS NNS O
. . . O

Neuroleptic NNP NNP B-CHEM
- - - O
associated VBN VBN O
hyperprolactinemia NN NN O
. . . O

Can MD MD O
it PRP PRP O
be VB VB O
treated VBN VBN O
with IN IN O
bromocriptine NN NN B-CHEM
? . . O

Six CD CD O
stable JJ JJ O
psychiatric JJ JJ O
outpatients NNS NNS O
with IN IN O
hyperprolactinemia NN NN O
and CC CC O
amenorrhea NN NN O
/ NN NN O
oligomenorrhea NN NN O
associated VBN VBN O
with IN IN O
their PRP$ PRP$ O
neuroleptic JJ JJ B-CHEM
medications NNS NNS I-CHEM
were VBD VBD O
treated VBN VBN O
with IN IN O
bromocriptine NN NN B-CHEM
. . . O

Daily NNP NNP O
dosages NNS NNS O
of IN IN O
5 CD CD O
- : : O
10 CD CD O
mg NN NN O
corrected VBD VBD O
the DT DT O
hyperprolactinemia NN NN O
and CC CC O
restored VBN VBN O
menstruation NN NN O
in IN IN O
four CD CD O
of IN IN O
the DT DT O
six CD CD O
patients NNS NNS O
. . . O

One CD CD O
woman NN NN O
, , , O
however RB RB O
, , , O
developed VBN VBN O
worsened JJ JJ O
psychiatric JJ JJ O
symptoms NNS NNS O
while IN IN O
taking VBG VBG O
bromocriptine NN NN B-CHEM
, , , O
and CC CC O
it PRP PRP O
was VBD VBD O
discontinued VBN VBN O
. . . O

Thus RB RB O
, , , O
three CD CD O
of IN IN O
six CD CD O
patients NNS NNS O
had VBD VBD O
their PRP$ PRP$ O
menstrual JJ JJ O
irregularity NN NN O
successfully RB RB O
corrected VBD VBD O
with IN IN O
bromocriptine NN NN B-CHEM
. . . O

This DT DT O
suggests VBZ VBZ O
that IN IN O
bromocriptine NN NN B-CHEM
should MD MD O
be VB VB O
further RB RB O
evaluated VBN VBN O
as IN IN O
potential JJ JJ O
therapy NN NN O
for IN IN O
neuroleptic JJ JJ B-CHEM
- - - O
associated VBN VBN O
hyperprolactinemia NN NN O
and CC CC O
amenorrhea NN NN O
/ NN NN O
galactorrhea NN NN O
. . . O

Ethacrynic JJ JJ B-CHEM
acid NN NN I-CHEM
- - - O
induced JJ JJ O
convulsions NNS NNS O
and CC CC O
brain NN NN O
neurotransmitters NNS NNS O
in IN IN O
mice NN NN O
. . . O

Intracerebroventricular NNP NNP O
injection NN NN O
of IN IN O
ethacrynic JJ JJ B-CHEM
acid NN NN I-CHEM
( ( ( O
50 CD CD O
% NN NN O
convulsive JJ JJ O
dose NN NN O
; : : O
50 CD CD O
micrograms NNS NNS O
/ NN NN O
mouse NN NN O
) ) ) O
accelerated VBD VBD O
the DT DT O
synthesis NN NN O
/ NN NN O
turnover NN NN O
of IN IN O
5 CD CD B-CHEM
- : : I-CHEM
hydroxytryptamine NN NN I-CHEM
( ( ( O
5 CD CD B-CHEM
- : : I-CHEM
HT NNP NNP I-CHEM
) ) ) O
but CC CC O
suppressed VBD VBD O
the DT DT O
synthesis NN NN O
of IN IN O
gamma NN NN B-CHEM
- - - I-CHEM
aminobutyric JJ JJ I-CHEM
acid NN NN I-CHEM
and CC CC O
acetylcholine NN NN B-CHEM
in IN IN O
mouse NN NN O
brain NN NN O
. . . O

These DT DT O
effects NNS NNS O
were VBD VBD O
completely RB RB O
antagonized VBN VBN O
by IN IN O
pretreatment NN NN O
with IN IN O
a DT DT O
glutamate NN NN B-CHEM
/ NN NN O
N NNP NNP B-CHEM
- - - I-CHEM
methyl NN NN I-CHEM
- - - I-CHEM
D NNP NNP I-CHEM
- : : I-CHEM
aspartate NN NN I-CHEM
antagonist NN NN O
, , , O
aminophosphonovaleric JJ JJ B-CHEM
acid NN NN I-CHEM
. . . O

In IN IN O
ethacrynic JJ JJ B-CHEM
acid NN NN I-CHEM
- - - O
induced JJ JJ O
convulsions NNS NNS O
, , , O
these DT DT O
neurotransmitter NN NN O
systems NNS NNS O
may MD MD O
be VB VB O
differentially RB RB O
modulated VBN VBN O
, , , O
probably RB RB O
through IN IN O
activation NN NN O
of IN IN O
glutaminergic JJ JJ O
neurons NNS NNS O
in IN IN O
the DT DT O
brain NN NN O
. . . O

Pharmacology NNP NNP O
of IN IN O
gamma NN NN B-CHEM
- - - I-CHEM
aminobutyric JJ JJ I-CHEM
acidA NN NN I-CHEM
receptor NN NN O
complex JJ JJ O
after IN IN O
the DT DT O
in IN IN O
vivo NN NN O
administration NN NN O
of IN IN O
the DT DT O
anxioselective JJ JJ O
and CC CC O
anticonvulsant JJ JJ O
beta NN NN B-CHEM
- - - I-CHEM
carboline NN NN I-CHEM
derivative JJ JJ O
abecarnil NN NN B-CHEM
. . . O

In IN IN O
rodents NNS NNS O
, , , O
the DT DT O
effect NN NN O
of IN IN O
the DT DT O
beta NN NN B-CHEM
- - - I-CHEM
carboline NN NN I-CHEM
derivative JJ JJ O
isopropyl NN NN B-CHEM
- - - I-CHEM
6 CD CD I-CHEM
- - - I-CHEM
benzyloxy NN NN I-CHEM
- - - I-CHEM
4 CD CD I-CHEM
- - - I-CHEM
methoxymethyl NN NN I-CHEM
- - - I-CHEM
beta NN NN I-CHEM
- - - I-CHEM
carboline NN NN I-CHEM
- - - I-CHEM
3 CD CD I-CHEM
- : : I-CHEM
carboxylate NN NN I-CHEM
( ( ( O
abecarrnil NN NN B-CHEM
) ) ) O
, , , O
a DT DT O
new JJ JJ O
ligand NN NN O
for IN IN O
benzodiazepine NN NN B-CHEM
receptors NNS NNS O
possessing VBG VBG O
anxiolytic JJ JJ O
and CC CC O
anticonvulsant JJ JJ O
properties NNS NNS O
, , , O
was VBD VBD O
evaluated VBN VBN O
on IN IN O
the DT DT O
function NN NN O
of IN IN O
central JJ JJ O
gamma NN NN B-CHEM
- - - I-CHEM
aminobutyric JJ JJ I-CHEM
acid NN NN I-CHEM
( ( ( O
GABA NNP NNP B-CHEM
) ) ) O
A DT DT O
receptor NN NN O
complex JJ JJ O
, , , O
both DT DT O
in IN IN O
vitro NN NN O
and CC CC O
in IN IN O
vivo NN NN O
. . . O

Added NNP NNP O
in IN IN O
vitro NN NN O
to TO TO O
rat VB VB O
cortical JJ JJ O
membrane NN NN O
preparation NN NN O
, , , O
abecarnil NN NN B-CHEM
increased VBN VBN O
[ NN NN O
3H CD CD O
] NN NN O
GABA NNP NNP B-CHEM
binding JJ JJ O
, , , O
enhanced VBN VBN O
muscimol NN NN B-CHEM
- - - O
stimulated VBN VBN O
36Cl CD CD O
- : : O
uptake NN NN O
and CC CC O
reduced VBD VBD O
the DT DT O
binding NN NN O
of IN IN O
t NN NN B-CHEM
- - - I-CHEM
[ NN NN I-CHEM
35S CD CD I-CHEM
] NN NN I-CHEM
butylbicyclophosphorothionate NN NN I-CHEM
( ( ( O
[ NN NN B-CHEM
35S CD CD I-CHEM
] NN NN I-CHEM
TBPS NNP NNP I-CHEM
) ) ) O
. . . O

These DT DT O
effects NNS NNS O
were VBD VBD O
similar JJ JJ O
to TO TO O
those DT DT O
induced VBN VBN O
by IN IN O
diazepam NN NN B-CHEM
, , , O
whereas IN IN O
the DT DT O
partial JJ JJ O
agonist NN NN O
Ro NNP NNP B-CHEM
16 CD CD I-CHEM
- : : I-CHEM
6028 CD CD I-CHEM
( ( ( O
tert NN NN B-CHEM
- - - I-CHEM
butyl NN NN I-CHEM
- - - I-CHEM
( ( ( I-CHEM
S NNP NNP I-CHEM
) ) ) I-CHEM
- : : I-CHEM
8 CD CD I-CHEM
- : : I-CHEM
bromo NN NN I-CHEM
- : : I-CHEM
11 CD CD I-CHEM
, , , I-CHEM
12 CD CD I-CHEM
, , , I-CHEM
13 CD CD I-CHEM
, , , I-CHEM
13a CD CD I-CHEM
- : : I-CHEM
tetrahydro NN NN I-CHEM
- : : I-CHEM
9 CD CD I-CHEM
- : : I-CHEM
oxo NN NN I-CHEM
- : : I-CHEM
9H CD CD I-CHEM
- : : I-CHEM
imidazo NN NN I-CHEM
[ NN NN I-CHEM
1 CD CD I-CHEM
, , , I-CHEM
5 CD CD I-CHEM
- : : I-CHEM
a DT DT I-CHEM
] NN NN I-CHEM
- - - I-CHEM
pyrrolo NN NN I-CHEM
- : : I-CHEM
[ NN NN I-CHEM
2 CD CD I-CHEM
, , , I-CHEM
1 CD CD I-CHEM
- : : I-CHEM
c SYM SYM I-CHEM
] NN NN I-CHEM
[ NN NN I-CHEM
1 CD CD I-CHEM
, , , I-CHEM
4 CD CD I-CHEM
] NN NN I-CHEM
benzodiazepine NN NN I-CHEM
- : : I-CHEM
1 CD CD I-CHEM
- : : I-CHEM
carboxylate NN NN I-CHEM
) ) ) O
showed VBD VBD O
very RB RB O
weak JJ JJ O
efficacy NN NN O
in IN IN O
these DT DT O
biochemical JJ JJ O
tests NNS NNS O
. . . O

After IN IN O
i NNP NNP O
. . . O
p NN NN O
. . . O
injection NN NN O
to TO TO O
rats NNS NNS O
, , , O
abecarnil NN NN B-CHEM
and CC CC O
diazepam NN NN B-CHEM
decreased VBD VBD O
in IN IN O
a DT DT O
time NN NN O
- : : O
dependent JJ JJ O
and CC CC O
dose VB VB O
- - - O
related VBN VBN O
( ( ( O
0 CD CD O
. . . O
25 CD CD O
- : : O
20 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
manner NN NN O
[ NN NN B-CHEM
35S CD CD I-CHEM
] NN NN I-CHEM
TBPS NNP NNP I-CHEM
binding VBG VBG O
measured VBN VBN O
ex FW FW O
vivo NN NN O
in IN IN O
the DT DT O
cerebral NN NN O
cortex NN NN O
. . . O

Moreover RB RB O
, , , O
both DT DT O
drugs NNS NNS O
at IN IN O
the DT DT O
dose NN NN O
of IN IN O
0 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
antagonized VBN VBN O
completely RB RB O
the DT DT O
convulsant NN NN O
activity NN NN O
and CC CC O
the DT DT O
increase NN NN O
of IN IN O
[ NN NN B-CHEM
35S CD CD I-CHEM
] NN NN I-CHEM
TBPS NNP NNP I-CHEM
binding VBG VBG O
induced VBN VBN O
by IN IN O
isoniazide NN NN B-CHEM
( ( ( O
350 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
s VBZ VBZ O
. . . O
c SYM SYM O
. . . O
) ) ) O
as RB RB O
well RB RB O
as IN IN O
the DT DT O
increase NN NN O
of IN IN O
[ NN NN B-CHEM
35S CD CD I-CHEM
] NN NN I-CHEM
TBPS NNP NNP I-CHEM
binding VBG VBG O
induced VBN VBN O
by IN IN O
foot NN NN O
- - - O
shock NN NN O
stress NN NN O
. . . O

To TO TO O
better JJR JJR O
correlate NN NN O
the DT DT O
biochemical JJ JJ O
and CC CC O
the DT DT O
pharmacological JJ JJ O
effects NNS NNS O
, , , O
we PRP PRP O
studied VBD VBD O
the DT DT O
action NN NN O
of IN IN O
abecarnil NN NN B-CHEM
on IN IN O
[ NN NN B-CHEM
35S CD CD I-CHEM
] NN NN I-CHEM
TBPS NNP NNP I-CHEM
binding JJ JJ O
, , , O
exploratory JJ JJ O
motility NN NN O
and CC CC O
on IN IN O
isoniazid NN NN B-CHEM
- : : O
induced JJ JJ O
biochemical JJ JJ O
and CC CC O
pharmacological JJ JJ O
effects NNS NNS O
in IN IN O
mice NN NN O
. . . O

In IN IN O
these DT DT O
animals NNS NNS O
, , , O
abecarnil NN NN B-CHEM
produced VBD VBD O
a DT DT O
paralleled JJ JJ O
dose NN NN O
- : : O
dependent NN NN O
( ( ( O
0 CD CD O
. . . O
05 CD CD O
- : : O
1 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
reduction NN NN O
of IN IN O
both DT DT O
motor NN NN O
behavior NN NN O
and CC CC O
cortical JJ JJ O
[ NN NN O
35S CD CD O
] NN NN O
TBPS NNP NNP O
binding JJ JJ O
. . . O

Moreover RB RB O
, , , O
0 CD CD O
. . . O
05 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
of IN IN O
this DT DT O
beta NN NN B-CHEM
- - - I-CHEM
carboline NN NN I-CHEM
reduced VBD VBD O
markedly RB RB O
the DT DT O
increase NN NN O
of IN IN O
[ NN NN B-CHEM
35S CD CD I-CHEM
] NN NN I-CHEM
TBPS NNP NNP I-CHEM
binding JJ JJ O
and CC CC O
the DT DT O
convulsions NNS NNS O
induced VBN VBN O
by IN IN O
isoniazid NN NN B-CHEM
( ( ( O
200 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
s VBZ VBZ O
. . . O
c SYM SYM O
. . . O
) ) ) O
. . . O
( ( ( O
ABSTRACT NNP NNP O
TRUNCATED NNP NNP O
AT IN IN O
250 CD CD O
WORDS NNP NNP O
) ) ) O

Recurrent NNP NNP O
myocardial NN NN O
infarction NN NN O
in IN IN O
a DT DT O
postpartum NN NN O
patient NN NN O
receiving VBG VBG O
bromocriptine NN NN B-CHEM
. . . O

Myocardial NNP NNP O
infarction NN NN O
in IN IN O
puerperium NN NN O
is VBZ VBZ O
infrequently RB RB O
reported VBN VBN O
. . . O

Spasm NNP NNP O
, , , O
coronary JJ JJ O
dissection NN NN O
, , , O
or CC CC O
atheromatous JJ JJ O
etiology NN NN O
has VBZ VBZ O
been VBN VBN O
described VBN VBN O
. . . O

Bromocriptine NNP NNP B-CHEM
has VBZ VBZ O
been VBN VBN O
implicated VBN VBN O
in IN IN O
several JJ JJ O
previous JJ JJ O
case NN NN O
reports NNS NNS O
of IN IN O
myocardial NN NN O
infarction NN NN O
in IN IN O
the DT DT O
puerperium NN NN O
. . . O

Our PRP$ PRP$ O
case NN NN O
( ( ( O
including VBG VBG O
an DT DT O
inadvertent NN NN O
rechallenge NN NN O
) ) ) O
suggests VBZ VBZ O
such JJ JJ O
a DT DT O
relationship NN NN O
. . . O

Although IN IN O
generally RB RB O
regarded VBN VBN O
as IN IN O
" '' '' O
safe JJ JJ O
, , , O
" '' '' O
possible JJ JJ O
serious JJ JJ O
cardiac JJ JJ O
effects NNS NNS O
of IN IN O
bromocriptine NN NN B-CHEM
should MD MD O
be VB VB O
acknowledged VBN VBN O
. . . O

Asterixis NNP NNP O
induced VBN VBN O
by IN IN O
carbamazepine NN NN B-CHEM
therapy NN NN O
. . . O

There EX EX O
are VBP VBP O
very RB RB O
few JJ JJ O
reports NNS NNS O
about IN IN O
asterixis NN NN O
as IN IN O
a DT DT O
side NN NN O
effect NN NN O
of IN IN O
treatment NN NN O
with IN IN O
psychopharmacologic JJ JJ O
agents NNS NNS O
. . . O

In IN IN O
this DT DT O
report NN NN O
we PRP PRP O
present JJ JJ O
four CD CD O
patients NNS NNS O
treated VBN VBN O
with IN IN O
a DT DT O
combination NN NN O
of IN IN O
different JJ JJ O
psychotropic JJ JJ O
drugs NNS NNS O
, , , O
in IN IN O
whom WP WP O
asterixis NN NN O
was VBD VBD O
triggered VBN VBN O
either CC CC O
by IN IN O
adding VBG VBG O
carbamazepine NN NN B-CHEM
( ( ( O
CBZ NNP NNP B-CHEM
) ) ) O
to TO TO O
a DT DT O
treatment NN NN O
regimen NNS NNS O
, , , O
or CC CC O
by IN IN O
increasing VBG VBG O
its PRP$ PRP$ O
dosage NN NN O
. . . O

Neither DT DT O
dosage NN NN O
nor CC CC O
serum NN NN O
levels NNS NNS O
of IN IN O
CBZ NNP NNP B-CHEM
were VBD VBD O
in IN IN O
a DT DT O
higher JJR JJR O
range NN NN O
. . . O

We PRP PRP O
consider VBP VBP O
asterixis NNS NNS O
to TO TO O
be VB VB O
an DT DT O
easily RB RB O
overlooked JJ JJ O
sign NN NN O
of IN IN O
neurotoxicity NN NN O
, , , O
which WDT WDT O
may MD MD O
occur VB VB O
even RB RB O
at IN IN O
low JJ JJ O
or CC CC O
moderate JJ JJ O
dosage NN NN O
levels NNS NNS O
, , , O
if IN IN O
certain JJ JJ O
drugs NNS NNS O
as IN IN O
lithium NN NN B-CHEM
or CC CC O
clozapine NN NN B-CHEM
are VBP VBP O
used VBN VBN O
in IN IN O
combination NN NN O
with IN IN O
CBZ NNP NNP B-CHEM
. . . O

Pharmacodynamics NNP NNP O
of IN IN O
the DT DT O
hypotensive JJ JJ O
effect NN NN O
of IN IN O
levodopa NN NN B-CHEM
in IN IN O
parkinsonian NN NN O
patients NNS NNS O
. . . O

Blood NNP NNP O
pressure NN NN O
effects NNS NNS O
of IN IN O
i NNP NNP O
. . . O
v NN NN O
. . . O
levodopa NN NN B-CHEM
were VBD VBD O
examined VBN VBN O
in IN IN O
parkinsonian NN NN O
patients NNS NNS O
with IN IN O
stable JJ JJ O
and CC CC O
fluctuating VBG VBG O
responses NNS NNS O
to TO TO O
levodopa VB VB B-CHEM
. . . O

The DT DT O
magnitude NN NN O
of IN IN O
the DT DT O
hypotensive JJ JJ O
effect NN NN O
of IN IN O
levodopa NN NN B-CHEM
was VBD VBD O
concentration NN NN O
dependent NN NN O
and CC CC O
was VBD VBD O
fit VBN VBN O
to TO TO O
an DT DT O
Emax NNP NNP O
model NN NN O
in IN IN O
fluctuating VBG VBG O
responders NNS NNS O
. . . O

Stable JJ JJ O
responders NNS NNS O
demonstrated VBD VBD O
a DT DT O
small JJ JJ O
hypotensive JJ JJ O
response NN NN O
. . . O

Baseline NNP NNP O
blood NN NN O
pressures NNS NNS O
were VBD VBD O
higher JJR JJR O
in IN IN O
fluctuating VBG VBG O
patients NNS NNS O
; : : O
a DT DT O
higher JJR JJR O
baseline NN NN O
blood NN NN O
pressure NN NN O
correlated VBD VBD O
with IN IN O
greater NN NN O
hypotensive JJ JJ O
effects NNS NNS O
. . . O

Antiparkinsonian NNP NNP O
effects NNS NNS O
of IN IN O
levodopa NN NN B-CHEM
temporally RB RB O
correlated JJ JJ O
with IN IN O
blood NN NN O
pressure NN NN O
changes NNS NNS O
. . . O

Phenylalanine NNP NNP B-CHEM
, , , O
a DT DT O
large JJ JJ O
neutral JJ JJ O
amino JJ JJ B-CHEM
acid NN NN I-CHEM
( ( ( O
LNAA NNP NNP O
) ) ) O
competing VBG VBG O
with IN IN O
levodopa NN NN B-CHEM
for IN IN O
transport NN NN O
across IN IN O
the DT DT O
blood NN NN O
- - - O
brain NN NN O
barrier NN NN O
, , , O
reduced VBD VBD O
the DT DT O
hypotensive JJ JJ O
and CC CC O
antiparkinsonian JJ JJ O
effects NNS NNS O
of IN IN O
levodopa NN NN B-CHEM
. . . O

We PRP PRP O
conclude VBP VBP O
that IN IN O
levodopa NN NN B-CHEM
has VBZ VBZ O
a DT DT O
central JJ JJ O
hypotensive JJ JJ O
action NN NN O
that IN IN O
parallels VBZ VBZ O
the DT DT O
motor NN NN O
effects NNS NNS O
in IN IN O
fluctuating VBG VBG O
patients NNS NNS O
. . . O

The DT DT O
hypotensive JJ JJ O
effect NN NN O
appears VBZ VBZ O
to TO TO O
be VB VB O
related VBN VBN O
to TO TO O
the DT DT O
higher JJR JJR O
baseline NN NN O
blood NN NN O
pressure NN NN O
we PRP PRP O
observed VBD VBD O
in IN IN O
fluctuating VBG VBG O
patients NNS NNS O
relative JJ JJ O
to TO TO O
stable JJ JJ O
patients NNS NNS O
. . . O

Syndrome NN NN O
of IN IN O
inappropriate JJ JJ O
secretion NN NN O
of IN IN O
antidiuretic JJ JJ O
hormone NN NN O
after IN IN O
infusional JJ JJ O
vincristine NN NN B-CHEM
. . . O

A DT DT O
77 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
woman NN NN O
with IN IN O
refractory NN NN O
multiple JJ JJ O
myeloma NN NN O
was VBD VBD O
treated VBN VBN O
with IN IN O
a DT DT O
4 CD CD O
- : : O
day NN NN O
continuous JJ JJ O
intravenous JJ JJ O
infusion NN NN O
of IN IN O
vincristine NN NN B-CHEM
and CC CC O
doxorubicin NN NN B-CHEM
and CC CC O
4 CD CD O
days NNS NNS O
of IN IN O
oral JJ JJ O
dexamethasone NN NN B-CHEM
. . . O

Nine CD CD O
days NNS NNS O
after IN IN O
her PRP$ PRP$ O
second JJ JJ O
cycle NN NN O
she PRP PRP O
presented VBD VBD O
with IN IN O
lethargy NN NN O
and CC CC O
weakness NN NN O
associated VBN VBN O
with IN IN O
hyponatremia NN NN O
. . . O

Evaluation NNP NNP O
revealed VBD VBD O
the DT DT O
syndrome NN NN O
of IN IN O
inappropriate JJ JJ O
secretion NN NN O
of IN IN O
antidiuretic JJ JJ O
hormone NN NN O
, , , O
which WDT WDT O
was VBD VBD O
attributed VBN VBN O
to TO TO O
the DT DT O
vincristine NN NN B-CHEM
infusion NN NN O
. . . O

After IN IN O
normal JJ JJ O
serum NN NN O
sodium NN NN B-CHEM
levels NNS NNS O
returned VBD VBD O
, , , O
further RB RB O
doxorubicin NN NN B-CHEM
and CC CC O
dexamethasone NN NN B-CHEM
chemotherapy NN NN O
without IN IN O
vincristine NN NN B-CHEM
did VBD VBD O
not RB RB O
produce VB VB O
this DT DT O
complication NN NN O
. . . O

Heart NNP NNP O
failure NN NN O
: : : O
to TO TO O
digitalise VB VB O
or CC CC O
not RB RB O
? . . O

The DT DT O
view NN NN O
against IN IN O
. . . O

Despite IN IN O
extensive JJ JJ O
clinical JJ JJ O
experience NN NN O
the DT DT O
role NN NN O
of IN IN O
digoxin NN NN B-CHEM
is VBZ VBZ O
still RB RB O
not RB RB O
well RB RB O
defined VBN VBN O
. . . O

In IN IN O
patients NNS NNS O
with IN IN O
atrial JJ JJ O
fibrillation NN NN O
digoxin NN NN B-CHEM
is VBZ VBZ O
beneficial JJ JJ O
for IN IN O
ventricular NN NN O
rate NN NN O
control NN NN O
. . . O

For IN IN O
patients NNS NNS O
in IN IN O
sinus NN NN O
rhythm NN NN O
and CC CC O
heart NN NN O
failure NN NN O
the DT DT O
situation NN NN O
is VBZ VBZ O
less JJR JJR O
clear JJ JJ O
. . . O

Digoxin NNP NNP B-CHEM
has VBZ VBZ O
a DT DT O
narrow JJ JJ O
therapeutic JJ JJ O
: : : O
toxic JJ JJ O
ratio NN NN O
and CC CC O
concentrations NNS NNS O
are VBP VBP O
affected VBN VBN O
by IN IN O
a DT DT O
number NN NN O
of IN IN O
drugs NNS NNS O
. . . O

Also RB RB O
, , , O
digoxin NN NN B-CHEM
has VBZ VBZ O
undesirable JJ JJ O
effects NNS NNS O
such JJ JJ O
as IN IN O
increasing VBG VBG O
peripheral JJ JJ O
resistance NN NN O
and CC CC O
myocardial JJ JJ O
demands NNS NNS O
, , , O
and CC CC O
causing VBG VBG O
arrhythmias NNS NNS O
. . . O

There EX EX O
is VBZ VBZ O
a DT DT O
paucity NN NN O
of IN IN O
data NNS NNS O
from IN IN O
well RB RB O
- : : O
designed VBN VBN O
trials NNS NNS O
. . . O

The DT DT O
trials NNS NNS O
that WDT WDT O
are VBP VBP O
available JJ JJ O
are VBP VBP O
generally RB RB O
small JJ JJ O
with IN IN O
limitations NNS NNS O
in IN IN O
design NN NN O
and CC CC O
these DT DT O
show NN NN O
variation NN NN O
in IN IN O
patient NN NN O
benefit NN NN O
. . . O

More JJR JJR O
convincing JJ JJ O
evidence NN NN O
is VBZ VBZ O
required VBN VBN O
showing VBG VBG O
that IN IN O
digoxin NN NN B-CHEM
improves VBZ VBZ O
symptoms NNS NNS O
or CC CC O
exercise NN NN O
capacity NN NN O
. . . O

Furthermore RB RB O
, , , O
no DT DT O
trial NN NN O
has VBZ VBZ O
had VBN VBN O
sufficient JJ JJ O
power NN NN O
to TO TO O
evaluate VB VB O
mortality NN NN O
. . . O

Pooled NNP NNP O
analysis NN NN O
of IN IN O
the DT DT O
effects NNS NNS O
of IN IN O
other JJ JJ O
inotropic JJ JJ O
drugs NNS NNS O
shows VBZ VBZ O
an DT DT O
excess JJ JJ O
mortality NN NN O
and CC CC O
there EX EX O
is VBZ VBZ O
a DT DT O
possibility NN NN O
that IN IN O
digoxin NN NN B-CHEM
may MD MD O
increase VB VB O
mortality NN NN O
after IN IN O
myocardial NN NN O
infarction NN NN O
( ( ( O
MI NNP NNP O
) ) ) O
. . . O

Angiotensin NNP NNP B-CHEM
- : : O
converting VBG VBG O
enzyme NN NN O
( ( ( O
ACE NNP NNP O
) ) ) O
inhibitors NNS NNS O
should MD MD O
be VB VB O
used VBN VBN O
first JJ JJ O
as IN IN O
they PRP PRP O
are VBP VBP O
safer JJR JJR O
, , , O
do VBP VBP O
not RB RB O
require VB VB O
blood NN NN O
level NN NN O
monitoring NN NN O
, , , O
modify JJ JJ O
progression NN NN O
of IN IN O
disease NN NN O
, , , O
relieve VB VB O
symptoms NNS NNS O
, , , O
improve VB VB O
exercise NN NN O
tolerance NN NN O
and CC CC O
reduce VB VB O
mortality NN NN O
. . . O

Caution NNP NNP O
should MD MD O
be VB VB O
exercised VBN VBN O
in IN IN O
using VBG VBG O
digoxin NN NN B-CHEM
until IN IN O
large JJ JJ O
mortality NN NN O
trials NNS NNS O
are VBP VBP O
completed VBN VBN O
showing VBG VBG O
either CC CC O
benefit NN NN O
or CC CC O
harm NN NN O
. . . O

Until IN IN O
then RB RB O
digoxin NN NN B-CHEM
should MD MD O
be VB VB O
considered VBN VBN O
a DT DT O
third JJ JJ O
- - - O
line NN NN O
therapy NN NN O
. . . O

Isradipine NNP NNP B-CHEM
treatment NN NN O
for IN IN O
hypertension NN NN O
in IN IN O
general JJ JJ O
practice NN NN O
in IN IN O
Hong NNP NNP O
Kong NNP NNP O
. . . O

A DT DT O
6 CD CD O
- : : O
week NN NN O
open JJ JJ O
study NN NN O
of IN IN O
the DT DT O
introduction NN NN O
of IN IN O
isradipine JJ JJ B-CHEM
treatment NN NN O
was VBD VBD O
conducted VBN VBN O
in IN IN O
general JJ JJ O
practice NN NN O
in IN IN O
Hong NNP NNP O
Kong NNP NNP O
. . . O

303 CD CD O
Chinese JJ JJ O
patients NNS NNS O
with IN IN O
mild NN NN O
to TO TO O
moderate VB VB O
hypertension NN NN O
entered VBD VBD O
the DT DT O
study NN NN O
. . . O

Side NNP NNP O
effects NNS NNS O
were VBD VBD O
reported VBN VBN O
in IN IN O
21 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
and CC CC O
caused VBD VBD O
withdrawal NN NN O
from IN IN O
the DT DT O
study NN NN O
in IN IN O
3 CD CD O
patients NNS NNS O
. . . O

The DT DT O
main JJ JJ O
side NN NN O
- - - O
effects NNS NNS O
were VBD VBD O
headache NN NN O
, , , O
dizziness NN NN O
, , , O
palpitation NN NN O
and CC CC O
flushing VBG VBG O
and CC CC O
these DT DT O
were VBD VBD O
not RB RB O
more RBR RBR O
frequent JJ JJ O
than IN IN O
reported VBD VBD O
in IN IN O
other JJ JJ O
studies NNS NNS O
with IN IN O
isradipine NN NN B-CHEM
or CC CC O
with IN IN O
placebo NN NN O
. . . O

Supine NNP NNP O
blood NN NN O
pressure NN NN O
was VBD VBD O
reduced VBN VBN O
( ( ( O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
from IN IN O
170 CD CD O
+ NN NN O
/ NN NN O
- : : O
20 CD CD O
/ NN NN O
102 CD CD O
+ NN NN O
/ NN NN O
- : : O
6 CD CD O
mmHg NN NN O
to TO TO O
153 CD CD O
+ NN NN O
/ NN NN O
- : : O
19 CD CD O
/ NN NN O
92 CD CD O
+ NN NN O
/ NN NN O
- : : O
8 CD CD O
, , , O
147 CD CD O
+ NN NN O
/ NN NN O
- : : O
18 CD CD O
/ NN NN O
88 CD CD O
+ NN NN O
/ NN NN O
- : : O
7 CD CD O
and CC CC O
144 CD CD O
+ NN NN O
/ NN NN O
- : : O
14 CD CD O
/ NN NN O
87 CD CD O
+ NN NN O
/ NN NN O
- : : O
6 CD CD O
mmHg NN NN O
at IN IN O
2 CD CD O
, , , O
4 CD CD O
and CC CC O
6 CD CD O
weeks NNS NNS O
respectively RB RB O
in IN IN O
evaluable JJ JJ O
patients NNS NNS O
. . . O

Similar JJ JJ O
reductions NNS NNS O
occurred VBD VBD O
in IN IN O
standing NN NN O
blood NN NN O
pressure NN NN O
and CC CC O
there EX EX O
was VBD VBD O
no DT DT O
evidence NN NN O
of IN IN O
postural JJ JJ O
hypotension NN NN O
. . . O

Normalization NNP NNP O
and CC CC O
responder NN NN O
rates NNS NNS O
at IN IN O
6 CD CD O
weeks NNS NNS O
were VBD VBD O
86 CD CD O
% NN NN O
and CC CC O
69 CD CD O
% NN NN O
respectively RB RB O
. . . O

Dosage NNP NNP O
was VBD VBD O
increased VBN VBN O
from IN IN O
2 CD CD O
. . . O
5 CD CD O
mg NN NN O
b SYM SYM O
. . . O
d SYM SYM O
. . . O
to TO TO O
5 CD CD O
mg NN NN O
b SYM SYM O
. . . O
d SYM SYM O
. . . O
at IN IN O
4 CD CD O
weeks NNS NNS O
in IN IN O
patients NNS NNS O
with IN IN O
diastolic JJ JJ O
blood NN NN O
pressure NN NN O
greater JJR JJR O
than IN IN O
90 CD CD O
mmHg NN NN O
and CC CC O
their PRP$ PRP$ O
further JJ JJ O
response NN NN O
was VBD VBD O
greater JJR JJR O
than IN IN O
those DT DT O
remaining VBG VBG O
on IN IN O
2 CD CD O
. . . O
5 CD CD O
mg NN NN O
b SYM SYM O
. . . O
d SYM SYM O
. . . O

Pharmacological NNP NNP O
characteristics NNS NNS O
and CC CC O
side NN NN O
effects NNS NNS O
of IN IN O
a DT DT O
new JJ JJ O
galenic JJ JJ O
formulation NN NN O
of IN IN O
propofol NN NN B-CHEM
without IN IN O
soyabean JJ JJ O
oil NN NN O
. . . O

We PRP PRP O
compared VBD VBD O
the DT DT O
pharmacokinetics NNS NNS O
, , , O
pharmacodynamics NNS NNS O
and CC CC O
safety NN NN O
profile NN NN O
of IN IN O
a DT DT O
new JJ JJ O
galenic JJ JJ O
formulation NN NN O
of IN IN O
propofol NN NN B-CHEM
( ( ( O
AM149 NNP NNP O
1 CD CD O
% NN NN O
) ) ) O
, , , O
which WDT WDT O
does VBZ VBZ O
not RB RB O
contain VB VB O
soyabean JJ JJ O
oil NN NN O
, , , O
with IN IN O
a DT DT O
standard JJ JJ O
formulation NN NN O
of IN IN O
propofol NN NN B-CHEM
( ( ( O
Disoprivan NNP NNP B-CHEM
1 CD CD O
% NN NN O
) ) ) O
. . . O

In IN IN O
a DT DT O
randomised JJ JJ O
, , , O
double JJ JJ O
- - - O
blind JJ JJ O
, , , O
cross JJ JJ O
- - - O
over IN IN O
study NN NN O
, , , O
30 CD CD O
healthy JJ JJ O
volunteers NNS NNS O
received VBD VBD O
a DT DT O
single JJ JJ O
intravenous JJ JJ O
bolus JJ JJ O
injection NN NN O
of IN IN O
2 CD CD O
. . . O
5 CD CD O
mg NN NN O
. . . O
kg NN NN O
- : : O
1 CD CD O
propofol NN NN B-CHEM
. . . O

Plasma NNP NNP O
propofol NN NN B-CHEM
levels NNS NNS O
were VBD VBD O
measured VBN VBN O
for IN IN O
48 CD CD O
h NN NN O
following VBG VBG O
drug NN NN O
administration NN NN O
and CC CC O
evaluated VBD VBD O
according VBG VBG O
to TO TO O
a DT DT O
three CD CD O
- - - O
compartment NN NN O
model NN NN O
. . . O

The DT DT O
pharmacodynamic JJ JJ O
parameters NNS NNS O
assessed VBD VBD O
included VBN VBN O
induction NN NN O
and CC CC O
emergence NN NN O
times NNS NNS O
, , , O
respiratory NN NN O
and CC CC O
cardiovascular JJ JJ O
effects NNS NNS O
, , , O
and CC CC O
pain NN NN O
on IN IN O
injection NN NN O
. . . O

Patients NNS NNS O
were VBD VBD O
monitored VBN VBN O
for IN IN O
side NN NN O
effects NNS NNS O
over IN IN O
48 CD CD O
h NN NN O
. . . O

Owing NNP NNP O
to TO TO O
a DT DT O
high JJ JJ O
incidence NN NN O
of IN IN O
thrombophlebitis NNS NNS O
, , , O
the DT DT O
study NN NN O
was VBD VBD O
terminated VBN VBN O
prematurely RB RB O
and CC CC O
only RB RB O
the DT DT O
data NNS NNS O
of IN IN O
the DT DT O
two CD CD O
parallel JJ JJ O
treatment NN NN O
groups NNS NNS O
( ( ( O
15 CD CD O
patients NNS NNS O
in IN IN O
each DT DT O
group NN NN O
) ) ) O
were VBD VBD O
analysed VBN VBN O
. . . O

Plasma NNP NNP O
concentrations NNS NNS O
did VBD VBD O
not RB RB O
differ VB VB O
significantly RB RB O
between IN IN O
the DT DT O
two CD CD O
formulations NNS NNS O
. . . O

Anaesthesia NNP NNP O
induction NN NN O
and CC CC O
emergence NN NN O
times NNS NNS O
, , , O
respiratory NN NN O
and CC CC O
cardiovascular JJ JJ O
variables NNS NNS O
showed VBD VBD O
no DT DT O
significant JJ JJ O
differences NNS NNS O
between IN IN O
the DT DT O
two CD CD O
treatment NN NN O
groups NNS NNS O
. . . O

Pain NN NN O
on IN IN O
injection NN NN O
( ( ( O
80 CD CD O
vs NNS NNS O
. . . O
20 CD CD O
% NN NN O
, , , O
p NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
and CC CC O
thrombophlebitis NNS NNS O
( ( ( O
93 CD CD O
. . . O
3 CD CD O
vs NNS NNS O
. . . O
6 CD CD O
. . . O
6 CD CD O
% NN NN O
, , , O
p NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
occurred VBD VBD O
more RBR RBR O
frequently RB RB O
with IN IN O
AM149 NNP NNP O
than IN IN O
with IN IN O
Disoprivan NNP NNP B-CHEM
. . . O

Although IN IN O
both DT DT O
formulations NNS NNS O
had VBD VBD O
similar JJ JJ O
pharmacokinetic JJ JJ O
and CC CC O
pharmacodynamic JJ JJ O
profiles NNS NNS O
the DT DT O
new JJ JJ O
formulation NN NN O
is VBZ VBZ O
not RB RB O
suitable JJ JJ O
for IN IN O
clinical JJ JJ O
use NN NN O
due JJ JJ O
to TO TO O
the DT DT O
high JJ JJ O
incidence NN NN O
of IN IN O
thrombophlebitis NNS NNS O
produced VBN VBN O
. . . O

Pure NNP NNP O
red JJ JJ O
cell NN NN O
aplasia NN NN O
, , , O
toxic JJ JJ O
dermatitis NNS NNS O
and CC CC O
lymphadenopathy NN NN O
in IN IN O
a DT DT O
patient NN NN O
taking VBG VBG O
diphenylhydantoin NN NN B-CHEM
. . . O

A DT DT O
patient NN NN O
taking VBG VBG O
diphenylhydantoin NN NN B-CHEM
for IN IN O
3 CD CD O
weeks NNS NNS O
developed VBD VBD O
a DT DT O
generalized JJ JJ O
skin NN NN O
rash NN NN O
, , , O
lymphadenopathy NN NN O
and CC CC O
pure JJ JJ O
red JJ JJ O
cell NN NN O
aplasia NN NN O
. . . O

After IN IN O
withdrawal NN NN O
of IN IN O
the DT DT O
pharmacon NN NN O
all DT DT O
symptoms NNS NNS O
disappeared VBD VBD O
spontaneously RB RB O
. . . O

Skin NNP NNP O
rash NN NN O
is VBZ VBZ O
a DT DT O
well RB RB O
- - - O
known VBN VBN O
complication NN NN O
of IN IN O
diphenylhydantoin NN NN B-CHEM
treatment NN NN O
as IN IN O
is VBZ VBZ O
benign NN NN O
and CC CC O
malignant JJ JJ O
lymphadenopathy NN NN O
. . . O

Pure NNP NNP O
red JJ JJ O
cell NN NN O
aplasia NN NN O
associated VBN VBN O
with IN IN O
diphenylhydantoin NN NN B-CHEM
medication NN NN O
has VBZ VBZ O
been VBN VBN O
reported VBN VBN O
in IN IN O
3 CD CD O
patients NNS NNS O
. . . O

The DT DT O
exact JJ JJ O
mechanism NN NN O
by IN IN O
which WDT WDT O
diphenylhydantoin VBP VBP B-CHEM
exerts VBZ VBZ O
its PRP$ PRP$ O
toxic JJ JJ O
effects NNS NNS O
is VBZ VBZ O
not RB RB O
known VBN VBN O
. . . O

In IN IN O
this DT DT O
patient NN NN O
the DT DT O
time NN NN O
relation NN NN O
between IN IN O
the DT DT O
ingestion NN NN O
of IN IN O
diphenylhydantoin NN NN B-CHEM
and CC CC O
the DT DT O
occurrence NN NN O
of IN IN O
the DT DT O
skin NN NN O
rash NN NN O
, , , O
lymphadenopathy NN NN O
and CC CC O
pure JJ JJ O
red JJ JJ O
cell NN NN O
aplasia NN NN O
is VBZ VBZ O
very RB RB O
suggestive JJ JJ O
of IN IN O
a DT DT O
direct JJ JJ O
connection NN NN O
. . . O

Vinorelbine NNP NNP B-CHEM
- - - O
related JJ JJ O
cardiac NN NN O
events NNS NNS O
: : : O
a DT DT O
meta NN NN O
- - - O
analysis NN NN O
of IN IN O
randomized JJ JJ O
clinical JJ JJ O
trials NNS NNS O
. . . O

Several JJ JJ O
cases NNS NNS O
of IN IN O
cardiac JJ JJ O
adverse JJ JJ O
reactions NNS NNS O
related VBN VBN O
to TO TO O
vinorelbine NN NN B-CHEM
( ( ( O
VNR NNP NNP B-CHEM
) ) ) O
have VBP VBP O
been VBN VBN O
reported VBN VBN O
in IN IN O
the DT DT O
literature NN NN O
. . . O

In IN IN O
order NN NN O
to TO TO O
quantify VB VB O
the DT DT O
incidence NN NN O
of IN IN O
these DT DT O
cardiac JJ JJ O
events NNS NNS O
, , , O
we PRP PRP O
performed VBD VBD O
a DT DT O
meta NN NN O
- - - O
analysis NN NN O
of IN IN O
clinical JJ JJ O
trials NNS NNS O
comparing VBG VBG O
VNR NNP NNP B-CHEM
with IN IN O
other JJ JJ O
chemotherapeutic JJ JJ O
agents NNS NNS O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
various JJ JJ O
malignancies NNS NNS O
. . . O

Randomized NNP NNP O
clinical JJ JJ O
trials NNS NNS O
comparing VBG VBG O
VNR NNP NNP B-CHEM
with IN IN O
other JJ JJ O
drugs NNS NNS O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
cancer NN NN O
were VBD VBD O
searched VBN VBN O
in IN IN O
Medline NNP NNP O
, , , O
Embase NNP NNP O
, , , O
Evidence NN NN O
- - - O
based JJ JJ O
Medicine NNP NNP O
Reviews NNP NNP O
databases NNS NNS O
and CC CC O
the DT DT O
Cochrane NNP NNP O
library NN NN O
from IN IN O
1987 CD CD O
to TO TO O
2002 CD CD O
. . . O

Outcomes NNP NNP O
of IN IN O
interest NN NN O
were VBD VBD O
severe JJ JJ O
cardiac JJ JJ O
events NNS NNS O
, , , O
toxic JJ JJ O
deaths NNS NNS O
and CC CC O
cardiac JJ JJ O
event NN NN O
- - - O
related VBN VBN O
deaths NNS NNS O
reported VBD VBD O
in IN IN O
each DT DT O
publication NN NN O
. . . O

We PRP PRP O
found VBD VBD O
19 CD CD O
trials NNS NNS O
, , , O
involving VBG VBG O
2441 CD CD O
patients NNS NNS O
treated VBN VBN O
by IN IN O
VNR NNP NNP B-CHEM
and CC CC O
2050 CD CD O
control NN NN O
patients NNS NNS O
. . . O

The DT DT O
incidence NN NN O
of IN IN O
cardiac JJ JJ O
events NNS NNS O
with IN IN O
VNR NNP NNP B-CHEM
was VBD VBD O
1 CD CD O
. . . O
19 CD CD O
% NN NN O
[ NN NN O
95 CD CD O
% NN NN O
confidence NN NN O
interval NN NN O
( ( ( O
CI NNP NNP O
) ) ) O
( ( ( O
0 CD CD O
. . . O
75 CD CD O
; : : O
1 CD CD O
. . . O
67 CD CD O
) ) ) O
] NN NN O
. . . O

There EX EX O
was VBD VBD O
no DT DT O
difference NN NN O
in IN IN O
the DT DT O
risk NN NN O
of IN IN O
cardiac JJ JJ O
events NNS NNS O
between IN IN O
VNR NNP NNP B-CHEM
and CC CC O
other JJ JJ O
drugs NNS NNS O
[ NN NN O
odds NNS NNS O
ratio NN NN O
: : : O
0 CD CD O
. . . O
92 CD CD O
, , , O
95 CD CD O
% NN NN O
CI NNP NNP O
( ( ( O
0 CD CD O
. . . O
54 CD CD O
; : : O
1 CD CD O
. . . O
55 CD CD O
) ) ) O
] NN NN O
. . . O

The DT DT O
risk NN NN O
of IN IN O
VNR NNP NNP B-CHEM
cardiac JJ JJ O
events NNS NNS O
was VBD VBD O
similar JJ JJ O
to TO TO O
vindesine NN NN B-CHEM
( ( ( O
VDS NNP NNP B-CHEM
) ) ) O
and CC CC O
other JJ JJ O
cardiotoxic JJ JJ O
drugs NNS NNS O
[ NN NN O
fluorouracil NN NN B-CHEM
, , , O
anthracyclines NNS NNS B-CHEM
, , , O
gemcitabine NN NN B-CHEM
( ( ( O
GEM NNP NNP B-CHEM
) ) ) O
em NN NN O
leader NN NN O
] NN NN O
. . . O

Even RB RB O
if IN IN O
it PRP PRP O
did VBD VBD O
not RB RB O
reach VB VB O
statistical JJ JJ O
significance NN NN O
because IN IN O
of IN IN O
a DT DT O
few JJ JJ O
number NN NN O
of IN IN O
cases NNS NNS O
, , , O
the DT DT O
risk NN NN O
was VBD VBD O
lower JJR JJR O
in IN IN O
trials NNS NNS O
excluding VBG VBG O
patients NNS NNS O
with IN IN O
cardiac JJ JJ O
history NN NN O
, , , O
and CC CC O
seemed VBD VBD O
to TO TO O
be VB VB O
higher JJR JJR O
in IN IN O
trials NNS NNS O
including VBG VBG O
patients NNS NNS O
with IN IN O
pre NN NN O
- - - O
existing VBG VBG O
cardiac NN NN O
diseases NNS NNS O
. . . O

Vinorelbine NNP NNP B-CHEM
- - - O
related JJ JJ O
cardiac JJ JJ O
events NNS NNS O
concern NN NN O
about IN IN O
1 CD CD O
% NN NN O
of IN IN O
treated VBN VBN O
patients NNS NNS O
in IN IN O
clinical JJ JJ O
trials NNS NNS O
. . . O

However RB RB O
, , , O
the DT DT O
risk NN NN O
associated VBN VBN O
with IN IN O
VNR NNP NNP B-CHEM
seems VBZ VBZ O
to TO TO O
be VB VB O
similar JJ JJ O
to TO TO O
that DT DT O
of IN IN O
other JJ JJ O
chemotherapeutic JJ JJ O
agents NNS NNS O
in IN IN O
the DT DT O
same JJ JJ O
indications NNS NNS O
. . . O

MRI NNP NNP O
findings NNS NNS O
of IN IN O
hypoxic JJ JJ O
cortical JJ JJ O
laminar NN NN O
necrosis NN NN O
in IN IN O
a DT DT O
child NN NN O
with IN IN O
hemolytic JJ JJ O
anemia NN NN O
crisis NN NN O
. . . O

We PRP PRP O
present JJ JJ O
magnetic JJ JJ O
resonance NN NN O
imaging VBG VBG O
findings NNS NNS O
of IN IN O
a DT DT O
5 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
girl NN NN O
who WP WP O
had VBD VBD O
a DT DT O
rapidly RB RB O
installing VBG VBG O
hemolytic JJ JJ O
anemia NN NN O
crisis NN NN O
induced VBN VBN O
by IN IN O
trimethoprim JJ JJ B-CHEM
- : : I-CHEM
sulfomethoxazole NN NN I-CHEM
, , , O
resulting VBG VBG O
in IN IN O
cerebral JJ JJ O
anoxia NN NN O
leading VBG VBG O
to TO TO O
permanent VB VB O
damage NN NN O
. . . O

Magnetic NNP NNP O
Resonance NNP NNP O
imaging VBG VBG O
revealed JJ JJ O
cortical JJ JJ O
laminar NN NN O
necrosis NN NN O
in IN IN O
arterial JJ JJ O
border NN NN O
zones NNS NNS O
in IN IN O
both DT DT O
cerebral JJ JJ O
hemispheres NNS NNS O
, , , O
ischemic JJ JJ O
changes NNS NNS O
in IN IN O
subcortical JJ JJ O
white JJ JJ O
matter NN NN O
of IN IN O
left VBD VBD O
cerebral JJ JJ O
hemisphere NN NN O
, , , O
and CC CC O
in IN IN O
the DT DT O
left NN NN O
putamen NN NN O
. . . O

Although IN IN O
cortical JJ JJ O
laminar NN NN O
necrosis NN NN O
is VBZ VBZ O
a DT DT O
classic JJ JJ O
entity NN NN O
in IN IN O
adulthood NN NN O
related VBN VBN O
to TO TO O
conditions NNS NNS O
of IN IN O
energy NN NN O
depletions NNS NNS O
, , , O
there EX EX O
are VBP VBP O
few JJ JJ O
reports NNS NNS O
available JJ JJ O
in IN IN O
children NNS NNS O
. . . O

A DT DT O
wide JJ JJ O
review NN NN O
of IN IN O
the DT DT O
literature NN NN O
is VBZ VBZ O
also RB RB O
presented VBN VBN O
. . . O

The DT DT O
natural JJ JJ O
history NN NN O
of IN IN O
Vigabatrin NNP NNP B-CHEM
associated VBN VBN O
visual JJ JJ O
field NN NN O
defects NNS NNS O
in IN IN O
patients NNS NNS O
electing VBG VBG O
to TO TO O
continue VB VB O
their PRP$ PRP$ O
medication NN NN O
. . . O

PURPOSE NNP NNP O
: : : O
To TO TO O
determine VB VB O
the DT DT O
natural JJ JJ O
history NN NN O
of IN IN O
visual JJ JJ O
field NN NN O
defects NNS NNS O
in IN IN O
a DT DT O
group NN NN O
of IN IN O
patients NNS NNS O
known VBN VBN O
to TO TO O
have VB VB O
Vigabatrin NNP NNP B-CHEM
- : : O
associated VBN VBN O
changes NNS NNS O
who WP WP O
elected VBD VBD O
to TO TO O
continue VB VB O
the DT DT O
medication NN NN O
because IN IN O
of IN IN O
good JJ JJ O
seizure NN NN O
control NN NN O
. . . O

METHODS NNP NNP O
: : : O
All DT DT O
patients NNS NNS O
taking VBG VBG O
Vigabatrin NNP NNP B-CHEM
alone RB RB O
or CC CC O
in IN IN O
combination NN NN O
with IN IN O
other JJ JJ O
antiepileptic JJ JJ O
drugs NNS NNS O
for IN IN O
at IN IN O
least JJS JJS O
5 CD CD O
years NNS NNS O
( ( ( O
range NN NN O
5 CD CD O
- : : O
12 CD CD O
years NNS NNS O
) ) ) O
were VBD VBD O
entered VBN VBN O
into IN IN O
a DT DT O
visual JJ JJ O
surveillance NN NN O
programme NN NN O
. . . O

Patients NNS NNS O
were VBD VBD O
followed VBN VBN O
up RB RB O
at IN IN O
6 CD CD O
- : : O
monthly JJ JJ O
intervals NNS NNS O
for IN IN O
not RB RB O
less JJR JJR O
than IN IN O
18 CD CD O
months NNS NNS O
( ( ( O
range NN NN O
18 CD CD O
- : : O
43 CD CD O
months NNS NNS O
) ) ) O
. . . O

In IN IN O
all DT DT O
, , , O
16 CD CD O
patients NNS NNS O
with IN IN O
unequivocal JJ JJ O
defects NNS NNS O
continued VBD VBD O
the DT DT O
medication NN NN O
. . . O

Following VBG VBG O
already RB RB O
published VBN VBN O
methodology NN NN O
( ( ( O
Eye NNP NNP O
2002 CD CD O
; : : O
16 CD CD O
; : : O
567 CD CD O
- : : O
571 CD CD O
) ) ) O
monocular JJ JJ O
mean NN NN O
radial JJ JJ O
degrees NNS NNS O
( ( ( O
MRDs NNP NNP O
) ) ) O
to TO TO O
the DT DT O
I PRP PRP O
/ NN NN O
4e CD CD O
isopter NN NN O
on IN IN O
Goldmann NNP NNP O
perimetry NN NN O
was VBD VBD O
calculated VBN VBN O
for IN IN O
the DT DT O
right JJ JJ O
eye NN NN O
at IN IN O
the DT DT O
time NN NN O
of IN IN O
discovery NN NN O
of IN IN O
a DT DT O
visual JJ JJ O
field NN NN O
defect NN NN O
and CC CC O
again RB RB O
after IN IN O
not RB RB O
less JJR JJR O
than IN IN O
18 CD CD O
months NNS NNS O
follow VB VB O
- - - O
up RP RP O
. . . O

RESULTS NNS NNS O
: : : O
Mean VB VB O
right NN NN O
eye NN NN O
MRD NNP NNP O
at IN IN O
presentation NN NN O
was VBD VBD O
36 CD CD O
. . . O
98 CD CD O
degrees NNS NNS O
( ( ( O
range NN NN O
22 CD CD O
. . . O
25 CD CD O
- : : O
51 CD CD O
. . . O
0 CD CD O
) ) ) O
, , , O
compared VBN VBN O
to TO TO O
38 CD CD O
. . . O
40 CD CD O
degrees NNS NNS O
( ( ( O
range NN NN O
22 CD CD O
. . . O
5 CD CD O
- : : O
49 CD CD O
. . . O
75 CD CD O
) ) ) O
after IN IN O
follow VB VB O
- - - O
up RP RP O
; : : O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
338 CD CD O
unpaired VBN VBN O
t NN NN O
- - - O
test NN NN O
. . . O

Only RB RB O
one CD CD O
patient NN NN O
demonstrated VBD VBD O
a DT DT O
deterioration NN NN O
in IN IN O
visual JJ JJ O
field NN NN O
during IN IN O
the DT DT O
study NN NN O
period NN NN O
and CC CC O
discontinued VBD VBD O
treatment NN NN O
. . . O

CONCLUSION NNP NNP O
: : : O
Established NNP NNP O
visual JJ JJ O
field NN NN O
defects NNS NNS O
presumed VBN VBN O
to TO TO O
be VB VB O
due JJ JJ O
to TO TO O
Vigabatrin NNP NNP B-CHEM
therapy NN NN O
did VBD VBD O
not RB RB O
usually RB RB O
progress NN NN O
in IN IN O
spite NN NN O
of IN IN O
continuing VBG VBG O
use NN NN O
of IN IN O
the DT DT O
medication NN NN O
. . . O

These DT DT O
data NNS NNS O
give VBP VBP O
support NN NN O
to TO TO O
the DT DT O
hypothesis NNS NNS O
that IN IN O
the DT DT O
pathogenesis NNS NNS O
of IN IN O
Vigabatrin NNP NNP B-CHEM
- - - O
associated VBN VBN O
visual JJ JJ O
field NN NN O
defects NNS NNS O
may MD MD O
be VB VB O
an DT DT O
idiosyncratic JJ JJ O
adverse NN NN O
drug NN NN O
reaction NN NN O
rather RB RB O
than IN IN O
dose VB VB O
- - - O
dependent JJ JJ O
toxicity NN NN O
. . . O

Induction NNP NNP O
of IN IN O
rosaceiform NN NN O
dermatitis NNS NNS O
during IN IN O
treatment NN NN O
of IN IN O
facial JJ JJ O
inflammatory NN NN O
dermatoses NNS NNS O
with IN IN O
tacrolimus NN NN B-CHEM
ointment NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
Tacrolimus NNP NNP B-CHEM
ointment NN NN O
is VBZ VBZ O
increasingly RB RB O
used VBN VBN O
for IN IN O
anti JJ JJ O
- : : O
inflammatory JJ JJ O
treatment NN NN O
of IN IN O
sensitive JJ JJ O
areas NNS NNS O
such JJ JJ O
as IN IN O
the DT DT O
face NN NN O
, , , O
and CC CC O
recent JJ JJ O
observations NNS NNS O
indicate VBP VBP O
that IN IN O
the DT DT O
treatment NN NN O
is VBZ VBZ O
effective JJ JJ O
in IN IN O
steroid NN NN B-CHEM
- - - O
aggravated JJ JJ O
rosacea NN NN O
and CC CC O
perioral JJ JJ O
dermatitis NNS NNS O
. . . O

We PRP PRP O
report VBP VBP O
on IN IN O
rosaceiform NN NN O
dermatitis NNS NNS O
as IN IN O
a DT DT O
complication NN NN O
of IN IN O
treatment NN NN O
with IN IN O
tacrolimus NN NN B-CHEM
ointment NN NN O
. . . O

OBSERVATIONS NNP NNP O
: : : O
Six CD CD O
adult NN NN O
patients NNS NNS O
with IN IN O
inflammatory JJ JJ O
facial JJ JJ O
dermatoses NNS NNS O
were VBD VBD O
treated VBN VBN O
with IN IN O
tacrolimus NN NN B-CHEM
ointment NN NN O
because IN IN O
of IN IN O
the DT DT O
ineffectiveness NN NN O
of IN IN O
standard JJ JJ O
treatments NNS NNS O
. . . O

Within IN IN O
2 CD CD O
to TO TO O
3 CD CD O
weeks NNS NNS O
of IN IN O
initially RB RB O
effective JJ JJ O
and CC CC O
well RB RB O
- - - O
tolerated JJ JJ O
treatment NN NN O
, , , O
3 CD CD O
patients NNS NNS O
with IN IN O
a DT DT O
history NN NN O
of IN IN O
rosacea NN NN O
and CC CC O
1 CD CD O
with IN IN O
a DT DT O
history NN NN O
of IN IN O
acne NN NN O
experienced VBN VBN O
sudden JJ JJ O
worsening VBG VBG O
with IN IN O
pustular JJ JJ O
rosaceiform NN NN O
lesions NNS NNS O
. . . O

Biopsy NNP NNP O
revealed VBD VBD O
an DT DT O
abundance NN NN O
of IN IN O
Demodex NNP NNP O
mites NNS NNS O
in IN IN O
2 CD CD O
of IN IN O
these DT DT O
patients NNS NNS O
. . . O

In IN IN O
1 CD CD O
patient NN NN O
with IN IN O
eyelid JJ JJ O
eczema NN NN O
, , , O
rosaceiform NN NN O
periocular JJ JJ O
dermatitis NN NN O
gradually RB RB O
appeared VBD VBD O
after IN IN O
3 CD CD O
weeks NNS NNS O
of IN IN O
treatment NN NN O
. . . O

In IN IN O
1 CD CD O
patient NN NN O
with IN IN O
atopic JJ JJ O
dermatitis NNS NNS O
, , , O
telangiectatic JJ JJ O
and CC CC O
papular JJ JJ O
rosacea NN NN O
insidiously RB RB O
appeared VBD VBD O
after IN IN O
5 CD CD O
months NNS NNS O
of IN IN O
treatment NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Our PRP$ PRP$ O
observations NNS NNS O
suggest VBP VBP O
that IN IN O
the DT DT O
spectrum NN NN O
of IN IN O
rosaceiform NN NN O
dermatitis NNS NNS O
as IN IN O
a DT DT O
complication NN NN O
of IN IN O
treatment NN NN O
with IN IN O
tacrolimus NN NN B-CHEM
ointment NN NN O
is VBZ VBZ O
heterogeneous JJ JJ O
. . . O

A DT DT O
variety NN NN O
of IN IN O
factors NNS NNS O
, , , O
such JJ JJ O
as IN IN O
vasoactive JJ JJ O
properties NNS NNS O
of IN IN O
tacrolimus NN NN B-CHEM
, , , O
proliferation NN NN O
of IN IN O
Demodex NNP NNP O
due JJ JJ O
to TO TO O
local JJ JJ O
immunosuppression NN NN O
, , , O
and CC CC O
the DT DT O
occlusive JJ JJ O
properties NNS NNS O
of IN IN O
the DT DT O
ointment NN NN O
, , , O
may MD MD O
be VB VB O
involved VBN VBN O
in IN IN O
the DT DT O
observed VBN VBN O
phenomena NN NN O
. . . O

Future NNP NNP O
studies NNS NNS O
are VBP VBP O
needed VBN VBN O
to TO TO O
identify VB VB O
individual JJ JJ O
risk NN NN O
factors NNS NNS O
. . . O

Intravascular NNP NNP O
hemolysis NN NN O
and CC CC O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
following VBG VBG O
intermittent NN NN O
rifampin NN NN B-CHEM
therapy NN NN O
. . . O

Renal NNP NNP O
failure NN NN O
is VBZ VBZ O
a DT DT O
rare JJ JJ O
complication NN NN O
associated VBN VBN O
with IN IN O
the DT DT O
use NN NN O
of IN IN O
rifampin NN NN B-CHEM
. . . O

Intravascular NNP NNP O
hemolysis NN NN O
leading VBG VBG O
to TO TO O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
following VBG VBG O
rifampin NN NN B-CHEM
therapy NN NN O
is VBZ VBZ O
extremely RB RB O
rare JJ JJ O
. . . O

Two CD CD O
patients NNS NNS O
with IN IN O
leprosy NN NN O
who WP WP O
developed VBD VBD O
hemolysis NNS NNS O
and CC CC O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
following VBG VBG O
rifampin NN NN B-CHEM
are VBP VBP O
reported VBN VBN O
. . . O

Structural NNP NNP O
abnormalities NNS NNS O
in IN IN O
the DT DT O
brains NNS NNS O
of IN IN O
human JJ JJ O
subjects NNS NNS O
who WP WP O
use VBP VBP O
methamphetamine NN NN B-CHEM
. . . O

We PRP PRP O
visualize NN NN O
, , , O
for IN IN O
the DT DT O
first JJ JJ O
time NN NN O
, , , O
the DT DT O
profile NN NN O
of IN IN O
structural JJ JJ O
deficits NNS NNS O
in IN IN O
the DT DT O
human JJ JJ O
brain NN NN O
associated VBN VBN O
with IN IN O
chronic JJ JJ O
methamphetamine NN NN B-CHEM
( ( ( O
MA NNP NNP B-CHEM
) ) ) O
abuse NN NN O
. . . O

Studies NNS NNS O
of IN IN O
human JJ JJ O
subjects NNS NNS O
who WP WP O
have VBP VBP O
used VBN VBN O
MA NNP NNP B-CHEM
chronically RB RB O
have VBP VBP O
revealed VBN VBN O
deficits NNS NNS O
in IN IN O
dopaminergic JJ JJ O
and CC CC O
serotonergic JJ JJ O
systems NNS NNS O
and CC CC O
cerebral JJ JJ O
metabolic JJ JJ O
abnormalities NNS NNS O
. . . O

Using VBG VBG O
magnetic JJ JJ O
resonance NN NN O
imaging VBG VBG O
( ( ( O
MRI NNP NNP O
) ) ) O
and CC CC O
new JJ JJ O
computational NN NN O
brain NN NN O
- : : O
mapping NN NN O
techniques NNS NNS O
, , , O
we PRP PRP O
determined VBD VBD O
the DT DT O
pattern NN NN O
of IN IN O
structural JJ JJ O
brain NN NN O
alterations NNS NNS O
associated VBN VBN O
with IN IN O
chronic JJ JJ O
MA NNP NNP B-CHEM
abuse NN NN O
in IN IN O
human JJ JJ O
subjects NNS NNS O
and CC CC O
related VBN VBN O
these DT DT O
deficits NNS NNS O
to TO TO O
cognitive JJ JJ O
impairment NN NN O
. . . O

We PRP PRP O
used VBD VBD O
high JJ JJ O
- - - O
resolution NN NN O
MRI NNP NNP O
and CC CC O
surface NN NN O
- - - O
based JJ JJ O
computational NN NN O
image NN NN O
analyses NNS NNS O
to TO TO O
map VB VB O
regional JJ JJ O
abnormalities NNS NNS O
in IN IN O
the DT DT O
cortex NN NN O
, , , O
hippocampus NN NN O
, , , O
white JJ JJ O
matter NN NN O
, , , O
and CC CC O
ventricles NNS NNS O
in IN IN O
22 CD CD O
human JJ JJ O
subjects NNS NNS O
who WP WP O
used VBD VBD O
MA NNP NNP B-CHEM
and CC CC O
21 CD CD O
age NN NN O
- : : O
matched JJ JJ O
, , , O
healthy JJ JJ O
controls NNS NNS O
. . . O

Cortical NNP NNP O
maps NNS NNS O
revealed VBD VBD O
severe JJ JJ O
gray JJ JJ O
- - - O
matter NN NN O
deficits NNS NNS O
in IN IN O
the DT DT O
cingulate NN NN O
, , , O
limbic NN NN O
, , , O
and CC CC O
paralimbic NN NN O
cortices NNS NNS O
of IN IN O
MA NNP NNP B-CHEM
abusers NNS NNS O
( ( ( O
averaging VBG VBG O
11 CD CD O
. . . O
3 CD CD O
% NN NN O
below IN IN O
control NN NN O
; : : O
p NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

On IN IN O
average JJ JJ O
, , , O
MA NNP NNP B-CHEM
abusers NNS NNS O
had VBD VBD O
7 CD CD O
. . . O
8 CD CD O
% NN NN O
smaller JJR JJR O
hippocampal NN NN O
volumes NNS NNS O
than IN IN O
control NN NN O
subjects NNS NNS O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
; : : O
left VBD VBD O
, , , O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
01 CD CD O
; : : O
right NN NN O
, , , O
p NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
and CC CC O
significant JJ JJ O
white JJ JJ O
- - - O
matter NN NN O
hypertrophy NN NN O
( ( ( O
7 CD CD O
. . . O
0 CD CD O
% NN NN O
; : : O
p NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
. . . O

Hippocampal NNP NNP O
deficits NNS NNS O
were VBD VBD O
mapped VBN VBN O
and CC CC O
correlated JJ JJ O
with IN IN O
memory NN NN O
performance NN NN O
on IN IN O
a DT DT O
word NN NN O
- - - O
recall NN NN O
test NN NN O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

MRI NNP NNP O
- - - O
based JJ JJ O
maps NNS NNS O
suggest VBP VBP O
that IN IN O
chronic JJ JJ O
methamphetamine NN NN B-CHEM
abuse NN NN O
causes NNS NNS O
a DT DT O
selective JJ JJ O
pattern NN NN O
of IN IN O
cerebral JJ JJ O
deterioration NN NN O
that WDT WDT O
contributes VBZ VBZ O
to TO TO O
impaired JJ JJ O
memory NN NN O
performance NN NN O
. . . O

MA NNP NNP B-CHEM
may MD MD O
selectively RB RB O
damage VB VB O
the DT DT O
medial JJ JJ O
temporal NN NN O
lobe NN NN O
and CC CC O
, , , O
consistent JJ JJ O
with IN IN O
metabolic JJ JJ O
studies NNS NNS O
, , , O
the DT DT O
cingulate NN NN O
- - - O
limbic NN NN O
cortex NN NN O
, , , O
inducing VBG VBG O
neuroadaptation NN NN O
, , , O
neuropil NN NN O
reduction NN NN O
, , , O
or CC CC O
cell NN NN O
death NN NN O
. . . O

Prominent NNP NNP O
white JJ JJ O
- - - O
matter NN NN O
hypertrophy NN NN O
may MD MD O
result VB VB O
from IN IN O
altered VBN VBN O
myelination NN NN O
and CC CC O
adaptive JJ JJ O
glial JJ JJ O
changes NNS NNS O
, , , O
including VBG VBG O
gliosis NN NN O
secondary JJ JJ O
to TO TO O
neuronal JJ JJ O
damage NN NN O
. . . O

These DT DT O
brain NN NN O
substrates NNS NNS O
may MD MD O
help VB VB O
account VB VB O
for IN IN O
the DT DT O
symptoms NNS NNS O
of IN IN O
MA NNP NNP B-CHEM
abuse NN NN O
, , , O
providing VBG VBG O
therapeutic JJ JJ O
targets NNS NNS O
for IN IN O
drug NN NN O
- - - O
induced JJ JJ O
brain NN NN O
injury NN NN O
. . . O

Disruption NNP NNP O
of IN IN O
hepatic JJ JJ O
lipid NN NN O
homeostasis NN NN O
in IN IN O
mice NN NN O
after IN IN O
amiodarone NN NN B-CHEM
treatment NN NN O
is VBZ VBZ O
associated VBN VBN O
with IN IN O
peroxisome NN NN O
proliferator NN NN O
- : : O
activated VBN VBN O
receptor NN NN O
- - - O
alpha NN NN O
target NN NN O
gene NN NN O
activation NN NN O
. . . O

Amiodarone NNP NNP B-CHEM
, , , O
an DT DT O
efficacious JJ JJ O
and CC CC O
widely RB RB O
used VBN VBN O
antiarrhythmic JJ JJ O
agent NN NN O
, , , O
has VBZ VBZ O
been VBN VBN O
reported VBN VBN O
to TO TO O
cause VB VB O
hepatotoxicity NN NN O
in IN IN O
some DT DT O
patients NNS NNS O
. . . O

To TO TO O
gain VB VB O
insight NN NN O
into IN IN O
the DT DT O
mechanism NN NN O
of IN IN O
this DT DT O
unwanted JJ JJ O
effect NN NN O
, , , O
mice NN NN O
were VBD VBD O
administered VBN VBN O
various JJ JJ O
doses NNS NNS O
of IN IN O
amiodarone NN NN B-CHEM
and CC CC O
examined VBD VBD O
for IN IN O
changes NNS NNS O
in IN IN O
hepatic JJ JJ O
histology NN NN O
and CC CC O
gene NN NN O
regulation NN NN O
. . . O

Amiodarone NNP NNP B-CHEM
induced VBD VBD O
hepatomegaly RB RB O
, , , O
hepatocyte NN NN O
microvesicular NN NN O
lipid JJ JJ O
accumulation NN NN O
, , , O
and CC CC O
a DT DT O
significant JJ JJ O
decrease NN NN O
in IN IN O
serum NN NN O
triglycerides NNS NNS B-CHEM
and CC CC O
glucose NN NN B-CHEM
. . . O

Northern NNP NNP O
blot NN NN O
analysis NN NN O
of IN IN O
hepatic JJ JJ O
RNA NNP NNP O
revealed VBD VBD O
a DT DT O
dose NN NN O
- - - O
dependent JJ JJ O
increase NN NN O
in IN IN O
the DT DT O
expression NN NN O
of IN IN O
a DT DT O
number NN NN O
of IN IN O
genes NNS NNS O
critical JJ JJ O
for IN IN O
fatty JJ JJ B-CHEM
acid NN NN I-CHEM
oxidation NN NN O
, , , O
lipoprotein NN NN O
assembly RB RB O
, , , O
and CC CC O
lipid JJ JJ O
transport NN NN O
. . . O

Many JJ JJ O
of IN IN O
these DT DT O
genes NNS NNS O
are VBP VBP O
regulated VBN VBN O
by IN IN O
the DT DT O
peroxisome NN NN O
proliferator NN NN O
- : : O
activated VBN VBN O
receptor NN NN O
- : : O
alpha NN NN O
( ( ( O
PPARalpha NNP NNP O
) ) ) O
, , , O
a DT DT O
ligand NN NN O
- - - O
activated VBN VBN O
nuclear JJ JJ O
hormone NN NN O
receptor NN NN O
transcription NN NN O
factor NN NN O
. . . O

The DT DT O
absence NN NN O
of IN IN O
induction NN NN O
of IN IN O
these DT DT O
genes NNS NNS O
as RB RB O
well RB RB O
as IN IN O
hepatomegaly NN NN O
in IN IN O
PPARalpha NNP NNP O
knockout NN NN O
[ NN NN O
PPARalpha NNP NNP O
- : : O
/ NN NN O
- : : O
] NN NN O
mice NN NN O
indicated VBD VBD O
that IN IN O
the DT DT O
effects NNS NNS O
of IN IN O
amiodarone NN NN B-CHEM
were VBD VBD O
dependent JJ JJ O
upon IN IN O
the DT DT O
presence NN NN O
of IN IN O
a DT DT O
functional JJ JJ O
PPARalpha NNP NNP O
gene NN NN O
. . . O

Compared VBN VBN O
to TO TO O
wild JJ JJ O
- - - O
type NN NN O
mice NN NN O
, , , O
treatment NN NN O
of IN IN O
PPARalpha NNP NNP O
- - - O
/ NN NN O
- - - O
mice NN NN O
with IN IN O
amiodarone NN NN B-CHEM
resulted VBD VBD O
in IN IN O
an DT DT O
increased JJ JJ O
rate NN NN O
and CC CC O
extent NN NN O
of IN IN O
total JJ JJ O
body NN NN O
weight NN NN O
loss NN NN O
. . . O

The DT DT O
inability NN NN O
of IN IN O
amiodarone NN NN B-CHEM
to TO TO O
directly RB RB O
activate VB VB O
either CC CC O
human JJ JJ O
or CC CC O
mouse NN NN O
PPARalpha NNP NNP O
transiently RB RB O
expressed VBD VBD O
in IN IN O
human JJ JJ O
HepG2 NNP NNP O
hepatoma NN NN O
cells NNS NNS O
indicates NNS NNS O
that IN IN O
the DT DT O
effects NNS NNS O
of IN IN O
amiodarone NN NN B-CHEM
on IN IN O
the DT DT O
function NN NN O
of IN IN O
this DT DT O
receptor NN NN O
were VBD VBD O
indirect JJ JJ O
. . . O

Based VBN VBN O
upon IN IN O
these DT DT O
results NNS NNS O
, , , O
we PRP PRP O
conclude VBP VBP O
that DT DT O
amiodarone NN NN B-CHEM
disrupts NNS NNS O
hepatic JJ JJ O
lipid NN NN O
homeostasis NN NN O
and CC CC O
that IN IN O
the DT DT O
increased JJ JJ O
expression NN NN O
of IN IN O
PPARalpha NNP NNP O
target NN NN O
genes NNS NNS O
is VBZ VBZ O
secondary JJ JJ O
to TO TO O
this DT DT O
toxic JJ JJ O
effect NN NN O
. . . O

These DT DT O
results NNS NNS O
provide VBP VBP O
important JJ JJ O
new JJ JJ O
mechanistic JJ JJ O
information NN NN O
regarding VBG VBG O
the DT DT O
hepatotoxic JJ JJ O
effects NNS NNS O
of IN IN O
amiodarone NN NN B-CHEM
and CC CC O
indicate VBP VBP O
that IN IN O
PPARalpha NNP NNP O
protects VBZ VBZ O
against IN IN O
amiodarone NN NN B-CHEM
- - - O
induced JJ JJ O
hepatotoxicity NN NN O
. . . O

Safety NNP NNP O
and CC CC O
compliance NN NN O
with IN IN O
once RB RB O
- : : O
daily JJ JJ O
niacin NN NN B-CHEM
extended VBD VBD I-CHEM
- - - I-CHEM
release NN NN I-CHEM
/ NN NN I-CHEM
lovastatin NN NN I-CHEM
as IN IN O
initial JJ JJ O
therapy NN NN O
in IN IN O
the DT DT O
Impact NNP NNP O
of IN IN O
Medical NNP NNP O
Subspecialty NNP NNP O
on IN IN O
Patient NNP NNP O
Compliance NNP NNP O
to TO TO O
Treatment NN NN O
( ( ( O
IMPACT NNP NNP O
) ) ) O
study NN NN O
. . . O

Niacin NNP NNP B-CHEM
extended VBD VBD I-CHEM
- - - I-CHEM
release NN NN I-CHEM
/ NN NN I-CHEM
lovastatin NN NN I-CHEM
is VBZ VBZ O
a DT DT O
new JJ JJ O
combination NN NN O
product NN NN O
approved VBD VBD O
for IN IN O
treatment NN NN O
of IN IN O
primary JJ JJ O
hypercholesterolemia NN NN O
and CC CC O
mixed JJ JJ O
dyslipidemia NN NN O
. . . O

This DT DT O
open JJ JJ O
- : : O
labeled VBN VBN O
, , , O
multicenter NN NN O
study NN NN O
evaluated VBD VBD O
the DT DT O
safety NN NN O
of IN IN O
bedtime NN NN O
niacin NN NN B-CHEM
extended VBD VBD I-CHEM
- - - I-CHEM
release NN NN I-CHEM
/ NN NN I-CHEM
lovastatin NN NN I-CHEM
when WRB WRB O
dosed VBN VBN O
as IN IN O
initial JJ JJ O
therapy NN NN O
and CC CC O
patient NN NN O
compliance NN NN O
to TO TO O
treatment NN NN O
in IN IN O
various JJ JJ O
clinical JJ JJ O
practice NN NN O
settings NNS NNS O
. . . O

A DT DT O
total NN NN O
of IN IN O
4 CD CD O
, , , O
499 CD CD O
patients NNS NNS O
with IN IN O
dyslipidemia NN NN O
requiring VBG VBG O
drug NN NN O
intervention NN NN O
was VBD VBD O
enrolled VBN VBN O
at IN IN O
1 CD CD O
, , , O
081 CD CD O
sites NNS NNS O
. . . O

Patients NNS NNS O
were VBD VBD O
treated VBN VBN O
with IN IN O
1 CD CD O
tablet NN NN O
( ( ( O
500 CD CD O
mg NN NN O
of IN IN O
niacin NN NN B-CHEM
extended VBD VBD O
- - - O
release NN NN O
/ NN NN O
20 CD CD O
mg NN NN O
of IN IN O
lovastatin NN NN B-CHEM
) ) ) O
once RB RB O
nightly RB RB O
for IN IN O
4 CD CD O
weeks NNS NNS O
and CC CC O
then RB RB O
2 CD CD O
tablets NNS NNS O
for IN IN O
8 CD CD O
weeks NNS NNS O
. . . O

Patients NNS NNS O
also RB RB O
received VBD VBD O
dietary JJ JJ O
counseling NN NN O
, , , O
educational JJ JJ O
materials NNS NNS O
, , , O
and CC CC O
reminders NNS NNS O
to TO TO O
call VB VB O
a DT DT O
toll NN NN O
- - - O
free JJ JJ O
number NN NN O
that WDT WDT O
provided VBD VBD O
further JJ JJ O
education NN NN O
about IN IN O
dyslipidemia NN NN O
and CC CC O
niacin NN NN B-CHEM
extended VBD VBD I-CHEM
- - - I-CHEM
release NN NN I-CHEM
/ NN NN I-CHEM
lovastatin NN NN I-CHEM
. . . O

Primary JJ JJ O
end NN NN O
points NNS NNS O
were VBD VBD O
study JJ JJ O
compliance NN NN O
, , , O
increases NNS NNS O
in IN IN O
liver NN NN O
transaminases NNS NNS O
to TO TO O
> NN NN O
3 CD CD O
times NNS NNS O
the DT DT O
upper JJ JJ O
limit NN NN O
of IN IN O
normal JJ JJ O
, , , O
and CC CC O
clinical JJ JJ O
myopathy NN NN O
. . . O

Final NNP NNP O
study NN NN O
status NN NN O
was VBD VBD O
available JJ JJ O
for IN IN O
4 CD CD O
, , , O
217 CD CD O
patients NNS NNS O
( ( ( O
94 CD CD O
% NN NN O
) ) ) O
. . . O

Compliance NNP NNP O
to TO TO O
niacin NN NN B-CHEM
extended VBD VBD I-CHEM
- - - I-CHEM
release NN NN I-CHEM
/ NN NN I-CHEM
lovastatin NN NN I-CHEM
was VBD VBD O
77 CD CD O
% NN NN O
, , , O
with IN IN O
3 CD CD O
, , , O
245 CD CD O
patients NNS NNS O
completing VBG VBG O
the DT DT O
study NN NN O
. . . O

Patients NNS NNS O
in IN IN O
the DT DT O
southeast NN NN O
and CC CC O
those DT DT O
enrolled VBN VBN O
by IN IN O
endocrinologists NNS NNS O
had VBD VBD O
the DT DT O
lowest JJS JJS O
compliance NN NN O
and CC CC O
highest JJS JJS O
adverse JJ JJ O
event NN NN O
rates NNS NNS O
. . . O

Flushing NNP NNP O
was VBD VBD O
the DT DT O
most RBS RBS O
common JJ JJ O
adverse JJ JJ O
event NN NN O
, , , O
reported VBN VBN O
by IN IN O
18 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
and CC CC O
leading VBG VBG O
to TO TO O
discontinuation NN NN O
by IN IN O
6 CD CD O
% NN NN O
. . . O

Incidence NNP NNP O
of IN IN O
increased VBD VBD O
aspartate NN NN B-CHEM
aminotransferase NN NN O
and CC CC O
/ NN NN O
or CC CC O
alanine NN NN B-CHEM
aminotransferase NN NN O
> NN NN O
3 CD CD O
times NNS NNS O
the DT DT O
upper JJ JJ O
limit NN NN O
of IN IN O
normal JJ JJ O
was VBD VBD O
< NN NN O
0 CD CD O
. . . O
3 CD CD O
% NN NN O
. . . O

An DT DT O
increase NN NN O
of IN IN O
creatine NN NN B-CHEM
phosphokinase NN NN O
to TO TO O
> NN NN O
5 CD CD O
times NNS NNS O
the DT DT O
upper JJ JJ O
limit NN NN O
of IN IN O
normal JJ JJ O
occurred VBD VBD O
in IN IN O
0 CD CD O
. . . O
24 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
, , , O
and CC CC O
no DT DT O
cases NNS NNS O
of IN IN O
drug NN NN O
- - - O
induced JJ JJ O
myopathy NN NN O
were VBD VBD O
observed VBN VBN O
. . . O

Niacin NNP NNP B-CHEM
extended VBD VBD I-CHEM
- - - I-CHEM
release NN NN I-CHEM
/ NN NN I-CHEM
lovastatin NN NN I-CHEM
1 CD CD O
, , , O
000 CD CD O
/ NN NN O
40 CD CD O
mg NN NN O
, , , O
dosed VBN VBN O
as IN IN O
initial JJ JJ O
therapy NN NN O
, , , O
was VBD VBD O
associated VBN VBN O
with IN IN O
good JJ JJ O
compliance NN NN O
and CC CC O
safety NN NN O
and CC CC O
had VBD VBD O
very RB RB O
low JJ JJ O
incidences NNS NNS O
of IN IN O
increased VBN VBN O
liver NN NN O
and CC CC O
muscle NN NN O
enzymes NNS NNS O
. . . O

Protective JJ JJ O
effect NN NN O
of IN IN O
Terminalia NNP NNP B-CHEM
chebula NN NN I-CHEM
against IN IN O
experimental JJ JJ O
myocardial NN NN O
injury NN NN O
induced VBN VBN O
by IN IN O
isoproterenol NN NN B-CHEM
. . . O

Cardioprotective NNP NNP O
effect NN NN O
of IN IN O
ethanolic JJ JJ B-CHEM
extract NN NN I-CHEM
of IN IN I-CHEM
Terminalia NNP NNP I-CHEM
chebula NN NN I-CHEM
fruits NNS NNS I-CHEM
( ( ( O
500 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
body NN NN O
wt NN NN O
) ) ) O
was VBD VBD O
examined VBN VBN O
in IN IN O
isoproterenol NN NN B-CHEM
( ( ( O
200 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
body NN NN O
wt NN NN O
) ) ) O
induced JJ JJ O
myocardial NN NN O
damage NN NN O
in IN IN O
rats NNS NNS O
. . . O

In IN IN O
isoproterenol NN NN B-CHEM
administered VBD VBD O
rats NNS NNS O
, , , O
the DT DT O
level NN NN O
of IN IN O
lipid JJ JJ O
peroxides NNS NNS B-CHEM
increased VBN VBN O
significantly RB RB O
in IN IN O
the DT DT O
serum NN NN O
and CC CC O
heart NN NN O
. . . O

A DT DT O
significant JJ JJ O
decrease NN NN O
was VBD VBD O
observed VBN VBN O
in IN IN O
the DT DT O
activity NN NN O
of IN IN O
the DT DT O
myocardial NN NN O
marker NN NN O
enzymes NNS NNS O
with IN IN O
a DT DT O
concomitant NN NN O
increase NN NN O
in IN IN O
their PRP$ PRP$ O
activity NN NN O
in IN IN O
serum NN NN O
. . . O

Histopathological NNP NNP O
examination NN NN O
was VBD VBD O
carried VBN VBN O
out IN IN O
to TO TO O
confirm VB VB O
the DT DT O
myocardial NN NN O
necrosis NN NN O
. . . O

T NN NN B-CHEM
. . . I-CHEM
chebula NN NN I-CHEM
extract NN NN I-CHEM
pretreatment NN NN O
was VBD VBD O
found VBN VBN O
to TO TO O
ameliorate VB VB O
the DT DT O
effect NN NN O
of IN IN O
isoproterenol NN NN B-CHEM
on IN IN O
lipid NN NN O
peroxide NN NN B-CHEM
formation NN NN O
and CC CC O
retained VBD VBD O
the DT DT O
activities NNS NNS O
of IN IN O
the DT DT O
diagnostic JJ JJ O
marker NN NN O
enzymes NNS NNS O
. . . O

A DT DT O
case NN NN O
of IN IN O
postoperative JJ JJ O
anxiety NN NN O
due JJ JJ O
to TO TO O
low JJ JJ O
dose NN NN O
droperidol NN NN B-CHEM
used VBN VBN O
with IN IN O
patient NN NN O
- - - O
controlled JJ JJ O
analgesia NN NN O
. . . O

A DT DT O
multiparous JJ JJ O
woman NN NN O
in IN IN O
good JJ JJ O
psychological JJ JJ O
health NN NN O
underwent JJ JJ O
urgent JJ JJ O
caesarean NN NN O
section NN NN O
in IN IN O
labour NN NN O
. . . O

Postoperatively NNP NNP O
, , , O
she PRP PRP O
was VBD VBD O
given VBN VBN O
a DT DT O
patient NN NN O
- - - O
controlled JJ JJ O
analgesia NN NN O
device NN NN O
delivering VBG VBG O
boluses NNS NNS O
of IN IN O
diamorphine NN NN B-CHEM
0 CD CD O
. . . O
5 CD CD O
mg NN NN O
and CC CC O
droperidol NN NN B-CHEM
0 CD CD O
. . . O
025 CD CD O
mg NN NN O
. . . O

Whilst NNP NNP O
using VBG VBG O
the DT DT O
device NN NN O
she PRP PRP O
gradually RB RB O
became VBD VBD O
anxious JJ JJ O
, , , O
the DT DT O
feeling NN NN O
worsening VBG VBG O
after IN IN O
each DT DT O
bolus NN NN O
. . . O

The DT DT O
diagnosis NN NN O
of IN IN O
droperidol NN NN B-CHEM
- - - O
induced JJ JJ O
psychological JJ JJ O
disturbance NN NN O
was VBD VBD O
not RB RB O
made VBN VBN O
straight JJ JJ O
away RB RB O
although IN IN O
on IN IN O
subsequent JJ JJ O
close NN NN O
questioning VBG VBG O
the DT DT O
patient NN NN O
gave VBD VBD O
a DT DT O
very RB RB O
clear JJ JJ O
history NN NN O
. . . O

After IN IN O
she PRP PRP O
had VBD VBD O
received VBN VBN O
a DT DT O
total NN NN O
of IN IN O
only RB RB O
0 CD CD O
. . . O
9 CD CD O
mg NN NN O
droperidol NN NN B-CHEM
, , , O
a DT DT O
syringe NN NN O
containing VBG VBG O
diamorphine NN NN B-CHEM
only RB RB O
was VBD VBD O
substituted VBN VBN O
and CC CC O
her PRP$ PRP$ O
unease NN NN O
resolved VBD VBD O
completely RB RB O
. . . O

We PRP PRP O
feel VBP VBP O
that IN IN O
, , , O
although IN IN O
the DT DT O
dramatic JJ JJ O
extrapyramidal NN NN O
side NN NN O
effects NNS NNS O
of IN IN O
dopaminergic JJ JJ O
antiemetics NNS NNS O
are VBP VBP O
well RB RB O
known VBN VBN O
, , , O
more RBR RBR O
subtle JJ JJ O
manifestations NNS NNS O
may MD MD O
easily RB RB O
be VB VB O
overlooked VBN VBN O
. . . O

Accurate NNP NNP O
patient NN NN O
history NN NN O
contributes NNS NNS O
to TO TO O
differentiating VBG VBG O
diabetes NNS NNS O
insipidus NN NN O
: : : O
a DT DT O
case NN NN O
study NN NN O
. . . O

This DT DT O
case NN NN O
study NN NN O
highlights VBZ VBZ O
the DT DT O
important JJ JJ O
contribution NN NN O
of IN IN O
nursing VBG VBG O
in IN IN O
obtaining VBG VBG O
an DT DT O
accurate JJ JJ O
health NN NN O
history NN NN O
. . . O

The DT DT O
case NN NN O
discussed VBD VBD O
herein NN NN O
initially RB RB O
appeared VBD VBD O
to TO TO O
be VB VB O
neurogenic JJ JJ O
diabetes NNS NNS O
insipidus NN NN O
( ( ( O
DI NNP NNP O
) ) ) O
secondary JJ JJ O
to TO TO O
a DT DT O
traumatic JJ JJ O
brain NN NN O
injury NN NN O
. . . O

The DT DT O
nursing VBG VBG O
staff NN NN O
, , , O
by IN IN O
reviewing VBG VBG O
the DT DT O
patient NN NN O
' '' '' O
s VBZ VBZ O
health NN NN O
history NN NN O
with IN IN O
his PRP$ PRP$ O
family NN NN O
, , , O
discovered VBD VBD O
a DT DT O
history NN NN O
of IN IN O
polydipsia NN NN O
and CC CC O
long JJ JJ O
- - - O
standing NN NN O
lithium NN NN B-CHEM
use NN NN O
. . . O

Lithium NNP NNP B-CHEM
is VBZ VBZ O
implicated VBN VBN O
in IN IN O
drug NN NN O
- - - O
induced JJ JJ O
nephrogenic JJ JJ O
DI NNP NNP O
, , , O
and CC CC O
because IN IN O
the DT DT O
patient NN NN O
had VBD VBD O
not RB RB O
received VBN VBN O
lithium NN NN B-CHEM
since IN IN O
being VBG VBG O
admitted VBN VBN O
to TO TO O
the DT DT O
hospital NN NN O
, , , O
his PRP$ PRP$ O
treatment NN NN O
changed VBN VBN O
to TO TO O
focus VB VB O
on IN IN O
nephrogenic JJ JJ O
DI NNP NNP O
. . . O

By IN IN O
combining VBG VBG O
information NN NN O
from IN IN O
the DT DT O
patient NN NN O
history NN NN O
, , , O
the DT DT O
physical JJ JJ O
examination NN NN O
, , , O
and CC CC O
radiologic JJ JJ O
and CC CC O
laboratory NN NN O
studies NNS NNS O
, , , O
the DT DT O
critical JJ JJ O
care NN NN O
team NN NN O
demonstrated VBN VBN O
that IN IN O
the DT DT O
patient NN NN O
had VBD VBD O
been VBN VBN O
self NN NN O
- - - O
treating VBG VBG O
his PRP$ PRP$ O
lithium NN NN B-CHEM
- - - O
induced JJ JJ O
nephrogenic NN NN O
DI NNP NNP O
and CC CC O
developed VBN VBN O
neurogenic JJ JJ O
DI NNP NNP O
secondary JJ JJ O
to TO TO O
brain VB VB O
trauma NN NN O
. . . O

Thus RB RB O
successful JJ JJ O
treatment NN NN O
required VBN VBN O
that IN IN O
nephrogenic JJ JJ O
and CC CC O
neurogenic JJ JJ O
DI NNP NNP O
be VB VB O
treated VBN VBN O
concomitantly RB RB O
. . . O

Factors NNS NNS O
contributing VBG VBG O
to TO TO O
ribavirin VB VB B-CHEM
- - - O
induced JJ JJ O
anemia NN NN O
. . . O

BACKGROUND NNP NNP O
AND CC CC O
AIM NNP NNP O
: : : O
Interferon NNP NNP B-CHEM
and CC CC O
ribavirin NN NN B-CHEM
combination NN NN O
therapy NN NN O
for IN IN O
chronic JJ JJ O
hepatitis NNP NNP O
C NNP NNP O
produces VBZ VBZ O
hemolytic JJ JJ O
anemia NN NN O
. . . O

This DT DT O
study NN NN O
was VBD VBD O
conducted VBN VBN O
to TO TO O
identify VB VB O
the DT DT O
factors NNS NNS O
contributing VBG VBG O
to TO TO O
ribavirin VB VB B-CHEM
- - - O
induced JJ JJ O
anemia NN NN O
. . . O

METHODS NNP NNP O
: : : O
Eighty NNP NNP O
- - - O
eight CD CD O
patients NNS NNS O
with IN IN O
chronic JJ JJ O
hepatitis NNP NNP O
C NNP NNP O
who WP WP O
received VBD VBD O
interferon NN NN B-CHEM
- - - I-CHEM
alpha NN NN I-CHEM
- - - I-CHEM
2b CD CD I-CHEM
at IN IN O
a DT DT O
dose NN NN O
of IN IN O
6 CD CD O
MU NNP NNP O
administered VBD VBD O
intramuscularly RB RB O
for IN IN O
24 CD CD O
weeks NNS NNS O
in IN IN O
combination NN NN O
with IN IN O
ribavirin NN NN B-CHEM
administered VBN VBN O
orally RB RB O
at IN IN O
a DT DT O
dose NN NN O
of IN IN O
600 CD CD O
mg NN NN O
or CC CC O
800 CD CD O
mg NN NN O
participated VBD VBD O
in IN IN O
the DT DT O
study NN NN O
. . . O

A DT DT O
hemoglobin NN NN O
concentration NN NN O
of IN IN O
< NN NN O
10 CD CD O
g SYM SYM O
/ NN NN O
dL NN NN O
was VBD VBD O
defined VBN VBN O
as IN IN O
ribavirin NN NN B-CHEM
- - - O
induced JJ JJ O
anemia NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Ribavirin NNP NNP B-CHEM
- - - O
induced JJ JJ O
anemia NN NN O
occurred VBD VBD O
in IN IN O
18 CD CD O
( ( ( O
20 CD CD O
. . . O
5 CD CD O
% NN NN O
) ) ) O
patients NNS NNS O
during IN IN O
treatment NN NN O
. . . O

A DT DT O
2 CD CD O
g SYM SYM O
/ NN NN O
dL NN NN O
decrease NN NN O
in IN IN O
hemoglobin NN NN O
concentrations NNS NNS O
in IN IN O
patients NNS NNS O
with IN IN O
anemia NN NN O
was VBD VBD O
observed VBN VBN O
at IN IN O
week NN NN O
2 CD CD O
after IN IN O
the DT DT O
start NN NN O
of IN IN O
treatment NN NN O
. . . O

The DT DT O
hemoglobin NN NN O
concentration NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
> NN NN O
or CC CC O
= SYM SYM O
2 CD CD O
g SYM SYM O
/ NN NN O
dL NN NN O
decrease NN NN O
at IN IN O
week NN NN O
2 CD CD O
was VBD VBD O
observed VBN VBN O
to TO TO O
be VB VB O
significantly RB RB O
lower JJR JJR O
even RB RB O
after IN IN O
week NN NN O
2 CD CD O
than IN IN O
in IN IN O
patients NNS NNS O
with IN IN O
< NN NN O
2 CD CD O
g SYM SYM O
/ NN NN O
dL NN NN O
decrease NN NN O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
. . . O

A DT DT O
significant JJ JJ O
relationship NN NN O
was VBD VBD O
observed VBN VBN O
between IN IN O
the DT DT O
rate NN NN O
of IN IN O
reduction NN NN O
of IN IN O
hemoglobin NN NN O
concentrations NNS NNS O
at IN IN O
week NN NN O
2 CD CD O
and CC CC O
the DT DT O
severity NN NN O
of IN IN O
anemia NN NN O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
. . . O

Such JJ JJ O
factors NNS NNS O
as IN IN O
sex NN NN O
( ( ( O
female NN NN O
) ) ) O
, , , O
age NN NN O
( ( ( O
> NN NN O
or CC CC O
= SYM SYM O
60 CD CD O
years NNS NNS O
old JJ JJ O
) ) ) O
, , , O
and CC CC O
the DT DT O
ribavirin NN NN B-CHEM
dose NN NN O
by IN IN O
body NN NN O
weight NN NN O
( ( ( O
12 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
or CC CC O
more JJR JJR O
) ) ) O
were VBD VBD O
significant JJ JJ O
by IN IN O
univariate JJ JJ O
analysis NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Careful NNP NNP O
administration NN NN O
is VBZ VBZ O
necessary JJ JJ O
in IN IN O
patients NNS NNS O
> NN NN O
or CC CC O
= SYM SYM O
60 CD CD O
years NNS NNS O
old JJ JJ O
, , , O
in IN IN O
female JJ JJ O
patients NNS NNS O
, , , O
and CC CC O
in IN IN O
patients NNS NNS O
receiving VBG VBG O
a DT DT O
ribavirin NN NN B-CHEM
dose NN NN O
of IN IN O
12 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
or CC CC O
more JJR JJR O
. . . O

Patients NNS NNS O
who WP WP O
experience VBP VBP O
a DT DT O
fall NN NN O
in IN IN O
hemoglobin NN NN O
concentrations NNS NNS O
of IN IN O
2 CD CD O
g SYM SYM O
/ NN NN O
dL NN NN O
or CC CC O
more JJR JJR O
at IN IN O
week NN NN O
2 CD CD O
after IN IN O
the DT DT O
start NN NN O
of IN IN O
treatment NN NN O
should MD MD O
be VB VB O
monitored VBN VBN O
with IN IN O
particular JJ JJ O
care NN NN O
. . . O

Zidovudine NNP NNP B-CHEM
- : : O
induced JJ JJ O
hepatitis NN NN O
. . . O

A DT DT O
case NN NN O
of IN IN O
acute JJ JJ O
hepatitis NN NN O
induced VBN VBN O
by IN IN O
zidovudine NN NN B-CHEM
in IN IN O
a DT DT O
38 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
patient NN NN O
with IN IN O
AIDS NNP NNP O
is VBZ VBZ O
presented VBN VBN O
. . . O

The DT DT O
mechanism NN NN O
whereby NN NN O
the DT DT O
hepatitis NN NN O
was VBD VBD O
induced VBN VBN O
is VBZ VBZ O
not RB RB O
known VBN VBN O
. . . O

However RB RB O
, , , O
the DT DT O
patient NN NN O
tolerated VBD VBD O
well RB RB O
an DT DT O
alternative JJ JJ O
reverse NN NN O
transcriptase NN NN O
inhibitor NN NN O
, , , O
2 CD CD B-CHEM
' POS POS I-CHEM
3 CD CD I-CHEM
' POS POS I-CHEM
dideoxyinosine NN NN I-CHEM
. . . O

Physicians NNP NNP O
caring VBG VBG O
for IN IN O
patients NNS NNS O
with IN IN O
AIDS NNP NNP O
should MD MD O
be VB VB O
aware JJ JJ O
of IN IN O
this DT DT O
hitherto NN NN O
rarely RB RB O
reported VBD VBD O
complication NN NN O
. . . O

Oxidative NNP NNP O
damage NN NN O
precedes NNS NNS O
nitrative JJ JJ O
damage NN NN O
in IN IN O
adriamycin NN NN B-CHEM
- - - O
induced JJ JJ O
cardiac NN NN O
mitochondrial JJ JJ O
injury NN NN O
. . . O

The DT DT O
purpose NN NN O
of IN IN O
the DT DT O
present JJ JJ O
study NN NN O
was VBD VBD O
to TO TO O
determine VB VB O
if IN IN O
elevated VBD VBD O
reactive JJ JJ O
oxygen NN NN B-CHEM
( ( ( O
ROS NNP NNP O
) ) ) O
/ NN NN O
nitrogen NN NN B-CHEM
species NNS NNS O
( ( ( O
RNS NNP NNP O
) ) ) O
reported VBD VBD O
to TO TO O
be VB VB O
present JJ JJ O
in IN IN O
adriamycin NN NN B-CHEM
( ( ( O
ADR NNP NNP B-CHEM
) ) ) O
- : : O
induced JJ JJ O
cardiotoxicity NN NN O
actually RB RB O
resulted VBD VBD O
in IN IN O
cardiomyocyte NN NN O
oxidative JJ JJ O
/ NN NN O
nitrative JJ JJ O
damage NN NN O
, , , O
and CC CC O
to TO TO O
quantitatively RB RB O
determine VB VB O
the DT DT O
time NN NN O
course NN NN O
and CC CC O
subcellular JJ JJ O
localization NN NN O
of IN IN O
these DT DT O
postulated JJ JJ O
damage NN NN O
products NNS NNS O
using VBG VBG O
an DT DT O
in IN IN O
vivo NN NN O
approach NN NN O
. . . O

B6C3 NNP NNP O
mice NNS NNS O
were VBD VBD O
treated VBN VBN O
with IN IN O
a DT DT O
single JJ JJ O
dose NN NN O
of IN IN O
20 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
ADR NNP NNP B-CHEM
. . . O

Ultrastructural NNP NNP O
damage NN NN O
and CC CC O
levels NNS NNS O
of IN IN O
4 CD CD B-CHEM
- : : I-CHEM
hydroxy NN NN I-CHEM
- : : I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
nonenal NN NN I-CHEM
( ( ( O
4HNE CD CD B-CHEM
) ) ) O
- : : O
protein NN NN O
adducts NNS NNS O
and CC CC O
3 CD CD B-CHEM
- : : I-CHEM
nitrotyrosine NN NN I-CHEM
( ( ( O
3NT CD CD B-CHEM
) ) ) O
were VBD VBD O
analyzed VBN VBN O
. . . O

Quantitative NNP NNP O
ultrastructural JJ JJ O
damage NN NN O
using VBG VBG O
computerized JJ JJ O
image NN NN O
techniques NNS NNS O
showed VBD VBD O
cardiomyocyte NN NN O
injury NN NN O
as RB RB O
early JJ JJ O
as IN IN O
3 CD CD O
hours NNS NNS O
, , , O
with IN IN O
mitochondria NN NN O
being VBG VBG O
the DT DT O
most RBS RBS O
extensively RB RB O
and CC CC O
progressively RB RB O
injured VBN VBN O
subcellular NN NN O
organelle NN NN O
. . . O

Analysis NNP NNP O
of IN IN O
4HNE CD CD B-CHEM
protein NN NN O
adducts NNS NNS O
by IN IN O
immunogold JJ JJ O
electron NN NN O
microscopy NN NN O
showed VBD VBD O
appearance NN NN O
of IN IN O
4HNE CD CD B-CHEM
protein NN NN O
adducts NNS NNS O
in IN IN O
mitochondria NN NN O
as RB RB O
early JJ JJ O
as IN IN O
3 CD CD O
hours NNS NNS O
, , , O
with IN IN O
a DT DT O
peak NN NN O
at IN IN O
6 CD CD O
hours NNS NNS O
and CC CC O
subsequent JJ JJ O
decline NN NN O
at IN IN O
24 CD CD O
hours NNS NNS O
. . . O

3NT CD CD B-CHEM
levels NNS NNS O
were VBD VBD O
significantly RB RB O
increased VBN VBN O
in IN IN O
all DT DT O
subcellular JJ JJ O
compartments NNS NNS O
at IN IN O
6 CD CD O
hours NNS NNS O
and CC CC O
subsequently RB RB O
declined VBD VBD O
at IN IN O
24 CD CD O
hours NNS NNS O
. . . O

Our PRP$ PRP$ O
data NNS NNS O
showed VBD VBD O
ADR NNP NNP B-CHEM
induced VBD VBD O
4HNE CD CD B-CHEM
- : : O
protein NN NN O
adducts NNS NNS O
in IN IN O
mitochondria NN NN O
at IN IN O
the DT DT O
same JJ JJ O
time NN NN O
point NN NN O
as IN IN O
when WRB WRB O
mitochondrial JJ JJ O
injury NN NN O
initially RB RB O
appeared VBD VBD O
. . . O

These DT DT O
results NNS NNS O
document NN NN O
for IN IN O
the DT DT O
first JJ JJ O
time NN NN O
in IN IN O
vivo NN NN O
that IN IN O
mitochondrial JJ JJ O
oxidative JJ JJ O
damage NN NN O
precedes NNS NNS O
nitrative JJ JJ O
damage NN NN O
. . . O

The DT DT O
progressive JJ JJ O
nature NN NN O
of IN IN O
mitochondrial JJ JJ O
injury NN NN O
suggests VBZ VBZ O
that IN IN O
mitochondria NN NN O
, , , O
not RB RB O
other JJ JJ O
subcellular JJ JJ O
organelles NNS NNS O
, , , O
are VBP VBP O
the DT DT O
major JJ JJ O
site NN NN O
of IN IN O
intracellular JJ JJ O
injury NN NN O
. . . O

Sotalol NNP NNP B-CHEM
- : : O
induced JJ JJ O
coronary JJ JJ O
spasm NN NN O
in IN IN O
a DT DT O
patient NN NN O
with IN IN O
dilated JJ JJ O
cardiomyopathy NN NN O
associated VBN VBN O
with IN IN O
sustained JJ JJ O
ventricular NN NN O
tachycardia NNS NNS O
. . . O

A DT DT O
54 JJ JJ O
- - - O
year NN NN O
- - - O
old JJ JJ O
man NN NN O
with IN IN O
severe JJ JJ O
left VBD VBD O
ventricular NN NN O
dysfunction NN NN O
due JJ JJ O
to TO TO O
dilated VBN VBN O
cardiomyopathy NN NN O
was VBD VBD O
referred VBN VBN O
to TO TO O
our PRP$ PRP$ O
hospital NN NN O
for IN IN O
symptomatic JJ JJ O
incessant NN NN O
sustained VBD VBD O
ventricular JJ JJ O
tachycardia NNS NNS O
( ( ( O
VT NNP NNP O
) ) ) O
. . . O

After IN IN O
the DT DT O
administration NN NN O
of IN IN O
nifekalant NN NN B-CHEM
hydrochloride NN NN I-CHEM
, , , O
sustained VBD VBD O
VT NNP NNP O
was VBD VBD O
terminated VBN VBN O
. . . O

An DT DT O
alternate JJ JJ O
class NN NN O
III NNP NNP O
agent NN NN O
, , , O
sotalol NN NN B-CHEM
, , , O
was VBD VBD O
also RB RB O
effective JJ JJ O
for IN IN O
the DT DT O
prevention NN NN O
of IN IN O
VT NNP NNP O
. . . O

However RB RB O
, , , O
one CD CD O
month NN NN O
after IN IN O
switching VBG VBG O
over IN IN O
nifekalant NN NN B-CHEM
to TO TO O
sotalol VB VB B-CHEM
, , , O
a DT DT O
short JJ JJ O
duration NN NN O
of IN IN O
ST NNP NNP O
elevation NN NN O
was VBD VBD O
documented VBN VBN O
in IN IN O
ECG NNP NNP O
monitoring VBG VBG O
at IN IN O
almost RB RB O
the DT DT O
same JJ JJ O
time NN NN O
for IN IN O
three CD CD O
consecutive JJ JJ O
days NNS NNS O
. . . O

ST NNP NNP O
elevation NN NN O
with IN IN O
chest NN NN O
discomfort NN NN O
disappeared VBD VBD O
since IN IN O
he PRP PRP O
began VBD VBD O
taking VBG VBG O
long JJ JJ O
- - - O
acting VBG VBG O
diltiazem NN NN B-CHEM
. . . O

Coronary JJ JJ O
vasospasm NN NN O
may MD MD O
be VB VB O
induced VBN VBN O
by IN IN O
the DT DT O
non NN NN O
- - - O
selective JJ JJ O
beta NN NN O
- - - O
blocking VBG VBG O
properties NNS NNS O
of IN IN O
sotalol NN NN B-CHEM
. . . O

Effects NNP NNP O
of IN IN O
the DT DT O
antidepressant NN NN O
trazodone NN NN B-CHEM
, , , O
a DT DT O
5 CD CD B-CHEM
- : : I-CHEM
HT NNP NNP I-CHEM
2A CD CD O
/ NN NN O
2C CD CD O
receptor NN NN O
antagonist NN NN O
, , , O
on IN IN O
dopamine NN NN B-CHEM
- : : O
dependent JJ JJ O
behaviors NNS NNS O
in IN IN O
rats NNS NNS O
. . . O

RATIONALE NNP NNP O
: : : O
5 CD CD B-CHEM
- : : I-CHEM
Hydroxytryptamine NNP NNP I-CHEM
, , , O
via IN IN O
stimulation NN NN O
of IN IN O
5 CD CD B-CHEM
- : : I-CHEM
HT NNP NNP I-CHEM
2C CD CD O
receptors NNS NNS O
, , , O
exerts VBZ VBZ O
a DT DT O
tonic NN NN O
inhibitory JJ JJ O
influence NN NN O
on IN IN O
dopaminergic JJ JJ O
neurotransmission NN NN O
, , , O
whereas IN IN O
activation NN NN O
of IN IN O
5 CD CD B-CHEM
- : : I-CHEM
HT NNP NNP I-CHEM
2A CD CD O
receptors NNS NNS O
enhances NNS NNS O
stimulated VBN VBN O
DAergic NNP NNP O
neurotransmission NN NN O
. . . O

The DT DT O
antidepressant NN NN O
trazodone NN NN B-CHEM
is VBZ VBZ O
a DT DT O
5 CD CD B-CHEM
- : : I-CHEM
HT NNP NNP I-CHEM
2A CD CD O
/ NN NN O
2C CD CD O
receptor NN NN O
antagonist NN NN O
. . . O

OBJECTIVES NNP NNP O
: : : O
To TO TO O
evaluate VB VB O
the DT DT O
effect NN NN O
of IN IN O
trazodone NN NN B-CHEM
treatment NN NN O
on IN IN O
behaviors NNS NNS O
dependent JJ JJ O
on IN IN O
the DT DT O
functional JJ JJ O
status NN NN O
of IN IN O
the DT DT O
nigrostriatal JJ JJ O
DAergic NNP NNP O
system NN NN O
. . . O

METHODS NNP NNP O
: : : O
The DT DT O
effect NN NN O
of IN IN O
pretreatment NN NN O
with IN IN O
trazodone NN NN B-CHEM
on IN IN O
dexamphetamine NN NN B-CHEM
- : : O
and CC CC O
apomorphine JJ JJ B-CHEM
- - - O
induced JJ JJ O
oral JJ JJ O
stereotypies NNS NNS O
, , , O
on IN IN O
catalepsy NN NN O
induced VBN VBN O
by IN IN O
haloperidol NN NN B-CHEM
and CC CC O
apomorphine NN NN B-CHEM
( ( ( O
0 CD CD O
. . . O
05 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
, , , O
on IN IN O
ergometrine NN NN B-CHEM
- : : O
induced JJ JJ O
wet JJ JJ O
dog NN NN O
shake NN NN O
( ( ( O
WDS NNP NNP O
) ) ) O
behavior NN NN O
and CC CC O
fluoxetine NN NN B-CHEM
- - - O
induced JJ JJ O
penile NN NN O
erections NNS NNS O
was VBD VBD O
studied VBN VBN O
in IN IN O
rats NNS NNS O
. . . O

We PRP PRP O
also RB RB O
investigated VBD VBD O
whether IN IN O
trazodone NN NN B-CHEM
induces NNS NNS O
catalepsy NN NN O
in IN IN O
rats NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
Trazodone NNP NNP B-CHEM
at IN IN O
2 CD CD O
. . . O
5 CD CD O
- : : O
20 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
p NN NN O
. . . O
did VBD VBD O
not RB RB O
induce VB VB O
catalepsy NN NN O
, , , O
and CC CC O
did VBD VBD O
not RB RB O
antagonize VB VB O
apomorphine NN NN B-CHEM
( ( ( O
1 CD CD O
. . . O
5 CD CD O
and CC CC O
3 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
stereotypy NN NN O
and CC CC O
apomorphine NN NN B-CHEM
( ( ( O
0 CD CD O
. . . O
05 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
- : : O
induced JJ JJ O
catalepsy NN NN O
. . . O

However RB RB O
, , , O
pretreatment NN NN O
with IN IN O
5 CD CD O
, , , O
10 CD CD O
and CC CC O
20 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
p NN NN O
. . . O
trazodone NN NN B-CHEM
enhanced VBD VBD O
dexamphetamine NN NN B-CHEM
stereotypy NN NN O
, , , O
and CC CC O
antagonized VBD VBD O
haloperidol NN NN B-CHEM
catalepsy NN NN O
, , , O
ergometrine NN NN B-CHEM
- - - O
induced JJ JJ O
WDS NNP NNP O
behavior NN NN O
and CC CC O
fluoxetine NN NN B-CHEM
- - - O
induced JJ JJ O
penile NN NN O
erections NNS NNS O
. . . O

Trazodone NNP NNP B-CHEM
at IN IN O
30 CD CD O
, , , O
40 CD CD O
and CC CC O
50 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
p NN NN O
. . . O
induced VBN VBN O
catalepsy NN NN O
and CC CC O
antagonized JJ JJ O
apomorphine NN NN B-CHEM
and CC CC O
dexamphetamine NN NN B-CHEM
stereotypies NNS NNS O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Our PRP$ PRP$ O
results NNS NNS O
indicate VBP VBP O
that DT DT O
trazodone NN NN B-CHEM
at IN IN O
2 CD CD O
. . . O
5 CD CD O
- : : O
20 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
does VBZ VBZ O
not RB RB O
block VB VB O
pre NN NN O
- : : O
and CC CC O
postsynaptic JJ JJ O
striatal NN NN O
D2 NN NN O
DA NNP NNP O
receptors NNS NNS O
, , , O
while IN IN O
at IN IN O
30 CD CD O
, , , O
40 CD CD O
and CC CC O
50 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
it PRP PRP O
blocks VBZ VBZ O
postsynaptic JJ JJ O
striatal NN NN O
D2 NN NN O
DA NNP NNP O
receptors NNS NNS O
. . . O

Furthermore RB RB O
, , , O
at IN IN O
5 CD CD O
, , , O
10 CD CD O
and CC CC O
20 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
trazodone NN NN B-CHEM
blocks NNS NNS O
5 CD CD B-CHEM
- : : I-CHEM
HT NNP NNP I-CHEM
2A CD CD O
and CC CC O
5 CD CD B-CHEM
- : : I-CHEM
HT NNP NNP I-CHEM
2C CD CD O
receptors NNS NNS O
. . . O

We PRP PRP O
suggest VBP VBP O
that IN IN O
trazodone NN NN B-CHEM
( ( ( O
5 CD CD O
, , , O
10 CD CD O
and CC CC O
20 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
, , , O
by IN IN O
blocking VBG VBG O
the DT DT O
5 CD CD B-CHEM
- : : I-CHEM
HT NNP NNP I-CHEM
2C CD CD O
receptors NNS NNS O
, , , O
releases VBZ VBZ O
the DT DT O
nigrostriatal JJ JJ O
DAergic NNP NNP O
neurons NNS NNS O
from IN IN O
tonic JJ JJ O
inhibition NN NN O
caused VBN VBN O
by IN IN O
5 CD CD B-CHEM
- : : I-CHEM
HT NNP NNP I-CHEM
, , , O
and CC CC O
thereby RB RB O
potentiates NNS NNS O
dexamphetamine NN NN B-CHEM
stereotypy NN NN O
and CC CC O
antagonizes NNS NNS O
haloperidol NN NN B-CHEM
catalepsy NN NN O
. . . O

Swallowing NNP NNP O
abnormalities NNS NNS O
and CC CC O
dyskinesia NN NN O
in IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
. . . O

Gastrointestinal NNP NNP O
abnormalities NNS NNS O
in IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
( ( ( O
PD NNP NNP O
) ) ) O
have VBP VBP O
been VBN VBN O
known VBN VBN O
for IN IN O
almost RB RB O
two CD CD O
centuries NNS NNS O
, , , O
but CC CC O
many JJ JJ O
aspects NNS NNS O
concerning VBG VBG O
their PRP$ PRP$ O
pathophysiology NN NN O
have VBP VBP O
not RB RB O
been VBN VBN O
completely RB RB O
clarified VBN VBN O
. . . O

The DT DT O
aim NN NN O
of IN IN O
this DT DT O
study NN NN O
was VBD VBD O
to TO TO O
characterize VB VB O
the DT DT O
oropharyngeal NN NN O
dynamics NNS NNS O
in IN IN O
PD NNP NNP O
patients NNS NNS O
with IN IN O
and CC CC O
without IN IN O
levodopa NN NN B-CHEM
- - - O
induced JJ JJ O
dyskinesia NN NN O
. . . O

Fifteen NNP NNP O
dyskinetic JJ JJ O
, , , O
12 CD CD O
nondyskinetic JJ JJ O
patients NNS NNS O
, , , O
and CC CC O
a DT DT O
control NN NN O
group NN NN O
were VBD VBD O
included VBN VBN O
. . . O

Patients NNS NNS O
were VBD VBD O
asked VBN VBN O
about IN IN O
dysphagia NN NN O
and CC CC O
evaluated VBN VBN O
with IN IN O
the DT DT O
Unified NNP NNP O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
Disease NNP NNP O
Rating NNP NNP O
Scale NNP NNP O
Parts NNS NNS O
II NNP NNP O
and CC CC O
III NNP NNP O
and CC CC O
the DT DT O
Hoehn NNP NNP O
and CC CC O
Yahr NNP NNP O
scale NN NN O
. . . O

Deglutition NNP NNP O
was VBD VBD O
assessed VBN VBN O
using VBG VBG O
modified VBN VBN O
barium NN NN B-CHEM
swallow NN NN O
with IN IN O
videofluoroscopy NN NN O
. . . O

Nondyskinetic NNP NNP O
patients NNS NNS O
, , , O
but CC CC O
not RB RB O
the DT DT O
dyskinetic JJ JJ O
ones NNS NNS O
, , , O
showed VBD VBD O
less JJR JJR O
oropharyngeal JJ JJ O
swallowing VBG VBG O
efficiency NN NN O
( ( ( O
OPSE NNP NNP O
) ) ) O
for IN IN O
liquid JJ JJ O
food NN NN O
than IN IN O
controls NNS NNS O
( ( ( O
Dunnett NNP NNP O
, , , O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
02 CD CD O
) ) ) O
. . . O

Dyskinetic NNP NNP O
patients NNS NNS O
tended VBD VBD O
to TO TO O
have VB VB O
a DT DT O
greater JJR JJR O
OPSE NNP NNP O
than IN IN O
nondyskinetic JJ JJ O
( ( ( O
Dunnett NNP NNP O
, , , O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
06 CD CD O
) ) ) O
. . . O

Patients NNS NNS O
who WP WP O
were VBD VBD O
using VBG VBG O
a DT DT O
higher JJR JJR O
dose NN NN O
of IN IN O
levodopa NN NN B-CHEM
had VBD VBD O
a DT DT O
greater JJR JJR O
OPSE NNP NNP O
and CC CC O
a DT DT O
trend NN NN O
toward IN IN O
a DT DT O
smaller JJR JJR O
oral JJ JJ O
transit NN NN O
time NN NN O
( ( ( O
Pearson NNP NNP O
' POS POS O
s VBZ VBZ O
correlation NN NN O
, , , O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
01 CD CD O
and CC CC O
0 CD CD O
. . . O
08 CD CD O
, , , O
respectively RB RB O
) ) ) O
. . . O

Neither DT DT O
the DT DT O
report NN NN O
of IN IN O
dysphagia NN NN O
nor CC CC O
any DT DT O
of IN IN O
the DT DT O
PD NNP NNP O
severity NN NN O
parameters NNS NNS O
correlated JJ JJ O
to TO TO O
the DT DT O
videofluoroscopic NN NN O
variables NNS NNS O
. . . O

In IN IN O
the DT DT O
current JJ JJ O
study NN NN O
, , , O
dyskinetic JJ JJ O
patients NNS NNS O
performed VBN VBN O
better JJR JJR O
in IN IN O
swallowing VBG VBG O
function NN NN O
, , , O
which WDT WDT O
could MD MD O
be VB VB O
explained VBN VBN O
on IN IN O
the DT DT O
basis NN NN O
of IN IN O
a DT DT O
greater JJR JJR O
levodopa NN NN B-CHEM
dose NN NN O
. . . O

Our PRP$ PRP$ O
results NNS NNS O
suggest VBP VBP O
a DT DT O
role NN NN O
for IN IN O
levodopa NN NN B-CHEM
in IN IN O
the DT DT O
oral JJ JJ O
phase NN NN O
of IN IN O
deglutition NN NN O
and CC CC O
confirm NN NN O
that DT DT O
dysphagia NN NN O
is VBZ VBZ O
not RB RB O
a DT DT O
good JJ JJ O
predictor NN NN O
of IN IN O
deglutition NN NN O
alterations NNS NNS O
in IN IN O
PD NNP NNP O
. . . O

Inhibition NNP NNP O
of IN IN O
nuclear NN NN O
factor NN NN O
- : : O
kappaB NN NN O
activation NN NN O
attenuates NNS NNS O
tubulointerstitial JJ JJ O
nephritis NN NN O
induced VBN VBN O
by IN IN O
gentamicin NN NN B-CHEM
. . . O

BACKGROUND NNP NNP O
: : : O
Animals NNS NNS O
treated VBN VBN O
with IN IN O
gentamicin NN NN B-CHEM
can MD MD O
show VB VB O
residual JJ JJ O
areas NNS NNS O
of IN IN O
interstitial JJ JJ O
fibrosis NNS NNS O
in IN IN O
the DT DT O
renal NN NN O
cortex NN NN O
. . . O

This DT DT O
study NN NN O
investigated VBD VBD O
the DT DT O
expression NN NN O
of IN IN O
nuclear NN NN O
factor NN NN O
- : : O
kappaB NN NN O
( ( ( O
NF NNP NNP O
- - - O
kappaB NN NN O
) ) ) O
, , , O
mitogen NN NN O
- - - O
activated JJ JJ O
protein NN NN O
( ( ( O
MAP NNP NNP O
) ) ) O
kinases NNS NNS O
and CC CC O
macrophages NNS NNS O
in IN IN O
the DT DT O
renal NN NN O
cortex NN NN O
and CC CC O
structural JJ JJ O
and CC CC O
functional JJ JJ O
renal JJ JJ O
changes NNS NNS O
of IN IN O
rats NNS NNS O
treated VBN VBN O
with IN IN O
gentamicin NN NN B-CHEM
or CC CC O
gentamicin NN NN B-CHEM
+ NN NN O
pyrrolidine NN NN B-CHEM
dithiocarbamate NN NN I-CHEM
( ( ( O
PDTC NNP NNP B-CHEM
) ) ) O
, , , O
an DT DT O
NF NNP NNP O
- - - O
kappaB NN NN O
inhibitor NN NN O
. . . O

METHODS NNP NNP O
: : : O
38 CD CD O
female JJ JJ O
Wistar NNP NNP O
rats NNS NNS O
were VBD VBD O
injected VBN VBN O
with IN IN O
gentamicin NN NN B-CHEM
, , , O
40 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
twice RB RB O
a DT DT O
day NN NN O
for IN IN O
9 CD CD O
days NNS NNS O
, , , O
38 CD CD O
with IN IN O
gentamicin NN NN B-CHEM
+ NN NN O
PDTC NNP NNP B-CHEM
, , , O
and CC CC O
28 CD CD O
with IN IN O
0 CD CD O
. . . O
15 CD CD O
M NNP NNP O
NaCl NNP NNP B-CHEM
solution NN NN O
. . . O

The DT DT O
animals NNS NNS O
were VBD VBD O
killed VBN VBN O
5 CD CD O
and CC CC O
30 CD CD O
days NNS NNS O
after IN IN O
these DT DT O
injections NNS NNS O
and CC CC O
the DT DT O
kidneys NNS NNS O
were VBD VBD O
removed VBN VBN O
for IN IN O
histological JJ JJ O
and CC CC O
immunohistochemical JJ JJ O
studies NNS NNS O
. . . O

The DT DT O
results NNS NNS O
of IN IN O
the DT DT O
immunohistochemical JJ JJ O
studies NNS NNS O
were VBD VBD O
scored VBN VBN O
according VBG VBG O
to TO TO O
the DT DT O
extent NN NN O
of IN IN O
staining VBG VBG O
. . . O

The DT DT O
fractional JJ JJ O
interstitial JJ JJ O
area NN NN O
was VBD VBD O
determined VBN VBN O
by IN IN O
morphometry NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Gentamicin NNP NNP B-CHEM
- - - O
treated JJ JJ O
rats NNS NNS O
presented VBD VBD O
a DT DT O
transitory JJ JJ O
increase NN NN O
in IN IN O
plasma NN NN O
creatinine NN NN B-CHEM
levels NNS NNS O
. . . O

Increased VBN VBN O
ED NNP NNP O
- : : O
1 CD CD O
, , , O
MAP NNP NNP O
kinases NNS NNS O
and CC CC O
NF NNP NNP O
- : : O
kappaB NN NN O
staining VBG VBG O
were VBD VBD O
also RB RB O
observed VBN VBN O
in IN IN O
the DT DT O
renal NN NN O
cortex NN NN O
from IN IN O
all DT DT O
gentamicin NN NN B-CHEM
- - - O
treated VBN VBN O
rats NNS NNS O
compared VBN VBN O
to TO TO O
control VB VB O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

The DT DT O
animals NNS NNS O
killed VBN VBN O
on IN IN O
day NN NN O
30 CD CD O
also RB RB O
presented VBN VBN O
fibrosis NNS NNS O
in IN IN O
the DT DT O
renal NN NN O
cortex NN NN O
despite IN IN O
the DT DT O
recovery NN NN O
of IN IN O
renal JJ JJ O
function NN NN O
. . . O

Treatment NN NN O
with IN IN O
PDTC NNP NNP B-CHEM
reduced VBD VBD O
the DT DT O
functional JJ JJ O
and CC CC O
structural JJ JJ O
changes NNS NNS O
induced VBN VBN O
by IN IN O
gentamicin NN NN B-CHEM
. . . O

CONCLUSIONS NNP NNP O
: : : O
These DT DT O
data NNS NNS O
show VBP VBP O
that DT DT O
inhibition NN NN O
of IN IN O
NF NNP NNP O
- : : O
kappaB NN NN O
activation NN NN O
attenuates NNS NNS O
tubulointerstitial JJ JJ O
nephritis NN NN O
induced VBN VBN O
by IN IN O
gentamicin NN NN B-CHEM
. . . O

Glucose NNP NNP B-CHEM
metabolism NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
schizophrenia NN NN O
treated VBN VBN O
with IN IN O
atypical JJ JJ O
antipsychotic JJ JJ O
agents NNS NNS O
: : : O
a DT DT O
frequently RB RB O
sampled VBN VBN O
intravenous JJ JJ O
glucose NN NN B-CHEM
tolerance NN NN O
test NN NN O
and CC CC O
minimal JJ JJ O
model NN NN O
analysis NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
While IN IN O
the DT DT O
incidence NN NN O
of IN IN O
new JJ JJ O
- - - O
onset NN NN O
diabetes NN NN O
mellitus NN NN O
may MD MD O
be VB VB O
increasing VBG VBG O
in IN IN O
patients NNS NNS O
with IN IN O
schizophrenia NN NN O
treated VBN VBN O
with IN IN O
certain JJ JJ O
atypical JJ JJ O
antipsychotic JJ JJ O
agents NNS NNS O
, , , O
it PRP PRP O
remains VBZ VBZ O
unclear JJ JJ O
whether IN IN O
atypical JJ JJ O
agents NNS NNS O
are VBP VBP O
directly RB RB O
affecting VBG VBG O
glucose NN NN B-CHEM
metabolism NN NN O
or CC CC O
simply RB RB O
increasing VBG VBG O
known VBN VBN O
risk NN NN O
factors NNS NNS O
for IN IN O
diabetes NN NN O
. . . O

OBJECTIVE NNP NNP O
: : : O
To TO TO O
study VB VB O
the DT DT O
2 CD CD O
drugs NNS NNS O
most JJS JJS O
clearly RB RB O
implicated VBN VBN O
( ( ( O
clozapine NN NN B-CHEM
and CC CC O
olanzapine NN NN B-CHEM
) ) ) O
and CC CC O
risperidone NN NN B-CHEM
using VBG VBG O
a DT DT O
frequently RB RB O
sampled VBN VBN O
intravenous JJ JJ O
glucose NN NN B-CHEM
tolerance NN NN O
test NN NN O
. . . O

DESIGN NNP NNP O
: : : O
A DT DT O
cross JJ JJ O
- - - O
sectional JJ JJ O
design NN NN O
in IN IN O
stable JJ JJ O
, , , O
treated VBN VBN O
patients NNS NNS O
with IN IN O
schizophrenia NN NN O
evaluated VBD VBD O
using VBG VBG O
a DT DT O
frequently RB RB O
sampled VBN VBN O
intravenous JJ JJ O
glucose NN NN B-CHEM
tolerance NN NN O
test NN NN O
and CC CC O
the DT DT O
Bergman NNP NNP O
minimal JJ JJ O
model NN NN O
analysis NN NN O
. . . O

SETTING NNP NNP O
: : : O
Subjects NNP NNP O
were VBD VBD O
recruited VBN VBN O
from IN IN O
an DT DT O
urban JJ JJ O
community NN NN O
mental JJ JJ O
health NN NN O
clinic NN NN O
and CC CC O
were VBD VBD O
studied VBN VBN O
at IN IN O
a DT DT O
general JJ JJ O
clinical JJ JJ O
research NN NN O
center NN NN O
. . . O

Patients NNS NNS O
Fifty NNP NNP O
subjects NNS NNS O
signed VBN VBN O
informed JJ JJ O
consent NN NN O
and CC CC O
41 CD CD O
underwent NN NN O
the DT DT O
frequently RB RB O
sampled VBN VBN O
intravenous JJ JJ O
glucose NN NN B-CHEM
tolerance NN NN O
test NN NN O
. . . O

Thirty NNP NNP O
- : : O
six CD CD O
nonobese JJ JJ O
subjects NNS NNS O
with IN IN O
schizophrenia NN NN O
or CC CC O
schizoaffective JJ JJ O
disorder NN NN O
, , , O
matched VBN VBN O
by IN IN O
body NN NN O
mass NN NN O
index NN NN O
and CC CC O
treated VBN VBN O
with IN IN O
either DT DT O
clozapine NN NN B-CHEM
, , , O
olanzapine NN NN B-CHEM
, , , O
or CC CC O
risperidone NN NN B-CHEM
, , , O
were VBD VBD O
included VBN VBN O
in IN IN O
the DT DT O
analysis NN NN O
. . . O

MAIN NNP NNP O
OUTCOME NNP NNP O
MEASURES NNS NNS O
: : : O
Fasting NNP NNP O
plasma NN NN O
glucose NN NN B-CHEM
and CC CC O
fasting VBG VBG O
serum NN NN O
insulin NN NN O
levels NNS NNS O
, , , O
insulin NN NN O
sensitivity NN NN O
index NN NN O
, , , O
homeostasis NN NN O
model NN NN O
assessment NN NN O
of IN IN O
insulin NN NN O
resistance NN NN O
, , , O
and CC CC O
glucose NN NN B-CHEM
effectiveness NN NN O
. . . O

RESULTS NNS NNS O
: : : O
The DT DT O
mean NN NN O
+ NN NN O
/ NN NN O
- : : O
SD NNP NNP O
duration NN NN O
of IN IN O
treatment NN NN O
with IN IN O
the DT DT O
identified JJ JJ O
atypical JJ JJ O
antipsychotic JJ JJ O
agent NN NN O
was VBD VBD O
68 CD CD O
. . . O
3 CD CD O
+ NN NN O
/ NN NN O
- : : O
28 CD CD O
. . . O
9 CD CD O
months NNS NNS O
( ( ( O
clozapine NN NN B-CHEM
) ) ) O
, , , O
29 CD CD O
. . . O
5 CD CD O
+ NN NN O
/ NN NN O
- : : O
17 CD CD O
. . . O
5 CD CD O
months NNS NNS O
( ( ( O
olanzapine NN NN B-CHEM
) ) ) O
, , , O
and CC CC O
40 CD CD O
. . . O
9 CD CD O
+ NN NN O
/ NN NN O
- : : O
33 CD CD O
. . . O
7 CD CD O
( ( ( O
risperidone NN NN B-CHEM
) ) ) O
. . . O

Fasting NNP NNP O
serum NN NN O
insulin NN NN O
concentrations NNS NNS O
differed VBD VBD O
among IN IN O
groups NNS NNS O
( ( ( O
F NN NN O
( ( ( O
33 CD CD O
) ) ) O
= SYM SYM O
3 CD CD O
. . . O
35 CD CD O
; : : O
P NN NN O
= SYM SYM O
. . . O
047 CD CD O
) ) ) O
( ( ( O
clozapine NN NN B-CHEM
> NN NN O
olanzapine NN NN B-CHEM
> NN NN O
risperidone NN NN B-CHEM
) ) ) O
with IN IN O
significant JJ JJ O
differences NNS NNS O
between IN IN O
clozapine NN NN B-CHEM
and CC CC O
risperidone NN NN B-CHEM
( ( ( O
t NN NN O
( ( ( O
33 CD CD O
) ) ) O
= SYM SYM O
2 CD CD O
. . . O
32 CD CD O
; : : O
P NN NN O
= SYM SYM O
. . . O
03 CD CD O
) ) ) O
and CC CC O
olanzapine NN NN B-CHEM
and CC CC O
risperidone NN NN B-CHEM
( ( ( O
t NN NN O
( ( ( O
33 CD CD O
) ) ) O
= SYM SYM O
2 CD CD O
. . . O
15 CD CD O
; : : O
P NN NN O
= SYM SYM O
. . . O
04 CD CD O
) ) ) O
. . . O

There EX EX O
was VBD VBD O
a DT DT O
significant JJ JJ O
difference NN NN O
in IN IN O
insulin NN NN O
sensitivity NN NN O
index NN NN O
among IN IN O
groups NNS NNS O
( ( ( O
F NN NN O
( ( ( O
33 CD CD O
) ) ) O
= SYM SYM O
10 CD CD O
. . . O
66 CD CD O
; : : O
P NN NN O
< NN NN O
. . . O
001 CD CD O
) ) ) O
( ( ( O
clozapine NN NN B-CHEM
< NN NN O
olanzapine NN NN B-CHEM
< NN NN O
risperidone NN NN B-CHEM
) ) ) O
, , , O
with IN IN O
subjects NNS NNS O
who WP WP O
received VBD VBD O
clozapine NN NN B-CHEM
and CC CC O
olanzapine NN NN B-CHEM
exhibiting VBG VBG O
significant JJ JJ O
insulin NN NN O
resistance NN NN O
compared VBN VBN O
with IN IN O
subjects NNS NNS O
who WP WP O
were VBD VBD O
treated VBN VBN O
with IN IN O
risperidone NN NN B-CHEM
( ( ( O
clozapine NN NN B-CHEM
vs NNS NNS O
risperidone NN NN B-CHEM
, , , O
t NN NN O
( ( ( O
33 CD CD O
) ) ) O
= SYM SYM O
- : : O
4 CD CD O
. . . O
29 CD CD O
; : : O
P NN NN O
< NN NN O
. . . O
001 CD CD O
; : : O
olanzapine NN NN B-CHEM
vs NNS NNS O
risperidone NN NN B-CHEM
, , , O
t NN NN O
( ( ( O
33 CD CD O
) ) ) O
= SYM SYM O
- : : O
3 CD CD O
. . . O
62 CD CD O
; : : O
P NN NN O
= SYM SYM O
. . . O
001 CD CD O
[ NN NN O
P NN NN O
< NN NN O
. . . O
001 CD CD O
] NN NN O
) ) ) O
. . . O

The DT DT O
homeostasis NN NN O
model NN NN O
assessment NN NN O
of IN IN O
insulin NN NN O
resistance NN NN O
also RB RB O
differed VBD VBD O
significantly RB RB O
among IN IN O
groups NNS NNS O
( ( ( O
F NN NN O
( ( ( O
33 CD CD O
) ) ) O
= SYM SYM O
4 CD CD O
. . . O
92 CD CD O
; : : O
P NN NN O
= SYM SYM O
. . . O
01 CD CD O
) ) ) O
( ( ( O
clozapine NN NN B-CHEM
> NN NN O
olanzapine NN NN B-CHEM
> NN NN O
risperidone NN NN B-CHEM
) ) ) O
( ( ( O
clozapine NN NN B-CHEM
vs NNS NNS O
risperidone NN NN B-CHEM
, , , O
t NN NN O
( ( ( O
33 CD CD O
) ) ) O
= SYM SYM O
2 CD CD O
. . . O
94 CD CD O
; : : O
P NN NN O
= SYM SYM O
. . . O
006 CD CD O
; : : O
olanzapine NN NN B-CHEM
vs NNS NNS O
risperidone NN NN B-CHEM
, , , O
t NN NN O
( ( ( O
33 CD CD O
) ) ) O
= SYM SYM O
2 CD CD O
. . . O
42 CD CD O
; : : O
P NN NN O
= SYM SYM O
. . . O
02 CD CD O
) ) ) O
. . . O

There EX EX O
was VBD VBD O
a DT DT O
significant JJ JJ O
difference NN NN O
among IN IN O
groups NNS NNS O
in IN IN O
glucose NN NN B-CHEM
effectiveness NN NN O
( ( ( O
F NN NN O
( ( ( O
30 CD CD O
) ) ) O
= SYM SYM O
4 CD CD O
. . . O
18 CD CD O
; : : O
P NN NN O
= SYM SYM O
. . . O
02 CD CD O
) ) ) O
( ( ( O
clozapine NN NN B-CHEM
< NN NN O
olanzapine NN NN B-CHEM
< NN NN O
risperidone NN NN B-CHEM
) ) ) O
with IN IN O
significant JJ JJ O
differences NNS NNS O
between IN IN O
clozapine NN NN B-CHEM
and CC CC O
risperidone NN NN B-CHEM
( ( ( O
t NN NN O
( ( ( O
30 CD CD O
) ) ) O
= SYM SYM O
- : : O
2 CD CD O
. . . O
59 CD CD O
; : : O
P NN NN O
= SYM SYM O
. . . O
02 CD CD O
) ) ) O
and CC CC O
olanzapine NN NN B-CHEM
and CC CC O
risperidone NN NN B-CHEM
( ( ( O
t NN NN O
( ( ( O
30 CD CD O
) ) ) O
= SYM SYM O
- : : O
2 CD CD O
. . . O
34 CD CD O
, , , O
P NN NN O
= SYM SYM O
. . . O
03 CD CD O
) ) ) O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Both DT DT O
nonobese NN NN O
clozapine NN NN B-CHEM
- : : O
and CC CC O
olanzapine JJ JJ B-CHEM
- - - O
treated JJ JJ O
groups NNS NNS O
displayed VBD VBD O
significant JJ JJ O
insulin NN NN O
resistance NN NN O
and CC CC O
impairment NN NN O
of IN IN O
glucose NN NN B-CHEM
effectiveness NN NN O
compared VBN VBN O
with IN IN O
risperidone NN NN B-CHEM
- - - O
treated JJ JJ O
subjects NNS NNS O
. . . O

Patients NNS NNS O
taking VBG VBG O
clozapine NN NN B-CHEM
and CC CC O
olanzapine NN NN B-CHEM
must MD MD O
be VB VB O
examined VBN VBN O
for IN IN O
insulin NN NN O
resistance NN NN O
and CC CC O
its PRP$ PRP$ O
consequences NNS NNS O
. . . O

Thoracic NNP NNP O
hematomyelia NN NN O
secondary JJ JJ O
to TO TO O
coumadin VB VB B-CHEM
anticoagulant NN NN O
therapy NN NN O
: : : O
a DT DT O
case NN NN O
report NN NN O
. . . O

A DT DT O
case NN NN O
of IN IN O
thoracic NN NN O
hematomyelia NN NN O
secondary JJ JJ O
to TO TO O
anticoagulant VB VB O
therapy NN NN O
is VBZ VBZ O
presented VBN VBN O
. . . O

Clinical NNP NNP O
features NNS NNS O
, , , O
similar JJ JJ O
to TO TO O
2 CD CD O
other JJ JJ O
previously RB RB O
reported VBD VBD O
cases NNS NNS O
, , , O
are VBP VBP O
discussed VBN VBN O
. . . O

A DT DT O
high JJ JJ O
index NN NN O
of IN IN O
suspicion NN NN O
may MD MD O
lead VB VB O
to TO TO O
a DT DT O
quick JJ JJ O
diagnostic JJ JJ O
procedure NN NN O
and CC CC O
successful JJ JJ O
decompressive JJ JJ O
surgery NN NN O
. . . O

Mania NNP NNP O
associated VBN VBN O
with IN IN O
fluoxetine NN NN B-CHEM
treatment NN NN O
in IN IN O
adolescents NNS NNS O
. . . O

Fluoxetine NNP NNP B-CHEM
, , , O
a DT DT O
selective JJ JJ O
serotonin NN NN B-CHEM
reuptake NN NN O
inhibitor NN NN O
, , , O
is VBZ VBZ O
gaining VBG VBG O
increased VBN VBN O
acceptance NN NN O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
adolescent NN NN O
depression NN NN O
. . . O

Generally RB RB O
safe JJ JJ O
and CC CC O
well RB RB O
tolerated VBN VBN O
by IN IN O
adults NNS NNS O
, , , O
fluoxetine NN NN B-CHEM
has VBZ VBZ O
been VBN VBN O
reported VBN VBN O
to TO TO O
induce VB VB O
mania NN NN O
. . . O

The DT DT O
cases NNS NNS O
of IN IN O
five CD CD O
depressed VBN VBN O
adolescents NNS NNS O
, , , O
14 CD CD O
- : : O
16 CD CD O
years NNS NNS O
of IN IN O
age NN NN O
, , , O
who WP WP O
developed VBD VBD O
mania NN NN O
during IN IN O
pharmacotherapy NN NN O
with IN IN O
fluoxetine NN NN B-CHEM
, , , O
are VBP VBP O
reported VBN VBN O
here RB RB O
. . . O

Apparent NNP NNP O
risk NN NN O
factors NNS NNS O
for IN IN O
the DT DT O
development NN NN O
of IN IN O
mania NN NN O
or CC CC O
hypomania NN NN O
during IN IN O
fluoxetine NN NN B-CHEM
pharmacotherapy NN NN O
in IN IN O
this DT DT O
population NN NN O
were VBD VBD O
the DT DT O
combination NN NN O
of IN IN O
attention NN NN O
- - - O
deficit JJ JJ O
hyperactivity NN NN O
disorder NN NN O
and CC CC O
affective JJ JJ O
instability NN NN O
; : : O
major JJ JJ O
depression NN NN O
with IN IN O
psychotic JJ JJ O
features NNS NNS O
; : : O
a DT DT O
family NN NN O
history NN NN O
of IN IN O
affective JJ JJ O
disorder NN NN O
, , , O
especially RB RB O
bipolar JJ JJ O
disorder NN NN O
; : : O
and CC CC O
a DT DT O
diagnosis NN NN O
of IN IN O
bipolar JJ JJ O
disorder NN NN O
. . . O

Further RB RB O
study NN NN O
is VBZ VBZ O
needed VBN VBN O
to TO TO O
determine VB VB O
the DT DT O
optimal NN NN O
dosage NN NN O
and CC CC O
to TO TO O
identify VB VB O
risk NN NN O
factors NNS NNS O
that WDT WDT O
increase NN NN O
individual JJ JJ O
vulnerability NN NN O
to TO TO O
fluoxetine VB VB B-CHEM
induced VBN VBN O
mania NN NN O
in IN IN O
adolescents NNS NNS O
. . . O

Acute JJ JJ O
renal JJ JJ O
insufficiency NN NN O
after IN IN O
high JJ JJ O
- - - O
dose NN NN O
melphalan NN NN B-CHEM
in IN IN O
patients NNS NNS O
with IN IN O
primary JJ JJ O
systemic JJ JJ O
amyloidosis NN NN O
during IN IN O
stem NN NN O
cell NN NN O
transplantation NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
Patients NNS NNS O
with IN IN O
primary JJ JJ O
systemic JJ JJ O
amyloidosis NN NN O
( ( ( O
AL NNP NNP O
) ) ) O
have VBP VBP O
a DT DT O
poor JJ JJ O
prognosis NN NN O
. . . O

Median NNP NNP O
survival NN NN O
time NN NN O
from IN IN O
standard JJ JJ O
treatments NNS NNS O
is VBZ VBZ O
only RB RB O
17 CD CD O
months NNS NNS O
. . . O

High NNP NNP O
- - - O
dose NN NN O
intravenous JJ JJ O
melphalan NN NN B-CHEM
followed VBN VBN O
by IN IN O
peripheral JJ JJ O
blood NN NN O
stem NN NN O
cell NN NN O
transplant NN NN O
( ( ( O
PBSCT NNP NNP O
) ) ) O
appears VBZ VBZ O
to TO TO O
be VB VB O
the DT DT O
most RBS RBS O
promising JJ JJ O
therapy NN NN O
, , , O
but CC CC O
treatment NN NN O
mortality NN NN O
can MD MD O
be VB VB O
high JJ JJ O
. . . O

The DT DT O
authors NNS NNS O
have VBP VBP O
noted VBN VBN O
the DT DT O
development NN NN O
of IN IN O
acute JJ JJ O
renal JJ JJ O
insufficiency NN NN O
immediately RB RB O
after IN IN O
melphalan NN NN B-CHEM
conditioning NN NN O
. . . O

This DT DT O
study NN NN O
was VBD VBD O
undertaken VBN VBN O
to TO TO O
further VB VB O
examine VB VB O
its PRP$ PRP$ O
risk NN NN O
factors NNS NNS O
and CC CC O
impact NN NN O
on IN IN O
posttransplant JJ JJ O
mortality NN NN O
. . . O

METHODS NNP NNP O
: : : O
Consecutive NNP NNP O
AL NNP NNP O
patients NNS NNS O
who WP WP O
underwent VBD VBD O
PBSCT NNP NNP O
were VBD VBD O
studied VBN VBN O
retrospectively RB RB O
. . . O

Acute JJ JJ O
renal JJ JJ O
insufficiency NN NN O
( ( ( O
ARI NNP NNP O
) ) ) O
after IN IN O
high JJ JJ O
- - - O
dose NN NN O
melphalan NN NN B-CHEM
was VBD VBD O
defined VBN VBN O
by IN IN O
a DT DT O
minimum JJ JJ O
increase NN NN O
of IN IN O
0 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
dL NN NN O
( ( ( O
44 CD CD O
micromol NN NN O
/ NN NN O
L NNP NNP O
) ) ) O
in IN IN O
the DT DT O
serum NN NN O
creatinine NN NN B-CHEM
level NN NN O
that WDT WDT O
is VBZ VBZ O
greater JJR JJR O
than IN IN O
50 CD CD O
% NN NN O
of IN IN O
baseline NN NN O
immediately RB RB O
after IN IN O
conditioning VBG VBG O
. . . O

Urine NNP NNP O
sediment NN NN O
score NN NN O
was VBD VBD O
the DT DT O
sum NN NN O
of IN IN O
the DT DT O
individual JJ JJ O
types NNS NNS O
of IN IN O
sediment NN NN O
identified VBN VBN O
on IN IN O
urine JJ JJ O
microscopy NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Of IN IN O
the DT DT O
80 CD CD O
patients NNS NNS O
studied VBN VBN O
, , , O
ARI NNP NNP O
developed VBD VBD O
in IN IN O
18 CD CD O
. . . O
8 CD CD O
% NN NN O
of IN IN O
the DT DT O
patients NNS NNS O
after IN IN O
high JJ JJ O
- - - O
dose NN NN O
melphalan NN NN B-CHEM
. . . O

Univariate NNP NNP O
analysis NN NN O
identified VBN VBN O
age NN NN O
, , , O
hypoalbuminemia NN NN O
, , , O
heavy JJ JJ O
proteinuria NNS NNS O
, , , O
diuretic JJ JJ O
use NN NN O
, , , O
and CC CC O
urine JJ JJ O
sediment NN NN O
score NN NN O
( ( ( O
> NN NN O
3 CD CD O
) ) ) O
as IN IN O
risk NN NN O
factors NNS NNS O
. . . O

Age NNP NNP O
and CC CC O
urine NN NN O
sediment NN NN O
score NN NN O
remained VBD VBD O
independently RB RB O
significant JJ JJ O
risk NN NN O
factors NNS NNS O
in IN IN O
the DT DT O
multivariate NN NN O
analysis NN NN O
. . . O

Patients NNS NNS O
who WP WP O
had VBD VBD O
ARI NNP NNP O
after IN IN O
high JJ JJ O
- - - O
dose NN NN O
melphalan NN NN B-CHEM
underwent JJ JJ O
dialysis NN NN O
more RBR RBR O
often RB RB O
( ( ( O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
007 CD CD O
) ) ) O
, , , O
and CC CC O
had VBD VBD O
a DT DT O
worse JJR JJR O
1 CD CD O
- : : O
year NN NN O
survival NN NN O
( ( ( O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
03 CD CD O
) ) ) O
. . . O

CONCLUSION NNP NNP O
: : : O
The DT DT O
timing NN NN O
of IN IN O
renal JJ JJ O
injury NN NN O
strongly RB RB O
suggests VBZ VBZ O
melphalan NN NN B-CHEM
as IN IN O
the DT DT O
causative JJ JJ O
agent NN NN O
. . . O

Ongoing NNP NNP O
tubular JJ JJ O
injury NN NN O
may MD MD O
be VB VB O
a DT DT O
prerequisite NN NN O
for IN IN O
renal JJ JJ O
injury NN NN O
by IN IN O
melphalan NN NN B-CHEM
as IN IN O
evidenced VBN VBN O
by IN IN O
the DT DT O
active JJ JJ O
urinary JJ JJ O
sediment NN NN O
. . . O

Development NNP NNP O
of IN IN O
ARI NNP NNP O
adversely RB RB O
affected VBD VBD O
the DT DT O
outcome NN NN O
after IN IN O
PBSCT NNP NNP O
. . . O

Effective NNP NNP O
preventive JJ JJ O
measures NNS NNS O
may MD MD O
help VB VB O
decrease VB VB O
the DT DT O
treatment NN NN O
mortality NN NN O
of IN IN O
PBSCT NNP NNP O
in IN IN O
AL NNP NNP O
patients NNS NNS O
. . . O

Focal NNP NNP O
cerebral JJ JJ O
ischemia NN NN O
in IN IN O
rats NNS NNS O
: : : O
effect NN NN O
of IN IN O
phenylephrine NN NN B-CHEM
- - - O
induced JJ JJ O
hypertension NN NN O
during IN IN O
reperfusion NN NN O
. . . O

After IN IN O
180 CD CD O
min NN NN O
of IN IN O
temporary JJ JJ O
middle NN NN O
cerebral JJ JJ O
artery NN NN O
occlusion NN NN O
in IN IN O
spontaneously RB RB O
hypertensive JJ JJ O
rats NNS NNS O
, , , O
the DT DT O
effect NN NN O
of IN IN O
phenylephrine NN NN B-CHEM
- - - O
induced JJ JJ O
hypertension NN NN O
on IN IN O
ischemic JJ JJ O
brain NN NN O
injury NN NN O
and CC CC O
blood NN NN O
- - - O
brain NN NN O
barrier NN NN O
permeability NN NN O
was VBD VBD O
determined VBN VBN O
. . . O

Blood NNP NNP O
pressure NN NN O
was VBD VBD O
manipulated VBN VBN O
by IN IN O
one CD CD O
of IN IN O
the DT DT O
following VBG VBG O
schedules NNS NNS O
during IN IN O
120 CD CD O
min NN NN O
of IN IN O
reperfusion NN NN O
: : : O
Control NNP NNP O
, , , O
normotensive JJ JJ O
reperfusion NN NN O
; : : O
90 CD CD O
/ NN NN O
hypertension NN NN O
( ( ( O
90 CD CD O
/ NN NN O
HTN NNP NNP O
) ) ) O
, , , O
blood NN NN O
pressure NN NN O
was VBD VBD O
increased VBN VBN O
by IN IN O
35 CD CD O
mm NN NN O
Hg NNP NNP O
during IN IN O
the DT DT O
initial JJ JJ O
90 CD CD O
min NN NN O
of IN IN O
reperfusion NN NN O
only RB RB O
; : : O
15 CD CD O
/ NN NN O
hypertension NN NN O
( ( ( O
15 CD CD O
/ NN NN O
HTN NNP NNP O
) ) ) O
, , , O
normotensive JJ JJ O
reperfusion NN NN O
for IN IN O
30 CD CD O
min NN NN O
followed VBN VBN O
by IN IN O
15 CD CD O
min NN NN O
of IN IN O
hypertension NN NN O
and CC CC O
75 CD CD O
min NN NN O
of IN IN O
normotension NN NN O
. . . O

Part NN NN O
A DT DT O
, , , O
for IN IN O
eight CD CD O
rats NNS NNS O
in IN IN O
each DT DT O
group NN NN O
brain NN NN O
injury NN NN O
was VBD VBD O
evaluated VBN VBN O
by IN IN O
staining VBG VBG O
tissue NN NN O
using VBG VBG O
2 CD CD B-CHEM
, , , I-CHEM
3 CD CD I-CHEM
, , , I-CHEM
5 CD CD I-CHEM
- : : I-CHEM
triphenyltetrazolium NN NN I-CHEM
chloride NN NN I-CHEM
and CC CC O
edema NN NN O
was VBD VBD O
evaluated VBN VBN O
by IN IN O
microgravimetry NN NN O
. . . O

Part NN NN O
B NNP NNP O
, , , O
for IN IN O
eight CD CD O
different JJ JJ O
rats NNS NNS O
in IN IN O
each DT DT O
group NN NN O
blood NN NN O
- : : O
brain NN NN O
barrier NN NN O
permeability NN NN O
was VBD VBD O
evaluated VBN VBN O
by IN IN O
measuring VBG VBG O
the DT DT O
amount NN NN O
and CC CC O
extent NN NN O
of IN IN O
extravasation NN NN O
of IN IN O
Evans NNP NNP O
Blue NNP NNP O
dye NN NN O
. . . O

Brain NNP NNP O
injury NN NN O
( ( ( O
percentage NN NN O
of IN IN O
the DT DT O
ischemic JJ JJ O
hemisphere NN NN O
) ) ) O
was VBD VBD O
less JJR JJR O
in IN IN O
the DT DT O
15 CD CD O
/ NN NN O
HTN NNP NNP O
group NN NN O
( ( ( O
16 CD CD O
+ NN NN O
/ NN NN O
- : : O
6 CD CD O
, , , O
mean NN NN O
+ NN NN O
/ NN NN O
- - - O
SD NNP NNP O
) ) ) O
versus CC CC O
the DT DT O
90 CD CD O
/ NN NN O
HTN NNP NNP O
group NN NN O
( ( ( O
30 CD CD O
+ NN NN O
/ NN NN O
- : : O
6 CD CD O
) ) ) O
, , , O
which WDT WDT O
was VBD VBD O
in IN IN O
turn NN NN O
less JJR JJR O
than IN IN O
the DT DT O
control NN NN O
group NN NN O
( ( ( O
42 CD CD O
+ NN NN O
/ NN NN O
- : : O
5 CD CD O
) ) ) O
. . . O

Specific JJ JJ O
gravity NN NN O
was VBD VBD O
greater JJR JJR O
in IN IN O
the DT DT O
15 CD CD O
/ NN NN O
HTN NNP NNP O
group NN NN O
( ( ( O
1 CD CD O
. . . O
043 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
002 CD CD O
) ) ) O
versus CC CC O
the DT DT O
90 CD CD O
/ NN NN O
HTN NNP NNP O
( ( ( O
1 CD CD O
. . . O
036 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
003 CD CD O
) ) ) O
and CC CC O
control NN NN O
( ( ( O
1 CD CD O
. . . O
037 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
003 CD CD O
) ) ) O
groups NNS NNS O
. . . O

Evans NNP NNP B-CHEM
Blue NNP NNP I-CHEM
( ( ( O
mug NN NN O
g SYM SYM O
- : : O
1 CD CD O
of IN IN O
brain NN NN O
tissue NN NN O
) ) ) O
was VBD VBD O
greater JJR JJR O
in IN IN O
the DT DT O
90 CD CD O
/ NN NN O
HTN NNP NNP O
group NN NN O
( ( ( O
24 CD CD O
. . . O
4 CD CD O
+ NN NN O
/ NN NN O
- : : O
6 CD CD O
. . . O
0 CD CD O
) ) ) O
versus CC CC O
the DT DT O
control NN NN O
group NN NN O
( ( ( O
12 CD CD O
. . . O
3 CD CD O
+ NN NN O
/ NN NN O
- : : O
4 CD CD O
. . . O
1 CD CD O
) ) ) O
, , , O
which WDT WDT O
was VBD VBD O
in IN IN O
turn NN NN O
greater JJR JJR O
than IN IN O
the DT DT O
15 CD CD O
/ NN NN O
HTN NNP NNP O
group NN NN O
( ( ( O
7 CD CD O
. . . O
3 CD CD O
+ NN NN O
/ NN NN O
- : : O
3 CD CD O
. . . O
2 CD CD O
) ) ) O
. . . O

This DT DT O
study NN NN O
supports VBZ VBZ O
a DT DT O
hypothesis NNS NNS O
that IN IN O
during IN IN O
reperfusion NN NN O
, , , O
a DT DT O
short JJ JJ O
interval NN NN O
of IN IN O
hypertension NN NN O
decreases NNS NNS O
brain NN NN O
injury NN NN O
and CC CC O
edema NN NN O
; : : O
and CC CC O
that DT DT O
sustained JJ JJ O
hypertension NN NN O
increases VBZ VBZ O
the DT DT O
risk NN NN O
of IN IN O
vasogenic JJ JJ O
edema NN NN O
. . . O

People NNS NNS O
aged VBN VBN O
over IN IN O
75 CD CD O
in IN IN O
atrial JJ JJ O
fibrillation NN NN O
on IN IN O
warfarin NN NN B-CHEM
: : : O
the DT DT O
rate NN NN O
of IN IN O
major JJ JJ O
hemorrhage NN NN O
and CC CC O
stroke NN NN O
in IN IN O
more JJR JJR O
than IN IN O
500 CD CD O
patient NN NN O
- : : O
years NNS NNS O
of IN IN O
follow VB VB O
- - - O
up RP RP O
. . . O

OBJECTIVES NNP NNP O
: : : O
To TO TO O
determine VB VB O
the DT DT O
incidence NN NN O
of IN IN O
major JJ JJ O
hemorrhage NN NN O
and CC CC O
stroke NN NN O
in IN IN O
people NNS NNS O
aged VBN VBN O
76 CD CD O
and CC CC O
older JJR JJR O
with IN IN O
atrial JJ JJ O
fibrillation NN NN O
on IN IN O
adjusted VBN VBN O
- : : O
dose VB VB O
warfarin NN NN B-CHEM
who WP WP O
had VBD VBD O
been VBN VBN O
recently RB RB O
been VBN VBN O
admitted VBN VBN O
to TO TO O
hospital NN NN O
. . . O

DESIGN NNP NNP O
: : : O
A DT DT O
retrospective NN NN O
observational JJ JJ O
cohort NN NN O
study NN NN O
. . . O

SETTING NNP NNP O
: : : O
A DT DT O
major JJ JJ O
healthcare NN NN O
network NN NN O
involving VBG VBG O
four CD CD O
tertiary JJ JJ O
hospitals NNS NNS O
. . . O

PARTICIPANTS NNS NNS O
: : : O
Two CD CD O
hundred CD CD O
thirty CD CD O
- : : O
five CD CD O
patients NNS NNS O
aged VBD VBD O
76 CD CD O
and CC CC O
older JJR JJR O
admitted VBD VBD O
to TO TO O
a DT DT O
major JJ JJ O
healthcare NN NN O
network NN NN O
between IN IN O
July NNP NNP O
1 CD CD O
, , , O
2001 CD CD O
, , , O
and CC CC O
June NNP NNP O
30 CD CD O
, , , O
2002 CD CD O
, , , O
with IN IN O
atrial JJ JJ O
fibrillation NN NN O
on IN IN O
warfarin NN NN B-CHEM
were VBD VBD O
enrolled VBN VBN O
. . . O

MEASUREMENTS NNP NNP O
: : : O
Information NNP NNP O
regarding VBG VBG O
major JJ JJ O
bleeding NN NN O
episodes NNS NNS O
, , , O
strokes NNS NNS O
, , , O
and CC CC O
warfarin NN NN B-CHEM
use NN NN O
was VBD VBD O
obtained VBN VBN O
from IN IN O
patients NNS NNS O
, , , O
relatives NNS NNS O
, , , O
primary JJ JJ O
physicians NNS NNS O
, , , O
and CC CC O
medical JJ JJ O
records NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
Two CD CD O
hundred CD CD O
twenty CD CD O
- : : O
eight CD CD O
patients NNS NNS O
( ( ( O
42 CD CD O
% NN NN O
men NNS NNS O
) ) ) O
with IN IN O
a DT DT O
mean JJ JJ O
age NN NN O
of IN IN O
81 CD CD O
. . . O
1 CD CD O
( ( ( O
range NN NN O
76 CD CD O
- : : O
94 CD CD O
) ) ) O
were VBD VBD O
included VBN VBN O
in IN IN O
the DT DT O
analysis NN NN O
. . . O

Total NNP NNP O
follow VB VB O
- - - O
up RP RP O
on IN IN O
warfarin NN NN B-CHEM
was VBD VBD O
530 CD CD O
years NNS NNS O
( ( ( O
mean NN NN O
28 CD CD O
months NNS NNS O
) ) ) O
. . . O

There EX EX O
were VBD VBD O
53 CD CD O
major JJ JJ O
hemorrhages NNS NNS O
, , , O
for IN IN O
an DT DT O
annual JJ JJ O
rate NN NN O
of IN IN O
10 CD CD O
. . . O
0 CD CD O
% NN NN O
, , , O
including VBG VBG O
24 CD CD O
( ( ( O
45 CD CD O
. . . O
3 CD CD O
% NN NN O
) ) ) O
life NN NN O
- : : O
threatening VBG VBG O
and CC CC O
five CD CD O
( ( ( O
9 CD CD O
. . . O
4 CD CD O
% NN NN O
) ) ) O
fatal JJ JJ O
bleeds NNS NNS O
. . . O

The DT DT O
annual JJ JJ O
stroke NN NN O
rate NN NN O
after IN IN O
initiation NN NN O
of IN IN O
warfarin NN NN B-CHEM
was VBD VBD O
2 CD CD O
. . . O
6 CD CD O
% NN NN O
. . . O

CONCLUSION NNP NNP O
: : : O
The DT DT O
rate NN NN O
of IN IN O
major JJ JJ O
hemorrhage NN NN O
was VBD VBD O
high JJ JJ O
in IN IN O
this DT DT O
old JJ JJ O
, , , O
frail JJ JJ O
group NN NN O
, , , O
but CC CC O
excluding VBG VBG O
fatalities NNS NNS O
, , , O
resulted VBD VBD O
in IN IN O
no DT DT O
long JJ JJ O
- - - O
term NN NN O
sequelae NN NN O
, , , O
and CC CC O
the DT DT O
stroke NN NN O
rate NN NN O
on IN IN O
warfarin NN NN B-CHEM
was VBD VBD O
low JJ JJ O
, , , O
demonstrating VBG VBG O
how WRB WRB O
effective JJ JJ O
warfarin NN NN B-CHEM
treatment NN NN O
is VBZ VBZ O
. . . O

Safety NNP NNP O
of IN IN O
celecoxib NN NN B-CHEM
in IN IN O
patients NNS NNS O
with IN IN O
adverse JJ JJ O
skin NN NN O
reactions NNS NNS O
to TO TO O
acetaminophen VB VB B-CHEM
( ( ( O
paracetamol NN NN B-CHEM
) ) ) O
and CC CC O
nimesulide IN IN B-CHEM
associated VBN VBN O
or CC CC O
not RB RB O
with IN IN O
common JJ JJ O
non NN NN O
- - - O
steroidal NN NN O
anti NN NN O
- : : O
inflammatory JJ JJ O
drugs NNS NNS O
. . . O

BACKGROUND NNP NNP O
: : : O
Acetaminophen NNP NNP B-CHEM
( ( ( O
paracetamol NN NN B-CHEM
- - - O
- - - O
P NN NN B-CHEM
) ) ) O
and CC CC O
Nimesulide NNP NNP B-CHEM
( ( ( O
N NNP NNP B-CHEM
) ) ) O
are VBP VBP O
widely RB RB O
used VBN VBN O
analgesic JJ JJ O
- - - O
antipyretic JJ JJ O
/ NN NN O
anti NN NN O
- : : O
inflammatory JJ JJ O
drugs NNS NNS O
. . . O

The DT DT O
rate NN NN O
of IN IN O
adverse JJ JJ O
hypersensitivity NN NN O
reactions NNS NNS O
to TO TO O
these DT DT O
agents NNS NNS O
is VBZ VBZ O
generally RB RB O
low JJ JJ O
. . . O

On IN IN O
the DT DT O
contrary JJ JJ O
non NN NN O
- - - O
steroidal NN NN O
anti NN NN O
- : : O
inflammatory JJ JJ O
drugs NNS NNS O
( ( ( O
NSAIDs NNP NNP O
) ) ) O
are VBP VBP O
commonly RB RB O
involved VBN VBN O
in IN IN O
such JJ JJ O
reactions NNS NNS O
. . . O

Celecoxib NNP NNP B-CHEM
( ( ( O
CE NNP NNP B-CHEM
) ) ) O
is VBZ VBZ O
a DT DT O
novel NN NN O
drug NN NN O
, , , O
with IN IN O
high JJ JJ O
selectivity NN NN O
and CC CC O
affinity NN NN O
for IN IN O
COX NNP NNP O
- : : O
2 CD CD O
enzyme NN NN O
. . . O

OBJECTIVE NNP NNP O
: : : O
We PRP PRP O
evaluated VBD VBD O
the DT DT O
tolerability NN NN O
of IN IN O
CE NNP NNP B-CHEM
in IN IN O
a DT DT O
group NN NN O
of IN IN O
patients NNS NNS O
with IN IN O
documented VBN VBN O
history NN NN O
of IN IN O
adverse JJ JJ O
cutaneous JJ JJ O
reactions NNS NNS O
to TO TO O
P NN NN B-CHEM
and CC CC O
N NNP NNP B-CHEM
associated VBN VBN O
or CC CC O
not RB RB O
to TO TO O
classic JJ JJ O
NSAIDs NNP NNP O
. . . O

METHODS NNP NNP O
: : : O
We PRP PRP O
studied VBD VBD O
9 CD CD O
patients NNS NNS O
with IN IN O
hypersensitivity NN NN O
to TO TO O
P NN NN B-CHEM
and CC CC O
N NNP NNP B-CHEM
with IN IN O
or CC CC O
without IN IN O
associated VBN VBN O
reactions NNS NNS O
to TO TO O
classic JJ JJ O
NSAIDs NNP NNP O
. . . O

The DT DT O
diagnosis NN NN O
of IN IN O
P NN NN B-CHEM
and CC CC O
N NNP NNP B-CHEM
- : : O
induced JJ JJ O
skin NN NN O
reactions NNS NNS O
was VBD VBD O
based VBN VBN O
in IN IN O
vivo NN NN O
challenge NN NN O
. . . O

The DT DT O
placebo NN NN O
was VBD VBD O
blindly RB RB O
administered VBN VBN O
at IN IN O
the DT DT O
beginning NN NN O
of IN IN O
each DT DT O
challenge NN NN O
. . . O

After IN IN O
three CD CD O
days NNS NNS O
, , , O
a DT DT O
cumulative JJ JJ O
dosage NN NN O
of IN IN O
200 CD CD O
mg NN NN O
of IN IN O
CE NNP NNP B-CHEM
in IN IN O
refracted JJ JJ O
doses NNS NNS O
were VBD VBD O
given VBN VBN O
. . . O

After IN IN O
2 CD CD O
- : : O
3 CD CD O
days NNS NNS O
, , , O
a DT DT O
single JJ JJ O
dose NN NN O
of IN IN O
200 CD CD O
mg NN NN O
was VBD VBD O
administered VBN VBN O
. . . O

All DT DT O
patients NNS NNS O
were VBD VBD O
observed VBN VBN O
for IN IN O
6 CD CD O
hours NNS NNS O
after IN IN O
each DT DT O
challenge NN NN O
, , , O
and CC CC O
controlled VBD VBD O
again RB RB O
after IN IN O
24 CD CD O
hours NNS NNS O
to TO TO O
exclude VB VB O
delayed JJ JJ O
reactions NNS NNS O
. . . O

The DT DT O
challenge NN NN O
was VBD VBD O
considered VBN VBN O
positive JJ JJ O
if IN IN O
one CD CD O
or CC CC O
more JJR JJR O
of IN IN O
the DT DT O
following VBG VBG O
appeared VBN VBN O
: : : O
erythema NN NN O
, , , O
rush NN NN O
or CC CC O
urticaria JJ JJ O
- - - O
angioedema NN NN O
. . . O

RESULTS NNS NNS O
: : : O
No DT DT O
reaction NN NN O
was VBD VBD O
observed VBN VBN O
with IN IN O
placebo NN NN O
and CC CC O
eight CD CD O
patients NNS NNS O
( ( ( O
88 CD CD O
. . . O
8 CD CD O
% NN NN O
) ) ) O
tolerated JJ JJ O
CE NNP NNP B-CHEM
. . . O

Only RB RB O
one CD CD O
patient NN NN O
developed VBD VBD O
a DT DT O
moderate JJ JJ O
angioedema NN NN O
of IN IN O
the DT DT O
lips NNS NNS O
. . . O

CONCLUSION NNP NNP O
: : : O
Only RB RB O
one CD CD O
hypersensitivity NN NN O
reaction NN NN O
to TO TO O
CE NNP NNP B-CHEM
was VBD VBD O
documented VBN VBN O
among IN IN O
9 CD CD O
P NN NN B-CHEM
and CC CC O
N NNP NNP B-CHEM
- : : O
highly RB RB O
NSAIDs NNP NNP O
intolerant NN NN O
patients NNS NNS O
. . . O

Thus RB RB O
, , , O
we PRP PRP O
conclude VBP VBP O
that IN IN O
CE NNP NNP B-CHEM
is VBZ VBZ O
a DT DT O
reasonably RB RB O
safe JJ JJ O
alternative NN NN O
to TO TO O
be VB VB O
used VBN VBN O
in IN IN O
subjects NNS NNS O
who WP WP O
do VBP VBP O
not RB RB O
tolerate VB VB O
P NN NN B-CHEM
and CC CC O
N NNP NNP B-CHEM
. . . O

Case NN NN O
- : : O
control NN NN O
study NN NN O
of IN IN O
regular JJ JJ O
analgesic NN NN O
and CC CC O
nonsteroidal NN NN O
anti JJ JJ O
- : : O
inflammatory JJ JJ O
use NN NN O
and CC CC O
end VB VB O
- : : O
stage NN NN O
renal NN NN O
disease NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
Studies NNS NNS O
on IN IN O
the DT DT O
association NN NN O
between IN IN O
the DT DT O
long JJ JJ O
- - - O
term NN NN O
use NN NN O
of IN IN O
aspirin NN NN B-CHEM
and CC CC O
other JJ JJ O
analgesic JJ JJ O
and CC CC O
nonsteroidal JJ JJ O
anti NN NN O
- : : O
inflammatory JJ JJ O
drugs NNS NNS O
( ( ( O
NSAIDs NNP NNP O
) ) ) O
and CC CC O
end VB VB O
- : : O
stage NN NN O
renal NN NN O
disease NN NN O
( ( ( O
ESRD NNP NNP O
) ) ) O
have VBP VBP O
given VBN VBN O
conflicting JJ JJ O
results NNS NNS O
. . . O

In IN IN O
order NN NN O
to TO TO O
examine VB VB O
this DT DT O
association NN NN O
, , , O
a DT DT O
case NN NN O
- - - O
control NN NN O
study NN NN O
with IN IN O
incident NN NN O
cases NNS NNS O
of IN IN O
ESRD NNP NNP O
was VBD VBD O
carried VBN VBN O
out IN IN O
. . . O

METHODS NNP NNP O
: : : O
The DT DT O
cases NNS NNS O
were VBD VBD O
all DT DT O
patients NNS NNS O
entering VBG VBG O
the DT DT O
local JJ JJ O
dialysis NN NN O
program NN NN O
because IN IN O
of IN IN O
ESRD NNP NNP O
in IN IN O
the DT DT O
study NN NN O
area NN NN O
between IN IN O
June NNP NNP O
1 CD CD O
, , , O
1995 CD CD O
and CC CC O
November NNP NNP O
30 CD CD O
, , , O
1997 CD CD O
. . . O

They PRP PRP O
were VBD VBD O
classified VBN VBN O
according VBG VBG O
to TO TO O
the DT DT O
underlying VBG VBG O
disease NN NN O
, , , O
which WDT WDT O
had VBD VBD O
presumably RB RB O
led VBN VBN O
them PRP PRP O
to TO TO O
ESRD NNP NNP O
. . . O

Controls NNP NNP O
were VBD VBD O
patients NNS NNS O
admitted VBN VBN O
to TO TO O
the DT DT O
same JJ JJ O
hospitals NNS NNS O
from IN IN O
where WRB WRB O
the DT DT O
cases NNS NNS O
arose VBP VBP O
, , , O
also RB RB O
matched VBN VBN O
by IN IN O
age NN NN O
and CC CC O
sex NN NN O
. . . O

Odds NNP NNP O
ratios NNS NNS O
were VBD VBD O
calculated VBN VBN O
using VBG VBG O
a DT DT O
conditional JJ JJ O
logistic JJ JJ O
model NN NN O
, , , O
including VBG VBG O
potential JJ JJ O
confounding NN NN O
factors NNS NNS O
, , , O
both DT DT O
for IN IN O
the DT DT O
whole JJ JJ O
study NN NN O
population NN NN O
and CC CC O
for IN IN O
the DT DT O
various JJ JJ O
underlying VBG VBG O
diseases NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
Five CD CD O
hundred CD CD O
and CC CC O
eighty NN NN O
- - - O
three CD CD O
cases NNS NNS O
and CC CC O
1190 CD CD O
controls NNS NNS O
were VBD VBD O
included VBN VBN O
in IN IN O
the DT DT O
analysis NN NN O
. . . O

Long JJ JJ O
- - - O
term NN NN O
use NN NN O
of IN IN O
any DT DT O
analgesic NN NN O
was VBD VBD O
associated VBN VBN O
with IN IN O
an DT DT O
overall JJ JJ O
odds NN NN O
ratio NN NN O
of IN IN O
1 CD CD O
. . . O
22 CD CD O
( ( ( O
95 CD CD O
% NN NN O
CI NNP NNP O
, , , O
0 CD CD O
. . . O
89 CD CD O
- : : O
1 CD CD O
. . . O
66 CD CD O
) ) ) O
. . . O

For IN IN O
specific JJ JJ O
groups NNS NNS O
of IN IN O
drugs NNS NNS O
, , , O
the DT DT O
risks NNS NNS O
were VBD VBD O
1 CD CD O
. . . O
56 CD CD O
( ( ( O
1 CD CD O
. . . O
05 CD CD O
- : : O
2 CD CD O
. . . O
30 CD CD O
) ) ) O
for IN IN O
aspirin NN NN B-CHEM
, , , O
1 CD CD O
. . . O
03 CD CD O
( ( ( O
0 CD CD O
. . . O
60 CD CD O
- : : O
1 CD CD O
. . . O
76 CD CD O
) ) ) O
for IN IN O
pyrazolones NNS NNS B-CHEM
, , , O
0 CD CD O
. . . O
80 CD CD O
( ( ( O
0 CD CD O
. . . O
39 CD CD O
- : : O
1 CD CD O
. . . O
63 CD CD O
) ) ) O
for IN IN O
paracetamol NN NN B-CHEM
, , , O
and CC CC O
0 CD CD O
. . . O
94 CD CD O
( ( ( O
0 CD CD O
. . . O
57 CD CD O
- : : O
1 CD CD O
. . . O
56 CD CD O
) ) ) O
for IN IN O
nonaspirin NN NN O
NSAIDs NNP NNP O
. . . O

The DT DT O
risk NN NN O
of IN IN O
ESRD NNP NNP O
associated VBN VBN O
with IN IN O
aspirin NN NN B-CHEM
was VBD VBD O
related VBN VBN O
to TO TO O
the DT DT O
cumulated JJ JJ O
dose NN NN O
and CC CC O
duration NN NN O
of IN IN O
use NN NN O
, , , O
and CC CC O
it PRP PRP O
was VBD VBD O
particularly RB RB O
high JJ JJ O
among IN IN O
the DT DT O
subset NN NN O
of IN IN O
patients NNS NNS O
with IN IN O
vascular NN NN O
nephropathy JJ JJ O
as IN IN O
underlying VBG VBG O
disease NN NN O
[ NN NN O
2 CD CD O
. . . O
35 CD CD O
( ( ( O
1 CD CD O
. . . O
17 CD CD O
- : : O
4 CD CD O
. . . O
72 CD CD O
) ) ) O
] NN NN O
. . . O

CONCLUSION NNP NNP O
: : : O
Our PRP$ PRP$ O
data NNS NNS O
indicate VBP VBP O
that IN IN O
long JJ JJ O
- - - O
term NN NN O
use NN NN O
of IN IN O
nonaspirin NN NN O
analgesic JJ JJ O
drugs NNS NNS O
and CC CC O
NSAIDs NNP NNP O
is VBZ VBZ O
not RB RB O
associated VBN VBN O
with IN IN O
an DT DT O
increased JJ JJ O
risk NN NN O
of IN IN O
ESRD NNP NNP O
. . . O

However RB RB O
, , , O
the DT DT O
chronic JJ JJ O
use NN NN O
of IN IN O
aspirin NN NN B-CHEM
may MD MD O
increase VB VB O
the DT DT O
risk NN NN O
of IN IN O
ESRD NNP NNP O
. . . O

Two CD CD O
cases NNS NNS O
of IN IN O
amisulpride NN NN B-CHEM
overdose NN NN O
: : : O
a DT DT O
cause NN NN O
for IN IN O
prolonged JJ JJ O
QT NNP NNP O
syndrome NN NN O
. . . O

Two CD CD O
cases NNS NNS O
of IN IN O
deliberate JJ JJ O
self NN NN O
- - - O
poisoning NN NN O
with IN IN O
5 CD CD O
g SYM SYM O
and CC CC O
3 CD CD O
. . . O
6 CD CD O
g SYM SYM O
of IN IN O
amisulpride NN NN B-CHEM
, , , O
respectively RB RB O
, , , O
are VBP VBP O
reported VBN VBN O
. . . O

In IN IN O
both DT DT O
cases NNS NNS O
, , , O
QT NNP NNP O
prolongation NN NN O
and CC CC O
hypocalcaemia NN NN O
were VBD VBD O
noted VBN VBN O
. . . O

The DT DT O
QT NNP NNP O
prolongation NN NN O
appeared VBD VBD O
to TO TO O
respond VB VB O
to TO TO O
administration NN NN O
of IN IN O
i NNP NNP O
. . . O
v NN NN O
. . . O
calcium NN NN B-CHEM
gluconate NN NN I-CHEM
. . . O

Growth NN NN O
- - - O
associated VBN VBN O
protein NN NN O
43 CD CD O
expression NN NN O
in IN IN O
hippocampal NN NN O
molecular JJ JJ O
layer NN NN O
of IN IN O
chronic JJ JJ O
epileptic JJ JJ O
rats NNS NNS O
treated VBN VBN O
with IN IN O
cycloheximide NN NN B-CHEM
. . . O

PURPOSE NNP NNP O
: : : O
GAP43 NNP NNP O
has VBZ VBZ O
been VBN VBN O
thought VBN VBN O
to TO TO O
be VB VB O
linked VBN VBN O
with IN IN O
mossy NN NN O
fiber NN NN O
sprouting VBG VBG O
( ( ( O
MFS NNP NNP O
) ) ) O
in IN IN O
various JJ JJ O
experimental JJ JJ O
models NNS NNS O
of IN IN O
epilepsy NN NN O
. . . O

To TO TO O
investigate VB VB O
how WRB WRB O
GAP43 NNP NNP O
expression NN NN O
( ( ( O
GAP43 NNP NNP O
- - - O
ir NN NN O
) ) ) O
correlates NNS NNS O
with IN IN O
MFS NNP NNP O
, , , O
we PRP PRP O
assessed VBD VBD O
the DT DT O
intensity NN NN O
( ( ( O
densitometry NN NN O
) ) ) O
and CC CC O
extension NN NN O
( ( ( O
width NN NN O
) ) ) O
of IN IN O
GAP43 NNP NNP O
- : : O
ir NN NN O
in IN IN O
the DT DT O
inner JJ JJ O
molecular JJ JJ O
layer NN NN O
of IN IN O
the DT DT O
dentate NN NN O
gyrus NN NN O
( ( ( O
IML NNP NNP O
) ) ) O
of IN IN O
rats NNS NNS O
subject JJ JJ O
to TO TO O
status VB VB O
epilepticus NN NN O
induced VBN VBN O
by IN IN O
pilocarpine NN NN B-CHEM
( ( ( O
Pilo NNP NNP B-CHEM
) ) ) O
, , , O
previously RB RB O
injected VBN VBN O
or CC CC O
not RB RB O
with IN IN O
cycloheximide NN NN B-CHEM
( ( ( O
CHX NNP NNP B-CHEM
) ) ) O
, , , O
which WDT WDT O
has VBZ VBZ O
been VBN VBN O
shown VBN VBN O
to TO TO O
inhibit NN NN O
MFS NNP NNP O
. . . O

METHODS NNP NNP O
: : : O
CHX NNP NNP B-CHEM
was VBD VBD O
injected VBN VBN O
before IN IN O
the DT DT O
Pilo NNP NNP B-CHEM
injection NN NN O
in IN IN O
adult NN NN O
Wistar NNP NNP O
rats NNS NNS O
. . . O

The DT DT O
Pilo NNP NNP B-CHEM
group NN NN O
was VBD VBD O
injected VBN VBN O
with IN IN O
the DT DT O
same JJ JJ O
drugs NNS NNS O
, , , O
except IN IN O
for IN IN O
CHX NNP NNP B-CHEM
. . . O

Animals NNS NNS O
were VBD VBD O
killed VBN VBN O
between IN IN O
30 CD CD O
and CC CC O
60 CD CD O
days NNS NNS O
later RB RB O
, , , O
and CC CC O
brain NN NN O
sections NNS NNS O
were VBD VBD O
processed VBN VBN O
for IN IN O
GAP43 NNP NNP O
immunohistochemistry NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Densitometry NNP NNP O
showed VBD VBD O
no DT DT O
significant JJ JJ O
difference NN NN O
regarding VBG VBG O
GAP43 NNP NNP O
- : : O
ir NN NN O
in IN IN O
the DT DT O
IML NNP NNP O
between IN IN O
Pilo NNP NNP B-CHEM
, , , O
CHX NNP NNP B-CHEM
+ NN NN O
Pilo NNP NNP B-CHEM
, , , O
and CC CC O
control NN NN O
groups NNS NNS O
. . . O

However RB RB O
, , , O
the DT DT O
results NNS NNS O
of IN IN O
the DT DT O
width NN NN O
of IN IN O
the DT DT O
GAP43 NNP NNP O
- - - O
ir NN NN O
band NN NN O
in IN IN O
the DT DT O
IML NNP NNP O
showed VBD VBD O
that IN IN O
CHX NNP NNP B-CHEM
+ NN NN O
Pilo NNP NNP B-CHEM
and CC CC O
control NN NN O
animals NNS NNS O
had VBD VBD O
a DT DT O
significantly RB RB O
larger JJR JJR O
band NN NN O
( ( ( O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
03 CD CD O
) ) ) O
as IN IN O
compared VBN VBN O
with IN IN O
that DT DT O
in IN IN O
the DT DT O
Pilo NNP NNP B-CHEM
group NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Our PRP$ PRP$ O
current JJ JJ O
finding VBG VBG O
that IN IN O
animals NNS NNS O
in IN IN O
the DT DT O
CHX NNP NNP B-CHEM
+ NN NN O
Pilo NNP NNP B-CHEM
group NN NN O
have VBP VBP O
a DT DT O
GAP43 NNP NNP O
- - - O
ir NN NN O
band NN NN O
in IN IN O
the DT DT O
IML NNP NNP O
, , , O
similar JJ JJ O
to TO TO O
that DT DT O
of IN IN O
controls NNS NNS O
, , , O
reinforces NNS NNS O
prior RB RB O
data NNS NNS O
on IN IN O
the DT DT O
blockade NN NN O
of IN IN O
MFS NNP NNP O
in IN IN O
these DT DT O
animals NNS NNS O
. . . O

The DT DT O
change NN NN O
in IN IN O
GAP43 NNP NNP O
- : : O
ir NN NN O
present JJ JJ O
in IN IN O
Pilo NNP NNP B-CHEM
- - - O
treated JJ JJ O
animals NNS NNS O
was VBD VBD O
a DT DT O
thinning NN NN O
of IN IN O
the DT DT O
band NN NN O
to TO TO O
a DT DT O
very RB RB O
narrow JJ JJ O
layer NN NN O
just RB RB O
above IN IN O
the DT DT O
granule NN NN O
cell NN NN O
layer NN NN O
that WDT WDT O
is VBZ VBZ O
likely JJ JJ O
to TO TO O
be VB VB O
associated VBN VBN O
with IN IN O
the DT DT O
loss NN NN O
of IN IN O
hilar NN NN O
cell NN NN O
projections NNS NNS O
that WDT WDT O
express VBP VBP O
GAP NNP NNP O
- : : O
43 CD CD O
. . . O

Nicotine NNP NNP B-CHEM
antagonizes NNS NNS O
caffeine NN NN B-CHEM
- : : O
but CC CC O
not RB RB O
pentylenetetrazole JJ JJ B-CHEM
- - - O
induced JJ JJ O
anxiogenic JJ JJ O
effect NN NN O
in IN IN O
mice NN NN O
. . . O

RATIONALE NNP NNP O
: : : O
Nicotine NNP NNP B-CHEM
and CC CC O
caffeine NN NN B-CHEM
are VBP VBP O
widely RB RB O
consumed VBN VBN O
licit NN NN O
psychoactive JJ JJ O
drugs NNS NNS O
worldwide NN NN O
. . . O

Epidemiological NNP NNP O
studies NNS NNS O
showed VBD VBD O
that IN IN O
they PRP PRP O
were VBD VBD O
generally RB RB O
used VBN VBN O
concurrently RB RB O
. . . O

Although IN IN O
some DT DT O
studies NNS NNS O
in IN IN O
experimental JJ JJ O
animals NNS NNS O
indicate VBP VBP O
clear JJ JJ O
pharmacological JJ JJ O
interactions NNS NNS O
between IN IN O
them PRP PRP O
, , , O
no DT DT O
studies NNS NNS O
have VBP VBP O
shown VBN VBN O
a DT DT O
specific JJ JJ O
interaction NN NN O
on IN IN O
anxiety NN NN O
responses NNS NNS O
. . . O

OBJECTIVES NNP NNP O
: : : O
The DT DT O
present JJ JJ O
study NN NN O
investigates VBZ VBZ O
the DT DT O
effects NNS NNS O
of IN IN O
nicotine NN NN B-CHEM
on IN IN O
anxiety NN NN O
induced VBN VBN O
by IN IN O
caffeine NN NN B-CHEM
and CC CC O
another DT DT O
anxiogenic JJ JJ O
drug NN NN O
, , , O
pentylenetetrazole NN NN B-CHEM
, , , O
in IN IN O
mice NN NN O
. . . O

The DT DT O
elevated JJ JJ O
plus CC CC O
- : : O
maze NN NN O
( ( ( O
EPM NNP NNP O
) ) ) O
test NN NN O
was VBD VBD O
used VBN VBN O
to TO TO O
evaluate VB VB O
the DT DT O
effects NNS NNS O
of IN IN O
drugs NNS NNS O
on IN IN O
anxiety NN NN O
. . . O

METHODS NNP NNP O
: : : O
Adult NNP NNP O
male JJ JJ O
Swiss NNP NNP O
Webster NNP NNP O
mice NNS NNS O
( ( ( O
25 CD CD O
- : : O
32 CD CD O
g SYM SYM O
) ) ) O
were VBD VBD O
given VBN VBN O
nicotine NN NN B-CHEM
( ( ( O
0 CD CD O
. . . O
05 CD CD O
- : : O
0 CD CD O
. . . O
25 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
s VBZ VBZ O
. . . O
c SYM SYM O
. . . O
) ) ) O
or CC CC O
saline NN NN O
10 CD CD O
min NN NN O
before IN IN O
caffeine NN NN B-CHEM
( ( ( O
70 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
or CC CC O
pentylenetetrazole NN NN B-CHEM
( ( ( O
15 CD CD O
and CC CC O
30 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
injections NNS NNS O
. . . O

After IN IN O
15 CD CD O
min NN NN O
, , , O
mice NN NN O
were VBD VBD O
evaluated VBN VBN O
for IN IN O
their PRP$ PRP$ O
open JJ JJ O
- : : O
and CC CC O
closed VBD VBD O
- : : O
arm NN NN O
time NN NN O
and CC CC O
entries NNS NNS O
on IN IN O
the DT DT O
EPM NNP NNP O
for IN IN O
a DT DT O
10 CD CD O
- : : O
min NN NN O
session NN NN O
. . . O

Locomotor NNP NNP O
activity NN NN O
was VBD VBD O
recorded VBN VBN O
for IN IN O
individual JJ JJ O
groups NNS NNS O
by IN IN O
using VBG VBG O
the DT DT O
same JJ JJ O
treatment NN NN O
protocol NN NN O
with IN IN O
the DT DT O
EPM NNP NNP O
test NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Nicotine NNP NNP B-CHEM
( ( ( O
0 CD CD O
. . . O
05 CD CD O
- : : O
0 CD CD O
. . . O
25 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
itself PRP PRP O
did VBD VBD O
not RB RB O
produce VB VB O
any DT DT O
significant JJ JJ O
effect NN NN O
in IN IN O
the DT DT O
EPM NNP NNP O
test NN NN O
, , , O
whereas IN IN O
caffeine NN NN B-CHEM
( ( ( O
70 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
and CC CC O
pentylenetetrazole NN NN B-CHEM
( ( ( O
30 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
produced VBD VBD O
an DT DT O
anxiogenic JJ JJ O
effect NN NN O
, , , O
apparent JJ JJ O
with IN IN O
decreases NNS NNS O
in IN IN O
open JJ JJ O
- - - O
arm NN NN O
time NN NN O
and CC CC O
entry NN NN O
. . . O

Nicotine NNP NNP B-CHEM
( ( ( O
0 CD CD O
. . . O
25 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
pretreatment NN NN O
blocked VBD VBD O
the DT DT O
caffeine NN NN B-CHEM
- - - O
but CC CC O
not RB RB O
pentylenetetrazole JJ JJ B-CHEM
- - - O
induced JJ JJ O
anxiety NN NN O
. . . O

Administration NNP NNP O
of IN IN O
each DT DT O
drug NN NN O
and CC CC O
their PRP$ PRP$ O
combinations NNS NNS O
did VBD VBD O
not RB RB O
produce VB VB O
any DT DT O
effect NN NN O
on IN IN O
locomotor NN NN O
activity NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Our PRP$ PRP$ O
results NNS NNS O
suggest VBP VBP O
that IN IN O
the DT DT O
antagonistic JJ JJ O
effect NN NN O
of IN IN O
nicotine NN NN B-CHEM
on IN IN O
caffeine NN NN B-CHEM
- : : O
induced JJ JJ O
anxiety NN NN O
is VBZ VBZ O
specific JJ JJ O
to TO TO O
caffeine VB VB B-CHEM
, , , O
instead RB RB O
of IN IN O
a DT DT O
non NN NN O
- - - O
specific JJ JJ O
anxiolytic JJ JJ O
effect NN NN O
. . . O

Thus RB RB O
, , , O
it PRP PRP O
may MD MD O
extend VB VB O
the DT DT O
current JJ JJ O
findings NNS NNS O
on IN IN O
the DT DT O
interaction NN NN O
between IN IN O
nicotine NN NN B-CHEM
and CC CC O
caffeine NN NN B-CHEM
. . . O

Long NNP NNP O
term NN NN O
hormone NN NN O
therapy NN NN O
for IN IN O
perimenopausal NN NN O
and CC CC O
postmenopausal NN NN O
women NNS NNS O
. . . O

BACKGROUND NNP NNP O
: : : O
Hormone NNP NNP O
therapy NN NN O
( ( ( O
HT NNP NNP O
) ) ) O
is VBZ VBZ O
widely RB RB O
used VBN VBN O
for IN IN O
controlling VBG VBG O
menopausal NN NN O
symptoms NNS NNS O
. . . O

It PRP PRP O
has VBZ VBZ O
also RB RB O
been VBN VBN O
used VBN VBN O
for IN IN O
the DT DT O
management NN NN O
and CC CC O
prevention NN NN O
of IN IN O
cardiovascular JJ JJ O
disease NN NN O
, , , O
osteoporosis NN NN O
and CC CC O
dementia NN NN O
in IN IN O
older JJR JJR O
women NNS NNS O
but CC CC O
the DT DT O
evidence NN NN O
supporting VBG VBG O
its PRP$ PRP$ O
use NN NN O
for IN IN O
these DT DT O
indications NNS NNS O
is VBZ VBZ O
largely RB RB O
observational JJ JJ O
. . . O

OBJECTIVES NNP NNP O
: : : O
To TO TO O
assess VB VB O
the DT DT O
effect NN NN O
of IN IN O
long JJ JJ O
- - - O
term NN NN O
HT NNP NNP O
on IN IN O
mortality NN NN O
, , , O
heart NN NN O
disease NN NN O
, , , O
venous JJ JJ O
thromboembolism NN NN O
, , , O
stroke NN NN O
, , , O
transient JJ JJ O
ischaemic JJ JJ O
attacks NNS NNS O
, , , O
breast NN NN O
cancer NN NN O
, , , O
colorectal JJ JJ O
cancer NN NN O
, , , O
ovarian JJ JJ O
cancer NN NN O
, , , O
endometrial JJ JJ O
cancer NN NN O
, , , O
gallbladder NN NN O
disease NN NN O
, , , O
cognitive JJ JJ O
function NN NN O
, , , O
dementia NN NN O
, , , O
fractures NNS NNS O
and CC CC O
quality NN NN O
of IN IN O
life NN NN O
. . . O

SEARCH NNP NNP O
STRATEGY NNP NNP O
: : : O
We PRP PRP O
searched VBD VBD O
the DT DT O
following VBG VBG O
databases NNS NNS O
up IN IN O
to TO TO O
November NNP NNP O
2004 CD CD O
: : : O
the DT DT O
Cochrane NNP NNP O
Menstrual NNP NNP O
Disorders NNP NNP O
and CC CC O
Subfertility NNP NNP O
Group NNP NNP O
Trials NNP NNP O
Register NNP NNP O
, , , O
Cochrane NNP NNP O
Central NNP NNP O
Register NNP NNP O
of IN IN O
Controlled NNP NNP O
Trials NNP NNP O
( ( ( O
CENTRAL NNP NNP O
) ) ) O
, , , O
MEDLINE NNP NNP O
, , , O
EMBASE NNP NNP O
, , , O
Biological NNP NNP O
Abstracts NNP NNP O
. . . O

Relevant JJ JJ O
non NN NN O
- - - O
indexed JJ JJ O
journals NNS NNS O
and CC CC O
conference NN NN O
abstracts NNS NNS O
were VBD VBD O
also RB RB O
searched VBN VBN O
. . . O

SELECTION NN NN O
CRITERIA NNP NNP O
: : : O
Randomised NNP NNP O
double JJ JJ O
- : : O
blind JJ JJ O
trials NNS NNS O
of IN IN O
HT NNP NNP O
( ( ( O
oestrogens NNS NNS B-CHEM
with IN IN O
or CC CC O
without IN IN O
progestogens NNS NNS B-CHEM
) ) ) O
versus CC CC O
placebo NN NN O
, , , O
taken VBN VBN O
for IN IN O
at IN IN O
least JJS JJS O
one CD CD O
year NN NN O
by IN IN O
perimenopausal NN NN O
or CC CC O
postmenopausal NN NN O
women NNS NNS O
. . . O

DATA NNP NNP O
COLLECTION NNP NNP O
AND CC CC O
ANALYSIS NNP NNP O
: : : O
Fifteen CD CD O
RCTs NNP NNP O
were VBD VBD O
included VBN VBN O
. . . O

Trials NNP NNP O
were VBD VBD O
assessed VBN VBN O
for IN IN O
quality NN NN O
and CC CC O
two CD CD O
review NN NN O
authors NNS NNS O
extracted VBD VBD O
data NNS NNS O
independently RB RB O
. . . O

They PRP PRP O
calculated VBD VBD O
risk NN NN O
ratios NN NN O
for IN IN O
dichotomous JJ JJ O
outcomes NNS NNS O
and CC CC O
weighted JJ JJ O
mean NN NN O
differences NNS NNS O
for IN IN O
continuous JJ JJ O
outcomes NNS NNS O
. . . O

Clinical NNP NNP O
heterogeneity NN NN O
precluded VBD VBD O
meta NN NN O
- : : O
analysis NN NN O
for IN IN O
most JJS JJS O
outcomes NNS NNS O
. . . O

MAIN NNP NNP O
RESULTS NNS NNS O
: : : O
All DT DT O
the DT DT O
statistically RB RB O
significant JJ JJ O
results NNS NNS O
were VBD VBD O
derived VBN VBN O
from IN IN O
the DT DT O
two CD CD O
biggest JJS JJS O
trials NNS NNS O
. . . O

In IN IN O
relatively RB RB O
healthy JJ JJ O
women NNS NNS O
, , , O
combined VBN VBN O
continuous JJ JJ O
HT NNP NNP O
significantly RB RB O
increased VBD VBD O
the DT DT O
risk NN NN O
of IN IN O
venous JJ JJ O
thromboembolism NN NN O
or CC CC O
coronary JJ JJ O
event NN NN O
( ( ( O
after IN IN O
one CD CD O
year NN NN O
' '' '' O
s VBZ VBZ O
use NN NN O
) ) ) O
, , , O
stroke NN NN O
( ( ( O
after IN IN O
3 CD CD O
years NNS NNS O
) ) ) O
, , , O
breast NN NN O
cancer NN NN O
( ( ( O
after IN IN O
5 CD CD O
years NNS NNS O
) ) ) O
and CC CC O
gallbladder NN NN O
disease NN NN O
. . . O

Long JJ JJ O
- - - O
term NN NN O
oestrogen NN NN B-CHEM
- : : O
only RB RB O
HT NNP NNP O
also RB RB O
significantly RB RB O
increased VBN VBN O
the DT DT O
risk NN NN O
of IN IN O
stroke NN NN O
and CC CC O
gallbladder NN NN O
disease NN NN O
. . . O

Overall RB RB O
, , , O
the DT DT O
only RB RB O
statistically RB RB O
significant JJ JJ O
benefits NNS NNS O
of IN IN O
HT NNP NNP O
were VBD VBD O
a DT DT O
decreased VBN VBN O
incidence NN NN O
of IN IN O
fractures NNS NNS O
and CC CC O
colon NN NN O
cancer NN NN O
with IN IN O
long JJ JJ O
- - - O
term NN NN O
use NN NN O
. . . O

Among IN IN O
relatively RB RB O
healthy JJ JJ O
women NNS NNS O
over IN IN O
65 CD CD O
years NNS NNS O
taking VBG VBG O
continuous JJ JJ O
combined VBN VBN O
HT NNP NNP O
, , , O
there EX EX O
was VBD VBD O
a DT DT O
statistically RB RB O
significant JJ JJ O
increase NN NN O
in IN IN O
the DT DT O
incidence NN NN O
of IN IN O
dementia NN NN O
. . . O

Among IN IN O
women NNS NNS O
with IN IN O
cardiovascular JJ JJ O
disease NN NN O
, , , O
long JJ JJ O
- - - O
term NN NN O
use NN NN O
of IN IN O
combined VBN VBN O
continuous JJ JJ O
HT NNP NNP O
significantly RB RB O
increased VBD VBD O
the DT DT O
risk NN NN O
of IN IN O
venous JJ JJ O
thromboembolism NN NN O
. . . O

No DT DT O
trials NNS NNS O
focussed VBD VBD O
specifically RB RB O
on IN IN O
younger JJR JJR O
women NNS NNS O
. . . O

However RB RB O
, , , O
one CD CD O
trial NN NN O
analysed VBN VBN O
subgroups NNS NNS O
of IN IN O
2839 CD CD O
relatively RB RB O
healthy JJ JJ O
50 CD CD O
to TO TO O
59 CD CD O
year NN NN O
- : : O
old JJ JJ O
women NNS NNS O
taking VBG VBG O
combined VBN VBN O
continuous JJ JJ O
HT NNP NNP O
and CC CC O
1637 CD CD O
taking VBG VBG O
oestrogen NN NN B-CHEM
- - - O
only RB RB O
HT NNP NNP O
, , , O
versus CC CC O
similar JJ JJ O
- - - O
sized JJ JJ O
placebo NN NN O
groups NNS NNS O
. . . O

The DT DT O
only RB RB O
significantly RB RB O
increased VBN VBN O
risk NN NN O
reported VBD VBD O
was VBD VBD O
for IN IN O
venous JJ JJ O
thromboembolism NN NN O
in IN IN O
women NNS NNS O
taking VBG VBG O
combined VBN VBN O
continuous JJ JJ O
HT NNP NNP O
; : : O
their PRP$ PRP$ O
absolute JJ JJ O
risk NN NN O
remained VBD VBD O
very RB RB O
low JJ JJ O
. . . O

AUTHORS NNP NNP O
' POS POS O
CONCLUSIONS NNP NNP O
: : : O
HT NNP NNP O
is VBZ VBZ O
not RB RB O
indicated VBN VBN O
for IN IN O
the DT DT O
routine JJ JJ O
management NN NN O
of IN IN O
chronic JJ JJ O
disease NN NN O
. . . O

We PRP PRP O
need VBP VBP O
more JJR JJR O
evidence NN NN O
on IN IN O
the DT DT O
safety NN NN O
of IN IN O
HT NNP NNP O
for IN IN O
menopausal NN NN O
symptom NN NN O
control NN NN O
, , , O
though IN IN O
short JJ JJ O
- - - O
term NN NN O
use NN NN O
appears VBZ VBZ O
to TO TO O
be VB VB O
relatively RB RB O
safe JJ JJ O
for IN IN O
healthy JJ JJ O
younger NN NN O
women NNS NNS O
. . . O

Drug NN NN O
- : : O
induced JJ JJ O
liver NN NN O
injury NN NN O
: : : O
an DT DT O
analysis NN NN O
of IN IN O
461 CD CD O
incidences NNS NNS O
submitted VBN VBN O
to TO TO O
the DT DT O
Spanish JJ JJ O
registry NN NN O
over IN IN O
a DT DT O
10 CD CD O
- : : O
year NN NN O
period NN NN O
. . . O

BACKGROUND NNP NNP O
& CC CC O
AIMS NNP NNP O
: : : O
Progress NNP NNP O
in IN IN O
the DT DT O
understanding NN NN O
of IN IN O
susceptibility NN NN O
factors NNS NNS O
to TO TO O
drug NN NN O
- - - O
induced JJ JJ O
liver NN NN O
injury NN NN O
( ( ( O
DILI NNP NNP O
) ) ) O
and CC CC O
outcome JJ JJ O
predictability NN NN O
are VBP VBP O
hampered VBN VBN O
by IN IN O
the DT DT O
lack NN NN O
of IN IN O
systematic JJ JJ O
programs NNS NNS O
to TO TO O
detect VB VB O
bona NN NN O
fide NN NN O
cases NNS NNS O
. . . O

METHODS NNP NNP O
: : : O
A DT DT O
cooperative JJ JJ O
network NN NN O
was VBD VBD O
created VBN VBN O
in IN IN O
1994 CD CD O
in IN IN O
Spain NNP NNP O
to TO TO O
identify VB VB O
all DT DT O
suspicions NNS NNS O
of IN IN O
DILI NNP NNP O
following VBG VBG O
a DT DT O
prospective JJ JJ O
structured JJ JJ O
report NN NN O
form NN NN O
. . . O

The DT DT O
liver NN NN O
damage NN NN O
was VBD VBD O
characterized VBN VBN O
according VBG VBG O
to TO TO O
hepatocellular NN NN O
, , , O
cholestatic JJ JJ O
, , , O
and CC CC O
mixed JJ JJ O
laboratory NN NN O
criteria NNS NNS O
and CC CC O
to TO TO O
histologic VB VB O
criteria NNS NNS O
when WRB WRB O
available JJ JJ O
. . . O

Further RB RB O
evaluation NN NN O
of IN IN O
causality NN NN O
assessment NN NN O
was VBD VBD O
centrally RB RB O
performed VBN VBN O
. . . O

RESULTS NNS NNS O
: : : O
Since IN IN O
April NNP NNP O
1994 CD CD O
to TO TO O
August NNP NNP O
2004 CD CD O
, , , O
461 CD CD O
out IN IN O
of IN IN O
570 CD CD O
submitted VBD VBD O
cases NNS NNS O
, , , O
involving VBG VBG O
505 CD CD O
drugs NNS NNS O
, , , O
were VBD VBD O
deemed VBN VBN O
to TO TO O
be VB VB O
related VBN VBN O
to TO TO O
DILI NNP NNP O
. . . O

The DT DT O
antiinfective JJ JJ O
group NN NN O
of IN IN O
drugs NNS NNS O
was VBD VBD O
the DT DT O
more RBR RBR O
frequently RB RB O
incriminated VBN VBN O
, , , O
amoxicillin NN NN B-CHEM
- - - I-CHEM
clavulanate NN NN I-CHEM
accounting NN NN O
for IN IN O
the DT DT O
12 CD CD O
. . . O
8 CD CD O
% NN NN O
of IN IN O
the DT DT O
whole JJ JJ O
series NN NN O
. . . O

The DT DT O
hepatocellular NN NN O
pattern NN NN O
of IN IN O
damage NN NN O
was VBD VBD O
the DT DT O
most RBS RBS O
common JJ JJ O
( ( ( O
58 CD CD O
% NN NN O
) ) ) O
, , , O
was VBD VBD O
inversely RB RB O
correlated JJ JJ O
with IN IN O
age NN NN O
( ( ( O
P NN NN O
< NN NN O
. . . O
0001 CD CD O
) ) ) O
, , , O
and CC CC O
had VBD VBD O
the DT DT O
worst JJS JJS O
outcome NN NN O
( ( ( O
Cox NNP NNP O
regression NN NN O
, , , O
P NN NN O
< NN NN O
. . . O
034 CD CD O
) ) ) O
. . . O

Indeed RB RB O
, , , O
the DT DT O
incidence NN NN O
of IN IN O
liver NN NN O
transplantation NN NN O
and CC CC O
death NN NN O
in IN IN O
this DT DT O
group NN NN O
was VBD VBD O
11 CD CD O
. . . O
7 CD CD O
% NN NN O
if IN IN O
patients NNS NNS O
had VBD VBD O
jaundice NN NN O
at IN IN O
presentation NN NN O
, , , O
whereas IN IN O
the DT DT O
corresponding JJ JJ O
figure NN NN O
was VBD VBD O
3 CD CD O
. . . O
8 CD CD O
% NN NN O
in IN IN O
nonjaundiced JJ JJ O
patients NNS NNS O
( ( ( O
P NN NN O
< NN NN O
. . . O
04 CD CD O
) ) ) O
. . . O

Factors NNS NNS O
associated VBN VBN O
with IN IN O
the DT DT O
development NN NN O
of IN IN O
fulminant JJ JJ O
hepatic JJ JJ O
failure NN NN O
were VBD VBD O
female JJ JJ O
sex NN NN O
( ( ( O
OR CC CC O
= SYM SYM O
25 CD CD O
; : : O
95 CD CD O
% NN NN O
CI NNP NNP O
: : : O
4 CD CD O
. . . O
1 CD CD O
- : : O
151 CD CD O
; : : O
P NN NN O
< NN NN O
. . . O
0001 CD CD O
) ) ) O
, , , O
hepatocellular NN NN O
damage NN NN O
( ( ( O
OR CC CC O
= SYM SYM O
7 CD CD O
. . . O
9 CD CD O
; : : O
95 CD CD O
% NN NN O
CI NNP NNP O
: : : O
1 CD CD O
. . . O
6 CD CD O
- : : O
37 CD CD O
; : : O
P NN NN O
< NN NN O
. . . O
009 CD CD O
) ) ) O
, , , O
and CC CC O
higher JJR JJR O
baseline NN NN O
plasma NN NN O
bilirubin NN NN B-CHEM
value NN NN O
( ( ( O
OR CC CC O
= SYM SYM O
1 CD CD O
. . . O
15 CD CD O
; : : O
95 CD CD O
% NN NN O
CI NNP NNP O
: : : O
1 CD CD O
. . . O
09 CD CD O
- : : O
1 CD CD O
. . . O
22 CD CD O
; : : O
P NN NN O
< NN NN O
. . . O
0001 CD CD O
) ) ) O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Patients NNS NNS O
with IN IN O
drug NN NN O
- - - O
induced JJ JJ O
hepatocellular NN NN O
jaundice NN NN O
have VBP VBP O
11 CD CD O
. . . O
7 CD CD O
% NN NN O
chance NN NN O
of IN IN O
progressing VBG VBG O
to TO TO O
death NN NN O
or CC CC O
transplantation NN NN O
. . . O

Amoxicillin NNP NNP B-CHEM
- : : I-CHEM
clavulanate NN NN I-CHEM
stands VBZ VBZ O
out IN IN O
as IN IN O
the DT DT O
most RBS RBS O
common JJ JJ O
drug NN NN O
related VBN VBN O
to TO TO O
DILI NNP NNP O
. . . O

Morphological NNP NNP O
evaluation NN NN O
of IN IN O
the DT DT O
effect NN NN O
of IN IN O
d SYM SYM B-CHEM
- : : I-CHEM
ribose NN NN I-CHEM
on IN IN O
adriamycin NN NN B-CHEM
- : : O
evoked JJ JJ O
cardiotoxicity NN NN O
in IN IN O
rats NNS NNS O
. . . O

The DT DT O
influence NN NN O
of IN IN O
d SYM SYM B-CHEM
- : : I-CHEM
ribose NN NN I-CHEM
on IN IN O
adriamycin NN NN B-CHEM
- : : O
induced JJ JJ O
myocardiopathy NN NN O
in IN IN O
rats NNS NNS O
was VBD VBD O
studied VBN VBN O
. . . O

Adriamycin NNP NNP B-CHEM
in IN IN O
the DT DT O
cumulative JJ JJ O
dose NN NN O
of IN IN O
25 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
evoked JJ JJ O
fully RB RB O
developed VBN VBN O
cardiac JJ JJ O
toxicity NN NN O
. . . O

D NNP NNP B-CHEM
- : : I-CHEM
ribose VB VB I-CHEM
in IN IN O
the DT DT O
multiple JJ JJ O
doses NNS NNS O
of IN IN O
200 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
did VBD VBD O
not RB RB O
influence VB VB O
ADR NNP NNP B-CHEM
cardiotoxicity NN NN O
. . . O

In IN IN O
vivo NN NN O
evidences NNS NNS O
suggesting VBG VBG O
the DT DT O
role NN NN O
of IN IN O
oxidative JJ JJ O
stress NN NN O
in IN IN O
pathogenesis NNS NNS O
of IN IN O
vancomycin NN NN B-CHEM
- - - O
induced JJ JJ O
nephrotoxicity NN NN O
: : : O
protection NN NN O
by IN IN O
erdosteine NN NN B-CHEM
. . . O

The DT DT O
aims NNS NNS O
of IN IN O
this DT DT O
study NN NN O
were VBD VBD O
to TO TO O
examine VB VB O
vancomycin NN NN B-CHEM
( ( ( O
VCM NNP NNP B-CHEM
) ) ) O
- : : O
induced JJ JJ O
oxidative JJ JJ O
stress NN NN O
that WDT WDT O
promotes VBZ VBZ O
production NN NN O
of IN IN O
reactive JJ JJ O
oxygen NN NN B-CHEM
species NNS NNS O
( ( ( O
ROS NNP NNP O
) ) ) O
and CC CC O
to TO TO O
investigate VB VB O
the DT DT O
role NN NN O
of IN IN O
erdosteine NN NN B-CHEM
, , , O
an DT DT O
expectorant JJ JJ O
agent NN NN O
, , , O
which WDT WDT O
has VBZ VBZ O
also RB RB O
antioxidant JJ JJ O
properties NNS NNS O
, , , O
on IN IN O
kidney NN NN O
tissue NN NN O
against IN IN O
the DT DT O
possible JJ JJ O
VCM NNP NNP B-CHEM
- : : O
induced JJ JJ O
renal JJ JJ O
impairment NN NN O
in IN IN O
rats NNS NNS O
. . . O

Rats NNP NNP O
were VBD VBD O
divided VBN VBN O
into IN IN O
three CD CD O
groups NNS NNS O
: : : O
sham NN NN O
, , , O
VCM NNP NNP B-CHEM
and CC CC O
VCM NNP NNP B-CHEM
plus CC CC O
erdosteine NN NN B-CHEM
. . . O

VCM NNP NNP B-CHEM
was VBD VBD O
administrated VBN VBN O
intraperitoneally RB RB O
( ( ( O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
with IN IN O
200mgkg CD CD O
( ( ( O
- : : O
1 CD CD O
) ) ) O
twice RB RB O
daily JJ JJ O
for IN IN O
7 CD CD O
days NNS NNS O
. . . O

Erdosteine NNP NNP B-CHEM
was VBD VBD O
administered VBN VBN O
orally RB RB O
. . . O

VCM NNP NNP B-CHEM
administration NN NN O
to TO TO O
control VB VB O
rats NNS NNS O
significantly RB RB O
increased VBN VBN O
renal JJ JJ O
malondialdehyde NN NN B-CHEM
( ( ( O
MDA NNP NNP B-CHEM
) ) ) O
and CC CC O
urinary JJ JJ O
N NNP NNP O
- : : O
acetyl NN NN O
- - - O
beta NN NN O
- - - O
d SYM SYM O
- : : O
glucosaminidase NN NN O
( ( ( O
NAG NNP NNP O
, , , O
a DT DT O
marker NN NN O
of IN IN O
renal JJ JJ O
tubular NN NN O
injury NN NN O
) ) ) O
excretion NN NN O
but CC CC O
decreased VBD VBD O
superoxide JJ JJ B-CHEM
dismutase NN NN O
( ( ( O
SOD NNP NNP O
) ) ) O
and CC CC O
catalase NN NN O
( ( ( O
CAT NNP NNP O
) ) ) O
activities NNS NNS O
. . . O

Erdosteine NNP NNP B-CHEM
administration NN NN O
with IN IN O
VCM NNP NNP B-CHEM
injections NNS NNS O
caused VBD VBD O
significantly RB RB O
decreased VBN VBN O
renal JJ JJ O
MDA NNP NNP B-CHEM
and CC CC O
urinary JJ JJ O
NAG NNP NNP O
excretion NN NN O
, , , O
and CC CC O
increased VBD VBD O
SOD NNP NNP O
activity NN NN O
, , , O
but CC CC O
not RB RB O
CAT NNP NNP O
activity NN NN O
in IN IN O
renal JJ JJ O
tissue NN NN O
when WRB WRB O
compared VBN VBN O
with IN IN O
VCM NNP NNP B-CHEM
alone RB RB O
. . . O

Erdosteine NNP NNP B-CHEM
showed VBD VBD O
histopathological JJ JJ O
protection NN NN O
against IN IN O
VCM NNP NNP B-CHEM
- : : O
induced JJ JJ O
nephrotoxicity NN NN O
. . . O

There EX EX O
were VBD VBD O
a DT DT O
significant JJ JJ O
dilatation NN NN O
of IN IN O
tubular JJ JJ O
lumens NNS NNS O
, , , O
extensive JJ JJ O
epithelial NN NN O
cell NN NN O
vacuolization NN NN O
, , , O
atrophy NN NN O
, , , O
desquamation NN NN O
, , , O
and CC CC O
necrosis NN NN O
in IN IN O
VCM NNP NNP B-CHEM
- - - O
treated JJ JJ O
rats NNS NNS O
more JJR JJR O
than IN IN O
those DT DT O
of IN IN O
the DT DT O
control NN NN O
and CC CC O
the DT DT O
erdosteine NN NN B-CHEM
groups NNS NNS O
. . . O

Erdosteine NNP NNP B-CHEM
caused VBD VBD O
a DT DT O
marked JJ JJ O
reduction NN NN O
in IN IN O
the DT DT O
extent NN NN O
of IN IN O
tubular NN NN O
damage NN NN O
. . . O

It PRP PRP O
is VBZ VBZ O
concluded VBN VBN O
that IN IN O
oxidative JJ JJ O
tubular NN NN O
damage NN NN O
plays VBZ VBZ O
an DT DT O
important JJ JJ O
role NN NN O
in IN IN O
the DT DT O
VCM NNP NNP B-CHEM
- - - O
induced JJ JJ O
nephrotoxicity NN NN O
and CC CC O
the DT DT O
modulation NN NN O
of IN IN O
oxidative JJ JJ O
stress NN NN O
with IN IN O
erdosteine NN NN B-CHEM
reduces VBZ VBZ O
the DT DT O
VCM NNP NNP B-CHEM
- - - O
induced JJ JJ O
kidney NN NN O
damage NN NN O
both DT DT O
at IN IN O
the DT DT O
biochemical JJ JJ O
and CC CC O
histological JJ JJ O
levels NNS NNS O
. . . O

Gemfibrozil NNP NNP B-CHEM
- : : O
lovastatin NN NN B-CHEM
therapy NN NN O
for IN IN O
primary JJ JJ O
hyperlipoproteinemias NN NN O
. . . O

The DT DT O
specific JJ JJ O
aim NN NN O
of IN IN O
this DT DT O
retrospective NN NN O
, , , O
observational JJ JJ O
study NN NN O
was VBD VBD O
to TO TO O
assess VB VB O
safety NN NN O
and CC CC O
efficacy NN NN O
of IN IN O
long JJ JJ O
- - - O
term NN NN O
( ( ( O
21 CD CD O
months NNS NNS O
/ NN NN O
patient NN NN O
) ) ) O
, , , O
open JJ JJ O
- - - O
label NN NN O
, , , O
gemfibrozil NN NN B-CHEM
- - - O
lovastatin NN NN B-CHEM
treatment NN NN O
in IN IN O
80 CD CD O
patients NNS NNS O
with IN IN O
primary JJ JJ O
mixed JJ JJ O
hyperlipidemia NN NN O
( ( ( O
68 CD CD O
% NN NN O
of IN IN O
whom WP WP O
had VBD VBD O
atherosclerotic JJ JJ O
vascular NN NN O
disease NN NN O
) ) ) O
. . . O

Because IN IN O
ideal JJ JJ O
lipid JJ JJ O
targets NNS NNS O
were VBD VBD O
not RB RB O
reached VBN VBN O
( ( ( O
low JJ JJ O
- - - O
density NN NN O
lipoprotein NN NN O
( ( ( O
LDL NNP NNP O
) ) ) O
cholesterol NN NN B-CHEM
less JJR JJR O
than IN IN O
130 CD CD O
mg NN NN O
/ NN NN O
dl NN NN O
, , , O
high JJ JJ O
- - - O
density NN NN O
lipoprotein NN NN O
( ( ( O
HDL NNP NNP O
) ) ) O
cholesterol NN NN B-CHEM
greater JJR JJR O
than IN IN O
35 CD CD O
mg NN NN O
/ NN NN O
dl NN NN O
, , , O
or CC CC O
total JJ JJ O
cholesterol NN NN B-CHEM
/ NN NN O
HDL NNP NNP O
cholesterol NN NN B-CHEM
less JJR JJR O
than IN IN O
4 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
dl NN NN O
) ) ) O
with IN IN O
diet NN NN O
plus CC CC O
a DT DT O
single JJ JJ O
drug NN NN O
, , , O
gemfibrozil NN NN B-CHEM
( ( ( O
1 CD CD O
. . . O
2 CD CD O
g SYM SYM O
/ NN NN O
day NN NN O
) ) ) O
- : : O
lovastatin NN NN B-CHEM
( ( ( O
primarily RB RB O
20 CD CD O
or CC CC O
40 CD CD O
mg NN NN O
) ) ) O
treatment NN NN O
was VBD VBD O
given VBN VBN O
. . . O

Follow VB VB O
- - - O
up RP RP O
visits NNS NNS O
were VBD VBD O
scheduled VBN VBN O
with IN IN O
2 CD CD O
- : : O
drug NN NN O
therapy NN NN O
every DT DT O
6 CD CD O
to TO TO O
8 CD CD O
weeks NNS NNS O
, , , O
an DT DT O
average JJ JJ O
of IN IN O
10 CD CD O
. . . O
3 CD CD O
visits NNS NNS O
per IN IN O
patient NN NN O
, , , O
with IN IN O
741 CD CD O
batteries NNS NNS O
of IN IN O
6 CD CD O
liver NN NN O
function NN NN O
tests NNS NNS O
and CC CC O
714 CD CD O
creatine NN NN B-CHEM
phosphokinase NN NN O
levels NNS NNS O
measured VBN VBN O
. . . O

Only RB RB O
1 CD CD O
of IN IN O
the DT DT O
4 CD CD O
, , , O
446 CD CD O
liver NN NN O
function NN NN O
tests NNS NNS O
( ( ( O
0 CD CD O
. . . O
02 CD CD O
% NN NN O
) ) ) O
, , , O
a DT DT O
gamma NN NN O
glutamyl NN NN O
transferase NN NN O
, , , O
was VBD VBD O
greater JJR JJR O
than IN IN O
or CC CC O
equal JJ JJ O
to TO TO O
3 CD CD O
times NNS NNS O
the DT DT O
upper JJ JJ O
normal JJ JJ O
limit NN NN O
. . . O

Of IN IN O
the DT DT O
714 CD CD O
creatine NN NN B-CHEM
phosphokinase NN NN O
levels NNS NNS O
, , , O
9 CD CD O
% NN NN O
were VBD VBD O
high JJ JJ O
; : : O
only RB RB O
1 CD CD O
( ( ( O
0 CD CD O
. . . O
1 CD CD O
% NN NN O
) ) ) O
was VBD VBD O
greater JJR JJR O
than IN IN O
or CC CC O
equal JJ JJ O
to TO TO O
3 CD CD O
times NNS NNS O
the DT DT O
upper JJ JJ O
normal JJ JJ O
limit NN NN O
. . . O

With IN IN O
2 CD CD O
- : : O
drug NN NN O
therapy NN NN O
, , , O
mean VB VB O
total JJ JJ O
cholesterol NN NN B-CHEM
decreased VBD VBD O
22 CD CD O
% NN NN O
from IN IN O
255 CD CD O
to TO TO O
200 CD CD O
mg NN NN O
/ NN NN O
dl NN NN O
, , , O
triglyceride NN NN B-CHEM
levels NNS NNS O
decreased VBD VBD O
35 CD CD O
% NN NN O
from IN IN O
236 CD CD O
to TO TO O
154 CD CD O
mg NN NN O
/ NN NN O
dl NN NN O
, , , O
LDL NNP NNP O
cholesterol NN NN B-CHEM
decreased VBD VBD O
26 CD CD O
% NN NN O
from IN IN O
176 CD CD O
to TO TO O
131 CD CD O
mg NN NN O
/ NN NN O
dl NN NN O
, , , O
and CC CC O
the DT DT O
total JJ JJ O
cholesterol NN NN B-CHEM
/ NN NN O
HDL NNP NNP O
cholesterol NN NN B-CHEM
ratio NN NN O
decreased VBD VBD O
24 CD CD O
% NN NN O
from IN IN O
7 CD CD O
. . . O
1 CD CD O
to TO TO O
5 CD CD O
. . . O
4 CD CD O
, , , O
all DT DT O
p NN NN O
less JJR JJR O
than IN IN O
or CC CC O
equal JJ JJ O
to TO TO O
0 CD CD O
. . . O
0001 CD CD O
. . . O

Myositis NNP NNP O
, , , O
attributable JJ JJ O
to TO TO O
the DT DT O
drug NN NN O
combination NN NN O
and CC CC O
symptomatic JJ JJ O
enough RB RB O
to TO TO O
discontinue VB VB O
it PRP PRP O
, , , O
occurred VBD VBD O
in IN IN O
3 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
, , , O
and CC CC O
in IN IN O
1 CD CD O
% NN NN O
with IN IN O
concurrent NN NN O
high JJ JJ O
creatine NN NN B-CHEM
phosphokinase NN NN O
( ( ( O
769 CD CD O
U NNP NNP O
/ NN NN O
liter NN NN O
) ) ) O
; : : O
no DT DT O
patients NNS NNS O
had VBD VBD O
rhabdomyolysis NN NN O
or CC CC O
myoglobinuria NN NN O
. . . O
( ( ( O
ABSTRACT NNP NNP O
TRUNCATED NNP NNP O
AT IN IN O
250 CD CD O
WORDS NNP NNP O
) ) ) O

Does VBZ VBZ O
domperidone NN NN B-CHEM
potentiate NN NN O
mirtazapine NN NN B-CHEM
- - - O
associated VBN VBN O
restless NN NN O
legs NNS NNS O
syndrome NN NN O
? . . O

There EX EX O
is VBZ VBZ O
now RB RB O
evidence NN NN O
to TO TO O
suggest VB VB O
a DT DT O
central JJ JJ O
role NN NN O
for IN IN O
the DT DT O
dopaminergic JJ JJ O
system NN NN O
in IN IN O
restless NN NN O
legs NNS NNS O
syndrome NN NN O
( ( ( O
RLS NNP NNP O
) ) ) O
. . . O

For IN IN O
example NN NN O
, , , O
the DT DT O
symptoms NNS NNS O
of IN IN O
RLS NNP NNP O
can MD MD O
be VB VB O
dramatically RB RB O
improved VBN VBN O
by IN IN O
levodopa NN NN B-CHEM
and CC CC O
dopamine NN NN B-CHEM
agonists NNS NNS O
, , , O
whereas IN IN O
central JJ JJ O
dopamine NN NN B-CHEM
D2 NN NN O
receptor NN NN O
antagonists NNS NNS O
can MD MD O
induce VB VB O
or CC CC O
aggravate VB VB O
RLS NNP NNP O
symptoms NNS NNS O
. . . O

To TO TO O
our PRP$ PRP$ O
knowledge NN NN O
, , , O
there EX EX O
is VBZ VBZ O
no DT DT O
previous JJ JJ O
report NN NN O
regarding VBG VBG O
whether IN IN O
domperidone NN NN B-CHEM
, , , O
a DT DT O
peripheral JJ JJ O
dopamine NN NN B-CHEM
D2 NN NN O
receptor NN NN O
antagonist NN NN O
, , , O
can MD MD O
also RB RB O
induce VB VB O
or CC CC O
aggravate VB VB O
symptoms NNS NNS O
of IN IN O
RLS NNP NNP O
. . . O

Mirtazapine NNP NNP B-CHEM
, , , O
the DT DT O
first JJ JJ O
noradrenergic NN NN O
and CC CC O
specific JJ JJ O
serotonergic JJ JJ O
antidepressant NN NN O
( ( ( O
NaSSA NNP NNP O
) ) ) O
, , , O
has VBZ VBZ O
been VBN VBN O
associated VBN VBN O
with IN IN O
RLS NNP NNP O
in IN IN O
several JJ JJ O
recent JJ JJ O
publications NNS NNS O
. . . O

The DT DT O
authors NNS NNS O
report VBP VBP O
here RB RB O
a DT DT O
depressed VBN VBN O
patient NN NN O
comorbid NN NN O
with IN IN O
postprandial JJ JJ O
dyspepsia NN NN O
who WP WP O
developed VBD VBD O
RLS NNP NNP O
after IN IN O
mirtazapine NN NN B-CHEM
had VBD VBD O
been VBN VBN O
added VBN VBN O
to TO TO O
his PRP$ PRP$ O
domperidone NN NN B-CHEM
therapy NN NN O
. . . O

Our PRP$ PRP$ O
patient NN NN O
started VBD VBD O
to TO TO O
have VB VB O
symptoms NNS NNS O
of IN IN O
RLS NNP NNP O
only RB RB O
after IN IN O
he PRP PRP O
had VBD VBD O
been VBN VBN O
treated VBN VBN O
with IN IN O
mirtazapine NN NN B-CHEM
, , , O
and CC CC O
his PRP$ PRP$ O
RLS NNP NNP O
symptoms NNS NNS O
resolved VBD VBD O
completely RB RB O
upon IN IN O
discontinuation NN NN O
of IN IN O
his PRP$ PRP$ O
mirtazapine NN NN B-CHEM
. . . O

Such JJ JJ O
a DT DT O
temporal JJ JJ O
relationship NN NN O
between IN IN O
the DT DT O
use NN NN O
of IN IN O
mirtazapine NN NN B-CHEM
and CC CC O
the DT DT O
symptoms NNS NNS O
of IN IN O
RLS NNP NNP O
in IN IN O
our PRP$ PRP$ O
patient NN NN O
did VBD VBD O
not RB RB O
support VB VB O
a DT DT O
potentiating VBG VBG O
effect NN NN O
of IN IN O
domperione NN NN B-CHEM
on IN IN O
mirtazapine NN NN B-CHEM
- : : O
associated VBN VBN O
RLS NNP NNP O
. . . O

However RB RB O
, , , O
physicians NNS NNS O
should MD MD O
be VB VB O
aware JJ JJ O
of IN IN O
the DT DT O
possibility NN NN O
that IN IN O
mirtazapine NN NN B-CHEM
can MD MD O
be VB VB O
associated VBN VBN O
with IN IN O
RLS NNP NNP O
in IN IN O
some DT DT O
individuals NNS NNS O
, , , O
especially RB RB O
those DT DT O
receiving VBG VBG O
concomitant JJ JJ O
dopamine NN NN B-CHEM
D2 NN NN O
receptor NN NN O
antagonists NNS NNS O
. . . O

Antiandrogenic JJ JJ O
therapy NN NN O
can MD MD O
cause VB VB O
coronary JJ JJ O
arterial NN NN O
disease NN NN O
. . . O

AIM NNP NNP O
: : : O
To TO TO O
study VB VB O
the DT DT O
change NN NN O
of IN IN O
lipid NN NN O
metabolism NN NN O
by IN IN O
antiandrogen NN NN O
therapy NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
prostate NN NN O
cancer NN NN O
. . . O

MATERIALS NNS NNS O
AND CC CC O
METHODS NNP NNP O
: : : O
We PRP PRP O
studied VBD VBD O
with IN IN O
a DT DT O
2 CD CD O
. . . O
5 CD CD O
years NNS NNS O
follow VB VB O
- : : O
up RP RP O
the DT DT O
changes NNS NNS O
in IN IN O
plasma NN NN O
cholesterols NNS NNS B-CHEM
( ( ( O
C NNP NNP B-CHEM
) ) ) O
, , , O
triglycerides NNS NNS B-CHEM
( ( ( O
TG NNP NNP B-CHEM
) ) ) O
, , , O
lipoproteins NNS NNS O
( ( ( O
LP NNP NNP O
) ) ) O
, , , O
and CC CC O
apolipoproteins NNS NNS O
( ( ( O
Apo NNP NNP O
) ) ) O
B NNP NNP O
- - - O
100 CD CD O
, , , O
A DT DT O
- - - O
I PRP PRP O
, , , O
and CC CC O
A DT DT O
- - - O
II NNP NNP O
pro FW FW O
fi NN NN O
les NNS NNS O
in IN IN O
24 CD CD O
patients NNS NNS O
of IN IN O
mean NN NN O
age NN NN O
60 CD CD O
years NNS NNS O
with IN IN O
low JJ JJ O
risk NN NN O
prostate NN NN O
cancer NN NN O
( ( ( O
stage NN NN O
: : : O
T1cN0M0 NNP NNP O
, , , O
Gleason NNP NNP O
score NN NN O
: : : O
2 CD CD O
- : : O
5 CD CD O
) ) ) O
during IN IN O
treatment NN NN O
with IN IN O
cyproterone NN NN B-CHEM
acetate NN NN I-CHEM
( ( ( O
CPA NNP NNP B-CHEM
) ) ) O
without IN IN O
surgical JJ JJ O
management NN NN O
or CC CC O
radiation NN NN O
therapy NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Significant JJ JJ O
decreases NNS NNS O
of IN IN O
HDL NNP NNP O
- : : O
C NNP NNP O
, , , O
Apo NNP NNP O
A DT DT O
- : : O
I PRP PRP O
and CC CC O
Apo NNP NNP O
A DT DT O
- - - O
II NNP NNP O
and CC CC O
an DT DT O
increase NN NN O
of IN IN O
triglyceride NN NN B-CHEM
levels NNS NNS O
in IN IN O
VLDL NNP NNP O
were VBD VBD O
induced VBN VBN O
by IN IN O
CPA NNP NNP B-CHEM
. . . O

After IN IN O
a DT DT O
period NN NN O
of IN IN O
2 CD CD O
. . . O
5 CD CD O
years NNS NNS O
on IN IN O
CPA NNP NNP B-CHEM
treatment NN NN O
, , , O
four CD CD O
patients NNS NNS O
out IN IN O
of IN IN O
twenty CD CD O
- - - O
four CD CD O
were VBD VBD O
found VBN VBN O
to TO TO O
be VB VB O
affected VBN VBN O
by IN IN O
coronary JJ JJ O
heart NN NN O
disease NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Ischaemic NNP NNP O
coronary JJ JJ O
arteriosclerosis NN NN O
with IN IN O
an DT DT O
incidence NN NN O
rate NN NN O
of IN IN O
16 CD CD O
. . . O
6 CD CD O
% NN NN O
as IN IN O
caused VBN VBN O
by IN IN O
prolonged JJ JJ O
CPA NNP NNP B-CHEM
therapy NN NN O
is VBZ VBZ O
mediated VBN VBN O
through IN IN O
changes NNS NNS O
in IN IN O
HDL NNP NNP O
cholesterol NN NN B-CHEM
, , , O
Apo NNP NNP O
A DT DT O
- : : O
I PRP PRP O
and CC CC O
Apo NNP NNP O
A DT DT O
- - - O
II NNP NNP O
pro FW FW O
fi NN NN O
les NNS NNS O
, , , O
other JJ JJ O
than IN IN O
the DT DT O
well RB RB O
- - - O
known VBN VBN O
hyperglyceridemic JJ JJ O
effect NN NN O
caused VBN VBN O
by IN IN O
estrogen NN NN B-CHEM
. . . O

5 CD CD B-CHEM
- : : I-CHEM
Fluorouracil NNP NNP I-CHEM
cardiotoxicity NN NN O
induced VBN VBN O
by IN IN O
alpha NN NN B-CHEM
- - - I-CHEM
fluoro NN NN I-CHEM
- - - I-CHEM
beta NN NN I-CHEM
- - - I-CHEM
alanine NN NN I-CHEM
. . . O

Cardiotoxicity NNP NNP O
is VBZ VBZ O
a DT DT O
rare JJ JJ O
complication NN NN O
occurring VBG VBG O
during IN IN O
5 CD CD B-CHEM
- : : I-CHEM
fluorouracil NN NN I-CHEM
( ( ( O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
) ) ) O
treatment NN NN O
for IN IN O
malignancies NNS NNS O
. . . O

We PRP PRP O
herein NN NN O
report NN NN O
the DT DT O
case NN NN O
of IN IN O
a DT DT O
70 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
man NN NN O
with IN IN O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
- : : O
induced JJ JJ O
cardiotoxicity NN NN O
, , , O
in IN IN O
whom WP WP O
a DT DT O
high JJ JJ O
serum NN NN O
level NN NN O
of IN IN O
alpha JJ JJ B-CHEM
- - - I-CHEM
fluoro NN NN I-CHEM
- - - I-CHEM
beta NN NN I-CHEM
- - - I-CHEM
alanine NN NN I-CHEM
( ( ( O
FBAL NNP NNP B-CHEM
) ) ) O
was VBD VBD O
observed VBN VBN O
. . . O

The DT DT O
patient NN NN O
, , , O
who WP WP O
had VBD VBD O
unresectable JJ JJ O
colon NN NN O
cancer NN NN O
metastases NNS NNS O
to TO TO O
the DT DT O
liver NN NN O
and CC CC O
lung NN NN O
, , , O
was VBD VBD O
referred VBN VBN O
to TO TO O
us PRP PRP O
for IN IN O
chemotherapy NN NN O
from IN IN O
an DT DT O
affiliated JJ JJ O
hospital NN NN O
; : : O
he PRP PRP O
had VBD VBD O
no DT DT O
cardiac NN NN O
history NN NN O
. . . O

After IN IN O
admission NN NN O
, , , O
the DT DT O
patient NN NN O
received VBD VBD O
a DT DT O
continuous JJ JJ O
intravenous JJ JJ O
infusion NN NN O
of IN IN O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
( ( ( O
1000 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
) ) ) O
, , , O
during IN IN O
which WDT WDT O
precordial JJ JJ O
pain NN NN O
with IN IN O
right NN NN O
bundle NN NN O
branch NN NN O
block NN NN O
occurred VBD VBD O
concomitantly RB RB O
with IN IN O
a DT DT O
high JJ JJ O
serum NN NN O
FBAL NNP NNP B-CHEM
concentration NN NN O
of IN IN O
1955 CD CD O
ng NN NN O
/ NN NN O
ml NN NN O
. . . O

Both DT DT O
the DT DT O
precordial JJ JJ O
pain NN NN O
and CC CC O
the DT DT O
electrocardiographic JJ JJ O
changes NNS NNS O
disappeared VBD VBD O
spontaneously RB RB O
after IN IN O
the DT DT O
discontinuation NN NN O
of IN IN O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
. . . O

As IN IN O
the DT DT O
precordial JJ JJ O
pain NN NN O
in IN IN O
this DT DT O
patient NN NN O
was VBD VBD O
considered VBN VBN O
to TO TO O
have VB VB O
been VBN VBN O
due JJ JJ O
to TO TO O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
- : : O
induced JJ JJ O
cardiotoxicity NN NN O
, , , O
the DT DT O
administration NN NN O
of IN IN O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
was VBD VBD O
abandoned VBN VBN O
. . . O

Instead RB RB O
, , , O
oral JJ JJ O
administration NN NN O
of IN IN O
S NNP NNP O
- : : O
1 CD CD O
( ( ( O
a DT DT O
derivative NN NN O
of IN IN O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
) ) ) O
, , , O
at IN IN O
200 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
twice RB RB O
a DT DT O
week NN NN O
, , , O
was VBD VBD O
instituted VBN VBN O
, , , O
because IN IN O
S NNP NNP O
- : : O
1 CD CD O
has VBZ VBZ O
a DT DT O
strong JJ JJ O
inhibitory NN NN O
effect NN NN O
on IN IN O
dihydropyrimidine NN NN B-CHEM
dehydrogenase NN NN O
, , , O
which WDT WDT O
catalyzes VBZ VBZ O
the DT DT O
degradative NN NN O
of IN IN O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
into IN IN O
FBAL NNP NNP B-CHEM
. . . O

The DT DT O
serum NN NN O
FBAL NNP NNP B-CHEM
concentration NN NN O
subsequently RB RB O
decreased VBD VBD O
to TO TO O
352 CD CD O
ng NN NN O
/ NN NN O
ml NN NN O
, , , O
the DT DT O
same JJ JJ O
as IN IN O
the DT DT O
value NN NN O
measured VBN VBN O
on IN IN O
the DT DT O
first JJ JJ O
day NN NN O
of IN IN O
S NNP NNP O
- : : O
1 CD CD O
administration NN NN O
. . . O

Thereafter NNP NNP O
, , , O
no DT DT O
cardiac NN NN O
symptoms NNS NNS O
were VBD VBD O
observed VBN VBN O
. . . O

The DT DT O
patient NN NN O
achieved VBD VBD O
a DT DT O
partial JJ JJ O
response NN NN O
6 CD CD O
months NNS NNS O
after IN IN O
the DT DT O
initiation NN NN O
of IN IN O
the DT DT O
S NNP NNP O
- - - O
1 CD CD O
treatment NN NN O
. . . O

The DT DT O
experience NN NN O
of IN IN O
this DT DT O
case NN NN O
, , , O
together RB RB O
with IN IN O
a DT DT O
review NN NN O
of IN IN O
the DT DT O
literature NN NN O
, , , O
suggests VBZ VBZ O
that IN IN O
FBAL NNP NNP B-CHEM
is VBZ VBZ O
related VBN VBN O
to TO TO O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
- : : O
induced JJ JJ O
cardiotoxicity NN NN O
. . . O

S NNP NNP O
- : : O
1 CD CD O
may MD MD O
be VB VB O
administered VBN VBN O
safely RB RB O
to TO TO O
patients NNS NNS O
with IN IN O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
- : : O
induced JJ JJ O
cardiotoxicity NN NN O
. . . O

Hepatocellular NNP NNP O
carcinoma NN NN O
in IN IN O
Fanconi NNP NNP O
' POS POS O
s VBZ VBZ O
anemia NN NN O
treated VBN VBN O
with IN IN O
androgen NN NN B-CHEM
and CC CC O
corticosteroid NN NN B-CHEM
. . . O

The DT DT O
case NN NN O
of IN IN O
an DT DT O
11 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
boy NN NN O
is VBZ VBZ O
reported VBN VBN O
who WP WP O
was VBD VBD O
known VBN VBN O
to TO TO O
have VB VB O
Fanconi NNP NNP O
' POS POS O
s VBZ VBZ O
anemia NN NN O
for IN IN O
3 CD CD O
years NNS NNS O
and CC CC O
was VBD VBD O
treated VBN VBN O
with IN IN O
androgens NNS NNS B-CHEM
, , , O
corticosteroids NNS NNS B-CHEM
and CC CC O
transfusions NNS NNS O
. . . O

Two CD CD O
weeks NNS NNS O
before IN IN O
his PRP$ PRP$ O
death NN NN O
he PRP PRP O
was VBD VBD O
readmitted VBN VBN O
because IN IN O
of IN IN O
aplastic JJ JJ O
crisis NN NN O
with IN IN O
septicemia NN NN O
and CC CC O
marked VBN VBN O
abnormalities NNS NNS O
in IN IN O
liver NN NN O
function NN NN O
and CC CC O
died VBD VBD O
of IN IN O
hemorrhagic NN NN O
bronchopneumonia NN NN O
. . . O

At IN IN O
autopsy NN NN O
peliosis NN NN O
and CC CC O
multiple JJ JJ O
hepatic JJ JJ O
tumors NNS NNS O
were VBD VBD O
found VBN VBN O
which WDT WDT O
histologically RB RB O
proved VBN VBN O
to TO TO O
be VB VB O
well RB RB O
- - - O
differentiated JJ JJ O
hepatocellular NN NN O
carcinoma NN NN O
. . . O

This DT DT O
case NN NN O
contributes VBZ VBZ O
to TO TO O
the DT DT O
previous JJ JJ O
observations NNS NNS O
that WDT WDT O
non NN NN O
- - - O
metastasizing VBG VBG O
hepatic JJ JJ O
neoplasms NNS NNS O
and CC CC O
peliosis NNS NNS O
can MD MD O
develop VB VB O
in IN IN O
patients NNS NNS O
with IN IN O
androgen NN NN B-CHEM
- - - O
and CC CC O
corticosteroid NN NN B-CHEM
- - - O
treated VBN VBN O
Fanconi NNP NNP O
' POS POS O
s VBZ VBZ O
anemia NN NN O
. . . O

The DT DT O
influence NN NN O
of IN IN O
the DT DT O
time NN NN O
interval NN NN O
between IN IN O
monoHER NN NN B-CHEM
and CC CC O
doxorubicin NN NN B-CHEM
administration NN NN O
on IN IN O
the DT DT O
protection NN NN O
against IN IN O
doxorubicin NN NN B-CHEM
- - - O
induced JJ JJ O
cardiotoxicity NN NN O
in IN IN O
mice NN NN O
. . . O

PURPOSE NNP NNP O
: : : O
Despite IN IN O
its PRP$ PRP$ O
well RB RB O
- - - O
known VBN VBN O
cardiotoxicity NN NN O
, , , O
the DT DT O
anthracyclin NN NN O
doxorubicin NN NN B-CHEM
( ( ( O
DOX NNP NNP B-CHEM
) ) ) O
continues VBZ VBZ O
to TO TO O
be VB VB O
an DT DT O
effective JJ JJ O
and CC CC O
widely RB RB O
used VBN VBN O
chemotherapeutic JJ JJ O
agent NN NN O
. . . O

DOX NNP NNP B-CHEM
- : : O
induced JJ JJ O
cardiac NN NN O
damage NN NN O
presumably RB RB O
results NNS NNS O
from IN IN O
the DT DT O
formation NN NN O
of IN IN O
free JJ JJ O
radicals NNS NNS O
by IN IN O
DOX NNP NNP B-CHEM
. . . O

Reactive JJ JJ O
oxygen NN NN B-CHEM
species NNS NNS O
particularly RB RB O
affect VBP VBP O
the DT DT O
cardiac NN NN O
myocytes NNS NNS O
because IN IN O
these DT DT O
cells NNS NNS O
seem VBP VBP O
to TO TO O
have VB VB O
a DT DT O
relatively RB RB O
poor JJ JJ O
antioxidant JJ JJ O
defense NN NN O
system NN NN O
. . . O

The DT DT O
semisynthetic JJ JJ O
flavonoid NN NN B-CHEM
monohydroxyethylrutoside NN NN B-CHEM
( ( ( O
monoHER NN NN B-CHEM
) ) ) O
showed VBD VBD O
cardioprotection NN NN O
against IN IN O
DOX NNP NNP B-CHEM
- : : O
induced JJ JJ O
cardiotoxicity NN NN O
through IN IN O
its PRP$ PRP$ O
radical JJ JJ O
scavenging NN NN O
and CC CC O
iron NN NN B-CHEM
chelating VBG VBG O
properties NNS NNS O
. . . O

Because IN IN O
of IN IN O
the DT DT O
relatively RB RB O
short JJ JJ O
final JJ JJ O
half NN NN O
- - - O
life NN NN O
of IN IN O
monoHER NN NN B-CHEM
( ( ( O
about IN IN O
30 CD CD O
min NN NN O
) ) ) O
, , , O
it PRP PRP O
is VBZ VBZ O
expected VBN VBN O
that IN IN O
the DT DT O
time NN NN O
interval NN NN O
between IN IN O
monoHER NN NN B-CHEM
and CC CC O
DOX NNP NNP B-CHEM
might MD MD O
be VB VB O
of IN IN O
influence NN NN O
on IN IN O
the DT DT O
cardioprotective JJ JJ O
effect NN NN O
of IN IN O
monoHER NN NN B-CHEM
. . . O

Therefore RB RB O
, , , O
the DT DT O
aim NN NN O
of IN IN O
the DT DT O
present JJ JJ O
study NN NN O
was VBD VBD O
to TO TO O
investigate VB VB O
this DT DT O
possible JJ JJ O
effect NN NN O
. . . O

METHODS NNP NNP O
: : : O
Six CD CD O
groups NNS NNS O
of IN IN O
6 CD CD O
BALB NNP NNP O
/ NN NN O
c SYM SYM O
mice NN NN O
were VBD VBD O
treated VBN VBN O
with IN IN O
saline NN NN O
, , , O
DOX NNP NNP B-CHEM
alone RB RB O
or CC CC O
DOX NNP NNP B-CHEM
( ( ( O
4 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
v NN NN O
. . . O
) ) ) O
preceded VBN VBN O
by IN IN O
monoHER NN NN B-CHEM
( ( ( O
500 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
with IN IN O
an DT DT O
interval NN NN O
of IN IN O
10 CD CD O
, , , O
30 CD CD O
, , , O
60 CD CD O
or CC CC O
120 CD CD O
min NN NN O
. . . O

After IN IN O
a DT DT O
6 CD CD O
- : : O
week NN NN O
treatment NN NN O
period NN NN O
and CC CC O
additional JJ JJ O
observation NN NN O
for IN IN O
2 CD CD O
weeks NNS NNS O
, , , O
the DT DT O
mice NN NN O
were VBD VBD O
sacrificed VBN VBN O
. . . O

Their PRP$ PRP$ O
cardiac JJ JJ O
tissues NNS NNS O
were VBD VBD O
processed VBN VBN O
for IN IN O
light JJ JJ O
microscopy NN NN O
, , , O
after IN IN O
which WDT WDT O
cardiomyocyte NN NN O
damage NN NN O
was VBD VBD O
evaluated VBN VBN O
according VBG VBG O
to TO TO O
Billingham NNP NNP O
( ( ( O
in IN IN O
Cancer NNP NNP O
Treat NNP NNP O
Rep NNP NNP O
62 CD CD O
( ( ( O
6 CD CD O
) ) ) O
: : : O
865 CD CD O
- : : O
872 CD CD O
, , , O
1978 CD CD O
) ) ) O
. . . O

Microscopic NNP NNP O
evaluation NN NN O
revealed VBD VBD O
that IN IN O
treatment NN NN O
with IN IN O
DOX NNP NNP B-CHEM
alone RB RB O
induced VBD VBD O
significant JJ JJ O
cardiac NN NN O
damage NN NN O
in IN IN O
comparison NN NN O
to TO TO O
the DT DT O
saline NN NN O
control NN NN O
group NN NN O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
. . . O

RESULTS NNS NNS O
: : : O
The DT DT O
number NN NN O
of IN IN O
damaged JJ JJ O
cardiomyocytes NNS NNS O
was VBD VBD O
9 CD CD O
. . . O
6 CD CD O
- : : O
fold NN NN O
( ( ( O
95 CD CD O
% NN NN O
CI NNP NNP O
4 CD CD O
. . . O
4 CD CD O
- : : O
21 CD CD O
. . . O
0 CD CD O
) ) ) O
higher JJR JJR O
in IN IN O
mice NNS NNS O
treated VBN VBN O
with IN IN O
DOX NNP NNP B-CHEM
alone RB RB O
than IN IN O
that DT DT O
in IN IN O
animals NNS NNS O
of IN IN O
the DT DT O
control NN NN O
group NN NN O
. . . O

The DT DT O
ratio NN NN O
of IN IN O
aberrant JJ JJ O
cardiomyocytes NNS NNS O
in IN IN O
mice NN NN O
treated VBN VBN O
with IN IN O
DOX NNP NNP B-CHEM
preceded VBN VBN O
by IN IN O
monoHER NN NN B-CHEM
and CC CC O
those DT DT O
in IN IN O
mice NNS NNS O
treated VBN VBN O
with IN IN O
saline NN NN O
ranged VBD VBD O
from IN IN O
1 CD CD O
. . . O
6 CD CD O
to TO TO O
2 CD CD O
. . . O
8 CD CD O
( ( ( O
mean NN NN O
2 CD CD O
. . . O
2 CD CD O
, , , O
95 CD CD O
% NN NN O
CI NNP NNP O
1 CD CD O
. . . O
2 CD CD O
- : : O
4 CD CD O
. . . O
1 CD CD O
, , , O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
019 CD CD O
) ) ) O
. . . O

The DT DT O
mean NN NN O
protective JJ JJ O
effect NN NN O
by IN IN O
adding VBG VBG O
monoHER NN NN B-CHEM
before IN IN O
DOX NNP NNP B-CHEM
led VBD VBD O
to TO TO O
a DT DT O
significant JJ JJ O
4 CD CD O
. . . O
4 CD CD O
- : : O
fold JJ JJ O
reduction NN NN O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
, , , O
95 CD CD O
% NN NN O
CI NNP NNP O
2 CD CD O
. . . O
3 CD CD O
- : : O
8 CD CD O
. . . O
2 CD CD O
) ) ) O
of IN IN O
abnormal JJ JJ O
cardiomyocytes NNS NNS O
. . . O

This DT DT O
protective JJ JJ O
effect NN NN O
did VBD VBD O
not RB RB O
depend VB VB O
on IN IN O
the DT DT O
time NN NN O
interval NN NN O
between IN IN O
monoHER NN NN B-CHEM
and CC CC O
DOX NNP NNP B-CHEM
administration NN NN O
( ( ( O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
345 CD CD O
) ) ) O
. . . O

CONCLUSION NNP NNP O
: : : O
The DT DT O
results NNS NNS O
indicate VBP VBP O
that IN IN O
in IN IN O
an DT DT O
outpatient NN NN O
clinical JJ JJ O
setting VBG VBG O
monoHER NN NN B-CHEM
may MD MD O
be VB VB O
administered VBN VBN O
shortly RB RB O
before RB RB O
DOX NNP NNP B-CHEM
. . . O

Clinical NNP NNP O
evaluation NN NN O
of IN IN O
adverse JJ JJ O
effects NNS NNS O
during IN IN O
bepridil NN NN B-CHEM
administration NN NN O
for IN IN O
atrial JJ JJ O
fibrillation NN NN O
and CC CC O
flutter NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
Bepridil NNP NNP B-CHEM
hydrochloride NN NN I-CHEM
( ( ( O
Bpd NNP NNP B-CHEM
) ) ) O
has VBZ VBZ O
attracted VBN VBN O
attention NN NN O
as IN IN O
an DT DT O
effective JJ JJ O
drug NN NN O
for IN IN O
atrial JJ JJ O
fibrillation NN NN O
( ( ( O
AF NNP NNP O
) ) ) O
and CC CC O
atrial JJ JJ O
flutter NN NN O
( ( ( O
AFL NNP NNP O
) ) ) O
. . . O

However RB RB O
, , , O
serious JJ JJ O
adverse JJ JJ O
effects NNS NNS O
, , , O
including VBG VBG O
torsade NN NN O
de IN IN O
pointes NNS NNS O
( ( ( O
Tdp NNP NNP O
) ) ) O
, , , O
have VBP VBP O
been VBN VBN O
reported VBN VBN O
. . . O

METHODS NNP NNP O
AND CC CC O
RESULTS NNS NNS O
: : : O
Adverse NNP NNP O
effects NNS NNS O
of IN IN O
Bpd NNP NNP B-CHEM
requiring VBG VBG O
discontinuation NN NN O
of IN IN O
treatment NN NN O
were VBD VBD O
evaluated VBN VBN O
. . . O

Bpd NNP NNP B-CHEM
was VBD VBD O
administered VBN VBN O
to TO TO O
459 CD CD O
patients NNS NNS O
( ( ( O
361 CD CD O
males NNS NNS O
, , , O
63 CD CD O
+ NN NN O
/ NN NN O
- : : O
12 CD CD O
years NNS NNS O
old JJ JJ O
) ) ) O
comprising VBG VBG O
378 CD CD O
AF NNP NNP O
and CC CC O
81 CD CD O
AFL NNP NNP O
cases NNS NNS O
. . . O

Mean VB VB O
left VBD VBD O
ventricular JJ JJ O
ejection NN NN O
fraction NN NN O
and CC CC O
atrial JJ JJ O
dimension NN NN O
( ( ( O
LAD NNP NNP O
) ) ) O
were VBD VBD O
66 CD CD O
+ NN NN O
/ NN NN O
- : : O
11 CD CD O
% NN NN O
and CC CC O
40 CD CD O
+ NN NN O
/ NN NN O
- : : O
6 CD CD O
mm NN NN O
, , , O
respectively RB RB O
. . . O

Adverse NNP NNP O
effects NNS NNS O
were VBD VBD O
observed VBN VBN O
in IN IN O
19 CD CD O
patients NNS NNS O
( ( ( O
4 CD CD O
% NN NN O
) ) ) O
during IN IN O
an DT DT O
average JJ JJ O
follow VB VB O
- - - O
up RP RP O
of IN IN O
20 CD CD O
months NNS NNS O
. . . O

There EX EX O
was VBD VBD O
marked VBN VBN O
QT NNP NNP O
prolongation NN NN O
greater JJR JJR O
than IN IN O
0 CD CD O
. . . O
55 CD CD O
s VBZ VBZ O
in IN IN O
13 CD CD O
patients NNS NNS O
, , , O
bradycardia NN NN O
less JJR JJR O
than IN IN O
40 CD CD O
beats NNS NNS O
/ NN NN O
min NN NN O
in IN IN O
6 CD CD O
patients NNS NNS O
, , , O
dizziness NN NN O
and CC CC O
general JJ JJ O
fatigue NN NN O
in IN IN O
1 CD CD O
patient NN NN O
each DT DT O
. . . O

In IN IN O
4 CD CD O
of IN IN O
13 CD CD O
patients NNS NNS O
with IN IN O
QT NNP NNP O
prolongation NN NN O
, , , O
Tdp NNP NNP O
occurred VBD VBD O
. . . O

The DT DT O
major JJ JJ O
triggering JJ JJ O
factors NNS NNS O
of IN IN O
Tdp NNP NNP O
were VBD VBD O
hypokalemia NN NN O
and CC CC O
sudden JJ JJ O
decrease NN NN O
in IN IN O
heart NN NN O
rate NN NN O
. . . O

There EX EX O
were VBD VBD O
no DT DT O
differences NNS NNS O
in IN IN O
the DT DT O
clinical JJ JJ O
backgrounds NNS NNS O
of IN IN O
the DT DT O
patients NNS NNS O
with IN IN O
and CC CC O
without IN IN O
Tdp NNP NNP O
other JJ JJ O
than IN IN O
LAD NNP NNP O
and CC CC O
age NN NN O
, , , O
which WDT WDT O
were VBD VBD O
larger JJR JJR O
and CC CC O
older JJR JJR O
in IN IN O
the DT DT O
patients NNS NNS O
with IN IN O
Tdp NNP NNP O
. . . O

CONCLUSION NNP NNP O
: : : O
Careful NNP NNP O
observation NN NN O
of IN IN O
serum NN NN O
potassium NN NN B-CHEM
concentration NN NN O
and CC CC O
the DT DT O
ECG NNP NNP O
should MD MD O
always RB RB O
be VB VB O
done VBN VBN O
during IN IN O
Bpd NNP NNP B-CHEM
administration NN NN O
, , , O
particularly RB RB O
in IN IN O
elderly JJ JJ O
patients NNS NNS O
. . . O

Enhanced NNP NNP O
isoproterenol NN NN B-CHEM
- : : O
induced JJ JJ O
cardiac NN NN O
hypertrophy NN NN O
in IN IN O
transgenic JJ JJ O
rats NNS NNS O
with IN IN O
low JJ JJ O
brain NN NN O
angiotensinogen NN NN O
. . . O

We PRP PRP O
have VBP VBP O
previously RB RB O
shown VBN VBN O
that IN IN O
a DT DT O
permanent JJ JJ O
deficiency NN NN O
in IN IN O
the DT DT O
brain NN NN O
renin NN NN O
- : : O
angiotensin NN NN B-CHEM
system NN NN O
( ( ( O
RAS NNP NNP O
) ) ) O
may MD MD O
increase VB VB O
the DT DT O
sensitivity NN NN O
of IN IN O
the DT DT O
baroreflex NN NN O
control NN NN O
of IN IN O
heart NN NN O
rate NN NN O
. . . O

In IN IN O
this DT DT O
study NN NN O
we PRP PRP O
aimed VBD VBD O
at IN IN O
studying VBG VBG O
the DT DT O
involvement NN NN O
of IN IN O
the DT DT O
brain NN NN O
RAS NNP NNP O
in IN IN O
the DT DT O
cardiac JJ JJ O
reactivity NN NN O
to TO TO O
the DT DT O
beta NN NN O
- - - O
adrenoceptor NN NN O
( ( ( O
beta NN NN O
- - - O
AR NNP NNP O
) ) ) O
agonist NN NN O
isoproterenol NN NN B-CHEM
( ( ( O
Iso NNP NNP B-CHEM
) ) ) O
. . . O

Transgenic NNP NNP O
rats NNS NNS O
with IN IN O
low JJ JJ O
brain NN NN O
angiotensinogen NN NN O
( ( ( O
TGR NNP NNP O
) ) ) O
were VBD VBD O
used VBN VBN O
. . . O

In IN IN O
isolated VBN VBN O
hearts NNS NNS O
, , , O
Iso NNP NNP B-CHEM
induced VBD VBD O
a DT DT O
significantly RB RB O
greater JJR JJR O
increase NN NN O
in IN IN O
left VBD VBD O
ventricular NN NN O
( ( ( O
LV NNP NNP O
) ) ) O
pressure NN NN O
and CC CC O
maximal NN NN O
contraction NN NN O
( ( ( O
+ NN NN O
dP NN NN O
/ NN NN O
dt NN NN O
( ( ( O
max NN NN O
) ) ) O
) ) ) O
in IN IN O
the DT DT O
TGR NNP NNP O
than IN IN O
in IN IN O
the DT DT O
Sprague NNP NNP O
- : : O
Dawley NNP NNP O
( ( ( O
SD NNP NNP O
) ) ) O
rats NNS NNS O
. . . O

LV NNP NNP O
hypertrophy NN NN O
induced VBN VBN O
by IN IN O
Iso NNP NNP B-CHEM
treatment NN NN O
was VBD VBD O
significantly RB RB O
higher JJR JJR O
in IN IN O
TGR NNP NNP O
than IN IN O
in IN IN O
SD NNP NNP O
rats NNS NNS O
( ( ( O
in IN IN O
g SYM SYM O
LV NNP NNP O
wt NN NN O
/ NN NN O
100 CD CD O
g SYM SYM O
body NN NN O
wt NN NN O
, , , O
0 CD CD O
. . . O
28 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
004 CD CD O
vs NNS NNS O
. . . O
0 CD CD O
. . . O
24 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
004 CD CD O
, , , O
respectively RB RB O
) ) ) O
. . . O

The DT DT O
greater JJR JJR O
LV NNP NNP O
hypertrophy NN NN O
in IN IN O
TGR NNP NNP O
rats NNS NNS O
was VBD VBD O
associated VBN VBN O
with IN IN O
more RBR RBR O
pronounced JJ JJ O
downregulation NN NN O
of IN IN O
beta NN NN O
- - - O
AR NNP NNP O
and CC CC O
upregulation NN NN O
of IN IN O
LV NNP NNP O
beta NN NN O
- : : O
AR NNP NNP O
kinase NN NN O
- : : O
1 CD CD O
mRNA NN NN O
levels NNS NNS O
compared VBN VBN O
with IN IN O
those DT DT O
in IN IN O
SD NNP NNP O
rats NNS NNS O
. . . O

The DT DT O
decrease NN NN O
in IN IN O
the DT DT O
heart NN NN O
rate NN NN O
( ( ( O
HR NNP NNP O
) ) ) O
induced VBN VBN O
by IN IN O
the DT DT O
beta NN NN O
- - - O
AR NNP NNP O
antagonist NN NN O
metoprolol NN NN B-CHEM
in IN IN O
conscious JJ JJ O
rats NNS NNS O
was VBD VBD O
significantly RB RB O
attenuated VBN VBN O
in IN IN O
TGR NNP NNP O
compared VBD VBD O
with IN IN O
SD NNP NNP O
rats NNS NNS O
( ( ( O
- : : O
9 CD CD O
. . . O
9 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
7 CD CD O
% NN NN O
vs NNS NNS O
. . . O
- : : O
18 CD CD O
. . . O
1 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
5 CD CD O
% NN NN O
) ) ) O
, , , O
whereas IN IN O
the DT DT O
effect NN NN O
of IN IN O
parasympathetic JJ JJ O
blockade NN NN O
by IN IN O
atropine NN NN B-CHEM
on IN IN O
HR NNP NNP O
was VBD VBD O
similar JJ JJ O
in IN IN O
both DT DT O
strains NNS NNS O
. . . O

These DT DT O
results NNS NNS O
indicate VBP VBP O
that IN IN O
TGR NNP NNP O
are VBP VBP O
more RBR RBR O
sensitive JJ JJ O
to TO TO O
beta NN NN O
- - - O
AR NNP NNP O
agonist NN NN O
- : : O
induced JJ JJ O
cardiac NN NN O
inotropic NN NN O
response NN NN O
and CC CC O
hypertrophy NN NN O
, , , O
possibly RB RB O
due JJ JJ O
to TO TO O
chronically RB RB O
low JJ JJ O
sympathetic JJ JJ O
outflow NN NN O
directed VBD VBD O
to TO TO O
the DT DT O
heart NN NN O
. . . O

Drug NN NN O
- : : O
induced VBN VBN O
long JJ JJ O
QT NNP NNP O
syndrome NN NN O
in IN IN O
injection NN NN O
drug NN NN O
users NNS NNS O
receiving VBG VBG O
methadone NN NN B-CHEM
: : : O
high JJ JJ O
frequency NN NN O
in IN IN O
hospitalized JJ JJ O
patients NNS NNS O
and CC CC O
risk NN NN O
factors NNS NNS O
. . . O

BACKGROUND NNP NNP O
: : : O
Drug NN NN O
- - - O
induced VBN VBN O
long JJ JJ O
QT NNP NNP O
syndrome NN NN O
is VBZ VBZ O
a DT DT O
serious JJ JJ O
adverse JJ JJ O
drug NN NN O
reaction NN NN O
. . . O

Methadone NNP NNP B-CHEM
prolongs NNS NNS O
the DT DT O
QT NNP NNP O
interval NN NN O
in IN IN O
vitro NN NN O
in IN IN O
a DT DT O
dose NN NN O
- - - O
dependent JJ JJ O
manner NN NN O
. . . O

In IN IN O
the DT DT O
inpatient NN NN O
setting VBG VBG O
, , , O
the DT DT O
frequency NN NN O
of IN IN O
QT NNP NNP O
interval NN NN O
prolongation NN NN O
with IN IN O
methadone NN NN B-CHEM
treatment NN NN O
, , , O
its PRP$ PRP$ O
dose NN NN O
dependence NN NN O
, , , O
and CC CC O
the DT DT O
importance NN NN O
of IN IN O
cofactors NNS NNS O
such JJ JJ O
as IN IN O
drug NN NN O
- - - O
drug NN NN O
interactions NNS NNS O
remain VBP VBP O
unknown JJ JJ O
. . . O

METHODS NNP NNP O
: : : O
We PRP PRP O
performed VBD VBD O
a DT DT O
systematic JJ JJ O
, , , O
retrospective JJ JJ O
study NN NN O
comparing VBG VBG O
active JJ JJ O
or CC CC O
former JJ JJ O
intravenous JJ JJ O
drug NN NN O
users NNS NNS O
receiving VBG VBG O
methadone NN NN B-CHEM
and CC CC O
those DT DT O
not RB RB O
receiving VBG VBG O
methadone NN NN B-CHEM
among IN IN O
all DT DT O
patients NNS NNS O
hospitalized VBN VBN O
over IN IN O
a DT DT O
5 CD CD O
- : : O
year NN NN O
period NN NN O
in IN IN O
a DT DT O
tertiary JJ JJ O
care NN NN O
hospital NN NN O
. . . O

A DT DT O
total NN NN O
of IN IN O
167 CD CD O
patients NNS NNS O
receiving VBG VBG O
methadone NN NN B-CHEM
fulfilled VBD VBD O
the DT DT O
inclusion NN NN O
criteria NNS NNS O
and CC CC O
were VBD VBD O
compared VBN VBN O
with IN IN O
a DT DT O
control NN NN O
group NN NN O
of IN IN O
80 CD CD O
injection NN NN O
drug NN NN O
users NNS NNS O
not RB RB O
receiving VBG VBG O
methadone NN NN B-CHEM
. . . O

In IN IN O
addition NN NN O
to TO TO O
methadone NN NN B-CHEM
dose NN NN O
, , , O
15 CD CD O
demographic JJ JJ O
, , , O
biological JJ JJ O
, , , O
and CC CC O
pharmacological JJ JJ O
variables NNS NNS O
were VBD VBD O
considered VBN VBN O
as IN IN O
potential JJ JJ O
risk NN NN O
factors NNS NNS O
for IN IN O
QT NNP NNP O
prolongation NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Among IN IN O
167 CD CD O
methadone CD CD B-CHEM
maintenance NN NN O
patients NNS NNS O
, , , O
the DT DT O
prevalence NN NN O
of IN IN O
QTc NNP NNP O
prolongation NN NN O
to TO TO O
0 CD CD O
. . . O
50 CD CD O
second JJ JJ O
( ( ( O
( ( ( O
1 CD CD O
/ NN NN O
2 CD CD O
) ) ) O
) ) ) O
or CC CC O
longer RBR RBR O
was VBD VBD O
16 CD CD O
. . . O
2 CD CD O
% NN NN O
compared VBN VBN O
with IN IN O
0 CD CD O
% NN NN O
in IN IN O
80 CD CD O
control NN NN O
subjects NNS NNS O
. . . O

Six CD CD O
patients NNS NNS O
( ( ( O
3 CD CD O
. . . O
6 CD CD O
% NN NN O
) ) ) O
in IN IN O
the DT DT O
methadone NN NN B-CHEM
group NN NN O
presented VBN VBN O
torsades NNS NNS O
de IN IN O
pointes NNS NNS O
. . . O

QTc NNP NNP O
length NN NN O
was VBD VBD O
weakly JJ JJ O
but CC CC O
significantly RB RB O
associated VBN VBN O
with IN IN O
methadone NN NN B-CHEM
daily JJ JJ O
dose NN NN O
( ( ( O
Spearman NNP NNP O
rank NN NN O
correlation NN NN O
coefficient NN NN O
, , , O
0 CD CD O
. . . O
20 CD CD O
; : : O
P NN NN O
< NN NN O
. . . O
01 CD CD O
) ) ) O
. . . O

Multivariate NNP NNP O
regression NN NN O
analysis NN NN O
allowed VBD VBD O
attribution NN NN O
of IN IN O
31 CD CD O
. . . O
8 CD CD O
% NN NN O
of IN IN O
QTc NNP NNP O
variability NN NN O
to TO TO O
methadone NN NN B-CHEM
dose NN NN O
, , , O
cytochrome NN NN O
P NN NN O
- : : O
450 CD CD O
3A4 CD CD O
drug NN NN O
- : : O
drug NN NN O
interactions NNS NNS O
, , , O
hypokalemia NN NN O
, , , O
and CC CC O
altered JJ JJ O
liver NN NN O
function NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
QT NNP NNP O
interval NN NN O
prolongation NN NN O
in IN IN O
methadone NN NN B-CHEM
maintenance NN NN O
patients NNS NNS O
hospitalized VBN VBN O
in IN IN O
a DT DT O
tertiary JJ JJ O
care NN NN O
center NN NN O
is VBZ VBZ O
a DT DT O
frequent JJ JJ O
finding NN NN O
. . . O

Methadone NNP NNP B-CHEM
dose NN NN O
, , , O
presence NN NN O
of IN IN O
cytochrome NN NN O
P NN NN O
- : : O
450 CD CD O
3A4 CD CD O
inhibitors NNS NNS O
, , , O
potassium NN NN B-CHEM
level NN NN O
, , , O
and CC CC O
liver NN NN O
function NN NN O
contribute VB VB O
to TO TO O
QT NNP NNP O
prolongation NN NN O
. . . O

Long NNP NNP O
QT NNP NNP O
syndrome NN NN O
can MD MD O
occur VB VB O
with IN IN O
low JJ JJ O
doses NNS NNS O
of IN IN O
methadone NN NN B-CHEM
. . . O

Mechanisms NNP NNP O
of IN IN O
hypertension NN NN O
induced VBN VBN O
by IN IN O
nitric JJ JJ B-CHEM
oxide NN NN I-CHEM
( ( ( O
NO NNP NNP B-CHEM
) ) ) O
deficiency NN NN O
: : : O
focus NN NN O
on IN IN O
venous JJ JJ O
function NN NN O
. . . O

Loss NN NN O
of IN IN O
endothelial JJ JJ O
cell NN NN O
- - - O
derived VBN VBN O
nitric JJ JJ B-CHEM
oxide NN NN I-CHEM
( ( ( O
NO DT DT B-CHEM
) ) ) O
in IN IN O
hypertension NN NN O
is VBZ VBZ O
a DT DT O
hallmark NN NN O
of IN IN O
arterial JJ JJ O
dysfunction NN NN O
. . . O

Experimental NNP NNP O
hypertension NN NN O
created VBN VBN O
by IN IN O
the DT DT O
removal NN NN O
of IN IN O
NO UH UH B-CHEM
, , , O
however RB RB O
, , , O
involves VBZ VBZ O
mechanisms NNS NNS O
in IN IN O
addition NN NN O
to TO TO O
decreased VBD VBD O
arterial JJ JJ O
vasodilator NN NN O
activity NN NN O
. . . O

These DT DT O
include VBP VBP O
augmented VBN VBN O
endothelin NN NN O
- : : O
1 CD CD O
( ( ( O
ET NNP NNP O
- - - O
1 CD CD O
) ) ) O
release NN NN O
, , , O
increased VBN VBN O
sympathetic JJ JJ O
nervous JJ JJ O
system NN NN O
activity NN NN O
, , , O
and CC CC O
elevated VBD VBD O
tissue NN NN O
oxidative JJ JJ O
stress NN NN O
. . . O

We PRP PRP O
hypothesized VBN VBN O
that IN IN O
increased VBD VBD O
venous JJ JJ O
smooth JJ JJ O
muscle NN NN O
( ( ( O
venomotor NN NN O
) ) ) O
tone NN NN O
plays VBZ VBZ O
a DT DT O
role NN NN O
in IN IN O
Nomega NNP NNP B-CHEM
- - - I-CHEM
nitro NN NN I-CHEM
- - - I-CHEM
L NNP NNP I-CHEM
- : : I-CHEM
arginine NN NN I-CHEM
( ( ( O
LNNA NNP NNP B-CHEM
) ) ) O
hypertension NN NN O
through IN IN O
these DT DT O
mechanisms NNS NNS O
. . . O

Rats NNP NNP O
were VBD VBD O
treated VBN VBN O
with IN IN O
the DT DT O
NO DT DT B-CHEM
synthase NN NN O
inhibitor NN NN O
LNNA NNP NNP B-CHEM
( ( ( O
0 CD CD O
. . . O
5 CD CD O
g SYM SYM O
/ NN NN O
L NNP NNP O
in IN IN O
drinking NN NN O
water NN NN O
) ) ) O
for IN IN O
2 CD CD O
weeks NNS NNS O
. . . O

Mean VB VB O
arterial JJ JJ O
pressure NN NN O
of IN IN O
conscious JJ JJ O
rats NNS NNS O
was VBD VBD O
119 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
mm NN NN O
Hg NNP NNP O
in IN IN O
control NN NN O
and CC CC O
194 CD CD O
+ NN NN O
/ NN NN O
- : : O
5 CD CD O
mm NN NN O
Hg NNP NNP O
in IN IN O
LNNA NNP NNP B-CHEM
rats NNS NNS O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

Carotid NNP NNP O
arteries NNS NNS O
and CC CC O
vena NN NN O
cava NN NN O
were VBD VBD O
removed VBN VBN O
for IN IN O
measurement NN NN O
of IN IN O
isometric JJ JJ O
contraction NN NN O
. . . O

Maximal NNP NNP O
contraction NN NN O
to TO TO O
norepinephrine NN NN B-CHEM
was VBD VBD O
modestly RB RB O
reduced VBN VBN O
in IN IN O
arteries NNS NNS O
from IN IN O
LNNA NNP NNP B-CHEM
compared VBD VBD O
with IN IN O
control NN NN O
rats NNS NNS O
whereas IN IN O
the DT DT O
maximum NN NN O
contraction NN NN O
to TO TO O
ET NNP NNP O
- : : O
1 CD CD O
was VBD VBD O
significantly RB RB O
reduced VBN VBN O
( ( ( O
54 CD CD O
% NN NN O
control NN NN O
) ) ) O
. . . O

Maximum NNP NNP O
contraction NN NN O
of IN IN O
vena NN NN O
cava NN NN O
to TO TO O
norepinephrine NN NN B-CHEM
( ( ( O
37 CD CD O
% NN NN O
control NN NN O
) ) ) O
also RB RB O
was VBD VBD O
reduced VBN VBN O
but CC CC O
no DT DT O
change NN NN O
in IN IN O
response NN NN O
to TO TO O
ET NNP NNP O
- : : O
1 CD CD O
was VBD VBD O
observed VBN VBN O
. . . O

Mean VB VB O
circulatory NN NN O
filling VBG VBG O
pressure NN NN O
, , , O
an DT DT O
in IN IN O
vivo NN NN O
measure NN NN O
of IN IN O
venomotor NN NN O
tone NN NN O
, , , O
was VBD VBD O
not RB RB O
elevated VBN VBN O
in IN IN O
LNNA NNP NNP B-CHEM
hypertension NN NN O
at IN IN O
1 CD CD O
or CC CC O
2 CD CD O
weeks NNS NNS O
after IN IN O
LNNA NNP NNP B-CHEM
. . . O

The DT DT O
superoxide NN NN B-CHEM
scavenger NN NN O
tempol NN NN B-CHEM
( ( ( O
30 CD CD O
, , , O
100 CD CD O
, , , O
and CC CC O
300 CD CD O
micromol NN NN O
kg NN NN O
( ( ( O
- : : O
1 CD CD O
) ) ) O
, , , O
IV NNP NNP O
) ) ) O
did VBD VBD O
not RB RB O
change VB VB O
arterial JJ JJ O
pressure NN NN O
in IN IN O
control NN NN O
rats NNS NNS O
but CC CC O
caused VBD VBD O
a DT DT O
dose NN NN O
- - - O
dependent JJ JJ O
decrease NN NN O
in IN IN O
LNNA NNP NNP B-CHEM
rats NNS NNS O
( ( ( O
- : : O
18 CD CD O
+ NN NN O
/ NN NN O
- : : O
8 CD CD O
, , , O
- : : O
26 CD CD O
+ NN NN O
/ NN NN O
- : : O
15 CD CD O
, , , O
and CC CC O
- : : O
54 CD CD O
+ NN NN O
/ NN NN O
- : : O
11 CD CD O
mm NN NN O
Hg NNP NNP O
) ) ) O
. . . O

Similarly RB RB O
, , , O
ganglionic JJ JJ O
blockade NN NN O
with IN IN O
hexamethonium NN NN B-CHEM
caused VBD VBD O
a DT DT O
significantly RB RB O
greater JJR JJR O
fall NN NN O
in IN IN O
LNNA NNP NNP B-CHEM
hypertensive JJ JJ O
rats NNS NNS O
( ( ( O
76 CD CD O
+ NN NN O
/ NN NN O
- : : O
9 CD CD O
mm NN NN O
Hg NNP NNP O
) ) ) O
compared VBN VBN O
with IN IN O
control NN NN O
rats NNS NNS O
( ( ( O
35 CD CD O
+ NN NN O
/ NN NN O
- : : O
10 CD CD O
mm NN NN O
Hg NNP NNP O
) ) ) O
. . . O

Carotid NNP NNP O
arteries NNS NNS O
, , , O
vena NN NN O
cava NN NN O
, , , O
and CC CC O
sympathetic JJ JJ O
ganglia NN NN O
from IN IN O
LNNA NNP NNP B-CHEM
rats NNS NNS O
had VBD VBD O
higher JJR JJR O
basal NN NN O
levels NNS NNS O
of IN IN O
superoxide NN NN B-CHEM
compared VBN VBN O
with IN IN O
those DT DT O
from IN IN O
control NN NN O
rats NNS NNS O
. . . O

These DT DT O
data NNS NNS O
suggest VBP VBP O
that IN IN O
while IN IN O
NO DT DT B-CHEM
deficiency NN NN O
increases NNS NNS O
oxidative JJ JJ O
stress NN NN O
and CC CC O
sympathetic JJ JJ O
activity NN NN O
in IN IN O
both DT DT O
arterial NN NN O
and CC CC O
venous JJ JJ O
vessels NNS NNS O
, , , O
the DT DT O
impact NN NN O
on IN IN O
veins NNS NNS O
does VBZ VBZ O
not RB RB O
make VB VB O
a DT DT O
major JJ JJ O
contribution NN NN O
to TO TO O
this DT DT O
form NN NN O
of IN IN O
hypertension NN NN O
. . . O

Association NNP NNP O
of IN IN O
DRD2 NNP NNP O
polymorphisms NNS NNS O
and CC CC O
chlorpromazine NN NN B-CHEM
- - - O
induced JJ JJ O
extrapyramidal NN NN O
syndrome NN NN O
in IN IN O
Chinese JJ JJ O
schizophrenic JJ JJ O
patients NNS NNS O
. . . O

AIM NNP NNP O
: : : O
Extrapyramidal NNP NNP O
syndrome NN NN O
( ( ( O
EPS NNP NNP O
) ) ) O
is VBZ VBZ O
most RBS RBS O
commonly RB RB O
affected VBN VBN O
by IN IN O
typical JJ JJ O
antipsychotic JJ JJ O
drugs NNS NNS O
that WDT WDT O
have VBP VBP O
a DT DT O
high JJ JJ O
affinity NN NN O
with IN IN O
the DT DT O
D2 NN NN O
receptor NN NN O
. . . O

Recently RB RB O
, , , O
many JJ JJ O
research NN NN O
groups NNS NNS O
have VBP VBP O
reported VBN VBN O
on IN IN O
the DT DT O
positive JJ JJ O
relationship NN NN O
between IN IN O
the DT DT O
genetic JJ JJ O
variations NNS NNS O
in IN IN O
the DT DT O
DRD2 NNP NNP O
gene NN NN O
and CC CC O
the DT DT O
therapeutic JJ JJ O
response NN NN O
in IN IN O
schizophrenia NN NN O
patients NNS NNS O
as IN IN O
a DT DT O
result NN NN O
of IN IN O
the DT DT O
role NN NN O
of IN IN O
variations NNS NNS O
in IN IN O
the DT DT O
receptor NN NN O
in IN IN O
modulating VBG VBG O
receptor NN NN O
expression NN NN O
. . . O

In IN IN O
this DT DT O
study NN NN O
, , , O
we PRP PRP O
evaluate VBP VBP O
the DT DT O
role NN NN O
DRD2 NNP NNP O
plays VBZ VBZ O
in IN IN O
chlorpromazine NN NN B-CHEM
- - - O
induced JJ JJ O
EPS NNP NNP O
in IN IN O
schizophrenic JJ JJ O
patients NNS NNS O
. . . O

METHODS NNP NNP O
: : : O
We PRP PRP O
identified VBD VBD O
seven CD CD O
SNP NNP NNP O
( ( ( O
single JJ JJ O
nucleotide NN NN O
polymorphism NN NN O
) ) ) O
( ( ( O
- : : O
141Cins NNS NNS O
> NN NN O
del NN NN O
, , , O
TaqIB NNP NNP O
, , , O
TaqID NNP NNP O
, , , O
Ser311Cys NNP NNP O
, , , O
rs6275 NN NN O
, , , O
rs6277 NN NN O
and CC CC O
TaqIA NNP NNP O
) ) ) O
in IN IN O
the DT DT O
DRD2 NNP NNP O
gene NN NN O
in IN IN O
146 CD CD O
schizophrenic JJ JJ O
inpatients NNS NNS O
( ( ( O
59 CD CD O
with IN IN O
EPS NNP NNP O
and CC CC O
87 CD CD O
without IN IN O
EPS NNP NNP O
according VBG VBG O
to TO TO O
the DT DT O
Simpson NNP NNP O
- : : O
Angus NNP NNP O
Scale NNP NNP O
) ) ) O
treated VBN VBN O
with IN IN O
chlorpromazine NN NN B-CHEM
after IN IN O
8 CD CD O
weeks NNS NNS O
. . . O

The DT DT O
alleles NNS NNS O
of IN IN O
all DT DT O
loci NN NN O
were VBD VBD O
determined VBN VBN O
by IN IN O
PCR NNP NNP O
( ( ( O
polymerase NN NN O
chain NN NN O
reaction NN NN O
) ) ) O
. . . O

RESULTS NNS NNS O
: : : O
Polymorphisms NNP NNP O
TaqID NNP NNP O
, , , O
Ser311Cys NNP NNP O
and CC CC O
rs6277 NN NN O
were VBD VBD O
not RB RB O
polymorphic JJ JJ O
in IN IN O
the DT DT O
population NN NN O
recruited VBD VBD O
in IN IN O
the DT DT O
present JJ JJ O
study NN NN O
. . . O

No DT DT O
statistical JJ JJ O
significance NN NN O
was VBD VBD O
found VBN VBN O
in IN IN O
the DT DT O
allele NN NN O
distribution NN NN O
of IN IN O
- : : O
141Cins NNS NNS O
> NN NN O
del NN NN O
, , , O
TaqIB NNP NNP O
, , , O
rs6275 NN NN O
and CC CC O
TaqIA NNP NNP O
or CC CC O
in IN IN O
the DT DT O
estimated JJ JJ O
haplotypes NNS NNS O
( ( ( O
constituted VBN VBN O
by IN IN O
TaqIB NNP NNP O
, , , O
rs6275 NN NN O
and CC CC O
TaqIA NNP NNP O
) ) ) O
in IN IN O
linkage NN NN O
disequilibrium NN NN O
between IN IN O
the DT DT O
two CD CD O
groups NNS NNS O
. . . O

CONCLUSION NNP NNP O
: : : O
Our PRP$ PRP$ O
results NNS NNS O
did VBD VBD O
not RB RB O
lend VB VB O
strong JJ JJ O
support NN NN O
to TO TO O
the DT DT O
view NN NN O
that IN IN O
the DT DT O
genetic JJ JJ O
variation NN NN O
of IN IN O
the DT DT O
DRD2 NNP NNP O
gene NN NN O
plays VBZ VBZ O
a DT DT O
major JJ JJ O
role NN NN O
in IN IN O
the DT DT O
individually RB RB O
variable JJ JJ O
adverse JJ JJ O
effect NN NN O
induced VBN VBN O
by IN IN O
chlorpromazine NN NN B-CHEM
, , , O
at IN IN O
least JJS JJS O
in IN IN O
Chinese JJ JJ O
patients NNS NNS O
with IN IN O
schizophrenia NN NN O
. . . O

Our PRP$ PRP$ O
results NNS NNS O
confirmed VBD VBD O
a DT DT O
previous JJ JJ O
study NN NN O
on IN IN O
the DT DT O
relationship NN NN O
between IN IN O
DRD2 NNP NNP O
and CC CC O
EPS NNP NNP O
in IN IN O
Caucasians NNP NNP O
. . . O

Physical JJ JJ O
training NN NN O
decreases NNS NNS O
susceptibility NN NN O
to TO TO O
subsequent JJ JJ O
pilocarpine NN NN B-CHEM
- - - O
induced JJ JJ O
seizures NNS NNS O
in IN IN O
the DT DT O
rat NN NN O
. . . O

Regular NNP NNP O
motor NN NN O
activity NN NN O
has VBZ VBZ O
many JJ JJ O
benefits NNS NNS O
for IN IN O
mental JJ JJ O
and CC CC O
physical JJ JJ O
condition NN NN O
but CC CC O
its PRP$ PRP$ O
implications NNS NNS O
for IN IN O
epilepsy NN NN O
are VBP VBP O
still RB RB O
controversial JJ JJ O
. . . O

In IN IN O
order NN NN O
to TO TO O
elucidate VB VB O
this DT DT O
problem NN NN O
, , , O
we PRP PRP O
have VBP VBP O
studied VBN VBN O
the DT DT O
effect NN NN O
of IN IN O
long JJ JJ O
- - - O
term NN NN O
physical JJ JJ O
activity NN NN O
on IN IN O
susceptibility NN NN O
to TO TO O
subsequent JJ JJ O
seizures NNS NNS O
. . . O

Male NNP NNP O
Wistar NNP NNP O
rats NNS NNS O
were VBD VBD O
subjected VBN VBN O
to TO TO O
repeated VBN VBN O
training NN NN O
sessions NNS NNS O
in IN IN O
a DT DT O
treadmill NN NN O
and CC CC O
swimming NN NN O
pool NN NN O
. . . O

Thereafter RB RB O
, , , O
seizures NNS NNS O
were VBD VBD O
induced VBN VBN O
by IN IN O
pilocarpine NN NN B-CHEM
injections NNS NNS O
in IN IN O
trained VBN VBN O
and CC CC O
non NN NN O
- - - O
trained VBN VBN O
control NN NN O
groups NNS NNS O
. . . O

During IN IN O
the DT DT O
acute JJ JJ O
period NN NN O
of IN IN O
status NN NN O
epilepticus NN NN O
, , , O
we PRP PRP O
measured VBD VBD O
: : : O
( ( ( O
1 CD CD O
) ) ) O
the DT DT O
latency NN NN O
of IN IN O
the DT DT O
first JJ JJ O
motor NN NN O
sign NN NN O
, , , O
( ( ( O
2 CD CD O
) ) ) O
the DT DT O
intensity NN NN O
of IN IN O
seizures NNS NNS O
, , , O
( ( ( O
3 CD CD O
) ) ) O
the DT DT O
time NN NN O
when WRB WRB O
it PRP PRP O
occurred VBD VBD O
within IN IN O
the DT DT O
6 CD CD O
- : : O
h NN NN O
observation NN NN O
period NN NN O
, , , O
and CC CC O
( ( ( O
4 CD CD O
) ) ) O
the DT DT O
time NN NN O
when WRB WRB O
the DT DT O
acute JJ JJ O
period NN NN O
ended VBD VBD O
. . . O

All DT DT O
these DT DT O
behavioral JJ JJ O
parameters NNS NNS O
showed VBD VBD O
statistically RB RB O
significant JJ JJ O
changes NNS NNS O
suggesting VBG VBG O
that IN IN O
regular JJ JJ O
physical JJ JJ O
exercises NNS NNS O
decrease VBP VBP O
susceptibility NN NN O
to TO TO O
subsequently RB RB O
induced JJ JJ O
seizures NNS NNS O
and CC CC O
ameliorate VB VB O
the DT DT O
course NN NN O
of IN IN O
experimentally RB RB O
induced VBN VBN O
status NN NN O
epilepticus NN NN O
. . . O

Tonic NNP NNP O
dopaminergic JJ JJ O
stimulation NN NN O
impairs NNS NNS O
associative JJ JJ O
learning VBG VBG O
in IN IN O
healthy JJ JJ O
subjects NNS NNS O
. . . O

Endogenous NNP NNP O
dopamine NN NN B-CHEM
plays VBZ VBZ O
a DT DT O
central JJ JJ O
role NN NN O
in IN IN O
salience NN NN O
coding VBG VBG O
during IN IN O
associative JJ JJ O
learning NN NN O
. . . O

Administration NNP NNP O
of IN IN O
the DT DT O
dopamine NN NN B-CHEM
precursor NN NN O
levodopa NN NN B-CHEM
enhances NNS NNS O
learning VBG VBG O
in IN IN O
healthy JJ JJ O
subjects NNS NNS O
and CC CC O
stroke NN NN O
patients NNS NNS O
. . . O

Because IN IN O
levodopa NN NN B-CHEM
increases NNS NNS O
both DT DT O
phasic NN NN O
and CC CC O
tonic JJ JJ O
dopaminergic JJ JJ O
neurotransmission NN NN O
, , , O
the DT DT O
critical JJ JJ O
mechanism NN NN O
mediating VBG VBG O
the DT DT O
enhancement NN NN O
of IN IN O
learning VBG VBG O
is VBZ VBZ O
unresolved JJ JJ O
. . . O

We PRP PRP O
here RB RB O
probed VBD VBD O
how WRB WRB O
selective JJ JJ O
tonic JJ JJ O
dopaminergic JJ JJ O
stimulation NN NN O
affects VBZ VBZ O
associative JJ JJ O
learning NN NN O
. . . O

Forty CD CD O
healthy JJ JJ O
subjects NNS NNS O
were VBD VBD O
trained VBN VBN O
in IN IN O
a DT DT O
novel NN NN O
vocabulary NN NN O
of IN IN O
45 CD CD O
concrete JJ JJ O
nouns NNS NNS O
over IN IN O
the DT DT O
course NN NN O
of IN IN O
5 CD CD O
consecutive JJ JJ O
training NN NN O
days NNS NNS O
in IN IN O
a DT DT O
prospective JJ JJ O
, , , O
randomized JJ JJ O
, , , O
double JJ JJ O
- - - O
blind JJ JJ O
, , , O
placebo NN NN O
- - - O
controlled JJ JJ O
design NN NN O
. . . O

Subjects NNP NNP O
received VBD VBD O
the DT DT O
tonically RB RB O
stimulating VBG VBG O
dopamine NN NN B-CHEM
- - - O
receptor NN NN O
agonist NN NN O
pergolide NN NN B-CHEM
( ( ( O
0 CD CD O
. . . O
1 CD CD O
mg NN NN O
) ) ) O
vs NN NN O
placebo NN NN O
120 CD CD O
min NN NN O
before IN IN O
training NN NN O
on IN IN O
each DT DT O
training NN NN O
day NN NN O
. . . O

The DT DT O
dopamine NN NN B-CHEM
agonist NN NN O
significantly RB RB O
impaired VBD VBD O
novel NN NN O
word NN NN O
learning VBG VBG O
compared VBN VBN O
to TO TO O
placebo NN NN O
. . . O

This DT DT O
learning VBG VBG O
decrement NN NN O
persisted VBD VBD O
up IN IN O
to TO TO O
the DT DT O
last JJ JJ O
follow VB VB O
- - - O
up RP RP O
4 CD CD O
weeks NNS NNS O
post NN NN O
- : : O
training NN NN O
. . . O

Subjects NNP NNP O
treated VBN VBN O
with IN IN O
pergolide NN NN B-CHEM
also RB RB O
showed VBD VBD O
restricted VBN VBN O
emotional JJ JJ O
responses NNS NNS O
compared VBN VBN O
to TO TO O
the DT DT O
PLACEBO NNP NNP O
group NN NN O
. . . O

The DT DT O
extent NN NN O
of IN IN O
' POS POS O
flattened VBD VBD O
' POS POS O
affect NN NN O
with IN IN O
pergolide NN NN B-CHEM
was VBD VBD O
related VBN VBN O
to TO TO O
the DT DT O
degree NN NN O
of IN IN O
learning VBG VBG O
inhibition NN NN O
. . . O

These DT DT O
findings NNS NNS O
suggest VBP VBP O
that IN IN O
tonic JJ JJ O
occupation NN NN O
of IN IN O
dopamine NN NN B-CHEM
receptors NNS NNS O
impairs NNS NNS O
learning VBG VBG O
by IN IN O
competition NN NN O
with IN IN O
phasic JJ JJ O
dopamine NN NN B-CHEM
signals NNS NNS O
. . . O

Thus RB RB O
, , , O
phasic JJ JJ O
signaling VBG VBG O
seems VBZ VBZ O
to TO TO O
be VB VB O
the DT DT O
critical JJ JJ O
mechanism NN NN O
by IN IN O
which WDT WDT O
dopamine VBP VBP B-CHEM
enhances NNS NNS O
associative JJ JJ O
learning VBG VBG O
in IN IN O
healthy JJ JJ O
subjects NNS NNS O
and CC CC O
stroke NN NN O
patients NNS NNS O
. . . O

Minocycline NNP NNP B-CHEM
- : : O
induced JJ JJ O
vasculitis NN NN O
fulfilling VBG VBG O
the DT DT O
criteria NNS NNS O
of IN IN O
polyarteritis NN NN O
nodosa NN NN O
. . . O

A DT DT O
47 JJ JJ O
- - - O
year NN NN O
- - - O
old JJ JJ O
man NN NN O
who WP WP O
had VBD VBD O
been VBN VBN O
taking VBG VBG O
minocycline NN NN B-CHEM
for IN IN O
palmoplantar NN NN O
pustulosis NN NN O
developed VBN VBN O
fever RB RB O
, , , O
myalgias NN NN O
, , , O
polyneuropathy NN NN O
, , , O
and CC CC O
testicular JJ JJ O
pain NN NN O
, , , O
with IN IN O
elevated VBD VBD O
C NNP NNP O
- : : O
reactive JJ JJ O
protein NN NN O
( ( ( O
CRP NNP NNP O
) ) ) O
. . . O

Neither DT DT O
myeloperoxidase NN NN O
- - - O
nor CC CC O
proteinase NN NN O
- - - O
3 CD CD O
- : : O
antineutrophil NN NN O
cytoplasmic JJ JJ O
antibody NN NN O
was VBD VBD O
positive JJ JJ O
. . . O

These DT DT O
manifestations NNS NNS O
met VBD VBD O
the DT DT O
American NNP NNP O
College NNP NNP O
of IN IN O
Rheumatology NNP NNP O
1990 CD CD O
criteria NNS NNS O
for IN IN O
the DT DT O
classification NN NN O
of IN IN O
polyarteritis NN NN O
nodosa NN NN O
. . . O

Stopping NNP NNP O
minocycline NN NN B-CHEM
led VBN VBN O
to TO TO O
amelioration NN NN O
of IN IN O
symptoms NNS NNS O
and CC CC O
normalization NN NN O
of IN IN O
CRP NNP NNP O
level NN NN O
. . . O

To TO TO O
our PRP$ PRP$ O
knowledge NN NN O
, , , O
this DT DT O
is VBZ VBZ O
the DT DT O
second JJ JJ O
case NN NN O
of IN IN O
minocycline NN NN B-CHEM
- - - O
induced JJ JJ O
vasculitis NNS NNS O
satisfying VBG VBG O
the DT DT O
criteria NNS NNS O
. . . O

Differential NNP NNP O
diagnosis NN NN O
for IN IN O
drug NN NN O
- - - O
induced JJ JJ O
disease NN NN O
is VBZ VBZ O
invaluable JJ JJ O
even RB RB O
for IN IN O
patients NNS NNS O
with IN IN O
classical JJ JJ O
polyarteritis NN NN O
nodosa NN NN O
. . . O

Intramuscular JJ JJ O
hepatitis NN NN O
B NNP NNP O
immune JJ JJ O
globulin NN NN O
combined VBN VBN O
with IN IN O
lamivudine NN NN B-CHEM
in IN IN O
prevention NN NN O
of IN IN O
hepatitis NN NN O
B NNP NNP O
recurrence NN NN O
after IN IN O
liver NN NN O
transplantation NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
Combined VBN VBN O
hepatitis NN NN O
B NNP NNP O
immune JJ JJ O
globulin NN NN O
( ( ( O
HBIg NNP NNP O
) ) ) O
and CC CC O
lamivudine NN NN B-CHEM
in IN IN O
prophylaxis NN NN O
of IN IN O
the DT DT O
recurrence NN NN O
of IN IN O
hepatitis NN NN O
B NNP NNP O
after IN IN O
liver NN NN O
transplantation NN NN O
has VBZ VBZ O
significantly RB RB O
improved VBN VBN O
the DT DT O
survival NN NN O
of IN IN O
HBsAg NNP NNP B-CHEM
positive JJ JJ O
patients NNS NNS O
. . . O

This DT DT O
study NN NN O
was VBD VBD O
undertaken VBN VBN O
to TO TO O
evaluate VB VB O
the DT DT O
outcomes NNS NNS O
of IN IN O
liver NN NN O
transplantation NN NN O
for IN IN O
patients NNS NNS O
with IN IN O
hepatitis NNP NNP O
B NNP NNP O
virus NN NN O
( ( ( O
HBV NNP NNP O
) ) ) O
. . . O

METHODS NNP NNP O
: : : O
A DT DT O
retrospective NN NN O
chart NN NN O
analysis NN NN O
and CC CC O
a DT DT O
review NN NN O
of IN IN O
the DT DT O
organ NN NN O
transplant JJ JJ O
database NN NN O
identified VBD VBD O
51 CD CD O
patients NNS NNS O
( ( ( O
43 CD CD O
men NNS NNS O
and CC CC O
8 CD CD O
women NNS NNS O
) ) ) O
transplanted VBN VBN O
for IN IN O
benign NN NN O
HBV NNP NNP O
- - - O
related VBN VBN O
cirrhotic JJ JJ O
diseases NNS NNS O
between IN IN O
June NNP NNP O
2002 CD CD O
and CC CC O
December NNP NNP O
2004 CD CD O
who WP WP O
had VBD VBD O
survived VBN VBN O
more JJR JJR O
than IN IN O
3 CD CD O
months NNS NNS O
. . . O

HBIg NNP NNP O
was VBD VBD O
administered VBN VBN O
intravenously RB RB O
during IN IN O
the DT DT O
first JJ JJ O
week NN NN O
and CC CC O
intramuscularly RB RB O
thereafter RB RB O
. . . O

RESULTS NNS NNS O
: : : O
At IN IN O
a DT DT O
median NN NN O
follow VB VB O
- - - O
up RP RP O
of IN IN O
14 CD CD O
. . . O
1 CD CD O
months NNS NNS O
, , , O
the DT DT O
overall JJ JJ O
recurrence NN NN O
rate NN NN O
in IN IN O
the DT DT O
51 CD CD O
patients NNS NNS O
was VBD VBD O
3 CD CD O
. . . O
9 CD CD O
% NN NN O
( ( ( O
2 CD CD O
/ NN NN O
51 CD CD O
) ) ) O
. . . O

The DT DT O
overall JJ JJ O
patient NN NN O
survival NN NN O
was VBD VBD O
88 CD CD O
. . . O
3 CD CD O
% NN NN O
, , , O
and CC CC O
82 CD CD O
. . . O
4 CD CD O
% NN NN O
after IN IN O
1 CD CD O
and CC CC O
2 CD CD O
years NNS NNS O
, , , O
respectively RB RB O
. . . O

A DT DT O
daily JJ JJ O
oral JJ JJ O
dose NN NN O
of IN IN O
100 CD CD O
mg NN NN O
lamivudine NN NN B-CHEM
for IN IN O
2 CD CD O
weeks NNS NNS O
before IN IN O
transplantation NN NN O
for IN IN O
10 CD CD O
patients NNS NNS O
enabled VBD VBD O
57 CD CD O
. . . O
1 CD CD O
% NN NN O
( ( ( O
4 CD CD O
/ NN NN O
7 CD CD O
) ) ) O
and CC CC O
62 CD CD O
. . . O
5 CD CD O
% NN NN O
( ( ( O
5 CD CD O
/ NN NN O
8 CD CD O
) ) ) O
of IN IN O
HBV NNP NNP O
- : : O
DNA NNP NNP O
and CC CC O
HBeAg NNP NNP B-CHEM
positive JJ JJ O
patients NNS NNS O
respectively RB RB O
to TO TO O
convert VB VB O
to TO TO O
be VB VB O
negative JJ JJ O
. . . O

Intramuscular NNP NNP O
HBIg NNP NNP O
was VBD VBD O
well RB RB O
tolerated VBN VBN O
in IN IN O
all DT DT O
patients NNS NNS O
. . . O

CONCLUSION NNP NNP O
: : : O
Lamivudine NNP NNP B-CHEM
combined VBN VBN O
with IN IN O
intramuscular JJ JJ O
HBIg NNP NNP O
can MD MD O
effectively RB RB O
prevent VB VB O
allograft NN NN O
from IN IN O
the DT DT O
recurrence NN NN O
of IN IN O
HBV NNP NNP O
after IN IN O
liver NN NN O
transplantation NN NN O
. . . O

Anticonvulsant NNP NNP O
effect NN NN O
of IN IN O
eslicarbazepine NN NN B-CHEM
acetate NN NN I-CHEM
( ( ( O
BIA NNP NNP B-CHEM
2 CD CD I-CHEM
- : : I-CHEM
093 CD CD I-CHEM
) ) ) O
on IN IN O
seizures NNS NNS O
induced VBN VBN O
by IN IN O
microperfusion NN NN O
of IN IN O
picrotoxin NN NN B-CHEM
in IN IN O
the DT DT O
hippocampus NN NN O
of IN IN O
freely RB RB O
moving VBG VBG O
rats NNS NNS O
. . . O

Eslicarbazepine NNP NNP B-CHEM
acetate NN NN I-CHEM
( ( ( O
BIA NNP NNP B-CHEM
2 CD CD I-CHEM
- : : I-CHEM
093 CD CD I-CHEM
, , , O
S NNP NNP B-CHEM
- : : I-CHEM
( ( ( I-CHEM
- : : I-CHEM
) ) ) I-CHEM
- : : I-CHEM
10 CD CD I-CHEM
- : : I-CHEM
acetoxy NN NN I-CHEM
- : : I-CHEM
10 CD CD I-CHEM
, , , I-CHEM
11 CD CD I-CHEM
- : : I-CHEM
dihydro NN NN I-CHEM
- : : I-CHEM
5H CD CD I-CHEM
- : : I-CHEM
dibenzo NN NN I-CHEM
/ NN NN I-CHEM
b SYM SYM I-CHEM
, , , I-CHEM
f NN NN I-CHEM
/ NN NN I-CHEM
azepine NN NN I-CHEM
- : : I-CHEM
5 CD CD I-CHEM
- : : I-CHEM
carboxamide NN NN I-CHEM
) ) ) O
is VBZ VBZ O
a DT DT O
novel NN NN O
antiepileptic JJ JJ O
drug NN NN O
, , , O
now RB RB O
in IN IN O
Phase NNP NNP O
III NNP NNP O
clinical JJ JJ O
trials NNS NNS O
, , , O
designed VBN VBN O
with IN IN O
the DT DT O
aim NN NN O
of IN IN O
improving VBG VBG O
efficacy NN NN O
and CC CC O
safety NN NN O
in IN IN O
comparison NN NN O
with IN IN O
the DT DT O
structurally RB RB O
related VBN VBN O
drugs NNS NNS O
carbamazepine NN NN B-CHEM
( ( ( O
CBZ NNP NNP B-CHEM
) ) ) O
and CC CC O
oxcarbazepine NN NN B-CHEM
( ( ( O
OXC NNP NNP B-CHEM
) ) ) O
. . . O

We PRP PRP O
have VBP VBP O
studied VBN VBN O
the DT DT O
effects NNS NNS O
of IN IN O
oral JJ JJ O
treatment NN NN O
with IN IN O
eslicarbazepine NN NN B-CHEM
acetate NN NN I-CHEM
on IN IN O
a DT DT O
whole JJ JJ O
- - - O
animal NN NN O
model NN NN O
in IN IN O
which WDT WDT O
partial JJ JJ O
seizures NNS NNS O
can MD MD O
be VB VB O
elicited JJ JJ O
repeatedly RB RB O
on IN IN O
different JJ JJ O
days NNS NNS O
without IN IN O
changes NNS NNS O
in IN IN O
threshold NN NN O
or CC CC O
seizure NN NN O
patterns NNS NNS O
. . . O

In IN IN O
the DT DT O
animals NNS NNS O
treated VBN VBN O
with IN IN O
threshold JJ JJ O
doses NNS NNS O
of IN IN O
picrotoxin NN NN B-CHEM
, , , O
the DT DT O
average JJ JJ O
number NN NN O
of IN IN O
seizures NNS NNS O
was VBD VBD O
2 CD CD O
. . . O
3 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
2 CD CD O
, , , O
and CC CC O
average JJ JJ O
seizure NN NN O
duration NN NN O
was VBD VBD O
39 CD CD O
. . . O
5 CD CD O
+ NN NN O
/ NN NN O
- : : O
8 CD CD O
. . . O
4s CD CD O
. . . O

Pre NNP NNP O
- : : O
treatment NN NN O
with IN IN O
a DT DT O
dose NN NN O
of IN IN O
30 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
2h CD CD O
before IN IN O
picrotoxin NN NN B-CHEM
microperfusion NN NN O
prevented VBN VBN O
seizures NNS NNS O
in IN IN O
the DT DT O
75 CD CD O
% NN NN O
of IN IN O
the DT DT O
rats NNS NNS O
. . . O

Lower JJR JJR O
doses NNS NNS O
( ( ( O
3 CD CD O
and CC CC O
10mg CD CD O
/ NN NN O
kg NN NN O
) ) ) O
did VBD VBD O
not RB RB O
suppress JJ JJ O
seizures NNS NNS O
, , , O
however RB RB O
, , , O
after IN IN O
administration NN NN O
of IN IN O
10mg CD CD O
/ NN NN O
kg NN NN O
, , , O
significant JJ JJ O
reductions NNS NNS O
in IN IN O
seizures NNS NNS O
duration NN NN O
( ( ( O
24 CD CD O
. . . O
3 CD CD O
+ NN NN O
/ NN NN O
- : : O
6 CD CD O
. . . O
8s CD CD O
) ) ) O
and CC CC O
seizure JJ JJ O
number NN NN O
( ( ( O
1 CD CD O
. . . O
6 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
34 CD CD O
) ) ) O
were VBD VBD O
found VBN VBN O
. . . O

No DT DT O
adverse JJ JJ O
effects NNS NNS O
of IN IN O
eslicarbazepine NN NN B-CHEM
acetate NN NN I-CHEM
were VBD VBD O
observed VBN VBN O
in IN IN O
the DT DT O
behavioral JJ JJ O
/ NN NN O
EEG NNP NNP O
patterns NNS NNS O
studied VBN VBN O
, , , O
including VBG VBG O
sleep NN NN O
/ NN NN O
wakefulness NN NN O
cycle NN NN O
, , , O
at IN IN O
the DT DT O
doses NNS NNS O
studied VBN VBN O
. . . O

Acute JJ JJ O
renal JJ JJ O
failure NN NN O
associated VBN VBN O
with IN IN O
prolonged JJ JJ O
intake NN NN O
of IN IN O
slimming VBG VBG O
pills NNS NNS O
containing VBG VBG O
anthraquinones NNS NNS B-CHEM
. . . O

Chinese JJ JJ B-CHEM
herbal JJ JJ I-CHEM
medicine NN NN O
preparations NNS NNS O
are VBP VBP O
widely RB RB O
available JJ JJ O
and CC CC O
often RB RB O
regarded VBN VBN O
by IN IN O
the DT DT O
public NN NN O
as IN IN O
natural JJ JJ O
and CC CC O
safe JJ JJ O
remedies NNS NNS O
for IN IN O
a DT DT O
variety NN NN O
of IN IN O
medical JJ JJ O
conditions NNS NNS O
. . . O

Nephropathy NNP NNP O
caused VBN VBN O
by IN IN O
Chinese JJ JJ B-CHEM
herbs NNS NNS I-CHEM
has VBZ VBZ O
previously RB RB O
been VBN VBN O
reported VBN VBN O
, , , O
usually RB RB O
involving VBG VBG O
the DT DT O
use NN NN O
of IN IN O
aristolochic JJ JJ B-CHEM
acids NNS NNS I-CHEM
. . . O

We PRP PRP O
report VBP VBP O
a DT DT O
23 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
woman NN NN O
who WP WP O
developed VBD VBD O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
following VBG VBG O
prolonged JJ JJ O
use NN NN O
of IN IN O
a DT DT O
proprietary JJ JJ O
Chinese JJ JJ B-CHEM
herbal NN NN I-CHEM
slimming VBG VBG O
pill NN NN O
that WDT WDT O
contained VBD VBD O
anthraquinone NN NN B-CHEM
derivatives NNS NNS O
, , , O
extracted VBN VBN O
from IN IN O
Rhizoma NNP NNP O
Rhei NNP NNP O
( ( ( O
rhubarb NN NN O
) ) ) O
. . . O

The DT DT O
renal JJ JJ O
injury NN NN O
was VBD VBD O
probably RB RB O
aggravated VBN VBN O
by IN IN O
the DT DT O
concomitant NN NN O
intake NN NN O
of IN IN O
a DT DT O
non NN NN O
- - - O
steroidal NN NN O
anti NN NN O
- : : O
inflammatory JJ JJ O
drug NN NN O
, , , O
diclofenac NN NN B-CHEM
. . . O

Renal NNP NNP O
pathology NN NN O
was VBD VBD O
that IN IN O
of IN IN O
hypocellular NN NN O
interstitial JJ JJ O
fibrosis NNS NNS O
. . . O

Spontaneous NNP NNP O
renal JJ JJ O
recovery NN NN O
occurred VBD VBD O
upon IN IN O
cessation NN NN O
of IN IN O
the DT DT O
slimming VBG VBG O
pills NNS NNS O
, , , O
but CC CC O
mild JJ JJ O
interstitial JJ JJ O
fibrosis NNS NNS O
and CC CC O
tubular JJ JJ O
atrophy NN NN O
was VBD VBD O
still RB RB O
evident JJ JJ O
histologically RB RB O
4 CD CD O
months NNS NNS O
later RB RB O
. . . O

Although IN IN O
a DT DT O
causal NN NN O
relationship NN NN O
between IN IN O
the DT DT O
use NN NN O
of IN IN O
an DT DT O
anthraquinone NN NN B-CHEM
- - - O
containing VBG VBG O
herbal JJ JJ O
agent NN NN O
and CC CC O
renal JJ JJ O
injury NN NN O
remains VBZ VBZ O
to TO TO O
be VB VB O
proven VBN VBN O
, , , O
phytotherapy NN NN O
- - - O
associated VBN VBN O
interstitial JJ JJ O
nephropathy NN NN O
should MD MD O
be VB VB O
considered VBN VBN O
in IN IN O
patients NNS NNS O
who WP WP O
present JJ JJ O
with IN IN O
unexplained JJ JJ O
renal JJ JJ O
failure NN NN O
. . . O

Chloroacetaldehyde NNP NNP B-CHEM
as IN IN O
a DT DT O
sulfhydryl NN NN B-CHEM
reagent NN NN O
: : : O
the DT DT O
role NN NN O
of IN IN O
critical JJ JJ O
thiol NN NN B-CHEM
groups NNS NNS O
in IN IN O
ifosfamide NN NN B-CHEM
nephropathy NN NN O
. . . O

Chloroacetaldehyde NNP NNP B-CHEM
( ( ( O
CAA NNP NNP B-CHEM
) ) ) O
is VBZ VBZ O
a DT DT O
metabolite NN NN O
of IN IN O
the DT DT O
alkylating VBG VBG O
agent NN NN O
ifosfamide NN NN B-CHEM
( ( ( O
IFO NNP NNP B-CHEM
) ) ) O
and CC CC O
putatively RB RB O
responsible JJ JJ O
for IN IN O
renal JJ JJ O
damage NN NN O
following VBG VBG O
anti JJ JJ O
- : : O
tumor NN NN O
therapy NN NN O
with IN IN O
IFO NNP NNP B-CHEM
. . . O

Depletion NNP NNP O
of IN IN O
sulfhydryl NN NN B-CHEM
( ( ( O
SH NNP NNP B-CHEM
) ) ) O
groups NNS NNS O
has VBZ VBZ O
been VBN VBN O
reported VBN VBN O
from IN IN O
cell NN NN O
culture NN NN O
, , , O
animal NN NN O
and CC CC O
clinical JJ JJ O
studies NNS NNS O
. . . O

In IN IN O
this DT DT O
work NN NN O
the DT DT O
effect NN NN O
of IN IN O
CAA NNP NNP B-CHEM
on IN IN O
human JJ JJ O
proximal NN NN O
tubule NN NN O
cells NNS NNS O
in IN IN O
primary JJ JJ O
culture NN NN O
( ( ( O
hRPTEC NN NN O
) ) ) O
was VBD VBD O
investigated VBN VBN O
. . . O

Toxicity NNP NNP O
of IN IN O
CAA NNP NNP B-CHEM
was VBD VBD O
determined VBN VBN O
by IN IN O
protein NN NN O
content NN NN O
, , , O
cell NN NN O
number NN NN O
, , , O
LDH NNP NNP O
release NN NN O
, , , O
trypan NN NN B-CHEM
blue JJ JJ I-CHEM
exclusion NN NN O
assay NN NN O
and CC CC O
caspase NN NN O
- - - O
3 CD CD O
activity NN NN O
. . . O

Free JJ JJ O
thiols NNS NNS B-CHEM
were VBD VBD O
measured VBN VBN O
by IN IN O
the DT DT O
method NN NN O
of IN IN O
Ellman NNP NNP O
. . . O

CAA NNP NNP B-CHEM
reduced VBD VBD O
hRPTEC NN NN O
cell NN NN O
number NN NN O
and CC CC O
protein NN NN O
, , , O
induced VBD VBD O
a DT DT O
loss NN NN O
in IN IN O
free JJ JJ O
intracellular NN NN O
thiols NNS NNS B-CHEM
and CC CC O
an DT DT O
increase NN NN O
in IN IN O
necrosis NN NN O
markers NNS NNS O
. . . O

CAA NNP NNP B-CHEM
but CC CC O
not RB RB O
acrolein VB VB B-CHEM
inhibited VBN VBN O
the DT DT O
cysteine NN NN B-CHEM
proteases NNS NNS O
caspase NN NN O
- : : O
3 CD CD O
, , , O
caspase NN NN O
- : : O
8 CD CD O
and CC CC O
cathepsin NN NN O
B NNP NNP O
. . . O

Caspase NNP NNP O
activation NN NN O
by IN IN O
cisplatin NN NN B-CHEM
was VBD VBD O
inhibited VBN VBN O
by IN IN O
CAA NNP NNP B-CHEM
. . . O

In IN IN O
cells NNS NNS O
stained JJ JJ O
with IN IN O
fluorescent NN NN O
dyes NN NN O
targeting VBG VBG O
lysosomes NNS NNS O
, , , O
CAA NNP NNP B-CHEM
induced VBD VBD O
an DT DT O
increase NN NN O
in IN IN O
lysosomal NN NN O
size NN NN O
and CC CC O
lysosomal JJ JJ O
leakage NN NN O
. . . O

The DT DT O
effects NNS NNS O
of IN IN O
CAA NNP NNP B-CHEM
on IN IN O
cysteine NN NN B-CHEM
protease NN NN O
activities NNS NNS O
and CC CC O
thiols NNS NNS B-CHEM
could MD MD O
be VB VB O
reproduced VBN VBN O
in IN IN O
cell NN NN O
lysate NN NN O
. . . O

Acidification NNP NNP O
, , , O
which WDT WDT O
slowed VBD VBD O
the DT DT O
reaction NN NN O
of IN IN O
CAA NNP NNP B-CHEM
with IN IN O
thiol NN NN B-CHEM
donors NNS NNS O
, , , O
could MD MD O
also RB RB O
attenuate VB VB O
effects NNS NNS O
of IN IN O
CAA NNP NNP B-CHEM
on IN IN O
necrosis NN NN O
markers NNS NNS O
, , , O
thiol NN NN B-CHEM
depletion NN NN O
and CC CC O
cysteine NN NN B-CHEM
protease NN NN O
inhibition NN NN O
in IN IN O
living VBG VBG O
cells NNS NNS O
. . . O

Thus RB RB O
, , , O
CAA NNP NNP B-CHEM
directly RB RB O
reacts VBZ VBZ O
with IN IN O
cellular JJ JJ O
protein NN NN O
and CC CC O
non NN NN O
- - - O
protein NN NN O
thiols NNS NNS B-CHEM
, , , O
mediating VBG VBG O
its PRP$ PRP$ O
toxicity NN NN O
on IN IN O
hRPTEC NN NN O
. . . O

This DT DT O
effect NN NN O
can MD MD O
be VB VB O
reduced VBN VBN O
by IN IN O
acidification NN NN O
. . . O

Therefore RB RB O
, , , O
urinary JJ JJ O
acidification NN NN O
could MD MD O
be VB VB O
an DT DT O
option NN NN O
to TO TO O
prevent VB VB O
IFO NNP NNP B-CHEM
nephropathy JJ JJ O
in IN IN O
patients NNS NNS O
. . . O

Stereological NNP NNP O
methods NNS NNS O
reveal VBP VBP O
the DT DT O
robust NN NN O
size NN NN O
and CC CC O
stability NN NN O
of IN IN O
ectopic NN NN O
hilar NN NN O
granule NN NN O
cells NNS NNS O
after IN IN O
pilocarpine NN NN B-CHEM
- - - O
induced JJ JJ O
status NN NN O
epilepticus NN NN O
in IN IN O
the DT DT O
adult NN NN O
rat NN NN O
. . . O

Following VBG VBG O
status NN NN O
epilepticus NN NN O
in IN IN O
the DT DT O
rat NN NN O
, , , O
dentate JJ JJ O
granule NN NN O
cell NN NN O
neurogenesis NN NN O
increases NNS NNS O
greatly RB RB O
, , , O
and CC CC O
many JJ JJ O
of IN IN O
the DT DT O
new JJ JJ O
neurons NNS NNS O
appear VBP VBP O
to TO TO O
develop VB VB O
ectopically RB RB O
, , , O
in IN IN O
the DT DT O
hilar JJ JJ O
region NN NN O
of IN IN O
the DT DT O
hippocampal JJ JJ O
formation NN NN O
. . . O

It PRP PRP O
has VBZ VBZ O
been VBN VBN O
suggested VBN VBN O
that IN IN O
the DT DT O
ectopic NN NN O
hilar NN NN O
granule NN NN O
cells NNS NNS O
could MD MD O
contribute VB VB O
to TO TO O
the DT DT O
spontaneous JJ JJ O
seizures NNS NNS O
that WDT WDT O
ultimately RB RB O
develop VB VB O
after IN IN O
status NN NN O
epilepticus NN NN O
. . . O

However RB RB O
, , , O
the DT DT O
population NN NN O
has VBZ VBZ O
never RB RB O
been VBN VBN O
quantified VBN VBN O
, , , O
so IN IN O
it PRP PRP O
is VBZ VBZ O
unclear JJ JJ O
whether IN IN O
it PRP PRP O
is VBZ VBZ O
substantial JJ JJ O
enough RB RB O
to TO TO O
have VB VB O
a DT DT O
strong JJ JJ O
influence NN NN O
on IN IN O
epileptogenesis NN NN O
. . . O

To TO TO O
quantify VB VB O
this DT DT O
population NN NN O
, , , O
the DT DT O
total JJ JJ O
number NN NN O
of IN IN O
ectopic NN NN O
hilar NN NN O
granule NN NN O
cells NNS NNS O
was VBD VBD O
estimated VBN VBN O
using VBG VBG O
unbiased JJ JJ O
stereology NN NN O
at IN IN O
different JJ JJ O
times NNS NNS O
after IN IN O
pilocarpine NN NN B-CHEM
- - - O
induced JJ JJ O
status NN NN O
epilepticus NN NN O
. . . O

The DT DT O
number NN NN O
of IN IN O
hilar JJ JJ O
neurons NNS NNS O
immunoreactive JJ JJ O
for IN IN O
Prox NNP NNP O
- : : O
1 CD CD O
, , , O
a DT DT O
granule NN NN O
- - - O
cell NN NN O
- - - O
specific JJ JJ O
marker NN NN O
, , , O
was VBD VBD O
estimated VBN VBN O
using VBG VBG O
the DT DT O
optical JJ JJ O
fractionator NN NN O
method NN NN O
. . . O

The DT DT O
results NNS NNS O
indicate VBP VBP O
that IN IN O
the DT DT O
size NN NN O
of IN IN O
the DT DT O
hilar NN NN O
ectopic NN NN O
granule NN NN O
cell NN NN O
population NN NN O
after IN IN O
status NN NN O
epilepticus NN NN O
is VBZ VBZ O
substantial JJ JJ O
, , , O
and CC CC O
stable JJ JJ O
over IN IN O
time NN NN O
. . . O

Interestingly RB RB O
, , , O
the DT DT O
size NN NN O
of IN IN O
the DT DT O
population NN NN O
appears VBZ VBZ O
to TO TO O
be VB VB O
correlated VBN VBN O
with IN IN O
the DT DT O
frequency NN NN O
of IN IN O
behavioral JJ JJ O
seizures NNS NNS O
, , , O
because IN IN O
animals NNS NNS O
with IN IN O
more JJR JJR O
ectopic NN NN O
granule NN NN O
cells NNS NNS O
in IN IN O
the DT DT O
hilus NN NN O
have VBP VBP O
more JJR JJR O
frequent JJ JJ O
behavioral JJ JJ O
seizures NNS NNS O
. . . O

The DT DT O
hilar NN NN O
ectopic NN NN O
granule NN NN O
cell NN NN O
population NN NN O
does VBZ VBZ O
not RB RB O
appear VB VB O
to TO TO O
vary JJ JJ O
systematically RB RB O
across IN IN O
the DT DT O
septotemporal JJ JJ O
axis NNS NNS O
, , , O
although IN IN O
it PRP PRP O
is VBZ VBZ O
associated VBN VBN O
with IN IN O
an DT DT O
increase NN NN O
in IN IN O
volume NN NN O
of IN IN O
the DT DT O
hilus NN NN O
. . . O

The DT DT O
results NNS NNS O
provide VBP VBP O
new JJ JJ O
insight NN NN O
into IN IN O
the DT DT O
potential JJ JJ O
role NN NN O
of IN IN O
ectopic NN NN O
hilar NN NN O
granule NN NN O
cells NNS NNS O
in IN IN O
the DT DT O
pilocarpine NN NN B-CHEM
model NN NN O
of IN IN O
temporal JJ JJ O
lobe NN NN O
epilepsy NN NN O
. . . O

A DT DT O
prospective JJ JJ O
, , , O
open JJ JJ O
- - - O
label NN NN O
trial NN NN O
of IN IN O
galantamine NN NN B-CHEM
in IN IN O
autistic JJ JJ O
disorder NN NN O
. . . O

OBJECTIVE NNP NNP O
: : : O
Post NNP NNP O
- - - O
mortem NN NN O
studies NNS NNS O
have VBP VBP O
reported VBN VBN O
abnormalities NNS NNS O
of IN IN O
the DT DT O
cholinergic JJ JJ O
system NN NN O
in IN IN O
autism NN NN O
. . . O

The DT DT O
purpose NN NN O
of IN IN O
this DT DT O
study NN NN O
was VBD VBD O
to TO TO O
assess VB VB O
the DT DT O
use NN NN O
of IN IN O
galantamine NN NN B-CHEM
, , , O
an DT DT O
acetylcholinesterase NN NN O
inhibitor NN NN O
and CC CC O
nicotinic JJ JJ O
receptor NN NN O
modulator NN NN O
, , , O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
interfering VBG VBG O
behaviors NNS NNS O
in IN IN O
children NNS NNS O
with IN IN O
autism NN NN O
. . . O

METHODS NNP NNP O
: : : O
Thirteen NNP NNP O
medication NN NN O
- - - O
free JJ JJ O
children NNS NNS O
with IN IN O
autism NN NN O
( ( ( O
mean VB VB O
age NN NN O
, , , O
8 CD CD O
. . . O
8 CD CD O
+ NN NN O
/ NN NN O
- : : O
3 CD CD O
. . . O
5 CD CD O
years NNS NNS O
) ) ) O
participated VBN VBN O
in IN IN O
a DT DT O
12 CD CD O
- : : O
week NN NN O
, , , O
open JJ JJ O
- - - O
label NN NN O
trial NN NN O
of IN IN O
galantamine NN NN B-CHEM
. . . O

Patients NNS NNS O
were VBD VBD O
rated VBN VBN O
monthly RB RB O
by IN IN O
parents NNS NNS O
on IN IN O
the DT DT O
Aberrant NNP NNP O
Behavior NNP NNP O
Checklist NNP NNP O
( ( ( O
ABC NNP NNP O
) ) ) O
and CC CC O
the DT DT O
Conners NNP NNP O
' POS POS O
Parent NNP NNP O
Rating NNP NNP O
Scale NNP NNP O
- : : O
Revised NNP NNP O
, , , O
and CC CC O
by IN IN O
a DT DT O
physician NN NN O
using VBG VBG O
the DT DT O
Children NNP NNP O
' POS POS O
s VBZ VBZ O
Psychiatric NNP NNP O
Rating NNP NNP O
Scale NNP NNP O
and CC CC O
the DT DT O
Clinical NNP NNP O
Global NNP NNP O
Impressions NNP NNP O
scale NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Patients NNS NNS O
showed VBD VBD O
a DT DT O
significant JJ JJ O
reduction NN NN O
in IN IN O
parent NN NN O
- - - O
rated JJ JJ O
irritability NN NN O
and CC CC O
social JJ JJ O
withdrawal NN NN O
on IN IN O
the DT DT O
ABC NNP NNP O
as RB RB O
well RB RB O
as IN IN O
significant JJ JJ O
improvements NNS NNS O
in IN IN O
emotional JJ JJ O
lability NN NN O
and CC CC O
inattention NN NN O
on IN IN O
the DT DT O
Conners NNP NNP O
' POS POS O
Parent NNP NNP O
Rating NNP NNP O
Scale NNP NNP O
- : : O
- - - O
Revised NNP NNP O
. . . O

Similarly RB RB O
, , , O
clinician NN NN O
ratings NNS NNS O
showed VBD VBD O
reductions NNS NNS O
in IN IN O
the DT DT O
anger NN NN O
subscale NN NN O
of IN IN O
the DT DT O
Children NNP NNP O
' POS POS O
s VBZ VBZ O
Psychiatric NNP NNP O
Rating NNP NNP O
Scale NNP NNP O
. . . O

Eight CD CD O
of IN IN O
13 CD CD O
participants NNS NNS O
were VBD VBD O
rated VBN VBN O
as IN IN O
responders NNS NNS O
on IN IN O
the DT DT O
basis NN NN O
of IN IN O
their PRP$ PRP$ O
improvement NN NN O
scores NNS NNS O
on IN IN O
the DT DT O
Clinical NNP NNP O
Global NNP NNP O
Impressions NNP NNP O
scale NN NN O
. . . O

Overall RB RB O
, , , O
galantamine NN NN B-CHEM
was VBD VBD O
well RB RB O
- - - O
tolerated JJ JJ O
, , , O
with IN IN O
no DT DT O
significant JJ JJ O
adverse JJ JJ O
effects NNS NNS O
apart RB RB O
from IN IN O
headaches NNS NNS O
in IN IN O
one CD CD O
patient NN NN O
. . . O

CONCLUSION NNP NNP O
: : : O
In IN IN O
this DT DT O
open JJ JJ O
trial NN NN O
, , , O
galantamine NN NN B-CHEM
was VBD VBD O
well RB RB O
- : : O
tolerated VBN VBN O
and CC CC O
appeared VBN VBN O
to TO TO O
be VB VB O
beneficial JJ JJ O
for IN IN O
the DT DT O
treatment NN NN O
of IN IN O
interfering VBG VBG O
behaviors NNS NNS O
in IN IN O
children NNS NNS O
with IN IN O
autism NN NN O
, , , O
particularly RB RB O
aggression NN NN O
, , , O
behavioral JJ JJ O
dyscontrol NN NN O
, , , O
and CC CC O
inattention NN NN O
. . . O

Further RB RB O
controlled VBN VBN O
trials NNS NNS O
are VBP VBP O
warranted VBN VBN O
. . . O

Randomized NNP NNP O
comparison NN NN O
of IN IN O
olanzapine NN NN B-CHEM
versus CC CC O
risperidone NN NN B-CHEM
for IN IN O
the DT DT O
treatment NN NN O
of IN IN O
first JJ JJ O
- - - O
episode NN NN O
schizophrenia NN NN O
: : : O
4 CD CD O
- : : O
month NN NN O
outcomes NNS NNS O
. . . O

OBJECTIVE NNP NNP O
: : : O
The DT DT O
authors NNS NNS O
compared VBN VBN O
4 CD CD O
- : : O
month NN NN O
treatment NN NN O
outcomes NNS NNS O
for IN IN O
olanzapine NN NN B-CHEM
versus CC CC O
risperidone NN NN B-CHEM
in IN IN O
patients NNS NNS O
with IN IN O
first JJ JJ O
- - - O
episode NN NN O
schizophrenia NN NN O
spectrum NN NN O
disorders NNS NNS O
. . . O

METHOD NNP NNP O
: : : O
One CD CD O
hundred CD CD O
twelve CD CD O
subjects NNS NNS O
( ( ( O
70 CD CD O
% NN NN O
male JJ JJ O
; : : O
mean VB VB O
age NN NN O
= SYM SYM O
23 CD CD O
. . . O
3 CD CD O
years NNS NNS O
[ NN NN O
SD NNP NNP O
= SYM SYM O
5 CD CD O
. . . O
1 CD CD O
] NN NN O
) ) ) O
with IN IN O
first JJ JJ O
- - - O
episode NN NN O
schizophrenia NN NN O
( ( ( O
75 CD CD O
% NN NN O
) ) ) O
, , , O
schizophreniform NN NN O
disorder NN NN O
( ( ( O
17 CD CD O
% NN NN O
) ) ) O
, , , O
or CC CC O
schizoaffective JJ JJ O
disorder NN NN O
( ( ( O
8 CD CD O
% NN NN O
) ) ) O
were VBD VBD O
randomly RB RB O
assigned VBN VBN O
to TO TO O
treatment NN NN O
with IN IN O
olanzapine NN NN B-CHEM
( ( ( O
2 CD CD O
. . . O
5 CD CD O
- : : O
20 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
) ) ) O
or CC CC O
risperidone NN NN B-CHEM
( ( ( O
1 CD CD O
- : : O
6 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
) ) ) O
. . . O

RESULTS NNS NNS O
: : : O
Response NNP NNP O
rates NNS NNS O
did VBD VBD O
not RB RB O
significantly RB RB O
differ VB VB O
between IN IN O
olanzapine NN NN B-CHEM
( ( ( O
43 CD CD O
. . . O
7 CD CD O
% NN NN O
, , , O
95 CD CD O
% NN NN O
CI NNP NNP O
= SYM SYM O
28 CD CD O
. . . O
8 CD CD O
% NN NN O
- : : O
58 CD CD O
. . . O
6 CD CD O
% NN NN O
) ) ) O
and CC CC O
risperidone NN NN B-CHEM
( ( ( O
54 CD CD O
. . . O
3 CD CD O
% NN NN O
, , , O
95 CD CD O
% NN NN O
CI NNP NNP O
= SYM SYM O
39 CD CD O
. . . O
9 CD CD O
% NN NN O
- : : O
68 CD CD O
. . . O
7 CD CD O
% NN NN O
) ) ) O
. . . O

Among IN IN O
those DT DT O
responding VBG VBG O
to TO TO O
treatment NN NN O
, , , O
more JJR JJR O
subjects NNS NNS O
in IN IN O
the DT DT O
olanzapine NN NN B-CHEM
group NN NN O
( ( ( O
40 CD CD O
. . . O
9 CD CD O
% NN NN O
, , , O
95 CD CD O
% NN NN O
CI NNP NNP O
= SYM SYM O
16 CD CD O
. . . O
8 CD CD O
% NN NN O
- : : O
65 CD CD O
. . . O
0 CD CD O
% NN NN O
) ) ) O
than IN IN O
in IN IN O
the DT DT O
risperidone NN NN B-CHEM
group NN NN O
( ( ( O
18 CD CD O
. . . O
9 CD CD O
% NN NN O
, , , O
95 CD CD O
% NN NN O
CI NNP NNP O
= SYM SYM O
0 CD CD O
% NN NN O
- : : O
39 CD CD O
. . . O
2 CD CD O
% NN NN O
) ) ) O
had VBD VBD O
subsequent JJ JJ O
ratings NNS NNS O
not RB RB O
meeting VBG VBG O
response NN NN O
criteria NNS NNS O
. . . O

Negative NNP NNP O
symptom NN NN O
outcomes NNS NNS O
and CC CC O
measures NNS NNS O
of IN IN O
parkinsonism NN NN O
and CC CC O
akathisia NN NN O
did VBD VBD O
not RB RB O
differ VB VB O
between IN IN O
medications NNS NNS O
. . . O

Extrapyramidal NNP NNP O
symptom NN NN O
severity NN NN O
scores NNS NNS O
were VBD VBD O
1 CD CD O
. . . O
4 CD CD O
( ( ( O
95 CD CD O
% NN NN O
CI NNP NNP O
= SYM SYM O
1 CD CD O
. . . O
2 CD CD O
- : : O
1 CD CD O
. . . O
6 CD CD O
) ) ) O
with IN IN O
risperidone NN NN B-CHEM
and CC CC O
1 CD CD O
. . . O
2 CD CD O
( ( ( O
95 CD CD O
% NN NN O
CI NNP NNP O
= SYM SYM O
1 CD CD O
. . . O
0 CD CD O
- : : O
1 CD CD O
. . . O
4 CD CD O
) ) ) O
with IN IN O
olanzapine NN NN B-CHEM
. . . O

Significantly RB RB O
more JJR JJR O
weight NN NN O
gain NN NN O
occurred VBD VBD O
with IN IN O
olanzapine NN NN B-CHEM
than IN IN O
with IN IN O
risperidone NN NN B-CHEM
: : : O
the DT DT O
increase NN NN O
in IN IN O
weight NN NN O
at IN IN O
4 CD CD O
months NNS NNS O
relative JJ JJ O
to TO TO O
baseline VB VB O
weight NN NN O
was VBD VBD O
17 CD CD O
. . . O
3 CD CD O
% NN NN O
( ( ( O
95 CD CD O
% NN NN O
CI NNP NNP O
= SYM SYM O
14 CD CD O
. . . O
2 CD CD O
% NN NN O
- : : O
20 CD CD O
. . . O
5 CD CD O
% NN NN O
) ) ) O
with IN IN O
olanzapine NN NN B-CHEM
and CC CC O
11 CD CD O
. . . O
3 CD CD O
% NN NN O
( ( ( O
95 CD CD O
% NN NN O
CI NNP NNP O
= SYM SYM O
8 CD CD O
. . . O
4 CD CD O
% NN NN O
- : : O
14 CD CD O
. . . O
3 CD CD O
% NN NN O
) ) ) O
with IN IN O
risperidone NN NN B-CHEM
. . . O

Body NN NN O
mass NN NN O
index NN NN O
at IN IN O
baseline NN NN O
and CC CC O
at IN IN O
4 CD CD O
months NNS NNS O
was VBD VBD O
24 CD CD O
. . . O
3 CD CD O
( ( ( O
95 CD CD O
% NN NN O
CI NNP NNP O
= SYM SYM O
22 CD CD O
. . . O
8 CD CD O
- : : O
25 CD CD O
. . . O
7 CD CD O
) ) ) O
versus CC CC O
28 CD CD O
. . . O
2 CD CD O
( ( ( O
95 CD CD O
% NN NN O
CI NNP NNP O
= SYM SYM O
26 CD CD O
. . . O
7 CD CD O
- : : O
29 CD CD O
. . . O
7 CD CD O
) ) ) O
with IN IN O
olanzapine NN NN B-CHEM
and CC CC O
23 CD CD O
. . . O
9 CD CD O
( ( ( O
95 CD CD O
% NN NN O
CI NNP NNP O
= SYM SYM O
22 CD CD O
. . . O
5 CD CD O
- : : O
25 CD CD O
. . . O
3 CD CD O
) ) ) O
versus CC CC O
26 CD CD O
. . . O
7 CD CD O
( ( ( O
95 CD CD O
% NN NN O
CI NNP NNP O
= SYM SYM O
25 CD CD O
. . . O
2 CD CD O
- : : O
28 CD CD O
. . . O
2 CD CD O
) ) ) O
with IN IN O
risperidone NN NN B-CHEM
. . . O

CONCLUSIONS NNP NNP O
: : : O
Clinical NNP NNP O
outcomes NNS NNS O
with IN IN O
risperidone NN NN B-CHEM
were VBD VBD O
equal JJ JJ O
to TO TO O
those DT DT O
with IN IN O
olanzapine NN NN B-CHEM
, , , O
and CC CC O
response NN NN O
may MD MD O
be VB VB O
more RBR RBR O
stable JJ JJ O
. . . O

Olanzapine NNP NNP B-CHEM
may MD MD O
have VB VB O
an DT DT O
advantage NN NN O
for IN IN O
motor NN NN O
side NN NN O
effects NNS NNS O
. . . O

Both DT DT O
medications NNS NNS O
caused VBD VBD O
substantial JJ JJ O
rapid JJ JJ O
weight NN NN O
gain NN NN O
, , , O
but CC CC O
weight NN NN O
gain NN NN O
was VBD VBD O
greater JJR JJR O
with IN IN O
olanzapine NN NN B-CHEM
. . . O

Early RB RB O
paracentral JJ JJ O
visual JJ JJ O
field NN NN O
loss NN NN O
in IN IN O
patients NNS NNS O
taking VBG VBG O
hydroxychloroquine NN NN B-CHEM
. . . O

OBJECTIVE NNP NNP O
: : : O
To TO TO O
review VB VB O
the DT DT O
natural JJ JJ O
history NN NN O
and CC CC O
ocular JJ JJ O
and CC CC O
systemic JJ JJ O
adverse JJ JJ O
effects NNS NNS O
of IN IN O
patients NNS NNS O
taking VBG VBG O
hydroxychloroquine NN NN B-CHEM
sulfate NN NN I-CHEM
who WP WP O
attended VBD VBD O
an DT DT O
ophthalmic JJ JJ O
screening NN NN O
program NN NN O
. . . O

DESIGN NNP NNP O
: : : O
Retrospective NNP NNP O
study NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Records NNPS NNPS O
of IN IN O
262 CD CD O
patients NNS NNS O
who WP WP O
were VBD VBD O
taking VBG VBG O
hydroxychloroquine NN NN B-CHEM
and CC CC O
screened VBD VBD O
in IN IN O
the DT DT O
Department NNP NNP O
of IN IN O
Ophthalmology NNP NNP O
were VBD VBD O
reviewed VBN VBN O
. . . O

Of IN IN O
the DT DT O
262 CD CD O
patients NNS NNS O
, , , O
14 CD CD O
( ( ( O
18 CD CD O
% NN NN O
) ) ) O
of IN IN O
76 CD CD O
who WP WP O
had VBD VBD O
stopped VBN VBN O
treatment NN NN O
at IN IN O
the DT DT O
time NN NN O
of IN IN O
the DT DT O
study NN NN O
experienced VBD VBD O
documented VBN VBN O
adverse JJ JJ O
effects NNS NNS O
. . . O

Systemic NNP NNP O
adverse JJ JJ O
effects NNS NNS O
occurred VBD VBD O
in IN IN O
8 CD CD O
patients NNS NNS O
( ( ( O
10 CD CD O
. . . O
5 CD CD O
% NN NN O
) ) ) O
and CC CC O
ocular JJ JJ O
adverse JJ JJ O
effects NNS NNS O
, , , O
in IN IN O
5 CD CD O
( ( ( O
6 CD CD O
. . . O
5 CD CD O
% NN NN O
) ) ) O
. . . O

Thirty NNP NNP O
- : : O
five CD CD O
patients NNS NNS O
( ( ( O
13 CD CD O
. . . O
4 CD CD O
% NN NN O
) ) ) O
had VBD VBD O
visual JJ JJ O
field NN NN O
abnormalities NNS NNS O
, , , O
which WDT WDT O
were VBD VBD O
attributed VBN VBN O
to TO TO O
hydroxychloroquine NN NN B-CHEM
treatment NN NN O
in IN IN O
4 CD CD O
patients NNS NNS O
( ( ( O
1 CD CD O
. . . O
5 CD CD O
% NN NN O
) ) ) O
. . . O

Three CD CD O
of IN IN O
the DT DT O
4 CD CD O
patients NNS NNS O
were VBD VBD O
taking VBG VBG O
less JJR JJR O
than IN IN O
6 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
per IN IN O
day NN NN O
and CC CC O
all DT DT O
patients NNS NNS O
had VBD VBD O
normal JJ JJ O
renal NN NN O
and CC CC O
liver NN NN O
function NN NN O
test NN NN O
results NNS NNS O
. . . O

CONCLUSIONS NNP NNP O
: : : O
The DT DT O
current JJ JJ O
study NN NN O
used VBD VBD O
a DT DT O
protocol NN NN O
of IN IN O
visual JJ JJ O
acuity NN NN O
and CC CC O
color NN NN O
vision NN NN O
assessment NN NN O
, , , O
funduscopy NN NN O
, , , O
and CC CC O
Humphrey NNP NNP O
10 CD CD O
- : : O
2 CD CD O
visual JJ JJ O
field NN NN O
testing NN NN O
and CC CC O
shows VBZ VBZ O
that IN IN O
visual JJ JJ O
field NN NN O
defects NNS NNS O
appeared VBD VBD O
before IN IN O
any DT DT O
corresponding JJ JJ O
changes NNS NNS O
in IN IN O
any DT DT O
other JJ JJ O
tested VBN VBN O
clinical JJ JJ O
parameters NNS NNS O
; : : O
the DT DT O
defects NNS NNS O
were VBD VBD O
reproducible JJ JJ O
and CC CC O
the DT DT O
test NN NN O
parameters NNS NNS O
were VBD VBD O
reliable JJ JJ O
. . . O

Patients NNS NNS O
taking VBG VBG O
hydroxychloroquine NN NN B-CHEM
can MD MD O
demonstrate VB VB O
a DT DT O
toxic JJ JJ O
reaction NN NN O
in IN IN O
the DT DT O
retina NN NN O
despite IN IN O
the DT DT O
absence NN NN O
of IN IN O
known VBN VBN O
risk NN NN O
factors NNS NNS O
. . . O

Screening NNP NNP O
, , , O
including VBG VBG O
Humphrey NNP NNP O
10 CD CD O
- : : O
2 CD CD O
visual JJ JJ O
field NN NN O
assessment NN NN O
, , , O
is VBZ VBZ O
recommended VBN VBN O
2 CD CD O
years NNS NNS O
after IN IN O
the DT DT O
initial JJ JJ O
baseline NN NN O
and CC CC O
yearly RB RB O
thereafter RB RB O
. . . O

Peri NNP NNP O
- : : O
operative JJ JJ O
atrioventricular NN NN O
block NN NN O
as IN IN O
a DT DT O
result NN NN O
of IN IN O
chemotherapy NN NN O
with IN IN O
epirubicin NN NN B-CHEM
and CC CC O
paclitaxel NN NN B-CHEM
. . . O

A DT DT O
47 JJ JJ O
- - - O
year NN NN O
- - - O
old JJ JJ O
woman NN NN O
presented VBN VBN O
for IN IN O
mastectomy NN NN O
and CC CC O
immediate JJ JJ O
latissimus NN NN O
dorsi NN NN O
flap NN NN O
reconstruction NN NN O
having VBG VBG O
been VBN VBN O
diagnosed VBN VBN O
with IN IN O
carcinoma NN NN O
of IN IN O
the DT DT O
breast NN NN O
6 CD CD O
months NNS NNS O
previously RB RB O
. . . O

In IN IN O
the DT DT O
preceding VBG VBG O
months NNS NNS O
she PRP PRP O
had VBD VBD O
received VBN VBN O
neo NN NN O
- - - O
adjuvant NN NN O
chemotherapy NN NN O
with IN IN O
epirubicin NN NN B-CHEM
, , , O
paclitaxel NN NN B-CHEM
( ( ( O
Taxol NNP NNP B-CHEM
) ) ) O
and CC CC O
cyclophosphamide NN NN B-CHEM
. . . O

This DT DT O
had VBD VBD O
been VBN VBN O
apparently RB RB O
uncomplicated JJ JJ O
and CC CC O
she PRP PRP O
had VBD VBD O
maintained VBN VBN O
a DT DT O
remarkably RB RB O
high JJ JJ O
level NN NN O
of IN IN O
physical JJ JJ O
activity NN NN O
. . . O

She PRP PRP O
was VBD VBD O
found VBN VBN O
to TO TO O
be VB VB O
bradycardic JJ JJ O
at IN IN O
pre NN NN O
- - - O
operative JJ JJ O
assessment NN NN O
but CC CC O
had VBD VBD O
no DT DT O
cardiac NN NN O
symptoms NNS NNS O
. . . O

Second JJ JJ O
degree NN NN O
Mobitz NNP NNP O
type NN NN O
II NNP NNP O
atrioventricular NN NN O
block NN NN O
was VBD VBD O
diagnosed VBN VBN O
on IN IN O
electrocardiogram NN NN O
, , , O
and CC CC O
temporary JJ JJ O
transvenous JJ JJ O
ventricular NN NN O
pacing VBG VBG O
instituted VBN VBN O
in IN IN O
the DT DT O
peri NN NN O
- - - O
operative JJ JJ O
period NN NN O
. . . O

We PRP PRP O
discuss VBP VBP O
how WRB WRB O
evidence NN NN O
- - - O
based JJ JJ O
guidelines NNS NNS O
would MD MD O
not RB RB O
have VB VB O
been VBN VBN O
helpful JJ JJ O
in IN IN O
this DT DT O
case NN NN O
, , , O
and CC CC O
how WRB WRB O
chemotherapy NN NN O
can MD MD O
exhibit VB VB O
substantial JJ JJ O
cardiotoxicity NN NN O
that WDT WDT O
may MD MD O
develop VB VB O
over IN IN O
many JJ JJ O
years NNS NNS O
. . . O

We PRP PRP O
suggest VBP VBP O
that IN IN O
patients NNS NNS O
who WP WP O
have VBP VBP O
received VBN VBN O
chemotherapy NN NN O
at IN IN O
any DT DT O
time NN NN O
should MD MD O
have VB VB O
a DT DT O
pre NN NN O
- - - O
operative JJ JJ O
electrocardiogram NN NN O
even RB RB O
if IN IN O
they PRP PRP O
are VBP VBP O
asymptomatic JJ JJ O
. . . O

Risks NNS NNS O
and CC CC O
benefits NNS NNS O
of IN IN O
COX NNP NNP B-CHEM
- : : I-CHEM
2 CD CD I-CHEM
inhibitors NNS NNS I-CHEM
vs NNS NNS O
non NN NN O
- : : O
selective JJ JJ O
NSAIDs NNP NNP O
: : : O
does VBZ VBZ O
their PRP$ PRP$ O
cardiovascular JJ JJ O
risk NN NN O
exceed NN NN O
their PRP$ PRP$ O
gastrointestinal JJ JJ O
benefit NN NN O
? . . O

A DT DT O
retrospective NN NN O
cohort NN NN O
study NN NN O
. . . O

OBJECTIVES NNP NNP O
: : : O
The DT DT O
risk NN NN O
of IN IN O
acute JJ JJ O
myocardial NN NN O
infarction NN NN O
( ( ( O
AMI NNP NNP O
) ) ) O
with IN IN O
COX NNP NNP B-CHEM
- : : I-CHEM
2 CD CD I-CHEM
inhibitors NNS NNS I-CHEM
may MD MD O
offset VB VB O
their PRP$ PRP$ O
gastrointestinal NN NN O
( ( ( O
GI NNP NNP O
) ) ) O
benefit NN NN O
compared VBN VBN O
with IN IN O
non NN NN O
- - - O
selective JJ JJ O
( ( ( O
NS NNP NNP O
) ) ) O
non NN NN B-CHEM
- - - I-CHEM
steroidal NN NN I-CHEM
anti NN NN I-CHEM
- : : I-CHEM
inflammatory JJ JJ I-CHEM
drugs NNS NNS I-CHEM
( ( ( O
NSAIDs NNP NNP O
) ) ) O
. . . O

We PRP PRP O
aimed VBD VBD O
to TO TO O
compare VB VB O
the DT DT O
risks NNS NNS O
of IN IN O
hospitalization NN NN O
for IN IN O
AMI NNP NNP O
and CC CC O
GI NNP NNP O
bleeding VBG VBG O
among IN IN O
elderly JJ JJ O
patients NNS NNS O
using VBG VBG O
COX NNP NNP B-CHEM
- : : I-CHEM
2 CD CD I-CHEM
inhibitors NNS NNS I-CHEM
, , , O
NS NNP NNP O
- : : O
NSAIDs NNP NNP O
and CC CC O
acetaminophen NN NN B-CHEM
. . . O

METHODS NNP NNP O
: : : O
We PRP PRP O
conducted VBD VBD O
a DT DT O
retrospective NN NN O
cohort NN NN O
study NN NN O
using VBG VBG O
administrative JJ JJ O
data NNS NNS O
of IN IN O
patients NNS NNS O
> NN NN O
or CC CC O
= SYM SYM O
65 CD CD O
years NNS NNS O
of IN IN O
age NN NN O
who WP WP O
filled VBD VBD O
a DT DT O
prescription NN NN O
for IN IN O
NSAID NNP NNP O
or CC CC O
acetaminophen NN NN B-CHEM
during IN IN O
1999 CD CD O
- : : O
2002 CD CD O
. . . O

Outcomes NNP NNP O
were VBD VBD O
compared VBN VBN O
using VBG VBG O
Cox NNP NNP O
regression NN NN O
models NNS NNS O
with IN IN O
time NN NN O
- : : O
dependent JJ JJ O
exposures NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
Person NN NN O
- - - O
years NNS NNS O
of IN IN O
exposure NN NN O
among IN IN O
non NN NN O
- : : O
users NNS NNS O
of IN IN O
aspirin NN NN B-CHEM
were VBD VBD O
: : : O
75 CD CD O
, , , O
761 CD CD O
to TO TO O
acetaminophen VB VB B-CHEM
, , , O
42 CD CD O
, , , O
671 CD CD O
to TO TO O
rofecoxib NN NN B-CHEM
65 CD CD O
, , , O
860 CD CD O
to TO TO O
celecoxib VB VB B-CHEM
, , , O
and CC CC O
37 CD CD O
, , , O
495 CD CD O
to TO TO O
NS NNP NNP O
- : : O
NSAIDs NNP NNP O
. . . O

Among IN IN O
users NNS NNS O
of IN IN O
aspirin NN NN B-CHEM
, , , O
they PRP PRP O
were VBD VBD O
: : : O
14 CD CD O
, , , O
671 CD CD O
to TO TO O
rofecoxib VB VB B-CHEM
, , , O
22 CD CD O
, , , O
875 CD CD O
to TO TO O
celecoxib VB VB B-CHEM
, , , O
9 CD CD O
, , , O
832 CD CD O
to TO TO O
NS NNP NNP O
- : : O
NSAIDs NNP NNP O
and CC CC O
38 CD CD O
, , , O
048 CD CD O
to TO TO O
acetaminophen VB VB B-CHEM
. . . O

Among IN IN O
non NN NN O
- : : O
users NNS NNS O
of IN IN O
aspirin NN NN B-CHEM
, , , O
the DT DT O
adjusted JJ JJ O
hazard NN NN O
ratios NN NN O
( ( ( O
95 CD CD O
% NN NN O
confidence NN NN O
interval NN NN O
) ) ) O
of IN IN O
hospitalization NN NN O
for IN IN O
AMI NNP NNP O
/ NN NN O
GI NNP NNP O
vs NNS NNS O
the DT DT O
acetaminophen NN NN B-CHEM
( ( ( O
with IN IN O
no DT DT O
aspirin NN NN B-CHEM
) ) ) O
group NN NN O
were VBD VBD O
: : : O
rofecoxib NN NN B-CHEM
1 CD CD O
. . . O
27 CD CD O
( ( ( O
1 CD CD O
. . . O
13 CD CD O
, , , O
1 CD CD O
. . . O
42 CD CD O
) ) ) O
, , , O
celecoxib NN NN B-CHEM
0 CD CD O
. . . O
93 CD CD O
( ( ( O
0 CD CD O
. . . O
83 CD CD O
, , , O
1 CD CD O
. . . O
03 CD CD O
) ) ) O
, , , O
naproxen NN NN B-CHEM
1 CD CD O
. . . O
59 CD CD O
( ( ( O
1 CD CD O
. . . O
31 CD CD O
, , , O
1 CD CD O
. . . O
93 CD CD O
) ) ) O
, , , O
diclofenac NN NN B-CHEM
1 CD CD O
. . . O
17 CD CD O
( ( ( O
0 CD CD O
. . . O
99 CD CD O
, , , O
1 CD CD O
. . . O
38 CD CD O
) ) ) O
and CC CC O
ibuprofen NN NN B-CHEM
1 CD CD O
. . . O
05 CD CD O
( ( ( O
0 CD CD O
. . . O
74 CD CD O
, , , O
1 CD CD O
. . . O
51 CD CD O
) ) ) O
. . . O

Among IN IN O
users NNS NNS O
of IN IN O
aspirin NN NN B-CHEM
, , , O
they PRP PRP O
were VBD VBD O
: : : O
rofecoxib NN NN B-CHEM
1 CD CD O
. . . O
73 CD CD O
( ( ( O
1 CD CD O
. . . O
52 CD CD O
, , , O
1 CD CD O
. . . O
98 CD CD O
) ) ) O
, , , O
celecoxib NN NN B-CHEM
1 CD CD O
. . . O
34 CD CD O
( ( ( O
1 CD CD O
. . . O
19 CD CD O
, , , O
1 CD CD O
. . . O
52 CD CD O
) ) ) O
, , , O
ibuprofen NN NN B-CHEM
1 CD CD O
. . . O
51 CD CD O
( ( ( O
0 CD CD O
. . . O
95 CD CD O
, , , O
2 CD CD O
. . . O
41 CD CD O
) ) ) O
, , , O
diclofenac NN NN B-CHEM
1 CD CD O
. . . O
69 CD CD O
( ( ( O
1 CD CD O
. . . O
35 CD CD O
, , , O
2 CD CD O
. . . O
10 CD CD O
) ) ) O
, , , O
naproxen NN NN B-CHEM
1 CD CD O
. . . O
35 CD CD O
( ( ( O
0 CD CD O
. . . O
97 CD CD O
, , , O
1 CD CD O
. . . O
88 CD CD O
) ) ) O
and CC CC O
acetaminophen NN NN B-CHEM
1 CD CD O
. . . O
29 CD CD O
( ( ( O
1 CD CD O
. . . O
17 CD CD O
, , , O
1 CD CD O
. . . O
42 CD CD O
) ) ) O
. . . O

CONCLUSION NNP NNP O
: : : O
Among IN IN O
non NN NN O
- : : O
users NNS NNS O
of IN IN O
aspirin NN NN B-CHEM
, , , O
naproxen NN NN B-CHEM
seemed VBD VBD O
to TO TO O
carry VB VB O
the DT DT O
highest JJS JJS O
risk NN NN O
for IN IN O
AMI NNP NNP O
/ NN NN O
GI NNP NNP O
bleeding VBG VBG O
. . . O

The DT DT O
AMI NNP NNP O
/ NN NN O
GI NNP NNP O
toxicity NN NN O
of IN IN O
celecoxib NN NN B-CHEM
was VBD VBD O
similar JJ JJ O
to TO TO O
that DT DT O
of IN IN O
acetaminophen NN NN B-CHEM
and CC CC O
seemed VBD VBD O
to TO TO O
be VB VB O
better JJR JJR O
than IN IN O
those DT DT O
of IN IN O
rofecoxib NN NN B-CHEM
and CC CC O
NS NNP NNP O
- : : O
NSAIDs NNP NNP O
. . . O

Among IN IN O
users NNS NNS O
of IN IN O
aspirin NN NN B-CHEM
, , , O
both DT DT O
celecoxib NN NN B-CHEM
and CC CC O
naproxen NN NN B-CHEM
seemed VBD VBD O
to TO TO O
be VB VB O
the DT DT O
least JJS JJS O
toxic JJ JJ O
. . . O

Quinine NNP NNP B-CHEM
- : : O
induced JJ JJ O
arrhythmia NN NN O
in IN IN O
a DT DT O
patient NN NN O
with IN IN O
severe JJ JJ O
malaria NN NN O
. . . O

It PRP PRP O
was VBD VBD O
reported VBN VBN O
that IN IN O
there EX EX O
was VBD VBD O
a DT DT O
case NN NN O
of IN IN O
severe JJ JJ O
malaria NN NN O
patient NN NN O
with IN IN O
jaundice NN NN O
who WP WP O
presented VBD VBD O
with IN IN O
arrhythmia NN NN O
( ( ( O
premature NN NN O
ventricular NN NN O
contraction NN NN O
) ) ) O
while IN IN O
getting VBG VBG O
quinine NN NN B-CHEM
infusion NN NN O
was VBD VBD O
reported VBN VBN O
. . . O

A DT DT O
man NN NN O
, , , O
25 CD CD O
years NNS NNS O
old JJ JJ O
, , , O
was VBD VBD O
admitted VBN VBN O
to TO TO O
hospital NN NN O
with IN IN O
high JJ JJ O
fever NN NN O
, , , O
chill NN NN O
, , , O
vomiting VBG VBG O
, , , O
jaundice NN NN O
. . . O

The DT DT O
patient NN NN O
was VBD VBD O
fully RB RB O
conscious JJ JJ O
, , , O
blood NN NN O
pressure NN NN O
120 CD CD O
/ NN NN O
80 CD CD O
mmHg NN NN O
, , , O
pulse NN NN O
rate NN NN O
100 CD CD O
x SYM SYM O
/ NN NN O
minute NN NN O
, , , O
regular JJ JJ O
. . . O

On IN IN O
admission NN NN O
, , , O
laboratory NN NN O
examination NN NN O
showed VBD VBD O
Plasmodium NNP NNP O
falciparum NN NN O
( ( ( O
+ NN NN O
+ NN NN O
+ NN NN O
+ NN NN O
) ) ) O
, , , O
total JJ JJ O
bilirubin NN NN B-CHEM
8 CD CD O
. . . O
25 CD CD O
mg NN NN O
/ NN NN O
dL NN NN O
, , , O
conjugated VBN VBN O
bilirubin NN NN B-CHEM
4 CD CD O
. . . O
36 CD CD O
mg NN NN O
/ NN NN O
dL NN NN O
, , , O
unconjugated JJ JJ O
bilirubin NN NN B-CHEM
3 CD CD O
. . . O
89 CD CD O
mg NN NN O
/ NN NN O
dL NN NN O
, , , O
potassium NN NN B-CHEM
3 CD CD O
. . . O
52 CD CD O
meq NN NN O
/ NN NN O
L NNP NNP O
Patient NNP NNP O
was VBD VBD O
diagnosed VBN VBN O
as IN IN O
severe JJ JJ O
malaria NN NN O
with IN IN O
jaundice NN NN O
and CC CC O
got VBD VBD O
quinine JJ JJ B-CHEM
infusion NN NN O
in IN IN O
dextrose NN NN B-CHEM
5 CD CD O
% NN NN O
500 CD CD O
mg NN NN O
/ NN NN O
8 CD CD O
hour NN NN O
. . . O

On IN IN O
the DT DT O
second JJ JJ O
day NN NN O
the DT DT O
patient NN NN O
had VBD VBD O
vomitus NN NN O
, , , O
diarrhea NN NN O
, , , O
tinnitus NN NN O
, , , O
loss NN NN O
of IN IN O
hearing NN NN O
. . . O

After IN IN O
30 CD CD O
hours NNS NNS O
of IN IN O
quinine NN NN B-CHEM
infusion NN NN O
the DT DT O
patient NN NN O
felt VBD VBD O
palpitation NN NN O
and CC CC O
electrocardiography NN NN O
( ( ( O
ECG NNP NNP O
) ) ) O
recording VBG VBG O
showed VBD VBD O
premature JJ JJ O
ventricular NN NN O
contraction NN NN O
( ( ( O
PVC NNP NNP O
) ) ) O
> NN NN O
5 CD CD O
x SYM SYM O
/ NN NN O
minute NN NN O
, , , O
trigemini NN NN O
, , , O
constant JJ JJ O
type NN NN O
- - - O
- - - O
sinoatrial JJ JJ O
block NN NN O
, , , O
positive JJ JJ O
U NNP NNP O
wave NN NN O
. . . O

He PRP PRP O
was VBD VBD O
treated VBN VBN O
with IN IN O
lidocaine NN NN B-CHEM
50 CD CD O
mg NN NN O
intravenously RB RB O
followed VBN VBN O
by IN IN O
infusion NN NN O
1500 CD CD O
mg NN NN O
in IN IN O
dextrose NN NN B-CHEM
5 CD CD O
% NN NN O
/ NN NN O
24 CD CD O
hour NN NN O
and CC CC O
potassium NN NN B-CHEM
aspartate NN NN I-CHEM
tablet NN NN O
. . . O

Quinine NNP NNP B-CHEM
infusion NN NN O
was VBD VBD O
discontinued VBN VBN O
and CC CC O
changed VBN VBN O
with IN IN O
sulfate JJ JJ O
quinine NN NN B-CHEM
tablets NNS NNS O
. . . O

Three CD CD O
hours NNS NNS O
later RB RB O
the DT DT O
patient NN NN O
felt VBD VBD O
better JJR JJR O
, , , O
the DT DT O
frequency NN NN O
of IN IN O
PVC NNP NNP O
reduced VBD VBD O
to TO TO O
4 CD CD O
- : : O
5 CD CD O
x SYM SYM O
/ NN NN O
minute NN NN O
and CC CC O
on IN IN O
the DT DT O
third JJ JJ O
day NN NN O
ECG NNP NNP O
was VBD VBD O
normal JJ JJ O
, , , O
potassium NN NN B-CHEM
level NN NN O
was VBD VBD O
3 CD CD O
. . . O
34 CD CD O
meq NN NN O
/ NN NN O
L NNP NNP O
. . . O

He PRP PRP O
was VBD VBD O
discharged VBN VBN O
on IN IN O
7th CD CD O
day NN NN O
in IN IN O
good JJ JJ O
condition NN NN O
. . . O

Quinine NNP NNP B-CHEM
, , , O
like IN IN O
quinidine NN NN B-CHEM
, , , O
is VBZ VBZ O
a DT DT O
chincona NN NN O
alkaloid NN NN O
that WDT WDT O
has VBZ VBZ O
anti JJ JJ O
- : : O
arrhythmic JJ JJ O
property NN NN O
, , , O
although IN IN O
it PRP PRP O
also RB RB O
pro FW FW O
- - - O
arrhythmic JJ JJ O
that WDT WDT O
can MD MD O
cause VB VB O
various JJ JJ O
arrhythmias NNS NNS O
, , , O
including VBG VBG O
severe JJ JJ O
arrhythmia NN NN O
such JJ JJ O
as IN IN O
multiple JJ JJ O
PVC NNP NNP O
. . . O

Administration NNP NNP O
of IN IN O
parenteral JJ JJ O
quinine NN NN B-CHEM
must MD MD O
be VB VB O
done VBN VBN O
carefully RB RB O
and CC CC O
with IN IN O
good JJ JJ O
observation NN NN O
because IN IN O
of IN IN O
its PRP$ PRP$ O
pro FW FW O
- - - O
arrhythmic JJ JJ O
effect NN NN O
, , , O
especially RB RB O
in IN IN O
older JJR JJR O
patients NNS NNS O
who WP WP O
have VBP VBP O
heart NN NN O
diseases NNS NNS O
or CC CC O
patients NNS NNS O
with IN IN O
electrolyte NN NN O
disorder NN NN O
( ( ( O
hypokalemia NN NN O
) ) ) O
which WDT WDT O
frequently RB RB O
occurs VBZ VBZ O
due JJ JJ O
to TO TO O
vomiting VBG VBG O
and CC CC O
or CC CC O
diarrhea NN NN O
in IN IN O
malaria NN NN O
cases NNS NNS O
. . . O

Penicillamine NNP NNP B-CHEM
- - - O
related VBN VBN O
lichenoid NN NN O
dermatitis NN NN O
and CC CC O
utility NN NN O
of IN IN O
zinc NN NN B-CHEM
acetate NN NN I-CHEM
in IN IN O
a DT DT O
Wilson NNP NNP O
disease NN NN O
patient NN NN O
with IN IN O
hepatic JJ JJ O
presentation NN NN O
, , , O
anxiety NN NN O
and CC CC O
SPECT NNP NNP O
abnormalities NNS NNS O
. . . O

Wilson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
is VBZ VBZ O
an DT DT O
autosomal NN NN O
recessive JJ JJ O
disorder NN NN O
of IN IN O
hepatic JJ JJ O
copper NN NN B-CHEM
metabolism NN NN O
with IN IN O
consequent NN NN O
copper NN NN B-CHEM
accumulation NN NN O
and CC CC O
toxicity NN NN O
in IN IN O
many JJ JJ O
tissues NNS NNS O
and CC CC O
consequent NN NN O
hepatic JJ JJ O
, , , O
neurologic JJ JJ O
and CC CC O
psychiatric JJ JJ O
disorders NNS NNS O
. . . O

We PRP PRP O
report VBP VBP O
a DT DT O
case NN NN O
of IN IN O
Wilson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
with IN IN O
chronic JJ JJ O
liver NN NN O
disease NN NN O
; : : O
moreover NN NN O
, , , O
in IN IN O
our PRP$ PRP$ O
patient NN NN O
, , , O
presenting VBG VBG O
also RB RB O
with IN IN O
high JJ JJ O
levels NNS NNS O
of IN IN O
state NN NN O
anxiety NN NN O
without IN IN O
depression NN NN O
, , , O
99mTc CD CD O
- : : O
ECD NNP NNP O
- : : O
SPECT NNP NNP O
showed VBD VBD O
cortical JJ JJ O
hypoperfusion NN NN O
in IN IN O
frontal JJ JJ O
lobes NNS NNS O
, , , O
more JJR JJR O
marked JJ JJ O
on IN IN O
the DT DT O
left VBN VBN O
frontal JJ JJ O
lobe NN NN O
. . . O

During IN IN O
the DT DT O
follow VB VB O
- - - O
up RP RP O
of IN IN O
our PRP$ PRP$ O
patient NN NN O
, , , O
penicillamine NN NN B-CHEM
was VBD VBD O
interrupted VBN VBN O
after IN IN O
the DT DT O
appearance NN NN O
of IN IN O
a DT DT O
lichenoid JJ JJ O
dermatitis NN NN O
, , , O
and CC CC O
zinc NN NN B-CHEM
acetate NN NN I-CHEM
permitted VBN VBN O
to TO TO O
continue VB VB O
the DT DT O
successful JJ JJ O
treatment NN NN O
of IN IN O
the DT DT O
patient NN NN O
without IN IN O
side NN NN O
- - - O
effects NNS NNS O
. . . O

In IN IN O
our PRP$ PRP$ O
case NN NN O
the DT DT O
therapy NN NN O
with IN IN O
zinc NN NN B-CHEM
acetate NN NN I-CHEM
represented VBD VBD O
an DT DT O
effective JJ JJ O
treatment NN NN O
for IN IN O
a DT DT O
Wilson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
patient NN NN O
in IN IN O
which WDT WDT O
penicillamine NN NN B-CHEM
- - - O
related VBN VBN O
side NN NN O
effects NNS NNS O
appeared VBD VBD O
. . . O

The DT DT O
safety NN NN O
of IN IN O
the DT DT O
zinc NN NN B-CHEM
acetate NN NN I-CHEM
allowed VBD VBD O
us PRP PRP O
to TO TO O
avoid VB VB O
other JJ JJ O
potentially RB RB O
toxic JJ JJ O
chelating JJ JJ O
drugs NNS NNS O
; : : O
this DT DT O
observation NN NN O
is VBZ VBZ O
in IN IN O
line NN NN O
with IN IN O
the DT DT O
growing VBG VBG O
evidence NN NN O
on IN IN O
the DT DT O
efficacy NN NN O
of IN IN O
the DT DT O
drug NN NN O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
Wilson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
. . . O

Since IN IN O
most JJS JJS O
of IN IN O
Wilson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
penicillamine NN NN B-CHEM
- - - O
treated VBN VBN O
patients NNS NNS O
do VBP VBP O
not RB RB O
seem VB VB O
to TO TO O
develop VB VB O
this DT DT O
skin NN NN O
lesion NN NN O
, , , O
it PRP PRP O
could MD MD O
be VB VB O
conceivable JJ JJ O
that IN IN O
a DT DT O
specific JJ JJ O
genetic JJ JJ O
factor NN NN O
is VBZ VBZ O
involved VBN VBN O
in IN IN O
drug NN NN O
response NN NN O
. . . O

Further RB RB O
studies NNS NNS O
are VBP VBP O
needed VBN VBN O
for IN IN O
a DT DT O
better JJR JJR O
clarification NN NN O
of IN IN O
Wilson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
therapy NN NN O
, , , O
and CC CC O
in IN IN O
particular JJ JJ O
to TO TO O
differentiate VB VB O
specific JJ JJ O
therapies NNS NNS O
for IN IN O
different JJ JJ O
Wilson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
phenotypes NNS NNS O
. . . O

A DT DT O
dramatic JJ JJ O
drop NN NN O
in IN IN O
blood NN NN O
pressure NN NN O
following VBG VBG O
prehospital JJ JJ O
GTN NNP NNP B-CHEM
administration NN NN O
. . . O

A DT DT O
male NN NN O
in IN IN O
his PRP$ PRP$ O
sixties NNS NNS O
with IN IN O
no DT DT O
history NN NN O
of IN IN O
cardiac JJ JJ O
chest NN NN O
pain NN NN O
awoke NN NN O
with IN IN O
chest NN NN O
pain NN NN O
following VBG VBG O
an DT DT O
afternoon NN NN O
sleep NN NN O
. . . O

The DT DT O
patient NN NN O
did VBD VBD O
not RB RB O
self NN NN O
medicate NN NN O
. . . O

The DT DT O
patient NN NN O
' '' '' O
s VBZ VBZ O
observations NNS NNS O
were VBD VBD O
within IN IN O
normal JJ JJ O
limits NNS NNS O
, , , O
he PRP PRP O
was VBD VBD O
administered JJ JJ O
oxygen NN NN B-CHEM
via IN IN O
a DT DT O
face NN NN O
mask NN NN O
and CC CC O
glyceryl NN NN B-CHEM
trinitrate NN NN I-CHEM
( ( ( O
GTN NNP NNP B-CHEM
) ) ) O
. . . O

Several JJ JJ O
minutes NNS NNS O
after IN IN O
the DT DT O
GTN NNP NNP B-CHEM
the DT DT O
patient NN NN O
experienced VBD VBD O
a DT DT O
sudden JJ JJ O
drop NN NN O
in IN IN O
blood NN NN O
pressure NN NN O
and CC CC O
heart NN NN O
rate NN NN O
, , , O
this DT DT O
was VBD VBD O
rectified VBN VBN O
by IN IN O
atropine NN NN B-CHEM
sulphate NN NN I-CHEM
and CC CC O
a DT DT O
fluid JJ JJ O
challenge NN NN O
. . . O

There EX EX O
was VBD VBD O
no DT DT O
further JJ JJ O
deterioration NN NN O
in IN IN O
the DT DT O
patient NN NN O
' '' '' O
s VBZ VBZ O
condition NN NN O
during IN IN O
transport NN NN O
to TO TO O
hospital NN NN O
. . . O

There EX EX O
are VBP VBP O
very RB RB O
few JJ JJ O
documented VBN VBN O
case NN NN O
like IN IN O
this DT DT O
in IN IN O
the DT DT O
prehospital JJ JJ O
scientific JJ JJ O
literature NN NN O
. . . O

The DT DT O
cause NN NN O
appears VBZ VBZ O
to TO TO O
be VB VB O
the DT DT O
Bezold NNP NNP O
- - - O
Jarish NNP NNP O
reflex NN NN O
, , , O
stimulation NN NN O
of IN IN O
the DT DT O
ventricular NN NN O
walls NNS NNS O
which WDT WDT O
in IN IN O
turn NN NN O
decreases NNS NNS O
sympathetic JJ JJ O
outflow NN NN O
from IN IN O
the DT DT O
vasomotor NN NN O
centre NN NN O
. . . O

Prehospital NNP NNP O
care NN NN O
providers NNS NNS O
who WP WP O
are VBP VBP O
managing VBG VBG O
any DT DT O
patient NN NN O
with IN IN O
a DT DT O
syncopal JJ JJ O
episode NN NN O
that WDT WDT O
fails VBZ VBZ O
to TO TO O
recover VB VB O
within IN IN O
a DT DT O
reasonable JJ JJ O
time NN NN O
frame NN NN O
should MD MD O
consider VB VB O
the DT DT O
Bezold NNP NNP O
- - - O
Jarisch NNP NNP O
reflex NN NN O
as IN IN O
the DT DT O
cause NN NN O
and CC CC O
manage VB VB O
the DT DT O
patient NN NN O
accordingly RB RB O
. . . O

Chronic JJ JJ O
lesion NN NN O
of IN IN O
rostral JJ JJ O
ventrolateral NN NN O
medulla NN NN O
in IN IN O
spontaneously RB RB O
hypertensive JJ JJ O
rats NNS NNS O
. . . O

We PRP PRP O
studied VBD VBD O
the DT DT O
effects NNS NNS O
of IN IN O
chronic JJ JJ O
selective JJ JJ O
neuronal JJ JJ O
lesion NN NN O
of IN IN O
rostral JJ JJ O
ventrolateral NN NN O
medulla NN NN O
on IN IN O
mean NN NN O
arterial JJ JJ O
pressure NN NN O
, , , O
heart NN NN O
rate NN NN O
, , , O
and CC CC O
neurogenic JJ JJ O
tone NN NN O
in IN IN O
conscious JJ JJ O
, , , O
unrestrained JJ JJ O
spontaneously RB RB O
hypertensive JJ JJ O
rats NNS NNS O
. . . O

The DT DT O
lesions NNS NNS O
were VBD VBD O
placed VBN VBN O
via IN IN O
bilateral JJ JJ O
microinjections NNS NNS O
of IN IN O
30 CD CD O
nmol NN NN O
/ NN NN O
200 CD CD O
nl NN NN O
N NNP NNP B-CHEM
- : : I-CHEM
methyl NN NN I-CHEM
- : : I-CHEM
D NNP NNP I-CHEM
- : : I-CHEM
aspartic JJ JJ I-CHEM
acid NN NN I-CHEM
. . . O

The DT DT O
restimulation NN NN O
of IN IN O
this DT DT O
area NN NN O
with IN IN O
N NNP NNP B-CHEM
- : : I-CHEM
methyl NN NN I-CHEM
- : : I-CHEM
D NNP NNP I-CHEM
- : : I-CHEM
aspartic JJ JJ I-CHEM
acid NN NN I-CHEM
15 CD CD O
days NNS NNS O
postlesion NN NN O
failed VBD VBD O
to TO TO O
produce VB VB O
a DT DT O
pressor NN NN O
response NN NN O
. . . O

One CD CD O
day NN NN O
postlesion NN NN O
, , , O
the DT DT O
resting VBG VBG O
mean NN NN O
arterial JJ JJ O
pressure NN NN O
was VBD VBD O
significantly RB RB O
decreased VBN VBN O
in IN IN O
lesioned JJ JJ O
rats NNS NNS O
when WRB WRB O
compared VBN VBN O
with IN IN O
sham NN NN O
rats NNS NNS O
( ( ( O
100 CD CD O
+ NN NN O
/ NN NN O
- : : O
7 CD CD O
versus CC CC O
173 CD CD O
+ NN NN O
/ NN NN O
- : : O
4 CD CD O
mm NN NN O
Hg NNP NNP O
, , , O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

Fifteen NNP NNP O
days NNS NNS O
later RB RB O
, , , O
the DT DT O
lesioned JJ JJ O
group NN NN O
still RB RB O
showed VBD VBD O
values NNS NNS O
significantly RB RB O
lower JJR JJR O
than IN IN O
the DT DT O
sham NN NN O
group NN NN O
( ( ( O
150 CD CD O
+ NN NN O
/ NN NN O
- : : O
6 CD CD O
versus CC CC O
167 CD CD O
+ NN NN O
/ NN NN O
- : : O
5 CD CD O
mm NN NN O
Hg NNP NNP O
, , , O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

No DT DT O
significant JJ JJ O
heart NN NN O
rate NN NN O
differences NNS NNS O
were VBD VBD O
observed VBN VBN O
between IN IN O
the DT DT O
sham NN NN O
and CC CC O
lesioned VBD VBD O
groups NNS NNS O
. . . O

The DT DT O
ganglionic JJ JJ O
blocker NN NN O
trimethaphan NN NN B-CHEM
( ( ( O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
v NN NN O
. . . O
) ) ) O
caused VBD VBD O
similar JJ JJ O
reductions NNS NNS O
in IN IN O
mean NN NN O
arterial JJ JJ O
pressure NN NN O
in IN IN O
both DT DT O
lesioned VBN VBN O
and CC CC O
sham NN NN O
groups NNS NNS O
. . . O

The DT DT O
trimethaphan NN NN B-CHEM
- - - O
induced JJ JJ O
hypotension NN NN O
was VBD VBD O
accompanied VBN VBN O
by IN IN O
a DT DT O
significant JJ JJ O
bradycardia NN NN O
in IN IN O
lesioned VBN VBN O
rats NNS NNS O
( ( ( O
- : : O
32 CD CD O
+ NN NN O
/ NN NN O
- : : O
13 CD CD O
beats NNS NNS O
per IN IN O
minute NN NN O
) ) ) O
but CC CC O
a DT DT O
tachycardia NN NN O
in IN IN O
sham NN NN O
rats NNS NNS O
( ( ( O
+ NN NN O
33 CD CD O
+ NN NN O
/ NN NN O
- : : O
12 CD CD O
beats NNS NNS O
per IN IN O
minute NN NN O
) ) ) O
1 CD CD O
day NN NN O
postlesion NN NN O
. . . O

Therefore RB RB O
, , , O
rostral JJ JJ O
ventrolateral NN NN O
medulla NN NN O
neurons NNS NNS O
appear VBP VBP O
to TO TO O
play VB VB O
a DT DT O
significant JJ JJ O
role NN NN O
in IN IN O
maintaining VBG VBG O
hypertension NN NN O
in IN IN O
conscious JJ JJ O
spontaneously RB RB O
hypertensive JJ JJ O
rats NNS NNS O
. . . O

Spinal NNP NNP O
or CC CC O
suprabulbar NN NN O
structures NNS NNS O
could MD MD O
be VB VB O
responsible JJ JJ O
for IN IN O
the DT DT O
gradual JJ JJ O
recovery NN NN O
of IN IN O
the DT DT O
hypertension NN NN O
in IN IN O
the DT DT O
lesioned JJ JJ O
rats NNS NNS O
. . . O

Acute JJ JJ O
encephalopathy JJ JJ O
and CC CC O
cerebral JJ JJ O
vasospasm NN NN O
after IN IN O
multiagent NN NN O
chemotherapy NN NN O
including VBG VBG O
PEG NNP NNP B-CHEM
- : : I-CHEM
asparaginase NN NN I-CHEM
and CC CC O
intrathecal JJ JJ O
cytarabine NN NN B-CHEM
for IN IN O
the DT DT O
treatment NN NN O
of IN IN O
acute JJ JJ O
lymphoblastic JJ JJ O
leukemia NN NN O
. . . O

A DT DT O
7 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
girl NN NN O
with IN IN O
an DT DT O
unusual JJ JJ O
reaction NN NN O
to TO TO O
induction NN NN O
chemotherapy NN NN O
for IN IN O
precursor NN NN O
B NNP NNP O
- - - O
cell NN NN O
acute JJ JJ O
lymphoblastic JJ JJ O
leukemia NN NN O
( ( ( O
ALL NNP NNP O
) ) ) O
is VBZ VBZ O
described VBN VBN O
. . . O

The DT DT O
patient NN NN O
developed VBN VBN O
acute JJ JJ O
encephalopathy NN NN O
evidenced VBN VBN O
by IN IN O
behavioral JJ JJ O
changes NNS NNS O
, , , O
aphasia NN NN O
, , , O
incontinence NN NN O
, , , O
visual JJ JJ O
hallucinations NNS NNS O
, , , O
and CC CC O
right JJ JJ O
- - - O
sided JJ JJ O
weakness NN NN O
with IN IN O
diffuse NN NN O
cerebral JJ JJ O
vasospasm NN NN O
on IN IN O
magnetic JJ JJ O
resonance NN NN O
angiography NN NN O
after IN IN O
the DT DT O
administration NN NN O
of IN IN O
intrathecal JJ JJ O
cytarabine NN NN B-CHEM
. . . O

Vincristine NNP NNP B-CHEM
, , , O
dexamethasone NN NN B-CHEM
, , , O
and CC CC O
polyethylene NN NN B-CHEM
glycol NN NN I-CHEM
- : : I-CHEM
asparaginase NN NN I-CHEM
were VBD VBD O
also RB RB O
administered VBN VBN O
before IN IN O
the DT DT O
episode NN NN O
as IN IN O
part NN NN O
of IN IN O
induction NN NN O
therapy NN NN O
. . . O

Neurologic NNP NNP O
status NN NN O
returned VBD VBD O
to TO TO O
baseline VB VB O
within IN IN O
10 CD CD O
days NNS NNS O
of IN IN O
the DT DT O
acute JJ JJ O
event NN NN O
, , , O
and CC CC O
magnetic JJ JJ O
resonance NN NN O
angiography NN NN O
findings NNS NNS O
returned VBD VBD O
to TO TO O
normal JJ JJ O
4 CD CD O
months NNS NNS O
later RB RB O
. . . O

Comparison NNP NNP O
of IN IN O
valsartan NN NN B-CHEM
/ NN NN O
hydrochlorothiazide NN NN B-CHEM
combination NN NN O
therapy NN NN O
at IN IN O
doses NNS NNS O
up IN IN O
to TO TO O
320 CD CD O
/ NN NN O
25 CD CD O
mg NN NN O
versus CC CC O
monotherapy NN NN O
: : : O
a DT DT O
double JJ JJ O
- - - O
blind JJ JJ O
, , , O
placebo NN NN O
- - - O
controlled JJ JJ O
study NN NN O
followed VBN VBN O
by IN IN O
long JJ JJ O
- - - O
term NN NN O
combination NN NN O
therapy NN NN O
in IN IN O
hypertensive JJ JJ O
adults NNS NNS O
. . . O

BACKGROUND NNP NNP O
: : : O
One CD CD O
third JJ JJ O
of IN IN O
patients NNS NNS O
treated VBN VBN O
for IN IN O
hypertension NN NN O
attain NN NN O
adequate JJ JJ O
blood NN NN O
pressure NN NN O
( ( ( O
BP NNP NNP O
) ) ) O
control NN NN O
, , , O
and CC CC O
multidrug NN NN O
regimens NNS NNS O
are VBP VBP O
often RB RB O
required VBN VBN O
. . . O

Given VBN VBN O
the DT DT O
lifelong JJ JJ O
nature NN NN O
of IN IN O
hypertension NN NN O
, , , O
there EX EX O
is VBZ VBZ O
a DT DT O
need NN NN O
to TO TO O
evaluate VB VB O
the DT DT O
long JJ JJ O
- - - O
term NN NN O
efficacy NN NN O
and CC CC O
tolerability NN NN O
of IN IN O
higher JJR JJR O
doses NNS NNS O
of IN IN O
combination NN NN O
anti JJ JJ O
- : : O
hypertensive JJ JJ O
therapies NNS NNS O
. . . O

OBJECTIVE NNP NNP O
: : : O
This DT DT O
study NN NN O
investigated VBD VBD O
the DT DT O
efficacy NN NN O
and CC CC O
tolerability NN NN O
of IN IN O
valsartan NN NN B-CHEM
( ( ( O
VAL NNP NNP B-CHEM
) ) ) O
or CC CC O
hydrochlorothiazide NN NN B-CHEM
( ( ( O
HCTZ NNP NNP B-CHEM
) ) ) O
- : : O
monotherapy NN NN O
and CC CC O
higher JJR JJR O
- : : O
dose NN NN O
combinations NNS NNS O
in IN IN O
patients NNS NNS O
with IN IN O
essential JJ JJ O
hypertension NN NN O
. . . O

METHODS NNP NNP O
: : : O
The DT DT O
first JJ JJ O
part NN NN O
of IN IN O
this DT DT O
study NN NN O
was VBD VBD O
an DT DT O
8 CD CD O
- : : O
week NN NN O
, , , O
multicenter NN NN O
, , , O
randomized JJ JJ O
, , , O
double JJ JJ O
- - - O
blind JJ JJ O
, , , O
placebo NN NN O
controlled VBN VBN O
, , , O
parallel JJ JJ O
- - - O
group NN NN O
trial NN NN O
. . . O

Patients NNS NNS O
with IN IN O
essential JJ JJ O
hypertension NN NN O
( ( ( O
mean VB VB O
sitting VBG VBG O
diastolic JJ JJ O
BP NNP NNP O
[ NN NN O
MSDBP NNP NNP O
] NN NN O
, , , O
> NN NN O
or CC CC O
= SYM SYM O
95 CD CD O
mm NN NN O
Hg NNP NNP O
and CC CC O
< NN NN O
110 CD CD O
mm NN NN O
Hg NNP NNP O
) ) ) O
were VBD VBD O
randomized VBN VBN O
to TO TO O
1 CD CD O
of IN IN O
8 CD CD O
treatment NN NN O
groups NNS NNS O
: : : O
VAL NNP NNP B-CHEM
160 CD CD O
or CC CC O
320 CD CD O
mg NN NN O
; : : O
HCTZ NNP NNP B-CHEM
12 CD CD O
. . . O
5 CD CD O
or CC CC O
25 CD CD O
mg NN NN O
; : : O
VAL NNP NNP B-CHEM
/ NN NN O
HCTZ NNP NNP B-CHEM
160 CD CD O
/ NN NN O
12 CD CD O
. . . O
5 CD CD O
, , , O
320 CD CD O
/ NN NN O
12 CD CD O
. . . O
5 CD CD O
, , , O
or CC CC O
320 CD CD O
/ NN NN O
25 CD CD O
mg NN NN O
; : : O
or CC CC O
placebo NN NN O
. . . O

Mean VB VB O
changes NNS NNS O
in IN IN O
MSDBP NNP NNP O
and CC CC O
mean VB VB O
sitting VBG VBG O
systolic JJ JJ O
BP NNP NNP O
( ( ( O
MSSBP NNP NNP O
) ) ) O
were VBD VBD O
analyzed VBN VBN O
at IN IN O
the DT DT O
8 CD CD O
- : : O
week NN NN O
core NN NN O
study NN NN O
end NN NN O
point NN NN O
. . . O

VAL NNP NNP B-CHEM
/ NN NN O
HCTZ NNP NNP B-CHEM
320 CD CD O
/ NN NN O
12 CD CD O
. . . O
5 CD CD O
and CC CC O
320 CD CD O
/ NN NN O
25 CD CD O
mg NN NN O
were VBD VBD O
further RBR RBR O
investigated VBN VBN O
in IN IN O
a DT DT O
54 CD CD O
- : : O
week NN NN O
, , , O
open JJ JJ O
- - - O
label NN NN O
extension NN NN O
. . . O

Response NNP NNP O
was VBD VBD O
defined VBN VBN O
as IN IN O
MSDBP NNP NNP O
< NN NN O
90 CD CD O
mm NN NN O
Hg NNP NNP O
or CC CC O
a DT DT O
> NN NN O
or CC CC O
= SYM SYM O
10 CD CD O
mm NN NN O
Hg NNP NNP O
decrease NN NN O
compared VBN VBN O
to TO TO O
baseline NN NN O
. . . O

Control NN NN O
was VBD VBD O
defined VBN VBN O
as IN IN O
MSDBP NNP NNP O
< NN NN O
90 CD CD O
mm NN NN O
Hg NNP NNP O
compared VBD VBD O
with IN IN O
baseline NN NN O
. . . O

Tolerability NNP NNP O
was VBD VBD O
assessed VBN VBN O
by IN IN O
monitoring VBG VBG O
adverse JJ JJ O
events NNS NNS O
at IN IN O
randomization NN NN O
and CC CC O
all DT DT O
subsequent JJ JJ O
study NN NN O
visits NNS NNS O
and CC CC O
regular JJ JJ O
evaluation NN NN O
of IN IN O
hematology NN NN O
and CC CC O
blood NN NN O
chemistry NN NN O
. . . O

RESULTS NNS NNS O
: : : O
A DT DT O
total NN NN O
of IN IN O
1346 CD CD O
patients NNS NNS O
were VBD VBD O
randomized VBN VBN O
into IN IN O
the DT DT O
8 CD CD O
- : : O
week NN NN O
core NN NN O
study NN NN O
( ( ( O
734 CD CD O
men NNS NNS O
, , , O
612 CD CD O
women NNS NNS O
; : : O
924 CD CD O
white JJ JJ O
, , , O
291 CD CD O
black JJ JJ O
, , , O
23 CD CD O
Asian NNP NNP O
, , , O
108 CD CD O
other JJ JJ O
; : : O
mean VB VB O
age NN NN O
, , , O
52 CD CD O
. . . O
7 CD CD O
years NNS NNS O
; : : O
mean VB VB O
weight NN NN O
, , , O
92 CD CD O
. . . O
6 CD CD O
kg NN NN O
) ) ) O
. . . O

All DT DT O
active JJ JJ O
treatments NNS NNS O
were VBD VBD O
associated VBN VBN O
with IN IN O
significantly RB RB O
reduced VBN VBN O
MSSBP NNP NNP O
and CC CC O
MSDBP NNP NNP O
during IN IN O
the DT DT O
core NN NN O
8 CD CD O
- : : O
week NN NN O
study NN NN O
, , , O
with IN IN O
each DT DT O
monotherapy NN NN O
significantly RB RB O
contributing VBG VBG O
to TO TO O
the DT DT O
overall JJ JJ O
effect NN NN O
of IN IN O
combination NN NN O
therapy NN NN O
( ( ( O
VAL NNP NNP B-CHEM
and CC CC O
HCTZ NNP NNP B-CHEM
, , , O
P NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
. . . O

Each DT DT O
combination NN NN O
was VBD VBD O
associated VBN VBN O
with IN IN O
significantly RB RB O
greater JJR JJR O
reductions NNS NNS O
in IN IN O
MSSBP NNP NNP O
and CC CC O
MSDBP NNP NNP O
compared VBD VBD O
with IN IN O
the DT DT O
monotherapies NNS NNS O
and CC CC O
placebo NN NN O
( ( ( O
all DT DT O
, , , O
P NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
. . . O

The DT DT O
mean JJ JJ O
reduction NN NN O
in IN IN O
MSSBP NNP NNP O
/ NN NN O
MSDBP NNP NNP O
with IN IN O
VAL NNP NNP B-CHEM
/ NN NN O
HCTZ NNP NNP B-CHEM
320 CD CD O
/ NN NN O
25 CD CD O
mg NN NN O
was VBD VBD O
24 CD CD O
. . . O
7 CD CD O
/ NN NN O
16 CD CD O
. . . O
6 CD CD O
mm NN NN O
Hg NNP NNP O
, , , O
compared VBN VBN O
with IN IN O
5 CD CD O
. . . O
9 CD CD O
/ NN NN O
7 CD CD O
. . . O
0 CD CD O
mm NN NN O
Hg NNP NNP O
with IN IN O
placebo NN NN O
. . . O

The DT DT O
reduction NN NN O
in IN IN O
MSSBP NNP NNP O
was VBD VBD O
significantly RB RB O
greater JJR JJR O
with IN IN O
VAL NNP NNP B-CHEM
/ NN NN O
HCTZ NNP NNP B-CHEM
320 CD CD O
/ NN NN O
25 CD CD O
mg NN NN O
compared VBN VBN O
with IN IN O
VAL NNP NNP B-CHEM
/ NN NN O
HCTZ NNP NNP B-CHEM
160 CD CD O
/ NN NN O
12 CD CD O
. . . O
5 CD CD O
mg NN NN O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
002 CD CD O
) ) ) O
. . . O

Rates NNP NNP O
of IN IN O
response NN NN O
and CC CC O
BP NNP NNP O
control NN NN O
were VBD VBD O
significantly RB RB O
higher JJR JJR O
in IN IN O
the DT DT O
groups NNS NNS O
that WDT WDT O
received VBD VBD O
combination NN NN O
treatment NN NN O
compared VBN VBN O
with IN IN O
those DT DT O
that WDT WDT O
received VBD VBD O
monotherapy NN NN O
. . . O

The DT DT O
incidence NN NN O
of IN IN O
hypokalemia NN NN O
was VBD VBD O
lower JJR JJR O
with IN IN O
VAL NNP NNP B-CHEM
/ NN NN O
HCTZ NNP NNP B-CHEM
combinations NNS NNS O
( ( ( O
1 CD CD O
. . . O
8 CD CD O
% NN NN O
- : : O
6 CD CD O
. . . O
1 CD CD O
% NN NN O
) ) ) O
than IN IN O
with IN IN O
HCTZ NNP NNP B-CHEM
monotherapies NNS NNS O
( ( ( O
7 CD CD O
. . . O
1 CD CD O
% NN NN O
- : : O
13 CD CD O
. . . O
3 CD CD O
% NN NN O
) ) ) O
. . . O

The DT DT O
majority NN NN O
of IN IN O
adverse JJ JJ O
events NNS NNS O
in IN IN O
the DT DT O
core NN NN O
study NN NN O
were VBD VBD O
of IN IN O
mild JJ JJ O
to TO TO O
moderate VB VB O
severity NN NN O
. . . O

The DT DT O
efficacy NN NN O
and CC CC O
tolerability NN NN O
of IN IN O
VAL NNP NNP B-CHEM
/ NN NN O
HCTZ NNP NNP B-CHEM
combinations NNS NNS O
were VBD VBD O
maintained VBN VBN O
during IN IN O
the DT DT O
extension NN NN O
( ( ( O
797 CD CD O
patients NNS NNS O
) ) ) O
. . . O

CONCLUSIONS NNP NNP O
: : : O
In IN IN O
this DT DT O
study NN NN O
population NN NN O
, , , O
combination NN NN O
therapies NNS NNS O
with IN IN O
VAL NNP NNP B-CHEM
/ NN NN O
HCTZ NNP NNP B-CHEM
were VBD VBD O
associated VBN VBN O
with IN IN O
significantly RB RB O
greater JJR JJR O
BP NNP NNP O
reductions NNS NNS O
compared VBN VBN O
with IN IN O
either DT DT O
monotherapy NN NN O
, , , O
were VBD VBD O
well RB RB O
tolerated VBN VBN O
, , , O
and CC CC O
were VBD VBD O
associated VBN VBN O
with IN IN O
less JJR JJR O
hypokalemia NN NN O
than IN IN O
HCTZ NNP NNP B-CHEM
alone RB RB O
. . . O

Succimer NNP NNP B-CHEM
chelation NN NN O
improves VBZ VBZ O
learning VBG VBG O
, , , O
attention NN NN O
, , , O
and CC CC O
arousal JJ JJ O
regulation NN NN O
in IN IN O
lead NN NN B-CHEM
- - - O
exposed VBN VBN O
rats NNS NNS O
but CC CC O
produces VBZ VBZ O
lasting VBG VBG O
cognitive JJ JJ O
impairment NN NN O
in IN IN O
the DT DT O
absence NN NN O
of IN IN O
lead JJ JJ B-CHEM
exposure NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
There EX EX O
is VBZ VBZ O
growing VBG VBG O
pressure NN NN O
for IN IN O
clinicians NNS NNS O
to TO TO O
prescribe VB VB O
chelation NN NN O
therapy NN NN O
at IN IN O
only RB RB O
slightly RB RB O
elevated VBD VBD O
blood NN NN O
lead NN NN B-CHEM
levels NNS NNS O
. . . O

However RB RB O
, , , O
very RB RB O
few JJ JJ O
studies NNS NNS O
have VBP VBP O
evaluated VBN VBN O
whether IN IN O
chelation NN NN O
improves VBZ VBZ O
cognitive JJ JJ O
outcomes NNS NNS O
in IN IN O
Pb NNP NNP B-CHEM
- - - O
exposed JJ JJ O
children NNS NNS O
, , , O
or CC CC O
whether IN IN O
these DT DT O
agents NNS NNS O
have VBP VBP O
adverse JJ JJ O
effects NNS NNS O
that WDT WDT O
may MD MD O
affect VB VB O
brain NN NN O
development NN NN O
in IN IN O
the DT DT O
absence NN NN O
of IN IN O
Pb NNP NNP B-CHEM
exposure NN NN O
. . . O

OBJECTIVES NNP NNP O
: : : O
The DT DT O
present JJ JJ O
study NN NN O
was VBD VBD O
designed VBN VBN O
to TO TO O
answer VB VB O
these DT DT O
questions NNS NNS O
, , , O
using VBG VBG O
a DT DT O
rodent JJ JJ O
model NN NN O
of IN IN O
early JJ JJ O
childhood NN NN O
Pb NNP NNP B-CHEM
exposure NN NN O
and CC CC O
treatment NN NN O
with IN IN O
succimer NN NN B-CHEM
, , , O
a DT DT O
widely RB RB O
used VBN VBN O
chelating VBG VBG O
agent NN NN O
for IN IN O
the DT DT O
treatment NN NN O
of IN IN O
Pb NNP NNP O
poisoning NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Pb NNP NNP B-CHEM
exposure NN NN O
produced VBD VBD O
lasting VBG VBG O
impairments NNS NNS O
in IN IN O
learning VBG VBG O
, , , O
attention NN NN O
, , , O
inhibitory NN NN O
control NN NN O
, , , O
and CC CC O
arousal JJ JJ O
regulation NN NN O
, , , O
paralleling VBG VBG O
the DT DT O
areas NNS NNS O
of IN IN O
dysfunction NN NN O
seen VBN VBN O
in IN IN O
Pb NNP NNP B-CHEM
- - - O
exposed JJ JJ O
children NNS NNS O
. . . O

Succimer NNP NNP B-CHEM
treatment NN NN O
of IN IN O
the DT DT O
Pb NNP NNP B-CHEM
- - - O
exposed JJ JJ O
rats NNS NNS O
significantly RB RB O
improved VBN VBN O
learning VBG VBG O
, , , O
attention NN NN O
, , , O
and CC CC O
arousal JJ JJ O
regulation NN NN O
, , , O
although IN IN O
the DT DT O
efficacy NN NN O
of IN IN O
the DT DT O
treatment NN NN O
varied VBD VBD O
as IN IN O
a DT DT O
function NN NN O
of IN IN O
the DT DT O
Pb NNP NNP B-CHEM
exposure NN NN O
level NN NN O
and CC CC O
the DT DT O
specific JJ JJ O
functional JJ JJ O
deficit NN NN O
. . . O

In IN IN O
contrast NN NN O
, , , O
succimer JJ JJ B-CHEM
treatment NN NN O
of IN IN O
rats NNS NNS O
not RB RB O
previously RB RB O
exposed VBN VBN O
to TO TO O
Pb NNP NNP B-CHEM
produced VBD VBD O
lasting VBG VBG O
and CC CC O
pervasive JJ JJ O
cognitive JJ JJ O
and CC CC O
affective JJ JJ O
dysfunction NN NN O
comparable JJ JJ O
in IN IN O
magnitude NN NN O
to TO TO O
that DT DT O
produced VBN VBN O
by IN IN O
the DT DT O
higher JJR JJR O
Pb NNP NNP B-CHEM
exposure NN NN O
regimen NNS NNS O
. . . O

CONCLUSIONS NNP NNP O
: : : O
These DT DT O
are VBP VBP O
the DT DT O
first JJ JJ O
data NNS NNS O
, , , O
to TO TO O
our PRP$ PRP$ O
knowledge NN NN O
, , , O
to TO TO O
show VB VB O
that IN IN O
treatment NN NN O
with IN IN O
any DT DT O
chelating VBG VBG O
agent NN NN O
can MD MD O
alleviate VB VB O
cognitive JJ JJ O
deficits NNS NNS O
due JJ JJ O
to TO TO O
Pb NNP NNP B-CHEM
exposure NN NN O
. . . O

These DT DT O
findings NNS NNS O
suggest VBP VBP O
that IN IN O
it PRP PRP O
may MD MD O
be VB VB O
possible JJ JJ O
to TO TO O
identify VB VB O
a DT DT O
succimer NN NN B-CHEM
treatment NN NN O
protocol NN NN O
that WDT WDT O
improves VBZ VBZ O
cognitive JJ JJ O
outcomes NNS NNS O
in IN IN O
Pb NNP NNP B-CHEM
- - - O
exposed JJ JJ O
children NNS NNS O
. . . O

However RB RB O
, , , O
they PRP PRP O
also RB RB O
suggest VBP VBP O
that IN IN O
succimer NN NN B-CHEM
treatment NN NN O
should MD MD O
be VB VB O
strongly RB RB O
discouraged VBN VBN O
for IN IN O
children NNS NNS O
who WP WP O
do VBP VBP O
not RB RB O
have VB VB O
elevated VBN VBN O
tissue NN NN O
levels NNS NNS O
of IN IN O
Pb NNP NNP B-CHEM
or CC CC O
other JJ JJ O
heavy JJ JJ O
metals NNS NNS O
. . . O

Caffeine NNP NNP B-CHEM
challenge NN NN O
test NN NN O
in IN IN O
panic NN NN O
disorder NN NN O
and CC CC O
depression NN NN O
with IN IN O
panic NN NN O
attacks NNS NNS O
. . . O

Our PRP$ PRP$ O
aim NN NN O
was VBD VBD O
to TO TO O
observe VB VB O
if IN IN O
patients NNS NNS O
with IN IN O
panic NN NN O
disorder NN NN O
( ( ( O
PD NNP NNP O
) ) ) O
and CC CC O
patients NNS NNS O
with IN IN O
major JJ JJ O
depression NN NN O
with IN IN O
panic NN NN O
attacks NNS NNS O
( ( ( O
MDP NNP NNP O
) ) ) O
( ( ( O
Diagnostic NNP NNP O
and CC CC O
Statistical NNP NNP O
Manual NNP NNP O
of IN IN O
Mental NNP NNP O
Disorders NNP NNP O
, , , O
Fourth NNP NNP O
Edition NNP NNP O
criteria NNS NNS O
) ) ) O
respond VB VB O
in IN IN O
a DT DT O
similar JJ JJ O
way NN NN O
to TO TO O
the DT DT O
induction NN NN O
of IN IN O
panic NN NN O
attacks NNS NNS O
by IN IN O
an DT DT O
oral JJ JJ O
caffeine NN NN B-CHEM
challenge NN NN O
test NN NN O
. . . O

We PRP PRP O
randomly VBP VBP O
selected VBN VBN O
29 CD CD O
patients NNS NNS O
with IN IN O
PD NNP NNP O
, , , O
27 CD CD O
with IN IN O
MDP NNP NNP O
, , , O
25 CD CD O
with IN IN O
major JJ JJ O
depression NN NN O
without IN IN O
panic NN NN O
attacks NNS NNS O
( ( ( O
MD NNP NNP O
) ) ) O
, , , O
and CC CC O
28 CD CD O
healthy JJ JJ O
volunteers NNS NNS O
. . . O

The DT DT O
patients NNS NNS O
had VBD VBD O
no DT DT O
psychotropic NN NN O
drug NN NN O
for IN IN O
at IN IN O
least JJS JJS O
a DT DT O
4 CD CD O
- : : O
week NN NN O
period NN NN O
. . . O

In IN IN O
a DT DT O
randomized JJ JJ O
double JJ JJ O
- - - O
blind JJ JJ O
experiment NN NN O
performed VBN VBN O
in IN IN O
2 CD CD O
occasions NNS NNS O
7 CD CD O
days NNS NNS O
apart RB RB O
, , , O
480 CD CD O
mg NN NN O
caffeine NN NN B-CHEM
and CC CC O
a DT DT O
caffeine NN NN B-CHEM
- - - O
free JJ JJ O
( ( ( O
placebo NN NN O
) ) ) O
solution NN NN O
were VBD VBD O
administered VBN VBN O
in IN IN O
a DT DT O
coffee NN NN O
form NN NN O
and CC CC O
anxiety NN NN O
scales NNS NNS O
were VBD VBD O
applied VBN VBN O
before IN IN O
and CC CC O
after IN IN O
each DT DT O
test NN NN O
. . . O

A DT DT O
total NN NN O
of IN IN O
58 CD CD O
. . . O
6 CD CD O
% NN NN O
( ( ( O
n NN NN O
= SYM SYM O
17 CD CD O
) ) ) O
of IN IN O
patients NNS NNS O
with IN IN O
PD NNP NNP O
, , , O
44 CD CD O
. . . O
4 CD CD O
% NN NN O
( ( ( O
n NN NN O
= SYM SYM O
12 CD CD O
) ) ) O
of IN IN O
patients NNS NNS O
with IN IN O
MDP NNP NNP O
, , , O
12 CD CD O
. . . O
0 CD CD O
% NN NN O
( ( ( O
n NN NN O
= SYM SYM O
3 CD CD O
) ) ) O
of IN IN O
patients NNS NNS O
with IN IN O
MD NNP NNP O
, , , O
and CC CC O
7 CD CD O
. . . O
1 CD CD O
% NN NN O
( ( ( O
n NN NN O
= SYM SYM O
2 CD CD O
) ) ) O
of IN IN O
control NN NN O
subjects NNS NNS O
had VBD VBD O
a DT DT O
panic NN NN O
attack NN NN O
after IN IN O
the DT DT O
480 CD CD O
- : : O
mg NN NN O
caffeine NN NN B-CHEM
challenge NN NN O
test NN NN O
( ( ( O
chi NN NN O
( ( ( O
2 CD CD O
) ) ) O
( ( ( O
3 CD CD O
) ) ) O
= SYM SYM O
16 CD CD O
. . . O
22 CD CD O
, , , O
P NN NN O
= SYM SYM O
. . . O
001 CD CD O
) ) ) O
. . . O

The DT DT O
patients NNS NNS O
with IN IN O
PD NNP NNP O
and CC CC O
MDP NNP NNP O
were VBD VBD O
more RBR RBR O
sensitive JJ JJ O
to TO TO O
caffeine NN NN B-CHEM
than IN IN O
were VBD VBD O
patients NNS NNS O
with IN IN O
MD NNP NNP O
and CC CC O
healthy JJ JJ O
volunteers NNS NNS O
. . . O

No DT DT O
panic NN NN O
attack NN NN O
was VBD VBD O
observed VBN VBN O
after IN IN O
the DT DT O
caffeine NN NN B-CHEM
- - - O
free JJ JJ O
solution NN NN O
intake NN NN O
. . . O

The DT DT O
patients NNS NNS O
with IN IN O
MD NNP NNP O
had VBD VBD O
a DT DT O
lower JJR JJR O
heart NN NN O
rate NN NN O
response NN NN O
to TO TO O
the DT DT O
test NN NN O
than IN IN O
all PDT PDT O
the DT DT O
other JJ JJ O
groups NNS NNS O
( ( ( O
2 CD CD O
- : : O
way NN NN O
analysis NN NN O
of IN IN O
variance NN NN O
, , , O
group NN NN O
by IN IN O
time NN NN O
interaction NN NN O
with IN IN O
Greenhouse NNP NNP O
- : : O
Geisser NNP NNP O
correction NN NN O
: : : O
F NN NN O
( ( ( O
3 CD CD O
, , , O
762 CD CD O
) ) ) O
= SYM SYM O
2 CD CD O
. . . O
85 CD CD O
, , , O
P NN NN O
= SYM SYM O
. . . O
026 CD CD O
) ) ) O
. . . O

Our PRP$ PRP$ O
data NNS NNS O
suggest VBP VBP O
that IN IN O
there EX EX O
is VBZ VBZ O
an DT DT O
association NN NN O
between IN IN O
panic NN NN O
attacks NNS NNS O
, , , O
no DT DT O
matter NN NN O
if IN IN O
associated VBN VBN O
with IN IN O
PD NNP NNP O
or CC CC O
MDP NNP NNP O
, , , O
and CC CC O
hyperreactivity NN NN O
to TO TO O
an DT DT O
oral JJ JJ O
caffeine NN NN B-CHEM
challenge NN NN O
test NN NN O
. . . O

Mitral NNP NNP O
annuloplasty NN NN O
as IN IN O
a DT DT O
ventricular NN NN O
restoration NN NN O
method NN NN O
for IN IN O
the DT DT O
failing VBG VBG O
left VBN VBN O
ventricle NN NN O
: : : O
a DT DT O
pilot NN NN O
study NN NN O
. . . O

BACKGROUND NNP NNP O
AND CC CC O
AIM NNP NNP O
OF IN IN O
THE DT DT O
STUDY NNP NNP O
: : : O
Undersized NNP NNP O
mitral NN NN O
annuloplasty NN NN O
( ( ( O
MAP NNP NNP O
) ) ) O
is VBZ VBZ O
effective JJ JJ O
in IN IN O
patients NNS NNS O
with IN IN O
dilated VBN VBN O
cardiomyopathy NN NN O
and CC CC O
functional JJ JJ O
mitral JJ JJ O
regurgitation NN NN O
( ( ( O
MR NNP NNP O
) ) ) O
since IN IN O
, , , O
as RB RB O
well RB RB O
as IN IN O
addressing VBG VBG O
the DT DT O
MR NNP NNP O
, , , O
the DT DT O
MAP NNP NNP O
may MD MD O
also RB RB O
reshape VB VB O
the DT DT O
dilated VBN VBN O
left VBD VBD O
ventricular NN NN O
( ( ( O
LV NNP NNP O
) ) ) O
base NN NN O
. . . O

However RB RB O
, , , O
the DT DT O
direct JJ JJ O
benefits NNS NNS O
of IN IN O
this DT DT O
possible JJ JJ O
reshaping VBG VBG O
on IN IN O
LV NNP NNP O
function NN NN O
in IN IN O
the DT DT O
absence NN NN O
of IN IN O
underlying VBG VBG O
MR NNP NNP O
remain VB VB O
incompletely RB RB O
understood VBN VBN O
. . . O

The DT DT O
study NN NN O
aim NN NN O
was VBD VBD O
to TO TO O
identify VB VB O
these DT DT O
benefits NNS NNS O
in IN IN O
a DT DT O
canine NN NN O
model NN NN O
of IN IN O
acute JJ JJ O
heart NN NN O
failure NN NN O
. . . O

METHODS NNP NNP O
: : : O
Six CD CD O
dogs NNS NNS O
underwent JJ JJ O
MAP NNP NNP O
with IN IN O
a DT DT O
prosthetic JJ JJ O
band NN NN O
on IN IN O
the DT DT O
posterior NN NN O
mitral NN NN O
annulus NN NN O
, , , O
using VBG VBG O
four CD CD O
mattress JJ JJ O
sutures NNS NNS O
. . . O

The DT DT O
sutures NNS NNS O
were VBD VBD O
passed VBN VBN O
individually RB RB O
through IN IN O
four CD CD O
tourniquets NNS NNS O
and CC CC O
exteriorized JJ JJ O
untied JJ JJ O
via IN IN O
the DT DT O
left NN NN O
atriotomy NN NN O
. . . O

Sonomicrometry NNP NNP O
crystals NNS NNS O
were VBD VBD O
implanted VBN VBN O
around IN IN O
the DT DT O
mitral JJ JJ O
annulus NN NN O
and CC CC O
left VBD VBD O
ventricle NN NN O
to TO TO O
measure VB VB O
geometry NN NN O
and CC CC O
regional JJ JJ O
function NN NN O
. . . O

Acute JJ JJ O
heart NN NN O
failure NN NN O
was VBD VBD O
induced VBN VBN O
by IN IN O
propranolol NN NN B-CHEM
and CC CC O
volume NN NN O
loading NN NN O
after IN IN O
weaning VBG VBG O
from IN IN O
cardiopulmonary JJ JJ O
bypass NN NN O
; : : O
an DT DT O
absence NN NN O
of IN IN O
MR NNP NNP O
was VBD VBD O
confirmed VBN VBN O
by IN IN O
echocardiography NN NN O
. . . O

MAP NNP NNP O
was VBD VBD O
accomplished VBN VBN O
by IN IN O
cinching VBG VBG O
the DT DT O
tourniquets NNS NNS O
. . . O

Data NNP NNP O
were VBD VBD O
acquired VBN VBN O
at IN IN O
baseline NN NN O
, , , O
after IN IN O
induction NN NN O
of IN IN O
acute JJ JJ O
heart NN NN O
failure NN NN O
, , , O
and CC CC O
after IN IN O
MAP NNP NNP O
. . . O

RESULTS NNS NNS O
: : : O
MAP NNP NNP O
decreased VBD VBD O
mitral JJ JJ O
annular NN NN O
dimensions NNS NNS O
in IN IN O
both DT DT O
commissure NN NN O
- - - O
commissure NN NN O
and CC CC O
septal JJ JJ O
- : : O
lateral NN NN O
directions NNS NNS O
. . . O

Concomitantly NNP NNP O
, , , O
the DT DT O
diastolic JJ JJ O
diameter NN NN O
of IN IN O
the DT DT O
LV NNP NNP O
base NN NN O
and CC CC O
LV NNP NNP O
sphericity NN NN O
decreased VBD VBD O
( ( ( O
i NNP NNP O
. . . O
e SYM SYM O
. . . O
, , , O
improved VBN VBN O
) ) ) O
from IN IN O
37 CD CD O
. . . O
4 CD CD O
+ NN NN O
/ NN NN O
- : : O
9 CD CD O
. . . O
3 CD CD O
to TO TO O
35 CD CD O
. . . O
9 CD CD O
+ NN NN O
/ NN NN O
- : : O
10 CD CD O
mm NN NN O
( ( ( O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
063 CD CD O
) ) ) O
, , , O
and CC CC O
from IN IN O
67 CD CD O
. . . O
9 CD CD O
+ NN NN O
/ NN NN O
- : : O
18 CD CD O
. . . O
6 CD CD O
% NN NN O
to TO TO O
65 CD CD O
. . . O
3 CD CD O
+ NN NN O
/ NN NN O
- : : O
18 CD CD O
. . . O
9 CD CD O
% NN NN O
( ( ( O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
016 CD CD O
) ) ) O
, , , O
respectively RB RB O
. . . O

Decreases NNP NNP O
were VBD VBD O
evident JJ JJ O
in IN IN O
both DT DT O
LV NNP NNP O
end NN NN O
- : : O
diastolic JJ JJ O
pressure NN NN O
( ( ( O
from IN IN O
17 CD CD O
+ NN NN O
/ NN NN O
- : : O
7 CD CD O
to TO TO O
15 CD CD O
+ NN NN O
/ NN NN O
- : : O
6 CD CD O
mmHg NN NN O
, , , O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
0480 CD CD O
and CC CC O
Tau NNP NNP O
( ( ( O
from IN IN O
48 CD CD O
+ NN NN O
/ NN NN O
- : : O
8 CD CD O
to TO TO O
45 CD CD O
+ NN NN O
/ NN NN O
- : : O
8 CD CD O
ms NN NN O
, , , O
p NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
, , , O
while IN IN O
fractional JJ JJ O
shortening NN NN O
at IN IN O
the DT DT O
LV NNP NNP O
base NN NN O
increased VBD VBD O
from IN IN O
7 CD CD O
. . . O
7 CD CD O
+ NN NN O
/ NN NN O
- : : O
4 CD CD O
. . . O
5 CD CD O
% NN NN O
to TO TO O
9 CD CD O
. . . O
4 CD CD O
+ NN NN O
/ NN NN O
- : : O
4 CD CD O
. . . O
5 CD CD O
% NN NN O
( ( ( O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
045 CD CD O
) ) ) O
. . . O

After IN IN O
MAP NNP NNP O
, , , O
increases NNS NNS O
were VBD VBD O
identified VBN VBN O
in IN IN O
both DT DT O
cardiac NN NN O
output NN NN O
( ( ( O
from IN IN O
1 CD CD O
. . . O
54 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
57 CD CD O
to TO TO O
1 CD CD O
. . . O
65 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
57 CD CD O
1 CD CD O
/ NN NN O
min NN NN O
) ) ) O
and CC CC O
Emax NNP NNP O
( ( ( O
from IN IN O
1 CD CD O
. . . O
86 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
9 CD CD O
to TO TO O
2 CD CD O
. . . O
41 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
31 CD CD O
mmHg NN NN O
/ NN NN O
ml NN NN O
) ) ) O
. . . O

CONCLUSION NNP NNP O
: : : O
The DT DT O
data NNS NNS O
acquired VBD VBD O
suggest JJS JJS O
that IN IN O
isolated VBN VBN O
MAP NNP NNP O
may MD MD O
have VB VB O
certain JJ JJ O
benefits NNS NNS O
on IN IN O
LV NNP NNP O
dimension NN NN O
/ NN NN O
function NN NN O
in IN IN O
acute JJ JJ O
heart NN NN O
failure NN NN O
, , , O
even RB RB O
in IN IN O
the DT DT O
absence NN NN O
of IN IN O
MR NNP NNP O
. . . O

However RB RB O
, , , O
further JJ JJ O
investigations NNS NNS O
are VBP VBP O
warranted VBN VBN O
in IN IN O
a DT DT O
model NN NN O
of IN IN O
chronic JJ JJ O
heart NN NN O
failure NN NN O
. . . O

Piperacillin NNP NNP B-CHEM
/ NN NN I-CHEM
tazobactam NN NN I-CHEM
- - - O
induced JJ JJ O
seizure NN NN O
rapidly RB RB O
reversed VBN VBN O
by IN IN O
high JJ JJ O
flux NN NN O
hemodialysis NN NN O
in IN IN O
a DT DT O
patient NN NN O
on IN IN O
peritoneal NN NN O
dialysis NN NN O
. . . O

Despite IN IN O
popular JJ JJ O
use NN NN O
of IN IN O
piperacillin NN NN B-CHEM
, , , O
the DT DT O
dire NN NN O
neurotoxicity NN NN O
associated VBN VBN O
with IN IN O
piperacillin NN NN B-CHEM
still RB RB O
goes VBZ VBZ O
unrecognized JJ JJ O
, , , O
leading VBG VBG O
to TO TO O
a DT DT O
delay NN NN O
in IN IN O
appropriate JJ JJ O
management NN NN O
. . . O

We PRP PRP O
report VBP VBP O
a DT DT O
57 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
woman NN NN O
with IN IN O
end NN NN O
- : : O
stage NN NN O
renal NN NN O
disease NN NN O
receiving VBG VBG O
continuous JJ JJ O
ambulatory NN NN O
peritoneal NN NN O
dialysis NN NN O
( ( ( O
CAPD NNP NNP O
) ) ) O
, , , O
who WP WP O
developed VBD VBD O
slurred JJ JJ O
speech NN NN O
, , , O
tremor NN NN O
, , , O
bizarre JJ JJ O
behavior NN NN O
, , , O
progressive JJ JJ O
mental JJ JJ O
confusion NN NN O
, , , O
and CC CC O
2 CD CD O
episodes NNS NNS O
of IN IN O
generalized JJ JJ O
tonic NN NN O
- - - O
clonic JJ JJ O
seizure NN NN O
( ( ( O
GTCS NNP NNP O
) ) ) O
after IN IN O
5 CD CD O
doses NNS NNS O
of IN IN O
piperacillin NN NN B-CHEM
/ NN NN I-CHEM
tazobactam NN NN I-CHEM
( ( ( O
2 CD CD O
g SYM SYM O
/ NN NN O
250 CD CD O
mg NN NN O
) ) ) O
were VBD VBD O
given VBN VBN O
for IN IN O
bronchiectasis NN NN O
with IN IN O
secondary JJ JJ O
infection NN NN O
. . . O

The DT DT O
laboratory NN NN O
data NNS NNS O
revealed VBD VBD O
normal JJ JJ O
plasma NN NN O
electrolyte NN NN O
and CC CC O
ammonia NN NN B-CHEM
levels NNS NNS O
but CC CC O
leukocytosis NN NN O
. . . O

Neurologic NNP NNP O
examinations NNS NNS O
showed VBD VBD O
dysarthria NN NN O
and CC CC O
bilateral JJ JJ O
Babinski NNP NNP O
sign NN NN O
. . . O

Computed NNP NNP O
tomography NN NN O
of IN IN O
brain NN NN O
and CC CC O
electroencephalogram NN NN O
were VBD VBD O
unremarkable JJ JJ O
. . . O

Despite IN IN O
the DT DT O
use NN NN O
of IN IN O
antiepileptic JJ JJ O
agents NNS NNS O
, , , O
another DT DT O
GTCS NNP NNP O
episode NN NN O
recurred VBD VBD O
after IN IN O
the DT DT O
sixth JJ JJ O
dose NN NN O
of IN IN O
piperacillin NN NN B-CHEM
/ NN NN I-CHEM
tazobactam NN NN I-CHEM
. . . O

Brain NNP NNP O
magnetic JJ JJ O
resonance NN NN O
imaging VBG VBG O
did VBD VBD O
not RB RB O
demonstrate VB VB O
acute JJ JJ O
infarction NN NN O
and CC CC O
organic JJ JJ O
brain NN NN O
lesions NNS NNS O
. . . O

Initiation NNP NNP O
of IN IN O
high JJ JJ O
- - - O
flux NN NN O
hemodialysis NN NN O
rapidly RB RB O
reversed VBD VBD O
the DT DT O
neurologic JJ JJ O
symptoms NNS NNS O
within IN IN O
4 CD CD O
hours NNS NNS O
. . . O

Piperacillin NNP NNP B-CHEM
- : : O
induced JJ JJ O
encephalopathy NN NN O
should MD MD O
be VB VB O
considered VBN VBN O
in IN IN O
any DT DT O
uremic JJ JJ O
patients NNS NNS O
with IN IN O
unexplained JJ JJ O
neurological JJ JJ O
manifestations NNS NNS O
. . . O

CAPD NNP NNP O
is VBZ VBZ O
inefficient JJ JJ O
in IN IN O
removing VBG VBG O
piperacillin NN NN B-CHEM
, , , O
whereas IN IN O
hemodialysis NN NN O
can MD MD O
rapidly RB RB O
terminate VB VB O
the DT DT O
piperacillin NN NN B-CHEM
- - - O
induced JJ JJ O
encephalopathy NN NN O
. . . O

Frequency NNP NNP O
of IN IN O
transient NN NN O
ipsilateral JJ JJ O
vocal JJ JJ O
cord NN NN O
paralysis NN NN O
in IN IN O
patients NNS NNS O
undergoing VBG VBG O
carotid NN NN O
endarterectomy NN NN O
under IN IN O
local JJ JJ O
anesthesia NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
Especially RB RB O
because IN IN O
of IN IN O
improvements NNS NNS O
in IN IN O
clinical JJ JJ O
neurologic NN NN O
monitoring NN NN O
, , , O
carotid NN NN O
endarterectomy NN NN O
done VBN VBN O
under IN IN O
local JJ JJ O
anesthesia NN NN O
has VBZ VBZ O
become VBN VBN O
the DT DT O
technique NN NN O
of IN IN O
choice NN NN O
in IN IN O
several JJ JJ O
centers NNS NNS O
. . . O

Temporary NNP NNP O
ipsilateral JJ JJ O
vocal JJ JJ O
nerve NN NN O
palsies NNS NNS O
due JJ JJ O
to TO TO O
local JJ JJ O
anesthetics NNS NNS O
have VBP VBP O
been VBN VBN O
described VBN VBN O
, , , O
however RB RB O
. . . O

Such JJ JJ O
complications NNS NNS O
are VBP VBP O
most RBS RBS O
important JJ JJ O
in IN IN O
situations NNS NNS O
where WRB WRB O
there EX EX O
is VBZ VBZ O
a DT DT O
pre NN NN O
- - - O
existing VBG VBG O
contralateral JJ JJ O
paralysis NN NN O
. . . O

We PRP PRP O
therefore RB RB O
examined VBD VBD O
the DT DT O
effect NN NN O
of IN IN O
local JJ JJ O
anesthesia NN NN O
on IN IN O
vocal JJ JJ O
cord NN NN O
function NN NN O
to TO TO O
better JJR JJR O
understand VB VB O
its PRP$ PRP$ O
possible JJ JJ O
consequences NNS NNS O
. . . O

METHODS NNP NNP O
: : : O
This DT DT O
prospective JJ JJ O
study NN NN O
included VBD VBD O
28 CD CD O
patients NNS NNS O
undergoing VBG VBG O
carotid NN NN O
endarterectomy NN NN O
under IN IN O
local JJ JJ O
anesthesia NN NN O
. . . O

Vocal NNP NNP O
cord NN NN O
function NN NN O
was VBD VBD O
evaluated VBN VBN O
before IN IN O
, , , O
during IN IN O
, , , O
and CC CC O
after IN IN O
surgery NN NN O
( ( ( O
postoperative JJ JJ O
day NN NN O
1 CD CD O
) ) ) O
using VBG VBG O
flexible JJ JJ O
laryngoscopy NN NN O
. . . O

Anesthesia NNP NNP O
was VBD VBD O
performed VBN VBN O
by IN IN O
injecting VBG VBG O
20 CD CD O
to TO TO O
40 CD CD O
mL NN NN O
of IN IN O
a DT DT O
mixture NN NN O
of IN IN O
long JJ JJ O
- - - O
acting VBG VBG O
( ( ( O
ropivacaine NN NN B-CHEM
) ) ) O
and CC CC O
short JJ JJ O
- : : O
acting VBG VBG O
( ( ( O
prilocaine NN NN B-CHEM
) ) ) O
anesthetic JJ JJ O
. . . O

RESULTS NNS NNS O
: : : O
All DT DT O
patients NNS NNS O
had VBD VBD O
normal JJ JJ O
vocal JJ JJ O
cord NN NN O
function NN NN O
preoperatively RB RB O
. . . O

Twelve CD CD O
patients NNS NNS O
( ( ( O
43 CD CD O
% NN NN O
) ) ) O
were VBD VBD O
found VBN VBN O
to TO TO O
have VB VB O
intraoperative JJ JJ O
ipsilateral JJ JJ O
vocal JJ JJ O
cord NN NN O
paralysis NN NN O
. . . O

It PRP PRP O
resolved VBD VBD O
in IN IN O
all DT DT O
cases NNS NNS O
< NN NN O
or CC CC O
= SYM SYM O
24 CD CD O
hours NNS NNS O
. . . O

There EX EX O
were VBD VBD O
no DT DT O
significant JJ JJ O
differences NNS NNS O
in IN IN O
operating VBG VBG O
time NN NN O
or CC CC O
volume NN NN O
or CC CC O
frequency NN NN O
of IN IN O
anesthetic JJ JJ O
administration NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
temporary JJ JJ O
vocal JJ JJ O
cord NN NN O
paralysis NN NN O
compared VBN VBN O
with IN IN O
those DT DT O
without IN IN O
. . . O

CONCLUSION NNP NNP O
: : : O
Local JJ JJ O
anesthesia NN NN O
led VBN VBN O
to TO TO O
temporary JJ JJ O
ipsilateral JJ JJ O
vocal JJ JJ O
cord NN NN O
paralysis NN NN O
in IN IN O
almost RB RB O
half NN NN O
of IN IN O
these DT DT O
patients NNS NNS O
. . . O

Because IN IN O
pre NN NN O
- - - O
existing VBG VBG O
paralysis NN NN O
is VBZ VBZ O
of IN IN O
a DT DT O
relevant JJ JJ O
frequency NN NN O
( ( ( O
up IN IN O
to TO TO O
3 CD CD O
% NN NN O
) ) ) O
, , , O
a DT DT O
preoperative JJ JJ O
evaluation NN NN O
of IN IN O
vocal JJ JJ O
cord NN NN O
function NN NN O
before IN IN O
carotid NN NN O
endarterectomy NN NN O
under IN IN O
local JJ JJ O
anesthesia NN NN O
is VBZ VBZ O
recommended VBN VBN O
to TO TO O
avoid VB VB O
intraoperative JJ JJ O
bilateral JJ JJ O
paralysis NN NN O
. . . O

In IN IN O
patients NNS NNS O
with IN IN O
preoperative JJ JJ O
contralateral JJ JJ O
vocal JJ JJ O
cord NN NN O
paralysis NN NN O
, , , O
surgery NN NN O
under IN IN O
general JJ JJ O
anesthesia NN NN O
should MD MD O
be VB VB O
considered VBN VBN O
. . . O

Impaired NNP NNP O
fear NN NN O
recognition NN NN O
in IN IN O
regular JJ JJ O
recreational JJ JJ O
cocaine NN NN B-CHEM
users NNS NNS O
. . . O

INTRODUCTION NNP NNP O
: : : O
The DT DT O
ability NN NN O
to TO TO O
read VB VB O
facial JJ JJ O
expressions NNS NNS O
is VBZ VBZ O
essential JJ JJ O
for IN IN O
normal JJ JJ O
human JJ JJ O
social JJ JJ O
interaction NN NN O
. . . O

The DT DT O
aim NN NN O
of IN IN O
the DT DT O
present JJ JJ O
study NN NN O
was VBD VBD O
to TO TO O
conduct VB VB O
the DT DT O
first JJ JJ O
investigation NN NN O
of IN IN O
facial JJ JJ O
expression NN NN O
recognition NN NN O
performance NN NN O
in IN IN O
recreational JJ JJ O
cocaine NN NN B-CHEM
users NNS NNS O
. . . O

MATERIALS NNS NNS O
AND CC CC O
METHODS NNP NNP O
: : : O
Three CD CD O
groups NNS NNS O
, , , O
comprised VBN VBN O
of IN IN O
21 CD CD O
cocaine NN NN B-CHEM
naive JJ JJ O
participants NNS NNS O
( ( ( O
CN NNP NNP O
) ) ) O
, , , O
30 CD CD O
occasional JJ JJ O
cocaine NN NN B-CHEM
( ( ( O
OC NNP NNP O
) ) ) O
, , , O
and CC CC O
48 CD CD O
regular JJ JJ O
recreational JJ JJ O
cocaine NN NN B-CHEM
( ( ( O
RC NNP NNP O
) ) ) O
users NNS NNS O
, , , O
were VBD VBD O
compared VBN VBN O
. . . O

An DT DT O
emotional JJ JJ O
facial JJ JJ O
expression NN NN O
( ( ( O
EFE NNP NNP O
) ) ) O
task NN NN O
consisting VBG VBG O
of IN IN O
a DT DT O
male NN NN O
and CC CC O
female JJ JJ O
face NN NN O
expressing VBG VBG O
six CD CD O
basic JJ JJ O
emotions NNS NNS O
( ( ( O
happiness NN NN O
, , , O
surprise NN NN O
, , , O
sadness NNS NNS O
, , , O
anger NN NN O
, , , O
fear NN NN O
, , , O
and CC CC O
disgust NN NN O
) ) ) O
was VBD VBD O
administered VBN VBN O
. . . O

Mean VB VB O
percent NN NN O
accuracy NN NN O
and CC CC O
latencies NNS NNS O
for IN IN O
correct JJ JJ O
responses NNS NNS O
across IN IN O
eight CD CD O
presentations NNS NNS O
of IN IN O
each DT DT O
basic JJ JJ O
emotion NN NN O
were VBD VBD O
derived VBN VBN O
. . . O

Participants NNS NNS O
were VBD VBD O
also RB RB O
assessed VBN VBN O
with IN IN O
the DT DT O
" '' '' O
Eyes NNS NNS O
task VBP VBP O
" '' '' O
to TO TO O
investigate VB VB O
their PRP$ PRP$ O
ability NN NN O
to TO TO O
recognize VB VB O
more RBR RBR O
complex JJ JJ O
emotional JJ JJ O
states NNS NNS O
and CC CC O
the DT DT O
Symptom NNP NNP O
CheckList NNP NNP O
- : : O
90 CD CD O
- : : O
Revised NNP NNP O
to TO TO O
measure VB VB O
psychopathology NN NN O
. . . O

RESULTS NNS NNS O
: : : O
There EX EX O
were VBD VBD O
no DT DT O
group NN NN O
differences NNS NNS O
in IN IN O
psychopathology NN NN O
or CC CC O
" '' '' O
eyes NNS NNS O
task NN NN O
" '' '' O
performance NN NN O
, , , O
but CC CC O
the DT DT O
RC NNP NNP O
group NN NN O
, , , O
who WP WP O
otherwise RB RB O
had VBD VBD O
similar JJ JJ O
illicit JJ JJ O
substance NN NN O
use NN NN O
histories NNS NNS O
to TO TO O
the DT DT O
OC NNP NNP O
group NN NN O
, , , O
exhibited VBN VBN O
impaired VBN VBN O
fear NN NN O
recognition NN NN O
accuracy NN NN O
compared VBN VBN O
to TO TO O
the DT DT O
OC NNP NNP O
and CC CC O
CN NNP NNP O
groups NNS NNS O
. . . O

The DT DT O
RC NNP NNP O
group NN NN O
also RB RB O
correctly RB RB O
identified VBN VBN O
anger NN NN O
, , , O
fear NN NN O
, , , O
happiness NN NN O
, , , O
and CC CC O
surprise NN NN O
, , , O
more RBR RBR O
slowly RB RB O
than IN IN O
CN NNP NNP O
, , , O
but CC CC O
not RB RB O
OC NNP NNP O
participants NNS NNS O
. . . O

The DT DT O
OC NNP NNP O
group NN NN O
was VBD VBD O
slower JJR JJR O
than IN IN O
CN NNP NNP O
when WRB WRB O
correctly RB RB O
identifying VBG VBG O
disgust NN NN O
. . . O

The DT DT O
selective JJ JJ O
deficit NN NN O
in IN IN O
fear NN NN O
recognition NN NN O
accuracy NN NN O
manifested VBN VBN O
by IN IN O
the DT DT O
RC NNP NNP O
group NN NN O
cannot NN NN O
be VB VB O
explained VBN VBN O
by IN IN O
the DT DT O
subacute JJ JJ O
effects NNS NNS O
of IN IN O
cocaine NN NN B-CHEM
, , , O
or CC CC O
ecstasy NN NN B-CHEM
, , , O
because IN IN O
recent JJ JJ O
and CC CC O
less RBR RBR O
recent JJ JJ O
users NNS NNS O
of IN IN O
these DT DT O
drugs NNS NNS O
within IN IN O
this DT DT O
group NN NN O
were VBD VBD O
similarly RB RB O
impaired VBN VBN O
. . . O

Possible JJ JJ O
parallels NNS NNS O
between IN IN O
RC NNP NNP O
users NNS NNS O
and CC CC O
psychopaths NNS NNS O
with IN IN O
respect NN NN O
to TO TO O
impaired VBN VBN O
fear NN NN O
recognition NN NN O
, , , O
amygdala NN NN O
dysfunction NN NN O
, , , O
and CC CC O
etiology NN NN O
are VBP VBP O
discussed VBN VBN O
. . . O

Damage NNP NNP O
of IN IN O
substantia NN NN O
nigra NN NN O
pars NNS NNS O
reticulata NN NN O
during IN IN O
pilocarpine NN NN B-CHEM
- - - O
induced JJ JJ O
status NN NN O
epilepticus NN NN O
in IN IN O
the DT DT O
rat NN NN O
: : : O
immunohistochemical JJ JJ O
study NN NN O
of IN IN O
neurons NNS NNS O
, , , O
astrocytes NNS NNS O
and CC CC O
serum NN NN O
- - - O
protein NN NN O
extravasation NN NN O
. . . O

The DT DT O
substantia NN NN O
nigra NN NN O
has VBZ VBZ O
a DT DT O
gating VBG VBG O
function NN NN O
controlling VBG VBG O
the DT DT O
spread NN NN O
of IN IN O
epileptic JJ JJ O
seizure NN NN O
activity NN NN O
. . . O

Additionally RB RB O
, , , O
in IN IN O
models NNS NNS O
of IN IN O
prolonged JJ JJ O
status NN NN O
epilepticus VBZ VBZ O
the DT DT O
pars NNS NNS O
reticulata NN NN O
of IN IN O
substantia NN NN O
nigra NN NN O
( ( ( O
SNR NNP NNP O
) ) ) O
suffers NNS NNS O
from IN IN O
a DT DT O
massive JJ JJ O
lesion NN NN O
which WDT WDT O
may MD MD O
arise VB VB O
from IN IN O
a DT DT O
massive JJ JJ O
metabolic JJ JJ O
derangement NN NN O
and CC CC O
hyperexcitation NN NN O
developing VBG VBG O
in IN IN O
the DT DT O
activated JJ JJ O
SNR NNP NNP O
. . . O

In IN IN O
this DT DT O
study NN NN O
, , , O
status NN NN O
epilepticus NN NN O
was VBD VBD O
induced VBN VBN O
by IN IN O
systemic JJ JJ O
injection NN NN O
of IN IN O
pilocarpine NN NN B-CHEM
in IN IN O
rats NNS NNS O
. . . O

The DT DT O
neuropathology NN NN O
of IN IN O
SNR NNP NNP O
was VBD VBD O
investigated VBN VBN O
using VBG VBG O
immunohistochemical JJ JJ O
techniques NNS NNS O
with IN IN O
the DT DT O
major JJ JJ O
emphasis NN NN O
on IN IN O
the DT DT O
time NN NN O
- - - O
course NN NN O
of IN IN O
changes NNS NNS O
in IN IN O
neurons NNS NNS O
and CC CC O
astrocytes NNS NNS O
. . . O

Animals NNS NNS O
surviving VBG VBG O
20 CD CD O
, , , O
30 CD CD O
, , , O
40 CD CD O
, , , O
60 CD CD O
min NN NN O
, , , O
2 CD CD O
, , , O
3 CD CD O
, , , O
6 CD CD O
hours NNS NNS O
, , , O
1 CD CD O
, , , O
2 CD CD O
, , , O
and CC CC O
3 CD CD O
days NNS NNS O
after IN IN O
induction NN NN O
of IN IN O
status NN NN O
epilepticus NN NN O
were VBD VBD O
perfusion NN NN O
- : : O
fixed VBN VBN O
, , , O
and CC CC O
brains NNS NNS O
processed VBN VBN O
for IN IN O
immunohistochemical JJ JJ O
staining VBG VBG O
of IN IN O
SNR NNP NNP O
. . . O

Nissl NNP NNP O
- : : O
staining VBG VBG O
and CC CC O
antibodies NNS NNS O
against IN IN O
the DT DT O
neuron NN NN O
- - - O
specific JJ JJ O
calcium NN NN B-CHEM
- - - O
binding JJ JJ O
protein NN NN O
, , , O
parvalbumin NN NN O
, , , O
served VBD VBD O
to TO TO O
detect VB VB O
neuronal JJ JJ O
damage NN NN O
in IN IN O
SNR NNP NNP O
. . . O

Antibodies NNP NNP O
against IN IN O
the DT DT O
astroglia NN NN O
- - - O
specific JJ JJ O
cytoskeletal NN NN O
protein NN NN O
, , , O
glial JJ JJ O
fibrillary JJ JJ O
acidic JJ JJ O
protein NN NN O
( ( ( O
GFAP NNP NNP O
) ) ) O
, , , O
and CC CC O
against IN IN O
the DT DT O
glial JJ JJ O
calcium NN NN B-CHEM
- - - O
binding JJ JJ O
protein NN NN O
, , , O
S NNP NNP O
- : : O
100 CD CD O
protein NN NN O
, , , O
were VBD VBD O
used VBN VBN O
to TO TO O
assess VB VB O
the DT DT O
status NN NN O
of IN IN O
astrocytes NNS NNS O
. . . O

Immunohistochemical NNP NNP O
staining VBG VBG O
for IN IN O
serum NN NN O
- - - O
albumin NN NN O
and CC CC O
immunoglobulins NNS NNS O
in IN IN O
brain NN NN O
tissue NN NN O
was VBD VBD O
taken VBN VBN O
as IN IN O
indicator NN NN O
of IN IN O
blood NN NN O
- - - O
brain NN NN O
barrier NN NN O
disturbances NNS NNS O
and CC CC O
vasogenic JJ JJ O
edema NN NN O
formation NN NN O
. . . O

Immunohistochemical NNP NNP O
staining VBG VBG O
indicated VBN VBN O
loss NN NN O
of IN IN O
GFAP NNP NNP O
- : : O
staining VBG VBG O
already RB RB O
at IN IN O
30 CD CD O
min NN NN O
after IN IN O
induction NN NN O
of IN IN O
seizures NNS NNS O
in IN IN O
an DT DT O
oval NN NN O
focus NN NN O
situated VBN VBN O
in IN IN O
the DT DT O
center NN NN O
of IN IN O
SNR NNP NNP O
while IN IN O
sparing VBG VBG O
medial JJ JJ O
and CC CC O
lateral NN NN O
aspects NNS NNS O
. . . O

At IN IN O
1 CD CD O
h NN NN O
there EX EX O
was VBD VBD O
additional JJ JJ O
vacuolation NN NN O
in IN IN O
S NNP NNP O
- : : O
100 CD CD O
protein NN NN O
staining VBG VBG O
. . . O

By IN IN O
2 CD CD O
hours NNS NNS O
, , , O
parvalbumin NN NN O
- - - O
staining VBG VBG O
changed VBN VBN O
in IN IN O
the DT DT O
central JJ JJ O
SNR NNP NNP O
indicating VBG VBG O
neuronal NN NN O
damage NN NN O
, , , O
and CC CC O
Nissl NNP NNP O
- : : O
staining VBG VBG O
visualized JJ JJ O
some DT DT O
neuronal JJ JJ O
distortion NN NN O
. . . O

Staining NNP NNP O
for IN IN O
serum NN NN O
- - - O
proteins NNS NNS O
occurred VBD VBD O
in IN IN O
a DT DT O
patchy NN NN O
manner NN NN O
throughout IN IN O
the DT DT O
forebrain NN NN O
during IN IN O
the DT DT O
first JJ JJ O
hours NNS NNS O
. . . O

By IN IN O
6 CD CD O
h NN NN O
, , , O
vasogenic JJ JJ O
edema NN NN O
covered VBN VBN O
the DT DT O
lesioned JJ JJ O
SNR NNP NNP O
. . . O

By IN IN O
24 CD CD O
h NN NN O
, , , O
glial JJ JJ O
and CC CC O
neuronal JJ JJ O
markers NNS NNS O
indicated VBD VBD O
a DT DT O
massive JJ JJ O
lesion NN NN O
in IN IN O
the DT DT O
center NN NN O
of IN IN O
SNR NNP NNP O
. . . O

By IN IN O
48 CD CD O
- : : O
72 CD CD O
h NN NN O
, , , O
astrocytes NNS NNS O
surrounding VBG VBG O
the DT DT O
lesion NN NN O
increased VBN VBN O
in IN IN O
size NN NN O
, , , O
and CC CC O
polymorphic JJ JJ O
phagocytotic JJ JJ O
cells NNS NNS O
invaded VBD VBD O
the DT DT O
damaged JJ JJ O
area NN NN O
. . . O

In IN IN O
a DT DT O
further JJ JJ O
group NN NN O
of IN IN O
animals NNS NNS O
surviving VBG VBG O
1 CD CD O
to TO TO O
5 CD CD O
days NNS NNS O
, , , O
conventional JJ JJ O
paraffin NN NN O
- - - O
sections NNS NNS O
confirmed VBD VBD O
the DT DT O
neuronal NN NN O
and CC CC O
glial JJ JJ O
damage NN NN O
of IN IN O
SNR NNP NNP O
. . . O

Additional JJ JJ O
pathology NN NN O
of IN IN O
similar JJ JJ O
quality NN NN O
was VBD VBD O
found VBN VBN O
in IN IN O
the DT DT O
globus NN NN O
pallidus NN NN O
. . . O

Since IN IN O
astrocytes NNS NNS O
were VBD VBD O
always RB RB O
damaged VBN VBN O
in IN IN O
parallel JJ JJ O
with IN IN O
neurons NNS NNS O
in IN IN O
SNR NNP NNP O
it PRP PRP O
is VBZ VBZ O
proposed VBN VBN O
that IN IN O
the DT DT O
anatomical JJ JJ O
and CC CC O
functional JJ JJ O
interrelationship NN NN O
between IN IN O
neurons NNS NNS O
and CC CC O
astrocytes NNS NNS O
is VBZ VBZ O
particularly RB RB O
tight JJ JJ O
in IN IN O
SNR NNP NNP O
. . . O

Both DT DT O
cell NN NN O
elements NNS NNS O
may MD MD O
suffer VB VB O
in IN IN O
common JJ JJ O
from IN IN O
metabolic JJ JJ O
disturbance NN NN O
and CC CC O
neurotransmitter NN NN O
dysfunction NN NN O
as IN IN O
occur NN NN O
during IN IN O
massive JJ JJ O
status NN NN O
epilepticus NN NN O
. . . O

Neuroprotective NNP NNP O
effects NNS NNS O
of IN IN O
melatonin NN NN B-CHEM
upon IN IN O
the DT DT O
offspring VBG VBG O
cerebellar NN NN O
cortex NN NN O
in IN IN O
the DT DT O
rat NN NN O
model NN NN O
of IN IN O
BCNU NNP NNP B-CHEM
- : : O
induced JJ JJ O
cortical JJ JJ O
dysplasia NN NN O
. . . O

Cortical NNP NNP O
dysplasia NN NN O
is VBZ VBZ O
a DT DT O
malformation NN NN O
characterized VBN VBN O
by IN IN O
defects NNS NNS O
in IN IN O
proliferation NN NN O
, , , O
migration NN NN O
and CC CC O
maturation NN NN O
. . . O

This DT DT O
study NN NN O
was VBD VBD O
designed VBN VBN O
to TO TO O
evaluate VB VB O
the DT DT O
alterations NNS NNS O
in IN IN O
offspring VBG VBG O
rat NN NN O
cerebellum NN NN O
induced VBN VBN O
by IN IN O
maternal JJ JJ O
exposure NN NN O
to TO TO O
carmustine VB VB B-CHEM
- : : O
[ NN NN O
1 CD CD B-CHEM
, , , I-CHEM
3 CD CD I-CHEM
- : : I-CHEM
bis NN NN I-CHEM
( ( ( I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
chloroethyl NN NN I-CHEM
) ) ) I-CHEM
- : : I-CHEM
1 CD CD I-CHEM
- : : I-CHEM
nitrosoure NN NN I-CHEM
] NN NN O
( ( ( O
BCNU NNP NNP B-CHEM
) ) ) O
and CC CC O
to TO TO O
investigate VB VB O
the DT DT O
effects NNS NNS O
of IN IN O
exogenous JJ JJ O
melatonin NN NN B-CHEM
upon IN IN O
cerebellar NN NN O
BCNU NNP NNP B-CHEM
- : : O
induced JJ JJ O
cortical JJ JJ O
dysplasia NN NN O
, , , O
using VBG VBG O
histological JJ JJ O
and CC CC O
biochemical JJ JJ O
analyses NNS NNS O
. . . O

Pregnant NNP NNP O
Wistar NNP NNP O
rats NNS NNS O
were VBD VBD O
assigned VBN VBN O
to TO TO O
five CD CD O
groups NNS NNS O
: : : O
intact JJ JJ O
- - - O
control NN NN O
, , , O
saline NN NN O
- - - O
control NN NN O
, , , O
melatonin NN NN B-CHEM
- - - O
treated VBN VBN O
, , , O
BCNU NNP NNP B-CHEM
- - - O
exposed VBN VBN O
and CC CC O
BCNU NNP NNP B-CHEM
- - - O
exposed VBN VBN O
plus CC CC O
melatonin NN NN B-CHEM
. . . O

Rats NNP NNP O
were VBD VBD O
exposed VBN VBN O
to TO TO O
BCNU NNP NNP B-CHEM
on IN IN O
embryonic JJ JJ O
day NN NN O
15 CD CD O
and CC CC O
melatonin NN NN B-CHEM
was VBD VBD O
given VBN VBN O
until IN IN O
delivery NN NN O
. . . O

Immuno NNP NNP O
/ NN NN O
histochemistry NN NN O
and CC CC O
electron NN NN O
microscopy NN NN O
were VBD VBD O
carried VBN VBN O
out IN IN O
on IN IN O
the DT DT O
offspring VBG VBG O
cerebellum NN NN O
, , , O
and CC CC O
levels NNS NNS O
of IN IN O
malondialdehyde NN NN B-CHEM
and CC CC O
superoxide NN NN B-CHEM
dismutase NN NN O
were VBD VBD O
determined VBN VBN O
. . . O

Histopathologically NNP NNP O
, , , O
typical JJ JJ O
findings NNS NNS O
were VBD VBD O
observed VBN VBN O
in IN IN O
the DT DT O
cerebella NN NN O
from IN IN O
the DT DT O
control NN NN O
groups NNS NNS O
, , , O
but CC CC O
the DT DT O
findings NNS NNS O
consistent JJ JJ O
with IN IN O
early JJ JJ O
embryonic JJ JJ O
development NN NN O
were VBD VBD O
noted VBN VBN O
in IN IN O
BCNU NNP NNP B-CHEM
- - - O
exposed JJ JJ O
cortical JJ JJ O
dysplasia NN NN O
group NN NN O
. . . O

There EX EX O
was VBD VBD O
a DT DT O
marked VBN VBN O
increase NN NN O
in IN IN O
the DT DT O
number NN NN O
of IN IN O
TUNEL NNP NNP O
positive JJ JJ O
cells NNS NNS O
and CC CC O
nestin NN NN O
positive JJ JJ O
cells NNS NNS O
in IN IN O
BCNU NNP NNP B-CHEM
- - - O
exposed JJ JJ O
group NN NN O
, , , O
but CC CC O
a DT DT O
decreased JJ JJ O
immunoreactivity NN NN O
to TO TO O
glial JJ JJ O
fibrillary JJ JJ O
acidic JJ JJ O
protein NN NN O
, , , O
synaptophysin NN NN O
and CC CC O
transforming VBG VBG O
growth NN NN O
factor NN NN O
beta1 NN NN O
was VBD VBD O
observed VBN VBN O
, , , O
indicating VBG VBG O
a DT DT O
delayed JJ JJ O
maturation NN NN O
, , , O
and CC CC O
melatonin NN NN B-CHEM
significantly RB RB O
reversed VBD VBD O
these DT DT O
changes NNS NNS O
. . . O

Malondialdehyde NNP NNP B-CHEM
level NN NN O
in IN IN O
BCNU NNP NNP B-CHEM
- - - O
exposed JJ JJ O
group NN NN O
was VBD VBD O
higher JJR JJR O
than IN IN O
those DT DT O
in IN IN O
control NN NN O
groups NNS NNS O
and CC CC O
melatonin NN NN B-CHEM
decreased VBD VBD O
malondialdehyde NN NN B-CHEM
levels NNS NNS O
in IN IN O
BCNU NNP NNP B-CHEM
group NN NN O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
, , , O
while IN IN O
there EX EX O
were VBD VBD O
no DT DT O
significant JJ JJ O
differences NNS NNS O
in IN IN O
the DT DT O
superoxide NN NN B-CHEM
dismutase NN NN O
levels NNS NNS O
between IN IN O
these DT DT O
groups NNS NNS O
. . . O

These DT DT O
data NNS NNS O
suggest VBP VBP O
that IN IN O
exposure NN NN O
of IN IN O
animals NNS NNS O
to TO TO O
BCNU NNP NNP B-CHEM
during IN IN O
pregnancy NN NN O
leads VBZ VBZ O
to TO TO O
delayed VB VB O
maturation NN NN O
of IN IN O
offspring VBG VBG O
cerebellum NN NN O
and CC CC O
melatonin NN NN B-CHEM
protects VBZ VBZ O
the DT DT O
cerebellum NN NN O
against IN IN O
the DT DT O
effects NNS NNS O
of IN IN O
BCNU NNP NNP B-CHEM
. . . O

Reduced NNP NNP O
cardiotoxicity NN NN O
of IN IN O
doxorubicin NN NN B-CHEM
given VBN VBN O
in IN IN O
the DT DT O
form NN NN O
of IN IN O
N NNP NNP B-CHEM
- : : I-CHEM
( ( ( I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
hydroxypropyl NN NN I-CHEM
) ) ) I-CHEM
methacrylamide NN NN I-CHEM
conjugates NNS NNS O
: : : O
and CC CC O
experimental JJ JJ O
study NN NN O
in IN IN O
the DT DT O
rat NN NN O
. . . O

A DT DT O
rat NN NN O
model NN NN O
was VBD VBD O
used VBN VBN O
to TO TO O
evaluate VB VB O
the DT DT O
general JJ JJ O
acute JJ JJ O
toxicity NN NN O
and CC CC O
the DT DT O
late JJ JJ O
cardiotoxicity NN NN O
of IN IN O
4 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
doxorubicin NN NN B-CHEM
( ( ( O
DOX NNP NNP B-CHEM
) ) ) O
given VBN VBN O
either CC CC O
as IN IN O
free JJ JJ O
drug NN NN O
or CC CC O
in IN IN O
the DT DT O
form NN NN O
of IN IN O
three CD CD O
N NNP NNP B-CHEM
- : : I-CHEM
( ( ( I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
hydroxypropyl NN NN I-CHEM
) ) ) I-CHEM
methacrylamide NN NN I-CHEM
( ( ( O
HPMA NNP NNP B-CHEM
) ) ) O
copolymer NN NN O
conjugates NNS NNS O
. . . O

In IN IN O
these DT DT O
HPMA NNP NNP B-CHEM
copolymers NNS NNS O
, , , O
DOX NNP NNP B-CHEM
was VBD VBD O
covalently RB RB O
bound VBN VBN O
via IN IN O
peptide NN NN O
linkages NNS NNS O
that WDT WDT O
were VBD VBD O
either CC CC O
non NN NN O
- - - O
biodegradable JJ JJ O
( ( ( O
Gly NNP NNP O
- - - O
Gly NNP NNP O
) ) ) O
or CC CC O
degradable JJ JJ O
by IN IN O
lysosomal NN NN O
proteinases NNS NNS O
( ( ( O
Gly NNP NNP B-CHEM
- - - I-CHEM
Phe NNP NNP I-CHEM
- - - I-CHEM
Leu NNP NNP I-CHEM
- - - I-CHEM
Gly NNP NNP I-CHEM
) ) ) O
. . . O

In IN IN O
addition NN NN O
, , , O
one CD CD O
biodegradable JJ JJ O
conjugate NN NN O
containing VBG VBG O
galactosamine NN NN B-CHEM
was VBD VBD O
used VBN VBN O
; : : O
this DT DT O
residue NN NN O
was VBD VBD O
targeted VBN VBN O
to TO TO O
the DT DT O
liver NN NN O
. . . O

Over IN IN O
the DT DT O
first JJ JJ O
3 CD CD O
weeks NNS NNS O
after IN IN O
the DT DT O
i NNP NNP O
. . . O
v NN NN O
. . . O
administration NN NN O
of IN IN O
free JJ JJ O
and CC CC O
polymer NN NN O
- - - O
bound VBN VBN O
DOX NNP NNP B-CHEM
, , , O
all DT DT O
animals NNS NNS O
showed VBD VBD O
a DT DT O
transient JJ JJ O
reduction NN NN O
in IN IN O
body NN NN O
weight NN NN O
. . . O

However RB RB O
, , , O
the DT DT O
maximal NN NN O
reduction NN NN O
in IN IN O
body NN NN O
weight NN NN O
seen VBN VBN O
in IN IN O
animals NNS NNS O
that WDT WDT O
received VBD VBD O
polymer NN NN O
- - - O
bound VBN VBN O
DOX NNP NNP B-CHEM
( ( ( O
4 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
was VBD VBD O
significantly RB RB O
lower JJR JJR O
than IN IN O
that DT DT O
observed VBD VBD O
in IN IN O
those DT DT O
that WDT WDT O
received VBD VBD O
free JJ JJ O
DOX NNP NNP B-CHEM
( ( ( O
4 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
or CC CC O
a DT DT O
mixture NN NN O
of IN IN O
the DT DT O
unmodified JJ JJ O
parent NN NN O
HPMA NNP NNP B-CHEM
copolymer NN NN O
and CC CC O
free JJ JJ O
DOX NNP NNP B-CHEM
( ( ( O
4 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
; : : O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
. . . O

Throughout IN IN O
the DT DT O
study NN NN O
( ( ( O
20 CD CD O
weeks NNS NNS O
) ) ) O
, , , O
deaths NNS NNS O
related VBN VBN O
to TO TO O
cardiotoxicity NN NN O
were VBD VBD O
observed VBN VBN O
only RB RB O
in IN IN O
animals NNS NNS O
that WDT WDT O
received VBD VBD O
either CC CC O
free JJ JJ O
DOX NNP NNP B-CHEM
or CC CC O
the DT DT O
mixture NN NN O
of IN IN O
HPMA NNP NNP B-CHEM
copolymer NN NN O
and CC CC O
free JJ JJ O
DOX NNP NNP B-CHEM
; : : O
in IN IN O
these DT DT O
cases NNS NNS O
, , , O
histological JJ JJ O
investigations NNS NNS O
revealed VBD VBD O
marked VBN VBN O
changes NNS NNS O
in IN IN O
the DT DT O
heart NN NN O
that WDT WDT O
were VBD VBD O
consistent JJ JJ O
with IN IN O
DOX NNP NNP B-CHEM
- : : O
induced JJ JJ O
cardiotoxicity NN NN O
. . . O

Sequential NNP NNP O
measurements NNS NNS O
of IN IN O
cardiac JJ JJ O
output NN NN O
in IN IN O
surviving VBG VBG O
animals NNS NNS O
that WDT WDT O
received VBD VBD O
either CC CC O
free JJ JJ O
DOX NNP NNP B-CHEM
or CC CC O
the DT DT O
mixture NN NN O
of IN IN O
HPMA NNP NNP B-CHEM
copolymer NN NN O
and CC CC O
free JJ JJ O
DOX NNP NNP B-CHEM
showed VBD VBD O
a DT DT O
reduction NN NN O
of IN IN O
approximately RB RB O
30 CD CD O
% NN NN O
in IN IN O
function NN NN O
beginning VBG VBG O
at IN IN O
the DT DT O
4th JJ JJ O
week NN NN O
after IN IN O
drug NN NN O
administration NN NN O
. . . O

The DT DT O
heart NN NN O
rate NN NN O
in IN IN O
these DT DT O
animals NNS NNS O
was VBD VBD O
approximately RB RB O
12 CD CD O
% NN NN O
lower JJR JJR O
than IN IN O
that DT DT O
measured VBN VBN O
in IN IN O
age NN NN O
- - - O
matched JJ JJ O
control NN NN O
rats NNS NNS O
( ( ( O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

Animals NNS NNS O
that WDT WDT O
were VBD VBD O
given VBN VBN O
the DT DT O
HPMA NNP NNP B-CHEM
copolymer NN NN O
conjugates NNS NNS O
containing VBG VBG O
DOX NNP NNP B-CHEM
exhibited VBD VBD O
no DT DT O
significant JJ JJ O
change NN NN O
in IN IN O
cardiac JJ JJ O
output NN NN O
throughout IN IN O
the DT DT O
study NN NN O
( ( ( O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

In IN IN O
addition NN NN O
, , , O
no DT DT O
significant JJ JJ O
histological JJ JJ O
change NN NN O
was VBD VBD O
observed VBN VBN O
in IN IN O
the DT DT O
heart NN NN O
of IN IN O
animals NNS NNS O
that WDT WDT O
received VBD VBD O
DOX NNP NNP B-CHEM
in IN IN O
the DT DT O
form NN NN O
of IN IN O
HPMA NNP NNP B-CHEM
copolymer NN NN O
conjugates NNS NNS O
and CC CC O
were VBD VBD O
killed VBN VBN O
at IN IN O
the DT DT O
end NN NN O
of IN IN O
the DT DT O
study NN NN O
. . . O

However RB RB O
, , , O
these DT DT O
animals NNS NNS O
had VBD VBD O
shown VBN VBN O
a DT DT O
significant JJ JJ O
increase NN NN O
in IN IN O
heart NN NN O
rate NN NN O
beginning VBG VBG O
at IN IN O
8 CD CD O
weeks NNS NNS O
after IN IN O
drug NN NN O
administration NN NN O
( ( ( O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
. . . O
( ( ( O
ABSTRACT NNP NNP O
TRUNCATED NNP NNP O
AT IN IN O
400 CD CD O
WORDS NNP NNP O
) ) ) O

Corneal NNP NNP O
ulcers NNS NNS O
associated VBN VBN O
with IN IN O
aerosolized JJ JJ O
crack NN NN B-CHEM
cocaine NN NN I-CHEM
use NN NN O
. . . O

PURPOSE NNP NNP O
: : : O
We PRP PRP O
report VBP VBP O
4 CD CD O
cases NNS NNS O
of IN IN O
corneal NN NN O
ulcers NNS NNS O
associated VBN VBN O
with IN IN O
drug NN NN O
abuse NN NN O
. . . O

The DT DT O
pathogenesis NNS NNS O
of IN IN O
these DT DT O
ulcers NNS NNS O
and CC CC O
management NN NN O
of IN IN O
these DT DT O
patients NNS NNS O
are VBP VBP O
also RB RB O
reviewed VBN VBN O
. . . O

METHODS NNP NNP O
: : : O
Review NNP NNP O
of IN IN O
all DT DT O
cases NNS NNS O
of IN IN O
corneal NN NN O
ulcers NNS NNS O
associated VBN VBN O
with IN IN O
drug NN NN O
abuse NN NN O
seen VBN VBN O
at IN IN O
our PRP$ PRP$ O
institution NN NN O
from IN IN O
July NNP NNP O
2006 CD CD O
to TO TO O
December NNP NNP O
2006 CD CD O
. . . O

RESULTS NNS NNS O
: : : O
Four CD CD O
patients NNS NNS O
with IN IN O
corneal NN NN O
ulcers NNS NNS O
associated VBN VBN O
with IN IN O
crack NN NN B-CHEM
cocaine NN NN I-CHEM
use NN NN O
were VBD VBD O
reviewed VBN VBN O
. . . O

All DT DT O
corneal NN NN O
ulcers NNS NNS O
were VBD VBD O
cultured JJ JJ O
, , , O
and CC CC O
the DT DT O
patients NNS NNS O
were VBD VBD O
admitted VBN VBN O
to TO TO O
the DT DT O
hospital NN NN O
for IN IN O
intensive JJ JJ O
topical JJ JJ O
antibiotic JJ JJ O
treatment NN NN O
. . . O

Each DT DT O
patient NN NN O
received VBD VBD O
comprehensive JJ JJ O
health NN NN O
care NN NN O
, , , O
including VBG VBG O
medical JJ JJ O
and CC CC O
substance NN NN O
abuse NN NN O
consultations NNS NNS O
. . . O

Streptococcal NNP NNP O
organisms NNS NNS O
were VBD VBD O
found VBN VBN O
in IN IN O
3 CD CD O
cases NNS NNS O
and CC CC O
Capnocytophaga NNP NNP O
and CC CC O
Brevibacterium NNP NNP O
casei NN NN O
in IN IN O
1 CD CD O
patient NN NN O
. . . O

The DT DT O
infections NNS NNS O
responded VBD VBD O
to TO TO O
antibiotic JJ JJ O
treatment NN NN O
. . . O

Two CD CD O
patients NNS NNS O
needed VBD VBD O
a DT DT O
lateral NN NN O
tarsorrhaphy NN NN O
for IN IN O
persistent JJ JJ O
epithelial NN NN O
defects NNS NNS O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Aerosolized NNP NNP O
crack NN NN B-CHEM
cocaine NN NN I-CHEM
use NN NN O
can MD MD O
be VB VB O
associated VBN VBN O
with IN IN O
the DT DT O
development NN NN O
of IN IN O
corneal NN NN O
ulcers NNS NNS O
. . . O

Drug NN NN O
abuse NN NN O
provides VBZ VBZ O
additional JJ JJ O
challenges NNS NNS O
for IN IN O
management NN NN O
. . . O

Not RB RB O
only RB RB O
treatment NN NN O
of IN IN O
their PRP$ PRP$ O
infections NNS NNS O
but CC CC O
also RB RB O
the DT DT O
overall JJ JJ O
poor JJ JJ O
health NN NN O
of IN IN O
the DT DT O
patients NNS NNS O
and CC CC O
increased VBN VBN O
risk NN NN O
of IN IN O
noncompliance NN NN O
need VBP VBP O
to TO TO O
be VB VB O
addressed VBN VBN O
. . . O

Comprehensive NNP NNP O
care NN NN O
may MD MD O
provide VB VB O
the DT DT O
patient NN NN O
the DT DT O
opportunity NN NN O
to TO TO O
discontinue VB VB O
their PRP$ PRP$ O
substance NN NN O
abuse NN NN O
, , , O
improve VB VB O
their PRP$ PRP$ O
overall JJ JJ O
health NN NN O
, , , O
and CC CC O
prevent VB VB O
future JJ JJ O
corneal NN NN O
complications NNS NNS O
. . . O

Topical NNP NNP O
0 CD CD O
. . . O
025 CD CD O
% NN NN O
capsaicin NN NN B-CHEM
in IN IN O
chronic JJ JJ O
post NN NN O
- : : O
herpetic JJ JJ O
neuralgia NN NN O
: : : O
efficacy NN NN O
, , , O
predictors NNS NNS O
of IN IN O
response NN NN O
and CC CC O
long JJ JJ O
- - - O
term NN NN O
course NN NN O
. . . O

In IN IN O
order NN NN O
to TO TO O
evaluate VB VB O
the DT DT O
efficacy NN NN O
, , , O
time NN NN O
- : : O
course NN NN O
of IN IN O
action NN NN O
and CC CC O
predictors NNS NNS O
of IN IN O
response NN NN O
to TO TO O
topical JJ JJ O
capsaicin NN NN B-CHEM
, , , O
39 CD CD O
patients NNS NNS O
with IN IN O
chronic JJ JJ O
post NN NN O
- : : O
herpetic JJ JJ O
neuralgia NN NN O
( ( ( O
PHN NNP NNP O
) ) ) O
, , , O
median JJ JJ O
duration NN NN O
24 CD CD O
months NNS NNS O
, , , O
were VBD VBD O
treated VBN VBN O
with IN IN O
0 CD CD O
. . . O
025 CD CD O
% NN NN O
capsaicin NN NN B-CHEM
cream NN NN O
for IN IN O
8 CD CD O
weeks NNS NNS O
. . . O

During IN IN O
therapy NN NN O
the DT DT O
patients NNS NNS O
rated VBD VBD O
their PRP$ PRP$ O
pain NN NN O
on IN IN O
a DT DT O
visual JJ JJ O
analogue NN NN O
scale NN NN O
( ( ( O
VAS NNP NNP O
) ) ) O
and CC CC O
a DT DT O
verbal JJ JJ O
outcome NN NN O
scale NN NN O
. . . O

A DT DT O
follow VB VB O
- - - O
up RP RP O
investigation NN NN O
was VBD VBD O
performed VBN VBN O
10 CD CD O
- : : O
12 CD CD O
months NNS NNS O
after IN IN O
study NN NN O
onset NN NN O
on IN IN O
the DT DT O
patients NNS NNS O
who WP WP O
had VBD VBD O
improved VBN VBN O
. . . O

Nineteen NNP NNP O
patients NNS NNS O
( ( ( O
48 CD CD O
. . . O
7 CD CD O
% NN NN O
) ) ) O
substantially RB RB O
improved VBN VBN O
after IN IN O
the DT DT O
8 CD CD O
- : : O
week NN NN O
trial NN NN O
; : : O
5 CD CD O
( ( ( O
12 CD CD O
. . . O
8 CD CD O
% NN NN O
) ) ) O
discontinued VBD VBD O
therapy NN NN O
due JJ JJ O
to TO TO O
side VB VB O
- - - O
effects NNS NNS O
such JJ JJ O
as IN IN O
intolerable JJ JJ O
capsaicin NN NN B-CHEM
- - - O
induced JJ JJ O
burning NN NN O
sensations NNS NNS O
( ( ( O
4 CD CD O
) ) ) O
or CC CC O
mastitis NNS NNS O
( ( ( O
1 CD CD O
) ) ) O
; : : O
15 CD CD O
( ( ( O
38 CD CD O
. . . O
5 CD CD O
% NN NN O
) ) ) O
reported VBD VBD O
no DT DT O
benefit NN NN O
. . . O

The DT DT O
decrease NN NN O
in IN IN O
VAS NNP NNP O
ratings NNS NNS O
was VBD VBD O
significant JJ JJ O
after IN IN O
2 CD CD O
weeks NNS NNS O
of IN IN O
continuous JJ JJ O
application NN NN O
. . . O

Of IN IN O
the DT DT O
responders NNS NNS O
72 CD CD O
. . . O
2 CD CD O
% NN NN O
were VBD VBD O
still RB RB O
improved VBN VBN O
at IN IN O
the DT DT O
follow VB VB O
- - - O
up RP RP O
; : : O
only RB RB O
one CD CD O
- - - O
third NN NN O
of IN IN O
them PRP PRP O
had VBD VBD O
continued VBN VBN O
application NN NN O
irregularly RB RB O
. . . O

Treatment NN NN O
effect NN NN O
was VBD VBD O
not RB RB O
dependent JJ JJ O
on IN IN O
patient NN NN O
' '' '' O
s VBZ VBZ O
age NN NN O
, , , O
duration NN NN O
or CC CC O
localization NN NN O
of IN IN O
PHN NNP NNP O
( ( ( O
trigeminal JJ JJ O
involvement NN NN O
was VBD VBD O
excluded VBN VBN O
) ) ) O
, , , O
sensory JJ JJ O
disturbance NN NN O
or CC CC O
pain NN NN O
character NN NN O
. . . O

Treatment NN NN O
response NN NN O
was VBD VBD O
not RB RB O
correlated JJ JJ O
with IN IN O
the DT DT O
incidence NN NN O
, , , O
time NN NN O
- - - O
course NN NN O
or CC CC O
severity NN NN O
of IN IN O
capsaicin NN NN B-CHEM
- - - O
induced JJ JJ O
burning NN NN O
. . . O

If IN IN O
confirmed VBN VBN O
in IN IN O
controlled VBN VBN O
trials NNS NNS O
, , , O
the DT DT O
long JJ JJ O
- - - O
term NN NN O
results NNS NNS O
of IN IN O
this DT DT O
open JJ JJ O
, , , O
non NN NN O
- - - O
randomized JJ JJ O
study NN NN O
might MD MD O
indicate VB VB O
that IN IN O
the DT DT O
analgesic JJ JJ O
effect NN NN O
of IN IN O
capsaicin NN NN B-CHEM
in IN IN O
PHN NNP NNP O
is VBZ VBZ O
mediated VBN VBN O
by IN IN O
both DT DT O
interference NN NN O
with IN IN O
neuropeptide NN NN O
metabolism NN NN O
and CC CC O
morphological JJ JJ O
changes NNS NNS O
( ( ( O
perhaps RB RB O
degeneration NN NN O
) ) ) O
of IN IN O
nociceptive JJ JJ O
afferents NNS NNS O
. . . O

Myo NNP NNP B-CHEM
- : : I-CHEM
inositol NN NN I-CHEM
- : : I-CHEM
1 CD CD I-CHEM
- : : I-CHEM
phosphate NN NN I-CHEM
( ( ( O
MIP NNP NNP B-CHEM
) ) ) O
synthase NN NN O
inhibition NN NN O
: : : O
in IN IN O
- - - O
vivo NN NN O
study NN NN O
in IN IN O
rats NNS NNS O
. . . O

Lithium NNP NNP B-CHEM
and CC CC O
valproate NN NN B-CHEM
are VBP VBP O
the DT DT O
prototypic NN NN O
mood NN NN O
stabilizers NNS NNS O
and CC CC O
have VBP VBP O
diverse JJ JJ O
structures NNS NNS O
and CC CC O
targets NNS NNS O
. . . O

Both DT DT O
drugs NNS NNS O
influence NN NN O
inositol NN NN B-CHEM
metabolism NN NN O
. . . O

Lithium NNP NNP B-CHEM
inhibits NNS NNS O
IMPase NNP NNP O
and CC CC O
valproate NN NN B-CHEM
inhibits NNS NNS O
MIP NNP NNP B-CHEM
synthase NN NN O
. . . O

This DT DT O
study NN NN O
shows VBZ VBZ O
that IN IN O
MIP NNP NNP B-CHEM
synthase NN NN O
inhibition NN NN O
does VBZ VBZ O
not RB RB O
replicate VB VB O
or CC CC O
augment VB VB O
the DT DT O
effects NNS NNS O
of IN IN O
lithium NN NN B-CHEM
in IN IN O
the DT DT O
inositol NN NN B-CHEM
sensitive JJ JJ O
pilocarpine NN NN B-CHEM
- - - O
induced JJ JJ O
seizures NNS NNS O
model NN NN O
. . . O

This DT DT O
lack NN NN O
of IN IN O
effects NNS NNS O
may MD MD O
stem VB VB O
from IN IN O
the DT DT O
low JJ JJ O
contribution NN NN O
of IN IN O
de IN IN O
- - - O
novo NN NN O
synthesis NN NN O
to TO TO O
cellular VB VB O
inositol NN NN B-CHEM
supply NN NN O
or CC CC O
to TO TO O
the DT DT O
inhibition NN NN O
of IN IN O
the DT DT O
de NN NN O
- - - O
novo NN NN O
synthesis NN NN O
by IN IN O
lithium NN NN B-CHEM
itself PRP PRP O
. . . O

Non NNP NNP O
- : : O
steroidal NN NN O
anti NN NN O
- : : O
inflammatory JJ JJ O
drugs NNS NNS O
- - - O
associated VBN VBN O
acute JJ JJ O
interstitial JJ JJ O
nephritis NN NN O
with IN IN O
granular NN NN O
tubular NN NN O
basement NN NN O
membrane NN NN O
deposits NNS NNS O
. . . O

Acute JJ JJ O
tubulo NN NN O
- : : O
interstitial JJ JJ O
nephritis NN NN O
( ( ( O
ATIN NNP NNP O
) ) ) O
is VBZ VBZ O
an DT DT O
important JJ JJ O
cause NN NN O
of IN IN O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
resulting VBG VBG O
from IN IN O
a DT DT O
variety NN NN O
of IN IN O
insults NNS NNS O
, , , O
including VBG VBG O
immune JJ JJ O
complex JJ JJ O
- - - O
mediated JJ JJ O
tubulo NN NN O
- : : O
interstitial JJ JJ O
injury NN NN O
, , , O
but CC CC O
drugs NNS NNS O
such JJ JJ O
as IN IN O
non NN NN O
- - - O
steroidal NN NN O
anti NN NN O
- : : O
inflammatory JJ JJ O
drugs NNS NNS O
( ( ( O
NSAIDs NNP NNP O
) ) ) O
are VBP VBP O
a DT DT O
far RB RB O
more RBR RBR O
frequent JJ JJ O
cause NN NN O
. . . O

Overall RB RB O
, , , O
as IN IN O
an DT DT O
entity NN NN O
, , , O
ATIN NNP NNP O
remains VBZ VBZ O
under IN IN O
- - - O
diagnosed VBN VBN O
, , , O
as IN IN O
symptoms NNS NNS O
resolve NN NN O
spontaneously RB RB O
if IN IN O
the DT DT O
medication NN NN O
is VBZ VBZ O
stopped VBN VBN O
. . . O

We PRP PRP O
report VBP VBP O
on IN IN O
a DT DT O
14 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
boy NN NN O
who WP WP O
developed VBD VBD O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
2 CD CD O
weeks NNS NNS O
after IN IN O
aortic JJ JJ O
valve NN NN O
surgery NN NN O
. . . O

He PRP PRP O
was VBD VBD O
put VBN VBN O
on IN IN O
aspirin NN NN B-CHEM
following VBG VBG O
surgery NN NN O
and CC CC O
took VBD VBD O
ibuprofen NN NN B-CHEM
for IN IN O
fever NN NN O
for IN IN O
nearly RB RB O
a DT DT O
week NN NN O
prior RB RB O
to TO TO O
presentation NN NN O
. . . O

He PRP PRP O
then RB RB O
presented VBD VBD O
to TO TO O
the DT DT O
emergency NN NN O
department NN NN O
feeling NN NN O
quite RB RB O
ill JJ JJ O
and CC CC O
was VBD VBD O
found VBN VBN O
to TO TO O
have VB VB O
a DT DT O
blood NN NN B-CHEM
urea JJ JJ I-CHEM
nitrogen NN NN I-CHEM
( ( ( O
BUN NNP NNP B-CHEM
) ) ) O
concentration NN NN O
of IN IN O
of IN IN O
147 CD CD O
mg NN NN O
/ NN NN O
dl NN NN O
, , , O
creatinine NN NN B-CHEM
of IN IN O
15 CD CD O
. . . O
3 CD CD O
mg NN NN O
/ NN NN O
dl NN NN O
and CC CC O
serum NN NN O
potassium NN NN B-CHEM
of IN IN O
8 CD CD O
. . . O
7 CD CD O
mEq NN NN O
/ NN NN O
l NN NN O
. . . O

Dialysis NNP NNP O
was VBD VBD O
immediately RB RB O
initiated VBN VBN O
. . . O

A DT DT O
kidney NN NN O
biopsy NN NN O
showed VBD VBD O
inflammatory JJ JJ O
infiltrate JJ JJ O
consistent JJ JJ O
with IN IN O
ATIN NNP NNP O
. . . O

However RB RB O
, , , O
in IN IN O
the DT DT O
tubular NN NN O
basement NN NN O
membrane NN NN O
( ( ( O
TBM NNP NNP O
) ) ) O
, , , O
very RB RB O
intense JJ JJ O
granular JJ JJ O
deposits NNS NNS O
of IN IN O
polyclonal JJ JJ O
IgG NNP NNP O
and CC CC O
C3 NNP NNP O
were VBD VBD O
noted VBN VBN O
. . . O

He PRP PRP O
needed VBD VBD O
dialysis NN NN O
for IN IN O
2 CD CD O
weeks NNS NNS O
and CC CC O
was VBD VBD O
treated VBN VBN O
successfully RB RB O
with IN IN O
steroids NNS NNS B-CHEM
for IN IN O
6 CD CD O
months NNS NNS O
. . . O

His PRP$ PRP$ O
renal JJ JJ O
recovery NN NN O
and CC CC O
disappearance NN NN O
of IN IN O
proteinuria NN NN O
took VBD VBD O
a DT DT O
year NN NN O
. . . O

In IN IN O
conclusion NN NN O
, , , O
this DT DT O
is VBZ VBZ O
a DT DT O
first JJ JJ O
report NN NN O
of IN IN O
NSAIDs NNP NNP O
- - - O
associated VBN VBN O
ATIN NNP NNP O
, , , O
showing VBG VBG O
deposits NNS NNS O
of IN IN O
granular JJ JJ O
immune JJ JJ O
complex JJ JJ O
present JJ JJ O
only RB RB O
in IN IN O
the DT DT O
TBM NNP NNP O
and CC CC O
not RB RB O
in IN IN O
the DT DT O
glomeruli NN NN O
. . . O

Rifampicin NNP NNP B-CHEM
- - - O
associated VBN VBN O
segmental JJ JJ O
necrotizing JJ JJ O
glomerulonephritis NNS NNS O
in IN IN O
staphylococcal JJ JJ O
endocarditis NN NN O
. . . O

Segmental NNP NNP O
necrotising VBG VBG O
glomerulonephritis NN NN O
has VBZ VBZ O
been VBN VBN O
reported VBN VBN O
as IN IN O
complication NN NN O
of IN IN O
rifampicin NN NN B-CHEM
therapy NN NN O
in IN IN O
patients NNS NNS O
receiving VBG VBG O
treatment NN NN O
for IN IN O
tuberculosis NN NN O
. . . O

Changing VBG VBG O
epidemiology NN NN O
of IN IN O
infections NNS NNS O
such JJ JJ O
as IN IN O
infective JJ JJ O
endocarditis NN NN O
( ( ( O
IE NNP NNP O
) ) ) O
has VBZ VBZ O
led VBN VBN O
to TO TO O
an DT DT O
increase NN NN O
in IN IN O
the DT DT O
use NN NN O
of IN IN O
rifampicin NN NN B-CHEM
for IN IN O
Staphylococcal NNP NNP O
infections NNS NNS O
. . . O

We PRP PRP O
describe VBP VBP O
a DT DT O
case NN NN O
of IN IN O
a DT DT O
patient NN NN O
with IN IN O
Staphylococcal NNP NNP O
IE NNP NNP O
who WP WP O
developed VBD VBD O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
secondary JJ JJ O
to TO TO O
a DT DT O
segmental JJ JJ O
necrotising VBG VBG O
glomerulonephritis NN NN O
while IN IN O
being VBG VBG O
treated VBN VBN O
with IN IN O
rifampicin NN NN B-CHEM
, , , O
and CC CC O
review NN NN O
the DT DT O
literature NN NN O
regarding VBG VBG O
this DT DT O
complication NN NN O
of IN IN O
rifampicin NN NN B-CHEM
therapy NN NN O
. . . O

Rate NNP NNP O
of IN IN O
YMDD NNP NNP O
motif NN NN O
mutants NNS NNS O
in IN IN O
lamivudine NN NN B-CHEM
- - - O
untreated JJ JJ O
Iranian JJ JJ O
patients NNS NNS O
with IN IN O
chronic JJ JJ O
hepatitis NN NN O
B NNP NNP O
virus NN NN O
infection NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
Lamivudine NNP NNP B-CHEM
is VBZ VBZ O
used VBN VBN O
for IN IN O
the DT DT O
treatment NN NN O
of IN IN O
chronic JJ JJ O
hepatitis NN NN O
B NNP NNP O
patients NNS NNS O
. . . O

Recent JJ JJ O
studies NNS NNS O
show VBP VBP O
that IN IN O
the DT DT O
YMDD NNP NNP O
motif NN NN O
mutants NNS NNS O
( ( ( O
resistant JJ JJ O
hepatitis NN NN O
B NNP NNP O
virus NN NN O
) ) ) O
occur VB VB O
as IN IN O
natural JJ JJ O
genome NN NN O
variability NN NN O
in IN IN O
lamivudine NN NN B-CHEM
- - - O
untreated JJ JJ O
chronic JJ JJ O
hepatitis NN NN O
B NNP NNP O
patients NNS NNS O
. . . O

In IN IN O
this DT DT O
study NN NN O
we PRP PRP O
aimed VBD VBD O
to TO TO O
determine VB VB O
the DT DT O
rate NN NN O
of IN IN O
YMDD NNP NNP O
motif NN NN O
mutants NNS NNS O
in IN IN O
lamivudine NN NN B-CHEM
- - - O
untreated JJ JJ O
chronic JJ JJ O
hepatitis NN NN O
B NNP NNP O
patients NNS NNS O
in IN IN O
Iran NNP NNP O
. . . O

PATIENTS NNS NNS O
AND CC CC O
METHODS NNP NNP O
: : : O
A DT DT O
total NN NN O
of IN IN O
77 CD CD O
chronic JJ JJ O
hepatitis NN NN O
B NNP NNP O
patients NNS NNS O
who WP WP O
had VBD VBD O
not RB RB O
been VBN VBN O
treated VBN VBN O
with IN IN O
lamivudine NN NN B-CHEM
were VBD VBD O
included VBN VBN O
in IN IN O
the DT DT O
study NN NN O
. . . O

Serum NNP NNP O
samples NNS NNS O
from IN IN O
patients NNS NNS O
were VBD VBD O
tested VBN VBN O
by IN IN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
- - - O
restriction NN NN O
fragment NN NN O
length NN NN O
polymorphism NN NN O
( ( ( O
PCR NNP NNP O
- - - O
RFLP NNP NNP O
) ) ) O
for IN IN O
detection NN NN O
of IN IN O
YMDD NNP NNP O
motif NN NN O
mutants NNS NNS O
. . . O

All DT DT O
patients NNS NNS O
were VBD VBD O
also RB RB O
tested VBN VBN O
for IN IN O
liver NN NN O
enzymes NNS NNS O
, , , O
anti JJ JJ O
- : : O
HCV NNP NNP O
, , , O
HBeAg NNP NNP B-CHEM
, , , O
and CC CC O
anti JJ JJ O
- : : O
HBe NNP NNP O
. . . O

RESULTS NNS NNS O
: : : O
Of IN IN O
the DT DT O
77 CD CD O
patients NNS NNS O
enrolled VBD VBD O
in IN IN O
the DT DT O
study NN NN O
, , , O
73 CD CD O
% NN NN O
were VBD VBD O
male JJ JJ O
and CC CC O
27 CD CD O
% NN NN O
were VBD VBD O
female JJ JJ O
. . . O

Mean VB VB O
ALT NNP NNP O
and CC CC O
AST NNP NNP O
levels NNS NNS O
were VBD VBD O
124 CD CD O
. . . O
4 CD CD O
+ NN NN O
/ NN NN O
- : : O
73 CD CD O
. . . O
4 CD CD O
and CC CC O
103 CD CD O
. . . O
1 CD CD O
+ NN NN O
/ NN NN O
- : : O
81 CD CD O
IU NNP NNP O
/ NN NN O
l NN NN O
, , , O
respectively RB RB O
. . . O

HBeAg NNP NNP B-CHEM
was VBD VBD O
positive JJ JJ O
in IN IN O
40 CD CD O
% NN NN O
and CC CC O
anti JJ JJ O
- : : O
HBe NNP NNP O
in IN IN O
60 CD CD O
% NN NN O
of IN IN O
the DT DT O
patients NNS NNS O
. . . O

Anti NNP NNP O
- : : O
HCV NNP NNP O
was VBD VBD O
negative JJ JJ O
in IN IN O
all DT DT O
of IN IN O
them PRP PRP O
. . . O

YMDD NNP NNP O
motif NN NN O
mutants NNS NNS O
were VBD VBD O
not RB RB O
detected VBN VBN O
in IN IN O
any DT DT O
of IN IN O
the DT DT O
patients NNS NNS O
despite IN IN O
the DT DT O
liver NN NN O
enzyme NN NN O
levels NNS NNS O
and CC CC O
the DT DT O
presence NN NN O
of IN IN O
HBeAg NNP NNP B-CHEM
or CC CC O
anti JJ JJ O
- : : O
HBe NNP NNP O
. . . O

CONCLUSION NNP NNP O
: : : O
Although IN IN O
the DT DT O
natural JJ JJ O
occurrence NN NN O
of IN IN O
YMDD NNP NNP O
motif NN NN O
mutants NNS NNS O
in IN IN O
lamivudine NN NN B-CHEM
- - - O
untreated JJ JJ O
patients NNS NNS O
with IN IN O
chronic JJ JJ O
hepatitis NN NN O
B NNP NNP O
has VBZ VBZ O
been VBN VBN O
reported VBN VBN O
, , , O
these DT DT O
mutants NNS NNS O
were VBD VBD O
not RB RB O
detected VBN VBN O
in IN IN O
Iranian JJ JJ O
lamivudine NN NN B-CHEM
- - - O
untreated JJ JJ O
chronic JJ JJ O
hepatitis NN NN O
B NNP NNP O
patients NNS NNS O
. . . O

Branch NNP NNP O
retinal JJ JJ O
vein NN NN O
occlusion NN NN O
and CC CC O
fluoxetine NN NN B-CHEM
. . . O

A DT DT O
case NN NN O
of IN IN O
branch NN NN O
retinal JJ JJ O
vein NN NN O
occlusion NN NN O
associated VBN VBN O
with IN IN O
fluoxetine NN NN B-CHEM
- - - O
induced JJ JJ O
secondary JJ JJ O
hypertension NN NN O
is VBZ VBZ O
described VBN VBN O
. . . O

Although IN IN O
an DT DT O
infrequent JJ JJ O
complication NN NN O
of IN IN O
selective JJ JJ O
serotonin NN NN B-CHEM
reuptake NN NN O
inhibitor NN NN O
therapy NN NN O
, , , O
it PRP PRP O
is VBZ VBZ O
important JJ JJ O
that IN IN O
ophthalmologists NNS NNS O
are VBP VBP O
aware JJ JJ O
that IN IN O
these DT DT O
agents NNS NNS O
can MD MD O
cause VB VB O
hypertension NN NN O
because IN IN O
this DT DT O
class NN NN O
of IN IN O
drugs NNS NNS O
is VBZ VBZ O
widely RB RB O
prescribed VBN VBN O
. . . O

The DT DT O
differential JJ JJ O
effects NNS NNS O
of IN IN O
bupivacaine NN NN B-CHEM
and CC CC O
lidocaine NN NN B-CHEM
on IN IN O
prostaglandin NN NN B-CHEM
E2 NNP NNP I-CHEM
release NN NN O
, , , O
cyclooxygenase NN NN O
gene NN NN O
expression NN NN O
and CC CC O
pain NN NN O
in IN IN O
a DT DT O
clinical JJ JJ O
pain NN NN O
model NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
In IN IN O
addition NN NN O
to TO TO O
blocking VBG VBG O
nociceptive JJ JJ O
input NN NN O
from IN IN O
surgical JJ JJ O
sites NNS NNS O
, , , O
long JJ JJ O
- - - O
acting VBG VBG O
local JJ JJ O
anesthetics NNS NNS O
might MD MD O
directly RB RB O
modulate JJ JJ O
inflammation NN NN O
. . . O

In IN IN O
the DT DT O
present JJ JJ O
study NN NN O
, , , O
we PRP PRP O
describe VBP VBP O
the DT DT O
proinflammatory NN NN O
effects NNS NNS O
of IN IN O
bupivacaine NN NN B-CHEM
on IN IN O
local JJ JJ O
prostaglandin NN NN B-CHEM
E2 NNP NNP I-CHEM
( ( ( O
PGE2 NNP NNP B-CHEM
) ) ) O
production NN NN O
and CC CC O
cyclooxygenase NN NN O
( ( ( O
COX NNP NNP O
) ) ) O
gene NN NN O
expression NN NN O
that IN IN O
increases NNS NNS O
postoperative JJ JJ O
pain NN NN O
in IN IN O
human JJ JJ O
subjects NNS NNS O
. . . O

METHODS NNP NNP O
: : : O
Subjects NNP NNP O
( ( ( O
n NN NN O
= SYM SYM O
114 CD CD O
) ) ) O
undergoing VBG VBG O
extraction NN NN O
of IN IN O
impacted VBN VBN O
third JJ JJ O
molars NNS NNS O
received VBD VBD O
either CC CC O
2 CD CD O
% NN NN O
lidocaine NN NN B-CHEM
or CC CC O
0 CD CD O
. . . O
5 CD CD O
% NN NN O
bupivacaine NN NN B-CHEM
before IN IN O
surgery NN NN O
and CC CC O
either CC CC O
rofecoxib NN NN B-CHEM
50 CD CD O
mg NN NN O
or CC CC O
placebo NN NN O
orally RB RB O
90 CD CD O
min NN NN O
before IN IN O
surgery NN NN O
and CC CC O
for IN IN O
the DT DT O
following VBG VBG O
48 CD CD O
h NN NN O
. . . O

Oral NNP NNP O
mucosal NN NN O
biopsies NNS NNS O
were VBD VBD O
taken VBN VBN O
before IN IN O
surgery NN NN O
and CC CC O
48 CD CD O
h NN NN O
after IN IN O
surgery NN NN O
. . . O

After IN IN O
extraction NN NN O
, , , O
a DT DT O
microdialysis NN NN O
probe NN NN O
was VBD VBD O
placed VBN VBN O
at IN IN O
the DT DT O
surgical JJ JJ O
site NN NN O
for IN IN O
PGE2 NNP NNP B-CHEM
and CC CC O
thromboxane NN NN B-CHEM
B2 NNP NNP I-CHEM
( ( ( O
TXB2 NNP NNP B-CHEM
) ) ) O
measurements NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
The DT DT O
bupivacaine NN NN B-CHEM
/ NN NN O
rofecoxib NN NN B-CHEM
group NN NN O
reported VBD VBD O
significantly RB RB O
less JJR JJR O
pain NN NN O
, , , O
as IN IN O
assessed VBN VBN O
by IN IN O
a DT DT O
visual JJ JJ O
analog NN NN O
scale NN NN O
, , , O
compared VBN VBN O
with IN IN O
the DT DT O
other JJ JJ O
three CD CD O
treatment NN NN O
groups NNS NNS O
over IN IN O
the DT DT O
first JJ JJ O
4 CD CD O
h NN NN O
. . . O

However RB RB O
, , , O
the DT DT O
bupivacaine NN NN B-CHEM
/ NN NN O
placebo NN NN O
group NN NN O
reported VBD VBD O
significantly RB RB O
more JJR JJR O
pain NN NN O
at IN IN O
24 CD CD O
h NN NN O
and CC CC O
PGE2 NNP NNP B-CHEM
levels NNS NNS O
during IN IN O
the DT DT O
first JJ JJ O
4 CD CD O
h NN NN O
were VBD VBD O
significantly RB RB O
higher JJR JJR O
than IN IN O
the DT DT O
other JJ JJ O
three CD CD O
treatment NN NN O
groups NNS NNS O
. . . O

Moreover RB RB O
, , , O
bupivacaine NN NN B-CHEM
significantly RB RB O
increased VBN VBN O
COX NNP NNP O
- : : O
2 CD CD O
gene NN NN O
expression NN NN O
at IN IN O
48 CD CD O
h NN NN O
as IN IN O
compared VBN VBN O
with IN IN O
the DT DT O
lidocaine NN NN B-CHEM
/ NN NN O
placebo NN NN O
group NN NN O
. . . O

Thromboxane NNP NNP B-CHEM
levels NNS NNS O
were VBD VBD O
not RB RB O
significantly RB RB O
affected VBN VBN O
by IN IN O
any DT DT O
of IN IN O
the DT DT O
treatments NNS NNS O
, , , O
indicating VBG VBG O
that IN IN O
the DT DT O
effects NNS NNS O
seen VBN VBN O
were VBD VBD O
attributable JJ JJ O
to TO TO O
inhibition NN NN O
of IN IN O
COX NNP NNP O
- : : O
2 CD CD O
, , , O
but CC CC O
not RB RB O
COX NNP NNP O
- : : O
1 CD CD O
. . . O

CONCLUSIONS NNP NNP O
: : : O
These DT DT O
results NNS NNS O
suggest VBP VBP O
that IN IN O
bupivacaine NN NN B-CHEM
stimulates NNS NNS O
COX NNP NNP O
- : : O
2 CD CD O
gene NN NN O
expression NN NN O
after IN IN O
tissue NN NN O
injury NN NN O
, , , O
which WDT WDT O
is VBZ VBZ O
associated VBN VBN O
with IN IN O
higher JJR JJR O
PGE2 NNP NNP B-CHEM
production NN NN O
and CC CC O
pain NN NN O
after IN IN O
the DT DT O
local JJ JJ O
anesthetic JJ JJ O
effect NN NN O
dissipates NNS NNS O
. . . O

p75NTR NN NN O
expression NN NN O
in IN IN O
rat NN NN O
urinary JJ JJ O
bladder NN NN O
sensory JJ JJ O
neurons NNS NNS O
and CC CC O
spinal JJ JJ O
cord NN NN O
with IN IN O
cyclophosphamide NN NN B-CHEM
- - - O
induced JJ JJ O
cystitis NNS NNS O
. . . O

A DT DT O
role NN NN O
for IN IN O
nerve NN NN O
growth NN NN O
factor NN NN O
( ( ( O
NGF NNP NNP O
) ) ) O
in IN IN O
contributing VBG VBG O
to TO TO O
increased VBN VBN O
voiding VBG VBG O
frequency NN NN O
and CC CC O
altered VBN VBN O
sensation NN NN O
from IN IN O
the DT DT O
urinary JJ JJ O
bladder NN NN O
has VBZ VBZ O
been VBN VBN O
suggested VBN VBN O
. . . O

Previous JJ JJ O
studies NNS NNS O
have VBP VBP O
examined VBN VBN O
the DT DT O
expression NN NN O
and CC CC O
regulation NN NN O
of IN IN O
tyrosine NN NN B-CHEM
kinase NN NN O
receptors NNS NNS O
( ( ( O
Trks NNP NNP O
) ) ) O
in IN IN O
micturition NN NN O
reflexes NNS NNS O
with IN IN O
urinary JJ JJ O
bladder NN NN O
inflammation NN NN O
. . . O

The DT DT O
present JJ JJ O
studies NNS NNS O
examine VBP VBP O
the DT DT O
expression NN NN O
and CC CC O
regulation NN NN O
of IN IN O
another DT DT O
receptor NN NN O
known VBN VBN O
to TO TO O
bind NN NN O
NGF NNP NNP O
, , , O
p75 NN NN O
( ( ( O
NTR NNP NNP O
) ) ) O
, , , O
after IN IN O
various JJ JJ O
durations NNS NNS O
of IN IN O
bladder NN NN O
inflammation NN NN O
induced VBN VBN O
by IN IN O
cyclophosphamide NN NN B-CHEM
( ( ( O
CYP NNP NNP B-CHEM
) ) ) O
. . . O

CYP NNP NNP B-CHEM
- : : O
induced JJ JJ O
cystitis NNS NNS O
increased VBN VBN O
( ( ( O
P NN NN O
< NN NN O
or CC CC O
= SYM SYM O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
p75 NN NN O
( ( ( O
NTR NNP NNP O
) ) ) O
expression NN NN O
in IN IN O
the DT DT O
superficial JJ JJ O
lateral NN NN O
and CC CC O
medial NN NN O
dorsal NN NN O
horn NN NN O
in IN IN O
L1 NNP NNP O
- : : O
L2 NNP NNP O
and CC CC O
L6 NNP NNP O
- : : O
S1 NNP NNP O
spinal JJ JJ O
segments NNS NNS O
. . . O

The DT DT O
number NN NN O
of IN IN O
p75 NN NN O
( ( ( O
NTR NNP NNP O
) ) ) O
- : : O
immunoreactive JJ JJ O
( ( ( O
- : : O
IR NNP NNP O
) ) ) O
cells NNS NNS O
in IN IN O
the DT DT O
lumbosacral NN NN O
dorsal NN NN O
root NN NN O
ganglia NN NN O
( ( ( O
DRG NNP NNP O
) ) ) O
also RB RB O
increased VBN VBN O
( ( ( O
P NN NN O
< NN NN O
or CC CC O
= SYM SYM O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
with IN IN O
CYP NNP NNP B-CHEM
- : : O
induced JJ JJ O
cystitis NN NN O
( ( ( O
acute JJ JJ O
, , , O
intermediate JJ JJ O
, , , O
and CC CC O
chronic JJ JJ O
) ) ) O
. . . O

Quantitative NNP NNP O
, , , O
real JJ JJ O
- - - O
time NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
also RB RB O
demonstrated VBD VBD O
significant JJ JJ O
increases NNS NNS O
( ( ( O
P NN NN O
< NN NN O
or CC CC O
= SYM SYM O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
in IN IN O
p75 NN NN O
( ( ( O
NTR NNP NNP O
) ) ) O
mRNA NN NN O
in IN IN O
DRG NNP NNP O
with IN IN O
intermediate JJ JJ O
and CC CC O
chronic JJ JJ O
CYP NNP NNP B-CHEM
- : : O
induced JJ JJ O
cystitis NN NN O
. . . O

Retrograde NNP NNP O
dye NN NN O
- : : O
tracing VBG VBG O
techniques NNS NNS O
with IN IN O
Fastblue NNP NNP O
were VBD VBD O
used VBN VBN O
to TO TO O
identify VB VB O
presumptive JJ JJ O
bladder NN NN O
afferent NN NN O
cells NNS NNS O
in IN IN O
the DT DT O
lumbosacral JJ JJ O
DRG NNP NNP O
. . . O

In IN IN O
bladder NN NN O
afferent NN NN O
cells NNS NNS O
in IN IN O
DRG NNP NNP O
, , , O
p75 NN NN O
( ( ( O
NTR NNP NNP O
) ) ) O
- : : O
IR NNP NNP O
was VBD VBD O
also RB RB O
increased VBN VBN O
( ( ( O
P NN NN O
< NN NN O
or CC CC O
= SYM SYM O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
with IN IN O
cystitis NN NN O
. . . O

In IN IN O
addition NN NN O
to TO TO O
increases NNS NNS O
in IN IN O
p75 NN NN O
( ( ( O
NTR NNP NNP O
) ) ) O
- : : O
IR NNP NNP O
in IN IN O
DRG NNP NNP O
cell NN NN O
bodies NNS NNS O
, , , O
increases NNS NNS O
( ( ( O
P NN NN O
< NN NN O
or CC CC O
= SYM SYM O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
in IN IN O
pericellular NN NN O
( ( ( O
encircling VBG VBG O
DRG NNP NNP O
cells NNS NNS O
) ) ) O
p75 NN NN O
( ( ( O
NTR NNP NNP O
) ) ) O
- : : O
IR NNP NNP O
in IN IN O
DRG NNP NNP O
also RB RB O
increased VBD VBD O
. . . O

Confocal NNP NNP O
analyses NNS NNS O
demonstrated VBN VBN O
that IN IN O
pericellular NN NN O
p75 NN NN O
( ( ( O
NTR NNP NNP O
) ) ) O
- : : O
IR NNP NNP O
was VBD VBD O
not RB RB O
colocalized VBN VBN O
with IN IN O
the DT DT O
glial JJ JJ O
marker NN NN O
, , , O
glial JJ JJ O
fibrillary JJ JJ O
acidic JJ JJ O
protein NN NN O
( ( ( O
GFAP NNP NNP O
) ) ) O
. . . O

These DT DT O
studies NNS NNS O
demonstrate VBP VBP O
that IN IN O
p75 NN NN O
( ( ( O
NTR NNP NNP O
) ) ) O
expression NN NN O
in IN IN O
micturition NN NN O
reflexes NNS NNS O
is VBZ VBZ O
present JJ JJ O
constitutively RB RB O
and CC CC O
modified VBN VBN O
by IN IN O
bladder NN NN O
inflammation NN NN O
. . . O

The DT DT O
functional JJ JJ O
significance NN NN O
of IN IN O
p75 NN NN O
( ( ( O
NTR NNP NNP O
) ) ) O
expression NN NN O
in IN IN O
micturition NN NN O
reflexes NNS NNS O
remains NNS NNS O
to TO TO O
be VB VB O
determined VBN VBN O
. . . O

Azathioprine NNP NNP B-CHEM
- : : O
induced JJ JJ O
suicidal NN NN O
erythrocyte NN NN O
death NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
Azathioprine NNP NNP B-CHEM
is VBZ VBZ O
widely RB RB O
used VBN VBN O
as IN IN O
an DT DT O
immunosuppressive JJ JJ O
drug NN NN O
. . . O

The DT DT O
side NN NN O
effects NNS NNS O
of IN IN O
azathioprine NN NN B-CHEM
include VBP VBP O
anemia NN NN O
, , , O
which WDT WDT O
has VBZ VBZ O
been VBN VBN O
attributed VBN VBN O
to TO TO O
bone NN NN O
marrow NN NN O
suppression NN NN O
. . . O

Alternatively RB RB O
, , , O
anemia NN NN O
could MD MD O
result VB VB O
from IN IN O
accelerated VBD VBD O
suicidal NN NN O
erythrocyte NN NN O
death NN NN O
or CC CC O
eryptosis NN NN O
, , , O
which WDT WDT O
is VBZ VBZ O
characterized VBN VBN O
by IN IN O
exposure NN NN O
of IN IN O
phosphatidylserine NN NN B-CHEM
( ( ( O
PS NNP NNP B-CHEM
) ) ) O
at IN IN O
the DT DT O
erythrocyte NN NN O
surface NN NN O
and CC CC O
by IN IN O
cell NN NN O
shrinkage NN NN O
. . . O

METHODS NNP NNP O
: : : O
The DT DT O
present JJ JJ O
experiments NNS NNS O
explored JJ JJ O
whether IN IN O
azathioprine NN NN B-CHEM
influences VBZ VBZ O
eryptosis NN NN O
. . . O

According VBG VBG O
to TO TO O
annexin NN NN O
V NNP NNP O
binding JJ JJ O
, , , O
erythrocytes NNS NNS O
from IN IN O
patients NNS NNS O
indeed RB RB O
showed VBD VBD O
a DT DT O
significant JJ JJ O
increase NN NN O
of IN IN O
PS NNP NNP B-CHEM
exposure NN NN O
within IN IN O
1 CD CD O
week NN NN O
of IN IN O
treatment NN NN O
with IN IN O
azathioprine NN NN B-CHEM
. . . O

In IN IN O
a DT DT O
second JJ JJ O
series NN NN O
, , , O
cytosolic JJ JJ O
Ca2 NNP NNP B-CHEM
+ NN NN O
activity NN NN O
( ( ( O
Fluo3 NNP NNP B-CHEM
fluorescence NN NN O
) ) ) O
, , , O
cell NN NN O
volume NN NN O
( ( ( O
forward RB RB O
scatter NN NN O
) ) ) O
, , , O
and CC CC O
PS NNP NNP B-CHEM
- : : O
exposure NN NN O
( ( ( O
annexin NN NN O
V NNP NNP O
binding JJ JJ O
) ) ) O
were VBD VBD O
determined VBN VBN O
by IN IN O
FACS NNP NNP O
analysis NN NN O
in IN IN O
erythrocytes NNS NNS O
from IN IN O
healthy JJ JJ O
volunteers NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
Exposure NNP NNP O
to TO TO O
azathioprine NN NN B-CHEM
( ( ( O
> NN NN O
or CC CC O
= SYM SYM O
2 CD CD O
microg NN NN O
/ NN NN O
mL NN NN O
) ) ) O
for IN IN O
48 CD CD O
hours NNS NNS O
increased VBN VBN O
cytosolic JJ JJ O
Ca2 NNP NNP B-CHEM
+ NN NN O
activity NN NN O
and CC CC O
annexin NN NN O
V NNP NNP O
binding JJ JJ O
and CC CC O
decreased VBD VBD O
forward RB RB O
scatter NN NN O
. . . O

The DT DT O
effect NN NN O
of IN IN O
azathioprine NN NN B-CHEM
on IN IN O
both DT DT O
annexin NN NN O
V NNP NNP O
binding JJ JJ O
and CC CC O
forward RB RB O
scatter NN NN O
was VBD VBD O
significantly RB RB O
blunted VBN VBN O
in IN IN O
the DT DT O
nominal JJ JJ O
absence NN NN O
of IN IN O
extracellular NN NN O
Ca2 NNP NNP B-CHEM
+ NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Azathioprine NNP NNP B-CHEM
triggers NNS NNS O
suicidal VBP VBP O
erythrocyte JJ JJ O
death NN NN O
, , , O
an DT DT O
effect NN NN O
presumably RB RB O
contributing VBG VBG O
to TO TO O
azathioprine VB VB B-CHEM
- : : O
induced JJ JJ O
anemia NN NN O
. . . O

Levetiracetam NNP NNP B-CHEM
as IN IN O
an DT DT O
adjunct NN NN O
to TO TO O
phenobarbital JJ JJ B-CHEM
treatment NN NN O
in IN IN O
cats NNS NNS O
with IN IN O
suspected JJ JJ O
idiopathic JJ JJ O
epilepsy NN NN O
. . . O

OBJECTIVE NNP NNP O
: : : O
To TO TO O
assess VB VB O
pharmacokinetics NNS NNS O
, , , O
efficacy NN NN O
, , , O
and CC CC O
tolerability NN NN O
of IN IN O
oral JJ JJ O
levetiracetam NN NN B-CHEM
administered VBD VBD O
as IN IN O
an DT DT O
adjunct NN NN O
to TO TO O
phenobarbital JJ JJ B-CHEM
treatment NN NN O
in IN IN O
cats NNS NNS O
with IN IN O
poorly RB RB O
controlled VBN VBN O
suspected VBN VBN O
idiopathic JJ JJ O
epilepsy NN NN O
. . . O

DESIGN NNP NNP O
- : : O
Open NNP NNP O
- : : O
label NN NN O
, , , O
noncomparative JJ JJ O
clinical JJ JJ O
trial NN NN O
. . . O

ANIMALS NNS NNS O
: : : O
12 CD CD O
cats NNS NNS O
suspected VBD VBD O
to TO TO O
have VB VB O
idiopathic JJ JJ O
epilepsy NN NN O
that WDT WDT O
was VBD VBD O
poorly RB RB O
controlled VBN VBN O
with IN IN O
phenobarbital JJ JJ B-CHEM
or CC CC O
that DT DT O
had VBD VBD O
unacceptable JJ JJ O
adverse JJ JJ O
effects NNS NNS O
when WRB WRB O
treated VBN VBN O
with IN IN O
phenobarbital NN NN B-CHEM
. . . O

PROCEDURES NNP NNP O
: : : O
Cats NNP NNP O
were VBD VBD O
treated VBN VBN O
with IN IN O
levetiracetam NN NN B-CHEM
( ( ( O
20 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
[ NN NN O
9 CD CD O
. . . O
1 CD CD O
mg NN NN O
/ NN NN O
lb NN NN O
] NN NN O
, , , O
PO NNP NNP O
, , , O
q NN NN O
8 CD CD O
h NN NN O
) ) ) O
. . . O

After IN IN O
a DT DT O
minimum NN NN O
of IN IN O
1 CD CD O
week NN NN O
of IN IN O
treatment NN NN O
, , , O
serum NN NN O
levetiracetam NN NN B-CHEM
concentrations NNS NNS O
were VBD VBD O
measured VBN VBN O
before IN IN O
and CC CC O
2 CD CD O
, , , O
4 CD CD O
, , , O
and CC CC O
6 CD CD O
hours NNS NNS O
after IN IN O
drug NN NN O
administration NN NN O
, , , O
and CC CC O
maximum NN NN O
and CC CC O
minimum JJ JJ O
serum NN NN O
concentrations NNS NNS O
and CC CC O
elimination NN NN O
half NN NN O
- - - O
life NN NN O
were VBD VBD O
calculated VBN VBN O
. . . O

Seizure NNP NNP O
frequencies NNS NNS O
before IN IN O
and CC CC O
after IN IN O
initiation NN NN O
of IN IN O
levetiracetam NN NN B-CHEM
treatment NN NN O
were VBD VBD O
compared VBN VBN O
, , , O
and CC CC O
adverse JJ JJ O
effects NNS NNS O
were VBD VBD O
recorded VBN VBN O
. . . O

RESULTS NNS NNS O
: : : O
Median NNP NNP O
maximum NN NN O
serum NN NN O
levetiracetam NN NN B-CHEM
concentration NN NN O
was VBD VBD O
25 CD CD O
. . . O
5 CD CD O
microg NN NN O
/ NN NN O
mL NN NN O
, , , O
median JJ JJ O
minimum JJ JJ O
serum NN NN O
levetiracetam NN NN B-CHEM
concentration NN NN O
was VBD VBD O
8 CD CD O
. . . O
3 CD CD O
microg NN NN O
/ NN NN O
mL NN NN O
, , , O
and CC CC O
median JJ JJ O
elimination NN NN O
half NN NN O
- : : O
life NN NN O
was VBD VBD O
2 CD CD O
. . . O
9 CD CD O
hours NNS NNS O
. . . O

Median NNP NNP O
seizure NN NN O
frequency NN NN O
prior RB RB O
to TO TO O
treatment NN NN O
with IN IN O
levetiracetam NN NN B-CHEM
( ( ( O
2 CD CD O
. . . O
1 CD CD O
seizures NNS NNS O
/ NN NN O
mo NN NN O
) ) ) O
was VBD VBD O
significantly RB RB O
higher JJR JJR O
than IN IN O
median JJ JJ O
seizure NN NN O
frequency NN NN O
after IN IN O
initiation NN NN O
of IN IN O
levetiracetam NN NN B-CHEM
treatment NN NN O
( ( ( O
0 CD CD O
. . . O
42 CD CD O
seizures NNS NNS O
/ NN NN O
mo NN NN O
) ) ) O
, , , O
and CC CC O
7 CD CD O
of IN IN O
10 CD CD O
cats NNS NNS O
were VBD VBD O
classified VBN VBN O
as IN IN O
having VBG VBG O
responded VBN VBN O
to TO TO O
levetiracetam NN NN B-CHEM
treatment NN NN O
( ( ( O
ie NN NN O
, , , O
reduction NN NN O
in IN IN O
seizure NN NN O
frequency NN NN O
of IN IN O
> NN NN O
or CC CC O
= SYM SYM O
50 CD CD O
% NN NN O
) ) ) O
. . . O

Two CD CD O
cats NNS NNS O
had VBD VBD O
transient NN NN O
lethargy NN NN O
and CC CC O
inappetence NN NN O
. . . O

CONCLUSIONS NNP NNP O
AND CC CC O
CLINICAL NNP NNP O
RELEVANCE NNP NNP O
: : : O
Results NNS NNS O
suggested VBD VBD O
that IN IN O
levetiracetam NN NN B-CHEM
is VBZ VBZ O
well RB RB O
tolerated VBN VBN O
in IN IN O
cats NNS NNS O
and CC CC O
may MD MD O
be VB VB O
useful JJ JJ O
as IN IN O
an DT DT O
adjunct NN NN O
to TO TO O
phenobarbital JJ JJ B-CHEM
treatment NN NN O
in IN IN O
cats NNS NNS O
with IN IN O
idiopathic JJ JJ O
epilepsy NN NN O
. . . O

Serotonin NNP NNP B-CHEM
reuptake NN NN O
inhibitors NNS NNS O
, , , O
paranoia NN NN O
, , , O
and CC CC O
the DT DT O
ventral NN NN O
basal NN NN O
ganglia NN NN O
. . . O

Antidepressants NNP NNP O
have VBP VBP O
previously RB RB O
been VBN VBN O
associated VBN VBN O
with IN IN O
paranoid NN NN O
reactions NNS NNS O
in IN IN O
psychiatric JJ JJ O
patients NNS NNS O
. . . O

Five CD CD O
cases NNS NNS O
of IN IN O
paranoid JJ JJ O
exacerbation NN NN O
with IN IN O
the DT DT O
serotonin NN NN B-CHEM
reuptake NN NN O
inhibitors NNS NNS O
fluoxetine NN NN B-CHEM
and CC CC O
amitriptyline NN NN B-CHEM
are VBP VBP O
reported VBN VBN O
here RB RB O
. . . O

Elements NNS NNS O
common JJ JJ O
to TO TO O
these DT DT O
cases NNS NNS O
included VBD VBD O
a DT DT O
history NN NN O
of IN IN O
paranoid NN NN O
symptomatology NN NN O
and CC CC O
the DT DT O
concomitant JJ JJ O
occurrence NN NN O
of IN IN O
depressive JJ JJ O
and CC CC O
psychotic JJ JJ O
symptoms NNS NNS O
. . . O

Complicated NNP NNP O
depressive JJ JJ O
disorders NNS NNS O
( ( ( O
including VBG VBG O
atypicality NN NN O
of IN IN O
course NN NN O
and CC CC O
symptomatology NN NN O
, , , O
chronicity NN NN O
, , , O
psychosis NN NN O
, , , O
bipolarity NN NN O
, , , O
and CC CC O
secondary JJ JJ O
onset NN NN O
in IN IN O
the DT DT O
course NN NN O
of IN IN O
a DT DT O
primary JJ JJ O
psychosis NN NN O
) ) ) O
may MD MD O
present VB VB O
particular JJ JJ O
vulnerability NN NN O
to TO TO O
paranoid VB VB O
exacerbations NNS NNS O
associated VBN VBN O
with IN IN O
serotonin NN NN B-CHEM
reuptake NN NN O
inhibitors NNS NNS O
. . . O

Although IN IN O
the DT DT O
pharmacology NN NN O
and CC CC O
neurobiology NN NN O
of IN IN O
paranoia NN NN O
remain VB VB O
cryptic JJ JJ O
, , , O
several JJ JJ O
mechanisms NNS NNS O
, , , O
including VBG VBG O
5HT3 CD CD O
receptor NN NN O
- : : O
mediated JJ JJ O
dopamine NN NN B-CHEM
release NN NN O
, , , O
beta NN NN O
- - - O
noradrenergic JJ JJ O
receptor NN NN O
downregulation NN NN O
, , , O
or CC CC O
GABAB NNP NNP O
receptor NN NN O
upregulation NN NN O
acting VBG VBG O
in IN IN O
the DT DT O
vicinity NN NN O
of IN IN O
the DT DT O
ventral NN NN O
basal NN NN O
ganglia NN NN O
( ( ( O
possibly RB RB O
in IN IN O
lateral NN NN O
orbitofrontal NN NN O
or CC CC O
anterior NN NN O
cingulate NN NN O
circuits NNS NNS O
) ) ) O
, , , O
might MD MD O
apply VB VB O
to TO TO O
this DT DT O
phenomenon NN NN O
. . . O

These DT DT O
cases NNS NNS O
call VBP VBP O
attention NN NN O
to TO TO O
possible JJ JJ O
paranoid NN NN O
exacerbations NNS NNS O
with IN IN O
serotonin NN NN B-CHEM
reuptake NN NN O
blockers NNS NNS O
in IN IN O
select JJ JJ O
patients NNS NNS O
and CC CC O
raise VB VB O
neurobiological JJ JJ O
considerations NNS NNS O
regarding VBG VBG O
paranoia NN NN O
. . . O

Clinical NNP NNP O
comparison NN NN O
of IN IN O
cardiorespiratory NN NN O
effects NNS NNS O
during IN IN O
unilateral JJ JJ O
and CC CC O
conventional JJ JJ O
spinal JJ JJ O
anaesthesia NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
Spinal NNP NNP O
anaesthesia NN NN O
is VBZ VBZ O
widely RB RB O
employed VBN VBN O
in IN IN O
clinical JJ JJ O
practice NN NN O
but CC CC O
has VBZ VBZ O
the DT DT O
main JJ JJ O
drawback NN NN O
of IN IN O
post NN NN O
- - - O
spinal JJ JJ O
block NN NN O
hypotension NN NN O
. . . O

Efforts NNS NNS O
must MD MD O
therefore RB RB O
continue VB VB O
to TO TO O
be VB VB O
made VBN VBN O
to TO TO O
obviate VB VB O
this DT DT O
setback NN NN O
OBJECTIVE NNP NNP O
: : : O
To TO TO O
evaluate VB VB O
the DT DT O
cardiovascular JJ JJ O
and CC CC O
respiratory JJ JJ O
changes NNS NNS O
during IN IN O
unilateral JJ JJ O
and CC CC O
conventional JJ JJ O
spinal JJ JJ O
anaesthesia NN NN O
. . . O

METHODS NNP NNP O
: : : O
With IN IN O
ethical JJ JJ O
approval NN NN O
, , , O
we PRP PRP O
studied VBD VBD O
74 CD CD O
American JJ JJ O
Society NNP NNP O
of IN IN O
Anesthesiologists NNP NNP O
( ( ( O
ASA NNP NNP O
) ) ) O
, , , O
physical JJ JJ O
status NN NN O
class NN NN O
1 CD CD O
and CC CC O
2 CD CD O
patients NNS NNS O
scheduled VBN VBN O
for IN IN O
elective JJ JJ O
unilateral JJ JJ O
lower JJR JJR O
limb NN NN O
surgery NN NN O
. . . O

Patients NNS NNS O
were VBD VBD O
randomly RB RB O
allocated VBN VBN O
into IN IN O
one CD CD O
of IN IN O
two CD CD O
groups NNS NNS O
: : : O
lateral NN NN O
and CC CC O
conventional JJ JJ O
spinal JJ JJ O
anaesthesia NN NN O
groups NNS NNS O
. . . O

In IN IN O
the DT DT O
lateral NN NN O
position NN NN O
with IN IN O
operative JJ JJ O
side NN NN O
down RB RB O
, , , O
patients NNS NNS O
recived VBD VBD O
10 CD CD O
mg NN NN O
( ( ( O
2mls CD CD O
) ) ) O
of IN IN O
0 CD CD O
. . . O
5 CD CD O
% NN NN O
hyperbaric JJ JJ O
bupivacaine NN NN B-CHEM
through IN IN O
a DT DT O
25 CD CD O
- : : O
gauge JJ JJ O
spinal JJ JJ O
needle NN NN O
. . . O

Patients NNS NNS O
in IN IN O
the DT DT O
unilateral JJ JJ O
group NN NN O
were VBD VBD O
maintained VBN VBN O
in IN IN O
the DT DT O
lateral NN NN O
position NN NN O
for IN IN O
15 CD CD O
minutes NNS NNS O
following VBG VBG O
spinal JJ JJ O
injection NN NN O
while IN IN O
those DT DT O
in IN IN O
the DT DT O
conventional JJ JJ O
group NN NN O
were VBD VBD O
turned VBN VBN O
supine NN NN O
immediately RB RB O
after IN IN O
injection NN NN O
. . . O

Blood NNP NNP O
pressure NN NN O
, , , O
heart NN NN O
rate NN NN O
, , , O
respiratory JJ JJ O
rate NN NN O
and CC CC O
oxygen NN NN B-CHEM
saturation NN NN O
were VBD VBD O
monitored VBN VBN O
over IN IN O
1 CD CD O
hour NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Three CD CD O
patients NNS NNS O
( ( ( O
8 CD CD O
. . . O
1 CD CD O
% NN NN O
) ) ) O
in IN IN O
the DT DT O
unilateral JJ JJ O
group NN NN O
and CC CC O
5 CD CD O
( ( ( O
13 CD CD O
. . . O
5 CD CD O
% NN NN O
) ) ) O
in IN IN O
the DT DT O
conventional JJ JJ O
group NN NN O
developed VBN VBN O
hypotension NN NN O
, , , O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
71 CD CD O
. . . O

Four CD CD O
( ( ( O
10 CD CD O
. . . O
8 CD CD O
% NN NN O
) ) ) O
patients NNS NNS O
in IN IN O
the DT DT O
conventional JJ JJ O
group NN NN O
and CC CC O
1 CD CD O
( ( ( O
2 CD CD O
. . . O
7 CD CD O
% NN NN O
) ) ) O
in IN IN O
the DT DT O
unilateral JJ JJ O
group NN NN O
, , , O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
17 CD CD O
required VBN VBN O
epinephrine NN NN B-CHEM
infusion NN NN O
to TO TO O
treat VB VB O
hypotension NN NN O
. . . O

Patients NNS NNS O
in IN IN O
the DT DT O
conventional JJ JJ O
group NN NN O
had VBD VBD O
statistically RB RB O
significant JJ JJ O
greater JJR JJR O
fall NN NN O
in IN IN O
the DT DT O
systolic JJ JJ O
blood NN NN O
pressures NNS NNS O
at IN IN O
15 CD CD O
, , , O
30 CD CD O
and CC CC O
45 CD CD O
minutes NNS NNS O
when WRB WRB O
compared VBN VBN O
to TO TO O
the DT DT O
baseline NN NN O
( ( ( O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
003 CD CD O
, , , O
0 CD CD O
. . . O
001 CD CD O
and CC CC O
0 CD CD O
. . . O
004 CD CD O
) ) ) O
. . . O

The DT DT O
mean NN NN O
respiratory NN NN O
rate NN NN O
and CC CC O
oxygen NN NN B-CHEM
saturations NNS NNS O
in IN IN O
the DT DT O
two CD CD O
groups NNS NNS O
were VBD VBD O
similar JJ JJ O
. . . O

CONCLUSION NNP NNP O
: : : O
Compared VBN VBN O
to TO TO O
conventional JJ JJ O
spinal JJ JJ O
anaesthesia NN NN O
, , , O
unilateral JJ JJ O
spinal JJ JJ O
anaesthesia NN NN O
was VBD VBD O
associated VBN VBN O
with IN IN O
fewer JJR JJR O
cardiovascular NN NN O
perturbations NNS NNS O
. . . O

Also RB RB O
, , , O
the DT DT O
type NN NN O
of IN IN O
spinal JJ JJ O
block NN NN O
instituted VBD VBD O
affected VBN VBN O
neither DT DT O
the DT DT O
respiratory NN NN O
rate NN NN O
nor CC CC O
the DT DT O
arterial JJ JJ O
oxygen NN NN B-CHEM
saturation NN NN O
. . . O

Spectrum NNP NNP O
of IN IN O
adverse JJ JJ O
events NNS NNS O
after IN IN O
generic JJ JJ O
HAART NNP NNP O
in IN IN O
southern JJ JJ O
Indian JJ JJ O
HIV NNP NNP O
- - - O
infected JJ JJ O
patients NNS NNS O
. . . O

To TO TO O
determine VB VB O
the DT DT O
incidence NN NN O
of IN IN O
clinically RB RB O
significant JJ JJ O
adverse JJ JJ O
events NNS NNS O
after IN IN O
long JJ JJ O
- - - O
term NN NN O
, , , O
fixed JJ JJ O
- - - O
dose NN NN O
, , , O
generic JJ JJ O
highly RB RB O
active JJ JJ O
antiretroviral NN NN O
therapy NN NN O
( ( ( O
HAART NNP NNP O
) ) ) O
use NN NN O
among IN IN O
HIV NNP NNP O
- : : O
infected JJ JJ O
individuals NNS NNS O
in IN IN O
South NNP NNP O
India NNP NNP O
, , , O
we PRP PRP O
examined VBD VBD O
the DT DT O
experiences NNS NNS O
of IN IN O
3154 CD CD O
HIV NNP NNP O
- : : O
infected JJ JJ O
individuals NNS NNS O
who WP WP O
received VBD VBD O
a DT DT O
minimum NN NN O
of IN IN O
3 CD CD O
months NNS NNS O
of IN IN O
generic JJ JJ O
HAART NNP NNP O
between IN IN O
February NNP NNP O
1996 CD CD O
and CC CC O
December NNP NNP O
2006 CD CD O
at IN IN O
a DT DT O
tertiary JJ JJ O
HIV NNP NNP O
care NN NN O
referral NN NN O
center NN NN O
in IN IN O
South NNP NNP O
India NNP NNP O
. . . O

The DT DT O
most RBS RBS O
common JJ JJ O
regimens NNS NNS O
were VBD VBD O
3TC CD CD B-CHEM
+ NN NN O
d4T NN NN B-CHEM
+ NN NN O
nevirapine NN NN B-CHEM
( ( ( O
NVP NNP NNP B-CHEM
) ) ) O
( ( ( O
54 CD CD O
. . . O
8 CD CD O
% NN NN O
) ) ) O
, , , O
zidovudine NN NN B-CHEM
( ( ( O
AZT NNP NNP B-CHEM
) ) ) O
+ NN NN O
3TC CD CD B-CHEM
+ NN NN O
NVP NNP NNP B-CHEM
( ( ( O
14 CD CD O
. . . O
5 CD CD O
% NN NN O
) ) ) O
, , , O
3TC CD CD B-CHEM
+ NN NN O
d4T NN NN B-CHEM
+ NN NN O
efavirenz NN NN B-CHEM
( ( ( O
EFV NNP NNP B-CHEM
) ) ) O
( ( ( O
20 CD CD O
. . . O
1 CD CD O
% NN NN O
) ) ) O
, , , O
and CC CC O
AZT NNP NNP B-CHEM
+ NN NN O
3TC CD CD B-CHEM
+ NN NN O
EFV NNP NNP B-CHEM
( ( ( O
5 CD CD O
. . . O
4 CD CD O
% NN NN O
) ) ) O
. . . O

The DT DT O
most RBS RBS O
common JJ JJ O
adverse JJ JJ O
events NNS NNS O
and CC CC O
median NN NN O
CD4 NNP NNP O
at IN IN O
time NN NN O
of IN IN O
event NN NN O
were VBD VBD O
rash NN NN O
( ( ( O
15 CD CD O
. . . O
2 CD CD O
% NN NN O
; : : O
CD4 NNP NNP O
, , , O
285 CD CD O
cells NNS NNS O
/ NN NN O
microL NN NN O
) ) ) O
and CC CC O
peripheral JJ JJ O
neuropathy NN NN O
( ( ( O
9 CD CD O
. . . O
0 CD CD O
% NN NN O
and CC CC O
348 CD CD O
cells NNS NNS O
/ NN NN O
microL NN NN O
) ) ) O
. . . O

Clinically NNP NNP O
significant JJ JJ O
anemia NN NN O
( ( ( O
hemoglobin NN NN O
< NN NN O
7 CD CD O
g SYM SYM O
/ NN NN O
dL NN NN O
) ) ) O
was VBD VBD O
observed VBN VBN O
in IN IN O
5 CD CD O
. . . O
4 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
( ( ( O
CD4 NNP NNP O
, , , O
165 CD CD O
cells NNS NNS O
/ NN NN O
microL NN NN O
) ) ) O
and CC CC O
hepatitis NN NN O
( ( ( O
clinical JJ JJ O
jaundice NN NN O
with IN IN O
alanine NN NN B-CHEM
aminotransferase NN NN O
> NN NN O
5 CD CD O
times NNS NNS O
upper JJ JJ O
limits NNS NNS O
of IN IN O
normal JJ JJ O
) ) ) O
in IN IN O
3 CD CD O
. . . O
5 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
( ( ( O
CD4 NNP NNP O
, , , O
260 CD CD O
cells NNS NNS O
/ NN NN O
microL NN NN O
) ) ) O
. . . O

Women NNP NNP O
were VBD VBD O
significantly RB RB O
more RBR RBR O
likely JJ JJ O
to TO TO O
experience VB VB O
lactic JJ JJ O
acidosis NN NN O
, , , O
while IN IN O
men NNS NNS O
were VBD VBD O
significantly RB RB O
more RBR RBR O
likely JJ JJ O
to TO TO O
experience VB VB O
immune JJ JJ O
reconstitution NN NN O
syndrome NN NN O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

Among IN IN O
the DT DT O
patients NNS NNS O
with IN IN O
1 CD CD O
year NN NN O
of IN IN O
follow VB VB O
- - - O
up RP RP O
, , , O
NVP NNP NNP B-CHEM
therapy NN NN O
was VBD VBD O
significantly RB RB O
associated VBN VBN O
with IN IN O
developing VBG VBG O
rash NN NN O
and CC CC O
d4T NN NN B-CHEM
therapy NN NN O
with IN IN O
developing VBG VBG O
peripheral JJ JJ O
neuropathy NN NN O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

Anemia NNP NNP O
and CC CC O
hepatitis NN NN O
often RB RB O
occur VB VB O
within IN IN O
12 CD CD O
weeks NNS NNS O
of IN IN O
initiating VBG VBG O
generic JJ JJ O
HAART NNP NNP O
. . . O

Frequent NNP NNP O
and CC CC O
early JJ JJ O
monitoring NN NN O
for IN IN O
these DT DT O
toxicities NNS NNS O
is VBZ VBZ O
warranted VBN VBN O
in IN IN O
developing VBG VBG O
countries NNS NNS O
where WRB WRB O
generic JJ JJ O
HAART NNP NNP O
is VBZ VBZ O
increasingly RB RB O
available JJ JJ O
. . . O

Thalidomide NNP NNP B-CHEM
and CC CC O
sensory JJ JJ O
neurotoxicity NN NN O
: : : O
a DT DT O
neurophysiological JJ JJ O
study NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
Recent JJ JJ O
studies NNS NNS O
confirmed VBD VBD O
a DT DT O
high JJ JJ O
incidence NN NN O
of IN IN O
sensory JJ JJ O
axonal JJ JJ O
neuropathy NN NN O
in IN IN O
patients NNS NNS O
treated VBN VBN O
with IN IN O
different JJ JJ O
doses NNS NNS O
of IN IN O
thalidomide NN NN B-CHEM
. . . O

The DT DT O
study NN NN O
' '' '' O
s VBZ VBZ O
aims NNS NNS O
were VBD VBD O
to TO TO O
measure VB VB O
variations NNS NNS O
in IN IN O
sural JJ JJ O
nerve NN NN O
sensory JJ JJ O
action NN NN O
potential JJ JJ O
( ( ( O
SAP NNP NNP O
) ) ) O
amplitude NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
refractory NN NN O
cutaneous JJ JJ O
lupus NN NN O
erythematosus NN NN O
( ( ( O
CLE NNP NNP O
) ) ) O
treated VBN VBN O
with IN IN O
thalidomide NN NN B-CHEM
and CC CC O
use VB VB O
these DT DT O
findings NNS NNS O
to TO TO O
identify VB VB O
the DT DT O
neurotoxic JJ JJ O
potential NN NN O
of IN IN O
thalidomide NN NN B-CHEM
and CC CC O
the DT DT O
recovery NN NN O
capacity NN NN O
of IN IN O
sensory JJ JJ O
fibres NNS NNS O
after IN IN O
discontinuation NN NN O
of IN IN O
treatment NN NN O
. . . O

PATIENTS NNS NNS O
AND CC CC O
METHODS NNP NNP O
: : : O
Clinical NNP NNP O
and CC CC O
electrophysiological JJ JJ O
data NNS NNS O
in IN IN O
12 CD CD O
female JJ JJ O
patients NNS NNS O
with IN IN O
CLE NNP NNP O
during IN IN O
treatment NN NN O
with IN IN O
thalidomide NN NN B-CHEM
and CC CC O
up IN IN O
to TO TO O
47 CD CD O
months NNS NNS O
after IN IN O
discontinuation NN NN O
of IN IN O
treatment NN NN O
were VBD VBD O
analysed VBN VBN O
. . . O

Sural NNP NNP O
nerve NN NN O
SAP NNP NNP O
amplitude NN NN O
reduction NN NN O
> NN NN O
or CC CC O
= SYM SYM O
40 CD CD O
% NN NN O
was VBD VBD O
the DT DT O
criteria NNS NNS O
for IN IN O
discontinuing VBG VBG O
therapy NN NN O
. . . O

RESULTS NNS NNS O
: : : O
During IN IN O
treatment NN NN O
, , , O
11 CD CD O
patients NNS NNS O
showed VBD VBD O
a DT DT O
reduction NN NN O
in IN IN O
sural JJ JJ O
nerve NN NN O
SAP NNP NNP O
amplitude NN NN O
compared VBN VBN O
to TO TO O
baseline NN NN O
values NNS NNS O
( ( ( O
9 CD CD O
with IN IN O
a DT DT O
reduction NN NN O
> NN NN O
or CC CC O
= SYM SYM O
50 CD CD O
% NN NN O
and CC CC O
2 CD CD O
< NN NN O
50 CD CD O
% NN NN O
) ) ) O
. . . O

One CD CD O
patient NN NN O
showed VBD VBD O
no DT DT O
changes NNS NNS O
in IN IN O
SAP NNP NNP O
amplitude NN NN O
. . . O

Five CD CD O
patients NNS NNS O
complained VBD VBD O
of IN IN O
paresthesias NN NN O
and CC CC O
leg NN NN O
cramps NNS NNS O
. . . O

After IN IN O
thalidomide NN NN B-CHEM
treatment NN NN O
, , , O
sural JJ JJ O
SAP NNP NNP O
amplitude NN NN O
recovered VBD VBD O
in IN IN O
3 CD CD O
patients NNS NNS O
. . . O

At IN IN O
detection NN NN O
of IN IN O
reduction NN NN O
in IN IN O
sural JJ JJ O
nerve NN NN O
SAP NNP NNP O
amplitude NN NN O
, , , O
the DT DT O
median NN NN O
thalidomide NN NN B-CHEM
cumulative JJ JJ O
dose NN NN O
was VBD VBD O
21 CD CD O
. . . O
4 CD CD O
g SYM SYM O
. . . O

The DT DT O
threshold NN NN O
neurotoxic JJ JJ O
dosage NN NN O
is VBZ VBZ O
lower JJR JJR O
than IN IN O
previously RB RB O
reported VBD VBD O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Sural NNP NNP O
nerve NN NN O
SAP NNP NNP O
amplitude NN NN O
reduction NN NN O
is VBZ VBZ O
a DT DT O
reliable JJ JJ O
and CC CC O
sensitive JJ JJ O
marker NN NN O
of IN IN O
degeneration NN NN O
and CC CC O
recovery NN NN O
of IN IN O
sensory JJ JJ O
fibres NNS NNS O
. . . O

This DT DT O
electrophysiological JJ JJ O
parameter NN NN O
provides VBZ VBZ O
information NN NN O
about IN IN O
subclinical JJ JJ O
neurotoxic JJ JJ O
potential NN NN O
of IN IN O
thalidomide NN NN B-CHEM
but CC CC O
is VBZ VBZ O
not RB RB O
helpful JJ JJ O
in IN IN O
predicting VBG VBG O
the DT DT O
appearance NN NN O
of IN IN O
sensory JJ JJ O
symptoms NNS NNS O
. . . O

Five CD CD O
cases NNS NNS O
of IN IN O
encephalitis NNS NNS O
during IN IN O
treatment NN NN O
of IN IN O
loiasis NN NN O
with IN IN O
diethylcarbamazine NN NN B-CHEM
. . . O

Five CD CD O
cases NNS NNS O
of IN IN O
encephalitis NNS NNS O
following VBG VBG O
treatment NN NN O
with IN IN O
diethylcarbamazine NN NN B-CHEM
( ( ( O
DEC NNP NNP B-CHEM
) ) ) O
were VBD VBD O
observed VBN VBN O
in IN IN O
Congolese NNP NNP O
patients NNS NNS O
with IN IN O
Loa NNP NNP O
loa NN NN O
filariasis NN NN O
. . . O

Two CD CD O
cases NNS NNS O
had VBD VBD O
a DT DT O
fatal JJ JJ O
outcome NN NN O
and CC CC O
one CD CD O
resulted VBD VBD O
in IN IN O
severe JJ JJ O
sequelae NN NN O
. . . O

The DT DT O
notable JJ JJ O
fact NN NN O
was VBD VBD O
that IN IN O
this DT DT O
complication NN NN O
occurred VBD VBD O
in IN IN O
three CD CD O
patients NNS NNS O
hospitalized VBD VBD O
before IN IN O
treatment NN NN O
began VBD VBD O
, , , O
with IN IN O
whom WP WP O
particularly RB RB O
strict JJ JJ O
therapeutic JJ JJ O
precautions NNS NNS O
were VBD VBD O
taken VBN VBN O
, , , O
i NNP NNP O
. . . O
e SYM SYM O
. . . O
, , , O
initial JJ JJ O
dose NN NN O
less JJR JJR O
than IN IN O
10 CD CD O
mg NN NN O
of IN IN O
DEC NNP NNP B-CHEM
, , , O
very RB RB O
gradual JJ JJ O
dose NN NN O
increases NNS NNS O
, , , O
and CC CC O
associated VBN VBN O
anti JJ JJ O
- : : O
allergic JJ JJ O
treatment NN NN O
. . . O

This DT DT O
type NN NN O
of IN IN O
drug NN NN O
- - - O
induced JJ JJ O
complication NN NN O
may MD MD O
not RB RB O
be VB VB O
that DT DT O
uncommon JJ JJ O
in IN IN O
highly RB RB O
endemic JJ JJ O
regions NNS NNS O
. . . O

It PRP PRP O
occurs VBZ VBZ O
primarily RB RB O
, , , O
but CC CC O
not RB RB O
exclusively RB RB O
, , , O
in IN IN O
subjects NNS NNS O
presenting VBG VBG O
with IN IN O
a DT DT O
high JJ JJ O
microfilarial NN NN O
load NN NN O
. . . O

The DT DT O
relationship NN NN O
between IN IN O
the DT DT O
occurrence NN NN O
of IN IN O
encephalitis NNS NNS O
and CC CC O
the DT DT O
decrease NN NN O
in IN IN O
microfilaremia NN NN O
is VBZ VBZ O
evident JJ JJ O
. . . O

The DT DT O
pathophysiological JJ JJ O
mechanisms NNS NNS O
are VBP VBP O
discussed VBN VBN O
in IN IN O
the DT DT O
light NN NN O
of IN IN O
these DT DT O
observations NNS NNS O
and CC CC O
the DT DT O
few JJ JJ O
other JJ JJ O
comments NNS NNS O
on IN IN O
this DT DT O
subject NN NN O
published VBN VBN O
in IN IN O
the DT DT O
literature NN NN O
. . . O

Amiodarone NNP NNP B-CHEM
- - - O
related VBN VBN O
pulmonary JJ JJ O
mass NN NN O
and CC CC O
unique JJ JJ O
membranous JJ JJ O
glomerulonephritis NNS NNS O
in IN IN O
a DT DT O
patient NN NN O
with IN IN O
valvular JJ JJ O
heart NN NN O
disease NN NN O
: : : O
Diagnostic NNP NNP O
pitfall NN NN O
and CC CC O
new JJ JJ O
findings NNS NNS O
. . . O

Amiodarone NNP NNP B-CHEM
is VBZ VBZ O
an DT DT O
anti JJ JJ O
- : : O
arrhythmic JJ JJ O
drug NN NN O
for IN IN O
life NN NN O
- - - O
threatening VBG VBG O
tachycardia NNS NNS O
, , , O
but CC CC O
various JJ JJ O
adverse JJ JJ O
effects NNS NNS O
have VBP VBP O
been VBN VBN O
reported VBN VBN O
. . . O

Reported NNP NNP O
herein NN NN O
is VBZ VBZ O
an DT DT O
autopsy JJ JJ O
case NN NN O
of IN IN O
valvular JJ JJ O
heart NN NN O
disease NN NN O
, , , O
in IN IN O
a DT DT O
patient NN NN O
who WP WP O
developed VBD VBD O
a DT DT O
lung NN NN O
mass NN NN O
( ( ( O
1 CD CD O
. . . O
5 CD CD O
cm NN NN O
in IN IN O
diameter NN NN O
) ) ) O
and CC CC O
proteinuria NN NN O
( ( ( O
2 CD CD O
. . . O
76 CD CD O
g SYM SYM O
/ NN NN O
day NN NN O
) ) ) O
after IN IN O
treatment NN NN O
with IN IN O
amiodarone NN NN B-CHEM
for IN IN O
a DT DT O
long JJ JJ O
time NN NN O
. . . O

The DT DT O
lung NN NN O
mass NN NN O
was VBD VBD O
highly RB RB O
suspected VBN VBN O
to TO TO O
be VB VB O
lung NN NN O
cancer NN NN O
on IN IN O
CT NNP NNP O
and CC CC O
positron NN NN O
emission NN NN O
tomography NN NN O
, , , O
but CC CC O
histologically RB RB O
the DT DT O
lesion NN NN O
was VBD VBD O
composed VBN VBN O
of IN IN O
lymphoplasmacytic JJ JJ O
infiltrates NNS NNS O
in IN IN O
alveolar JJ JJ O
walls NNS NNS O
and CC CC O
intra NN NN O
- - - O
alveolar JJ JJ O
accumulation NN NN O
of IN IN O
foamy NN NN O
macrophages NNS NNS O
containing VBG VBG O
characteristic JJ JJ O
myelinoid NN NN O
bodies NNS NNS O
, , , O
indicating VBG VBG O
that IN IN O
it PRP PRP O
was VBD VBD O
an DT DT O
amiodarone NN NN B-CHEM
- - - O
related VBN VBN O
lesion NN NN O
. . . O

In IN IN O
addition NN NN O
, , , O
the DT DT O
lung NN NN O
tissue NN NN O
had VBD VBD O
unevenly RB RB O
distributed VBN VBN O
hemosiderin NN NN O
deposition NN NN O
, , , O
and CC CC O
abnormally RB RB O
tortuous JJ JJ O
capillaries NNS NNS O
were VBD VBD O
seen VBN VBN O
in IN IN O
the DT DT O
mass NN NN O
and CC CC O
in IN IN O
heavily RB RB O
hemosiderotic JJ JJ O
lung NN NN O
portions NNS NNS O
outside IN IN O
the DT DT O
mass NN NN O
. . . O

In IN IN O
the DT DT O
kidneys NNS NNS O
, , , O
glomeruli NN NN O
had VBD VBD O
membrane NN NN O
spikes NNS NNS O
, , , O
prominent JJ JJ O
swelling NN NN O
of IN IN O
podocytes NNS NNS O
and CC CC O
subepithelial JJ JJ O
deposits NNS NNS O
, , , O
which WDT WDT O
were VBD VBD O
sometimes RB RB O
large JJ JJ O
and CC CC O
hump NN NN O
- - - O
like IN IN O
. . . O

Autoimmune NNP NNP O
diseases NNS NNS O
, , , O
viral JJ JJ O
hepatitis NN NN O
, , , O
malignant JJ JJ O
neoplasms NNS NNS O
or CC CC O
other JJ JJ O
diseases NNS NNS O
with IN IN O
a DT DT O
known VBN VBN O
relationship NN NN O
to TO TO O
membranous JJ JJ O
glomerulonephritis NNS NNS O
were VBD VBD O
not RB RB O
found VBN VBN O
. . . O

The DT DT O
present JJ JJ O
case NN NN O
highlights NNS NNS O
the DT DT O
possibility NN NN O
that IN IN O
differential JJ JJ O
diagnosis NN NN O
between IN IN O
an DT DT O
amiodarone NN NN B-CHEM
- - - O
related VBN VBN O
pulmonary JJ JJ O
lesion NN NN O
and CC CC O
a DT DT O
neoplasm NN NN O
can MD MD O
be VB VB O
very RB RB O
difficult JJ JJ O
radiologically RB RB O
, , , O
and CC CC O
suggests VBZ VBZ O
that IN IN O
membranous JJ JJ O
glomerulonephritis NNS NNS O
might MD MD O
be VB VB O
another DT DT O
possible JJ JJ O
complication NN NN O
of IN IN O
amiodarone NN NN B-CHEM
treatment NN NN O
. . . O

Risk NN NN O
of IN IN O
coronary JJ JJ O
artery NN NN O
disease NN NN O
associated VBN VBN O
with IN IN O
initial JJ JJ O
sulphonylurea NN NN B-CHEM
treatment NN NN O
of IN IN O
patients NNS NNS O
with IN IN O
type NN NN O
2 CD CD O
diabetes NNS NNS O
: : : O
a DT DT O
matched JJ JJ O
case NN NN O
- - - O
control NN NN O
study NN NN O
. . . O

AIMS NNP NNP O
: : : O
This DT DT O
study NN NN O
sought VBN VBN O
to TO TO O
assess VB VB O
the DT DT O
risk NN NN O
of IN IN O
developing VBG VBG O
coronary JJ JJ O
artery NN NN O
disease NN NN O
( ( ( O
CAD NNP NNP O
) ) ) O
associated VBN VBN O
with IN IN O
initial JJ JJ O
treatment NN NN O
of IN IN O
type NN NN O
2 CD CD O
diabetes NNS NNS O
with IN IN O
different JJ JJ O
sulphonylureas NNS NNS B-CHEM
. . . O

METHODS NNP NNP O
: : : O
In IN IN O
type NN NN O
2 CD CD O
diabetic JJ JJ O
patients NNS NNS O
, , , O
cases NNS NNS O
who WP WP O
developed JJ JJ O
CAD NNP NNP O
were VBD VBD O
compared VBN VBN O
retrospectively RB RB O
with IN IN O
controls NNS NNS O
that WDT WDT O
did VBD VBD O
not RB RB O
. . . O

The DT DT O
20 CD CD O
- : : O
year NN NN O
risk NN NN O
of IN IN O
CAD NNP NNP O
at IN IN O
diagnosis NN NN O
of IN IN O
diabetes NN NN O
, , , O
using VBG VBG O
the DT DT O
UKPDS NNP NNP O
risk NN NN O
engine NN NN O
, , , O
was VBD VBD O
used VBN VBN O
to TO TO O
match VB VB O
cases NNS NNS O
with IN IN O
controls NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
The DT DT O
76 CD CD O
cases NNS NNS O
of IN IN O
CAD NNP NNP O
were VBD VBD O
compared VBN VBN O
with IN IN O
152 CD CD O
controls NNS NNS O
. . . O

The DT DT O
hazard NN NN O
of IN IN O
developing VBG VBG O
CAD NNP NNP O
( ( ( O
95 CD CD O
% NN NN O
CI NNP NNP O
) ) ) O
associated VBN VBN O
with IN IN O
initial JJ JJ O
treatment NN NN O
increased VBN VBN O
by IN IN O
2 CD CD O
. . . O
4 CD CD O
- : : O
fold NN NN O
( ( ( O
1 CD CD O
. . . O
3 CD CD O
- : : O
4 CD CD O
. . . O
3 CD CD O
, , , O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
004 CD CD O
) ) ) O
with IN IN O
glibenclamide NN NN B-CHEM
; : : O
2 CD CD O
- : : O
fold NN NN O
( ( ( O
0 CD CD O
. . . O
9 CD CD O
- : : O
4 CD CD O
. . . O
6 CD CD O
, , , O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
099 CD CD O
) ) ) O
with IN IN O
glipizide NN NN B-CHEM
; : : O
2 CD CD O
. . . O
9 CD CD O
- : : O
fold NN NN O
( ( ( O
1 CD CD O
. . . O
6 CD CD O
- : : O
5 CD CD O
. . . O
1 CD CD O
, , , O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
000 CD CD O
) ) ) O
with IN IN O
either DT DT O
, , , O
and CC CC O
was VBD VBD O
unchanged JJ JJ O
with IN IN O
metformin NN NN B-CHEM
. . . O

The DT DT O
hazard NN NN O
decreased VBD VBD O
0 CD CD O
. . . O
3 CD CD O
- : : O
fold NN NN O
( ( ( O
0 CD CD O
. . . O
7 CD CD O
- : : O
1 CD CD O
. . . O
7 CD CD O
, , , O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
385 CD CD O
) ) ) O
with IN IN O
glimepiride NN NN B-CHEM
, , , O
0 CD CD O
. . . O
4 CD CD O
- : : O
fold NN NN O
( ( ( O
0 CD CD O
. . . O
7 CD CD O
- : : O
1 CD CD O
. . . O
3 CD CD O
, , , O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
192 CD CD O
) ) ) O
with IN IN O
gliclazide NN NN B-CHEM
, , , O
and CC CC O
0 CD CD O
. . . O
4 CD CD O
- : : O
fold NN NN O
( ( ( O
0 CD CD O
. . . O
7 CD CD O
- : : O
1 CD CD O
. . . O
1 CD CD O
, , , O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
09 CD CD O
) ) ) O
with IN IN O
either DT DT O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Initiating NNP NNP O
treatment NN NN O
of IN IN O
type NN NN O
2 CD CD O
diabetes NN NN O
with IN IN O
glibenclamide NN NN B-CHEM
or CC CC O
glipizide NN NN B-CHEM
is VBZ VBZ O
associated VBN VBN O
with IN IN O
increased VBN VBN O
risk NN NN O
of IN IN O
CAD NNP NNP O
in IN IN O
comparison NN NN O
to TO TO O
gliclazide VB VB B-CHEM
or CC CC O
glimepiride VB VB B-CHEM
. . . O

If IN IN O
confirmed VBN VBN O
, , , O
this DT DT O
may MD MD O
be VB VB O
important JJ JJ O
because IN IN O
most JJS JJS O
Indian JJ JJ O
patients NNS NNS O
receive VBP VBP O
the DT DT O
cheaper NN NN O
older JJR JJR O
sulphonylureas NN NN B-CHEM
, , , O
and CC CC O
present JJ JJ O
guidelines NNS NNS O
do VBP VBP O
not RB RB O
distinguish VB VB O
between IN IN O
individual JJ JJ O
agents NNS NNS O
. . . O

Reduced NNP NNP O
progression NN NN O
of IN IN O
adriamycin NN NN B-CHEM
nephropathy NN NN O
in IN IN O
spontaneously RB RB O
hypertensive JJ JJ O
rats NNS NNS O
treated VBN VBN O
by IN IN O
losartan NN NN B-CHEM
. . . O

BACKGROUND NNP NNP O
: : : O
The DT DT O
aim NN NN O
of IN IN O
the DT DT O
study NN NN O
was VBD VBD O
to TO TO O
investigate VB VB O
the DT DT O
antihypertensive JJ JJ O
effects NNS NNS O
of IN IN O
angiotensin NN NN B-CHEM
II NNP NNP I-CHEM
type NN NN O
- : : O
1 CD CD O
receptor NN NN O
blocker NN NN O
, , , O
losartan NN NN B-CHEM
, , , O
and CC CC O
its PRP$ PRP$ O
potential JJ JJ O
in IN IN O
slowing VBG VBG O
down RB RB O
renal JJ JJ O
disease NN NN O
progression NN NN O
in IN IN O
spontaneously RB RB O
hypertensive JJ JJ O
rats NNS NNS O
( ( ( O
SHR NNP NNP O
) ) ) O
with IN IN O
adriamycin NN NN B-CHEM
( ( ( O
ADR NNP NNP B-CHEM
) ) ) O
nephropathy NN NN O
. . . O

METHODS NNP NNP O
: : : O
Six CD CD O
- - - O
month NN NN O
- - - O
old JJ JJ O
female JJ JJ O
SHR NNP NNP O
were VBD VBD O
randomly RB RB O
selected VBN VBN O
in IN IN O
six CD CD O
groups NNS NNS O
. . . O

Two CD CD O
control NN NN O
groups NNS NNS O
( ( ( O
SH NNP NNP O
( ( ( O
6 CD CD O
) ) ) O
, , , O
SH NNP NNP O
( ( ( O
12 CD CD O
) ) ) O
) ) ) O
received VBD VBD O
vehicle NN NN O
. . . O

Groups NNS NNS O
ADR NNP NNP B-CHEM
( ( ( O
6 CD CD O
) ) ) O
, , , O
ADR NNP NNP B-CHEM
+ NN NN O
LOS NNP NNP B-CHEM
( ( ( O
6 CD CD O
) ) ) O
and CC CC O
ADR NNP NNP B-CHEM
( ( ( O
12 CD CD O
) ) ) O
, , , O
and CC CC O
ADR NNP NNP B-CHEM
+ NN NN O
LOS NNP NNP B-CHEM
( ( ( O
12 CD CD O
) ) ) O
received VBD VBD O
ADR NNP NNP B-CHEM
( ( ( O
2 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
b SYM SYM O
. . . O
w NN NN O
. . . O
i NNP NNP O
. . . O
v NN NN O
. . . O
) ) ) O
twice RB RB O
in IN IN O
a DT DT O
3 CD CD O
- : : O
week NN NN O
interval NN NN O
. . . O

Group NNP NNP O
ADR NNP NNP B-CHEM
+ NN NN O
LOS NNP NNP B-CHEM
( ( ( O
6 CD CD O
) ) ) O
received VBD VBD O
losartan NN NN B-CHEM
( ( ( O
10 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
b SYM SYM O
. . . O
w NN NN O
. . . O
/ NN NN O
day NN NN O
by IN IN O
gavages NNS NNS O
) ) ) O
for IN IN O
6 CD CD O
weeks NNS NNS O
and CC CC O
group NN NN O
ADR NNP NNP B-CHEM
+ NN NN O
LOS NNP NNP B-CHEM
( ( ( O
12 CD CD O
) ) ) O
for IN IN O
12 CD CD O
weeks NNS NNS O
after IN IN O
second JJ JJ O
injection NN NN O
of IN IN O
ADR NNP NNP B-CHEM
. . . O

Animals NNS NNS O
were VBD VBD O
killed VBN VBN O
after IN IN O
6 CD CD O
or CC CC O
12 CD CD O
weeks NNS NNS O
, , , O
respectively RB RB O
. . . O

Haemodynamic NNP NNP O
measurements NNS NNS O
were VBD VBD O
performed VBN VBN O
on IN IN O
anaesthetized JJ JJ O
animals NNS NNS O
, , , O
blood NN NN O
and CC CC O
urine JJ JJ O
samples NNS NNS O
were VBD VBD O
taken VBN VBN O
for IN IN O
biochemical JJ JJ O
analysis NN NN O
and CC CC O
the DT DT O
left NN NN O
kidney NN NN O
was VBD VBD O
processed VBN VBN O
for IN IN O
morphological JJ JJ O
studies NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
Short JJ JJ O
- - - O
term NN NN O
losartan NN NN B-CHEM
treatment NN NN O
, , , O
besides IN IN O
antihypertensive JJ JJ O
effect NN NN O
, , , O
improved VBN VBN O
glomerular JJ JJ O
filtration NN NN O
rate NN NN O
and CC CC O
ameliorated JJ JJ O
glomerulosclerosis NN NN O
resulting VBG VBG O
in IN IN O
decreased VBD VBD O
proteinuria NN NN O
. . . O

Prolonged NNP NNP O
treatment NN NN O
with IN IN O
losartan NN NN B-CHEM
showed VBD VBD O
further JJ JJ O
reduction NN NN O
of IN IN O
glomerulosclerosis NN NN O
associated VBN VBN O
with IN IN O
reduced VBN VBN O
progression NN NN O
of IN IN O
tubular JJ JJ O
atrophy NN NN O
and CC CC O
interstitial JJ JJ O
fibrosis NNS NNS O
, , , O
thus RB RB O
preventing VBG VBG O
heavy JJ JJ O
proteinuria NNS NNS O
and CC CC O
chronic JJ JJ O
renal JJ JJ O
failure NN NN O
. . . O

Losartan NNP NNP B-CHEM
reduced VBD VBD O
uraemia NN NN O
and CC CC O
increased VBN VBN O
urea NN NN B-CHEM
clearance NN NN O
in IN IN O
advanced VBN VBN O
ADR NNP NNP B-CHEM
nephropathy JJ JJ O
in IN IN O
SHR NNP NNP O
. . . O

Histological NNP NNP O
examination NN NN O
showed VBD VBD O
that IN IN O
losartan NN NN B-CHEM
could MD MD O
prevent VB VB O
tubular JJ JJ O
atrophy NN NN O
, , , O
interstitial JJ JJ O
infiltration NN NN O
and CC CC O
fibrosis NNS NNS O
in IN IN O
ADR NNP NNP B-CHEM
nephropathy NN NN O
. . . O

CONCLUSION NNP NNP O
: : : O
Losartan NNP NNP B-CHEM
reduces VBZ VBZ O
the DT DT O
rate NN NN O
of IN IN O
progression NN NN O
of IN IN O
ADR NNP NNP B-CHEM
- : : O
induced JJ JJ O
focal JJ JJ O
segmental JJ JJ O
glomerulosclerosis NN NN O
to TO TO O
end VB VB O
- : : O
stage NN NN O
renal NN NN O
disease NN NN O
in IN IN O
SHR NNP NNP O
. . . O

The DT DT O
risks NNS NNS O
of IN IN O
aprotinin NN NN O
and CC CC O
tranexamic JJ JJ B-CHEM
acid NN NN I-CHEM
in IN IN O
cardiac NN NN O
surgery NN NN O
: : : O
a DT DT O
one CD CD O
- - - O
year NN NN O
follow VB VB O
- - - O
up RP RP O
of IN IN O
1188 CD CD O
consecutive JJ JJ O
patients NNS NNS O
. . . O

BACKGROUND NNP NNP O
: : : O
Our PRP$ PRP$ O
aim NN NN O
was VBD VBD O
to TO TO O
investigate VB VB O
postoperative JJ JJ O
complications NNS NNS O
and CC CC O
mortality NN NN O
after IN IN O
administration NN NN O
of IN IN O
aprotinin NN NN O
compared VBN VBN O
to TO TO O
tranexamic JJ JJ B-CHEM
acid NN NN I-CHEM
in IN IN O
an DT DT O
unselected JJ JJ O
, , , O
consecutive JJ JJ O
cohort NN NN O
. . . O

METHODS NNP NNP O
: : : O
Perioperative NNP NNP O
data NNS NNS O
from IN IN O
consecutive JJ JJ O
cardiac NN NN O
surgery NN NN O
patients NNS NNS O
were VBD VBD O
prospectively RB RB O
collected VBN VBN O
between IN IN O
September NNP NNP O
2005 CD CD O
and CC CC O
June NNP NNP O
2006 CD CD O
in IN IN O
a DT DT O
university NN NN O
- - - O
affiliated JJ JJ O
clinic NN NN O
( ( ( O
n NN NN O
= SYM SYM O
1188 CD CD O
) ) ) O
. . . O

During IN IN O
the DT DT O
first JJ JJ O
5 CD CD O
mo NN NN O
, , , O
596 CD CD O
patients NNS NNS O
received VBD VBD O
aprotinin NN NN O
( ( ( O
Group NNP NNP O
A DT DT O
) ) ) O
; : : O
in IN IN O
the DT DT O
next JJ JJ O
5 CD CD O
mo NN NN O
, , , O
592 CD CD O
patients NNS NNS O
were VBD VBD O
treated VBN VBN O
with IN IN O
tranexamic JJ JJ B-CHEM
acid NN NN I-CHEM
( ( ( O
Group NNP NNP O
T NN NN O
) ) ) O
. . . O

Except IN IN O
for IN IN O
antifibrinolytic JJ JJ O
therapy NN NN O
, , , O
the DT DT O
anesthetic JJ JJ O
and CC CC O
surgical JJ JJ O
protocols NNS NNS O
remained VBD VBD O
unchanged JJ JJ O
. . . O

RESULTS NNS NNS O
: : : O
The DT DT O
pre NN NN O
- - - O
and CC CC O
intraoperative JJ JJ O
variables NNS NNS O
were VBD VBD O
comparable JJ JJ O
between IN IN O
the DT DT O
treatment NN NN O
groups NNS NNS O
. . . O

Postoperatively NNP NNP O
, , , O
a DT DT O
significantly RB RB O
higher JJR JJR O
incidence NN NN O
of IN IN O
seizures NNS NNS O
was VBD VBD O
found VBN VBN O
in IN IN O
Group NNP NNP O
T NN NN O
( ( ( O
4 CD CD O
. . . O
6 CD CD O
% NN NN O
vs NNS NNS O
1 CD CD O
. . . O
2 CD CD O
% NN NN O
, , , O
P NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
. . . O

This DT DT O
difference NN NN O
was VBD VBD O
also RB RB O
significant JJ JJ O
in IN IN O
the DT DT O
primary JJ JJ O
valve NN NN O
surgery NN NN O
and CC CC O
the DT DT O
high JJ JJ O
risk NN NN O
surgery NN NN O
subgroups NNS NNS O
( ( ( O
7 CD CD O
. . . O
9 CD CD O
% NN NN O
vs NNS NNS O
1 CD CD O
. . . O
2 CD CD O
% NN NN O
, , , O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
003 CD CD O
; : : O
7 CD CD O
. . . O
3 CD CD O
% NN NN O
vs NNS NNS O
2 CD CD O
. . . O
4 CD CD O
% NN NN O
, , , O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
035 CD CD O
, , , O
respectively RB RB O
) ) ) O
. . . O

Persistent NNP NNP O
atrial JJ JJ O
fibrillation NN NN O
( ( ( O
7 CD CD O
. . . O
9 CD CD O
% NN NN O
vs NNS NNS O
2 CD CD O
. . . O
3 CD CD O
% NN NN O
, , , O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
020 CD CD O
) ) ) O
and CC CC O
renal JJ JJ O
failure NN NN O
( ( ( O
9 CD CD O
. . . O
7 CD CD O
% NN NN O
vs NNS NNS O
1 CD CD O
. . . O
7 CD CD O
% NN NN O
, , , O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
002 CD CD O
) ) ) O
were VBD VBD O
also RB RB O
more RBR RBR O
common JJ JJ O
in IN IN O
Group NNP NNP O
T NN NN O
, , , O
in IN IN O
the DT DT O
primary JJ JJ O
valve NN NN O
surgery NN NN O
subgroup NN NN O
. . . O

On IN IN O
the DT DT O
contrary NN NN O
, , , O
among IN IN O
primary JJ JJ O
coronary JJ JJ O
artery NN NN O
bypass NN NN O
surgery NN NN O
patients NNS NNS O
, , , O
there EX EX O
were VBD VBD O
more JJR JJR O
acute JJ JJ O
myocardial NN NN O
infarctions NNS NNS O
and CC CC O
renal JJ JJ O
dysfunction NN NN O
in IN IN O
Group NNP NNP O
A DT DT O
( ( ( O
5 CD CD O
. . . O
8 CD CD O
% NN NN O
vs NNS NNS O
2 CD CD O
. . . O
0 CD CD O
% NN NN O
, , , O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
027 CD CD O
; : : O
22 CD CD O
. . . O
5 CD CD O
% NN NN O
vs NNS NNS O
15 CD CD O
. . . O
2 CD CD O
% NN NN O
, , , O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
036 CD CD O
, , , O
respectively RB RB O
) ) ) O
. . . O

The DT DT O
1 CD CD O
- : : O
yr NN NN O
mortality NN NN O
was VBD VBD O
significantly RB RB O
higher JJR JJR O
after IN IN O
aprotinin NN NN O
treatment NN NN O
in IN IN O
the DT DT O
high JJ JJ O
risk NN NN O
surgery NN NN O
group NN NN O
( ( ( O
17 CD CD O
. . . O
7 CD CD O
% NN NN O
vs NNS NNS O
9 CD CD O
. . . O
8 CD CD O
% NN NN O
, , , O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
034 CD CD O
) ) ) O
. . . O

CONCLUSION NNP NNP O
: : : O
Both DT DT O
antifibrinolytic JJ JJ O
drugs NNS NNS O
bear VBP VBP O
the DT DT O
risk NN NN O
of IN IN O
adverse JJ JJ O
outcome NN NN O
depending VBG VBG O
on IN IN O
the DT DT O
type NN NN O
of IN IN O
cardiac JJ JJ O
surgery NN NN O
. . . O

Administration NNP NNP O
of IN IN O
aprotinin NN NN O
should MD MD O
be VB VB O
avoided VBN VBN O
in IN IN O
coronary JJ JJ O
artery NN NN O
bypass NN NN O
graft NN NN O
and CC CC O
high JJ JJ O
risk NN NN O
patients NNS NNS O
, , , O
whereas IN IN O
administration NN NN O
of IN IN O
tranexamic JJ JJ B-CHEM
acid NN NN I-CHEM
is VBZ VBZ O
not RB RB O
recommended VBN VBN O
in IN IN O
valve NN NN O
surgery NN NN O
. . . O

Delirium NNP NNP O
in IN IN O
an DT DT O
elderly JJ JJ O
woman NN NN O
possibly RB RB O
associated VBN VBN O
with IN IN O
administration NN NN O
of IN IN O
misoprostol NN NN B-CHEM
. . . O

Misoprostol NNP NNP B-CHEM
has VBZ VBZ O
been VBN VBN O
associated VBN VBN O
with IN IN O
adverse JJ JJ O
reactions NNS NNS O
, , , O
including VBG VBG O
gastrointestinal JJ JJ O
symptoms NNS NNS O
, , , O
gynecologic JJ JJ O
problems NNS NNS O
, , , O
and CC CC O
headache NN NN O
. . . O

Changes NNS NNS O
in IN IN O
mental JJ JJ O
status NN NN O
, , , O
however RB RB O
, , , O
have VBP VBP O
not RB RB O
been VBN VBN O
reported VBN VBN O
. . . O

We PRP PRP O
present JJ JJ O
a DT DT O
case NN NN O
in IN IN O
which WDT WDT O
an DT DT O
89 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
woman NN NN O
in IN IN O
a DT DT O
long JJ JJ O
- - - O
term NN NN O
care NN NN O
facility NN NN O
became VBD VBD O
confused VBN VBN O
after IN IN O
the DT DT O
initiation NN NN O
of IN IN O
misoprostol NN NN B-CHEM
therapy NN NN O
. . . O

The DT DT O
patient NN NN O
' '' '' O
s VBZ VBZ O
change NN NN O
in IN IN O
mental JJ JJ O
status NN NN O
was VBD VBD O
first RB RB O
reported VBD VBD O
nine CD CD O
days NNS NNS O
after IN IN O
the DT DT O
initiation NN NN O
of IN IN O
therapy NN NN O
. . . O

Her PRP$ PRP$ O
delirium NN NN O
significantly RB RB O
improved VBD VBD O
after IN IN O
misoprostol NN NN B-CHEM
was VBD VBD O
discontinued VBN VBN O
and CC CC O
her PRP$ PRP$ O
mental JJ JJ O
status NN NN O
returned VBD VBD O
to TO TO O
normal JJ JJ O
within IN IN O
a DT DT O
week NN NN O
. . . O

Because IN IN O
no DT DT O
other JJ JJ O
factors NNS NNS O
related VBN VBN O
to TO TO O
this DT DT O
patient NN NN O
changed VBN VBN O
significantly RB RB O
, , , O
the DT DT O
delirium NN NN O
experienced VBN VBN O
by IN IN O
this DT DT O
patient NN NN O
possibly RB RB O
resulted VBD VBD O
from IN IN O
misoprostol NN NN B-CHEM
therapy NN NN O
. . . O

The DT DT O
biological JJ JJ O
properties NNS NNS O
of IN IN O
the DT DT O
optical JJ JJ O
isomers NNS NNS O
of IN IN O
propranolol NN NN B-CHEM
and CC CC O
their PRP$ PRP$ O
effects NNS NNS O
on IN IN O
cardiac JJ JJ O
arrhythmias NNS NNS O
. . . O

1 CD CD O
. . . O

The DT DT O
optical JJ JJ O
isomers NNS NNS O
of IN IN O
propranolol NN NN B-CHEM
have VBP VBP O
been VBN VBN O
compared VBN VBN O
for IN IN O
their PRP$ PRP$ O
beta NN NN O
- : : O
blocking NN NN O
and CC CC O
antiarrhythmic JJ JJ O
activities NNS NNS O
. . . O
2 CD CD O
. . . O

In IN IN O
blocking VBG VBG O
the DT DT O
positive JJ JJ O
inotropic NN NN O
and CC CC O
chronotropic NN NN O
responses NNS NNS O
to TO TO O
isoprenaline VB VB B-CHEM
, , , O
( ( ( O
+ NN NN O
) ) ) O
- : : O
propranolol NN NN B-CHEM
had VBD VBD O
less JJR JJR O
than IN IN O
one CD CD O
hundredth NN NN O
the DT DT O
potency NN NN O
of IN IN O
( ( ( O
- : : O
) ) ) O
- : : O
propranolol NN NN B-CHEM
. . . O

At IN IN O
dose NN NN O
levels NNS NNS O
of IN IN O
( ( ( O
+ NN NN O
) ) ) O
- : : O
propranolol NN NN B-CHEM
which WDT WDT O
attenuated VBD VBD O
the DT DT O
responses NNS NNS O
to TO TO O
isoprenaline VB VB B-CHEM
, , , O
there EX EX O
was VBD VBD O
a DT DT O
significant JJ JJ O
prolongation NN NN O
of IN IN O
the DT DT O
PR NNP NNP O
interval NN NN O
of IN IN O
the DT DT O
electrocardiogram NN NN O
. . . O
3 CD CD O
. . . O

The DT DT O
metabolic JJ JJ O
responses NNS NNS O
to TO TO O
isoprenaline VB VB B-CHEM
in IN IN O
dogs NNS NNS O
( ( ( O
an DT DT O
increase NN NN O
in IN IN O
circulating VBG VBG O
glucose NN NN B-CHEM
, , , O
lactate NN NN B-CHEM
and CC CC O
free JJ JJ O
fatty NN NN B-CHEM
acids NNS NNS I-CHEM
) ) ) O
were VBD VBD O
all DT DT O
blocked VBN VBN O
by IN IN O
( ( ( O
- : : O
) ) ) O
- : : O
propranolol NN NN B-CHEM
. . . O

( ( ( O
+ NN NN O
) ) ) O
- : : O
Propranolol NNP NNP B-CHEM
had VBD VBD O
no DT DT O
effect NN NN O
on IN IN O
fatty JJ JJ B-CHEM
acid NN NN I-CHEM
mobilization NN NN O
but CC CC O
significantly RB RB O
reduced VBD VBD O
the DT DT O
increments NNS NNS O
in IN IN O
both DT DT O
lactate NN NN B-CHEM
and CC CC O
glucose NN NN B-CHEM
. . . O
4 CD CD O
. . . O

Both DT DT O
isomers NNS NNS O
of IN IN O
propranolol NN NN B-CHEM
possessed VBD VBD O
similar JJ JJ O
depressant NN NN O
potency NN NN O
on IN IN O
isolated VBN VBN O
atrial JJ JJ O
muscle NN NN O
taken VBN VBN O
from IN IN O
guinea NN NN O
- - - O
pigs NNS NNS O
. . . O
5 CD CD O
. . . O

The DT DT O
isomers NNS NNS O
of IN IN O
propranolol NN NN B-CHEM
exhibited VBD VBD O
similar JJ JJ O
local JJ JJ O
anaesthetic JJ JJ O
potencies NNS NNS O
on IN IN O
an DT DT O
isolated VBN VBN O
frog NN NN O
nerve NN NN O
preparation NN NN O
at IN IN O
a DT DT O
level NN NN O
approximately RB RB O
three CD CD O
times NNS NNS O
that IN IN O
of IN IN O
procaine NN NN B-CHEM
. . . O

The DT DT O
racemic JJ JJ O
compound NN NN O
was VBD VBD O
significantly RB RB O
less RBR RBR O
potent JJ JJ O
than IN IN O
either DT DT O
isomer NN NN O
. . . O
6 CD CD O
. . . O

Both DT DT O
isomers NNS NNS O
of IN IN O
propranolol NN NN B-CHEM
were VBD VBD O
capable JJ JJ O
of IN IN O
preventing VBG VBG O
adrenaline NN NN B-CHEM
- - - O
induced JJ JJ O
cardiac NN NN O
arrhythmias NNS NNS O
in IN IN O
cats NNS NNS O
anaesthetized VBN VBN O
with IN IN O
halothane NN NN B-CHEM
, , , O
but CC CC O
the DT DT O
mean JJ JJ O
dose NN NN O
of IN IN O
( ( ( O
- : : O
) ) ) O
- : : O
propranolol NN NN B-CHEM
was VBD VBD O
0 CD CD O
. . . O
09 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
02 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
whereas IN IN O
that DT DT O
of IN IN O
( ( ( O
+ NN NN O
) ) ) O
- : : O
propranolol NN NN B-CHEM
was VBD VBD O
4 CD CD O
. . . O
2 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
2 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
. . . O

At IN IN O
the DT DT O
effective JJ JJ O
dose NN NN O
level NN NN O
of IN IN O
( ( ( O
+ NN NN O
) ) ) O
- : : O
propranolol NN NN B-CHEM
there EX EX O
was VBD VBD O
a DT DT O
significant JJ JJ O
prolongation NN NN O
of IN IN O
the DT DT O
PR NNP NNP O
interval NN NN O
of IN IN O
the DT DT O
electrocardiogram NN NN O
. . . O

Blockade NNP NNP O
of IN IN O
arrhythmias NNS NNS O
with IN IN O
both DT DT O
isomers NNS NNS O
was VBD VBD O
surmountable JJ JJ O
by IN IN O
increasing VBG VBG O
the DT DT O
dose NN NN O
of IN IN O
adrenaline NN NN B-CHEM
. . . O
7 CD CD O
. . . O

Both DT DT O
isomers NNS NNS O
of IN IN O
propranolol NN NN B-CHEM
were VBD VBD O
also RB RB O
capable JJ JJ O
of IN IN O
reversing VBG VBG O
ventricular NN NN O
tachycardia NNS NNS O
caused VBN VBN O
by IN IN O
ouabain NN NN B-CHEM
in IN IN O
anaesthetized JJ JJ O
cats NNS NNS O
and CC CC O
dogs NNS NNS O
. . . O

The DT DT O
dose NN NN O
of IN IN O
( ( ( O
- : : O
) ) ) O
- : : O
propranolol NN NN B-CHEM
was VBD VBD O
significantly RB RB O
smaller JJR JJR O
than IN IN O
that DT DT O
of IN IN O
( ( ( O
+ NN NN O
) ) ) O
- : : O
propranolol NN NN B-CHEM
in IN IN O
both DT DT O
species NNS NNS O
but CC CC O
much RB RB O
higher JJR JJR O
than IN IN O
that DT DT O
required VBN VBN O
to TO TO O
produce VB VB O
evidence NN NN O
of IN IN O
beta NN NN O
- - - O
blockade NN NN O
. . . O
8 CD CD O
. . . O

The DT DT O
implications NNS NNS O
of IN IN O
these DT DT O
results NNS NNS O
are VBP VBP O
discussed VBN VBN O
. . . O

Topotecan NNP NNP B-CHEM
in IN IN O
combination NN NN O
with IN IN O
radiotherapy NN NN O
in IN IN O
unresectable JJ JJ O
glioblastoma NN NN O
: : : O
a DT DT O
phase NN NN O
2 CD CD O
study NN NN O
. . . O

Improving NNP NNP O
glioblastoma NN NN O
multiforme NN NN O
( ( ( O
GBM NNP NNP O
) ) ) O
treatment NN NN O
with IN IN O
radio NN NN O
- - - O
chemotherapy NN NN O
remains VBZ VBZ O
a DT DT O
challenge NN NN O
. . . O

Topotecan NNP NNP B-CHEM
is VBZ VBZ O
an DT DT O
attractive JJ JJ O
option NN NN O
as IN IN O
it PRP PRP O
exhibits VBZ VBZ O
growth NN NN O
inhibition NN NN O
of IN IN O
human JJ JJ O
glioma NN NN O
as RB RB O
well RB RB O
as IN IN O
brain NN NN O
penetration NN NN O
. . . O

The DT DT O
present JJ JJ O
study NN NN O
assessed VBD VBD O
the DT DT O
combination NN NN O
of IN IN O
radiotherapy NN NN O
( ( ( O
60 CD CD O
Gy NNP NNP O
/ NN NN O
30 CD CD O
fractions NNS NNS O
/ NN NN O
40 CD CD O
days NNS NNS O
) ) ) O
and CC CC O
topotecan JJ JJ B-CHEM
( ( ( O
0 CD CD O
. . . O
9 CD CD O
mg NN NN O
/ NN NN O
m NN NN O
( ( ( O
2 CD CD O
) ) ) O
/ NN NN O
day NN NN O
on IN IN O
days NNS NNS O
1 CD CD O
- : : O
5 CD CD O
on IN IN O
weeks NNS NNS O
1 CD CD O
, , , O
3 CD CD O
and CC CC O
5 CD CD O
) ) ) O
in IN IN O
50 CD CD O
adults NNS NNS O
with IN IN O
histologically RB RB O
proven VBN VBN O
and CC CC O
untreated JJ JJ O
GBM NNP NNP O
. . . O

The DT DT O
incidence NN NN O
of IN IN O
non NN NN O
- - - O
hematological JJ JJ O
toxicities NNS NNS O
was VBD VBD O
low JJ JJ O
and CC CC O
grade NN NN O
3 CD CD O
- : : O
4 CD CD O
hematological JJ JJ O
toxicities NNS NNS O
were VBD VBD O
reported VBN VBN O
in IN IN O
20 CD CD O
patients NNS NNS O
( ( ( O
mainly RB RB O
lymphopenia NN NN O
and CC CC O
neutropenia NN NN O
) ) ) O
. . . O

Partial NNP NNP O
response NN NN O
and CC CC O
stabilization NN NN O
rates NNS NNS O
were VBD VBD O
2 CD CD O
% NN NN O
and CC CC O
32 CD CD O
% NN NN O
, , , O
respectively RB RB O
, , , O
with IN IN O
an DT DT O
overall JJ JJ O
time NN NN O
to TO TO O
progression NN NN O
of IN IN O
12 CD CD O
weeks NNS NNS O
. . . O

One CD CD O
- - - O
year NN NN O
overall JJ JJ O
survival NN NN O
( ( ( O
OS NNP NNP O
) ) ) O
rate NN NN O
was VBD VBD O
42 CD CD O
% NN NN O
, , , O
with IN IN O
a DT DT O
median JJ JJ O
OS NNP NNP O
of IN IN O
40 CD CD O
weeks NNS NNS O
. . . O

Topotecan NNP NNP B-CHEM
in IN IN O
combination NN NN O
with IN IN O
radiotherapy NN NN O
was VBD VBD O
well RB RB O
tolerated VBN VBN O
. . . O

However RB RB O
, , , O
while IN IN O
response NN NN O
and CC CC O
stabilization NN NN O
concerned VBN VBN O
one CD CD O
- - - O
third NN NN O
of IN IN O
the DT DT O
patients NNS NNS O
, , , O
the DT DT O
study NN NN O
did VBD VBD O
not RB RB O
show VB VB O
increased VBN VBN O
benefits NNS NNS O
in IN IN O
terms NNS NNS O
of IN IN O
survival NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
unresectable JJ JJ O
GBM NNP NNP O
. . . O

Long JJ JJ O
- - - O
term NN NN O
lithium NN NN B-CHEM
therapy NN NN O
leading VBG VBG O
to TO TO O
hyperparathyroidism NN NN O
: : : O
a DT DT O
case NN NN O
report NN NN O
. . . O

PURPOSE NNP NNP O
: : : O
This DT DT O
paper NN NN O
reviews NN NN O
the DT DT O
effect NN NN O
of IN IN O
chronic JJ JJ O
lithium NN NN B-CHEM
therapy NN NN O
on IN IN O
serum NN NN O
calcium NN NN B-CHEM
level NN NN O
and CC CC O
parathyroid VB VB O
glands NNS NNS O
, , , O
its PRP$ PRP$ O
pathogenesis NNS NNS O
, , , O
and CC CC O
treatment NN NN O
options NNS NNS O
. . . O

We PRP PRP O
examined VBD VBD O
the DT DT O
case NN NN O
of IN IN O
a DT DT O
lithium NN NN B-CHEM
- - - O
treated VBN VBN O
patient NN NN O
who WP WP O
had VBD VBD O
recurrent JJ JJ O
hypercalcemia NN NN O
to TO TO O
better JJR JJR O
understand VB VB O
the DT DT O
disease NN NN O
process NN NN O
. . . O

CONCLUSION NNP NNP O
: : : O
Primary JJ JJ O
hyperparathyroidism NN NN O
is VBZ VBZ O
a DT DT O
rare JJ JJ O
but CC CC O
potentially RB RB O
life NN NN O
- : : O
threatening VBG VBG O
side NN NN O
effect NN NN O
of IN IN O
long JJ JJ O
- - - O
term NN NN O
lithium NN NN B-CHEM
therapy NN NN O
. . . O

Careful NNP NNP O
patient NN NN O
selection NN NN O
and CC CC O
long JJ JJ O
- - - O
term NN NN O
follow VB VB O
- : : O
up RP RP O
can MD MD O
reduce VB VB O
morbidity NN NN O
. . . O

PRACTICAL NNP NNP O
IMPLICATIONS NNP NNP O
: : : O
As RB RB O
much JJ JJ O
as IN IN O
15 CD CD O
% NN NN O
of IN IN O
lithium NN NN B-CHEM
- - - O
treated VBN VBN O
patients NNS NNS O
become VBP VBP O
hypercalcemic JJ JJ O
. . . O

By IN IN O
routinely RB RB O
monitoring VBG VBG O
serum NN NN O
calcium NN NN B-CHEM
levels NNS NNS O
, , , O
healthcare NN NN O
providers NNS NNS O
can MD MD O
improve VB VB O
the DT DT O
quality NN NN O
of IN IN O
life NN NN O
of IN IN O
this DT DT O
patient NN NN O
group NN NN O
. . . O

Comparison NNP NNP O
of IN IN O
laryngeal NN NN O
mask NN NN O
with IN IN O
endotracheal NN NN O
tube NN NN O
for IN IN O
anesthesia NN NN O
in IN IN O
endoscopic JJ JJ O
sinus NN NN O
surgery NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
The DT DT O
purpose NN NN O
of IN IN O
this DT DT O
study NN NN O
was VBD VBD O
to TO TO O
compare VB VB O
surgical JJ JJ O
conditions NNS NNS O
, , , O
including VBG VBG O
the DT DT O
amount NN NN O
of IN IN O
intraoperative JJ JJ O
bleeding NN NN O
as RB RB O
well RB RB O
as IN IN O
intraoperative JJ JJ O
blood NN NN O
pressure NN NN O
, , , O
during IN IN O
functional JJ JJ O
endoscopic NN NN O
sinus NN NN O
surgery NN NN O
( ( ( O
FESS NNP NNP O
) ) ) O
using VBG VBG O
flexible JJ JJ O
reinforced VBN VBN O
laryngeal NN NN O
mask NN NN O
airway NN NN O
( ( ( O
FRLMA NNP NNP O
) ) ) O
versus CC CC O
endotracheal JJ JJ O
tube NN NN O
( ( ( O
ETT NNP NNP O
) ) ) O
in IN IN O
maintaining VBG VBG O
controlled JJ JJ O
hypotension NN NN O
anesthesia NN NN O
induced VBN VBN O
by IN IN O
propofol NN NN B-CHEM
- - - O
remifentanil NN NN B-CHEM
total NN NN O
i NNP NNP O
. . . O
v NN NN O
. . . O
anesthesia NN NN O
( ( ( O
TIVA NNP NNP O
) ) ) O
. . . O

METHODS NNP NNP O
: : : O
Sixty NNP NNP O
normotensive JJ JJ O
American JJ JJ O
Society NNP NNP O
of IN IN O
Anesthesiologists NNP NNP O
I PRP PRP O
- : : O
II NNP NNP O
adult NN NN O
patients NNS NNS O
undergoing VBG VBG O
FESS NNP NNP O
under IN IN O
controlled JJ JJ O
hypotension NN NN O
anesthesia NN NN O
caused VBN VBN O
by IN IN O
propofol NN NN B-CHEM
- - - O
remifentanil NN NN B-CHEM
- - - O
TIVA NNP NNP O
were VBD VBD O
randomly RB RB O
assigned VBN VBN O
into IN IN O
two CD CD O
groups NNS NNS O
: : : O
group NN NN O
I PRP PRP O
, , , O
FRLMA NNP NNP O
; : : O
group NN NN O
II NNP NNP O
, , , O
ETT NNP NNP O
. . . O

Hemorrhage NNP NNP O
was VBD VBD O
measured VBN VBN O
and CC CC O
the DT DT O
visibility NN NN O
of IN IN O
the DT DT O
operative JJ JJ O
field NN NN O
was VBD VBD O
evaluated VBN VBN O
according VBG VBG O
to TO TO O
a DT DT O
six CD CD O
- - - O
point NN NN O
scale NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Controlled NNP NNP O
hypotension NN NN O
was VBD VBD O
achieved VBN VBN O
within IN IN O
a DT DT O
shorter JJR JJR O
period NN NN O
using VBG VBG O
laryngeal NN NN O
mask NN NN O
using VBG VBG O
lower JJR JJR O
rates NNS NNS O
of IN IN O
remifentanil NN NN B-CHEM
infusion NN NN O
and CC CC O
lower JJR JJR O
total NN NN O
dose NN NN O
of IN IN O
remifentanil NN NN B-CHEM
. . . O

CONCLUSION NNP NNP O
: : : O
In IN IN O
summary NN NN O
, , , O
our PRP$ PRP$ O
results NNS NNS O
indicate VBP VBP O
that IN IN O
airway NN NN O
management NN NN O
using VBG VBG O
FRLMA NNP NNP O
during IN IN O
controlled VBN VBN O
hypotension NN NN O
anesthesia NN NN O
provided VBN VBN O
better JJR JJR O
surgical JJ JJ O
conditions NNS NNS O
in IN IN O
terms NNS NNS O
of IN IN O
quality NN NN O
of IN IN O
operative JJ JJ O
field NN NN O
and CC CC O
blood NN NN O
loss NN NN O
and CC CC O
allowed VBD VBD O
for IN IN O
convenient NN NN O
induced JJ JJ O
hypotension NN NN O
with IN IN O
low JJ JJ O
doses NNS NNS O
of IN IN O
remifentanil NN NN B-CHEM
during IN IN O
TIVA NNP NNP O
in IN IN O
patients NNS NNS O
undergoing VBG VBG O
FESS NNP NNP O
. . . O

Nonalcoholic NNP NNP O
fatty JJ JJ O
liver NN NN O
disease NN NN O
during IN IN O
valproate NN NN B-CHEM
therapy NN NN O
. . . O

Valproic NNP NNP B-CHEM
acid NN NN I-CHEM
( ( ( O
VPA NNP NNP B-CHEM
) ) ) O
is VBZ VBZ O
effective JJ JJ O
for IN IN O
the DT DT O
treatment NN NN O
of IN IN O
many JJ JJ O
types NNS NNS O
of IN IN O
epilepsy NN NN O
, , , O
but CC CC O
its PRP$ PRP$ O
use NN NN O
can MD MD O
be VB VB O
associated VBN VBN O
with IN IN O
an DT DT O
increase NN NN O
in IN IN O
body NN NN O
weight NN NN O
. . . O

We PRP PRP O
report VBP VBP O
a DT DT O
case NN NN O
of IN IN O
nonalcoholic JJ JJ O
fatty NN NN O
liver NN NN O
disease NN NN O
( ( ( O
NAFLD NNP NNP O
) ) ) O
arising VBG VBG O
in IN IN O
a DT DT O
child NN NN O
who WP WP O
developed VBD VBD O
obesity NN NN O
during IN IN O
VPA NNP NNP B-CHEM
treatment NN NN O
. . . O

Laboratory NNP NNP O
data NNS NNS O
revealed VBD VBD O
hyperinsulinemia NN NN O
with IN IN O
insulin NN NN O
resistance NN NN O
. . . O

After IN IN O
the DT DT O
withdrawal NN NN O
of IN IN O
VPA NNP NNP B-CHEM
therapy NN NN O
, , , O
our PRP$ PRP$ O
patient NN NN O
showed VBD VBD O
a DT DT O
significant JJ JJ O
weight NN NN O
loss NN NN O
, , , O
a DT DT O
decrease NN NN O
of IN IN O
body NN NN O
mass NN NN O
index NN NN O
, , , O
and CC CC O
normalization NN NN O
of IN IN O
metabolic JJ JJ O
and CC CC O
endocrine JJ JJ O
parameters NNS NNS O
; : : O
moreover RB RB O
, , , O
ultrasound JJ JJ O
measurements NNS NNS O
showed VBD VBD O
a DT DT O
complete JJ JJ O
normalization NN NN O
. . . O

The DT DT O
present JJ JJ O
case NN NN O
suggests VBZ VBZ O
that DT DT O
obesity NN NN O
, , , O
hyperinsulinemia NN NN O
, , , O
insulin NN NN O
resistance NN NN O
, , , O
and CC CC O
long JJ JJ O
- - - O
term NN NN O
treatment NN NN O
with IN IN O
VPA NNP NNP B-CHEM
may MD MD O
be VB VB O
all DT DT O
associated VBN VBN O
with IN IN O
the DT DT O
development NN NN O
of IN IN O
NAFLD NNP NNP O
; : : O
this DT DT O
side NN NN O
effect NN NN O
is VBZ VBZ O
reversible JJ JJ O
after IN IN O
VPA NNP NNP B-CHEM
withdrawal NN NN O
. . . O

Carbimazole NNP NNP B-CHEM
induced VBD VBD O
ANCA NNP NNP O
positive JJ JJ O
vasculitis NN NN O
. . . O

Anti NNP NNP B-CHEM
- : : I-CHEM
thyroid NN NN I-CHEM
drugs NNS NNS I-CHEM
, , , O
like IN IN O
carbimazole NN NN B-CHEM
and CC CC O
propylthiouracil NN NN B-CHEM
( ( ( O
PTU NNP NNP B-CHEM
) ) ) O
are VBP VBP O
commonly RB RB O
prescribed VBN VBN O
for IN IN O
the DT DT O
treatment NN NN O
of IN IN O
hyperthyroidism NN NN O
. . . O

One PRP PRP O
should MD MD O
be VB VB O
aware JJ JJ O
of IN IN O
the DT DT O
side NN NN O
effects NNS NNS O
of IN IN O
antithyroid NN NN B-CHEM
medications NNS NNS I-CHEM
. . . O

Antineutrophil NNP NNP O
cytoplasmic JJ JJ O
antibody NN NN O
( ( ( O
ANCA NNP NNP O
) ) ) O
- : : O
- - - O
associated JJ JJ O
vasculitis NNS NNS O
is VBZ VBZ O
a DT DT O
potentially RB RB O
life NN NN O
- : : O
threatening VBG VBG O
adverse JJ JJ O
effect NN NN O
of IN IN O
antithyroidmedications NNS NNS B-CHEM
. . . O

We PRP PRP O
report VBP VBP O
a DT DT O
patient NN NN O
with IN IN O
Graves NNP NNP O
' POS POS O
disease NN NN O
who WP WP O
developed VBD VBD O
ANCA NNP NNP O
positive JJ JJ O
carbimazole NN NN B-CHEM
induced JJ JJ O
vasculitis NN NN O
. . . O

The DT DT O
episode NN NN O
was VBD VBD O
characterized VBN VBN O
by IN IN O
a DT DT O
vasculitic JJ JJ O
skin NN NN O
rash NN NN O
associated VBN VBN O
with IN IN O
large JJ JJ O
joint JJ JJ O
arthritis NN NN O
, , , O
pyrexia NN NN O
and CC CC O
parotiditis NN NN O
but CC CC O
no DT DT O
renal NN NN O
or CC CC O
pulmonary JJ JJ O
involvement NN NN O
. . . O

He PRP PRP O
was VBD VBD O
referred VBN VBN O
to TO TO O
us PRP PRP O
for IN IN O
neurological JJ JJ O
evaluation NN NN O
because IN IN O
he PRP PRP O
had VBD VBD O
difficulty NN NN O
in IN IN O
getting VBG VBG O
up RP RP O
from IN IN O
squatting VBG VBG O
position NN NN O
and CC CC O
was VBD VBD O
suspected VBN VBN O
to TO TO O
have VB VB O
myositis NNS NNS O
. . . O

Carbimazole NNP NNP B-CHEM
and CC CC O
methimazole NN NN B-CHEM
have VBP VBP O
a DT DT O
lower JJR JJR O
incidence NN NN O
of IN IN O
reported VBD VBD O
ANCA NNP NNP O
positive JJ JJ O
side NN NN O
effects NNS NNS O
than IN IN O
PUT NNP NNP O
. . . O

To TO TO O
the DT DT O
best JJS JJS O
of IN IN O
our PRP$ PRP$ O
knowledge NN NN O
this DT DT O
is VBZ VBZ O
the DT DT O
first JJ JJ O
ANCA NNP NNP O
positive JJ JJ O
carbimazole NN NN B-CHEM
induced JJ JJ O
vasculitis NNS NNS O
case NN NN O
reported VBD VBD O
from IN IN O
India NNP NNP O
. . . O

Aspirin NNP NNP B-CHEM
for IN IN O
the DT DT O
primary JJ JJ O
prevention NN NN O
of IN IN O
cardiovascular JJ JJ O
events NNS NNS O
: : : O
an DT DT O
update NN NN O
of IN IN O
the DT DT O
evidence NN NN O
for IN IN O
the DT DT O
U NNP NNP O
. . . O
S NNP NNP O
. . . O

Preventive NNP NNP O
Services NNPS NNPS O
Task NNP NNP O
Force NNP NNP O
. . . O

BACKGROUND NNP NNP O
: : : O
Coronary JJ JJ O
heart NN NN O
disease NN NN O
and CC CC O
cerebrovascular NN NN O
disease NN NN O
are VBP VBP O
leading VBG VBG O
causes NNS NNS O
of IN IN O
death NN NN O
in IN IN O
the DT DT O
United NNP NNP O
States NNPS NNPS O
. . . O

In IN IN O
2002 CD CD O
, , , O
the DT DT O
U NNP NNP O
. . . O
S NNP NNP O
. . . O

Preventive NNP NNP O
Services NNPS NNPS O
Task NNP NNP O
Force NNP NNP O
( ( ( O
USPSTF NNP NNP O
) ) ) O
strongly RB RB O
recommended VBN VBN O
that IN IN O
clinicians NNS NNS O
discuss VBP VBP O
aspirin NN NN B-CHEM
with IN IN O
adults NNS NNS O
who WP WP O
are VBP VBP O
at IN IN O
increased VBN VBN O
risk NN NN O
for IN IN O
coronary JJ JJ O
heart NN NN O
disease NN NN O
. . . O

PURPOSE NNP NNP O
: : : O
To TO TO O
determine VB VB O
the DT DT O
benefits NNS NNS O
and CC CC O
harms NNS NNS O
of IN IN O
taking VBG VBG O
aspirin NN NN B-CHEM
for IN IN O
the DT DT O
primary JJ JJ O
prevention NN NN O
of IN IN O
myocardial NN NN O
infarctions NNS NNS O
, , , O
strokes NNS NNS O
, , , O
and CC CC O
death NN NN O
. . . O

DATA NNP NNP O
SOURCES NNS NNS O
: : : O
MEDLINE NNP NNP O
and CC CC O
Cochrane NNP NNP O
Library NNP NNP O
( ( ( O
search NN NN O
dates NNS NNS O
, , , O
1 CD CD O
January NNP NNP O
2001 CD CD O
to TO TO O
28 CD CD O
August NNP NNP O
2008 CD CD O
) ) ) O
, , , O
recent JJ JJ O
systematic JJ JJ O
reviews NN NN O
, , , O
reference NN NN O
lists NNS NNS O
of IN IN O
retrieved VBN VBN O
articles NNS NNS O
, , , O
and CC CC O
suggestions NNS NNS O
from IN IN O
experts NNS NNS O
. . . O

STUDY NNP NNP O
SELECTION NN NN O
: : : O
English NNP NNP O
- - - O
language NN NN O
randomized JJ JJ O
, , , O
controlled VBN VBN O
trials NNS NNS O
( ( ( O
RCTs NNP NNP O
) ) ) O
; : : O
case NN NN O
- : : O
control NN NN O
studies NNS NNS O
; : : O
meta NN NN O
- : : O
analyses NNS NNS O
; : : O
and CC CC O
systematic JJ JJ O
reviews NNS NNS O
of IN IN O
aspirin NN NN B-CHEM
versus CC CC O
control NN NN O
for IN IN O
the DT DT O
primary JJ JJ O
prevention NN NN O
of IN IN O
cardiovascular JJ JJ O
disease NN NN O
( ( ( O
CVD NNP NNP O
) ) ) O
were VBD VBD O
selected VBN VBN O
to TO TO O
answer VB VB O
the DT DT O
following VBG VBG O
questions NNS NNS O
: : : O
Does VBZ VBZ O
aspirin NN NN B-CHEM
decrease VB VB O
coronary JJ JJ O
heart NN NN O
events NNS NNS O
, , , O
strokes NNS NNS O
, , , O
death NN NN O
from IN IN O
coronary JJ JJ O
heart NN NN O
events NNS NNS O
or CC CC O
stroke NN NN O
, , , O
or CC CC O
all DT DT O
- - - O
cause NN NN O
mortality NN NN O
in IN IN O
adults NNS NNS O
without IN IN O
known VBN VBN O
CVD NNP NNP O
? . . O

Does VBZ VBZ O
aspirin NN NN B-CHEM
increase VB VB O
gastrointestinal NN NN O
bleeding NN NN O
or CC CC O
hemorrhagic JJ JJ O
strokes NNS NNS O
? . . O

DATA NNP NNP O
EXTRACTION NNP NNP O
: : : O
All DT DT O
studies NNS NNS O
were VBD VBD O
reviewed VBN VBN O
, , , O
abstracted VBN VBN O
, , , O
and CC CC O
rated VBD VBD O
for IN IN O
quality NN NN O
by IN IN O
using VBG VBG O
predefined JJ JJ O
USPSTF NNP NNP O
criteria NNS NNS O
. . . O

DATA NNP NNP O
SYNTHESIS NNP NNP O
: : : O
New NNP NNP O
evidence NN NN O
from IN IN O
1 CD CD O
good JJ JJ O
- - - O
quality NN NN O
RCT NNP NNP O
, , , O
1 CD CD O
good JJ JJ O
- - - O
quality NN NN O
meta NN NN O
- : : O
analysis NN NN O
, , , O
and CC CC O
2 CD CD O
fair JJ JJ O
- : : O
quality NN NN O
subanalyses NNS NNS O
of IN IN O
RCTs NNP NNP O
demonstrates VBZ VBZ O
that IN IN O
aspirin NN NN B-CHEM
use NN NN O
reduces VBZ VBZ O
the DT DT O
number NN NN O
of IN IN O
CVD NNP NNP O
events NNS NNS O
in IN IN O
patients NNS NNS O
without IN IN O
known VBN VBN O
CVD NNP NNP O
. . . O

Men NN NN O
in IN IN O
these DT DT O
studies NNS NNS O
experienced VBN VBN O
fewer JJR JJR O
myocardial NN NN O
infarctions NNS NNS O
and CC CC O
women NNS NNS O
experienced VBD VBD O
fewer JJR JJR O
ischemic JJ JJ O
strokes NNS NNS O
. . . O

Aspirin NNP NNP B-CHEM
does VBZ VBZ O
not RB RB O
seem VB VB O
to TO TO O
affect VB VB O
CVD NNP NNP O
mortality NN NN O
or CC CC O
all DT DT O
- - - O
cause NN NN O
mortality NN NN O
in IN IN O
either DT DT O
men NNS NNS O
or CC CC O
women NNS NNS O
. . . O

The DT DT O
use NN NN O
of IN IN O
aspirin NN NN B-CHEM
for IN IN O
primary JJ JJ O
prevention NN NN O
increases NNS NNS O
the DT DT O
risk NN NN O
for IN IN O
major JJ JJ O
bleeding JJ JJ O
events NNS NNS O
, , , O
primarily RB RB O
gastrointestinal JJ JJ O
bleeding VBG VBG O
events NNS NNS O
, , , O
in IN IN O
both DT DT O
men NNS NNS O
and CC CC O
women NNS NNS O
. . . O

Men NN NN O
have VBP VBP O
an DT DT O
increased VBN VBN O
risk NN NN O
for IN IN O
hemorrhagic NN NN O
strokes NNS NNS O
with IN IN O
aspirin NN NN B-CHEM
use NN NN O
. . . O

A DT DT O
new JJ JJ O
RCT NNP NNP O
and CC CC O
meta NN NN O
- - - O
analysis NN NN O
suggest NN NN O
that IN IN O
the DT DT O
risk NN NN O
for IN IN O
hemorrhagic NN NN O
strokes NNS NNS O
in IN IN O
women NNS NNS O
is VBZ VBZ O
not RB RB O
statistically RB RB O
significantly RB RB O
increased VBN VBN O
. . . O

LIMITATIONS NNP NNP O
: : : O
New NNP NNP O
evidence NN NN O
on IN IN O
aspirin NN NN B-CHEM
for IN IN O
the DT DT O
primary JJ JJ O
prevention NN NN O
of IN IN O
CVD NNP NNP O
is VBZ VBZ O
limited VBN VBN O
. . . O

The DT DT O
dose NN NN O
of IN IN O
aspirin NN NN B-CHEM
used VBN VBN O
in IN IN O
the DT DT O
RCTs NNP NNP O
varied VBD VBD O
, , , O
which WDT WDT O
prevented VBD VBD O
the DT DT O
estimation NN NN O
of IN IN O
the DT DT O
most RBS RBS O
appropriate JJ JJ O
dose NN NN O
for IN IN O
primary JJ JJ O
prevention NN NN O
. . . O

Several JJ JJ O
of IN IN O
the DT DT O
RCTs NNP NNP O
were VBD VBD O
conducted VBN VBN O
within IN IN O
populations NNS NNS O
of IN IN O
health NN NN O
professionals NNS NNS O
, , , O
which WDT WDT O
potentially RB RB O
limits VBZ VBZ O
generalizability NN NN O
. . . O

CONCLUSION NNP NNP O
: : : O
Aspirin NNP NNP B-CHEM
reduces VBZ VBZ O
the DT DT O
risk NN NN O
for IN IN O
myocardial NN NN O
infarction NN NN O
in IN IN O
men NNS NNS O
and CC CC O
strokes NNS NNS O
in IN IN O
women NNS NNS O
. . . O

Aspirin NNP NNP B-CHEM
use NN NN O
increases NNS NNS O
the DT DT O
risk NN NN O
for IN IN O
serious JJ JJ O
bleeding VBG VBG O
events NNS NNS O
. . . O

Reducing NNP NNP O
harm NN NN O
associated VBN VBN O
with IN IN O
anticoagulation NN NN O
: : : O
practical JJ JJ O
considerations NNS NNS O
of IN IN O
argatroban NN NN B-CHEM
therapy NN NN O
in IN IN O
heparin NN NN B-CHEM
- - - O
induced JJ JJ O
thrombocytopenia NN NN O
. . . O

Argatroban NNP NNP B-CHEM
is VBZ VBZ O
a DT DT O
hepatically RB RB O
metabolized VBN VBN O
, , , O
direct JJ JJ O
thrombin NN NN O
inhibitor NN NN O
used VBN VBN O
for IN IN O
prophylaxis NNS NNS O
or CC CC O
treatment NN NN O
of IN IN O
thrombosis NN NN O
in IN IN O
heparin NN NN B-CHEM
- - - O
induced JJ JJ O
thrombocytopenia NN NN O
( ( ( O
HIT NNP NNP O
) ) ) O
and CC CC O
for IN IN O
patients NNS NNS O
with IN IN O
or CC CC O
at IN IN O
risk NN NN O
of IN IN O
HIT NNP NNP O
undergoing VBG VBG O
percutaneous JJ JJ O
coronary JJ JJ O
intervention NN NN O
( ( ( O
PCI NNP NNP O
) ) ) O
. . . O

The DT DT O
objective NN NN O
of IN IN O
this DT DT O
review NN NN O
is VBZ VBZ O
to TO TO O
summarize VB VB O
practical JJ JJ O
considerations NNS NNS O
of IN IN O
argatroban NN NN B-CHEM
therapy NN NN O
in IN IN O
HIT NNP NNP O
. . . O

The DT DT O
US NNP NNP O
FDA NNP NNP O
- : : O
recommended VBD VBD O
argatroban NN NN B-CHEM
dose NN NN O
in IN IN O
HIT NNP NNP O
is VBZ VBZ O
2 CD CD O
microg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
( ( ( O
reduced VBN VBN O
in IN IN O
patients NNS NNS O
with IN IN O
hepatic JJ JJ O
impairment NN NN O
and CC CC O
in IN IN O
paediatric JJ JJ O
patients NNS NNS O
) ) ) O
, , , O
adjusted VBN VBN O
to TO TO O
achieve VB VB O
activated VBN VBN O
partial JJ JJ O
thromboplastin NN NN O
times NNS NNS O
( ( ( O
aPTTs NN NN O
) ) ) O
1 CD CD O
. . . O
5 CD CD O
- : : O
3 CD CD O
times NNS NNS O
baseline NN NN O
( ( ( O
not RB RB O
> NN NN O
100 CD CD O
seconds NNS NNS O
) ) ) O
. . . O

Contemporary NNP NNP O
experiences NNS NNS O
indicate VBP VBP O
that IN IN O
reduced JJ JJ O
doses NNS NNS O
are VBP VBP O
also RB RB O
needed VBN VBN O
in IN IN O
patients NNS NNS O
with IN IN O
conditions NNS NNS O
associated VBN VBN O
with IN IN O
hepatic JJ JJ O
hypoperfusion NN NN O
, , , O
e SYM SYM O
. . . O
g SYM SYM O
. . . O
heart NN NN O
failure NN NN O
, , , O
yet RB RB O
are VBP VBP O
unnecessary JJ JJ O
for IN IN O
renal JJ JJ O
dysfunction NN NN O
, , , O
adult NN NN O
age NN NN O
, , , O
sex NN NN O
, , , O
race NN NN O
/ NN NN O
ethnicity NN NN O
or CC CC O
obesity NN NN O
. . . O

Argatroban NNP NNP B-CHEM
0 CD CD O
. . . O
5 CD CD O
- : : O
1 CD CD O
. . . O
2 CD CD O
microg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
typically RB RB O
supports VBZ VBZ O
therapeutic JJ JJ O
aPTTs NN NN O
. . . O

The DT DT O
FDA NNP NNP O
- - - O
recommended JJ JJ O
dose NN NN O
during IN IN O
PCI NNP NNP O
is VBZ VBZ O
25 CD CD O
microg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
( ( ( O
350 CD CD O
microg NN NN O
/ NN NN O
kg NN NN O
initial JJ JJ O
bolus NN NN O
) ) ) O
, , , O
adjusted VBN VBN O
to TO TO O
achieve VB VB O
activated VBN VBN O
clotting VBG VBG O
times NNS NNS O
( ( ( O
ACTs NNP NNP O
) ) ) O
of IN IN O
300 CD CD O
- : : O
450 CD CD O
sec NN NN O
. . . O

For IN IN O
PCI NNP NNP O
, , , O
argatroban NN NN B-CHEM
has VBZ VBZ O
not RB RB O
been VBN VBN O
investigated VBN VBN O
in IN IN O
hepatically RB RB O
impaired VBN VBN O
patients NNS NNS O
; : : O
dose NN NN O
adjustment NN NN O
is VBZ VBZ O
unnecessary JJ JJ O
for IN IN O
adult NN NN O
age NN NN O
, , , O
sex NN NN O
, , , O
race NN NN O
/ NN NN O
ethnicity NN NN O
or CC CC O
obesity NN NN O
, , , O
and CC CC O
lesser JJR JJR O
doses NNS NNS O
may MD MD O
be VB VB O
adequate JJ JJ O
with IN IN O
concurrent NN NN O
glycoprotein NN NN O
IIb NNP NNP O
/ NN NN O
IIIa NNP NNP O
inhibition NN NN O
. . . O

Argatroban NNP NNP B-CHEM
prolongs NNS NNS O
the DT DT O
International NNP NNP O
Normalized NNP NNP O
Ratio NN NN O
, , , O
and CC CC O
published VBD VBD O
approaches NNS NNS O
for IN IN O
monitoring VBG VBG O
the DT DT O
argatroban NN NN B-CHEM
- - - O
to TO TO O
- - - O
warfarin NN NN B-CHEM
transition NN NN O
should MD MD O
be VB VB O
followed VBN VBN O
. . . O

Major NNP NNP O
bleeding NN NN O
with IN IN O
argatroban NN NN B-CHEM
is VBZ VBZ O
0 CD CD O
- : : O
10 CD CD O
% NN NN O
in IN IN O
the DT DT O
non NN NN O
- - - O
interventional JJ JJ O
setting NN NN O
and CC CC O
0 CD CD O
- : : O
5 CD CD O
. . . O
8 CD CD O
% NN NN O
periprocedurally RB RB O
. . . O

Argatroban NNP NNP B-CHEM
has VBZ VBZ O
no DT DT O
specific JJ JJ O
antidote NN NN O
, , , O
and CC CC O
if IN IN O
excessive JJ JJ O
anticoagulation NN NN O
occurs VBZ VBZ O
, , , O
argatroban NN NN B-CHEM
infusion NN NN O
should MD MD O
be VB VB O
stopped VBN VBN O
or CC CC O
reduced VBN VBN O
. . . O

Improved NNP NNP O
familiarity NN NN O
of IN IN O
healthcare NN NN O
professionals NNS NNS O
with IN IN O
argatroban NN NN B-CHEM
therapy NN NN O
in IN IN O
HIT NNP NNP O
, , , O
including VBG VBG O
in IN IN O
special JJ JJ O
populations NNS NNS O
and CC CC O
during IN IN O
PCI NNP NNP O
, , , O
may MD MD O
facilitate VB VB O
reduction NN NN O
of IN IN O
harm NN NN O
associated VBN VBN O
with IN IN O
HIT NNP NNP O
( ( ( O
e SYM SYM O
. . . O
g SYM SYM O
. . . O
fewer JJR JJR O
thromboses NNS NNS O
) ) ) O
or CC CC O
its PRP$ PRP$ O
treatment NN NN O
( ( ( O
e SYM SYM O
. . . O
g SYM SYM O
. . . O
fewer JJR JJR O
argatroban NN NN B-CHEM
medication NN NN O
errors NNS NNS O
) ) ) O
. . . O

Rhabdomyolysis NNP NNP O
and CC CC O
brain NN NN O
ischemic JJ JJ O
stroke NN NN O
in IN IN O
a DT DT O
heroin NN NN B-CHEM
- - - O
dependent JJ JJ O
male NN NN O
under IN IN O
methadone NN NN B-CHEM
maintenance NN NN O
therapy NN NN O
. . . O

OBJECTIVE NNP NNP O
: : : O
There EX EX O
are VBP VBP O
several JJ JJ O
complications NNS NNS O
associated VBN VBN O
with IN IN O
heroin NN NN O
abuse NN NN O
, , , O
some DT DT O
of IN IN O
which WDT WDT O
are VBP VBP O
life NN NN O
- - - O
threatening VBG VBG O
. . . O

Methadone NNP NNP B-CHEM
may MD MD O
aggravate VB VB O
this DT DT O
problem NN NN O
. . . O

METHOD NNP NNP O
: : : O
A DT DT O
clinical JJ JJ O
case NN NN O
description NN NN O
. . . O

RESULTS NNS NNS O
: : : O
A DT DT O
33 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
man NN NN O
presented VBN VBN O
with IN IN O
rhabdomyolysis NN NN O
and CC CC O
cerebral JJ JJ O
ischemic JJ JJ O
stroke NN NN O
after IN IN O
intravenous JJ JJ O
heroin NN NN B-CHEM
. . . O

He PRP PRP O
had VBD VBD O
used VBN VBN O
heroin NN NN B-CHEM
since IN IN O
age NN NN O
20 CD CD O
, , , O
and CC CC O
had VBD VBD O
used VBN VBN O
150 CD CD O
mg NN NN O
methadone NN NN B-CHEM
daily JJ JJ O
for IN IN O
6 CD CD O
months NNS NNS O
. . . O

He PRP PRP O
was VBD VBD O
found VBN VBN O
unconsciousness JJ JJ O
at IN IN O
home NN NN O
and CC CC O
was VBD VBD O
sent VBN VBN O
to TO TO O
our PRP$ PRP$ O
hospital NN NN O
. . . O

In IN IN O
the DT DT O
ER NNP NNP O
, , , O
his PRP$ PRP$ O
opiate JJ JJ O
level NN NN O
was VBD VBD O
4497 CD CD O
ng NN NN O
/ NN NN O
ml NN NN O
. . . O

In IN IN O
the DT DT O
ICU NNP NNP O
, , , O
we PRP PRP O
found VBD VBD O
rhabdomyolysis NN NN O
, , , O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
and CC CC O
acute JJ JJ O
respiratory JJ JJ O
failure NN NN O
. . . O

After IN IN O
transfer NN NN O
to TO TO O
an DT DT O
internal JJ JJ O
ward NN NN O
, , , O
we PRP PRP O
noted VBD VBD O
aphasia NN NN O
and CC CC O
weakness NN NN O
of IN IN O
his PRP$ PRP$ O
left JJ JJ O
limbs NNS NNS O
. . . O

After IN IN O
MRI NNP NNP O
, , , O
we PRP PRP O
found VBD VBD O
cerebral JJ JJ O
ischemic JJ JJ O
infarction NN NN O
. . . O

CONCLUSION NNP NNP O
: : : O
Those DT DT O
using VBG VBG O
methadone NN NN B-CHEM
and CC CC O
heroin NN NN B-CHEM
simultaneously RB RB O
may MD MD O
increase VB VB O
risk NN NN O
of IN IN O
rhabdomyolysis NN NN O
and CC CC O
ischemic JJ JJ O
stroke NN NN O
. . . O

Patients NNS NNS O
under IN IN O
methadone NN NN B-CHEM
maintenance NN NN O
therapy NN NN O
should MD MD O
be VB VB O
warned VBN VBN O
regarding VBG VBG O
these DT DT O
serious JJ JJ O
adverse JJ JJ O
events NNS NNS O
. . . O

Hypotheses NNP NNP O
of IN IN O
heroin NN NN B-CHEM
- - - O
related VBN VBN O
rhabdomyolysis NN NN O
and CC CC O
stroke NN NN O
in IN IN O
heroin NN NN B-CHEM
abusers NNS NNS O
are VBP VBP O
discussed VBN VBN O
. . . O

Increased NNP NNP O
vulnerability NN NN O
to TO TO O
6 CD CD B-CHEM
- : : I-CHEM
hydroxydopamine NN NN I-CHEM
lesion NN NN O
and CC CC O
reduced VBN VBN O
development NN NN O
of IN IN O
dyskinesias NNS NNS O
in IN IN O
mice NN NN O
lacking VBG VBG O
CB1 NNP NNP O
cannabinoid NN NN O
receptors NNS NNS O
. . . O

Motor NNP NNP O
impairment NN NN O
, , , O
dopamine NN NN B-CHEM
( ( ( O
DA NNP NNP B-CHEM
) ) ) O
neuronal NN NN O
activity NN NN O
and CC CC O
proenkephalin NN NN B-CHEM
( ( ( O
PENK NNP NNP B-CHEM
) ) ) O
gene NN NN O
expression NN NN O
in IN IN O
the DT DT O
caudate NN NN O
- - - O
putamen NNS NNS O
( ( ( O
CPu NNP NNP O
) ) ) O
were VBD VBD O
measured VBN VBN O
in IN IN O
6 CD CD B-CHEM
- : : I-CHEM
OHDA NNP NNP I-CHEM
- : : O
lesioned JJ JJ O
and CC CC O
treated VBN VBN O
( ( ( O
L NNP NNP B-CHEM
- : : I-CHEM
DOPA NNP NNP I-CHEM
+ NN NN I-CHEM
benserazide NN NN I-CHEM
) ) ) O
CB1 NNP NNP O
KO NNP NNP O
and CC CC O
WT NNP NNP O
mice NN NN O
. . . O

A DT DT O
lesion NN NN O
induced VBN VBN O
by IN IN O
6 CD CD B-CHEM
- : : I-CHEM
OHDA NNP NNP I-CHEM
produced VBD VBD O
more JJR JJR O
severe JJ JJ O
motor NN NN O
deterioration NN NN O
in IN IN O
CB1 NNP NNP O
KO NNP NNP O
mice NN NN O
accompanied VBN VBN O
by IN IN O
more JJR JJR O
loss NN NN O
of IN IN O
DA NNP NNP B-CHEM
neurons NNS NNS O
and CC CC O
increased VBN VBN O
PENK NNP NNP B-CHEM
gene NN NN O
expression NN NN O
in IN IN O
the DT DT O
CPu NNP NNP O
. . . O

Oxidative NNP NNP O
/ NN NN O
nitrosative JJ JJ O
and CC CC O
neuroinflammatory JJ JJ O
parameters NNS NNS O
were VBD VBD O
estimated VBN VBN O
in IN IN O
the DT DT O
CPu NNP NNP O
and CC CC O
cingulate NN NN O
cortex NN NN O
( ( ( O
Cg NNP NNP O
) ) ) O
. . . O

CB1 NNP NNP O
KO NNP NNP O
mice NN NN O
exhibited VBD VBD O
higher JJR JJR O
MDA NNP NNP B-CHEM
levels NNS NNS O
and CC CC O
iNOS NN NN O
protein NN NN O
expression NN NN O
in IN IN O
the DT DT O
CPu NNP NNP O
and CC CC O
Cg NNP NNP O
compared VBD VBD O
to TO TO O
WT NNP NNP O
mice NNS NNS O
. . . O

Treatment NN NN O
with IN IN O
L NNP NNP B-CHEM
- : : I-CHEM
DOPA NNP NNP I-CHEM
+ NN NN I-CHEM
benserazide NN NN I-CHEM
( ( ( O
12 CD CD O
weeks NNS NNS O
) ) ) O
resulted VBD VBD O
in IN IN O
less JJR JJR O
severe JJ JJ O
dyskinesias NNS NNS O
in IN IN O
CB1 NNP NNP O
KO NNP NNP O
than IN IN O
in IN IN O
WT NNP NNP O
mice NN NN O
. . . O

The DT DT O
results NNS NNS O
revealed VBD VBD O
that IN IN O
the DT DT O
lack NN NN O
of IN IN O
cannabinoid NN NN O
CB1 NNP NNP O
receptors NNS NNS O
increased VBD VBD O
the DT DT O
severity NN NN O
of IN IN O
motor NN NN O
impairment NN NN O
and CC CC O
DA NNP NNP B-CHEM
lesion NN NN O
, , , O
and CC CC O
reduced VBD VBD O
L NNP NNP B-CHEM
- : : I-CHEM
DOPA NNP NNP I-CHEM
- : : O
induced JJ JJ O
dyskinesias NN NN O
. . . O

These DT DT O
results NNS NNS O
suggest VBP VBP O
that DT DT O
activation NN NN O
of IN IN O
CB1 NNP NNP O
receptors NNS NNS O
offers VBZ VBZ O
neuroprotection NN NN O
against IN IN O
dopaminergic JJ JJ O
lesion NN NN O
and CC CC O
the DT DT O
development NN NN O
of IN IN O
L NNP NNP B-CHEM
- - - I-CHEM
DOPA NNP NNP I-CHEM
- : : O
induced JJ JJ O
dyskinesias NN NN O
. . . O

Hepatocellular NNP NNP O
oxidant JJ JJ O
stress NN NN O
following VBG VBG O
intestinal JJ JJ O
ischemia NN NN O
- - - O
reperfusion NN NN O
injury NN NN O
. . . O

Reperfusion NNP NNP O
of IN IN O
ischemic JJ JJ O
intestine NN NN O
results NNS NNS O
in IN IN O
acute JJ JJ O
liver NN NN O
dysfunction NN NN O
characterized VBN VBN O
by IN IN O
hepatocellular NN NN O
enzyme NN NN O
release NN NN O
into IN IN O
plasma NN NN O
, , , O
reduction NN NN O
in IN IN O
bile NN NN O
flow NN NN O
rate NN NN O
, , , O
and CC CC O
neutrophil NN NN O
sequestration NN NN O
within IN IN O
the DT DT O
liver NN NN O
. . . O

The DT DT O
pathophysiology NN NN O
underlying VBG VBG O
this DT DT O
acute JJ JJ O
hepatic JJ JJ O
injury NN NN O
is VBZ VBZ O
unknown JJ JJ O
. . . O

This DT DT O
study NN NN O
was VBD VBD O
undertaken VBN VBN O
to TO TO O
determine VB VB O
whether IN IN O
oxidants NNS NNS O
are VBP VBP O
associated VBN VBN O
with IN IN O
the DT DT O
hepatic JJ JJ O
injury NN NN O
and CC CC O
to TO TO O
determine VB VB O
the DT DT O
relative JJ JJ O
value NN NN O
of IN IN O
several JJ JJ O
indirect JJ JJ O
methods NNS NNS O
of IN IN O
assessing VBG VBG O
oxidant JJ JJ O
exposure NN NN O
in IN IN O
vivo NN NN O
. . . O

Rats NNP NNP O
were VBD VBD O
subjected VBN VBN O
to TO TO O
a DT DT O
standardized JJ JJ O
intestinal JJ JJ O
ischemia NN NN O
- - - O
reperfusion NN NN O
injury NN NN O
. . . O

Hepatic NNP NNP O
tissue NN NN O
was VBD VBD O
assayed VBN VBN O
for IN IN O
lipid JJ JJ O
peroxidation NN NN O
products NNS NNS O
and CC CC O
oxidized JJ JJ B-CHEM
and CC CC I-CHEM
reduced VBN VBN I-CHEM
glutathione NN NN I-CHEM
. . . O

There EX EX O
was VBD VBD O
no DT DT O
change NN NN O
in IN IN O
hepatic JJ JJ O
tissue NN NN O
total JJ JJ O
glutathione NN NN B-CHEM
following VBG VBG O
intestinal JJ JJ O
ischemia NN NN O
- - - O
reperfusion NN NN O
injury NN NN O
. . . O

Oxidized NNP NNP B-CHEM
glutathione NN NN I-CHEM
( ( ( O
GSSG NNP NNP B-CHEM
) ) ) O
increased VBN VBN O
significantly RB RB O
following VBG VBG O
30 CD CD O
and CC CC O
60 CD CD O
min NN NN O
of IN IN O
reperfusion NN NN O
. . . O

There EX EX O
was VBD VBD O
no DT DT O
increase NN NN O
in IN IN O
any DT DT O
of IN IN O
the DT DT O
products NNS NNS O
of IN IN O
lipid JJ JJ O
peroxidation NN NN O
associated VBN VBN O
with IN IN O
this DT DT O
injury NN NN O
. . . O

An DT DT O
increase NN NN O
in IN IN O
GSSG NNP NNP B-CHEM
within IN IN O
hepatic JJ JJ O
tissue NN NN O
during IN IN O
intestinal JJ JJ O
reperfusion NN NN O
suggests VBZ VBZ O
exposure NN NN O
of IN IN O
hepatocytes NNS NNS O
to TO TO O
an DT DT O
oxidant JJ JJ O
stress NN NN O
. . . O

The DT DT O
lack NN NN O
of IN IN O
a DT DT O
significant JJ JJ O
increase NN NN O
in IN IN O
products NNS NNS O
of IN IN O
lipid JJ JJ O
peroxidation NN NN O
suggests VBZ VBZ O
that IN IN O
the DT DT O
oxidant JJ JJ O
stress NN NN O
is VBZ VBZ O
of IN IN O
insufficient NN NN O
magnitude NN NN O
to TO TO O
result VB VB O
in IN IN O
irreversible JJ JJ O
injury NN NN O
to TO TO O
hepatocyte VB VB O
cell NN NN O
membranes NNS NNS O
. . . O

These DT DT O
data NNS NNS O
also RB RB O
suggest VBP VBP O
that IN IN O
the DT DT O
measurement NN NN O
of IN IN O
tissue NN NN O
GSSG NNP NNP B-CHEM
may MD MD O
be VB VB O
a DT DT O
more RBR RBR O
sensitive JJ JJ O
indicator NN NN O
of IN IN O
oxidant JJ JJ O
stress NN NN O
than IN IN O
measurement NN NN O
of IN IN O
products NNS NNS O
of IN IN O
lipid JJ JJ O
peroxidation NN NN O
. . . O

Animal NNP NNP O
model NN NN O
of IN IN O
mania NN NN O
induced VBN VBN O
by IN IN O
ouabain NN NN B-CHEM
: : : O
Evidence NN NN O
of IN IN O
oxidative JJ JJ O
stress NN NN O
in IN IN O
submitochondrial JJ JJ O
particles NNS NNS O
of IN IN O
the DT DT O
rat NN NN O
brain NN NN O
. . . O

The DT DT O
intracerebroventricular NN NN O
( ( ( O
ICV NNP NNP O
) ) ) O
administration NN NN O
of IN IN O
ouabain NN NN B-CHEM
( ( ( O
a DT DT O
Na NNP NNP B-CHEM
( ( ( O
+ NN NN O
) ) ) O
/ NN NN O
K NNP NNP B-CHEM
( ( ( O
+ NN NN O
) ) ) O
- : : O
ATPase NNP NNP O
inhibitor NN NN O
) ) ) O
in IN IN O
rats NNS NNS O
has VBZ VBZ O
been VBN VBN O
suggested VBN VBN O
to TO TO O
mimic VB VB O
some DT DT O
symptoms NNS NNS O
of IN IN O
human JJ JJ O
bipolar NN NN O
mania NN NN O
. . . O

Clinical NNP NNP O
studies NNS NNS O
have VBP VBP O
shown VBN VBN O
that IN IN O
bipolar JJ JJ O
disorder NN NN O
may MD MD O
be VB VB O
related VBN VBN O
to TO TO O
mitochondrial JJ JJ O
dysfunction NN NN O
. . . O

Herein NNP NNP O
, , , O
we PRP PRP O
investigated VBD VBD O
the DT DT O
behavioral JJ JJ O
and CC CC O
biochemical JJ JJ O
effects NNS NNS O
induced VBN VBN O
by IN IN O
the DT DT O
ICV NNP NNP O
administration NN NN O
of IN IN O
ouabain NN NN B-CHEM
in IN IN O
rats NNS NNS O
. . . O

To TO TO O
achieve VB VB O
this DT DT O
aim NN NN O
, , , O
the DT DT O
effects NNS NNS O
of IN IN O
ouabain JJ JJ B-CHEM
injection NN NN O
immediately RB RB O
after IN IN O
and CC CC O
7 CD CD O
days NNS NNS O
following VBG VBG O
a DT DT O
single JJ JJ O
ICV NNP NNP O
administration NN NN O
( ( ( O
at IN IN O
concentrations NNS NNS O
of IN IN O
10 CD CD O
( ( ( O
- : : O
2 CD CD O
) ) ) O
and CC CC O
10 CD CD O
( ( ( O
- : : O
3 CD CD O
) ) ) O
M NNP NNP O
) ) ) O
on IN IN O
locomotion NN NN O
was VBD VBD O
measured VBN VBN O
using VBG VBG O
the DT DT O
open JJ JJ O
- - - O
field NN NN O
test NN NN O
. . . O

Additionally RB RB O
, , , O
thiobarbituric JJ JJ B-CHEM
acid NN NN I-CHEM
reactive JJ JJ O
substances NNS NNS O
( ( ( O
TBARSs NNP NNP O
) ) ) O
and CC CC O
superoxide JJ JJ B-CHEM
production NN NN O
were VBD VBD O
measured VBN VBN O
in IN IN O
submitochondrial JJ JJ O
particles NNS NNS O
of IN IN O
the DT DT O
prefrontal NN NN O
cortex NN NN O
, , , O
hippocampus NN NN O
, , , O
striatum NN NN O
and CC CC O
amygdala NN NN O
. . . O

Our PRP$ PRP$ O
findings NNS NNS O
demonstrated VBN VBN O
that IN IN O
ouabain NN NN B-CHEM
at IN IN O
10 CD CD O
( ( ( O
- : : O
2 CD CD O
) ) ) O
and CC CC O
10 CD CD O
( ( ( O
- : : O
3 CD CD O
) ) ) O
M NNP NNP O
induced VBD VBD O
hyperlocomotion NN NN O
in IN IN O
rats NNS NNS O
, , , O
and CC CC O
this DT DT O
response NN NN O
remained VBD VBD O
up IN IN O
to TO TO O
7 CD CD O
days NNS NNS O
following VBG VBG O
a DT DT O
single JJ JJ O
ICV NNP NNP O
injection NN NN O
. . . O

In IN IN O
addition NN NN O
, , , O
we PRP PRP O
observed VBD VBD O
that IN IN O
the DT DT O
persistent JJ JJ O
increase NN NN O
in IN IN O
the DT DT O
rat NN NN O
spontaneous JJ JJ O
locomotion NN NN O
is VBZ VBZ O
associated VBN VBN O
with IN IN O
increased VBN VBN O
TBARS NNP NNP O
levels NNS NNS O
and CC CC O
superoxide NN NN B-CHEM
generation NN NN O
in IN IN O
submitochondrial JJ JJ O
particles NNS NNS O
in IN IN O
the DT DT O
prefrontal NN NN O
cortex NN NN O
, , , O
striatum NN NN O
and CC CC O
amygdala NN NN O
. . . O

In IN IN O
conclusion NN NN O
, , , O
ouabain NN NN B-CHEM
- - - O
induced VBN VBN O
mania NN NN O
- - - O
like IN IN O
behavior NN NN O
may MD MD O
provide VB VB O
a DT DT O
useful JJ JJ O
animal NN NN O
model NN NN O
to TO TO O
test VB VB O
the DT DT O
hypothesis NNS NNS O
of IN IN O
the DT DT O
involvement NN NN O
of IN IN O
oxidative JJ JJ O
stress NN NN O
in IN IN O
bipolar JJ JJ O
disorder NN NN O
. . . O

Intraoperative NNP NNP O
dialysis NN NN O
during IN IN O
liver NN NN O
transplantation NN NN O
with IN IN O
citrate NN NN B-CHEM
dialysate NN NN O
. . . O

Liver NNP NNP O
transplantation NN NN O
for IN IN O
acutely RB RB O
ill JJ JJ O
patients NNS NNS O
with IN IN O
fulminant JJ JJ O
liver NN NN O
failure NN NN O
carries VBZ VBZ O
high JJ JJ O
intraoperative JJ JJ O
and CC CC O
immediate JJ JJ O
postoperative JJ JJ O
risks NNS NNS O
. . . O

These DT DT O
are VBP VBP O
increased VBN VBN O
with IN IN O
the DT DT O
presence NN NN O
of IN IN O
concomitant NN NN O
acute JJ JJ O
kidney NN NN O
injury NN NN O
( ( ( O
AKI NNP NNP O
) ) ) O
and CC CC O
intraoperative JJ JJ O
dialysis NN NN O
is VBZ VBZ O
sometimes RB RB O
required VBN VBN O
to TO TO O
allow VB VB O
the DT DT O
transplant NN NN O
to TO TO O
proceed VB VB O
. . . O

The DT DT O
derangements NNS NNS O
in IN IN O
the DT DT O
procoagulant NN NN O
and CC CC O
anticoagulant JJ JJ O
pathways NNS NNS O
during IN IN O
fulminant JJ JJ O
liver NN NN O
failure NN NN O
can MD MD O
lead VB VB O
to TO TO O
difficulties NNS NNS O
with IN IN O
anticoagulation NN NN O
during IN IN O
dialysis NN NN O
, , , O
especially RB RB O
when WRB WRB O
continued VBD VBD O
in IN IN O
the DT DT O
operating VBG VBG O
room NN NN O
. . . O

Systemic NNP NNP O
anticoagulation NN NN O
is VBZ VBZ O
unsafe JJ JJ O
and CC CC O
regional JJ JJ O
citrate NN NN B-CHEM
anticoagulation NN NN O
in IN IN O
the DT DT O
absence NN NN O
of IN IN O
a DT DT O
functional JJ JJ O
liver NN NN O
carries VBZ VBZ O
the DT DT O
risk NN NN O
of IN IN O
citrate NN NN B-CHEM
toxicity NN NN O
. . . O

Citrate NNP NNP B-CHEM
dialysate NN NN O
, , , O
a DT DT O
new JJ JJ O
dialysate NN NN O
with IN IN O
citric JJ JJ B-CHEM
acid NN NN I-CHEM
can MD MD O
be VB VB O
used VBN VBN O
for IN IN O
anticoagulation NN NN O
in IN IN O
patients NNS NNS O
who WP WP O
cannot NN NN O
tolerate NN NN O
heparin NN NN B-CHEM
or CC CC O
regional JJ JJ O
citrate NN NN B-CHEM
. . . O

We PRP PRP O
report VBP VBP O
a DT DT O
case NN NN O
of IN IN O
a DT DT O
40 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
female NN NN O
with IN IN O
acetaminophen NN NN B-CHEM
- - - O
induced JJ JJ O
fulminant NN NN O
liver NN NN O
failure NN NN O
with IN IN O
associated VBN VBN O
AKI NNP NNP O
who WP WP O
underwent VBD VBD O
intraoperative JJ JJ O
dialytic JJ JJ O
support NN NN O
during IN IN O
liver NN NN O
transplantation NN NN O
anticoagulated VBN VBN O
with IN IN O
citrate JJ JJ B-CHEM
dialysate NN NN O
during IN IN O
the DT DT O
entire JJ JJ O
procedure NN NN O
. . . O

The DT DT O
patient NN NN O
tolerated VBD VBD O
the DT DT O
procedure NN NN O
well RB RB O
without IN IN O
any DT DT O
signs NNS NNS O
of IN IN O
citrate NN NN B-CHEM
toxicity NN NN O
and CC CC O
maintained VBD VBD O
adequate JJ JJ O
anticoagulation NN NN O
for IN IN O
patency NN NN O
of IN IN O
the DT DT O
dialysis NN NN O
circuit NN NN O
. . . O

Citrate NNP NNP B-CHEM
dialysate NN NN O
is VBZ VBZ O
a DT DT O
safe JJ JJ O
alternative NN NN O
for IN IN O
intradialytic JJ JJ O
support NN NN O
of IN IN O
liver NN NN O
transplantation NN NN O
in IN IN O
fulminant JJ JJ O
liver NN NN O
failure NN NN O
. . . O

Delirium NNP NNP O
in IN IN O
a DT DT O
patient NN NN O
with IN IN O
toxic JJ JJ O
flecainide NN NN B-CHEM
plasma NN NN O
concentrations NNS NNS O
: : : O
the DT DT O
role NN NN O
of IN IN O
a DT DT O
pharmacokinetic JJ JJ O
drug NN NN O
interaction NN NN O
with IN IN O
paroxetine NN NN B-CHEM
. . . O

OBJECTIVE NNP NNP O
: : : O
To TO TO O
describe VB VB O
a DT DT O
case NN NN O
of IN IN O
flecainide NN NN B-CHEM
- - - O
induced JJ JJ O
delirium NN NN O
associated VBN VBN O
with IN IN O
a DT DT O
pharmacokinetic JJ JJ O
drug NN NN O
interaction NN NN O
with IN IN O
paroxetine NN NN B-CHEM
. . . O

CASE NN NN O
SUMMARY NNP NNP O
: : : O
A DT DT O
69 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
white JJ JJ O
female NN NN O
presented VBN VBN O
to TO TO O
the DT DT O
emergency NN NN O
department NN NN O
with IN IN O
a DT DT O
history NN NN O
of IN IN O
confusion NN NN O
and CC CC O
paranoia NN NN O
over IN IN O
the DT DT O
past JJ JJ O
several JJ JJ O
days NNS NNS O
. . . O

On IN IN O
admission NN NN O
the DT DT O
patient NN NN O
was VBD VBD O
taking VBG VBG O
carvedilol NN NN B-CHEM
12 CD CD O
mg NN NN O
twice RB RB O
daily RB RB O
, , , O
warfarin NN NN B-CHEM
2 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
, , , O
folic JJ JJ B-CHEM
acid NN NN I-CHEM
1 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
, , , O
levothyroxine NN NN B-CHEM
100 CD CD O
microg NN NN O
/ NN NN O
day NN NN O
, , , O
pantoprazole NN NN B-CHEM
40 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
, , , O
paroxetine NN NN B-CHEM
40 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
, , , O
and CC CC O
flecainide NN NN B-CHEM
100 CD CD O
mg NN NN O
twice RB RB O
daily JJ JJ O
. . . O

Flecainide NNP NNP B-CHEM
had VBD VBD O
been VBN VBN O
started VBD VBD O
2 CD CD O
weeks NNS NNS O
prior RB RB O
for IN IN O
atrial JJ JJ O
fibrillation NN NN O
. . . O

Laboratory NNP NNP O
test NN NN O
findings NNS NNS O
on IN IN O
admission NN NN O
were VBD VBD O
notable JJ JJ O
only RB RB O
for IN IN O
a DT DT O
flecainide NN NN B-CHEM
plasma NN NN O
concentration NN NN O
of IN IN O
1360 CD CD O
microg NN NN O
/ NN NN O
L NNP NNP O
( ( ( O
reference NN NN O
range NN NN O
200 CD CD O
- : : O
1000 CD CD O
) ) ) O
. . . O

A DT DT O
metabolic JJ JJ O
drug NN NN O
interaction NN NN O
between IN IN O
flecainide NN NN B-CHEM
and CC CC O
paroxetine NN NN B-CHEM
, , , O
which WDT WDT O
the DT DT O
patient NN NN O
had VBD VBD O
been VBN VBN O
taking VBG VBG O
for IN IN O
more JJR JJR O
than IN IN O
5 CD CD O
years NNS NNS O
, , , O
was VBD VBD O
considered VBN VBN O
. . . O

Paroxetine NNP NNP B-CHEM
was VBD VBD O
discontinued VBN VBN O
and CC CC O
the DT DT O
dose NN NN O
of IN IN O
flecainide NN NN B-CHEM
was VBD VBD O
reduced VBN VBN O
to TO TO O
50 CD CD O
mg NN NN O
twice RB RB O
daily JJ JJ O
. . . O

Her PRP$ PRP$ O
delirium NN NN O
resolved VBD VBD O
3 CD CD O
days NNS NNS O
later RB RB O
. . . O

DISCUSSION NNP NNP O
: : : O
Flecainide NNP NNP B-CHEM
and CC CC O
pharmacologically RB RB O
similar JJ JJ O
agents NNS NNS O
that WDT WDT O
interact NN NN O
with IN IN O
sodium NN NN B-CHEM
channels NNS NNS O
may MD MD O
cause VB VB O
delirium NN NN O
in IN IN O
susceptible JJ JJ O
patients NNS NNS O
. . . O

A DT DT O
MEDLINE NNP NNP O
search NN NN O
( ( ( O
1966 CD CD O
- - - O
January NNP NNP O
2009 CD CD O
) ) ) O
revealed VBD VBD O
one CD CD O
in IN IN O
vivo NN NN O
pharmacokinetic JJ JJ O
study NN NN O
on IN IN O
the DT DT O
interaction NN NN O
between IN IN O
flecainide NN NN B-CHEM
, , , O
a DT DT O
CYP2D6 NNP NNP O
substrate NN NN O
, , , O
and CC CC O
paroxetine NN NN B-CHEM
, , , O
a DT DT O
CYP2D6 NNP NNP O
inhibitor NN NN O
, , , O
as RB RB O
well RB RB O
as IN IN O
3 CD CD O
case NN NN O
reports NNS NNS O
of IN IN O
flecainide NN NN B-CHEM
- - - O
induced JJ JJ O
delirium NN NN O
. . . O

According VBG VBG O
to TO TO O
the DT DT O
Naranjo NNP NNP O
probability NN NN O
scale NN NN O
, , , O
flecainide NN NN B-CHEM
was VBD VBD O
the DT DT O
probable JJ JJ O
cause NN NN O
of IN IN O
the DT DT O
patient NN NN O
' '' '' O
s VBZ VBZ O
delirium NN NN O
; : : O
the DT DT O
Horn NNP NNP O
Drug NN NN O
Interaction NNP NNP O
Probability NNP NNP O
Scale NNP NNP O
indicates VBZ VBZ O
a DT DT O
possible JJ JJ O
pharmacokinetic JJ JJ O
drug NN NN O
interaction NN NN O
between IN IN O
flecainide NN NN B-CHEM
and CC CC O
paroxetine NN NN B-CHEM
. . . O

CONCLUSIONS NNP NNP O
: : : O
Supratherapeutic NNP NNP O
flecainide NN NN B-CHEM
plasma NN NN O
concentrations NNS NNS O
may MD MD O
cause VB VB O
delirium NN NN O
. . . O

Because IN IN O
toxicity NN NN O
may MD MD O
occur VB VB O
when WRB WRB O
flecainide NN NN B-CHEM
is VBZ VBZ O
prescribed VBN VBN O
with IN IN O
paroxetine NN NN B-CHEM
and CC CC O
other JJ JJ O
potent JJ JJ O
CYP2D6 NNP NNP O
inhibitors NNS NNS O
, , , O
flecainide NN NN B-CHEM
plasma NN NN O
concentrations NNS NNS O
should MD MD O
be VB VB O
monitored VBN VBN O
closely RB RB O
with IN IN O
commencement NN NN O
of IN IN O
CYP2D6 NNP NNP O
inhibitors NNS NNS O
. . . O

Efficacy NNP NNP O
of IN IN O
everolimus NN NN B-CHEM
( ( ( O
RAD001 NNP NNP B-CHEM
) ) ) O
in IN IN O
patients NNS NNS O
with IN IN O
advanced VBD VBD O
NSCLC NNP NNP O
previously RB RB O
treated VBD VBD O
with IN IN O
chemotherapy NN NN O
alone RB RB O
or CC CC O
with IN IN O
chemotherapy NN NN O
and CC CC O
EGFR NNP NNP O
inhibitors NNS NNS O
. . . O

BACKGROUND NNP NNP O
: : : O
Treatment NN NN O
options NNS NNS O
are VBP VBP O
scarce JJ JJ O
in IN IN O
pretreated VBN VBN O
advanced VBN VBN O
non NN NN O
- - - O
small JJ JJ O
- - - O
cell NN NN O
lung NN NN O
cancer NN NN O
( ( ( O
NSCLC NNP NNP O
) ) ) O
patients NNS NNS O
. . . O

RAD001 NNP NNP B-CHEM
, , , O
an DT DT O
oral JJ JJ O
inhibitor NN NN O
of IN IN O
the DT DT O
mammalian NN NN O
target NN NN O
of IN IN O
rapamycin NN NN B-CHEM
( ( ( O
mTOR NN NN O
) ) ) O
, , , O
has VBZ VBZ O
shown VBN VBN O
phase NN NN O
I PRP PRP O
efficacy NN NN O
in IN IN O
NSCLC NNP NNP O
. . . O

METHODS NNP NNP O
: : : O
Stage NN NN O
IIIb NNP NNP O
or CC CC O
IV NNP NNP O
NSCLC NNP NNP O
patients NNS NNS O
, , , O
with IN IN O
two CD CD O
or CC CC O
fewer JJR JJR O
prior RB RB O
chemotherapy NN NN O
regimens NNS NNS O
, , , O
one CD CD O
platinum NN NN B-CHEM
based VBN VBN O
( ( ( O
stratum NN NN O
1 CD CD O
) ) ) O
or CC CC O
both DT DT O
chemotherapy NN NN O
and CC CC O
epidermal JJ JJ O
growth NN NN O
factor NN NN O
receptor NN NN O
tyrosine NN NN B-CHEM
kinase NN NN O
inhibitors NNS NNS O
( ( ( O
stratum NN NN O
2 CD CD O
) ) ) O
, , , O
received VBD VBD O
RAD001 NNP NNP B-CHEM
10 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
until IN IN O
progression NN NN O
or CC CC O
unacceptable JJ JJ O
toxicity NN NN O
. . . O

Primary JJ JJ O
objective NN NN O
was VBD VBD O
overall JJ JJ O
response NN NN O
rate NN NN O
( ( ( O
ORR NNP NNP O
) ) ) O
. . . O

Analyses NNP NNP O
of IN IN O
markers NNS NNS O
associated VBN VBN O
with IN IN O
the DT DT O
mTOR NN NN O
pathway NN NN O
were VBD VBD O
carried VBN VBN O
out IN IN O
on IN IN O
archival NN NN O
tumor NN NN O
from IN IN O
a DT DT O
subgroup NN NN O
using VBG VBG O
immunohistochemistry NN NN O
( ( ( O
IHC NNP NNP O
) ) ) O
and CC CC O
direct JJ JJ O
mutation NN NN O
sequencing VBG VBG O
. . . O

RESULTS NNS NNS O
: : : O
Eighty NNP NNP O
- - - O
five CD CD O
patients NNS NNS O
were VBD VBD O
enrolled VBN VBN O
, , , O
42 CD CD O
in IN IN O
stratum NN NN O
1 CD CD O
and CC CC O
43 CD CD O
in IN IN O
stratum NN NN O
. . . O

ORR NNP NNP O
was VBD VBD O
4 CD CD O
. . . O
7 CD CD O
% NN NN O
( ( ( O
7 CD CD O
. . . O
1 CD CD O
% NN NN O
stratum NN NN O
1 CD CD O
; : : O
2 CD CD O
. . . O
3 CD CD O
% NN NN O
stratum NN NN O
2 CD CD O
) ) ) O
. . . O

Overall NNP NNP O
disease NN NN O
control NN NN O
rate NN NN O
was VBD VBD O
47 CD CD O
. . . O
1 CD CD O
% NN NN O
. . . O

Median NNP NNP O
progression NN NN O
- - - O
free JJ JJ O
survivals NNS NNS O
( ( ( O
PFSs NNP NNP O
) ) ) O
were VBD VBD O
2 CD CD O
. . . O
6 CD CD O
( ( ( O
stratum NN NN O
1 CD CD O
) ) ) O
and CC CC O
2 CD CD O
. . . O
7 CD CD O
months NNS NNS O
( ( ( O
stratum NN NN O
2 CD CD O
) ) ) O
. . . O

Common NNP NNP O
> NN NN O
or CC CC O
= SYM SYM O
grade NN NN O
3 CD CD O
events NNS NNS O
were VBD VBD O
fatigue NN NN O
, , , O
dyspnea NN NN O
, , , O
stomatitis NNS NNS O
, , , O
anemia NN NN O
, , , O
and CC CC O
thrombocytopenia NN NN O
. . . O

Pneumonitis NNP NNP O
, , , O
probably RB RB O
or CC CC O
possibly RB RB O
related VBN VBN O
, , , O
mainly RB RB O
grade NN NN O
1 CD CD O
/ NN NN O
2 CD CD O
, , , O
occurred VBD VBD O
in IN IN O
25 CD CD O
% NN NN O
. . . O

Cox NNP NNP O
regression NN NN O
analysis NN NN O
of IN IN O
IHC NNP NNP O
scores NNS NNS O
found VBD VBD O
that IN IN O
only RB RB O
phospho NN NN O
AKT NNP NNP O
( ( ( O
pAKT NN NN O
) ) ) O
was VBD VBD O
a DT DT O
significant JJ JJ O
independent JJ JJ O
predictor NN NN O
of IN IN O
worse JJR JJR O
PFS NNP NNP O
. . . O

CONCLUSIONS NNP NNP O
: : : O
RAD001 NNP NNP B-CHEM
10 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
was VBD VBD O
well RB RB O
tolerated VBN VBN O
, , , O
showing VBG VBG O
modest JJ JJ O
clinical JJ JJ O
activity NN NN O
in IN IN O
pretreated JJ JJ O
NSCLC NNP NNP O
. . . O

Evaluation NNP NNP O
of IN IN O
RAD001 NNP NNP B-CHEM
plus CC CC O
standard JJ JJ O
therapy NN NN O
for IN IN O
metastatic JJ JJ O
NSCLC NNP NNP O
continues VBZ VBZ O
. . . O

Posttransplant NNP NNP O
anemia NN NN O
: : : O
the DT DT O
role NN NN O
of IN IN O
sirolimus NN NN B-CHEM
. . . O

Posttransplant NNP NNP O
anemia NN NN O
is VBZ VBZ O
a DT DT O
common JJ JJ O
problem NN NN O
that WDT WDT O
may MD MD O
hinder VB VB O
patients NNS NNS O
' POS POS O
quality NN NN O
of IN IN O
life NN NN O
. . . O

It PRP PRP O
occurs VBZ VBZ O
in IN IN O
12 CD CD O
to TO TO O
76 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
, , , O
and CC CC O
is VBZ VBZ O
most RBS RBS O
common JJ JJ O
in IN IN O
the DT DT O
immediate JJ JJ O
posttransplant NN NN O
period NN NN O
. . . O

A DT DT O
variety NN NN O
of IN IN O
factors NNS NNS O
have VBP VBP O
been VBN VBN O
identified VBN VBN O
that IN IN O
increase NN NN O
the DT DT O
risk NN NN O
of IN IN O
posttransplant NN NN O
anemia NN NN O
, , , O
of IN IN O
which WDT WDT O
the DT DT O
level NN NN O
of IN IN O
renal JJ JJ O
function NN NN O
is VBZ VBZ O
most RBS RBS O
important JJ JJ O
. . . O

Sirolimus NNP NNP B-CHEM
, , , O
a DT DT O
mammalian JJ JJ O
target NN NN O
of IN IN O
rapamycin NN NN B-CHEM
inhibitor NN NN O
, , , O
has VBZ VBZ O
been VBN VBN O
implicated VBN VBN O
as IN IN O
playing VBG VBG O
a DT DT O
special JJ JJ O
role NN NN O
in IN IN O
posttransplant NN NN O
anemia NN NN O
. . . O

This DT DT O
review NN NN O
considers NNS NNS O
anemia VBP VBP O
associated VBN VBN O
with IN IN O
sirolimus NN NN B-CHEM
, , , O
including VBG VBG O
its PRP$ PRP$ O
presentation NN NN O
, , , O
mechanisms NNS NNS O
, , , O
and CC CC O
management NN NN O
. . . O

Coronary JJ JJ O
computerized JJ JJ O
tomography NN NN O
angiography NN NN O
for IN IN O
rapid JJ JJ O
discharge NN NN O
of IN IN O
low JJ JJ O
- - - O
risk NN NN O
patients NNS NNS O
with IN IN O
cocaine NN NN B-CHEM
- - - O
associated JJ JJ O
chest NN NN O
pain NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
Most JJS JJS O
patients NNS NNS O
presenting VBG VBG O
to TO TO O
emergency NN NN O
departments NNS NNS O
( ( ( O
EDs NNP NNP O
) ) ) O
with IN IN O
cocaine NN NN B-CHEM
- - - O
associated JJ JJ O
chest NN NN O
pain NN NN O
are VBP VBP O
admitted VBN VBN O
for IN IN O
at IN IN O
least JJS JJS O
12 CD CD O
hours NNS NNS O
and CC CC O
receive VB VB O
a DT DT O
" '' '' O
rule NN NN O
out IN IN O
acute JJ JJ O
coronary JJ JJ O
syndrome NN NN O
" '' '' O
protocol NN NN O
, , , O
often RB RB O
with IN IN O
noninvasive JJ JJ O
testing NN NN O
prior RB RB O
to TO TO O
discharge VB VB O
. . . O

In IN IN O
patients NNS NNS O
without IN IN O
cocaine NN NN B-CHEM
use NN NN O
, , , O
coronary JJ JJ O
computerized JJ JJ O
tomography NN NN O
angiography NN NN O
( ( ( O
CTA NNP NNP O
) ) ) O
has VBZ VBZ O
been VBN VBN O
shown VBN VBN O
to TO TO O
be VB VB O
useful JJ JJ O
for IN IN O
identifying VBG VBG O
a DT DT O
group NN NN O
of IN IN O
patients NNS NNS O
at IN IN O
low JJ JJ O
risk NN NN O
for IN IN O
cardiac JJ JJ O
events NNS NNS O
who WP WP O
can MD MD O
be VB VB O
safely RB RB O
discharged VBN VBN O
. . . O

It PRP PRP O
is VBZ VBZ O
unclear JJ JJ O
whether IN IN O
a DT DT O
coronary JJ JJ O
CTA NNP NNP O
strategy NN NN O
would MD MD O
be VB VB O
efficacious JJ JJ O
in IN IN O
cocaine NN NN B-CHEM
- - - O
associated JJ JJ O
chest NN NN O
pain NN NN O
, , , O
as IN IN O
coronary JJ JJ O
vasospasm NN NN O
may MD MD O
account VB VB O
for IN IN O
some DT DT O
of IN IN O
the DT DT O
ischemia NN NN O
. . . O

We PRP PRP O
studied VBD VBD O
whether IN IN O
a DT DT O
negative JJ JJ O
coronary JJ JJ O
CTA NNP NNP O
in IN IN O
patients NNS NNS O
with IN IN O
cocaine NN NN B-CHEM
- - - O
associated JJ JJ O
chest NN NN O
pain NN NN O
could MD MD O
identify VB VB O
a DT DT O
subset NN NN O
safe JJ JJ O
for IN IN O
discharge NN NN O
. . . O

METHODS NNP NNP O
: : : O
We PRP PRP O
prospectively RB RB O
evaluated VBD VBD O
the DT DT O
safety NN NN O
of IN IN O
coronary JJ JJ O
CTA NNP NNP O
for IN IN O
low JJ JJ O
- - - O
risk NN NN O
patients NNS NNS O
who WP WP O
presented VBD VBD O
to TO TO O
the DT DT O
ED NNP NNP O
with IN IN O
cocaineassociated JJ JJ O
chest NN NN O
pain NN NN O
( ( ( O
self NN NN O
- - - O
reported VBN VBN O
or CC CC O
positive JJ JJ O
urine NN NN O
test NN NN O
) ) ) O
. . . O

Consecutive NNP NNP O
patients NNS NNS O
received VBD VBD O
either CC CC O
immediate JJ JJ O
coronary JJ JJ O
CTA NNP NNP O
in IN IN O
the DT DT O
ED NNP NNP O
( ( ( O
without IN IN O
serial JJ JJ O
markers NNS NNS O
) ) ) O
or CC CC O
underwent JJ JJ O
coronary JJ JJ O
CTA NNP NNP O
after IN IN O
a DT DT O
brief JJ JJ O
observation NN NN O
period NN NN O
with IN IN O
serial JJ JJ O
cardiac NN NN O
marker NN NN O
measurements NNS NNS O
. . . O

Patients NNS NNS O
with IN IN O
negative JJ JJ O
coronary JJ JJ O
CTA NNP NNP O
( ( ( O
maximal NN NN O
stenosis NN NN O
less JJR JJR O
than IN IN O
50 CD CD O
% NN NN O
) ) ) O
were VBD VBD O
discharged VBN VBN O
. . . O

The DT DT O
main JJ JJ O
outcome NN NN O
was VBD VBD O
30 CD CD O
- : : O
day NN NN O
cardiovascular JJ JJ O
death NN NN O
or CC CC O
myocardial NN NN O
infarction NN NN O
. . . O

RESULTS NNS NNS O
: : : O
A DT DT O
total NN NN O
of IN IN O
59 CD CD O
patients NNS NNS O
with IN IN O
cocaine NN NN B-CHEM
- - - O
associated JJ JJ O
chest NN NN O
pain NN NN O
were VBD VBD O
evaluated VBN VBN O
. . . O

Patients NNS NNS O
had VBD VBD O
a DT DT O
mean JJ JJ O
age NN NN O
of IN IN O
45 CD CD O
. . . O
6 CD CD O
+ NN NN O
/ NN NN O
- : : O
6 CD CD O
. . . O
6 CD CD O
yrs NNS NNS O
and CC CC O
were VBD VBD O
86 CD CD O
% NN NN O
black JJ JJ O
, , , O
66 CD CD O
% NN NN O
male JJ JJ O
. . . O

Seventy NNP NNP O
- - - O
nine CD CD O
percent NN NN O
had VBD VBD O
a DT DT O
normal JJ JJ O
or CC CC O
nonspecific JJ JJ O
ECG NNP NNP O
and CC CC O
85 CD CD O
% NN NN O
had VBD VBD O
a DT DT O
TIMI NNP NNP O
score NN NN O
< NN NN O
2 CD CD O
. . . O

Twenty NNP NNP O
patients NNS NNS O
received VBD VBD O
coronary JJ JJ O
CTA NNP NNP O
immediately RB RB O
in IN IN O
the DT DT O
ED NNP NNP O
, , , O
18 CD CD O
of IN IN O
whom WP WP O
were VBD VBD O
discharged VBN VBN O
following VBG VBG O
CTA NNP NNP O
( ( ( O
90 CD CD O
% NN NN O
) ) ) O
. . . O

Thirty NNP NNP O
- - - O
nine CD CD O
received VBD VBD O
coronary JJ JJ O
CTA NNP NNP O
after IN IN O
a DT DT O
brief JJ JJ O
observation NN NN O
period NN NN O
, , , O
with IN IN O
37 CD CD O
discharged JJ JJ O
home NN NN O
following VBG VBG O
CTA NNP NNP O
( ( ( O
95 CD CD O
% NN NN O
) ) ) O
. . . O

Six CD CD O
patients NNS NNS O
had VBD VBD O
coronary JJ JJ O
stenosis NN NN O
> NN NN O
or CC CC O
= SYM SYM O
50 CD CD O
% NN NN O
. . . O

During IN IN O
the DT DT O
30 CD CD O
- : : O
day NN NN O
follow VB VB O
- - - O
up RP RP O
period NN NN O
, , , O
no DT DT O
patients NNS NNS O
died VBD VBD O
of IN IN O
a DT DT O
cardiovascular JJ JJ O
event NN NN O
( ( ( O
0 CD CD O
% NN NN O
; : : O
95 CD CD O
% NN NN O
CI NNP NNP O
, , , O
0 CD CD O
- : : O
6 CD CD O
. . . O
1 CD CD O
% NN NN O
) ) ) O
and CC CC O
no DT DT O
patient NN NN O
sustained VBD VBD O
a DT DT O
nonfatal NN NN O
myocardial NN NN O
infarction NN NN O
( ( ( O
0 CD CD O
% NN NN O
; : : O
95 CD CD O
% NN NN O
CI NNP NNP O
, , , O
0 CD CD O
- : : O
6 CD CD O
. . . O
1 CD CD O
% NN NN O
) ) ) O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Although IN IN O
cocaine NN NN B-CHEM
- - - O
associated VBN VBN O
myocardial NN NN O
ischemia NN NN O
can MD MD O
result VB VB O
from IN IN O
coronary JJ JJ O
vasoconstriction NN NN O
, , , O
patients NNS NNS O
with IN IN O
cocaine NN NN B-CHEM
associated VBN VBN O
chest NN NN O
pain NN NN O
, , , O
a DT DT O
non NN NN O
- - - O
ischemic JJ JJ O
ECG NNP NNP O
, , , O
and CC CC O
a DT DT O
TIMI NNP NNP O
risk NN NN O
score NN NN O
< NN NN O
2 CD CD O
may MD MD O
be VB VB O
safely RB RB O
discharged VBN VBN O
from IN IN O
the DT DT O
ED NNP NNP O
after IN IN O
a DT DT O
negative JJ JJ O
coronary JJ JJ O
CTA NNP NNP O
with IN IN O
a DT DT O
low JJ JJ O
risk NN NN O
of IN IN O
30 CD CD O
- : : O
day NN NN O
adverse JJ JJ O
events NNS NNS O
. . . O

Bilateral NNP NNP O
haemorrhagic JJ JJ O
infarction NN NN O
of IN IN O
the DT DT O
globus NN NN O
pallidus NN NN O
after IN IN O
cocaine NN NN B-CHEM
and CC CC O
alcohol NN NN B-CHEM
intoxication NN NN O
. . . O

Cocaine NNP NNP B-CHEM
is VBZ VBZ O
a DT DT O
risk NN NN O
factor NN NN O
for IN IN O
both DT DT O
ischemic JJ JJ O
and CC CC O
haemorrhagic JJ JJ O
stroke NN NN O
. . . O

We PRP PRP O
present JJ JJ O
the DT DT O
case NN NN O
of IN IN O
a DT DT O
31 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
man NN NN O
with IN IN O
bilateral JJ JJ O
ischemia NN NN O
of IN IN O
the DT DT O
globus NN NN O
pallidus NN NN O
after IN IN O
excessive JJ JJ O
alcohol NN NN B-CHEM
and CC CC O
intranasal NN NN O
cocaine NN NN B-CHEM
use NN NN O
. . . O

Drug NN NN O
- - - O
related VBN VBN O
globus NN NN O
pallidus NN NN O
infarctions NNS NNS O
are VBP VBP O
most RBS RBS O
often RB RB O
associated VBN VBN O
with IN IN O
heroin NN NN B-CHEM
. . . O

Bilateral NNP NNP O
basal NN NN O
ganglia NN NN O
infarcts NNS NNS O
after IN IN O
the DT DT O
use NN NN O
of IN IN O
cocaine NN NN B-CHEM
, , , O
without IN IN O
concurrent JJ JJ O
heroin NN NN B-CHEM
use NN NN O
, , , O
have VBP VBP O
never RB RB O
been VBN VBN O
reported VBN VBN O
. . . O

In IN IN O
our PRP$ PRP$ O
patient NN NN O
, , , O
transient JJ JJ O
cardiac NN NN O
arrhythmia NN NN O
or CC CC O
respiratory JJ JJ O
dysfunction NN NN O
related VBN VBN O
to TO TO O
cocaine NN NN B-CHEM
and CC CC O
/ NN NN O
or CC CC O
ethanol JJ JJ B-CHEM
use NN NN O
were VBD VBD O
the DT DT O
most RBS RBS O
likely JJ JJ O
causes NNS NNS O
of IN IN O
cerebral JJ JJ O
hypoperfusion NN NN O
. . . O

Late RB RB O
fulminant JJ JJ O
posterior NN NN O
reversible JJ JJ O
encephalopathy NN NN O
syndrome NN NN O
after IN IN O
liver NN NN O
transplant NN NN O
. . . O

OBJECTIVES NNP NNP O
: : : O
Posterior NNP NNP O
leukoencephalopathy NN NN O
due JJ JJ O
to TO TO O
calcineurin VB VB O
- - - O
inhibitor NN NN O
- - - O
related VBN VBN O
neurotoxicity NN NN O
is VBZ VBZ O
a DT DT O
rare JJ JJ O
but CC CC O
severe JJ JJ O
complication NN NN O
that IN IN O
results NNS NNS O
from IN IN O
treatment NN NN O
with IN IN O
immunosuppressive JJ JJ O
agents NNS NNS O
( ( ( O
primarily RB RB O
those DT DT O
administered VBN VBN O
after IN IN O
a DT DT O
liver NN NN O
or CC CC O
kidney NN NN O
transplant NN NN O
) ) ) O
. . . O

The DT DT O
pathophysiologic JJ JJ O
mechanisms NNS NNS O
of IN IN O
that DT DT O
disorder NN NN O
remain VB VB O
unknown JJ JJ O
. . . O

CASE NN NN O
: : : O
We PRP PRP O
report VBP VBP O
the DT DT O
case NN NN O
of IN IN O
a DT DT O
46 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
woman NN NN O
who WP WP O
received VBD VBD O
a DT DT O
liver NN NN O
transplant NN NN O
in IN IN O
our PRP$ PRP$ O
center NN NN O
as IN IN O
treatment NN NN O
for IN IN O
alcoholic JJ JJ O
cirrhosis NNS NNS O
and CC CC O
in IN IN O
whom WP WP O
either CC CC O
a DT DT O
fulminant JJ JJ O
course NN NN O
of IN IN O
posterior NN NN O
leukoencephalopathy NN NN O
or CC CC O
posterior NN NN O
reversible JJ JJ O
encephalopathy NN NN O
syndrome NN NN O
developed VBN VBN O
110 CD CD O
days NNS NNS O
after IN IN O
transplant NN NN O
. . . O

After IN IN O
an DT DT O
initially RB RB O
uneventful JJ JJ O
course NN NN O
after IN IN O
the DT DT O
transplant NN NN O
, , , O
the DT DT O
patient NN NN O
rapidly RB RB O
fell VBD VBD O
into IN IN O
deep JJ JJ O
coma NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Cerebral NNP NNP O
MRI NNP NNP O
scan VB VB O
showed VBD VBD O
typical JJ JJ O
signs NNS NNS O
of IN IN O
enhancement NN NN O
in IN IN O
the DT DT O
pontine NN NN O
and CC CC O
posterior NN NN O
regions NNS NNS O
. . . O

Switching NNP NNP O
the DT DT O
immunosuppressive JJ JJ O
regimen NNS NNS O
from IN IN O
tacrolimus NN NN B-CHEM
to TO TO O
cyclosporine VB VB B-CHEM
did VBD VBD O
not RB RB O
improve VB VB O
the DT DT O
clinical JJ JJ O
situation NN NN O
. . . O

The DT DT O
termination NN NN O
of IN IN O
treatment NN NN O
with IN IN O
any DT DT O
calcineurin NN NN O
inhibitor NN NN O
resulted VBD VBD O
in IN IN O
a DT DT O
complete JJ JJ O
resolution NN NN O
of IN IN O
that DT DT O
complication NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Posterior NNP NNP O
reversible JJ JJ O
encephalopathy NN NN O
syndrome NN NN O
after IN IN O
liver NN NN O
transplant NN NN O
is VBZ VBZ O
rare JJ JJ O
. . . O

We PRP PRP O
recommend VBP VBP O
a DT DT O
complete JJ JJ O
cessation NN NN O
of IN IN O
any DT DT O
calcineurin NN NN O
inhibitor NN NN O
rather RB RB O
than IN IN O
a DT DT O
dose NN NN O
reduction NN NN O
. . . O

Prolonged NNP NNP O
hypothermia NN NN O
as IN IN O
a DT DT O
bridge NN NN O
to TO TO O
recovery NN NN O
for IN IN O
cerebral JJ JJ O
edema NN NN O
and CC CC O
intracranial JJ JJ O
hypertension NN NN O
associated VBN VBN O
with IN IN O
fulminant JJ JJ O
hepatic JJ JJ O
failure NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
To TO TO O
review VB VB O
evidence NN NN O
- - - O
based JJ JJ O
treatment NN NN O
options NNS NNS O
in IN IN O
patients NNS NNS O
with IN IN O
cerebral JJ JJ O
edema NN NN O
complicating VBG VBG O
fulminant JJ JJ O
hepatic JJ JJ O
failure NN NN O
( ( ( O
FHF NNP NNP O
) ) ) O
and CC CC O
discuss VB VB O
the DT DT O
potential JJ JJ O
applications NNS NNS O
of IN IN O
hypothermia NN NN O
. . . O

METHOD NNP NNP O
: : : O
Case NN NN O
- - - O
based JJ JJ O
observations NNS NNS O
from IN IN O
a DT DT O
medical JJ JJ O
intensive JJ JJ O
care NN NN O
unit NN NN O
( ( ( O
MICU NNP NNP O
) ) ) O
in IN IN O
a DT DT O
tertiary JJ JJ O
care NN NN O
facility NN NN O
in IN IN O
a DT DT O
27 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
female NN NN O
with IN IN O
FHF NNP NNP O
from IN IN O
acetaminophen NN NN B-CHEM
and CC CC O
resultant JJ JJ O
cerebral JJ JJ O
edema NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Our PRP$ PRP$ O
patient NN NN O
was VBD VBD O
admitted VBN VBN O
to TO TO O
the DT DT O
MICU NNP NNP O
after IN IN O
being VBG VBG O
found VBN VBN O
unresponsive JJ JJ O
with IN IN O
presumed JJ JJ O
toxicity NN NN O
from IN IN O
acetaminophen NN NN B-CHEM
which WDT WDT O
was VBD VBD O
ingested VBN VBN O
over IN IN O
a DT DT O
2 CD CD O
- : : O
day NN NN O
period NN NN O
. . . O

The DT DT O
patient NN NN O
had VBD VBD O
depressed VBN VBN O
of IN IN O
mental JJ JJ O
status NN NN O
lasting VBG VBG O
at IN IN O
least JJS JJS O
24 CD CD O
h NN NN O
prior RB RB O
to TO TO O
admission NN NN O
. . . O

Initial JJ JJ O
evaluation NN NN O
confirmed VBD VBD O
FHF NNP NNP O
from IN IN O
acetaminophen NN NN B-CHEM
and CC CC O
cerebral JJ JJ O
edema NN NN O
. . . O

The DT DT O
patient NN NN O
was VBD VBD O
treated VBN VBN O
with IN IN O
hyperosmolar NN NN O
therapy NN NN O
, , , O
hyperventilation NN NN O
, , , O
sedation NN NN O
, , , O
and CC CC O
chemical NN NN O
paralysis NN NN O
. . . O

Her PRP$ PRP$ O
intracranial JJ JJ O
pressure NN NN O
remained VBD VBD O
elevated JJ JJ O
despite IN IN O
maximal NN NN O
medical JJ JJ O
therapy NN NN O
. . . O

We PRP PRP O
then RB RB O
initiated VBD VBD O
therapeutic JJ JJ O
hypothermia NN NN O
which WDT WDT O
was VBD VBD O
continued VBN VBN O
for IN IN O
5 CD CD O
days NNS NNS O
. . . O

At IN IN O
re NN NN O
- - - O
warming NN NN O
, , , O
patient NN NN O
had VBD VBD O
resolution NN NN O
of IN IN O
her PRP$ PRP$ O
cerebral JJ JJ O
edema NN NN O
and CC CC O
intracranial JJ JJ O
hypertension NN NN O
. . . O

At IN IN O
discharge NN NN O
, , , O
she PRP PRP O
had VBD VBD O
complete JJ JJ O
recovery NN NN O
of IN IN O
neurological JJ JJ O
and CC CC O
hepatic JJ JJ O
functions NNS NNS O
. . . O

CONCLUSION NNP NNP O
: : : O
In IN IN O
patients NNS NNS O
with IN IN O
FHF NNP NNP O
and CC CC O
cerebral JJ JJ O
edema NN NN O
from IN IN O
acetaminophen NN NN B-CHEM
overdose NN NN O
, , , O
prolonged JJ JJ O
therapeutic JJ JJ O
hypothermia NN NN O
could MD MD O
potentially RB RB O
be VB VB O
used VBN VBN O
as IN IN O
a DT DT O
life NN NN O
saving VBG VBG O
therapy NN NN O
and CC CC O
a DT DT O
bridge NN NN O
to TO TO O
hepatic JJ JJ O
and CC CC O
neurological JJ JJ O
recovery NN NN O
. . . O

A DT DT O
clinical JJ JJ O
trial NN NN O
of IN IN O
hypothermia NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
this DT DT O
condition NN NN O
is VBZ VBZ O
warranted VBN VBN O
. . . O

Binasal NNP NNP O
visual JJ JJ O
field NN NN O
defects NNS NNS O
are VBP VBP O
not RB RB O
specific JJ JJ O
to TO TO O
vigabatrin NN NN B-CHEM
. . . O

This DT DT O
study NN NN O
investigated VBD VBD O
the DT DT O
visual JJ JJ O
defects NNS NNS O
associated VBN VBN O
with IN IN O
the DT DT O
antiepileptic JJ JJ O
drug NN NN O
vigabatrin NN NN B-CHEM
( ( ( O
VGB NNP NNP B-CHEM
) ) ) O
. . . O

Two CD CD O
hundred CD CD O
four CD CD O
people NNS NNS O
with IN IN O
epilepsy NN NN O
were VBD VBD O
grouped VBN VBN O
on IN IN O
the DT DT O
basis NN NN O
of IN IN O
antiepileptic JJ JJ O
drug NN NN O
therapy NN NN O
( ( ( O
current JJ JJ O
, , , O
previous JJ JJ O
, , , O
or CC CC O
no DT DT O
exposure NN NN O
to TO TO O
VGB NNP NNP B-CHEM
) ) ) O
. . . O

Groups NNS NNS O
were VBD VBD O
matched VBN VBN O
with IN IN O
respect NN NN O
to TO TO O
age NN NN O
, , , O
gender NN NN O
, , , O
and CC CC O
seizure NN NN O
frequency NN NN O
. . . O

All DT DT O
patients NNS NNS O
underwent VBD VBD O
objective NN NN O
assessment NN NN O
of IN IN O
electrophysiological JJ JJ O
function NN NN O
( ( ( O
wide JJ JJ O
- - - O
field NN NN O
multifocal JJ JJ O
electroretinography NN NN O
) ) ) O
and CC CC O
conventional JJ JJ O
visual JJ JJ O
field NN NN O
testing NN NN O
( ( ( O
static JJ JJ O
perimetry NN NN O
) ) ) O
. . . O

Bilateral NNP NNP O
visual JJ JJ O
field NN NN O
constriction NN NN O
was VBD VBD O
observed VBN VBN O
in IN IN O
59 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
currently RB RB O
taking VBG VBG O
VGB NNP NNP B-CHEM
, , , O
43 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
who WP WP O
previously RB RB O
took VBD VBD O
VGB NNP NNP B-CHEM
, , , O
and CC CC O
24 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
with IN IN O
no DT DT O
exposure NN NN O
to TO TO O
VGB NNP NNP B-CHEM
. . . O

Assessment NNP NNP O
of IN IN O
retinal JJ JJ O
function NN NN O
revealed VBD VBD O
abnormal JJ JJ O
responses NNS NNS O
in IN IN O
48 CD CD O
% NN NN O
of IN IN O
current JJ JJ O
VGB NNP NNP B-CHEM
users NNS NNS O
and CC CC O
22 CD CD O
% NN NN O
of IN IN O
prior RB RB O
VGB NNP NNP B-CHEM
users NNS NNS O
, , , O
but CC CC O
in IN IN O
none NN NN O
of IN IN O
the DT DT O
patients NNS NNS O
without IN IN O
previous JJ JJ O
exposure NN NN O
to TO TO O
VGB NNP NNP B-CHEM
. . . O

Bilateral NNP NNP O
visual JJ JJ O
field NN NN O
abnormalities NNS NNS O
are VBP VBP O
common JJ JJ O
in IN IN O
the DT DT O
treated VBN VBN O
epilepsy NN NN O
population NN NN O
, , , O
irrespective JJ JJ O
of IN IN O
drug NN NN O
history NN NN O
. . . O

Assessment NNP NNP O
by IN IN O
conventional JJ JJ O
static JJ JJ O
perimetry NN NN O
may MD MD O
neither DT DT O
be VB VB O
sufficiently RB RB O
sensitive JJ JJ O
nor CC CC O
specific JJ JJ O
to TO TO O
reliably RB RB O
identify VB VB O
retinal JJ JJ O
toxicity NN NN O
associated VBN VBN O
with IN IN O
VGB NNP NNP B-CHEM
. . . O

Smoking NNP NNP O
of IN IN O
crack NN NN B-CHEM
cocaine NN NN I-CHEM
as IN IN O
a DT DT O
risk NN NN O
factor NN NN O
for IN IN O
HIV NNP NNP O
infection NN NN O
among IN IN O
people NNS NNS O
who WP WP O
use VBP VBP O
injection NN NN O
drugs NNS NNS O
. . . O

BACKGROUND NNP NNP O
: : : O
Little NNP NNP O
is VBZ VBZ O
known VBN VBN O
about IN IN O
the DT DT O
possible JJ JJ O
role NN NN O
that IN IN O
smoking NN NN O
crack NN NN B-CHEM
cocaine NN NN I-CHEM
has VBZ VBZ O
on IN IN O
the DT DT O
incidence NN NN O
of IN IN O
HIV NNP NNP O
infection NN NN O
. . . O

Given VBN VBN O
the DT DT O
increasing VBG VBG O
use NN NN O
of IN IN O
crack NN NN B-CHEM
cocaine NN NN I-CHEM
, , , O
we PRP PRP O
sought VBD VBD O
to TO TO O
examine VB VB O
whether IN IN O
use NN NN O
of IN IN O
this DT DT O
illicit JJ JJ O
drug NN NN O
has VBZ VBZ O
become VBN VBN O
a DT DT O
risk NN NN O
factor NN NN O
for IN IN O
HIV NNP NNP O
infection NN NN O
. . . O

METHODS NNP NNP O
: : : O
We PRP PRP O
included VBD VBD O
data NNS NNS O
from IN IN O
people NNS NNS O
participating VBG VBG O
in IN IN O
the DT DT O
Vancouver NNP NNP O
Injection NNP NNP O
Drug NN NN O
Users NNS NNS O
Study NNP NNP O
who WP WP O
reported VBD VBD O
injecting VBG VBG O
illicit JJ JJ O
drugs NNS NNS O
at IN IN O
least JJS JJS O
once RB RB O
in IN IN O
the DT DT O
month NN NN O
before IN IN O
enrolment NN NN O
, , , O
lived VBD VBD O
in IN IN O
the DT DT O
greater JJR JJR O
Vancouver NNP NNP O
area NN NN O
, , , O
were VBD VBD O
HIV NNP NNP O
- : : O
negative JJ JJ O
at IN IN O
enrolment NN NN O
and CC CC O
completed VBN VBN O
at IN IN O
least JJS JJS O
1 CD CD O
follow VB VB O
- - - O
up RP RP O
study NN NN O
visit NN NN O
. . . O

To TO TO O
determine VB VB O
whether IN IN O
the DT DT O
risk NN NN O
of IN IN O
HIV NNP NNP O
seroconversion NN NN O
among IN IN O
daily JJ JJ O
smokers NNS NNS O
of IN IN O
crack NN NN B-CHEM
cocaine NN NN I-CHEM
changed VBN VBN O
over IN IN O
time NN NN O
, , , O
we PRP PRP O
used VBD VBD O
Cox NNP NNP O
proportional JJ JJ O
hazards NNS NNS O
regression NN NN O
and CC CC O
divided VBD VBD O
the DT DT O
study NN NN O
into IN IN O
3 CD CD O
periods NNS NNS O
: : : O
May NNP NNP O
1 CD CD O
, , , O
1996 CD CD O
- : : O
Nov NNP NNP O
. . . O

30 CD CD O
, , , O
1999 CD CD O
( ( ( O
period NN NN O
1 CD CD O
) ) ) O
, , , O
Dec NNP NNP O
. . . O

1 CD CD O
, , , O
1999 CD CD O
- : : O
Nov NNP NNP O
. . . O

30 CD CD O
, , , O
2002 CD CD O
( ( ( O
period NN NN O
2 CD CD O
) ) ) O
, , , O
and CC CC O
Dec NNP NNP O
. . . O

1 CD CD O
, , , O
2002 CD CD O
- : : O
Dec NNP NNP O
. . . O

30 CD CD O
, , , O
2005 CD CD O
( ( ( O
period NN NN O
3 CD CD O
) ) ) O
. . . O

RESULTS NNS NNS O
: : : O
Overall NNP NNP O
, , , O
1048 CD CD O
eligible JJ JJ O
injection NN NN O
drug NN NN O
users NNS NNS O
were VBD VBD O
included VBN VBN O
in IN IN O
our PRP$ PRP$ O
study NN NN O
. . . O

Of IN IN O
these DT DT O
, , , O
137 CD CD O
acquired JJ JJ O
HIV NNP NNP O
infection NN NN O
during IN IN O
follow VB VB O
- - - O
up RP RP O
. . . O

The DT DT O
mean JJ JJ O
proportion NN NN O
of IN IN O
participants NNS NNS O
who WP WP O
reported VBD VBD O
daily JJ JJ O
smoking NN NN O
of IN IN O
crack NN NN B-CHEM
cocaine NN NN I-CHEM
increased VBN VBN O
from IN IN O
11 CD CD O
. . . O
6 CD CD O
% NN NN O
in IN IN O
period NN NN O
1 CD CD O
to TO TO O
39 CD CD O
. . . O
7 CD CD O
% NN NN O
in IN IN O
period NN NN O
3 CD CD O
. . . O

After IN IN O
adjusting VBG VBG O
for IN IN O
potential JJ JJ O
confounders NNS NNS O
, , , O
we PRP PRP O
found VBD VBD O
that IN IN O
the DT DT O
risk NN NN O
of IN IN O
HIV NNP NNP O
seroconversion NN NN O
among IN IN O
participants NNS NNS O
who WP WP O
were VBD VBD O
daily JJ JJ O
smokers NNS NNS O
of IN IN O
crack NN NN B-CHEM
cocaine NN NN I-CHEM
increased VBN VBN O
over IN IN O
time NN NN O
( ( ( O
period NN NN O
1 CD CD O
: : : O
hazard NN NN O
ratio NN NN O
[ NN NN O
HR NNP NNP O
] NN NN O
1 CD CD O
. . . O
03 CD CD O
, , , O
95 CD CD O
% NN NN O
confidence NN NN O
interval NN NN O
[ NN NN O
CI NNP NNP O
] NN NN O
0 CD CD O
. . . O
57 CD CD O
- : : O
1 CD CD O
. . . O
85 CD CD O
; : : O
period NN NN O
2 CD CD O
: : : O
HR NNP NNP O
1 CD CD O
. . . O
68 CD CD O
, , , O
95 CD CD O
% NN NN O
CI NNP NNP O
1 CD CD O
. . . O
01 CD CD O
- : : O
2 CD CD O
. . . O
80 CD CD O
; : : O
and CC CC O
period NN NN O
3 CD CD O
: : : O
HR NNP NNP O
2 CD CD O
. . . O
74 CD CD O
, , , O
95 CD CD O
% NN NN O
CI NNP NNP O
1 CD CD O
. . . O
06 CD CD O
- : : O
7 CD CD O
. . . O
11 CD CD O
) ) ) O
. . . O

INTERPRETATION NN NN O
: : : O
Smoking NNP NNP O
of IN IN O
crack NN NN B-CHEM
cocaine NN NN I-CHEM
was VBD VBD O
found VBN VBN O
to TO TO O
be VB VB O
an DT DT O
independent JJ JJ O
risk NN NN O
factor NN NN O
for IN IN O
HIV NNP NNP O
seroconversion NN NN O
among IN IN O
people NNS NNS O
who WP WP O
were VBD VBD O
injection NN NN O
drug NN NN O
users NNS NNS O
. . . O

This DT DT O
finding VBG VBG O
points NNS NNS O
to TO TO O
the DT DT O
urgent JJ JJ O
need VBP VBP O
for IN IN O
evidence NN NN O
- - - O
based JJ JJ O
public JJ JJ O
health NN NN O
initiatives NNS NNS O
targeted VBN VBN O
at IN IN O
people NNS NNS O
who WP WP O
smoke VBP VBP O
crack JJ JJ B-CHEM
cocaine NN NN I-CHEM
. . . O

Fluoxetine NNP NNP B-CHEM
improves VBZ VBZ O
the DT DT O
memory NN NN O
deficits NNS NNS O
caused VBN VBN O
by IN IN O
the DT DT O
chemotherapy NN NN O
agent NN NN O
5 CD CD B-CHEM
- : : I-CHEM
fluorouracil NN NN I-CHEM
. . . O

Cancer NNP NNP O
patients NNS NNS O
who WP WP O
have VBP VBP O
been VBN VBN O
treated VBN VBN O
with IN IN O
systemic JJ JJ O
adjuvant NN NN O
chemotherapy NN NN O
have VBP VBP O
described VBN VBN O
experiencing VBG VBG O
deteriorations NNS NNS O
in IN IN O
cognition NN NN O
. . . O

A DT DT O
widely RB RB O
used VBN VBN O
chemotherapeutic JJ JJ O
agent NN NN O
, , , O
5 CD CD B-CHEM
- : : I-CHEM
fluorouracil NN NN I-CHEM
( ( ( O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
) ) ) O
, , , O
readily RB RB O
crosses VBZ VBZ O
the DT DT O
blood NN NN O
- - - O
brain NN NN O
barrier NN NN O
and CC CC O
so RB RB O
could MD MD O
have VB VB O
a DT DT O
direct JJ JJ O
effect NN NN O
on IN IN O
brain NN NN O
function NN NN O
. . . O

In IN IN O
particular JJ JJ O
this DT DT O
anti JJ JJ O
mitotic JJ JJ O
drug NN NN O
could MD MD O
reduce VB VB O
cell NN NN O
proliferation NN NN O
in IN IN O
the DT DT O
neurogenic JJ JJ O
regions NNS NNS O
of IN IN O
the DT DT O
adult NN NN O
brain NN NN O
. . . O

In IN IN O
contrast NN NN O
reports NNS NNS O
indicate VBP VBP O
that IN IN O
hippocampal JJ JJ O
dependent JJ JJ O
neurogenesis NN NN O
and CC CC O
cognition NN NN O
are VBP VBP O
enhanced VBN VBN O
by IN IN O
the DT DT O
SSRI NNP NNP B-CHEM
antidepressant NN NN O
Fluoxetine NNP NNP B-CHEM
. . . O

In IN IN O
this DT DT O
investigation NN NN O
the DT DT O
behavioural JJ JJ O
effects NNS NNS O
of IN IN O
chronic JJ JJ O
( ( ( O
two CD CD O
week NN NN O
) ) ) O
treatment NN NN O
with IN IN O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
and CC CC O
( ( ( O
three CD CD O
weeks NNS NNS O
) ) ) O
with IN IN O
Fluoxetine NNP NNP B-CHEM
either CC CC O
separately RB RB O
or CC CC O
in IN IN O
combination NN NN O
with IN IN O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
were VBD VBD O
tested VBN VBN O
on IN IN O
adult NN NN O
Lister NNP NNP O
hooded VBD VBD O
rats NNS NNS O
. . . O

Behavioural NNP NNP O
effects NNS NNS O
were VBD VBD O
tested VBN VBN O
using VBG VBG O
a DT DT O
context NN NN O
dependent NN NN O
conditioned VBN VBN O
emotional JJ JJ O
response NN NN O
test NN NN O
( ( ( O
CER NNP NNP O
) ) ) O
which WDT WDT O
showed VBD VBD O
that IN IN O
animals NNS NNS O
treated VBN VBN O
with IN IN O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
had VBD VBD O
a DT DT O
significant JJ JJ O
reduction NN NN O
in IN IN O
freezing VBG VBG O
time NN NN O
compared VBN VBN O
to TO TO O
controls NNS NNS O
. . . O

A DT DT O
separate JJ JJ O
group NN NN O
of IN IN O
animals NNS NNS O
was VBD VBD O
tested VBN VBN O
using VBG VBG O
a DT DT O
hippocampal JJ JJ O
dependent JJ JJ O
spatial NN NN O
working VBG VBG O
memory NN NN O
test NN NN O
, , , O
the DT DT O
object VBP VBP O
location NN NN O
recognition NN NN O
test NN NN O
( ( ( O
OLR NNP NNP O
) ) ) O
. . . O

Animals NNS NNS O
treated VBN VBN O
only RB RB O
with IN IN O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
showed VBD VBD O
significant JJ JJ O
deficits NNS NNS O
in IN IN O
their PRP$ PRP$ O
ability NN NN O
to TO TO O
carry VB VB O
out RP RP O
the DT DT O
OLR NNP NNP O
task NN NN O
but CC CC O
co JJ JJ O
administration NN NN O
of IN IN O
Fluoxetine NNP NNP B-CHEM
improved VBD VBD O
their PRP$ PRP$ O
performance NN NN O
. . . O

5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
chemotherapy NN NN O
caused VBD VBD O
a DT DT O
significant JJ JJ O
reduction NN NN O
in IN IN O
the DT DT O
number NN NN O
of IN IN O
proliferating VBG VBG O
cells NNS NNS O
in IN IN O
the DT DT O
sub NN NN O
granular NN NN O
zone NN NN O
of IN IN O
the DT DT O
dentate NN NN O
gyrus NN NN O
compared VBN VBN O
to TO TO O
controls NNS NNS O
. . . O

This DT DT O
reduction NN NN O
was VBD VBD O
eliminated VBN VBN O
when WRB WRB O
Fluoxetine NNP NNP B-CHEM
was VBD VBD O
co NN NN O
administered VBN VBN O
with IN IN O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
. . . O

Fluoxetine NNP NNP B-CHEM
on IN IN O
its PRP$ PRP$ O
own JJ JJ O
had VBD VBD O
no DT DT O
effect NN NN O
on IN IN O
proliferating VBG VBG O
cell NN NN O
number NN NN O
or CC CC O
behaviour NN NN O
. . . O

These DT DT O
findings NNS NNS O
suggest VBP VBP O
that IN IN O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
can MD MD O
negatively RB RB O
affect VB VB O
both DT DT O
cell NN NN O
proliferation NN NN O
and CC CC O
hippocampal NN NN O
dependent NN NN O
working VBG VBG O
memory NN NN O
and CC CC O
that IN IN O
these DT DT O
deficits NNS NNS O
can MD MD O
be VB VB O
reversed VBN VBN O
by IN IN O
the DT DT O
simultaneous JJ JJ O
administration NN NN O
of IN IN O
the DT DT O
antidepressant NN NN O
Fluoxetine NNP NNP B-CHEM
. . . O

Liver NNP NNP O
- - - O
specific JJ JJ O
ablation NN NN O
of IN IN O
integrin NN NN O
- - - O
linked VBN VBN O
kinase NN NN O
in IN IN O
mice NN NN O
results NNS NNS O
in IN IN O
enhanced JJ JJ O
and CC CC O
prolonged JJ JJ O
cell NN NN O
proliferation NN NN O
and CC CC O
hepatomegaly NN NN O
after IN IN O
phenobarbital JJ JJ B-CHEM
administration NN NN O
. . . O

We PRP PRP O
have VBP VBP O
recently RB RB O
demonstrated VBN VBN O
that DT DT O
disruption NN NN O
of IN IN O
extracellular NN NN O
matrix NN NN O
( ( ( O
ECM NNP NNP O
) ) ) O
/ NN NN O
integrin NN NN O
signaling VBG VBG O
via IN IN O
elimination NN NN O
of IN IN O
integrin NN NN O
- - - O
linked VBN VBN O
kinase NN NN O
( ( ( O
ILK NNP NNP O
) ) ) O
in IN IN O
hepatocytes NNS NNS O
interferes VBZ VBZ O
with IN IN O
signals NNS NNS O
leading VBG VBG O
to TO TO O
termination NN NN O
of IN IN O
liver NN NN O
regeneration NN NN O
. . . O

This DT DT O
study NN NN O
investigates VBZ VBZ O
the DT DT O
role NN NN O
of IN IN O
ILK NNP NNP O
in IN IN O
liver NN NN O
enlargement NN NN O
induced VBN VBN O
by IN IN O
phenobarbital JJ JJ B-CHEM
( ( ( O
PB NNP NNP B-CHEM
) ) ) O
. . . O

Wild NNP NNP O
- : : O
type NN NN O
( ( ( O
WT NNP NNP O
) ) ) O
and CC CC O
ILK NNP NNP O
: : : O
liver NN NN O
- - - O
/ NN NN O
- - - O
mice NN NN O
were VBD VBD O
given VBN VBN O
PB NNP NNP B-CHEM
( ( ( O
0 CD CD O
. . . O
1 CD CD O
% NN NN O
in IN IN O
drinking NN NN O
water NN NN O
) ) ) O
for IN IN O
10 CD CD O
days NNS NNS O
. . . O

Livers NNP NNP O
were VBD VBD O
harvested VBN VBN O
on IN IN O
2 CD CD O
, , , O
5 CD CD O
, , , O
and CC CC O
10 CD CD O
days NNS NNS O
during IN IN O
PB NNP NNP B-CHEM
administration NN NN O
. . . O

In IN IN O
the DT DT O
hepatocyte NN NN O
- - - O
specific JJ JJ O
ILK NNP NNP O
/ NN NN O
liver NN NN O
- - - O
/ NN NN O
- - - O
mice NN NN O
, , , O
the DT DT O
liver NN NN O
: : : O
body NN NN O
weight NN NN O
ratio NN NN O
was VBD VBD O
more RBR RBR O
than IN IN O
double RB RB O
as IN IN O
compared VBN VBN O
to TO TO O
0 CD CD O
h NN NN O
at IN IN O
day NN NN O
2 CD CD O
( ( ( O
2 CD CD O
. . . O
5 CD CD O
times NNS NNS O
) ) ) O
, , , O
while IN IN O
at IN IN O
days NNS NNS O
5 CD CD O
and CC CC O
10 CD CD O
, , , O
it PRP PRP O
was VBD VBD O
enlarged VBN VBN O
three CD CD O
times NNS NNS O
. . . O

In IN IN O
the DT DT O
WT NNP NNP O
mice NN NN O
, , , O
the DT DT O
increase NN NN O
was VBD VBD O
as IN IN O
expected VBN VBN O
from IN IN O
previous JJ JJ O
literature NN NN O
( ( ( O
1 CD CD O
. . . O
8 CD CD O
times NNS NNS O
) ) ) O
and CC CC O
seems VBZ VBZ O
to TO TO O
have VB VB O
leveled VBN VBN O
off RP RP O
after IN IN O
day NN NN O
2 CD CD O
. . . O

There EX EX O
were VBD VBD O
slightly RB RB O
increased VBN VBN O
proliferating VBG VBG O
cell NN NN O
nuclear JJ JJ O
antigen NN NN O
- - - O
positive JJ JJ O
cells NNS NNS O
in IN IN O
the DT DT O
ILK NNP NNP O
/ NN NN O
liver NN NN O
- - - O
/ NN NN O
- - - O
animals NNS NNS O
at IN IN O
day NN NN O
2 CD CD O
as IN IN O
compared VBN VBN O
to TO TO O
WT NNP NNP O
after IN IN O
PB NNP NNP B-CHEM
administration NN NN O
. . . O

In IN IN O
the DT DT O
WT NNP NNP O
animals NNS NNS O
, , , O
the DT DT O
proliferative JJ JJ O
response NN NN O
had VBD VBD O
come VBN VBN O
back RB RB O
to TO TO O
normal JJ JJ O
by IN IN O
days NNS NNS O
5 CD CD O
and CC CC O
10 CD CD O
. . . O

Hepatocytes NNP NNP O
of IN IN O
the DT DT O
ILK NNP NNP O
/ NN NN O
liver NN NN O
- - - O
/ NN NN O
- - - O
mice NN NN O
continued VBD VBD O
to TO TO O
proliferate VB VB O
up RP RP O
until IN IN O
day NN NN O
10 CD CD O
. . . O

ILK NNP NNP O
/ NN NN O
liver NN NN O
- - - O
/ NN NN O
- - - O
mice NN NN O
also RB RB O
showed VBD VBD O
increased VBN VBN O
expression NN NN O
of IN IN O
key JJ JJ O
genes NNS NNS O
involved VBN VBN O
in IN IN O
hepatocyte NN NN O
proliferation NN NN O
at IN IN O
different JJ JJ O
time NN NN O
points NNS NNS O
during IN IN O
PB NNP NNP B-CHEM
administration NN NN O
. . . O

In IN IN O
summary JJ JJ O
, , , O
ECM NNP NNP O
proteins NNS NNS O
communicate VBP VBP O
with IN IN O
the DT DT O
signaling VBG VBG O
machinery NN NN O
of IN IN O
dividing VBG VBG O
cells NNS NNS O
via IN IN O
ILK NNP NNP O
to TO TO O
regulate VB VB O
hepatocyte NN NN O
proliferation NN NN O
and CC CC O
termination NN NN O
of IN IN O
the DT DT O
proliferative JJ JJ O
response NN NN O
. . . O

Lack NNP NNP O
of IN IN O
ILK NNP NNP O
in IN IN O
the DT DT O
hepatocytes NNS NNS O
imparts NNS NNS O
prolonged JJ JJ O
proliferative JJ JJ O
response NN NN O
not RB RB O
only RB RB O
to TO TO O
stimuli VB VB O
related VBN VBN O
to TO TO O
liver NN NN O
regeneration NN NN O
but CC CC O
also RB RB O
to TO TO O
xenobiotic JJ JJ O
chemical NN NN O
mitogens NNS NNS O
, , , O
such JJ JJ O
as IN IN O
PB NNP NNP B-CHEM
. . . O

Decreased NNP NNP O
Expression NNP NNP O
of IN IN O
Na NNP NNP B-CHEM
/ NN NN O
K NNP NNP B-CHEM
- : : O
ATPase NNP NNP O
, , , O
NHE3 NNP NNP O
, , , O
NBC1 NNP NNP O
, , , O
AQP1 NNP NNP O
and CC CC O
OAT NNP NNP O
in IN IN O
Gentamicin NNP NNP B-CHEM
- : : O
induced JJ JJ O
Nephropathy NNP NNP O
. . . O

The DT DT O
present JJ JJ O
study NN NN O
was VBD VBD O
aimed VBN VBN O
to TO TO O
determine VB VB O
whether IN IN O
there EX EX O
is VBZ VBZ O
an DT DT O
altered JJ JJ O
regulation NN NN O
of IN IN O
tubular NN NN O
transporters NNS NNS O
in IN IN O
gentamicin NN NN B-CHEM
- - - O
induced JJ JJ O
nephropathy NN NN O
. . . O

Sprague NNP NNP O
- : : O
Dawley NNP NNP O
male JJ JJ O
rats NNS NNS O
( ( ( O
200 CD CD O
~ NN NN O
250 CD CD O
g SYM SYM O
) ) ) O
were VBD VBD O
subcutaneously RB RB O
injected VBN VBN O
with IN IN O
gentamicin NN NN B-CHEM
( ( ( O
100 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
per IN IN O
day NN NN O
) ) ) O
for IN IN O
7 CD CD O
days NNS NNS O
, , , O
and CC CC O
the DT DT O
expression NN NN O
of IN IN O
tubular NN NN O
transporters NNS NNS O
was VBD VBD O
determined VBN VBN O
by IN IN O
immunoblotting VBG VBG O
and CC CC O
immunohistochemistry NN NN O
. . . O

The DT DT O
mRNA NN NN O
and CC CC O
protein NN NN O
expression NN NN O
of IN IN O
OAT NNP NNP O
was VBD VBD O
also RB RB O
determined VBN VBN O
. . . O

Gentamicin NNP NNP B-CHEM
- - - O
treated JJ JJ O
rats NNS NNS O
exhibited VBN VBN O
significantly RB RB O
decreased VBN VBN O
creatinine NN NN B-CHEM
clearance NN NN O
along IN IN O
with IN IN O
increased VBN VBN O
plasma NN NN O
creatinine NN NN B-CHEM
levels NNS NNS O
. . . O

Accordingly RB RB O
, , , O
the DT DT O
fractional JJ JJ O
excretion NN NN O
of IN IN O
sodium NN NN B-CHEM
increased VBN VBN O
. . . O

Urine NNP NNP O
volume NN NN O
was VBD VBD O
increased VBN VBN O
, , , O
while IN IN O
urine JJ JJ O
osmolality NN NN O
and CC CC O
free JJ JJ O
water NN NN O
reabsorption NN NN O
were VBD VBD O
decreased VBN VBN O
. . . O

Immunoblotting NNP NNP O
and CC CC O
immunohistochemistry NN NN O
revealed VBD VBD O
decreased VBD VBD O
expression NN NN O
of IN IN O
Na NNP NNP B-CHEM
( ( ( O
+ NN NN O
) ) ) O
/ NN NN O
K NNP NNP B-CHEM
( ( ( O
+ NN NN O
) ) ) O
- : : O
ATPase NNP NNP O
, , , O
NHE3 NNP NNP O
, , , O
NBC1 NNP NNP O
, , , O
and CC CC O
AQP1 NNP NNP O
in IN IN O
the DT DT O
kidney NN NN O
of IN IN O
gentamicin NN NN B-CHEM
- - - O
treated VBN VBN O
rats NNS NNS O
. . . O

The DT DT O
expression NN NN O
of IN IN O
OAT1 NNP NNP O
and CC CC O
OAT3 NNP NNP O
was VBD VBD O
also RB RB O
decreased VBN VBN O
. . . O

Gentamicin NNP NNP B-CHEM
- : : O
induced JJ JJ O
nephropathy NN NN O
may MD MD O
at IN IN O
least JJS JJS O
in IN IN O
part NN NN O
be VB VB O
causally RB RB O
related VBN VBN O
with IN IN O
a DT DT O
decreased JJ JJ O
expression NN NN O
of IN IN O
Na NNP NNP B-CHEM
( ( ( O
+ NN NN O
) ) ) O
/ NN NN O
K NNP NNP B-CHEM
( ( ( O
+ NN NN O
) ) ) O
- : : O
ATPase NNP NNP O
, , , O
NHE3 NNP NNP O
, , , O
NBC1 NNP NNP O
, , , O
AQP1 NNP NNP O
and CC CC O
OAT NNP NNP O
. . . O

Acute JJ JJ O
renal JJ JJ O
failure NN NN O
after IN IN O
high JJ JJ O
- - - O
dose NN NN O
methotrexate NN NN B-CHEM
therapy NN NN O
in IN IN O
a DT DT O
patient NN NN O
with IN IN O
ileostomy NN NN O
. . . O

High NNP NNP O
- - - O
dose NN NN O
methotrexate NN NN B-CHEM
( ( ( O
HD NNP NNP O
- - - O
MTX NNP NNP B-CHEM
) ) ) O
is VBZ VBZ O
an DT DT O
important JJ JJ O
treatment NN NN O
for IN IN O
Burkitt NNP NNP O
lymphoma NN NN O
, , , O
but CC CC O
can MD MD O
cause VB VB O
hepatic JJ JJ O
and CC CC O
renal JJ JJ O
toxicity NN NN O
when WRB WRB O
its PRP$ PRP$ O
clearance NN NN O
is VBZ VBZ O
delayed VBN VBN O
. . . O

We PRP PRP O
report VBP VBP O
a DT DT O
case NN NN O
of IN IN O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
after IN IN O
HD NNP NNP O
- : : O
MTX NNP NNP B-CHEM
therapy NN NN O
in IN IN O
a DT DT O
patient NN NN O
with IN IN O
ileostomy NN NN O
, , , O
The DT DT O
patient NN NN O
was VBD VBD O
a DT DT O
3 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
boy NN NN O
who WP WP O
had VBD VBD O
received VBN VBN O
a DT DT O
living VBG VBG O
- - - O
related VBN VBN O
liver NN NN O
transplantation NN NN O
for IN IN O
congenital NN NN O
biliary JJ JJ O
atresia NN NN O
. . . O

At IN IN O
day NN NN O
833 CD CD O
after IN IN O
the DT DT O
transplantation NN NN O
, , , O
he PRP PRP O
was VBD VBD O
diagnosed VBN VBN O
with IN IN O
PTLD NNP NNP O
( ( ( O
post NN NN O
- - - O
transplantation NN NN O
lymphoproliferative JJ JJ O
disorder NN NN O
, , , O
Burkitt NNP NNP O
- : : O
type NN NN O
malignant JJ JJ O
lymphoma NN NN O
) ) ) O
. . . O

During IN IN O
induction NN NN O
therapy NN NN O
, , , O
he PRP PRP O
suffered VBD VBD O
ileal JJ JJ O
perforation NN NN O
and CC CC O
ileostomy NN NN O
was VBD VBD O
performed VBN VBN O
. . . O

Subsequent NNP NNP O
HD NNP NNP O
- : : O
MTX NNP NNP B-CHEM
therapy NN NN O
caused VBD VBD O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
that WDT WDT O
required VBD VBD O
continuous JJ JJ O
hemodialysis NN NN O
. . . O

We PRP PRP O
supposed VBD VBD O
that IN IN O
intravascular JJ JJ O
hypovolemia NN NN O
due JJ JJ O
to TO TO O
substantial JJ JJ O
drainage NN NN O
from IN IN O
the DT DT O
ileostoma NN NN O
caused VBD VBD O
acute JJ JJ O
prerenal JJ JJ O
failure NN NN O
. . . O

After IN IN O
recovery NN NN O
of IN IN O
his PRP$ PRP$ O
renal JJ JJ O
function NN NN O
, , , O
we PRP PRP O
could MD MD O
safely RB RB O
treat VB VB O
the DT DT O
patient NN NN O
with IN IN O
HD NNP NNP O
- : : O
MTX NNP NNP B-CHEM
therapy NN NN O
by IN IN O
controlling VBG VBG O
drainage NN NN O
from IN IN O
ileostoma NN NN O
with IN IN O
total JJ JJ O
parenteral JJ JJ O
nutrition NN NN O
. . . O

Longitudinal NNP NNP O
association NN NN O
of IN IN O
alcohol NN NN B-CHEM
use NN NN O
with IN IN O
HIV NNP NNP O
disease NN NN O
progression NN NN O
and CC CC O
psychological JJ JJ O
health NN NN O
of IN IN O
women NNS NNS O
with IN IN O
HIV NNP NNP O
. . . O

We PRP PRP O
evaluated VBD VBD O
the DT DT O
association NN NN O
of IN IN O
alcohol NN NN B-CHEM
consumption NN NN O
and CC CC O
depression NN NN O
, , , O
and CC CC O
their PRP$ PRP$ O
effects NNS NNS O
on IN IN O
HIV NNP NNP O
disease NN NN O
progression NN NN O
among IN IN O
women NNS NNS O
with IN IN O
HIV NNP NNP O
. . . O

The DT DT O
study NN NN O
included VBD VBD O
871 CD CD O
women NNS NNS O
with IN IN O
HIV NNP NNP O
who WP WP O
were VBD VBD O
recruited VBN VBN O
from IN IN O
1993 CD CD O
- : : O
1995 CD CD O
in IN IN O
four CD CD O
US NNP NNP O
cities NNS NNS O
. . . O

The DT DT O
participants NNS NNS O
had VBD VBD O
physical JJ JJ O
examination NN NN O
, , , O
medical JJ JJ O
record NN NN O
extraction NN NN O
, , , O
and CC CC O
venipuncture NN NN O
, , , O
CD4 NNP NNP O
+ NN NN O
T NN NN O
- - - O
cell NN NN O
counts VBZ VBZ O
determination NN NN O
, , , O
measurement NN NN O
of IN IN O
depression NN NN O
symptoms NNS NNS O
( ( ( O
using VBG VBG O
the DT DT O
self NN NN O
- - - O
report NN NN O
Center NNP NNP O
for IN IN O
Epidemiological NNP NNP O
Studies NNPS NNPS O
- : : O
Depression NNP NNP O
Scale NNP NNP O
) ) ) O
, , , O
and CC CC O
alcohol NN NN B-CHEM
use NN NN O
assessment NN NN O
at IN IN O
enrollment NN NN O
, , , O
and CC CC O
semiannually RB RB O
until IN IN O
March NNP NNP O
2000 CD CD O
. . . O

Multilevel NNP NNP O
random JJ JJ O
coefficient NN NN O
ordinal JJ JJ O
models NNS NNS O
as RB RB O
well RB RB O
as IN IN O
multilevel NN NN O
models NNS NNS O
with IN IN O
joint JJ JJ O
responses NNS NNS O
were VBD VBD O
used VBN VBN O
in IN IN O
the DT DT O
analysis NN NN O
. . . O

There EX EX O
was VBD VBD O
no DT DT O
significant JJ JJ O
association NN NN O
between IN IN O
level NN NN O
of IN IN O
alcohol NN NN B-CHEM
use NN NN O
and CC CC O
CD4 NNP NNP O
+ NN NN O
T NN NN O
- - - O
cell NN NN O
counts NNS NNS O
. . . O

When WRB WRB O
participants NNS NNS O
were VBD VBD O
stratified VBN VBN O
by IN IN O
antiretroviral JJ JJ O
therapy NN NN O
( ( ( O
ART NNP NNP O
) ) ) O
use NN NN O
, , , O
the DT DT O
association NN NN O
between IN IN O
alcohol NN NN B-CHEM
and CC CC O
CD4 NNP NNP O
+ NN NN O
T NN NN O
- - - O
cell NN NN O
did VBD VBD O
not RB RB O
reach VB VB O
statistical JJ JJ O
significance NN NN O
. . . O

The DT DT O
association NN NN O
between IN IN O
alcohol NN NN B-CHEM
consumption NN NN O
and CC CC O
depression NN NN O
was VBD VBD O
significant JJ JJ O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
. . . O

Depression NNP NNP O
had VBD VBD O
a DT DT O
significant JJ JJ O
negative JJ JJ O
effect NN NN O
on IN IN O
CD4 NNP NNP O
+ NN NN O
T NN NN O
- - - O
cell NN NN O
counts VBZ VBZ O
over IN IN O
time NN NN O
regardless RB RB O
of IN IN O
ART NNP NNP O
use NN NN O
. . . O

Our PRP$ PRP$ O
findings NNS NNS O
suggest VBP VBP O
that IN IN O
alcohol NN NN B-CHEM
consumption NN NN O
has VBZ VBZ O
a DT DT O
direct JJ JJ O
association NN NN O
with IN IN O
depression NN NN O
. . . O

Moreover RB RB O
, , , O
depression NN NN O
is VBZ VBZ O
associated VBN VBN O
with IN IN O
HIV NNP NNP O
disease NN NN O
progression NN NN O
. . . O

Our PRP$ PRP$ O
findings NNS NNS O
have VBP VBP O
implications NNS NNS O
for IN IN O
the DT DT O
provision NN NN O
of IN IN O
alcohol NN NN B-CHEM
use NN NN O
interventions NNS NNS O
and CC CC O
psychological JJ JJ O
resources NNS NNS O
to TO TO O
improve VB VB O
the DT DT O
health NN NN O
of IN IN O
women NNS NNS O
with IN IN O
HIV NNP NNP O
. . . O

Chemokine NNP NNP O
CCL2 NNP NNP O
and CC CC O
its PRP$ PRP$ O
receptor NN NN O
CCR2 NNP NNP O
are VBP VBP O
increased VBN VBN O
in IN IN O
the DT DT O
hippocampus NN NN O
following VBG VBG O
pilocarpine NN NN B-CHEM
- - - O
induced JJ JJ O
status NN NN O
epilepticus NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
Neuroinflammation NNP NNP O
occurs VBZ VBZ O
after IN IN O
seizures NNS NNS O
and CC CC O
is VBZ VBZ O
implicated VBN VBN O
in IN IN O
epileptogenesis NN NN O
. . . O

CCR2 NNP NNP O
is VBZ VBZ O
a DT DT O
chemokine NN NN O
receptor NN NN O
for IN IN O
CCL2 NNP NNP O
and CC CC O
their PRP$ PRP$ O
interaction NN NN O
mediates NNS NNS O
monocyte NN NN O
infiltration NN NN O
in IN IN O
the DT DT O
neuroinflammatory NN NN O
cascade NN NN O
triggered VBN VBN O
in IN IN O
different JJ JJ O
brain NN NN O
pathologies NNS NNS O
. . . O

In IN IN O
this DT DT O
work NN NN O
CCR2 NNP NNP O
and CC CC O
CCL2 NNP NNP O
expression NN NN O
were VBD VBD O
examined VBN VBN O
following VBG VBG O
status NN NN O
epilepticus NN NN O
( ( ( O
SE NNP NNP O
) ) ) O
induced VBN VBN O
by IN IN O
pilocarpine NN NN B-CHEM
injection NN NN O
. . . O

METHODS NNP NNP O
: : : O
SE NNP NNP O
was VBD VBD O
induced VBN VBN O
by IN IN O
pilocarpine NN NN B-CHEM
injection NN NN O
. . . O

Control NNP NNP O
rats NNS NNS O
were VBD VBD O
injected VBN VBN O
with IN IN O
saline NN NN O
instead RB RB O
of IN IN O
pilocarpine NN NN B-CHEM
. . . O

Five CD CD O
days NNS NNS O
after IN IN O
SE NNP NNP O
, , , O
CCR2 NNP NNP O
staining VBG VBG O
in IN IN O
neurons NNS NNS O
and CC CC O
glial JJ JJ O
cells NNS NNS O
was VBD VBD O
examined VBN VBN O
using VBG VBG O
imunohistochemical JJ JJ O
analyses NNS NNS O
. . . O

The DT DT O
number NN NN O
of IN IN O
CCR2 NNP NNP O
positive JJ JJ O
cells NNS NNS O
was VBD VBD O
determined VBN VBN O
using VBG VBG O
stereology NN NN O
probes NNS NNS O
in IN IN O
the DT DT O
hippocampus NN NN O
. . . O

CCL2 NNP NNP O
expression NN NN O
in IN IN O
the DT DT O
hippocampus NN NN O
was VBD VBD O
examined VBN VBN O
by IN IN O
molecular JJ JJ O
assay NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Increased NNP NNP O
CCR2 NNP NNP O
was VBD VBD O
observed VBN VBN O
in IN IN O
the DT DT O
hippocampus NN NN O
after IN IN O
SE NNP NNP O
. . . O

Seizures NNP NNP O
also RB RB O
resulted VBD VBD O
in IN IN O
alterations NNS NNS O
to TO TO O
the DT DT O
cell NN NN O
types NNS NNS O
expressing VBG VBG O
CCR2 NNP NNP O
. . . O

Increased NNP NNP O
numbers NNS NNS O
of IN IN O
neurons NNS NNS O
that WDT WDT O
expressed VBD VBD O
CCR2 NNP NNP O
was VBD VBD O
observed VBN VBN O
following VBG VBG O
SE NNP NNP O
. . . O

Microglial NNP NNP O
cells NNS NNS O
were VBD VBD O
more RBR RBR O
closely RB RB O
apposed VBN VBN O
to TO TO O
the DT DT O
CCR2 NNP NNP O
- - - O
labeled JJ JJ O
cells NNS NNS O
in IN IN O
SE NNP NNP O
rats NNS NNS O
. . . O

In IN IN O
addition NN NN O
, , , O
rats NNS NNS O
that WDT WDT O
experienced VBD VBD O
SE NNP NNP O
exhibited VBN VBN O
CCR2 NNP NNP O
- : : O
labeling VBG VBG O
in IN IN O
populations NNS NNS O
of IN IN O
hypertrophied JJ JJ O
astrocytes NNS NNS O
, , , O
especially RB RB O
in IN IN O
CA1 NNP NNP O
and CC CC O
dentate NN NN O
gyrus NN NN O
. . . O

These DT DT O
CCR2 NNP NNP O
+ NN NN O
astroctytes NNS NNS O
were VBD VBD O
not RB RB O
observed VBN VBN O
in IN IN O
control NN NN O
rats NNS NNS O
. . . O

Examination NNP NNP O
of IN IN O
CCL2 NNP NNP O
expression NN NN O
showed VBD VBD O
that IN IN O
it PRP PRP O
was VBD VBD O
elevated VBN VBN O
in IN IN O
the DT DT O
hippocampus NN NN O
following VBG VBG O
SE NNP NNP O
. . . O

CONCLUSION NNP NNP O
: : : O
The DT DT O
data NNS NNS O
show VBP VBP O
that IN IN O
CCR2 NNP NNP O
and CC CC O
CCL2 NNP NNP O
are VBP VBP O
up RB RB O
- - - O
regulated JJ JJ O
in IN IN O
the DT DT O
hippocampus NN NN O
after IN IN O
pilocarpine NN NN B-CHEM
- - - O
induced JJ JJ O
SE NNP NNP O
. . . O

Seizures NNP NNP O
also RB RB O
result NN NN O
in IN IN O
changes NNS NNS O
to TO TO O
CCR2 NNP NNP O
receptor NN NN O
expression NN NN O
in IN IN O
neurons NNS NNS O
and CC CC O
astrocytes NNS NNS O
. . . O

These DT DT O
changes NNS NNS O
might MD MD O
be VB VB O
involved VBN VBN O
in IN IN O
detrimental JJ JJ O
neuroplasticity NN NN O
and CC CC O
neuroinflammatory NN NN O
changes NNS NNS O
that WDT WDT O
occur VBP VBP O
following VBG VBG O
seizures NNS NNS O
. . . O

Metallothionein NNP NNP B-CHEM
induction NN NN O
reduces VBZ VBZ O
caspase NN NN O
- - - O
3 CD CD O
activity NN NN O
and CC CC O
TNFalpha NNP NNP O
levels NNS NNS O
with IN IN O
preservation NN NN O
of IN IN O
cognitive JJ JJ O
function NN NN O
and CC CC O
intact JJ JJ O
hippocampal JJ JJ O
neurons NNS NNS O
in IN IN O
carmustine NN NN B-CHEM
- - - O
treated VBN VBN O
rats NNS NNS O
. . . O

Hippocampal NNP NNP O
integrity NN NN O
is VBZ VBZ O
essential JJ JJ O
for IN IN O
cognitive JJ JJ O
functions NNS NNS O
. . . O

On IN IN O
the DT DT O
other JJ JJ O
hand NN NN O
, , , O
induction NN NN O
of IN IN O
metallothionein NN NN B-CHEM
( ( ( O
MT NNP NNP B-CHEM
) ) ) O
by IN IN O
ZnSO NNP NNP B-CHEM
( ( ( I-CHEM
4 CD CD I-CHEM
) ) ) I-CHEM
and CC CC O
its PRP$ PRP$ O
role NN NN O
in IN IN O
neuroprotection NN NN O
has VBZ VBZ O
been VBN VBN O
documented VBN VBN O
. . . O

The DT DT O
present JJ JJ O
study NN NN O
aimed VBN VBN O
to TO TO O
explore VB VB O
the DT DT O
effect NN NN O
of IN IN O
MT NNP NNP B-CHEM
induction NN NN O
on IN IN O
carmustine NN NN B-CHEM
( ( ( O
BCNU NNP NNP B-CHEM
) ) ) O
- : : O
induced JJ JJ O
hippocampal NN NN O
cognitive JJ JJ O
dysfunction NN NN O
in IN IN O
rats NNS NNS O
. . . O

A DT DT O
total NN NN O
of IN IN O
60 CD CD O
male JJ JJ O
Wistar NNP NNP O
albino NN NN O
rats NNS NNS O
were VBD VBD O
randomly RB RB O
divided VBN VBN O
into IN IN O
four CD CD O
groups NNS NNS O
( ( ( O
15 CD CD O
/ NN NN O
group NN NN O
) ) ) O
: : : O
The DT DT O
control NN NN O
group NN NN O
injected VBN VBN O
with IN IN O
single JJ JJ O
doses NNS NNS O
of IN IN O
normal JJ JJ O
saline NN NN O
( ( ( O
i NNP NNP O
. . . O
c SYM SYM O
. . . O
v NN NN O
) ) ) O
followed VBD VBD O
24 CD CD O
h NN NN O
later RB RB O
by IN IN O
BCNU NNP NNP B-CHEM
solvent NN NN O
( ( ( O
i NNP NNP O
. . . O
v NN NN O
) ) ) O
. . . O

The DT DT O
second JJ JJ O
group NN NN O
administered VBD VBD O
ZnSO NNP NNP B-CHEM
( ( ( I-CHEM
4 CD CD I-CHEM
) ) ) I-CHEM
( ( ( O
0 CD CD O
. . . O
1 CD CD O
micromol NN NN O
/ NN NN O
10 CD CD O
microl NN NN O
normal JJ JJ O
saline NN NN O
, , , O
i NNP NNP O
. . . O
c SYM SYM O
. . . O
v NN NN O
, , , O
once RB RB O
) ) ) O
then RB RB O
BCNU NNP NNP B-CHEM
solvent NN NN O
( ( ( O
i NNP NNP O
. . . O
v NN NN O
) ) ) O
after IN IN O
24 CD CD O
h NN NN O
. . . O

Third NNP NNP O
group NN NN O
received VBD VBD O
BCNU NNP NNP B-CHEM
( ( ( O
20 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
i NNP NNP O
. . . O
v NN NN O
, , , O
once RB RB O
) ) ) O
24 CD CD O
h NN NN O
after IN IN O
injection NN NN O
with IN IN O
normal JJ JJ O
saline NN NN O
( ( ( O
i NNP NNP O
. . . O
c SYM SYM O
. . . O
v NN NN O
) ) ) O
. . . O

Fourth JJ JJ O
group NN NN O
received VBD VBD O
a DT DT O
single JJ JJ O
dose NN NN O
of IN IN O
ZnSO NNP NNP B-CHEM
( ( ( I-CHEM
4 CD CD I-CHEM
) ) ) I-CHEM
( ( ( O
0 CD CD O
. . . O
1 CD CD O
micromol NN NN O
/ NN NN O
10 CD CD O
microl NN NN O
normal JJ JJ O
saline NN NN O
, , , O
i NNP NNP O
. . . O
c SYM SYM O
. . . O
v NN NN O
) ) ) O
then RB RB O
BCNU NNP NNP B-CHEM
( ( ( O
20 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
i NNP NNP O
. . . O
v NN NN O
, , , O
once RB RB O
) ) ) O
after IN IN O
24 CD CD O
h NN NN O
. . . O

The DT DT O
obtained VBN VBN O
data NNS NNS O
revealed VBN VBN O
that IN IN O
BCNU NNP NNP B-CHEM
administration NN NN O
resulted VBD VBD O
in IN IN O
deterioration NN NN O
of IN IN O
learning VBG VBG O
and CC CC O
short JJ JJ O
- - - O
term NN NN O
memory NN NN O
( ( ( O
STM NNP NNP O
) ) ) O
, , , O
as IN IN O
measured VBN VBN O
by IN IN O
using VBG VBG O
radial JJ JJ O
arm NN NN O
water NN NN O
maze NN NN O
, , , O
accompanied VBN VBN O
with IN IN O
decreased VBD VBD O
hippocampal JJ JJ O
glutathione NN NN B-CHEM
reductase NN NN O
( ( ( O
GR NNP NNP O
) ) ) O
activity NN NN O
and CC CC O
reduced VBN VBN O
glutathione NN NN B-CHEM
( ( ( O
GSH NNP NNP B-CHEM
) ) ) O
content NN NN O
. . . O

Also RB RB O
, , , O
BCNU NNP NNP B-CHEM
administration NN NN O
increased VBD VBD O
serum NN NN O
tumor NN NN O
necrosis NN NN O
factor NN NN O
- : : O
alpha NN NN O
( ( ( O
TNFalpha NNP NNP O
) ) ) O
, , , O
hippocampal JJ JJ O
MT NNP NNP B-CHEM
and CC CC O
malondialdehyde NN NN B-CHEM
( ( ( O
MDA NNP NNP B-CHEM
) ) ) O
contents NNS NNS O
as RB RB O
well RB RB O
as IN IN O
caspase NN NN O
- - - O
3 CD CD O
activity NN NN O
in IN IN O
addition NN NN O
to TO TO O
histological JJ JJ O
alterations NNS NNS O
. . . O

ZnSO NNP NNP B-CHEM
( ( ( I-CHEM
4 CD CD I-CHEM
) ) ) I-CHEM
pretreatment NN NN O
counteracted VBN VBN O
BCNU NNP NNP B-CHEM
- : : O
induced JJ JJ O
inhibition NN NN O
of IN IN O
GR NNP NNP O
and CC CC O
depletion NN NN O
of IN IN O
GSH NNP NNP B-CHEM
and CC CC O
resulted VBD VBD O
in IN IN O
significant JJ JJ O
reduction NN NN O
in IN IN O
the DT DT O
levels NNS NNS O
of IN IN O
MDA NNP NNP B-CHEM
and CC CC O
TNFalpha NNP NNP O
as RB RB O
well RB RB O
as IN IN O
the DT DT O
activity NN NN O
of IN IN O
caspase NN NN O
- - - O
3 CD CD O
. . . O

The DT DT O
histological JJ JJ O
features NNS NNS O
were VBD VBD O
improved VBN VBN O
in IN IN O
hippocampus NN NN O
of IN IN O
rats NNS NNS O
treated VBN VBN O
with IN IN O
ZnSO NNP NNP B-CHEM
( ( ( I-CHEM
4 CD CD I-CHEM
) ) ) I-CHEM
+ NN NN O
BCNU NNP NNP B-CHEM
compared VBD VBD O
to TO TO O
only RB RB O
BCNU NNP NNP B-CHEM
- - - O
treated JJ JJ O
animals NNS NNS O
. . . O

In IN IN O
conclusion NN NN O
, , , O
MT NNP NNP B-CHEM
induction NN NN O
halts NNS NNS O
BCNU NNP NNP B-CHEM
- : : O
induced JJ JJ O
hippocampal NN NN O
toxicity NN NN O
as IN IN O
it PRP PRP O
prevented VBD VBD O
GR NNP NNP O
inhibition NN NN O
and CC CC O
GSH NNP NNP B-CHEM
depletion NN NN O
and CC CC O
counteracted VBD VBD O
the DT DT O
increased VBN VBN O
levels NNS NNS O
of IN IN O
TNFalpha NNP NNP O
, , , O
MDA NNP NNP B-CHEM
and CC CC O
caspase NN NN O
- - - O
3 CD CD O
activity NN NN O
with IN IN O
subsequent JJ JJ O
preservation NN NN O
of IN IN O
cognition NN NN O
. . . O

Fatal NNP NNP O
carbamazepine NN NN B-CHEM
induced VBN VBN O
fulminant JJ JJ O
eosinophilic JJ JJ O
( ( ( O
hypersensitivity NN NN O
) ) ) O
myocarditis NN NN O
: : : O
emphasis NN NN O
on IN IN O
anatomical JJ JJ O
and CC CC O
histological JJ JJ O
characteristics NNS NNS O
, , , O
mechanisms NNS NNS O
and CC CC O
genetics NNS NNS O
of IN IN O
drug NN NN O
hypersensitivity NN NN O
and CC CC O
differential JJ JJ O
diagnosis NN NN O
. . . O

The DT DT O
most RBS RBS O
severe JJ JJ O
adverse JJ JJ O
reactions NNS NNS O
to TO TO O
carbamazepine NN NN B-CHEM
have VBP VBP O
been VBN VBN O
observed VBN VBN O
in IN IN O
the DT DT O
haemopoietic JJ JJ O
system NN NN O
, , , O
the DT DT O
liver NN NN O
and CC CC O
the DT DT O
cardiovascular JJ JJ O
system NN NN O
. . . O

A DT DT O
frequently RB RB O
fatal JJ JJ O
, , , O
although IN IN O
exceptionally RB RB O
rare JJ JJ O
side NN NN O
effect NN NN O
of IN IN O
carbamazepine NN NN B-CHEM
is VBZ VBZ O
necrotizing VBG VBG O
eosinophilic JJ JJ O
( ( ( O
hypersensitivity NN NN O
) ) ) O
myocarditis NN NN O
. . . O

We PRP PRP O
report VBP VBP O
a DT DT O
case NN NN O
of IN IN O
hypersensitivity NN NN O
myocarditis NNS NNS O
secondary JJ JJ O
to TO TO O
administration NN NN O
of IN IN O
carbamazepine NN NN B-CHEM
. . . O

Acute JJ JJ O
hypersensitivity NN NN O
myocarditis NN NN O
was VBD VBD O
not RB RB O
suspected VBN VBN O
clinically RB RB O
, , , O
and CC CC O
the DT DT O
diagnosis NN NN O
was VBD VBD O
made VBN VBN O
post JJ JJ O
- - - O
mortem NN NN O
. . . O

Histology NNP NNP O
revealed VBD VBD O
diffuse NN NN O
infiltration NN NN O
of IN IN O
the DT DT O
myocardium NN NN O
by IN IN O
eosinophils NNS NNS O
and CC CC O
lymphocytes NNS NNS O
with IN IN O
myocyte NN NN O
damage NN NN O
. . . O

Clinically NNP NNP O
, , , O
death NN NN O
was VBD VBD O
due JJ JJ O
to TO TO O
cardiogenic JJ JJ O
shock NN NN O
. . . O

To TO TO O
best JJS JJS O
of IN IN O
our PRP$ PRP$ O
knowledge NN NN O
this DT DT O
is VBZ VBZ O
the DT DT O
second JJ JJ O
case NN NN O
of IN IN O
fatal JJ JJ O
carbamazepine NN NN B-CHEM
induced JJ JJ O
myocarditis NN NN O
reported VBD VBD O
in IN IN O
English NNP NNP O
literature NN NN O
. . . O

Neuropsychiatric NNP NNP O
behaviors NNS NNS O
in IN IN O
the DT DT O
MPTP NNP NNP B-CHEM
marmoset NN NN O
model NN NN O
of IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
. . . O

OBJECTIVES NNP NNP O
: : : O
Neuropsychiatric NNP NNP O
symptoms NNS NNS O
are VBP VBP O
increasingly RB RB O
recognised JJ JJ O
as IN IN O
a DT DT O
significant JJ JJ O
problem NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
( ( ( O
PD NNP NNP O
) ) ) O
. . . O

These DT DT O
symptoms NNS NNS O
may MD MD O
be VB VB O
due JJ JJ O
to TO TO O
' POS POS O
sensitisation NN NN O
' '' '' O
following VBG VBG O
repeated VBN VBN O
levodopa NN NN B-CHEM
treatment NN NN O
or CC CC O
a DT DT O
direct JJ JJ O
effect NN NN O
of IN IN O
dopamine NN NN B-CHEM
on IN IN O
the DT DT O
disease NN NN O
state NN NN O
. . . O

The DT DT O
levodopa NN NN B-CHEM
- - - O
treated VBN VBN O
MPTP NNP NNP B-CHEM
- : : O
lesioned JJ JJ O
marmoset NN NN O
was VBD VBD O
used VBN VBN O
as IN IN O
a DT DT O
model NN NN O
of IN IN O
neuropsychiatric JJ JJ O
symptoms NNS NNS O
in IN IN O
PD NNP NNP O
patients NNS NNS O
. . . O

Here RB RB O
we PRP PRP O
compare VBP VBP O
the DT DT O
time NN NN O
course NN NN O
of IN IN O
levodopa NN NN B-CHEM
- - - O
induced JJ JJ O
motor NN NN O
fluctuations NNS NNS O
and CC CC O
neuropsychiatric JJ JJ O
- - - O
like IN IN O
behaviors NNS NNS O
to TO TO O
determine VB VB O
the DT DT O
relationship NN NN O
between IN IN O
duration NN NN O
of IN IN O
treatment NN NN O
and CC CC O
onset NN NN O
of IN IN O
symptoms NNS NNS O
. . . O

METHODS NNP NNP O
: : : O
Marmosets NNP NNP O
were VBD VBD O
administered VBN VBN O
1 CD CD B-CHEM
- : : I-CHEM
methyl NN NN I-CHEM
- : : I-CHEM
4 CD CD I-CHEM
- : : I-CHEM
phenyl NN NN I-CHEM
- : : I-CHEM
1 CD CD I-CHEM
, , , I-CHEM
2 CD CD I-CHEM
, , , I-CHEM
3 CD CD I-CHEM
, , , I-CHEM
6 CD CD I-CHEM
- : : I-CHEM
tetrahydropyridine NN NN I-CHEM
( ( ( O
2 CD CD O
. . . O
0 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
s VBZ VBZ O
. . . O
c SYM SYM O
. . . O
) ) ) O
for IN IN O
five CD CD O
days NNS NNS O
, , , O
resulting VBG VBG O
in IN IN O
stable JJ JJ O
parkinsonism NN NN O
. . . O

Levodopa NNP NNP B-CHEM
( ( ( O
15 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
and CC CC O
benserazide NN NN B-CHEM
, , , O
3 CD CD O
. . . O
75 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
p NN NN O
. . . O
o NN NN O
. . . O

b SYM SYM O
. . . O
i NNP NNP O
. . . O
d SYM SYM O
, , , O
was VBD VBD O
administered VBN VBN O
for IN IN O
30 CD CD O
days NNS NNS O
. . . O

Animals NNS NNS O
were VBD VBD O
evaluated VBN VBN O
for IN IN O
parkinsonian JJ JJ O
disability NN NN O
, , , O
dyskinesia NN NN O
and CC CC O
on IN IN O
- : : O
time NN NN O
( ( ( O
motor NN NN O
fluctuations NNS NNS O
) ) ) O
and CC CC O
neuropsychiatric JJ JJ O
- - - O
like IN IN O
behaviors NNS NNS O
on IN IN O
Day NNP NNP O
0 CD CD O
( ( ( O
prior RB RB O
to TO TO O
levodopa VB VB B-CHEM
) ) ) O
and CC CC O
on IN IN O
Days NNS NNS O
1 CD CD O
, , , O
7 CD CD O
, , , O
13 CD CD O
, , , O
27 CD CD O
and CC CC O
30 CD CD O
of IN IN O
treatment NN NN O
using VBG VBG O
post NN NN O
hoc NN NN O
DVD NNP NNP O
analysis NN NN O
by IN IN O
a DT DT O
trained JJ JJ O
rater NN NN O
, , , O
blind JJ JJ O
to TO TO O
the DT DT O
treatment NN NN O
day NN NN O
. . . O

RESULTS NNS NNS O
: : : O
The DT DT O
neuropsychiatric JJ JJ O
- - - O
like IN IN O
behavior NN NN O
rating NN NN O
scale NN NN O
demonstrated VBN VBN O
high JJ JJ O
interrater NN NN O
reliability NN NN O
between IN IN O
three CD CD O
trained VBN VBN O
raters NNS NNS O
of IN IN O
differing VBG VBG O
professional JJ JJ O
backgrounds NNS NNS O
. . . O

As IN IN O
anticipated VBN VBN O
, , , O
animals NNS NNS O
exhibited VBD VBD O
a DT DT O
progressive JJ JJ O
increase NN NN O
in IN IN O
levodopa NN NN B-CHEM
- - - O
induced JJ JJ O
motor NN NN O
fluctuations NNS NNS O
, , , O
dyskinesia NN NN O
and CC CC O
wearing VBG VBG O
- - - O
off RP RP O
, , , O
that WDT WDT O
correlated VBD VBD O
with IN IN O
the DT DT O
duration NN NN O
of IN IN O
levodopa NN NN B-CHEM
therapy NN NN O
. . . O

In IN IN O
contrast NN NN O
, , , O
levodopa NN NN B-CHEM
- - - O
induced JJ JJ O
neuropsychiatric JJ JJ O
- - - O
like IN IN O
behaviors NNS NNS O
were VBD VBD O
present JJ JJ O
on IN IN O
Day NNP NNP O
1 CD CD O
of IN IN O
levodopa NN NN B-CHEM
treatment NN NN O
and CC CC O
their PRP$ PRP$ O
severity NN NN O
did VBD VBD O
not RB RB O
correlate VB VB O
with IN IN O
duration NN NN O
of IN IN O
treatment NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
The DT DT O
data NNS NNS O
suggest VBP VBP O
that IN IN O
neuropsychiatric JJ JJ O
disorders NNS NNS O
in IN IN O
PD NNP NNP O
are VBP VBP O
more RBR RBR O
likely JJ JJ O
an DT DT O
interaction NN NN O
between IN IN O
levodopa NN NN B-CHEM
and CC CC O
the DT DT O
disease NN NN O
state NN NN O
than IN IN O
a DT DT O
consequence NN NN O
of IN IN O
sensitisation NN NN O
to TO TO O
repeated VBN VBN O
dopaminergic JJ JJ O
therapy NN NN O
. . . O

Contrast NN NN B-CHEM
medium NN NN I-CHEM
nephrotoxicity NN NN O
after IN IN O
renal JJ JJ O
artery NN NN O
and CC CC O
coronary JJ JJ O
angioplasty NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
Renal NNP NNP O
dysfunction NN NN O
induced VBN VBN O
by IN IN O
iodinated JJ JJ O
contrast NN NN B-CHEM
medium NN NN I-CHEM
( ( ( O
CM NNP NNP B-CHEM
) ) ) O
administration NN NN O
can MD MD O
minimize VB VB O
the DT DT O
benefit NN NN O
of IN IN O
the DT DT O
interventional JJ JJ O
procedure NN NN O
in IN IN O
patients NNS NNS O
undergoing VBG VBG O
renal NN NN O
angioplasty NN NN O
( ( ( O
PTRA NNP NNP O
) ) ) O
. . . O

PURPOSE NNP NNP O
: : : O
To TO TO O
compare VB VB O
the DT DT O
susceptibility NN NN O
to TO TO O
nephrotoxic JJ JJ O
effect NN NN O
of IN IN O
CM NNP NNP B-CHEM
in IN IN O
patients NNS NNS O
undergoing VBG VBG O
PTRA NNP NNP O
with IN IN O
that DT DT O
of IN IN O
patients NNS NNS O
submitted VBN VBN O
to TO TO O
percutaneous JJ JJ O
coronary JJ JJ O
intervention NN NN O
( ( ( O
PCI NNP NNP O
) ) ) O
. . . O

MATERIAL NN NN O
AND CC CC O
METHODS NNP NNP O
: : : O
A DT DT O
total NN NN O
of IN IN O
33 CD CD O
patients NNS NNS O
successfully RB RB O
treated VBN VBN O
with IN IN O
PTRA NNP NNP O
( ( ( O
PTRA NNP NNP O
group NN NN O
, , , O
mean VB VB O
age NN NN O
70 CD CD O
+ NN NN O
/ NN NN O
- : : O
12 CD CD O
years NNS NNS O
, , , O
23 CD CD O
female JJ JJ O
, , , O
basal NN NN O
creatinine NN NN B-CHEM
1 CD CD O
. . . O
46 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
79 CD CD O
, , , O
range NN NN O
0 CD CD O
. . . O
7 CD CD O
- : : O
4 CD CD O
. . . O
9 CD CD O
mg NN NN O
/ NN NN O
dl NN NN O
) ) ) O
were VBD VBD O
compared VBN VBN O
with IN IN O
33 CD CD O
patients NNS NNS O
undergoing VBG VBG O
successful JJ JJ O
PCI NNP NNP O
( ( ( O
PCI NNP NNP O
group NN NN O
) ) ) O
, , , O
matched VBD VBD O
for IN IN O
basal NN NN O
creatinine NN NN B-CHEM
( ( ( O
1 CD CD O
. . . O
44 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
6 CD CD O
, , , O
range NN NN O
0 CD CD O
. . . O
7 CD CD O
- : : O
3 CD CD O
. . . O
4 CD CD O
mg NN NN O
/ NN NN O
dl NN NN O
) ) ) O
, , , O
gender NN NN O
, , , O
and CC CC O
age NN NN O
. . . O

In IN IN O
both DT DT O
groups NNS NNS O
postprocedural NN NN O
( ( ( O
48 CD CD O
h NN NN O
) ) ) O
serum NN NN O
creatinine NN NN B-CHEM
was VBD VBD O
measured VBN VBN O
. . . O

RESULTS NNS NNS O
: : : O
Postprocedural NNP NNP O
creatinine NN NN B-CHEM
level NN NN O
decreased VBD VBD O
nonsignificantly RB RB O
in IN IN O
the DT DT O
PTRA NNP NNP O
group NN NN O
( ( ( O
1 CD CD O
. . . O
46 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
8 CD CD O
vs NNS NNS O
. . . O
1 CD CD O
. . . O
34 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
dl NN NN O
, , , O
P NN NN O
= SYM SYM O
NS NNP NNP O
) ) ) O
and CC CC O
increased VBN VBN O
significantly RB RB O
in IN IN O
the DT DT O
PCI NNP NNP O
group NN NN O
( ( ( O
1 CD CD O
. . . O
44 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
6 CD CD O
vs NNS NNS O
. . . O
1 CD CD O
. . . O
57 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
7 CD CD O
mg NN NN O
/ NN NN O
dl NN NN O
, , , O
P NN NN O
< NN NN O
0 CD CD O
. . . O
02 CD CD O
) ) ) O
. . . O

Changes NNS NNS O
in IN IN O
serum NN NN O
creatinine NN NN B-CHEM
after IN IN O
intervention NN NN O
( ( ( O
after IN IN O
- - - O
before IN IN O
) ) ) O
were VBD VBD O
significantly RB RB O
different JJ JJ O
between IN IN O
the DT DT O
PTRA NNP NNP O
and CC CC O
PCI NNP NNP O
groups NNS NNS O
( ( ( O
- : : O
0 CD CD O
. . . O
12 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
5 CD CD O
vs NNS NNS O
. . . O
0 CD CD O
. . . O
13 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
3 CD CD O
, , , O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
014 CD CD O
) ) ) O
. . . O

This DT DT O
difference NN NN O
was VBD VBD O
not RB RB O
related VBN VBN O
to TO TO O
either CC CC O
a DT DT O
different JJ JJ O
clinical JJ JJ O
risk NN NN O
profile NN NN O
or CC CC O
to TO TO O
the DT DT O
volume NN NN O
of IN IN O
CM NNP NNP B-CHEM
administered VBD VBD O
. . . O

CONCLUSION NNP NNP O
: : : O
In IN IN O
this DT DT O
preliminary JJ JJ O
study NN NN O
patients NNS NNS O
submitted VBN VBN O
to TO TO O
PTRA NNP NNP O
showed VBD VBD O
a DT DT O
lower JJR JJR O
susceptibility NN NN O
to TO TO O
renal VB VB O
damage NN NN O
induced VBN VBN O
by IN IN O
CM NNP NNP B-CHEM
administration NN NN O
than IN IN O
PCI NNP NNP O
patients NNS NNS O
. . . O

The DT DT O
effectiveness NN NN O
of IN IN O
PTRA NNP NNP O
on IN IN O
renal JJ JJ O
function NN NN O
seems VBZ VBZ O
to TO TO O
be VB VB O
barely RB RB O
influenced VBN VBN O
by IN IN O
CM NNP NNP B-CHEM
toxicity NN NN O
. . . O

Diphenhydramine NNP NNP B-CHEM
prevents NNS NNS O
the DT DT O
haemodynamic JJ JJ O
changes NNS NNS O
of IN IN O
cimetidine NN NN B-CHEM
in IN IN O
ICU NNP NNP O
patients NNS NNS O
. . . O

Cimetidine NNP NNP B-CHEM
, , , O
a DT DT O
histamine NN NN B-CHEM
2 CD CD O
( ( ( O
H2 NNP NNP O
) ) ) O
antagonist NN NN O
, , , O
produces VBZ VBZ O
a DT DT O
decrease NN NN O
in IN IN O
arterial JJ JJ O
pressure NN NN O
due JJ JJ O
to TO TO O
vasodilatation NN NN O
, , , O
especially RB RB O
in IN IN O
critically RB RB O
ill JJ JJ O
patients NNS NNS O
. . . O

This DT DT O
may MD MD O
be VB VB O
because IN IN O
cimetidine JJ JJ B-CHEM
acts NNS NNS O
as IN IN O
a DT DT O
histamine NN NN B-CHEM
agonist NN NN O
. . . O

We PRP PRP O
, , , O
therefore RB RB O
, , , O
investigated VBD VBD O
the DT DT O
effects NNS NNS O
of IN IN O
the DT DT O
histamine NN NN B-CHEM
1 CD CD O
( ( ( O
H1 NNP NNP O
) ) ) O
receptor NN NN O
antagonist NN NN O
, , , O
diphenhydramine NN NN B-CHEM
, , , O
on IN IN O
the DT DT O
haemodynamic JJ JJ O
changes NNS NNS O
observed VBD VBD O
after IN IN O
cimetidine NN NN B-CHEM
in IN IN O
ICU NNP NNP O
patients NNS NNS O
. . . O

Each DT DT O
patient NN NN O
was VBD VBD O
studied VBN VBN O
on IN IN O
two CD CD O
separate JJ JJ O
days NNS NNS O
. . . O

In IN IN O
a DT DT O
random JJ JJ O
fashion NN NN O
, , , O
they PRP PRP O
received VBD VBD O
cimetidine NN NN B-CHEM
200 CD CD O
mg NN NN O
iv NN NN O
on IN IN O
one CD CD O
day NN NN O
, , , O
and CC CC O
on IN IN O
the DT DT O
other JJ JJ O
, , , O
a DT DT O
pretreatment NN NN O
of IN IN O
diphenhydramine NN NN B-CHEM
40 CD CD O
mg NN NN O
iv NN NN O
with IN IN O
cimetidine NN NN B-CHEM
200 CD CD O
mg NN NN O
iv NN NN O
. . . O

In IN IN O
the DT DT O
non NN NN O
- - - O
pretreatment NN NN O
group NN NN O
, , , O
mean VB VB O
arterial JJ JJ O
pressure NN NN O
( ( ( O
MAP NNP NNP O
) ) ) O
decreased VBD VBD O
from IN IN O
107 CD CD O
. . . O
4 CD CD O
+ NN NN O
/ NN NN O
- : : O
8 CD CD O
. . . O
4 CD CD O
mmHg NN NN O
to TO TO O
86 CD CD O
. . . O
7 CD CD O
+ NN NN O
/ NN NN O
- : : O
11 CD CD O
. . . O
4 CD CD O
mmHg NN NN O
( ( ( O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
two CD CD O
minutes NNS NNS O
after IN IN O
cimetidine NN NN B-CHEM
. . . O

Also RB RB O
, , , O
systemic JJ JJ O
vascular NN NN O
resistance NN NN O
( ( ( O
SVR NNP NNP O
) ) ) O
decreased VBD VBD O
during IN IN O
the DT DT O
eight CD CD O
- - - O
minute NN NN O
observation NN NN O
period NN NN O
( ( ( O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
. . . O

In IN IN O
contrast NN NN O
, , , O
in IN IN O
the DT DT O
pretreatment NN NN O
group NN NN O
, , , O
little JJ JJ O
haemodynamic JJ JJ O
change NN NN O
was VBD VBD O
seen VBN VBN O
. . . O

We PRP PRP O
conclude VBP VBP O
that IN IN O
an DT DT O
H1 NNP NNP O
antagonist NN NN O
may MD MD O
be VB VB O
useful JJ JJ O
in IN IN O
preventing VBG VBG O
hypotension NN NN O
caused VBN VBN O
by IN IN O
iv NN NN O
cimetidine NN NN B-CHEM
, , , O
since IN IN O
the DT DT O
vasodilating VBG VBG O
activity NN NN O
of IN IN O
cimetidine NN NN B-CHEM
is VBZ VBZ O
mediated VBN VBN O
, , , O
in IN IN O
part NN NN O
, , , O
through IN IN O
the DT DT O
H1 NNP NNP O
receptor NN NN O
. . . O

Medical NNP NNP O
and CC CC O
psychiatric JJ JJ O
outcomes NNS NNS O
for IN IN O
patients NNS NNS O
transplanted VBN VBN O
for IN IN O
acetaminophen NN NN B-CHEM
- - - O
induced JJ JJ O
acute JJ JJ O
liver NN NN O
failure NN NN O
: : : O
a DT DT O
case NN NN O
- - - O
control NN NN O
study NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
Acetaminophen NNP NNP B-CHEM
- - - O
induced JJ JJ O
hepatotoxicity NN NN O
is VBZ VBZ O
the DT DT O
most RBS RBS O
common JJ JJ O
cause NN NN O
of IN IN O
acute JJ JJ O
liver NN NN O
failure NN NN O
( ( ( O
ALF NNP NNP O
) ) ) O
in IN IN O
the DT DT O
UK NNP NNP O
. . . O

Patients NNS NNS O
often RB RB O
consume VBP VBP O
the DT DT O
drug NN NN O
with IN IN O
suicidal JJ JJ O
intent NN NN O
or CC CC O
with IN IN O
a DT DT O
background NN NN O
of IN IN O
substance NN NN O
dependence NN NN O
. . . O

AIMS NNP NNP O
AND CC CC O
METHODS NNP NNP O
: : : O
We PRP PRP O
compared VBD VBD O
the DT DT O
severity NN NN O
of IN IN O
pretransplant JJ JJ O
illness NN NN O
, , , O
psychiatric JJ JJ O
co NN NN O
- - - O
morbidity NN NN O
, , , O
medical JJ JJ O
and CC CC O
psychosocial JJ JJ O
outcomes NNS NNS O
of IN IN O
all DT DT O
patients NNS NNS O
who WP WP O
had VBD VBD O
undergone JJ JJ O
liver NN NN O
transplantation NN NN O
( ( ( O
LT NNP NNP O
) ) ) O
emergently RB RB O
between IN IN O
1999 CD CD O
- : : O
2004 CD CD O
for IN IN O
acetaminophen NN NN B-CHEM
- - - O
induced JJ JJ O
ALF NNP NNP O
( ( ( O
n NN NN O
= SYM SYM O
36 CD CD O
) ) ) O
with IN IN O
age NN NN O
- - - O
and CC CC O
sex NN NN O
- - - O
matched JJ JJ O
patients NNS NNS O
undergoing VBG VBG O
emergent NN NN O
LT NNP NNP O
for IN IN O
non NN NN O
- - - O
acetaminophen NN NN B-CHEM
- - - O
induced JJ JJ O
ALF NNP NNP O
( ( ( O
n NN NN O
= SYM SYM O
35 CD CD O
) ) ) O
and CC CC O
elective JJ JJ O
LT NNP NNP O
for IN IN O
chronic JJ JJ O
liver NN NN O
disease NN NN O
( ( ( O
CLD NNP NNP O
, , , O
n NN NN O
= SYM SYM O
34 CD CD O
) ) ) O
. . . O

RESULTS NNS NNS O
: : : O
Acetaminophen NNP NNP B-CHEM
- - - O
induced JJ JJ O
ALF NNP NNP O
patients NNS NNS O
undergoing VBG VBG O
LT NNP NNP O
had VBD VBD O
a DT DT O
greater JJR JJR O
severity NN NN O
of IN IN O
pre NN NN O
- - - O
LT NNP NNP O
illness NN NN O
reflected VBN VBN O
by IN IN O
higher JJR JJR O
Acute JJ JJ O
Physiology NNP NNP O
and CC CC O
Chronic NNP NNP O
Health NNP NNP O
Evaluation NNP NNP O
II NNP NNP O
scores NNS NNS O
and CC CC O
requirement NN NN O
for IN IN O
organ NN NN O
support NN NN O
compared VBN VBN O
with IN IN O
the DT DT O
other JJ JJ O
two CD CD O
groups NNS NNS O
. . . O

Twenty NNP NNP O
( ( ( O
56 CD CD O
% NN NN O
) ) ) O
acetaminophen NN NN B-CHEM
- - - O
induced JJ JJ O
ALF NNP NNP O
patients NNS NNS O
had VBD VBD O
a DT DT O
formal JJ JJ O
psychiatric JJ JJ O
diagnosis NN NN O
before IN IN O
LT NNP NNP O
( ( ( O
non NN NN O
- - - O
acetaminophen NN NN B-CHEM
- - - O
induced JJ JJ O
ALF NNP NNP O
= SYM SYM O
0 CD CD O
/ NN NN O
35 CD CD O
, , , O
CLD NNP NNP O
= SYM SYM O
2 CD CD O
/ NN NN O
34 CD CD O
; : : O
P NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
for IN IN O
all DT DT O
) ) ) O
and CC CC O
nine CD CD O
( ( ( O
25 CD CD O
% NN NN O
) ) ) O
had VBD VBD O
a DT DT O
previous JJ JJ O
suicide NN NN O
attempt NN NN O
. . . O

During IN IN O
follow VB VB O
- - - O
up RP RP O
( ( ( O
median JJ JJ O
5 CD CD O
years NNS NNS O
) ) ) O
, , , O
there EX EX O
were VBD VBD O
no DT DT O
significant JJ JJ O
differences NNS NNS O
in IN IN O
rejection NN NN O
( ( ( O
acute JJ JJ O
and CC CC O
chronic JJ JJ O
) ) ) O
, , , O
graft NN NN O
failure NN NN O
or CC CC O
survival NN NN O
between IN IN O
the DT DT O
groups NNS NNS O
( ( ( O
acetaminophen NN NN B-CHEM
- - - O
induced JJ JJ O
ALF NNP NNP O
1 CD CD O
year NN NN O
87 CD CD O
% NN NN O
, , , O
5 CD CD O
years NNS NNS O
75 CD CD O
% NN NN O
; : : O
non NN NN O
- - - O
acetaminophen NN NN B-CHEM
- - - O
induced JJ JJ O
ALF NNP NNP O
88 CD CD O
% NN NN O
, , , O
78 CD CD O
% NN NN O
; : : O
CLD NNP NNP O
93 CD CD O
% NN NN O
, , , O
82 CD CD O
% NN NN O
: : : O
P NN NN O
> NN NN O
0 CD CD O
. . . O
6 CD CD O
log NN NN O
rank NN NN O
) ) ) O
. . . O

Two CD CD O
acetaminophen NNS NNS B-CHEM
- : : O
induced VBN VBN O
ALF NNP NNP O
patients NNS NNS O
reattempted VBD VBD O
suicide NN NN O
post NN NN O
- : : O
LT NNP NNP O
( ( ( O
one CD CD O
died VBD VBD O
8 CD CD O
years NNS NNS O
post NN NN O
- : : O
LT NNP NNP O
) ) ) O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Despite IN IN O
a DT DT O
high JJ JJ O
prevalence NN NN O
of IN IN O
psychiatric JJ JJ O
disturbance NN NN O
, , , O
outcomes NNS NNS O
for IN IN O
patients NNS NNS O
transplanted VBN VBN O
emergently RB RB O
for IN IN O
acetaminophen NN NN B-CHEM
- - - O
induced JJ JJ O
ALF NNP NNP O
were VBD VBD O
comparable JJ JJ O
to TO TO O
those DT DT O
transplanted VBN VBN O
for IN IN O
non NN NN O
- - - O
acetaminophen NN NN B-CHEM
- - - O
induced JJ JJ O
ALF NNP NNP O
and CC CC O
electively RB RB O
for IN IN O
CLD NNP NNP O
. . . O

Multidisciplinary NNP NNP O
approaches NNS NNS O
with IN IN O
long JJ JJ O
- - - O
term NN NN O
psychiatric JJ JJ O
follow VB VB O
- - - O
up RP RP O
may MD MD O
contribute VB VB O
to TO TO O
low JJ JJ O
post NN NN O
- : : O
transplant NN NN O
suicide NN NN O
rates NNS NNS O
seen VBN VBN O
and CC CC O
low JJ JJ O
rates NNS NNS O
of IN IN O
graft NN NN O
loss NN NN O
because IN IN O
of IN IN O
non NN NN O
- - - O
compliance NN NN O
. . . O

Antithrombotic NNP NNP O
drug NN NN O
use NN NN O
, , , O
cerebral JJ JJ O
microbleeds NNS NNS O
, , , O
and CC CC O
intracerebral JJ JJ O
hemorrhage NN NN O
: : : O
a DT DT O
systematic JJ JJ O
review NN NN O
of IN IN O
published VBN VBN O
and CC CC O
unpublished JJ JJ O
studies NNS NNS O
. . . O

BACKGROUND NNP NNP O
AND CC CC O
PURPOSE NNP NNP O
: : : O
Cerebral NNP NNP O
microbleeds NNS NNS O
( ( ( O
MB NNP NNP O
) ) ) O
are VBP VBP O
potential JJ JJ O
risk NN NN O
factors NNS NNS O
for IN IN O
intracerebral JJ JJ O
hemorrhage NN NN O
( ( ( O
ICH NNP NNP O
) ) ) O
, , , O
but CC CC O
it PRP PRP O
is VBZ VBZ O
unclear JJ JJ O
if IN IN O
they PRP PRP O
are VBP VBP O
a DT DT O
contraindication NN NN O
to TO TO O
using VBG VBG O
antithrombotic JJ JJ O
drugs NNS NNS O
. . . O

Insights NNP NNP O
could MD MD O
be VB VB O
gained VBN VBN O
by IN IN O
pooling VBG VBG O
data NNS NNS O
on IN IN O
MB NNP NNP O
frequency NN NN O
stratified VBN VBN O
by IN IN O
antithrombotic JJ JJ O
use NN NN O
in IN IN O
cohorts NNS NNS O
with IN IN O
ICH NNP NNP O
and CC CC O
ischemic JJ JJ O
stroke NN NN O
( ( ( O
IS VBZ VBZ O
) ) ) O
/ NN NN O
transient NN NN O
ischemic JJ JJ O
attack NN NN O
( ( ( O
TIA NNP NNP O
) ) ) O
. . . O

METHODS NNP NNP O
: : : O
We PRP PRP O
performed VBD VBD O
a DT DT O
systematic JJ JJ O
review NN NN O
of IN IN O
published VBN VBN O
and CC CC O
unpublished JJ JJ O
data NNS NNS O
from IN IN O
cohorts NNS NNS O
with IN IN O
stroke NN NN O
or CC CC O
TIA NNP NNP O
to TO TO O
compare VB VB O
the DT DT O
presence NN NN O
of IN IN O
MB NNP NNP O
in IN IN O
: : : O
( ( ( O
1 CD CD O
) ) ) O
antithrombotic JJ JJ O
users NNS NNS O
vs NNS NNS O
nonantithrombotic JJ JJ O
users NNS NNS O
with IN IN O
ICH NNP NNP O
; : : O
( ( ( O
2 CD CD O
) ) ) O
antithrombotic JJ JJ O
users NNS NNS O
vs NN NN O
nonusers NNS NNS O
with IN IN O
IS VBZ VBZ O
/ NN NN O
TIA NNP NNP O
; : : O
and CC CC O
( ( ( O
3 CD CD O
) ) ) O
ICH NNP NNP O
vs NNS NNS O
ischemic JJ JJ O
events NNS NNS O
stratified VBN VBN O
by IN IN O
antithrombotic JJ JJ O
use NN NN O
. . . O

We PRP PRP O
also RB RB O
analyzed VBD VBD O
published VBN VBN O
and CC CC O
unpublished JJ JJ O
follow VB VB O
- - - O
up RP RP O
data NNS NNS O
to TO TO O
determine VB VB O
the DT DT O
risk NN NN O
of IN IN O
ICH NNP NNP O
in IN IN O
antithrombotic JJ JJ O
users NNS NNS O
with IN IN O
MB NNP NNP O
. . . O

RESULTS NNS NNS O
: : : O
In IN IN O
a DT DT O
pooled JJ JJ O
analysis NN NN O
of IN IN O
1460 CD CD O
ICH NNP NNP O
and CC CC O
3817 CD CD O
IS VBZ VBZ O
/ NN NN O
TIA NNP NNP O
, , , O
MB NNP NNP O
were VBD VBD O
more RBR RBR O
frequent JJ JJ O
in IN IN O
ICH NNP NNP O
vs NNS NNS O
IS VBZ VBZ O
/ NN NN O
TIA NNP NNP O
in IN IN O
all DT DT O
treatment NN NN O
groups NNS NNS O
, , , O
but CC CC O
the DT DT O
excess NNS NNS O
increased VBN VBN O
from IN IN O
2 CD CD O
. . . O
8 CD CD O
( ( ( O
odds NN NN O
ratio NN NN O
; : : O
range NN NN O
, , , O
2 CD CD O
. . . O
3 CD CD O
- : : O
3 CD CD O
. . . O
5 CD CD O
) ) ) O
in IN IN O
nonantithrombotic JJ JJ O
users NNS NNS O
to TO TO O
5 CD CD O
. . . O
7 CD CD O
( ( ( O
range NN NN O
, , , O
3 CD CD O
. . . O
4 CD CD O
- : : O
9 CD CD O
. . . O
7 CD CD O
) ) ) O
in IN IN O
antiplatelet NN NN O
users NNS NNS O
and CC CC O
8 CD CD O
. . . O
0 CD CD O
( ( ( O
range NN NN O
, , , O
3 CD CD O
. . . O
5 CD CD O
- : : O
17 CD CD O
. . . O
8 CD CD O
) ) ) O
in IN IN O
warfarin NN NN B-CHEM
users NNS NNS O
( ( ( O
P NN NN O
difference NN NN O
= SYM SYM O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
. . . O

There EX EX O
was VBD VBD O
also RB RB O
an DT DT O
excess NN NN O
of IN IN O
MB NNP NNP O
in IN IN O
warfarin NN NN B-CHEM
users NNS NNS O
vs NN NN O
nonusers NNS NNS O
with IN IN O
ICH NNP NNP O
( ( ( O
OR CC CC O
, , , O
2 CD CD O
. . . O
7 CD CD O
; : : O
95 CD CD O
% NN NN O
CI NNP NNP O
, , , O
1 CD CD O
. . . O
6 CD CD O
- : : O
4 CD CD O
. . . O
4 CD CD O
; : : O
P NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
but CC CC O
none NN NN O
in IN IN O
warfarin NN NN B-CHEM
users NNS NNS O
with IN IN O
IS VBZ VBZ O
/ NN NN O
TIA NNP NNP O
( ( ( O
OR CC CC O
, , , O
1 CD CD O
. . . O
3 CD CD O
; : : O
95 CD CD O
% NN NN O
CI NNP NNP O
, , , O
0 CD CD O
. . . O
9 CD CD O
- : : O
1 CD CD O
. . . O
7 CD CD O
; : : O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
33 CD CD O
; : : O
P NN NN O
difference NN NN O
= SYM SYM O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
. . . O

There EX EX O
was VBD VBD O
a DT DT O
smaller JJR JJR O
excess NN NN O
of IN IN O
MB NNP NNP O
in IN IN O
antiplatelet NN NN O
users NNS NNS O
vs NN NN O
nonusers NNS NNS O
with IN IN O
ICH NNP NNP O
( ( ( O
OR CC CC O
, , , O
1 CD CD O
. . . O
7 CD CD O
; : : O
95 CD CD O
% NN NN O
CI NNP NNP O
, , , O
1 CD CD O
. . . O
3 CD CD O
- : : O
2 CD CD O
. . . O
3 CD CD O
; : : O
P NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
, , , O
but CC CC O
findings NNS NNS O
were VBD VBD O
similar JJ JJ O
for IN IN O
antiplatelet NN NN O
users NNS NNS O
with IN IN O
IS VBZ VBZ O
/ NN NN O
TIA NNP NNP O
( ( ( O
OR CC CC O
, , , O
1 CD CD O
. . . O
4 CD CD O
; : : O
95 CD CD O
% NN NN O
CI NNP NNP O
, , , O
1 CD CD O
. . . O
2 CD CD O
- : : O
1 CD CD O
. . . O
7 CD CD O
; : : O
P NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
; : : O
P NN NN O
difference NN NN O
= SYM SYM O
0 CD CD O
. . . O
25 CD CD O
) ) ) O
. . . O

In IN IN O
pooled JJ JJ O
follow VB VB O
- - - O
up RP RP O
data NNS NNS O
for IN IN O
768 CD CD O
antithrombotic JJ JJ O
users NNS NNS O
, , , O
presence NN NN O
of IN IN O
MB NNP NNP O
at IN IN O
baseline NN NN O
was VBD VBD O
associated VBN VBN O
with IN IN O
a DT DT O
substantially RB RB O
increased VBN VBN O
risk NN NN O
of IN IN O
subsequent JJ JJ O
ICH NNP NNP O
( ( ( O
OR CC CC O
, , , O
12 CD CD O
. . . O
1 CD CD O
; : : O
95 CD CD O
% NN NN O
CI NNP NNP O
, , , O
3 CD CD O
. . . O
4 CD CD O
- : : O
42 CD CD O
. . . O
5 CD CD O
; : : O
P NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
. . . O

CONCLUSIONS NNP NNP O
: : : O
The DT DT O
excess NN NN O
of IN IN O
MB NNP NNP O
in IN IN O
warfarin NN NN B-CHEM
users NNS NNS O
with IN IN O
ICH NNP NNP O
compared VBD VBD O
to TO TO O
other JJ JJ O
groups NNS NNS O
suggests VBZ VBZ O
that IN IN O
MB NNP NNP O
increase VB VB O
the DT DT O
risk NN NN O
of IN IN O
warfarin NN NN B-CHEM
- - - O
associated VBN VBN O
ICH NNP NNP O
. . . O

Limited NNP NNP O
prospective JJ JJ O
data NNS NNS O
corroborate VBP VBP O
these DT DT O
findings NNS NNS O
, , , O
but CC CC O
larger JJR JJR O
prospective JJ JJ O
studies NNS NNS O
are VBP VBP O
urgently RB RB O
required VBN VBN O
. . . O

Studies NNS NNS O
of IN IN O
synergy NN NN O
between IN IN O
morphine NN NN B-CHEM
and CC CC O
a DT DT O
novel NN NN O
sodium NN NN B-CHEM
channel NN NN O
blocker NN NN O
, , , O
CNSB002 NNP NNP B-CHEM
, , , O
in IN IN O
rat NN NN O
models NNS NNS O
of IN IN O
inflammatory JJ JJ O
and CC CC O
neuropathic JJ JJ O
pain NN NN O
. . . O

OBJECTIVE NNP NNP O
: : : O
This DT DT O
study NN NN O
determined VBD VBD O
the DT DT O
antihyperalgesic JJ JJ O
effect NN NN O
of IN IN O
CNSB002 NNP NNP B-CHEM
, , , O
a DT DT O
sodium NN NN B-CHEM
channel NN NN O
blocker NN NN O
with IN IN O
antioxidant JJ JJ O
properties NNS NNS O
given VBN VBN O
alone RB RB O
and CC CC O
in IN IN O
combinations NNS NNS O
with IN IN O
morphine NN NN B-CHEM
in IN IN O
rat NN NN O
models NNS NNS O
of IN IN O
inflammatory JJ JJ O
and CC CC O
neuropathic JJ JJ O
pain NN NN O
. . . O

DESIGN NNP NNP O
: : : O
Dose NNP NNP O
response NN NN O
curves NNS NNS O
for IN IN O
nonsedating VBG VBG O
doses NNS NNS O
of IN IN O
morphine NN NN B-CHEM
and CC CC O
CNSB002 NNP NNP B-CHEM
given VBN VBN O
intraperitoneally RB RB O
alone RB RB O
and CC CC O
together RB RB O
in IN IN O
combinations NNS NNS O
were VBD VBD O
constructed VBN VBN O
for IN IN O
antihyperalgesic JJ JJ O
effect NN NN O
using VBG VBG O
paw NN NN O
withdrawal NN NN O
from IN IN O
noxious JJ JJ O
heat NN NN O
in IN IN O
two CD CD O
rat NN NN O
pain NN NN O
models NNS NNS O
: : : O
carrageenan NN NN B-CHEM
- - - O
induced JJ JJ O
paw NN NN O
inflammation NN NN O
and CC CC O
streptozotocin NN NN B-CHEM
( ( ( O
STZ NNP NNP B-CHEM
) ) ) O
- : : O
induced JJ JJ O
diabetic JJ JJ O
neuropathy NN NN O
. . . O

RESULTS NNS NNS O
: : : O
The DT DT O
maximum NN NN O
nonsedating NN NN O
doses NNS NNS O
were VBD VBD O
: : : O
morphine NN NN B-CHEM
, , , O
3 CD CD O
. . . O
2 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
; : : O
CNSB002 NNP NNP B-CHEM
10 CD CD O
. . . O
0 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
; : : O
5 CD CD O
. . . O
0 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
CNSB002 NNP NNP B-CHEM
with IN IN O
morphine NN NN B-CHEM
3 CD CD O
. . . O
2 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
in IN IN O
combination NN NN O
. . . O

The DT DT O
doses NNS NNS O
calculated VBN VBN O
to TO TO O
cause VB VB O
50 CD CD O
% NN NN O
reversal NN NN O
of IN IN O
hyperalgesia NN NN O
( ( ( O
ED50 NNP NNP O
) ) ) O
were VBD VBD O
7 CD CD O
. . . O
54 CD CD O
( ( ( O
1 CD CD O
. . . O
81 CD CD O
) ) ) O
and CC CC O
4 CD CD O
. . . O
83 CD CD O
( ( ( O
1 CD CD O
. . . O
54 CD CD O
) ) ) O
in IN IN O
the DT DT O
carrageenan NN NN B-CHEM
model NN NN O
and CC CC O
44 CD CD O
. . . O
18 CD CD O
( ( ( O
1 CD CD O
. . . O
37 CD CD O
) ) ) O
and CC CC O
9 CD CD O
. . . O
14 CD CD O
( ( ( O
1 CD CD O
. . . O
24 CD CD O
) ) ) O
in IN IN O
the DT DT O
STZ NNP NNP B-CHEM
- - - O
induced JJ JJ O
neuropathy NN NN O
model NN NN O
for IN IN O
CNSB002 NNP NNP B-CHEM
and CC CC O
morphine NN NN B-CHEM
, , , O
respectively RB RB O
( ( ( O
mg NN NN O
/ NN NN O
kg NN NN O
; : : O
mean NN NN O
, , , O
SEM NNP NNP O
) ) ) O
. . . O

These DT DT O
values NNS NNS O
were VBD VBD O
greater JJR JJR O
than IN IN O
the DT DT O
maximum NN NN O
nonsedating VBG VBG O
doses NNS NNS O
. . . O

The DT DT O
ED50 NNP NNP O
values NNS NNS O
for IN IN O
morphine NN NN B-CHEM
when WRB WRB O
given VBN VBN O
in IN IN O
combination NN NN O
with IN IN O
CNSB002 NNP NNP B-CHEM
( ( ( O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
were VBD VBD O
less JJR JJR O
than IN IN O
the DT DT O
maximum NN NN O
nonsedating NN NN O
dose NN NN O
: : : O
0 CD CD O
. . . O
56 CD CD O
( ( ( O
1 CD CD O
. . . O
55 CD CD O
) ) ) O
in IN IN O
the DT DT O
carrageenan NN NN B-CHEM
model NN NN O
and CC CC O
1 CD CD O
. . . O
37 CD CD O
( ( ( O
1 CD CD O
. . . O
23 CD CD O
) ) ) O
in IN IN O
the DT DT O
neuropathy JJ JJ O
model NN NN O
( ( ( O
mg NN NN O
/ NN NN O
kg NN NN O
; : : O
mean NN NN O
, , , O
SEM NNP NNP O
) ) ) O
. . . O

The DT DT O
antinociception NN NN O
after IN IN O
morphine NN NN B-CHEM
( ( ( O
3 CD CD O
. . . O
2 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
was VBD VBD O
increased VBN VBN O
by IN IN O
co NN NN O
- - - O
administration NN NN O
with IN IN O
CNSB002 NNP NNP B-CHEM
from IN IN O
28 CD CD O
. . . O
0 CD CD O
and CC CC O
31 CD CD O
. . . O
7 CD CD O
% NN NN O
to TO TO O
114 CD CD O
. . . O
6 CD CD O
and CC CC O
56 CD CD O
. . . O
9 CD CD O
% NN NN O
reversal NN NN O
of IN IN O
hyperalgesia NN NN O
in IN IN O
the DT DT O
inflammatory JJ JJ O
and CC CC O
neuropathic JJ JJ O
models NNS NNS O
, , , O
respectively RB RB O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
; : : O
one CD CD O
- - - O
way NN NN O
analysis NN NN O
of IN IN O
variance NN NN O
- - - O
significantly RB RB O
greater JJR JJR O
than IN IN O
either DT DT O
drug NN NN O
given VBN VBN O
alone RB RB O
) ) ) O
. . . O

CONCLUSIONS NNP NNP O
: : : O
The DT DT O
maximum NN NN O
antihyperalgesic JJ JJ O
effect NN NN O
achievable JJ JJ O
with IN IN O
nonsedating JJ JJ O
doses NNS NNS O
of IN IN O
morphine NN NN B-CHEM
may MD MD O
be VB VB O
increased VBN VBN O
significantly RB RB O
when WRB WRB O
the DT DT O
drug NN NN O
is VBZ VBZ O
used VBN VBN O
in IN IN O
combination NN NN O
with IN IN O
CNSB002 NNP NNP B-CHEM
. . . O

Heparin NNP NNP B-CHEM
- : : O
induced VBN VBN O
thrombocytopenia NN NN O
: : : O
a DT DT O
practical JJ JJ O
review NN NN O
. . . O

Heparin NNP NNP B-CHEM
- : : O
induced JJ JJ O
thrombocytopenia NN NN O
( ( ( O
HIT NNP NNP O
) ) ) O
remains NNS NNS O
under IN IN O
- : : O
recognized VBN VBN O
despite IN IN O
its PRP$ PRP$ O
potentially RB RB O
devastating JJ JJ O
outcomes NNS NNS O
. . . O

It PRP PRP O
begins VBZ VBZ O
when WRB WRB O
heparin NN NN B-CHEM
exposure NN NN O
stimulates NNS NNS O
the DT DT O
formation NN NN O
of IN IN O
heparin NN NN B-CHEM
- - - O
platelet NN NN O
factor NN NN O
4 CD CD O
antibodies NNS NNS O
, , , O
which WDT WDT O
in IN IN O
turn NN NN O
triggers NNS NNS O
the DT DT O
release NN NN O
of IN IN O
procoagulant JJ JJ O
platelet NN NN O
particles NNS NNS O
. . . O

Thrombosis NNP NNP O
and CC CC O
thrombocytopenia NN NN O
that IN IN O
follow VBP VBP O
comprise NN NN O
the DT DT O
2 CD CD O
hallmark NN NN O
traits NNS NNS O
of IN IN O
HIT NNP NNP O
, , , O
with IN IN O
the DT DT O
former JJ JJ O
largely RB RB O
responsible JJ JJ O
for IN IN O
significant JJ JJ O
vascular NN NN O
complications NNS NNS O
. . . O

The DT DT O
prevalence NN NN O
of IN IN O
HIT NNP NNP O
varies NNS NNS O
among IN IN O
several JJ JJ O
subgroups NNS NNS O
, , , O
with IN IN O
greater JJR JJR O
incidence NN NN O
in IN IN O
surgical JJ JJ O
as IN IN O
compared VBN VBN O
with IN IN O
medical JJ JJ O
populations NNS NNS O
. . . O

HIT NNP NNP O
must MD MD O
be VB VB O
acknowledged VBN VBN O
for IN IN O
its PRP$ PRP$ O
intense JJ JJ O
predilection NN NN O
for IN IN O
thrombosis NN NN O
and CC CC O
suspected VBD VBD O
whenever WRB WRB O
thrombosis NN NN O
occurs VBZ VBZ O
after IN IN O
heparin NN NN B-CHEM
exposure NN NN O
. . . O

Early RB RB O
recognition NN NN O
that IN IN O
incorporates VBZ VBZ O
the DT DT O
clinical JJ JJ O
and CC CC O
serologic JJ JJ O
clues NNS NNS O
is VBZ VBZ O
paramount NN NN O
to TO TO O
timely JJ JJ O
institution NN NN O
of IN IN O
treatment NN NN O
, , , O
as IN IN O
its PRP$ PRP$ O
delay NN NN O
may MD MD O
result VB VB O
in IN IN O
catastrophic JJ JJ O
outcomes NNS NNS O
. . . O

The DT DT O
treatment NN NN O
of IN IN O
HIT NNP NNP O
mandates VBZ VBZ O
an DT DT O
immediate JJ JJ O
cessation NN NN O
of IN IN O
all DT DT O
heparin NN NN B-CHEM
exposure NN NN O
and CC CC O
the DT DT O
institution NN NN O
of IN IN O
an DT DT O
antithrombotic JJ JJ O
therapy NN NN O
, , , O
most RBS RBS O
commonly RB RB O
using VBG VBG O
a DT DT O
direct JJ JJ B-CHEM
thrombin NN NN I-CHEM
inhibitor NN NN I-CHEM
. . . O

Current JJ JJ O
" '' '' O
diagnostic JJ JJ O
" '' '' O
tests NNS NNS O
, , , O
which WDT WDT O
primarily RB RB O
include VBP VBP O
functional JJ JJ O
and CC CC O
antigenic JJ JJ O
assays NNS NNS O
, , , O
have VBP VBP O
more JJR JJR O
of IN IN O
a DT DT O
confirmatory NN NN O
than IN IN O
diagnostic JJ JJ O
role NN NN O
in IN IN O
the DT DT O
management NN NN O
of IN IN O
HIT NNP NNP O
. . . O

Special JJ JJ O
attention NN NN O
must MD MD O
be VB VB O
paid VBN VBN O
to TO TO O
cardiac VB VB O
patients NNS NNS O
who WP WP O
are VBP VBP O
often RB RB O
exposed VBN VBN O
to TO TO O
heparin VB VB B-CHEM
multiple JJ JJ O
times NNS NNS O
during IN IN O
their PRP$ PRP$ O
course NN NN O
of IN IN O
treatment NN NN O
. . . O

Direct NNP NNP B-CHEM
thrombin NN NN I-CHEM
inhibitors NNS NNS I-CHEM
are VBP VBP O
appropriate JJ JJ O
, , , O
evidence NN NN O
- - - O
based JJ JJ O
alternatives NNS NNS O
to TO TO O
heparin NN NN B-CHEM
in IN IN O
patients NNS NNS O
with IN IN O
a DT DT O
history NN NN O
of IN IN O
HIT NNP NNP O
, , , O
who WP WP O
need VBP VBP O
to TO TO O
undergo VB VB O
percutaneous JJ JJ O
coronary JJ JJ O
intervention NN NN O
. . . O

As IN IN O
heparin NN NN B-CHEM
remains VBZ VBZ O
one CD CD O
of IN IN O
the DT DT O
most RBS RBS O
frequently RB RB O
used VBN VBN O
medications NNS NNS O
today NN NN O
with IN IN O
potential JJ JJ O
for IN IN O
HIT NNP NNP O
with IN IN O
every DT DT O
heparin NN NN B-CHEM
exposure NN NN O
, , , O
a DT DT O
close JJ JJ O
vigilance NN NN O
of IN IN O
platelet NN NN O
counts NNS NNS O
must MD MD O
be VB VB O
practiced VBN VBN O
whenever WRB WRB O
heparin NN NN B-CHEM
is VBZ VBZ O
initiated VBN VBN O
. . . O

Abductor NNP NNP O
paralysis NN NN O
after IN IN O
botox NN NN B-CHEM
injection NN NN O
for IN IN O
adductor NN NN O
spasmodic NN NN O
dysphonia NN NN O
. . . O

OBJECTIVES NNP NNP O
/ NN NN O
HYPOTHESIS NNP NNP O
: : : O
Botulinum NNP NNP O
toxin NN NN O
( ( ( O
Botox NNP NNP B-CHEM
) ) ) O
injections NNS NNS O
into IN IN O
the DT DT O
thyroarytenoid NN NN O
muscles NNS NNS O
are VBP VBP O
the DT DT O
current JJ JJ O
standard NN NN O
of IN IN O
care NN NN O
for IN IN O
adductor NN NN O
spasmodic NN NN O
dysphonia NN NN O
( ( ( O
ADSD NNP NNP O
) ) ) O
. . . O

Reported NNP NNP O
adverse NN NN O
effects NNS NNS O
include VBP VBP O
a DT DT O
period NN NN O
of IN IN O
breathiness NN NN O
, , , O
throat NN NN O
pain NN NN O
, , , O
and CC CC O
difficulty NN NN O
with IN IN O
swallowing VBG VBG O
liquids NNS NNS O
. . . O

Here RB RB O
we PRP PRP O
report VBP VBP O
multiple JJ JJ O
cases NNS NNS O
of IN IN O
bilateral JJ JJ O
abductor NN NN O
paralysis NN NN O
following VBG VBG O
Botox NNP NNP B-CHEM
injections NNS NNS O
for IN IN O
ADSD NNP NNP O
, , , O
a DT DT O
complication NN NN O
previously RB RB O
unreported VBD VBD O
. . . O

STUDY NNP NNP O
DESIGN NNP NNP O
: : : O
Retrospective NNP NNP O
case NN NN O
series NN NN O
. . . O

METHODS NNP NNP O
: : : O
Patients NNS NNS O
that WDT WDT O
received VBD VBD O
Botox NNP NNP B-CHEM
injections NNS NNS O
for IN IN O
spasmodic JJ JJ O
dysphonia NN NN O
between IN IN O
January NNP NNP O
2000 CD CD O
and CC CC O
October NNP NNP O
2009 CD CD O
were VBD VBD O
evaluated VBN VBN O
. . . O

Patients NNS NNS O
with IN IN O
ADSD NNP NNP O
were VBD VBD O
identified VBN VBN O
. . . O

The DT DT O
number NN NN O
of IN IN O
treatments NNS NNS O
received VBD VBD O
and CC CC O
adverse JJ JJ O
effects NNS NNS O
were VBD VBD O
noted VBN VBN O
. . . O

For IN IN O
patients NNS NNS O
with IN IN O
bilateral JJ JJ O
abductor NN NN O
paralysis NN NN O
, , , O
age NN NN O
, , , O
sex NN NN O
, , , O
paralytic JJ JJ O
Botox NNP NNP B-CHEM
dose NN NN O
, , , O
prior RB RB O
Botox NNP NNP B-CHEM
dose NN NN O
, , , O
and CC CC O
course NN NN O
following JJ JJ O
paralysis NN NN O
were VBD VBD O
noted VBN VBN O
. . . O

RESULTS NNS NNS O
: : : O
From IN IN O
a DT DT O
database NN NN O
of IN IN O
452 CD CD O
patients NNS NNS O
receiving VBG VBG O
Botox NNP NNP B-CHEM
, , , O
352 CD CD O
patients NNS NNS O
had VBD VBD O
been VBN VBN O
diagnosed VBN VBN O
with IN IN O
ADSD NNP NNP O
. . . O

Of IN IN O
these DT DT O
352 CD CD O
patients NNS NNS O
, , , O
eight CD CD O
patients NNS NNS O
suffered VBD VBD O
bilateral JJ JJ O
abductor NN NN O
paralysis NN NN O
, , , O
and CC CC O
two CD CD O
suffered VBD VBD O
this DT DT O
complication NN NN O
twice RB RB O
. . . O

All DT DT O
affected VBN VBN O
patients NNS NNS O
were VBD VBD O
females NNS NNS O
over IN IN O
the DT DT O
age NN NN O
of IN IN O
50 CD CD O
years NNS NNS O
. . . O

Most JJS JJS O
patients NNS NNS O
had VBD VBD O
received VBN VBN O
treatments NNS NNS O
prior RB RB O
to TO TO O
abductor VB VB O
paralysis NN NN O
and CC CC O
continued VBD VBD O
receiving VBG VBG O
after IN IN O
paralysis NN NN O
. . . O

Seven CD CD O
patients NNS NNS O
recovered VBD VBD O
after IN IN O
a DT DT O
brief JJ JJ O
period NN NN O
of IN IN O
activity NN NN O
restrictions NNS NNS O
, , , O
and CC CC O
one CD CD O
underwent JJ JJ O
a DT DT O
tracheotomy NN NN O
. . . O

The DT DT O
incidence NN NN O
of IN IN O
abductor NN NN O
paralysis NN NN O
after IN IN O
Botox NNP NNP B-CHEM
injection NN NN O
for IN IN O
ADSD NNP NNP O
was VBD VBD O
0 CD CD O
. . . O
34 CD CD O
% NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Bilateral NNP NNP O
abductor NN NN O
paralysis NN NN O
is VBZ VBZ O
a DT DT O
rare JJ JJ O
complication NN NN O
of IN IN O
Botox NNP NNP B-CHEM
injections NNS NNS O
for IN IN O
ADSD NNP NNP O
, , , O
causing VBG VBG O
difficulty NN NN O
with IN IN O
breathing VBG VBG O
upon IN IN O
exertion NN NN O
. . . O

The DT DT O
likely JJ JJ O
mechanism NN NN O
of IN IN O
paralysis NN NN O
is VBZ VBZ O
diffusion NN NN O
of IN IN O
Botox NNP NNP B-CHEM
around IN IN O
the DT DT O
muscular NN NN O
process NN NN O
of IN IN O
the DT DT O
arytenoid NN NN O
to TO TO O
the DT DT O
posterior NN NN O
cricoarytenoid NN NN O
muscles NNS NNS O
. . . O

The DT DT O
paralysis NN NN O
is VBZ VBZ O
temporary JJ JJ O
, , , O
and CC CC O
watchful JJ JJ O
waiting VBG VBG O
with IN IN O
restriction NN NN O
of IN IN O
activity NN NN O
is VBZ VBZ O
the DT DT O
recommended JJ JJ O
management NN NN O
. . . O

Mitochondrial NNP NNP O
impairment NN NN O
contributes NNS NNS O
to TO TO O
cocaine VB VB B-CHEM
- : : O
induced JJ JJ O
cardiac NN NN O
dysfunction NN NN O
: : : O
Prevention NNP NNP O
by IN IN O
the DT DT O
targeted VBN VBN O
antioxidant NN NN O
MitoQ NNP NNP B-CHEM
. . . O

The DT DT O
goal NN NN O
of IN IN O
this DT DT O
study NN NN O
was VBD VBD O
to TO TO O
assess VB VB O
mitochondrial JJ JJ O
function NN NN O
and CC CC O
ROS NNP NNP O
production NN NN O
in IN IN O
an DT DT O
experimental JJ JJ O
model NN NN O
of IN IN O
cocaine NN NN B-CHEM
- - - O
induced JJ JJ O
cardiac NN NN O
dysfunction NN NN O
. . . O

We PRP PRP O
hypothesized VBN VBN O
that IN IN O
cocaine NN NN O
abuse NN NN O
may MD MD O
lead VB VB O
to TO TO O
altered VBN VBN O
mitochondrial JJ JJ O
function NN NN O
that IN IN O
in IN IN O
turn NN NN O
may MD MD O
cause VB VB O
left VBD VBD O
ventricular NN NN O
dysfunction NN NN O
. . . O

Seven CD CD O
days NNS NNS O
of IN IN O
cocaine NN NN B-CHEM
administration NN NN O
to TO TO O
rats NNS NNS O
led VBN VBN O
to TO TO O
an DT DT O
increased JJ JJ O
oxygen NN NN B-CHEM
consumption NN NN O
detected VBN VBN O
in IN IN O
cardiac JJ JJ O
fibers NNS NNS O
, , , O
specifically RB RB O
through IN IN O
complex JJ JJ O
I PRP PRP O
and CC CC O
complex JJ JJ O
III NNP NNP O
. . . O

ROS NNP NNP O
levels NNS NNS O
were VBD VBD O
increased VBN VBN O
, , , O
specifically RB RB O
in IN IN O
interfibrillar JJ JJ O
mitochondria NN NN O
. . . O

In IN IN O
parallel JJ JJ O
there EX EX O
was VBD VBD O
a DT DT O
decrease NN NN O
in IN IN O
ATP NNP NNP B-CHEM
synthesis NN NN O
, , , O
whereas IN IN O
no DT DT O
difference NN NN O
was VBD VBD O
observed VBN VBN O
in IN IN O
subsarcolemmal JJ JJ O
mitochondria NN NN O
. . . O

This DT DT O
uncoupling JJ JJ O
effect NN NN O
on IN IN O
oxidative JJ JJ O
phosphorylation NN NN O
was VBD VBD O
not RB RB O
detectable JJ JJ O
after IN IN O
short JJ JJ O
- - - O
term NN NN O
exposure NN NN O
to TO TO O
cocaine VB VB B-CHEM
, , , O
suggesting VBG VBG O
that IN IN O
these DT DT O
mitochondrial JJ JJ O
abnormalities NNS NNS O
were VBD VBD O
a DT DT O
late JJ JJ O
rather RB RB O
than IN IN O
a DT DT O
primary JJ JJ O
event NN NN O
in IN IN O
the DT DT O
pathological JJ JJ O
response NN NN O
to TO TO O
cocaine NN NN B-CHEM
. . . O

MitoQ NNP NNP B-CHEM
, , , O
a DT DT O
mitochondrial JJ JJ O
- - - O
targeted VBN VBN O
antioxidant NN NN O
, , , O
was VBD VBD O
shown VBN VBN O
to TO TO O
completely RB RB O
prevent VB VB O
these DT DT O
mitochondrial JJ JJ O
abnormalities NNS NNS O
as RB RB O
well RB RB O
as IN IN O
cardiac JJ JJ O
dysfunction NN NN O
characterized VBN VBN O
here RB RB O
by IN IN O
a DT DT O
diastolic JJ JJ O
dysfunction NN NN O
studied VBN VBN O
with IN IN O
a DT DT O
conductance NN NN O
catheter NN NN O
to TO TO O
obtain VB VB O
pressure NN NN O
- : : O
volume NN NN O
data NNS NNS O
. . . O

Taken VBN VBN O
together RB RB O
, , , O
these DT DT O
results NNS NNS O
extend VB VB O
previous JJ JJ O
studies NNS NNS O
and CC CC O
demonstrate VB VB O
that IN IN O
cocaine NN NN B-CHEM
- : : O
induced JJ JJ O
cardiac NN NN O
dysfunction NN NN O
may MD MD O
be VB VB O
due JJ JJ O
to TO TO O
a DT DT O
mitochondrial JJ JJ O
defect NN NN O
. . . O

Trimethoprim NNP NNP B-CHEM
- : : O
induced JJ JJ O
immune JJ JJ O
hemolytic JJ JJ O
anemia NN NN O
in IN IN O
a DT DT O
pediatric JJ JJ O
oncology NN NN O
patient NN NN O
presenting NN NN O
as IN IN O
an DT DT O
acute JJ JJ O
hemolytic JJ JJ O
transfusion NN NN O
reaction NN NN O
. . . O

A DT DT O
10 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
male NN NN O
with IN IN O
acute JJ JJ O
leukemia NN NN O
presented VBN VBN O
with IN IN O
post NN NN O
- - - O
chemotherapy NN NN O
anemia NN NN O
. . . O

During IN IN O
red JJ JJ O
cell NN NN O
transfusion NN NN O
, , , O
he PRP PRP O
developed VBD VBD O
hemoglobinuria NN NN O
. . . O

Transfusion NNP NNP O
reaction NN NN O
workup NN NN O
was VBD VBD O
negative JJ JJ O
. . . O

Drug NN NN O
- : : O
induced JJ JJ O
immune JJ JJ O
hemolytic JJ JJ O
anemia NN NN O
was VBD VBD O
suspected VBN VBN O
because IN IN O
of IN IN O
positive JJ JJ O
direct JJ JJ O
antiglobulin NN NN O
test NN NN O
, , , O
negative JJ JJ O
eluate NN NN O
, , , O
and CC CC O
microspherocytes NNS NNS O
on IN IN O
smear NN NN O
pre NN NN O
- : : O
and CC CC O
post JJ JJ O
- - - O
transfusion NN NN O
. . . O

Drug NN NN O
studies NNS NNS O
using VBG VBG O
the DT DT O
indirect NN NN O
antiglobulin NN NN O
test NN NN O
were VBD VBD O
strongly RB RB O
positive JJ JJ O
with IN IN O
trimethoprim NN NN B-CHEM
and CC CC O
trimethoprim VB VB B-CHEM
- : : I-CHEM
sulfamethoxazole NN NN I-CHEM
but CC CC O
negative JJ JJ O
with IN IN O
sulfamethoxazole NN NN B-CHEM
. . . O

The DT DT O
patient NN NN O
recovered VBD VBD O
after IN IN O
discontinuing VBG VBG O
the DT DT O
drug NN NN O
, , , O
with IN IN O
no DT DT O
recurrence NN NN O
in IN IN O
2 CD CD O
years NNS NNS O
. . . O

Other JJ JJ O
causes NNS NNS O
of IN IN O
anemia NN NN O
should MD MD O
be VB VB O
considered VBN VBN O
in IN IN O
patients NNS NNS O
with IN IN O
worse JJR JJR O
- - - O
than IN IN O
- - - O
expected JJ JJ O
anemia NN NN O
after IN IN O
chemotherapy NN NN O
. . . O

Furthermore RB RB O
, , , O
hemolysis NN NN O
during IN IN O
transfusion NN NN O
is VBZ VBZ O
not RB RB O
always RB RB O
a DT DT O
transfusion NN NN O
reaction NN NN O
. . . O

Verapamil NNP NNP B-CHEM
stimulation NN NN O
test NN NN O
in IN IN O
hyperprolactinemia NN NN O
: : : O
loss NN NN O
of IN IN O
prolactin NN NN O
response NN NN O
in IN IN O
anatomic JJ JJ O
or CC CC O
functional JJ JJ O
stalk NN NN O
effect NN NN O
. . . O

AIM NNP NNP O
: : : O
Verapamil NNP NNP B-CHEM
stimulation NN NN O
test NN NN O
was VBD VBD O
previously RB RB O
investigated VBN VBN O
as IN IN O
a DT DT O
tool NN NN O
for IN IN O
differential JJ JJ O
diagnosis NN NN O
of IN IN O
hyperprolactinemia NN NN O
, , , O
but CC CC O
with IN IN O
conflicting JJ JJ O
results NNS NNS O
. . . O

Macroprolactinemia NNP NNP O
was VBD VBD O
never RB RB O
considered VBN VBN O
in IN IN O
those DT DT O
previous JJ JJ O
studies NNS NNS O
. . . O

Here RB RB O
, , , O
we PRP PRP O
aimed VBD VBD O
to TO TO O
re VB VB O
- : : O
investigate VB VB O
the DT DT O
diagnostic JJ JJ O
value NN NN O
of IN IN O
verapamil NN NN B-CHEM
in IN IN O
a DT DT O
population NN NN O
who WP WP O
were VBD VBD O
all DT DT O
screened VBN VBN O
for IN IN O
macroprolactinemia NN NN O
. . . O

Prolactin NNP NNP O
responses NNS NNS O
to TO TO O
verapamil NN NN B-CHEM
in IN IN O
65 CD CD O
female JJ JJ O
patients NNS NNS O
( ( ( O
age NN NN O
: : : O
29 CD CD O
. . . O
9 CD CD O
+ NN NN O
/ NN NN O
- : : O
8 CD CD O
. . . O
1 CD CD O
years NNS NNS O
) ) ) O
with IN IN O
hyperprolactinemia NN NN O
were VBD VBD O
tested VBN VBN O
in IN IN O
a DT DT O
descriptive JJ JJ O
, , , O
matched VBN VBN O
case NN NN O
- - - O
control NN NN O
study NN NN O
. . . O

METHODS NNP NNP O
: : : O
Verapamil NNP NNP B-CHEM
80 CD CD O
mg NN NN O
, , , O
p NN NN O
. . . O
o NN NN O
. . . O
was VBD VBD O
administered VBN VBN O
, , , O
and CC CC O
then RB RB O
PRL NNP NNP O
levels NNS NNS O
were VBD VBD O
measured VBN VBN O
at IN IN O
8th CD CD O
and CC CC O
16th CD CD O
hours NNS NNS O
, , , O
by IN IN O
immunometric JJ JJ O
chemiluminescence NN NN O
. . . O

Verapamil NNP NNP B-CHEM
responsiveness NN NN O
was VBD VBD O
determined VBN VBN O
by IN IN O
peak NN NN O
percent NN NN O
change NN NN O
in IN IN O
basal NN NN O
prolactin NN NN O
levels NNS NNS O
( ( ( O
PRL NNP NNP O
) ) ) O
. . . O

RESULTS NNS NNS O
: : : O
Verapamil NNP NNP B-CHEM
significantly RB RB O
increased VBD VBD O
PRL NNP NNP O
levels NNS NNS O
in IN IN O
healthy JJ JJ O
controls NNS NNS O
( ( ( O
N NNP NNP O
. . . O
8 CD CD O
, , , O
PRL NNP NNP O
: : : O
183 CD CD O
% NN NN O
) ) ) O
, , , O
macroprolactinoma NN NN O
( ( ( O
N NNP NNP O
. . . O
8 CD CD O
, , , O
PRL NNP NNP O
: : : O
7 CD CD O
% NN NN O
) ) ) O
, , , O
microprolactinoma NN NN O
( ( ( O
N NNP NNP O
. . . O
19 CD CD O
, , , O
PRL NNP NNP O
: : : O
21 CD CD O
% NN NN O
) ) ) O
, , , O
macroprolactinemia NN NN O
( ( ( O
N NNP NNP O
. . . O
23 CD CD O
, , , O
PRL NNP NNP O
: : : O
126 CD CD O
% NN NN O
) ) ) O
, , , O
but CC CC O
not RB RB O
in IN IN O
pseudoprolactinoma NN NN O
( ( ( O
N NNP NNP O
. . . O
8 CD CD O
, , , O
PRL NNP NNP O
: : : O
0 CD CD O
. . . O
8 CD CD O
% NN NN O
) ) ) O
, , , O
and CC CC O
risperidone NN NN B-CHEM
- - - O
induced JJ JJ O
hyperprolactinemia NN NN O
( ( ( O
N NNP NNP O
. . . O
7 CD CD O
, , , O
PRL NNP NNP O
: : : O
3 CD CD O
% NN NN O
) ) ) O
. . . O

ROC NNP NNP O
curve NN NN O
analysis NN NN O
revealed VBD VBD O
that IN IN O
unresponsiveness JJ JJ O
to TO TO O
verapamil VB VB B-CHEM
defined VBN VBN O
as IN IN O
PRL NNP NNP O
< NN NN O
7 CD CD O
% NN NN O
, , , O
discriminated VBD VBD O
anatomical JJ JJ O
or CC CC O
functional JJ JJ O
stalk NN NN O
effect NN NN O
( ( ( O
sensitivity NN NN O
: : : O
74 CD CD O
% NN NN O
, , , O
specificity NN NN O
: : : O
73 CD CD O
% NN NN O
, , , O
AUC NNP NNP O
: : : O
0 CD CD O
. . . O
855 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
04 CD CD O
, , , O
P NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
, , , O
CI NNP NNP O
: : : O
0 CD CD O
. . . O
768 CD CD O
- : : O
0 CD CD O
. . . O
942 CD CD O
) ) ) O
associated VBN VBN O
with IN IN O
pseudoprolactinoma NN NN O
or CC CC O
risperidone NN NN B-CHEM
- - - O
induced JJ JJ O
hyperprolactinemia NN NN O
, , , O
respectively RB RB O
. . . O

CONCLUSION NNP NNP O
: : : O
Verapamil NNP NNP B-CHEM
responsiveness NN NN O
is VBZ VBZ O
not RB RB O
a DT DT O
reliable JJ JJ O
finding VBG VBG O
for IN IN O
the DT DT O
differential JJ JJ O
diagnosis NN NN O
of IN IN O
hyperprolactinemia NN NN O
. . . O

However RB RB O
, , , O
verapamil NN NN B-CHEM
unresponsiveness JJ JJ O
discriminates NNS NNS O
stalk NN NN O
effect NN NN O
( ( ( O
i NNP NNP O
. . . O
e SYM SYM O
. . . O
, , , O
anatomically RB RB O
or CC CC O
functionally RB RB O
inhibited VBN VBN O
dopaminergic JJ JJ O
tonus NN NN O
) ) ) O
from IN IN O
other JJ JJ O
causes NNS NNS O
of IN IN O
hyperprolactinemia NN NN O
with IN IN O
varying VBG VBG O
degrees NNS NNS O
of IN IN O
responsiveness NN NN O
. . . O

Blockade NNP NNP O
of IN IN O
endothelial JJ JJ O
- - - O
mesenchymal JJ JJ O
transition NN NN O
by IN IN O
a DT DT O
Smad3 NNP NNP O
inhibitor NN NN O
delays NNS NNS O
the DT DT O
early JJ JJ O
development NN NN O
of IN IN O
streptozotocin NN NN B-CHEM
- - - O
induced JJ JJ O
diabetic JJ JJ O
nephropathy NN NN O
. . . O

OBJECTIVE NNP NNP O
: : : O
A DT DT O
multicenter NN NN O
, , , O
controlled VBN VBN O
trial NN NN O
showed VBD VBD O
that IN IN O
early JJ JJ O
blockade NN NN O
of IN IN O
the DT DT O
renin NN NN O
- - - O
angiotensin NN NN B-CHEM
system NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
type NN NN O
1 CD CD O
diabetes NNS NNS O
and CC CC O
normoalbuminuria NN NN O
did VBD VBD O
not RB RB O
retard VB VB O
the DT DT O
progression NN NN O
of IN IN O
nephropathy NN NN O
, , , O
suggesting VBG VBG O
that IN IN O
other JJ JJ O
mechanism NN NN O
( ( ( O
s VBZ VBZ O
) ) ) O
are VBP VBP O
involved VBN VBN O
in IN IN O
the DT DT O
pathogenesis NNS NNS O
of IN IN O
early JJ JJ O
diabetic JJ JJ O
nephropathy NN NN O
( ( ( O
diabetic JJ JJ O
nephropathy NN NN O
) ) ) O
. . . O

We PRP PRP O
have VBP VBP O
previously RB RB O
demonstrated VBN VBN O
that IN IN O
endothelial JJ JJ O
- - - O
mesenchymal NN NN O
- - - O
transition NN NN O
( ( ( O
EndoMT NNP NNP O
) ) ) O
contributes VBZ VBZ O
to TO TO O
the DT DT O
early JJ JJ O
development NN NN O
of IN IN O
renal JJ JJ O
interstitial JJ JJ O
fibrosis NNS NNS O
independently RB RB O
of IN IN O
microalbuminuria NNS NNS O
in IN IN O
mice NN NN O
with IN IN O
streptozotocin NN NN B-CHEM
( ( ( O
STZ NNP NNP B-CHEM
) ) ) O
- : : O
induced JJ JJ O
diabetes NNS NNS O
. . . O

In IN IN O
the DT DT O
present JJ JJ O
study NN NN O
, , , O
we PRP PRP O
hypothesized VBN VBN O
that IN IN O
blocking VBG VBG O
EndoMT NNP NNP O
reduces VBZ VBZ O
the DT DT O
early JJ JJ O
development NN NN O
of IN IN O
diabetic JJ JJ O
nephropathy NN NN O
. . . O

RESEARCH NNP NNP O
DESIGN NNP NNP O
AND CC CC O
METHODS NNP NNP O
: : : O
EndoMT NNP NNP O
was VBD VBD O
induced VBN VBN O
in IN IN O
a DT DT O
mouse NN NN O
pancreatic JJ JJ O
microvascular NN NN O
endothelial JJ JJ O
cell NN NN O
line NN NN O
( ( ( O
MMEC NNP NNP O
) ) ) O
in IN IN O
the DT DT O
presence NN NN O
of IN IN O
advanced JJ JJ O
glycation NN NN O
end NN NN O
products NNS NNS O
( ( ( O
AGEs NNP NNP O
) ) ) O
and CC CC O
in IN IN O
the DT DT O
endothelial JJ JJ O
lineage NN NN O
- - - O
traceble JJ JJ O
mouse NN NN O
line NN NN O
Tie2 NNP NNP O
- : : O
Cre NNP NNP O
; : : O
Loxp NNP NNP O
- - - O
EGFP NNP NNP O
by IN IN O
administration NN NN O
of IN IN O
AGEs NNP NNP O
, , , O
with IN IN O
nonglycated JJ JJ O
mouse NN NN O
albumin NN NN O
serving VBG VBG O
as IN IN O
a DT DT O
control NN NN O
. . . O

Phosphorylated NNP NNP O
Smad3 NNP NNP O
was VBD VBD O
detected VBN VBN O
by IN IN O
immunoprecipitation NN NN O
/ NN NN O
Western JJ JJ O
blotting NN NN O
and CC CC O
confocal JJ JJ O
microscopy NN NN O
. . . O

Blocking NNP NNP O
studies NNS NNS O
using VBG VBG O
receptor NN NN O
for IN IN O
AGE NNP NNP O
siRNA NN NN O
and CC CC O
a DT DT O
specific JJ JJ O
inhibitor NN NN O
of IN IN O
Smad3 NNP NNP O
( ( ( O
SIS3 NNP NNP O
) ) ) O
were VBD VBD O
performed VBN VBN O
in IN IN O
MMECs NNP NNP O
and CC CC O
in IN IN O
STZ NNP NNP B-CHEM
- : : O
induced JJ JJ O
diabetic JJ JJ O
nephropathy NN NN O
in IN IN O
Tie2 NNP NNP O
- : : O
Cre NNP NNP O
; : : O
Loxp NNP NNP O
- : : O
EGFP NNP NNP O
mice NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Confocal NNP NNP O
microscopy NN NN O
and CC CC O
real JJ JJ O
- : : O
time NN NN O
PCR NNP NNP O
demonstrated VBD VBD O
that IN IN O
AGEs NNP NNP O
induced VBD VBD O
EndoMT NNP NNP O
in IN IN O
MMECs NNP NNP O
and CC CC O
in IN IN O
Tie2 NNP NNP O
- : : O
Cre NNP NNP O
; : : O
Loxp NNP NNP O
- : : O
EGFP NNP NNP O
mice NN NN O
. . . O

Immunoprecipitation NNP NNP O
/ NN NN O
Western NNP NNP O
blotting VBG VBG O
showed VBN VBN O
that IN IN O
Smad3 NNP NNP O
was VBD VBD O
activated VBN VBN O
by IN IN O
AGEs NNP NNP O
but CC CC O
was VBD VBD O
inhibited VBN VBN O
by IN IN O
SIS3 NNP NNP O
in IN IN O
MMECs NNP NNP O
and CC CC O
in IN IN O
STZ NNP NNP B-CHEM
- : : O
induced JJ JJ O
diabetic JJ JJ O
nephropathy NN NN O
. . . O

Confocal NNP NNP O
microscopy NN NN O
and CC CC O
real JJ JJ O
- : : O
time NN NN O
PCR NNP NNP O
further RBR RBR O
demonstrated VBD VBD O
that IN IN O
SIS3 NNP NNP O
abrogated VBD VBD O
EndoMT NNP NNP O
, , , O
reduced VBD VBD O
renal JJ JJ O
fibrosis NNS NNS O
, , , O
and CC CC O
retarded JJ JJ O
progression NN NN O
of IN IN O
nephropathy NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
EndoMT NNP NNP O
is VBZ VBZ O
a DT DT O
novel NN NN O
pathway NN NN O
leading VBG VBG O
to TO TO O
early JJ JJ O
development NN NN O
of IN IN O
diabetic JJ JJ O
nephropathy NN NN O
. . . O

Blockade NNP NNP O
of IN IN O
EndoMT NNP NNP O
by IN IN O
SIS3 NNP NNP O
may MD MD O
provide VB VB O
a DT DT O
new JJ JJ O
strategy NN NN O
to TO TO O
retard VB VB O
the DT DT O
progression NN NN O
of IN IN O
diabetic JJ JJ O
nephropathy NN NN O
and CC CC O
other JJ JJ O
diabetes NN NN O
complications NNS NNS O
. . . O

Cytostatic NNP NNP O
and CC CC O
anti JJ JJ O
- : : O
angiogenic JJ JJ O
effects NNS NNS O
of IN IN O
temsirolimus NN NN B-CHEM
in IN IN O
refractory NN NN O
mantle NN NN O
cell NN NN O
lymphoma NN NN O
. . . O

Mantle NNP NNP O
cell NN NN O
lymphoma NN NN O
( ( ( O
MCL NNP NNP O
) ) ) O
is VBZ VBZ O
a DT DT O
rare JJ JJ O
and CC CC O
aggressive JJ JJ O
type NN NN O
of IN IN O
B NNP NNP O
- - - O
cell NN NN O
non NN NN O
- : : O
Hodgkin NNP NNP O
' POS POS O
s VBZ VBZ O
lymphoma NN NN O
. . . O

Patients NNS NNS O
become VBP VBP O
progressively RB RB O
refractory NN NN O
to TO TO O
conventional JJ JJ O
chemotherapy NN NN O
, , , O
and CC CC O
their PRP$ PRP$ O
prognosis NN NN O
is VBZ VBZ O
poor JJ JJ O
. . . O

However RB RB O
, , , O
a DT DT O
38 CD CD O
% NN NN O
remission NN NN O
rate NN NN O
has VBZ VBZ O
been VBN VBN O
recently RB RB O
reported VBN VBN O
in IN IN O
refractory NN NN O
MCL NNP NNP O
treated VBN VBN O
with IN IN O
temsirolimus NN NN B-CHEM
, , , O
a DT DT O
mTOR NN NN O
inhibitor NN NN O
. . . O
Here RB RB O
we PRP PRP O
had VBD VBD O
the DT DT O
opportunity NN NN O
to TO TO O
study VB VB O
a DT DT O
case NN NN O
of IN IN O
refractory NN NN O
MCL NNP NNP O
who WP WP O
had VBD VBD O
tumor NN NN O
regression NN NN O
two CD CD O
months NNS NNS O
after IN IN O
temsirolimus NN NN B-CHEM
treatment NN NN O
, , , O
and CC CC O
a DT DT O
progression NN NN O
- - - O
free JJ JJ O
survival NN NN O
of IN IN O
10 CD CD O
months NNS NNS O
. . . O

In IN IN O
this DT DT O
case NN NN O
, , , O
lymph NN NN O
node NN NN O
biopsies NNS NNS O
were VBD VBD O
performed VBN VBN O
before IN IN O
and CC CC O
six CD CD O
months NNS NNS O
after IN IN O
temsirolimus NN NN B-CHEM
therapy NN NN O
. . . O

Comparison NNP NNP O
of IN IN O
the DT DT O
two CD CD O
biopsies NNS NNS O
showed VBD VBD O
that IN IN O
temsirolimus NN NN B-CHEM
inhibited JJ JJ O
tumor NN NN O
cell NN NN O
proliferation NN NN O
through IN IN O
cell NN NN O
cycle NN NN O
arrest NN NN O
, , , O
but CC CC O
did VBD VBD O
not RB RB O
induce VB VB O
any DT DT O
change NN NN O
in IN IN O
the DT DT O
number NN NN O
of IN IN O
apoptotic JJ JJ O
tumor NN NN O
cells NNS NNS O
. . . O

Apart RB RB O
from IN IN O
this DT DT O
cytostatic JJ JJ O
effect NN NN O
, , , O
temsirolimus NN NN B-CHEM
had VBD VBD O
an DT DT O
antiangiogenic JJ JJ O
effect NN NN O
with IN IN O
decrease NN NN O
of IN IN O
tumor NN NN O
microvessel NN NN O
density NN NN O
and CC CC O
of IN IN O
VEGF NNP NNP O
expression NN NN O
. . . O

Moreover RB RB O
, , , O
numerous JJ JJ O
patchy NN NN O
, , , O
well RB RB O
- - - O
limited JJ JJ O
fibrotic JJ JJ O
areas NNS NNS O
, , , O
compatible JJ JJ O
with IN IN O
post NN NN O
- - - O
necrotic JJ JJ O
tissue NN NN O
repair NN NN O
, , , O
were VBD VBD O
found VBN VBN O
after IN IN O
6 CD CD O
- : : O
month NN NN O
temsirolimus NN NN B-CHEM
therapy NN NN O
. . . O

Thus RB RB O
, , , O
temsirolimus NN NN B-CHEM
reduced VBN VBN O
tumor NN NN O
burden NN NN O
through IN IN O
associated VBN VBN O
cytostatic JJ JJ O
and CC CC O
anti JJ JJ O
- : : O
angiogenic JJ JJ O
effects NNS NNS O
. . . O
This DT DT O
dual JJ JJ O
effect NN NN O
of IN IN O
temsirolimus NN NN B-CHEM
on IN IN O
tumor NN NN O
tissue NN NN O
could MD MD O
contribute VB VB O
to TO TO O
its PRP$ PRP$ O
recently RB RB O
reported VBN VBN O
efficiency NN NN O
in IN IN O
refractory NN NN O
MCL NNP NNP O
resistant NN NN O
to TO TO O
conventional JJ JJ O
chemotherapy NN NN O
. . . O

Acute JJ JJ O
renal JJ JJ O
failure NN NN O
due JJ JJ O
to TO TO O
rifampicin VB VB B-CHEM
. . . O

A DT DT O
23 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
male JJ JJ O
patient NN NN O
with IN IN O
bacteriologically RB RB O
proven VBN VBN O
pulmonary JJ JJ O
tuberculosis NNS NNS O
was VBD VBD O
treated VBN VBN O
with IN IN O
the DT DT O
various JJ JJ O
regimens NNS NNS O
of IN IN O
antituberculosis NNS NNS O
drugs NNS NNS O
for IN IN O
nearly RB RB O
15 CD CD O
months NNS NNS O
. . . O

Rifampicin NNP NNP B-CHEM
was VBD VBD O
administered VBN VBN O
thrice NN NN O
as IN IN O
one CD CD O
of IN IN O
the DT DT O
3 CD CD O
- : : O
4 CD CD O
drug NN NN O
regimen NNS NNS O
and CC CC O
each DT DT O
time NN NN O
he PRP PRP O
developed VBD VBD O
untoward JJ JJ O
side NN NN O
effects NNS NNS O
like IN IN O
nausea NN NN O
, , , O
vomiting VBG VBG O
and CC CC O
fever NN NN O
with IN IN O
chills NNS NNS O
and CC CC O
rigors NNS NNS O
. . . O

The DT DT O
last JJ JJ O
such JJ JJ O
episode NN NN O
was VBD VBD O
of IN IN O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
at IN IN O
which WDT WDT O
stage NN NN O
the DT DT O
patient NN NN O
was VBD VBD O
seen VBN VBN O
by IN IN O
the DT DT O
authors NNS NNS O
of IN IN O
this DT DT O
report NN NN O
. . . O

The DT DT O
patient NN NN O
, , , O
however RB RB O
, , , O
made VBD VBD O
a DT DT O
full JJ JJ O
recovery NN NN O
. . . O

Syncope NNP NNP O
caused VBN VBN O
by IN IN O
hyperkalemia NN NN O
during IN IN O
use NN NN O
of IN IN O
a DT DT O
combined VBN VBN O
therapy NN NN O
with IN IN O
the DT DT O
angiotensin NN NN B-CHEM
- - - O
converting VBG VBG O
enzyme NN NN O
inhibitor NN NN O
and CC CC O
spironolactone NN NN B-CHEM
. . . O

A DT DT O
76 CD CD O
year NN NN O
- : : O
old JJ JJ O
woman NN NN O
with IN IN O
a DT DT O
history NN NN O
of IN IN O
coronary JJ JJ O
artery NN NN O
bypass NN NN O
grafting VBG VBG O
and CC CC O
prior RB RB O
myocardial NN NN O
infarction NN NN O
was VBD VBD O
transferred VBN VBN O
to TO TO O
the DT DT O
emergency NN NN O
room NN NN O
with IN IN O
loss NN NN O
of IN IN O
consciousness NN NN O
due JJ JJ O
to TO TO O
marked VBN VBN O
bradycardia NNS NNS O
caused VBN VBN O
by IN IN O
hyperkalemia NN NN O
. . . O

The DT DT O
concentration NN NN O
of IN IN O
serum NN NN O
potassium NN NN B-CHEM
was VBD VBD O
high JJ JJ O
, , , O
and CC CC O
normal JJ JJ O
sinus NN NN O
rhythm NN NN O
was VBD VBD O
restored VBN VBN O
after IN IN O
correction NN NN O
of IN IN O
the DT DT O
serum NN NN O
potassium NN NN B-CHEM
level NN NN O
. . . O

The DT DT O
cause NN NN O
of IN IN O
hyperkalemia NN NN O
was VBD VBD O
considered VBN VBN O
to TO TO O
be VB VB O
several JJ JJ O
doses NNS NNS O
of IN IN O
spiranolactone NN NN B-CHEM
, , , O
an DT DT O
aldosterone NN NN B-CHEM
antagonist NN NN O
, , , O
in IN IN O
addition NN NN O
to TO TO O
the DT DT O
long JJ JJ O
- - - O
term NN NN O
intake NN NN O
of IN IN O
ramipril NN NN B-CHEM
, , , O
an DT DT O
ACE NNP NNP O
inhibitor NN NN O
. . . O

This DT DT O
case NN NN O
is VBZ VBZ O
a DT DT O
good JJ JJ O
example NN NN O
of IN IN O
electrolyte NN NN O
imbalance NN NN O
causing VBG VBG O
acute JJ JJ O
life NN NN O
- : : O
threatening VBG VBG O
cardiac JJ JJ O
events NNS NNS O
. . . O

Clinicians NNP NNP O
should MD MD O
be VB VB O
alert VB VB O
to TO TO O
the DT DT O
possibility NN NN O
of IN IN O
hyperkalemia NN NN O
, , , O
especially RB RB O
in IN IN O
elderly JJ JJ O
patients NNS NNS O
using VBG VBG O
ACE NNP NNP O
/ NN NN O
ARB NNP NNP O
in IN IN O
combination NN NN O
with IN IN O
potassium NN NN B-CHEM
sparing VBG VBG O
agents NNS NNS O
and CC CC O
who WP WP O
have VBP VBP O
mild JJ JJ O
renal JJ JJ O
disturbance NN NN O
. . . O

Diffuse NNP NNP O
skeletal JJ JJ O
pain NN NN O
after IN IN O
administration NN NN O
of IN IN O
alendronate NN NN B-CHEM
. . . O

BACKGROUND NNP NNP O
: : : O
Osteoporosis NNP NNP O
is VBZ VBZ O
caused VBN VBN O
by IN IN O
bone NN NN O
resorption NN NN O
in IN IN O
excess NN NN O
of IN IN O
bone NN NN O
formation NN NN O
, , , O
and CC CC O
bisphosphonates NNS NNS B-CHEM
, , , O
are VBP VBP O
used VBN VBN O
to TO TO O
inhibit VB VB O
bone NN NN O
resorption NN NN O
. . . O

Alendronate NNP NNP B-CHEM
, , , O
a DT DT O
biphosphonate NN NN B-CHEM
, , , O
is VBZ VBZ O
effective JJ JJ O
for IN IN O
both DT DT O
the DT DT O
treatment NN NN O
and CC CC O
prevention NN NN O
of IN IN O
osteoporosis NN NN O
in IN IN O
postmenopausal NN NN O
women NNS NNS O
. . . O

Side NNP NNP O
effects NNS NNS O
are VBP VBP O
relatively RB RB O
few JJ JJ O
and CC CC O
prominently RB RB O
gastrointestinal JJ JJ O
. . . O

Musculoskeletal NNP NNP O
pain NN NN O
may MD MD O
be VB VB O
an DT DT O
important JJ JJ O
side NN NN O
effect NN NN O
in IN IN O
these DT DT O
patients NNS NNS O
. . . O

We PRP PRP O
presented VBD VBD O
a DT DT O
patient NN NN O
admitted VBN VBN O
to TO TO O
our PRP$ PRP$ O
out IN IN O
- : : O
patient NN NN O
clinic NN NN O
with IN IN O
diffuse NN NN O
skeletal JJ JJ O
pain NN NN O
after IN IN O
three CD CD O
consecutive JJ JJ O
administration NN NN O
of IN IN O
alendronate NN NN B-CHEM
. . . O

CONCLUSION NNP NNP O
: : : O
We PRP PRP O
conclude VBP VBP O
that IN IN O
patients NNS NNS O
with IN IN O
osteoporosis NN NN O
can MD MD O
report VB VB O
pain NN NN O
, , , O
and CC CC O
bisphosphonate JJ JJ B-CHEM
- - - O
related VBN VBN O
pain NN NN O
should MD MD O
also RB RB O
be VB VB O
considered VBN VBN O
before IN IN O
ascribing VBG VBG O
this DT DT O
complaint NN NN O
to TO TO O
osteoporosis NNS NNS O
. . . O

Cerebrospinal NNP NNP O
fluid JJ JJ O
penetration NN NN O
of IN IN O
high JJ JJ O
- - - O
dose NN NN O
daptomycin NN NN B-CHEM
in IN IN O
suspected VBN VBN O
Staphylococcus NNP NNP O
aureus JJ JJ O
meningitis NNS NNS O
. . . O

OBJECTIVE NNP NNP O
: : : O
To TO TO O
report VB VB O
a DT DT O
case NN NN O
of IN IN O
methicillin NN NN B-CHEM
- - - O
sensitive JJ JJ O
Staphylococcus NNP NNP O
aureus NN NN O
( ( ( O
MSSA NNP NNP O
) ) ) O
bacteremia NN NN O
with IN IN O
suspected JJ JJ O
MSSA NNP NNP O
meningitis NNS NNS O
treated VBN VBN O
with IN IN O
high JJ JJ O
- - - O
dose NN NN O
daptomycin NN NN B-CHEM
assessed VBN VBN O
with IN IN O
concurrent JJ JJ O
serum NN NN O
and CC CC O
cerebrospinal JJ JJ O
fluid NN NN O
( ( ( O
CSF NNP NNP O
) ) ) O
concentrations NNS NNS O
. . . O

CASE NN NN O
SUMMARY NNP NNP O
: : : O
A DT DT O
54 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
male NN NN O
presented VBN VBN O
to TO TO O
the DT DT O
emergency NN NN O
department NN NN O
with IN IN O
generalized JJ JJ O
weakness NN NN O
and CC CC O
presumed VBN VBN O
health NN NN O
- - - O
care NN NN O
- - - O
associated VBN VBN O
pneumonia NN NN O
shown VBN VBN O
on IN IN O
chest NN NN O
radiograph NN NN O
. . . O

Treatment NN NN O
was VBD VBD O
empirically RB RB O
initiated VBN VBN O
with IN IN O
vancomycin NN NN B-CHEM
, , , O
levofloxacin NN NN B-CHEM
, , , O
and CC CC O
piperacillin NN NN B-CHEM
/ NN NN O
tazobactam NN NN B-CHEM
. . . O

Blood NNP NNP O
cultures NNS NNS O
revealed VBD VBD O
S NNP NNP O
. . . O
aureus JJ JJ O
susceptible JJ JJ O
to TO TO O
oxacillin VB VB B-CHEM
. . . O

Empiric NNP NNP O
antibiotic JJ JJ O
treatment NN NN O
was VBD VBD O
narrowed VBN VBN O
to TO TO O
nafcillin NN NN B-CHEM
on IN IN O
day NN NN O
4 CD CD O
. . . O

On IN IN O
day NN NN O
8 CD CD O
, , , O
the DT DT O
patient NN NN O
developed VBN VBN O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
( ( ( O
serum NN NN O
creatinine NN NN B-CHEM
1 CD CD O
. . . O
9 CD CD O
mg NN NN O
/ NN NN O
dL NN NN O
, , , O
increased VBN VBN O
from IN IN O
1 CD CD O
. . . O
2 CD CD O
mg NN NN O
/ NN NN O
dL NN NN O
the DT DT O
previous JJ JJ O
day NN NN O
and CC CC O
0 CD CD O
. . . O
8 CD CD O
mg NN NN O
/ NN NN O
dL NN NN O
on IN IN O
admission NN NN O
) ) ) O
. . . O

The DT DT O
patient NN NN O
' '' '' O
s VBZ VBZ O
Glasgow NNP NNP O
Coma NNP NNP O
Score NNP NNP O
was VBD VBD O
3 CD CD O
, , , O
with IN IN O
normal JJ JJ O
findings NNS NNS O
shown VBN VBN O
on IN IN O
computed JJ JJ O
tomography NN NN O
scan NN NN O
of IN IN O
the DT DT O
head NN NN O
72 CD CD O
hours NNS NNS O
following VBG VBG O
an DT DT O
episode NN NN O
of IN IN O
cardiac JJ JJ O
arrest NN NN O
on IN IN O
day NN NN O
10 CD CD O
. . . O

The DT DT O
patient NN NN O
experienced VBD VBD O
relapsing VBG VBG O
MSSA NNP NNP O
bacteremia NN NN O
on IN IN O
day NN NN O
9 CD CD O
, , , O
increasing VBG VBG O
the DT DT O
suspicion NN NN O
for IN IN O
a DT DT O
central JJ JJ O
nervous JJ JJ O
system NN NN O
( ( ( O
CNS NNP NNP O
) ) ) O
infection NN NN O
. . . O

Nafcillin NNP NNP B-CHEM
was VBD VBD O
discontinued VBN VBN O
and CC CC O
daptomycin NN NN B-CHEM
9 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
daily JJ JJ O
was VBD VBD O
initiated VBN VBN O
for IN IN O
suspected JJ JJ O
meningitis NN NN O
and CC CC O
was VBD VBD O
continued VBN VBN O
until IN IN O
the DT DT O
patient NN NN O
' '' '' O
s VBZ VBZ O
death NN NN O
on IN IN O
day NN NN O
16 CD CD O
. . . O

Daptomycin NNP NNP B-CHEM
serum NN NN O
and CC CC O
CSF NNP NNP O
trough IN IN O
concentrations NNS NNS O
were VBD VBD O
11 CD CD O
. . . O
21 CD CD O
ug NN NN O
/ NN NN O
mL NN NN O
and CC CC O
0 CD CD O
. . . O
52 CD CD O
ug NN NN O
/ NN NN O
mL NN NN O
, , , O
respectively RB RB O
, , , O
prior RB RB O
to TO TO O
the DT DT O
third JJ JJ O
dose NN NN O
. . . O

Lumbar NNP NNP O
puncture NN NN O
results NNS NNS O
were VBD VBD O
inconclusive JJ JJ O
and CC CC O
no DT DT O
further JJ JJ O
blood NN NN O
cultures NNS NNS O
were VBD VBD O
positive JJ JJ O
for IN IN O
MSSA NNP NNP O
. . . O

Creatine NNP NNP B-CHEM
kinase NN NN O
levels NNS NNS O
were VBD VBD O
normal JJ JJ O
prior RB RB O
to TO TO O
daptomycin NN NN B-CHEM
therapy NN NN O
and CC CC O
were VBD VBD O
not RB RB O
reassessed VBN VBN O
. . . O

DISCUSSION NNP NNP O
: : : O
Daptomycin NNP NNP B-CHEM
was VBD VBD O
initiated VBN VBN O
in IN IN O
our PRP$ PRP$ O
patient NN NN O
secondary JJ JJ O
to TO TO O
possible JJ JJ O
nafcillin NN NN B-CHEM
- - - O
induced JJ JJ O
acute JJ JJ O
interstitial JJ JJ O
nephritis NNS NNS O
and CC CC O
relapsing VBG VBG O
bacteremia NN NN O
. . . O

At IN IN O
a DT DT O
dose NN NN O
of IN IN O
9 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
resultant JJ JJ O
penetration NN NN O
of IN IN O
5 CD CD O
% NN NN O
was VBD VBD O
higher JJR JJR O
than IN IN O
in IN IN O
previous JJ JJ O
reports NNS NNS O
, , , O
more RBR RBR O
consistent JJ JJ O
with IN IN O
inflamed JJ JJ O
meninges NNS NNS O
. . . O

CONCLUSIONS NNP NNP O
: : : O
High JJ JJ O
- - - O
dose NN NN O
daptomycin NN NN B-CHEM
may MD MD O
be VB VB O
an DT DT O
alternative JJ JJ O
option NN NN O
for IN IN O
MSSA NNP NNP O
bacteremia NN NN O
with IN IN O
or CC CC O
without IN IN O
a DT DT O
CNS NNP NNP O
source NN NN O
in IN IN O
patients NNS NNS O
who WP WP O
have VBP VBP O
failed VBN VBN O
or CC CC O
cannot NN NN O
tolerate NN NN O
standard JJ JJ O
therapy NN NN O
. . . O

Further RB RB O
clinical JJ JJ O
evaluation NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
confirmed JJ JJ O
meningitis NN NN O
is VBZ VBZ O
warranted VBN VBN O
. . . O

The DT DT O
role NN NN O
of IN IN O
nitric JJ JJ B-CHEM
oxide NN NN I-CHEM
in IN IN O
convulsions NNS NNS O
induced VBN VBN O
by IN IN O
lindane NN NN B-CHEM
in IN IN O
rats NNS NNS O
. . . O

Lindane NNP NNP B-CHEM
is VBZ VBZ O
an DT DT O
organochloride NN NN O
pesticide NN NN O
and CC CC O
scabicide NN NN O
. . . O

It PRP PRP O
evokes VBZ VBZ O
convulsions NNS NNS O
mainly RB RB O
trough IN IN O
the DT DT O
blockage NN NN O
of IN IN O
GABA NNP NNP B-CHEM
( ( ( O
A DT DT O
) ) ) O
receptors NNS NNS O
. . . O

Nitric NNP NNP B-CHEM
oxide NN NN I-CHEM
( ( ( O
NO DT DT B-CHEM
) ) ) O
, , , O
gaseous JJ JJ O
neurotransmitter NN NN O
, , , O
has VBZ VBZ O
contradictor NN NN O
role NN NN O
in IN IN O
epileptogenesis NN NN O
due JJ JJ O
to TO TO O
opposite JJ JJ O
effects NNS NNS O
of IN IN O
L NNP NNP B-CHEM
- - - I-CHEM
arginine NN NN I-CHEM
, , , O
precursor NN NN O
of IN IN O
NO NN NN B-CHEM
syntheses NNS NNS O
( ( ( O
NOS NNP NNP O
) ) ) O
, , , O
and CC CC O
L NNP NNP B-CHEM
- : : I-CHEM
NAME NN NN I-CHEM
( ( ( O
NOS NNP NNP O
inhibitor NN NN O
) ) ) O
observed VBD VBD O
in IN IN O
different JJ JJ O
epilepsy NN NN O
models NNS NNS O
. . . O

The DT DT O
aim NN NN O
of IN IN O
the DT DT O
current JJ JJ O
study NN NN O
was VBD VBD O
to TO TO O
determine VB VB O
the DT DT O
effects NNS NNS O
of IN IN O
NO NN NN B-CHEM
on IN IN O
the DT DT O
behavioral JJ JJ O
and CC CC O
EEG NNP NNP O
characteristics NNS NNS O
of IN IN O
lindane NN NN B-CHEM
- - - O
induced JJ JJ O
epilepsy NN NN O
in IN IN O
male JJ JJ O
Wistar NNP NNP O
albino NN NN O
rats NNS NNS O
. . . O

The DT DT O
administration NN NN O
of IN IN O
L NNP NNP B-CHEM
- : : I-CHEM
arginine NN NN I-CHEM
( ( ( O
600 CD CD O
, , , O
800 CD CD O
and CC CC O
1000 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
in IN IN O
dose NN NN O
- - - O
dependent JJ JJ O
manner NN NN O
significantly RB RB O
increased VBD VBD O
convulsion NN NN O
incidence NN NN O
and CC CC O
severity NN NN O
and CC CC O
shortened VBD VBD O
latency JJ JJ O
time NN NN O
to TO TO O
first JJ JJ O
convulsion NN NN O
elicited VBN VBN O
by IN IN O
lower JJR JJR O
lindane NN NN B-CHEM
dose NN NN O
( ( ( O
4 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
. . . O

On IN IN O
the DT DT O
contrary NN NN O
, , , O
pretreatment NN NN O
with IN IN O
L NNP NNP B-CHEM
- : : I-CHEM
NAME NN NN I-CHEM
( ( ( O
500 CD CD O
, , , O
700 CD CD O
and CC CC O
900 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
decreased VBD VBD O
convulsion NN NN O
incidence NN NN O
and CC CC O
severity NN NN O
and CC CC O
prolonged JJ JJ O
latency NN NN O
time NN NN O
to TO TO O
convulsion NN NN O
following VBG VBG O
injection NN NN O
with IN IN O
a DT DT O
convulsive JJ JJ O
dose NN NN O
of IN IN O
lindane NN NN B-CHEM
( ( ( O
8 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
. . . O

EEG NNP NNP O
analyses NNS NNS O
showed VBD VBD O
increase NN NN O
of IN IN O
number NN NN O
and CC CC O
duration NN NN O
of IN IN O
ictal JJ JJ O
periods NNS NNS O
in IN IN O
EEG NNP NNP O
of IN IN O
rats NNS NNS O
receiving VBG VBG O
l NN NN B-CHEM
- - - I-CHEM
arginine JJ JJ I-CHEM
prior RB RB O
to TO TO O
lindane VB VB B-CHEM
and CC CC O
decrease VB VB O
of IN IN O
this DT DT O
number NN NN O
in IN IN O
rats NNS NNS O
pretreated VBN VBN O
with IN IN O
L NNP NNP B-CHEM
- - - I-CHEM
NAME NN NN I-CHEM
. . . O

These DT DT O
results NNS NNS O
support VBP VBP O
the DT DT O
conclusion NN NN O
that IN IN O
NO DT DT B-CHEM
plays VBZ VBZ O
a DT DT O
role NN NN O
of IN IN O
endogenous JJ JJ O
convulsant NN NN O
in IN IN O
rat NN NN O
model NN NN O
of IN IN O
lindane NN NN B-CHEM
seizures NNS NNS O
. . . O

Severe NNP NNP O
polyneuropathy JJ JJ O
and CC CC O
motor NN NN O
loss NN NN O
after IN IN O
intrathecal JJ JJ O
thiotepa NN NN B-CHEM
combination NN NN O
chemotherapy NN NN O
: : : O
description NN NN O
of IN IN O
two CD CD O
cases NNS NNS O
. . . O

Two CD CD O
cases NNS NNS O
of IN IN O
severe JJ JJ O
delayed JJ JJ O
neurologic JJ JJ O
toxicity NN NN O
related VBN VBN O
to TO TO O
the DT DT O
administration NN NN O
of IN IN O
intrathecal JJ JJ O
( ( ( O
IT PRP PRP O
) ) ) O
combination NN NN O
chemotherapy NN NN O
including VBG VBG O
thiotepa NN NN B-CHEM
( ( ( O
TSPA NNP NNP B-CHEM
) ) ) O
are VBP VBP O
presented VBN VBN O
. . . O

Both DT DT O
cases NNS NNS O
developed VBN VBN O
axonal JJ JJ O
neuropathy JJ JJ O
with IN IN O
motor NN NN O
predominance NN NN O
in IN IN O
the DT DT O
lower JJR JJR O
extremities NNS NNS O
1 CD CD O
and CC CC O
6 CD CD O
months NNS NNS O
after IN IN O
IT PRP PRP O
chemotherapy NN NN O
was VBD VBD O
administered VBN VBN O
. . . O

Neurologic NNP NNP O
toxicities NNS NNS O
have VBP VBP O
been VBN VBN O
described VBN VBN O
with IN IN O
IT PRP PRP O
- : : O
methotrexate NN NN B-CHEM
, , , O
IT PRP PRP O
- - - O
cytosine NN NN B-CHEM
arabinoside NN NN I-CHEM
and CC CC O
IT PRP PRP O
- : : O
TSPA NNP NNP B-CHEM
. . . O

To TO TO O
our PRP$ PRP$ O
knowledge NN NN O
, , , O
however RB RB O
, , , O
axonal JJ JJ O
neuropathy JJ JJ O
following NN NN O
administration NN NN O
of IN IN O
these DT DT O
three CD CD O
agents NNS NNS O
has VBZ VBZ O
not RB RB O
been VBN VBN O
previously RB RB O
described VBN VBN O
. . . O

In IN IN O
spite NN NN O
of IN IN O
the DT DT O
fact NN NN O
that IN IN O
TSPA NNP NNP B-CHEM
is VBZ VBZ O
a DT DT O
useful JJ JJ O
IT PRP PRP O
agent NN NN O
, , , O
its PRP$ PRP$ O
combination NN NN O
with IN IN O
MTX NNP NNP B-CHEM
, , , O
ara NN NN B-CHEM
- - - I-CHEM
C NNP NNP I-CHEM
and CC CC O
radiotherapy NN NN O
could MD MD O
cause VB VB O
severe JJ JJ O
neurotoxicity NN NN O
. . . O

This DT DT O
unexpected JJ JJ O
complication NN NN O
indicates VBZ VBZ O
the DT DT O
need NN NN O
for IN IN O
further JJ JJ O
toxicology NN NN O
research NN NN O
on IN IN O
IT PRP PRP O
- : : O
TSPA NNP NNP B-CHEM
. . . O

Effects NNP NNP O
of IN IN O
cromakalim NN NN B-CHEM
and CC CC O
pinacidil NN NN B-CHEM
on IN IN O
large JJ JJ O
epicardial NN NN O
and CC CC O
small JJ JJ O
coronary JJ JJ O
arteries NNS NNS O
in IN IN O
conscious JJ JJ O
dogs NNS NNS O
. . . O

The DT DT O
effects NNS NNS O
of IN IN O
i NNP NNP O
. . . O
v NN NN O
. . . O
bolus JJ JJ O
administration NN NN O
of IN IN O
cromakalim NN NN B-CHEM
( ( ( O
1 CD CD O
- : : O
10 CD CD O
micrograms NNS NNS O
/ NN NN O
kg NN NN O
) ) ) O
and CC CC O
pinacidil NN NN B-CHEM
( ( ( O
3 CD CD O
- : : O
100 CD CD O
micrograms NNS NNS O
/ NN NN O
kg NN NN O
) ) ) O
on IN IN O
large JJ JJ O
( ( ( O
circumflex NN NN O
artery NN NN O
) ) ) O
and CC CC O
small JJ JJ O
coronary JJ JJ O
arteries NNS NNS O
and CC CC O
on IN IN O
systemic JJ JJ O
hemodynamics NNS NNS O
were VBD VBD O
investigated VBN VBN O
in IN IN O
chronically RB RB O
instrumented VBN VBN O
conscious JJ JJ O
dogs NNS NNS O
and CC CC O
compared VBN VBN O
to TO TO O
those DT DT O
of IN IN O
nitroglycerin NN NN B-CHEM
( ( ( O
0 CD CD O
. . . O
03 CD CD O
- : : O
10 CD CD O
micrograms NNS NNS O
/ NN NN O
kg NN NN O
) ) ) O
. . . O

Nitroglycerin NNP NNP B-CHEM
, , , O
up IN IN O
to TO TO O
0 CD CD O
. . . O
3 CD CD O
micrograms NNS NNS O
/ NN NN O
kg NN NN O
, , , O
selectively RB RB O
increased VBN VBN O
circumflex NN NN O
artery NN NN O
diameter NN NN O
( ( ( O
CxAD NNP NNP O
) ) ) O
without IN IN O
simultaneously RB RB O
affecting VBG VBG O
any DT DT O
other JJ JJ O
cardiac NN NN O
or CC CC O
systemic JJ JJ O
hemodynamic JJ JJ O
parameter NN NN O
. . . O

In IN IN O
contrast NN NN O
, , , O
cromakalim NN NN B-CHEM
and CC CC O
pinacidil NN NN B-CHEM
at IN IN O
all DT DT O
doses NNS NNS O
and CC CC O
nitroglycerin NN NN B-CHEM
at IN IN O
doses NNS NNS O
higher JJR JJR O
than IN IN O
0 CD CD O
. . . O
3 CD CD O
micrograms NNS NNS O
/ NN NN O
kg NN NN O
simultaneously RB RB O
and CC CC O
dose VB VB O
- : : O
dependently RB RB O
increased VBN VBN O
CxAD NNP NNP O
, , , O
coronary JJ JJ O
blood NN NN O
flow NN NN O
and CC CC O
heart NN NN O
rate NN NN O
and CC CC O
decreased VBD VBD O
coronary JJ JJ O
vascular NN NN O
resistance NN NN O
and CC CC O
aortic JJ JJ O
pressure NN NN O
. . . O

Cromakalim NNP NNP B-CHEM
was VBD VBD O
approximately RB RB O
8 CD CD O
- : : O
to TO TO O
9 CD CD O
. . . O
5 CD CD O
- : : O
fold VB VB O
more RBR RBR O
potent JJ JJ O
than IN IN O
pinacidil NN NN B-CHEM
in IN IN O
increasing VBG VBG O
CxAD NNP NNP O
. . . O

Vasodilation NNP NNP O
of IN IN O
large JJ JJ O
and CC CC O
small JJ JJ O
coronary JJ JJ O
vessels NNS NNS O
and CC CC O
hypotension NN NN O
induced VBN VBN O
by IN IN O
cromakalim NN NN B-CHEM
and CC CC O
pinacidil NN NN B-CHEM
were VBD VBD O
not RB RB O
affected VBN VBN O
by IN IN O
prior RB RB O
combined VBN VBN O
beta NN NN B-CHEM
adrenergic JJ JJ I-CHEM
and CC CC I-CHEM
muscarinic JJ JJ I-CHEM
receptors NNS NNS I-CHEM
blockade NN NN I-CHEM
but CC CC O
drug NN NN O
- - - O
induced JJ JJ O
tachycardia NN NN O
was VBD VBD O
abolished VBN VBN O
. . . O

When WRB WRB O
circumflex NN NN O
artery NN NN O
blood NN NN O
flow NN NN O
was VBD VBD O
maintained VBN VBN O
constant JJ JJ O
, , , O
the DT DT O
increases NNS NNS O
in IN IN O
CxAD NNP NNP O
induced VBN VBN O
by IN IN O
cromakalim NN NN B-CHEM
( ( ( O
10 CD CD O
micrograms NNS NNS O
/ NN NN O
kg NN NN O
) ) ) O
, , , O
pinacidil NN NN B-CHEM
( ( ( O
30 CD CD O
micrograms NNS NNS O
/ NN NN O
kg NN NN O
) ) ) O
and CC CC O
nitroglycerin NN NN B-CHEM
( ( ( O
10 CD CD O
micrograms NNS NNS O
/ NN NN O
kg NN NN O
) ) ) O
were VBD VBD O
reduced VBN VBN O
by IN IN O
68 CD CD O
+ NN NN O
/ NN NN O
- : : O
7 CD CD O
, , , O
54 CD CD O
+ NN NN O
/ NN NN O
- : : O
9 CD CD O
and CC CC O
1 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
% NN NN O
, , , O
respectively RB RB O
. . . O

Thus RB RB O
, , , O
whereas IN IN O
nitroglycerin NN NN B-CHEM
preferentially RB RB O
and CC CC O
flow VB VB O
- - - O
independently RB RB O
dilates VBZ VBZ O
large JJ JJ O
coronary JJ JJ O
arteries NNS NNS O
, , , O
cromakalim NN NN B-CHEM
and CC CC O
pinacidil NN NN B-CHEM
dilate NN NN O
both DT DT O
large JJ JJ O
and CC CC O
small JJ JJ O
coronary JJ JJ O
arteries NNS NNS O
and CC CC O
this DT DT O
effect NN NN O
is VBZ VBZ O
not RB RB O
dependent JJ JJ O
upon IN IN O
the DT DT O
simultaneous JJ JJ O
beta NN NN O
adrenoceptors NNS NNS O
- : : O
mediated JJ JJ O
rise NN NN O
in IN IN O
myocardial JJ JJ O
metabolic JJ JJ O
demand NN NN O
. . . O

Finally RB RB O
, , , O
two CD CD O
mechanisms NNS NNS O
at IN IN O
least JJS JJS O
, , , O
direct JJ JJ O
vasodilation NN NN O
and CC CC O
flow NN NN O
dependency NN NN O
, , , O
are VBP VBP O
involved VBN VBN O
in IN IN O
the DT DT O
cromakalim NN NN B-CHEM
- - - O
and CC CC O
pinacidil NN NN B-CHEM
- - - O
induced JJ JJ O
increase NN NN O
in IN IN O
CxAD NNP NNP O
. . . O

Mefenamic NNP NNP B-CHEM
acid NN NN I-CHEM
- : : O
induced JJ JJ O
neutropenia NN NN O
and CC CC O
renal JJ JJ O
failure NN NN O
in IN IN O
elderly JJ JJ O
females NNS NNS O
with IN IN O
hypothyroidism NN NN O
. . . O

We PRP PRP O
report VBP VBP O
mefenamic JJ JJ B-CHEM
acid NN NN I-CHEM
- - - O
induced JJ JJ O
non NN NN O
- - - O
oliguric JJ JJ O
renal NN NN O
failure NN NN O
and CC CC O
severe JJ JJ O
neutropenia NN NN O
occurring VBG VBG O
simultaneously RB RB O
in IN IN O
two CD CD O
elderly JJ JJ O
females NNS NNS O
. . . O

The DT DT O
neutropenia NN NN O
was VBD VBD O
due JJ JJ O
to TO TO O
maturation NN NN O
arrest NN NN O
of IN IN O
the DT DT O
myeloid NN NN O
series NN NN O
in IN IN O
one CD CD O
patient NN NN O
. . . O

Both DT DT O
patients NNS NNS O
were VBD VBD O
also RB RB O
hypothyroid NN NN O
, , , O
but CC CC O
it PRP PRP O
is VBZ VBZ O
not RB RB O
clear JJ JJ O
whether IN IN O
this DT DT O
was VBD VBD O
a DT DT O
predisposing VBG VBG O
factor NN NN O
to TO TO O
the DT DT O
development NN NN O
of IN IN O
these DT DT O
adverse JJ JJ O
reactions NNS NNS O
. . . O

However RB RB O
, , , O
it PRP PRP O
would MD MD O
seem VB VB O
prudent NN NN O
not RB RB O
to TO TO O
use VB VB O
mefenamic JJ JJ B-CHEM
acid NN NN I-CHEM
in IN IN O
hypothyroid NN NN O
patients NNS NNS O
until IN IN O
the DT DT O
hypothyroidism NN NN O
has VBZ VBZ O
been VBN VBN O
corrected VBN VBN O
. . . O

Etiology NNP NNP O
of IN IN O
hypercalcemia NN NN O
in IN IN O
hemodialysis NN NN O
patients NNS NNS O
on IN IN O
calcium NN NN B-CHEM
carbonate NN NN I-CHEM
therapy NN NN O
. . . O

Fourteen CD CD O
of IN IN O
39 CD CD O
dialysis NN NN O
patients NNS NNS O
( ( ( O
36 CD CD O
% NN NN O
) ) ) O
became VBD VBD O
hypercalcemic JJ JJ O
after IN IN O
switching VBG VBG O
to TO TO O
calcium NN NN B-CHEM
carbonate NN NN I-CHEM
as IN IN O
their PRP$ PRP$ O
principal JJ JJ O
phosphate NN NN B-CHEM
binder NN NN O
. . . O

In IN IN O
order NN NN O
to TO TO O
identify VB VB O
risk NN NN O
factors NNS NNS O
associated VBN VBN O
with IN IN O
the DT DT O
development NN NN O
of IN IN O
hypercalcemia NN NN O
, , , O
indirect JJ JJ O
parameters NNS NNS O
of IN IN O
intestinal JJ JJ O
calcium NN NN B-CHEM
reabsorption NN NN O
and CC CC O
bone NN NN O
turnover NN NN O
rate NN NN O
in IN IN O
these DT DT O
14 CD CD O
patients NNS NNS O
were VBD VBD O
compared VBN VBN O
with IN IN O
results NNS NNS O
in IN IN O
14 CD CD O
eucalcemic JJ JJ O
patients NNS NNS O
matched VBD VBD O
for IN IN O
age NN NN O
, , , O
sex NN NN O
, , , O
length NN NN O
of IN IN O
time NN NN O
on IN IN O
dialysis NN NN O
, , , O
and CC CC O
etiology NN NN O
of IN IN O
renal JJ JJ O
disease NN NN O
. . . O

In IN IN O
addition NN NN O
to TO TO O
experiencing VBG VBG O
hypercalcemic JJ JJ O
episodes NNS NNS O
with IN IN O
peak NN NN O
calcium NN NN B-CHEM
values NNS NNS O
of IN IN O
2 CD CD O
. . . O
7 CD CD O
to TO TO O
3 CD CD O
. . . O
8 CD CD O
mmol NN NN O
/ NN NN O
L NNP NNP O
( ( ( O
10 CD CD O
. . . O
7 CD CD O
to TO TO O
15 CD CD O
. . . O
0 CD CD O
mg NN NN O
/ NN NN O
dL NN NN O
) ) ) O
, , , O
patients NNS NNS O
in IN IN O
the DT DT O
hypercalcemic JJ JJ O
group NN NN O
exhibited VBD VBD O
a DT DT O
significant JJ JJ O
increase NN NN O
in IN IN O
the DT DT O
mean NN NN O
calcium NN NN B-CHEM
concentration NN NN O
obtained VBN VBN O
during IN IN O
6 CD CD O
months NNS NNS O
before IN IN O
the DT DT O
switch NN NN O
, , , O
compared VBN VBN O
with IN IN O
the DT DT O
mean NN NN O
value NN NN O
obtained VBD VBD O
during IN IN O
the DT DT O
7 CD CD O
months NNS NNS O
of IN IN O
observation NN NN O
after IN IN O
the DT DT O
switch NN NN O
( ( ( O
2 CD CD O
. . . O
4 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
03 CD CD O
to TO TO O
2 CD CD O
. . . O
5 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
03 CD CD O
mmol NN NN O
/ NN NN O
L NNP NNP O
[ NN NN O
9 CD CD O
. . . O
7 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
2 CD CD O
to TO TO O
10 CD CD O
. . . O
2 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
1 CD CD O
mg NN NN O
/ NN NN O
dL NN NN O
] NN NN O
, , , O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
006 CD CD O
) ) ) O
. . . O

In IN IN O
contrast NN NN O
, , , O
eucalcemic JJ JJ O
patients NNS NNS O
exhibited VBD VBD O
no DT DT O
change NN NN O
in IN IN O
mean NN NN O
calcium NN NN B-CHEM
values NNS NNS O
over IN IN O
the DT DT O
same JJ JJ O
time NN NN O
period NN NN O
( ( ( O
2 CD CD O
. . . O
3 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
05 CD CD O
to TO TO O
2 CD CD O
. . . O
3 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
05 CD CD O
mmol NN NN O
/ NN NN O
L NNP NNP O
[ NN NN O
9 CD CD O
. . . O
2 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
2 CD CD O
to TO TO O
9 CD CD O
. . . O
2 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
2 CD CD O
mg NN NN O
/ NN NN O
dL NN NN O
] NN NN O
) ) ) O
. . . O

CaCO3 NNP NNP B-CHEM
dosage NN NN O
, , , O
calculated VBN VBN O
dietary JJ JJ O
calcium NN NN B-CHEM
intake NN NN O
, , , O
and CC CC O
circulating VBG VBG O
levels NNS NNS O
of IN IN O
vitamin NN NN B-CHEM
D NNP NNP I-CHEM
metabolites NNS NNS O
were VBD VBD O
similar JJ JJ O
in IN IN O
both DT DT O
groups NNS NNS O
. . . O

Physical JJ JJ O
activity NN NN O
index NN NN O
and CC CC O
predialysis NNS NNS O
serum NN NN O
bicarbonate NN NN B-CHEM
levels NNS NNS O
also RB RB O
were VBD VBD O
similar JJ JJ O
in IN IN O
both DT DT O
groups NNS NNS O
. . . O

However RB RB O
, , , O
there EX EX O
was VBD VBD O
a DT DT O
significant JJ JJ O
difference NN NN O
in IN IN O
parameters NNS NNS O
reflecting VBG VBG O
bone NN NN O
turnover NN NN O
rates NNS NNS O
between IN IN O
groups NNS NNS O
. . . O
( ( ( O
ABSTRACT NNP NNP O
TRUNCATED NNP NNP O
AT IN IN O
250 CD CD O
WORDS NNP NNP O
) ) ) O

Late JJ JJ O
- : : O
onset NN NN O
scleroderma NN NN O
renal JJ JJ O
crisis NN NN O
induced VBN VBN O
by IN IN O
tacrolimus NN NN B-CHEM
and CC CC O
prednisolone NN NN B-CHEM
: : : O
a DT DT O
case NN NN O
report NN NN O
. . . O

Scleroderma NNP NNP O
renal JJ JJ O
crisis NN NN O
( ( ( O
SRC NNP NNP O
) ) ) O
is VBZ VBZ O
a DT DT O
rare JJ JJ O
complication NN NN O
of IN IN O
systemic JJ JJ O
sclerosis NN NN O
( ( ( O
SSc NNP NNP O
) ) ) O
but CC CC O
can MD MD O
be VB VB O
severe JJ JJ O
enough RB RB O
to TO TO O
require VB VB O
temporary JJ JJ O
or CC CC O
permanent JJ JJ O
renal JJ JJ O
replacement NN NN O
therapy NN NN O
. . . O

Moderate NNP NNP O
to TO TO O
high JJ JJ O
dose NN NN O
corticosteroid NN NN B-CHEM
use NN NN O
is VBZ VBZ O
recognized VBN VBN O
as IN IN O
a DT DT O
major JJ JJ O
risk NN NN O
factor NN NN O
for IN IN O
SRC NNP NNP O
. . . O

Furthermore RB RB O
, , , O
there EX EX O
have VBP VBP O
been VBN VBN O
reports NNS NNS O
of IN IN O
thrombotic JJ JJ O
microangiopathy NN NN O
precipitated VBN VBN O
by IN IN O
cyclosporine NN NN B-CHEM
in IN IN O
patients NNS NNS O
with IN IN O
SSc NNP NNP O
. . . O

In IN IN O
this DT DT O
article NN NN O
, , , O
we PRP PRP O
report VBP VBP O
a DT DT O
patient NN NN O
with IN IN O
SRC NNP NNP O
induced VBN VBN O
by IN IN O
tacrolimus NN NN B-CHEM
and CC CC O
corticosteroids NNS NNS B-CHEM
. . . O

The DT DT O
aim NN NN O
of IN IN O
this DT DT O
work NN NN O
is VBZ VBZ O
to TO TO O
call VB VB O
attention NN NN O
to TO TO O
the DT DT O
risk NN NN O
of IN IN O
tacrolimus NN NN B-CHEM
use NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
SSc NNP NNP O
. . . O

Methyldopa NNP NNP B-CHEM
- : : O
induced JJ JJ O
hemolytic JJ JJ O
anemia NN NN O
in IN IN O
a DT DT O
15 CD CD O
year NN NN O
old JJ JJ O
presenting NN NN O
as IN IN O
near IN IN O
- - - O
syncope NN NN O
. . . O

Methyldopa NNP NNP B-CHEM
is VBZ VBZ O
an DT DT O
antihypertensive JJ JJ O
medication NN NN O
which WDT WDT O
is VBZ VBZ O
available JJ JJ O
generically RB RB O
and CC CC O
under IN IN O
the DT DT O
trade NN NN O
name NN NN O
Aldomet NNP NNP B-CHEM
that WDT WDT O
is VBZ VBZ O
widely RB RB O
prescribed VBN VBN O
in IN IN O
the DT DT O
adult NN NN O
population NN NN O
and CC CC O
infrequently RB RB O
used VBN VBN O
in IN IN O
children NNS NNS O
. . . O

Methyldopa NNP NNP B-CHEM
causes VBZ VBZ O
an DT DT O
autoimmune JJ JJ O
hemolytic JJ JJ O
anemia NN NN O
in IN IN O
a DT DT O
small JJ JJ O
percentage NN NN O
of IN IN O
patients NNS NNS O
who WP WP O
take VBP VBP O
the DT DT O
drug NN NN O
. . . O

We PRP PRP O
report VBP VBP O
a DT DT O
case NN NN O
of IN IN O
methyldopa NN NN B-CHEM
- - - O
induced JJ JJ O
hemolytic JJ JJ O
anemia NN NN O
in IN IN O
a DT DT O
15 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
boy NN NN O
who WP WP O
presented VBD VBD O
to TO TO O
the DT DT O
emergency NN NN O
department NN NN O
with IN IN O
near IN IN O
- - - O
syncope NN NN O
. . . O

The DT DT O
boy NN NN O
had VBD VBD O
been VBN VBN O
treated VBN VBN O
with IN IN O
intravenous JJ JJ O
methyldopa NN NN B-CHEM
during IN IN O
a DT DT O
trauma NN NN O
admission NN NN O
seven CD CD O
weeks NNS NNS O
prior RB RB O
to TO TO O
presentation NN NN O
. . . O

Evaluation NNP NNP O
revealed VBD VBD O
a DT DT O
hemoglobin NN NN O
of IN IN O
three CD CD O
grams NNS NNS O
, , , O
3 CD CD O
+ NN NN O
Coombs NNP NNP O
' POS POS O
test NN NN O
with IN IN O
polyspecific JJ JJ O
anti NN NN O
- : : O
human JJ JJ O
globulin NN NN O
and CC CC O
monospecific JJ JJ O
IgG NNP NNP O
reagents NNS NNS O
, , , O
and CC CC O
a DT DT O
warm JJ JJ O
reacting VBG VBG O
autoantibody NN NN O
. . . O

Transfusion NNP NNP O
and CC CC O
corticosteroid NN NN B-CHEM
therapy NN NN O
resulted VBD VBD O
in IN IN O
a DT DT O
complete JJ JJ O
recovery NN NN O
of IN IN O
the DT DT O
patient NN NN O
. . . O

Emergency NNP NNP O
physicians NNS NNS O
treating VBG VBG O
children NNS NNS O
must MD MD O
be VB VB O
aware JJ JJ O
of IN IN O
this DT DT O
syndrome NN NN O
in IN IN O
order NN NN O
to TO TO O
diagnose VB VB O
and CC CC O
treat VB VB O
it PRP PRP O
correctly RB RB O
. . . O

A DT DT O
brief JJ JJ O
review NN NN O
of IN IN O
autoimmune NN NN O
and CC CC O
drug NN NN O
- - - O
induced JJ JJ O
hemolytic JJ JJ O
anemias NN NN O
is VBZ VBZ O
provided VBN VBN O
. . . O

The DT DT O
risk NN NN O
and CC CC O
associated VBD VBD O
factors NNS NNS O
of IN IN O
methamphetamine NN NN B-CHEM
psychosis NN NN O
in IN IN O
methamphetamine NN NN B-CHEM
- - - O
dependent JJ JJ O
patients NNS NNS O
in IN IN O
Malaysia NNP NNP O
. . . O

OBJECTIVE NNP NNP O
: : : O
The DT DT O
objective NN NN O
of IN IN O
this DT DT O
study NN NN O
was VBD VBD O
to TO TO O
determine VB VB O
the DT DT O
risk NN NN O
of IN IN O
lifetime NN NN O
and CC CC O
current JJ JJ O
methamphetamine NN NN B-CHEM
- - - O
induced JJ JJ O
psychosis NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
methamphetamine NN NN B-CHEM
dependence NN NN O
. . . O

The DT DT O
association NN NN O
between IN IN O
psychiatric JJ JJ O
co NN NN O
- : : O
morbidity NN NN O
and CC CC O
methamphetamine NN NN B-CHEM
- - - O
induced JJ JJ O
psychosis NN NN O
was VBD VBD O
also RB RB O
studied VBN VBN O
. . . O

METHODS NNP NNP O
: : : O
This DT DT O
was VBD VBD O
a DT DT O
cross JJ JJ O
- - - O
sectional JJ JJ O
study NN NN O
conducted VBD VBD O
concurrently RB RB O
at IN IN O
a DT DT O
teaching NN NN O
hospital NN NN O
and CC CC O
a DT DT O
drug NN NN O
rehabilitation NN NN O
center NN NN O
in IN IN O
Malaysia NNP NNP O
. . . O

Patients NNS NNS O
with IN IN O
the DT DT O
diagnosis NN NN O
of IN IN O
methamphetamine NN NN B-CHEM
based VBN VBN O
on IN IN O
DSM NNP NNP O
- : : O
IV NNP NNP O
were VBD VBD O
interviewed VBN VBN O
using VBG VBG O
the DT DT O
Mini NNP NNP O
International NNP NNP O
Neuropsychiatric NNP NNP O
Interview NNP NNP O
( ( ( O
M NNP NNP O
. . . O
I PRP PRP O
. . . O
N NNP NNP O
. . . O
I PRP PRP O
. . . O
) ) ) O
for IN IN O
methamphetamine NN NN B-CHEM
- - - O
induced JJ JJ O
psychosis NN NN O
and CC CC O
other JJ JJ O
Axis NNP NNP O
I PRP PRP O
psychiatric JJ JJ O
disorders NNS NNS O
. . . O

The DT DT O
information NN NN O
on IN IN O
sociodemographic JJ JJ O
background NN NN O
and CC CC O
drug NN NN O
use NN NN O
history NN NN O
was VBD VBD O
obtained VBN VBN O
from IN IN O
interview NN NN O
or CC CC O
medical JJ JJ O
records NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
Of IN IN O
292 CD CD O
subjects NNS NNS O
, , , O
47 CD CD O
. . . O
9 CD CD O
% NN NN O
of IN IN O
the DT DT O
subjects NNS NNS O
had VBD VBD O
a DT DT O
past JJ JJ O
history NN NN O
of IN IN O
psychotic JJ JJ O
symptoms NNS NNS O
and CC CC O
13 CD CD O
. . . O
0 CD CD O
% NN NN O
of IN IN O
the DT DT O
patients NNS NNS O
were VBD VBD O
having VBG VBG O
current JJ JJ O
psychotic JJ JJ O
symptoms NNS NNS O
. . . O

Co NNP NNP O
- : : O
morbid NN NN O
major JJ JJ O
depressive JJ JJ O
disorder NN NN O
( ( ( O
OR CC CC O
= SYM SYM O
7 CD CD O
. . . O
18 CD CD O
, , , O
95 CD CD O
CI NNP NNP O
= SYM SYM O
2 CD CD O
. . . O
612 CD CD O
- : : O
19 CD CD O
. . . O
708 CD CD O
) ) ) O
, , , O
bipolar JJ JJ O
disorder NN NN O
( ( ( O
OR CC CC O
= SYM SYM O
13 CD CD O
. . . O
807 CD CD O
, , , O
95 CD CD O
CI NNP NNP O
= SYM SYM O
5 CD CD O
. . . O
194 CD CD O
- : : O
36 CD CD O
. . . O
706 CD CD O
) ) ) O
, , , O
antisocial JJ JJ O
personality NN NN O
disorder NN NN O
( ( ( O
OR CC CC O
= SYM SYM O
12 CD CD O
. . . O
619 CD CD O
, , , O
95 CD CD O
CI NNP NNP O
= SYM SYM O
6 CD CD O
. . . O
702 CD CD O
- : : O
23 CD CD O
. . . O
759 CD CD O
) ) ) O
and CC CC O
heavy JJ JJ O
methamphetamine NN NN B-CHEM
uses NNS NNS O
were VBD VBD O
significantly RB RB O
associated VBN VBN O
with IN IN O
lifetime NN NN O
methamphetamine NN NN B-CHEM
- : : O
induced JJ JJ O
psychosis NN NN O
after IN IN O
adjusted VBN VBN O
for IN IN O
other JJ JJ O
factors NNS NNS O
. . . O

Major NNP NNP O
depressive JJ JJ O
disorder NN NN O
( ( ( O
OR CC CC O
= SYM SYM O
2 CD CD O
. . . O
870 CD CD O
, , , O
CI NNP NNP O
= SYM SYM O
1 CD CD O
. . . O
154 CD CD O
- : : O
7 CD CD O
. . . O
142 CD CD O
) ) ) O
and CC CC O
antisocial JJ JJ O
personality NN NN O
disorder NN NN O
( ( ( O
OR CC CC O
= SYM SYM O
3 CD CD O
. . . O
299 CD CD O
, , , O
95 CD CD O
CI NNP NNP O
= SYM SYM O
1 CD CD O
. . . O
375 CD CD O
- : : O
7 CD CD O
. . . O
914 CD CD O
) ) ) O
were VBD VBD O
the DT DT O
only JJ JJ O
factors NNS NNS O
associated VBN VBN O
with IN IN O
current JJ JJ O
psychosis NNS NNS O
. . . O

CONCLUSION NNP NNP O
: : : O
There EX EX O
was VBD VBD O
a DT DT O
high JJ JJ O
risk NN NN O
of IN IN O
psychosis NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
methamphetamine NN NN B-CHEM
dependence NN NN O
. . . O

It PRP PRP O
was VBD VBD O
associated VBN VBN O
with IN IN O
co NN NN O
- - - O
morbid NN NN O
affective JJ JJ O
disorder NN NN O
, , , O
antisocial JJ JJ O
personality NN NN O
, , , O
and CC CC O
heavy JJ JJ O
methamphetamine NN NN B-CHEM
use NN NN O
. . . O

It PRP PRP O
is VBZ VBZ O
recommended VBN VBN O
that IN IN O
all DT DT O
cases NNS NNS O
of IN IN O
methamphetamine NN NN B-CHEM
dependence NN NN O
should MD MD O
be VB VB O
screened VBN VBN O
for IN IN O
psychotic JJ JJ O
symptoms NNS NNS O
. . . O

Cerebellar NNP NNP O
sensory NN NN O
processing NN NN O
alterations NNS NNS O
impact VBP VBP O
motor NN NN O
cortical JJ JJ O
plasticity NN NN O
in IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
: : : O
clues NNS NNS O
from IN IN O
dyskinetic JJ JJ O
patients NNS NNS O
. . . O

The DT DT O
plasticity NN NN O
of IN IN O
primary JJ JJ O
motor NN NN O
cortex NN NN O
( ( ( O
M1 NNP NNP O
) ) ) O
in IN IN O
patients NNS NNS O
with IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
( ( ( O
PD NNP NNP O
) ) ) O
and CC CC O
levodopa NN NN B-CHEM
- - - O
induced JJ JJ O
dyskinesias NN NN O
( ( ( O
LIDs NNP NNP O
) ) ) O
is VBZ VBZ O
severely RB RB O
impaired VBN VBN O
. . . O

We PRP PRP O
recently RB RB O
reported VBD VBD O
in IN IN O
young JJ JJ O
healthy JJ JJ O
subjects NNS NNS O
that WDT WDT O
inhibitory NN NN O
cerebellar JJ JJ O
stimulation NN NN O
enhanced VBD VBD O
the DT DT O
sensorimotor NN NN O
plasticity NN NN O
of IN IN O
M1 NNP NNP O
that WDT WDT O
was VBD VBD O
induced VBN VBN O
by IN IN O
paired JJ JJ O
associative JJ JJ O
stimulation NN NN O
( ( ( O
PAS NNP NNP O
) ) ) O
. . . O

This DT DT O
study NN NN O
demonstrates VBZ VBZ O
that IN IN O
the DT DT O
deficient NN NN O
sensorimotor NN NN O
M1 NNP NNP O
plasticity NN NN O
in IN IN O
16 CD CD O
patients NNS NNS O
with IN IN O
LIDs NNP NNP O
could MD MD O
be VB VB O
reinstated VBN VBN O
by IN IN O
a DT DT O
single JJ JJ O
session NN NN O
of IN IN O
real JJ JJ O
inhibitory NN NN O
cerebellar JJ JJ O
stimulation NN NN O
but CC CC O
not RB RB O
sham VB VB O
stimulation NN NN O
. . . O

This DT DT O
was VBD VBD O
evident JJ JJ O
only RB RB O
when WRB WRB O
a DT DT O
sensory JJ JJ O
component NN NN O
was VBD VBD O
involved VBN VBN O
in IN IN O
the DT DT O
induction NN NN O
of IN IN O
plasticity NN NN O
, , , O
indicating VBG VBG O
that IN IN O
cerebellar JJ JJ O
sensory NN NN O
processing NN NN O
function NN NN O
is VBZ VBZ O
involved VBN VBN O
in IN IN O
the DT DT O
resurgence NN NN O
of IN IN O
M1 NNP NNP O
plasticity NN NN O
. . . O

The DT DT O
benefit NN NN O
of IN IN O
inhibitory NN NN O
cerebellar JJ JJ O
stimulation NN NN O
on IN IN O
LIDs NNP NNP O
is VBZ VBZ O
known VBN VBN O
. . . O

To TO TO O
explore VB VB O
whether IN IN O
this DT DT O
benefit NN NN O
is VBZ VBZ O
linked VBN VBN O
to TO TO O
the DT DT O
restoration NN NN O
of IN IN O
sensorimotor NN NN O
plasticity NN NN O
of IN IN O
M1 NNP NNP O
, , , O
we PRP PRP O
conducted VBD VBD O
an DT DT O
additional JJ JJ O
study NN NN O
looking VBG VBG O
at IN IN O
changes NNS NNS O
in IN IN O
LIDs NNP NNP O
and CC CC O
PAS NNP NNP O
- : : O
induced JJ JJ O
plasticity NN NN O
after IN IN O
10 CD CD O
sessions NNS NNS O
of IN IN O
either DT DT O
bilateral JJ JJ O
, , , O
real JJ JJ O
inhibitory NN NN O
cerebellar JJ JJ O
stimulation NN NN O
or CC CC O
sham NN NN O
stimulation NN NN O
. . . O

Only RB RB O
real JJ JJ O
and CC CC O
not RB RB O
sham JJ JJ O
stimulation NN NN O
had VBD VBD O
an DT DT O
antidyskinetic JJ JJ O
effect NN NN O
and CC CC O
it PRP PRP O
was VBD VBD O
paralleled VBN VBN O
by IN IN O
a DT DT O
resurgence NN NN O
in IN IN O
the DT DT O
sensorimotor NN NN O
plasticity NN NN O
of IN IN O
M1 NNP NNP O
. . . O

These DT DT O
results NNS NNS O
suggest VBP VBP O
that IN IN O
alterations NNS NNS O
in IN IN O
cerebellar JJ JJ O
sensory NN NN O
processing NN NN O
function NN NN O
, , , O
occurring VBG VBG O
secondary JJ JJ O
to TO TO O
abnormal JJ JJ O
basal NN NN O
ganglia NN NN O
signals NNS NNS O
reaching VBG VBG O
it PRP PRP O
, , , O
may MD MD O
be VB VB O
an DT DT O
important JJ JJ O
element NN NN O
contributing VBG VBG O
to TO TO O
the DT DT O
maladaptive JJ JJ O
sensorimotor NN NN O
plasticity NN NN O
of IN IN O
M1 NNP NNP O
and CC CC O
the DT DT O
emergence NN NN O
of IN IN O
abnormal JJ JJ O
involuntary JJ JJ O
movements NNS NNS O
. . . O

The DT DT O
long JJ JJ O
- - - O
term NN NN O
safety NN NN O
of IN IN O
danazol NN NN B-CHEM
in IN IN O
women NNS NNS O
with IN IN O
hereditary JJ JJ O
angioedema NN NN O
. . . O

Although IN IN O
the DT DT O
short JJ JJ O
- - - O
term NN NN O
safety NN NN O
( ( ( O
less RBR RBR O
than IN IN O
or CC CC O
equal JJ JJ O
to TO TO O
6 CD CD O
months NNS NNS O
) ) ) O
of IN IN O
danazol NN NN B-CHEM
has VBZ VBZ O
been VBN VBN O
established VBN VBN O
in IN IN O
a DT DT O
variety NN NN O
of IN IN O
settings NNS NNS O
, , , O
no DT DT O
information NN NN O
exists VBZ VBZ O
as IN IN O
to TO TO O
its PRP$ PRP$ O
long JJ JJ O
- - - O
term NN NN O
safety NN NN O
. . . O

We PRP PRP O
therefore RB RB O
investigated VBD VBD O
the DT DT O
long JJ JJ O
- - - O
term NN NN O
safety NN NN O
of IN IN O
danazol NN NN B-CHEM
by IN IN O
performing VBG VBG O
a DT DT O
retrospective NN NN O
chart NN NN O
review NN NN O
of IN IN O
60 CD CD O
female JJ JJ O
patients NNS NNS O
with IN IN O
hereditary JJ JJ O
angioedema NN NN O
treated VBN VBN O
with IN IN O
danazol NN NN B-CHEM
for IN IN O
a DT DT O
continuous JJ JJ O
period NN NN O
of IN IN O
6 CD CD O
months NNS NNS O
or CC CC O
longer RBR RBR O
. . . O

The DT DT O
mean JJ JJ O
age NN NN O
of IN IN O
the DT DT O
patients NNS NNS O
was VBD VBD O
35 CD CD O
. . . O
2 CD CD O
years NNS NNS O
and CC CC O
the DT DT O
mean JJ JJ O
duration NN NN O
of IN IN O
therapy NN NN O
was VBD VBD O
59 CD CD O
. . . O
7 CD CD O
months NNS NNS O
. . . O

Virtually RB RB O
all DT DT O
patients NNS NNS O
experienced VBN VBN O
one CD CD O
or CC CC O
more JJR JJR O
adverse JJ JJ O
reactions NNS NNS O
. . . O

Menstrual NNP NNP O
abnormalities NNS NNS O
( ( ( O
79 CD CD O
% NN NN O
) ) ) O
, , , O
weight NN NN O
gain NN NN O
( ( ( O
60 CD CD O
% NN NN O
) ) ) O
, , , O
muscle NN NN O
cramps NNS NNS O
/ NN NN O
myalgias NN NN O
( ( ( O
40 CD CD O
% NN NN O
) ) ) O
, , , O
and CC CC O
transaminase NN NN O
elevations NNS NNS O
( ( ( O
40 CD CD O
% NN NN O
) ) ) O
were VBD VBD O
the DT DT O
most RBS RBS O
common JJ JJ O
adverse JJ JJ O
reactions NNS NNS O
. . . O

The DT DT O
drug NN NN O
was VBD VBD O
discontinued VBN VBN O
due JJ JJ O
to TO TO O
adverse JJ JJ O
reactions NNS NNS O
in IN IN O
8 CD CD O
patients NNS NNS O
. . . O

No DT DT O
patient NN NN O
has VBZ VBZ O
died VBN VBN O
or CC CC O
suffered VBN VBN O
any DT DT O
apparent NN NN O
long JJ JJ O
- - - O
term NN NN O
sequelae NN NN O
that WDT WDT O
were VBD VBD O
directly RB RB O
attributable JJ JJ O
to TO TO O
the DT DT O
drug NN NN O
. . . O

We PRP PRP O
conclude VBP VBP O
that IN IN O
, , , O
despite IN IN O
a DT DT O
relatively RB RB O
high JJ JJ O
incidence NN NN O
of IN IN O
adverse JJ JJ O
reactions NNS NNS O
, , , O
danazol NN NN B-CHEM
has VBZ VBZ O
proven VBN VBN O
to TO TO O
be VB VB O
remarkably RB RB O
safe JJ JJ O
over IN IN O
the DT DT O
long JJ JJ O
- - - O
term NN NN O
in IN IN O
this DT DT O
group NN NN O
of IN IN O
patients NNS NNS O
. . . O

The DT DT O
function NN NN O
of IN IN O
P2X3 NNP NNP O
receptor NN NN O
and CC CC O
NK1 NNP NNP O
receptor NN NN O
antagonists NNS NNS O
on IN IN O
cyclophosphamide NN NN B-CHEM
- : : O
induced JJ JJ O
cystitis NN NN O
in IN IN O
rats NNS NNS O
. . . O

PURPOSE NNP NNP O
: : : O
The DT DT O
purpose NN NN O
of IN IN O
the DT DT O
study NN NN O
is VBZ VBZ O
to TO TO O
explore VB VB O
the DT DT O
function NN NN O
of IN IN O
P2X3 NNP NNP O
and CC CC O
NK1 NNP NNP O
receptors NNS NNS O
antagonists NNS NNS O
on IN IN O
cyclophosphamide NN NN B-CHEM
( ( ( O
CYP NNP NNP B-CHEM
) ) ) O
- : : O
induced JJ JJ O
cystitis NN NN O
in IN IN O
rats NNS NNS O
. . . O

METHODS NNP NNP O
: : : O
Sixty NNP NNP O
female JJ JJ O
Sprague NNP NNP O
- : : O
Dawley NNP NNP O
( ( ( O
SD NNP NNP O
) ) ) O
rats NNS NNS O
were VBD VBD O
randomly RB RB O
divided VBN VBN O
into IN IN O
three CD CD O
groups NNS NNS O
. . . O

The DT DT O
rats NNS NNS O
in IN IN O
the DT DT O
control NN NN O
group NN NN O
were VBD VBD O
intraperitoneally RB RB O
( ( ( O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
injected VBN VBN O
with IN IN O
0 CD CD O
. . . O
9 CD CD O
% NN NN O
saline NN NN O
( ( ( O
4 CD CD O
ml NN NN O
/ NN NN O
kg NN NN O
) ) ) O
; : : O
the DT DT O
rats NNS NNS O
in IN IN O
the DT DT O
model NN NN O
group NN NN O
were VBD VBD O
i NNP NNP O
. . . O
p NN NN O
. . . O
injected VBN VBN O
with IN IN O
CYP NNP NNP B-CHEM
( ( ( O
150 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
; : : O
and CC CC O
the DT DT O
rats NNS NNS O
in IN IN O
the DT DT O
intervention NN NN O
group NN NN O
were VBD VBD O
i NNP NNP O
. . . O
p NN NN O
. . . O
injected VBN VBN O
with IN IN O
CYP NNP NNP B-CHEM
with IN IN O
subsequently RB RB O
perfusion NN NN O
of IN IN O
bladder NN NN O
with IN IN O
P2X3 NNP NNP O
and CC CC O
NK1 NNP NNP O
receptors NNS NNS O
' POS POS O
antagonists NNS NNS O
, , , O
Suramin NNP NNP B-CHEM
and CC CC O
GR NNP NNP B-CHEM
82334 CD CD I-CHEM
. . . O

Spontaneous NNP NNP O
pain NN NN O
behaviors NNS NNS O
following VBG VBG O
the DT DT O
administration NN NN O
of IN IN O
CYP NNP NNP B-CHEM
were VBD VBD O
observed VBN VBN O
. . . O

Urodynamic NNP NNP O
parameters NNS NNS O
, , , O
bladder NN NN O
pressure NN NN O
- : : O
volume NN NN O
curve NN NN O
, , , O
maximum NN NN O
voiding VBG VBG O
pressure NN NN O
( ( ( O
MVP NNP NNP O
) ) ) O
, , , O
and CC CC O
maximum NN NN O
cystometric JJ JJ O
capacity NN NN O
( ( ( O
MCC NNP NNP O
) ) ) O
, , , O
were VBD VBD O
recorded VBN VBN O
. . . O

Pathological NNP NNP O
changes NNS NNS O
in IN IN O
bladder NN NN O
tissue NN NN O
were VBD VBD O
observed VBN VBN O
. . . O

Immunofluorescence NNP NNP O
was VBD VBD O
used VBN VBN O
to TO TO O
detect VB VB O
the DT DT O
expression NN NN O
of IN IN O
P2X3 NNP NNP O
and CC CC O
NK1 NNP NNP O
receptors NNS NNS O
in IN IN O
bladder NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Cyclophosphamide NNP NNP B-CHEM
treatment NN NN O
increased VBD VBD O
the DT DT O
spontaneous JJ JJ O
pain NN NN O
behaviors NNS NNS O
scores NNS NNS O
. . . O

The DT DT O
incidence NN NN O
of IN IN O
bladder NN NN O
instability NN NN O
during IN IN O
urine JJ JJ O
storage NN NN O
period NN NN O
of IN IN O
model NN NN O
group NN NN O
was VBD VBD O
significantly RB RB O
higher JJR JJR O
than IN IN O
intervention NN NN O
group NN NN O
( ( ( O
X NNP NNP O
( ( ( O
2 CD CD O
) ) ) O
= SYM SYM O
7 CD CD O
. . . O
619 CD CD O
, , , O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
007 CD CD O
) ) ) O
and CC CC O
control NN NN O
group NN NN O
( ( ( O
X NNP NNP O
( ( ( O
2 CD CD O
) ) ) O
= SYM SYM O
13 CD CD O
. . . O
755 CD CD O
, , , O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
000 CD CD O
) ) ) O
. . . O

MCC NNP NNP O
in IN IN O
the DT DT O
model NN NN O
group NN NN O
was VBD VBD O
lower JJR JJR O
than IN IN O
the DT DT O
control NN NN O
and CC CC O
intervention NN NN O
groups NNS NNS O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
. . . O

Histological NNP NNP O
changes NNS NNS O
evident NN NN O
in IN IN O
model NN NN O
and CC CC O
intervention NN NN O
groups NNS NNS O
rats NNS NNS O
' POS POS O
bladder NN NN O
included VBD VBD O
edema NN NN O
, , , O
vasodilation NN NN O
, , , O
and CC CC O
infiltration NN NN O
of IN IN O
inflammatory JJ JJ O
cells NNS NNS O
. . . O

In IN IN O
model NN NN O
group NN NN O
, , , O
the DT DT O
expression NN NN O
of IN IN O
P2X3 NNP NNP O
receptor NN NN O
increased VBD VBD O
in IN IN O
urothelium NN NN O
and CC CC O
suburothelium NN NN O
, , , O
and CC CC O
NK1 NNP NNP O
receptor NN NN O
increased VBD VBD O
in IN IN O
suburothelium NN NN O
, , , O
while IN IN O
the DT DT O
expression NN NN O
of IN IN O
them PRP PRP O
in IN IN O
intervention NN NN O
group NN NN O
was VBD VBD O
lower JJR JJR O
. . . O

CONCLUSIONS NNP NNP O
: : : O
In IN IN O
CYP NNP NNP B-CHEM
- : : O
induced JJ JJ O
cystitis NNS NNS O
, , , O
the DT DT O
expression NN NN O
of IN IN O
P2X3 NNP NNP O
and CC CC O
NK1 NNP NNP O
receptors NNS NNS O
increased VBN VBN O
in IN IN O
urothelium NN NN O
and CC CC O
/ NN NN O
or CC CC O
suburothelium NN NN O
. . . O

Perfusion NNP NNP O
of IN IN O
bladder NN NN O
with IN IN O
P2X3 NNP NNP O
and CC CC O
NK1 NNP NNP O
receptors NNS NNS O
antagonists NNS NNS O
ameliorated VBD VBD O
the DT DT O
bladder NN NN O
function NN NN O
. . . O

Patient NNP NNP O
tolerance NN NN O
study NN NN O
of IN IN O
topical JJ JJ O
chlorhexidine NN NN B-CHEM
diphosphanilate NN NN I-CHEM
: : : O
a DT DT O
new JJ JJ O
topical JJ JJ O
agent NN NN O
for IN IN O
burns NNS NNS O
. . . O

Effective NNP NNP O
topical JJ JJ O
antimicrobial JJ JJ O
agents NNS NNS O
decrease VBP VBP O
infection NN NN O
and CC CC O
mortality NN NN O
in IN IN O
burn NN NN O
patients NNS NNS O
. . . O

Chlorhexidine NNP NNP B-CHEM
phosphanilate NN NN I-CHEM
( ( ( O
CHP NNP NNP B-CHEM
) ) ) O
, , , O
a DT DT O
new JJ JJ O
broad JJ JJ O
- - - O
spectrum NN NN O
antimicrobial JJ JJ O
agent NN NN O
, , , O
has VBZ VBZ O
been VBN VBN O
evaluated VBN VBN O
as IN IN O
a DT DT O
topical JJ JJ O
burn NN NN O
wound VBD VBD O
dressing VBG VBG O
in IN IN O
cream NN NN O
form NN NN O
, , , O
but CC CC O
preliminary JJ JJ O
clinical JJ JJ O
trials NNS NNS O
reported VBD VBD O
that IN IN O
it PRP PRP O
was VBD VBD O
painful JJ JJ O
upon IN IN O
application NN NN O
. . . O

This DT DT O
study NN NN O
compared VBN VBN O
various JJ JJ O
concentrations NNS NNS O
of IN IN O
CHP NNP NNP B-CHEM
to TO TO O
determine VB VB O
if IN IN O
a DT DT O
tolerable JJ JJ O
concentration NN NN O
could MD MD O
be VB VB O
identified VBN VBN O
with IN IN O
retention NN NN O
of IN IN O
antimicrobial JJ JJ O
efficacy NN NN O
. . . O

Twenty CD CD O
- - - O
nine CD CD O
burn NN NN O
patients NNS NNS O
, , , O
each DT DT O
with IN IN O
two CD CD O
similar JJ JJ O
burns NNS NNS O
which WDT WDT O
could MD MD O
be VB VB O
separately RB RB O
treated VBN VBN O
, , , O
were VBD VBD O
given VBN VBN O
pairs NNS NNS O
of IN IN O
treatments NNS NNS O
at IN IN O
successive JJ JJ O
12 CD CD O
- : : O
h NN NN O
intervals NNS NNS O
over IN IN O
a DT DT O
3 CD CD O
- : : O
day NN NN O
period NN NN O
. . . O

One CD CD O
burn NN NN O
site NN NN O
was VBD VBD O
treated VBN VBN O
with IN IN O
each DT DT O
of IN IN O
four CD CD O
different JJ JJ O
CHP NNP NNP B-CHEM
concentrations NNS NNS O
, , , O
from IN IN O
0 CD CD O
. . . O
25 CD CD O
per IN IN O
cent NN NN O
to TO TO O
2 CD CD O
per IN IN O
cent NN NN O
, , , O
their PRP$ PRP$ O
vehicle NN NN O
, , , O
and CC CC O
1 CD CD O
per IN IN O
cent NN NN O
silver NN NN B-CHEM
sulphadiazine NN NN I-CHEM
( ( ( O
AgSD NNP NNP B-CHEM
) ) ) O
cream NN NN O
, , , O
an DT DT O
antimicrobial JJ JJ O
agent NN NN O
frequently RB RB O
used VBN VBN O
for IN IN O
topical JJ JJ O
treatment NN NN O
of IN IN O
burn NN NN O
wounds NNS NNS O
. . . O

The DT DT O
other JJ JJ O
site NN NN O
was VBD VBD O
always RB RB O
treated VBN VBN O
with IN IN O
AgSD NNP NNP B-CHEM
cream NN NN O
. . . O

There EX EX O
was VBD VBD O
a DT DT O
direct JJ JJ O
relationship NN NN O
between IN IN O
CHP NNP NNP B-CHEM
concentration NN NN O
and CC CC O
patients NNS NNS O
' POS POS O
ratings NNS NNS O
of IN IN O
pain NN NN O
on IN IN O
an DT DT O
analogue NN NN O
scale NN NN O
. . . O

The DT DT O
0 CD CD O
. . . O
25 CD CD O
per IN IN O
cent NN NN O
CHP NNP NNP B-CHEM
cream NN NN O
was VBD VBD O
closest JJS JJS O
to TO TO O
AgSD NNP NNP B-CHEM
in IN IN O
pain NN NN O
tolerance NN NN O
; : : O
however RB RB O
, , , O
none NN NN O
of IN IN O
the DT DT O
treatments NNS NNS O
differed VBD VBD O
statistically RB RB O
from IN IN O
AgSD NNP NNP B-CHEM
or CC CC O
from IN IN O
each DT DT O
other JJ JJ O
. . . O

In IN IN O
addition NN NN O
, , , O
ease NN NN O
of IN IN O
application NN NN O
of IN IN O
CHP NNP NNP B-CHEM
creams NNS NNS O
was VBD VBD O
less RBR RBR O
satisfactory JJ JJ O
than IN IN O
that DT DT O
of IN IN O
AgSD NNP NNP B-CHEM
. . . O

It PRP PRP O
was VBD VBD O
concluded VBN VBN O
that IN IN O
formulations NNS NNS O
at IN IN O
or CC CC O
below IN IN O
0 CD CD O
. . . O
5 CD CD O
per IN IN O
cent NN NN O
CHP NNP NNP B-CHEM
may MD MD O
prove VB VB O
acceptable JJ JJ O
for IN IN O
wound NN NN O
care NN NN O
, , , O
but CC CC O
the DT DT O
vehicle NN NN O
system NN NN O
needs VBZ VBZ O
pharmaceutical JJ JJ O
improvement NN NN O
to TO TO O
render VB VB O
it PRP PRP O
more RBR RBR O
tolerable JJ JJ O
and CC CC O
easier JJR JJR O
to TO TO O
use VB VB O
. . . O

Acute JJ JJ O
hepatitis NN NN O
associated VBN VBN O
with IN IN O
clopidogrel NN NN B-CHEM
: : : O
a DT DT O
case NN NN O
report NN NN O
and CC CC O
review NN NN O
of IN IN O
the DT DT O
literature NN NN O
. . . O

Drug NN NN O
- : : O
induced JJ JJ O
hepatotoxicity NN NN O
is VBZ VBZ O
a DT DT O
common JJ JJ O
cause NN NN O
of IN IN O
acute JJ JJ O
hepatitis NN NN O
, , , O
and CC CC O
the DT DT O
recognition NN NN O
of IN IN O
the DT DT O
responsible JJ JJ O
drug NN NN O
may MD MD O
be VB VB O
difficult JJ JJ O
. . . O

We PRP PRP O
describe VBP VBP O
a DT DT O
case NN NN O
of IN IN O
clopidogrel NN NN B-CHEM
- - - O
related VBN VBN O
acute JJ JJ O
hepatitis NN NN O
. . . O

The DT DT O
diagnosis NN NN O
is VBZ VBZ O
strongly RB RB O
suggested VBN VBN O
by IN IN O
an DT DT O
accurate JJ JJ O
medical JJ JJ O
history NN NN O
and CC CC O
liver NN NN O
biopsy NN NN O
. . . O

Reports NNP NNP O
about IN IN O
cases NNS NNS O
of IN IN O
hepatotoxicity NN NN O
due JJ JJ O
to TO TO O
clopidogrel VB VB B-CHEM
are VBP VBP O
increasing VBG VBG O
in IN IN O
the DT DT O
last JJ JJ O
few JJ JJ O
years NNS NNS O
, , , O
after IN IN O
the DT DT O
increased JJ JJ O
use NN NN O
of IN IN O
this DT DT O
drug NN NN O
. . . O

In IN IN O
conclusion NN NN O
, , , O
we PRP PRP O
believe VBP VBP O
that IN IN O
physicians NNS NNS O
should MD MD O
carefully RB RB O
consider VB VB O
the DT DT O
risk NN NN O
of IN IN O
drug NN NN O
- - - O
induced JJ JJ O
hepatic JJ JJ O
injury NN NN O
when WRB WRB O
clopidogrel NN NN B-CHEM
is VBZ VBZ O
prescribed VBN VBN O
. . . O

Bortezomib NNP NNP B-CHEM
and CC CC O
dexamethasone NN NN B-CHEM
as IN IN O
salvage NN NN O
therapy NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
relapsed JJ JJ O
/ NN NN O
refractory NN NN O
multiple JJ JJ O
myeloma NN NN O
: : : O
analysis NN NN O
of IN IN O
long JJ JJ O
- - - O
term NN NN O
clinical JJ JJ O
outcomes NNS NNS O
. . . O

Bortezomib NNP NNP B-CHEM
( ( ( O
bort NN NN B-CHEM
) ) ) O
- : : O
dexamethasone NN NN B-CHEM
( ( ( O
dex NN NN B-CHEM
) ) ) O
is VBZ VBZ O
an DT DT O
effective JJ JJ O
therapy NN NN O
for IN IN O
relapsed JJ JJ O
/ NN NN O
refractory NN NN O
( ( ( O
R NN NN O
/ NN NN O
R NN NN O
) ) ) O
multiple JJ JJ O
myeloma NN NN O
( ( ( O
MM NNP NNP O
) ) ) O
. . . O

This DT DT O
retrospective NN NN O
study NN NN O
investigated VBD VBD O
the DT DT O
combination NN NN O
of IN IN O
bort NN NN B-CHEM
( ( ( O
1 CD CD O
. . . O
3 CD CD O
mg NN NN O
/ NN NN O
m NN NN O
( ( ( O
2 CD CD O
) ) ) O
on IN IN O
days NNS NNS O
1 CD CD O
, , , O
4 CD CD O
, , , O
8 CD CD O
, , , O
and CC CC O
11 CD CD O
every DT DT O
3 CD CD O
weeks NNS NNS O
) ) ) O
and CC CC O
dex NN NN B-CHEM
( ( ( O
20 CD CD O
mg NN NN O
on IN IN O
the DT DT O
day NN NN O
of IN IN O
and CC CC O
the DT DT O
day NN NN O
after IN IN O
bort NN NN B-CHEM
) ) ) O
as IN IN O
salvage NN NN O
treatment NN NN O
in IN IN O
85 CD CD O
patients NNS NNS O
with IN IN O
R NNP NNP O
/ NN NN O
R NN NN O
MM NNP NNP O
after IN IN O
prior RB RB O
autologous JJ JJ O
stem NN NN O
cell NN NN O
transplantation NN NN O
or CC CC O
conventional JJ JJ O
chemotherapy NN NN O
. . . O

The DT DT O
median JJ JJ O
number NN NN O
of IN IN O
prior JJ JJ O
lines NNS NNS O
of IN IN O
therapy NN NN O
was VBD VBD O
2 CD CD O
. . . O

Eighty NNP NNP O
- : : O
seven CD CD O
percent NN NN O
of IN IN O
the DT DT O
patients NNS NNS O
had VBD VBD O
received VBN VBN O
immunomodulatory JJ JJ O
drugs NNS NNS O
included VBN VBN O
in IN IN O
some DT DT O
line NN NN O
of IN IN O
therapy NN NN O
before IN IN O
bort NN NN B-CHEM
- - - O
dex NN NN B-CHEM
. . . O

The DT DT O
median JJ JJ O
number NN NN O
of IN IN O
bort NN NN B-CHEM
- - - O
dex NN NN B-CHEM
cycles NNS NNS O
was VBD VBD O
6 CD CD O
, , , O
up RB RB O
to TO TO O
a DT DT O
maximum NN NN O
of IN IN O
12 CD CD O
cycles NNS NNS O
. . . O

On IN IN O
an DT DT O
intention NN NN O
- - - O
to TO TO O
- - - O
treat NN NN O
basis NN NN O
, , , O
55 CD CD O
% NN NN O
of IN IN O
the DT DT O
patients NNS NNS O
achieved VBN VBN O
at IN IN O
least JJS JJS O
partial JJ JJ O
response NN NN O
, , , O
including VBG VBG O
19 CD CD O
% NN NN O
CR NNP NNP O
and CC CC O
35 CD CD O
% NN NN O
achieved VBN VBN O
at IN IN O
least JJS JJS O
very RB RB O
good JJ JJ O
partial JJ JJ O
response NN NN O
. . . O

Median NNP NNP O
durations NNS NNS O
of IN IN O
response NN NN O
, , , O
time NN NN O
to TO TO O
next JJ JJ O
therapy NN NN O
and CC CC O
treatment NN NN O
- - - O
free JJ JJ O
interval NN NN O
were VBD VBD O
8 CD CD O
, , , O
11 CD CD O
. . . O
2 CD CD O
, , , O
and CC CC O
5 CD CD O
. . . O
1 CD CD O
months NNS NNS O
, , , O
respectively RB RB O
. . . O

The DT DT O
most RBS RBS O
relevant JJ JJ O
adverse JJ JJ O
event NN NN O
was VBD VBD O
peripheral JJ JJ O
neuropathy NN NN O
, , , O
which WDT WDT O
occurred VBD VBD O
in IN IN O
78 CD CD O
% NN NN O
of IN IN O
the DT DT O
patients NNS NNS O
( ( ( O
grade NN NN O
II NNP NNP O
, , , O
38 CD CD O
% NN NN O
; : : O
grade NN NN O
III NNP NNP O
, , , O
21 CD CD O
% NN NN O
) ) ) O
and CC CC O
led VBN VBN O
to TO TO O
treatment NN NN O
discontinuation NN NN O
in IN IN O
6 CD CD O
% NN NN O
. . . O

With IN IN O
a DT DT O
median JJ JJ O
follow VB VB O
up NNS NNS O
of IN IN O
22 CD CD O
months NNS NNS O
, , , O
median JJ JJ O
time NN NN O
to TO TO O
progression NN NN O
, , , O
progression NN NN O
- - - O
free JJ JJ O
survival NN NN O
( ( ( O
PFS NNP NNP O
) ) ) O
and CC CC O
overall JJ JJ O
survival NN NN O
( ( ( O
OS NNP NNP O
) ) ) O
were VBD VBD O
8 CD CD O
. . . O
9 CD CD O
, , , O
8 CD CD O
. . . O
7 CD CD O
, , , O
and CC CC O
22 CD CD O
months NNS NNS O
, , , O
respectively RB RB O
. . . O

Prolonged NNP NNP O
PFS NNP NNP O
and CC CC O
OS NNP NNP O
were VBD VBD O
observed VBN VBN O
in IN IN O
patients NNS NNS O
achieving VBG VBG O
CR NNP NNP O
and CC CC O
receiving VBG VBG O
bort NN NN B-CHEM
- - - O
dex NN NN B-CHEM
a DT DT O
single JJ JJ O
line NN NN O
of IN IN O
prior RB RB O
therapy NN NN O
. . . O

Bort NNP NNP B-CHEM
- : : O
dex NN NN B-CHEM
was VBD VBD O
an DT DT O
effective JJ JJ O
salvage NN NN O
treatment NN NN O
for IN IN O
MM NNP NNP O
patients NNS NNS O
, , , O
particularly RB RB O
for IN IN O
those DT DT O
in IN IN O
first JJ JJ O
relapse NN NN O
. . . O

Pubertal NNP NNP O
exposure NN NN O
to TO TO O
Bisphenol NNP NNP B-CHEM
A DT DT I-CHEM
increases NNS NNS O
anxiety NN NN O
- - - O
like IN IN O
behavior NN NN O
and CC CC O
decreases NNS NNS O
acetylcholinesterase NN NN O
activity NN NN O
of IN IN O
hippocampus NN NN O
in IN IN O
adult NN NN O
male JJ JJ O
mice NN NN O
. . . O

The DT DT O
negative JJ JJ O
effects NNS NNS O
of IN IN O
Bisphenol NNP NNP B-CHEM
A DT DT I-CHEM
( ( ( O
BPA NNP NNP B-CHEM
) ) ) O
on IN IN O
neurodevelopment NN NN O
and CC CC O
behaviors NNS NNS O
have VBP VBP O
been VBN VBN O
well RB RB O
established VBN VBN O
. . . O

Acetylcholinesterase NNP NNP O
( ( ( O
AChE NNP NNP O
) ) ) O
is VBZ VBZ O
a DT DT O
regulatory JJ JJ O
enzyme NN NN O
which WDT WDT O
is VBZ VBZ O
involved VBN VBN O
in IN IN O
anxiety NN NN O
- - - O
like IN IN O
behavior NN NN O
. . . O

This DT DT O
study NN NN O
investigated VBD VBD O
behavioral JJ JJ O
phenotypes NNS NNS O
and CC CC O
AChE NNP NNP O
activity NN NN O
in IN IN O
male JJ JJ O
mice NN NN O
following VBG VBG O
BPA NNP NNP B-CHEM
exposure NN NN O
during IN IN O
puberty NN NN O
. . . O

On IN IN O
postnatal JJ JJ O
day NN NN O
( ( ( O
PND NNP NNP O
) ) ) O
35 CD CD O
, , , O
male JJ JJ O
mice NN NN O
were VBD VBD O
exposed VBN VBN O
to TO TO O
50mg CD CD O
BPA NNP NNP B-CHEM
/ NN NN O
kg NN NN O
diet NN NN O
per IN IN O
day NN NN O
for IN IN O
a DT DT O
period NN NN O
of IN IN O
35 CD CD O
days NNS NNS O
. . . O

On IN IN O
PND71 NNP NNP O
, , , O
a DT DT O
behavioral JJ JJ O
assay NN NN O
was VBD VBD O
performed VBN VBN O
using VBG VBG O
the DT DT O
elevated JJ JJ O
plus CC CC O
maze NN NN O
( ( ( O
EPM NNP NNP O
) ) ) O
and CC CC O
the DT DT O
light JJ JJ O
/ NN NN O
dark JJ JJ O
test NN NN O
. . . O

In IN IN O
addition NN NN O
, , , O
AChE NNP NNP O
activity NN NN O
was VBD VBD O
measured VBN VBN O
in IN IN O
the DT DT O
prefrontal NN NN O
cortex NN NN O
, , , O
hypothalamus NN NN O
, , , O
cerebellum NN NN O
and CC CC O
hippocampus NN NN O
. . . O

Results NNS NNS O
from IN IN O
our PRP$ PRP$ O
behavioral JJ JJ O
phenotyping NN NN O
indicated VBD VBD O
that IN IN O
anxiety NN NN O
- - - O
like IN IN O
behavior NN NN O
was VBD VBD O
increased VBN VBN O
in IN IN O
mice NNS NNS O
exposed VBN VBN O
to TO TO O
BPA NNP NNP B-CHEM
. . . O

AChE NNP NNP O
activity NN NN O
was VBD VBD O
significantly RB RB O
decreased VBN VBN O
in IN IN O
the DT DT O
hippocampus NN NN O
of IN IN O
mice NNS NNS O
with IN IN O
BPA NNP NNP B-CHEM
compared VBD VBD O
to TO TO O
control VB VB O
mice NN NN O
, , , O
whereas IN IN O
no DT DT O
difference NN NN O
was VBD VBD O
found VBN VBN O
in IN IN O
the DT DT O
prefrontal NN NN O
cortex NN NN O
, , , O
hypothalamus NN NN O
and CC CC O
cerebellum NN NN O
. . . O

Our PRP$ PRP$ O
findings NNS NNS O
showed VBD VBD O
that IN IN O
pubertal JJ JJ O
BPA NNP NNP B-CHEM
exposure NN NN O
increased VBD VBD O
anxiety NN NN O
- - - O
like IN IN O
behavior NN NN O
, , , O
which WDT WDT O
may MD MD O
be VB VB O
associated VBN VBN O
with IN IN O
decreased VBD VBD O
AChE NNP NNP O
activity NN NN O
of IN IN O
the DT DT O
hippocampus NN NN O
in IN IN O
adult NN NN O
male JJ JJ O
mice NN NN O
. . . O

Further RB RB O
studies NNS NNS O
are VBP VBP O
necessary JJ JJ O
to TO TO O
investigate VB VB O
the DT DT O
cholinergic JJ JJ O
signaling NN NN O
of IN IN O
the DT DT O
hippocampus NN NN O
in IN IN O
PBE NNP NNP O
induced VBD VBD O
anxiety NN NN O
- - - O
like IN IN O
behaviors NNS NNS O
. . . O

Biochemical NNP NNP O
effects NNS NNS O
of IN IN O
Solidago NNP NNP O
virgaurea NN NN O
extract NN NN O
on IN IN O
experimental JJ JJ O
cardiotoxicity NN NN O
. . . O

Cardiovascular NNP NNP O
diseases NNS NNS O
( ( ( O
CVDs NNP NNP O
) ) ) O
are VBP VBP O
the DT DT O
major JJ JJ O
health NN NN O
problem NN NN O
of IN IN O
advanced VBN VBN O
as RB RB O
well RB RB O
as IN IN O
developing VBG VBG O
countries NNS NNS O
of IN IN O
the DT DT O
world NN NN O
. . . O

The DT DT O
aim NN NN O
of IN IN O
the DT DT O
present JJ JJ O
study NN NN O
was VBD VBD O
to TO TO O
investigate VB VB O
the DT DT O
protective JJ JJ O
effect NN NN O
of IN IN O
the DT DT O
Solidago NNP NNP O
virgaurea NN NN O
extract NN NN O
on IN IN O
isoproterenol NN NN B-CHEM
- : : O
induced JJ JJ O
cardiotoxicity NN NN O
in IN IN O
rats NNS NNS O
. . . O

The DT DT O
subcutaneous JJ JJ O
injection NN NN O
of IN IN O
isoproterenol NN NN B-CHEM
( ( ( O
30 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
into IN IN O
rats NNS NNS O
twice RB RB O
at IN IN O
an DT DT O
interval NN NN O
of IN IN O
24 CD CD O
h NN NN O
, , , O
for IN IN O
two CD CD O
consecutive JJ JJ O
days NNS NNS O
, , , O
led VBN VBN O
to TO TO O
a DT DT O
significant JJ JJ O
increase NN NN O
in IN IN O
serum NN NN O
lactate NN NN B-CHEM
dehydrogenase NN NN O
, , , O
creatine NN NN B-CHEM
phosphokinase NN NN O
, , , O
alanine NN NN B-CHEM
transaminase NN NN O
, , , O
aspartate NN NN B-CHEM
transaminase NN NN O
, , , O
and CC CC O
angiotensin NN NN B-CHEM
- - - O
converting VBG VBG O
enzyme NN NN O
activities NNS NNS O
, , , O
total JJ JJ O
cholesterol NN NN B-CHEM
, , , O
triglycerides NNS NNS B-CHEM
, , , O
free JJ JJ O
serum NN NN O
fatty JJ JJ B-CHEM
acid NN NN I-CHEM
, , , O
cardiac NN NN O
tissue NN NN O
malondialdehyde NN NN B-CHEM
( ( ( O
MDA NNP NNP B-CHEM
) ) ) O
, , , O
and CC CC O
nitric JJ JJ B-CHEM
oxide NN NN I-CHEM
levels NNS NNS O
and CC CC O
a DT DT O
significant JJ JJ O
decrease NN NN O
in IN IN O
levels NNS NNS O
of IN IN O
glutathione NN NN B-CHEM
and CC CC O
superoxide NN NN B-CHEM
dismutase NN NN O
in IN IN O
cardiac JJ JJ O
tissue NN NN O
as IN IN O
compared VBN VBN O
to TO TO O
the DT DT O
normal JJ JJ O
control NN NN O
group NN NN O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

Pretreatment NNP NNP O
with IN IN O
S NNP NNP O
. . . O
virgaurea NN NN O
extract NN NN O
for IN IN O
5 CD CD O
weeks NNS NNS O
at IN IN O
a DT DT O
dose NN NN O
of IN IN O
250 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
followed VBN VBN O
by IN IN O
isoproterenol JJ JJ B-CHEM
injection NN NN O
significantly RB RB O
prevented VBD VBD O
the DT DT O
observed VBN VBN O
alterations NNS NNS O
. . . O

Captopril NNP NNP B-CHEM
( ( ( O
50 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
, , , O
given VBN VBN O
orally RB RB O
) ) ) O
, , , O
an DT DT O
inhibitor NN NN O
of IN IN O
angiotensin NN NN B-CHEM
- - - O
converting VBG VBG O
enzyme NN NN O
used VBN VBN O
as IN IN O
a DT DT O
standard JJ JJ O
cardioprotective JJ JJ O
drug NN NN O
, , , O
was VBD VBD O
used VBN VBN O
as IN IN O
a DT DT O
positive JJ JJ O
control NN NN O
in IN IN O
this DT DT O
study NN NN O
. . . O

The DT DT O
data NNS NNS O
of IN IN O
the DT DT O
present NN NN O
study NN NN O
suggest VBP VBP O
that IN IN O
S NNP NNP O
. . . O
virgaurea NN NN O
extract NN NN O
exerts VBZ VBZ O
its PRP$ PRP$ O
protective JJ JJ O
effect NN NN O
by IN IN O
decreasing VBG VBG O
MDA NNP NNP B-CHEM
level NN NN O
and CC CC O
increasing VBG VBG O
the DT DT O
antioxidant NN NN O
status NN NN O
in IN IN O
isoproterenol NN NN B-CHEM
- - - O
treated VBN VBN O
rats NNS NNS O
. . . O

The DT DT O
study NN NN O
emphasizes VBZ VBZ O
the DT DT O
beneficial JJ JJ O
action NN NN O
of IN IN O
S NNP NNP O
. . . O
virgaurea NN NN O
extract NN NN O
as IN IN O
a DT DT O
cardioprotective JJ JJ O
agent NN NN O
. . . O

" '' '' O
Real JJ JJ O
- - - O
world NN NN O
" '' '' O
data NNS NNS O
on IN IN O
the DT DT O
efficacy NN NN O
and CC CC O
safety NN NN O
of IN IN O
lenalidomide NN NN B-CHEM
and CC CC O
dexamethasone NN NN B-CHEM
in IN IN O
patients NNS NNS O
with IN IN O
relapsed JJ JJ O
/ NN NN O
refractory NN NN O
multiple JJ JJ O
myeloma NN NN O
who WP WP O
were VBD VBD O
treated VBN VBN O
according VBG VBG O
to TO TO O
the DT DT O
standard JJ JJ O
clinical JJ JJ O
practice NN NN O
: : : O
a DT DT O
study NN NN O
of IN IN O
the DT DT O
Greek JJ JJ O
Myeloma NNP NNP O
Study NNP NNP O
Group NNP NNP O
. . . O

Lenalidomide NNP NNP B-CHEM
and CC CC O
dexamethasone NN NN B-CHEM
( ( ( O
RD NNP NNP B-CHEM
) ) ) O
is VBZ VBZ O
a DT DT O
standard NN NN O
of IN IN O
care NN NN O
for IN IN O
relapsed JJ JJ O
/ NN NN O
refractory NN NN O
multiple JJ JJ O
myeloma NN NN O
( ( ( O
RRMM NNP NNP O
) ) ) O
, , , O
but CC CC O
there EX EX O
is VBZ VBZ O
limited VBN VBN O
published VBN VBN O
data NNS NNS O
on IN IN O
its PRP$ PRP$ O
efficacy NN NN O
and CC CC O
safety NN NN O
in IN IN O
the DT DT O
" '' '' O
real JJ JJ O
world NN NN O
" '' '' O
( ( ( O
RW NNP NNP O
) ) ) O
, , , O
according VBG VBG O
to TO TO O
the DT DT O
International NNP NNP O
Society NNP NNP O
of IN IN O
Pharmacoeconomics NNP NNP O
and CC CC O
Outcomes NNP NNP O
Research NNP NNP O
definition NN NN O
. . . O

We PRP PRP O
studied VBD VBD O
212 CD CD O
RRMM NNP NNP O
patients NNS NNS O
who WP WP O
received VBD VBD O
RD NNP NNP B-CHEM
in IN IN O
RW NNP NNP O
. . . O

Objective NNP NNP O
response NN NN O
( ( ( O
> NN NN O
PR NNP NNP O
( ( ( O
partial JJ JJ O
response NN NN O
) ) ) O
) ) ) O
rate NN NN O
was VBD VBD O
77 CD CD O
. . . O
4 CD CD O
% NN NN O
( ( ( O
complete JJ JJ O
response NN NN O
( ( ( O
CR NNP NNP O
) ) ) O
, , , O
20 CD CD O
. . . O
2 CD CD O
% NN NN O
) ) ) O
. . . O

Median JJ JJ O
time NN NN O
to TO TO O
first JJ JJ O
and CC CC O
best JJS JJS O
response NN NN O
was VBD VBD O
2 CD CD O
and CC CC O
5 CD CD O
months NNS NNS O
, , , O
respectively RB RB O
. . . O

Median JJ JJ O
time NN NN O
to TO TO O
CR NNP NNP O
when WRB WRB O
RD NNP NNP B-CHEM
was VBD VBD O
given VBN VBN O
as IN IN O
2nd CD CD O
or CC CC O
> NN NN O
2 CD CD O
( ( ( O
nd NN NN O
) ) ) O
- : : O
line NN NN O
treatment NN NN O
at IN IN O
4 CD CD O
and CC CC O
11 CD CD O
months NNS NNS O
, , , O
respectively RB RB O
. . . O

Quality NNP NNP O
of IN IN O
response NN NN O
was VBD VBD O
independent JJ JJ O
of IN IN O
previous JJ JJ O
lines NNS NNS O
of IN IN O
therapies NNS NNS O
or CC CC O
previous JJ JJ O
exposure NN NN O
to TO TO O
thalidomide VB VB B-CHEM
or CC CC O
bortezomib NN NN B-CHEM
. . . O

Median NNP NNP O
duration NN NN O
of IN IN O
response NN NN O
was VBD VBD O
34 CD CD O
. . . O
4 CD CD O
months NNS NNS O
, , , O
and CC CC O
it PRP PRP O
was VBD VBD O
higher JJR JJR O
in IN IN O
patients NNS NNS O
who WP WP O
received VBD VBD O
RD NNP NNP B-CHEM
until IN IN O
progression NN NN O
( ( ( O
not RB RB O
reached VBN VBN O
versus CC CC O
19 CD CD O
months NNS NNS O
, , , O
p NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
. . . O

Improvement NNP NNP O
of IN IN O
humoral JJ JJ O
immunity NN NN O
occurred VBD VBD O
in IN IN O
60 CD CD O
% NN NN O
of IN IN O
responders NNS NNS O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
and CC CC O
in IN IN O
the DT DT O
majority NN NN O
of IN IN O
patients NNS NNS O
who WP WP O
achieved VBD VBD O
stable JJ JJ O
disease NN NN O
. . . O

Adverse NNP NNP O
events NNS NNS O
were VBD VBD O
reported VBN VBN O
in IN IN O
68 CD CD O
. . . O
9 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
( ( ( O
myelosuppression NN NN O
in IN IN O
49 CD CD O
. . . O
4 CD CD O
% NN NN O
) ) ) O
and CC CC O
12 CD CD O
. . . O
7 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
needed VBN VBN O
hospitalization NN NN O
. . . O

Peripheral NNP NNP O
neuropathy NN NN O
was VBD VBD O
observed VBN VBN O
only RB RB O
in IN IN O
2 CD CD O
. . . O
5 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
and CC CC O
deep JJ JJ O
vein NN NN O
thrombosis NN NN O
in IN IN O
5 CD CD O
. . . O
7 CD CD O
% NN NN O
. . . O

Dose NNP NNP O
reductions NNS NNS O
were VBD VBD O
needed VBN VBN O
in IN IN O
31 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
and CC CC O
permanent JJ JJ O
discontinuation NN NN O
in IN IN O
38 CD CD O
. . . O
9 CD CD O
% NN NN O
. . . O

Median JJ JJ O
time NN NN O
to TO TO O
treatment NN NN O
discontinuation NN NN O
was VBD VBD O
16 CD CD O
. . . O
8 CD CD O
months NNS NNS O
. . . O

Performance NNP NNP O
status NN NN O
( ( ( O
PS NNP NNP O
) ) ) O
and CC CC O
initial JJ JJ O
lenalidomide NN NN B-CHEM
dose NN NN O
predicted VBN VBN O
for IN IN O
treatment NN NN O
discontinuation NN NN O
. . . O

Extra NNP NNP O
- : : O
medullary JJ JJ O
relapses NNS NNS O
occurred VBD VBD O
in IN IN O
3 CD CD O
. . . O
8 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
. . . O

Our PRP$ PRP$ O
study NN NN O
confirms VBZ VBZ O
that IN IN O
RD NNP NNP B-CHEM
is VBZ VBZ O
effective JJ JJ O
and CC CC O
safe JJ JJ O
in IN IN O
RRMM NNP NNP O
in IN IN O
the DT DT O
RW NNP NNP O
; : : O
it PRP PRP O
produces VBZ VBZ O
durable JJ JJ O
responses NNS NNS O
especially RB RB O
in IN IN O
patients NNS NNS O
who WP WP O
continue VBP VBP O
on IN IN O
treatment NN NN O
till NN NN O
progression NN NN O
and CC CC O
improves VBZ VBZ O
humoral JJ JJ O
immunity NN NN O
even RB RB O
in IN IN O
patients NNS NNS O
with IN IN O
stable JJ JJ O
disease NN NN O
. . . O

The DT DT O
cytogenetic JJ JJ O
action NN NN O
of IN IN O
ifosfamide NN NN B-CHEM
, , , O
mesna NN NN B-CHEM
, , , O
and CC CC O
their PRP$ PRP$ O
combination NN NN O
on IN IN O
peripheral JJ JJ O
rabbit NN NN O
lymphocytes NNS NNS O
: : : O
an DT DT O
in IN IN O
vivo NN NN O
/ NN NN O
in IN IN O
vitro NN NN O
cytogenetic JJ JJ O
study NN NN O
. . . O

Ifosfamide NNP NNP B-CHEM
( ( ( O
IFO NNP NNP B-CHEM
) ) ) O
is VBZ VBZ O
an DT DT O
alkylating VBG VBG O
nitrogen NN NN B-CHEM
mustard NN NN O
, , , O
administrated VBN VBN O
as IN IN O
an DT DT O
antineoplasmic JJ JJ O
agent NN NN O
. . . O

It PRP PRP O
is VBZ VBZ O
characterized VBN VBN O
by IN IN O
its PRP$ PRP$ O
intense JJ JJ O
urotoxic JJ JJ O
action NN NN O
, , , O
leading VBG VBG O
to TO TO O
hemorrhagic JJ JJ O
cystitis NNS NNS O
. . . O

This DT DT O
side NN NN O
effect NN NN O
of IN IN O
IFO NNP NNP B-CHEM
raises VBZ VBZ O
the DT DT O
requirement NN NN O
for IN IN O
the DT DT O
co NN NN O
- - - O
administration NN NN O
with IN IN O
sodium NN NN B-CHEM
2 CD CD I-CHEM
- : : I-CHEM
sulfanylethanesulfonate NN NN I-CHEM
( ( ( O
Mesna NNP NNP B-CHEM
) ) ) O
aiming VBG VBG O
to TO TO O
avoid VB VB O
or CC CC O
minimize VB VB O
this DT DT O
effect NN NN O
. . . O

IFO NNP NNP B-CHEM
and CC CC O
Mesna NNP NNP B-CHEM
were VBD VBD O
administrated VBN VBN O
separately RB RB O
on IN IN O
rabbit NN NN O
' '' '' O
s VBZ VBZ O
lymphocytes NNS NNS O
in IN IN O
vivo NN NN O
, , , O
which WDT WDT O
were VBD VBD O
later RB RB O
developed VBN VBN O
in IN IN O
vitro NN NN O
. . . O

Cytogenetic NNP NNP O
markers NNS NNS O
for IN IN O
sister NN NN O
chromatid NN NN O
exchanges NNS NNS O
( ( ( O
SCEs NNP NNP O
) ) ) O
, , , O
proliferation NN NN O
rate NN NN O
index NN NN O
( ( ( O
PRI NNP NNP O
) ) ) O
and CC CC O
Mitotic NNP NNP O
Index NNP NNP O
were VBD VBD O
recorded VBN VBN O
. . . O

Mesna NNP NNP B-CHEM
' POS POS O
s VBZ VBZ O
action NN NN O
, , , O
in IN IN O
conjunction NN NN O
with IN IN O
IFO NNP NNP B-CHEM
reduces VBZ VBZ O
the DT DT O
frequency NN NN O
of IN IN O
SCEs NNP NNP O
, , , O
in IN IN O
comparison NN NN O
with IN IN O
the DT DT O
SCEs NNP NNP O
recordings NNS NNS O
obtained VBN VBN O
when WRB WRB O
IFO NNP NNP B-CHEM
is VBZ VBZ O
administered VBN VBN O
alone RB RB O
. . . O

In IN IN O
addition NN NN O
to TO TO O
this DT DT O
, , , O
when WRB WRB O
high JJ JJ O
concentrations NNS NNS O
of IN IN O
Mesna NNP NNP B-CHEM
were VBD VBD O
administered VBN VBN O
alone RB RB O
significant JJ JJ O
reductions NNS NNS O
of IN IN O
the DT DT O
PRI NNP NNP O
were VBD VBD O
noted VBN VBN O
, , , O
than IN IN O
with IN IN O
IFO NNP NNP B-CHEM
acting VBG VBG O
at IN IN O
the DT DT O
same JJ JJ O
concentration NN NN O
on IN IN O
the DT DT O
lymphocytes NNS NNS O
. . . O

Mesna NNP NNP B-CHEM
significantly RB RB O
reduces VBZ VBZ O
IFO NNP NNP B-CHEM
' POS POS O
s VBZ VBZ O
genotoxicity NN NN O
, , , O
while IN IN O
when WRB WRB O
administered VBN VBN O
in IN IN O
high JJ JJ O
concentrations NNS NNS O
it PRP PRP O
acts VBZ VBZ O
in IN IN O
an DT DT O
inhibitory NN NN O
fashion NN NN O
on IN IN O
the DT DT O
cytostatic JJ JJ O
action NN NN O
of IN IN O
the DT DT O
drug NN NN O
. . . O

Risk NN NN O
factors NNS NNS O
and CC CC O
predictors NNS NNS O
of IN IN O
levodopa NN NN B-CHEM
- - - O
induced JJ JJ O
dyskinesia NN NN O
among IN IN O
multiethnic JJ JJ O
Malaysians NNP NNP O
with IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
. . . O

Chronic NNP NNP O
pulsatile NN NN O
levodopa NN NN B-CHEM
therapy NN NN O
for IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
( ( ( O
PD NNP NNP O
) ) ) O
leads VBZ VBZ O
to TO TO O
the DT DT O
development NN NN O
of IN IN O
motor NN NN O
fluctuations NNS NNS O
and CC CC O
dyskinesia NN NN O
. . . O

We PRP PRP O
studied VBD VBD O
the DT DT O
prevalence NN NN O
and CC CC O
predictors NNS NNS O
of IN IN O
levodopa NN NN B-CHEM
- - - O
induced JJ JJ O
dyskinesia NN NN O
among IN IN O
multiethnic JJ JJ O
Malaysian NNP NNP O
patients NNS NNS O
with IN IN O
PD NNP NNP O
. . . O

METHODS NNP NNP O
: : : O
This DT DT O
is VBZ VBZ O
a DT DT O
cross JJ JJ O
- - - O
sectional JJ JJ O
study NN NN O
involving VBG VBG O
95 CD CD O
patients NNS NNS O
with IN IN O
PD NNP NNP O
on IN IN O
uninterrupted JJ JJ O
levodopa NN NN B-CHEM
therapy NN NN O
for IN IN O
at IN IN O
least JJS JJS O
6 CD CD O
months NNS NNS O
. . . O

The DT DT O
instrument NN NN O
used VBN VBN O
was VBD VBD O
the DT DT O
UPDRS NNP NNP O
questionnaires NNS NNS O
. . . O

The DT DT O
predictors NNS NNS O
of IN IN O
dyskinesia NN NN O
were VBD VBD O
determined VBN VBN O
using VBG VBG O
multivariate NN NN O
logistic JJ JJ O
regression NN NN O
analysis NN NN O
. . . O

RESULTS NNS NNS O
: : : O
The DT DT O
mean JJ JJ O
age NN NN O
was VBD VBD O
65 CD CD O
. . . O
6 CD CD O
+ NN NN O
8 CD CD O
. . . O
5 CD CD O
years NNS NNS O
. . . O

The DT DT O
mean JJ JJ O
onset NN NN O
age NN NN O
was VBD VBD O
58 CD CD O
. . . O
5 CD CD O
+ NN NN O
9 CD CD O
. . . O
8 CD CD O
years NNS NNS O
. . . O

The DT DT O
median NN NN O
disease NN NN O
duration NN NN O
was VBD VBD O
6 CD CD O
( ( ( O
7 CD CD O
) ) ) O
years NNS NNS O
. . . O

Dyskinesia NNP NNP O
was VBD VBD O
present JJ JJ O
in IN IN O
44 CD CD O
% NN NN O
( ( ( O
n NN NN O
= SYM SYM O
42 CD CD O
) ) ) O
with IN IN O
median NN NN O
levodopa NN NN B-CHEM
therapy NN NN O
of IN IN O
3 CD CD O
years NNS NNS O
. . . O

There EX EX O
were VBD VBD O
64 CD CD O
. . . O
3 CD CD O
% NN NN O
Chinese JJ JJ O
, , , O
31 CD CD O
% NN NN O
Malays NNP NNP O
, , , O
and CC CC O
3 CD CD O
. . . O
7 CD CD O
% NN NN O
Indians NNPS NNPS O
and CC CC O
other JJ JJ O
ethnic JJ JJ O
groups NNS NNS O
. . . O

Eighty NNP NNP O
- : : O
one CD CD O
percent NN NN O
of IN IN O
patients NNS NNS O
with IN IN O
dyskinesia NN NN O
had VBD VBD O
clinical JJ JJ O
fluctuations NNS NNS O
. . . O

Patients NNS NNS O
with IN IN O
dyskinesia NN NN O
had VBD VBD O
lower JJR JJR O
onset NN NN O
age NN NN O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
, , , O
longer JJR JJR O
duration NN NN O
of IN IN O
levodopa NN NN B-CHEM
therapy NN NN O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
, , , O
longer RBR RBR O
disease NN NN O
duration NN NN O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
, , , O
higher JJR JJR O
total JJ JJ O
daily JJ JJ O
levodopa NN NN B-CHEM
dose NN NN O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
, , , O
and CC CC O
higher JJR JJR O
total JJ JJ O
UPDRS NNP NNP O
scores NNS NNS O
( ( ( O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
005 CD CD O
) ) ) O
than IN IN O
patients NNS NNS O
without IN IN O
dyskinesia NN NN O
. . . O

The DT DT O
three CD CD O
significant JJ JJ O
predictors NNS NNS O
of IN IN O
dyskinesia NN NN O
were VBD VBD O
duration NN NN O
of IN IN O
levodopa NN NN B-CHEM
therapy NN NN O
, , , O
onset JJ JJ O
age NN NN O
, , , O
and CC CC O
total JJ JJ O
daily JJ JJ O
levodopa NN NN B-CHEM
dose NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
The DT DT O
prevalence NN NN O
of IN IN O
levodopa NN NN B-CHEM
- - - O
induced JJ JJ O
dyskinesia NN NN O
in IN IN O
our PRP$ PRP$ O
patients NNS NNS O
was VBD VBD O
44 CD CD O
% NN NN O
. . . O

The DT DT O
most RBS RBS O
significant JJ JJ O
predictors NNS NNS O
were VBD VBD O
duration NN NN O
of IN IN O
levodopa NN NN B-CHEM
therapy NN NN O
, , , O
total JJ JJ O
daily JJ JJ O
levodopa NN NN B-CHEM
dose NN NN O
, , , O
and CC CC O
onset JJ JJ O
age NN NN O
. . . O

Dose NNP NNP O
- : : O
dependent JJ JJ O
neurotoxicity NN NN O
of IN IN O
high JJ JJ O
- - - O
dose NN NN O
busulfan NN NN B-CHEM
in IN IN O
children NNS NNS O
: : : O
a DT DT O
clinical JJ JJ O
and CC CC O
pharmacological JJ JJ O
study NN NN O
. . . O

Busulfan NNP NNP B-CHEM
is VBZ VBZ O
known VBN VBN O
to TO TO O
be VB VB O
neurotoxic JJ JJ O
in IN IN O
animals NNS NNS O
and CC CC O
humans NNS NNS O
, , , O
but CC CC O
its PRP$ PRP$ O
acute JJ JJ O
neurotoxicity NN NN O
remains VBZ VBZ O
poorly RB RB O
characterized VBN VBN O
in IN IN O
children NNS NNS O
. . . O

We PRP PRP O
report VBP VBP O
here RB RB O
a DT DT O
retrospective NN NN O
study NN NN O
of IN IN O
123 CD CD O
children NNS NNS O
( ( ( O
median JJ JJ O
age NN NN O
, , , O
6 CD CD O
. . . O
5 CD CD O
years NNS NNS O
) ) ) O
receiving VBG VBG O
high JJ JJ O
- - - O
dose NN NN O
busulfan NN NN B-CHEM
in IN IN O
combined VBN VBN O
chemotherapy NN NN O
before IN IN O
bone NN NN O
marrow NN NN O
transplantation NN NN O
for IN IN O
malignant JJ JJ O
solid JJ JJ O
tumors NNS NNS O
, , , O
brain NN NN O
tumors NNS NNS O
excluded VBD VBD O
. . . O

Busulfan NNP NNP B-CHEM
was VBD VBD O
given VBN VBN O
p NN NN O
. . . O
o NN NN O
. . . O
, , , O
every DT DT O
6 CD CD O
hours NNS NNS O
for IN IN O
16 CD CD O
doses NNS NNS O
over IN IN O
4 CD CD O
days NNS NNS O
. . . O

Two CD CD O
total JJ JJ O
doses NNS NNS O
were VBD VBD O
consecutively RB RB O
used VBN VBN O
: : : O
16 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
then RB RB O
600 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
. . . O

The DT DT O
dose NN NN O
calculation NN NN O
on IN IN O
the DT DT O
basis NN NN O
of IN IN O
body NN NN O
surface NN NN O
area NN NN O
results NNS NNS O
in IN IN O
higher JJR JJR O
doses NNS NNS O
in IN IN O
young JJ JJ O
children NNS NNS O
than IN IN O
in IN IN O
older JJR JJR O
patients NNS NNS O
( ( ( O
16 CD CD O
to TO TO O
28 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
. . . O

Ninety CD CD O
- - - O
six CD CD O
patients NNS NNS O
were VBD VBD O
not RB RB O
given VBN VBN O
anticonvulsive JJ JJ O
prophylaxis NN NN O
; : : O
7 CD CD O
( ( ( O
7 CD CD O
. . . O
5 CD CD O
% NN NN O
) ) ) O
developed JJ JJ O
seizures NNS NNS O
during IN IN O
the DT DT O
4 CD CD O
days NNS NNS O
of IN IN O
the DT DT O
busulfan NN NN B-CHEM
course NN NN O
or CC CC O
within IN IN O
24 CD CD O
h NN NN O
after IN IN O
the DT DT O
last JJ JJ O
dosing NN NN O
. . . O

When WRB WRB O
the DT DT O
total JJ JJ O
busulfan NN NN B-CHEM
dose NN NN O
was VBD VBD O
taken VBN VBN O
into IN IN O
account NN NN O
, , , O
there EX EX O
was VBD VBD O
a DT DT O
significant JJ JJ O
difference NN NN O
in IN IN O
terms NNS NNS O
of IN IN O
neurotoxicity NN NN O
incidence NN NN O
among IN IN O
patients NNS NNS O
under IN IN O
16 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
( ( ( O
1 CD CD O
of IN IN O
57 CD CD O
, , , O
1 CD CD O
. . . O
7 CD CD O
% NN NN O
) ) ) O
and CC CC O
patients NNS NNS O
under IN IN O
600 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
( ( ( O
6 CD CD O
of IN IN O
39 CD CD O
, , , O
15 CD CD O
. . . O
4 CD CD O
% NN NN O
) ) ) O
( ( ( O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
02 CD CD O
) ) ) O
. . . O

Twenty CD CD O
- - - O
seven CD CD O
patients NNS NNS O
were VBD VBD O
given VBN VBN O
a DT DT O
600 CD CD O
- : : O
mg NN NN O
/ NN NN O
m2 NN NN O
busulfan NN NN B-CHEM
total JJ JJ O
dose NN NN O
with IN IN O
continuous JJ JJ O
i NNP NNP O
. . . O
v NN NN O
. . . O
infusion NN NN O
of IN IN O
clonazepam NN NN B-CHEM
; : : O
none NN NN O
had VBD VBD O
any DT DT O
neurological JJ JJ O
symptoms NNS NNS O
. . . O

Busulfan NNP NNP B-CHEM
levels NNS NNS O
were VBD VBD O
measured VBN VBN O
by IN IN O
a DT DT O
gas NN NN O
chromatographic JJ JJ O
- : : O
mass NN NN O
spectrometry NN NN O
assay NN NN O
in IN IN O
the DT DT O
plasma NN NN O
and CC CC O
cerebrospinal JJ JJ O
fluid NN NN O
of IN IN O
9 CD CD O
children NNS NNS O
without IN IN O
central JJ JJ O
nervous JJ JJ O
system NN NN O
disease NN NN O
under IN IN O
600 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
busulfan NN NN B-CHEM
with IN IN O
clonazepam NN NN B-CHEM
: : : O
busulfan NN NN B-CHEM
cerebrospinal JJ JJ O
fluid NN NN O
: : : O
plasma NN NN O
ratio NN NN O
was VBD VBD O
1 CD CD O
. . . O
39 CD CD O
. . . O

This DT DT O
was VBD VBD O
significantly RB RB O
different JJ JJ O
( ( ( O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
02 CD CD O
) ) ) O
from IN IN O
the DT DT O
cerebrospinal JJ JJ O
fluid NN NN O
: : : O
plasma NN NN O
ratio NN NN O
previously RB RB O
defined VBD VBD O
in IN IN O
children NNS NNS O
receiving VBG VBG O
a DT DT O
16 CD CD O
- : : O
mg NN NN O
/ NN NN O
kg NN NN O
total JJ JJ O
dose NN NN O
of IN IN O
busulfan NN NN B-CHEM
. . . O

This DT DT O
study NN NN O
shows VBZ VBZ O
that IN IN O
busulfan NN NN B-CHEM
neurotoxicity NN NN O
is VBZ VBZ O
dose JJ JJ O
- : : O
dependent NN NN O
in IN IN O
children NNS NNS O
and CC CC O
efficiently RB RB O
prevented VBN VBN O
by IN IN O
clonazepam NN NN B-CHEM
. . . O

A DT DT O
busulfan NN NN B-CHEM
dose NN NN O
calculated VBN VBN O
on IN IN O
the DT DT O
basis NN NN O
of IN IN O
body NN NN O
surface NN NN O
area NN NN O
, , , O
resulting VBG VBG O
in IN IN O
higher JJR JJR O
doses NNS NNS O
in IN IN O
young JJ JJ O
children NNS NNS O
, , , O
was VBD VBD O
followed VBN VBN O
by IN IN O
increased VBN VBN O
neurotoxicity NN NN O
, , , O
close VB VB O
to TO TO O
neurotoxicity NN NN O
incidence NN NN O
observed VBD VBD O
in IN IN O
adults NNS NNS O
. . . O

Since IN IN O
plasma NN NN O
pharmacokinetic JJ JJ O
studies NNS NNS O
showed VBD VBD O
a DT DT O
faster RBR RBR O
busulfan NN NN B-CHEM
clearance NN NN O
in IN IN O
children NNS NNS O
than IN IN O
in IN IN O
adults NNS NNS O
, , , O
this DT DT O
new JJ JJ O
dose NN NN O
may MD MD O
approximate VB VB O
more RBR RBR O
closely RB RB O
the DT DT O
adult NN NN O
systemic JJ JJ O
exposure NN NN O
obtained VBD VBD O
after IN IN O
the DT DT O
usual JJ JJ O
16 CD CD O
- : : O
mg NN NN O
/ NN NN O
kg NN NN O
total JJ JJ O
dose NN NN O
, , , O
with IN IN O
potential JJ JJ O
inferences NNS NNS O
in IN IN O
terms NNS NNS O
of IN IN O
anticancer NN NN O
or CC CC O
myeloablative JJ JJ O
effects NNS NNS O
. . . O

The DT DT O
busulfan NN NN B-CHEM
dose NN NN O
in IN IN O
children NNS NNS O
and CC CC O
infants NNS NNS O
undergoing VBG VBG O
bone NN NN O
marrow NN NN O
transplantation NN NN O
should MD MD O
be VB VB O
reconsidered VBN VBN O
on IN IN O
the DT DT O
basis NN NN O
of IN IN O
pharmacokinetic JJ JJ O
studies NNS NNS O
. . . O

An DT DT O
unexpected JJ JJ O
diagnosis NN NN O
in IN IN O
a DT DT O
renal JJ JJ O
- - - O
transplant NN NN O
patient NN NN O
with IN IN O
proteinuria NN NN O
treated VBN VBN O
with IN IN O
everolimus NN NN B-CHEM
: : : O
AL NNP NNP O
amyloidosis NN NN O
. . . O

Proteinuria NNP NNP O
is VBZ VBZ O
an DT DT O
expected VBN VBN O
complication NN NN O
in IN IN O
transplant NN NN O
patients NNS NNS O
treated VBN VBN O
with IN IN O
mammalian JJ JJ O
target NN NN O
of IN IN O
rapamycin NN NN B-CHEM
inhibitors NNS NNS O
( ( ( O
mTOR NN NN O
- : : O
i NNP NNP O
) ) ) O
. . . O

However RB RB O
, , , O
clinical JJ JJ O
suspicion NN NN O
should MD MD O
always RB RB O
be VB VB O
supported VBN VBN O
by IN IN O
histological JJ JJ O
evidence NN NN O
in IN IN O
order NN NN O
to TO TO O
investigate VB VB O
potential JJ JJ O
alternate JJ JJ O
diagnoses NNS NNS O
such JJ JJ O
as IN IN O
acute JJ JJ O
or CC CC O
chronic JJ JJ O
rejection NN NN O
, , , O
interstitial JJ JJ O
fibrosis NNS NNS O
and CC CC O
tubular JJ JJ O
atrophy NN NN O
, , , O
or CC CC O
recurrent NN NN O
or CC CC O
de IN IN O
novo NN NN O
glomerulopathy NN NN O
. . . O

In IN IN O
this DT DT O
case NN NN O
we PRP PRP O
report VBP VBP O
the DT DT O
unexpected JJ JJ O
diagnosis NN NN O
of IN IN O
amyloidosis NN NN O
in IN IN O
a DT DT O
renal JJ JJ O
- - - O
transplant NN NN O
patient NN NN O
with IN IN O
pre NN NN O
- - - O
transplant NN NN O
monoclonal JJ JJ O
gammapathy NN NN O
of IN IN O
undetermined JJ JJ O
significance NN NN O
who WP WP O
developed VBD VBD O
proteinuria NN NN O
after IN IN O
conversion NN NN O
from IN IN O
tacrolimus NN NN B-CHEM
to TO TO O
everolimus VB VB B-CHEM
. . . O

Long JJ JJ O
- - - O
term NN NN O
oral JJ JJ O
galactose NN NN B-CHEM
treatment NN NN O
prevents NNS NNS O
cognitive VBP VBP O
deficits NNS NNS O
in IN IN O
male JJ JJ O
Wistar NNP NNP O
rats NNS NNS O
treated VBN VBN O
intracerebroventricularly RB RB O
with IN IN O
streptozotocin NN NN B-CHEM
. . . O

Basic NNP NNP O
and CC CC O
clinical JJ JJ O
research NN NN O
has VBZ VBZ O
demonstrated VBN VBN O
that IN IN O
dementia NN NN O
of IN IN O
sporadic JJ JJ O
Alzheimer NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
( ( ( O
sAD JJ JJ O
) ) ) O
type NN NN O
is VBZ VBZ O
associated VBN VBN O
with IN IN O
dysfunction NN NN O
of IN IN O
the DT DT O
insulin NN NN O
- - - O
receptor NN NN O
( ( ( O
IR NNP NNP O
) ) ) O
system NN NN O
followed VBN VBN O
by IN IN O
decreased VBD VBD O
glucose NN NN B-CHEM
transport NN NN O
via IN IN O
glucose NN NN B-CHEM
transporter NN NN O
GLUT4 NNP NNP O
and CC CC O
decreased VBD VBD O
glucose NN NN B-CHEM
metabolism NN NN O
in IN IN O
brain NN NN O
cells NNS NNS O
. . . O

An DT DT O
alternative JJ JJ O
source NN NN O
of IN IN O
energy NN NN O
is VBZ VBZ O
d SYM SYM B-CHEM
- : : I-CHEM
galactose NN NN I-CHEM
( ( ( O
the DT DT O
C NNP NNP O
- - - O
4 CD CD O
- : : O
epimer NN NN O
of IN IN O
d SYM SYM B-CHEM
- : : I-CHEM
glucose NN NN I-CHEM
) ) ) O
which WDT WDT O
is VBZ VBZ O
transported VBN VBN O
into IN IN O
the DT DT O
brain NN NN O
by IN IN O
insulin NN NN O
- - - O
independent JJ JJ O
GLUT3 NNP NNP O
transporter NN NN O
where WRB WRB O
it PRP PRP O
might MD MD O
be VB VB O
metabolized VBN VBN O
to TO TO O
glucose VB VB B-CHEM
via IN IN O
the DT DT O
Leloir NNP NNP O
pathway NN NN O
. . . O

Exclusively NNP NNP O
parenteral JJ JJ O
daily JJ JJ O
injections NNS NNS O
of IN IN O
galactose NN NN B-CHEM
induce NN NN O
memory NN NN O
deterioration NN NN O
in IN IN O
rodents NNS NNS O
and CC CC O
are VBP VBP O
used VBN VBN O
to TO TO O
generate VB VB O
animal NN NN O
aging VBG VBG O
model NN NN O
, , , O
but CC CC O
the DT DT O
effects NNS NNS O
of IN IN O
oral JJ JJ O
galactose NN NN B-CHEM
treatment NN NN O
on IN IN O
cognitive JJ JJ O
functions NNS NNS O
have VBP VBP O
never RB RB O
been VBN VBN O
tested VBN VBN O
. . . O

We PRP PRP O
have VBP VBP O
investigated VBN VBN O
the DT DT O
effects NNS NNS O
of IN IN O
continuous JJ JJ O
daily JJ JJ O
oral JJ JJ O
galactose NN NN B-CHEM
( ( ( O
200 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
) ) ) O
treatment NN NN O
on IN IN O
cognitive JJ JJ O
deficits NNS NNS O
in IN IN O
streptozotocin NN NN B-CHEM
- - - O
induced JJ JJ O
( ( ( O
STZ NNP NNP B-CHEM
- - - O
icv NN NN O
) ) ) O
rat NN NN O
model NN NN O
of IN IN O
sAD JJ JJ O
, , , O
tested VBN VBN O
by IN IN O
Morris NNP NNP O
Water NNP NNP O
Maze NNP NNP O
and CC CC O
Passive NNP NNP O
Avoidance NNP NNP O
test NN NN O
, , , O
respectively RB RB O
. . . O

One CD CD O
month NN NN O
of IN IN O
oral JJ JJ O
galactose NN NN B-CHEM
treatment NN NN O
initiated VBD VBD O
immediately RB RB O
after IN IN O
the DT DT O
STZ NNP NNP B-CHEM
- - - O
icv NN NN O
administration NN NN O
, , , O
successfully RB RB O
prevented VBN VBN O
development NN NN O
of IN IN O
the DT DT O
STZ NNP NNP B-CHEM
- - - O
icv NN NN O
- - - O
induced JJ JJ O
cognitive JJ JJ O
deficits NNS NNS O
. . . O

Beneficial NNP NNP O
effect NN NN O
of IN IN O
oral JJ JJ O
galactose NN NN B-CHEM
was VBD VBD O
independent JJ JJ O
of IN IN O
the DT DT O
rat NN NN O
age NN NN O
and CC CC O
of IN IN O
the DT DT O
galactose NN NN B-CHEM
dose NN NN O
ranging VBG VBG O
from IN IN O
100 CD CD O
to TO TO O
300 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
. . . O

Additionally RB RB O
, , , O
oral JJ JJ O
galactose NN NN B-CHEM
administration NN NN O
led VBN VBN O
to TO TO O
the DT DT O
appearance NN NN O
of IN IN O
galactose NN NN B-CHEM
in IN IN O
the DT DT O
blood NN NN O
. . . O

The DT DT O
increase NN NN O
of IN IN O
galactose NN NN B-CHEM
concentration NN NN O
in IN IN O
the DT DT O
cerebrospinal JJ JJ O
fluid NN NN O
was VBD VBD O
several JJ JJ O
times NNS NNS O
lower JJR JJR O
after IN IN O
oral JJ JJ O
than IN IN O
after IN IN O
parenteral JJ JJ O
administration NN NN O
of IN IN O
the DT DT O
same JJ JJ O
galactose NN NN B-CHEM
dose NN NN O
. . . O

Oral NNP NNP O
galactose NN NN B-CHEM
exposure NN NN O
might MD MD O
have VB VB O
beneficial JJ JJ O
effects NNS NNS O
on IN IN O
learning VBG VBG O
and CC CC O
memory NN NN O
ability NN NN O
and CC CC O
could MD MD O
be VB VB O
worth JJ JJ O
investigating VBG VBG O
for IN IN O
improvement NN NN O
of IN IN O
cognitive JJ JJ O
deficits NNS NNS O
associated VBN VBN O
with IN IN O
glucose NN NN O
hypometabolism NN NN O
in IN IN O
AD NNP NNP O
. . . O

An DT DT O
investigation NN NN O
of IN IN O
the DT DT O
pattern NN NN O
of IN IN O
kidney NN NN O
injury NN NN O
in IN IN O
HIV NNP NNP O
- - - O
positive JJ JJ O
persons NNS NNS O
exposed VBN VBN O
to TO TO O
tenofovir VB VB B-CHEM
disoproxil NN NN I-CHEM
fumarate NN NN I-CHEM
: : : O
an DT DT O
examination NN NN O
of IN IN O
a DT DT O
large JJ JJ O
population NN NN O
database NN NN O
( ( ( O
MHRA NNP NNP O
database NN NN O
) ) ) O
. . . O

The DT DT O
potential JJ JJ O
for IN IN O
tenofovir NN NN B-CHEM
to TO TO O
cause VB VB O
a DT DT O
range NN NN O
of IN IN O
kidney NN NN O
syndromes NNS NNS O
has VBZ VBZ O
been VBN VBN O
established VBN VBN O
from IN IN O
mechanistic JJ JJ O
and CC CC O
randomised VBN VBN O
clinical JJ JJ O
trials NNS NNS O
. . . O

However RB RB O
, , , O
the DT DT O
exact JJ JJ O
pattern NN NN O
of IN IN O
kidney NN NN O
involvement NN NN O
is VBZ VBZ O
still RB RB O
uncertain JJ JJ O
. . . O

We PRP PRP O
undertook VBP VBP O
a DT DT O
descriptive JJ JJ O
analysis NN NN O
of IN IN O
Yellow NNP NNP O
Card NNP NNP O
records NNS NNS O
of IN IN O
407 CD CD O
HIV NNP NNP O
- : : O
positive JJ JJ O
persons NNS NNS O
taking VBG VBG O
tenofovir NN NN B-CHEM
disoproxil NN NN I-CHEM
fumarate NN NN I-CHEM
( ( ( O
TDF NNP NNP B-CHEM
) ) ) O
as IN IN O
part NN NN O
of IN IN O
their PRP$ PRP$ O
antiretroviral JJ JJ O
therapy NN NN O
regimen NNS NNS O
and CC CC O
submitted VBN VBN O
to TO TO O
the DT DT O
Medicines NNP NNP O
and CC CC O
Healthcare NNP NNP O
Products NNPS NNPS O
Regulatory NNP NNP O
Agency NNP NNP O
( ( ( O
MHRA NNP NNP O
) ) ) O
with IN IN O
suspected VBD VBD O
kidney NN NN O
adverse NN NN O
effects NNS NNS O
. . . O

Reports NNS NNS O
that IN IN O
satisfy NN NN O
defined VBD VBD O
criteria NNS NNS O
were VBD VBD O
classified VBN VBN O
as IN IN O
acute JJ JJ O
kidney NN NN O
injury NN NN O
, , , O
kidney NN NN O
tubular NN NN O
dysfunction NN NN O
and CC CC O
Fanconi NNP NNP O
syndrome NN NN O
. . . O

Of IN IN O
the DT DT O
407 CD CD O
Yellow NNP NNP O
Card NNP NNP O
records NNS NNS O
analysed VBN VBN O
, , , O
106 CD CD O
satisfied VBN VBN O
criteria NNS NNS O
for IN IN O
TDF NNP NNP B-CHEM
- - - O
related VBN VBN O
kidney NN NN O
disease NN NN O
, , , O
of IN IN O
which WDT WDT O
53 CD CD O
( ( ( O
50 CD CD O
% NN NN O
) ) ) O
had VBD VBD O
features NNS NNS O
of IN IN O
kidney NN NN O
tubular NN NN O
dysfunction NN NN O
, , , O
35 CD CD O
( ( ( O
33 CD CD O
% NN NN O
) ) ) O
were VBD VBD O
found VBN VBN O
to TO TO O
have VB VB O
features NNS NNS O
of IN IN O
glomerular NN NN O
dysfunction NN NN O
and CC CC O
18 CD CD O
( ( ( O
17 CD CD O
% NN NN O
) ) ) O
had VBD VBD O
Fanconi NNP NNP O
syndrome NN NN O
. . . O

The DT DT O
median NN NN O
TDF NNP NNP B-CHEM
exposure NN NN O
was VBD VBD O
316 CD CD O
days NNS NNS O
( ( ( O
interquartile JJ JJ O
range NN NN O
120 CD CD O
- : : O
740 CD CD O
) ) ) O
. . . O

The DT DT O
incidence NN NN O
of IN IN O
hospitalisation NN NN O
for IN IN O
TDF NNP NNP B-CHEM
kidney NN NN O
adverse NN NN O
effects NNS NNS O
was VBD VBD O
high JJ JJ O
, , , O
particularly RB RB O
amongst IN IN O
patients NNS NNS O
with IN IN O
features NNS NNS O
of IN IN O
Fanconi NNP NNP O
syndrome NN NN O
. . . O

The DT DT O
pattern NN NN O
of IN IN O
kidney NN NN O
syndromes NNS NNS O
in IN IN O
this DT DT O
population NN NN O
series NN NN O
mirrors NNS NNS O
that WDT WDT O
reported VBD VBD O
in IN IN O
randomised VBN VBN O
clinical JJ JJ O
trials NNS NNS O
. . . O

Cessation NNP NNP O
of IN IN O
TDF NNP NNP B-CHEM
was VBD VBD O
associated VBN VBN O
with IN IN O
complete JJ JJ O
restoration NN NN O
of IN IN O
kidney NN NN O
function NN NN O
in IN IN O
up RB RB O
half NN NN O
of IN IN O
the DT DT O
patients NNS NNS O
in IN IN O
this DT DT O
report NN NN O
. . . O

Incidence NNP NNP O
of IN IN O
postoperative JJ JJ O
delirium NN NN O
is VBZ VBZ O
high JJ JJ O
even RB RB O
in IN IN O
a DT DT O
population NN NN O
without IN IN O
known VBN VBN O
risk NN NN O
factors NNS NNS O
. . . O

PURPOSE NNP NNP O
: : : O
Postoperative NNP NNP O
delirium NN NN O
is VBZ VBZ O
a DT DT O
recognized JJ JJ O
complication NN NN O
in IN IN O
populations NNS NNS O
at IN IN O
risk NN NN O
. . . O

The DT DT O
aim NN NN O
of IN IN O
this DT DT O
study NN NN O
is VBZ VBZ O
to TO TO O
assess VB VB O
the DT DT O
prevalence NN NN O
of IN IN O
early JJ JJ O
postoperative JJ JJ O
delirium NN NN O
in IN IN O
a DT DT O
population NN NN O
without IN IN O
known VBN VBN O
risk NN NN O
factors NNS NNS O
admitted VBD VBD O
to TO TO O
the DT DT O
ICU NNP NNP O
for IN IN O
postoperative JJ JJ O
monitoring NN NN O
after IN IN O
elective JJ JJ O
major JJ JJ O
surgery NN NN O
. . . O

The DT DT O
secondary JJ JJ O
outcome NN NN O
investigated VBN VBN O
is VBZ VBZ O
to TO TO O
identify VB VB O
eventual JJ JJ O
independent JJ JJ O
risk NN NN O
factors NNS NNS O
among IN IN O
demographic JJ JJ O
data NNS NNS O
and CC CC O
anesthetic JJ JJ O
drugs NNS NNS O
used VBN VBN O
. . . O

METHODS NNP NNP O
: : : O
An DT DT O
observational JJ JJ O
, , , O
prospective JJ JJ O
study NN NN O
was VBD VBD O
conducted VBN VBN O
on IN IN O
a DT DT O
consecutive JJ JJ O
cohort NN NN O
of IN IN O
patients NNS NNS O
admitted VBN VBN O
to TO TO O
our PRP$ PRP$ O
ICU NNP NNP O
within IN IN O
and CC CC O
for IN IN O
at IN IN O
least JJS JJS O
24 CD CD O
h NN NN O
after IN IN O
major JJ JJ O
surgical JJ JJ O
procedures NNS NNS O
. . . O

Exclusion NNP NNP O
criteria NNS NNS O
were VBD VBD O
any DT DT O
preexisting VBG VBG O
predisposing VBG VBG O
factor NN NN O
for IN IN O
delirium NN NN O
or CC CC O
other JJ JJ O
potentially RB RB O
confounding VBG VBG O
neurological JJ JJ O
dysfunctions NNS NNS O
. . . O

Patients NNS NNS O
were VBD VBD O
assessed VBN VBN O
daily JJ JJ O
using VBG VBG O
the DT DT O
confusion NN NN O
assessment NN NN O
method NN NN O
for IN IN O
the DT DT O
ICU NNP NNP O
scale NN NN O
for IN IN O
3 CD CD O
days NNS NNS O
after IN IN O
the DT DT O
surgical JJ JJ O
procedure NN NN O
. . . O

Early RB RB O
postoperative JJ JJ O
delirium NN NN O
incidence NN NN O
risk NN NN O
factors NNS NNS O
were VBD VBD O
then RB RB O
assessed VBN VBN O
through IN IN O
three CD CD O
different JJ JJ O
multiple JJ JJ O
regression NN NN O
models NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
According VBG VBG O
to TO TO O
the DT DT O
confusion NN NN O
assessment NN NN O
method NN NN O
for IN IN O
the DT DT O
ICU NNP NNP O
scale NN NN O
, , , O
28 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
were VBD VBD O
diagnosed VBN VBN O
with IN IN O
early JJ JJ O
postoperative JJ JJ O
delirium NN NN O
. . . O

The DT DT O
use NN NN O
of IN IN O
thiopentone NN NN B-CHEM
was VBD VBD O
significantly RB RB O
associated VBN VBN O
with IN IN O
an DT DT O
eight CD CD O
- - - O
fold JJ JJ O
- - - O
higher JJR JJR O
risk NN NN O
for IN IN O
delirium NN NN O
compared VBN VBN O
to TO TO O
propofol NN NN B-CHEM
( ( ( O
57 CD CD O
. . . O
1 CD CD O
% NN NN O
vs NNS NNS O
. . . O
7 CD CD O
. . . O
1 CD CD O
% NN NN O
, , , O
RR NNP NNP O
= SYM SYM O
8 CD CD O
. . . O
0 CD CD O
, , , O
X2 NNP NNP O
= SYM SYM O
4 CD CD O
. . . O
256 CD CD O
; : : O
df NN NN O
= SYM SYM O
1 CD CD O
; : : O
0 CD CD O
. . . O
05 CD CD O
< NN NN O
p NN NN O
< NN NN O
0 CD CD O
. . . O
02 CD CD O
) ) ) O
. . . O

CONCLUSION NNP NNP O
: : : O
In IN IN O
this DT DT O
study NN NN O
early JJ JJ O
postoperative JJ JJ O
delirium NN NN O
was VBD VBD O
found VBN VBN O
to TO TO O
be VB VB O
a DT DT O
very RB RB O
common JJ JJ O
complication NN NN O
after IN IN O
major JJ JJ O
surgery NN NN O
, , , O
even RB RB O
in IN IN O
a DT DT O
population NN NN O
without IN IN O
known VBN VBN O
risk NN NN O
factors NNS NNS O
. . . O

Thiopentone NNP NNP B-CHEM
was VBD VBD O
independently RB RB O
associated VBN VBN O
with IN IN O
an DT DT O
increase NN NN O
in IN IN O
its PRP$ PRP$ O
relative JJ JJ O
risk NN NN O
. . . O

A DT DT O
single JJ JJ O
neurotoxic JJ JJ O
dose NN NN O
of IN IN O
methamphetamine NN NN B-CHEM
induces NNS NNS O
a DT DT O
long JJ JJ O
- - - O
lasting VBG VBG O
depressive JJ JJ O
- - - O
like IN IN O
behaviour NN NN O
in IN IN O
mice NN NN O
. . . O

Methamphetamine NNP NNP B-CHEM
( ( ( O
METH NNP NNP B-CHEM
) ) ) O
triggers NNS NNS O
a DT DT O
disruption NN NN O
of IN IN O
the DT DT O
monoaminergic JJ JJ O
system NN NN O
and CC CC O
METH NNP NNP B-CHEM
abuse NN NN O
leads VBZ VBZ O
to TO TO O
negative VB VB O
emotional JJ JJ O
states NNS NNS O
including VBG VBG O
depressive JJ JJ O
symptoms NNS NNS O
during IN IN O
drug NN NN O
withdrawal NN NN O
. . . O

However RB RB O
, , , O
it PRP PRP O
is VBZ VBZ O
currently RB RB O
unknown JJ JJ O
if IN IN O
the DT DT O
acute JJ JJ O
toxic JJ JJ O
dosage NN NN O
of IN IN O
METH NNP NNP B-CHEM
also RB RB O
causes VBZ VBZ O
a DT DT O
long JJ JJ O
- - - O
lasting VBG VBG O
depressive JJ JJ O
phenotype NN NN O
and CC CC O
persistent JJ JJ O
monoaminergic JJ JJ O
deficits NNS NNS O
. . . O

Thus RB RB O
, , , O
we PRP PRP O
now RB RB O
assessed VBD VBD O
the DT DT O
depressive JJ JJ O
- - - O
like IN IN O
behaviour NN NN O
in IN IN O
mice NN NN O
at IN IN O
early JJ JJ O
and CC CC O
long JJ JJ O
- - - O
term NN NN O
periods NNS NNS O
following VBG VBG O
a DT DT O
single JJ JJ O
high JJ JJ O
METH NNP NNP B-CHEM
dose NN NN O
( ( ( O
30 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
. . . O

METH NNP NNP B-CHEM
did VBD VBD O
not RB RB O
alter VB VB O
the DT DT O
motor NN NN O
function NN NN O
and CC CC O
procedural JJ JJ O
memory NN NN O
of IN IN O
mice NNS NNS O
as IN IN O
assessed VBN VBN O
by IN IN O
swimming NN NN O
speed NN NN O
and CC CC O
escape NN NN O
latency NN NN O
to TO TO O
find VB VB O
the DT DT O
platform NN NN O
in IN IN O
a DT DT O
cued JJ JJ O
version NN NN O
of IN IN O
the DT DT O
water NN NN O
maze NN NN O
task NN NN O
. . . O

However RB RB O
, , , O
METH NNP NNP B-CHEM
significantly RB RB O
increased VBD VBD O
the DT DT O
immobility NN NN O
time NN NN O
in IN IN O
the DT DT O
tail NN NN O
suspension NN NN O
test NN NN O
at IN IN O
3 CD CD O
and CC CC O
49 CD CD O
days NNS NNS O
post JJ JJ O
- - - O
administration NN NN O
. . . O

This DT DT O
depressive JJ JJ O
- - - O
like IN IN O
profile NN NN O
induced VBN VBN O
by IN IN O
METH NNP NNP B-CHEM
was VBD VBD O
accompanied VBN VBN O
by IN IN O
a DT DT O
marked JJ JJ O
depletion NN NN O
of IN IN O
frontostriatal JJ JJ O
dopaminergic NN NN O
and CC CC O
serotonergic JJ JJ O
neurotransmission NN NN O
, , , O
indicated VBN VBN O
by IN IN O
a DT DT O
reduction NN NN O
in IN IN O
the DT DT O
levels NNS NNS O
of IN IN O
dopamine NN NN B-CHEM
, , , O
DOPAC NNP NNP B-CHEM
and CC CC O
HVA NNP NNP B-CHEM
, , , O
tyrosine NN NN B-CHEM
hydroxylase NN NN O
and CC CC O
serotonin NN NN B-CHEM
, , , O
observed VBD VBD O
at IN IN O
both DT DT O
3 CD CD O
and CC CC O
49 CD CD O
days NNS NNS O
post JJ JJ O
- - - O
administration NN NN O
. . . O

In IN IN O
parallel NN NN O
, , , O
another DT DT O
neurochemical JJ JJ O
feature NN NN O
of IN IN O
depression NN NN O
- - - O
- - - O
astroglial JJ JJ O
dysfunction NN NN O
- - - O
- - - O
was VBD VBD O
unaffected JJ JJ O
in IN IN O
the DT DT O
cortex NN NN O
and CC CC O
the DT DT O
striatal JJ JJ O
levels NNS NNS O
of IN IN O
the DT DT O
astrocytic JJ JJ O
protein NN NN O
marker NN NN O
, , , O
glial JJ JJ O
fibrillary JJ JJ O
acidic JJ JJ O
protein NN NN O
, , , O
were VBD VBD O
only RB RB O
transiently RB RB O
increased VBN VBN O
at IN IN O
3 CD CD O
days NNS NNS O
. . . O

These DT DT O
findings NNS NNS O
demonstrate VBP VBP O
for IN IN O
the DT DT O
first JJ JJ O
time NN NN O
that IN IN O
a DT DT O
single JJ JJ O
high JJ JJ O
dose NN NN O
of IN IN O
METH NNP NNP B-CHEM
induces NNS NNS O
long JJ JJ O
- : : O
lasting VBG VBG O
depressive JJ JJ O
- - - O
like IN IN O
behaviour NN NN O
in IN IN O
mice NN NN O
associated VBN VBN O
with IN IN O
a DT DT O
persistent JJ JJ O
disruption NN NN O
of IN IN O
frontostriatal JJ JJ O
dopaminergic NN NN O
and CC CC O
serotonergic JJ JJ O
homoeostasis NN NN O
. . . O

Linezolid NNP NNP B-CHEM
- : : O
induced JJ JJ O
optic JJ JJ O
neuropathy NN NN O
. . . O

Many JJ JJ O
systemic JJ JJ O
antimicrobials NNS NNS O
have VBP VBP O
been VBN VBN O
implicated VBN VBN O
to TO TO O
cause VB VB O
ocular JJ JJ O
adverse JJ JJ O
effects NNS NNS O
. . . O

This DT DT O
is VBZ VBZ O
especially RB RB O
relevant JJ JJ O
in IN IN O
multidrug NN NN O
therapy NN NN O
where WRB WRB O
more JJR JJR O
than IN IN O
one CD CD O
drug NN NN O
can MD MD O
cause VB VB O
a DT DT O
similar JJ JJ O
ocular JJ JJ O
adverse JJ JJ O
effect NN NN O
. . . O

We PRP PRP O
describe VBP VBP O
a DT DT O
case NN NN O
of IN IN O
progressive JJ JJ O
loss NN NN O
of IN IN O
vision NN NN O
associated VBN VBN O
with IN IN O
linezolid JJ JJ B-CHEM
therapy NN NN O
. . . O

A DT DT O
45 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
male JJ JJ O
patient NN NN O
who WP WP O
was VBD VBD O
on IN IN O
treatment NN NN O
with IN IN O
multiple JJ JJ O
second JJ JJ O
- - - O
line NN NN O
anti NN NN O
- : : O
tuberculous JJ JJ O
drugs NNS NNS O
including VBG VBG O
linezolid JJ JJ B-CHEM
and CC CC O
ethambutol NN NN B-CHEM
for IN IN O
extensively RB RB O
drug NN NN O
- : : O
resistant JJ JJ O
tuberculosis NN NN O
( ( ( O
XDR NNP NNP O
- - - O
TB NNP NNP O
) ) ) O
presented VBN VBN O
to TO TO O
us PRP PRP O
with IN IN O
painless NN NN O
progressive JJ JJ O
loss NN NN O
of IN IN O
vision NN NN O
in IN IN O
both DT DT O
eyes NNS NNS O
. . . O

Color NNP NNP O
vision NN NN O
was VBD VBD O
defective JJ JJ O
and CC CC O
fundus JJ JJ O
examination NN NN O
revealed VBD VBD O
optic JJ JJ O
disc NN NN O
edema NN NN O
in IN IN O
both DT DT O
eyes NNS NNS O
. . . O

Ethambutol NNP NNP B-CHEM
- : : O
induced JJ JJ O
toxic JJ JJ O
optic JJ JJ O
neuropathy NN NN O
was VBD VBD O
suspected VBN VBN O
and CC CC O
tablet NN NN O
ethambutol NN NN B-CHEM
was VBD VBD O
withdrawn VBN VBN O
. . . O

Deterioration NNP NNP O
of IN IN O
vision NN NN O
occurred VBD VBD O
despite IN IN O
withdrawal NN NN O
of IN IN O
ethambutol NN NN B-CHEM
. . . O

Discontinuation NNP NNP O
of IN IN O
linezolid NN NN B-CHEM
resulted VBD VBD O
in IN IN O
marked JJ JJ O
improvement NN NN O
of IN IN O
vision NN NN O
. . . O

Our PRP$ PRP$ O
report NN NN O
emphasizes NNS NNS O
the DT DT O
need NN NN O
for IN IN O
monitoring VBG VBG O
of IN IN O
visual JJ JJ O
function NN NN O
in IN IN O
patients NNS NNS O
on IN IN O
long JJ JJ O
- - - O
term NN NN O
linezolid JJ JJ B-CHEM
treatment NN NN O
. . . O

Resuscitation NNP NNP O
with IN IN O
lipid NN NN O
, , , O
epinephrine NN NN B-CHEM
, , , O
or CC CC O
both DT DT O
in IN IN O
levobupivacaine NN NN B-CHEM
- - - O
induced JJ JJ O
cardiac NN NN O
toxicity NN NN O
in IN IN O
newborn JJ JJ O
piglets NNS NNS O
. . . O

BACKGROUND NNP NNP O
: : : O
The DT DT O
optimal NN NN O
dosing VBG VBG O
regimens NNS NNS O
of IN IN O
lipid JJ JJ O
emulsion NN NN O
, , , O
epinephrine NN NN B-CHEM
, , , O
or CC CC O
both DT DT O
are VBP VBP O
not RB RB O
yet RB RB O
determined VBN VBN O
in IN IN O
neonates NNS NNS O
in IN IN O
cases NNS NNS O
of IN IN O
local JJ JJ O
anaesthetic JJ JJ O
systemic JJ JJ O
toxicity NN NN O
( ( ( O
LAST NNP NNP O
) ) ) O
. . . O

METHODS NNP NNP O
: : : O
Newborn NNP NNP O
piglets NNS NNS O
received VBD VBD O
levobupivacaine NN NN B-CHEM
until IN IN O
cardiovascular JJ JJ O
collapse NN NN O
occurred VBD VBD O
. . . O

Standard NNP NNP O
cardiopulmonary JJ JJ O
resuscitation NN NN O
was VBD VBD O
started VBN VBN O
and CC CC O
electrocardiogram NN NN O
( ( ( O
ECG NNP NNP O
) ) ) O
was VBD VBD O
monitored VBN VBN O
for IN IN O
ventricular NN NN O
tachycardia NNS NNS O
, , , O
fibrillation NN NN O
, , , O
or CC CC O
QRS NNP NNP O
prolongation NN NN O
. . . O

Piglets NNP NNP O
were VBD VBD O
then RB RB O
randomly RB RB O
allocated VBN VBN O
to TO TO O
four CD CD O
groups NNS NNS O
: : : O
control NN NN O
( ( ( O
saline NN NN O
) ) ) O
, , , O
Intralipid NNP NNP O
( ( ( O
) ) ) O
alone RB RB O
, , , O
epinephrine NN NN B-CHEM
alone RB RB O
, , , O
or CC CC O
a DT DT O
combination NN NN O
of IN IN O
Intralipd NNP NNP O
plus CC CC O
epinephrine NN NN B-CHEM
. . . O

Resuscitation NNP NNP O
continued VBD VBD O
for IN IN O
30 CD CD O
min NN NN O
or CC CC O
until IN IN O
there EX EX O
was VBD VBD O
a DT DT O
return NN NN O
of IN IN O
spontaneous JJ JJ O
circulation NN NN O
( ( ( O
ROSC NNP NNP O
) ) ) O
accompanied VBN VBN O
by IN IN O
a DT DT O
mean NN NN O
arterial JJ JJ O
pressure NN NN O
at IN IN O
or CC CC O
superior NN NN O
to TO TO O
the DT DT O
baseline NN NN O
pressure NN NN O
and CC CC O
normal JJ JJ O
sinus NN NN O
rhythm NN NN O
for IN IN O
a DT DT O
period NN NN O
of IN IN O
30 CD CD O
min NN NN O
. . . O

RESULTS NNS NNS O
: : : O
ROSC NNP NNP O
was VBD VBD O
achieved VBN VBN O
in IN IN O
only RB RB O
one CD CD O
of IN IN O
the DT DT O
control NN NN O
piglets NNS NNS O
compared VBN VBN O
with IN IN O
most JJS JJS O
of IN IN O
the DT DT O
treated VBN VBN O
piglets NNS NNS O
. . . O

Mortality NNP NNP O
was VBD VBD O
not RB RB O
significantly RB RB O
different JJ JJ O
between IN IN O
the DT DT O
three CD CD O
treatment NN NN O
groups NNS NNS O
, , , O
but CC CC O
was VBD VBD O
significantly RB RB O
lower JJR JJR O
in IN IN O
all PDT PDT O
the DT DT O
treatment NN NN O
groups NNS NNS O
compared VBN VBN O
with IN IN O
control NN NN O
. . . O

The DT DT O
number NN NN O
of IN IN O
ECG NNP NNP O
abnormalities NNS NNS O
was VBD VBD O
zero CD CD O
in IN IN O
the DT DT O
Intralipid NNP NNP O
only RB RB O
group NN NN O
, , , O
but CC CC O
14 CD CD O
and CC CC O
17 CD CD O
, , , O
respectively RB RB O
, , , O
in IN IN O
the DT DT O
epinephrine NN NN B-CHEM
and CC CC O
epinephrine NN NN B-CHEM
plus CC CC O
lipid JJ JJ O
groups NNS NNS O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Lipid NNP NNP O
emulsion NN NN O
with IN IN O
or CC CC O
without IN IN O
epinephrine NN NN B-CHEM
, , , O
or CC CC O
epinephrine NN NN B-CHEM
alone RB RB O
were VBD VBD O
equally RB RB O
effective JJ JJ O
in IN IN O
achieving VBG VBG O
a DT DT O
return NN NN O
to TO TO O
spontaneous JJ JJ O
circulation NN NN O
in IN IN O
this DT DT O
model NN NN O
of IN IN O
LAST NNP NNP O
. . . O

Epinephrine NNP NNP B-CHEM
alone RB RB O
or CC CC O
in IN IN O
combination NN NN O
with IN IN O
lipid NN NN O
was VBD VBD O
associated VBN VBN O
with IN IN O
an DT DT O
increased JJ JJ O
number NN NN O
of IN IN O
ECG NNP NNP O
abnormalities NNS NNS O
compared VBN VBN O
with IN IN O
lipid JJ JJ O
emulsion NN NN O
alone RB RB O
. . . O

Incidence NNP NNP O
of IN IN O
heparin NN NN B-CHEM
- - - O
induced JJ JJ O
thrombocytopenia NN NN O
type NN NN O
II NNP NNP O
and CC CC O
postoperative JJ JJ O
recovery NN NN O
of IN IN O
platelet NN NN O
count NN NN O
in IN IN O
liver NN NN O
graft NN NN O
recipients NNS NNS O
: : : O
a DT DT O
retrospective NN NN O
cohort NN NN O
analysis NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
Thrombocytopenia NNP NNP O
in IN IN O
patients NNS NNS O
with IN IN O
end NN NN O
- : : O
stage NN NN O
liver NN NN O
disease NN NN O
is VBZ VBZ O
a DT DT O
common JJ JJ O
disorder NN NN O
caused VBD VBD O
mainly RB RB O
by IN IN O
portal JJ JJ O
hypertension NN NN O
, , , O
low JJ JJ O
levels NNS NNS O
of IN IN O
thrombopoetin NN NN O
, , , O
and CC CC O
endotoxemia NN NN O
. . . O

The DT DT O
impact NN NN O
of IN IN O
immune JJ JJ O
- - - O
mediated JJ JJ O
heparin NN NN B-CHEM
- - - O
induced JJ JJ O
thrombocytopenia NN NN O
type NN NN O
II NNP NNP O
( ( ( O
HIT NNP NNP O
type NN NN O
II NNP NNP O
) ) ) O
as IN IN O
a DT DT O
cause NN NN O
of IN IN O
thrombocytopenia NN NN O
after IN IN O
liver NN NN O
transplantation NN NN O
is VBZ VBZ O
not RB RB O
yet RB RB O
understood VBN VBN O
, , , O
with IN IN O
few JJ JJ O
literature NN NN O
citations NNS NNS O
reporting VBG VBG O
contradictory NN NN O
results NNS NNS O
. . . O

The DT DT O
aim NN NN O
of IN IN O
our PRP$ PRP$ O
study NN NN O
was VBD VBD O
to TO TO O
demonstrate VB VB O
the DT DT O
perioperative JJ JJ O
course NN NN O
of IN IN O
thrombocytopenia NN NN O
after IN IN O
liver NN NN O
transplantation NN NN O
and CC CC O
determine VB VB O
the DT DT O
occurrence NN NN O
of IN IN O
clinical JJ JJ O
HIT NNP NNP O
type NN NN O
II NNP NNP O
. . . O

METHOD NNP NNP O
: : : O
We PRP PRP O
retrospectively RB RB O
evaluated VBD VBD O
the DT DT O
medical JJ JJ O
records NNS NNS O
of IN IN O
205 CD CD O
consecutive JJ JJ O
adult NN NN O
patients NNS NNS O
who WP WP O
underwent VBD VBD O
full JJ JJ O
- : : O
size NN NN O
liver NN NN O
transplantation NN NN O
between IN IN O
January NNP NNP O
2006 CD CD O
and CC CC O
December NNP NNP O
2010 CD CD O
due JJ JJ O
to TO TO O
end VB VB O
- : : O
stage NN NN O
or CC CC O
malignant JJ JJ O
liver NN NN O
disease NN NN O
. . . O

Preoperative NNP NNP O
platelet NN NN O
count NN NN O
, , , O
postoperative JJ JJ O
course NN NN O
of IN IN O
platelets NNS NNS O
, , , O
and CC CC O
clinical JJ JJ O
signs NNS NNS O
of IN IN O
HIT NNP NNP O
type NN NN O
II NNP NNP O
were VBD VBD O
analyzed VBN VBN O
. . . O

RESULTS NNS NNS O
: : : O
A DT DT O
total NN NN O
of IN IN O
155 CD CD O
( ( ( O
75 CD CD O
. . . O
6 CD CD O
% NN NN O
) ) ) O
of IN IN O
205 CD CD O
patients NNS NNS O
had VBD VBD O
thrombocytopenia NN NN O
before IN IN O
transplantation NN NN O
, , , O
significantly RB RB O
influenced VBN VBN O
by IN IN O
Model NNP NNP O
of IN IN O
End NN NN O
- : : O
Stage NN NN O
Liver NNP NNP O
Disease NNP NNP O
score NN NN O
and CC CC O
liver NN NN O
cirrhosis NNS NNS O
. . . O

The DT DT O
platelet NN NN O
count NN NN O
exceeded VBD VBD O
100 CD CD O
, , , O
000 CD CD O
/ NN NN O
uL NN NN O
in IN IN O
most JJS JJS O
of IN IN O
the DT DT O
patients NNS NNS O
( ( ( O
n NN NN O
= SYM SYM O
193 CD CD O
) ) ) O
at IN IN O
a DT DT O
medium NN NN O
of IN IN O
7 CD CD O
d SYM SYM O
. . . O

Regarding VBG VBG O
HIT NNP NNP O
II NNP NNP O
, , , O
there EX EX O
were VBD VBD O
four CD CD O
( ( ( O
1 CD CD O
. . . O
95 CD CD O
% NN NN O
) ) ) O
patients NNS NNS O
with IN IN O
a DT DT O
background NN NN O
of IN IN O
HIT NNP NNP O
type NN NN O
II NNP NNP O
. . . O

CONCLUSIONS NNP NNP O
: : : O
The DT DT O
incidence NN NN O
of IN IN O
HIT NNP NNP O
in IN IN O
patients NNS NNS O
with IN IN O
end NN NN O
- : : O
stage NN NN O
hepatic JJ JJ O
failure NN NN O
is VBZ VBZ O
, , , O
with IN IN O
about IN IN O
1 CD CD O
. . . O
95 CD CD O
% NN NN O
, , , O
rare JJ JJ O
. . . O

For IN IN O
further JJ JJ O
reduction NN NN O
of IN IN O
HIT NNP NNP O
type NN NN O
II NNP NNP O
, , , O
the DT DT O
use NN NN O
of IN IN O
intravenous JJ JJ O
heparin NN NN B-CHEM
should MD MD O
be VB VB O
avoided VBN VBN O
and CC CC O
the DT DT O
prophylactic JJ JJ O
anticoagulation NN NN O
should MD MD O
be VB VB O
performed VBN VBN O
with IN IN O
low JJ JJ O
- - - O
molecular JJ JJ O
- - - O
weight NN NN O
heparin NN NN B-CHEM
after IN IN O
normalization NN NN O
of IN IN O
platelet NN NN O
count NN NN O
. . . O

Takotsubo NNP NNP O
syndrome NN NN O
( ( ( O
or CC CC O
apical JJ JJ O
ballooning NN NN O
syndrome NN NN O
) ) ) O
secondary JJ JJ O
to TO TO O
Zolmitriptan NNP NNP B-CHEM
. . . O

Takotsubo NNP NNP O
syndrome NN NN O
( ( ( O
TS NNP NNP O
) ) ) O
, , , O
also RB RB O
known VBN VBN O
as IN IN O
broken VBN VBN O
heart NN NN O
syndrome NN NN O
, , , O
is VBZ VBZ O
characterized VBN VBN O
by IN IN O
left VBD VBD O
ventricle NN NN O
apical JJ JJ O
ballooning NN NN O
with IN IN O
elevated VBD VBD O
cardiac JJ JJ O
biomarkers NNS NNS O
and CC CC O
electrocardiographic JJ JJ O
changes NNS NNS O
suggestive NN NN O
of IN IN O
an DT DT O
acute JJ JJ O
coronary JJ JJ O
syndrome NN NN O
( ( ( O
ie NN NN O
, , , O
ST NNP NNP O
- : : O
segment NN NN O
elevation NN NN O
, , , O
T NN NN O
wave NN NN O
inversions NNS NNS O
, , , O
and CC CC O
pathologic JJ JJ O
Q NNP NNP O
waves NNS NNS O
) ) ) O
. . . O

We PRP PRP O
report VBP VBP O
a DT DT O
case NN NN O
of IN IN O
54 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
woman NN NN O
with IN IN O
medical JJ JJ O
history NN NN O
of IN IN O
mitral JJ JJ O
valve NN NN O
prolapse NN NN O
and CC CC O
migraines NNS NNS O
, , , O
who WP WP O
was VBD VBD O
admitted VBN VBN O
to TO TO O
the DT DT O
hospital NN NN O
for IN IN O
substernal JJ JJ O
chest NN NN O
pain NN NN O
and CC CC O
electrocardiogram NN NN O
demonstrated VBD VBD O
1 CD CD O
/ NN NN O
2 CD CD O
mm NN NN O
ST NNP NNP O
- : : O
segment NN NN O
elevation NN NN O
in IN IN O
leads NNS NNS O
II NNP NNP O
, , , O
III NNP NNP O
, , , O
aVF NN NN O
, , , O
V5 NNP NNP O
, , , O
and CC CC O
V6 NNP NNP O
and CC CC O
positive JJ JJ O
troponin NN NN O
I PRP PRP O
. . . O

Emergent NNP NNP O
coronary JJ JJ O
angiogram NN NN O
revealed VBD VBD O
normal JJ JJ O
coronary JJ JJ O
arteries NNS NNS O
with IN IN O
moderately RB RB O
reduced VBN VBN O
left VBN VBN O
ventricular JJ JJ O
ejection NN NN O
fraction NN NN O
with IN IN O
wall NN NN O
motion NN NN O
abnormalities NNS NNS O
consistent JJ JJ O
with IN IN O
TS NNP NNP O
. . . O

Detailed NNP NNP O
history NN NN O
obtained VBD VBD O
retrospectively RB RB O
revealed VBN VBN O
that IN IN O
the DT DT O
patient NN NN O
took VBD VBD O
zolmitriptan NN NN B-CHEM
sparingly RB RB O
only RB RB O
when WRB WRB O
she PRP PRP O
had VBD VBD O
migraines NNS NNS O
. . . O

But CC CC O
before IN IN O
this DT DT O
event NN NN O
, , , O
she PRP PRP O
was VBD VBD O
taking VBG VBG O
zolmitriptan NN NN B-CHEM
2 CD CD O
- : : O
3 CD CD O
times NNS NNS O
daily RB RB O
for IN IN O
several JJ JJ O
days NNS NNS O
because IN IN O
of IN IN O
a DT DT O
persistent JJ JJ O
migraine NN NN O
headache NN NN O
. . . O

She PRP PRP O
otherwise RB RB O
reported VBD VBD O
that IN IN O
she PRP PRP O
is VBZ VBZ O
quite RB RB O
active JJ JJ O
, , , O
rides NNS NNS O
horses NNS NNS O
, , , O
and CC CC O
does VBZ VBZ O
show NN NN O
jumping VBG VBG O
without IN IN O
any DT DT O
limitations NNS NNS O
in IN IN O
her PRP$ PRP$ O
physical JJ JJ O
activity NN NN O
. . . O

There EX EX O
was VBD VBD O
no DT DT O
evidence NN NN O
of IN IN O
any DT DT O
recent JJ JJ O
stress NN NN O
or CC CC O
status NN NN O
migrainosus NN NN O
. . . O

Extensive NNP NNP O
literature NN NN O
search NN NN O
revealed JJ JJ O
multiple JJ JJ O
cases NNS NNS O
of IN IN O
coronary JJ JJ O
artery NN NN O
vasospasm NN NN O
secondary JJ JJ O
to TO TO O
zolmitriptan NN NN B-CHEM
, , , O
but CC CC O
none NN NN O
of IN IN O
the DT DT O
cases NNS NNS O
were VBD VBD O
associated VBN VBN O
with IN IN O
TS NNP NNP O
. . . O

Depression NNP NNP O
, , , O
impulsiveness NN NN O
, , , O
sleep VB VB O
, , , O
and CC CC O
memory NN NN O
in IN IN O
past JJ JJ O
and CC CC O
present JJ JJ O
polydrug NN NN O
users NNS NNS O
of IN IN O
3 CD CD B-CHEM
, , , I-CHEM
4 CD CD I-CHEM
- : : I-CHEM
methylenedioxymethamphetamine NN NN I-CHEM
( ( ( O
MDMA NNP NNP B-CHEM
, , , O
ecstasy JJ JJ B-CHEM
) ) ) O
. . . O

RATIONALE NNP NNP O
: : : O
Ecstasy NNP NNP B-CHEM
( ( ( O
3 CD CD B-CHEM
, , , I-CHEM
4 CD CD I-CHEM
- : : I-CHEM
methylenedioxymethamphetamine NN NN I-CHEM
, , , O
MDMA NNP NNP B-CHEM
) ) ) O
is VBZ VBZ O
a DT DT O
worldwide NN NN O
recreational JJ JJ O
drug NN NN O
of IN IN O
abuse NN NN O
. . . O

Unfortunately RB RB O
, , , O
the DT DT O
results NNS NNS O
from IN IN O
human JJ JJ O
research NN NN O
investigating VBG VBG O
its PRP$ PRP$ O
psychological JJ JJ O
effects NNS NNS O
have VBP VBP O
been VBN VBN O
inconsistent JJ JJ O
. . . O

OBJECTIVES NNP NNP O
: : : O
The DT DT O
present JJ JJ O
study NN NN O
aimed VBN VBN O
to TO TO O
be VB VB O
the DT DT O
largest JJS JJS O
to TO TO O
date NN NN O
in IN IN O
sample NN NN O
size NN NN O
and CC CC O
5HT CD CD O
- : : O
related JJ JJ O
behaviors NNS NNS O
; : : O
the DT DT O
first JJ JJ O
to TO TO O
compare VB VB O
present JJ JJ O
ecstasy NN NN B-CHEM
users NNS NNS O
with IN IN O
past JJ JJ O
users NNS NNS O
after IN IN O
an DT DT O
abstinence NN NN O
of IN IN O
4 CD CD O
or CC CC O
more JJR JJR O
years NNS NNS O
, , , O
and CC CC O
the DT DT O
first JJ JJ O
to TO TO O
include VB VB O
robust JJ JJ O
controls NNS NNS O
for IN IN O
other JJ JJ O
recreational JJ JJ O
substances NNS NNS O
. . . O

METHODS NNP NNP O
: : : O
A DT DT O
sample NN NN O
of IN IN O
997 CD CD O
participants NNS NNS O
( ( ( O
52 CD CD O
% NN NN O
male JJ JJ O
) ) ) O
was VBD VBD O
recruited VBN VBN O
to TO TO O
four CD CD O
control NN NN O
groups NNS NNS O
( ( ( O
non NN NN O
- : : O
drug NN NN O
( ( ( O
ND NNP NNP O
) ) ) O
, , , O
alcohol NN NN B-CHEM
/ NN NN O
nicotine NN NN B-CHEM
( ( ( O
AN DT DT B-CHEM
) ) ) O
, , , O
cannabis NN NN B-CHEM
/ NN NN O
alcohol NN NN B-CHEM
/ NN NN O
nicotine NN NN B-CHEM
( ( ( O
CAN MD MD B-CHEM
) ) ) O
, , , O
non NN NN O
- - - O
ecstasy JJ JJ B-CHEM
polydrug NN NN O
( ( ( O
PD NNP NNP O
) ) ) O
) ) ) O
, , , O
and CC CC O
two CD CD O
ecstasy JJ JJ B-CHEM
polydrug NN NN O
groups NNS NNS O
( ( ( O
present JJ JJ O
( ( ( O
MDMA NNP NNP B-CHEM
) ) ) O
and CC CC O
past JJ JJ O
users NNS NNS O
( ( ( O
EX NNP NNP O
- - - O
MDMA NNP NNP B-CHEM
) ) ) O
. . . O

Participants NNS NNS O
completed VBD VBD O
a DT DT O
drug NN NN O
history NN NN O
questionnaire NN NN O
, , , O
Beck NNP NNP O
Depression NNP NNP O
Inventory NNP NNP O
, , , O
Barratt NNP NNP O
Impulsiveness NNP NNP O
Scale NNP NNP O
, , , O
Pittsburgh NNP NNP O
Sleep NNP NNP O
Quality NNP NNP O
Index NNP NNP O
, , , O
and CC CC O
Wechsler NNP NNP O
Memory NN NN O
Scale NNP NNP O
- - - O
Revised NNP NNP O
which WDT WDT O
, , , O
in IN IN O
total JJ JJ O
, , , O
provided VBN VBN O
13 CD CD O
psychometric JJ JJ O
measures NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
While IN IN O
the DT DT O
CAN MD MD B-CHEM
and CC CC O
PD NNP NNP O
groups NNS NNS O
tended VBD VBD O
to TO TO O
record VB VB O
greater JJR JJR O
deficits NNS NNS O
than IN IN O
the DT DT O
non NN NN O
- - - O
drug NN NN O
controls NNS NNS O
, , , O
the DT DT O
MDMA NNP NNP B-CHEM
and CC CC O
EX NNP NNP O
- : : O
MDMA NNP NNP B-CHEM
groups NNS NNS O
recorded VBD VBD O
greater JJR JJR O
deficits NNS NNS O
than IN IN O
all PDT PDT O
the DT DT O
control NN NN O
groups NNS NNS O
on IN IN O
ten CD CD O
of IN IN O
the DT DT O
13 CD CD O
psychometric JJ JJ O
measures NNS NNS O
. . . O

Strikingly RB RB O
, , , O
despite IN IN O
prolonged JJ JJ O
abstinence NN NN O
( ( ( O
mean VB VB O
, , , O
4 CD CD O
. . . O
98 CD CD O
; : : O
range NN NN O
, , , O
4 CD CD O
- : : O
9 CD CD O
years NNS NNS O
) ) ) O
, , , O
past JJ JJ O
ecstasy JJ JJ B-CHEM
users NNS NNS O
showed VBD VBD O
few JJ JJ O
signs NNS NNS O
of IN IN O
recovery NN NN O
. . . O

Compared VBN VBN O
with IN IN O
present JJ JJ O
ecstasy NN NN B-CHEM
users NNS NNS O
, , , O
the DT DT O
past JJ JJ O
users NNS NNS O
showed VBD VBD O
no DT DT O
change NN NN O
for IN IN O
ten CD CD O
measures NNS NNS O
, , , O
increased VBN VBN O
impairment NN NN O
for IN IN O
two CD CD O
measures NNS NNS O
, , , O
and CC CC O
improvement NN NN O
on IN IN O
just RB RB O
one CD CD O
measure NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Given VBN VBN O
this DT DT O
record NN NN O
of IN IN O
impaired JJ JJ O
memory NN NN O
and CC CC O
clinically RB RB O
significant JJ JJ O
levels NNS NNS O
of IN IN O
depression NN NN O
, , , O
impulsiveness NN NN O
, , , O
and CC CC O
sleep VB VB O
disturbance NN NN O
, , , O
the DT DT O
prognosis NN NN O
for IN IN O
the DT DT O
current JJ JJ O
generation NN NN O
of IN IN O
ecstasy JJ JJ B-CHEM
users NNS NNS O
is VBZ VBZ O
a DT DT O
major JJ JJ O
cause NN NN O
for IN IN O
concern NN NN O
. . . O

Association NNP NNP O
of IN IN O
common JJ JJ O
genetic JJ JJ O
variants NNS NNS O
of IN IN O
HOMER1 NNP NNP O
gene NN NN O
with IN IN O
levodopa NN NN B-CHEM
adverse JJ JJ O
effects NNS NNS O
in IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
patients NNS NNS O
. . . O

Levodopa NNP NNP B-CHEM
is VBZ VBZ O
the DT DT O
most RBS RBS O
effective JJ JJ O
symptomatic JJ JJ O
therapy NN NN O
for IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
, , , O
but CC CC O
its PRP$ PRP$ O
chronic JJ JJ O
use NN NN O
could MD MD O
lead VB VB O
to TO TO O
chronic JJ JJ O
adverse JJ JJ O
outcomes NNS NNS O
, , , O
such JJ JJ O
as IN IN O
motor NN NN O
fluctuations NNS NNS O
, , , O
dyskinesia NN NN O
and CC CC O
visual JJ JJ O
hallucinations NNS NNS O
. . . O

HOMER1 NNP NNP O
is VBZ VBZ O
a DT DT O
protein NN NN O
with IN IN O
pivotal JJ JJ O
function NN NN O
in IN IN O
glutamate NN NN B-CHEM
transmission NN NN O
, , , O
which WDT WDT O
has VBZ VBZ O
been VBN VBN O
related VBN VBN O
to TO TO O
the DT DT O
pathogenesis NNS NNS O
of IN IN O
these DT DT O
complications NNS NNS O
. . . O

This DT DT O
study NN NN O
investigates VBZ VBZ O
whether IN IN O
polymorphisms NNS NNS O
in IN IN O
the DT DT O
HOMER1 NNP NNP O
gene NN NN O
promoter NN NN O
region NN NN O
are VBP VBP O
associated VBN VBN O
with IN IN O
the DT DT O
occurrence NN NN O
of IN IN O
the DT DT O
chronic JJ JJ O
complications NNS NNS O
of IN IN O
levodopa NN NN B-CHEM
therapy NN NN O
. . . O

A DT DT O
total NN NN O
of IN IN O
205 CD CD O
patients NNS NNS O
with IN IN O
idiopathic JJ JJ O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
were VBD VBD O
investigated VBN VBN O
. . . O

Patients NNS NNS O
were VBD VBD O
genotyped VBN VBN O
for IN IN O
rs4704559 NN NN O
, , , O
rs10942891 NN NN O
and CC CC O
rs4704560 NN NN O
by IN IN O
allelic JJ JJ O
discrimination NN NN O
with IN IN O
Taqman NNP NNP O
assays NNS NNS O
. . . O

The DT DT O
rs4704559 NN NN O
G NNP NNP O
allele NN NN O
was VBD VBD O
associated VBN VBN O
with IN IN O
a DT DT O
lower JJR JJR O
prevalence NN NN O
of IN IN O
dyskinesia NN NN O
( ( ( O
prevalence NN NN O
ratio NN NN O
( ( ( O
PR NNP NNP O
) ) ) O
= SYM SYM O
0 CD CD O
. . . O
615 CD CD O
, , , O
95 CD CD O
% NN NN O
confidence NN NN O
interval NN NN O
( ( ( O
CI NNP NNP O
) ) ) O
0 CD CD O
. . . O
426 CD CD O
- : : O
0 CD CD O
. . . O
887 CD CD O
, , , O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
009 CD CD O
) ) ) O
and CC CC O
visual JJ JJ O
hallucinations NNS NNS O
( ( ( O
PR NNP NNP O
= SYM SYM O
0 CD CD O
. . . O
515 CD CD O
, , , O
95 CD CD O
% NN NN O
CI NNP NNP O
0 CD CD O
. . . O
295 CD CD O
- : : O
0 CD CD O
. . . O
899 CD CD O
, , , O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
020 CD CD O
) ) ) O
. . . O

Our PRP$ PRP$ O
data NNS NNS O
suggest VBP VBP O
that IN IN O
HOMER1 NNP NNP O
rs4704559 NN NN O
G NNP NNP O
allele NN NN O
has VBZ VBZ O
a DT DT O
protective JJ JJ O
role NN NN O
for IN IN O
the DT DT O
development NN NN O
of IN IN O
levodopa NN NN B-CHEM
adverse JJ JJ O
effects NNS NNS O
. . . O

Crocin NNP NNP B-CHEM
improves VBZ VBZ O
lipid JJ JJ O
dysregulation NN NN O
in IN IN O
subacute NN NN O
diazinon NN NN B-CHEM
exposure NN NN O
through IN IN O
ERK1 NNP NNP O
/ NN NN O
2 CD CD O
pathway NN NN O
in IN IN O
rat NN NN O
liver NN NN O
. . . O

INTRODUCTION NNP NNP O
: : : O
Diazinon NNP NNP B-CHEM
Yis NNP NNP O
one CD CD O
of IN IN O
the DT DT O
most RBS RBS O
broadly RB RB O
used VBN VBN O
organophosphorus JJ JJ B-CHEM
insecticides NNS NNS O
in IN IN O
agriculture NN NN O
. . . O

It PRP PRP O
has VBZ VBZ O
been VBN VBN O
shown VBN VBN O
that WDT WDT O
exposure NN NN O
to TO TO O
diazinon VB VB B-CHEM
may MD MD O
interfere VB VB O
with IN IN O
lipid NN NN O
metabolism NN NN O
. . . O

Moreover RB RB O
, , , O
the DT DT O
hypolipidemic JJ JJ O
effect NN NN O
of IN IN O
crocin NN NN B-CHEM
has VBZ VBZ O
been VBN VBN O
established VBN VBN O
. . . O

Earlier RBR RBR O
studies NNS NNS O
revealed VBD VBD O
the DT DT O
major JJ JJ O
role NN NN O
of IN IN O
Extracellular NNP NNP O
signal NN NN O
- - - O
regulated JJ JJ O
kinase NN NN O
( ( ( O
ERK NNP NNP O
) ) ) O
pathways NNS NNS O
in IN IN O
low JJ JJ O
- - - O
density NN NN O
lipoprotein NN NN O
receptor NN NN O
( ( ( O
LDLr NNP NNP O
) ) ) O
expression NN NN O
. . . O

The DT DT O
aim NN NN O
of IN IN O
this DT DT O
study NN NN O
was VBD VBD O
to TO TO O
evaluate VB VB O
changes NNS NNS O
in IN IN O
the DT DT O
regulation NN NN O
of IN IN O
lipid NN NN O
metabolism NN NN O
, , , O
ERK NNP NNP O
and CC CC O
LDLr NNP NNP O
expression NN NN O
in IN IN O
the DT DT O
liver NN NN O
of IN IN O
rats NNS NNS O
exposed VBN VBN O
to TO TO O
subacute VB VB O
diazinon NN NN B-CHEM
. . . O

Furthermore RB RB O
ameliorating VBG VBG O
effect NN NN O
of IN IN O
crocin NN NN B-CHEM
on IN IN O
diazinon NN NN B-CHEM
induced VBN VBN O
disturbed VBN VBN O
cholesterol NN NN B-CHEM
homeostasis NNS NNS O
was VBD VBD O
studied VBN VBN O
. . . O

METHODS NNP NNP O
: : : O
24 CD CD O
Rats NNP NNP O
were VBD VBD O
divided VBN VBN O
into IN IN O
4 CD CD O
groups NNS NNS O
and CC CC O
received VBD VBD O
following VBG VBG O
treatments NNS NNS O
for IN IN O
4 CD CD O
weeks NNS NNS O
; : : O
Corn VBN VBN O
oil NN NN O
( ( ( O
control NN NN O
) ) ) O
, , , O
diazinon NN NN B-CHEM
( ( ( O
15mg CD CD O
/ NN NN O
kg NN NN O
per IN IN O
day NN NN O
, , , O
orally RB RB O
) ) ) O
and CC CC O
crocin NN NN B-CHEM
( ( ( O
12 CD CD O
. . . O
5 CD CD O
and CC CC O
25mg CD CD O
/ NN NN O
kg NN NN O
per IN IN O
day NN NN O
, , , O
intraperitoneally RB RB O
) ) ) O
in IN IN O
combination NN NN O
with IN IN O
diazinon NN NN B-CHEM
( ( ( O
15 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
. . . O

The DT DT O
levels NNS NNS O
of IN IN O
cholesterol NN NN B-CHEM
, , , O
triglyceride NN NN B-CHEM
and CC CC O
LDL NNP NNP O
in IN IN O
blood NN NN O
of IN IN O
rats NNS NNS O
were VBD VBD O
analyzed VBN VBN O
. . . O

Moreover RB RB O
mRNA NN NN O
levels NNS NNS O
of IN IN O
LDLr NNP NNP O
and CC CC O
ERK1 NNP NNP O
/ NN NN O
2 CD CD O
as RB RB O
well RB RB O
as IN IN O
protein NN NN O
levels NNS NNS O
of IN IN O
total JJ JJ O
and CC CC O
activated VBN VBN O
forms NNS NNS O
of IN IN O
ERK1 NNP NNP O
/ NN NN O
2 CD CD O
in IN IN O
rat NN NN O
liver NN NN O
were VBD VBD O
evaluated VBN VBN O
by IN IN O
Western JJ JJ O
blotting NN NN O
and CC CC O
quantitative JJ JJ O
real JJ JJ O
time NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
analysis NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Our PRP$ PRP$ O
data NNS NNS O
showed VBD VBD O
that IN IN O
subacute JJ JJ O
exposure NN NN O
to TO TO O
diazinon VB VB B-CHEM
significantly RB RB O
increased VBN VBN O
concentrations NNS NNS O
of IN IN O
cholesterol NN NN B-CHEM
, , , O
triglyceride NN NN B-CHEM
and CC CC O
LDL NNP NNP O
. . . O

Moreover RB RB O
diazinon NN NN B-CHEM
decreased VBD VBD O
ERK1 NNP NNP O
/ NN NN O
2 CD CD O
protein NN NN O
phosphorylation NN NN O
and CC CC O
LDLr NNP NNP O
transcript NN NN O
. . . O

Crocin NNP NNP B-CHEM
reduced VBD VBD O
inhibition NN NN O
of IN IN O
ERK NNP NNP O
activation NN NN O
and CC CC O
diazinon NN NN B-CHEM
- - - O
induced JJ JJ O
hyperlipemia NN NN O
and CC CC O
increased VBN VBN O
levels NNS NNS O
of IN IN O
LDLr NNP NNP O
transcript NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Crocin NNP NNP B-CHEM
may MD MD O
be VB VB O
considered VBN VBN O
as IN IN O
a DT DT O
novel NN NN O
protective JJ JJ O
agent NN NN O
in IN IN O
diazinon NN NN B-CHEM
- - - O
induced JJ JJ O
hyperlipemia NN NN O
through IN IN O
modulating NN NN O
of IN IN O
ERK NNP NNP O
pathway NN NN O
and CC CC O
increase NN NN O
of IN IN O
LDLr NNP NNP O
expression NN NN O
. . . O

GEM NNP NNP B-CHEM
- : : O
P NN NN O
chemotherapy NN NN O
is VBZ VBZ O
active JJ JJ O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
relapsed VBN VBN O
Hodgkin NNP NNP O
lymphoma NN NN O
. . . O

Hodgkin NNP NNP O
lymphoma NN NN O
( ( ( O
HL NNP NNP O
) ) ) O
is VBZ VBZ O
a DT DT O
relatively RB RB O
chemosensitive JJ JJ O
malignancy NN NN O
. . . O

However RB RB O
, , , O
for IN IN O
those DT DT O
who WP WP O
relapse VBP VBP O
, , , O
high JJ JJ O
- - - O
dose NN NN O
chemotherapy NN NN O
with IN IN O
autologous JJ JJ O
stem NN NN O
cell NN NN O
transplant NN NN O
is VBZ VBZ O
the DT DT O
treatment NN NN O
of IN IN O
choice NN NN O
which WDT WDT O
relies VBZ VBZ O
on IN IN O
adequate NN NN O
disease NN NN O
control NN NN O
with IN IN O
salvage NN NN O
chemotherapy NN NN O
. . . O

Regimens NNP NNP O
commonly RB RB O
used VBD VBD O
often RB RB O
require VB VB O
inpatient NN NN O
administration NN NN O
and CC CC O
can MD MD O
be VB VB O
difficult JJ JJ O
to TO TO O
deliver VB VB O
due JJ JJ O
to TO TO O
toxicity NN NN O
. . . O

Gemcitabine NNP NNP B-CHEM
and CC CC O
cisplatin NN NN B-CHEM
have VBP VBP O
activity NN NN O
in IN IN O
HL NNP NNP O
, , , O
non NN NN O
- - - O
overlapping VBG VBG O
toxicity NN NN O
with IN IN O
first JJ JJ O
- - - O
line NN NN O
chemotherapeutics NNS NNS O
, , , O
and CC CC O
may MD MD O
be VB VB O
delivered VBN VBN O
in IN IN O
an DT DT O
outpatient NN NN O
setting VBG VBG O
. . . O

In IN IN O
this DT DT O
retrospective NN NN O
single JJ JJ O
- : : O
centre NN NN O
analysis NN NN O
, , , O
patients NNS NNS O
with IN IN O
relapsed VBN VBN O
or CC CC O
refractory JJ JJ O
HL NNP NNP O
treated VBN VBN O
with IN IN O
gemcitabine NN NN B-CHEM
1 CD CD O
, , , O
000 CD CD O
mg NN NN O
/ NN NN O
m NN NN O
( ( ( O
2 CD CD O
) ) ) O
day NN NN O
( ( ( O
D NNP NNP O
) ) ) O
1 CD CD O
, , , O
D8 NNP NNP O
and CC CC O
D15 NNP NNP O
; : : O
methylprednisolone NN NN B-CHEM
1 CD CD O
, , , O
000 CD CD O
mg NN NN O
D1 NN NN O
- : : O
5 CD CD O
; : : O
and CC CC O
cisplatin NN NN B-CHEM
100 CD CD O
mg NN NN O
/ NN NN O
m NN NN O
( ( ( O
2 CD CD O
) ) ) O
D15 NNP NNP O
, , , O
every DT DT O
28 CD CD O
days NNS NNS O
( ( ( O
GEM NNP NNP B-CHEM
- - - O
P NN NN O
) ) ) O
were VBD VBD O
included VBN VBN O
. . . O

Demographic NNP NNP O
, , , O
survival NN NN O
, , , O
response NN NN O
and CC CC O
toxicity NN NN O
data NNS NNS O
were VBD VBD O
recorded VBN VBN O
. . . O

Forty CD CD O
- : : O
one CD CD O
eligible JJ JJ O
patients NNS NNS O
were VBD VBD O
identified VBN VBN O
: : : O
median JJ JJ O
age NN NN O
27 CD CD O
. . . O

One CD CD O
hundred CD CD O
and CC CC O
twenty CD CD O
- : : O
two CD CD O
cycles NNS NNS O
of IN IN O
GEM NNP NNP B-CHEM
- - - O
P NN NN O
were VBD VBD O
administered VBN VBN O
in IN IN O
total JJ JJ O
( ( ( O
median NN NN O
3 CD CD O
cycles NNS NNS O
; : : O
range NN NN O
1 CD CD O
- : : O
6 CD CD O
) ) ) O
. . . O

Twenty NNP NNP O
of IN IN O
41 CD CD O
( ( ( O
48 CD CD O
% NN NN O
) ) ) O
patients NNS NNS O
received VBD VBD O
GEM NNP NNP B-CHEM
- : : O
P NN NN O
as IN IN O
second JJ JJ O
- - - O
line NN NN O
treatment NN NN O
and CC CC O
11 CD CD O
/ NN NN O
41 CD CD O
( ( ( O
27 CD CD O
% NN NN O
) ) ) O
as IN IN O
third JJ JJ O
- - - O
line NN NN O
therapy NN NN O
. . . O

Overall RB RB O
response NN NN O
rate NN NN O
( ( ( O
ORR NNP NNP O
) ) ) O
to TO TO O
GEM NNP NNP B-CHEM
- : : O
P NN NN O
in IN IN O
the DT DT O
entire JJ JJ O
cohort NN NN O
was VBD VBD O
80 CD CD O
% NN NN O
( ( ( O
complete JJ JJ O
response NN NN O
( ( ( O
CR NNP NNP O
) ) ) O
37 CD CD O
% NN NN O
, , , O
partial JJ JJ O
response NN NN O
44 CD CD O
% NN NN O
) ) ) O
with IN IN O
14 CD CD O
/ NN NN O
15 CD CD O
CR NNP NNP O
confirmed VBD VBD O
as IN IN O
a DT DT O
metabolic JJ JJ O
CR NNP NNP O
on IN IN O
PET NNP NNP O
and CC CC O
ORR NNP NNP O
of IN IN O
85 CD CD O
% NN NN O
in IN IN O
the DT DT O
20 CD CD O
second JJ JJ O
- - - O
line NN NN O
patients NNS NNS O
. . . O

The DT DT O
most RBS RBS O
common JJ JJ O
grade NN NN O
3 CD CD O
/ NN NN O
4 CD CD O
toxicities NNS NNS O
were VBD VBD O
haematological JJ JJ O
: : : O
neutropenia NN NN O
54 CD CD O
% NN NN O
and CC CC O
thrombocytopenia NN NN O
51 CD CD O
% NN NN O
. . . O

Median NNP NNP O
follow VB VB O
- - - O
up RP RP O
from IN IN O
the DT DT O
start NN NN O
of IN IN O
GEM NNP NNP B-CHEM
- : : O
P NN NN O
was VBD VBD O
4 CD CD O
. . . O
5 CD CD O
years NNS NNS O
. . . O

Following VBG VBG O
GEM NNP NNP B-CHEM
- : : O
P NN NN O
, , , O
5 CD CD O
- : : O
year NN NN O
progression NN NN O
- - - O
free JJ JJ O
survival NN NN O
was VBD VBD O
46 CD CD O
% NN NN O
( ( ( O
95 CD CD O
% NN NN O
confidence NN NN O
interval NN NN O
( ( ( O
CI NNP NNP O
) ) ) O
, , , O
30 CD CD O
- : : O
62 CD CD O
% NN NN O
) ) ) O
and CC CC O
5 CD CD O
- : : O
year NN NN O
overall JJ JJ O
survival NN NN O
was VBD VBD O
59 CD CD O
% NN NN O
( ( ( O
95 CD CD O
% NN NN O
CI NNP NNP O
, , , O
43 CD CD O
- : : O
74 CD CD O
% NN NN O
) ) ) O
. . . O

Fourteen CD CD O
of IN IN O
41 CD CD O
patients NNS NNS O
proceeded VBD VBD O
directly RB RB O
to TO TO O
autologous JJ JJ O
transplant NN NN O
. . . O

GEM NNP NNP B-CHEM
- : : O
P NN NN O
is VBZ VBZ O
a DT DT O
salvage NN NN O
chemotherapy NN NN O
with IN IN O
relatively RB RB O
high JJ JJ O
response NN NN O
rates NNS NNS O
, , , O
leading VBG VBG O
to TO TO O
successful JJ JJ O
transplantation NN NN O
in IN IN O
appropriate JJ JJ O
patients NNS NNS O
, , , O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
relapsed VBN VBN O
or CC CC O
refractory JJ JJ O
HL NNP NNP O
. . . O

Basal NNP NNP O
functioning VBG VBG O
of IN IN O
the DT DT O
hypothalamic JJ JJ O
- - - O
pituitary JJ JJ O
- - - O
adrenal NN NN O
( ( ( O
HPA NNP NNP O
) ) ) O
axis NNS NNS O
and CC CC O
psychological JJ JJ O
distress NN NN O
in IN IN O
recreational JJ JJ O
ecstasy NN NN B-CHEM
polydrug NN NN O
users NNS NNS O
. . . O

RATIONALE NNP NNP O
: : : O
Ecstasy NNP NNP B-CHEM
( ( ( O
MDMA NNP NNP B-CHEM
) ) ) O
is VBZ VBZ O
a DT DT O
psychostimulant NN NN O
drug NN NN O
which WDT WDT O
is VBZ VBZ O
increasingly RB RB O
associated VBN VBN O
with IN IN O
psychobiological JJ JJ O
dysfunction NN NN O
. . . O

While IN IN O
some DT DT O
recent JJ JJ O
studies NNS NNS O
suggest VBP VBP O
acute JJ JJ O
changes NNS NNS O
in IN IN O
neuroendocrine NN NN O
function NN NN O
, , , O
less JJR JJR O
is VBZ VBZ O
known VBN VBN O
about IN IN O
long JJ JJ O
- - - O
term NN NN O
changes NNS NNS O
in IN IN O
HPA NNP NNP O
functionality NN NN O
in IN IN O
recreational JJ JJ O
users NNS NNS O
. . . O

OBJECTIVES NNP NNP O
: : : O
The DT DT O
current JJ JJ O
study NN NN O
is VBZ VBZ O
the DT DT O
first JJ JJ O
to TO TO O
explore VB VB O
the DT DT O
effects NNS NNS O
of IN IN O
ecstasy JJ JJ B-CHEM
- - - O
polydrug NN NN O
use NN NN O
on IN IN O
psychological JJ JJ O
distress NN NN O
and CC CC O
basal NN NN O
functioning VBG VBG O
of IN IN O
the DT DT O
HPA NNP NNP O
axis NNS NNS O
through IN IN O
assessing VBG VBG O
the DT DT O
secretion NN NN O
of IN IN O
cortisol NN NN B-CHEM
across IN IN O
the DT DT O
diurnal JJ JJ O
period NN NN O
. . . O

METHOD NNP NNP O
: : : O
Seventy NNP NNP O
- - - O
six CD CD O
participants NNS NNS O
( ( ( O
21 CD CD O
nonusers NNS NNS O
, , , O
29 CD CD O
light JJ JJ O
ecstasy NN NN B-CHEM
- : : O
polydrug NN NN O
users NNS NNS O
, , , O
26 CD CD O
heavy JJ JJ O
ecstasy NN NN B-CHEM
- : : O
polydrug NN NN O
users NNS NNS O
) ) ) O
completed VBD VBD O
a DT DT O
substance NN NN O
use NN NN O
inventory NN NN O
and CC CC O
measures NNS NNS O
of IN IN O
psychological JJ JJ O
distress NN NN O
at IN IN O
baseline NN NN O
, , , O
then RB RB O
two CD CD O
consecutive JJ JJ O
days NNS NNS O
of IN IN O
cortisol NN NN B-CHEM
sampling VBG VBG O
( ( ( O
on IN IN O
awakening VBG VBG O
, , , O
30 CD CD O
min NN NN O
post NN NN O
awakening NN NN O
, , , O
between IN IN O
1400 CD CD O
and CC CC O
1600 CD CD O
hours NNS NNS O
and CC CC O
pre NN NN O
bedtime NN NN O
) ) ) O
. . . O

On IN IN O
day NN NN O
2 CD CD O
, , , O
participants NNS NNS O
also RB RB O
attended VBD VBD O
the DT DT O
laboratory NN NN O
to TO TO O
complete VB VB O
a DT DT O
20 CD CD O
- : : O
min NN NN O
multitasking VBG VBG O
stressor NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Both DT DT O
user NN NN O
groups NNS NNS O
exhibited VBN VBN O
significantly RB RB O
greater JJR JJR O
levels NNS NNS O
of IN IN O
anxiety NN NN O
and CC CC O
depression NN NN O
than IN IN O
nonusers NNS NNS O
. . . O

On IN IN O
day NN NN O
1 CD CD O
, , , O
all DT DT O
participants NNS NNS O
exhibited VBD VBD O
a DT DT O
typical JJ JJ O
cortisol NN NN B-CHEM
profile NN NN O
, , , O
though RB RB O
light JJ JJ O
users NNS NNS O
had VBD VBD O
significantly RB RB O
elevated VBN VBN O
levels NNS NNS O
pre JJ JJ O
- : : O
bed NN NN O
. . . O

On IN IN O
day NN NN O
2 CD CD O
, , , O
heavy JJ JJ O
users NNS NNS O
demonstrated VBD VBD O
elevated VBD VBD O
levels NNS NNS O
upon IN IN O
awakening VBG VBG O
and CC CC O
all DT DT O
ecstasy JJ JJ B-CHEM
- - - O
polydrug NN NN O
users NNS NNS O
demonstrated VBD VBD O
elevated VBN VBN O
pre NN NN O
- - - O
bed NN NN O
levels NNS NNS O
compared VBN VBN O
to TO TO O
non NN NN O
- - - O
users NNS NNS O
. . . O

Significant JJ JJ O
between IN IN O
group NN NN O
differences NNS NNS O
were VBD VBD O
also RB RB O
observed VBN VBN O
in IN IN O
afternoon NN NN O
cortisol NN NN B-CHEM
levels NNS NNS O
and CC CC O
in IN IN O
overall JJ JJ O
cortisol NN NN B-CHEM
secretion NN NN O
across IN IN O
the DT DT O
day NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
The DT DT O
increases NNS NNS O
in IN IN O
anxiety NN NN O
and CC CC O
depression NN NN O
are VBP VBP O
in IN IN O
line NN NN O
with IN IN O
previous JJ JJ O
observations NNS NNS O
in IN IN O
recreational JJ JJ O
ecstasy NN NN B-CHEM
- : : O
polydrug NN NN O
users NNS NNS O
. . . O

Dysregulated NNP NNP O
diurnal JJ JJ O
cortisol NN NN B-CHEM
may MD MD O
be VB VB O
indicative JJ JJ O
of IN IN O
inappropriate JJ JJ O
anticipation NN NN O
of IN IN O
forthcoming JJ JJ O
demands NNS NNS O
and CC CC O
hypersecretion NN NN O
may MD MD O
lead VB VB O
to TO TO O
the DT DT O
increased JJ JJ O
psychological JJ JJ O
and CC CC O
physical JJ JJ O
morbidity NN NN O
associated VBN VBN O
with IN IN O
heavy JJ JJ O
recreational JJ JJ O
use NN NN O
of IN IN O
ecstasy NN NN B-CHEM
. . . O

Ifosfamide NNP NNP B-CHEM
related VBD VBD O
encephalopathy NN NN O
: : : O
the DT DT O
need NN NN O
for IN IN O
a DT DT O
timely JJ JJ O
EEG NNP NNP O
evaluation NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
Ifosfamide NNP NNP B-CHEM
is VBZ VBZ O
an DT DT O
alkylating VBG VBG O
agent NN NN O
useful JJ JJ O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
a DT DT O
wide JJ JJ O
range NN NN O
of IN IN O
cancers NNS NNS O
including VBG VBG O
sarcomas NN NN O
, , , O
lymphoma NN NN O
, , , O
gynecologic JJ JJ O
and CC CC O
testicular JJ JJ O
cancers NNS NNS O
. . . O

Encephalopathy NNP NNP O
has VBZ VBZ O
been VBN VBN O
reported VBN VBN O
in IN IN O
10 CD CD O
- : : O
40 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
receiving VBG VBG O
high JJ JJ O
- - - O
dose NN NN O
IV NNP NNP O
ifosfamide NN NN B-CHEM
. . . O

OBJECTIVE NNP NNP O
: : : O
To TO TO O
highlight VB VB O
the DT DT O
role NN NN O
of IN IN O
electroencephalogram NN NN O
( ( ( O
EEG NNP NNP O
) ) ) O
in IN IN O
the DT DT O
early JJ JJ O
detection NN NN O
and CC CC O
management NN NN O
of IN IN O
ifosfamide NN NN B-CHEM
related VBN VBN O
encephalopathy JJ JJ O
. . . O

METHODS NNP NNP O
: : : O
Retrospective NNP NNP O
chart NN NN O
review NN NN O
including VBG VBG O
clinical JJ JJ O
data NNS NNS O
and CC CC O
EEG NNP NNP O
recordings NNS NNS O
was VBD VBD O
done VBN VBN O
on IN IN O
five CD CD O
patients NNS NNS O
, , , O
admitted VBN VBN O
to TO TO O
MD NNP NNP O
Anderson NNP NNP O
Cancer NNP NNP O
Center NNP NNP O
between IN IN O
years NNS NNS O
2009 CD CD O
and CC CC O
2012 CD CD O
, , , O
who WP WP O
developed VBD VBD O
ifosfamide IN IN B-CHEM
related VBN VBN O
acute JJ JJ O
encephalopathy JJ JJ O
. . . O

RESULTS NNS NNS O
: : : O
All DT DT O
five CD CD O
patients NNS NNS O
experienced VBN VBN O
symptoms NNS NNS O
of IN IN O
encephalopathy JJ JJ O
soon RB RB O
after IN IN O
( ( ( O
within IN IN O
12 CD CD O
h NN NN O
- : : O
2 CD CD O
days NNS NNS O
) ) ) O
receiving VBG VBG O
ifosfamide NN NN B-CHEM
. . . O

Two CD CD O
patients NNS NNS O
developed VBN VBN O
generalized VBN VBN O
convulsions NNS NNS O
while IN IN O
one CD CD O
patient NN NN O
developed VBN VBN O
continuous JJ JJ O
non NN NN O
- - - O
convulsive JJ JJ O
status NN NN O
epilepticus NN NN O
( ( ( O
NCSE NNP NNP O
) ) ) O
that WDT WDT O
required VBD VBD O
ICU NNP NNP O
admission NN NN O
and CC CC O
intubation NN NN O
. . . O

Initial JJ JJ O
EEG NNP NNP O
showed VBD VBD O
epileptiform NN NN O
discharges NNS NNS O
in IN IN O
three CD CD O
patients NNS NNS O
; : : O
run NN NN O
of IN IN O
triphasic JJ JJ O
waves NNS NNS O
in IN IN O
one CD CD O
patient NN NN O
and CC CC O
moderate NN NN O
degree NN NN O
diffuse NN NN O
generalized JJ JJ O
slowing NN NN O
. . . O

Mixed NNP NNP O
pattern NN NN O
with IN IN O
the DT DT O
presence NN NN O
of IN IN O
both DT DT O
sharps NN NN O
and CC CC O
triphasic JJ JJ O
waves NNS NNS O
were VBD VBD O
also RB RB O
noted VBN VBN O
. . . O

Repeat NN NN O
EEGs NNP NNP O
within IN IN O
24 CD CD O
_ NN NN O
h NN NN O
of IN IN O
symptom NN NN O
onset NN NN O
showed VBD VBD O
marked VBN VBN O
improvement NN NN O
that WDT WDT O
was VBD VBD O
correlated VBN VBN O
with IN IN O
clinical JJ JJ O
improvement NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Severity NNP NNP O
of IN IN O
ifosfamide NN NN B-CHEM
related VBN VBN O
encephalopathy JJ JJ O
correlates NNS NNS O
with IN IN O
EEG NNP NNP O
changes NNS NNS O
. . . O

We PRP PRP O
suggest VBP VBP O
a DT DT O
timely JJ JJ O
EEG NNP NNP O
evaluation NN NN O
for IN IN O
patients NNS NNS O
receiving VBG VBG O
ifosfamide NN NN B-CHEM
who WP WP O
develop VBP VBP O
features NNS NNS O
of IN IN O
encephalopathy JJ JJ O
. . . O

Incidence NNP NNP O
of IN IN O
contrast NN NN B-CHEM
- - - O
induced JJ JJ O
nephropathy NN NN O
in IN IN O
hospitalised VBN VBN O
patients NNS NNS O
with IN IN O
cancer NN NN O
. . . O

OBJECTIVES NNP NNP O
: : : O
To TO TO O
determine VB VB O
the DT DT O
frequency NN NN O
of IN IN O
and CC CC O
possible JJ JJ O
factors NNS NNS O
related VBN VBN O
to TO TO O
contrast NN NN B-CHEM
- - - O
induced JJ JJ O
nephropathy NN NN O
( ( ( O
CIN NNP NNP O
) ) ) O
in IN IN O
hospitalised VBN VBN O
patients NNS NNS O
with IN IN O
cancer NN NN O
. . . O

METHODS NNP NNP O
: : : O
Ninety NNP NNP O
adult NN NN O
patients NNS NNS O
were VBD VBD O
enrolled VBN VBN O
. . . O

Patients NNS NNS O
with IN IN O
risk NN NN O
factors NNS NNS O
for IN IN O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
were VBD VBD O
excluded VBN VBN O
. . . O

Blood NNP NNP O
samples NNS NNS O
were VBD VBD O
examined VBN VBN O
the DT DT O
day NN NN O
before IN IN O
contrast NN NN B-CHEM
- - - O
enhanced JJ JJ O
computed VBN VBN O
tomography NN NN O
( ( ( O
CT NNP NNP O
) ) ) O
and CC CC O
serially RB RB O
for IN IN O
3 CD CD O
days NNS NNS O
thereafter RB RB O
. . . O

CIN NNP NNP O
was VBD VBD O
defined VBN VBN O
as IN IN O
an DT DT O
increase NN NN O
in IN IN O
serum NN NN O
creatinine NN NN B-CHEM
( ( ( O
Cr NNP NNP B-CHEM
) ) ) O
of IN IN O
0 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
dl NN NN O
or CC CC O
more JJR JJR O
, , , O
or CC CC O
elevation NN NN O
of IN IN O
Cr NNP NNP B-CHEM
to TO TO O
25 CD CD O
% NN NN O
over IN IN O
baseline NN NN O
. . . O

Relationships NNS NNS O
between IN IN O
CIN NNP NNP O
and CC CC O
possible JJ JJ O
risk NN NN O
factors NNS NNS O
were VBD VBD O
investigated VBN VBN O
. . . O

RESULTS NNS NNS O
: : : O
CIN NNP NNP O
was VBD VBD O
detected VBN VBN O
in IN IN O
18 CD CD O
/ NN NN O
90 CD CD O
( ( ( O
20 CD CD O
% NN NN O
) ) ) O
patients NNS NNS O
. . . O

CIN NNP NNP O
developed VBN VBN O
in IN IN O
25 CD CD O
. . . O
5 CD CD O
% NN NN O
patients NNS NNS O
who WP WP O
underwent VBD VBD O
chemotherapy NN NN O
and CC CC O
in IN IN O
11 CD CD O
% NN NN O
patients NNS NNS O
who WP WP O
did VBD VBD O
not RB RB O
( ( ( O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
1 CD CD O
) ) ) O
. . . O

CIN NNP NNP O
more RBR RBR O
frequently RB RB O
developed VBN VBN O
in IN IN O
patients NNS NNS O
who WP WP O
had VBD VBD O
undergone JJ JJ O
CT NNP NNP O
within IN IN O
45 CD CD O
days NNS NNS O
after IN IN O
the DT DT O
last JJ JJ O
chemotherapy NN NN O
( ( ( O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
005 CD CD O
) ) ) O
; : : O
it PRP PRP O
was VBD VBD O
also RB RB O
an DT DT O
independent JJ JJ O
risk NN NN O
factor NN NN O
( ( ( O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
017 CD CD O
) ) ) O
. . . O

CIN NNP NNP O
was VBD VBD O
significantly RB RB O
more JJR JJR O
after IN IN O
treatment NN NN O
with IN IN O
bevacizumab NN NN B-CHEM
/ NN NN O
irinotecan NN NN B-CHEM
( ( ( O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
021 CD CD O
) ) ) O
and CC CC O
in IN IN O
patients NNS NNS O
with IN IN O
hypertension NN NN O
( ( ( O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
044 CD CD O
) ) ) O
. . . O

CONCLUSIONS NNP NNP O
: : : O
The DT DT O
incidence NN NN O
of IN IN O
CIN NNP NNP O
after IN IN O
CT NNP NNP O
in IN IN O
hospitalised JJ JJ O
oncological JJ JJ O
patients NNS NNS O
was VBD VBD O
20 CD CD O
% NN NN O
. . . O

CIN NNP NNP O
developed VBD VBD O
4 CD CD O
. . . O
5 CD CD O
- : : O
times NNS NNS O
more RBR RBR O
frequently RB RB O
in IN IN O
patients NNS NNS O
with IN IN O
cancer NN NN O
who WP WP O
had VBD VBD O
undergone JJ JJ O
recent JJ JJ O
chemotherapy NN NN O
. . . O

Hypertension NNP NNP O
and CC CC O
the DT DT O
combination NN NN O
of IN IN O
bevacizumab NN NN B-CHEM
/ NN NN O
irinotecan NN NN B-CHEM
may MD MD O
be VB VB O
additional JJ JJ O
risk NN NN O
factors NNS NNS O
for IN IN O
CIN NNP NNP O
development NN NN O
. . . O

KEY NNP NNP O
POINTS NNP NNP O
: : : O
. . . O

Contrast NN NN B-CHEM
- : : O
induced JJ JJ O
nephropathy NN NN O
( ( ( O
CIN NNP NNP O
) ) ) O
is VBZ VBZ O
a DT DT O
concern NN NN O
for IN IN O
oncological JJ JJ O
patients NNS NNS O
undergoing VBG VBG O
CT NNP NNP O
. . . O

. . . O
CIN NNP NNP O
occurs VBZ VBZ O
more RBR RBR O
often RB RB O
when WRB WRB O
CT NNP NNP O
is VBZ VBZ O
performed VBN VBN O
< NN NN O
45 CD CD O
days NNS NNS O
after IN IN O
chemotherapy NN NN O
. . . O

. . . O
Hypertension NNP NNP O
and CC CC O
treatment NN NN O
with IN IN O
bevacizumab NN NN B-CHEM
appear VB VB O
to TO TO O
be VB VB O
additional JJ JJ O
risk NN NN O
factors NNS NNS O
. . . O

Syndrome NN NN O
of IN IN O
inappropriate JJ JJ O
antidiuretic JJ JJ O
hormone NN NN O
secretion NN NN O
associated VBN VBN O
with IN IN O
desvenlafaxine NN NN B-CHEM
. . . O

OBJECTIVE NNP NNP O
: : : O
To TO TO O
report VB VB O
a DT DT O
case NN NN O
of IN IN O
syndrome NN NN O
of IN IN O
inappropriate JJ JJ O
anti NN NN O
- : : O
diuretic JJ JJ O
hormone NN NN O
( ( ( O
SIADH NNP NNP O
) ) ) O
secretion NN NN O
associated VBN VBN O
with IN IN O
desvenlafaxine NN NN B-CHEM
. . . O

CASE NN NN O
SUMMARY NNP NNP O
: : : O
A DT DT O
57 CD CD O
- : : O
year NN NN O
old JJ JJ O
female JJ JJ O
with IN IN O
hyponatraemia NN NN O
. . . O

Her PRP$ PRP$ O
medications NNS NNS O
included VBD VBD O
desvenlafaxine NN NN B-CHEM
, , , O
and CC CC O
symptoms NNS NNS O
included VBD VBD O
nausea NN NN O
, , , O
anxiety NN NN O
and CC CC O
confusion NN NN O
. . . O

The DT DT O
serum NN NN O
sodium NN NN B-CHEM
at IN IN O
this DT DT O
time NN NN O
was VBD VBD O
120 CD CD O
mmol NN NN O
/ NN NN O
L NNP NNP O
, , , O
serum NN NN O
osmolality NN NN O
was VBD VBD O
263 CD CD O
mosmol NN NN O
/ NN NN O
kg NN NN O
, , , O
urine JJ JJ O
osmolality NN NN O
410 CD CD O
mosmol NN NN O
/ NN NN O
kg NN NN O
and CC CC O
urine NN NN O
sodium NN NN B-CHEM
63 CD CD O
mmol NN NN O
/ NN NN O
L NNP NNP O
, , , O
consistent JJ JJ O
with IN IN O
a DT DT O
diagnosis NN NN O
of IN IN O
SIADH NNP NNP O
. . . O

Desvenlafaxine NNP NNP B-CHEM
was VBD VBD O
ceased VBN VBN O
and CC CC O
fluid JJ JJ O
restriction NN NN O
implemented VBN VBN O
. . . O

After IN IN O
4 CD CD O
days NNS NNS O
the DT DT O
sodium NN NN B-CHEM
increased VBD VBD O
to TO TO O
128 CD CD O
mmol NN NN O
/ NN NN O
L NNP NNP O
and CC CC O
fluid JJ JJ O
restriction NN NN O
was VBD VBD O
relaxed VBN VBN O
. . . O

During IN IN O
her PRP$ PRP$ O
further JJ JJ O
3 CD CD O
weeks NNS NNS O
inpatient JJ JJ O
admission NN NN O
the DT DT O
serum NN NN O
sodium NN NN B-CHEM
ranged VBN VBN O
from IN IN O
134 CD CD O
to TO TO O
137 CD CD O
mmol NN NN O
/ NN NN O
L NNP NNP O
during IN IN O
treatment NN NN O
with IN IN O
mirtazapine NN NN B-CHEM
. . . O

DISCUSSION NNP NNP O
: : : O
SIADH NNP NNP O
has VBZ VBZ O
been VBN VBN O
widely RB RB O
reported VBN VBN O
with IN IN O
a DT DT O
range NN NN O
of IN IN O
antidepressants NNS NNS O
. . . O

This DT DT O
case NN NN O
report NN NN O
suggests VBZ VBZ O
that IN IN O
desvenlafaxine NN NN B-CHEM
might MD MD O
cause VB VB O
clinically RB RB O
significant JJ JJ O
hyponatremia NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Clinicians NNP NNP O
should MD MD O
be VB VB O
aware JJ JJ O
of IN IN O
the DT DT O
potential JJ JJ O
for IN IN O
antidepressants NNS NNS O
to TO TO O
cause VB VB O
hyponatremia NN NN O
, , , O
and CC CC O
take VB VB O
appropriate JJ JJ O
corrective JJ JJ O
action NN NN O
where WRB WRB O
necessary JJ JJ O
. . . O

Oxidative NNP NNP O
stress NN NN O
on IN IN O
cardiotoxicity NN NN O
after IN IN O
treatment NN NN O
with IN IN O
single JJ JJ O
and CC CC O
multiple JJ JJ O
doses NNS NNS O
of IN IN O
doxorubicin NN NN B-CHEM
. . . O

The DT DT O
mechanism NN NN O
of IN IN O
doxorubicin NN NN B-CHEM
( ( ( O
DOX NNP NNP B-CHEM
) ) ) O
- : : O
induced JJ JJ O
cardiotoxicity NN NN O
remains VBZ VBZ O
controversial JJ JJ O
. . . O

Wistar NNP NNP O
rats NNS NNS O
( ( ( O
n NN NN O
= SYM SYM O
66 CD CD O
) ) ) O
received VBD VBD O
DOX NNP NNP B-CHEM
injections NNS NNS O
intraperitoneally RB RB O
and CC CC O
were VBD VBD O
randomly RB RB O
assigned VBN VBN O
to TO TO O
2 CD CD O
experimental JJ JJ O
protocols NNS NNS O
: : : O
( ( ( O
1 CD CD O
) ) ) O
rats NNS NNS O
were VBD VBD O
killed VBN VBN O
before IN IN O
( ( ( O
- : : O
24 CD CD O
h NN NN O
, , , O
n NN NN O
= SYM SYM O
8 CD CD O
) ) ) O
and CC CC O
24 CD CD O
h NN NN O
after IN IN O
( ( ( O
+ NN NN O
24 CD CD O
h NN NN O
, , , O
n NN NN O
= SYM SYM O
8 CD CD O
) ) ) O
a DT DT O
single JJ JJ O
dose NN NN O
of IN IN O
DOX NNP NNP B-CHEM
( ( ( O
4 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
body NN NN O
weight NN NN O
) ) ) O
to TO TO O
determine VB VB O
the DT DT O
DOX NNP NNP B-CHEM
acute JJ JJ O
effect NN NN O
and CC CC O
( ( ( O
2 CD CD O
) ) ) O
rats NNS NNS O
( ( ( O
n NN NN O
= SYM SYM O
58 CD CD O
) ) ) O
received VBD VBD O
4 CD CD O
injections NNS NNS O
of IN IN O
DOX NNP NNP B-CHEM
( ( ( O
4 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
body NN NN O
weight NN NN O
/ NN NN O
week NN NN O
) ) ) O
and CC CC O
were VBD VBD O
killed VBN VBN O
before IN IN O
the DT DT O
first JJ JJ O
injection NN NN O
( ( ( O
M0 NNP NNP O
) ) ) O
and CC CC O
1 CD CD O
week NN NN O
after IN IN O
each DT DT O
injection NN NN O
( ( ( O
M1 NNP NNP O
, , , O
M2 NNP NNP O
, , , O
M3 NNP NNP O
, , , O
and CC CC O
M4 NNP NNP O
) ) ) O
to TO TO O
determine VB VB O
the DT DT O
chronological JJ JJ O
effects NNS NNS O
. . . O

Animals NNS NNS O
used VBN VBN O
at IN IN O
M0 NNP NNP O
( ( ( O
n NN NN O
= SYM SYM O
8 CD CD O
) ) ) O
were VBD VBD O
also RB RB O
used VBN VBN O
at IN IN O
moment NN NN O
- - - O
24 CD CD O
h NN NN O
of IN IN O
acute JJ JJ O
study NN NN O
. . . O

Cardiac NNP NNP O
total JJ JJ O
antioxidant NN NN O
performance NN NN O
( ( ( O
TAP NNP NNP O
) ) ) O
, , , O
DNA NNP NNP O
damage NN NN O
, , , O
and CC CC O
morphology NN NN O
analyses NNS NNS O
were VBD VBD O
carried VBN VBN O
out IN IN O
at IN IN O
each DT DT O
time NN NN O
point NN NN O
. . . O

Single NNP NNP O
dose NN NN O
of IN IN O
DOX NNP NNP B-CHEM
was VBD VBD O
associated VBN VBN O
with IN IN O
increased VBN VBN O
cardiac NN NN O
disarrangement NN NN O
, , , O
necrosis NN NN O
, , , O
and CC CC O
DNA NNP NNP O
damage NN NN O
( ( ( O
strand NN NN O
breaks NNS NNS O
( ( ( O
SBs NNP NNP O
) ) ) O
and CC CC O
oxidized JJ JJ O
pyrimidines NNS NNS O
) ) ) O
and CC CC O
decreased VBD VBD O
TAP NNP NNP O
. . . O

The DT DT O
chronological JJ JJ O
study NN NN O
showed VBD VBD O
an DT DT O
effect NN NN O
of IN IN O
a DT DT O
cumulative JJ JJ O
dose NN NN O
on IN IN O
body NN NN O
weight NN NN O
( ( ( O
R NN NN O
= SYM SYM O
- : : O
0 CD CD O
. . . O
99 CD CD O
, , , O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
011 CD CD O
) ) ) O
, , , O
necrosis NN NN O
( ( ( O
R NN NN O
= SYM SYM O
1 CD CD O
. . . O
00 CD CD O
, , , O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
004 CD CD O
) ) ) O
, , , O
TAP NNP NNP O
( ( ( O
R NN NN O
= SYM SYM O
0 CD CD O
. . . O
95 CD CD O
, , , O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
049 CD CD O
) ) ) O
, , , O
and CC CC O
DNA NNP NNP O
SBs NNP NNP O
( ( ( O
R NN NN O
= SYM SYM O
- : : O
0 CD CD O
. . . O
95 CD CD O
, , , O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
049 CD CD O
) ) ) O
. . . O

DNA NNP NNP O
SBs NNP NNP O
damage NN NN O
was VBD VBD O
negatively RB RB O
associated VBN VBN O
with IN IN O
TAP NNP NNP O
( ( ( O
R NN NN O
= SYM SYM O
- : : O
0 CD CD O
. . . O
98 CD CD O
, , , O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
018 CD CD O
) ) ) O
, , , O
and CC CC O
necrosis NN NN O
( ( ( O
R NN NN O
= SYM SYM O
- : : O
0 CD CD O
. . . O
97 CD CD O
, , , O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
027 CD CD O
) ) ) O
. . . O

Our PRP$ PRP$ O
results NNS NNS O
suggest VBP VBP O
that IN IN O
oxidative JJ JJ O
damage NN NN O
is VBZ VBZ O
associated VBN VBN O
with IN IN O
acute JJ JJ O
cardiotoxicity NN NN O
induced VBN VBN O
by IN IN O
a DT DT O
single JJ JJ O
dose NN NN O
of IN IN O
DOX NNP NNP B-CHEM
only RB RB O
. . . O

Increased VBN VBN O
resistance NN NN O
to TO TO O
the DT DT O
oxidative JJ JJ O
stress NN NN O
is VBZ VBZ O
plausible JJ JJ O
for IN IN O
the DT DT O
multiple JJ JJ O
dose NN NN O
of IN IN O
DOX NNP NNP B-CHEM
. . . O

Thus RB RB O
, , , O
different JJ JJ O
mechanisms NNS NNS O
may MD MD O
be VB VB O
involved VBN VBN O
in IN IN O
acute JJ JJ O
toxicity NN NN O
versus CC CC O
chronic JJ JJ O
toxicity NN NN O
. . . O

Tacrolimus NNP NNP B-CHEM
- - - O
related JJ JJ O
seizure NN NN O
after IN IN O
pediatric JJ JJ O
liver NN NN O
transplantation NN NN O
- - - O
- - - O
a DT DT O
single JJ JJ O
- - - O
center NN NN O
experience NN NN O
. . . O

To TO TO O
identify VB VB O
the DT DT O
risk NN NN O
factors NNS NNS O
for IN IN O
new JJ JJ O
- - - O
onset NN NN O
seizures NNS NNS O
after IN IN O
pediatric JJ JJ O
LT NNP NNP O
and CC CC O
to TO TO O
assess VB VB O
their PRP$ PRP$ O
clinical JJ JJ O
implications NNS NNS O
and CC CC O
long JJ JJ O
- - - O
term NN NN O
prognosis NN NN O
. . . O

The DT DT O
clinical JJ JJ O
and CC CC O
laboratory NN NN O
data NNS NNS O
of IN IN O
27 CD CD O
consecutive JJ JJ O
children NNS NNS O
who WP WP O
underwent VBD VBD O
LT NNP NNP O
from IN IN O
January NNP NNP O
2007 CD CD O
to TO TO O
December NNP NNP O
2010 CD CD O
in IN IN O
our PRP$ PRP$ O
center NN NN O
were VBD VBD O
analyzed VBN VBN O
retrospectively RB RB O
. . . O

Patients NNS NNS O
were VBD VBD O
divided VBN VBN O
into IN IN O
seizures NNS NNS O
group NN NN O
and CC CC O
a DT DT O
non NN NN O
- - - O
seizures NNS NNS O
group NN NN O
. . . O

Pre NNP NNP O
- : : O
operative JJ JJ O
, , , O
intra JJ JJ O
- - - O
operative JJ JJ O
, , , O
and CC CC O
post NN NN O
- - - O
operative JJ JJ O
data NNS NNS O
were VBD VBD O
collected VBN VBN O
. . . O

Seizures NNP NNP O
occurred VBD VBD O
in IN IN O
four CD CD O
children NNS NNS O
, , , O
an DT DT O
incidence NN NN O
of IN IN O
14 CD CD O
. . . O
8 CD CD O
% NN NN O
. . . O

All DT DT O
exhibited VBN VBN O
generalized JJ JJ O
tonic JJ JJ O
- - - O
clonic JJ JJ O
seizures NNS NNS O
within IN IN O
the DT DT O
first JJ JJ O
two CD CD O
wk NN NN O
after IN IN O
LT NNP NNP O
. . . O

Univariate NNP NNP O
analysis NN NN O
showed VBD VBD O
that IN IN O
the DT DT O
risk NN NN O
factors NNS NNS O
associated VBN VBN O
with IN IN O
seizures NNS NNS O
after IN IN O
pediatric JJ JJ O
LT NNP NNP O
included VBD VBD O
gender NN NN O
, , , O
pediatric JJ JJ O
end NN NN O
- : : O
stage NN NN O
liver NN NN O
disease NN NN O
score NN NN O
before IN IN O
surgery NN NN O
, , , O
Child NNP NNP O
- : : O
Pugh NNP NNP O
score NN NN O
before IN IN O
surgery NN NN O
, , , O
serum NN NN O
total JJ JJ O
bilirubin NN NN B-CHEM
after IN IN O
surgery NN NN O
, , , O
and CC CC O
trough JJ JJ O
TAC NNP NNP B-CHEM
level NN NN O
. . . O

Multivariate NNP NNP O
analysis NN NN O
showed VBD VBD O
that IN IN O
trough JJ JJ O
TAC NNP NNP B-CHEM
level NN NN O
was VBD VBD O
the DT DT O
only JJ JJ O
independent JJ JJ O
risk NN NN O
factor NN NN O
associated VBN VBN O
with IN IN O
the DT DT O
seizures NNS NNS O
. . . O

All DT DT O
children NNS NNS O
who WP WP O
experienced VBD VBD O
seizures NNS NNS O
survived VBN VBN O
with IN IN O
good JJ JJ O
graft NN NN O
function NN NN O
and CC CC O
remained VBD VBD O
seizure JJ JJ O
- - - O
free JJ JJ O
without IN IN O
anti NN NN O
- : : O
epileptic JJ JJ O
drugs NNS NNS O
over IN IN O
a DT DT O
mean JJ JJ O
follow VB VB O
- - - O
up RP RP O
period NN NN O
of IN IN O
33 CD CD O
. . . O
7 CD CD O
+ NN NN O
14 CD CD O
. . . O
6 CD CD O
months NNS NNS O
. . . O

High NNP NNP O
trough JJ JJ O
TAC NNP NNP B-CHEM
level NN NN O
was VBD VBD O
the DT DT O
predominant NN NN O
factor NN NN O
that WDT WDT O
contributed VBD VBD O
to TO TO O
seizures NNS NNS O
in IN IN O
the DT DT O
early JJ JJ O
post NN NN O
- - - O
operative JJ JJ O
period NN NN O
after IN IN O
pediatric JJ JJ O
LT NNP NNP O
. . . O

High NNP NNP O
PELD NNP NNP O
and CC CC O
Child NNP NNP O
- : : O
Pugh NNP NNP O
scores NNS NNS O
before IN IN O
LT NNP NNP O
and CC CC O
high JJ JJ O
post NN NN O
- - - O
operative JJ JJ O
serum NN NN O
Tbil NNP NNP O
may MD MD O
be VB VB O
contributory JJ JJ O
risk NN NN O
factors NNS NNS O
for IN IN O
TAC NNP NNP B-CHEM
- - - O
related JJ JJ O
seizures NNS NNS O
. . . O

The DT DT O
flavonoid NN NN B-CHEM
apigenin NN NN B-CHEM
delays NNS NNS O
forgetting VBG VBG O
of IN IN O
passive JJ JJ O
avoidance NN NN O
conditioning NN NN O
in IN IN O
rats NNS NNS O
. . . O

The DT DT O
present JJ JJ O
experiments NNS NNS O
were VBD VBD O
performed VBN VBN O
to TO TO O
study VB VB O
the DT DT O
effect NN NN O
of IN IN O
the DT DT O
flavonoid NN NN B-CHEM
apigenin NN NN B-CHEM
( ( ( O
20 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
intraperitoneally RB RB O
( ( ( O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
, , , O
1 CD CD O
h NN NN O
before IN IN O
acquisition NN NN O
) ) ) O
, , , O
on IN IN O
24 CD CD O
h NN NN O
retention NN NN O
performance NN NN O
and CC CC O
forgetting VBG VBG O
of IN IN O
a DT DT O
step NN NN O
- - - O
through IN IN O
passive JJ JJ O
avoidance NN NN O
task NN NN O
, , , O
in IN IN O
young JJ JJ O
male NN NN O
Wistar NNP NNP O
rats NNS NNS O
. . . O

There EX EX O
were VBD VBD O
no DT DT O
differences NNS NNS O
between IN IN O
saline NN NN O
- : : O
and CC CC O
apigenin NN NN B-CHEM
- - - O
treated VBN VBN O
groups NNS NNS O
in IN IN O
the DT DT O
24 CD CD O
h NN NN O
retention NN NN O
trial NN NN O
. . . O

Furthermore RB RB O
, , , O
apigenin NN NN B-CHEM
did VBD VBD O
not RB RB O
prevent VB VB O
the DT DT O
amnesia NN NN O
induced VBN VBN O
by IN IN O
scopolamine NN NN B-CHEM
( ( ( O
1mg CD CD O
/ NN NN O
kg NN NN O
, , , O
i NNP NNP O
. . . O
p NN NN O
. . . O
, , , O
30 CD CD O
min NN NN O
before IN IN O
the DT DT O
acquisition NN NN O
) ) ) O
. . . O

The DT DT O
saline NN NN O
- - - O
and CC CC O
apigenin NN NN B-CHEM
- - - O
treated VBN VBN O
rats NNS NNS O
that WDT WDT O
did VBD VBD O
not RB RB O
step VB VB O
through IN IN O
into IN IN O
the DT DT O
dark JJ JJ O
compartment NN NN O
during IN IN O
the DT DT O
cut NN NN O
- - - O
off RP RP O
time NN NN O
( ( ( O
540 CD CD O
s VBZ VBZ O
) ) ) O
were VBD VBD O
retested VBN VBN O
weekly IN IN O
for IN IN O
up IN IN O
to TO TO O
eight CD CD O
weeks NNS NNS O
. . . O

In IN IN O
the DT DT O
saline NN NN O
treated VBN VBN O
group NN NN O
, , , O
the DT DT O
first JJ JJ O
significant JJ JJ O
decline NN NN O
in IN IN O
passive JJ JJ O
avoidance NN NN O
response NN NN O
was VBD VBD O
observed VBN VBN O
at IN IN O
four CD CD O
weeks NNS NNS O
, , , O
and CC CC O
complete JJ JJ O
memory NN NN O
loss NN NN O
was VBD VBD O
found VBN VBN O
five CD CD O
weeks NNS NNS O
after IN IN O
the DT DT O
acquisition NN NN O
of IN IN O
the DT DT O
passive JJ JJ O
avoidance NN NN O
task NN NN O
. . . O

At IN IN O
the DT DT O
end NN NN O
of IN IN O
the DT DT O
experimental JJ JJ O
period NN NN O
, , , O
60 CD CD O
% NN NN O
of IN IN O
the DT DT O
animals NNS NNS O
treated VBN VBN O
with IN IN O
apigenin NN NN B-CHEM
still RB RB O
did VBD VBD O
not RB RB O
step NN NN O
through IN IN O
. . . O

These DT DT O
data NNS NNS O
suggest VBP VBP O
that IN IN O
1 CD CD O
) ) ) O
apigenin NN NN B-CHEM
delays NNS NNS O
the DT DT O
long JJ JJ O
- - - O
term NN NN O
forgetting NN NN O
but CC CC O
did VBD VBD O
not RB RB O
modulate VB VB O
the DT DT O
24 CD CD O
h NN NN O
retention NN NN O
of IN IN O
fear NN NN O
memory NN NN O
and CC CC O
2 CD CD O
) ) ) O
the DT DT O
obtained VBN VBN O
beneficial JJ JJ O
effect NN NN O
of IN IN O
apigenin NN NN B-CHEM
on IN IN O
the DT DT O
passive JJ JJ O
avoidance NN NN O
conditioning NN NN O
is VBZ VBZ O
mediated VBN VBN O
by IN IN O
mechanisms NNS NNS O
that WDT WDT O
do VBP VBP O
not RB RB O
implicate VB VB O
its PRP$ PRP$ O
action NN NN O
on IN IN O
the DT DT O
muscarinic JJ JJ O
cholinergic JJ JJ O
system NN NN O
. . . O

Histamine NNP NNP B-CHEM
antagonists NNS NNS O
and CC CC O
d SYM SYM B-CHEM
- : : I-CHEM
tubocurarine NN NN I-CHEM
- : : O
induced JJ JJ O
hypotension NN NN O
in IN IN O
cardiac JJ JJ O
surgical JJ JJ O
patients NNS NNS O
. . . O

Hemodynamic NNP NNP O
effects NNS NNS O
and CC CC O
histamine NN NN B-CHEM
release NN NN O
by IN IN O
bolus JJ JJ O
injection NN NN O
of IN IN O
0 CD CD O
. . . O
35 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
of IN IN O
d SYM SYM B-CHEM
- : : I-CHEM
tubocurarine NN NN I-CHEM
were VBD VBD O
studied VBN VBN O
in IN IN O
24 CD CD O
patients NNS NNS O
. . . O

H1 NNP NNP O
- : : O
and CC CC O
H2 NNP NNP O
- : : O
histamine NN NN B-CHEM
antagonists NNS NNS O
or CC CC O
placebo NN NN O
were VBD VBD O
given VBN VBN O
before IN IN O
dosing VBG VBG O
with IN IN O
d SYM SYM B-CHEM
- : : I-CHEM
tubocurarine NN NN I-CHEM
in IN IN O
a DT DT O
randomized JJ JJ O
double JJ JJ O
- - - O
blind JJ JJ O
fashion NN NN O
to TO TO O
four CD CD O
groups NNS NNS O
: : : O
group NN NN O
1 CD CD O
- : : O
- : : O
placebo NN NN O
; : : O
group NN NN O
2 CD CD O
- : : O
- : : O
cimetidine NN NN B-CHEM
, , , O
4 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
plus CC CC O
placebo NN NN O
; : : O
group NN NN O
3 CD CD O
- : : O
- : : O
chlorpheniramine NN NN B-CHEM
, , , O
0 CD CD O
. . . O
1 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
plus CC CC O
placebo NN NN O
; : : O
and CC CC O
group NN NN O
4 CD CD O
- : : O
- - - O
cimetidine NN NN B-CHEM
plus CC CC O
chlorpheniramine NN NN B-CHEM
. . . O

Histamine NNP NNP B-CHEM
release NN NN O
occurred VBD VBD O
in IN IN O
most JJS JJS O
patients NNS NNS O
, , , O
the DT DT O
highest JJS JJS O
level NN NN O
2 CD CD O
minutes NNS NNS O
after IN IN O
d SYM SYM B-CHEM
- : : I-CHEM
tubocurarine NN NN I-CHEM
dosing VBG VBG O
. . . O

Group NNP NNP O
1 CD CD O
had VBD VBD O
a DT DT O
moderate JJ JJ O
negative JJ JJ O
correlation NN NN O
between IN IN O
plasma NN NN O
histamine NN NN B-CHEM
change NN NN O
and CC CC O
systemic JJ JJ O
vascular NN NN O
resistance NN NN O
( ( ( O
r LS LS O
= SYM SYM O
0 CD CD O
. . . O
58 CD CD O
; : : O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
not RB RB O
present JJ JJ O
in IN IN O
group NN NN O
4 CD CD O
. . . O

Prior NNP NNP O
dosing VBG VBG O
with IN IN O
antagonists NNS NNS O
partially RB RB O
prevented VBD VBD O
the DT DT O
fall NN NN O
in IN IN O
systemic JJ JJ O
vascular NN NN O
resistance NN NN O
. . . O

These DT DT O
data NNS NNS O
demonstrate VBP VBP O
that IN IN O
the DT DT O
hemodynamic JJ JJ O
changes NNS NNS O
associated VBN VBN O
with IN IN O
d SYM SYM B-CHEM
- : : I-CHEM
tubocurarine NN NN I-CHEM
dosing VBG VBG O
are VBP VBP O
only RB RB O
partially RB RB O
explained VBN VBN O
by IN IN O
histamine NN NN B-CHEM
release NN NN O
. . . O

Thus RB RB O
prior RB RB O
dosing VBG VBG O
with IN IN O
H1 NNP NNP O
- : : O
and CC CC O
H2 NNP NNP O
- : : O
antagonists NNS NNS O
provides VBZ VBZ O
only RB RB O
partial JJ JJ O
protection NN NN O
. . . O

Cholecystokinin NNP NNP B-CHEM
- : : I-CHEM
octapeptide IN IN I-CHEM
restored VBN VBN O
morphine NN NN B-CHEM
- - - O
induced JJ JJ O
hippocampal NN NN O
long JJ JJ O
- - - O
term NN NN O
potentiation NN NN O
impairment NN NN O
in IN IN O
rats NNS NNS O
. . . O

Cholecystokinin NNP NNP B-CHEM
- : : I-CHEM
octapeptide NN NN I-CHEM
( ( ( O
CCK NNP NNP B-CHEM
- - - I-CHEM
8 CD CD I-CHEM
) ) ) O
, , , O
which WDT WDT O
is VBZ VBZ O
a DT DT O
typical JJ JJ O
brain NN NN O
- - - O
gut NN NN O
peptide NN NN O
, , , O
exerts VBZ VBZ O
a DT DT O
wide JJ JJ O
range NN NN O
of IN IN O
biological JJ JJ O
activities NNS NNS O
on IN IN O
the DT DT O
central JJ JJ O
nervous JJ JJ O
system NN NN O
. . . O

We PRP PRP O
have VBP VBP O
previously RB RB O
reported VBN VBN O
that IN IN O
CCK NNP NNP B-CHEM
- : : I-CHEM
8 CD CD I-CHEM
significantly RB RB O
alleviated VBN VBN O
morphine NN NN B-CHEM
- - - O
induced JJ JJ O
amnesia NN NN O
and CC CC O
reversed VBD VBD O
spine JJ JJ O
density NN NN O
decreases NNS NNS O
in IN IN O
the DT DT O
CA1 NNP NNP O
region NN NN O
of IN IN O
the DT DT O
hippocampus NN NN O
in IN IN O
morphine NN NN B-CHEM
- - - O
treated JJ JJ O
animals NNS NNS O
. . . O

Here RB RB O
, , , O
we PRP PRP O
investigated VBD VBD O
the DT DT O
effects NNS NNS O
of IN IN O
CCK NNP NNP B-CHEM
- : : I-CHEM
8 CD CD I-CHEM
on IN IN O
long JJ JJ O
- - - O
term NN NN O
potentiation NN NN O
( ( ( O
LTP NNP NNP O
) ) ) O
in IN IN O
the DT DT O
lateral NN NN O
perforant JJ JJ O
path NN NN O
( ( ( O
LPP NNP NNP O
) ) ) O
- : : O
granule NN NN O
cell NN NN O
synapse NN NN O
of IN IN O
rat NN NN O
dentate NN NN O
gyrus NN NN O
( ( ( O
DG NNP NNP O
) ) ) O
in IN IN O
acute JJ JJ O
saline NN NN O
or CC CC O
morphine NN NN B-CHEM
- - - O
treated VBN VBN O
rats NNS NNS O
. . . O

Population NN NN O
spikes NNS NNS O
( ( ( O
PS NNP NNP O
) ) ) O
, , , O
which WDT WDT O
were VBD VBD O
evoked VBN VBN O
by IN IN O
stimulation NN NN O
of IN IN O
the DT DT O
LPP NNP NNP O
, , , O
were VBD VBD O
recorded VBN VBN O
in IN IN O
the DT DT O
DG NNP NNP O
region NN NN O
. . . O

Acute JJ JJ O
morphine NN NN B-CHEM
( ( ( O
30mg CD CD O
/ NN NN O
kg NN NN O
, , , O
s VBZ VBZ O
. . . O
c SYM SYM O
. . . O
) ) ) O
treatment NN NN O
significantly RB RB O
attenuated VBD VBD O
hippocampal JJ JJ O
LTP NNP NNP O
and CC CC O
CCK NNP NNP B-CHEM
- : : I-CHEM
8 CD CD I-CHEM
( ( ( O
1ug CD CD O
, , , O
i NNP NNP O
. . . O
c SYM SYM O
. . . O
v NN NN O
. . . O
) ) ) O
restored VBD VBD O
the DT DT O
amplitude NN NN O
of IN IN O
PS NNP NNP O
that WDT WDT O
was VBD VBD O
attenuated VBN VBN O
by IN IN O
morphine NN NN B-CHEM
injection NN NN O
. . . O

Furthermore RB RB O
, , , O
microinjection NN NN O
of IN IN O
CCK NNP NNP B-CHEM
- : : I-CHEM
8 CD CD I-CHEM
( ( ( O
0 CD CD O
. . . O
1 CD CD O
and CC CC O
1ug CD CD O
, , , O
i NNP NNP O
. . . O
c SYM SYM O
. . . O
v NN NN O
. . . O
) ) ) O
also RB RB O
significantly RB RB O
augmented VBN VBN O
hippocampal JJ JJ O
LTP NNP NNP O
in IN IN O
saline NN NN O
- - - O
treated VBN VBN O
( ( ( O
1ml CD CD O
/ NN NN O
kg NN NN O
, , , O
s VBZ VBZ O
. . . O
c SYM SYM O
. . . O
) ) ) O
rats NNS NNS O
. . . O

Pre NNP NNP O
- : : O
treatment NN NN O
of IN IN O
the DT DT O
CCK2 NNP NNP O
receptor NN NN O
antagonist NN NN O
L NNP NNP O
- : : O
365 CD CD O
, , , O
260 CD CD O
( ( ( O
10ug CD CD O
, , , O
i NNP NNP O
. . . O
c SYM SYM O
. . . O
v NN NN O
) ) ) O
reversed VBD VBD O
the DT DT O
effects NNS NNS O
of IN IN O
CCK NNP NNP B-CHEM
- : : I-CHEM
8 CD CD I-CHEM
, , , O
but CC CC O
the DT DT O
CCK1 NNP NNP O
receptor NN NN O
antagonist NN NN O
L NNP NNP O
- : : O
364 CD CD O
, , , O
718 CD CD O
( ( ( O
10ug CD CD O
, , , O
i NNP NNP O
. . . O
c SYM SYM O
. . . O
v NN NN O
) ) ) O
did VBD VBD O
not RB RB O
. . . O

The DT DT O
present JJ JJ O
results NNS NNS O
demonstrate VBP VBP O
that IN IN O
CCK NNP NNP B-CHEM
- : : I-CHEM
8 CD CD I-CHEM
attenuates VBZ VBZ O
the DT DT O
effect NN NN O
of IN IN O
morphine NN NN B-CHEM
on IN IN O
hippocampal NN NN O
LTP NNP NNP O
through IN IN O
CCK2 NNP NNP O
receptors NNS NNS O
and CC CC O
suggest VBP VBP O
an DT DT O
ameliorative JJ JJ O
function NN NN O
of IN IN O
CCK NNP NNP B-CHEM
- : : I-CHEM
8 CD CD I-CHEM
on IN IN O
morphine NN NN B-CHEM
- : : O
induced JJ JJ O
memory NN NN O
impairment NN NN O
. . . O

Glial NNP NNP O
activation NN NN O
and CC CC O
post NN NN O
- - - O
synaptic JJ JJ O
neurotoxicity NN NN O
: : : O
the DT DT O
key JJ JJ O
events NNS NNS O
in IN IN O
Streptozotocin NNP NNP B-CHEM
( ( ( O
ICV NNP NNP O
) ) ) O
induced JJ JJ O
memory NN NN O
impairment NN NN O
in IN IN O
rats NNS NNS O
. . . O

In IN IN O
the DT DT O
present JJ JJ O
study NN NN O
the DT DT O
role NN NN O
of IN IN O
glial JJ JJ O
activation NN NN O
and CC CC O
post NN NN O
synaptic JJ JJ O
toxicity NN NN O
in IN IN O
ICV NNP NNP O
Streptozotocin NNP NNP B-CHEM
( ( ( O
STZ NNP NNP B-CHEM
) ) ) O
induced JJ JJ O
memory NN NN O
impaired VBD VBD O
rats NNS NNS O
was VBD VBD O
explored JJ JJ O
. . . O

In IN IN O
experiment NN NN O
set VBN VBN O
up RP RP O
1 CD CD O
: : : O
Memory NN NN O
deficit NN NN O
was VBD VBD O
found VBN VBN O
in IN IN O
Morris NNP NNP O
water NN NN O
maze NN NN O
test NN NN O
on IN IN O
14 CD CD O
- : : O
16 CD CD O
days NNS NNS O
after IN IN O
STZ NNP NNP B-CHEM
( ( ( O
ICV NNP NNP O
; : : O
3mg CD CD O
/ NN NN O
Kg NNP NNP O
) ) ) O
administration NN NN O
. . . O

STZ NNP NNP B-CHEM
causes NNS NNS O
increased VBN VBN O
expression NN NN O
of IN IN O
GFAP NNP NNP O
, , , O
CD11b NNP NNP O
and CC CC O
TNF NNP NNP O
- : : O
a DT DT O
indicating VBG VBG O
glial JJ JJ O
activation NN NN O
and CC CC O
neuroinflammation NN NN O
. . . O

STZ NNP NNP B-CHEM
also RB RB O
significantly RB RB O
increased VBN VBN O
the DT DT O
level NN NN O
of IN IN O
ROS NNP NNP O
, , , O
nitrite NN NN B-CHEM
, , , O
Ca NNP NNP B-CHEM
( ( ( O
2 CD CD O
+ NN NN O
) ) ) O
and CC CC O
reduced VBD VBD O
the DT DT O
mitochondrial JJ JJ O
activity NN NN O
in IN IN O
synaptosomal JJ JJ O
preparation NN NN O
illustrating VBG VBG O
free JJ JJ O
radical JJ JJ O
generation NN NN O
and CC CC O
excitotoxicity NN NN O
. . . O

Increased NNP NNP O
expression NN NN O
and CC CC O
activity NN NN O
of IN IN O
Caspase NNP NNP O
- : : O
3 CD CD O
was VBD VBD O
also RB RB O
observed VBN VBN O
in IN IN O
STZ NNP NNP B-CHEM
treated VBD VBD O
rat NN NN O
which WDT WDT O
specify VB VB O
apoptotic JJ JJ O
cell NN NN O
death NN NN O
in IN IN O
hippocampus NN NN O
and CC CC O
cortex NN NN O
. . . O

STZ NNP NNP B-CHEM
treatment NN NN O
showed VBD VBD O
decrease NN NN O
expression NN NN O
of IN IN O
post NN NN O
synaptic JJ JJ O
markers NNS NNS O
CaMKIIa NNP NNP O
and CC CC O
PSD NNP NNP O
- : : O
95 CD CD O
, , , O
while IN IN O
, , , O
expression NN NN O
of IN IN O
pre NN NN O
synaptic JJ JJ O
markers NNS NNS O
( ( ( O
synaptophysin NN NN O
and CC CC O
SNAP NNP NNP O
- : : O
25 CD CD O
) ) ) O
remains VBZ VBZ O
unaltered JJ JJ O
indicating VBG VBG O
selective JJ JJ O
post NN NN O
synaptic JJ JJ O
neurotoxicity NN NN O
. . . O

Oral NNP NNP O
treatment NN NN O
with IN IN O
Memantine NNP NNP B-CHEM
( ( ( O
10mg CD CD O
/ NN NN O
kg NN NN O
) ) ) O
and CC CC O
Ibuprofen NNP NNP B-CHEM
( ( ( O
50 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
daily JJ JJ O
for IN IN O
13 CD CD O
days NNS NNS O
attenuated VBD VBD O
STZ NNP NNP B-CHEM
induced VBD VBD O
glial JJ JJ O
activation NN NN O
, , , O
apoptotic JJ JJ O
cell NN NN O
death NN NN O
and CC CC O
post NN NN O
synaptic JJ JJ O
neurotoxicity NN NN O
in IN IN O
rat NN NN O
brain NN NN O
. . . O

Further RB RB O
, , , O
in IN IN O
experiment NN NN O
set VBN VBN O
up RP RP O
2 CD CD O
: : : O
where WRB WRB O
memory NN NN O
function NN NN O
was VBD VBD O
not RB RB O
affected VBN VBN O
i NNP NNP O
. . . O
e SYM SYM O
. . . O
7 CD CD O
- : : O
9 CD CD O
days NNS NNS O
after IN IN O
STZ NNP NNP B-CHEM
treatment NN NN O
. . . O

The DT DT O
level NN NN O
of IN IN O
GFAP NNP NNP O
, , , O
CD11b NNP NNP O
, , , O
TNF NNP NNP O
- : : O
a DT DT O
, , , O
ROS NNP NNP O
and CC CC O
nitrite NN NN B-CHEM
levels NNS NNS O
were VBD VBD O
increased VBN VBN O
. . . O

On IN IN O
the DT DT O
other JJ JJ O
hand NN NN O
, , , O
apoptotic JJ JJ O
marker NN NN O
, , , O
synaptic JJ JJ O
markers NNS NNS O
, , , O
mitochondrial JJ JJ O
activity NN NN O
and CC CC O
Ca MD MD B-CHEM
( ( ( O
2 CD CD O
+ NN NN O
) ) ) O
levels NNS NNS O
remained VBD VBD O
unaffected JJ JJ O
. . . O

Collective NNP NNP O
data NNS NNS O
indicates VBZ VBZ O
that IN IN O
neuroinflammatory NN NN O
process NN NN O
and CC CC O
oxidative JJ JJ O
stress NN NN O
occurs VBZ VBZ O
earlier JJR JJR O
to TO TO O
apoptosis NN NN O
and CC CC O
does VBZ VBZ O
not RB RB O
affect VB VB O
memory NN NN O
function NN NN O
. . . O

Present JJ JJ O
study NN NN O
clearly RB RB O
suggests VBZ VBZ O
that IN IN O
glial JJ JJ O
activation NN NN O
and CC CC O
post NN NN O
synaptic JJ JJ O
neurotoxicity NN NN O
are VBP VBP O
the DT DT O
key JJ JJ O
factors NNS NNS O
in IN IN O
STZ NNP NNP B-CHEM
induced VBD VBD O
memory NN NN O
impairment NN NN O
and CC CC O
neuronal JJ JJ O
cell NN NN O
death NN NN O
. . . O

Comparison NNP NNP O
of IN IN O
effects NNS NNS O
of IN IN O
isotonic JJ JJ O
sodium NN NN B-CHEM
chloride NN NN I-CHEM
with IN IN O
diltiazem NN NN B-CHEM
in IN IN O
prevention NN NN O
of IN IN O
contrast NN NN B-CHEM
- - - O
induced JJ JJ O
nephropathy NN NN O
. . . O

INTRODUCTION NNP NNP O
AND CC CC O
OBJECTIVE NNP NNP O
: : : O
Contrast NN NN B-CHEM
- - - O
induced JJ JJ O
nephropathy NN NN O
( ( ( O
CIN NNP NNP O
) ) ) O
significantly RB RB O
increases VBZ VBZ O
the DT DT O
morbidity NN NN O
and CC CC O
mortality NN NN O
of IN IN O
patients NNS NNS O
. . . O

The DT DT O
aim NN NN O
of IN IN O
this DT DT O
study NN NN O
is VBZ VBZ O
to TO TO O
investigate VB VB O
and CC CC O
compare VB VB O
the DT DT O
protective JJ JJ O
effects NNS NNS O
of IN IN O
isotonic JJ JJ O
sodium NN NN B-CHEM
chloride NN NN I-CHEM
with IN IN O
sodium NN NN B-CHEM
bicarbonate NN NN I-CHEM
infusion NN NN O
and CC CC O
isotonic JJ JJ O
sodium NN NN B-CHEM
chloride NN NN I-CHEM
infusion NN NN O
with IN IN O
diltiazem NN NN B-CHEM
, , , O
a DT DT O
calcium NN NN B-CHEM
channel NN NN O
blocker NN NN O
, , , O
in IN IN O
preventing VBG VBG O
CIN NNP NNP O
. . . O

MATERIALS NNS NNS O
AND CC CC O
METHODS NNP NNP O
: : : O
Our PRP$ PRP$ O
study NN NN O
included VBD VBD O
patients NNS NNS O
who WP WP O
were VBD VBD O
administered VBN VBN O
30 CD CD O
- : : O
60 CD CD O
mL NN NN O
of IN IN O
iodinated JJ JJ O
contrast NN NN B-CHEM
agent NN NN O
for IN IN O
percutaneous JJ JJ O
coronary JJ JJ O
angiography NN NN O
( ( ( O
PCAG NNP NNP O
) ) ) O
, , , O
all DT DT O
with IN IN O
creatinine NN NN B-CHEM
values NNS NNS O
between IN IN O
1 CD CD O
. . . O
1 CD CD O
and CC CC O
3 CD CD O
. . . O
1 CD CD O
mg NN NN O
/ NN NN O
dL NN NN O
. . . O

Patients NNS NNS O
were VBD VBD O
divided VBN VBN O
into IN IN O
three CD CD O
groups NNS NNS O
and CC CC O
each DT DT O
group NN NN O
had VBD VBD O
20 CD CD O
patients NNS NNS O
. . . O

The DT DT O
first JJ JJ O
group NN NN O
of IN IN O
patients NNS NNS O
was VBD VBD O
administered VBN VBN O
isotonic JJ JJ O
sodium NN NN B-CHEM
chloride NN NN I-CHEM
; : : O
the DT DT O
second JJ JJ O
group NN NN O
was VBD VBD O
administered VBN VBN O
a DT DT O
solution NN NN O
that IN IN O
of IN IN O
5 CD CD O
% NN NN O
dextrose NN NN B-CHEM
and CC CC O
sodium NN NN B-CHEM
bicarbonate NN NN I-CHEM
, , , O
while IN IN O
the DT DT O
third JJ JJ O
group NN NN O
was VBD VBD O
administered VBN VBN O
isotonic JJ JJ O
sodium NN NN B-CHEM
chloride NN NN I-CHEM
before IN IN O
and CC CC O
after IN IN O
the DT DT O
contrast NN NN B-CHEM
injection NN NN O
. . . O

The DT DT O
third JJ JJ O
group NN NN O
received VBD VBD O
an DT DT O
additional JJ JJ O
injection NN NN O
of IN IN O
diltiazem NN NN B-CHEM
the DT DT O
day NN NN O
before IN IN O
and CC CC O
first JJ JJ O
2 CD CD O
days NNS NNS O
after IN IN O
the DT DT O
contrast NN NN B-CHEM
injection NN NN O
. . . O

All DT DT O
of IN IN O
the DT DT O
patients NNS NNS O
' POS POS O
plasma NN NN O
blood NN NN B-CHEM
urea JJ JJ I-CHEM
nitrogen NN NN I-CHEM
( ( ( O
BUN NNP NNP B-CHEM
) ) ) O
and CC CC O
creatinine NN NN B-CHEM
levels NNS NNS O
were VBD VBD O
measured VBN VBN O
on IN IN O
the DT DT O
second JJ JJ O
and CC CC O
seventh JJ JJ O
day NN NN O
after IN IN O
the DT DT O
administration NN NN O
of IN IN O
intravenous JJ JJ O
contrast NN NN B-CHEM
material NN NN O
. . . O

RESULTS NNS NNS O
: : : O
The DT DT O
basal NN NN O
creatinine NN NN B-CHEM
levels NNS NNS O
were VBD VBD O
similar JJ JJ O
for IN IN O
all DT DT O
three CD CD O
groups NNS NNS O
( ( ( O
p NN NN O
> NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

Among IN IN O
a DT DT O
total NN NN O
of IN IN O
60 CD CD O
patients NNS NNS O
included VBD VBD O
in IN IN O
the DT DT O
study NN NN O
, , , O
16 CD CD O
patients NNS NNS O
developed VBN VBN O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
( ( ( O
ARF NNP NNP O
) ) ) O
on IN IN O
the DT DT O
second JJ JJ O
day NN NN O
after IN IN O
contrast NN NN B-CHEM
material NN NN O
was VBD VBD O
injected VBN VBN O
( ( ( O
26 CD CD O
. . . O
6 CD CD O
% NN NN O
) ) ) O
. . . O

The DT DT O
number NN NN O
of IN IN O
patients NNS NNS O
who WP WP O
developed VBD VBD O
ARF NNP NNP O
on IN IN O
the DT DT O
second JJ JJ O
day NN NN O
after IN IN O
the DT DT O
injection NN NN O
in IN IN O
the DT DT O
first JJ JJ O
group NN NN O
was VBD VBD O
five CD CD O
( ( ( O
25 CD CD O
% NN NN O
) ) ) O
, , , O
in IN IN O
the DT DT O
second JJ JJ O
group NN NN O
was VBD VBD O
six CD CD O
( ( ( O
30 CD CD O
% NN NN O
) ) ) O
and CC CC O
the DT DT O
third JJ JJ O
group NN NN O
was VBD VBD O
five CD CD O
( ( ( O
25 CD CD O
% NN NN O
) ) ) O
( ( ( O
p NN NN O
> NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

CONCLUSION NNP NNP O
: : : O
There EX EX O
was VBD VBD O
no DT DT O
significant JJ JJ O
difference NN NN O
between IN IN O
isotonic JJ JJ O
sodium NN NN B-CHEM
chloride NN NN I-CHEM
, , , O
sodium NN NN B-CHEM
bicarbonate NN NN I-CHEM
and CC CC O
isotonic JJ JJ O
sodium NN NN B-CHEM
chloride NN NN I-CHEM
with IN IN O
diltiazem NN NN B-CHEM
application NN NN O
in IN IN O
prevention NN NN O
of IN IN O
CIN NNP NNP O
. . . O

Neurocognitive NNP NNP O
and CC CC O
neuroradiologic JJ JJ O
central JJ JJ O
nervous JJ JJ O
system NN NN O
late JJ JJ O
effects NNS NNS O
in IN IN O
children NNS NNS O
treated VBN VBN O
on IN IN O
Pediatric NNP NNP O
Oncology NNP NNP O
Group NNP NNP O
( ( ( O
POG NNP NNP O
) ) ) O
P9605 NNP NNP O
( ( ( O
standard JJ JJ O
risk NN NN O
) ) ) O
and CC CC O
P9201 NNP NNP O
( ( ( O
lesser NN NN O
risk NN NN O
) ) ) O
acute JJ JJ O
lymphoblastic JJ JJ O
leukemia NN NN O
protocols NNS NNS O
( ( ( O
ACCL0131 NNP NNP O
) ) ) O
: : : O
a DT DT O
methotrexate JJ JJ B-CHEM
consequence NN NN O
? . . O

A DT DT O
report NN NN O
from IN IN O
the DT DT O
Children NNP NNP O
' POS POS O
s VBZ VBZ O
Oncology NNP NNP O
Group NNP NNP O
. . . O

Concerns NNS NNS O
about IN IN O
long JJ JJ O
- - - O
term NN NN O
methotrexate NN NN B-CHEM
( ( ( O
MTX NNP NNP B-CHEM
) ) ) O
neurotoxicity NN NN O
in IN IN O
the DT DT O
1990s NN NN O
led VBN VBN O
to TO TO O
modifications NNS NNS O
in IN IN O
intrathecal JJ JJ O
( ( ( O
IT PRP PRP O
) ) ) O
therapy NN NN O
, , , O
leucovorin NN NN O
rescue NN NN O
, , , O
and CC CC O
frequency NN NN O
of IN IN O
systemic JJ JJ O
MTX NNP NNP B-CHEM
administration NN NN O
in IN IN O
children NNS NNS O
with IN IN O
acute JJ JJ O
lymphoblastic JJ JJ O
leukemia NN NN O
. . . O

In IN IN O
this DT DT O
study NN NN O
, , , O
neurocognitive JJ JJ O
outcomes NNS NNS O
and CC CC O
neuroradiologic JJ JJ O
evidence NN NN O
of IN IN O
leukoencephalopathy NN NN O
were VBD VBD O
compared VBN VBN O
in IN IN O
children NNS NNS O
treated VBN VBN O
with IN IN O
intense JJ JJ O
central JJ JJ O
nervous JJ JJ O
system NN NN O
( ( ( O
CNS NNP NNP O
) ) ) O
- : : O
directed VBN VBN O
therapy NN NN O
( ( ( O
P9605 NNP NNP O
) ) ) O
versus CC CC O
those DT DT O
receiving VBG VBG O
fewer JJR JJR O
CNS NNP NNP O
- - - O
directed JJ JJ O
treatment NN NN O
days NNS NNS O
during IN IN O
intensive JJ JJ O
consolidation NN NN O
( ( ( O
P9201 NNP NNP O
) ) ) O
. . . O

A DT DT O
total NN NN O
of IN IN O
66 CD CD O
children NNS NNS O
from IN IN O
16 CD CD O
Pediatric NNP NNP O
Oncology NNP NNP O
Group NNP NNP O
institutions NNS NNS O
with IN IN O
" '' '' O
standard JJ JJ O
- - - O
risk NN NN O
" '' '' O
acute JJ JJ O
lymphoblastic JJ JJ O
leukemia NN NN O
, , , O
1 CD CD O
. . . O
00 CD CD O
to TO TO O
9 CD CD O
. . . O
99 CD CD O
years NNS NNS O
at IN IN O
diagnosis NN NN O
, , , O
without IN IN O
evidence NN NN O
of IN IN O
CNS NNP NNP O
leukemia NN NN O
at IN IN O
diagnosis NN NN O
were VBD VBD O
enrolled VBN VBN O
on IN IN O
ACCL0131 NNP NNP O
: : : O
28 CD CD O
from IN IN O
P9201 NNP NNP O
and CC CC O
38 CD CD O
from IN IN O
P9605 NNP NNP O
. . . O

Magnetic NNP NNP O
resonance NN NN O
imaging VBG VBG O
scans NNS NNS O
and CC CC O
standard JJ JJ O
neuropsychological JJ JJ O
tests NNS NNS O
were VBD VBD O
performed VBN VBN O
> NN NN O
2 CD CD O
. . . O
6 CD CD O
years NNS NNS O
after IN IN O
the DT DT O
end NN NN O
of IN IN O
treatment NN NN O
. . . O

Significantly RB RB O
more JJR JJR O
P9605 NNP NNP O
patients NNS NNS O
developed VBN VBN O
leukoencephalopathy NN NN O
compared VBN VBN O
with IN IN O
P9201 NNP NNP O
patients NNS NNS O
( ( ( O
68 CD CD O
% NN NN O
, , , O
95 CD CD O
% NN NN O
confidence NN NN O
interval NN NN O
49 CD CD O
% NN NN O
- : : O
83 CD CD O
% NN NN O
vs NNS NNS O
. . . O
22 CD CD O
% NN NN O
, , , O
95 CD CD O
% NN NN O
confidence NN NN O
interval NN NN O
5 CD CD O
% NN NN O
- : : O
44 CD CD O
% NN NN O
; : : O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
identified VBN VBN O
as RB RB O
late RB RB O
as IN IN O
7 CD CD O
. . . O
7 CD CD O
years NNS NNS O
after IN IN O
the DT DT O
end NN NN O
of IN IN O
treatment NN NN O
. . . O

Overall NNP NNP O
, , , O
40 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
scored VBD VBD O
< NN NN O
85 CD CD O
on IN IN O
either DT DT O
Verbal NNP NNP O
or CC CC O
Performance NNP NNP O
IQ NNP NNP O
. . . O

Children NNP NNP O
on IN IN O
both DT DT O
studies NNS NNS O
had VBD VBD O
significant JJ JJ O
attention NN NN O
problems NNS NNS O
, , , O
but CC CC O
P9605 NNP NNP O
children NNS NNS O
scored VBD VBD O
below IN IN O
average JJ JJ O
on IN IN O
more RBR RBR O
neurocognitive JJ JJ O
measures NNS NNS O
than IN IN O
those DT DT O
treated VBN VBN O
on IN IN O
P9201 NNP NNP O
( ( ( O
82 CD CD O
% NN NN O
, , , O
14 CD CD O
/ NN NN O
17 CD CD O
measures NNS NNS O
vs NNS NNS O
. . . O
24 CD CD O
% NN NN O
, , , O
4 CD CD O
/ NN NN O
17 CD CD O
measures NNS NNS O
) ) ) O
. . . O

This DT DT O
supports VBZ VBZ O
ongoing JJ JJ O
concerns NNS NNS O
about IN IN O
intensive JJ JJ O
MTX NNP NNP B-CHEM
exposure NN NN O
as IN IN O
a DT DT O
major JJ JJ O
contributor NN NN O
to TO TO O
CNS NNP NNP O
late JJ JJ O
effects NNS NNS O
. . . O

Tranexamic NNP NNP B-CHEM
acid NN NN I-CHEM
overdosage NN NN O
- : : O
induced VBN VBN O
generalized JJ JJ O
seizure NN NN O
in IN IN O
renal JJ JJ O
failure NN NN O
. . . O

We PRP PRP O
report VBP VBP O
a DT DT O
45 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
lady NN NN O
with IN IN O
chronic JJ JJ O
kidney NN NN O
disease NN NN O
stage NN NN O
4 CD CD O
due JJ JJ O
to TO TO O
chronic JJ JJ O
tubulointerstial JJ JJ O
disease NN NN O
. . . O

She PRP PRP O
was VBD VBD O
admitted VBN VBN O
to TO TO O
our PRP$ PRP$ O
center NN NN O
for IN IN O
severe JJ JJ O
anemia NN NN O
due JJ JJ O
to TO TO O
menorrhagia VB VB O
and CC CC O
deterioration NN NN O
of IN IN O
renal JJ JJ O
function NN NN O
. . . O

She PRP PRP O
was VBD VBD O
infused VBN VBN O
three CD CD O
units NNS NNS O
of IN IN O
packed JJ JJ O
cells NNS NNS O
during IN IN O
a DT DT O
session NN NN O
of IN IN O
hemodialysis NN NN O
. . . O

Tranexamic NNP NNP B-CHEM
acid NN NN I-CHEM
( ( ( O
TNA NNP NNP B-CHEM
) ) ) O
1 CD CD O
g SYM SYM O
8 CD CD O
- : : O
hourly RB RB O
was VBD VBD O
administered VBN VBN O
to TO TO O
her PRP PRP O
to TO TO O
control VB VB O
bleeding VBG VBG O
per IN IN O
vaginum NN NN O
. . . O

Two CD CD O
hours NNS NNS O
after IN IN O
the DT DT O
sixth JJ JJ O
dose NN NN O
of IN IN O
TNA NNP NNP B-CHEM
, , , O
she PRP PRP O
had VBD VBD O
an DT DT O
episode NN NN O
of IN IN O
generalized JJ JJ O
tonic NN NN O
clonic JJ JJ O
convulsions NNS NNS O
. . . O

TNA NNP NNP B-CHEM
was VBD VBD O
discontinued VBN VBN O
. . . O

Investigations NNP NNP O
of IN IN O
the DT DT O
patient NN NN O
revealed VBD VBD O
no DT DT O
biochemical JJ JJ O
or CC CC O
structural JJ JJ O
central JJ JJ O
nervous JJ JJ O
system NN NN O
abnormalities NNS NNS O
that WDT WDT O
could MD MD O
have VB VB O
provoked VBN VBN O
the DT DT O
convulsions NNS NNS O
. . . O

She PRP PRP O
did VBD VBD O
not RB RB O
require VB VB O
any DT DT O
further JJ JJ O
dialytic JJ JJ O
support NN NN O
. . . O

She PRP PRP O
had VBD VBD O
no DT DT O
further JJ JJ O
episodes NNS NNS O
of IN IN O
convulsion NN NN O
till IN IN O
dis NN NN O
- : : O
charge NN NN O
and CC CC O
during IN IN O
the DT DT O
two CD CD O
months NNS NNS O
of IN IN O
follow VB VB O
- - - O
up RP RP O
. . . O

Thus RB RB O
, , , O
the DT DT O
precipitating VBG VBG O
cause NN NN O
of IN IN O
convulsions NNS NNS O
was VBD VBD O
believed VBN VBN O
to TO TO O
be VB VB O
an DT DT O
overdose NN NN O
of IN IN O
TNA NNP NNP B-CHEM
. . . O

Pre NNP NNP O
- : : O
treatment NN NN O
of IN IN O
bupivacaine NN NN B-CHEM
- - - O
induced JJ JJ O
cardiovascular JJ JJ O
depression NN NN O
using VBG VBG O
different JJ JJ O
lipid NN NN O
formulations NNS NNS O
of IN IN O
propofol NN NN B-CHEM
. . . O

BACKGROUND NNP NNP O
: : : O
Pre NNP NNP O
- - - O
treatment NN NN O
with IN IN O
lipid NN NN O
emulsions NNS NNS O
has VBZ VBZ O
been VBN VBN O
shown VBN VBN O
to TO TO O
increase VB VB O
lethal JJ JJ O
doses NNS NNS O
of IN IN O
bupivacaine NN NN B-CHEM
, , , O
and CC CC O
the DT DT O
lipid JJ JJ O
content NN NN O
of IN IN O
propofol NN NN B-CHEM
may MD MD O
alleviate VB VB O
bupivacaine NN NN B-CHEM
- : : O
induced JJ JJ O
cardiotoxicity NN NN O
. . . O

The DT DT O
aim NN NN O
of IN IN O
this DT DT O
study NN NN O
is VBZ VBZ O
to TO TO O
investigate VB VB O
the DT DT O
effects NNS NNS O
of IN IN O
propofol NN NN B-CHEM
in IN IN O
intralipid JJ JJ O
or CC CC O
medialipid JJ JJ O
emulsions NNS NNS O
on IN IN O
bupivacaine NN NN B-CHEM
- : : O
induced JJ JJ O
cardiotoxicity NN NN O
. . . O

METHODS NNP NNP O
: : : O
Rats NNP NNP O
were VBD VBD O
anaesthetised VBN VBN O
with IN IN O
ketamine NN NN B-CHEM
and CC CC O
were VBD VBD O
given VBN VBN O
0 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
propofol NN NN B-CHEM
in IN IN O
intralipid JJ JJ O
( ( ( O
Group NNP NNP O
P NN NN O
) ) ) O
, , , O
propofol NN NN B-CHEM
in IN IN O
medialipid NN NN O
( ( ( O
Group NNP NNP O
L NNP NNP O
) ) ) O
, , , O
or CC CC O
saline NN NN O
( ( ( O
Group NNP NNP O
C NNP NNP O
) ) ) O
over IN IN O
20 CD CD O
min NN NN O
. . . O

Thereafter NNP NNP O
, , , O
2 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
bupivacaine NN NN B-CHEM
0 CD CD O
. . . O
5 CD CD O
% NN NN O
was VBD VBD O
infused VBN VBN O
. . . O

We PRP PRP O
recorded VBD VBD O
time NN NN O
to TO TO O
first JJ JJ O
dysrhythmia NN NN O
occurrence NN NN O
, , , O
respective JJ JJ O
times NNS NNS O
to TO TO O
25 CD CD O
% NN NN O
and CC CC O
50 CD CD O
% NN NN O
reduction NN NN O
of IN IN O
the DT DT O
heart NN NN O
rate NN NN O
( ( ( O
HR NNP NNP O
) ) ) O
and CC CC O
mean VB VB O
arterial JJ JJ O
pressure NN NN O
, , , O
and CC CC O
time NN NN O
to TO TO O
asystole VB VB O
and CC CC O
total JJ JJ O
amount NN NN O
of IN IN O
bupivacaine NN NN B-CHEM
consumption NN NN O
. . . O

Blood NNP NNP O
and CC CC O
tissue NN NN O
samples NNS NNS O
were VBD VBD O
collected VBN VBN O
following VBG VBG O
asystole NN NN O
. . . O

RESULTS NNS NNS O
: : : O
The DT DT O
time NN NN O
to TO TO O
first JJ JJ O
dysrhythmia NN NN O
occurrence NN NN O
, , , O
time NN NN O
to TO TO O
25 CD CD O
% NN NN O
and CC CC O
50 CD CD O
% NN NN O
reductions NNS NNS O
in IN IN O
HR NNP NNP O
, , , O
and CC CC O
time NN NN O
to TO TO O
asystole VB VB O
were VBD VBD O
longer RBR RBR O
in IN IN O
Group NNP NNP O
P NN NN O
than IN IN O
the DT DT O
other JJ JJ O
groups NNS NNS O
. . . O

The DT DT O
cumulative JJ JJ O
bupivacaine NN NN B-CHEM
dose NN NN O
given VBN VBN O
at IN IN O
those DT DT O
time NN NN O
points NNS NNS O
was VBD VBD O
higher JJR JJR O
in IN IN O
Group NNP NNP O
P NN NN O
. . . O
Plasma NNP NNP O
bupivacaine NN NN B-CHEM
levels NNS NNS O
were VBD VBD O
significantly RB RB O
lower JJR JJR O
in IN IN O
Group NNP NNP O
P NN NN O
than IN IN O
in IN IN O
Group NNP NNP O
C NNP NNP O
. . . O
Bupivacaine NNP NNP B-CHEM
levels NNS NNS O
in IN IN O
the DT DT O
brain NN NN O
and CC CC O
heart NN NN O
were VBD VBD O
significantly RB RB O
lower JJR JJR O
in IN IN O
Group NNP NNP O
P NN NN O
and CC CC O
Group NNP NNP O
L NNP NNP O
than IN IN O
in IN IN O
Group NNP NNP O
C NNP NNP O
. . . O

CONCLUSION NNP NNP O
: : : O
We PRP PRP O
conclude VBP VBP O
that IN IN O
pre NN NN O
- : : O
treatment NN NN O
with IN IN O
propofol NN NN B-CHEM
in IN IN O
intralipid JJ JJ O
, , , O
compared VBN VBN O
with IN IN O
propofol NN NN B-CHEM
in IN IN O
medialipid NN NN O
or CC CC O
saline NN NN O
, , , O
delayed VBD VBD O
the DT DT O
onset NN NN O
of IN IN O
bupivacaine NN NN B-CHEM
- - - O
induced JJ JJ O
cardiotoxic NN NN O
effects NNS NNS O
as RB RB O
well RB RB O
as IN IN O
reduced VBN VBN O
plasma NN NN O
bupivacaine NN NN B-CHEM
levels NNS NNS O
. . . O

Further RB RB O
studies NNS NNS O
are VBP VBP O
needed VBN VBN O
to TO TO O
explore VB VB O
tissue NN NN O
bupivacaine NN NN B-CHEM
levels NNS NNS O
of IN IN O
propofol NN NN B-CHEM
in IN IN O
medialipid NN NN O
and CC CC O
adapt NN NN O
these DT DT O
results NNS NNS O
to TO TO O
clinical JJ JJ O
practice NN NN O
. . . O

Drug NN NN O
- : : O
Induced NNP NNP O
Acute JJ JJ O
Liver NNP NNP O
Injury NNP NNP O
Within IN IN O
12 CD CD O
Hours NNS NNS O
After IN IN O
Fluvastatin NNP NNP B-CHEM
Therapy NNP NNP O
. . . O

Although IN IN O
statins NNS NNS B-CHEM
are VBP VBP O
generally RB RB O
well RB RB O
- - - O
tolerated JJ JJ O
drugs NNS NNS O
, , , O
recent JJ JJ O
cases NNS NNS O
of IN IN O
drug NN NN O
- - - O
induced JJ JJ O
liver NN NN O
injury NN NN O
associated VBN VBN O
with IN IN O
their PRP$ PRP$ O
use NN NN O
have VBP VBP O
been VBN VBN O
reported VBN VBN O
. . . O

A DT DT O
52 JJ JJ O
- - - O
year NN NN O
- - - O
old JJ JJ O
Chinese JJ JJ O
man NN NN O
reported VBD VBD O
with IN IN O
liver NN NN O
damage NN NN O
, , , O
which WDT WDT O
appeared VBD VBD O
12 CD CD O
hours NNS NNS O
after IN IN O
beginning VBG VBG O
treatment NN NN O
with IN IN O
fluvastatin NN NN B-CHEM
. . . O

Patient NNP NNP O
presented VBD VBD O
with IN IN O
complaints NNS NNS O
of IN IN O
increasing VBG VBG O
nausea NN NN O
, , , O
anorexia NN NN O
, , , O
and CC CC O
upper JJ JJ O
abdominal JJ JJ O
pain NN NN O
. . . O

His PRP$ PRP$ O
laboratory NN NN O
values NNS NNS O
showed VBD VBD O
elevated VBD VBD O
creatine NN NN B-CHEM
kinase NN NN O
and CC CC O
transaminases NNS NNS O
. . . O

Testing NNP NNP O
for IN IN O
autoantibodies NNS NNS O
was VBD VBD O
also RB RB O
negative JJ JJ O
. . . O

The DT DT O
liver NN NN O
biochemistries NNS NNS O
eventually RB RB O
normalized JJ JJ O
within IN IN O
3 CD CD O
weeks NNS NNS O
of IN IN O
stopping VBG VBG O
the DT DT O
fluvastatin NN NN B-CHEM
. . . O

Therefore RB RB O
, , , O
when WRB WRB O
prescribing VBG VBG O
statins NNS NNS O
, , , O
the DT DT O
possibility NN NN O
of IN IN O
hepatic JJ JJ O
damage NN NN O
should MD MD O
be VB VB O
taken VBN VBN O
into IN IN O
account NN NN O
. . . O

Fluconazole NNP NNP B-CHEM
associated VBD VBD O
agranulocytosis NNS NNS O
and CC CC O
thrombocytopenia NN NN O
. . . O

CASE NN NN O
: : : O
We PRP PRP O
describe VBP VBP O
a DT DT O
second JJ JJ O
case NN NN O
of IN IN O
fluconazole NN NN B-CHEM
associated VBN VBN O
agranulocytosis NNS NNS O
with IN IN O
thrombocytopenia NN NN O
and CC CC O
recovery NN NN O
upon IN IN O
discontinuation NN NN O
of IN IN O
therapy NN NN O
. . . O

The DT DT O
patient NN NN O
began VBD VBD O
to TO TO O
have VB VB O
changes NNS NNS O
in IN IN O
white JJ JJ O
blood NN NN O
cells NNS NNS O
and CC CC O
platelets NNS NNS O
within IN IN O
48 CD CD O
h NN NN O
of IN IN O
administration NN NN O
of IN IN O
fluconazole NN NN B-CHEM
and CC CC O
began VBD VBD O
to TO TO O
recover VB VB O
with IN IN O
48 CD CD O
h NN NN O
of IN IN O
discontinuation NN NN O
. . . O

This DT DT O
case NN NN O
highlights NNS NNS O
that WDT WDT O
drug NN NN O
- - - O
induced JJ JJ O
blood NN NN O
dyscrasias NN NN O
can MD MD O
occur VB VB O
unexpectedly RB RB O
as IN IN O
a DT DT O
result NN NN O
of IN IN O
treatment NN NN O
with IN IN O
a DT DT O
commonly RB RB O
used VBN VBN O
drug NN NN O
thought NN NN O
to TO TO O
be VB VB O
" '' '' O
safe JJ JJ O
" '' '' O
. . . O

CONCLUSION NNP NNP O
: : : O
According VBG VBG O
to TO TO O
Naranjo NNP NNP O
' POS POS O
s VBZ VBZ O
algorithm NN NN O
the DT DT O
likelihood NN NN O
that IN IN O
our PRP$ PRP$ O
patient NN NN O
' POS POS O
s VBZ VBZ O
agranulocytosis NN NN O
and CC CC O
thrombocytopenia NN NN O
occurred VBD VBD O
as IN IN O
a DT DT O
result NN NN O
of IN IN O
therapy NN NN O
with IN IN O
fluconazole NN NN B-CHEM
is VBZ VBZ O
probable JJ JJ O
, , , O
with IN IN O
a DT DT O
total NN NN O
of IN IN O
six CD CD O
points NNS NNS O
. . . O

We PRP PRP O
feel VBP VBP O
that IN IN O
the DT DT O
weight NN NN O
of IN IN O
the DT DT O
overall JJ JJ O
evidence NN NN O
of IN IN O
this DT DT O
evidence NN NN O
is VBZ VBZ O
strong JJ JJ O
. . . O

In IN IN O
particular JJ JJ O
the DT DT O
temporal JJ JJ O
relationship NN NN O
of IN IN O
bone NN NN O
marrow NN NN O
suppression NN NN O
to TO TO O
the DT DT O
initiation NN NN O
of IN IN O
fluconazole NN NN B-CHEM
and CC CC O
the DT DT O
abatement NN NN O
of IN IN O
symptoms NNS NNS O
that WDT WDT O
rapidly RB RB O
reversed VBD VBD O
immediately RB RB O
following VBG VBG O
discontinuation NN NN O
. . . O

Two CD CD O
- - - O
dimensional JJ JJ O
speckle NN NN O
tracking VBG VBG O
echocardiography NN NN O
combined VBN VBN O
with IN IN O
high JJ JJ O
- - - O
sensitive JJ JJ O
cardiac NN NN O
troponin NN NN O
T NN NN O
in IN IN O
early JJ JJ O
detection NN NN O
and CC CC O
prediction NN NN O
of IN IN O
cardiotoxicity NN NN O
during IN IN O
epirubicine NN NN B-CHEM
- - - O
based JJ JJ O
chemotherapy NN NN O
. . . O

AIMS NNP NNP O
: : : O
To TO TO O
investigate VB VB O
whether IN IN O
alterations NNS NNS O
of IN IN O
myocardial NN NN O
strain NN NN O
and CC CC O
high JJ JJ O
- - - O
sensitive JJ JJ O
cardiac NN NN O
troponin NN NN O
T NN NN O
( ( ( O
cTnT NN NN O
) ) ) O
could MD MD O
predict VB VB O
future JJ JJ O
cardiac NN NN O
dysfunction NN NN O
in IN IN O
patients NNS NNS O
after IN IN O
epirubicin NN NN B-CHEM
exposure NN NN O
. . . O

METHODS NNP NNP O
: : : O
Seventy NNP NNP O
- - - O
five CD CD O
patients NNS NNS O
with IN IN O
non NN NN O
- - - O
Hodgkin NNP NNP O
lymphoma NN NN O
treated VBN VBN O
with IN IN O
epirubicin NN NN B-CHEM
were VBD VBD O
studied VBN VBN O
. . . O

Blood NNP NNP O
collection NN NN O
and CC CC O
echocardiography NN NN O
were VBD VBD O
performed VBN VBN O
at IN IN O
baseline NN NN O
, , , O
1 CD CD O
day NN NN O
after IN IN O
the DT DT O
third JJ JJ O
cycle NN NN O
, , , O
and CC CC O
1 CD CD O
day NN NN O
after IN IN O
completion NN NN O
of IN IN O
chemotherapy NN NN O
. . . O

Patients NNS NNS O
were VBD VBD O
studied VBN VBN O
using VBG VBG O
echocardiography NN NN O
during IN IN O
follow VB VB O
- - - O
up RP RP O
. . . O

Global NNP NNP O
longitudinal NN NN O
( ( ( O
GLS NNP NNP O
) ) ) O
, , , O
circumferential JJ JJ O
( ( ( O
GCS NNP NNP O
) ) ) O
, , , O
and CC CC O
radial JJ JJ O
strain NN NN O
( ( ( O
GRS NNP NNP O
) ) ) O
were VBD VBD O
calculated VBN VBN O
using VBG VBG O
speckle NN NN O
tracking VBG VBG O
echocardiography NN NN O
. . . O

Left NNP NNP O
ventricular NN NN O
ejection NN NN O
fraction NN NN O
was VBD VBD O
analysed VBN VBN O
by IN IN O
real JJ JJ O
- : : O
time NN NN O
3D CD CD O
echocardiography NN NN O
. . . O

Cardiotoxicity NNP NNP O
was VBD VBD O
defined VBN VBN O
as IN IN O
a DT DT O
reduction NN NN O
of IN IN O
the DT DT O
LVEF NNP NNP O
of IN IN O
> NN NN O
5 CD CD O
% NN NN O
to TO TO O
< NN NN O
55 CD CD O
% NN NN O
with IN IN O
symptoms NNS NNS O
of IN IN O
heart NN NN O
failure NN NN O
or CC CC O
an DT DT O
asymptomatic JJ JJ O
reduction NN NN O
of IN IN O
the DT DT O
LVEF NNP NNP O
of IN IN O
> NN NN O
10 CD CD O
% NN NN O
to TO TO O
< NN NN O
55 CD CD O
% NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Fourteen CD CD O
patients NNS NNS O
( ( ( O
18 CD CD O
. . . O
67 CD CD O
% NN NN O
) ) ) O
developed JJ JJ O
cardiotoxicity NN NN O
after IN IN O
treatment NN NN O
. . . O

GLS NNP NNP O
( ( ( O
- : : O
18 CD CD O
. . . O
48 CD CD O
+ NN NN O
1 CD CD O
. . . O
72 CD CD O
% NN NN O
vs NNS NNS O
. . . O
- : : O
15 CD CD O
. . . O
96 CD CD O
+ NN NN O
1 CD CD O
. . . O
6 CD CD O
% NN NN O
) ) ) O
, , , O
GCS NNP NNP O
( ( ( O
- : : O
20 CD CD O
. . . O
93 CD CD O
+ NN NN O
2 CD CD O
. . . O
86 CD CD O
% NN NN O
vs NNS NNS O
. . . O
- : : O
19 CD CD O
. . . O
20 CD CD O
+ NN NN O
3 CD CD O
. . . O
21 CD CD O
% NN NN O
) ) ) O
, , , O
and CC CC O
GRS NNP NNP O
( ( ( O
39 CD CD O
. . . O
23 CD CD O
+ NN NN O
6 CD CD O
. . . O
44 CD CD O
% NN NN O
vs NNS NNS O
. . . O
34 CD CD O
. . . O
98 CD CD O
+ NN NN O
6 CD CD O
. . . O
2 CD CD O
% NN NN O
) ) ) O
were VBD VBD O
markedly RB RB O
reduced VBN VBN O
and CC CC O
cTnT NN NN O
was VBD VBD O
elevated VBN VBN O
from IN IN O
0 CD CD O
. . . O
0010 CD CD O
+ NN NN O
0 CD CD O
. . . O
0020 CD CD O
to TO TO O
0 CD CD O
. . . O
0073 CD CD O
+ NN NN O
0 CD CD O
. . . O
0038 CD CD O
ng NN NN O
/ NN NN O
mL NN NN O
( ( ( O
P NN NN O
all DT DT O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
at IN IN O
the DT DT O
completion NN NN O
of IN IN O
chemotherapy NN NN O
compared VBN VBN O
with IN IN O
baseline NN NN O
values NNS NNS O
. . . O

A DT DT O
> NN NN O
15 CD CD O
. . . O
9 CD CD O
% NN NN O
decrease NN NN O
in IN IN O
GLS NNP NNP O
[ NN NN O
sensitivity NN NN O
, , , O
86 CD CD O
% NN NN O
; : : O
specificity NN NN O
, , , O
75 CD CD O
% NN NN O
; : : O
area NN NN O
under IN IN O
the DT DT O
curve NN NN O
( ( ( O
AUC NNP NNP O
) ) ) O
= SYM SYM O
0 CD CD O
. . . O
815 CD CD O
; : : O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
001 CD CD O
] NN NN O
and CC CC O
a DT DT O
> NN NN O
0 CD CD O
. . . O
004 CD CD O
ng NN NN O
/ NN NN O
mL NN NN O
elevation NN NN O
in IN IN O
cTnT NN NN O
( ( ( O
sensitivity NN NN O
, , , O
79 CD CD O
% NN NN O
; : : O
specificity NN NN O
, , , O
64 CD CD O
% NN NN O
; : : O
AUC NNP NNP O
= SYM SYM O
0 CD CD O
. . . O
757 CD CD O
; : : O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
005 CD CD O
) ) ) O
from IN IN O
baseline NN NN O
to TO TO O
the DT DT O
third JJ JJ O
cycle NN NN O
of IN IN O
chemotherapy NN NN O
predicted VBD VBD O
later RB RB O
cardiotoxicity NN NN O
. . . O

The DT DT O
decrease NN NN O
in IN IN O
GLS NNP NNP O
remained VBD VBD O
the DT DT O
only JJ JJ O
independent JJ JJ O
predictor NN NN O
of IN IN O
cardiotoxicity NN NN O
( ( ( O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
000 CD CD O
) ) ) O
. . . O

CONCLUSIONS NNP NNP O
: : : O
GLS NNP NNP O
combined VBN VBN O
with IN IN O
cTnT NN NN O
may MD MD O
provide VB VB O
a DT DT O
reliable JJ JJ O
and CC CC O
non NN NN O
- - - O
invasive JJ JJ O
method NN NN O
to TO TO O
predict VB VB O
cardiac JJ JJ O
dysfunction NN NN O
in IN IN O
patients NNS NNS O
receiving VBG VBG O
anthracycline NN NN B-CHEM
- - - O
based JJ JJ O
chemotherapy NN NN O
. . . O

Prevention NNP NNP O
of IN IN O
etomidate NN NN B-CHEM
- - - O
induced JJ JJ O
myoclonus NN NN O
: : : O
which WDT WDT O
is VBZ VBZ O
superior JJ JJ O
: : : O
Fentanyl NNP NNP B-CHEM
, , , O
midazolam NN NN B-CHEM
, , , O
or CC CC O
a DT DT O
combination NN NN O
? . . O

A DT DT O
Retrospective NNP NNP O
comparative JJ JJ O
study NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
In IN IN O
this DT DT O
retrospective NN NN O
comparative JJ JJ O
study NN NN O
, , , O
we PRP PRP O
aimed VBD VBD O
to TO TO O
compare VB VB O
the DT DT O
effectiveness NN NN O
of IN IN O
fentanyl NN NN B-CHEM
, , , O
midazolam NN NN B-CHEM
, , , O
and CC CC O
a DT DT O
combination NN NN O
of IN IN O
fentanyl NN NN B-CHEM
and CC CC O
midazolam NN NN B-CHEM
to TO TO O
prevent VB VB O
etomidate JJ JJ B-CHEM
- - - O
induced JJ JJ O
myoclonus NN NN O
. . . O

MATERIAL NN NN O
AND CC CC O
METHODS NNP NNP O
: : : O
This DT DT O
study NN NN O
was VBD VBD O
performed VBN VBN O
based VBN VBN O
on IN IN O
anesthesia NN NN O
records NNS NNS O
. . . O

Depending VBG VBG O
on IN IN O
the DT DT O
drugs NNS NNS O
that WDT WDT O
would MD MD O
be VB VB O
given VBN VBN O
before IN IN O
the DT DT O
induction NN NN O
of IN IN O
anesthesia NN NN O
with IN IN O
etomidate NN NN B-CHEM
, , , O
the DT DT O
patients NNS NNS O
were VBD VBD O
separated VBN VBN O
into IN IN O
4 CD CD O
groups NNS NNS O
: : : O
no DT DT O
pretreatment NN NN O
( ( ( O
Group NNP NNP O
NP NNP NNP O
) ) ) O
, , , O
fentanyl NN NN B-CHEM
1 CD CD O
ug NN NN O
. . . O
kg NN NN O
- : : O
1 CD CD O
( ( ( O
Group NNP NNP O
F NN NN O
) ) ) O
, , , O
midazolam NN NN B-CHEM
0 CD CD O
. . . O
03 CD CD O
mg NN NN O
. . . O
kg NN NN O
- : : O
1 CD CD O
( ( ( O
Group NNP NNP O
M NNP NNP O
) ) ) O
, , , O
and CC CC O
midazolam NN NN B-CHEM
0 CD CD O
. . . O
015 CD CD O
mg NN NN O
. . . O
kg NN NN O
- : : O
1 CD CD O
+ NN NN O
fentanyl NN NN B-CHEM
0 CD CD O
. . . O
5 CD CD O
ug NN NN O
. . . O
kg NN NN O
- : : O
1 CD CD O
( ( ( O
Group NNP NNP O
FM NNP NNP O
) ) ) O
. . . O

Patients NNS NNS O
who WP WP O
received VBD VBD O
the DT DT O
same JJ JJ O
anesthetic JJ JJ O
procedure NN NN O
were VBD VBD O
selected VBN VBN O
: : : O
2 CD CD O
minutes NNS NNS O
after IN IN O
intravenous JJ JJ O
injections NNS NNS O
of IN IN O
the DT DT O
pretreatment NN NN O
drugs NNS NNS O
, , , O
anesthesia NN NN O
is VBZ VBZ O
induced VBN VBN O
with IN IN O
0 CD CD O
. . . O
3 CD CD O
mg NN NN O
. . . O
kg NN NN O
- : : O
1 CD CD O
etomidate NN NN B-CHEM
injected VBN VBN O
intravenously RB RB O
over IN IN O
a DT DT O
period NN NN O
of IN IN O
20 CD CD O
- : : O
30 CD CD O
seconds NNS NNS O
. . . O

Myoclonic JJ JJ O
movements NNS NNS O
are VBP VBP O
evaluated VBN VBN O
, , , O
which WDT WDT O
were VBD VBD O
observed VBN VBN O
and CC CC O
graded VBN VBN O
according VBG VBG O
to TO TO O
clinical JJ JJ O
severity NN NN O
during IN IN O
the DT DT O
2 CD CD O
minutes NNS NNS O
after IN IN O
etomidate JJ JJ B-CHEM
injection NN NN O
. . . O

The DT DT O
severity NN NN O
of IN IN O
pain NN NN O
due JJ JJ O
to TO TO O
etomidate VB VB B-CHEM
injection NN NN O
, , , O
mean VB VB O
arterial JJ JJ O
pressure NN NN O
, , , O
heart NN NN O
rate NN NN O
, , , O
and CC CC O
adverse JJ JJ O
effects NNS NNS O
were VBD VBD O
also RB RB O
evaluated VBN VBN O
. . . O

RESULTS NNS NNS O
: : : O
Study NNP NNP O
results NNS NNS O
showed VBD VBD O
that IN IN O
myoclonus JJ JJ O
incidence NN NN O
was VBD VBD O
85 CD CD O
% NN NN O
, , , O
40 CD CD O
% NN NN O
, , , O
70 CD CD O
% NN NN O
, , , O
and CC CC O
25 CD CD O
% NN NN O
in IN IN O
Group NNP NNP O
NP NNP NNP O
, , , O
Group NNP NNP O
F NN NN O
, , , O
Group NNP NNP O
M NNP NNP O
, , , O
and CC CC O
Group NNP NNP O
FM NNP NNP O
, , , O
respectively RB RB O
, , , O
and CC CC O
were VBD VBD O
significantly RB RB O
lower JJR JJR O
in IN IN O
Group NNP NNP O
F NNP NNP O
and CC CC O
Group NNP NNP O
FM NNP NNP O
. . . O

CONCLUSIONS NNP NNP O
: : : O
We PRP PRP O
conclude VBP VBP O
that IN IN O
pretreatment NN NN O
with IN IN O
fentanyl NN NN B-CHEM
or CC CC O
combination NN NN O
of IN IN O
fentanyl NN NN B-CHEM
and CC CC O
midazolam NN NN B-CHEM
was VBD VBD O
effective JJ JJ O
in IN IN O
preventing VBG VBG O
etomidate JJ JJ B-CHEM
- - - O
induced JJ JJ O
myoclonus NN NN O
. . . O

Convulsant NNP NNP O
effect NN NN O
of IN IN O
lindane NN NN B-CHEM
and CC CC O
regional JJ JJ O
brain NN NN O
concentration NN NN O
of IN IN O
GABA NNP NNP B-CHEM
and CC CC O
dopamine NN NN B-CHEM
. . . O

Lindane NNP NNP B-CHEM
( ( ( O
gamma NN NN B-CHEM
- - - I-CHEM
hexachlorocyclohexane NN NN I-CHEM
) ) ) O
is VBZ VBZ O
an DT DT O
organochlorine NN NN O
insecticide NN NN O
with IN IN O
known VBN VBN O
neurotoxic NN NN O
effects NNS NNS O
. . . O

Its PRP$ PRP$ O
mechanism NN NN O
of IN IN O
action NN NN O
is VBZ VBZ O
not RB RB O
well RB RB O
understood VBD VBD O
although IN IN O
it PRP PRP O
has VBZ VBZ O
been VBN VBN O
proposed VBN VBN O
that IN IN O
lindane NN NN B-CHEM
acts NNS NNS O
as IN IN O
a DT DT O
non NN NN O
- - - O
competitive JJ JJ O
antagonist NN NN O
at IN IN O
the DT DT O
gamma NN NN B-CHEM
- - - I-CHEM
aminobutyric JJ JJ I-CHEM
acid NN NN I-CHEM
( ( ( O
GABA NNP NNP B-CHEM
) ) ) O
- : : O
A DT DT O
receptor NN NN O
. . . O

We PRP PRP O
studied VBD VBD O
the DT DT O
effect NN NN O
of IN IN O
lindane NN NN B-CHEM
( ( ( O
150 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
on IN IN O
the DT DT O
GABAergic NNP NNP O
and CC CC O
dopaminergic JJ JJ O
systems NNS NNS O
by IN IN O
measuring VBG VBG O
the DT DT O
concentration NN NN O
of IN IN O
GABA NNP NNP B-CHEM
, , , O
dopamine NN NN B-CHEM
and CC CC O
its PRP$ PRP$ O
metabolites NNS NNS O
in IN IN O
7 CD CD O
brain NN NN O
areas NNS NNS O
at IN IN O
the DT DT O
onset NN NN O
of IN IN O
seizures NNS NNS O
. . . O

All DT DT O
animals NNS NNS O
suffered VBN VBN O
tonic JJ JJ O
convulsions NNS NNS O
at IN IN O
18 CD CD O
. . . O
3 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
4 CD CD O
min NN NN O
after IN IN O
lindane NN NN B-CHEM
administration NN NN O
. . . O

The DT DT O
concentration NN NN O
of IN IN O
GABA NNP NNP B-CHEM
was VBD VBD O
only RB RB O
slightly RB RB O
but CC CC O
significantly RB RB O
decreased VBN VBN O
in IN IN O
the DT DT O
colliculi NN NN O
without IN IN O
modifications NNS NNS O
in IN IN O
the DT DT O
other JJ JJ O
areas NNS NNS O
. . . O

The DT DT O
concentration NN NN O
of IN IN O
dopamine NN NN B-CHEM
was VBD VBD O
increased VBN VBN O
in IN IN O
the DT DT O
mesencephalon NN NN O
and CC CC O
that IN IN O
of IN IN O
its PRP$ PRP$ O
metabolite NN NN O
DOPAC NNP NNP B-CHEM
was VBD VBD O
also RB RB O
increased VBN VBN O
in IN IN O
the DT DT O
mesencephalon NN NN O
and CC CC O
the DT DT O
striatum NN NN O
. . . O

Cholestatic NNP NNP O
presentation NN NN O
of IN IN O
yellow JJ JJ O
phosphorus NN NN B-CHEM
poisoning NN NN O
. . . O

Yellow NNP NNP O
phosphorus NN NN B-CHEM
, , , O
a DT DT O
component NN NN O
of IN IN O
certain JJ JJ O
pesticide NN NN O
pastes NNS NNS O
and CC CC O
fireworks NNS NNS O
, , , O
is VBZ VBZ O
well RB RB O
known VBN VBN O
to TO TO O
cause VB VB O
hepatotoxicity NN NN O
. . . O

Poisoning NNP NNP O
with IN IN O
yellow JJ JJ O
phosphorus NN NN B-CHEM
classically RB RB O
manifests NNS NNS O
with IN IN O
acute JJ JJ O
hepatitis NN NN O
leading VBG VBG O
to TO TO O
acute JJ JJ O
liver NN NN O
failure NN NN O
which WDT WDT O
may MD MD O
need VB VB O
liver NN NN O
transplantation NN NN O
. . . O

We PRP PRP O
present JJ JJ O
a DT DT O
case NN NN O
of IN IN O
yellow JJ JJ O
phosphorus NN NN B-CHEM
poisoning NN NN O
in IN IN O
which WDT WDT O
a DT DT O
patient NN NN O
presented VBN VBN O
with IN IN O
florid JJ JJ O
clinical JJ JJ O
features NNS NNS O
of IN IN O
cholestasis NNS NNS O
highlighting VBG VBG O
the DT DT O
fact NN NN O
that IN IN O
cholestasis NNS NNS O
can MD MD O
rarely RB RB O
be VB VB O
a DT DT O
presenting VBG VBG O
feature NN NN O
of IN IN O
yellow JJ JJ O
phosphorus NN NN B-CHEM
hepatotoxicity NN NN O
. . . O

Vasovagal NNP NNP O
syncope NN NN O
and CC CC O
severe JJ JJ O
bradycardia NNS NNS O
following VBG VBG O
intranasal NN NN O
dexmedetomidine NN NN B-CHEM
for IN IN O
pediatric JJ JJ O
procedural JJ JJ O
sedation NN NN O
. . . O

We PRP PRP O
report VBP VBP O
syncope NN NN O
and CC CC O
bradycardia NN NN O
in IN IN O
an DT DT O
11 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
girl NN NN O
following VBG VBG O
administration NN NN O
of IN IN O
intranasal NN NN O
dexmedetomidine NN NN B-CHEM
for IN IN O
sedation NN NN O
for IN IN O
a DT DT O
voiding VBG VBG O
cystourethrogram NN NN O
. . . O

Following VBG VBG O
successful JJ JJ O
completion NN NN O
of IN IN O
VCUG NNP NNP O
and CC CC O
a DT DT O
60 CD CD O
- : : O
min NN NN O
recovery NN NN O
period NN NN O
, , , O
the DT DT O
patient NN NN O
' '' '' O
s VBZ VBZ O
level NN NN O
of IN IN O
consciousness NN NN O
and CC CC O
vital JJ JJ O
signs NNS NNS O
returned VBD VBD O
to TO TO O
presedation NN NN O
levels NNS NNS O
. . . O

Upon IN IN O
leaving VBG VBG O
the DT DT O
sedation NN NN O
area NN NN O
, , , O
the DT DT O
patient NN NN O
collapsed VBD VBD O
, , , O
with IN IN O
no DT DT O
apparent JJ JJ O
inciting VBG VBG O
event NN NN O
. . . O

The DT DT O
patient NN NN O
quickly RB RB O
regained VBD VBD O
consciousness NN NN O
and CC CC O
no DT DT O
injury NN NN O
occurred VBD VBD O
. . . O

The DT DT O
primary JJ JJ O
abnormality NN NN O
found VBD VBD O
was VBD VBD O
persistent JJ JJ O
bradycardia NN NN O
, , , O
and CC CC O
she PRP PRP O
was VBD VBD O
admitted VBN VBN O
to TO TO O
the DT DT O
hospital NN NN O
for IN IN O
telemetric JJ JJ O
observation NN NN O
. . . O

The DT DT O
bradycardia NN NN O
lasted VBD VBD O
~ NN NN O
2 CD CD O
h NN NN O
, , , O
and CC CC O
further JJ JJ O
cardiac NN NN O
workup NN NN O
revealed VBD VBD O
no DT DT O
underlying VBG VBG O
abnormality NN NN O
. . . O

Unanticipated NNP NNP O
and CC CC O
previously RB RB O
unreported JJ JJ O
outcomes NNS NNS O
may MD MD O
be VB VB O
witnessed VBN VBN O
as IN IN O
we PRP PRP O
expand VBP VBP O
the DT DT O
use NN NN O
of IN IN O
certain JJ JJ O
sedatives NNS NNS O
to TO TO O
alternative VB VB O
routes NNS NNS O
of IN IN O
administration NN NN O
. . . O

Paradoxical NNP NNP O
severe JJ JJ O
agitation NN NN O
induced VBN VBN O
by IN IN O
add NN NN O
- - - O
on IN IN O
high JJ JJ O
- - - O
doses NNS NNS O
quetiapine NN NN B-CHEM
in IN IN O
schizo NN NN O
- - - O
affective JJ JJ O
disorder NN NN O
. . . O

We PRP PRP O
report VBP VBP O
the DT DT O
case NN NN O
of IN IN O
a DT DT O
35 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
patient NN NN O
suffering VBG VBG O
from IN IN O
schizo NN NN O
- - - O
affective JJ JJ O
disorder NN NN O
since IN IN O
the DT DT O
age NN NN O
of IN IN O
19 CD CD O
years NNS NNS O
, , , O
treated VBN VBN O
by IN IN O
a DT DT O
combination NN NN O
of IN IN O
first JJ JJ O
- - - O
generation NN NN O
antipsychotics NNS NNS O
, , , O
zuclopenthixol NN NN B-CHEM
( ( ( O
100 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
) ) ) O
and CC CC O
lithium NN NN B-CHEM
( ( ( O
1200 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
) ) ) O
( ( ( O
serum NN NN O
lithium NN NN B-CHEM
= SYM SYM O
0 CD CD O
. . . O
85 CD CD O
mEq NN NN O
/ NN NN O
l NN NN O
) ) ) O
. . . O

This DT DT O
patient NN NN O
had VBD VBD O
no DT DT O
associated VBN VBN O
personality NN NN O
disorder NN NN O
( ( ( O
particularly RB RB O
no DT DT O
antisocial JJ JJ O
disorder NN NN O
) ) ) O
and CC CC O
no DT DT O
substance NN NN O
abuse NN NN O
disorder NN NN O
. . . O

Within IN IN O
the DT DT O
48 CD CD O
h NN NN O
following VBG VBG O
the DT DT O
gradual JJ JJ O
introduction NN NN O
of IN IN O
quetiapine NN NN B-CHEM
( ( ( O
up IN IN O
to TO TO O
600 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
) ) ) O
, , , O
the DT DT O
patient NN NN O
presented VBN VBN O
severe JJ JJ O
agitation NN NN O
without IN IN O
an DT DT O
environmental JJ JJ O
explanation NN NN O
, , , O
contrasting VBG VBG O
with IN IN O
the DT DT O
absence NN NN O
of IN IN O
a DT DT O
history NN NN O
of IN IN O
aggressiveness NN NN O
or CC CC O
personality NN NN O
disorder NN NN O
. . . O

The DT DT O
diagnoses NNS NNS O
of IN IN O
manic JJ JJ O
shift NN NN O
and CC CC O
akathisia NN NN O
were VBD VBD O
dismissed VBN VBN O
. . . O

The DT DT O
withdrawal NN NN O
and CC CC O
the DT DT O
gradual JJ JJ O
reintroduction NN NN O
of IN IN O
quetiapine NN NN B-CHEM
2 CD CD O
weeks NNS NNS O
later RB RB O
, , , O
which WDT WDT O
led VBD VBD O
to TO TO O
another DT DT O
severe JJ JJ O
agitation NN NN O
, , , O
enabled VBD VBD O
us PRP PRP O
to TO TO O
attribute VB VB O
the DT DT O
agitation NN NN O
specifically RB RB O
to TO TO O
quetiapine VB VB B-CHEM
. . . O

Antioxidant NNP NNP O
effects NNS NNS O
of IN IN O
bovine NN NN O
lactoferrin NN NN O
on IN IN O
dexamethasone NN NN B-CHEM
- : : O
induced JJ JJ O
hypertension NN NN O
in IN IN O
rat NN NN O
. . . O

Dexamethasone NNP NNP B-CHEM
- : : O
( ( ( O
Dex NNP NNP B-CHEM
- : : O
) ) ) O
induced JJ JJ O
hypertension NN NN O
is VBZ VBZ O
associated VBN VBN O
with IN IN O
enhanced JJ JJ O
oxidative JJ JJ O
stress NN NN O
. . . O

Lactoferrin NNP NNP O
( ( ( O
LF NNP NNP O
) ) ) O
is VBZ VBZ O
an DT DT O
iron NN NN B-CHEM
- - - O
binding JJ JJ O
glycoprotein NN NN O
with IN IN O
antihypertensive JJ JJ O
properties NNS NNS O
. . . O

In IN IN O
this DT DT O
study NN NN O
, , , O
we PRP PRP O
investigated VBD VBD O
the DT DT O
effect NN NN O
of IN IN O
chronic JJ JJ O
administration NN NN O
of IN IN O
LF NNP NNP O
on IN IN O
oxidative JJ JJ O
stress NN NN O
and CC CC O
hypertension NN NN O
upon IN IN O
Dex NNP NNP B-CHEM
administration NN NN O
. . . O

Male NNP NNP O
Wistar NNP NNP O
rats NNS NNS O
were VBD VBD O
treated VBN VBN O
by IN IN O
Dex NNP NNP B-CHEM
( ( ( O
30 CD CD O
u NN NN O
g SYM SYM O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
subcutaneously RB RB O
) ) ) O
or CC CC O
saline NN NN O
for IN IN O
14 CD CD O
days NNS NNS O
. . . O

Oral NNP NNP O
bovine NN NN O
LF NNP NNP O
( ( ( O
30 CD CD O
, , , O
100 CD CD O
, , , O
300 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
was VBD VBD O
given VBN VBN O
from IN IN O
day NN NN O
8 CD CD O
to TO TO O
14 CD CD O
in IN IN O
a DT DT O
reversal NN NN O
study NN NN O
. . . O

In IN IN O
a DT DT O
prevention NN NN O
study NN NN O
, , , O
rats NNS NNS O
received VBD VBD O
4 CD CD O
days NNS NNS O
of IN IN O
LF NNP NNP O
treatment NN NN O
followed VBN VBN O
by IN IN O
Dex NNP NNP B-CHEM
and CC CC O
continued VBD VBD O
during IN IN O
the DT DT O
test NN NN O
period NN NN O
. . . O

Systolic NNP NNP O
blood NN NN O
pressure NN NN O
( ( ( O
SBP NNP NNP O
) ) ) O
was VBD VBD O
measured VBN VBN O
using VBG VBG O
tail NN NN O
- : : O
cuff NN NN O
method NN NN O
. . . O

Thymus NNP NNP O
weight NN NN O
was VBD VBD O
used VBN VBN O
as IN IN O
a DT DT O
marker NN NN O
of IN IN O
glucocorticoid NN NN O
activity NN NN O
. . . O

Plasma NNP NNP O
hydrogen NN NN B-CHEM
peroxide NN NN I-CHEM
( ( ( O
H2O2 NNP NNP B-CHEM
) ) ) O
concentration NN NN O
and CC CC O
ferric JJ JJ O
reducing VBG VBG O
antioxidant JJ JJ O
power NN NN O
( ( ( O
FRAP NNP NNP O
) ) ) O
value NN NN O
were VBD VBD O
determined VBN VBN O
. . . O

Dexamethasone NNP NNP B-CHEM
significantly RB RB O
increased VBD VBD O
SBP NNP NNP O
and CC CC O
plasma NN NN O
H2O2 NNP NNP B-CHEM
level NN NN O
and CC CC O
decreased VBD VBD O
thymus NN NN O
and CC CC O
body NN NN O
weights NNS NNS O
. . . O

LF NNP NNP O
lowered VBD VBD O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
and CC CC O
dose VB VB O
dependently RB RB O
prevented VBN VBN O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
Dex NNP NNP B-CHEM
- : : O
induced JJ JJ O
hypertension NN NN O
. . . O

LF NNP NNP O
prevented JJ JJ O
body NN NN O
weight NN NN O
loss NN NN O
and CC CC O
significantly RB RB O
reduced VBD VBD O
the DT DT O
elevated JJ JJ O
plasma NN NN O
H2O2 NNP NNP B-CHEM
and CC CC O
increased VBN VBN O
FRAP NNP NNP O
values NNS NNS O
. . . O

Chronic NNP NNP O
administration NN NN O
of IN IN O
LF NNP NNP O
strongly RB RB O
reduced VBD VBD O
the DT DT O
blood NN NN O
pressure NN NN O
and CC CC O
production NN NN O
of IN IN O
ROS NNP NNP O
and CC CC O
improved VBN VBN O
antioxidant JJ JJ O
capacity NN NN O
in IN IN O
Dex NNP NNP B-CHEM
- : : O
induced JJ JJ O
hypertension NN NN O
, , , O
suggesting VBG VBG O
the DT DT O
role NN NN O
of IN IN O
inhibition NN NN O
of IN IN O
oxidative JJ JJ O
stress NN NN O
as IN IN O
another DT DT O
mechanism NN NN O
of IN IN O
antihypertensive JJ JJ O
action NN NN O
of IN IN O
LF NNP NNP O
. . . O

The DT DT O
association NN NN O
between IN IN O
tranexamic JJ JJ B-CHEM
acid NN NN I-CHEM
and CC CC O
convulsive JJ JJ O
seizures NNS NNS O
after IN IN O
cardiac JJ JJ O
surgery NN NN O
: : : O
a DT DT O
multivariate NN NN O
analysis NN NN O
in IN IN O
11 CD CD O
529 CD CD O
patients NNS NNS O
. . . O

Because IN IN O
of IN IN O
a DT DT O
lack NN NN O
of IN IN O
contemporary JJ JJ O
data NNS NNS O
regarding VBG VBG O
seizures NNS NNS O
after IN IN O
cardiac JJ JJ O
surgery NN NN O
, , , O
we PRP PRP O
undertook VBP VBP O
a DT DT O
retrospective NN NN O
analysis NN NN O
of IN IN O
prospectively RB RB O
collected VBN VBN O
data NNS NNS O
from IN IN O
11 CD CD O
529 CD CD O
patients NNS NNS O
in IN IN O
whom WP WP O
cardiopulmonary JJ JJ O
bypass NNS NNS O
was VBD VBD O
used VBN VBN O
from IN IN O
January NNP NNP O
2004 CD CD O
to TO TO O
December NNP NNP O
2010 CD CD O
. . . O

A DT DT O
convulsive JJ JJ O
seizure NN NN O
was VBD VBD O
defined VBN VBN O
as IN IN O
a DT DT O
transient NN NN O
episode NN NN O
of IN IN O
disturbed VBN VBN O
brain NN NN O
function NN NN O
characterised VBN VBN O
by IN IN O
abnormal JJ JJ O
involuntary JJ JJ O
motor NN NN O
movements NNS NNS O
. . . O

Multivariate NNP NNP O
regression NN NN O
analysis NN NN O
was VBD VBD O
performed VBN VBN O
to TO TO O
identify VB VB O
independent JJ JJ O
predictors NNS NNS O
of IN IN O
postoperative JJ JJ O
seizures NNS NNS O
. . . O

A DT DT O
total NN NN O
of IN IN O
100 CD CD O
( ( ( O
0 CD CD O
. . . O
9 CD CD O
% NN NN O
) ) ) O
patients NNS NNS O
developed VBN VBN O
postoperative JJ JJ O
convulsive JJ JJ O
seizures NNS NNS O
. . . O

Generalised NNP NNP O
and CC CC O
focal JJ JJ O
seizures NNS NNS O
were VBD VBD O
identified VBN VBN O
in IN IN O
68 CD CD O
and CC CC O
32 CD CD O
patients NNS NNS O
, , , O
respectively RB RB O
. . . O

The DT DT O
median NN NN O
( ( ( O
IQR NNP NNP O
[ NN NN O
range NN NN O
] NN NN O
) ) ) O
time NN NN O
after IN IN O
surgery NN NN O
when WRB WRB O
the DT DT O
seizure NN NN O
occurred VBD VBD O
was VBD VBD O
7 CD CD O
( ( ( O
6 CD CD O
- : : O
12 CD CD O
[ NN NN O
1 CD CD O
- : : O
216 CD CD O
] NN NN O
) ) ) O
h NN NN O
and CC CC O
8 CD CD O
( ( ( O
6 CD CD O
- : : O
11 CD CD O
[ NN NN O
4 CD CD O
- : : O
18 CD CD O
] NN NN O
) ) ) O
h NN NN O
, , , O
respectively RB RB O
. . . O

Epileptiform NNP NNP O
findings NNS NNS O
on IN IN O
electroencephalography NN NN O
were VBD VBD O
seen VBN VBN O
in IN IN O
19 CD CD O
patients NNS NNS O
. . . O

Independent JJ JJ O
predictors NNS NNS O
of IN IN O
postoperative JJ JJ O
seizures NNS NNS O
included VBD VBD O
age NN NN O
, , , O
female JJ JJ O
sex NN NN O
, , , O
redo VB VB O
cardiac JJ JJ O
surgery NN NN O
, , , O
calcification NN NN O
of IN IN O
ascending VBG VBG O
aorta NN NN O
, , , O
congestive JJ JJ O
heart NN NN O
failure NN NN O
, , , O
deep JJ JJ O
hypothermic JJ JJ O
circulatory NN NN O
arrest NN NN O
, , , O
duration NN NN O
of IN IN O
aortic JJ JJ O
cross NN NN O
- - - O
clamp NN NN O
and CC CC O
tranexamic JJ JJ B-CHEM
acid NN NN I-CHEM
. . . O

When WRB WRB O
tested VBN VBN O
in IN IN O
a DT DT O
multivariate JJ JJ O
regression NN NN O
analysis NN NN O
, , , O
tranexamic JJ JJ B-CHEM
acid NN NN I-CHEM
was VBD VBD O
a DT DT O
strong JJ JJ O
independent JJ JJ O
predictor NN NN O
of IN IN O
seizures NNS NNS O
( ( ( O
OR CC CC O
14 CD CD O
. . . O
3 CD CD O
, , , O
95 CD CD O
% NN NN O
CI NNP NNP O
5 CD CD O
. . . O
5 CD CD O
- : : O
36 CD CD O
. . . O
7 CD CD O
; : : O
p NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
. . . O

Patients NNS NNS O
with IN IN O
convulsive JJ JJ O
seizures NNS NNS O
had VBD VBD O
2 CD CD O
. . . O
5 CD CD O
times NNS NNS O
higher JJR JJR O
in IN IN O
- : : O
hospital NN NN O
mortality NN NN O
rates NNS NNS O
and CC CC O
twice RB RB O
the DT DT O
length NN NN O
of IN IN O
hospital NN NN O
stay NN NN O
compared VBN VBN O
with IN IN O
patients NNS NNS O
without IN IN O
convulsive JJ JJ O
seizures NNS NNS O
. . . O

Mean VB VB O
( ( ( O
IQR NNP NNP O
[ NN NN O
range NN NN O
] NN NN O
) ) ) O
length NN NN O
of IN IN O
stay NN NN O
in IN IN O
the DT DT O
intensive JJ JJ O
care NN NN O
unit NN NN O
was VBD VBD O
115 CD CD O
( ( ( O
49 CD CD O
- : : O
228 CD CD O
[ NN NN O
32 CD CD O
- : : O
481 CD CD O
] NN NN O
) ) ) O
h NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
convulsive JJ JJ O
seizures NNS NNS O
compared VBN VBN O
with IN IN O
26 CD CD O
( ( ( O
22 CD CD O
- : : O
69 CD CD O
[ NN NN O
14 CD CD O
- : : O
1080 CD CD O
] NN NN O
) ) ) O
h NN NN O
in IN IN O
patients NNS NNS O
without IN IN O
seizures NNS NNS O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
. . . O

Convulsive NNP NNP O
seizures NNS NNS O
are VBP VBP O
a DT DT O
serious JJ JJ O
postoperative JJ JJ O
complication NN NN O
after IN IN O
cardiac JJ JJ O
surgery NN NN O
. . . O

As IN IN O
tranexamic JJ JJ B-CHEM
acid NN NN I-CHEM
is VBZ VBZ O
the DT DT O
only RB RB O
modifiable JJ JJ O
factor NN NN O
, , , O
its PRP$ PRP$ O
administration NN NN O
, , , O
particularly RB RB O
in IN IN O
doses NNS NNS O
exceeding VBG VBG O
80 CD CD O
mg NN NN O
. . . O
kg NN NN O
( ( ( O
- : : O
1 CD CD O
) ) ) O
, , , O
should MD MD O
be VB VB O
weighed VBN VBN O
against IN IN O
the DT DT O
risk NN NN O
of IN IN O
postoperative JJ JJ O
seizures NNS NNS O
. . . O

Dysfunctional NNP NNP O
overnight JJ JJ O
memory NN NN O
consolidation NN NN O
in IN IN O
ecstasy JJ JJ B-CHEM
users NNS NNS O
. . . O

Sleep NNP NNP O
plays VBZ VBZ O
an DT DT O
important JJ JJ O
role NN NN O
in IN IN O
the DT DT O
consolidation NN NN O
and CC CC O
integration NN NN O
of IN IN O
memory NN NN O
in IN IN O
a DT DT O
process NN NN O
called VBN VBN O
overnight JJ JJ O
memory NN NN O
consolidation NN NN O
. . . O

Previous JJ JJ O
studies NNS NNS O
indicate VBP VBP O
that IN IN O
ecstasy JJ JJ B-CHEM
users NNS NNS O
have VBP VBP O
marked VBN VBN O
and CC CC O
persistent JJ JJ O
neurocognitive JJ JJ O
and CC CC O
sleep VB VB O
- - - O
related VBN VBN O
impairments NNS NNS O
. . . O

We PRP PRP O
extend VB VB O
past JJ JJ O
research NN NN O
by IN IN O
examining VBG VBG O
overnight JJ JJ O
memory NN NN O
consolidation NN NN O
among IN IN O
regular JJ JJ O
ecstasy JJ JJ B-CHEM
users NNS NNS O
( ( ( O
n NN NN O
= SYM SYM O
12 CD CD O
) ) ) O
and CC CC O
drug NN NN O
naive JJ JJ O
healthy JJ JJ O
controls NNS NNS O
( ( ( O
n NN NN O
= SYM SYM O
26 CD CD O
) ) ) O
. . . O

Memory NN NN O
recall NN NN O
of IN IN O
word NN NN O
pairs NNS NNS O
was VBD VBD O
evaluated VBN VBN O
before IN IN O
and CC CC O
after IN IN O
a DT DT O
period NN NN O
of IN IN O
sleep NN NN O
, , , O
with IN IN O
and CC CC O
without IN IN O
interference NN NN O
prior RB RB O
to TO TO O
testing NN NN O
. . . O

In IN IN O
addition NN NN O
, , , O
we PRP PRP O
assessed VBD VBD O
neurocognitive JJ JJ O
performances NNS NNS O
across IN IN O
tasks NNS NNS O
of IN IN O
learning VBG VBG O
, , , O
memory NN NN O
and CC CC O
executive JJ JJ O
functioning VBG VBG O
. . . O

Ecstasy NNP NNP B-CHEM
users NNS NNS O
demonstrated VBD VBD O
impaired VBN VBN O
overnight JJ JJ O
memory NN NN O
consolidation NN NN O
, , , O
a DT DT O
finding VBG VBG O
that WDT WDT O
was VBD VBD O
more RBR RBR O
pronounced JJ JJ O
following VBG VBG O
associative JJ JJ O
interference NN NN O
. . . O

Additionally RB RB O
, , , O
ecstasy JJ JJ B-CHEM
users NNS NNS O
demonstrated VBD VBD O
impairments NNS NNS O
on IN IN O
tasks NNS NNS O
recruiting VBG VBG O
frontostriatal JJ JJ O
and CC CC O
hippocampal JJ JJ O
neural NN NN O
circuitry NN NN O
, , , O
in IN IN O
the DT DT O
domains NNS NNS O
of IN IN O
proactive JJ JJ O
interference NN NN O
memory NN NN O
, , , O
long JJ JJ O
- - - O
term NN NN O
memory NN NN O
, , , O
encoding VBG VBG O
, , , O
working VBG VBG O
memory NN NN O
and CC CC O
complex JJ JJ O
planning NN NN O
. . . O

We PRP PRP O
suggest VBP VBP O
that IN IN O
ecstasy JJ JJ B-CHEM
- - - O
associated VBN VBN O
dysfunction NN NN O
in IN IN O
fronto NN NN O
- - - O
temporal JJ JJ O
circuitry NN NN O
may MD MD O
underlie VB VB O
overnight JJ JJ O
consolidation NN NN O
memory NN NN O
impairments NNS NNS O
in IN IN O
regular JJ JJ O
ecstasy NN NN B-CHEM
users NNS NNS O
. . . O

Normoammonemic NNP NNP O
encephalopathy NN NN O
: : : O
solely RB RB O
valproate NN NN B-CHEM
induced VBN VBN O
or CC CC O
multiple JJ JJ O
mechanisms NNS NNS O
? . . O

A DT DT O
77 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
woman NN NN O
presented VBN VBN O
with IN IN O
subacute JJ JJ O
onset NN NN O
progressive JJ JJ O
confusion NN NN O
, , , O
aggression NN NN O
, , , O
auditory NN NN O
hallucinations NNS NNS O
and CC CC O
delusions NNS NNS O
. . . O

In IN IN O
the DT DT O
preceding VBG VBG O
months NNS NNS O
, , , O
the DT DT O
patient NN NN O
had VBD VBD O
a DT DT O
number NN NN O
of IN IN O
admissions NNS NNS O
with IN IN O
transient NN NN O
unilateral JJ JJ O
hemiparesis NN NN O
with IN IN O
facial JJ JJ O
droop NN NN O
, , , O
and CC CC O
had VBD VBD O
been VBN VBN O
started VBN VBN O
on IN IN O
valproate NN NN B-CHEM
for IN IN O
presumed JJ JJ O
hemiplegic NN NN O
migraine NN NN O
. . . O

Valproate NNP NNP B-CHEM
was VBD VBD O
withdrawn VBN VBN O
soon RB RB O
after IN IN O
admission NN NN O
and CC CC O
her PRP$ PRP$ O
cognitive JJ JJ O
abilities NNS NNS O
have VBP VBP O
gradually RB RB O
improved VBN VBN O
over IN IN O
3 CD CD O
months NNS NNS O
of IN IN O
follow VB VB O
- - - O
up RP RP O
. . . O

Valproate NNP NNP B-CHEM
levels NNS NNS O
taken VBN VBN O
prior RB RB O
to TO TO O
withdrawal NN NN O
were VBD VBD O
subtherapeutic JJ JJ O
and CC CC O
the DT DT O
patient NN NN O
was VBD VBD O
normoammonaemic JJ JJ O
. . . O

EEG NNP NNP O
undertaken NN NN O
during IN IN O
inpatient NN NN O
stay NN NN O
showed VBD VBD O
changes NNS NNS O
consistent JJ JJ O
with IN IN O
encephalopathy NN NN O
, , , O
and CC CC O
low JJ JJ O
titre NN NN O
N NNP NNP B-CHEM
- : : I-CHEM
methyl NN NN I-CHEM
- : : I-CHEM
D NNP NNP I-CHEM
- : : I-CHEM
aspartate NN NN I-CHEM
( ( ( O
NMDA NNP NNP B-CHEM
) ) ) O
receptor NN NN O
antibodies NNS NNS O
were VBD VBD O
present JJ JJ O
in IN IN O
this DT DT O
patient NN NN O
. . . O

The DT DT O
possible JJ JJ O
aetiologies NNS NNS O
of IN IN O
valproate NN NN B-CHEM
- - - O
induced JJ JJ O
encephalopathy NN NN O
and CC CC O
NMDA NNP NNP B-CHEM
receptor NN NN O
- - - O
associated VBN VBN O
encephalitis NNS NNS O
present JJ JJ O
a DT DT O
diagnostic JJ JJ O
dilemma NN NN O
. . . O

We PRP PRP O
present JJ JJ O
a DT DT O
putative JJ JJ O
combinatorial NN NN O
hypothesis NNS NNS O
to TO TO O
explain VB VB O
this DT DT O
patient NN NN O
' '' '' O
s VBZ VBZ O
symptoms NNS NNS O
. . . O

Cerebellar NNP NNP O
and CC CC O
oculomotor NN NN O
dysfunction NN NN O
induced VBN VBN O
by IN IN O
rapid JJ JJ O
infusion NN NN O
of IN IN O
pethidine NN NN B-CHEM
. . . O

Pethidine NNP NNP B-CHEM
is VBZ VBZ O
an DT DT O
opioid NN NN O
that WDT WDT O
gains VBZ VBZ O
its PRP$ PRP$ O
popularity NN NN O
for IN IN O
the DT DT O
effective JJ JJ O
pain NN NN O
control NN NN O
through IN IN O
acting VBG VBG O
on IN IN O
the DT DT O
opioid NN NN O
- - - O
receptors NNS NNS O
. . . O

However RB RB O
, , , O
rapid JJ JJ O
pain NN NN O
relief NN NN O
sometimes RB RB O
brings VBZ VBZ O
about IN IN O
unfavourable JJ JJ O
side NN NN O
effects NNS NNS O
that WDT WDT O
largely RB RB O
limit VB VB O
its PRP$ PRP$ O
clinical JJ JJ O
utility NN NN O
. . . O

Common JJ JJ O
side NN NN O
effects NNS NNS O
include VBP VBP O
nausea NN NN O
, , , O
vomiting VBG VBG O
and CC CC O
hypotension NN NN O
. . . O

In IN IN O
patients NNS NNS O
with IN IN O
impaired VBN VBN O
renal NN NN O
and CC CC O
liver NN NN O
function NN NN O
, , , O
and CC CC O
those DT DT O
who WP WP O
need VBP VBP O
long JJ JJ O
- - - O
term NN NN O
pain NN NN O
control NN NN O
, , , O
pethidine NN NN B-CHEM
may MD MD O
cause VB VB O
excitatory JJ JJ O
central JJ JJ O
nervous JJ JJ O
system NN NN O
( ( ( O
CNS NNP NNP O
) ) ) O
effects NNS NNS O
through IN IN O
its PRP$ PRP$ O
neurotoxic JJ JJ O
metabolite NN NN O
, , , O
norpethidine NN NN B-CHEM
, , , O
resulting VBG VBG O
in IN IN O
irritability NN NN O
and CC CC O
seizure NN NN O
attack NN NN O
. . . O

On IN IN O
the DT DT O
contrary NN NN O
, , , O
though IN IN O
not RB RB O
clinically RB RB O
apparent JJ JJ O
, , , O
pethidine NN NN B-CHEM
potentially RB RB O
causes VBZ VBZ O
inhibitory JJ JJ O
impacts NNS NNS O
on IN IN O
the DT DT O
CNS NNP NNP O
and CC CC O
impairs NNS NNS O
normal JJ JJ O
cerebellar NN NN O
and CC CC O
oculomotor NN NN O
function NN NN O
in IN IN O
the DT DT O
short JJ JJ O
term NN NN O
. . . O

In IN IN O
this DT DT O
case NN NN O
report NN NN O
, , , O
we PRP PRP O
highlight VBD VBD O
opioid NN NN O
' '' '' O
s VBZ VBZ O
inhibitory NN NN O
side NN NN O
effects NNS NNS O
on IN IN O
the DT DT O
cerebellar NN NN O
structure NN NN O
that IN IN O
causes NNS NNS O
dysmetria NN NN O
, , , O
dysarthria NN NN O
, , , O
reduced VBD VBD O
smooth JJ JJ O
pursuit NN NN O
gain NN NN O
and CC CC O
decreased VBD VBD O
saccadic JJ JJ O
velocity NN NN O
. . . O

Baboon NNP NNP O
syndrome NN NN O
induced VBN VBN O
by IN IN O
ketoconazole NN NN B-CHEM
. . . O

A DT DT O
27 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
male JJ JJ O
patient NN NN O
presented VBN VBN O
with IN IN O
a DT DT O
maculopapular JJ JJ O
eruption NN NN O
on IN IN O
the DT DT O
flexural JJ JJ O
areas NNS NNS O
and CC CC O
buttocks NNS NNS O
after IN IN O
using VBG VBG O
oral JJ JJ O
ketoconazole NN NN B-CHEM
. . . O

The DT DT O
patient NN NN O
was VBD VBD O
diagnosed VBN VBN O
with IN IN O
drug NN NN O
- - - O
induced JJ JJ O
baboon NN NN O
syndrome NN NN O
based VBN VBN O
on IN IN O
his PRP$ PRP$ O
history NN NN O
, , , O
which WDT WDT O
included VBD VBD O
prior RB RB O
sensitivity NN NN O
to TO TO O
topical JJ JJ O
ketoconazole NN NN B-CHEM
, , , O
a DT DT O
physical JJ JJ O
examination NN NN O
, , , O
and CC CC O
histopathological JJ JJ O
findings NNS NNS O
. . . O

Baboon NNP NNP O
syndrome NN NN O
is VBZ VBZ O
a DT DT O
drug NN NN O
- - - O
or CC CC O
contact NN NN O
allergen NN NN O
- - - O
related VBN VBN O
maculopapular JJ JJ O
eruption NN NN O
that IN IN O
typically RB RB O
involves VBZ VBZ O
the DT DT O
flexural JJ JJ O
and CC CC O
gluteal JJ JJ O
areas NNS NNS O
. . . O

To TO TO O
the DT DT O
best JJS JJS O
of IN IN O
our PRP$ PRP$ O
knowledge NN NN O
, , , O
this DT DT O
is VBZ VBZ O
the DT DT O
first JJ JJ O
reported VBD VBD O
case NN NN O
of IN IN O
ketoconazole NN NN B-CHEM
- - - O
induced JJ JJ O
baboon NN NN O
syndrome NN NN O
in IN IN O
the DT DT O
English NNP NNP O
literature NN NN O
. . . O

A DT DT O
Case NN NN O
of IN IN O
Sudden NNP NNP O
Cardiac NNP NNP O
Death NN NN O
due JJ JJ O
to TO TO O
Pilsicainide NNP NNP B-CHEM
- : : O
Induced NNP NNP O
Torsades NNP NNP O
de IN IN O
Pointes NNP NNP O
. . . O

An DT DT O
84 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
male NN NN O
received VBD VBD O
oral JJ JJ O
pilsicainide NN NN B-CHEM
, , , O
a DT DT O
pure JJ JJ O
sodium NN NN B-CHEM
channel NN NN O
blocker NN NN O
with IN IN O
slow JJ JJ O
recovery NN NN O
kinetics NNS NNS O
, , , O
to TO TO O
convert VB VB O
his PRP$ PRP$ O
paroxysmal NN NN O
atrial JJ JJ O
fibrillation NN NN O
to TO TO O
a DT DT O
sinus NN NN O
rhythm NN NN O
; : : O
the DT DT O
patient NN NN O
developed JJ JJ O
sudden JJ JJ O
cardiac JJ JJ O
death NN NN O
two CD CD O
days NNS NNS O
later RB RB O
. . . O

The DT DT O
Holter NNP NNP O
electrocardiogram NN NN O
, , , O
which WDT WDT O
was VBD VBD O
worn VBN VBN O
by IN IN O
chance NN NN O
, , , O
revealed VBD VBD O
torsade NN NN O
de IN IN O
pointes NNS NNS O
with IN IN O
gradually RB RB O
prolonged JJ JJ O
QT NNP NNP O
intervals NNS NNS O
. . . O

This DT DT O
drug NN NN O
is VBZ VBZ O
rapidly RB RB O
absorbed VBN VBN O
from IN IN O
the DT DT O
gastrointestinal JJ JJ O
tract NN NN O
, , , O
and CC CC O
most JJS JJS O
of IN IN O
it PRP PRP O
is VBZ VBZ O
excreted VBN VBN O
from IN IN O
the DT DT O
kidney NN NN O
. . . O

Although IN IN O
the DT DT O
patient NN NN O
' '' '' O
s VBZ VBZ O
renal JJ JJ O
function NN NN O
was VBD VBD O
not RB RB O
highly RB RB O
impaired VBN VBN O
and CC CC O
the DT DT O
dose NN NN O
of IN IN O
pilsicainide NN NN B-CHEM
was VBD VBD O
low JJ JJ O
, , , O
the DT DT O
plasma NN NN O
concentration NN NN O
of IN IN O
pilsicainide NN NN B-CHEM
may MD MD O
have VB VB O
been VBN VBN O
high JJ JJ O
, , , O
which WDT WDT O
can MD MD O
produce VB VB O
torsades NNS NNS O
de IN IN O
pointes NNS NNS O
in IN IN O
the DT DT O
octogenarian NN NN O
. . . O

Although IN IN O
the DT DT O
oral JJ JJ O
administration NN NN O
of IN IN O
class NN NN O
IC NNP NNP O
drugs NNS NNS O
, , , O
including VBG VBG O
pilsicainide NN NN B-CHEM
, , , O
is VBZ VBZ O
effective JJ JJ O
to TO TO O
terminate VB VB O
atrial JJ JJ O
fibrillation NN NN O
, , , O
careful JJ JJ O
consideration NN NN O
must MD MD O
be VB VB O
taken VBN VBN O
before IN IN O
giving VBG VBG O
these DT DT O
drugs NNS NNS O
to TO TO O
octogenarians NNS NNS O
. . . O

All DT DT B-CHEM
- - - I-CHEM
trans NNS NNS I-CHEM
retinoic JJ JJ I-CHEM
acid NN NN I-CHEM
- - - O
induced JJ JJ O
inflammatory JJ JJ O
myositis NNS NNS O
in IN IN O
a DT DT O
patient NN NN O
with IN IN O
acute JJ JJ O
promyelocytic JJ JJ O
leukemia NN NN O
. . . O

All DT DT B-CHEM
- - - I-CHEM
trans NNS NNS I-CHEM
retinoic JJ JJ I-CHEM
acid NN NN I-CHEM
( ( ( O
ATRA NNP NNP B-CHEM
) ) ) O
, , , O
a DT DT O
component NN NN O
of IN IN O
standard JJ JJ O
therapy NN NN O
for IN IN O
acute JJ JJ O
promyelocytic JJ JJ O
leukemia NN NN O
( ( ( O
APL NNP NNP O
) ) ) O
, , , O
is VBZ VBZ O
associated VBN VBN O
with IN IN O
potentially RB RB O
serious JJ JJ O
but CC CC O
treatable JJ JJ O
adverse JJ JJ O
effects NNS NNS O
involving VBG VBG O
numerous JJ JJ O
organ NN NN O
systems NNS NNS O
, , , O
including VBG VBG O
rare JJ JJ O
skeletal JJ JJ O
muscle NN NN O
involvement NN NN O
. . . O

Only RB RB O
a DT DT O
handful NN NN O
of IN IN O
cases NNS NNS O
of IN IN O
ATRA NNP NNP B-CHEM
- : : O
induced JJ JJ O
myositis NN NN O
in IN IN O
children NNS NNS O
have VBP VBP O
been VBN VBN O
reported VBN VBN O
, , , O
and CC CC O
none NN NN O
in IN IN O
the DT DT O
radiology NN NN O
literature NN NN O
. . . O

We PRP PRP O
present JJ JJ O
such JJ JJ O
a DT DT O
case NN NN O
in IN IN O
a DT DT O
15 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
boy NN NN O
with IN IN O
APL NNP NNP O
, , , O
where WRB WRB O
recognition NN NN O
of IN IN O
imaging VBG VBG O
findings NNS NNS O
played VBD VBD O
a DT DT O
crucial JJ JJ O
role NN NN O
in IN IN O
making VBG VBG O
the DT DT O
diagnosis NN NN O
and CC CC O
facilitated JJ JJ O
prompt NN NN O
, , , O
effective JJ JJ O
treatment NN NN O
. . . O

Tolerability NNP NNP O
of IN IN O
lomustine NN NN B-CHEM
in IN IN O
combination NN NN O
with IN IN O
cyclophosphamide NN NN B-CHEM
in IN IN O
dogs NNS NNS O
with IN IN O
lymphoma NN NN O
. . . O

This DT DT O
retrospective NN NN O
study NN NN O
describes VBZ VBZ O
toxicity NN NN O
associated VBN VBN O
with IN IN O
a DT DT O
protocol NN NN O
of IN IN O
lomustine NN NN B-CHEM
( ( ( O
CCNU NNP NNP B-CHEM
) ) ) O
and CC CC O
cyclophosphamide NN NN B-CHEM
( ( ( O
CTX NNP NNP B-CHEM
) ) ) O
in IN IN O
dogs NNS NNS O
with IN IN O
lymphoma NN NN O
. . . O

CCNU NNP NNP B-CHEM
was VBD VBD O
administered VBN VBN O
per IN IN O
os NN NN O
( ( ( O
PO NNP NNP O
) ) ) O
at IN IN O
a DT DT O
targeted JJ JJ O
dosage NN NN O
of IN IN O
60 CD CD O
mg NN NN O
/ NN NN O
m NN NN O
( ( ( O
2 CD CD O
) ) ) O
body NN NN O
surface NN NN O
area NN NN O
on IN IN O
day NN NN O
0 CD CD O
, , , O
CTX NNP NNP B-CHEM
was VBD VBD O
administered VBN VBN O
PO NNP NNP O
at IN IN O
a DT DT O
targeted JJ JJ O
dosage NN NN O
of IN IN O
250 CD CD O
mg NN NN O
/ NN NN O
m NN NN O
( ( ( O
2 CD CD O
) ) ) O
divided VBN VBN O
over IN IN O
days NNS NNS O
0 CD CD O
through IN IN O
4 CD CD O
, , , O
and CC CC O
all DT DT O
dogs NNS NNS O
received VBD VBD O
prophylactic JJ JJ O
antibiotics NNS NNS O
. . . O

Ninety NNP NNP O
treatments NNS NNS O
were VBD VBD O
given VBN VBN O
to TO TO O
the DT DT O
57 CD CD O
dogs NNS NNS O
included VBD VBD O
in IN IN O
the DT DT O
study NN NN O
. . . O

Neutropenia NNP NNP O
was VBD VBD O
the DT DT O
principal JJ JJ O
toxic JJ JJ O
effect NN NN O
, , , O
and CC CC O
the DT DT O
overall JJ JJ O
frequency NN NN O
of IN IN O
grade NN NN O
4 CD CD O
neutropenia NN NN O
after IN IN O
the DT DT O
first JJ JJ O
treatment NN NN O
of IN IN O
CCNU NNP NNP B-CHEM
/ NN NN O
CTX NNP NNP B-CHEM
was VBD VBD O
30 CD CD O
% NN NN O
( ( ( O
95 CD CD O
% NN NN O
confidence NN NN O
interval NN NN O
, , , O
19 CD CD O
- : : O
43 CD CD O
% NN NN O
) ) ) O
. . . O

The DT DT O
mean JJ JJ O
body NN NN O
weight NN NN O
of IN IN O
dogs NNS NNS O
with IN IN O
grade NN NN O
4 CD CD O
neutropenia NN NN O
( ( ( O
19 CD CD O
. . . O
7 CD CD O
kg NN NN O
+ NN NN O
13 CD CD O
. . . O
4 CD CD O
kg NN NN O
) ) ) O
was VBD VBD O
significantly RB RB O
less JJR JJR O
than IN IN O
the DT DT O
mean JJ JJ O
body NN NN O
weight NN NN O
of IN IN O
dogs NNS NNS O
that WDT WDT O
did VBD VBD O
not RB RB O
develop VB VB O
grade NN NN O
4 CD CD O
neutropenia NN NN O
( ( ( O
31 CD CD O
. . . O
7 CD CD O
kg NN NN O
+ NN NN O
12 CD CD O
. . . O
4 CD CD O
kg NN NN O
; : : O
P NN NN O
= SYM SYM O
. . . O
005 CD CD O
) ) ) O
. . . O

One CD CD O
dog NN NN O
( ( ( O
3 CD CD O
% NN NN O
) ) ) O
developed JJ JJ O
hematologic JJ JJ O
changes NNS NNS O
suggestive VBP VBP O
of IN IN O
hepatotoxicity NN NN O
. . . O

No DT DT O
dogs NNS NNS O
had VBD VBD O
evidence NN NN O
of IN IN O
either DT DT O
renal JJ JJ O
toxicity NN NN O
or CC CC O
hemorrhagic JJ JJ O
cystitis NNS NNS O
. . . O

Adverse NNP NNP O
gastrointestinal JJ JJ O
effects NNS NNS O
were VBD VBD O
uncommon JJ JJ O
. . . O

On IN IN O
the DT DT O
basis NN NN O
of IN IN O
the DT DT O
findings NNS NNS O
reported VBD VBD O
herein NN NN O
, , , O
a DT DT O
dose NN NN O
of IN IN O
60 CD CD O
mg NN NN O
/ NN NN O
m NN NN O
( ( ( O
2 CD CD O
) ) ) O
of IN IN O
CCNU NNP NNP B-CHEM
combined VBD VBD O
with IN IN O
250 CD CD O
mg NN NN O
/ NN NN O
m NN NN O
( ( ( O
2 CD CD O
) ) ) O
of IN IN O
CTX NNP NNP B-CHEM
( ( ( O
divided VBN VBN O
over IN IN O
5 CD CD O
days NNS NNS O
) ) ) O
q NN NN O
4 CD CD O
wk NN NN O
is VBZ VBZ O
tolerable JJ JJ O
in IN IN O
tumor NN NN O
- - - O
bearing NN NN O
dogs NNS NNS O
. . . O

Nelarabine NNP NNP B-CHEM
neurotoxicity NN NN O
with IN IN O
concurrent NN NN O
intrathecal JJ JJ O
chemotherapy NN NN O
: : : O
Case NN NN O
report NN NN O
and CC CC O
review NN NN O
of IN IN O
literature NN NN O
. . . O

Severe NNP NNP O
nelarabine NN NN B-CHEM
neurotoxicity NN NN O
in IN IN O
a DT DT O
patient NN NN O
who WP WP O
received VBD VBD O
concurrent JJ JJ O
intrathecal JJ JJ O
( ( ( O
IT PRP PRP O
) ) ) O
chemotherapy NN NN O
is VBZ VBZ O
reported VBN VBN O
. . . O

A DT DT O
37 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
Caucasian NNP NNP O
woman NN NN O
with IN IN O
a DT DT O
history NN NN O
of IN IN O
T NN NN O
- - - O
cell NN NN O
lymphoblastic JJ JJ O
lymphoma NN NN O
was VBD VBD O
admitted VBN VBN O
for IN IN O
relapsed JJ JJ O
disease NN NN O
. . . O

She PRP PRP O
was VBD VBD O
originally RB RB O
treated VBN VBN O
with IN IN O
induction NN NN O
chemotherapy NN NN O
followed VBN VBN O
by IN IN O
an DT DT O
autologous JJ JJ O
transplant NN NN O
. . . O

She PRP PRP O
developed VBD VBD O
relapsed JJ JJ O
disease NN NN O
10 CD CD O
months NNS NNS O
later RB RB O
with IN IN O
leukemic JJ JJ O
involvement NN NN O
. . . O

She PRP PRP O
was VBD VBD O
re NN NN O
- : : O
induced VBN VBN O
with IN IN O
nelarabine NN NN B-CHEM
1500 CD CD O
mg NN NN O
/ NN NN O
m NN NN O
( ( ( O
2 CD CD O
) ) ) O
on IN IN O
days NNS NNS O
1 CD CD O
, , , O
3 CD CD O
, , , O
and CC CC O
5 CD CD O
with IN IN O
1 CD CD O
dose NN NN O
of IN IN O
IT PRP PRP O
cytarabine NN NN B-CHEM
100 CD CD O
mg NN NN O
on IN IN O
day NN NN O
2 CD CD O
as IN IN O
central JJ JJ O
nervous JJ JJ O
system NN NN O
( ( ( O
CNS NNP NNP O
) ) ) O
prophylaxis NN NN O
. . . O

At IN IN O
the DT DT O
time NN NN O
of IN IN O
treatment NN NN O
, , , O
she PRP PRP O
was VBD VBD O
on IN IN O
continuous JJ JJ O
renal NN NN O
replacement NN NN O
therapy NN NN O
due JJ JJ O
to TO TO O
sequelae NN NN O
of IN IN O
tumor NN NN O
lysis NN NN O
syndrome NN NN O
( ( ( O
TLS NNP NNP O
) ) ) O
. . . O

She PRP PRP O
tolerated JJ JJ O
therapy NN NN O
well RB RB O
, , , O
entered VBD VBD O
a DT DT O
complete JJ JJ O
remission NN NN O
, , , O
and CC CC O
recovered VBD VBD O
her PRP$ PRP$ O
renal JJ JJ O
function NN NN O
. . . O

She PRP PRP O
received VBD VBD O
a DT DT O
second JJ JJ O
cycle NN NN O
of IN IN O
nelarabine NN NN B-CHEM
without IN IN O
additional JJ JJ O
IT PRP PRP O
prophylaxis VBD VBD O
one CD CD O
month NN NN O
later RB RB O
. . . O

A DT DT O
week NN NN O
after IN IN O
this DT DT O
second JJ JJ O
cycle NN NN O
, , , O
she PRP PRP O
noted VBD VBD O
numbness NN NN O
in IN IN O
her PRP$ PRP$ O
lower JJR JJR O
extremities NNS NNS O
. . . O

Predominantly NNP NNP O
sensory NN NN O
, , , O
though IN IN O
also RB RB O
motor NN NN O
and CC CC O
autonomic JJ JJ O
, , , O
peripheral JJ JJ O
neuropathy NN NN O
started VBD VBD O
in IN IN O
her PRP$ PRP$ O
feet NNS NNS O
, , , O
ascended VBN VBN O
proximally RB RB O
to TO TO O
the DT DT O
mid JJ JJ O
- - - O
thoracic NN NN O
region NN NN O
, , , O
and CC CC O
eventually RB RB O
included VBD VBD O
her PRP$ PRP$ O
distal JJ JJ O
upper NN NN O
extremities NNS NNS O
. . . O

A DT DT O
magnetic JJ JJ O
resonance NN NN O
imaging VBG VBG O
( ( ( O
MRI NNP NNP O
) ) ) O
of IN IN O
her PRP$ PRP$ O
spine NN NN O
demonstrated VBN VBN O
changes NNS NNS O
from IN IN O
C2 NNP NNP O
to TO TO O
C6 NNP NNP O
consistent JJ JJ O
with IN IN O
subacute NN NN O
combined JJ JJ O
degeneration NN NN O
. . . O

Nelarabine NNP NNP B-CHEM
was VBD VBD O
felt VBN VBN O
to TO TO O
be VB VB O
the DT DT O
cause NN NN O
of IN IN O
her PRP$ PRP$ O
symptoms NNS NNS O
. . . O

Her PRP$ PRP$ O
neuropathy NN NN O
stabilized VBN VBN O
and CC CC O
showed VBN VBN O
slight JJ JJ O
improvement NN NN O
and CC CC O
ultimately RB RB O
received VBD VBD O
an DT DT O
unrelated JJ JJ O
, , , O
reduced VBN VBN O
- - - O
intensity NN NN O
allogeneic NN NN O
transplant NN NN O
while IN IN O
in IN IN O
complete JJ JJ O
remission NN NN O
, , , O
but CC CC O
relapsed VBD VBD O
disease NN NN O
10 CD CD O
weeks NNS NNS O
later RB RB O
. . . O

She PRP PRP O
is VBZ VBZ O
currently RB RB O
being VBG VBG O
treated VBN VBN O
with IN IN O
best JJS JJS O
supportive JJ JJ O
care NN NN O
. . . O

To TO TO O
our PRP$ PRP$ O
knowledge NN NN O
, , , O
this DT DT O
is VBZ VBZ O
the DT DT O
first JJ JJ O
published VBN VBN O
case NN NN O
report NN NN O
of IN IN O
severe JJ JJ O
neurotoxicity NN NN O
caused VBN VBN O
by IN IN O
nelarabine NN NN B-CHEM
in IN IN O
a DT DT O
patient NN NN O
who WP WP O
received VBD VBD O
concurrent NN NN O
IT PRP PRP O
chemotherapy NN NN O
. . . O

Valproate NNP NNP B-CHEM
- : : O
induced JJ JJ O
hyperammonemic JJ JJ O
encephalopathy NN NN O
in IN IN O
a DT DT O
renal NN NN O
transplanted JJ JJ O
patient NN NN O
. . . O

Neurological NNP NNP O
complications NNS NNS O
after IN IN O
renal JJ JJ O
transplantation NN NN O
constitute NN NN O
an DT DT O
important JJ JJ O
cause NN NN O
of IN IN O
morbidity NN NN O
and CC CC O
mortality NN NN O
. . . O

Their PRP$ PRP$ O
differential JJ JJ O
diagnosis NN NN O
is VBZ VBZ O
difficult JJ JJ O
and CC CC O
essential JJ JJ O
for IN IN O
subsequent JJ JJ O
patient NN NN O
' '' '' O
s VBZ VBZ O
management NN NN O
. . . O

Valproate NNP NNP B-CHEM
- : : O
induced JJ JJ O
hyperammonemic JJ JJ O
encephalopathy NN NN O
is VBZ VBZ O
an DT DT O
uncommon JJ JJ O
but CC CC O
serious JJ JJ O
effect NN NN O
of IN IN O
valproate JJ JJ B-CHEM
treatment NN NN O
. . . O

Here RB RB O
, , , O
we PRP PRP O
describe VBP VBP O
the DT DT O
case NN NN O
of IN IN O
a DT DT O
15 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
girl NN NN O
who WP WP O
was VBD VBD O
on IN IN O
a DT DT O
long JJ JJ O
- - - O
term NN NN O
therapy NN NN O
with IN IN O
valproate NN NN B-CHEM
due JJ JJ O
to TO TO O
epilepsy VB VB O
and CC CC O
revealed VBD VBD O
impaired JJ JJ O
consciousness NN NN O
with IN IN O
hyperammonemia NN NN O
12 CD CD O
days NNS NNS O
after IN IN O
renal JJ JJ O
transplantation NN NN O
. . . O

After IN IN O
withdraw NN NN O
of IN IN O
valproate NN NN B-CHEM
, , , O
patients NNS NNS O
' POS POS O
symptoms NNS NNS O
resolved VBN VBN O
within IN IN O
24 CD CD O
h NN NN O
. . . O

Clinicians NNP NNP O
should MD MD O
increase VB VB O
their PRP$ PRP$ O
awareness NN NN O
for IN IN O
potential JJ JJ O
complication NN NN O
of IN IN O
valproate NN NN B-CHEM
, , , O
especially RB RB O
in IN IN O
transplanted JJ JJ O
patients NNS NNS O
. . . O

Necrotising NNP NNP O
fasciitis NNS NNS O
after IN IN O
bortezomib NN NN B-CHEM
and CC CC O
dexamethasone NN NN B-CHEM
- - - O
containing VBG VBG O
regimen NN NN O
in IN IN O
an DT DT O
elderly JJ JJ O
patient NN NN O
of IN IN O
Waldenstrom NNP NNP O
macroglobulinaemia NN NN O
. . . O

Bortezomib NNP NNP B-CHEM
and CC CC O
high JJ JJ O
- - - O
dose NN NN O
dexamethasone NN NN B-CHEM
- : : O
containing VBG VBG O
regimens NNS NNS O
are VBP VBP O
considered VBN VBN O
to TO TO O
be VB VB O
generally RB RB O
tolerable JJ JJ O
with IN IN O
few JJ JJ O
severe JJ JJ O
bacterial JJ JJ O
infections NNS NNS O
in IN IN O
patients NNS NNS O
with IN IN O
B NNP NNP O
- - - O
cell NN NN O
malignancies NNS NNS O
. . . O

However RB RB O
, , , O
information NN NN O
is VBZ VBZ O
limited VBN VBN O
concerning VBG VBG O
the DT DT O
safety NN NN O
of IN IN O
the DT DT O
regimen NNS NNS O
in IN IN O
elderly JJ JJ O
patients NNS NNS O
. . . O

We PRP PRP O
report VBP VBP O
a DT DT O
case NN NN O
of IN IN O
a DT DT O
76 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
man NN NN O
with IN IN O
Waldenstrom NNP NNP O
macroglobulinaemia NN NN O
who WP WP O
suffered VBD VBD O
necrotising VBG VBG O
fasciitis NNS NNS O
without IN IN O
neutropenia NN NN O
after IN IN O
the DT DT O
combination NN NN O
treatment NN NN O
with IN IN O
bortezomib NN NN B-CHEM
, , , O
high JJ JJ O
- - - O
dose NN NN O
dexamethasone NN NN B-CHEM
and CC CC O
rituximab NN NN O
. . . O

Despite IN IN O
immediate JJ JJ O
intravenous JJ JJ O
antimicrobial JJ JJ O
therapy NN NN O
, , , O
he PRP PRP O
succumbed VBD VBD O
23 CD CD O
h NN NN O
after IN IN O
the DT DT O
onset NN NN O
. . . O

Physicians NNP NNP O
should MD MD O
recognise VB VB O
the DT DT O
possibility NN NN O
of IN IN O
fatal JJ JJ O
bacterial NN NN O
infections NNS NNS O
related VBN VBN O
to TO TO O
bortezomib VB VB B-CHEM
plus CC CC O
high JJ JJ O
- - - O
dose NN NN O
dexamethasone NN NN B-CHEM
in IN IN O
elderly JJ JJ O
patients NNS NNS O
, , , O
and CC CC O
we PRP PRP O
believe VBP VBP O
this DT DT O
case NN NN O
warrants VBZ VBZ O
further JJ JJ O
investigation NN NN O
. . . O

An DT DT O
integrated JJ JJ O
characterization NN NN O
of IN IN O
serological JJ JJ O
, , , O
pathological JJ JJ O
, , , O
and CC CC O
functional JJ JJ O
events NNS NNS O
in IN IN O
doxorubicin NN NN B-CHEM
- - - O
induced JJ JJ O
cardiotoxicity NN NN O
. . . O

Many JJ JJ O
efficacious JJ JJ O
cancer NN NN O
treatments NNS NNS O
cause VBP VBP O
significant JJ JJ O
cardiac NN NN O
morbidity NN NN O
, , , O
yet RB RB O
biomarkers NNS NNS O
or CC CC O
functional JJ JJ O
indices NNS NNS O
of IN IN O
early JJ JJ O
damage NN NN O
, , , O
which WDT WDT O
would MD MD O
allow VB VB O
monitoring VBG VBG O
and CC CC O
intervention NN NN O
, , , O
are VBP VBP O
lacking VBG VBG O
. . . O

In IN IN O
this DT DT O
study NN NN O
, , , O
we PRP PRP O
have VBP VBP O
utilized JJ JJ O
a DT DT O
rat NN NN O
model NN NN O
of IN IN O
progressive JJ JJ O
doxorubicin NN NN B-CHEM
( ( ( O
DOX NNP NNP B-CHEM
) ) ) O
- : : O
induced JJ JJ O
cardiomyopathy NN NN O
, , , O
applying VBG VBG O
multiple JJ JJ O
approaches NNS NNS O
, , , O
including VBG VBG O
cardiac JJ JJ O
magnetic JJ JJ O
resonance NN NN O
imaging VBG VBG O
( ( ( O
MRI NNP NNP O
) ) ) O
, , , O
to TO TO O
provide VB VB O
the DT DT O
most RBS RBS O
comprehensive JJ JJ O
characterization NN NN O
to TO TO O
date NN NN O
of IN IN O
the DT DT O
timecourse NN NN O
of IN IN O
serological JJ JJ O
, , , O
pathological JJ JJ O
, , , O
and CC CC O
functional JJ JJ O
events NNS NNS O
underlying VBG VBG O
this DT DT O
toxicity NN NN O
. . . O

Hannover NNP NNP O
Wistar NNP NNP O
rats NNS NNS O
were VBD VBD O
dosed VBN VBN O
with IN IN O
1 CD CD O
. . . O
25 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
DOX NNP NNP B-CHEM
weekly NN NN O
for IN IN O
8 CD CD O
weeks NNS NNS O
followed VBN VBN O
by IN IN O
a DT DT O
4 CD CD O
week NN NN O
off IN IN O
- - - O
dosing VBG VBG O
" '' '' O
recovery NN NN O
" '' '' O
period NN NN O
. . . O

Electron NNP NNP O
microscopy NN NN O
of IN IN O
the DT DT O
myocardium NN NN O
revealed VBD VBD O
subcellular JJ JJ O
degeneration NN NN O
and CC CC O
marked VBD VBD O
mitochondrial JJ JJ O
changes NNS NNS O
after IN IN O
a DT DT O
single JJ JJ O
dose NN NN O
. . . O

Histopathological NNP NNP O
analysis NN NN O
revealed VBD VBD O
progressive JJ JJ O
cardiomyocyte NN NN O
degeneration NN NN O
, , , O
hypertrophy NN NN O
/ NN NN O
cytomegaly NN NN O
, , , O
and CC CC O
extensive JJ JJ O
vacuolation NN NN O
after IN IN O
two CD CD O
doses NNS NNS O
. . . O

Extensive NNP NNP O
replacement NN NN O
fibrosis NNS NNS O
( ( ( O
quantified VBN VBN O
by IN IN O
Sirius NNP NNP O
red JJ JJ O
staining VBG VBG O
) ) ) O
developed VBN VBN O
during IN IN O
the DT DT O
off JJ JJ O
- - - O
dosing NN NN O
period NN NN O
. . . O

Functional NNP NNP O
indices NNS NNS O
assessed VBN VBN O
by IN IN O
cardiac JJ JJ O
MRI NNP NNP O
( ( ( O
including VBG VBG O
left VBD VBD O
ventricular JJ JJ O
ejection NN NN O
fraction NN NN O
( ( ( O
LVEF NNP NNP O
) ) ) O
, , , O
cardiac JJ JJ O
output NN NN O
, , , O
and CC CC O
E NNP NNP O
/ NN NN O
A DT DT O
ratio NN NN O
) ) ) O
declined VBD VBD O
progressively RB RB O
, , , O
reaching VBG VBG O
statistical JJ JJ O
significance NN NN O
after IN IN O
two CD CD O
doses NNS NNS O
and CC CC O
culminating VBG VBG O
in IN IN O
" '' '' O
clinical JJ JJ O
" '' '' O
LV NNP NNP O
dysfunction NN NN O
by IN IN O
12 CD CD O
weeks NNS NNS O
. . . O

Significant JJ JJ O
increases NNS NNS O
in IN IN O
peak NN NN O
myocardial JJ JJ O
contrast NN NN O
enhancement NN NN O
and CC CC O
serological JJ JJ O
cardiac NN NN O
troponin NN NN O
I PRP PRP O
( ( ( O
cTnI NN NN O
) ) ) O
emerged VBD VBD O
after IN IN O
eight CD CD O
doses NNS NNS O
, , , O
importantly RB RB O
preceding VBG VBG O
the DT DT O
LVEF NNP NNP O
decline NN NN O
to TO TO O
< NN NN O
50 CD CD O
% NN NN O
. . . O

Troponin NNP NNP O
I PRP PRP O
levels NNS NNS O
positively RB RB O
correlated JJ JJ O
with IN IN O
delayed JJ JJ O
and CC CC O
peak NN NN O
gadolinium NN NN B-CHEM
contrast NN NN O
enhancement NN NN O
, , , O
histopathological JJ JJ O
grading NN NN O
, , , O
and CC CC O
diastolic JJ JJ O
dysfunction NN NN O
. . . O

In IN IN O
summary JJ JJ O
, , , O
subcellular JJ JJ O
cardiomyocyte NN NN O
degeneration NN NN O
was VBD VBD O
the DT DT O
earliest JJS JJS O
marker NN NN O
, , , O
followed VBN VBN O
by IN IN O
progressive JJ JJ O
functional JJ JJ O
decline NN NN O
and CC CC O
histopathological JJ JJ O
manifestations NNS NNS O
. . . O

Myocardial NNP NNP O
contrast NN NN O
enhancement NN NN O
and CC CC O
elevations NNS NNS O
in IN IN O
cTnI NN NN O
occurred VBD VBD O
later RB RB O
. . . O

However RB RB O
, , , O
all DT DT O
indices NNS NNS O
predated VBN VBN O
" '' '' O
clinical JJ JJ O
" '' '' O
LV NNP NNP O
dysfunction NN NN O
and CC CC O
thus RB RB O
warrant JJ JJ O
further JJ JJ O
evaluation NN NN O
as IN IN O
predictive JJ JJ O
biomarkers NNS NNS O
. . . O

Intradermal NNP NNP O
glutamate NN NN B-CHEM
and CC CC O
capsaicin NN NN B-CHEM
injections NNS NNS O
: : : O
intra NN NN O
- - - O
and CC CC O
interindividual JJ JJ O
variability NN NN O
of IN IN O
provoked JJ JJ O
hyperalgesia NN NN O
and CC CC O
allodynia NN NN O
. . . O

Intradermal NNP NNP O
injections NNS NNS O
of IN IN O
glutamate NN NN B-CHEM
and CC CC O
capsaicin NN NN B-CHEM
are VBP VBP O
attractive JJ JJ O
to TO TO O
use VB VB O
in IN IN O
human JJ JJ O
experimental JJ JJ O
pain NN NN O
models NNS NNS O
because IN IN O
hyperalgesia NN NN O
and CC CC O
allodynia NN NN O
mimic JJ JJ O
isolated VBN VBN O
aspects NNS NNS O
of IN IN O
clinical JJ JJ O
pain NN NN O
disorders NNS NNS O
. . . O

The DT DT O
aim NN NN O
of IN IN O
the DT DT O
present JJ JJ O
study NN NN O
was VBD VBD O
to TO TO O
investigate VB VB O
the DT DT O
reproducibility NN NN O
of IN IN O
these DT DT O
models NNS NNS O
. . . O

Twenty NNP NNP O
healthy JJ JJ O
male NN NN O
volunteers NNS NNS O
( ( ( O
mean VB VB O
age NN NN O
24 CD CD O
years NNS NNS O
; : : O
range NN NN O
18 CD CD O
- : : O
38 CD CD O
years NNS NNS O
) ) ) O
received VBD VBD O
intradermal JJ JJ O
injections NNS NNS O
of IN IN O
glutamate NN NN B-CHEM
and CC CC O
capsaicin NN NN B-CHEM
in IN IN O
the DT DT O
volar JJ JJ O
forearm NN NN O
. . . O

Magnitudes NNP NNP O
of IN IN O
secondary JJ JJ O
pinprick NN NN O
hyperalgesia NN NN O
and CC CC O
brush NN NN O
- - - O
evoked JJ JJ O
allodynia NN NN O
were VBD VBD O
investigated VBN VBN O
using VBG VBG O
von NN NN O
Frey NNP NNP O
filaments NNS NNS O
( ( ( O
gauges NNS NNS O
10 CD CD O
, , , O
15 CD CD O
, , , O
60 CD CD O
and CC CC O
100 CD CD O
g SYM SYM O
) ) ) O
and CC CC O
brush NN NN O
strokes NNS NNS O
. . . O

Areas NNS NNS O
of IN IN O
secondary JJ JJ O
hyperalgesia NN NN O
and CC CC O
allodynia NN NN O
were VBD VBD O
quantified VBN VBN O
immediately RB RB O
after IN IN O
injection NN NN O
and CC CC O
after IN IN O
15 CD CD O
, , , O
30 CD CD O
and CC CC O
60 CD CD O
min NN NN O
. . . O

Two CD CD O
identical JJ JJ O
experiments NNS NNS O
separated VBN VBN O
by IN IN O
at IN IN O
least JJS JJS O
7 CD CD O
days NNS NNS O
were VBD VBD O
performed VBN VBN O
. . . O

Reproducibility NNP NNP O
across IN IN O
and CC CC O
within IN IN O
volunteers NNS NNS O
( ( ( O
inter NN NN O
- : : O
and CC CC O
intra JJ JJ O
- - - O
individual JJ JJ O
variation NN NN O
, , , O
respectively RB RB O
) ) ) O
was VBD VBD O
assessed VBN VBN O
using VBG VBG O
intraclass NN NN O
correlation NN NN O
coefficient NN NN O
( ( ( O
ICC NNP NNP O
) ) ) O
and CC CC O
coefficient NN NN O
of IN IN O
variation NN NN O
( ( ( O
CV NNP NNP O
) ) ) O
. . . O

Secondary JJ JJ O
pinprick NN NN O
hyperalgesia NN NN O
was VBD VBD O
observed VBN VBN O
as IN IN O
a DT DT O
marked VBN VBN O
increase NN NN O
in IN IN O
the DT DT O
visual JJ JJ O
analogue NN NN O
scale NN NN O
( ( ( O
VAS NNP NNP O
) ) ) O
response NN NN O
to TO TO O
von NN NN O
Frey NNP NNP O
gauges NNS NNS O
60 CD CD O
and CC CC O
100 CD CD O
g SYM SYM O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
after IN IN O
glutamate NN NN B-CHEM
injection NN NN O
. . . O

For IN IN O
capsaicin NN NN B-CHEM
, , , O
secondary JJ JJ O
pinprick NN NN O
hyperalgesia NN NN O
was VBD VBD O
detected VBN VBN O
with IN IN O
all DT DT O
von NN NN O
Frey NNP NNP O
gauges NNS NNS O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
. . . O

Glutamate NNP NNP B-CHEM
evoked VBD VBD O
reproducible JJ JJ O
VAS NNP NNP O
response NN NN O
to TO TO O
all DT DT O
von NN NN O
Frey NNP NNP O
gauges NNS NNS O
( ( ( O
ICC NNP NNP O
> NN NN O
0 CD CD O
. . . O
60 CD CD O
) ) ) O
and CC CC O
brush NN NN O
strokes NNS NNS O
( ( ( O
ICC NNP NNP O
> NN NN O
0 CD CD O
. . . O
83 CD CD O
) ) ) O
. . . O

Capsaicin NNP NNP B-CHEM
injection NN NN O
was VBD VBD O
reproducible JJ JJ O
for IN IN O
secondary JJ JJ O
hyperalgesia NN NN O
( ( ( O
ICC NNP NNP O
> NN NN O
0 CD CD O
. . . O
70 CD CD O
) ) ) O
and CC CC O
allodynia NN NN O
( ( ( O
ICC NNP NNP O
> NN NN O
0 CD CD O
. . . O
71 CD CD O
) ) ) O
. . . O

Intra NNP NNP O
- : : O
individual JJ JJ O
variability NN NN O
was VBD VBD O
generally RB RB O
lower JJR JJR O
for IN IN O
the DT DT O
VAS NNP NNP O
response NN NN O
to TO TO O
von NN NN O
Frey NNP NNP O
and CC CC O
brush NN NN O
compared VBN VBN O
with IN IN O
areas NNS NNS O
of IN IN O
secondary JJ JJ O
hyperalgesia NN NN O
and CC CC O
allodynia NN NN O
. . . O

In IN IN O
conclusion NN NN O
, , , O
glutamate NN NN B-CHEM
and CC CC O
capsaicin NN NN B-CHEM
yield NN NN O
reproducible JJ JJ O
hyperalgesic NN NN O
and CC CC O
allodynic JJ JJ O
responses NNS NNS O
, , , O
and CC CC O
the DT DT O
present JJ JJ O
model NN NN O
is VBZ VBZ O
well RB RB O
suited VBN VBN O
for IN IN O
basic JJ JJ O
research NN NN O
, , , O
as RB RB O
well RB RB O
as IN IN O
for IN IN O
assessing VBG VBG O
the DT DT O
modulation NN NN O
of IN IN O
central JJ JJ O
phenomena NN NN O
. . . O

Ocular NNP NNP O
- : : O
specific JJ JJ O
ER NNP NNP O
stress NN NN O
reduction NN NN O
rescues NNS NNS O
glaucoma NN NN O
in IN IN O
murine NN NN O
glucocorticoid NN NN O
- : : O
induced JJ JJ O
glaucoma NN NN O
. . . O

Administration NNP NNP O
of IN IN O
glucocorticoids NNS NNS O
induces NNS NNS O
ocular JJ JJ O
hypertension NN NN O
in IN IN O
some DT DT O
patients NNS NNS O
. . . O

If IN IN O
untreated JJ JJ O
, , , O
these DT DT O
patients NNS NNS O
can MD MD O
develop VB VB O
a DT DT O
secondary JJ JJ O
glaucoma NN NN O
that WDT WDT O
resembles VBZ VBZ O
primary JJ JJ O
open JJ JJ O
- : : O
angle NN NN O
glaucoma NN NN O
( ( ( O
POAG NNP NNP O
) ) ) O
. . . O

The DT DT O
underlying VBG VBG O
pathology NN NN O
of IN IN O
glucocorticoid NN NN O
- - - O
induced JJ JJ O
glaucoma NN NN O
is VBZ VBZ O
not RB RB O
fully RB RB O
understood VBN VBN O
, , , O
due JJ JJ O
in IN IN O
part NN NN O
to TO TO O
lack NN NN O
of IN IN O
an DT DT O
appropriate JJ JJ O
animal NN NN O
model NN NN O
. . . O

Here RB RB O
, , , O
we PRP PRP O
developed VBD VBD O
a DT DT O
murine JJ JJ O
model NN NN O
of IN IN O
glucocorticoid NN NN O
- - - O
induced JJ JJ O
glaucoma NN NN O
that IN IN O
exhibits VBZ VBZ O
glaucoma JJ JJ O
features NNS NNS O
that WDT WDT O
are VBP VBP O
observed VBN VBN O
in IN IN O
patients NNS NNS O
. . . O

Treatment NN NN O
of IN IN O
WT NNP NNP O
mice NNS NNS O
with IN IN O
topical JJ JJ O
ocular NN NN O
0 CD CD O
. . . O
1 CD CD O
% NN NN O
dexamethasone NN NN B-CHEM
led VBN VBN O
to TO TO O
elevation NN NN O
of IN IN O
intraocular JJ JJ O
pressure NN NN O
( ( ( O
IOP NNP NNP O
) ) ) O
, , , O
functional JJ JJ O
and CC CC O
structural JJ JJ O
loss NN NN O
of IN IN O
retinal JJ JJ O
ganglion NN NN O
cells NNS NNS O
, , , O
and CC CC O
axonal JJ JJ O
degeneration NN NN O
, , , O
resembling VBG VBG O
glucocorticoid NN NN O
- - - O
induced JJ JJ O
glaucoma NN NN O
in IN IN O
human JJ JJ O
patients NNS NNS O
. . . O

Furthermore RB RB O
, , , O
dexamethasone NN NN B-CHEM
- - - O
induced JJ JJ O
ocular NN NN O
hypertension NN NN O
was VBD VBD O
associated VBN VBN O
with IN IN O
chronic JJ JJ O
ER NNP NNP O
stress NN NN O
of IN IN O
the DT DT O
trabecular NN NN O
meshwork NN NN O
( ( ( O
TM NNP NNP O
) ) ) O
. . . O

Similar JJ JJ O
to TO TO O
patients NNS NNS O
, , , O
withdrawal NN NN O
of IN IN O
dexamethasone NN NN B-CHEM
treatment NN NN O
reduced VBD VBD O
elevated VBD VBD O
IOP NNP NNP O
and CC CC O
ER NNP NNP O
stress NN NN O
in IN IN O
this DT DT O
animal NN NN O
model NN NN O
. . . O

Dexamethasone NNP NNP B-CHEM
induced VBD VBD O
the DT DT O
transcriptional NN NN O
factor NN NN O
CHOP NNP NNP O
, , , O
a DT DT O
marker NN NN O
for IN IN O
chronic JJ JJ O
ER NNP NNP O
stress NN NN O
, , , O
in IN IN O
the DT DT O
anterior NN NN O
segment NN NN O
tissues NNS NNS O
, , , O
and CC CC O
Chop NNP NNP O
deletion NN NN O
reduced VBD VBD O
ER NNP NNP O
stress NN NN O
in IN IN O
these DT DT O
tissues NNS NNS O
and CC CC O
prevented VBN VBN O
dexamethasone NN NN B-CHEM
- - - O
induced JJ JJ O
ocular JJ JJ O
hypertension NN NN O
. . . O

Furthermore RB RB O
, , , O
reduction NN NN O
of IN IN O
ER NNP NNP O
stress NN NN O
in IN IN O
the DT DT O
TM NNP NNP O
with IN IN O
sodium NN NN B-CHEM
4 CD CD I-CHEM
- : : I-CHEM
phenylbutyrate NN NN I-CHEM
prevented VBN VBN O
dexamethasone NN NN B-CHEM
- - - O
induced JJ JJ O
ocular NN NN O
hypertension NN NN O
in IN IN O
WT NNP NNP O
mice NN NN O
. . . O

Our PRP$ PRP$ O
data NNS NNS O
indicate VBP VBP O
that IN IN O
ER NNP NNP O
stress NN NN O
contributes VBZ VBZ O
to TO TO O
glucocorticoid VB VB O
- - - O
induced JJ JJ O
ocular NN NN O
hypertension NN NN O
and CC CC O
suggest VB VB O
that IN IN O
reducing VBG VBG O
ER NNP NNP O
stress NN NN O
has VBZ VBZ O
potential JJ JJ O
as IN IN O
a DT DT O
therapeutic JJ JJ O
strategy NN NN O
for IN IN O
treating VBG VBG O
glucocorticoid NN NN O
- - - O
induced JJ JJ O
glaucoma NN NN O
. . . O

Effects NNP NNP O
of IN IN O
ginsenosides NNS NNS B-CHEM
on IN IN O
opioid NN NN O
- : : O
induced JJ JJ O
hyperalgesia NN NN O
in IN IN O
mice NN NN O
. . . O

Opioid NNP NNP O
- : : O
induced JJ JJ O
hyperalgesia NN NN O
( ( ( O
OIH NNP NNP O
) ) ) O
is VBZ VBZ O
characterized VBN VBN O
by IN IN O
nociceptive JJ JJ O
sensitization NN NN O
caused VBN VBN O
by IN IN O
the DT DT O
cessation NN NN O
of IN IN O
chronic JJ JJ O
opioid JJ JJ O
use NN NN O
. . . O

OIH NNP NNP O
can MD MD O
limit VB VB O
the DT DT O
clinical JJ JJ O
use NN NN O
of IN IN O
opioid NN NN O
analgesics NNS NNS O
and CC CC O
complicate NN NN O
withdrawal NN NN O
from IN IN O
opioid JJ JJ O
addiction NN NN O
. . . O

In IN IN O
this DT DT O
study NN NN O
, , , O
we PRP PRP O
investigated VBD VBD O
the DT DT O
effects NNS NNS O
of IN IN O
Re NNP NNP B-CHEM
, , , I-CHEM
Rg1 NNP NNP I-CHEM
, , , I-CHEM
and CC CC I-CHEM
Rb1 NNP NNP I-CHEM
ginsenosides NNS NNS I-CHEM
, , , O
the DT DT O
bioactive JJ JJ O
components NNS NNS O
of IN IN O
ginseng NN NN O
, , , O
on IN IN O
OIH NNP NNP O
. . . O

OIH NNP NNP O
was VBD VBD O
achieved VBN VBN O
in IN IN O
mice NN NN O
after IN IN O
subcutaneous JJ JJ O
administration NN NN O
of IN IN O
morphine NN NN B-CHEM
for IN IN O
7 CD CD O
consecutive JJ JJ O
days NNS NNS O
three CD CD O
times NNS NNS O
per IN IN O
day NN NN O
. . . O

During IN IN O
withdrawal NN NN O
( ( ( O
days NNS NNS O
8 CD CD O
and CC CC O
9 CD CD O
) ) ) O
, , , O
these DT DT O
mice NNS NNS O
were VBD VBD O
administered VBN VBN O
Re NNP NNP B-CHEM
, , , O
Rg1 NNP NNP B-CHEM
, , , O
or CC CC O
Rb1 NNP NNP B-CHEM
intragastrically RB RB O
two CD CD O
times NNS NNS O
per IN IN O
day NN NN O
. . . O

On IN IN O
the DT DT O
test NN NN O
day NN NN O
( ( ( O
day NN NN O
10 CD CD O
) ) ) O
, , , O
mice NN NN O
were VBD VBD O
subjected VBN VBN O
to TO TO O
the DT DT O
thermal NN NN O
sensitivity NN NN O
test NN NN O
and CC CC O
the DT DT O
acetic JJ JJ B-CHEM
acid NN NN I-CHEM
- - - O
induced JJ JJ O
writhing NN NN O
test NN NN O
. . . O

Re NNP NNP B-CHEM
( ( ( O
300 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
inhibited JJ JJ O
OIH NNP NNP O
in IN IN O
both DT DT O
the DT DT O
thermal NN NN O
sensitivity NN NN O
test NN NN O
and CC CC O
the DT DT O
acetic JJ JJ B-CHEM
acid NN NN I-CHEM
- - - O
induced JJ JJ O
writhing NN NN O
test NN NN O
. . . O

However RB RB O
, , , O
the DT DT O
Rg1 NNP NNP B-CHEM
and CC CC I-CHEM
Rb1 NNP NNP I-CHEM
ginsenosides NNS NNS I-CHEM
failed VBD VBD O
to TO TO O
prevent VB VB O
OIH NNP NNP O
in IN IN O
either DT DT O
test NN NN O
. . . O

Furthermore RB RB O
, , , O
Rg1 NNP NNP B-CHEM
showed VBD VBD O
a DT DT O
tendency NN NN O
to TO TO O
aggravate VB VB O
OIH NNP NNP O
in IN IN O
the DT DT O
acetic JJ JJ B-CHEM
acid NN NN I-CHEM
- - - O
induced JJ JJ O
writhing NN NN O
test NN NN O
. . . O

Our PRP$ PRP$ O
data NNS NNS O
suggested VBD VBD O
that IN IN O
the DT DT O
ginsenoside NN NN B-CHEM
Re NNP NNP I-CHEM
, , , O
but CC CC O
not RB RB O
Rg1 NNP NNP B-CHEM
or CC CC O
Rb1 NNP NNP B-CHEM
, , , O
may MD MD O
contribute VB VB O
toward IN IN O
reversal NN NN O
of IN IN O
OIH NNP NNP O
. . . O

A DT DT O
comparison NN NN O
of IN IN O
severe JJ JJ O
hemodynamic JJ JJ O
disturbances NNS NNS O
between IN IN O
dexmedetomidine NN NN B-CHEM
and CC CC O
propofol NN NN B-CHEM
for IN IN O
sedation NN NN O
in IN IN O
neurocritical JJ JJ O
care NN NN O
patients NNS NNS O
. . . O

OBJECTIVE NNP NNP O
: : : O
Dexmedetomidine NNP NNP B-CHEM
and CC CC O
propofol NN NN B-CHEM
are VBP VBP O
commonly RB RB O
used VBN VBN O
sedatives NNS NNS O
in IN IN O
neurocritical JJ JJ O
care NN NN O
as IN IN O
they PRP PRP O
allow VBP VBP O
for IN IN O
frequent JJ JJ O
neurologic JJ JJ O
examinations NNS NNS O
. . . O

However RB RB O
, , , O
both DT DT O
agents NNS NNS O
are VBP VBP O
associated VBN VBN O
with IN IN O
significant JJ JJ O
hemodynamic JJ JJ O
side NN NN O
effects NNS NNS O
. . . O

The DT DT O
primary JJ JJ O
objective NN NN O
of IN IN O
this DT DT O
study NN NN O
is VBZ VBZ O
to TO TO O
compare VB VB O
the DT DT O
prevalence NN NN O
of IN IN O
severe JJ JJ O
hemodynamic JJ JJ O
effects NNS NNS O
in IN IN O
neurocritical JJ JJ O
care NN NN O
patients NNS NNS O
receiving VBG VBG O
dexmedetomidine NN NN B-CHEM
and CC CC O
propofol NN NN B-CHEM
. . . O

DESIGN NNP NNP O
: : : O
Multicenter NNP NNP O
, , , O
retrospective NN NN O
, , , O
propensity NN NN O
- - - O
matched JJ JJ O
cohort NN NN O
study NN NN O
. . . O

SETTING NNP NNP O
: : : O
Neurocritical NNP NNP O
care NN NN O
units NNS NNS O
at IN IN O
two CD CD O
academic JJ JJ O
medical JJ JJ O
centers NNS NNS O
with IN IN O
dedicated VBN VBN O
neurocritical JJ JJ O
care NN NN O
teams NNS NNS O
and CC CC O
board NN NN O
- - - O
certified JJ JJ O
neurointensivists NNS NNS O
. . . O

PATIENTS NNS NNS O
: : : O
Neurocritical NNP NNP O
care NN NN O
patients NNS NNS O
admitted VBN VBN O
between IN IN O
July NNP NNP O
2009 CD CD O
and CC CC O
September NNP NNP O
2012 CD CD O
were VBD VBD O
evaluated VBN VBN O
and CC CC O
then RB RB O
matched VBD VBD O
1 CD CD O
: : : O
1 CD CD O
based VBN VBN O
on IN IN O
propensity NN NN O
scoring NN NN O
of IN IN O
baseline NN NN O
characteristics NNS NNS O
. . . O

INTERVENTIONS NNP NNP O
: : : O
Continuous NNP NNP O
sedation NN NN O
with IN IN O
dexmedetomidine NN NN B-CHEM
or CC CC O
propofol NN NN B-CHEM
. . . O

MEASUREMENTS NNP NNP O
AND CC CC O
MAIN NNP NNP O
RESULTS NNS NNS O
: : : O
A DT DT O
total NN NN O
of IN IN O
342 CD CD O
patients NNS NNS O
( ( ( O
105 CD CD O
dexmedetomidine NN NN B-CHEM
and CC CC O
237 CD CD O
propofol NN NN B-CHEM
) ) ) O
were VBD VBD O
included VBN VBN O
in IN IN O
the DT DT O
analysis NN NN O
, , , O
with IN IN O
190 CD CD O
matched JJ JJ O
( ( ( O
95 CD CD O
in IN IN O
each DT DT O
group NN NN O
) ) ) O
by IN IN O
propensity NN NN O
score NN NN O
. . . O

The DT DT O
primary JJ JJ O
outcome NN NN O
of IN IN O
this DT DT O
study NN NN O
was VBD VBD O
a DT DT O
composite NN NN O
of IN IN O
severe JJ JJ O
hypotension NN NN O
( ( ( O
mean VB VB O
arterial JJ JJ O
pressure NN NN O
< NN NN O
60 CD CD O
mm NN NN O
Hg NNP NNP O
) ) ) O
and CC CC O
bradycardia NNS NNS O
( ( ( O
heart NN NN O
rate NN NN O
< NN NN O
50 CD CD O
beats NNS NNS O
/ NN NN O
min NN NN O
) ) ) O
during IN IN O
sedative JJ JJ O
infusion NN NN O
. . . O

No DT DT O
difference NN NN O
in IN IN O
the DT DT O
primary JJ JJ O
composite NN NN O
outcome NN NN O
in IN IN O
both DT DT O
the DT DT O
unmatched JJ JJ O
( ( ( O
30 CD CD O
% NN NN O
vs NNS NNS O
30 CD CD O
% NN NN O
, , , O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
94 CD CD O
) ) ) O
or CC CC O
matched VBN VBN O
cohorts NNS NNS O
( ( ( O
28 CD CD O
% NN NN O
vs NNS NNS O
34 CD CD O
% NN NN O
, , , O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
35 CD CD O
) ) ) O
could MD MD O
be VB VB O
found VBN VBN O
. . . O

When WRB WRB O
analyzed VBD VBD O
separately RB RB O
, , , O
no DT DT O
differences NNS NNS O
could MD MD O
be VB VB O
found VBN VBN O
in IN IN O
the DT DT O
prevalence NN NN O
of IN IN O
severe JJ JJ O
hypotension NN NN O
or CC CC O
bradycardia NNS NNS O
in IN IN O
either CC CC O
the DT DT O
unmatched JJ JJ O
or CC CC O
matched JJ JJ O
cohorts NNS NNS O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Severe NNP NNP O
hypotension NN NN O
and CC CC O
bradycardia NN NN O
occur VB VB O
at IN IN O
similar JJ JJ O
prevalence NN NN O
in IN IN O
neurocritical JJ JJ O
care NN NN O
patients NNS NNS O
who WP WP O
receive VBP VBP O
dexmedetomidine NN NN B-CHEM
or CC CC O
propofol NN NN B-CHEM
. . . O

Providers NNP NNP O
should MD MD O
similarly RB RB O
consider VB VB O
the DT DT O
likelihood NN NN O
of IN IN O
hypotension NN NN O
or CC CC O
bradycardia NN NN O
before IN IN O
starting VBG VBG O
either CC CC O
sedative JJ JJ O
. . . O

Hydroxytyrosol NNP NNP B-CHEM
ameliorates NNS NNS O
oxidative JJ JJ O
stress NN NN O
and CC CC O
mitochondrial JJ JJ O
dysfunction NN NN O
in IN IN O
doxorubicin NN NN B-CHEM
- - - O
induced JJ JJ O
cardiotoxicity NN NN O
in IN IN O
rats NNS NNS O
with IN IN O
breast NN NN O
cancer NN NN O
. . . O

Oxidative NNP NNP O
stress NN NN O
is VBZ VBZ O
involved VBN VBN O
in IN IN O
several JJ JJ O
processes NNS NNS O
including VBG VBG O
cancer NN NN O
, , , O
aging VBG VBG O
and CC CC O
cardiovascular JJ JJ O
disease NN NN O
, , , O
and CC CC O
has VBZ VBZ O
been VBN VBN O
shown VBN VBN O
to TO TO O
potentiate VB VB O
the DT DT O
therapeutic JJ JJ O
effect NN NN O
of IN IN O
drugs NNS NNS O
such JJ JJ O
as IN IN O
doxorubicin NN NN B-CHEM
. . . O

Doxorubicin NNP NNP B-CHEM
causes VBZ VBZ O
significant JJ JJ O
cardiotoxicity NN NN O
characterized VBN VBN O
by IN IN O
marked JJ JJ O
increases NNS NNS O
in IN IN O
oxidative JJ JJ O
stress NN NN O
and CC CC O
mitochondrial JJ JJ O
dysfunction NN NN O
. . . O

Herein NNP NNP O
, , , O
we PRP PRP O
investigate VBP VBP O
whether IN IN O
doxorubicin NN NN B-CHEM
- - - O
associated VBN VBN O
chronic JJ JJ O
cardiac JJ JJ O
toxicity NN NN O
can MD MD O
be VB VB O
ameliorated VBN VBN O
with IN IN O
the DT DT O
antioxidant NN NN O
hydroxytyrosol NN NN B-CHEM
in IN IN O
rats NNS NNS O
with IN IN O
breast NN NN O
cancer NN NN O
. . . O

Thirty NNP NNP O
- : : O
six CD CD O
rats NNS NNS O
bearing VBG VBG O
breast NN NN O
tumors NNS NNS O
induced VBN VBN O
chemically RB RB O
were VBD VBD O
divided VBN VBN O
into IN IN O
4 CD CD O
groups NNS NNS O
: : : O
control NN NN O
, , , O
hydroxytyrosol NN NN B-CHEM
( ( ( O
0 CD CD O
. . . O
5mg CD CD O
/ NN NN O
kg NN NN O
, , , O
5days CD CD O
/ NN NN O
week NN NN O
) ) ) O
, , , O
doxorubicin NN NN B-CHEM
( ( ( O
1mg CD CD O
/ NN NN O
kg NN NN O
/ NN NN O
week NN NN O
) ) ) O
, , , O
and CC CC O
doxorubicin NN NN B-CHEM
plus CC CC O
hydroxytyrosol NN NN B-CHEM
. . . O

Cardiac NNP NNP O
disturbances NNS NNS O
at IN IN O
the DT DT O
cellular NN NN O
and CC CC O
mitochondrial JJ JJ O
level NN NN O
, , , O
mitochondrial JJ JJ O
electron NN NN O
transport NN NN O
chain NN NN O
complexes NNS NNS O
I PRP PRP O
- : : O
IV NNP NNP O
and CC CC O
apoptosis NN NN O
- - - O
inducing VBG VBG O
factor NN NN O
, , , O
and CC CC O
oxidative JJ JJ O
stress NN NN O
markers NNS NNS O
have VBP VBP O
been VBN VBN O
analyzed VBN VBN O
. . . O

Hydroxytyrosol NNP NNP B-CHEM
improved VBD VBD O
the DT DT O
cardiac JJ JJ O
disturbances NNS NNS O
enhanced VBN VBN O
by IN IN O
doxorubicin NN NN B-CHEM
by IN IN O
significantly RB RB O
reducing VBG VBG O
the DT DT O
percentage NN NN O
of IN IN O
altered VBN VBN O
mitochondria NN NN O
and CC CC O
oxidative JJ JJ O
damage NN NN O
. . . O

These DT DT O
results NNS NNS O
suggest VBP VBP O
that IN IN O
hydroxytyrosol NN NN B-CHEM
improve VB VB O
the DT DT O
mitochondrial JJ JJ O
electron NN NN O
transport NN NN O
chain NN NN O
. . . O

This DT DT O
study NN NN O
demonstrates VBZ VBZ O
that IN IN O
hydroxytyrosol NN NN B-CHEM
protect NN NN O
rat NN NN O
heart NN NN O
damage NN NN O
provoked VBN VBN O
by IN IN O
doxorubicin NN NN B-CHEM
decreasing VBG VBG O
oxidative JJ JJ O
damage NN NN O
and CC CC O
mitochondrial JJ JJ O
alterations NNS NNS O
. . . O

Amiodarone NNP NNP B-CHEM
- - - O
induced JJ JJ O
myxoedema NN NN O
coma NN NN O
. . . O

A DT DT O
62 NN NN O
- - - O
year NN NN O
- - - O
old JJ JJ O
man NN NN O
was VBD VBD O
found VBN VBN O
to TO TO O
have VB VB O
bradycardia NNS NNS O
, , , O
hypothermia NN NN O
and CC CC O
respiratory NN NN O
failure NN NN O
3 CD CD O
weeks NNS NNS O
after IN IN O
initiation NN NN O
of IN IN O
amiodarone NN NN B-CHEM
therapy NN NN O
for IN IN O
atrial JJ JJ O
fibrillation NN NN O
. . . O

Thyroid NNP NNP O
- : : O
stimulating VBG VBG O
hormone NN NN O
was VBD VBD O
found VBN VBN O
to TO TO O
be VB VB O
168 CD CD O
uIU NN NN O
/ NN NN O
mL NN NN O
( ( ( O
nl NN NN O
. . . O
0 CD CD O
. . . O
3 CD CD O
- : : O
5 CD CD O
uIU NN NN O
/ NN NN O
mL NN NN O
) ) ) O
and CC CC O
free JJ JJ O
thyroxine NN NN B-CHEM
( ( ( O
FT4 NNP NNP O
) ) ) O
was VBD VBD O
< NN NN O
0 CD CD O
. . . O
2 CD CD O
ng NN NN O
/ NN NN O
dL NN NN O
( ( ( O
nl NN NN O
. . . O
0 CD CD O
. . . O
8 CD CD O
- : : O
1 CD CD O
. . . O
8 CD CD O
ng NN NN O
/ NN NN O
dL NN NN O
) ) ) O
. . . O

He PRP PRP O
received VBD VBD O
intravenous JJ JJ O
fluids NNS NNS O
, , , O
vasopressor NN NN O
therapy NN NN O
and CC CC O
stress NN NN O
dose NN NN O
steroids NNS NNS B-CHEM
; : : O
he PRP PRP O
was VBD VBD O
intubated VBN VBN O
and CC CC O
admitted VBN VBN O
to TO TO O
the DT DT O
intensive JJ JJ O
care NN NN O
unit NN NN O
. . . O

He PRP PRP O
received VBD VBD O
500 CD CD O
ug NN NN O
of IN IN O
intravenous JJ JJ O
levothyroxine NN NN B-CHEM
in IN IN O
the DT DT O
first JJ JJ O
18 CD CD O
h NN NN O
of IN IN O
therapy NN NN O
, , , O
and CC CC O
150 CD CD O
ug JJ JJ O
intravenous JJ JJ O
daily JJ JJ O
thereafter NN NN O
. . . O

Haemodynamic NNP NNP O
improvement NN NN O
, , , O
along IN IN O
with IN IN O
complete JJ JJ O
recovery NN NN O
of IN IN O
mental JJ JJ O
status NN NN O
, , , O
occurred VBD VBD O
after IN IN O
48 CD CD O
h NN NN O
. . . O

Twelve CD CD O
hours NNS NNS O
after IN IN O
the DT DT O
initiation NN NN O
of IN IN O
therapy NN NN O
, , , O
FT4 NNP NNP O
was VBD VBD O
0 CD CD O
. . . O
96 CD CD O
ng NN NN O
/ NN NN O
dL NN NN O
. . . O

The DT DT O
patient NN NN O
was VBD VBD O
maintained VBN VBN O
on IN IN O
levothyroxine NN NN B-CHEM
175 CD CD O
( ( ( O
g SYM SYM O
POorally NNP NNP O
daily JJ JJ O
. . . O

A DT DT O
thyroid NN NN O
ultrasound NN NN O
showed VBD VBD O
diffuse NN NN O
heterogeneity NN NN O
. . . O

The DT DT O
24 CD CD O
hour NN NN O
excretion NN NN O
of IN IN O
iodine NN NN B-CHEM
was VBD VBD O
3657 CD CD O
( ( ( O
mcg NN NN O
( ( ( O
25 CD CD O
- : : O
756 CD CD O
( ( ( O
mcg NN NN O
) ) ) O
. . . O

The DT DT O
only JJ JJ O
two CD CD O
cases NNS NNS O
of IN IN O
amiodarone NN NN B-CHEM
- - - O
induced JJ JJ O
myxoedema NN NN O
coma NN NN O
in IN IN O
the DT DT O
literature NN NN O
report NN NN O
patient JJ JJ O
death NN NN O
despite IN IN O
supportive JJ JJ O
therapy NN NN O
and CC CC O
thyroid VB VB O
hormone NN NN O
replacement NN NN O
. . . O

This DT DT O
case NN NN O
represents VBZ VBZ O
the DT DT O
most RBS RBS O
thoroughly RB RB O
investigated JJ JJ O
case NN NN O
of IN IN O
amiodarone NN NN B-CHEM
- - - O
induced JJ JJ O
myxoedema NN NN O
coma NN NN O
with IN IN O
a DT DT O
history NN NN O
significant JJ JJ O
for IN IN O
subclinical JJ JJ O
thyroid NN NN O
disease NN NN O
. . . O

Use NN NN O
of IN IN O
argatroban NN NN B-CHEM
and CC CC O
catheter NN NN O
- - - O
directed JJ JJ O
thrombolysis NNS NNS O
with IN IN O
alteplase NN NN O
in IN IN O
an DT DT O
oncology NN NN O
patient NN NN O
with IN IN O
heparin NN NN B-CHEM
- - - O
induced JJ JJ O
thrombocytopenia NN NN O
with IN IN O
thrombosis NN NN O
. . . O

PURPOSE NNP NNP O
: : : O
The DT DT O
case NN NN O
of IN IN O
an DT DT O
oncology NN NN O
patient NN NN O
who WP WP O
developed VBD VBD O
heparin NN NN B-CHEM
- : : O
induced JJ JJ O
thrombocytopenia NN NN O
with IN IN O
thrombosis NN NN O
( ( ( O
HITT NNP NNP O
) ) ) O
and CC CC O
was VBD VBD O
treated VBN VBN O
with IN IN O
argatroban JJ JJ B-CHEM
plus CC CC O
catheter NN NN O
- - - O
directed JJ JJ O
thrombolysis NN NN O
( ( ( O
CDT NNP NNP O
) ) ) O
with IN IN O
alteplase NN NN O
is VBZ VBZ O
presented VBN VBN O
. . . O

SUMMARY NNP NNP O
: : : O
A DT DT O
63 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
Caucasian NNP NNP O
man NN NN O
with IN IN O
renal JJ JJ O
amyloidosis NN NN O
undergoing VBG VBG O
peripheral JJ JJ O
blood NN NN O
stem NN NN O
cell NN NN O
collection NN NN O
for IN IN O
an DT DT O
autologous JJ JJ O
stem NN NN O
cell NN NN O
transplant NN NN O
developed VBN VBN O
extensive JJ JJ O
bilateral JJ JJ O
upper NN NN O
- - - O
extremity NN NN O
deep JJ JJ O
venous JJ JJ O
thrombosis NNS NNS O
( ( ( O
DVT NNP NNP O
) ) ) O
and CC CC O
pulmonary JJ JJ O
embolism NN NN O
secondary JJ JJ O
to TO TO O
heparin VB VB B-CHEM
- - - O
induced JJ JJ O
thrombocytopenia NN NN O
. . . O

A DT DT O
continuous JJ JJ O
i NNP NNP O
. . . O
v NN NN O
. . . O
infusion NN NN O
of IN IN O
argatroban NN NN B-CHEM
was VBD VBD O
initiated VBN VBN O
, , , O
and CC CC O
the DT DT O
patient NN NN O
was VBD VBD O
managed VBN VBN O
on IN IN O
the DT DT O
general JJ JJ O
medical JJ JJ O
floor NN NN O
. . . O

After IN IN O
one CD CD O
week NN NN O
of IN IN O
therapy NN NN O
, , , O
he PRP PRP O
was VBD VBD O
transferred VBN VBN O
to TO TO O
the DT DT O
intensive JJ JJ O
care NN NN O
unit NN NN O
with IN IN O
cardiopulmonary JJ JJ O
compromise NN NN O
related VBN VBN O
to TO TO O
superior JJ JJ O
vena NN NN O
cava NN NN O
( ( ( O
SVC NNP NNP O
) ) ) O
syndrome NN NN O
. . . O

A DT DT O
percutaneous JJ JJ O
mechanical JJ JJ O
thrombectomy NN NN O
and CC CC O
CDT NNP NNP O
with IN IN O
alteplase NN NN O
were VBD VBD O
attempted VBN VBN O
, , , O
but CC CC O
the DT DT O
procedure NN NN O
was VBD VBD O
aborted VBN VBN O
due JJ JJ O
to TO TO O
epistaxis VB VB O
. . . O

The DT DT O
epistaxis NN NN O
resolved VBD VBD O
the DT DT O
next JJ JJ O
day NN NN O
, , , O
and CC CC O
the DT DT O
patient NN NN O
was VBD VBD O
restarted VBN VBN O
on IN IN O
argatroban NN NN B-CHEM
. . . O

A DT DT O
second JJ JJ O
percutaneous JJ JJ O
mechanical JJ JJ O
thrombectomy NN NN O
was VBD VBD O
performed VBN VBN O
six CD CD O
days NNS NNS O
later RB RB O
and CC CC O
resulted VBD VBD O
in IN IN O
partial JJ JJ O
revascularization NN NN O
of IN IN O
the DT DT O
SVC NNP NNP O
and CC CC O
central JJ JJ O
veins NNS NNS O
. . . O

Postthrombectomy NNP NNP O
continuous JJ JJ O
CDT NNP NNP O
with IN IN O
alteplase NN NN O
was VBD VBD O
commenced VBN VBN O
while IN IN O
argatroban NN NN B-CHEM
was VBD VBD O
withheld VBN VBN O
, , , O
and CC CC O
complete JJ JJ O
patency NN NN O
of IN IN O
the DT DT O
SVC NNP NNP O
and CC CC O
central JJ JJ O
veins NNS NNS O
was VBD VBD O
achieved VBN VBN O
after IN IN O
three CD CD O
days NNS NNS O
of IN IN O
therapy NN NN O
. . . O

Alteplase NNP NNP O
was VBD VBD O
discontinued VBN VBN O
, , , O
and CC CC O
the DT DT O
patient NN NN O
was VBD VBD O
reinitiated VBN VBN O
on IN IN O
argatroban NN NN B-CHEM
; : : O
ultimately RB RB O
, , , O
he PRP PRP O
was VBD VBD O
transitioned VBN VBN O
to TO TO O
warfarin NN NN B-CHEM
for IN IN O
long JJ JJ O
- - - O
term NN NN O
anticoagulation NN NN O
. . . O

Although IN IN O
the DT DT O
patient NN NN O
recovered VBD VBD O
, , , O
he PRP PRP O
experienced VBD VBD O
permanent JJ JJ O
vision NN NN O
and CC CC O
hearing NN NN O
loss NN NN O
, , , O
as RB RB O
well RB RB O
as IN IN O
end NN NN O
- : : O
stage NN NN O
renal NN NN O
disease NN NN O
. . . O

CONCLUSION NNP NNP O
: : : O
A DT DT O
63 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
man NN NN O
with IN IN O
renal JJ JJ O
amyloidosis NN NN O
and CC CC O
SVC NNP NNP O
syndrome NN NN O
secondary JJ JJ O
to TO TO O
HITT NNP NNP O
was VBD VBD O
successfully RB RB O
treated VBN VBN O
with IN IN O
argatroban NN NN B-CHEM
and CC CC O
CDT NNP NNP O
with IN IN O
alteplase NN NN O
. . . O

Effects NNP NNP O
of IN IN O
dehydroepiandrosterone NN NN B-CHEM
in IN IN O
amphetamine NN NN B-CHEM
- - - O
induced JJ JJ O
schizophrenia NN NN O
models NNS NNS O
in IN IN O
mice NN NN O
. . . O

OBJECTIVE NNP NNP O
: : : O
To TO TO O
examine VB VB O
the DT DT O
effects NNS NNS O
of IN IN O
dehydroepiandrosterone NN NN B-CHEM
( ( ( O
DHEA NNP NNP B-CHEM
) ) ) O
on IN IN O
animal NN NN O
models NNS NNS O
of IN IN O
schizophrenia NN NN O
. . . O

METHODS NNP NNP O
: : : O
Seventy NNP NNP O
Swiss NNP NNP O
albino NN NN O
female JJ JJ O
mice NN NN O
( ( ( O
25 CD CD O
- : : O
35 CD CD O
g SYM SYM O
) ) ) O
were VBD VBD O
divided VBN VBN O
into IN IN O
4 CD CD O
groups NNS NNS O
: : : O
amphetamine NN NN B-CHEM
- - - O
free JJ JJ O
( ( ( O
control NN NN O
) ) ) O
, , , O
amphetamine NN NN B-CHEM
, , , O
50 CD CD O
, , , O
and CC CC O
100 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
DHEA NNP NNP B-CHEM
. . . O

The DT DT O
DHEA NNP NNP B-CHEM
was VBD VBD O
administered VBN VBN O
intraperitoneally RB RB O
( ( ( O
ip NNP NNP O
) ) ) O
for IN IN O
5 CD CD O
days NNS NNS O
. . . O

Amphetamine NNP NNP B-CHEM
( ( ( O
3 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
ip NNP NNP O
) ) ) O
induced JJ JJ O
hyper NN NN O
locomotion NN NN O
, , , O
apomorphine NN NN B-CHEM
( ( ( O
1 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
subcutaneously RB RB O
[ NN NN O
sc NN NN O
] NN NN O
) ) ) O
induced JJ JJ O
climbing NN NN O
, , , O
and CC CC O
haloperidol NN NN B-CHEM
( ( ( O
1 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
sc NN NN O
) ) ) O
induced VBD VBD O
catalepsy NN NN O
tests NNS NNS O
were VBD VBD O
used VBN VBN O
as IN IN O
animal NN NN O
models NNS NNS O
of IN IN O
schizophrenia NN NN O
. . . O

The DT DT O
study NN NN O
was VBD VBD O
conducted VBN VBN O
at IN IN O
the DT DT O
Animal NNP NNP O
Experiment NNP NNP O
Laboratories NNP NNP O
, , , O
Department NNP NNP O
of IN IN O
Pharmacology NNP NNP O
, , , O
Medical NNP NNP O
School NNP NNP O
, , , O
Eskisehir NNP NNP O
Osmangazi NNP NNP O
University NNP NNP O
, , , O
Eskisehir NNP NNP O
, , , O
Turkey NNP NNP O
between IN IN O
March NNP NNP O
and CC CC O
May NNP NNP O
2012 CD CD O
. . . O

Statistical NNP NNP O
analysis NN NN O
was VBD VBD O
carried VBN VBN O
out IN IN O
using VBG VBG O
Kruskal NNP NNP O
- : : O
Wallis NNP NNP O
test NN NN O
for IN IN O
hyper NN NN O
locomotion NN NN O
, , , O
and CC CC O
one CD CD O
- - - O
way NN NN O
ANOVA NNP NNP O
for IN IN O
climbing VBG VBG O
and CC CC O
catalepsy NN NN O
tests NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
In IN IN O
the DT DT O
amphetamine NN NN B-CHEM
- - - O
induced JJ JJ O
locomotion NN NN O
test NN NN O
, , , O
there EX EX O
were VBD VBD O
significant JJ JJ O
increases NNS NNS O
in IN IN O
all DT DT O
movements NNS NNS O
compared VBN VBN O
with IN IN O
the DT DT O
amphetamine NN NN B-CHEM
- - - O
free JJ JJ O
group NN NN O
. . . O

Both DT DT O
DHEA NNP NNP B-CHEM
50 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
, , , O
and CC CC O
100 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
significantly RB RB O
decreased VBD VBD O
all DT DT O
movements NNS NNS O
compared VBN VBN O
with IN IN O
the DT DT O
amphetamine NN NN B-CHEM
- - - O
induced JJ JJ O
locomotion NN NN O
group NN NN O
. . . O

There EX EX O
was VBD VBD O
a DT DT O
significant JJ JJ O
difference NN NN O
between IN IN O
groups NNS NNS O
in IN IN O
the DT DT O
haloperidol NN NN B-CHEM
- - - O
induced JJ JJ O
catalepsy NN NN O
test NN NN O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

There EX EX O
was VBD VBD O
no DT DT O
significant JJ JJ O
difference NN NN O
between IN IN O
groups NNS NNS O
in IN IN O
terms NNS NNS O
of IN IN O
total JJ JJ O
climbing VBG VBG O
time NN NN O
in IN IN O
the DT DT O
apomorphine NN NN B-CHEM
- - - O
induced JJ JJ O
climbing NN NN O
test NN NN O
( ( ( O
p NN NN O
> NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

CONCLUSION NNP NNP O
: : : O
We PRP PRP O
observed VBD VBD O
that IN IN O
DHEA NNP NNP B-CHEM
reduced VBD VBD O
locomotor NN NN O
activity NN NN O
and CC CC O
increased VBN VBN O
catalepsy NN NN O
at IN IN O
both DT DT O
doses NNS NNS O
, , , O
while IN IN O
it PRP PRP O
had VBD VBD O
no DT DT O
effect NN NN O
on IN IN O
climbing VBG VBG O
behavior NN NN O
. . . O

We PRP PRP O
suggest VBP VBP O
that IN IN O
DHEA NNP NNP B-CHEM
displays NNS NNS O
typical JJ JJ O
neuroleptic JJ JJ O
- - - O
like IN IN O
effects NNS NNS O
, , , O
and CC CC O
may MD MD O
be VB VB O
used VBN VBN O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
schizophrenia NN NN O
. . . O

Availability NNP NNP O
of IN IN O
human JJ JJ O
induced VBN VBN O
pluripotent NN NN O
stem NN NN O
cell NN NN O
- : : O
derived JJ JJ O
cardiomyocytes NNS NNS O
in IN IN O
assessment NN NN O
of IN IN O
drug NN NN O
potential NN NN O
for IN IN O
QT NNP NNP O
prolongation NN NN O
. . . O

Field NNP NNP O
potential JJ JJ O
duration NN NN O
( ( ( O
FPD NNP NNP O
) ) ) O
in IN IN O
human JJ JJ O
- - - O
induced JJ JJ O
pluripotent NN NN O
stem NN NN O
cell NN NN O
- : : O
derived JJ JJ O
cardiomyocytes NNS NNS O
( ( ( O
hiPS NN NN O
- - - O
CMs NNP NNP O
) ) ) O
, , , O
which WDT WDT O
can MD MD O
express VB VB O
QT NNP NNP O
interval NN NN O
in IN IN O
an DT DT O
electrocardiogram NN NN O
, , , O
is VBZ VBZ O
reported VBN VBN O
to TO TO O
be VB VB O
a DT DT O
useful JJ JJ O
tool NN NN O
to TO TO O
predict VB VB O
K NNP NNP B-CHEM
( ( ( O
+ NN NN O
) ) ) O
channel NN NN O
and CC CC O
Ca MD MD B-CHEM
( ( ( O
2 CD CD O
+ NN NN O
) ) ) O
channel NN NN O
blocker NN NN O
effects NNS NNS O
on IN IN O
QT NNP NNP O
interval NN NN O
. . . O

However RB RB O
, , , O
there EX EX O
is VBZ VBZ O
no DT DT O
report NN NN O
showing VBG VBG O
that IN IN O
this DT DT O
technique NN NN O
can MD MD O
be VB VB O
used VBN VBN O
to TO TO O
predict VB VB O
multichannel NN NN O
blocker NN NN O
potential JJ JJ O
for IN IN O
QT NNP NNP O
prolongation NN NN O
. . . O

The DT DT O
aim NN NN O
of IN IN O
this DT DT O
study NN NN O
is VBZ VBZ O
to TO TO O
show VB VB O
that IN IN O
FPD NNP NNP O
from IN IN O
MEA NNP NNP O
( ( ( O
Multielectrode NNP NNP O
array NN NN O
) ) ) O
of IN IN O
hiPS NN NN O
- - - O
CMs NNP NNP O
can MD MD O
detect VB VB O
QT NNP NNP O
prolongation NN NN O
induced VBN VBN O
by IN IN O
multichannel NN NN O
blockers NNS NNS O
. . . O

hiPS NN NN O
- - - O
CMs NNP NNP O
were VBD VBD O
seeded VBN VBN O
onto IN IN O
MEA NNP NNP O
and CC CC O
FPD NNP NNP O
was VBD VBD O
measured VBN VBN O
for IN IN O
2min CD CD O
every DT DT O
10min CD CD O
for IN IN O
30min CD CD O
after IN IN O
drug NN NN O
exposure NN NN O
for IN IN O
the DT DT O
vehicle NN NN O
and CC CC O
each DT DT O
drug NN NN O
concentration NN NN O
. . . O

IKr NNP NNP O
and CC CC O
IKs NNP NNP O
blockers NNS NNS O
concentration NN NN O
- : : O
dependently RB RB O
prolonged JJ JJ O
corrected VBN VBN O
FPD NNP NNP O
( ( ( O
FPDc NNP NNP O
) ) ) O
, , , O
whereas IN IN O
Ca MD MD B-CHEM
( ( ( O
2 CD CD O
+ NN NN O
) ) ) O
channel NN NN O
blockers NNS NNS O
concentration NN NN O
- : : O
dependently RB RB O
shortened VBD VBD O
FPDc NNP NNP O
. . . O

Also RB RB O
, , , O
the DT DT O
multichannel NN NN O
blockers NNS NNS O
Amiodarone NNP NNP B-CHEM
, , , O
Paroxetine NNP NNP B-CHEM
, , , O
Terfenadine NNP NNP B-CHEM
and CC CC O
Citalopram NNP NNP B-CHEM
prolonged JJ JJ O
FPDc NNP NNP O
in IN IN O
a DT DT O
concentration NN NN O
dependent JJ JJ O
manner NN NN O
. . . O

Finally RB RB O
, , , O
the DT DT O
IKr NNP NNP O
blockers NNS NNS O
, , , O
Terfenadine NNP NNP B-CHEM
and CC CC O
Citalopram NNP NNP B-CHEM
, , , O
which WDT WDT O
are VBP VBP O
reported VBN VBN O
to TO TO O
cause VB VB O
Torsade NNP NNP O
de IN IN O
Pointes NNP NNP O
( ( ( O
TdP NNP NNP O
) ) ) O
in IN IN O
clinical JJ JJ O
practice NN NN O
, , , O
produced VBD VBD O
early JJ JJ O
afterdepolarization NN NN O
( ( ( O
EAD NNP NNP O
) ) ) O
. . . O

hiPS NN NN O
- : : O
CMs NNP NNP O
using VBG VBG O
MEA NNP NNP O
system NN NN O
and CC CC O
FPDc NNP NNP O
can MD MD O
predict VB VB O
the DT DT O
effects NNS NNS O
of IN IN O
drug NN NN O
candidates NNS NNS O
on IN IN O
QT NNP NNP O
interval NN NN O
. . . O

This DT DT O
study NN NN O
also RB RB O
shows VBZ VBZ O
that IN IN O
this DT DT O
assay NN NN O
can MD MD O
help VB VB O
detect VB VB O
EAD NNP NNP O
for IN IN O
drugs NNS NNS O
with IN IN O
TdP NNP NNP O
potential JJ JJ O
. . . O

Dermal NNP NNP O
developmental JJ JJ O
toxicity NN NN O
of IN IN O
N NNP NNP O
- : : O
phenylimide NN NN O
herbicides NNS NNS O
in IN IN O
rats NNS NNS O
. . . O

BACKGROUND NNP NNP O
: : : O
S UH UH B-CHEM
- - - I-CHEM
53482 CD CD I-CHEM
and CC CC O
S NNP NNP B-CHEM
- : : I-CHEM
23121 CD CD I-CHEM
are VBP VBP O
N NNP NNP O
- : : O
phenylimide NN NN O
herbicides NNS NNS O
and CC CC O
produced VBN VBN O
embryolethality NN NN O
, , , O
teratogenicity NN NN O
( ( ( O
mainly RB RB O
ventricular JJ JJ O
septal NN NN O
defects NNS NNS O
and CC CC O
wavy NN NN O
ribs NN NN O
) ) ) O
, , , O
and CC CC O
growth NN NN O
retardation NN NN O
in IN IN O
rats NNS NNS O
in IN IN O
conventional JJ JJ O
oral JJ JJ O
developmental NN NN O
toxicity NN NN O
studies NNS NNS O
. . . O

Our PRP$ PRP$ O
objective NN NN O
in IN IN O
this DT DT O
study NN NN O
was VBD VBD O
to TO TO O
investigate VB VB O
whether IN IN O
the DT DT O
compounds NNS NNS O
induce VBP VBP O
developmental JJ JJ O
toxicity NN NN O
via IN IN O
the DT DT O
dermal NN NN O
route NN NN O
, , , O
which WDT WDT O
is VBZ VBZ O
more RBR RBR O
relevant JJ JJ O
to TO TO O
occupational JJ JJ O
exposure NN NN O
, , , O
hence RB RB O
better JJR JJR O
addressing VBG VBG O
human JJ JJ O
health NN NN O
risks NNS NNS O
. . . O

METHODS NNP NNP O
: : : O
S UH UH B-CHEM
- - - I-CHEM
53482 CD CD I-CHEM
was VBD VBD O
administered VBN VBN O
dermally RB RB O
to TO TO O
rats NNS NNS O
at IN IN O
30 CD CD O
, , , O
100 CD CD O
, , , O
and CC CC O
300 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
during IN IN O
organogenesis NN NN O
, , , O
and CC CC O
S NNP NNP B-CHEM
- : : I-CHEM
23121 CD CD I-CHEM
was VBD VBD O
administered VBN VBN O
at IN IN O
200 CD CD O
, , , O
400 CD CD O
, , , O
and CC CC O
800 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
( ( ( O
the DT DT O
maximum NN NN O
applicable JJ JJ O
dose NN NN O
level NN NN O
) ) ) O
. . . O

Fetuses NNP NNP O
were VBD VBD O
obtained VBN VBN O
by IN IN O
a DT DT O
Cesarean NNP NNP O
section NN NN O
and CC CC O
examined VBD VBD O
for IN IN O
external JJ JJ O
, , , O
visceral JJ JJ O
, , , O
and CC CC O
skeletal JJ JJ O
alterations NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
Dermal NNP NNP O
exposure NN NN O
of IN IN O
rats NNS NNS O
to TO TO O
S NNP NNP B-CHEM
- : : I-CHEM
53482 CD CD I-CHEM
at IN IN O
300 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
produced VBN VBN O
patterns NNS NNS O
of IN IN O
developmental NN NN O
toxicity NN NN O
similar JJ JJ O
to TO TO O
those DT DT O
resulting VBG VBG O
from IN IN O
oral JJ JJ O
exposure NN NN O
. . . O

Toxicity NNP NNP O
included VBD VBD O
embryolethality NN NN O
, , , O
teratogenicity NN NN O
, , , O
and CC CC O
growth NN NN O
retardation NN NN O
. . . O

Dermal NNP NNP O
administration NN NN O
of IN IN O
S NNP NNP B-CHEM
- : : I-CHEM
23121 CD CD I-CHEM
at IN IN O
800 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
resulted VBD VBD O
in IN IN O
an DT DT O
increased JJ JJ O
incidence NN NN O
of IN IN O
embryonic JJ JJ O
death NN NN O
and CC CC O
ventricular NN NN O
septal JJ JJ O
defect NN NN O
, , , O
but CC CC O
retarded JJ JJ O
fetal JJ JJ O
growth NN NN O
was VBD VBD O
not RB RB O
observed VBN VBN O
as IN IN O
it PRP PRP O
was VBD VBD O
following VBG VBG O
oral JJ JJ O
exposure NN NN O
to TO TO O
S NNP NNP B-CHEM
- : : I-CHEM
23121 CD CD I-CHEM
. . . O

CONCLUSIONS NNP NNP O
: : : O
Based VBN VBN O
on IN IN O
the DT DT O
results NNS NNS O
, , , O
S NNP NNP B-CHEM
- : : I-CHEM
53482 CD CD I-CHEM
and CC CC O
S NNP NNP B-CHEM
- : : I-CHEM
23121 CD CD I-CHEM
were VBD VBD O
teratogenic JJ JJ O
when WRB WRB O
administered VBN VBN O
dermally RB RB O
to TO TO O
pregnant JJ JJ O
rats NNS NNS O
as IN IN O
were VBD VBD O
the DT DT O
compounds NNS NNS O
administered VBD VBD O
orally RB RB O
. . . O

Thus RB RB O
, , , O
investigation NN NN O
of IN IN O
the DT DT O
mechanism NN NN O
and CC CC O
its PRP$ PRP$ O
human JJ JJ O
relevancy NN NN O
become VB VB O
more RBR RBR O
important JJ JJ O
. . . O

Rates NNP NNP O
of IN IN O
Renal NNP NNP O
Toxicity NNP NNP O
in IN IN O
Cancer NNP NNP O
Patients NNS NNS O
Receiving NNP NNP O
Cisplatin NNP NNP B-CHEM
With IN IN O
and CC CC O
Without IN IN O
Mannitol NNP NNP B-CHEM
. . . O

BACKGROUND NNP NNP O
: : : O
Cisplatin NNP NNP B-CHEM
is VBZ VBZ O
a DT DT O
widely RB RB O
used VBN VBN O
antineoplastic JJ JJ O
. . . O

One CD CD O
of IN IN O
the DT DT O
major JJ JJ O
complications NNS NNS O
of IN IN O
cisplatin NN NN B-CHEM
use NN NN O
is VBZ VBZ O
dose JJ JJ O
- : : O
limiting VBG VBG O
nephrotoxicity NN NN O
. . . O

There EX EX O
are VBP VBP O
many JJ JJ O
strategies NNS NNS O
to TO TO O
prevent VB VB O
this DT DT O
toxicity NN NN O
, , , O
including VBG VBG O
the DT DT O
use NN NN O
of IN IN O
mannitol NN NN B-CHEM
as IN IN O
a DT DT O
nephroprotectant NN NN O
in IN IN O
combination NN NN O
with IN IN O
hydration NN NN O
. . . O

OBJECTIVE NNP NNP O
: : : O
We PRP PRP O
aimed VBD VBD O
to TO TO O
evaluate VB VB O
the DT DT O
rates NNS NNS O
of IN IN O
cisplatin NN NN B-CHEM
- - - O
induced JJ JJ O
nephrotoxicity NN NN O
in IN IN O
cancer NN NN O
patients NNS NNS O
receiving VBG VBG O
single JJ JJ O
- - - O
agent NN NN O
cisplatin NN NN B-CHEM
with IN IN O
and CC CC O
without IN IN O
mannitol NN NN B-CHEM
. . . O

METHODS NNP NNP O
: : : O
This DT DT O
single JJ JJ O
- - - O
center NN NN O
retrospective NN NN O
analysis NN NN O
was VBD VBD O
a DT DT O
quasi NN NN O
experiment NN NN O
created VBN VBN O
by IN IN O
the DT DT O
national JJ JJ O
mannitol NN NN B-CHEM
shortage NN NN O
. . . O

Data NNP NNP O
were VBD VBD O
collected VBN VBN O
on IN IN O
adult NN NN O
cancer NN NN O
patients NNS NNS O
receiving VBG VBG O
single JJ JJ O
- - - O
agent NN NN O
cisplatin NN NN B-CHEM
as IN IN O
an DT DT O
outpatient NN NN O
from IN IN O
January NNP NNP O
2011 CD CD O
to TO TO O
September NNP NNP O
2012 CD CD O
. . . O

The DT DT O
primary JJ JJ O
outcome NN NN O
was VBD VBD O
acute JJ JJ O
kidney NN NN O
injury NN NN O
( ( ( O
AKI NNP NNP O
) ) ) O
. . . O

RESULTS NNS NNS O
: : : O
We PRP PRP O
evaluated VBD VBD O
143 CD CD O
patients NNS NNS O
who WP WP O
received VBD VBD O
single JJ JJ O
- - - O
agent NN NN O
cisplatin NN NN B-CHEM
; : : O
97 CD CD O
. . . O
2 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
had VBD VBD O
head NN NN O
and CC CC O
neck NN NN O
cancer NN NN O
as IN IN O
their PRP$ PRP$ O
primary JJ JJ O
malignancy NN NN O
. . . O

Patients NNS NNS O
who WP WP O
did VBD VBD O
not RB RB O
receive VB VB O
mannitol NN NN B-CHEM
were VBD VBD O
more RBR RBR O
likely JJ JJ O
to TO TO O
develop VB VB O
nephrotoxicity NN NN O
: : : O
odds NNS NNS O
ratio NN NN O
[ NN NN O
OR CC CC O
] NN NN O
= SYM SYM O
2 CD CD O
. . . O
646 CD CD O
( ( ( O
95 CD CD O
% NN NN O
CI NNP NNP O
= SYM SYM O
1 CD CD O
. . . O
008 CD CD O
, , , O
6 CD CD O
. . . O
944 CD CD O
; : : O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
048 CD CD O
) ) ) O
. . . O

Patients NNS NNS O
who WP WP O
received VBD VBD O
the DT DT O
100 CD CD O
mg NN NN O
/ NN NN O
m NN NN O
( ( ( O
2 CD CD O
) ) ) O
dosing VBG VBG O
and CC CC O
patients NNS NNS O
who WP WP O
had VBD VBD O
a DT DT O
history NN NN O
of IN IN O
hypertension NN NN O
also RB RB O
had VBD VBD O
a DT DT O
higher JJR JJR O
likelihood NN NN O
of IN IN O
developing VBG VBG O
nephrotoxicity NN NN O
: : : O
OR CC CC O
= SYM SYM O
11 CD CD O
. . . O
494 CD CD O
( ( ( O
95 CD CD O
% NN NN O
CI NNP NNP O
= SYM SYM O
4 CD CD O
. . . O
149 CD CD O
, , , O
32 CD CD O
. . . O
258 CD CD O
; : : O
P NN NN O
< NN NN O
0 CD CD O
. . . O
0001 CD CD O
) ) ) O
and CC CC O
OR CC CC O
= SYM SYM O
3 CD CD O
. . . O
219 CD CD O
( ( ( O
95 CD CD O
% NN NN O
CI NNP NNP O
= SYM SYM O
1 CD CD O
. . . O
228 CD CD O
, , , O
8 CD CD O
. . . O
439 CD CD O
; : : O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
017 CD CD O
) ) ) O
, , , O
respectively RB RB O
. . . O

CONCLUSIONS NNP NNP O
: : : O
When WRB WRB O
limited JJ JJ O
quantities NNS NNS O
of IN IN O
mannitol NN NN B-CHEM
are VBP VBP O
available JJ JJ O
, , , O
it PRP PRP O
should MD MD O
preferentially RB RB O
be VB VB O
given VBN VBN O
to TO TO O
patients NNS NNS O
at IN IN O
particularly RB RB O
high JJ JJ O
risk NN NN O
of IN IN O
nephrotoxicity NN NN O
. . . O

Our PRP$ PRP$ O
analysis NN NN O
suggests VBZ VBZ O
that IN IN O
those DT DT O
patients NNS NNS O
receiving VBG VBG O
the DT DT O
dosing VBG VBG O
schedule NN NN O
of IN IN O
100 CD CD O
mg NN NN O
/ NN NN O
m NN NN O
( ( ( O
2 CD CD O
) ) ) O
cisplatin NN NN B-CHEM
every DT DT O
3 CD CD O
weeks NNS NNS O
and CC CC O
those DT DT O
with IN IN O
hypertension NN NN O
are VBP VBP O
at IN IN O
the DT DT O
greatest JJS JJS O
risk NN NN O
of IN IN O
nephrotoxicity NN NN O
and CC CC O
would MD MD O
benefit VB VB O
from IN IN O
the DT DT O
addition NN NN O
of IN IN O
mannitol NN NN B-CHEM
. . . O

Metformin NNP NNP B-CHEM
protects VBZ VBZ O
against IN IN O
seizures NNS NNS O
, , , O
learning VBG VBG O
and CC CC O
memory NN NN O
impairments NNS NNS O
and CC CC O
oxidative JJ JJ O
damage NN NN O
induced VBN VBN O
by IN IN O
pentylenetetrazole NN NN B-CHEM
- : : O
induced JJ JJ O
kindling VBG VBG O
in IN IN O
mice NN NN O
. . . O

Cognitive NNP NNP O
impairment NN NN O
, , , O
the DT DT O
most RBS RBS O
common JJ JJ O
and CC CC O
severe JJ JJ O
comorbidity NN NN O
of IN IN O
epilepsy NN NN O
, , , O
greatly RB RB O
diminishes VBZ VBZ O
the DT DT O
quality NN NN O
of IN IN O
life NN NN O
. . . O

However RB RB O
, , , O
current JJ JJ O
therapeutic JJ JJ O
interventions NNS NNS O
for IN IN O
epilepsy NN NN O
can MD MD O
also RB RB O
cause VB VB O
untoward NN NN O
cognitive JJ JJ O
effects NNS NNS O
. . . O

Thus RB RB O
, , , O
there EX EX O
is VBZ VBZ O
an DT DT O
urgent JJ JJ O
need VBP VBP O
for IN IN O
new JJ JJ O
kinds NNS NNS O
of IN IN O
agents NNS NNS O
targeting VBG VBG O
both DT DT O
seizures NNS NNS O
and CC CC O
cognition NN NN O
deficits NNS NNS O
. . . O

Oxidative NNP NNP O
stress NN NN O
is VBZ VBZ O
considered VBN VBN O
to TO TO O
play VB VB O
an DT DT O
important JJ JJ O
role NN NN O
in IN IN O
epileptogenesis NN NN O
and CC CC O
cognitive JJ JJ O
deficits NNS NNS O
, , , O
and CC CC O
antioxidants NNS NNS O
have VBP VBP O
a DT DT O
putative JJ JJ O
antiepileptic JJ JJ O
potential NN NN O
. . . O

Metformin NNP NNP B-CHEM
, , , O
the DT DT O
most RBS RBS O
commonly RB RB O
prescribed VBN VBN O
antidiabetic JJ JJ O
oral JJ JJ O
drug NN NN O
, , , O
has VBZ VBZ O
antioxidant JJ JJ O
properties NNS NNS O
. . . O

This DT DT O
study NN NN O
was VBD VBD O
designed VBN VBN O
to TO TO O
evaluate VB VB O
the DT DT O
ameliorative JJ JJ O
effects NNS NNS O
of IN IN O
metformin NN NN B-CHEM
on IN IN O
seizures NNS NNS O
, , , O
cognitive JJ JJ O
impairment NN NN O
and CC CC O
brain NN NN O
oxidative JJ JJ O
stress NN NN O
markers NNS NNS O
observed VBD VBD O
in IN IN O
pentylenetetrazole NN NN B-CHEM
- - - O
induced JJ JJ O
kindling VBG VBG O
animals NNS NNS O
. . . O

Male NNP NNP O
C57BL NNP NNP O
/ NN NN O
6 CD CD O
mice NN NN O
were VBD VBD O
administered VBN VBN O
with IN IN O
subconvulsive JJ JJ O
dose NN NN O
of IN IN O
pentylenetetrazole NN NN B-CHEM
( ( ( O
37 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
every DT DT O
other JJ JJ O
day NN NN O
for IN IN O
14 CD CD O
injections NNS NNS O
. . . O

Metformin NNP NNP B-CHEM
was VBD VBD O
injected VBN VBN O
intraperitoneally RB RB O
in IN IN O
dose NN NN O
of IN IN O
200mg CD CD O
/ NN NN O
kg NN NN O
along IN IN O
with IN IN O
alternate JJ JJ O
- - - O
day NN NN O
PTZ NNP NNP B-CHEM
. . . O

We PRP PRP O
found VBD VBD O
that IN IN O
metformin NN NN B-CHEM
suppressed VBD VBD O
the DT DT O
progression NN NN O
of IN IN O
kindling VBG VBG O
, , , O
ameliorated VBD VBD O
the DT DT O
cognitive JJ JJ O
impairment NN NN O
and CC CC O
decreased VBD VBD O
brain NN NN O
oxidative JJ JJ O
stress NN NN O
. . . O

Thus RB RB O
the DT DT O
present JJ JJ O
study NN NN O
concluded VBD VBD O
that IN IN O
metformin NN NN B-CHEM
may MD MD O
be VB VB O
a DT DT O
potential JJ JJ O
agent NN NN O
for IN IN O
the DT DT O
treatment NN NN O
of IN IN O
epilepsy NN NN O
as RB RB O
well RB RB O
as IN IN O
a DT DT O
protective JJ JJ O
medicine NN NN O
against IN IN O
cognitive JJ JJ O
impairment NN NN O
induced VBN VBN O
by IN IN O
seizures NNS NNS O
. . . O

P53 NNP NNP O
inhibition NN NN O
exacerbates NNS NNS O
late JJ JJ O
- : : O
stage NN NN O
anthracycline NN NN B-CHEM
cardiotoxicity NN NN O
. . . O

AIMS NNP NNP O
: : : O
Doxorubicin NNP NNP B-CHEM
( ( ( O
DOX NNP NNP B-CHEM
) ) ) O
is VBZ VBZ O
an DT DT O
effective JJ JJ O
anti NN NN O
- : : O
cancer NN NN O
therapeutic JJ JJ O
, , , O
but CC CC O
is VBZ VBZ O
associated VBN VBN O
with IN IN O
both DT DT O
acute JJ JJ O
and CC CC O
late JJ JJ O
- : : O
stage NN NN O
cardiotoxicity NN NN O
. . . O

Children NNP NNP O
are VBP VBP O
particularly RB RB O
sensitive JJ JJ O
to TO TO O
DOX NNP NNP B-CHEM
- : : O
induced JJ JJ O
heart NN NN O
failure NN NN O
. . . O

Here RB RB O
, , , O
the DT DT O
impact NN NN O
of IN IN O
p53 NN NN O
inhibition NN NN O
on IN IN O
acute JJ JJ O
vs NNS NNS O
. . . O
late JJ JJ O
- : : O
stage NN NN O
DOX NNP NNP B-CHEM
cardiotoxicity NN NN O
was VBD VBD O
examined VBN VBN O
in IN IN O
a DT DT O
juvenile JJ JJ O
model NN NN O
. . . O

METHODS NNP NNP O
AND CC CC O
RESULTS NNS NNS O
: : : O
Two CD CD O
- - - O
week NN NN O
- - - O
old JJ JJ O
MHC NNP NNP O
- : : O
CB7 NNP NNP O
mice NN NN O
( ( ( O
which WDT WDT O
express VBP VBP O
dominant JJ JJ O
- : : O
interfering VBG VBG O
p53 NN NN O
in IN IN O
cardiomyocytes NNS NNS O
) ) ) O
and CC CC O
their PRP$ PRP$ O
non NN NN O
- : : O
transgenic JJ JJ O
( ( ( O
NON NNP NNP O
- - - O
TXG NNP NNP O
) ) ) O
littermates NNS NNS O
received VBD VBD O
weekly JJ JJ O
DOX NNP NNP B-CHEM
injections NNS NNS O
for IN IN O
5 CD CD O
weeks NNS NNS O
( ( ( O
25 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
cumulative JJ JJ O
dose NN NN O
) ) ) O
. . . O

One CD CD O
week NN NN O
after IN IN O
the DT DT O
last JJ JJ O
DOX NNP NNP B-CHEM
treatment NN NN O
( ( ( O
acute JJ JJ O
stage NN NN O
) ) ) O
, , , O
MHC NNP NNP O
- : : O
CB7 NNP NNP O
mice NN NN O
exhibited VBD VBD O
improved VBN VBN O
cardiac JJ JJ O
function NN NN O
and CC CC O
lower JJR JJR O
levels NNS NNS O
of IN IN O
cardiomyocyte NN NN O
apoptosis NN NN O
when WRB WRB O
compared VBN VBN O
with IN IN O
the DT DT O
NON NNP NNP O
- - - O
TXG NNP NNP O
mice NN NN O
. . . O

Surprisingly RB RB O
, , , O
by IN IN O
13 CD CD O
weeks NNS NNS O
following VBG VBG O
the DT DT O
last JJ JJ O
DOX NNP NNP B-CHEM
treatment NN NN O
( ( ( O
late JJ JJ O
stage NN NN O
) ) ) O
, , , O
MHC NNP NNP O
- : : O
CB7 NNP NNP O
exhibited VBD VBD O
a DT DT O
progressive JJ JJ O
decrease NN NN O
in IN IN O
cardiac JJ JJ O
function NN NN O
and CC CC O
higher JJR JJR O
rates NNS NNS O
of IN IN O
cardiomyocyte NN NN O
apoptosis NN NN O
when WRB WRB O
compared VBN VBN O
with IN IN O
NON NNP NNP O
- : : O
TXG NNP NNP O
mice NN NN O
. . . O

p53 NN NN O
inhibition NN NN O
blocked VBD VBD O
transient JJ JJ O
DOX NNP NNP B-CHEM
- : : O
induced JJ JJ O
STAT3 NNP NNP O
activation NN NN O
in IN IN O
MHC NNP NNP O
- : : O
CB7 NNP NNP O
mice NN NN O
, , , O
which WDT WDT O
was VBD VBD O
associated VBN VBN O
with IN IN O
enhanced JJ JJ O
induction NN NN O
of IN IN O
the DT DT O
DNA NNP NNP O
repair NN NN O
proteins NNS NNS O
Ku70 NNP NNP O
and CC CC O
Ku80 NNP NNP O
. . . O

Mice NNP NNP O
with IN IN O
cardiomyocyte NN NN O
- - - O
restricted JJ JJ O
deletion NN NN O
of IN IN O
STAT3 NNP NNP O
exhibited VBD VBD O
worse JJR JJR O
cardiac NN NN O
function NN NN O
, , , O
higher JJR JJR O
levels NNS NNS O
of IN IN O
cardiomyocyte NN NN O
apoptosis NN NN O
, , , O
and CC CC O
a DT DT O
greater JJR JJR O
induction NN NN O
of IN IN O
Ku70 NNP NNP O
and CC CC O
Ku80 NNP NNP O
in IN IN O
response NN NN O
to TO TO O
DOX NNP NNP B-CHEM
treatment NN NN O
during IN IN O
the DT DT O
acute JJ JJ O
stage NN NN O
when WRB WRB O
compared VBN VBN O
with IN IN O
control NN NN O
animals NNS NNS O
. . . O

CONCLUSION NNP NNP O
: : : O
These DT DT O
data NNS NNS O
support VBP VBP O
a DT DT O
model NN NN O
wherein NN NN O
a DT DT O
p53 NN NN O
- - - O
dependent JJ JJ O
cardioprotective JJ JJ O
pathway NN NN O
, , , O
mediated JJ JJ O
via IN IN O
STAT3 NNP NNP O
activation NN NN O
, , , O
mitigates NNS NNS O
DOX NNP NNP B-CHEM
- : : O
induced JJ JJ O
myocardial NN NN O
stress NN NN O
during IN IN O
drug NN NN O
delivery NN NN O
. . . O

Furthermore RB RB O
, , , O
these DT DT O
data NNS NNS O
suggest VBP VBP O
an DT DT O
explanation NN NN O
as IN IN O
to TO TO O
how WRB WRB O
p53 JJ JJ O
inhibition NN NN O
can MD MD O
result VB VB O
in IN IN O
cardioprotection NN NN O
during IN IN O
drug NN NN O
treatment NN NN O
and CC CC O
, , , O
paradoxically RB RB O
, , , O
enhanced JJ JJ O
cardiotoxicity NN NN O
long RB RB O
after IN IN O
the DT DT O
cessation NN NN O
of IN IN O
drug NN NN O
treatment NN NN O
. . . O

Metronidazole NNP NNP B-CHEM
- : : O
induced JJ JJ O
encephalopathy NN NN O
: : : O
an DT DT O
uncommon JJ JJ O
scenario NN NN O
. . . O

Metronidazole NNP NNP B-CHEM
can MD MD O
produce VB VB O
neurological JJ JJ O
complications NNS NNS O
although IN IN O
it PRP PRP O
is VBZ VBZ O
not RB RB O
a DT DT O
common JJ JJ O
scenario NN NN O
. . . O

We PRP PRP O
present JJ JJ O
a DT DT O
case NN NN O
where WRB WRB O
a DT DT O
patient NN NN O
developed JJ JJ O
features NNS NNS O
of IN IN O
encephalopathy JJ JJ O
following VBG VBG O
prolonged JJ JJ O
metronidazole NN NN B-CHEM
intake NN NN O
. . . O

Magnetic NNP NNP O
resonance NN NN O
imaging VBG VBG O
( ( ( O
MRI NNP NNP O
) ) ) O
brain NN NN O
showed VBD VBD O
abnormal JJ JJ O
signal NN NN O
intensity NN NN O
involving VBG VBG O
both DT DT O
dentate NN NN O
nuclei NN NN O
of IN IN O
cerebellum NN NN O
and CC CC O
splenium NN NN O
of IN IN O
corpus NN NN O
callosum NN NN O
. . . O

The DT DT O
diagnosis NN NN O
of IN IN O
metronidazole NN NN B-CHEM
toxicity NN NN O
was VBD VBD O
made VBN VBN O
by IN IN O
the DT DT O
MRI NNP NNP O
findings NNS NNS O
and CC CC O
supported VBN VBN O
clinically RB RB O
. . . O

Aconitine NNP NNP B-CHEM
- : : O
induced JJ JJ O
Ca2 NNP NNP B-CHEM
+ NN NN O
overload NN NN O
causes NNS NNS O
arrhythmia NN NN O
and CC CC O
triggers NNS NNS O
apoptosis NN NN O
through IN IN O
p38 NN NN O
MAPK NNP NNP O
signaling VBG VBG O
pathway NN NN O
in IN IN O
rats NNS NNS O
. . . O

Aconitine NNP NNP B-CHEM
is VBZ VBZ O
a DT DT O
major JJ JJ O
bioactive JJ JJ O
diterpenoid NN NN O
alkaloid NN NN O
with IN IN O
high JJ JJ O
content NN NN O
derived VBD VBD O
from IN IN O
herbal JJ JJ O
aconitum NN NN O
plants NNS NNS O
. . . O

Emerging VBG VBG O
evidence NN NN O
indicates VBZ VBZ O
that IN IN O
voltage NN NN O
- : : O
dependent JJ JJ O
Na NNP NNP B-CHEM
( ( ( O
+ NN NN O
) ) ) O
channels NNS NNS O
have VBP VBP O
pivotal JJ JJ O
roles NNS NNS O
in IN IN O
the DT DT O
cardiotoxicity NN NN O
of IN IN O
aconitine NN NN B-CHEM
. . . O

However RB RB O
, , , O
no DT DT O
reports NNS NNS O
are VBP VBP O
available JJ JJ O
on IN IN O
the DT DT O
role NN NN O
of IN IN O
Ca MD MD B-CHEM
( ( ( O
2 CD CD O
+ NN NN O
) ) ) O
in IN IN O
aconitine NN NN B-CHEM
poisoning NN NN O
. . . O

In IN IN O
this DT DT O
study NN NN O
, , , O
we PRP PRP O
explored VBD VBD O
the DT DT O
importance NN NN O
of IN IN O
pathological JJ JJ O
Ca NNP NNP B-CHEM
( ( ( O
2 CD CD O
+ NN NN O
) ) ) O
signaling VBG VBG O
in IN IN O
aconitine NN NN B-CHEM
poisoning NN NN O
in IN IN O
vitro NN NN O
and CC CC O
in IN IN O
vivo NN NN O
. . . O

We PRP PRP O
found VBD VBD O
that IN IN O
Ca MD MD B-CHEM
( ( ( O
2 CD CD O
+ NN NN O
) ) ) O
overload NN NN O
lead NN NN O
to TO TO O
accelerated VBD VBD O
beating VBG VBG O
rhythm NN NN O
in IN IN O
adult NN NN O
rat NN NN O
ventricular NN NN O
myocytes NNS NNS O
and CC CC O
caused VBN VBN O
arrhythmia NN NN O
in IN IN O
conscious JJ JJ O
freely RB RB O
moving VBG VBG O
rats NNS NNS O
. . . O

To TO TO O
investigate VB VB O
effects NNS NNS O
of IN IN O
aconitine NN NN B-CHEM
on IN IN O
myocardial JJ JJ O
injury NN NN O
, , , O
we PRP PRP O
performed VBD VBD O
cytotoxicity NN NN O
assay NN NN O
in IN IN O
neonatal JJ JJ O
rat NN NN O
ventricular NN NN O
myocytes NNS NNS O
( ( ( O
NRVMs NNP NNP O
) ) ) O
, , , O
as RB RB O
well RB RB O
as IN IN O
measured VBN VBN O
lactate JJ JJ B-CHEM
dehydrogenase NN NN O
level NN NN O
in IN IN O
the DT DT O
culture NN NN O
medium NN NN O
of IN IN O
NRVMs NNP NNP O
and CC CC O
activities NNS NNS O
of IN IN O
serum NN NN O
cardiac NN NN O
enzymes NNS NNS O
in IN IN O
rats NNS NNS O
. . . O

The DT DT O
results NNS NNS O
showed VBD VBD O
that IN IN O
aconitine VBP VBP B-CHEM
resulted VBN VBN O
in IN IN O
myocardial JJ JJ O
injury NN NN O
and CC CC O
reduced VBN VBN O
NRVMs NNP NNP O
viability NN NN O
dose NN NN O
- : : O
dependently RB RB O
. . . O

To TO TO O
confirm VB VB O
the DT DT O
pro FW FW O
- - - O
apoptotic JJ JJ O
effects NNS NNS O
, , , O
we PRP PRP O
performed VBD VBD O
flow NN NN O
cytometric JJ JJ O
detection NN NN O
, , , O
cardiac JJ JJ O
histology NN NN O
, , , O
transmission NN NN O
electron NN NN O
microscopy NN NN O
and CC CC O
terminal NN NN O
deoxynucleotidyl NN NN O
transferase NN NN O
- - - O
mediated JJ JJ O
dUTP NN NN B-CHEM
- - - O
biotin NN NN B-CHEM
nick JJ JJ O
end NN NN O
labeling VBG VBG O
assay NN NN O
. . . O

The DT DT O
results NNS NNS O
showed VBD VBD O
that IN IN O
aconitine NN NN B-CHEM
stimulated VBN VBN O
apoptosis NNS NNS O
time NN NN O
- : : O
dependently RB RB O
. . . O

The DT DT O
expression NN NN O
analysis NN NN O
of IN IN O
Ca MD MD B-CHEM
( ( ( O
2 CD CD O
+ NN NN O
) ) ) O
handling VBG VBG O
proteins NNS NNS O
demonstrated VBN VBN O
that IN IN O
aconitine NN NN B-CHEM
promoted VBN VBN O
Ca NNP NNP B-CHEM
( ( ( O
2 CD CD O
+ NN NN O
) ) ) O
overload NN NN O
through IN IN O
the DT DT O
expression NN NN O
regulation NN NN O
of IN IN O
Ca MD MD B-CHEM
( ( ( O
2 CD CD O
+ NN NN O
) ) ) O
handling VBG VBG O
proteins NNS NNS O
. . . O

The DT DT O
expression NN NN O
analysis NN NN O
of IN IN O
apoptosis NN NN O
- - - O
related VBN VBN O
proteins NNS NNS O
revealed VBN VBN O
that IN IN O
pro FW FW O
- : : O
apoptotic JJ JJ O
protein NN NN O
expression NN NN O
was VBD VBD O
upregulated JJ JJ O
, , , O
and CC CC O
anti JJ JJ O
- : : O
apoptotic JJ JJ O
protein NN NN O
BCL NNP NNP O
- : : O
2 CD CD O
expression NN NN O
was VBD VBD O
downregulated VBN VBN O
. . . O

Furthermore RB RB O
, , , O
increased VBN VBN O
phosphorylation NN NN O
of IN IN O
MAPK NNP NNP O
family NN NN O
members NNS NNS O
, , , O
especially RB RB O
the DT DT O
P NN NN O
- - - O
P38 NNP NNP O
/ NN NN O
P38 NNP NNP O
ratio NN NN O
was VBD VBD O
found VBN VBN O
in IN IN O
cardiac JJ JJ O
tissues NNS NNS O
. . . O

Hence RB RB O
, , , O
our PRP$ PRP$ O
results NNS NNS O
suggest VBP VBP O
that IN IN O
aconitine NN NN B-CHEM
significantly RB RB O
aggravates VBZ VBZ O
Ca NNP NNP B-CHEM
( ( ( O
2 CD CD O
+ NN NN O
) ) ) O
overload NN NN O
and CC CC O
causes NNS NNS O
arrhythmia NN NN O
and CC CC O
finally RB RB O
promotes VBZ VBZ O
apoptotic JJ JJ O
development NN NN O
via IN IN O
phosphorylation NN NN O
of IN IN O
P38 NNP NNP O
mitogen NN NN O
- - - O
activated JJ JJ O
protein NN NN O
kinase NN NN O
. . . O

Chronic JJ JJ O
treatment NN NN O
with IN IN O
metformin NN NN B-CHEM
suppresses NNS NNS O
toll NN NN O
- - - O
like IN IN O
receptor NN NN O
4 CD CD O
signaling VBG VBG O
and CC CC O
attenuates NNS NNS O
left VBD VBD O
ventricular JJ JJ O
dysfunction NN NN O
following VBG VBG O
myocardial NN NN O
infarction NN NN O
. . . O

Acute JJ JJ O
treatment NN NN O
with IN IN O
metformin NN NN B-CHEM
has VBZ VBZ O
a DT DT O
protective JJ JJ O
effect NN NN O
in IN IN O
myocardial NN NN O
infarction NN NN O
by IN IN O
suppression NN NN O
of IN IN O
inflammatory JJ JJ O
responses NNS NNS O
due JJ JJ O
to TO TO O
activation NN NN O
of IN IN O
AMP NNP NNP B-CHEM
- - - O
activated JJ JJ O
protein NN NN O
kinase NN NN O
( ( ( O
AMPK NNP NNP O
) ) ) O
. . . O

In IN IN O
the DT DT O
present JJ JJ O
study NN NN O
, , , O
the DT DT O
effect NN NN O
of IN IN O
chronic JJ JJ O
pre NN NN O
- : : O
treatment NN NN O
with IN IN O
metformin NN NN B-CHEM
on IN IN O
cardiac JJ JJ O
dysfunction NN NN O
and CC CC O
toll NN NN O
- - - O
like IN IN O
receptor NN NN O
4 CD CD O
( ( ( O
TLR4 NNP NNP O
) ) ) O
activities NNS NNS O
following VBG VBG O
myocardial NN NN O
infarction NN NN O
and CC CC O
their PRP$ PRP$ O
relation NN NN O
with IN IN O
AMPK NNP NNP O
were VBD VBD O
assessed VBN VBN O
. . . O

Male NNP NNP O
Wistar NNP NNP O
rats NNS NNS O
were VBD VBD O
randomly RB RB O
assigned VBN VBN O
to TO TO O
one CD CD O
of IN IN O
5 CD CD O
groups NNS NNS O
( ( ( O
n NN NN O
= SYM SYM O
6 CD CD O
) ) ) O
: : : O
normal JJ JJ O
control NN NN O
and CC CC O
groups NNS NNS O
were VBD VBD O
injected VBN VBN O
isoproterenol NN NN B-CHEM
after IN IN O
chronic JJ JJ O
pre NN NN O
- : : O
treatment NN NN O
with IN IN O
0 CD CD O
, , , O
25 CD CD O
, , , O
50 CD CD O
, , , O
or CC CC O
100mg CD CD O
/ NN NN O
kg NN NN O
of IN IN O
metformin NN NN B-CHEM
twice RB RB O
daily JJ JJ O
for IN IN O
14 CD CD O
days NNS NNS O
. . . O

Isoproterenol NNP NNP B-CHEM
( ( ( O
100mg CD CD O
/ NN NN O
kg NN NN O
) ) ) O
was VBD VBD O
injected VBN VBN O
subcutaneously RB RB O
on IN IN O
the DT DT O
13th NN NN O
and CC CC O
14th JJ JJ O
days NNS NNS O
to TO TO O
induce VB VB O
acute JJ JJ O
myocardial NN NN O
infarction NN NN O
. . . O

Isoproterenol NNP NNP B-CHEM
alone RB RB O
decreased VBD VBD O
left VBN VBN O
ventricular NN NN O
systolic JJ JJ O
pressure NN NN O
and CC CC O
myocardial JJ JJ O
contractility NN NN O
indexed JJ JJ O
as IN IN O
LVdp NNP NNP O
/ NN NN O
dtmax NN NN O
and CC CC O
LVdp NNP NNP O
/ NN NN O
dtmin NN NN O
. . . O

The DT DT O
left NN NN O
ventricular NN NN O
dysfunction NN NN O
was VBD VBD O
significantly RB RB O
lower JJR JJR O
in IN IN O
the DT DT O
groups NNS NNS O
treated VBN VBN O
with IN IN O
25 CD CD O
and CC CC O
50mg CD CD O
/ NN NN O
kg NN NN O
of IN IN O
metformin NN NN B-CHEM
. . . O

Metfromin NNP NNP O
markedly RB RB O
lowered VBD VBD O
isoproterenol JJ JJ B-CHEM
- - - O
induced JJ JJ O
elevation NN NN O
in IN IN O
the DT DT O
levels NNS NNS O
of IN IN O
TLR4 NNP NNP O
mRNA NN NN O
, , , O
myeloid NN NN O
differentiation NN NN O
protein NN NN O
88 CD CD O
( ( ( O
MyD88 NNP NNP O
) ) ) O
, , , O
tumor NN NN O
necrosis NN NN O
factor NN NN O
- : : O
alpha NN NN O
( ( ( O
TNF NNP NNP O
- - - O
a DT DT O
) ) ) O
, , , O
and CC CC O
interleukin NN NN O
6 CD CD O
( ( ( O
IL NNP NNP O
- - - O
6 CD CD O
) ) ) O
in IN IN O
the DT DT O
heart NN NN O
tissues NNS NNS O
. . . O

Similar JJ JJ O
changes NNS NNS O
were VBD VBD O
also RB RB O
seen VBN VBN O
in IN IN O
the DT DT O
serum NN NN O
levels NNS NNS O
of IN IN O
TNF NNP NNP O
- : : O
a DT DT O
and CC CC O
IL NNP NNP O
- : : O
6 CD CD O
. . . O

However RB RB O
, , , O
the DT DT O
lower JJR JJR O
doses NNS NNS O
of IN IN O
25 CD CD O
and CC CC O
50mg CD CD O
/ NN NN O
kg NN NN O
were VBD VBD O
more RBR RBR O
effective JJ JJ O
than IN IN O
100mg CD CD O
/ NN NN O
kg NN NN O
. . . O

Phosphorylated NNP NNP O
AMPKa NNP NNP O
( ( ( O
p NN NN O
- - - O
AMPK NNP NNP O
) ) ) O
in IN IN O
the DT DT O
myocardium NN NN O
was VBD VBD O
significantly RB RB O
elevated VBN VBN O
by IN IN O
25mg CD CD O
/ NN NN O
kg NN NN O
of IN IN O
metformin NN NN B-CHEM
, , , O
slightly RB RB O
by IN IN O
50mg CD CD O
/ NN NN O
kg NN NN O
, , , O
but CC CC O
not RB RB O
by IN IN O
100mg CD CD O
/ NN NN O
kg NN NN O
. . . O

Chronic NNP NNP O
pre NN NN O
- : : O
treatment NN NN O
with IN IN O
metformin NN NN B-CHEM
reduces VBZ VBZ O
post NN NN O
- - - O
myocardial NN NN O
infarction NN NN O
cardiac JJ JJ O
dysfunction NN NN O
and CC CC O
suppresses NNS NNS O
inflammatory JJ JJ O
responses NNS NNS O
, , , O
possibly RB RB O
through IN IN O
inhibition NN NN O
of IN IN O
TLR4 NNP NNP O
activities NNS NNS O
. . . O

This DT DT O
mechanism NN NN O
can MD MD O
be VB VB O
considered VBN VBN O
as IN IN O
a DT DT O
target NN NN O
to TO TO O
protect VB VB O
infarcted JJ JJ O
myocardium NN NN O
. . . O

Unusual JJ JJ O
complications NNS NNS O
of IN IN O
antithyroid NN NN O
drug NN NN O
therapy NN NN O
: : : O
four CD CD O
case NN NN O
reports NNS NNS O
and CC CC O
review NN NN O
of IN IN O
literature NN NN O
. . . O

Two CD CD O
cases NNS NNS O
of IN IN O
propylthiouracil NN NN B-CHEM
- - - O
associated VBN VBN O
acute JJ JJ O
hepatitis NN NN O
, , , O
one CD CD O
case NN NN O
of IN IN O
fatal JJ JJ O
methimazole NN NN B-CHEM
- - - O
associated VBN VBN O
hepatocellular NN NN O
necrosis NNS NNS O
and CC CC O
one CD CD O
case NN NN O
of IN IN O
propylthiouracil NN NN B-CHEM
- - - O
associated VBN VBN O
lupus NN NN O
- - - O
like IN IN O
syndrome NN NN O
are VBP VBP O
described VBN VBN O
. . . O

The DT DT O
literature NN NN O
related VBN VBN O
to TO TO O
antithyroid VB VB O
drug NN NN O
side NN NN O
effects NNS NNS O
and CC CC O
the DT DT O
mechanisms NNS NNS O
for IN IN O
their PRP$ PRP$ O
occurrence NN NN O
are VBP VBP O
reviewed VBN VBN O
and CC CC O
the DT DT O
efficacy NN NN O
and CC CC O
complications NNS NNS O
of IN IN O
thyroidectomy NN NN O
and CC CC O
radioiodine NN NN O
compared VBN VBN O
to TO TO O
those DT DT O
of IN IN O
antithyroid JJ JJ O
drugs NNS NNS O
. . . O

It PRP PRP O
is VBZ VBZ O
concluded VBN VBN O
that IN IN O
in IN IN O
most JJS JJS O
circumstances NNS NNS O
131I CD CD O
is VBZ VBZ O
the DT DT O
therapy NN NN O
of IN IN O
choice NN NN O
for IN IN O
hyperthyroidism NN NN O
. . . O

Neuroleptic NNP NNP O
malignant NN NN O
syndrome NN NN O
induced VBN VBN O
by IN IN O
combination NN NN O
therapy NN NN O
with IN IN O
tetrabenazine NN NN B-CHEM
and CC CC O
tiapride NN NN B-CHEM
in IN IN O
a DT DT O
Japanese JJ JJ O
patient NN NN O
with IN IN O
Huntington NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
at IN IN O
the DT DT O
terminal JJ JJ O
stage NN NN O
of IN IN O
recurrent JJ JJ O
breast NN NN O
cancer NN NN O
. . . O

We PRP PRP O
herein VBP VBP O
describe VB VB O
the DT DT O
case NN NN O
of IN IN O
an DT DT O
81 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
Japanese JJ JJ O
woman NN NN O
with IN IN O
neuroleptic JJ JJ O
malignant NN NN O
syndrome NN NN O
that WDT WDT O
occurred VBD VBD O
36 CD CD O
days NNS NNS O
after IN IN O
the DT DT O
initiation NN NN O
of IN IN O
combination NN NN O
therapy NN NN O
with IN IN O
tiapride NN NN B-CHEM
( ( ( O
75 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
) ) ) O
and CC CC O
tetrabenazine NN NN B-CHEM
( ( ( O
12 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
) ) ) O
for IN IN O
Huntington NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
. . . O

The DT DT O
patient NN NN O
had VBD VBD O
been VBN VBN O
treated VBN VBN O
with IN IN O
tiapride NN NN B-CHEM
or CC CC O
tetrabenazine NN NN B-CHEM
alone RB RB O
without IN IN O
any DT DT O
adverse JJ JJ O
effects NNS NNS O
before IN IN O
the DT DT O
administration NN NN O
of IN IN O
the DT DT O
combination NN NN O
therapy NN NN O
. . . O

She PRP PRP O
also RB RB O
had VBD VBD O
advanced VBN VBN O
breast NN NN O
cancer NN NN O
when WRB WRB O
the DT DT O
combination NN NN O
therapy NN NN O
was VBD VBD O
initiated VBN VBN O
. . . O

To TO TO O
the DT DT O
best JJS JJS O
of IN IN O
our PRP$ PRP$ O
knowledge NN NN O
, , , O
the DT DT O
occurrence NN NN O
of IN IN O
neuroleptic JJ JJ O
malignant NN NN O
syndrome NN NN O
due JJ JJ O
to TO TO O
combination NN NN O
therapy NN NN O
with IN IN O
tetrabenazine NN NN B-CHEM
and CC CC O
tiapride NN NN B-CHEM
has VBZ VBZ O
not RB RB O
been VBN VBN O
previously RB RB O
reported VBN VBN O
. . . O

Tetrabenazine NNP NNP B-CHEM
should MD MD O
be VB VB O
administered VBN VBN O
very RB RB O
carefully RB RB O
in IN IN O
combination NN NN O
with IN IN O
other JJ JJ O
neuroleptic JJ JJ B-CHEM
drugs NNS NNS I-CHEM
, , , O
particularly RB RB O
in IN IN O
patients NNS NNS O
with IN IN O
a DT DT O
worsening VBG VBG O
general JJ JJ O
condition NN NN O
. . . O

A DT DT O
metoprolol NN NN B-CHEM
- - - O
terbinafine NN NN B-CHEM
combination NN NN O
induced JJ JJ O
bradycardia NN NN O
. . . O

To TO TO O
report VB VB O
a DT DT O
sinus JJ JJ O
bradycardia NN NN O
induced VBN VBN O
by IN IN O
metoprolol NN NN B-CHEM
and CC CC O
terbinafine NN NN B-CHEM
drug NN NN O
- : : O
drug NN NN O
interaction NN NN O
and CC CC O
its PRP$ PRP$ O
management NN NN O
. . . O

A DT DT O
63 CD CD O
year NN NN O
- : : O
old JJ JJ O
Caucasian JJ JJ O
man NN NN O
on IN IN O
metoprolol NN NN B-CHEM
200 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
for IN IN O
stable JJ JJ O
coronary JJ JJ O
artery NN NN O
disease NN NN O
was VBD VBD O
prescribed VBN VBN O
a DT DT O
90 CD CD O
- : : O
day NN NN O
course NN NN O
of IN IN O
oral JJ JJ O
terbinafine NN NN B-CHEM
250 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
for IN IN O
onychomycosis NN NN O
. . . O

On IN IN O
the DT DT O
49th CD CD O
day NN NN O
of IN IN O
terbinafine NN NN B-CHEM
therapy NN NN O
, , , O
he PRP PRP O
was VBD VBD O
brought VBN VBN O
to TO TO O
the DT DT O
emergency NN NN O
room NN NN O
for IN IN O
a DT DT O
decrease NN NN O
of IN IN O
his PRP$ PRP$ O
global JJ JJ O
health NN NN O
status NN NN O
, , , O
confusion NN NN O
and CC CC O
falls VBZ VBZ O
. . . O

The DT DT O
electrocardiogram NN NN O
revealed VBD VBD O
a DT DT O
37 CD CD O
beats NNS NNS O
/ NN NN O
min NN NN O
sinus NN NN O
bradycardia NN NN O
. . . O

A DT DT O
score NN NN O
of IN IN O
7 CD CD O
on IN IN O
the DT DT O
Naranjo NNP NNP O
adverse JJ JJ O
drug NN NN O
reaction NN NN O
probability NN NN O
scale NN NN O
indicates VBZ VBZ O
a DT DT O
probable JJ JJ O
relationship NN NN O
between IN IN O
the DT DT O
patient NN NN O
' '' '' O
s VBZ VBZ O
sinus NN NN O
bradycardia NNS NNS O
and CC CC O
the DT DT O
drug NN NN O
interaction NN NN O
between IN IN O
metoprolol NN NN B-CHEM
and CC CC O
terbinafine NN NN B-CHEM
. . . O

The DT DT O
heart NN NN O
rate NN NN O
ameliorated VBD VBD O
first RB RB O
with IN IN O
a DT DT O
decrease NN NN O
in IN IN O
the DT DT O
dose NN NN O
of IN IN O
metoprolol NN NN B-CHEM
. . . O

It PRP PRP O
was VBD VBD O
subsequently RB RB O
changed VBN VBN O
to TO TO O
bisoprolol VB VB B-CHEM
and CC CC O
the DT DT O
heart NN NN O
rate NN NN O
remained VBD VBD O
normal JJ JJ O
. . . O

By IN IN O
inhibiting VBG VBG O
the DT DT O
cytochrome NN NN O
P450 NNP NNP O
2D6 CD CD O
, , , O
terbinafine NN NN B-CHEM
had VBD VBD O
decreased VBN VBN O
metoprolol NN NN B-CHEM
' '' '' O
s VBZ VBZ O
clearance NN NN O
, , , O
leading VBG VBG O
in IN IN O
metoprolol NN NN B-CHEM
accumulation NN NN O
which WDT WDT O
has VBZ VBZ O
resulted VBN VBN O
in IN IN O
clinically RB RB O
significant JJ JJ O
sinus NN NN O
bradycardia NN NN O
. . . O

Optochiasmatic NNP NNP O
and CC CC O
peripheral JJ JJ O
neuropathy NN NN O
due JJ JJ O
to TO TO O
ethambutol DT DT B-CHEM
overtreatment NN NN O
. . . O

Ethambutol NNP NNP B-CHEM
is VBZ VBZ O
known VBN VBN O
to TO TO O
cause VB VB O
optic JJ JJ O
neuropathy NN NN O
and CC CC O
, , , O
more RBR RBR O
rarely RB RB O
, , , O
axonal JJ JJ O
polyneuropathy NN NN O
. . . O

We PRP PRP O
characterize VBP VBP O
the DT DT O
clinical JJ JJ O
, , , O
neurophysiological JJ JJ O
, , , O
and CC CC O
neuroimaging VBG VBG O
findings NNS NNS O
in IN IN O
a DT DT O
72 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
man NN NN O
who WP WP O
developed VBD VBD O
visual JJ JJ O
loss NN NN O
and CC CC O
paresthesias NN NN O
after IN IN O
11 CD CD O
weeks NNS NNS O
of IN IN O
exposure NN NN O
to TO TO O
a DT DT O
supratherapeutic JJ JJ O
dose NN NN O
of IN IN O
ethambutol NN NN B-CHEM
. . . O

This DT DT O
case NN NN O
demonstrates VBZ VBZ O
the DT DT O
selective JJ JJ O
vulnerability NN NN O
of IN IN O
the DT DT O
anterior NN NN O
visual JJ JJ O
pathways NNS NNS O
and CC CC O
peripheral JJ JJ O
nerves NNS NNS O
to TO TO O
ethambutol VB VB B-CHEM
toxicity NN NN O
. . . O

Testosterone NNP NNP B-CHEM
ameliorates NNS NNS O
streptozotocin NN NN B-CHEM
- : : O
induced JJ JJ O
memory NN NN O
impairment NN NN O
in IN IN O
male JJ JJ O
rats NNS NNS O
. . . O

AIM NNP NNP O
: : : O
To TO TO O
study VB VB O
the DT DT O
effects NNS NNS O
of IN IN O
testosterone NN NN B-CHEM
on IN IN O
streptozotocin NN NN B-CHEM
( ( ( O
STZ NNP NNP B-CHEM
) ) ) O
- : : O
induced JJ JJ O
memory NN NN O
impairment NN NN O
in IN IN O
male JJ JJ O
rats NNS NNS O
. . . O

METHODS NNP NNP O
: : : O
Adult NNP NNP O
male JJ JJ O
Wistar NNP NNP O
rats NNS NNS O
were VBD VBD O
intracerebroventricularly RB RB O
( ( ( O
icv NN NN O
) ) ) O
infused VBN VBN O
with IN IN O
STZ NNP NNP B-CHEM
( ( ( O
750 CD CD O
ug NN NN O
) ) ) O
on IN IN O
d SYM SYM O
1 CD CD O
and CC CC O
d SYM SYM O
3 CD CD O
, , , O
and CC CC O
a DT DT O
passive JJ JJ O
avoidance NN NN O
task NN NN O
was VBD VBD O
assessed VBN VBN O
2 CD CD O
weeks NNS NNS O
after IN IN O
the DT DT O
first JJ JJ O
injection NN NN O
of IN IN O
STZ NNP NNP B-CHEM
. . . O

Castration NNP NNP O
surgery NN NN O
was VBD VBD O
performed VBN VBN O
in IN IN O
another DT DT O
group NN NN O
of IN IN O
rats NNS NNS O
, , , O
and CC CC O
the DT DT O
passive JJ JJ O
avoidance NN NN O
task NN NN O
was VBD VBD O
assessed VBN VBN O
4 CD CD O
weeks NNS NNS O
after IN IN O
the DT DT O
operation NN NN O
. . . O

Testosterone NNP NNP B-CHEM
( ( ( O
1 CD CD O
mg NN NN O
. . . O
kg NN NN O
( ( ( O
- : : O
1 CD CD O
) ) ) O
. . . O
d SYM SYM O
( ( ( O
- : : O
1 CD CD O
) ) ) O
, , , O
sc NN NN O
) ) ) O
, , , O
the DT DT O
androgen NN NN B-CHEM
receptor NN NN O
antagonist NN NN O
flutamide NN NN B-CHEM
( ( ( O
10 CD CD O
mg NN NN O
. . . O
kg NN NN O
( ( ( O
- : : O
1 CD CD O
) ) ) O
. . . O
d SYM SYM O
( ( ( O
- : : O
1 CD CD O
) ) ) O
, , , O
ip NNP NNP O
) ) ) O
, , , O
the DT DT O
estrogen NN NN B-CHEM
receptor NN NN O
antagonist NN NN O
tamoxifen NN NN B-CHEM
( ( ( O
1 CD CD O
mg NN NN O
. . . O
kg NN NN O
( ( ( O
- : : O
1 CD CD O
) ) ) O
. . . O
d SYM SYM O
( ( ( O
- : : O
1 CD CD O
) ) ) O
, , , O
ip NNP NNP O
) ) ) O
or CC CC O
the DT DT O
aromatase NN NN O
inhibitor NN NN O
letrozole NN NN B-CHEM
( ( ( O
4 CD CD O
mg NN NN O
. . . O
kg NN NN O
( ( ( O
- : : O
1 CD CD O
) ) ) O
. . . O
d SYM SYM O
( ( ( O
- : : O
1 CD CD O
) ) ) O
, , , O
ip NNP NNP O
) ) ) O
were VBD VBD O
administered VBN VBN O
for IN IN O
6 CD CD O
d SYM SYM O
after IN IN O
the DT DT O
first JJ JJ O
injection NN NN O
of IN IN O
STZ NNP NNP B-CHEM
. . . O

RESULTS NNS NNS O
: : : O
STZ NNP NNP B-CHEM
administration NN NN O
and CC CC O
castration NN NN O
markedly RB RB O
decreased VBD VBD O
both DT DT O
STL1 NNP NNP O
( ( ( O
the DT DT O
short JJ JJ O
memory NN NN O
) ) ) O
and CC CC O
STL2 NNP NNP O
( ( ( O
the DT DT O
long JJ JJ O
memory NN NN O
) ) ) O
in IN IN O
passive JJ JJ O
avoidance NN NN O
tests NNS NNS O
. . . O

Testosterone NNP NNP B-CHEM
replacement NN NN O
almost RB RB O
restored VBD VBD O
the DT DT O
STL1 NNP NNP O
and CC CC O
STL2 NNP NNP O
in IN IN O
castrated JJ JJ O
rats NNS NNS O
, , , O
and CC CC O
significantly RB RB O
prolonged JJ JJ O
the DT DT O
STL1 NNP NNP O
and CC CC O
STL2 NNP NNP O
in IN IN O
STZ NNP NNP B-CHEM
- - - O
treated JJ JJ O
rats NNS NNS O
. . . O

Administration NNP NNP O
of IN IN O
flutamide NN NN B-CHEM
, , , O
letrozole NN NN B-CHEM
or CC CC O
tamoxifen NN NN B-CHEM
significantly RB RB O
impaired VBD VBD O
the DT DT O
memory NN NN O
in IN IN O
intact JJ JJ O
rats NNS NNS O
, , , O
and CC CC O
significantly RB RB O
attenuated VBD VBD O
the DT DT O
testosterone NN NN B-CHEM
replacement NN NN O
in IN IN O
improving VBG VBG O
STZ NNP NNP B-CHEM
- : : O
and CC CC O
castration NN NN O
- - - O
induced JJ JJ O
memory NN NN O
impairment NN NN O
. . . O

CONCLUSION NNP NNP O
: : : O
Testosterone NNP NNP B-CHEM
administration NN NN O
ameliorates NNS NNS O
STZ NNP NNP B-CHEM
- : : O
and CC CC O
castration NN NN O
- - - O
induced JJ JJ O
memory NN NN O
impairment NN NN O
in IN IN O
male JJ JJ O
Wistar NNP NNP O
rats NNS NNS O
. . . O

Behavioral NNP NNP O
and CC CC O
neurochemical JJ JJ O
studies NNS NNS O
in IN IN O
mice NN NN O
pretreated VBN VBN O
with IN IN O
garcinielliptone NN NN B-CHEM
FC NNP NNP I-CHEM
in IN IN O
pilocarpine NN NN B-CHEM
- - - O
induced JJ JJ O
seizures NNS NNS O
. . . O

Garcinielliptone NNP NNP B-CHEM
FC NNP NNP I-CHEM
( ( ( O
GFC NNP NNP B-CHEM
) ) ) O
isolated VBN VBN O
from IN IN O
hexanic JJ JJ O
fraction NN NN O
seed NN NN O
extract NN NN O
of IN IN O
species NNS NNS O
Platonia NNP NNP O
insignis NNS NNS O
Mart NNP NNP O
. . . O

It PRP PRP O
is VBZ VBZ O
widely RB RB O
used VBN VBN O
in IN IN O
folk NN NN O
medicine NN NN O
to TO TO O
treat VB VB O
skin NN NN O
diseases NNS NNS O
in IN IN O
both DT DT O
humans NNS NNS O
and CC CC O
animals NNS NNS O
as RB RB O
well RB RB O
as IN IN O
the DT DT O
seed NN NN O
decoction NN NN O
has VBZ VBZ O
been VBN VBN O
used VBN VBN O
to TO TO O
treat VB VB O
diarrheas NNS NNS O
and CC CC O
inflammatory JJ JJ O
diseases NNS NNS O
. . . O

However RB RB O
, , , O
there EX EX O
is VBZ VBZ O
no DT DT O
research NN NN O
on IN IN O
GFC NNP NNP B-CHEM
effects NNS NNS O
in IN IN O
the DT DT O
central JJ JJ O
nervous JJ JJ O
system NN NN O
of IN IN O
rodents NNS NNS O
. . . O

The DT DT O
present JJ JJ O
study NN NN O
aimed VBN VBN O
to TO TO O
evaluate VB VB O
the DT DT O
GFC NNP NNP B-CHEM
effects NNS NNS O
at IN IN O
doses NNS NNS O
of IN IN O
25 CD CD O
, , , O
50 CD CD O
or CC CC O
75 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
on IN IN O
seizure NN NN O
parameters NNS NNS O
to TO TO O
determine VB VB O
their PRP$ PRP$ O
anticonvulsant JJ JJ O
activity NN NN O
and CC CC O
its PRP$ PRP$ O
effects NNS NNS O
on IN IN O
amino JJ JJ B-CHEM
acid NN NN I-CHEM
( ( ( O
r LS LS B-CHEM
- - - I-CHEM
aminobutyric JJ JJ I-CHEM
acid NN NN I-CHEM
( ( ( O
GABA NNP NNP B-CHEM
) ) ) O
, , , O
glutamine NN NN B-CHEM
, , , O
aspartate NN NN B-CHEM
and CC CC O
glutathione NN NN B-CHEM
) ) ) O
levels NNS NNS O
as RB RB O
well RB RB O
as IN IN O
on IN IN O
acetylcholinesterase NN NN O
( ( ( O
AChE NNP NNP O
) ) ) O
activity NN NN O
in IN IN O
mice NN NN O
hippocampus NN NN O
after IN IN O
seizures NNS NNS O
. . . O

GFC NNP NNP B-CHEM
produced VBD VBD O
an DT DT O
increased JJ JJ O
latency NN NN O
to TO TO O
first JJ JJ O
seizure NN NN O
, , , O
at IN IN O
doses NNS NNS O
25mg CD CD O
/ NN NN O
kg NN NN O
( ( ( O
20 CD CD O
. . . O
12 CD CD O
+ NN NN O
2 CD CD O
. . . O
20 CD CD O
min NN NN O
) ) ) O
, , , O
50mg CD CD O
/ NN NN O
kg NN NN O
( ( ( O
20 CD CD O
. . . O
95 CD CD O
+ NN NN O
2 CD CD O
. . . O
21 CD CD O
min NN NN O
) ) ) O
or CC CC O
75 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
( ( ( O
23 CD CD O
. . . O
43 CD CD O
+ NN NN O
1 CD CD O
. . . O
99 CD CD O
min NN NN O
) ) ) O
when WRB WRB O
compared VBN VBN O
with IN IN O
seized JJ JJ O
mice NN NN O
. . . O

In IN IN O
addition NN NN O
, , , O
GABA NNP NNP B-CHEM
content NN NN O
of IN IN O
mice NNS NNS O
hippocampus NN NN O
treated VBN VBN O
with IN IN O
GFC75 NNP NNP O
plus CC CC O
P400 NNP NNP O
showed VBD VBD O
an DT DT O
increase NN NN O
of IN IN O
46 CD CD O
. . . O
90 CD CD O
% NN NN O
when WRB WRB O
compared VBN VBN O
with IN IN O
seized JJ JJ O
mice NN NN O
. . . O

In IN IN O
aspartate NN NN B-CHEM
, , , O
glutamine NN NN B-CHEM
and CC CC O
glutamate NN NN B-CHEM
levels NNS NNS O
detected VBD VBD O
a DT DT O
decrease NN NN O
of IN IN O
5 CD CD O
. . . O
21 CD CD O
% NN NN O
, , , O
13 CD CD O
. . . O
55 CD CD O
% NN NN O
and CC CC O
21 CD CD O
. . . O
80 CD CD O
% NN NN O
, , , O
respectively RB RB O
in IN IN O
mice NN NN O
hippocampus NN NN O
treated VBN VBN O
with IN IN O
GFC75 NNP NNP O
plus CC CC O
P400 NNP NNP O
when WRB WRB O
compared VBN VBN O
with IN IN O
seized JJ JJ O
mice NN NN O
. . . O

Hippocampus NNP NNP O
mice NNS NNS O
treated VBN VBN O
with IN IN O
GFC75 NNP NNP O
plus CC CC O
P400 NNP NNP O
showed VBD VBD O
an DT DT O
increase NN NN O
in IN IN O
AChE NNP NNP O
activity NN NN O
( ( ( O
63 CD CD O
. . . O
30 CD CD O
% NN NN O
) ) ) O
when WRB WRB O
compared VBN VBN O
with IN IN O
seized JJ JJ O
mice NN NN O
. . . O

The DT DT O
results NNS NNS O
indicate VBP VBP O
that IN IN O
GFC NNP NNP B-CHEM
can MD MD O
exert VB VB O
anticonvulsant JJ JJ O
activity NN NN O
and CC CC O
reduce VB VB O
the DT DT O
frequency NN NN O
of IN IN O
installation NN NN O
of IN IN O
pilocarpine NN NN B-CHEM
- - - O
induced JJ JJ O
status NN NN O
epilepticus NN NN O
, , , O
as IN IN O
demonstrated VBN VBN O
by IN IN O
increase NN NN O
in IN IN O
latency NN NN O
to TO TO O
first JJ JJ O
seizure NN NN O
and CC CC O
decrease VB VB O
in IN IN O
mortality NN NN O
rate NN NN O
of IN IN O
animals NNS NNS O
. . . O

In IN IN O
conclusion NN NN O
, , , O
our PRP$ PRP$ O
data NNS NNS O
suggest VBP VBP O
that IN IN O
GFC NNP NNP B-CHEM
may MD MD O
influence VB VB O
in IN IN O
epileptogenesis NN NN O
and CC CC O
promote VB VB O
anticonvulsant NN NN O
actions NNS NNS O
in IN IN O
pilocarpine NN NN B-CHEM
model NN NN O
by IN IN O
modulating VBG VBG O
the DT DT O
GABA NNP NNP B-CHEM
and CC CC O
glutamate NN NN B-CHEM
contents NNS NNS O
and CC CC O
of IN IN O
AChE NNP NNP O
activity NN NN O
in IN IN O
seized JJ JJ O
mice NN NN O
hippocampus NN NN O
. . . O

This DT DT O
compound NN NN O
may MD MD O
be VB VB O
useful JJ JJ O
to TO TO O
produce VB VB O
neuronal JJ JJ O
protection NN NN O
and CC CC O
it PRP PRP O
can MD MD O
be VB VB O
considered VBN VBN O
as IN IN O
an DT DT O
anticonvulsant JJ JJ O
agent NN NN O
. . . O

Standard NNP NNP O
operating VBG VBG O
procedures NNS NNS O
for IN IN O
antibiotic JJ JJ O
therapy NN NN O
and CC CC O
the DT DT O
occurrence NN NN O
of IN IN O
acute JJ JJ O
kidney NN NN O
injury NN NN O
: : : O
a DT DT O
prospective JJ JJ O
, , , O
clinical JJ JJ O
, , , O
non NN NN O
- - - O
interventional JJ JJ O
, , , O
observational JJ JJ O
study NN NN O
. . . O

INTRODUCTION NNP NNP O
: : : O
Acute JJ JJ O
kidney NN NN O
injury NN NN O
( ( ( O
AKI NNP NNP O
) ) ) O
occurs VBZ VBZ O
in IN IN O
7 CD CD O
% NN NN O
of IN IN O
hospitalized JJ JJ O
and CC CC O
66 CD CD O
% NN NN O
of IN IN O
Intensive NNP NNP O
Care NNP NNP O
Unit NNP NNP O
( ( ( O
ICU NNP NNP O
) ) ) O
patients NNS NNS O
. . . O

It PRP PRP O
increases VBZ VBZ O
mortality NN NN O
, , , O
hospital NN NN O
length NN NN O
of IN IN O
stay NN NN O
, , , O
and CC CC O
costs NNS NNS O
. . . O

The DT DT O
aim NN NN O
of IN IN O
this DT DT O
study NN NN O
was VBD VBD O
to TO TO O
investigate VB VB O
, , , O
whether IN IN O
there EX EX O
is VBZ VBZ O
an DT DT O
association NN NN O
between IN IN O
adherence NN NN O
to TO TO O
guidelines NNS NNS O
( ( ( O
standard JJ JJ O
operating NN NN O
procedures NNS NNS O
( ( ( O
SOP NNP NNP O
) ) ) O
) ) ) O
for IN IN O
potentially RB RB O
nephrotoxic JJ JJ O
antibiotics NNS NNS O
and CC CC O
the DT DT O
occurrence NN NN O
of IN IN O
AKI NNP NNP O
. . . O

METHODS NNP NNP O
: : : O
This DT DT O
study NN NN O
was VBD VBD O
carried VBN VBN O
out IN IN O
as IN IN O
a DT DT O
prospective JJ JJ O
, , , O
clinical JJ JJ O
, , , O
non NN NN O
- - - O
interventional JJ JJ O
, , , O
observational JJ JJ O
study NN NN O
. . . O

Data NNP NNP O
collection NN NN O
was VBD VBD O
performed VBN VBN O
over IN IN O
a DT DT O
total NN NN O
of IN IN O
170 CD CD O
days NNS NNS O
in IN IN O
three CD CD O
ICUs NNP NNP O
at IN IN O
Charite NNP NNP O
- - - O
Universitaetsmedizin NNP NNP O
Berlin NNP NNP O
. . . O

A DT DT O
total NN NN O
of IN IN O
675 CD CD O
patients NNS NNS O
were VBD VBD O
included VBN VBN O
; : : O
163 CD CD O
of IN IN O
these DT DT O
had VBD VBD O
therapy NN NN O
with IN IN O
vancomycin NN NN B-CHEM
, , , O
gentamicin NN NN B-CHEM
, , , O
or CC CC O
tobramycin NN NN B-CHEM
; : : O
were VBD VBD O
> NN NN O
18 CD CD O
years NNS NNS O
; : : O
and CC CC O
treated VBN VBN O
in IN IN O
the DT DT O
ICU NNP NNP O
for IN IN O
> NN NN O
24 CD CD O
hours NNS NNS O
. . . O

Patients NNS NNS O
with IN IN O
an DT DT O
adherence NN NN O
to TO TO O
SOP NNP NNP O
> NN NN O
70 CD CD O
% NN NN O
were VBD VBD O
classified VBN VBN O
into IN IN O
the DT DT O
high JJ JJ O
adherence NN NN O
group NN NN O
( ( ( O
HAG NNP NNP O
) ) ) O
and CC CC O
patients NNS NNS O
with IN IN O
an DT DT O
adherence NN NN O
of IN IN O
< NN NN O
70 CD CD O
% NN NN O
into IN IN O
the DT DT O
low JJ JJ O
adherence NN NN O
group NN NN O
( ( ( O
LAG NNP NNP O
) ) ) O
. . . O

AKI NNP NNP O
was VBD VBD O
defined VBN VBN O
according VBG VBG O
to TO TO O
RIFLE NNP NNP O
criteria NNS NNS O
. . . O

Adherence NNP NNP O
to TO TO O
SOPs NNP NNP O
was VBD VBD O
evaluated VBN VBN O
by IN IN O
retrospective JJ JJ O
expert NN NN O
audit NN NN O
. . . O

Development NNP NNP O
of IN IN O
AKI NNP NNP O
was VBD VBD O
compared VBN VBN O
between IN IN O
groups NNS NNS O
with IN IN O
exact JJ JJ O
Chi2 NNP NNP O
- : : O
test NN NN O
and CC CC O
multivariate NN NN O
logistic JJ JJ O
regression NN NN O
analysis NN NN O
( ( ( O
two CD CD O
- - - O
sided JJ JJ O
P NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

RESULTS NNS NNS O
: : : O
LAG NNP NNP O
consisted VBD VBD O
of IN IN O
75 CD CD O
patients NNS NNS O
( ( ( O
46 CD CD O
% NN NN O
) ) ) O
versus CC CC O
88 CD CD O
HAG NNP NNP O
patients NNS NNS O
( ( ( O
54 CD CD O
% NN NN O
) ) ) O
. . . O

AKI NNP NNP O
occurred VBD VBD O
significantly RB RB O
more RBR RBR O
often RB RB O
in IN IN O
LAG NNP NNP O
with IN IN O
36 CD CD O
% NN NN O
versus CC CC O
21 CD CD O
% NN NN O
in IN IN O
HAG NNP NNP O
( ( ( O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
035 CD CD O
) ) ) O
. . . O

Basic JJ JJ O
characteristics NNS NNS O
were VBD VBD O
comparable JJ JJ O
, , , O
except IN IN O
an DT DT O
increased JJ JJ O
rate NN NN O
of IN IN O
soft JJ JJ O
tissue NN NN O
infections NNS NNS O
in IN IN O
LAG NNP NNP O
. . . O

Multivariate NNP NNP O
analysis NN NN O
revealed VBD VBD O
an DT DT O
odds NNS NNS O
ratio NN NN O
of IN IN O
2 CD CD O
. . . O
5 CD CD O
- : : O
fold VB VB O
for IN IN O
LAG NNP NNP O
to TO TO O
develop VB VB O
AKI NNP NNP O
compared VBN VBN O
with IN IN O
HAG NNP NNP O
( ( ( O
95 CD CD O
% NN NN O
confidence NN NN O
interval NN NN O
1 CD CD O
. . . O
195 CD CD O
to TO TO O
5 CD CD O
. . . O
124 CD CD O
, , , O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
039 CD CD O
) ) ) O
. . . O

CONCLUSION NNP NNP O
: : : O
Low NNP NNP O
adherence NN NN O
to TO TO O
SOPs NNP NNP O
for IN IN O
potentially RB RB O
nephrotoxic JJ JJ O
antibiotics NNS NNS O
was VBD VBD O
associated VBN VBN O
with IN IN O
a DT DT O
higher JJR JJR O
occurrence NN NN O
of IN IN O
AKI NNP NNP O
. . . O

TRIAL NN NN O
REGISTRATION NNP NNP O
: : : O
Current NNP NNP O
Controlled NNP NNP O
Trials NNP NNP O
ISRCTN54598675 NNP NNP O
. . . O

Registered NNP NNP O
17 CD CD O
August NNP NNP O
2007 CD CD O
. . . O

Rhabdomyolysis NNP NNP O
in IN IN O
a DT DT O
hepatitis NNP NNP O
C NNP NNP O
virus NN NN O
infected JJ JJ O
patient NN NN O
treated VBN VBN O
with IN IN O
telaprevir NN NN B-CHEM
and CC CC O
simvastatin NN NN B-CHEM
. . . O

A DT DT O
46 CD CD O
- : : O
year NN NN O
old JJ JJ O
man NN NN O
with IN IN O
a DT DT O
chronic JJ JJ O
hepatitis NNP NNP O
C NNP NNP O
virus NN NN O
infection NN NN O
received VBD VBD O
triple JJ JJ O
therapy NN NN O
with IN IN O
ribavirin NN NN B-CHEM
, , , O
pegylated VBN VBN B-CHEM
interferon NN NN I-CHEM
and CC CC O
telaprevir NN NN B-CHEM
. . . O

The DT DT O
patient NN NN O
also RB RB O
received VBD VBD O
simvastatin NN NN B-CHEM
. . . O

One CD CD O
month NN NN O
after IN IN O
starting VBG VBG O
the DT DT O
antiviral JJ JJ O
therapy NN NN O
, , , O
the DT DT O
patient NN NN O
was VBD VBD O
admitted VBN VBN O
to TO TO O
the DT DT O
hospital NN NN O
because IN IN O
he PRP PRP O
developed VBD VBD O
rhabdomyolysis NNS NNS O
. . . O

At IN IN O
admission NN NN O
simvastatin NN NN B-CHEM
and CC CC O
all DT DT O
antiviral JJ JJ O
drugs NNS NNS O
were VBD VBD O
discontinued VBN VBN O
because IN IN O
toxicity NN NN O
due JJ JJ O
to TO TO O
a DT DT O
drug NN NN O
- - - O
drug NN NN O
interaction NN NN O
was VBD VBD O
suspected VBN VBN O
. . . O

The DT DT O
creatine NN NN B-CHEM
kinase NN NN O
peaked VBD VBD O
at IN IN O
62 CD CD O
, , , O
246 CD CD O
IU NNP NNP O
/ NN NN O
L NNP NNP O
and CC CC O
the DT DT O
patient NN NN O
was VBD VBD O
treated VBN VBN O
with IN IN O
intravenous JJ JJ O
normal JJ JJ O
saline NN NN O
. . . O

The DT DT O
patient NN NN O
' '' '' O
s VBZ VBZ O
renal JJ JJ O
function NN NN O
remained VBD VBD O
unaffected JJ JJ O
. . . O

Fourteen CD CD O
days NNS NNS O
after IN IN O
hospitalization NN NN O
, , , O
creatine NN NN B-CHEM
kinase NN NN O
level NN NN O
had VBD VBD O
returned VBN VBN O
to TO TO O
230 CD CD O
IU NNP NNP O
/ NN NN O
L NNP NNP O
and CC CC O
the DT DT O
patient NN NN O
was VBD VBD O
discharged VBN VBN O
. . . O

Telaprevir NNP NNP B-CHEM
was VBD VBD O
considered VBN VBN O
the DT DT O
probable JJ JJ O
causative JJ JJ O
agent NN NN O
of IN IN O
an DT DT O
interaction NN NN O
with IN IN O
simvastatin NN NN B-CHEM
according VBG VBG O
to TO TO O
the DT DT O
Drug NN NN O
Interaction NNP NNP O
Probability NNP NNP O
Scale NNP NNP O
. . . O

The DT DT O
interaction NN NN O
is VBZ VBZ O
due JJ JJ O
to TO TO O
inhibition NN NN O
of IN IN O
CYP3A4 NNP NNP O
- - - O
mediated JJ JJ O
simvastatin NN NN B-CHEM
clearance NN NN O
. . . O

Simvastatin NNP NNP B-CHEM
plasma NN NN O
concentration NN NN O
increased VBD VBD O
30 CD CD O
times NNS NNS O
in IN IN O
this DT DT O
patient NN NN O
and CC CC O
statin NN NN B-CHEM
induced JJ JJ O
muscle NN NN O
toxicity NN NN O
is VBZ VBZ O
related VBN VBN O
to TO TO O
the DT DT O
concentration NN NN O
of IN IN O
the DT DT O
statin NN NN B-CHEM
in IN IN O
blood NN NN O
. . . O

In IN IN O
conclusion NN NN O
, , , O
with IN IN O
this DT DT O
case NN NN O
we PRP PRP O
illustrate VBP VBP O
that RB RB O
telaprevir NN NN B-CHEM
as RB RB O
well RB RB O
as IN IN O
statins NNS NNS B-CHEM
are VBP VBP O
susceptible JJ JJ O
to TO TO O
clinical JJ JJ O
relevant JJ JJ O
drug NN NN O
- - - O
drug NN NN O
interactions NNS NNS O
. . . O

Combination NNP NNP O
of IN IN O
bortezomib NN NN B-CHEM
, , , O
thalidomide NN NN B-CHEM
, , , O
and CC CC O
dexamethasone NN NN B-CHEM
( ( ( O
VTD NNP NNP O
) ) ) O
as IN IN O
a DT DT O
consolidation NN NN O
therapy NN NN O
after IN IN O
autologous JJ JJ O
stem NN NN O
cell NN NN O
transplantation NN NN O
for IN IN O
symptomatic JJ JJ O
multiple JJ JJ O
myeloma NN NN O
in IN IN O
Japanese JJ JJ O
patients NNS NNS O
. . . O

Consolidation NNP NNP O
therapy NN NN O
for IN IN O
patients NNS NNS O
with IN IN O
multiple JJ JJ O
myeloma NN NN O
( ( ( O
MM NNP NNP O
) ) ) O
has VBZ VBZ O
been VBN VBN O
widely RB RB O
adopted VBN VBN O
to TO TO O
improve VB VB O
treatment NN NN O
response NN NN O
following VBG VBG O
autologous JJ JJ O
stem NN NN O
cell NN NN O
transplantation NN NN O
. . . O

In IN IN O
this DT DT O
study NN NN O
, , , O
we PRP PRP O
retrospectively RB RB O
analyzed VBD VBD O
the DT DT O
safety NN NN O
and CC CC O
efficacy NN NN O
of IN IN O
combination NN NN O
regimen NNS NNS O
of IN IN O
bortezomib NN NN B-CHEM
, , , O
thalidomide NN NN B-CHEM
, , , O
and CC CC O
dexamethasone NN NN B-CHEM
( ( ( O
VTD NNP NNP O
) ) ) O
as IN IN O
consolidation NN NN O
therapy NN NN O
in IN IN O
24 CD CD O
Japanese JJ JJ O
patients NNS NNS O
with IN IN O
newly RB RB O
diagnosed VBN VBN O
MM NNP NNP O
. . . O

VTD NNP NNP O
consisted VBD VBD O
of IN IN O
bortezomib NN NN B-CHEM
at IN IN O
a DT DT O
dose NN NN O
of IN IN O
1 CD CD O
. . . O
3 CD CD O
mg NN NN O
/ NN NN O
m NN NN O
( ( ( O
2 CD CD O
) ) ) O
and CC CC O
dexamethasone NN NN B-CHEM
at IN IN O
a DT DT O
dose NN NN O
of IN IN O
40 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
on IN IN O
days NNS NNS O
1 CD CD O
, , , O
8 CD CD O
, , , O
15 CD CD O
, , , O
and CC CC O
22 CD CD O
of IN IN O
a DT DT O
35 CD CD O
- : : O
day NN NN O
cycle NN NN O
, , , O
with IN IN O
daily JJ JJ O
oral JJ JJ O
thalidomide NN NN B-CHEM
at IN IN O
a DT DT O
dose NN NN O
of IN IN O
100 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
. . . O

Grade NNP NNP O
3 CD CD O
- : : O
4 CD CD O
neutropenia NN NN O
and CC CC O
thrombocytopenia NN NN O
were VBD VBD O
documented VBN VBN O
in IN IN O
four CD CD O
and CC CC O
three CD CD O
patients NNS NNS O
( ( ( O
17 CD CD O
and CC CC O
13 CD CD O
% NN NN O
) ) ) O
, , , O
respectively RB RB O
, , , O
but CC CC O
drug NN NN O
dose NN NN O
reduction NN NN O
due JJ JJ O
to TO TO O
cytopenia VB VB O
was VBD VBD O
not RB RB O
required VBN VBN O
in IN IN O
any DT DT O
case NN NN O
. . . O

Peripheral NNP NNP O
neuropathy NN NN O
was VBD VBD O
common JJ JJ O
( ( ( O
63 CD CD O
% NN NN O
) ) ) O
, , , O
but CC CC O
severe JJ JJ O
grade NN NN O
3 CD CD O
- : : O
4 CD CD O
peripheral JJ JJ O
neuropathy NN NN O
was VBD VBD O
not RB RB O
observed VBN VBN O
. . . O

Very RB RB O
good JJ JJ O
partial JJ JJ O
response NN NN O
or CC CC O
better JJR JJR O
response NN NN O
( ( ( O
> NN NN O
VGPR NNP NNP O
) ) ) O
rates NNS NNS O
before IN IN O
and CC CC O
after IN IN O
consolidation NN NN O
therapy NN NN O
were VBD VBD O
54 CD CD O
and CC CC O
79 CD CD O
% NN NN O
, , , O
respectively RB RB O
. . . O

Patients NNS NNS O
had VBD VBD O
a DT DT O
significant JJ JJ O
probability NN NN O
of IN IN O
improving VBG VBG O
from IN IN O
< NN NN O
VGPR NNP NNP O
before IN IN O
consolidation NN NN O
therapy NN NN O
to TO TO O
> NN NN O
VGPR NNP NNP O
after IN IN O
consolidation NN NN O
therapy NN NN O
( ( ( O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
041 CD CD O
) ) ) O
. . . O

The DT DT O
VTD NNP NNP O
regimen NNS NNS O
may MD MD O
be VB VB O
safe JJ JJ O
and CC CC O
effective JJ JJ O
as IN IN O
a DT DT O
consolidation NN NN O
therapy NN NN O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
MM NNP NNP O
in IN IN O
Japanese JJ JJ O
population NN NN O
. . . O

Conversion NNP NNP O
to TO TO O
sirolimus VB VB B-CHEM
ameliorates NNS NNS O
cyclosporine NN NN B-CHEM
- : : O
induced JJ JJ O
nephropathy NN NN O
in IN IN O
the DT DT O
rat NN NN O
: : : O
focus NN NN O
on IN IN O
serum NN NN O
, , , O
urine NN NN O
, , , O
gene NN NN O
, , , O
and CC CC O
protein NN NN O
renal JJ JJ O
expression NN NN O
biomarkers NNS NNS O
. . . O

Protocols NNP NNP O
of IN IN O
conversion NN NN O
from IN IN O
cyclosporin NN NN B-CHEM
A DT DT I-CHEM
( ( ( O
CsA NNP NNP B-CHEM
) ) ) O
to TO TO O
sirolimus VB VB B-CHEM
( ( ( O
SRL NNP NNP B-CHEM
) ) ) O
have VBP VBP O
been VBN VBN O
widely RB RB O
used VBN VBN O
in IN IN O
immunotherapy NN NN O
after IN IN O
transplantation NN NN O
to TO TO O
prevent VB VB O
CsA NNP NNP B-CHEM
- : : O
induced JJ JJ O
nephropathy NN NN O
, , , O
but CC CC O
the DT DT O
molecular JJ JJ O
mechanisms NNS NNS O
underlying VBG VBG O
these DT DT O
protocols NNS NNS O
remain VBP VBP O
nuclear JJ JJ O
. . . O

This DT DT O
study NN NN O
aimed VBN VBN O
to TO TO O
identify VB VB O
the DT DT O
molecular JJ JJ O
pathways NNS NNS O
and CC CC O
putative JJ JJ O
biomarkers NNS NNS O
of IN IN O
CsA NNP NNP B-CHEM
- - - O
to TO TO O
- - - O
SRL NNP NNP B-CHEM
conversion NN NN O
in IN IN O
a DT DT O
rat NN NN O
model NN NN O
. . . O

Four CD CD O
animal NN NN O
groups NNS NNS O
( ( ( O
n NN NN O
= SYM SYM O
6 CD CD O
) ) ) O
were VBD VBD O
tested VBN VBN O
during IN IN O
9 CD CD O
weeks NNS NNS O
: : : O
control NN NN O
, , , O
CsA NNP NNP B-CHEM
, , , O
SRL NNP NNP B-CHEM
, , , O
and CC CC O
conversion NN NN O
( ( ( O
CsA NNP NNP B-CHEM
for IN IN O
3 CD CD O
weeks NNS NNS O
followed VBN VBN O
by IN IN O
SRL NNP NNP B-CHEM
for IN IN O
6 CD CD O
weeks NNS NNS O
) ) ) O
. . . O

Classical NNP NNP O
and CC CC O
emergent NN NN O
serum NN NN O
, , , O
urinary JJ JJ O
, , , O
and CC CC O
kidney NN NN O
tissue NN NN O
( ( ( O
gene NN NN O
and CC CC O
protein NN NN O
expression NN NN O
) ) ) O
markers NNS NNS O
were VBD VBD O
assessed VBN VBN O
. . . O

Renal NNP NNP O
lesions NNS NNS O
were VBD VBD O
analyzed VBN VBN O
in IN IN O
hematoxylin NN NN B-CHEM
and CC CC O
eosin NN NN B-CHEM
, , , O
periodic JJ JJ O
acid NN NN O
- - - O
Schiff NNP NNP O
, , , O
and CC CC O
Masson NNP NNP O
' POS POS O
s VBZ VBZ O
trichrome NN NN O
stains NNS NNS O
. . . O

SRL NNP NNP B-CHEM
- - - O
treated JJ JJ O
rats NNS NNS O
presented VBN VBN O
proteinuria NN NN O
and CC CC O
NGAL NNP NNP O
( ( ( O
serum NN NN O
and CC CC O
urinary JJ JJ O
) ) ) O
as IN IN O
the DT DT O
best JJS JJS O
markers NNS NNS O
of IN IN O
renal JJ JJ O
impairment NN NN O
. . . O

Short NNP NNP O
CsA NNP NNP B-CHEM
treatment NN NN O
presented VBD VBD O
slight JJ JJ O
or CC CC O
even RB RB O
absent JJ JJ O
kidney NN NN O
lesions NNS NNS O
and CC CC O
TGF NNP NNP O
- : : O
b SYM SYM O
, , , O
NF NNP NNP O
- : : O
kb NN NN O
, , , O
mTOR NN NN O
, , , O
PCNA NNP NNP O
, , , O
TP53 NNP NNP O
, , , O
KIM NNP NNP O
- : : O
1 CD CD O
, , , O
and CC CC O
CTGF NNP NNP O
as IN IN O
relevant JJ JJ O
gene NN NN O
and CC CC O
protein NN NN O
changes NNS NNS O
. . . O

Prolonged NNP NNP O
CsA NNP NNP B-CHEM
exposure NN NN O
aggravated VBD VBD O
renal JJ JJ O
damage NN NN O
, , , O
without IN IN O
clear JJ JJ O
changes NNS NNS O
on IN IN O
the DT DT O
traditional JJ JJ O
markers NNS NNS O
, , , O
but CC CC O
with IN IN O
changes NNS NNS O
in IN IN O
serums NNS NNS O
TGF NNP NNP O
- : : O
b SYM SYM O
and CC CC O
IL NNP NNP O
- : : O
7 CD CD O
, , , O
TBARs NNP NNP O
clearance NN NN O
, , , O
and CC CC O
kidney NN NN O
TGF NNP NNP O
- : : O
b SYM SYM O
and CC CC O
mTOR NN NN O
. . . O

Conversion NNP NNP O
to TO TO O
SRL NNP NNP B-CHEM
prevented VBD VBD O
CsA NNP NNP B-CHEM
- : : O
induced JJ JJ O
renal JJ JJ O
damage NN NN O
evolution NN NN O
( ( ( O
absent NN NN O
/ NN NN O
mild JJ JJ O
grade NN NN O
lesions NNS NNS O
) ) ) O
, , , O
while IN IN O
NGAL NNP NNP O
( ( ( O
serum NN NN O
versus CC CC O
urine JJ JJ O
) ) ) O
seems VBZ VBZ O
to TO TO O
be VB VB O
a DT DT O
feasible JJ JJ O
biomarker NN NN O
of IN IN O
CsA NNP NNP B-CHEM
replacement NN NN O
to TO TO O
SRL NNP NNP B-CHEM
. . . O

Kinin NNP NNP O
B2 NNP NNP O
receptor NN NN O
deletion NN NN O
and CC CC O
blockage NN NN O
ameliorates NNS NNS O
cisplatin NN NN B-CHEM
- : : O
induced JJ JJ O
acute JJ JJ O
renal JJ JJ O
injury NN NN O
. . . O

Cisplatin NNP NNP B-CHEM
treatment NN NN O
has VBZ VBZ O
been VBN VBN O
adopted VBN VBN O
in IN IN O
some DT DT O
chemotherapies NNS NNS O
; : : O
however RB RB O
, , , O
this DT DT O
drug NN NN O
can MD MD O
induce VB VB O
acute JJ JJ O
kidney NN NN O
injury NN NN O
due JJ JJ O
its PRP$ PRP$ O
ability NN NN O
to TO TO O
negatively RB RB O
affect VB VB O
renal JJ JJ O
function NN NN O
, , , O
augment JJ JJ O
serum NN NN O
levels NNS NNS O
of IN IN O
creatinine NN NN B-CHEM
and CC CC O
urea NN NN B-CHEM
, , , O
increase NN NN O
the DT DT O
acute JJ JJ O
tubular NN NN O
necrosis NN NN O
score NN NN O
and CC CC O
up RP RP O
- : : O
regulate JJ JJ O
cytokines NNS NNS O
( ( ( O
e SYM SYM O
. . . O
g SYM SYM O
. . . O
, , , O
IL NNP NNP O
- : : O
1b CD CD O
and CC CC O
TNF NNP NNP O
- : : O
a DT DT O
) ) ) O
. . . O

The DT DT O
kinin NN NN O
B2 NNP NNP O
receptor NN NN O
has VBZ VBZ O
been VBN VBN O
associated VBN VBN O
with IN IN O
the DT DT O
inflammation NN NN O
process NN NN O
, , , O
as RB RB O
well RB RB O
as IN IN O
the DT DT O
regulation NN NN O
of IN IN O
cytokine NN NN O
expression NN NN O
, , , O
and CC CC O
its PRP$ PRP$ O
deletion NN NN O
resulted VBD VBD O
in IN IN O
an DT DT O
improvement NN NN O
in IN IN O
the DT DT O
diabetic JJ JJ O
nephropathy NN NN O
status NN NN O
. . . O

To TO TO O
examine VB VB O
the DT DT O
role NN NN O
of IN IN O
the DT DT O
kinin NN NN O
B2 NNP NNP O
receptor NN NN O
in IN IN O
cisplatin NN NN B-CHEM
- - - O
induced JJ JJ O
acute JJ JJ O
kidney NN NN O
injury NN NN O
, , , O
kinin NN NN O
B2 NNP NNP O
receptor NN NN O
knockout NN NN O
mice NN NN O
were VBD VBD O
challenged VBN VBN O
with IN IN O
cisplatin NN NN B-CHEM
. . . O

Additionally RB RB O
, , , O
WT NNP NNP O
mice NN NN O
were VBD VBD O
treated VBN VBN O
with IN IN O
a DT DT O
B2 NNP NNP O
receptor NN NN O
antagonist NN NN O
after IN IN O
cisplatin NN NN B-CHEM
administration NN NN O
. . . O

B2 NNP NNP O
receptor NN NN O
- : : O
deficient JJ JJ O
mice NN NN O
were VBD VBD O
less RBR RBR O
sensitive JJ JJ O
to TO TO O
this DT DT O
drug NN NN O
than IN IN O
the DT DT O
WT NNP NNP O
mice NN NN O
, , , O
as IN IN O
shown VBN VBN O
by IN IN O
reduced VBN VBN O
weight NN NN O
loss NN NN O
, , , O
better JJR JJR O
preservation NN NN O
of IN IN O
kidney NN NN O
function NN NN O
, , , O
down RB RB O
regulation NN NN O
of IN IN O
inflammatory JJ JJ O
cytokines NNS NNS O
and CC CC O
less JJR JJR O
acute JJ JJ O
tubular JJ JJ O
necrosis NN NN O
. . . O

Moreover RB RB O
, , , O
treatment NN NN O
with IN IN O
the DT DT O
kinin NN NN O
B2 NNP NNP O
receptor NN NN O
antagonist NN NN O
effectively RB RB O
reduced VBD VBD O
the DT DT O
levels NNS NNS O
of IN IN O
serum NN NN O
creatinine NN NN B-CHEM
and CC CC O
blood NN NN O
urea NN NN B-CHEM
after IN IN O
cisplatin NN NN B-CHEM
administration NN NN O
. . . O

Thus RB RB O
, , , O
our PRP$ PRP$ O
data NNS NNS O
suggest VBP VBP O
that IN IN O
the DT DT O
kinin NN NN O
B2 NNP NNP O
receptor NN NN O
is VBZ VBZ O
involved VBN VBN O
in IN IN O
cisplatin NN NN B-CHEM
- - - O
induced JJ JJ O
acute JJ JJ O
kidney NN NN O
injury NN NN O
by IN IN O
mediating VBG VBG O
the DT DT O
necrotic JJ JJ O
process NN NN O
and CC CC O
the DT DT O
expression NN NN O
of IN IN O
inflammatory JJ JJ O
cytokines NNS NNS O
, , , O
thus RB RB O
resulting VBG VBG O
in IN IN O
declined VBN VBN O
renal JJ JJ O
function NN NN O
. . . O

These DT DT O
results NNS NNS O
highlight VBD VBD O
the DT DT O
kinin NN NN O
B2 NNP NNP O
receptor NN NN O
antagonist NN NN O
treatment NN NN O
in IN IN O
amelioration NN NN O
of IN IN O
nephrotoxicity NN NN O
induced VBN VBN O
by IN IN O
cisplatin NN NN B-CHEM
therapy NN NN O
. . . O

Safety NNP NNP O
and CC CC O
efficacy NN NN O
of IN IN O
fluocinolone NN NN B-CHEM
acetonide IN IN I-CHEM
intravitreal NN NN O
implant NN NN O
( ( ( O
0 CD CD O
. . . O
59 CD CD O
mg NN NN O
) ) ) O
in IN IN O
birdshot NN NN O
retinochoroidopathy NN NN O
. . . O

PURPOSE NNP NNP O
: : : O
To TO TO O
report VB VB O
the DT DT O
treatment NN NN O
outcomes NNS NNS O
of IN IN O
the DT DT O
fluocinolone NN NN B-CHEM
acetonide NN NN I-CHEM
intravitreal NN NN O
implant NN NN O
( ( ( O
0 CD CD O
. . . O
59 CD CD O
mg NN NN O
) ) ) O
in IN IN O
patients NNS NNS O
with IN IN O
birdshot NN NN O
retinochoroidopathy NN NN O
whose WP$ WP$ O
disease NN NN O
is VBZ VBZ O
refractory JJ JJ O
or CC CC O
intolerant JJ JJ O
to TO TO O
conventional JJ JJ O
immunomodulatory NN NN O
therapy NN NN O
. . . O

METHODS NNP NNP O
: : : O
A DT DT O
retrospective NN NN O
case NN NN O
series NN NN O
involving VBG VBG O
11 CD CD O
birdshot NN NN O
retinochoroidopathy NN NN O
patients NNS NNS O
( ( ( O
11 CD CD O
eyes NNS NNS O
) ) ) O
. . . O

Eleven CD CD O
patients NNS NNS O
( ( ( O
11 CD CD O
eyes NNS NNS O
) ) ) O
underwent JJ JJ O
surgery NN NN O
for IN IN O
fluocinolone NN NN B-CHEM
acetonide IN IN I-CHEM
implant NN NN O
( ( ( O
0 CD CD O
. . . O
59 CD CD O
mg NN NN O
) ) ) O
. . . O

Treatment NN NN O
outcomes NNS NNS O
of IN IN O
interest NN NN O
were VBD VBD O
noted VBN VBN O
at IN IN O
baseline NN NN O
, , , O
before IN IN O
fluocinolone NN NN B-CHEM
acetonide IN IN I-CHEM
implant NN NN O
, , , O
and CC CC O
then RB RB O
at IN IN O
6 CD CD O
months NNS NNS O
, , , O
1 CD CD O
year NN NN O
, , , O
2 CD CD O
years NNS NNS O
, , , O
3 CD CD O
years NNS NNS O
, , , O
and CC CC O
beyond IN IN O
3 CD CD O
years NNS NNS O
. . . O

Disease NNP NNP O
activity NN NN O
markers NNS NNS O
, , , O
including VBG VBG O
signs NNS NNS O
of IN IN O
ocular JJ JJ O
inflammation NN NN O
, , , O
evidence NN NN O
of IN IN O
retinal JJ JJ O
vasculitis NNS NNS O
, , , O
Swedish JJ JJ O
interactive JJ JJ O
threshold NN NN O
algorithm NN NN O
- : : O
short JJ JJ O
wavelength NN NN O
automated VBN VBN O
perimetry NN NN O
Humphrey NNP NNP O
visual JJ JJ O
field NN NN O
analysis NN NN O
, , , O
electroretinographic JJ JJ O
parameters NNS NNS O
, , , O
and CC CC O
optical JJ JJ O
coherence NN NN O
tomography NN NN O
were VBD VBD O
recorded VBN VBN O
. . . O

Data NNP NNP O
on IN IN O
occurrence NN NN O
of IN IN O
cataract NN NN O
and CC CC O
raised VBD VBD O
intraocular JJ JJ O
pressure NN NN O
were VBD VBD O
collected VBN VBN O
in IN IN O
all DT DT O
eyes NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
Intraocular NNP NNP O
inflammation NN NN O
was VBD VBD O
present JJ JJ O
in IN IN O
54 CD CD O
. . . O
5 CD CD O
, , , O
9 CD CD O
. . . O
9 CD CD O
, , , O
11 CD CD O
. . . O
1 CD CD O
, , , O
and CC CC O
0 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
at IN IN O
baseline NN NN O
, , , O
6 CD CD O
months NNS NNS O
, , , O
1 CD CD O
year NN NN O
, , , O
2 CD CD O
years NNS NNS O
, , , O
3 CD CD O
years NNS NNS O
, , , O
and CC CC O
beyond IN IN O
3 CD CD O
years NNS NNS O
after IN IN O
receiving VBG VBG O
the DT DT O
implant NN NN O
, , , O
respectively RB RB O
. . . O

Active JJ JJ O
vasculitis NN NN O
was VBD VBD O
noted VBN VBN O
in IN IN O
36 CD CD O
. . . O
3 CD CD O
% NN NN O
patients NNS NNS O
at IN IN O
baseline NN NN O
and CC CC O
0 CD CD O
% NN NN O
at IN IN O
3 CD CD O
years NNS NNS O
of IN IN O
follow VB VB O
- - - O
up RP RP O
. . . O

More JJR JJR O
than IN IN O
20 CD CD O
% NN NN O
( ( ( O
47 CD CD O
. . . O
61 CD CD O
- : : O
67 CD CD O
. . . O
2 CD CD O
% NN NN O
) ) ) O
reduction NN NN O
in IN IN O
central JJ JJ O
retinal NN NN O
thickness NN NN O
was VBD VBD O
noted VBN VBN O
in IN IN O
all DT DT O
patients NNS NNS O
with IN IN O
cystoid NN NN O
macular NN NN O
edema NN NN O
at IN IN O
6 CD CD O
months NNS NNS O
, , , O
1 CD CD O
year NN NN O
, , , O
2 CD CD O
years NNS NNS O
, , , O
and CC CC O
3 CD CD O
years NNS NNS O
postimplant NN NN O
. . . O

At IN IN O
baseline NN NN O
, , , O
54 CD CD O
. . . O
5 CD CD O
% NN NN O
patients NNS NNS O
were VBD VBD O
on IN IN O
immunomodulatory JJ JJ O
agents NNS NNS O
. . . O

This DT DT O
percentage NN NN O
decreased VBD VBD O
to TO TO O
45 CD CD O
. . . O
45 CD CD O
, , , O
44 CD CD O
. . . O
4 CD CD O
, , , O
and CC CC O
14 CD CD O
. . . O
28 CD CD O
% NN NN O
at IN IN O
1 CD CD O
year NN NN O
, , , O
2 CD CD O
years NNS NNS O
, , , O
and CC CC O
3 CD CD O
years NNS NNS O
postimplant NN NN O
, , , O
respectively RB RB O
. . . O

Adverse NNP NNP O
events NNS NNS O
included VBN VBN O
increased VBN VBN O
intraocular JJ JJ O
pressure NN NN O
( ( ( O
54 CD CD O
. . . O
5 CD CD O
% NN NN O
) ) ) O
and CC CC O
cataract JJ JJ O
formation NN NN O
( ( ( O
100 CD CD O
% NN NN O
) ) ) O
. . . O

CONCLUSION NNP NNP O
: : : O
The DT DT O
data NNS NNS O
suggest VBP VBP O
that IN IN O
fluocinolone NN NN B-CHEM
acetonide IN IN I-CHEM
implant NN NN O
( ( ( O
0 CD CD O
. . . O
59 CD CD O
mg NN NN O
) ) ) O
helps VBZ VBZ O
to TO TO O
control VB VB O
inflammation NN NN O
in IN IN O
otherwise RB RB O
treatment NN NN O
- : : O
refractory NN NN O
cases NNS NNS O
of IN IN O
birdshot JJ JJ O
retinochoroidopathy NN NN O
. . . O

It PRP PRP O
is VBZ VBZ O
associated VBN VBN O
with IN IN O
significant JJ JJ O
side NN NN O
effects NNS NNS O
of IN IN O
cataract NN NN O
and CC CC O
ocular JJ JJ O
hypertension NN NN O
requiring VBG VBG O
treatment NN NN O
. . . O

Optimal NNP NNP O
precurarizing VBG VBG O
dose NN NN O
of IN IN O
rocuronium NN NN B-CHEM
to TO TO O
decrease VB VB O
fasciculation NN NN O
and CC CC O
myalgia NN NN O
following VBG VBG O
succinylcholine NN NN B-CHEM
administration NN NN O
. . . O

BACKGROUND NNP NNP O
: : : O
Succinylcholine NNP NNP B-CHEM
commonly RB RB O
produces VBZ VBZ O
frequent JJ JJ O
adverse JJ JJ O
effects NNS NNS O
, , , O
including VBG VBG O
muscle NN NN O
fasciculation NN NN O
and CC CC O
myalgia NN NN O
. . . O

The DT DT O
current JJ JJ O
study NN NN O
identified VBD VBD O
the DT DT O
optimal NN NN O
dose NN NN O
of IN IN O
rocuronium NN NN B-CHEM
to TO TO O
prevent VB VB O
succinylcholine NN NN B-CHEM
- : : O
induced JJ JJ O
fasciculation NN NN O
and CC CC O
myalgia NN NN O
and CC CC O
evaluated VBD VBD O
the DT DT O
influence NN NN O
of IN IN O
rocuronium NN NN B-CHEM
on IN IN O
the DT DT O
speed NN NN O
of IN IN O
onset NN NN O
produced VBN VBN O
by IN IN O
succinylcholine NN NN B-CHEM
. . . O

METHODS NNP NNP O
: : : O
This DT DT O
randomized JJ JJ O
, , , O
double JJ JJ O
- - - O
blinded JJ JJ O
study NN NN O
was VBD VBD O
conducted VBN VBN O
in IN IN O
100 CD CD O
patients NNS NNS O
randomly RB RB O
allocated VBN VBN O
into IN IN O
five CD CD O
groups NNS NNS O
of IN IN O
20 CD CD O
patients NNS NNS O
each DT DT O
. . . O

Patients NNS NNS O
were VBD VBD O
randomized VBN VBN O
to TO TO O
receive VB VB O
0 CD CD O
. . . O
02 CD CD O
, , , O
0 CD CD O
. . . O
03 CD CD O
, , , O
0 CD CD O
. . . O
04 CD CD O
, , , O
0 CD CD O
. . . O
05 CD CD O
and CC CC O
0 CD CD O
. . . O
06 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
rocuronium NN NN B-CHEM
as IN IN O
a DT DT O
precurarizing VBG VBG O
dose NN NN O
. . . O

Neuromuscular NNP NNP O
monitoring VBG VBG O
after IN IN O
each DT DT O
precurarizing VBG VBG O
dose NN NN O
was VBD VBD O
recorded VBN VBN O
from IN IN O
the DT DT O
adductor NN NN O
pollicis NN NN O
muscle NN NN O
using VBG VBG O
acceleromyography NN NN O
with IN IN O
train NN NN O
- - - O
of IN IN O
- - - O
four CD CD O
stimulation NN NN O
of IN IN O
the DT DT O
ulnar NN NN O
nerve NN NN O
. . . O

All DT DT O
patients NNS NNS O
received VBD VBD O
succinylcholine NN NN B-CHEM
1 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
at IN IN O
2 CD CD O
minutes NNS NNS O
after IN IN O
the DT DT O
precurarization NN NN O
, , , O
and CC CC O
were VBD VBD O
assessed VBN VBN O
the DT DT O
incidence NN NN O
and CC CC O
severity NN NN O
of IN IN O
fasciculations NNS NNS O
, , , O
while IN IN O
myalgia NN NN O
was VBD VBD O
assessed VBN VBN O
at IN IN O
24 CD CD O
hours NNS NNS O
after IN IN O
surgery NN NN O
. . . O

RESULTS NNS NNS O
: : : O
The DT DT O
incidence NN NN O
and CC CC O
severity NN NN O
of IN IN O
visible JJ JJ O
muscle NN NN O
fasciculation NN NN O
was VBD VBD O
significantly RB RB O
less JJR JJR O
with IN IN O
increasing VBG VBG O
the DT DT O
amount NN NN O
of IN IN O
precurarizing VBG VBG O
dose NN NN O
of IN IN O
rocuronium NN NN B-CHEM
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
. . . O

Those DT DT O
of IN IN O
myalgia NNS NNS O
tend VBP VBP O
to TO TO O
decrease VB VB O
according VBG VBG O
to TO TO O
increasing VBG VBG O
the DT DT O
amount NN NN O
of IN IN O
precurarizing VBG VBG O
dose NN NN O
of IN IN O
rocuronium NN NN B-CHEM
, , , O
but CC CC O
there EX EX O
was VBD VBD O
no DT DT O
significance NN NN O
( ( ( O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
072 CD CD O
) ) ) O
. . . O

The DT DT O
onset NN NN O
time NN NN O
of IN IN O
succinylcholine NN NN B-CHEM
was VBD VBD O
significantly RB RB O
longer RB RB O
with IN IN O
increasing VBG VBG O
the DT DT O
amount NN NN O
of IN IN O
precurarizing VBG VBG O
dose NN NN O
of IN IN O
rocuronium NN NN B-CHEM
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Precurarization NNP NNP O
with IN IN O
0 CD CD O
. . . O
04 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
rocuronium NN NN B-CHEM
was VBD VBD O
the DT DT O
optimal NN NN O
dose NN NN O
considering VBG VBG O
the DT DT O
reduction NN NN O
in IN IN O
the DT DT O
incidence NN NN O
and CC CC O
severity NN NN O
of IN IN O
fasciculation NN NN O
and CC CC O
myalgia NN NN O
with IN IN O
acceptable JJ JJ O
onset NN NN O
time NN NN O
, , , O
and CC CC O
the DT DT O
safe JJ JJ O
and CC CC O
effective JJ JJ O
precurarization NN NN O
. . . O

Absence NNP NNP O
of IN IN O
PKC NNP NNP O
- : : O
alpha NN NN O
attenuates NNS NNS O
lithium NN NN B-CHEM
- : : O
induced JJ JJ O
nephrogenic JJ JJ O
diabetes NNS NNS O
insipidus NN NN O
. . . O

Lithium NNP NNP B-CHEM
, , , O
an DT DT O
effective JJ JJ O
antipsychotic JJ JJ O
, , , O
induces NNS NNS O
nephrogenic JJ JJ O
diabetes NNS NNS O
insipidus NN NN O
( ( ( O
NDI NNP NNP O
) ) ) O
in IN IN O
40 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
. . . O

The DT DT O
decreased VBN VBN O
capacity NN NN O
to TO TO O
concentrate VB VB O
urine NN NN O
is VBZ VBZ O
likely JJ JJ O
due JJ JJ O
to TO TO O
lithium NN NN B-CHEM
acutely RB RB O
disrupting VBG VBG O
the DT DT O
cAMP NN NN B-CHEM
pathway NN NN O
and CC CC O
chronically RB RB O
reducing VBG VBG O
urea JJ JJ B-CHEM
transporter NN NN O
( ( ( O
UT NNP NNP O
- - - O
A1 NNP NNP O
) ) ) O
and CC CC O
water NN NN O
channel NN NN O
( ( ( O
AQP2 NNP NNP O
) ) ) O
expression NN NN O
in IN IN O
the DT DT O
inner JJ JJ O
medulla NN NN O
. . . O

Targeting NNP NNP O
an DT DT O
alternative JJ JJ O
signaling VBG VBG O
pathway NN NN O
, , , O
such JJ JJ O
as IN IN O
PKC NNP NNP O
- - - O
mediated JJ JJ O
signaling VBG VBG O
, , , O
may MD MD O
be VB VB O
an DT DT O
effective JJ JJ O
method NN NN O
of IN IN O
treating VBG VBG O
lithium NN NN B-CHEM
- - - O
induced JJ JJ O
polyuria NN NN O
. . . O

PKC NNP NNP O
- : : O
alpha NN NN O
null JJ JJ O
mice NN NN O
( ( ( O
PKCa NNP NNP O
KO NNP NNP O
) ) ) O
and CC CC O
strain VB VB O
- - - O
matched JJ JJ O
wild JJ JJ O
type NN NN O
( ( ( O
WT NNP NNP O
) ) ) O
controls NNS NNS O
were VBD VBD O
treated VBN VBN O
with IN IN O
lithium NN NN B-CHEM
for IN IN O
0 CD CD O
, , , O
3 CD CD O
or CC CC O
5 CD CD O
days NNS NNS O
. . . O

WT NNP NNP O
mice NNS NNS O
had VBD VBD O
increased VBN VBN O
urine NN NN O
output NN NN O
and CC CC O
lowered VBD VBD O
urine JJ JJ O
osmolality NN NN O
after IN IN O
3 CD CD O
and CC CC O
5 CD CD O
days NNS NNS O
of IN IN O
treatment NN NN O
whereas IN IN O
PKCa NNP NNP O
KO NNP NNP O
mice NN NN O
had VBD VBD O
no DT DT O
change NN NN O
in IN IN O
urine NN NN O
output NN NN O
or CC CC O
concentration NN NN O
. . . O

Western JJ JJ O
blot NN NN O
analysis NN NN O
revealed VBD VBD O
that IN IN O
AQP2 NNP NNP O
expression NN NN O
in IN IN O
medullary JJ JJ O
tissues NNS NNS O
was VBD VBD O
lowered VBN VBN O
after IN IN O
3 CD CD O
and CC CC O
5 CD CD O
days NNS NNS O
in IN IN O
WT NNP NNP O
mice NN NN O
; : : O
however RB RB O
, , , O
AQP2 NNP NNP O
was VBD VBD O
unchanged JJ JJ O
in IN IN O
PKCa NNP NNP O
KO NNP NNP O
. . . O

Similar JJ JJ O
results NNS NNS O
were VBD VBD O
observed VBN VBN O
with IN IN O
UT NNP NNP O
- : : O
A1 NNP NNP O
expression NN NN O
. . . O

Animals NNS NNS O
were VBD VBD O
also RB RB O
treated VBN VBN O
with IN IN O
lithium NN NN B-CHEM
for IN IN O
6 CD CD O
weeks NNS NNS O
. . . O

Lithium NNP NNP B-CHEM
- - - O
treated JJ JJ O
WT NNP NNP O
mice NNS NNS O
had VBD VBD O
19 CD CD O
- : : O
fold VB VB O
increased VBN VBN O
urine NN NN O
output NN NN O
whereas IN IN O
treated VBN VBN O
PKCa NNP NNP O
KO NNP NNP O
animals NNS NNS O
had VBD VBD O
a DT DT O
4 CD CD O
- : : O
fold VB VB O
increase NN NN O
in IN IN O
output NN NN O
. . . O

AQP2 NNP NNP O
and CC CC O
UT NNP NNP O
- : : O
A1 NNP NNP O
expression NN NN O
was VBD VBD O
lowered VBN VBN O
in IN IN O
6 CD CD O
week NN NN O
lithium NN NN B-CHEM
- - - O
treated VBN VBN O
WT NNP NNP O
animals NNS NNS O
whereas IN IN O
in IN IN O
treated VBN VBN O
PKCa NNP NNP O
KO NNP NNP O
mice NN NN O
, , , O
AQP2 NNP NNP O
was VBD VBD O
only RB RB O
reduced VBN VBN O
by IN IN O
2 CD CD O
- : : O
fold VB VB O
and CC CC O
UT NNP NNP O
- : : O
A1 NNP NNP O
expression NN NN O
was VBD VBD O
unaffected JJ JJ O
. . . O

Urinary NNP NNP O
sodium NN NN B-CHEM
, , , O
potassium NN NN B-CHEM
and CC CC O
calcium NN NN B-CHEM
were VBD VBD O
elevated VBN VBN O
in IN IN O
lithium NN NN B-CHEM
- - - O
fed VBN VBN O
WT NNP NNP O
but CC CC O
not RB RB O
in IN IN O
lithium NN NN B-CHEM
- - - O
fed VBN VBN O
PKCa NNP NNP O
KO NNP NNP O
mice NN NN O
. . . O

Our PRP$ PRP$ O
data NNS NNS O
show VBP VBP O
that DT DT O
ablation NN NN O
of IN IN O
PKCa NNP NNP O
preserves VBZ VBZ O
AQP2 NNP NNP O
and CC CC O
UT NNP NNP O
- : : O
A1 NNP NNP O
protein NN NN O
expression NN NN O
and CC CC O
localization NN NN O
in IN IN O
lithium NN NN B-CHEM
- - - O
induced JJ JJ O
NDI NNP NNP O
, , , O
and CC CC O
prevents VBZ VBZ O
the DT DT O
development NN NN O
of IN IN O
the DT DT O
severe JJ JJ O
polyuria NN NN O
associated VBN VBN O
with IN IN O
lithium NN NN B-CHEM
therapy NN NN O
. . . O

Is VBZ VBZ O
Dysguesia NNP NNP O
Going VBG VBG O
to TO TO O
be VB VB O
a DT DT O
Rare JJ JJ O
or CC CC O
a DT DT O
Common JJ JJ O
Side NNP NNP O
- : : O
effect NN NN O
of IN IN O
Amlodipine NNP NNP B-CHEM
? . . O

A DT DT O
very RB RB O
rare JJ JJ O
side NN NN O
- - - O
effect NN NN O
of IN IN O
amlodipine NN NN B-CHEM
is VBZ VBZ O
dysguesia NN NN O
. . . O

A DT DT O
review NN NN O
of IN IN O
the DT DT O
literature NN NN O
produced VBD VBD O
only RB RB O
one CD CD O
case NN NN O
. . . O

We PRP PRP O
report VBP VBP O
a DT DT O
case NN NN O
about IN IN O
a DT DT O
female JJ JJ O
with IN IN O
essential JJ JJ O
hypertension NN NN O
on IN IN O
drug NN NN O
treatment NN NN O
with IN IN O
amlodipine NN NN B-CHEM
developed VBN VBN O
loss NN NN O
of IN IN O
taste NN NN O
sensation NN NN O
. . . O

Condition NNP NNP O
moderately RB RB O
improved VBD VBD O
on IN IN O
stoppage NN NN O
of IN IN O
the DT DT O
drug NN NN O
for IN IN O
25 CD CD O
days NNS NNS O
. . . O

We PRP PRP O
conclude VBP VBP O
that IN IN O
amlodipine NN NN B-CHEM
can MD MD O
cause VB VB O
dysguesia NN NN O
. . . O

Here RB RB O
, , , O
we PRP PRP O
describe VBP VBP O
the DT DT O
clinical JJ JJ O
presentation NN NN O
and CC CC O
review NN NN O
the DT DT O
relevant JJ JJ O
literature NN NN O
on IN IN O
amlodipine NN NN B-CHEM
and CC CC O
dysguesia NN NN O
. . . O

Rhabdomyolysis NNP NNP O
in IN IN O
association NN NN O
with IN IN O
simvastatin NN NN B-CHEM
and CC CC O
dosage NN NN O
increment NN NN O
in IN IN O
clarithromycin NN NN B-CHEM
. . . O

Clarithromycin NNP NNP B-CHEM
is VBZ VBZ O
the DT DT O
most RBS RBS O
documented VBN VBN O
cytochrome NN NN O
P450 NNP NNP O
3A4 CD CD O
( ( ( O
CYP3A4 NNP NNP O
) ) ) O
inhibitor NN NN O
to TO TO O
cause VB VB O
an DT DT O
adverse JJ JJ O
interaction NN NN O
with IN IN O
simvastatin NN NN B-CHEM
. . . O

This DT DT O
particular JJ JJ O
case NN NN O
is VBZ VBZ O
of IN IN O
interest NN NN O
as IN IN O
rhabdomyolysis NN NN O
only RB RB O
occurred VBD VBD O
after IN IN O
an DT DT O
increase NN NN O
in IN IN O
the DT DT O
dose NN NN O
of IN IN O
clarithromycin NN NN B-CHEM
. . . O

The DT DT O
patient NN NN O
developed VBN VBN O
raised VBD VBD O
cardiac JJ JJ O
biomarkers NNS NNS O
without IN IN O
any DT DT O
obvious JJ JJ O
cardiac JJ JJ O
issues NNS NNS O
, , , O
a DT DT O
phenomenon NN NN O
that WDT WDT O
has VBZ VBZ O
been VBN VBN O
linked VBN VBN O
to TO TO O
rhabdomyolysis VB VB O
previously RB RB O
. . . O

To TO TO O
date NN NN O
, , , O
there EX EX O
has VBZ VBZ O
been VBN VBN O
no DT DT O
reported VBN VBN O
effect NN NN O
of IN IN O
rhabdomyolysis NN NN O
on IN IN O
the DT DT O
structure NN NN O
and CC CC O
function NN NN O
of IN IN O
cardiac JJ JJ O
muscle NN NN O
. . . O

Clinicians NNPS NNPS O
need VBP VBP O
to TO TO O
be VB VB O
aware JJ JJ O
of IN IN O
prescribing VBG VBG O
concomitant JJ JJ O
medications NNS NNS O
that WDT WDT O
increase VBP VBP O
the DT DT O
risk NN NN O
of IN IN O
myopathy NN NN O
or CC CC O
inhibit NN NN O
the DT DT O
CYP3A4 NNP NNP O
enzyme NN NN O
. . . O

Our PRP$ PRP$ O
case NN NN O
suggests VBZ VBZ O
that IN IN O
troponin NN NN O
elevation NN NN O
could MD MD O
be VB VB O
associated VBN VBN O
with IN IN O
statin NN NN B-CHEM
induced JJ JJ O
rhabdomyolysis NN NN O
, , , O
which WDT WDT O
may MD MD O
warrant VB VB O
further JJ JJ O
studies NNS NNS O
. . . O

Characterization NNP NNP O
of IN IN O
a DT DT O
novel NN NN O
BCHE NNP NNP O
" '' '' O
silent NN NN O
" '' '' O
allele NN NN O
: : : O
point NN NN O
mutation NN NN O
( ( ( O
p NN NN O
. . . O
Val204Asp NNP NNP O
) ) ) O
causes NNS NNS O
loss NN NN O
of IN IN O
activity NN NN O
and CC CC O
prolonged JJ JJ O
apnea NN NN O
with IN IN O
suxamethonium NN NN B-CHEM
. . . O

Butyrylcholinesterase NNP NNP O
deficiency NN NN O
is VBZ VBZ O
characterized VBN VBN O
by IN IN O
prolonged JJ JJ O
apnea NN NN O
after IN IN O
the DT DT O
use NN NN O
of IN IN O
muscle NN NN O
relaxants NNS NNS O
( ( ( O
suxamethonium NN NN B-CHEM
or CC CC O
mivacurium NN NN B-CHEM
) ) ) O
in IN IN O
patients NNS NNS O
who WP WP O
have VBP VBP O
mutations NNS NNS O
in IN IN O
the DT DT O
BCHE NNP NNP O
gene NN NN O
. . . O

Here RB RB O
, , , O
we PRP PRP O
report VBP VBP O
a DT DT O
case NN NN O
of IN IN O
prolonged JJ JJ O
neuromuscular NN NN O
block NN NN O
after IN IN O
administration NN NN O
of IN IN O
suxamethonium NN NN B-CHEM
leading VBG VBG O
to TO TO O
the DT DT O
discovery NN NN O
of IN IN O
a DT DT O
novel NN NN O
BCHE NNP NNP O
variant NN NN O
( ( ( O
c SYM SYM O
. . . O
695T NN NN O
> NN NN O
A DT DT O
, , , O
p NN NN O
. . . O
Val204Asp NNP NNP O
) ) ) O
. . . O

Inhibition NNP NNP O
studies NNS NNS O
, , , O
kinetic JJ JJ O
analysis NN NN O
and CC CC O
molecular JJ JJ O
dynamics NNS NNS O
were VBD VBD O
undertaken VBN VBN O
to TO TO O
understand VB VB O
how WRB WRB O
this DT DT O
mutation NN NN O
disrupts VBZ VBZ O
the DT DT O
catalytic JJ JJ O
triad NN NN O
and CC CC O
determines VBZ VBZ O
a DT DT O
" '' '' O
silent JJ JJ O
" '' '' O
phenotype NN NN O
. . . O

Low NNP NNP O
activity NN NN O
of IN IN O
patient NN NN O
plasma NN NN O
butyrylcholinesterase NN NN O
with IN IN O
butyrylthiocholine NN NN B-CHEM
( ( ( O
BTC NNP NNP B-CHEM
) ) ) O
and CC CC O
benzoylcholine NN NN B-CHEM
, , , O
and CC CC O
values NNS NNS O
of IN IN O
dibucaine NN NN B-CHEM
and CC CC O
fluoride NN NN B-CHEM
numbers NNS NNS O
fit VBP VBP O
with IN IN O
heterozygous JJ JJ O
atypical JJ JJ O
silent NN NN O
genotype NN NN O
. . . O

Electrophoretic NNP NNP O
analysis NN NN O
of IN IN O
plasma NN NN O
BChE NNP NNP O
of IN IN O
the DT DT O
proband NN NN O
and CC CC O
his PRP$ PRP$ O
mother NN NN O
showed VBD VBD O
that IN IN O
patient NN NN O
has VBZ VBZ O
a DT DT O
reduced VBN VBN O
amount NN NN O
of IN IN O
tetrameric JJ JJ O
enzyme NN NN O
in IN IN O
plasma NN NN O
and CC CC O
that IN IN O
minor JJ JJ O
fast RB RB O
- : : O
moving VBG VBG O
BChE NNP NNP O
components NNS NNS O
: : : O
monomer NN NN O
, , , O
dimer NN NN O
, , , O
and CC CC O
monomer NN NN O
- - - O
albumin NN NN O
conjugate NN NN O
are VBP VBP O
missing VBG VBG O
. . . O

Kinetic NNP NNP O
analysis NN NN O
showed VBD VBD O
that IN IN O
the DT DT O
p NN NN O
. . . O
Val204Asp NNP NNP O
/ NN NN O
p NN NN O
. . . O
Asp70Gly NNP NNP O
- : : O
p NN NN O
. . . O
Ala539Thr NNP NNP O
BChE NNP NNP O
displays NNS NNS O
a DT DT O
pure JJ JJ O
Michaelian NNP NNP O
behavior NN NN O
with IN IN O
BTC NNP NNP B-CHEM
as IN IN O
the DT DT O
substrate NN NN O
. . . O

Both DT DT O
catalytic JJ JJ O
parameters NNS NNS O
Km NN NN O
= SYM SYM O
265 CD CD O
uM NN NN O
for IN IN O
BTC NNP NNP B-CHEM
, , , O
two CD CD O
times NNS NNS O
higher JJR JJR O
than IN IN O
that DT DT O
of IN IN O
the DT DT O
atypical JJ JJ O
enzyme NN NN O
, , , O
and CC CC O
a DT DT O
low JJ JJ O
Vmax NNP NNP O
are VBP VBP O
consistent JJ JJ O
with IN IN O
the DT DT O
absence NN NN O
of IN IN O
activity NN NN O
against IN IN O
suxamethonium NN NN B-CHEM
. . . O

Molecular NNP NNP O
dynamic JJ JJ O
( ( ( O
MD NNP NNP O
) ) ) O
simulations NNS NNS O
showed VBD VBD O
that IN IN O
the DT DT O
overall JJ JJ O
effect NN NN O
of IN IN O
the DT DT O
mutation NN NN O
p NN NN O
. . . O
Val204Asp NNP NNP O
is VBZ VBZ O
disruption NN NN O
of IN IN O
hydrogen NN NN B-CHEM
bonding VBG VBG O
between IN IN O
Gln223 NNP NNP O
and CC CC O
Glu441 NNP NNP O
, , , O
leading VBG VBG O
Ser198 NNP NNP O
and CC CC O
His438 NNP NNP O
to TO TO O
move VB VB O
away RB RB O
from IN IN O
each DT DT O
other JJ JJ O
with IN IN O
subsequent JJ JJ O
disruption NN NN O
of IN IN O
the DT DT O
catalytic JJ JJ O
triad NN NN O
functionality NN NN O
regardless RB RB O
of IN IN O
the DT DT O
type NN NN O
of IN IN O
substrate NN NN O
. . . O

MD NNP NNP O
also RB RB O
showed VBD VBD O
that IN IN O
the DT DT O
enzyme NN NN O
volume NN NN O
is VBZ VBZ O
increased VBN VBN O
, , , O
suggesting VBG VBG O
a DT DT O
pre NN NN O
- - - O
denaturation NN NN O
state NN NN O
. . . O

This DT DT O
fits VBZ VBZ O
with IN IN O
the DT DT O
reduced JJ JJ O
concentration NN NN O
of IN IN O
p NN NN O
. . . O
Ala204Asp NNP NNP O
/ NN NN O
p NN NN O
. . . O
Asp70Gly NNP NNP O
- : : O
p NN NN O
. . . O
Ala539Thr NNP NNP O
tetrameric JJ JJ O
enzyme NN NN O
in IN IN O
the DT DT O
plasma NN NN O
and CC CC O
non NN NN O
- - - O
detectable JJ JJ O
fast RB RB O
moving VBG VBG O
- - - O
bands NNS NNS O
on IN IN O
electrophoresis NNS NNS O
gels NNS NNS O
. . . O

Delayed NNP NNP O
anemia NN NN O
after IN IN O
treatment NN NN O
with IN IN O
injectable JJ JJ O
artesunate NN NN B-CHEM
in IN IN O
the DT DT O
Democratic JJ JJ O
Republic NNP NNP O
of IN IN O
the DT DT O
Congo NNP NNP O
: : : O
a DT DT O
manageable JJ JJ O
issue NN NN O
. . . O

Cases NNS NNS O
of IN IN O
delayed JJ JJ O
hemolytic JJ JJ O
anemia NN NN O
have VBP VBP O
been VBN VBN O
described VBN VBN O
after IN IN O
treatment NN NN O
with IN IN O
injectable JJ JJ O
artesunate NN NN B-CHEM
, , , O
the DT DT O
current JJ JJ O
World NNP NNP O
Health NNP NNP O
Organization NNP NNP O
( ( ( O
WHO WP WP O
) ) ) O
- : : O
recommended VBD VBD O
first JJ JJ O
- - - O
line NN NN O
drug NN NN O
for IN IN O
the DT DT O
treatment NN NN O
of IN IN O
severe JJ JJ O
malaria NN NN O
. . . O

A DT DT O
total NN NN O
of IN IN O
350 CD CD O
patients NNS NNS O
( ( ( O
215 CD CD O
[ NN NN O
61 CD CD O
. . . O
4 CD CD O
% NN NN O
] NN NN O
< NN NN O
5 CD CD O
years NNS NNS O
of IN IN O
age NN NN O
and CC CC O
135 CD CD O
[ NN NN O
38 CD CD O
. . . O
6 CD CD O
% NN NN O
] NN NN O
> NN NN O
5 CD CD O
years NNS NNS O
of IN IN O
age NN NN O
) ) ) O
were VBD VBD O
followed VBN VBN O
- : : O
up RP RP O
after IN IN O
treatment NN NN O
with IN IN O
injectable JJ JJ O
artesunate NN NN B-CHEM
for IN IN O
severe JJ JJ O
malaria NN NN O
in IN IN O
hospitals NNS NNS O
and CC CC O
health NN NN O
centers NNS NNS O
of IN IN O
the DT DT O
Democratic JJ JJ O
Republic NNP NNP O
of IN IN O
the DT DT O
Congo NNP NNP O
. . . O

Complete JJ JJ O
series NN NN O
of IN IN O
hemoglobin NN NN O
( ( ( O
Hb NNP NNP O
) ) ) O
measurements NNS NNS O
were VBD VBD O
available JJ JJ O
for IN IN O
201 CD CD O
patients NNS NNS O
. . . O

A DT DT O
decrease NN NN O
in IN IN O
Hb NNP NNP O
levels NNS NNS O
between IN IN O
2 CD CD O
and CC CC O
5 CD CD O
g SYM SYM O
/ NN NN O
dL NN NN O
was VBD VBD O
detected VBN VBN O
in IN IN O
23 CD CD O
( ( ( O
11 CD CD O
. . . O
4 CD CD O
% NN NN O
) ) ) O
patients NNS NNS O
during IN IN O
the DT DT O
follow VB VB O
- - - O
up RP RP O
period NN NN O
. . . O

For IN IN O
five CD CD O
patients NNS NNS O
, , , O
Hb NNP NNP O
levels NNS NNS O
decreased VBD VBD O
below IN IN O
5 CD CD O
g SYM SYM O
/ NN NN O
dL NN NN O
during IN IN O
at IN IN O
least JJS JJS O
one CD CD O
follow VB VB O
- - - O
up RP RP O
visit NN NN O
. . . O

All DT DT O
cases NNS NNS O
of IN IN O
delayed JJ JJ O
anemia NN NN O
were VBD VBD O
clinically RB RB O
manageable JJ JJ O
and CC CC O
resolved VBN VBN O
within IN IN O
one CD CD O
month NN NN O
. . . O

Regulation NNP NNP O
of IN IN O
signal NN NN O
transducer NN NN O
and CC CC O
activator NN NN O
of IN IN O
transcription NN NN O
3 CD CD O
and CC CC O
apoptotic JJ JJ O
pathways NNS NNS O
by IN IN O
betaine NN NN B-CHEM
attenuates NNS NNS O
isoproterenol NN NN B-CHEM
- : : O
induced JJ JJ O
acute JJ JJ O
myocardial NN NN O
injury NN NN O
in IN IN O
rats NNS NNS O
. . . O

The DT DT O
present JJ JJ O
study NN NN O
was VBD VBD O
designed VBN VBN O
to TO TO O
investigate VB VB O
the DT DT O
cardioprotective JJ JJ O
effects NNS NNS O
of IN IN O
betaine NN NN B-CHEM
on IN IN O
acute JJ JJ O
myocardial NN NN O
ischemia NN NN O
induced VBN VBN O
experimentally RB RB O
in IN IN O
rats NNS NNS O
focusing VBG VBG O
on IN IN O
regulation NN NN O
of IN IN O
signal NN NN O
transducer NN NN O
and CC CC O
activator NN NN O
of IN IN O
transcription NN NN O
3 CD CD O
( ( ( O
STAT3 NNP NNP O
) ) ) O
and CC CC O
apoptotic JJ JJ O
pathways NNS NNS O
as IN IN O
the DT DT O
potential JJ JJ O
mechanism NN NN O
underlying VBG VBG O
the DT DT O
drug NN NN O
effect NN NN O
. . . O

Male NNP NNP O
Sprague NNP NNP O
Dawley NNP NNP O
rats NNS NNS O
were VBD VBD O
treated VBN VBN O
with IN IN O
betaine NN NN B-CHEM
( ( ( O
100 CD CD O
, , , O
200 CD CD O
, , , O
and CC CC O
400 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
orally RB RB O
for IN IN O
40 CD CD O
days NNS NNS O
. . . O

Acute JJ JJ O
myocardial JJ JJ O
ischemic JJ JJ O
injury NN NN O
was VBD VBD O
induced VBN VBN O
in IN IN O
rats NNS NNS O
by IN IN O
subcutaneous JJ JJ O
injection NN NN O
of IN IN O
isoproterenol NN NN B-CHEM
( ( ( O
85 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
, , , O
for IN IN O
two CD CD O
consecutive JJ JJ O
days NNS NNS O
. . . O

Serum NNP NNP O
cardiac JJ JJ O
marker NN NN O
enzyme NN NN O
, , , O
histopathological JJ JJ O
variables NNS NNS O
and CC CC O
expression NN NN O
of IN IN O
protein NN NN O
levels NNS NNS O
were VBD VBD O
analyzed VBN VBN O
. . . O

Oral NNP NNP O
administration NN NN O
of IN IN O
betaine NN NN B-CHEM
( ( ( O
200 CD CD O
and CC CC O
400 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
significantly RB RB O
reduced VBD VBD O
the DT DT O
level NN NN O
of IN IN O
cardiac JJ JJ O
marker NN NN O
enzyme NN NN O
in IN IN O
the DT DT O
serum NN NN O
and CC CC O
prevented VBD VBD O
left VBN VBN O
ventricular NN NN O
remodeling NN NN O
. . . O

Western JJ JJ O
blot NN NN O
analysis NN NN O
showed VBD VBD O
that IN IN O
isoproterenol JJ JJ B-CHEM
- : : O
induced JJ JJ O
phosphorylation NN NN O
of IN IN O
STAT3 NNP NNP O
was VBD VBD O
maintained VBN VBN O
or CC CC O
further RBR RBR O
enhanced VBN VBN O
by IN IN O
betaine NN NN B-CHEM
treatment NN NN O
in IN IN O
myocardium NN NN O
. . . O

Furthermore RB RB O
, , , O
betaine NN NN B-CHEM
( ( ( O
200 CD CD O
and CC CC O
400 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
treatment NN NN O
increased VBD VBD O
the DT DT O
ventricular JJ JJ O
expression NN NN O
of IN IN O
Bcl NNP NNP O
- : : O
2 CD CD O
and CC CC O
reduced VBD VBD O
the DT DT O
level NN NN O
of IN IN O
Bax NNP NNP O
, , , O
therefore RB RB O
causing VBG VBG O
a DT DT O
significant JJ JJ O
increase NN NN O
in IN IN O
the DT DT O
ratio NN NN O
of IN IN O
Bcl NNP NNP O
- - - O
2 CD CD O
/ NN NN O
Bax NNP NNP O
. . . O

The DT DT O
protective JJ JJ O
role NN NN O
of IN IN O
betaine NN NN B-CHEM
on IN IN O
myocardial NN NN O
damage NN NN O
was VBD VBD O
further RB RB O
confirmed VBN VBN O
by IN IN O
histopathological JJ JJ O
examination NN NN O
. . . O

In IN IN O
summary NN NN O
, , , O
our PRP$ PRP$ O
results NNS NNS O
showed VBD VBD O
that IN IN O
betaine NN NN B-CHEM
pretreatment NN NN O
attenuated VBN VBN O
isoproterenol JJ JJ B-CHEM
- - - O
induced JJ JJ O
acute JJ JJ O
myocardial NN NN O
ischemia NN NN O
via IN IN O
the DT DT O
regulation NN NN O
of IN IN O
STAT3 NNP NNP O
and CC CC O
apoptotic JJ JJ O
pathways NNS NNS O
. . . O

Quetiapine NNP NNP B-CHEM
- : : O
induced VBN VBN O
neutropenia NN NN O
in IN IN O
a DT DT O
bipolar JJ JJ O
patient NN NN O
with IN IN O
hepatocellular NN NN O
carcinoma NN NN O
. . . O

OBJECTIVE NNP NNP O
: : : O
Quetiapine NNP NNP B-CHEM
is VBZ VBZ O
a DT DT O
dibenzothiazepine NN NN O
derivative JJ JJ O
, , , O
similar JJ JJ O
to TO TO O
clozapine VB VB B-CHEM
, , , O
which WDT WDT O
has VBZ VBZ O
the DT DT O
highest JJS JJS O
risk NN NN O
of IN IN O
causing VBG VBG O
blood NN NN O
dyscrasias NNS NNS O
, , , O
especially RB RB O
neutropenia NN NN O
. . . O

There EX EX O
are VBP VBP O
some DT DT O
case NN NN O
reports NNS NNS O
about IN IN O
this DT DT O
side NN NN O
effect NN NN O
of IN IN O
quetiapine NN NN B-CHEM
, , , O
but CC CC O
possible JJ JJ O
risk NN NN O
factors NNS NNS O
are VBP VBP O
seldom RB RB O
discussed VBN VBN O
and CC CC O
identified VBN VBN O
. . . O

A DT DT O
case NN NN O
of IN IN O
a DT DT O
patient NN NN O
with IN IN O
hepatocellular NN NN O
carcinoma NN NN O
that WDT WDT O
developed VBD VBD O
neutropenia RB RB O
after IN IN O
treatment NN NN O
with IN IN O
quetiapine NN NN B-CHEM
is VBZ VBZ O
described VBN VBN O
here RB RB O
. . . O

CASE NN NN O
REPORT NNP NNP O
: : : O
A DT DT O
62 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
Taiwanese NNP NNP O
widow NN NN O
with IN IN O
bipolar JJ JJ O
disorder NN NN O
was VBD VBD O
diagnosed VBN VBN O
with IN IN O
hepatocellular NN NN O
carcinoma NN NN O
at IN IN O
age NN NN O
60 CD CD O
. . . O

She PRP PRP O
developed VBD VBD O
leucopenia NN NN O
after IN IN O
being VBG VBG O
treated VBN VBN O
with IN IN O
quetiapine NN NN B-CHEM
. . . O

After IN IN O
quetiapine NN NN B-CHEM
was VBD VBD O
discontinued VBN VBN O
, , , O
her PRP$ PRP$ O
white JJ JJ O
blood NN NN O
cell NN NN O
count NN NN O
returned VBD VBD O
to TO TO O
normal JJ JJ O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Although IN IN O
neutropenia NN NN O
is VBZ VBZ O
not RB RB O
a DT DT O
common JJ JJ O
side NN NN O
effect NN NN O
of IN IN O
quetiapine NN NN B-CHEM
, , , O
physicians NNS NNS O
should MD MD O
be VB VB O
cautious JJ JJ O
about IN IN O
its PRP$ PRP$ O
presentation NN NN O
and CC CC O
associated VBN VBN O
risk NN NN O
factors NNS NNS O
. . . O

Hepatic NNP NNP O
dysfunction NN NN O
may MD MD O
be VB VB O
one CD CD O
of IN IN O
the DT DT O
possible JJ JJ O
risk NN NN O
factors NNS NNS O
, , , O
and CC CC O
concomitant NN NN O
fever NN NN O
may MD MD O
be VB VB O
a DT DT O
diagnostic JJ JJ O
marker NN NN O
for IN IN O
adverse JJ JJ O
reaction NN NN O
to TO TO O
quetiapine VB VB B-CHEM
. . . O

Lateral NNP NNP O
antebrachial JJ JJ O
cutaneous JJ JJ O
neuropathy NN NN O
after IN IN O
steroid NN NN B-CHEM
injection NN NN O
at IN IN O
lateral NN NN O
epicondyle NN NN O
. . . O

BACKGROUND NNP NNP O
AND CC CC O
OBJECTIVES NNP NNP O
: : : O
This DT DT O
report NN NN O
aimed VBN VBN O
to TO TO O
present VB VB O
a DT DT O
case NN NN O
of IN IN O
lateral NN NN O
antebrachial JJ JJ O
cutaneous JJ JJ O
neuropathy NN NN O
( ( ( O
LACNP NNP NNP O
) ) ) O
that WDT WDT O
occurred VBD VBD O
after IN IN O
a DT DT O
steroid NN NN B-CHEM
injection NN NN O
in IN IN O
the DT DT O
lateral NN NN O
epicondyle NN NN O
to TO TO O
treat VB VB O
lateral NN NN O
epicondylitis NNS NNS O
in IN IN O
a DT DT O
40 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
woman NN NN O
. . . O

MATERIAL NN NN O
AND CC CC O
METHOD NNP NNP O
: : : O
A DT DT O
40 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
woman NN NN O
presented VBN VBN O
with IN IN O
decreased VBD VBD O
sensation NN NN O
and CC CC O
paresthesia NN NN O
over IN IN O
her PRP$ PRP$ O
right JJ JJ O
lateral NN NN O
forearm NN NN O
; : : O
the DT DT O
paresthesia NN NN O
had VBD VBD O
occurred VBN VBN O
after IN IN O
a DT DT O
steroid NN NN B-CHEM
injection NN NN O
in IN IN O
the DT DT O
right NN NN O
lateral NN NN O
epicondyle NN NN O
3 CD CD O
months NNS NNS O
before IN IN O
. . . O

Her PRP$ PRP$ O
sensation NN NN O
of IN IN O
light JJ JJ O
touch NN NN O
and CC CC O
pain NN NN O
was VBD VBD O
diminished VBN VBN O
over IN IN O
the DT DT O
lateral NN NN O
side NN NN O
of IN IN O
the DT DT O
right JJ JJ O
forearm NN NN O
and CC CC O
wrist NN NN O
area NN NN O
. . . O

RESULTS NNS NNS O
: : : O
The DT DT O
sensory JJ JJ O
action NN NN O
potential JJ JJ O
amplitude NN NN O
of IN IN O
the DT DT O
right NN NN O
lateral NN NN O
antebrachial JJ JJ O
cutaneous JJ JJ O
nerve NN NN O
( ( ( O
LACN NNP NNP O
) ) ) O
( ( ( O
6 CD CD O
. . . O
2 CD CD O
uV NN NN O
) ) ) O
was VBD VBD O
lower JJR JJR O
than IN IN O
that DT DT O
of IN IN O
the DT DT O
left NN NN O
( ( ( O
13 CD CD O
. . . O
1 CD CD O
uV NN NN O
) ) ) O
. . . O

The DT DT O
difference NN NN O
of IN IN O
amplitude NN NN O
between IN IN O
both DT DT O
sides NNS NNS O
was VBD VBD O
significant JJ JJ O
because IN IN O
there EX EX O
was VBD VBD O
more JJR JJR O
than IN IN O
a DT DT O
50 CD CD O
% NN NN O
reduction NN NN O
. . . O

She PRP PRP O
was VBD VBD O
diagnosed VBN VBN O
with IN IN O
right NN NN O
LACNP NNP NNP O
( ( ( O
mainly RB RB O
axonal JJ JJ O
involvement NN NN O
) ) ) O
on IN IN O
the DT DT O
basis NN NN O
of IN IN O
the DT DT O
clinical JJ JJ O
manifestation NN NN O
and CC CC O
the DT DT O
electrodiagnostic JJ JJ O
findings NNS NNS O
. . . O

Her PRP$ PRP$ O
symptoms NNS NNS O
improved VBN VBN O
through IN IN O
physical JJ JJ O
therapy NN NN O
but CC CC O
persisted VBD VBD O
to TO TO O
some DT DT O
degree NN NN O
. . . O

CONCLUSION NNP NNP O
: : : O
This DT DT O
report NN NN O
describes VBZ VBZ O
the DT DT O
case NN NN O
of IN IN O
a DT DT O
woman NN NN O
with IN IN O
LACNP NNP NNP O
that IN IN O
developed VBD VBD O
after IN IN O
a DT DT O
steroid NN NN B-CHEM
injection NN NN O
for IN IN O
the DT DT O
treatment NN NN O
of IN IN O
lateral NN NN O
epicondylitis NNS NNS O
. . . O

An DT DT O
electrodiagnostic JJ JJ O
study NN NN O
, , , O
including VBG VBG O
a DT DT O
nerve NN NN O
conduction NN NN O
study NN NN O
of IN IN O
the DT DT O
LACN NNP NNP O
, , , O
was VBD VBD O
helpful JJ JJ O
to TO TO O
diagnose VB VB O
right NN NN O
LACNP NNP NNP O
and CC CC O
to TO TO O
find VB VB O
the DT DT O
passage NN NN O
of IN IN O
the DT DT O
LACN NNP NNP O
on IN IN O
the DT DT O
lateral NN NN O
epicondyle NN NN O
. . . O

Curcumin NNP NNP B-CHEM
prevents NNS NNS O
maleate VBP VBP B-CHEM
- : : O
induced JJ JJ O
nephrotoxicity NN NN O
: : : O
relation NN NN O
to TO TO O
hemodynamic JJ JJ O
alterations NNS NNS O
, , , O
oxidative JJ JJ O
stress NN NN O
, , , O
mitochondrial JJ JJ O
oxygen NN NN B-CHEM
consumption NN NN O
and CC CC O
activity NN NN O
of IN IN O
respiratory NN NN O
complex JJ JJ O
I PRP PRP O
. . . O

The DT DT O
potential JJ JJ O
protective JJ JJ O
effect NN NN O
of IN IN O
the DT DT O
dietary JJ JJ O
antioxidant NN NN O
curcumin NN NN B-CHEM
( ( ( O
120 CD CD O
mg NN NN O
/ NN NN O
Kg NNP NNP O
/ NN NN O
day NN NN O
for IN IN O
6 CD CD O
days NNS NNS O
) ) ) O
against IN IN O
the DT DT O
renal JJ JJ O
injury NN NN O
induced VBN VBN O
by IN IN O
maleate NN NN B-CHEM
was VBD VBD O
evaluated VBN VBN O
. . . O

Tubular NNP NNP O
proteinuria NN NN O
and CC CC O
oxidative JJ JJ O
stress NN NN O
were VBD VBD O
induced VBN VBN O
by IN IN O
a DT DT O
single JJ JJ O
injection NN NN O
of IN IN O
maleate NN NN B-CHEM
( ( ( O
400 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
in IN IN O
rats NNS NNS O
. . . O

Maleate NNP NNP B-CHEM
- : : O
induced JJ JJ O
renal JJ JJ O
injury NN NN O
included VBD VBD O
increase NN NN O
in IN IN O
renal NN NN O
vascular NN NN O
resistance NN NN O
and CC CC O
in IN IN O
the DT DT O
urinary JJ JJ O
excretion NN NN O
of IN IN O
total JJ JJ O
protein NN NN O
, , , O
glucose NN NN B-CHEM
, , , O
sodium NN NN B-CHEM
, , , O
neutrophil NN NN O
gelatinase NN NN O
- - - O
associated VBN VBN O
lipocalin NN NN O
( ( ( O
NGAL NNP NNP O
) ) ) O
and CC CC O
N NNP NNP O
- : : O
acetyl NN NN O
b SYM SYM O
- - - O
D NNP NNP O
- : : O
glucosaminidase NN NN O
( ( ( O
NAG NNP NNP O
) ) ) O
, , , O
upregulation NN NN O
of IN IN O
kidney NN NN O
injury NN NN O
molecule NN NN O
( ( ( O
KIM NNP NNP O
) ) ) O
- : : O
1 CD CD O
, , , O
decrease NN NN O
in IN IN O
renal JJ JJ O
blood NN NN O
flow NN NN O
and CC CC O
claudin NN NN O
- - - O
2 CD CD O
expression NN NN O
besides NNS NNS O
of IN IN O
necrosis NN NN O
and CC CC O
apoptosis NN NN O
of IN IN O
tubular NN NN O
cells NNS NNS O
on IN IN O
24 CD CD O
h NN NN O
. . . O

Oxidative NNP NNP O
stress NN NN O
was VBD VBD O
determined VBN VBN O
by IN IN O
measuring VBG VBG O
the DT DT O
oxidation NN NN O
of IN IN O
lipids NNS NNS O
and CC CC O
proteins NNS NNS O
and CC CC O
diminution NN NN O
in IN IN O
renal JJ JJ O
Nrf2 NNP NNP O
levels NNS NNS O
. . . O

Studies NNS NNS O
were VBD VBD O
also RB RB O
conducted VBN VBN O
in IN IN O
renal JJ JJ O
epithelial NN NN O
LLC NNP NNP O
- : : O
PK1 NNP NNP O
cells NNS NNS O
and CC CC O
in IN IN O
mitochondria NN NN O
isolated VBN VBN O
from IN IN O
kidneys NNS NNS O
of IN IN O
all PDT PDT O
the DT DT O
experimental JJ JJ O
groups NNS NNS O
. . . O

Maleate NNP NNP B-CHEM
induced VBD VBD O
cell NN NN O
damage NN NN O
and CC CC O
reactive JJ JJ O
oxygen NN NN B-CHEM
species NNS NNS O
( ( ( O
ROS NNP NNP O
) ) ) O
production NN NN O
in IN IN O
LLC NNP NNP O
- : : O
PK1 NNP NNP O
cells NNS NNS O
in IN IN O
culture NN NN O
. . . O

In IN IN O
addition NN NN O
, , , O
maleate NN NN B-CHEM
treatment NN NN O
reduced VBD VBD O
oxygen NN NN B-CHEM
consumption NN NN O
in IN IN O
ADP NNP NNP B-CHEM
- - - O
stimulated JJ JJ O
mitochondria NN NN O
and CC CC O
diminished VBN VBN O
respiratory NN NN O
control NN NN O
index NN NN O
when WRB WRB O
using VBG VBG O
malate NN NN B-CHEM
/ NN NN O
glutamate NN NN B-CHEM
as IN IN O
substrate NN NN O
. . . O

The DT DT O
activities NNS NNS O
of IN IN O
both DT DT O
complex NN NN O
I PRP PRP O
and CC CC O
aconitase NN NN O
were VBD VBD O
also RB RB O
diminished VBN VBN O
. . . O

All DT DT O
the DT DT O
above JJ JJ O
- - - O
described JJ JJ O
alterations NNS NNS O
were VBD VBD O
prevented VBN VBN O
by IN IN O
curcumin NN NN B-CHEM
. . . O

It PRP PRP O
is VBZ VBZ O
concluded VBN VBN O
that IN IN O
curcumin NN NN B-CHEM
is VBZ VBZ O
able JJ JJ O
to TO TO O
attenuate VB VB O
in IN IN O
vivo NN NN O
maleate NN NN B-CHEM
- : : O
induced JJ JJ O
nephropathy NN NN O
and CC CC O
in IN IN O
vitro NN NN O
cell NN NN O
damage NN NN O
. . . O

The DT DT O
in IN IN O
vivo NN NN O
protection NN NN O
was VBD VBD O
associated VBN VBN O
to TO TO O
the DT DT O
prevention NN NN O
of IN IN O
oxidative JJ JJ O
stress NN NN O
and CC CC O
preservation NN NN O
of IN IN O
mitochondrial JJ JJ O
oxygen NN NN B-CHEM
consumption NN NN O
and CC CC O
activity NN NN O
of IN IN O
respiratory NN NN O
complex JJ JJ O
I PRP PRP O
, , , O
and CC CC O
the DT DT O
in IN IN O
vitro NN NN O
protection NN NN O
was VBD VBD O
associated VBN VBN O
to TO TO O
the DT DT O
prevention NN NN O
of IN IN O
ROS NNP NNP O
production NN NN O
. . . O

Anticonvulsant NNP NNP O
actions NNS NNS O
of IN IN O
MK NNP NNP B-CHEM
- : : I-CHEM
801 CD CD I-CHEM
on IN IN O
the DT DT O
lithium NN NN B-CHEM
- - - O
pilocarpine NN NN B-CHEM
model NN NN O
of IN IN O
status NN NN O
epilepticus NN NN O
in IN IN O
rats NNS NNS O
. . . O

MK NNP NNP B-CHEM
- : : I-CHEM
801 CD CD I-CHEM
, , , O
a DT DT O
noncompetitive JJ JJ O
N NNP NNP B-CHEM
- : : I-CHEM
methyl NN NN I-CHEM
- : : I-CHEM
D NNP NNP I-CHEM
- : : I-CHEM
aspartate NN NN I-CHEM
( ( ( O
NMDA NNP NNP B-CHEM
) ) ) O
receptor NN NN O
antagonist NN NN O
, , , O
was VBD VBD O
tested VBN VBN O
for IN IN O
anticonvulsant JJ JJ O
effects NNS NNS O
in IN IN O
rats NNS NNS O
using VBG VBG O
two CD CD O
seizure NN NN O
models NNS NNS O
, , , O
coadministration NN NN O
of IN IN O
lithium NN NN B-CHEM
and CC CC O
pilocarpine NN NN B-CHEM
and CC CC O
administration NN NN O
of IN IN O
a DT DT O
high JJ JJ O
dose NN NN O
of IN IN O
pilocarpine NN NN B-CHEM
alone RB RB O
. . . O

Three CD CD O
major JJ JJ O
results NNS NNS O
are VBP VBP O
reported VBN VBN O
. . . O

First LS LS O
, , , O
pretreatment NN NN O
with IN IN O
MK NNP NNP B-CHEM
- : : I-CHEM
801 CD CD I-CHEM
produced VBD VBD O
an DT DT O
effective JJ JJ O
and CC CC O
dose VB VB O
- : : O
dependent JJ JJ O
anticonvulsant JJ JJ O
action NN NN O
with IN IN O
the DT DT O
lithium NN NN B-CHEM
- - - O
pilocarpine NN NN B-CHEM
model NN NN O
but CC CC O
not RB RB O
with IN IN O
rats NNS NNS O
treated VBN VBN O
with IN IN O
pilocarpine NN NN B-CHEM
alone RB RB O
, , , O
suggesting VBG VBG O
that IN IN O
different JJ JJ O
biochemical JJ JJ O
mechanisms NNS NNS O
control NN NN O
seizures NNS NNS O
in IN IN O
these DT DT O
two CD CD O
models NNS NNS O
. . . O

Second JJ JJ O
, , , O
the DT DT O
anticonvulsant JJ JJ O
effect NN NN O
of IN IN O
MK NNP NNP B-CHEM
- : : I-CHEM
801 CD CD I-CHEM
in IN IN O
the DT DT O
lithium NN NN B-CHEM
- - - O
pilocarpine NN NN B-CHEM
model NN NN O
only RB RB O
occurred VBD VBD O
after IN IN O
initial JJ JJ O
periods NNS NNS O
of IN IN O
seizure NN NN O
activity NN NN O
. . . O

This DT DT O
observation NN NN O
is VBZ VBZ O
suggested VBN VBN O
to TO TO O
be VB VB O
an DT DT O
in IN IN O
vivo NN NN O
demonstration NN NN O
of IN IN O
the DT DT O
conclusion NN NN O
derived VBN VBN O
from IN IN O
in IN IN O
vitro NN NN O
experiments NNS NNS O
that WDT WDT O
MK NNP NNP B-CHEM
- : : I-CHEM
801 CD CD I-CHEM
binding JJ JJ O
requires VBZ VBZ O
agonist JJ JJ O
- : : O
induced JJ JJ O
opening NN NN O
of IN IN O
the DT DT O
channel NN NN O
sites NNS NNS O
of IN IN O
the DT DT O
NMDA NNP NNP B-CHEM
receptor NN NN O
. . . O

Third NNP NNP O
, , , O
although IN IN O
it PRP PRP O
is VBZ VBZ O
relatively RB RB O
easy JJ JJ O
to TO TO O
block VB VB O
seizures NNS NNS O
induced VBN VBN O
by IN IN O
lithium NN NN B-CHEM
and CC CC O
pilocarpine NN NN B-CHEM
by IN IN O
administration NN NN O
of IN IN O
anticonvulsants NNS NNS O
prior RB RB O
to TO TO O
pilocarpine VB VB B-CHEM
, , , O
it PRP PRP O
is VBZ VBZ O
more RBR RBR O
difficult JJ JJ O
to TO TO O
terminate VB VB O
ongoing JJ JJ O
status NN NN O
epilepticus NN NN O
and CC CC O
block NN NN O
the DT DT O
lethality NN NN O
of IN IN O
the DT DT O
seizures NNS NNS O
. . . O

Administration NNP NNP O
of IN IN O
MK NNP NNP B-CHEM
- : : I-CHEM
801 CD CD I-CHEM
30 CD CD O
or CC CC O
60 CD CD O
min NN NN O
after IN IN O
pilocarpine NN NN B-CHEM
, , , O
i NNP NNP O
. . . O
e SYM SYM O
. . . O
, , , O
during IN IN O
status NN NN O
epilepticus NN NN O
, , , O
gradually RB RB O
reduced VBN VBN O
electrical JJ JJ O
and CC CC O
behavioral JJ JJ O
seizure NN NN O
activity NN NN O
and CC CC O
greatly RB RB O
enhanced VBD VBD O
the DT DT O
survival NN NN O
rate NN NN O
. . . O

These DT DT O
results NNS NNS O
suggest VBP VBP O
that DT DT O
activation NN NN O
of IN IN O
NMDA NNP NNP B-CHEM
receptors NNS NNS O
plays VBZ VBZ O
an DT DT O
important JJ JJ O
role NN NN O
in IN IN O
status NN NN O
epilepticus NN NN O
and CC CC O
brain NN NN O
damage NN NN O
in IN IN O
the DT DT O
lithium NN NN B-CHEM
- - - O
pilocarpine NN NN B-CHEM
model NN NN O
. . . O

This DT DT O
was VBD VBD O
further RBR RBR O
supported VBN VBN O
by IN IN O
results NNS NNS O
showing VBG VBG O
that IN IN O
nonconvulsive JJ JJ O
doses NNS NNS O
of IN IN O
NMDA NNP NNP B-CHEM
and CC CC O
pilocarpine NN NN B-CHEM
were VBD VBD O
synergistic JJ JJ O
, , , O
resulting VBG VBG O
in IN IN O
status NN NN O
epilepticus NN NN O
and CC CC O
subsequent JJ JJ O
mortality NN NN O
. . . O

Continuous NNP NNP O
infusion NN NN O
tobramycin NN NN B-CHEM
combined VBN VBN O
with IN IN O
carbenicillin NN NN B-CHEM
for IN IN O
infections NNS NNS O
in IN IN O
cancer NN NN O
patients NNS NNS O
. . . O

The DT DT O
cure NN NN O
rate NN NN O
of IN IN O
infections NNS NNS O
in IN IN O
cancer NN NN O
patients NNS NNS O
is VBZ VBZ O
adversely RB RB O
affected VBN VBN O
by IN IN O
neutropenia NN NN O
( ( ( O
less JJR JJR O
than IN IN O
1 CD CD O
, , , O
000 CD CD O
/ NN NN O
mm3 NN NN O
) ) ) O
. . . O

In IN IN O
particular JJ JJ O
, , , O
patients NNS NNS O
with IN IN O
severe JJ JJ O
neutropenia NN NN O
( ( ( O
less JJR JJR O
than IN IN O
100 CD CD O
/ NN NN O
mm3 NN NN O
) ) ) O
have VBP VBP O
shown VBN VBN O
a DT DT O
poor JJ JJ O
response NN NN O
to TO TO O
antibiotics NNS NNS O
. . . O

To TO TO O
overcome VB VB O
the DT DT O
adverse JJ JJ O
effects NNS NNS O
of IN IN O
neutropenia NN NN O
, , , O
tobramycin NN NN B-CHEM
was VBD VBD O
given VBN VBN O
by IN IN O
continuous JJ JJ O
infusion NN NN O
and CC CC O
combined VBN VBN O
with IN IN O
intermittent JJ JJ O
carbenicillin NN NN B-CHEM
. . . O

Tobramycin NNP NNP B-CHEM
was VBD VBD O
given VBN VBN O
to TO TO O
a DT DT O
total JJ JJ O
daily JJ JJ O
dose NN NN O
of IN IN O
300 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
and CC CC O
carbenicillin NN NN B-CHEM
was VBD VBD O
given VBN VBN O
at IN IN O
a DT DT O
dose NN NN O
of IN IN O
5 CD CD O
gm NN NN O
every DT DT O
four CD CD O
hours NNS NNS O
. . . O

There EX EX O
were VBD VBD O
125 CD CD O
infectious JJ JJ O
episodes NNS NNS O
in IN IN O
116 CD CD O
cancer NN NN O
patients NNS NNS O
receiving VBG VBG O
myelosuppressive JJ JJ O
chemotherapy NN NN O
. . . O

The DT DT O
overall JJ JJ O
cure NN NN O
rate NN NN O
was VBD VBD O
70 CD CD O
% NN NN O
. . . O

Pneumonia NNP NNP O
was VBD VBD O
the DT DT O
most RBS RBS O
common JJ JJ O
infection NN NN O
and CC CC O
61 CD CD O
% NN NN O
of IN IN O
59 CD CD O
episodes NNS NNS O
were VBD VBD O
cured VBN VBN O
. . . O

Gram NNP NNP O
- : : O
negative JJ JJ O
bacilli NN NN O
were VBD VBD O
the DT DT O
most RBS RBS O
common JJ JJ O
causative JJ JJ O
organisms NNS NNS O
and CC CC O
69 CD CD O
% NN NN O
of IN IN O
these DT DT O
infections NNS NNS O
were VBD VBD O
cured VBN VBN O
. . . O

The DT DT O
most RBS RBS O
common JJ JJ O
pathogen NN NN O
was VBD VBD O
Klebsiella NNP NNP O
pneumoniae NN NN O
and CC CC O
this DT DT O
, , , O
together RB RB O
with IN IN O
Escherichia NNP NNP O
coli NNS NNS O
and CC CC O
Pseudomonas NNP NNP O
aeruginosa NN NN O
, , , O
accounted VBD VBD O
for IN IN O
74 CD CD O
% NN NN O
of IN IN O
all DT DT O
gram NN NN O
- - - O
negative JJ JJ O
bacillary JJ JJ O
infections NNS NNS O
. . . O

Response NNP NNP O
was VBD VBD O
not RB RB O
influenced VBN VBN O
by IN IN O
the DT DT O
initial JJ JJ O
neutrophil NN NN O
count NN NN O
, , , O
with IN IN O
a DT DT O
62 CD CD O
% NN NN O
cure NN NN O
rate NN NN O
for IN IN O
39 CD CD O
episodes NNS NNS O
associated VBN VBN O
with IN IN O
severe JJ JJ O
neutropenia NN NN O
. . . O

However RB RB O
, , , O
failure NN NN O
of IN IN O
the DT DT O
neutrophil NN NN O
count NN NN O
to TO TO O
increase VB VB O
during IN IN O
therapy NN NN O
adversely RB RB O
affected VBD VBD O
response NN NN O
. . . O

Azotemia NNP NNP O
was VBD VBD O
the DT DT O
major JJ JJ O
side NN NN O
effect NN NN O
recognized VBN VBN O
, , , O
and CC CC O
it PRP PRP O
occurred VBD VBD O
in IN IN O
11 CD CD O
% NN NN O
of IN IN O
episodes NNS NNS O
. . . O

Major NNP NNP O
azotemia NN NN O
( ( ( O
serum NN NN O
creatinine NN NN B-CHEM
greater JJR JJR O
than IN IN O
2 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
dl NN NN O
or CC CC O
BUN NNP NNP O
greater JJR JJR O
than IN IN O
50 CD CD O
mg NN NN O
/ NN NN O
dl NN NN O
) ) ) O
occurred VBD VBD O
in IN IN O
only RB RB O
2 CD CD O
% NN NN O
. . . O

Azotemia NNP NNP O
was VBD VBD O
not RB RB O
related VBN VBN O
to TO TO O
duration NN NN O
of IN IN O
therapy NN NN O
or CC CC O
serum NN NN O
tobramycin NN NN B-CHEM
concentration NN NN O
. . . O

This DT DT O
antibiotic JJ JJ O
regimen NN NN O
showed VBD VBD O
both DT DT O
therapeutic JJ JJ O
efficacy NN NN O
and CC CC O
acceptable JJ JJ O
renal JJ JJ O
toxicity NN NN O
for IN IN O
these DT DT O
patients NNS NNS O
. . . O

Incidence NNP NNP O
of IN IN O
solid JJ JJ O
tumours NNS NNS O
among IN IN O
pesticide NN NN O
applicators NNS NNS O
exposed VBN VBN O
to TO TO O
the DT DT O
organophosphate NN NN B-CHEM
insecticide NN NN O
diazinon NN NN B-CHEM
in IN IN O
the DT DT O
Agricultural NNP NNP O
Health NNP NNP O
Study NNP NNP O
: : : O
an DT DT O
updated JJ JJ O
analysis NN NN O
. . . O

OBJECTIVE NNP NNP O
: : : O
Diazinon NNP NNP B-CHEM
, , , O
a DT DT O
common JJ JJ O
organophosphate NN NN B-CHEM
insecticide NN NN O
with IN IN O
genotoxic JJ JJ O
properties NNS NNS O
, , , O
was VBD VBD O
previously RB RB O
associated VBN VBN O
with IN IN O
lung NN NN O
cancer NN NN O
in IN IN O
the DT DT O
Agricultural NNP NNP O
Health NNP NNP O
Study NNP NNP O
( ( ( O
AHS NNP NNP O
) ) ) O
cohort NN NN O
, , , O
but CC CC O
few JJ JJ O
other JJ JJ O
epidemiological JJ JJ O
studies NNS NNS O
have VBP VBP O
examined VBN VBN O
diazinon NN NN B-CHEM
- - - O
associated VBN VBN O
cancer NN NN O
risk NN NN O
. . . O

We PRP PRP O
used VBD VBD O
updated VBN VBN O
diazinon NN NN B-CHEM
exposure NN NN O
and CC CC O
cancer NN NN O
incidence NN NN O
information NN NN O
to TO TO O
evaluate VB VB O
solid JJ JJ O
tumour NN NN O
risk NN NN O
in IN IN O
the DT DT O
AHS NNP NNP O
. . . O

METHODS NNP NNP O
: : : O
Male NNP NNP O
pesticide NN NN O
applicators NNS NNS O
in IN IN O
Iowa NNP NNP O
and CC CC O
North NNP NNP O
Carolina NNP NNP O
reported VBD VBD O
lifetime NN NN O
diazinon NN NN B-CHEM
use NN NN O
at IN IN O
enrolment NN NN O
( ( ( O
1993 CD CD O
- : : O
1997 CD CD O
) ) ) O
and CC CC O
follow VB VB O
- - - O
up RP RP O
( ( ( O
1998 CD CD O
- : : O
2005 CD CD O
) ) ) O
; : : O
cancer NN NN O
incidence NN NN O
was VBD VBD O
assessed VBN VBN O
through IN IN O
2010 CD CD O
( ( ( O
North NNP NNP O
Carolina NNP NNP O
) ) ) O
/ NN NN O
2011 CD CD O
( ( ( O
Iowa NNP NNP O
) ) ) O
. . . O

Among IN IN O
applicators NNS NNS O
with IN IN O
usage NN NN O
information NN NN O
sufficient JJ JJ O
to TO TO O
evaluate VB VB O
exposure NN NN O
- : : O
response NN NN O
patterns NNS NNS O
, , , O
we PRP PRP O
used VBD VBD O
Poisson NNP NNP O
regression NN NN O
to TO TO O
estimate VB VB O
adjusted VBN VBN O
rate NN NN O
ratios NNS NNS O
( ( ( O
RRs NNP NNP O
) ) ) O
and CC CC O
95 CD CD O
% NN NN O
CI NNP NNP O
for IN IN O
cancer NN NN O
sites NNS NNS O
with IN IN O
> NN NN O
10 CD CD O
exposed VBN VBN O
cases NNS NNS O
for IN IN O
both DT DT O
lifetime NN NN O
( ( ( O
LT NNP NNP O
) ) ) O
exposure NN NN O
days NNS NNS O
and CC CC O
intensity NN NN O
- - - O
weighted JJ JJ O
( ( ( O
IW NNP NNP O
) ) ) O
lifetime NN NN O
exposure NN NN O
days NNS NNS O
( ( ( O
accounting VBG VBG O
for IN IN O
factors NNS NNS O
impacting VBG VBG O
exposure NN NN O
) ) ) O
. . . O

RESULTS NNS NNS O
: : : O
We PRP PRP O
observed VBD VBD O
elevated VBD VBD O
lung NN NN O
cancer NN NN O
risks NNS NNS O
( ( ( O
N NNP NNP O
= SYM SYM O
283 CD CD O
) ) ) O
among IN IN O
applicators NNS NNS O
with IN IN O
the DT DT O
greatest JJS JJS O
number NN NN O
of IN IN O
LT NNP NNP O
( ( ( O
RR NNP NNP O
= SYM SYM O
1 CD CD O
. . . O
60 CD CD O
; : : O
95 CD CD O
% NN NN O
CI NNP NNP O
1 CD CD O
. . . O
11 CD CD O
to TO TO O
2 CD CD O
. . . O
31 CD CD O
; : : O
Ptrend NNP NNP O
= SYM SYM O
0 CD CD O
. . . O
02 CD CD O
) ) ) O
and CC CC O
IW NNP NNP O
days NNS NNS O
of IN IN O
diazinon NN NN B-CHEM
use NN NN O
( ( ( O
RR NNP NNP O
= SYM SYM O
1 CD CD O
. . . O
41 CD CD O
; : : O
95 CD CD O
% NN NN O
CI NNP NNP O
0 CD CD O
. . . O
98 CD CD O
to TO TO O
2 CD CD O
. . . O
04 CD CD O
; : : O
Ptrend NNP NNP O
= SYM SYM O
0 CD CD O
. . . O
08 CD CD O
) ) ) O
. . . O

Kidney NNP NNP O
cancer NN NN O
( ( ( O
N NNP NNP O
= SYM SYM O
94 CD CD O
) ) ) O
risks NNS NNS O
were VBD VBD O
non NN NN O
- : : O
significantly RB RB O
elevated VBD VBD O
( ( ( O
RRLT NNP NNP O
days NNS NNS O
= SYM SYM O
1 CD CD O
. . . O
77 CD CD O
; : : O
95 CD CD O
% NN NN O
CI NNP NNP O
0 CD CD O
. . . O
90 CD CD O
to TO TO O
3 CD CD O
. . . O
51 CD CD O
; : : O
Ptrend NNP NNP O
= SYM SYM O
0 CD CD O
. . . O
09 CD CD O
; : : O
RRIW NNP NNP O
days NNS NNS O
1 CD CD O
. . . O
37 CD CD O
; : : O
95 CD CD O
% NN NN O
CI NNP NNP O
0 CD CD O
. . . O
64 CD CD O
to TO TO O
2 CD CD O
. . . O
92 CD CD O
; : : O
Ptrend NNP NNP O
= SYM SYM O
0 CD CD O
. . . O
50 CD CD O
) ) ) O
, , , O
as IN IN O
were VBD VBD O
risks NNS NNS O
for IN IN O
aggressive JJ JJ O
prostate NN NN O
cancer NN NN O
( ( ( O
N NNP NNP O
= SYM SYM O
656 CD CD O
) ) ) O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Our PRP$ PRP$ O
updated JJ JJ O
evaluation NN NN O
of IN IN O
diazinon NN NN B-CHEM
provides VBZ VBZ O
additional JJ JJ O
evidence NN NN O
of IN IN O
an DT DT O
association NN NN O
with IN IN O
lung NN NN O
cancer NN NN O
risk NN NN O
. . . O

Newly RB RB O
identified VBN VBN O
links NNS NNS O
to TO TO O
kidney NN NN O
cancer NN NN O
and CC CC O
associations NNS NNS O
with IN IN O
aggressive JJ JJ O
prostate NN NN O
cancer NN NN O
require VB VB O
further JJ JJ O
evaluation NN NN O
. . . O

Associations NNP NNP O
of IN IN O
Ozone NNP NNP B-CHEM
and CC CC O
PM2 NNP NNP O
. . . O
5 CD CD O
Concentrations NNP NNP O
With IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
Disease NNP NNP O
Among IN IN O
Participants NNS NNS O
in IN IN O
the DT DT O
Agricultural NNP NNP O
Health NNP NNP O
Study NNP NNP O
. . . O

OBJECTIVE NNP NNP O
: : : O
This DT DT O
study NN NN O
describes VBZ VBZ O
associations NNS NNS O
of IN IN O
ozone NN NN B-CHEM
and CC CC O
fine NN NN O
particulate NN NN B-CHEM
matter NN NN I-CHEM
with IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
observed VBN VBN O
among IN IN O
farmers NNS NNS O
in IN IN O
North NNP NNP O
Carolina NNP NNP O
and CC CC O
Iowa NNP NNP O
. . . O

METHODS NNP NNP O
: : : O
We PRP PRP O
used VBD VBD O
logistic JJ JJ O
regression NN NN O
to TO TO O
determine VB VB O
the DT DT O
associations NNS NNS O
of IN IN O
these DT DT O
pollutants NNS NNS O
with IN IN O
self NN NN O
- - - O
reported VBN VBN O
, , , O
doctor NN NN O
- - - O
diagnosed JJ JJ O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
. . . O

Daily NNP NNP O
predicted VBN VBN O
pollutant NN NN O
concentrations NNS NNS O
were VBD VBD O
used VBN VBN O
to TO TO O
derive VB VB O
surrogates NNS NNS O
of IN IN O
long JJ JJ O
- - - O
term NN NN O
exposure NN NN O
and CC CC O
link NN NN O
them PRP PRP O
to TO TO O
study VB VB O
participants NNS NNS O
' POS POS O
geocoded JJ JJ O
addresses NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
We PRP PRP O
observed VBD VBD O
positive JJ JJ O
associations NNS NNS O
of IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
with IN IN O
ozone NN NN B-CHEM
( ( ( O
odds NN NN O
ratio NN NN O
= SYM SYM O
1 CD CD O
. . . O
39 CD CD O
; : : O
95 CD CD O
% NN NN O
CI NNP NNP O
: : : O
0 CD CD O
. . . O
98 CD CD O
to TO TO O
1 CD CD O
. . . O
98 CD CD O
) ) ) O
and CC CC O
fine NN NN O
particulate NN NN B-CHEM
matter NN NN I-CHEM
( ( ( O
odds NN NN O
ratio NN NN O
= SYM SYM O
1 CD CD O
. . . O
34 CD CD O
; : : O
95 CD CD O
% NN NN O
CI NNP NNP O
: : : O
0 CD CD O
. . . O
93 CD CD O
to TO TO O
1 CD CD O
. . . O
93 CD CD O
) ) ) O
in IN IN O
North NNP NNP O
Carolina NNP NNP O
but CC CC O
not RB RB O
in IN IN O
Iowa NNP NNP O
. . . O

CONCLUSIONS NNP NNP O
: : : O
The DT DT O
plausibility NN NN O
of IN IN O
an DT DT O
effect NN NN O
of IN IN O
ambient JJ JJ O
concentrations NNS NNS O
of IN IN O
these DT DT O
pollutants NNS NNS O
on IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
risk NN NN O
is VBZ VBZ O
supported VBN VBN O
by IN IN O
experimental JJ JJ O
data NNS NNS O
demonstrating VBG VBG O
damage NN NN O
to TO TO O
dopaminergic JJ JJ O
neurons NNS NNS O
at IN IN O
relevant JJ JJ O
concentrations NNS NNS O
. . . O

Additional JJ JJ O
studies NNS NNS O
are VBP VBP O
needed VBN VBN O
to TO TO O
address VB VB O
uncertainties NNS NNS O
related VBN VBN O
to TO TO O
confounding VBG VBG O
and CC CC O
to TO TO O
examine VB VB O
temporal JJ JJ O
aspects NNS NNS O
of IN IN O
the DT DT O
associations NNS NNS O
we PRP PRP O
observed VBD VBD O
. . . O

Low NNP NNP O
functional JJ JJ O
programming NN NN O
of IN IN O
renal JJ JJ O
AT2R NNP NNP O
mediates VBZ VBZ O
the DT DT O
developmental NN NN O
origin NN NN O
of IN IN O
glomerulosclerosis NN NN O
in IN IN O
adult NN NN O
offspring VBG VBG O
induced VBN VBN O
by IN IN O
prenatal JJ JJ O
caffeine NN NN B-CHEM
exposure NN NN O
. . . O

UNASSIGNED NNP NNP O
: : : O
Our PRP$ PRP$ O
previous JJ JJ O
study NN NN O
has VBZ VBZ O
indicated VBN VBN O
that IN IN O
prenatal JJ JJ O
caffeine NN NN B-CHEM
exposure NN NN O
( ( ( O
PCE NNP NNP O
) ) ) O
could MD MD O
induce VB VB O
intrauterine JJ JJ O
growth NN NN O
retardation NN NN O
( ( ( O
IUGR NNP NNP O
) ) ) O
of IN IN O
offspring VBG VBG O
. . . O

Recent JJ JJ O
research NN NN O
suggested VBD VBD O
that IN IN O
IUGR NNP NNP O
is VBZ VBZ O
a DT DT O
risk NN NN O
factor NN NN O
for IN IN O
glomerulosclerosis NN NN O
. . . O

However RB RB O
, , , O
whether IN IN O
PCE NNP NNP O
could MD MD O
induce VB VB O
glomerulosclerosis NN NN O
and CC CC O
its PRP$ PRP$ O
underlying VBG VBG O
mechanisms NNS NNS O
remain VBP VBP O
unknown JJ JJ O
. . . O

This DT DT O
study NN NN O
aimed VBN VBN O
to TO TO O
demonstrate VB VB O
the DT DT O
induction NN NN O
to TO TO O
glomerulosclerosis NNS NNS O
in IN IN O
adult NN NN O
offspring NN NN O
by IN IN O
PCE NNP NNP O
and CC CC O
its PRP$ PRP$ O
intrauterine NN NN O
programming NN NN O
mechanisms NNS NNS O
. . . O

A DT DT O
rat NN NN O
model NN NN O
of IN IN O
IUGR NNP NNP O
was VBD VBD O
established VBN VBN O
by IN IN O
PCE NNP NNP O
, , , O
male JJ JJ O
fetuses NNS NNS O
and CC CC O
adult NN NN O
offspring VBG VBG O
at IN IN O
the DT DT O
age NN NN O
of IN IN O
postnatal JJ JJ O
week NN NN O
24 CD CD O
were VBD VBD O
euthanized VBN VBN O
. . . O

The DT DT O
results NNS NNS O
revealed VBD VBD O
that IN IN O
the DT DT O
adult NN NN O
offspring VBG VBG O
kidneys NNS NNS O
in IN IN O
the DT DT O
PCE NNP NNP O
group NN NN O
exhibited VBN VBN O
glomerulosclerosis NN NN O
as RB RB O
well RB RB O
as IN IN O
interstitial JJ JJ O
fibrosis NNS NNS O
, , , O
accompanied VBN VBN O
by IN IN O
elevated JJ JJ O
levels NNS NNS O
of IN IN O
serum NN NN O
creatinine NN NN B-CHEM
and CC CC O
urine JJ JJ O
protein NN NN O
. . . O

Renal NNP NNP O
angiotensin NN NN B-CHEM
II NNP NNP I-CHEM
receptor NN NN O
type NN NN O
2 CD CD O
( ( ( O
AT2R NNP NNP O
) ) ) O
gene NN NN O
expression NN NN O
in IN IN O
adult NN NN O
offspring NN NN O
was VBD VBD O
reduced VBN VBN O
by IN IN O
PCE NNP NNP O
, , , O
whereas IN IN O
the DT DT O
renal JJ JJ O
angiotensin NN NN B-CHEM
II NNP NNP I-CHEM
receptor NN NN O
type NN NN O
1a CD CD O
( ( ( O
AT1aR NNP NNP O
) ) ) O
/ NN NN O
AT2R NNP NNP O
expression NN NN O
ratio NN NN O
was VBD VBD O
increased VBN VBN O
. . . O

The DT DT O
fetal JJ JJ O
kidneys NNS NNS O
in IN IN O
the DT DT O
PCE NNP NNP O
group NN NN O
displayed VBD VBD O
an DT DT O
enlarged JJ JJ O
Bowman NNP NNP O
' POS POS O
s VBZ VBZ O
space NN NN O
and CC CC O
a DT DT O
shrunken NN NN O
glomerular NN NN O
tuft NN NN O
, , , O
accompanied VBN VBN O
by IN IN O
a DT DT O
reduced JJ JJ O
cortex NN NN O
width NN NN O
and CC CC O
an DT DT O
increase NN NN O
in IN IN O
the DT DT O
nephrogenic JJ JJ O
zone NN NN O
/ NN NN O
cortical JJ JJ O
zone NN NN O
ratio NN NN O
. . . O

Observation NNP NNP O
by IN IN O
electronic JJ JJ O
microscope NN NN O
revealed VBD VBD O
structural JJ JJ O
damage NN NN O
of IN IN O
podocytes NNS NNS O
; : : O
the DT DT O
reduced JJ JJ O
expression NN NN O
level NN NN O
of IN IN O
podocyte NN NN O
marker NN NN O
genes NNS NNS O
, , , O
nephrin NN NN O
and CC CC O
podocin NN NN O
, , , O
was VBD VBD O
also RB RB O
detected VBN VBN O
by IN IN O
q NN NN O
- - - O
PCR NNP NNP O
. . . O

Moreover RB RB O
, , , O
AT2R NNP NNP O
gene NN NN O
and CC CC O
protein NN NN O
expressions NNS NNS O
in IN IN O
fetal JJ JJ O
kidneys NNS NNS O
were VBD VBD O
inhibited VBN VBN O
by IN IN O
PCE NNP NNP O
, , , O
associated VBN VBN O
with IN IN O
the DT DT O
repression NN NN O
of IN IN O
the DT DT O
gene NN NN O
expression NN NN O
of IN IN O
glial JJ JJ O
- - - O
cell NN NN O
- - - O
line NN NN O
- - - O
derived VBN VBN O
neurotrophic JJ JJ O
factor NN NN O
( ( ( O
GDNF NNP NNP O
) ) ) O
/ NN NN O
tyrosine NN NN B-CHEM
kinase NN NN O
receptor NN NN O
( ( ( O
c SYM SYM O
- - - O
Ret NNP NNP O
) ) ) O
signaling VBG VBG O
pathway NN NN O
. . . O

These DT DT O
results NNS NNS O
demonstrated VBD VBD O
that IN IN O
PCE NNP NNP O
could MD MD O
induce VB VB O
dysplasia NN NN O
of IN IN O
fetal JJ JJ O
kidneys NNS NNS O
as RB RB O
well RB RB O
as IN IN O
glomerulosclerosis NN NN O
of IN IN O
adult NN NN O
offspring NN NN O
, , , O
and CC CC O
the DT DT O
low JJ JJ O
functional JJ JJ O
programming NN NN O
of IN IN O
renal JJ JJ O
AT2R NNP NNP O
might MD MD O
mediate VB VB O
the DT DT O
developmental NN NN O
origin NN NN O
of IN IN O
adult NN NN O
glomerulosclerosis NN NN O
. . . O

1 CD CD B-CHEM
, , , I-CHEM
3 CD CD I-CHEM
- : : I-CHEM
Butadiene NNP NNP I-CHEM
, , , O
CML NNP NNP O
and CC CC O
the DT DT O
t NN NN O
( ( ( O
9 CD CD O
: : : O
22 CD CD O
) ) ) O
translocation NN NN O
: : : O
A DT DT O
reality NN NN O
check NN NN O
. . . O

UNASSIGNED NNP NNP O
: : : O
Epidemiological NNP NNP O
studies NNS NNS O
of IN IN O
1 CD CD B-CHEM
, , , I-CHEM
3 CD CD I-CHEM
- : : I-CHEM
butadiene NN NN I-CHEM
have VBP VBP O
suggest JJS JJS O
that IN IN O
exposures NNS NNS O
to TO TO O
humans NNS NNS O
are VBP VBP O
associated VBN VBN O
with IN IN O
chronic JJ JJ O
myeloid NN NN O
leukemia NN NN O
( ( ( O
CML NNP NNP O
) ) ) O
. . . O

CML NNP NNP O
has VBZ VBZ O
a DT DT O
well RB RB O
- - - O
documented JJ JJ O
association NN NN O
with IN IN O
ionizing VBG VBG O
radiation NN NN O
, , , O
but CC CC O
reports NNS NNS O
of IN IN O
associations NNS NNS O
with IN IN O
chemical NN NN O
exposures NNS NNS O
have VBP VBP O
been VBN VBN O
questioned VBN VBN O
. . . O

Ionizing NNP NNP O
radiation NN NN O
is VBZ VBZ O
capable JJ JJ O
of IN IN O
inducing VBG VBG O
the DT DT O
requisite NN NN O
CML NNP NNP O
- - - O
associated VBN VBN O
t NN NN O
( ( ( O
9 CD CD O
: : : O
22 CD CD O
) ) ) O
translocation NN NN O
( ( ( O
Philadelphia NNP NNP O
chromosome NN NN O
) ) ) O
in IN IN O
appropriate JJ JJ O
cells NNS NNS O
in IN IN O
vitro NN NN O
but CC CC O
, , , O
thus RB RB O
far RB RB O
, , , O
chemicals NNS NNS O
have VBP VBP O
not RB RB O
shown VBN VBN O
this DT DT O
capacity NN NN O
. . . O

We PRP PRP O
have VBP VBP O
proposed VBN VBN O
that IN IN O
1 CD CD B-CHEM
, , , I-CHEM
3 CD CD I-CHEM
- : : I-CHEM
butadiene NN NN I-CHEM
metabolites NNS NNS O
be VB VB O
so RB RB O
tested VBN VBN O
as IN IN O
a DT DT O
reality NN NN O
check NN NN O
on IN IN O
the DT DT O
epidemiological JJ JJ O
reports NNS NNS O
. . . O

In IN IN O
order NN NN O
to TO TO O
conduct VB VB O
reliable JJ JJ O
testing NN NN O
in IN IN O
this DT DT O
regard NN NN O
, , , O
it PRP PRP O
is VBZ VBZ O
essential JJ JJ O
that IN IN O
a DT DT O
positive JJ JJ O
control NN NN O
for IN IN O
induction NN NN O
be VB VB O
available JJ JJ O
. . . O

We PRP PRP O
have VBP VBP O
used VBN VBN O
ionizing VBG VBG O
radiation NN NN O
to TO TO O
develop VB VB O
such PDT PDT O
a DT DT O
control NN NN O
. . . O

Results NNS NNS O
described VBD VBD O
here RB RB O
demonstrate NN NN O
that IN IN O
this DT DT O
agent NN NN O
does VBZ VBZ O
in IN IN O
fact NN NN O
induce NN NN O
pathogenic JJ JJ O
t NN NN O
( ( ( O
9 CD CD O
: : : O
22 CD CD O
) ) ) O
translocations NNS NNS O
in IN IN O
a DT DT O
human JJ JJ O
myeloid NN NN O
cell NN NN O
line NN NN O
in IN IN O
vitro NN NN O
, , , O
but CC CC O
does VBZ VBZ O
so RB RB O
at IN IN O
low JJ JJ O
frequencies NNS NNS O
. . . O

Conditions NNS NNS O
that WDT WDT O
will MD MD O
be VB VB O
required VBN VBN O
for IN IN O
studies NNS NNS O
of IN IN O
1 CD CD B-CHEM
, , , I-CHEM
3 CD CD I-CHEM
- : : I-CHEM
butadiene NN NN I-CHEM
are VBP VBP O
discussed VBN VBN O
. . . O

Cancer NNP NNP O
incidence NN NN O
and CC CC O
metolachlor NN NN B-CHEM
use NN NN O
in IN IN O
the DT DT O
Agricultural NNP NNP O
Health NNP NNP O
Study NNP NNP O
: : : O
An DT DT O
update NN NN O
. . . O

UNASSIGNED NNP NNP O
: : : O
Metolachlor NNP NNP B-CHEM
, , , O
a DT DT O
widely RB RB O
used VBN VBN O
herbicide NN NN O
, , , O
is VBZ VBZ O
classified VBN VBN O
as IN IN O
a DT DT O
Group NNP NNP O
C NNP NNP O
carcinogen NN NN O
by IN IN O
the DT DT O
U NNP NNP O
. . . O
S NNP NNP O
. . . O

Environmental NNP NNP O
Protection NNP NNP O
Agency NNP NNP O
based VBD VBD O
on IN IN O
increased VBN VBN O
liver NN NN O
neoplasms NNS NNS O
in IN IN O
female JJ JJ O
rats NNS NNS O
. . . O

Epidemiologic NNP NNP O
studies NNS NNS O
of IN IN O
the DT DT O
health NN NN O
effects NNS NNS O
of IN IN O
metolachlor NN NN B-CHEM
have VBP VBP O
been VBN VBN O
limited JJ JJ O
. . . O

The DT DT O
Agricultural NNP NNP O
Health NNP NNP O
Study NNP NNP O
( ( ( O
AHS NNP NNP O
) ) ) O
is VBZ VBZ O
a DT DT O
prospective JJ JJ O
cohort NN NN O
study NN NN O
including VBG VBG O
licensed JJ JJ O
private JJ JJ O
and CC CC O
commercial JJ JJ O
pesticide NN NN O
applicators NNS NNS O
in IN IN O
Iowa NNP NNP O
and CC CC O
North NNP NNP O
Carolina NNP NNP O
enrolled VBD VBD O
1993 CD CD O
- : : O
1997 CD CD O
. . . O

We PRP PRP O
evaluated VBD VBD O
cancer NN NN O
incidence NN NN O
through IN IN O
2010 CD CD O
/ NN NN O
2011 CD CD O
( ( ( O
NC NNP NNP O
/ NN NN O
IA NNP NNP O
) ) ) O
for IN IN O
49 CD CD O
, , , O
616 CD CD O
applicators NNS NNS O
, , , O
53 CD CD O
% NN NN O
of IN IN O
whom WP WP O
reported VBD VBD O
ever RB RB O
using VBG VBG O
metolachlor NN NN B-CHEM
. . . O

We PRP PRP O
used VBD VBD O
Poisson NNP NNP O
regression NN NN O
to TO TO O
evaluate VB VB O
relations NNS NNS O
between IN IN O
two CD CD O
metrics NNS NNS O
of IN IN O
metolachlor NN NN B-CHEM
use NN NN O
( ( ( O
lifetime NN NN O
days NNS NNS O
, , , O
intensity NN NN O
- - - O
weighted JJ JJ O
lifetime NN NN O
days NNS NNS O
) ) ) O
and CC CC O
cancer NN NN O
incidence NN NN O
. . . O

We PRP PRP O
saw VBD VBD O
no DT DT O
association NN NN O
between IN IN O
metolachlor NN NN B-CHEM
use NN NN O
and CC CC O
incidence NN NN O
of IN IN O
all DT DT O
cancers NNS NNS O
combined VBN VBN O
( ( ( O
n NN NN O
= SYM SYM O
5 CD CD O
, , , O
701 CD CD O
with IN IN O
a DT DT O
5 CD CD O
- : : O
year NN NN O
lag NN NN O
) ) ) O
or CC CC O
most JJS JJS O
site NN NN O
- - - O
specific JJ JJ O
cancers NNS NNS O
. . . O

For IN IN O
liver NN NN O
cancer NN NN O
, , , O
in IN IN O
analyses NNS NNS O
restricted VBN VBN O
to TO TO O
exposed VBN VBN O
workers NNS NNS O
, , , O
elevations NNS NNS O
observed VBD VBD O
at IN IN O
higher JJR JJR O
categories NNS NNS O
of IN IN O
use NN NN O
were VBD VBD O
not RB RB O
statistically RB RB O
significant JJ JJ O
. . . O

However RB RB O
, , , O
trends NNS NNS O
for IN IN O
both DT DT O
lifetime NN NN O
and CC CC O
intensity NN NN O
- - - O
weighted JJ JJ O
lifetime NN NN O
days NNS NNS O
of IN IN O
metolachor NN NN B-CHEM
use NN NN O
were VBD VBD O
positive JJ JJ O
and CC CC O
statistically RB RB O
significant JJ JJ O
with IN IN O
an DT DT O
unexposed JJ JJ O
reference NN NN O
group NN NN O
. . . O

A DT DT O
similar JJ JJ O
pattern NN NN O
was VBD VBD O
observed VBN VBN O
for IN IN O
follicular JJ JJ O
cell NN NN O
lymphoma NN NN O
, , , O
but CC CC O
no DT DT O
other JJ JJ O
lymphoma NN NN O
subtypes NNS NNS O
. . . O

An DT DT O
earlier JJR JJR O
suggestion NN NN O
of IN IN O
increased VBN VBN O
lung NN NN O
cancer NN NN O
risk NN NN O
at IN IN O
high JJ JJ O
levels NNS NNS O
of IN IN O
metolachlor NN NN B-CHEM
use NN NN O
in IN IN O
this DT DT O
cohort NN NN O
was VBD VBD O
not RB RB O
confirmed VBN VBN O
in IN IN O
this DT DT O
update NN NN O
. . . O

This DT DT O
suggestion NN NN O
of IN IN O
an DT DT O
association NN NN O
between IN IN O
metolachlor NN NN B-CHEM
and CC CC O
liver NN NN O
cancer NN NN O
among IN IN O
pesticide NN NN O
applicators NNS NNS O
is VBZ VBZ O
a DT DT O
novel NN NN O
finding VBG VBG O
and CC CC O
echoes NNS NNS O
observation NN NN O
of IN IN O
increased VBN VBN O
liver NN NN O
neoplasms NNS NNS O
in IN IN O
some DT DT O
animal NN NN O
studies NNS NNS O
. . . O

However RB RB O
, , , O
our PRP$ PRP$ O
findings NNS NNS O
for IN IN O
both DT DT O
liver NN NN O
cancer NN NN O
and CC CC O
follicular JJ JJ O
cell NN NN O
lymphoma NN NN O
warrant NN NN O
follow VB VB O
- - - O
up RP RP O
to TO TO O
better JJR JJR O
differentiate JJ JJ O
effects NNS NNS O
of IN IN O
metolachlor NN NN B-CHEM
use NN NN O
from IN IN O
other JJ JJ O
factors NNS NNS O
. . . O

Mechanisms NNP NNP O
Underlying NNP NNP O
Latent NNP NNP O
Disease NNP NNP O
Risk NNP NNP O
Associated NNP NNP O
with IN IN O
Early JJ JJ O
- - - O
Life NNP NNP O
Arsenic JJ JJ B-CHEM
Exposure NNP NNP O
: : : O
Current JJ JJ O
Research NNP NNP O
Trends NNP NNP O
and CC CC O
Scientific NNP NNP O
Gaps NNP NNP O
. . . O

BACKGROUND NNP NNP O
: : : O
Millions NNP NNP O
of IN IN O
individuals NNS NNS O
worldwide NN NN O
, , , O
particularly RB RB O
those DT DT O
living VBG VBG O
in IN IN O
rural JJ JJ O
and CC CC O
developing VBG VBG O
areas NNS NNS O
, , , O
are VBP VBP O
exposed VBN VBN O
to TO TO O
harmful JJ JJ O
levels NNS NNS O
of IN IN O
inorganic JJ JJ B-CHEM
arsenic JJ JJ I-CHEM
( ( ( O
iAs NN NN B-CHEM
) ) ) O
in IN IN O
their PRP$ PRP$ O
drinking NN NN O
water NN NN O
. . . O

Inorganic NNP NNP B-CHEM
As IN IN I-CHEM
exposure NN NN O
during IN IN O
key JJ JJ O
developmental NN NN O
periods NNS NNS O
is VBZ VBZ O
associated VBN VBN O
with IN IN O
a DT DT O
variety NN NN O
of IN IN O
adverse JJ JJ O
health NN NN O
effects NNS NNS O
including VBG VBG O
those DT DT O
that WDT WDT O
are VBP VBP O
evident JJ JJ O
in IN IN O
adulthood NN NN O
. . . O

There EX EX O
is VBZ VBZ O
considerable JJ JJ O
interest NN NN O
in IN IN O
identifying VBG VBG O
the DT DT O
molecular JJ JJ O
mechanisms NNS NNS O
that WDT WDT O
relate VBP VBP O
early JJ JJ O
- - - O
life NN NN O
iAs NN NN B-CHEM
exposure NN NN O
to TO TO O
the DT DT O
development NN NN O
of IN IN O
these DT DT O
latent NN NN O
diseases NNS NNS O
, , , O
particularly RB RB O
in IN IN O
relationship NN NN O
to TO TO O
cancer NN NN O
. . . O

OBJECTIVES NNP NNP O
: : : O
This DT DT O
work NN NN O
summarizes NNS NNS O
research NN NN O
on IN IN O
the DT DT O
molecular JJ JJ O
mechanisms NNS NNS O
that WDT WDT O
underlie VBP VBP O
the DT DT O
increased JJ JJ O
risk NN NN O
of IN IN O
cancer NN NN O
development NN NN O
in IN IN O
adulthood NN NN O
that WDT WDT O
is VBZ VBZ O
associated VBN VBN O
with IN IN O
early JJ JJ O
- - - O
life NN NN O
iAs NN NN B-CHEM
exposure NN NN O
. . . O

DISCUSSION NNP NNP O
: : : O
Epigenetic NNP NNP O
reprogramming VBG VBG O
that IN IN O
imparts NNS NNS O
functional JJ JJ O
changes NNS NNS O
in IN IN O
gene NN NN O
expression NN NN O
, , , O
the DT DT O
development NN NN O
of IN IN O
cancer NN NN O
stem NN NN O
cells NNS NNS O
, , , O
and CC CC O
immunomodulation NN NN O
are VBP VBP O
plausible JJ JJ O
underlying VBG VBG O
mechanisms NNS NNS O
by IN IN O
which WDT WDT O
early JJ JJ O
- - - O
life NN NN O
iAs NN NN B-CHEM
exposure NN NN O
elicits NNS NNS O
latent JJ JJ O
carcinogenic JJ JJ O
effects NNS NNS O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Evidence NN NN O
is VBZ VBZ O
mounting VBG VBG O
that IN IN O
relates VBZ VBZ O
early JJ JJ O
- : : O
life NN NN O
iAs NN NN B-CHEM
exposure NN NN O
and CC CC O
cancer NN NN O
development NN NN O
later RB RB O
in IN IN O
life NN NN O
. . . O

Future NNP NNP O
research NN NN O
should MD MD O
include VB VB O
animal NN NN O
studies NNS NNS O
that WDT WDT O
address VBP VBP O
mechanistic JJ JJ O
hypotheses NNS NNS O
and CC CC O
studies NNS NNS O
of IN IN O
human JJ JJ O
populations NNS NNS O
that WDT WDT O
integrate VBP VBP O
early JJ JJ O
- - - O
life NN NN O
exposure NN NN O
, , , O
molecular JJ JJ O
alterations NNS NNS O
, , , O
and CC CC O
latent NN NN O
disease NN NN O
outcomes NNS NNS O
. . . O

Nifedipine NNP NNP B-CHEM
induced VBD VBD O
bradycardia NN NN O
in IN IN O
a DT DT O
patient NN NN O
with IN IN O
autonomic JJ JJ O
neuropathy NN NN O
. . . O

An DT DT O
80 CD CD O
year NN NN O
old JJ JJ O
diabetic JJ JJ O
male NN NN O
with IN IN O
evidence NN NN O
of IN IN O
peripheral JJ JJ O
and CC CC O
autonomic JJ JJ O
neuropathy NN NN O
was VBD VBD O
admitted VBN VBN O
with IN IN O
chest NN NN O
pain NN NN O
. . . O

He PRP PRP O
was VBD VBD O
found VBN VBN O
to TO TO O
have VB VB O
atrial JJ JJ O
flutter NN NN O
at IN IN O
a DT DT O
ventricular NN NN O
rate NN NN O
of IN IN O
70 CD CD O
/ NN NN O
min NN NN O
which WDT WDT O
slowed VBD VBD O
down RB RB O
to TO TO O
30 CD CD O
- : : O
40 CD CD O
/ NN NN O
min NN NN O
when WRB WRB O
nifedipine NN NN B-CHEM
( ( ( O
60 CD CD O
mg NN NN O
) ) ) O
in IN IN O
3 CD CD O
divided JJ JJ O
doses NNS NNS O
, , , O
during IN IN O
which WDT WDT O
he PRP PRP O
was VBD VBD O
paced VBN VBN O
at IN IN O
a DT DT O
rate NN NN O
of IN IN O
70 CD CD O
/ NN NN O
min NN NN O
. . . O

This DT DT O
is VBZ VBZ O
inconsistent JJ JJ O
with IN IN O
the DT DT O
well RB RB O
- - - O
established VBN VBN O
finding VBG VBG O
that IN IN O
nifedipine NN NN B-CHEM
induces NNS NNS O
tachycardia NNS NNS O
in IN IN O
normally RB RB O
innervated VBN VBN O
hearts NNS NNS O
. . . O

However RB RB O
, , , O
in IN IN O
hearts NNS NNS O
deprived VBN VBN O
of IN IN O
compensatory JJ JJ O
sympathetic JJ JJ O
drive NN NN O
, , , O
it PRP PRP O
may MD MD O
lead VB VB O
to TO TO O
bradycardia NNS NNS O
. . . O

The DT DT O
effect NN NN O
of IN IN O
haloperidol NN NN B-CHEM
in IN IN O
cocaine NN NN B-CHEM
and CC CC O
amphetamine NN NN B-CHEM
intoxication NN NN O
. . . O

The DT DT O
effectiveness NN NN O
of IN IN O
haloperidol NN NN B-CHEM
pretreatment NN NN O
in IN IN O
preventing VBG VBG O
the DT DT O
toxic JJ JJ O
effects NNS NNS O
of IN IN O
high JJ JJ O
doses NNS NNS O
of IN IN O
amphetamine NN NN B-CHEM
and CC CC O
cocaine NN NN B-CHEM
was VBD VBD O
studied VBN VBN O
in IN IN O
rats NNS NNS O
. . . O

In IN IN O
this DT DT O
model NN NN O
, , , O
toxic JJ JJ O
effects NNS NNS O
were VBD VBD O
induced VBN VBN O
by IN IN O
intraperitoneal NN NN O
( ( ( O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
injection NN NN O
of IN IN O
amphetamine NN NN B-CHEM
75 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
( ( ( O
100 CD CD O
% NN NN O
death NN NN O
rate NN NN O
) ) ) O
or CC CC O
cocaine NN NN B-CHEM
70 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
( ( ( O
82 CD CD O
% NN NN O
death NN NN O
rate NN NN O
) ) ) O
. . . O

Haloperidol NNP NNP B-CHEM
failed VBD VBD O
to TO TO O
prevent VB VB O
amphetamine NN NN B-CHEM
- : : O
induced JJ JJ O
seizures NNS NNS O
, , , O
but CC CC O
did VBD VBD O
lower JJR JJR O
the DT DT O
mortality NN NN O
rate NN NN O
at IN IN O
most JJS JJS O
doses NNS NNS O
tested VBN VBN O
. . . O

Haloperidol NNP NNP B-CHEM
decreased VBD VBD O
the DT DT O
incidence NN NN O
of IN IN O
cocaine NN NN B-CHEM
- - - O
induced JJ JJ O
seizures NNS NNS O
at IN IN O
the DT DT O
two CD CD O
highest JJS JJS O
doses NNS NNS O
, , , O
but CC CC O
the DT DT O
lowering VBG VBG O
of IN IN O
the DT DT O
mortality NN NN O
rate NN NN O
did VBD VBD O
not RB RB O
reach VB VB O
statistical JJ JJ O
significance NN NN O
at IN IN O
any DT DT O
dose NN NN O
. . . O

These DT DT O
data NNS NNS O
suggest VBP VBP O
a DT DT O
protective JJ JJ O
role NN NN O
for IN IN O
the DT DT O
central JJ JJ O
dopamine NN NN B-CHEM
blocker NN NN O
haloperidol NN NN B-CHEM
against IN IN O
death NN NN O
from IN IN O
high JJ JJ O
- - - O
dose NN NN O
amphetamine NN NN B-CHEM
exposure NN NN O
without IN IN O
reducing VBG VBG O
the DT DT O
incidence NN NN O
of IN IN O
seizures NNS NNS O
. . . O

In IN IN O
contrast NN NN O
, , , O
haloperidol NN NN B-CHEM
demonstrated VBD VBD O
an DT DT O
ability NN NN O
to TO TO O
reduce VB VB O
cocaine NN NN B-CHEM
- : : O
induced JJ JJ O
seizures NNS NNS O
without IN IN O
significantly RB RB O
reducing VBG VBG O
mortality NN NN O
. . . O

Autoradiographic NNP NNP O
evidence NN NN O
of IN IN O
estrogen NN NN B-CHEM
binding JJ JJ O
sites NNS NNS O
in IN IN O
nuclei NN NN O
of IN IN O
diethylstilbesterol NN NN B-CHEM
induced VBD VBD O
hamster NN NN O
renal JJ JJ O
carcinomas NN NN O
. . . O

Estrogen NNP NNP B-CHEM
binding JJ JJ O
sites NNS NNS O
were VBD VBD O
demonstrated VBN VBN O
by IN IN O
autoradiography NN NN O
in IN IN O
one CD CD O
transplantable JJ JJ O
and CC CC O
five CD CD O
primary JJ JJ O
diethylstilbesterol NN NN B-CHEM
induced VBD VBD O
renal JJ JJ O
carcinomas NNS NNS O
in IN IN O
three CD CD O
hamsters NNS NNS O
. . . O

Radiolabelling NNP NNP O
, , , O
following VBG VBG O
the DT DT O
in IN IN O
vivo NN NN O
injection NN NN O
of IN IN O
3H CD CD O
- : : O
17 CD CD O
beta NN NN O
estradiol NN NN B-CHEM
, , , O
was VBD VBD O
increased VBN VBN O
only RB RB O
over IN IN O
the DT DT O
nuclei NN NN O
of IN IN O
tumor NN NN O
cells NNS NNS O
; : : O
stereologic JJ JJ O
analysis NN NN O
revealed VBD VBD O
a DT DT O
4 CD CD O
. . . O
5 CD CD O
- : : O
to TO TO O
6 CD CD O
. . . O
7 CD CD O
- : : O
times NNS NNS O
higher JJR JJR O
concentration NN NN O
of IN IN O
reduced VBN VBN O
silver NN NN B-CHEM
grains NNS NNS O
over IN IN O
nuclei NN NN O
than IN IN O
cytoplasm NN NN O
of IN IN O
these DT DT O
cells NNS NNS O
. . . O

Despite IN IN O
rapid JJ JJ O
tubular JJ JJ O
excretion NN NN O
of IN IN O
estradiol NN NN B-CHEM
which WDT WDT O
peaked VBD VBD O
in IN IN O
less JJR JJR O
than IN IN O
1 CD CD O
h NN NN O
, , , O
the DT DT O
normal JJ JJ O
cells NNS NNS O
did VBD VBD O
not RB RB O
appear VB VB O
to TO TO O
bind NN NN O
the DT DT O
ligand NN NN O
. . . O

This DT DT O
is VBZ VBZ O
the DT DT O
first JJ JJ O
published VBN VBN O
report NN NN O
documenting VBG VBG O
the DT DT O
preferential NN NN O
in IN IN O
vivo NN NN O
binding JJ JJ O
of IN IN O
estrogen NN NN B-CHEM
to TO TO O
nuclei NN NN O
of IN IN O
cells NNS NNS O
in IN IN O
estrogen NN NN B-CHEM
induced VBD VBD O
hamster NN NN O
renal JJ JJ O
carcinomas NN NN O
. . . O

Bradycardia NNP NNP O
due JJ JJ O
to TO TO O
biperiden NN NN B-CHEM
. . . O

In IN IN O
a DT DT O
38 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
male NN NN O
patient NN NN O
suffering VBG VBG O
from IN IN O
a DT DT O
severe JJ JJ O
postzosteric JJ JJ O
trigeminal NN NN O
neuralgia NN NN O
, , , O
intravenous JJ JJ O
application NN NN O
of IN IN O
10 CD CD O
mg NN NN O
biperiden NN NN B-CHEM
lactate NN NN I-CHEM
led VBN VBN O
to TO TO O
a DT DT O
long JJ JJ O
- - - O
lasting VBG VBG O
paradoxical JJ JJ O
reaction NN NN O
characterized VBN VBN O
by IN IN O
considerable JJ JJ O
bradycardia NN NN O
, , , O
dysarthria NN NN O
, , , O
and CC CC O
dysphagia NN NN O
. . . O

The DT DT O
heart NN NN O
rate NN NN O
was VBD VBD O
back RB RB O
to TO TO O
normal JJ JJ O
within IN IN O
12 CD CD O
hours NNS NNS O
upon IN IN O
administration NN NN O
of IN IN O
orciprenaline NN NN B-CHEM
under IN IN O
cardiac JJ JJ O
monitoring NN NN O
in IN IN O
an DT DT O
intensive JJ JJ O
care NN NN O
unit NN NN O
. . . O

Bradycardia NNP NNP O
induced VBN VBN O
by IN IN O
biperiden NN NN B-CHEM
is VBZ VBZ O
attributed VBN VBN O
to TO TO O
the DT DT O
speed NN NN O
of IN IN O
injection NN NN O
and CC CC O
to TO TO O
a DT DT O
dose NN NN O
- - - O
related VBN VBN O
dual JJ JJ O
effect NN NN O
of IN IN O
atropine NN NN B-CHEM
- - - O
like IN IN O
drugs NNS NNS O
on IN IN O
muscarine NN NN B-CHEM
receptors NNS NNS O
. . . O

Deliberate NNP NNP O
hypotension NN NN O
induced VBN VBN O
by IN IN O
labetalol NN NN B-CHEM
with IN IN O
halothane NN NN B-CHEM
, , , O
enflurane NN NN B-CHEM
or CC CC O
isoflurane NN NN B-CHEM
for IN IN O
middle JJ JJ O
- - - O
ear NN NN O
surgery NN NN O
. . . O

The DT DT O
feasibility NN NN O
of IN IN O
using VBG VBG O
labetalol NN NN B-CHEM
, , , O
an DT DT O
alpha NN NN O
- - - O
and CC CC O
beta NN NN O
- - - O
adrenergic JJ JJ O
blocking VBG VBG O
agent NN NN O
, , , O
as IN IN O
a DT DT O
hypotensive JJ JJ O
agent NN NN O
in IN IN O
combination NN NN O
with IN IN O
inhalation NN NN O
anaesthetics NNS NNS O
( ( ( O
halothane NN NN B-CHEM
, , , O
enflurane NN NN B-CHEM
or CC CC O
isoflurane NN NN B-CHEM
) ) ) O
was VBD VBD O
studied VBN VBN O
in IN IN O
23 CD CD O
adult NN NN O
patients NNS NNS O
undergoing VBG VBG O
middle NN NN O
- - - O
ear NN NN O
surgery NN NN O
. . . O

The DT DT O
mean NN NN O
arterial JJ JJ O
pressure NN NN O
was VBD VBD O
decreased VBN VBN O
from IN IN O
86 CD CD O
+ NN NN O
/ NN NN O
- : : O
5 CD CD O
( ( ( O
s VBZ VBZ O
. . . O
e SYM SYM O
. . . O
mean NN NN O
) ) ) O
mmHg NN NN O
to TO TO O
52 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
mmHg NN NN O
( ( ( O
11 CD CD O
. . . O
5 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
7 CD CD O
to TO TO O
6 CD CD O
. . . O
9 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
1 CD CD O
kPa NN NN O
) ) ) O
for IN IN O
98 CD CD O
+ NN NN O
/ NN NN O
- : : O
10 CD CD O
min NN NN O
in IN IN O
the DT DT O
halothane NN NN B-CHEM
( ( ( O
H NNP NNP B-CHEM
) ) ) O
group NN NN O
, , , O
from IN IN O
79 CD CD O
+ NN NN O
/ NN NN O
- : : O
5 CD CD O
to TO TO O
53 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
mmHg NN NN O
( ( ( O
10 CD CD O
. . . O
5 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
7 CD CD O
to TO TO O
7 CD CD O
. . . O
1 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
1 CD CD O
kPa NN NN O
) ) ) O
for IN IN O
129 CD CD O
+ NN NN O
/ NN NN O
- : : O
11 CD CD O
min NN NN O
in IN IN O
the DT DT O
enflurane NN NN B-CHEM
( ( ( O
E NNP NNP B-CHEM
) ) ) O
group NN NN O
, , , O
and CC CC O
from IN IN O
80 CD CD O
+ NN NN O
/ NN NN O
- : : O
4 CD CD O
to TO TO O
49 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
mmHg NN NN O
( ( ( O
10 CD CD O
. . . O
7 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
5 CD CD O
to TO TO O
6 CD CD O
. . . O
5 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
1 CD CD O
kPa NN NN O
) ) ) O
for IN IN O
135 CD CD O
+ NN NN O
/ NN NN O
- : : O
15 CD CD O
min NN NN O
in IN IN O
the DT DT O
isoflurane NN NN B-CHEM
( ( ( O
I NN NN B-CHEM
) ) ) O
group NN NN O
. . . O

The DT DT O
mean NN NN O
H NNP NNP B-CHEM
concentration NN NN O
during IN IN O
hypotension NN NN O
in IN IN O
the DT DT O
inspiratory NN NN O
gas NN NN O
was VBD VBD O
0 CD CD O
. . . O
7 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
1 CD CD O
vol NN NN O
% NN NN O
, , , O
the DT DT O
mean NN NN O
E NNP NNP B-CHEM
concentration NN NN O
1 CD CD O
. . . O
6 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
2 CD CD O
vol NN NN O
% NN NN O
, , , O
and CC CC O
the DT DT O
mean NN NN O
I PRP PRP B-CHEM
concentration NN NN O
1 CD CD O
. . . O
0 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
1 CD CD O
vol NN NN O
% NN NN O
. . . O

In IN IN O
addition NN NN O
, , , O
the DT DT O
patients NNS NNS O
received VBD VBD O
fentanyl NN NN B-CHEM
and CC CC O
d SYM SYM B-CHEM
- : : I-CHEM
tubocurarine NN NN I-CHEM
. . . O

The DT DT O
initial JJ JJ O
dose NN NN O
of IN IN O
labetalol NN NN B-CHEM
for IN IN O
lowering VBG VBG O
blood NN NN O
pressure NN NN O
was VBD VBD O
similar JJ JJ O
, , , O
0 CD CD O
. . . O
52 CD CD O
- : : O
0 CD CD O
. . . O
59 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
in IN IN O
all PDT PDT O
the DT DT O
groups NNS NNS O
. . . O

During IN IN O
hypotension NN NN O
, , , O
the DT DT O
heart NN NN O
rate NN NN O
was VBD VBD O
stable JJ JJ O
without IN IN O
tachy NN NN O
- - - O
or CC CC O
bradycardia NN NN O
. . . O

The DT DT O
operating VBG VBG O
conditions NNS NNS O
regarding VBG VBG O
bleeding NN NN O
were VBD VBD O
estimated VBN VBN O
in IN IN O
a DT DT O
double JJ JJ O
- - - O
blind JJ JJ O
manner NN NN O
, , , O
and CC CC O
did VBD VBD O
not RB RB O
differ VB VB O
significantly RB RB O
between IN IN O
the DT DT O
groups NNS NNS O
. . . O

During IN IN O
hypotension NN NN O
, , , O
the DT DT O
serum NN NN O
creatinine NN NN B-CHEM
concentration NN NN O
rose VBD VBD O
significantly RB RB O
in IN IN O
all DT DT O
groups NNS NNS O
from IN IN O
the DT DT O
values NNS NNS O
before IN IN O
hypotension NN NN O
and CC CC O
returned VBD VBD O
postoperatively RB RB O
to TO TO O
the DT DT O
initial JJ JJ O
level NN NN O
in IN IN O
the DT DT O
other JJ JJ O
groups NNS NNS O
, , , O
except IN IN O
the DT DT O
isoflurane NN NN B-CHEM
group NN NN O
. . . O

After IN IN O
hypotension NN NN O
there EX EX O
was VBD VBD O
no DT DT O
rebound NN NN O
phenomenon NN NN O
in IN IN O
either DT DT O
blood NN NN O
pressure NN NN O
or CC CC O
heart NN NN O
rate NN NN O
. . . O

These DT DT O
results NNS NNS O
indicate VBP VBP O
that IN IN O
labetalol NN NN B-CHEM
induces NNS NNS O
easily RB RB O
adjustable JJ JJ O
hypotension NN NN O
without IN IN O
compensatory JJ JJ O
tachycardia NNS NNS O
and CC CC O
rebound NN NN O
hypertension NN NN O
. . . O

Convulsion NNP NNP O
following VBG VBG O
intravenous JJ JJ O
fluorescein NN NN B-CHEM
angiography NN NN O
. . . O

Tonic NNP NNP O
- : : O
clonic JJ JJ O
seizures NNS NNS O
followed VBD VBD O
intravenous JJ JJ O
fluorescein NN NN B-CHEM
injection NN NN O
for IN IN O
fundus NN NN O
angiography NN NN O
in IN IN O
a DT DT O
47 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
male NN NN O
. . . O

Despite IN IN O
precautions NNS NNS O
this DT DT O
adverse JJ JJ O
reaction NN NN O
recurred VBD VBD O
on IN IN O
re NN NN O
- : : O
exposure NN NN O
to TO TO O
intravenous JJ JJ O
fluorescein NN NN B-CHEM
. . . O

Pharmacology NNP NNP O
of IN IN O
ACC NNP NNP B-CHEM
- : : I-CHEM
9653 CD CD I-CHEM
( ( ( O
phenytoin NN NN B-CHEM
prodrug NN NN O
) ) ) O
. . . O

ACC NNP NNP B-CHEM
- : : I-CHEM
9653 CD CD I-CHEM
, , , O
the DT DT O
disodium NN NN B-CHEM
phosphate NN NN I-CHEM
ester NN NN I-CHEM
of IN IN O
3 CD CD B-CHEM
- : : I-CHEM
hydroxymethyl NN NN I-CHEM
- : : I-CHEM
5 CD CD I-CHEM
, , , I-CHEM
5 CD CD I-CHEM
- : : I-CHEM
diphenylhydantoin NN NN I-CHEM
, , , O
is VBZ VBZ O
a DT DT O
prodrug NN NN O
of IN IN O
phenytoin NN NN B-CHEM
with IN IN O
advantageous JJ JJ O
physicochemical JJ JJ O
properties NNS NNS O
. . . O

ACC NNP NNP B-CHEM
- : : I-CHEM
9653 CD CD I-CHEM
is VBZ VBZ O
rapidly RB RB O
converted VBN VBN O
enzymatically RB RB O
to TO TO O
phenytoin VB VB B-CHEM
in IN IN O
vivo NN NN O
. . . O

ACC NNP NNP B-CHEM
- : : I-CHEM
9653 CD CD I-CHEM
and CC CC O
phenytoin NN NN B-CHEM
sodium NN NN I-CHEM
have VBP VBP O
equivalent VBN VBN O
anticonvulsant JJ JJ O
activity NN NN O
against IN IN O
seizures NNS NNS O
induced VBN VBN O
by IN IN O
maximal NN NN O
electroshock NN NN O
( ( ( O
MES NNP NNP O
) ) ) O
in IN IN O
mice NN NN O
following NN NN O
i NNP NNP O
. . . O
p NN NN O
. . . O
, , , O
oral JJ JJ O
, , , O
or CC CC O
i NNP NNP O
. . . O
v NN NN O
. . . O
administration NN NN O
. . . O

The DT DT O
ED50 NNP NNP O
doses NNS NNS O
were VBD VBD O
16 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
for IN IN O
i NNP NNP O
. . . O
v NN NN O
. . . O
ACC NNP NNP B-CHEM
- : : I-CHEM
9653 CD CD I-CHEM
and CC CC O
8 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
for IN IN O
i NNP NNP O
. . . O
v NN NN O
. . . O
phenytoin NN NN B-CHEM
sodium NN NN I-CHEM
. . . O

ACC NNP NNP B-CHEM
- : : I-CHEM
9653 CD CD I-CHEM
and CC CC O
phenytoin NN NN B-CHEM
sodium NN NN I-CHEM
have VBP VBP O
similar JJ JJ O
antiarrhythmic JJ JJ O
activity NN NN O
against IN IN O
ouabain JJ JJ B-CHEM
- - - O
induced JJ JJ O
ventricular NN NN O
tachycardia NNS NNS O
in IN IN O
anesthetized JJ JJ O
dogs NNS NNS O
. . . O

The DT DT O
total JJ JJ O
doses NNS NNS O
of IN IN O
ACC NNP NNP B-CHEM
- : : I-CHEM
9653 CD CD I-CHEM
or CC CC O
phenytoin NN NN B-CHEM
sodium NN NN I-CHEM
necessary JJ JJ O
to TO TO O
convert VB VB O
the DT DT O
arrhythmia NN NN O
to TO TO O
a DT DT O
normal JJ JJ O
sinus NN NN O
rhythm NN NN O
were VBD VBD O
24 CD CD O
+ NN NN O
/ NN NN O
- : : O
6 CD CD O
and CC CC O
14 CD CD O
+ NN NN O
/ NN NN O
- : : O
3 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
respectively RB RB O
. . . O

Only RB RB O
phenytoin VB VB B-CHEM
sodium NN NN I-CHEM
displayed VBD VBD O
in IN IN O
vitro NN NN O
antiarrhythmic JJ JJ O
activity NN NN O
against IN IN O
strophanthidin NN NN B-CHEM
- - - O
induced JJ JJ O
arrhythmias NNS NNS O
in IN IN O
guinea NN NN O
pig NN NN O
right NN NN O
atria NN NN O
. . . O

In IN IN O
anesthetized JJ JJ O
dogs NNS NNS O
, , , O
a DT DT O
high JJ JJ O
dose NN NN O
of IN IN O
ACC NNP NNP B-CHEM
- : : I-CHEM
9653 CD CD I-CHEM
( ( ( O
31 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
was VBD VBD O
infused VBN VBN O
over IN IN O
15 CD CD O
, , , O
20 CD CD O
, , , O
and CC CC O
30 CD CD O
min NN NN O
and CC CC O
the DT DT O
responses NNS NNS O
were VBD VBD O
compared VBN VBN O
to TO TO O
an DT DT O
equimolar JJ JJ O
dose NN NN O
of IN IN O
phenytoin NN NN B-CHEM
sodium NN NN I-CHEM
( ( ( O
21 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
. . . O

The DT DT O
ACC NNP NNP B-CHEM
- : : I-CHEM
9653 CD CD I-CHEM
and CC CC O
phenytoin NN NN B-CHEM
sodium NN NN I-CHEM
treatments NNS NNS O
produced VBN VBN O
similar JJ JJ O
marked VBN VBN O
reductions NNS NNS O
in IN IN O
diastolic JJ JJ O
blood NN NN O
pressure NN NN O
and CC CC O
contractile JJ JJ O
force NN NN O
( ( ( O
LVdP NNP NNP O
/ NN NN O
dt NN NN O
) ) ) O
. . . O

The DT DT O
maximum NN NN O
effects NNS NNS O
of IN IN O
each DT DT O
treatment NN NN O
occurred VBD VBD O
at IN IN O
the DT DT O
time NN NN O
of IN IN O
maximum NN NN O
phenytoin NN NN B-CHEM
sodium NN NN I-CHEM
levels NNS NNS O
. . . O

Acute JJ JJ O
toxicity NN NN O
studies NNS NNS O
of IN IN O
ACC NNP NNP B-CHEM
- : : I-CHEM
9653 CD CD I-CHEM
and CC CC O
phenytoin NN NN B-CHEM
sodium NN NN I-CHEM
were VBD VBD O
carried VBN VBN O
out IN IN O
in IN IN O
mice NN NN O
, , , O
rats NNS NNS O
, , , O
rabbits NNS NNS O
, , , O
and CC CC O
dogs NNS NNS O
by IN IN O
i NNP NNP O
. . . O
v NN NN O
. . . O
, , , O
i NNP NNP O
. . . O
m NN NN O
. . . O
, , , O
and CC CC O
i NNP NNP O
. . . O
p NN NN O
. . . O
routes NNS NNS O
of IN IN O
administration NN NN O
. . . O

The DT DT O
systemic JJ JJ O
toxic JJ JJ O
signs NNS NNS O
of IN IN O
both DT DT O
agents NNS NNS O
were VBD VBD O
similar JJ JJ O
and CC CC O
occurred VBD VBD O
at IN IN O
approximately RB RB O
equivalent NN NN O
doses NNS NNS O
. . . O

Importantly NNP NNP O
, , , O
the DT DT O
local JJ JJ O
irritation NN NN O
of IN IN O
ACC NNP NNP B-CHEM
- : : I-CHEM
9653 CD CD I-CHEM
was VBD VBD O
markedly RB RB O
less JJR JJR O
than IN IN O
phenytoin VB VB B-CHEM
sodium NN NN I-CHEM
following NN NN O
i NNP NNP O
. . . O
m NN NN O
. . . O
administration NN NN O
. . . O
( ( ( O
ABSTRACT NNP NNP O
TRUNCATED NNP NNP O
AT IN IN O
250 CD CD O
WORDS NNP NNP O
) ) ) O

Tachyphylaxis NNP NNP O
to TO TO O
systemic JJ JJ O
but CC CC O
not RB RB O
to TO TO O
airway VB VB O
responses NNS NNS O
during IN IN O
prolonged JJ JJ O
therapy NN NN O
with IN IN O
high JJ JJ O
dose NN NN O
inhaled VBN VBN O
salbutamol NN NN B-CHEM
in IN IN O
asthmatics NNS NNS O
. . . O

High NNP NNP O
doses NNS NNS O
of IN IN O
inhaled JJ JJ O
salbutamol NN NN B-CHEM
produce NN NN O
substantial JJ JJ O
improvements NNS NNS O
in IN IN O
airway NN NN O
response NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
asthma NN NN O
, , , O
and CC CC O
are VBP VBP O
associated VBN VBN O
with IN IN O
dose NN NN O
- - - O
dependent JJ JJ O
systemic JJ JJ O
beta NN NN O
- - - O
adrenoceptor NN NN O
responses NNS NNS O
. . . O

The DT DT O
purpose NN NN O
of IN IN O
the DT DT O
present JJ JJ O
study NN NN O
was VBD VBD O
to TO TO O
investigate VB VB O
whether IN IN O
tachyphylaxis NN NN O
occurs VBZ VBZ O
during IN IN O
prolonged JJ JJ O
treatment NN NN O
with IN IN O
high JJ JJ O
dose NN NN O
inhaled JJ JJ O
salbutamol NN NN B-CHEM
. . . O

Twelve NNP NNP O
asthmatic JJ JJ O
patients NNS NNS O
( ( ( O
FEV1 NNP NNP O
, , , O
81 CD CD O
+ NN NN O
/ NN NN O
- : : O
4 CD CD O
% NN NN O
predicted VBN VBN O
) ) ) O
, , , O
requiring VBG VBG O
only RB RB O
occasional JJ JJ O
inhaled VBN VBN O
beta NN NN O
- - - O
agonists NNS NNS O
as IN IN O
their PRP$ PRP$ O
sole JJ JJ O
therapy NN NN O
, , , O
were VBD VBD O
given VBN VBN O
a DT DT O
14 CD CD O
- : : O
day NN NN O
treatment NN NN O
with IN IN O
high JJ JJ O
dose NN NN O
inhaled VBN VBN O
salbutamol NN NN B-CHEM
( ( ( O
HDS NNP NNP O
) ) ) O
, , , O
4 CD CD O
, , , O
000 CD CD O
micrograms NNS NNS O
daily JJ JJ O
, , , O
low JJ JJ O
dose NN NN O
inhaled JJ JJ O
salbutamol NN NN B-CHEM
( ( ( O
LDS NNP NNP O
) ) ) O
, , , O
800 CD CD O
micrograms NNS NNS O
daily JJ JJ O
, , , O
or CC CC O
placebo NN NN O
( ( ( O
PI NNP NNP O
) ) ) O
by IN IN O
metered JJ JJ O
- - - O
dose NN NN O
inhaler NN NN O
in IN IN O
a DT DT O
double JJ JJ O
- - - O
blind JJ JJ O
, , , O
randomized JJ JJ O
crossover NN NN O
design NN NN O
. . . O

During IN IN O
the DT DT O
14 CD CD O
- : : O
day NN NN O
run VB VB O
- : : O
in IN IN O
and CC CC O
during IN IN O
washout NN NN O
periods NNS NNS O
, , , O
inhaled VBN VBN O
beta NN NN O
- - - O
agonists NNS NNS O
were VBD VBD O
withheld VBN VBN O
and CC CC O
ipratropium NN NN B-CHEM
bromide NN NN I-CHEM
was VBD VBD O
substituted VBN VBN O
for IN IN O
rescue NN NN O
purposes NNS NNS O
. . . O

At IN IN O
the DT DT O
end NN NN O
of IN IN O
each DT DT O
14 CD CD O
- : : O
day NN NN O
treatment NN NN O
, , , O
a DT DT O
dose NN NN O
- - - O
response NN NN O
curve NN NN O
( ( ( O
DRC NNP NNP O
) ) ) O
was VBD VBD O
performed VBN VBN O
, , , O
and CC CC O
airway NN NN O
( ( ( O
FEV1 NNP NNP O
, , , O
FEF25 NNP NNP O
- : : O
75 CD CD O
) ) ) O
chronotropic NN NN O
( ( ( O
HR NNP NNP O
) ) ) O
, , , O
tremor NN NN O
, , , O
and CC CC O
metabolic JJ JJ O
( ( ( O
K NNP NNP B-CHEM
, , , O
Glu NNP NNP B-CHEM
) ) ) O
responses NNS NNS O
were VBD VBD O
measured VBN VBN O
at IN IN O
each DT DT O
step NN NN O
( ( ( O
from IN IN O
100 CD CD O
to TO TO O
4 CD CD O
, , , O
000 CD CD O
micrograms NNS NNS O
) ) ) O
. . . O

Treatment NN NN O
had VBD VBD O
no DT DT O
significant JJ JJ O
effect NN NN O
on IN IN O
baseline NN NN O
values NNS NNS O
. . . O

There EX EX O
were VBD VBD O
dose JJ JJ O
- - - O
dependent JJ JJ O
increases NNS NNS O
in IN IN O
FEV1 NNP NNP O
and CC CC O
FEF25 NNP NNP O
- : : O
75 CD CD O
( ( ( O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
, , , O
and CC CC O
pretreatment NN NN O
with IN IN O
HDS NNP NNP O
did VBD VBD O
not RB RB O
displace VB VB O
the DT DT O
DRC NNP NNP O
to TO TO O
the DT DT O
right NN NN O
. . . O

DRC NNP NNP O
for IN IN O
HR NNP NNP O
( ( ( O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
, , , O
K NNP NNP B-CHEM
( ( ( O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
, , , O
and CC CC O
Glu NNP NNP B-CHEM
( ( ( O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
005 CD CD O
) ) ) O
were VBD VBD O
attenuated VBN VBN O
after IN IN O
treatment NN NN O
with IN IN O
HDS NNP NNP O
compared VBN VBN O
with IN IN O
PI NNP NNP O
. . . O

There EX EX O
were VBD VBD O
also RB RB O
differences NNS NNS O
between IN IN O
HDS NNP NNP O
and CC CC O
LDS NNP NNP O
for IN IN O
HR NNP NNP O
( ( ( O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
and CC CC O
Glu NNP NNP B-CHEM
( ( ( O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
responses NNS NNS O
. . . O

Frequency NNP NNP O
and CC CC O
severity NN NN O
of IN IN O
subjective JJ JJ O
adverse JJ JJ O
effects NNS NNS O
were VBD VBD O
also RB RB O
reduced VBN VBN O
after IN IN O
HDS NNP NNP O
: : : O
tremor NN NN O
( ( ( O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
, , , O
palpitations NNS NNS O
( ( ( O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
. . . O
( ( ( O
ABSTRACT NNP NNP O
TRUNCATED NNP NNP O
AT IN IN O
250 CD CD O
WORDS NNP NNP O
) ) ) O

Phenytoin NNP NNP B-CHEM
induced VBD VBD O
fatal JJ JJ O
hepatic JJ JJ O
injury NN NN O
. . . O

A DT DT O
61 CD CD O
year NN NN O
old JJ JJ O
female JJ JJ O
developed VBN VBN O
fatal JJ JJ O
hepatic JJ JJ O
failure NN NN O
after IN IN O
phenytoin NN NN B-CHEM
administration NN NN O
. . . O

A DT DT O
typical JJ JJ O
multisystem NN NN O
clinical JJ JJ O
pattern NN NN O
precedes VBZ VBZ O
the DT DT O
manifestations NNS NNS O
of IN IN O
hepatic JJ JJ O
injury NN NN O
. . . O

The DT DT O
hematologic NN NN O
, , , O
biochemical JJ JJ O
and CC CC O
pathologic JJ JJ O
features NNS NNS O
indicate VBP VBP O
a DT DT O
mixed JJ JJ O
hepatocellular NN NN O
damage NN NN O
due JJ JJ O
to TO TO O
drug NN NN O
hypersensitivity NN NN O
. . . O

In IN IN O
a DT DT O
patient NN NN O
receiving VBG VBG O
phenytoin NN NN B-CHEM
who WP WP O
presents VBZ VBZ O
a DT DT O
viral NN NN O
- - - O
like IN IN O
illness NN NN O
, , , O
early JJ JJ O
recognition NN NN O
and CC CC O
discontinuation NN NN O
of IN IN O
the DT DT O
drug NN NN O
are VBP VBP O
mandatory JJ JJ O
. . . O

Treatment NN NN O
of IN IN O
lethal JJ JJ O
pertussis NN NN B-CHEM
vaccine NN NN I-CHEM
reaction NN NN O
with IN IN O
histamine NN NN B-CHEM
H1 NNP NNP O
antagonists NNS NNS O
. . . O

We PRP PRP O
studied VBD VBD O
mortality NN NN O
after IN IN O
pertussis NN NN O
immunization NN NN O
in IN IN O
the DT DT O
mouse NN NN O
. . . O

Without IN IN O
treatment NN NN O
, , , O
73 CD CD O
of IN IN O
92 CD CD O
animals NNS NNS O
( ( ( O
80 CD CD O
% NN NN O
) ) ) O
died VBD VBD O
after IN IN O
injection NN NN O
of IN IN O
bovine NN NN O
serum NN NN O
albumin NN NN O
( ( ( O
BSA NNP NNP O
) ) ) O
on IN IN O
day NN NN O
+ NN NN O
7 CD CD O
of IN IN O
pertussis NN NN O
immunization NN NN O
. . . O

After IN IN O
pretreatment NN NN O
with IN IN O
3 CD CD O
mg NN NN O
of IN IN O
cyproheptadine NN NN B-CHEM
, , , O
2 CD CD O
mg NN NN O
mianserin NN NN B-CHEM
, , , O
or CC CC O
2 CD CD O
mg NN NN O
chlorpheniramine NN NN B-CHEM
, , , O
only RB RB O
5 CD CD O
of IN IN O
105 CD CD O
animals NNS NNS O
( ( ( O
5 CD CD O
% NN NN O
) ) ) O
died VBD VBD O
after IN IN O
receiving VBG VBG O
BSA NNP NNP O
on IN IN O
day NN NN O
+ NN NN O
7 CD CD O
( ( ( O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
. . . O

Blockade NNP NNP O
of IN IN O
histamine NN NN B-CHEM
H1 NNP NNP O
receptors NNS NNS O
may MD MD O
reduce VB VB O
mortality NN NN O
in IN IN O
pertussis NN NN O
immunization NN NN O
- : : O
induced JJ JJ O
encephalopathy NN NN O
in IN IN O
mice NN NN O
. . . O

Support NN NN O
for IN IN O
adrenaline NN NN B-CHEM
- - - O
hypertension NN NN O
hypothesis NNS NNS O
: : : O
18 CD CD O
hour NN NN O
pressor NN NN O
effect NN NN O
after IN IN O
6 CD CD O
hours NNS NNS O
adrenaline JJ JJ B-CHEM
infusion NN NN O
. . . O

In IN IN O
a DT DT O
double JJ JJ O
blind JJ JJ O
, , , O
crossover NN NN O
study NN NN O
6 CD CD O
h NN NN O
infusions NNS NNS O
of IN IN O
adrenaline NN NN B-CHEM
( ( ( O
15 CD CD O
ng NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
; : : O
1 CD CD O
ng NN NN O
= SYM SYM O
5 CD CD O
. . . O
458 CD CD O
pmol NN NN O
) ) ) O
, , , O
noradrenaline NN NN B-CHEM
( ( ( O
30 CD CD O
ng NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
; : : O
1 CD CD O
ng NN NN O
= SYM SYM O
5 CD CD O
. . . O
911 CD CD O
pmol NN NN O
) ) ) O
, , , O
and CC CC O
a DT DT O
5 CD CD O
% NN NN O
dextrose NN NN B-CHEM
solution NN NN O
( ( ( O
5 CD CD O
. . . O
4 CD CD O
ml NN NN O
/ NN NN O
h NN NN O
) ) ) O
, , , O
were VBD VBD O
given VBN VBN O
to TO TO O
ten CD CD O
healthy JJ JJ O
volunteers NNS NNS O
in IN IN O
random JJ JJ O
order NN NN O
2 CD CD O
weeks NNS NNS O
apart RB RB O
. . . O

By IN IN O
means NNS NNS O
of IN IN O
intra NN NN O
- - - O
arterial JJ JJ O
ambulatory NN NN O
monitoring VBG VBG O
the DT DT O
haemodynamic JJ JJ O
effects NNS NNS O
were VBD VBD O
followed VBN VBN O
for IN IN O
18 CD CD O
h NN NN O
after IN IN O
the DT DT O
infusions NNS NNS O
were VBD VBD O
stopped VBN VBN O
. . . O

Adrenaline NNP NNP B-CHEM
, , , O
but CC CC O
not RB RB O
noradrenaline NN NN B-CHEM
, , , O
caused VBD VBD O
a DT DT O
delayed JJ JJ O
and CC CC O
protracted JJ JJ O
pressor NN NN O
effect NN NN O
. . . O

Over IN IN O
the DT DT O
total JJ JJ O
postinfusion NN NN O
period NN NN O
systolic JJ JJ O
and CC CC O
diastolic JJ JJ O
arterial JJ JJ O
pressure NN NN O
were VBD VBD O
6 CD CD O
( ( ( O
SEM NNP NNP O
2 CD CD O
) ) ) O
% NN NN O
and CC CC O
7 CD CD O
( ( ( O
2 CD CD O
) ) ) O
% NN NN O
, , , O
respectively RB RB O
, , , O
higher JJR JJR O
than IN IN O
after IN IN O
dextrose NN NN B-CHEM
infusion NN NN O
( ( ( O
ANOVA NNP NNP O
, , , O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
. . . O

Thus RB RB O
, , , O
" '' '' O
stress NN NN O
" '' '' O
levels NNS NNS O
of IN IN O
adrenaline NN NN B-CHEM
( ( ( O
230 CD CD O
pg NN NN O
/ NN NN O
ml NN NN O
) ) ) O
for IN IN O
6 CD CD O
h NN NN O
cause NN NN O
a DT DT O
delayed JJ JJ O
and CC CC O
protracted JJ JJ O
pressor NN NN O
effect NN NN O
. . . O

These DT DT O
findings NNS NNS O
are VBP VBP O
strong JJ JJ O
support NN NN O
for IN IN O
the DT DT O
adrenaline NN NN B-CHEM
- - - O
hypertension NN NN O
hypothesis NNS NNS O
in IN IN O
man NN NN O
. . . O

Effect NN NN O
of IN IN O
alkylxanthines NNS NNS B-CHEM
on IN IN O
gentamicin NN NN B-CHEM
- : : O
induced JJ JJ O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
in IN IN O
the DT DT O
rat NN NN O
. . . O

Adenosine NNP NNP B-CHEM
antagonists NNS NNS O
have VBP VBP O
been VBN VBN O
previously RB RB O
shown VBN VBN O
to TO TO O
be VB VB O
of IN IN O
benefit NN NN O
in IN IN O
some DT DT O
ischaemic JJ JJ O
and CC CC O
nephrotoxic JJ JJ O
models NNS NNS O
of IN IN O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
( ( ( O
ARF NNP NNP O
) ) ) O
. . . O

In IN IN O
the DT DT O
present JJ JJ O
study NN NN O
, , , O
the DT DT O
effects NNS NNS O
of IN IN O
three CD CD O
alkylxanthines NNS NNS B-CHEM
with IN IN O
different JJ JJ O
potencies NNS NNS O
as IN IN O
adenosine NN NN B-CHEM
antagonists NNS NNS O
8 CD CD B-CHEM
- : : I-CHEM
phenyltheophylline NN NN I-CHEM
, , , O
theophylline NN NN B-CHEM
and CC CC O
enprofylline NN NN B-CHEM
, , , O
were VBD VBD O
examined VBN VBN O
in IN IN O
rats NNS NNS O
developing VBG VBG O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
after IN IN O
4 CD CD O
daily JJ JJ O
injections NNS NNS O
of IN IN O
gentamicin NN NN B-CHEM
( ( ( O
200 CD CD O
mg NN NN O
kg NN NN O
- : : O
1 CD CD O
) ) ) O
. . . O

Renal NNP NNP O
function NN NN O
was VBD VBD O
assessed VBN VBN O
by IN IN O
biochemical JJ JJ O
( ( ( O
plasma NN NN O
urea NN NN B-CHEM
and CC CC O
creatinine NN NN B-CHEM
) ) ) O
, , , O
functional JJ JJ O
( ( ( O
urine NN NN O
analysis NN NN O
and CC CC O
[ NN NN O
3H CD CD O
] NN NN O
inulin NN NN O
and CC CC O
[ NN NN O
14C CD CD O
] NN NN O
p NN NN B-CHEM
- : : I-CHEM
aminohippuric JJ JJ I-CHEM
acid NN NN I-CHEM
clearances NNS NNS O
) ) ) O
and CC CC O
morphological JJ JJ O
( ( ( O
degree NN NN O
of IN IN O
necrosis NN NN O
) ) ) O
indices NNS NNS O
. . . O

The DT DT O
various JJ JJ O
drug NN NN O
treatments NNS NNS O
produced VBN VBN O
improvements NNS NNS O
in IN IN O
some DT DT O
, , , O
but CC CC O
not RB RB O
all DT DT O
, , , O
measurements NNS NNS O
of IN IN O
renal JJ JJ O
function NN NN O
. . . O

However RB RB O
, , , O
any DT DT O
improvement NN NN O
produced VBN VBN O
by IN IN O
drug NN NN O
treatment NN NN O
was VBD VBD O
largely RB RB O
a DT DT O
result NN NN O
of IN IN O
a DT DT O
beneficial JJ JJ O
effect NN NN O
exerted VBN VBN O
by IN IN O
its PRP$ PRP$ O
vehicle NN NN O
( ( ( O
polyethylene NN NN B-CHEM
glycol NN NN I-CHEM
and CC CC O
NaOH NNP NNP B-CHEM
) ) ) O
. . . O

The DT DT O
lack NN NN O
of IN IN O
any DT DT O
consistent JJ JJ O
protective JJ JJ O
effect NN NN O
noted VBD VBD O
with IN IN O
the DT DT O
alkylxanthines NNS NNS B-CHEM
tested VBN VBN O
in IN IN O
the DT DT O
present JJ JJ O
study NN NN O
indicates VBZ VBZ O
that IN IN O
adenosine NN NN B-CHEM
plays VBZ VBZ O
little JJ JJ O
, , , O
if IN IN O
any DT DT O
, , , O
pathophysiological JJ JJ O
role NN NN O
in IN IN O
gentamicin NN NN B-CHEM
- - - O
induced JJ JJ O
ARF NNP NNP O
. . . O

Adverse NNP NNP O
ocular JJ JJ O
reactions NNS NNS O
possibly RB RB O
associated VBN VBN O
with IN IN O
isotretinoin NN NN B-CHEM
. . . O

A DT DT O
total NN NN O
of IN IN O
261 CD CD O
adverse NN NN O
ocular JJ JJ O
reactions NNS NNS O
occurred VBD VBD O
in IN IN O
237 CD CD O
patients NNS NNS O
who WP WP O
received VBD VBD O
isotretinoin NN NN B-CHEM
, , , O
a DT DT O
commonly RB RB O
used VBN VBN O
drug NN NN O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
severe JJ JJ O
cystic JJ JJ O
acne NN NN O
. . . O

Blepharoconjunctivitis NNP NNP O
, , , O
subjective JJ JJ O
complaints NNS NNS O
of IN IN O
dry JJ JJ O
eyes NNS NNS O
, , , O
blurred JJ JJ O
vision NN NN O
, , , O
contact NN NN O
lens JJ JJ O
intolerance NN NN O
, , , O
and CC CC O
photodermatitis NNS NNS O
are VBP VBP O
reversible JJ JJ O
side NN NN O
effects NNS NNS O
. . . O

More RBR RBR O
serious JJ JJ O
ocular JJ JJ O
adverse JJ JJ O
reactions NNS NNS O
include VBP VBP O
papilledema NN NN O
, , , O
pseudotumor NN NN O
cerebri NN NN O
, , , O
and CC CC O
white JJ JJ O
or CC CC O
gray JJ JJ O
subepithelial NN NN O
corneal NN NN O
opacities NNS NNS O
; : : O
all DT DT O
of IN IN O
these DT DT O
are VBP VBP O
reversible JJ JJ O
if IN IN O
the DT DT O
drug NN NN O
is VBZ VBZ O
discontinued VBN VBN O
. . . O

Reported NNP NNP O
cases NNS NNS O
of IN IN O
decreased VBD VBD O
dark JJ JJ O
adaptation NN NN O
are VBP VBP O
under IN IN O
investigation NN NN O
. . . O

Isotretinoin NNP NNP B-CHEM
is VBZ VBZ O
contraindicated VBN VBN O
in IN IN O
pregnancy NN NN O
because IN IN O
of IN IN O
the DT DT O
many JJ JJ O
reported VBD VBD O
congenital JJ JJ O
abnormalities NNS NNS O
after IN IN O
maternal JJ JJ O
use NN NN O
( ( ( O
including VBG VBG O
microphthalmos NNS NNS O
, , , O
orbital JJ JJ O
hypertelorism NN NN O
, , , O
and CC CC O
optic JJ JJ O
nerve NN NN O
hypoplasia NN NN O
) ) ) O
. . . O

Procaterol NNP NNP B-CHEM
and CC CC O
terbutaline NN NN B-CHEM
in IN IN O
bronchial JJ JJ O
asthma NN NN O
. . . O

A DT DT O
double JJ JJ O
- - - O
blind JJ JJ O
, , , O
placebo NN NN O
- - - O
controlled JJ JJ O
, , , O
cross JJ JJ O
- - - O
over IN IN O
study NN NN O
. . . O

Procaterol NNP NNP B-CHEM
, , , O
a DT DT O
new JJ JJ O
beta NN NN O
- : : O
2 CD CD O
adrenoceptor NN NN O
stimulant NN NN O
, , , O
was VBD VBD O
studied VBN VBN O
in IN IN O
a DT DT O
double JJ JJ O
- - - O
blind JJ JJ O
, , , O
placebo NN NN O
- - - O
controlled JJ JJ O
, , , O
cross JJ JJ O
- - - O
over IN IN O
trial NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
bronchial JJ JJ O
asthma NN NN O
. . . O

Oral NNP NNP O
procaterol NN NN B-CHEM
50 CD CD O
micrograms NNS NNS O
b SYM SYM O
. . . O
d SYM SYM O
. . . O
, , , O
procaterol NN NN B-CHEM
100 CD CD O
micrograms NNS NNS O
b SYM SYM O
. . . O
d SYM SYM O
. . . O
, , , O
and CC CC O
terbutaline NN NN B-CHEM
5 CD CD O
mg NN NN O
t NN NN O
. . . O
i NNP NNP O
. . . O
d SYM SYM O
. . . O
, , , O
were VBD VBD O
compared VBN VBN O
when WRB WRB O
given VBN VBN O
randomly NN NN O
in IN IN O
1 CD CD O
- : : O
week NN NN O
treatment NN NN O
periods NNS NNS O
. . . O

The DT DT O
best JJS JJS O
clinical JJ JJ O
effect NN NN O
was VBD VBD O
found VBN VBN O
with IN IN O
terbutaline NN NN B-CHEM
. . . O

Both DT DT O
anti JJ JJ O
- : : O
asthmatic JJ JJ O
and CC CC O
tremorgenic JJ JJ O
effects NNS NNS O
of IN IN O
procaterol NN NN B-CHEM
were VBD VBD O
dose JJ JJ O
- - - O
related VBN VBN O
. . . O

Procaterol NNP NNP B-CHEM
appeared VBD VBD O
effective JJ JJ O
in IN IN O
the DT DT O
doses NNS NNS O
tested VBN VBN O
, , , O
and CC CC O
a DT DT O
twice RB RB O
daily JJ JJ O
regimen NNS NNS O
would MD MD O
appear VB VB O
to TO TO O
be VB VB O
suitable JJ JJ O
with IN IN O
this DT DT O
drug NN NN O
. . . O

Subacute NNP NNP O
effects NNS NNS O
of IN IN O
propranolol NN NN B-CHEM
and CC CC O
B NNP NNP O
24 CD CD O
/ NN NN O
76 CD CD O
on IN IN O
isoproterenol NN NN B-CHEM
- : : O
induced JJ JJ O
rat NN NN O
heart NN NN O
hypertrophy NN NN O
in IN IN O
correlation NN NN O
with IN IN O
blood NN NN O
pressure NN NN O
. . . O

We PRP PRP O
compared VBD VBD O
the DT DT O
potential JJ JJ O
beta NN NN O
- - - O
receptor NN NN O
blocker NN NN O
, , , O
B NNP NNP O
24 CD CD O
/ NN NN O
76 CD CD O
i NNP NNP O
. . . O
e SYM SYM O
. . . O
1 CD CD O
- : : O
( ( ( O
2 CD CD O
, , , O
4 CD CD O
- : : O
dichlorophenoxy NN NN O
) ) ) O
- : : O
3 CD CD O
[ NN NN O
2 CD CD O
- : : O
3 CD CD O
, , , O
4 CD CD O
- : : O
dimethoxyphenyl NN NN O
) ) ) O
ethanolamino NN NN O
] NN NN O
- : : O
prop NN NN O
an DT DT O
- - - O
2 CD CD O
- : : O
ol NN NN O
, , , O
which WDT WDT O
is VBZ VBZ O
characterized VBN VBN O
by IN IN O
beta NN NN O
1 CD CD O
- : : O
adrenoceptor NN NN O
blocking VBG VBG O
and CC CC O
beta NN NN O
2 CD CD O
- : : O
adrenoceptor NN NN O
stimulating VBG VBG O
properties NNS NNS O
with IN IN O
propranolol NN NN B-CHEM
. . . O

The DT DT O
studies NNS NNS O
were VBD VBD O
performed VBN VBN O
using VBG VBG O
an DT DT O
experimental JJ JJ O
model NN NN O
of IN IN O
isoproterenol NN NN B-CHEM
- - - O
induced JJ JJ O
heart NN NN O
hypertrophy NN NN O
in IN IN O
rats NNS NNS O
. . . O

A DT DT O
correlation NN NN O
of IN IN O
the DT DT O
blood NN NN O
pressure NN NN O
was VBD VBD O
neither DT DT O
found VBN VBN O
in IN IN O
the DT DT O
development NN NN O
nor CC CC O
in IN IN O
the DT DT O
attempt NN NN O
to TO TO O
suppress VB VB O
the DT DT O
development NN NN O
of IN IN O
heart NN NN O
hypertrophy NN NN O
with IN IN O
the DT DT O
two CD CD O
beta NN NN O
- : : O
receptor NN NN O
blockers NNS NNS O
. . . O

Both DT DT O
beta NN NN O
- - - O
blockers NNS NNS O
influenced VBD VBD O
the DT DT O
development NN NN O
of IN IN O
hypertrophy NN NN O
to TO TO O
a DT DT O
different JJ JJ O
, , , O
but CC CC O
not RB RB O
reproducible JJ JJ O
extent NN NN O
. . . O

It PRP PRP O
was VBD VBD O
possible JJ JJ O
to TO TO O
suppress VB VB O
the DT DT O
increased VBN VBN O
ornithine NN NN B-CHEM
decarboxylase NN NN O
activity NN NN O
with IN IN O
both DT DT O
beta NN NN O
- - - O
blockers NNS NNS O
in IN IN O
hypertrophied VBN VBN O
hearts NNS NNS O
, , , O
but CC CC O
there EX EX O
was VBD VBD O
no DT DT O
effect NN NN O
on IN IN O
the DT DT O
heart NN NN O
mass NN NN O
. . . O

Neither DT DT O
propranolol NN NN B-CHEM
nor CC CC O
B NNP NNP O
24 CD CD O
/ NN NN O
76 CD CD O
could MD MD O
stop VB VB O
the DT DT O
changes NNS NNS O
in IN IN O
the DT DT O
characteristic JJ JJ O
myosin NN NN O
isoenzyme NN NN O
pattern NN NN O
of IN IN O
the DT DT O
hypertrophied VBN VBN O
rat NN NN O
heart NN NN O
. . . O

Thus RB RB O
, , , O
the DT DT O
investigations NNS NNS O
did VBD VBD O
not RB RB O
provide VB VB O
any DT DT O
evidence NN NN O
that IN IN O
the DT DT O
beta NN NN O
- - - O
receptor NN NN O
blockers NNS NNS O
propranolol NN NN B-CHEM
and CC CC O
B NNP NNP O
24 CD CD O
/ NN NN O
76 CD CD O
have VBP VBP O
the DT DT O
potency NN NN O
to TO TO O
prevent VB VB O
isoproterenol NN NN B-CHEM
from IN IN O
producing VBG VBG O
heart NN NN O
hypertrophy NN NN O
. . . O

Increased VBN VBN O
anxiogenic JJ JJ O
effects NNS NNS O
of IN IN O
caffeine NN NN B-CHEM
in IN IN O
panic NN NN O
disorders NNS NNS O
. . . O

The DT DT O
effects NNS NNS O
of IN IN O
oral JJ JJ O
administration NN NN O
of IN IN O
caffeine NN NN B-CHEM
( ( ( O
10 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
on IN IN O
behavioral JJ JJ O
ratings NNS NNS O
, , , O
somatic JJ JJ O
symptoms NNS NNS O
, , , O
blood NN NN O
pressure NN NN O
and CC CC O
plasma NN NN O
levels NNS NNS O
of IN IN O
3 CD CD B-CHEM
- : : I-CHEM
methoxy NN NN I-CHEM
- : : I-CHEM
4 CD CD I-CHEM
- : : I-CHEM
hydroxyphenethyleneglycol NN NN I-CHEM
( ( ( O
MHPG NNP NNP B-CHEM
) ) ) O
and CC CC O
cortisol NN NN B-CHEM
were VBD VBD O
determined VBN VBN O
in IN IN O
17 CD CD O
healthy JJ JJ O
subjects NNS NNS O
and CC CC O
21 CD CD O
patients NNS NNS O
meeting NN NN O
DSM NNP NNP O
- : : O
III NNP NNP O
criteria NNS NNS O
for IN IN O
agoraphobia NN NN O
with IN IN O
panic NN NN O
attacks NNS NNS O
or CC CC O
panic JJ JJ O
disorder NN NN O
. . . O

Caffeine NNP NNP B-CHEM
produced VBD VBD O
significantly RB RB O
greater JJR JJR O
increases NNS NNS O
in IN IN O
subject JJ JJ O
- - - O
rated JJ JJ O
anxiety NN NN O
, , , O
nervousness NN NN O
, , , O
fear NN NN O
, , , O
nausea NN NN O
, , , O
palpitations NNS NNS O
, , , O
restlessness NN NN O
, , , O
and CC CC O
tremors NNS NNS O
in IN IN O
the DT DT O
patients NNS NNS O
compared VBN VBN O
with IN IN O
healthy JJ JJ O
subjects NNS NNS O
. . . O

In IN IN O
the DT DT O
patients NNS NNS O
, , , O
but CC CC O
not RB RB O
the DT DT O
healthy JJ JJ O
subjects NNS NNS O
, , , O
these DT DT O
symptoms NNS NNS O
were VBD VBD O
significantly RB RB O
correlated JJ JJ O
with IN IN O
plasma NN NN O
caffeine NN NN B-CHEM
levels NNS NNS O
. . . O

Seventy NNP NNP O
- : : O
one CD CD O
percent NN NN O
of IN IN O
the DT DT O
patients NNS NNS O
reported VBD VBD O
that IN IN O
the DT DT O
behavioral JJ JJ O
effects NNS NNS O
of IN IN O
caffeine NN NN B-CHEM
were VBD VBD O
similar JJ JJ O
to TO TO O
those DT DT O
experienced VBN VBN O
during IN IN O
panic NN NN O
attacks NNS NNS O
. . . O

Caffeine NNP NNP B-CHEM
did VBD VBD O
not RB RB O
alter VB VB O
plasma NN NN O
MHPG NNP NNP B-CHEM
levels NNS NNS O
in IN IN O
either CC CC O
the DT DT O
healthy JJ JJ O
subjects NNS NNS O
or CC CC O
patients NNS NNS O
. . . O

Caffeine NNP NNP B-CHEM
increased VBD VBD O
plasma NN NN O
cortisol NN NN B-CHEM
levels NNS NNS O
equally RB RB O
in IN IN O
the DT DT O
patient NN NN O
and CC CC O
healthy JJ JJ O
groups NNS NNS O
. . . O

Because IN IN O
caffeine NN NN B-CHEM
is VBZ VBZ O
an DT DT O
adenosine NN NN B-CHEM
receptor NN NN O
antagonist NN NN O
, , , O
these DT DT O
results NNS NNS O
suggest VBP VBP O
that IN IN O
some DT DT O
panic JJ JJ O
disorder NN NN O
patients NNS NNS O
may MD MD O
have VB VB O
abnormalities NNS NNS O
in IN IN O
neuronal JJ JJ O
systems NNS NNS O
involving VBG VBG O
adenosine NN NN B-CHEM
. . . O

Patients NNS NNS O
with IN IN O
anxiety NN NN O
disorders NNS NNS O
may MD MD O
benefit VB VB O
by IN IN O
avoiding VBG VBG O
caffeine NN NN B-CHEM
- - - O
containing VBG VBG O
foods NNS NNS O
and CC CC O
beverages NNS NNS O
. . . O

Comparison NNP NNP O
of IN IN O
the DT DT O
effect NN NN O
of IN IN O
oxitropium NN NN B-CHEM
bromide NN NN I-CHEM
and CC CC O
of IN IN O
slow JJ JJ O
- - - O
release NN NN O
theophylline NN NN B-CHEM
on IN IN O
nocturnal JJ JJ O
asthma NN NN O
. . . O

The DT DT O
effects NNS NNS O
of IN IN O
a DT DT O
new JJ JJ O
inhaled JJ JJ O
antimuscarinic JJ JJ O
drug NN NN O
, , , O
oxitropium NN NN B-CHEM
bromide NN NN I-CHEM
, , , O
and CC CC O
of IN IN O
a DT DT O
slow JJ JJ O
- - - O
release NN NN O
theophylline NN NN B-CHEM
preparation NN NN O
upon IN IN O
nocturnal JJ JJ O
asthma NN NN O
were VBD VBD O
compared VBN VBN O
in IN IN O
a DT DT O
placebo NN NN O
- - - O
controlled VBN VBN O
double JJ JJ O
- - - O
blind JJ JJ O
study NN NN O
. . . O

Two CD CD O
samples NNS NNS O
were VBD VBD O
studied VBN VBN O
: : : O
12 CD CD O
patients NNS NNS O
received VBD VBD O
oxitropium NN NN B-CHEM
at IN IN O
600 CD CD O
micrograms NNS NNS O
( ( ( O
6 CD CD O
subjects NNS NNS O
) ) ) O
or CC CC O
at IN IN O
400 CD CD O
micrograms NNS NNS O
t NN NN O
. . . O
i NNP NNP O
. . . O
d SYM SYM O
. . . O

( ( ( O
6 CD CD O
subjects NNS NNS O
) ) ) O
whereas IN IN O
11 CD CD O
received VBD VBD O
theophylline NN NN B-CHEM
at IN IN O
300 CD CD O
mg NN NN O
b SYM SYM O
. . . O
i NNP NNP O
. . . O
d SYM SYM O
. . . O

Morning NNP NNP O
dipping VBG VBG O
, , , O
assessed VBN VBN O
by IN IN O
the DT DT O
fall NN NN O
in IN IN O
peak NN NN O
flow NN NN O
overnight JJ JJ O
, , , O
was VBD VBD O
significantly RB RB O
reduced VBN VBN O
in IN IN O
the DT DT O
periods NNS NNS O
when WRB WRB O
either CC CC O
active JJ JJ O
drug NN NN O
was VBD VBD O
taken VBN VBN O
, , , O
whereas IN IN O
no DT DT O
difference NN NN O
was VBD VBD O
noticed VBN VBN O
during IN IN O
the DT DT O
placebo NN NN O
administration NN NN O
. . . O

No DT DT O
significant JJ JJ O
difference NN NN O
was VBD VBD O
noticed VBN VBN O
between IN IN O
results NNS NNS O
obtained VBN VBN O
with IN IN O
either DT DT O
active JJ JJ O
drug NN NN O
, , , O
as RB RB O
well RB RB O
as IN IN O
with IN IN O
either DT DT O
dosage NN NN O
of IN IN O
oxitropium NN NN B-CHEM
. . . O

No DT DT O
subject NN NN O
reported VBD VBD O
side NN NN O
effects NNS NNS O
of IN IN O
oxitropium NN NN B-CHEM
, , , O
as IN IN O
compared VBN VBN O
to TO TO O
three CD CD O
subjects NNS NNS O
reporting VBG VBG O
nausea NN NN O
, , , O
vomiting VBG VBG O
and CC CC O
tremors NNS NNS O
after IN IN O
theophylline NN NN B-CHEM
. . . O

Oxitropium NNP NNP B-CHEM
proves NNS NNS O
to TO TO O
be VB VB O
a DT DT O
valuable JJ JJ O
alternative NN NN O
to TO TO O
theophylline VB VB B-CHEM
in IN IN O
nocturnal JJ JJ O
asthma NN NN O
, , , O
since IN IN O
it PRP PRP O
is VBZ VBZ O
equally RB RB O
potent JJ JJ O
, , , O
safer JJR JJR O
and CC CC O
does VBZ VBZ O
not RB RB O
require VB VB O
the DT DT O
titration NN NN O
of IN IN O
dosage NN NN O
. . . O

Penicillin NNP NNP B-CHEM
anaphylaxis NNS NNS O
. . . O

A DT DT O
case NN NN O
of IN IN O
oral JJ JJ O
penicillin NN NN B-CHEM
anaphylaxis NN NN O
is VBZ VBZ O
described VBN VBN O
, , , O
and CC CC O
the DT DT O
terminology NN NN O
, , , O
occurrence NN NN O
, , , O
clinical JJ JJ O
manifestations NNS NNS O
, , , O
pathogenesis NNS NNS O
, , , O
prevention NN NN O
, , , O
and CC CC O
treatment NN NN O
of IN IN O
anaphylaxis NNS NNS O
are VBP VBP O
reviewed VBN VBN O
. . . O

Emergency NNP NNP O
physicians NNS NNS O
should MD MD O
be VB VB O
aware JJ JJ O
of IN IN O
oral JJ JJ O
penicillin NN NN B-CHEM
anaphylaxis NN NN O
in IN IN O
order NN NN O
to TO TO O
prevent VB VB O
its PRP$ PRP$ O
occurrence NN NN O
by IN IN O
prescribing VBG VBG O
the DT DT O
antibiotic JJ JJ O
judiciously RB RB O
and CC CC O
knowledgeably RB RB O
and CC CC O
to TO TO O
offer VB VB O
optimal NN NN O
medical JJ JJ O
therapy NN NN O
once RB RB O
this DT DT O
life NN NN O
- : : O
threatening VBG VBG O
reaction NN NN O
has VBZ VBZ O
begun VBN VBN O
. . . O

Reversible NNP NNP O
valproic JJ JJ B-CHEM
acid NN NN I-CHEM
- - - O
induced JJ JJ O
dementia NN NN O
: : : O
a DT DT O
case NN NN O
report NN NN O
. . . O

Reversible NNP NNP O
valproic JJ JJ B-CHEM
acid NN NN I-CHEM
- - - O
induced JJ JJ O
dementia NN NN O
was VBD VBD O
documented VBN VBN O
in IN IN O
a DT DT O
21 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
man NN NN O
with IN IN O
epilepsy NN NN O
who WP WP O
had VBD VBD O
a DT DT O
3 CD CD O
- : : O
year NN NN O
history NN NN O
of IN IN O
insidious JJ JJ O
progressive JJ JJ O
decline NN NN O
in IN IN O
global JJ JJ O
cognitive NN NN O
abilities NNS NNS O
documented VBN VBN O
by IN IN O
serial JJ JJ O
neuropsychological JJ JJ O
studies NNS NNS O
. . . O

Repeat NN NN O
neuropsychological JJ JJ O
testing NN NN O
7 CD CD O
weeks NNS NNS O
after IN IN O
discontinuation NN NN O
of IN IN O
the DT DT O
drug NN NN O
revealed VBD VBD O
dramatic JJ JJ O
improvement NN NN O
in IN IN O
IQ NNP NNP O
, , , O
memory NN NN O
, , , O
naming VBG VBG O
, , , O
and CC CC O
other JJ JJ O
tasks NNS NNS O
commensurate VBP VBP O
with IN IN O
clinical JJ JJ O
recovery NN NN O
in IN IN O
his PRP$ PRP$ O
intellectual JJ JJ O
capacity NN NN O
. . . O

Possible JJ JJ O
pathophysiological JJ JJ O
mechanisms NNS NNS O
which WDT WDT O
may MD MD O
have VB VB O
been VBN VBN O
operative JJ JJ O
in IN IN O
this DT DT O
case NN NN O
include VBP VBP O
: : : O
a DT DT O
direct JJ JJ O
central JJ JJ O
nervous JJ JJ O
system NN NN O
( ( ( O
CNS NNP NNP O
) ) ) O
toxic JJ JJ O
effect NN NN O
of IN IN O
valproic JJ JJ B-CHEM
acid NN NN I-CHEM
; : : O
a DT DT O
paradoxical JJ JJ O
epileptogenic JJ JJ O
effect NN NN O
secondary JJ JJ O
to TO TO O
the DT DT O
drug NN NN O
; : : O
and CC CC O
an DT DT O
indirect NN NN O
CNS NNP NNP O
toxic JJ JJ O
effect NN NN O
mediated VBN VBN O
through IN IN O
valproic JJ JJ B-CHEM
acid NN NN I-CHEM
- - - O
induced JJ JJ O
hyperammonemia NN NN O
. . . O

Reversal NNP NNP O
of IN IN O
scopolamine NN NN B-CHEM
- - - O
induced JJ JJ O
amnesia NN NN O
of IN IN O
passive JJ JJ O
avoidance NN NN O
by IN IN O
pre NN NN O
- : : O
and CC CC O
post JJ JJ O
- : : O
training NN NN O
naloxone NN NN B-CHEM
. . . O

In IN IN O
a DT DT O
series NN NN O
of IN IN O
five CD CD O
experiments NNS NNS O
, , , O
the DT DT O
modulating VBG VBG O
role NN NN O
of IN IN O
naloxone NN NN B-CHEM
on IN IN O
a DT DT O
scopolamine NN NN B-CHEM
- - - O
induced JJ JJ O
retention NN NN O
deficit NN NN O
in IN IN O
a DT DT O
passive JJ JJ O
avoidance NN NN O
paradigm NN NN O
was VBD VBD O
investigated VBN VBN O
in IN IN O
mice NN NN O
. . . O

Scopolamine NNP NNP B-CHEM
, , , O
but CC CC O
not RB RB O
methyl NN NN B-CHEM
scopolamine NN NN I-CHEM
( ( ( O
1 CD CD O
and CC CC O
3 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
, , , O
induced VBD VBD O
an DT DT O
amnesia NN NN O
as IN IN O
measured VBN VBN O
by IN IN O
latency NN NN O
and CC CC O
duration NN NN O
parameters NNS NNS O
. . . O

Naloxone NNP NNP B-CHEM
( ( ( O
0 CD CD O
. . . O
3 CD CD O
, , , O
1 CD CD O
, , , O
3 CD CD O
, , , O
and CC CC O
10 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
injected JJ JJ O
prior RB RB O
to TO TO O
training NN NN O
attenuated VBD VBD O
the DT DT O
retention NN NN O
deficit NN NN O
with IN IN O
a DT DT O
peak NN NN O
of IN IN O
activity NN NN O
at IN IN O
3 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
. . . O

The DT DT O
effect NN NN O
of IN IN O
naloxone NN NN B-CHEM
could MD MD O
be VB VB O
antagonized VBN VBN O
with IN IN O
morphine NN NN B-CHEM
( ( ( O
1 CD CD O
, , , O
3 CD CD O
, , , O
and CC CC O
10 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
, , , O
demonstrating VBG VBG O
the DT DT O
opioid JJ JJ O
specificity NN NN O
of IN IN O
the DT DT O
naloxone NN NN B-CHEM
effect NN NN O
. . . O

Post NNP NNP O
- : : O
training NN NN O
administration NN NN O
of IN IN O
naloxone NN NN B-CHEM
( ( ( O
3 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
as IN IN O
a DT DT O
single JJ JJ O
or CC CC O
as IN IN O
a DT DT O
split NN NN O
dose NN NN O
also RB RB O
attenuated VBD VBD O
the DT DT O
scopolamine NN NN B-CHEM
- - - O
induced JJ JJ O
amnesia NN NN O
. . . O

Control NNP NNP O
experiments NNS NNS O
indicated VBD VBD O
that IN IN O
neither DT DT O
an DT DT O
increase NN NN O
in IN IN O
pain NN NN O
sensitivity NN NN O
( ( ( O
pre NN NN O
- - - O
training NN NN O
naloxone NN NN B-CHEM
) ) ) O
nor CC CC O
an DT DT O
induced JJ JJ O
aversive JJ JJ O
state NN NN O
( ( ( O
post NN NN O
- - - O
training NN NN O
naloxone NN NN B-CHEM
) ) ) O
appear VB VB O
to TO TO O
be VB VB O
responsible JJ JJ O
for IN IN O
the DT DT O
influence NN NN O
of IN IN O
naloxone NN NN B-CHEM
on IN IN O
the DT DT O
scopolamine NN NN B-CHEM
- - - O
induced JJ JJ O
retention NN NN O
deficit NN NN O
. . . O

These DT DT O
results NNS NNS O
extend VB VB O
previous JJ JJ O
findings NNS NNS O
implicating VBG VBG O
a DT DT O
cholinergic JJ JJ O
- - - O
opioid NN NN O
interaction NN NN O
in IN IN O
memory NN NN O
processes NNS NNS O
. . . O

A DT DT O
possible JJ JJ O
mechanism NN NN O
for IN IN O
this DT DT O
interaction NN NN O
involving VBG VBG O
the DT DT O
septo NN NN O
- - - O
hippocampal JJ JJ O
cholinergic JJ JJ O
pathway NN NN O
is VBZ VBZ O
discussed VBN VBN O
. . . O

Electron NNP NNP O
microscopic JJ JJ O
investigations NNS NNS O
of IN IN O
the DT DT O
cyclophosphamide NN NN B-CHEM
- - - O
induced JJ JJ O
lesions NNS NNS O
of IN IN O
the DT DT O
urinary JJ JJ O
bladder NN NN O
of IN IN O
the DT DT O
rat NN NN O
and CC CC O
their PRP$ PRP$ O
prevention NN NN O
by IN IN O
mesna NN NN B-CHEM
. . . O

Fully RB RB O
developed VBN VBN O
cyclophosphamide NN NN B-CHEM
- - - O
induced JJ JJ O
cystitis NN NN O
is VBZ VBZ O
characterized VBN VBN O
by IN IN O
nearly RB RB O
complete JJ JJ O
detachment NN NN O
of IN IN O
the DT DT O
urothelium NN NN O
, , , O
severe JJ JJ O
submucosal NN NN O
edema NN NN O
owing VBG VBG O
to TO TO O
damage VB VB O
to TO TO O
the DT DT O
microvascular NN NN O
bed NN NN O
and CC CC O
focal JJ JJ O
muscle NN NN O
necroses NNS NNS O
. . . O

The DT DT O
initial JJ JJ O
response NN NN O
to TO TO O
the DT DT O
primary JJ JJ O
attack NN NN O
by IN IN O
the DT DT O
cyclophosphamide NN NN B-CHEM
metabolites NNS NNS O
seems VBZ VBZ O
to TO TO O
be VB VB O
fragmentation NN NN O
of IN IN O
the DT DT O
luminal JJ JJ B-CHEM
membrane NN NN O
. . . O

This DT DT O
damages VBZ VBZ O
the DT DT O
cellular NN NN O
barrier NN NN O
against IN IN O
the DT DT O
hypertonic JJ JJ O
urine NN NN O
. . . O

Subsequent NNP NNP O
breaks NNS NNS O
in IN IN O
the DT DT O
lateral NN NN O
cell NN NN O
membranes NNS NNS O
of IN IN O
the DT DT O
superficial JJ JJ O
cells NNS NNS O
and CC CC O
in IN IN O
all PDT PDT O
the DT DT O
plasma NN NN O
membranes NNS NNS O
of IN IN O
the DT DT O
intermediate JJ JJ O
and CC CC O
basal NN NN O
cells NNS NNS O
, , , O
intercellular JJ JJ O
and CC CC O
intracellular JJ JJ O
edema NN NN O
and CC CC O
disintegration NN NN O
of IN IN O
the DT DT O
desmosomes NNS NNS O
and CC CC O
hemidesmosomes NNS NNS O
lead NN NN O
to TO TO O
progressive JJ JJ O
degeneration NN NN O
and CC CC O
detachment NN NN O
of IN IN O
the DT DT O
epithelial NN NN O
cells NNS NNS O
with IN IN O
exposure NN NN O
and CC CC O
splitting NN NN O
of IN IN O
the DT DT O
basal NN NN O
membrane NN NN O
. . . O

The DT DT O
morphological JJ JJ O
changes NNS NNS O
of IN IN O
the DT DT O
endothelial JJ JJ O
cells NNS NNS O
, , , O
which WDT WDT O
become VBP VBP O
more RBR RBR O
pronounced JJ JJ O
in IN IN O
the DT DT O
later JJ JJ O
stages NNS NNS O
of IN IN O
the DT DT O
experiment NN NN O
, , , O
the DT DT O
involvement NN NN O
of IN IN O
blood NN NN O
vessels NNS NNS O
regardless RB RB O
of IN IN O
their PRP$ PRP$ O
diameter NN NN O
and CC CC O
the DT DT O
location NN NN O
- - - O
dependent JJ JJ O
extent NN NN O
of IN IN O
the DT DT O
damage NN NN O
indicate VBP VBP O
a DT DT O
direct JJ JJ O
type NN NN O
of IN IN O
damage NN NN O
which WDT WDT O
is VBZ VBZ O
preceded VBN VBN O
by IN IN O
a DT DT O
mediator NN NN O
- - - O
induced JJ JJ O
increase NN NN O
in IN IN O
permeability NN NN O
, , , O
the DT DT O
morphological JJ JJ O
correlate NN NN O
of IN IN O
which WDT WDT O
is VBZ VBZ O
the DT DT O
formation NN NN O
of IN IN O
gaps NNS NNS O
in IN IN O
the DT DT O
interendothelial JJ JJ O
cell NN NN O
connections NNS NNS O
on IN IN O
the DT DT O
venules NNS NNS O
. . . O

These DT DT O
changes NNS NNS O
can MD MD O
be VB VB O
effectively RB RB O
prevented VBN VBN O
by IN IN O
mesna NN NN B-CHEM
. . . O

The DT DT O
only JJ JJ O
sign NN NN O
of IN IN O
a DT DT O
possible JJ JJ O
involvement NN NN O
is VBZ VBZ O
the DT DT O
increase NN NN O
in IN IN O
the DT DT O
number NN NN O
of IN IN O
specific JJ JJ O
granules NNS NNS O
with IN IN O
a DT DT O
presumed JJ JJ O
lysosomal NN NN O
function NN NN O
in IN IN O
the DT DT O
superficial JJ JJ O
cells NNS NNS O
. . . O

Increase VB VB O
in IN IN O
intragastric JJ JJ O
pressure NN NN O
during IN IN O
suxamethonium NN NN B-CHEM
- - - O
induced JJ JJ O
muscle NN NN O
fasciculations NNS NNS O
in IN IN O
children NNS NNS O
: : : O
inhibition NN NN O
by IN IN O
alfentanil NN NN B-CHEM
. . . O

Changes NNS NNS O
in IN IN O
intragastric JJ JJ O
pressure NN NN O
after IN IN O
the DT DT O
administration NN NN O
of IN IN O
suxamethonium NN NN B-CHEM
1 CD CD O
. . . O
5 CD CD O
mg NN NN O
kg NN NN O
- : : O
1 CD CD O
i NNP NNP O
. . . O
v NN NN O
. . . O
were VBD VBD O
studied VBN VBN O
in IN IN O
32 CD CD O
children NNS NNS O
( ( ( O
mean VB VB O
age NN NN O
6 CD CD O
. . . O
9 CD CD O
yr NN NN O
) ) ) O
pretreated VBN VBN O
with IN IN O
either DT DT O
physiological JJ JJ O
saline NN NN O
or CC CC O
alfentanil NN NN B-CHEM
50 CD CD O
micrograms NNS NNS O
kg NN NN O
- : : O
1 CD CD O
. . . O

Anaesthesia NNP NNP O
was VBD VBD O
induced VBN VBN O
with IN IN O
thiopentone NN NN B-CHEM
5 CD CD O
mg NN NN O
kg NN NN O
- : : O
1 CD CD O
. . . O

The DT DT O
incidence NN NN O
and CC CC O
intensity NN NN O
of IN IN O
muscle NN NN O
fasciculations NNS NNS O
caused VBN VBN O
by IN IN O
suxamethonium NN NN B-CHEM
were VBD VBD O
significantly RB RB O
greater JJR JJR O
in IN IN O
the DT DT O
control NN NN O
than IN IN O
in IN IN O
the DT DT O
alfentanil NN NN B-CHEM
group NN NN O
. . . O

The DT DT O
intragastric JJ JJ O
pressure NN NN O
during IN IN O
muscle NN NN O
fasciculations NNS NNS O
was VBD VBD O
significantly RB RB O
higher JJR JJR O
in IN IN O
the DT DT O
control NN NN O
group NN NN O
( ( ( O
16 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
7 CD CD O
( ( ( O
SEM NNP NNP O
) ) ) O
cm NN NN O
H2O NNP NNP B-CHEM
) ) ) O
than IN IN O
in IN IN O
the DT DT O
alfentanil NN NN B-CHEM
group NN NN O
( ( ( O
7 CD CD O
. . . O
7 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
5 CD CD O
( ( ( O
SEM NNP NNP O
) ) ) O
cm NN NN O
H2O NNP NNP B-CHEM
) ) ) O
. . . O

The DT DT O
increase NN NN O
in IN IN O
intragastric JJ JJ O
pressure NN NN O
was VBD VBD O
directly RB RB O
related VBN VBN O
to TO TO O
the DT DT O
intensity NN NN O
of IN IN O
muscle NN NN O
fasciculations NNS NNS O
( ( ( O
regression NN NN O
line NN NN O
: : : O
y NN NN O
= SYM SYM O
0 CD CD O
. . . O
5 CD CD O
+ NN NN O
4 CD CD O
. . . O
78x CD CD O
with IN IN O
r NN NN O
of IN IN O
0 CD CD O
. . . O
78 CD CD O
) ) ) O
. . . O

It PRP PRP O
is VBZ VBZ O
concluded VBN VBN O
that IN IN O
intragastric JJ JJ O
pressure NN NN O
increases NNS NNS O
significantly RB RB O
during IN IN O
muscle NN NN O
fasciculations NNS NNS O
caused VBN VBN O
by IN IN O
suxamethonium NN NN B-CHEM
in IN IN O
healthy JJ JJ O
children NNS NNS O
. . . O

Alfentanil NNP NNP B-CHEM
50 CD CD O
micrograms NNS NNS O
kg NN NN O
- : : O
1 CD CD O
effectively RB RB O
inhibits VBZ VBZ O
the DT DT O
incidence NN NN O
and CC CC O
intensity NN NN O
of IN IN O
suxamethonium NN NN B-CHEM
- - - O
induced JJ JJ O
muscle NN NN O
fasciculations NNS NNS O
; : : O
moreover RB RB O
, , , O
intragastric JJ JJ O
pressure NN NN O
remains NNS NNS O
at IN IN O
its PRP$ PRP$ O
control NN NN O
value NN NN O
. . . O

Acute JJ JJ O
insulin NN NN O
treatment NN NN O
normalizes NNS NNS O
the DT DT O
resistance NN NN O
to TO TO O
the DT DT O
cardiotoxic JJ JJ O
effect NN NN O
of IN IN O
isoproterenol NN NN B-CHEM
in IN IN O
streptozotocin NN NN B-CHEM
diabetic JJ JJ O
rats NNS NNS O
. . . O

A DT DT O
morphometric JJ JJ O
study NN NN O
of IN IN O
isoproterenol NN NN B-CHEM
induced VBD VBD O
myocardial JJ JJ O
fibrosis NNS NNS O
. . . O

The DT DT O
acute JJ JJ O
effect NN NN O
of IN IN O
insulin NN NN O
treatment NN NN O
on IN IN O
the DT DT O
earlier RBR RBR O
reported VBD VBD O
protective JJ JJ O
effect NN NN O
of IN IN O
streptozotocin NN NN B-CHEM
diabetes NN NN O
against IN IN O
the DT DT O
cardiotoxic JJ JJ O
effect NN NN O
of IN IN O
high JJ JJ O
doses NNS NNS O
of IN IN O
isoproterenol NN NN B-CHEM
( ( ( O
ISO NNP NNP B-CHEM
) ) ) O
was VBD VBD O
investigated VBN VBN O
in IN IN O
rats NNS NNS O
. . . O

Thirty NNP NNP O
to TO TO O
135 CD CD O
min NN NN O
after IN IN O
the DT DT O
injection NN NN O
of IN IN O
crystalline NN NN O
insulin NN NN O
, , , O
ISO NNP NNP B-CHEM
was VBD VBD O
given VBN VBN O
subcutaneously RB RB O
and CC CC O
when WRB WRB O
ISO NNP NNP B-CHEM
induced VBD VBD O
fibrosis NNS NNS O
in IN IN O
the DT DT O
myocardium NN NN O
was VBD VBD O
morphometrically RB RB O
analyzed VBN VBN O
7 CD CD O
days NNS NNS O
later RB RB O
, , , O
a DT DT O
highly RB RB O
significant JJ JJ O
correlation NN NN O
( ( ( O
r LS LS O
= SYM SYM O
0 CD CD O
. . . O
83 CD CD O
, , , O
2 CD CD O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
006 CD CD O
) ) ) O
to TO TO O
the DT DT O
slope NN NN O
of IN IN O
the DT DT O
fall NN NN O
in IN IN O
blood NN NN O
glucose NN NN B-CHEM
after IN IN O
insulin NN NN O
treatment NN NN O
appeared VBD VBD O
. . . O

The DT DT O
myocardial NN NN O
content NN NN O
of IN IN O
catecholamines NNS NNS B-CHEM
was VBD VBD O
estimated VBN VBN O
in IN IN O
these DT DT O
8 CD CD O
day NN NN O
diabetic JJ JJ O
rats NNS NNS O
. . . O

The DT DT O
norepinephrine NN NN B-CHEM
content NN NN O
was VBD VBD O
significantly RB RB O
increased VBN VBN O
while IN IN O
epinephrine NN NN B-CHEM
remained VBD VBD O
unchanged JJ JJ O
. . . O

An DT DT O
enhanced JJ JJ O
sympathetic JJ JJ O
nervous JJ JJ O
system NN NN O
activity NN NN O
with IN IN O
a DT DT O
consequent NN NN O
down RB RB O
regulation NN NN O
of IN IN O
the DT DT O
myocardial NN NN O
beta NN NN O
- : : O
adrenergic JJ JJ O
receptors NNS NNS O
could MD MD O
, , , O
therefore RB RB O
, , , O
explain VB VB O
this DT DT O
catecholamine NN NN B-CHEM
resistance NN NN O
. . . O

The DT DT O
rapid JJ JJ O
reversion NN NN O
after IN IN O
insulin NN NN O
treatment NN NN O
excludes NNS NNS O
the DT DT O
possibility NN NN O
that WDT WDT O
streptozotocin NN NN B-CHEM
in IN IN O
itself PRP PRP O
causes VBZ VBZ O
the DT DT O
ISO NNP NNP B-CHEM
resistance NN NN O
and CC CC O
points NNS NNS O
towards IN IN O
a DT DT O
direct JJ JJ O
insulin NN NN O
effect NN NN O
on IN IN O
myocardial NN NN O
catecholamine NN NN B-CHEM
sensitivity NN NN O
in IN IN O
diabetic JJ JJ O
rats NNS NNS O
. . . O

The DT DT O
phenomenon NN NN O
described VBD VBD O
might MD MD O
elucidate VB VB O
pathogenetic JJ JJ O
mechanisms NNS NNS O
behind IN IN O
toxic JJ JJ O
myocardial NN NN O
cell NN NN O
degeneration NN NN O
and CC CC O
may MD MD O
possibly RB RB O
have VB VB O
relevance NN NN O
for IN IN O
acute JJ JJ O
cardiovascular JJ JJ O
complications NNS NNS O
in IN IN O
diabetic JJ JJ O
patients NNS NNS O
. . . O

Differential NNP NNP O
effects NNS NNS O
of IN IN O
non NN NN O
- - - O
steroidal NN NN O
anti NN NN O
- : : O
inflammatory JJ JJ O
drugs NNS NNS O
on IN IN O
seizures NNS NNS O
produced VBN VBN O
by IN IN O
pilocarpine NN NN B-CHEM
in IN IN O
rats NNS NNS O
. . . O

The DT DT O
muscarinic JJ JJ O
cholinergic JJ JJ O
agonist NN NN O
pilocarpine NN NN B-CHEM
induces NNS NNS O
in IN IN O
rats NNS NNS O
seizures NNS NNS O
and CC CC O
status NN NN O
epilepticus NN NN O
followed VBN VBN O
by IN IN O
widespread NN NN O
damage NN NN O
to TO TO O
the DT DT O
forebrain NN NN O
. . . O

The DT DT O
present JJ JJ O
study NN NN O
was VBD VBD O
designed VBN VBN O
to TO TO O
investigate VB VB O
the DT DT O
effect NN NN O
of IN IN O
5 CD CD O
non NN NN O
- : : O
steroidal NN NN O
anti NN NN O
- : : O
inflammatory JJ JJ O
drugs NNS NNS O
, , , O
sodium NN NN B-CHEM
salicylate NN NN I-CHEM
, , , O
phenylbutazone NN NN B-CHEM
, , , O
indomethacin NN NN B-CHEM
, , , O
ibuprofen NN NN B-CHEM
and CC CC O
mefenamic JJ JJ B-CHEM
acid NN NN I-CHEM
, , , O
on IN IN O
seizures NNS NNS O
produced VBN VBN O
by IN IN O
pilocarpine NN NN B-CHEM
. . . O

Pretreatment NNP NNP O
of IN IN O
rats NNS NNS O
with IN IN O
sodium NN NN B-CHEM
salicylate NN NN I-CHEM
, , , O
ED50 NNP NNP O
103 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
( ( ( O
60 CD CD O
- : : O
174 CD CD O
) ) ) O
, , , O
and CC CC O
phenylbutazone NN NN B-CHEM
, , , O
59 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
( ( ( O
50 CD CD O
- : : O
70 CD CD O
) ) ) O
converted VBD VBD O
the DT DT O
non NN NN O
- - - O
convulsant NN NN O
dose NN NN O
of IN IN O
pilocarpine NN NN B-CHEM
, , , O
200 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
to TO TO O
a DT DT O
convulsant NN NN O
one CD CD O
. . . O

Indomethacin NNP NNP B-CHEM
, , , O
1 CD CD O
- : : O
10 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
and CC CC O
ibuprofen NN NN B-CHEM
, , , O
10 CD CD O
- : : O
100 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
failed VBD VBD O
to TO TO O
modulate VB VB O
seizures NNS NNS O
produced VBN VBN O
by IN IN O
pilocarpine NN NN B-CHEM
. . . O

Mefenamic NNP NNP B-CHEM
acid NN NN I-CHEM
, , , O
26 CD CD O
( ( ( O
22 CD CD O
- : : O
30 CD CD O
) ) ) O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
prevented JJ JJ O
seizures NNS NNS O
and CC CC O
protected VBN VBN O
rats NNS NNS O
from IN IN O
seizure NN NN O
- - - O
related VBN VBN O
brain NN NN O
damage NN NN O
induced VBN VBN O
by IN IN O
pilocarpine NN NN B-CHEM
, , , O
380 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
. . . O

These DT DT O
results NNS NNS O
indicate VBP VBP O
that IN IN O
non NN NN O
- : : O
steroidal NN NN O
anti NN NN O
- : : O
inflammatory JJ JJ O
drugs NNS NNS O
differentially RB RB O
modulate VBP VBP O
the DT DT O
threshold NN NN O
for IN IN O
pilocarpine NN NN B-CHEM
- - - O
induced JJ JJ O
seizures NNS NNS O
. . . O

Acute JJ JJ O
neurologic JJ JJ O
dysfunction NN NN O
after IN IN O
high JJ JJ O
- - - O
dose NN NN O
etoposide NN NN B-CHEM
therapy NN NN O
for IN IN O
malignant JJ JJ O
glioma NN NN O
. . . O

Etoposide NNP NNP B-CHEM
( ( ( O
VP NNP NNP B-CHEM
- : : I-CHEM
16 CD CD I-CHEM
- : : I-CHEM
213 CD CD I-CHEM
) ) ) O
has VBZ VBZ O
been VBN VBN O
used VBN VBN O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
many JJ JJ O
solid JJ JJ O
tumors NNS NNS O
and CC CC O
hematologic JJ JJ O
malignancies NNS NNS O
. . . O

When WRB WRB O
used VBN VBN O
in IN IN O
high JJ JJ O
doses NNS NNS O
and CC CC O
in IN IN O
conjunction NN NN O
with IN IN O
autologous JJ JJ O
bone NN NN O
marrow NN NN O
transplantation NN NN O
, , , O
this DT DT O
agent NN NN O
has VBZ VBZ O
activity NN NN O
against IN IN O
several JJ JJ O
treatment NN NN O
- - - O
resistant JJ JJ O
cancers NNS NNS O
including VBG VBG O
malignant JJ JJ O
glioma NN NN O
. . . O

In IN IN O
six CD CD O
of IN IN O
eight CD CD O
patients NNS NNS O
( ( ( O
75 CD CD O
% NN NN O
) ) ) O
who WP WP O
we PRP PRP O
treated VBD VBD O
for IN IN O
recurrent JJ JJ O
or CC CC O
resistant JJ JJ O
glioma NN NN O
, , , O
sudden JJ JJ O
severe JJ JJ O
neurologic JJ JJ O
deterioration NN NN O
occurred VBD VBD O
. . . O

This DT DT O
developed VBD VBD O
a DT DT O
median NN NN O
of IN IN O
9 CD CD O
days NNS NNS O
after IN IN O
initiation NN NN O
of IN IN O
high JJ JJ O
- - - O
dose NN NN O
etoposide NN NN B-CHEM
therapy NN NN O
. . . O

Significant JJ JJ O
clinical JJ JJ O
manifestations NNS NNS O
have VBP VBP O
included VBN VBN O
confusion NN NN O
, , , O
papilledema NN NN O
, , , O
somnolence NN NN O
, , , O
exacerbation NN NN O
of IN IN O
motor NN NN O
deficits NNS NNS O
, , , O
and CC CC O
sharp JJ JJ O
increase NN NN O
in IN IN O
seizure NN NN O
activity NN NN O
. . . O

These DT DT O
abnormalities NNS NNS O
resolved VBD VBD O
rapidly RB RB O
after IN IN O
initiation NN NN O
of IN IN O
high JJ JJ O
- - - O
dose NN NN O
intravenous JJ JJ O
dexamethasone NN NN B-CHEM
therapy NN NN O
. . . O

In IN IN O
all DT DT O
patients NNS NNS O
, , , O
computerized VBN VBN O
tomographic JJ JJ O
( ( ( O
CT NNP NNP O
) ) ) O
brain NN NN O
scans NNS NNS O
demonstrated VBN VBN O
stability NN NN O
in IN IN O
tumor NN NN O
size NN NN O
and CC CC O
peritumor NN NN O
edema NN NN O
when WRB WRB O
compared VBN VBN O
with IN IN O
pretransplant NN NN O
scans NNS NNS O
. . . O

This DT DT O
complication NN NN O
appears VBZ VBZ O
to TO TO O
represent VB VB O
a DT DT O
significant JJ JJ O
new JJ JJ O
toxicity NN NN O
of IN IN O
high JJ JJ O
- - - O
dose NN NN O
etoposide NN NN B-CHEM
therapy NN NN O
for IN IN O
malignant JJ JJ O
glioma NN NN O
. . . O

Progressive NNP NNP O
bile IN IN O
duct NN NN O
injury NN NN O
after IN IN O
thiabendazole NN NN B-CHEM
administration NN NN O
. . . O

A DT DT O
27 CD CD O
- : : O
yr NN NN O
- - - O
old JJ JJ O
man NN NN O
developed VBN VBN O
jaundice NN NN O
2 CD CD O
wk NN NN O
after IN IN O
exposure NN NN O
to TO TO O
thiabendazole NN NN B-CHEM
. . . O

Cholestasis NNP NNP O
persisted VBD VBD O
for IN IN O
3 CD CD O
yr NN NN O
, , , O
at IN IN O
which WDT WDT O
time NN NN O
a DT DT O
liver NN NN O
transplant NN NN O
was VBD VBD O
performed VBN VBN O
. . . O

Two CD CD O
liver NN NN O
biopsy NN NN O
specimens NNS NNS O
and CC CC O
the DT DT O
hepatectomy NN NN O
specimen NN NN O
were VBD VBD O
remarkable JJ JJ O
for IN IN O
almost RB RB O
complete JJ JJ O
disappearance NN NN O
of IN IN O
interlobular JJ JJ O
bile NN NN O
ducts NNS NNS O
. . . O

Prominent NNP NNP O
fibrosis NNS NNS O
and CC CC O
hepatocellular NN NN O
regeneration NN NN O
were VBD VBD O
also RB RB O
present JJ JJ O
; : : O
however RB RB O
, , , O
the DT DT O
lobular NN NN O
architecture NN NN O
was VBD VBD O
preserved VBN VBN O
. . . O

This DT DT O
case NN NN O
represents VBZ VBZ O
an DT DT O
example NN NN O
of IN IN O
" '' '' O
idiosyncratic JJ JJ O
" '' '' O
drug NN NN O
- - - O
induced JJ JJ O
liver NN NN O
damage NN NN O
in IN IN O
which WDT WDT O
the DT DT O
primary JJ JJ O
target NN NN O
of IN IN O
injury NN NN O
is VBZ VBZ O
the DT DT O
bile NN NN O
duct NN NN O
. . . O

An DT DT O
autoimmune JJ JJ O
pathogenesis NN NN O
of IN IN O
the DT DT O
bile NN NN O
duct NN NN O
destruction NN NN O
is VBZ VBZ O
suggested VBN VBN O
. . . O

Differential NNP NNP O
effects NNS NNS O
of IN IN O
1 CD CD B-CHEM
, , , I-CHEM
4 CD CD I-CHEM
- : : I-CHEM
dihydropyridine NN NN I-CHEM
calcium NN NN B-CHEM
channel NN NN I-CHEM
blockers NNS NNS I-CHEM
: : : O
therapeutic JJ JJ O
implications NNS NNS O
. . . O

Increasing NNP NNP O
recognition NN NN O
of IN IN O
the DT DT O
importance NN NN O
of IN IN O
calcium NN NN B-CHEM
in IN IN O
the DT DT O
pathogenesis NNS NNS O
of IN IN O
cardiovascular JJ JJ O
disease NN NN O
has VBZ VBZ O
stimulated VBN VBN O
research NN NN O
into IN IN O
the DT DT O
use NN NN O
of IN IN O
calcium NN NN B-CHEM
channel NN NN I-CHEM
blocking VBG VBG I-CHEM
agents NNS NNS I-CHEM
for IN IN O
treatment NN NN O
of IN IN O
a DT DT O
variety NN NN O
of IN IN O
cardiovascular JJ JJ O
diseases NNS NNS O
. . . O

The DT DT O
favorable JJ JJ O
efficacy NN NN O
and CC CC O
tolerability NN NN O
profiles NNS NNS O
of IN IN O
these DT DT O
agents NNS NNS O
make VBP VBP O
them PRP PRP O
attractive JJ JJ O
therapeutic JJ JJ O
modalities NNS NNS O
. . . O

Clinical NNP NNP O
applications NNS NNS O
of IN IN O
calcium NN NN B-CHEM
channel NN NN I-CHEM
blockers NNS NNS I-CHEM
parallel VBP VBP O
their PRP$ PRP$ O
tissue NN NN O
selectivity NN NN O
. . . O

In IN IN O
contrast NN NN O
to TO TO O
verapamil NN NN B-CHEM
and CC CC O
diltiazem NN NN B-CHEM
, , , O
which WDT WDT O
are VBP VBP O
roughly RB RB O
equipotent JJ JJ O
in IN IN O
their PRP$ PRP$ O
actions NNS NNS O
on IN IN O
the DT DT O
heart NN NN O
and CC CC O
vascular NN NN O
smooth JJ JJ O
muscle NN NN O
, , , O
the DT DT O
dihydropyridine NN NN B-CHEM
calcium NN NN B-CHEM
channel NN NN I-CHEM
blockers NNS NNS I-CHEM
are VBP VBP O
a DT DT O
group NN NN O
of IN IN O
potent NN NN O
peripheral JJ JJ O
vasodilator NN NN O
agents NNS NNS O
that WDT WDT O
exert NN NN O
minimal JJ JJ O
electrophysiologic JJ JJ O
effects NNS NNS O
on IN IN O
cardiac JJ JJ O
nodal NN NN O
or CC CC O
conduction NN NN O
tissue NN NN O
. . . O

As IN IN O
the DT DT O
first JJ JJ O
dihydropyridine NN NN B-CHEM
available JJ JJ O
for IN IN O
use NN NN O
in IN IN O
the DT DT O
United NNP NNP O
States NNPS NNPS O
, , , O
nifedipine NN NN B-CHEM
controls NNS NNS O
angina NN NN O
and CC CC O
hypertension NN NN O
with IN IN O
minimal JJ JJ O
depression NN NN O
of IN IN O
cardiac JJ JJ O
function NN NN O
. . . O

Additional JJ JJ O
members NNS NNS O
of IN IN O
this DT DT O
group NN NN O
of IN IN O
calcium NN NN B-CHEM
channel NN NN I-CHEM
blockers NNS NNS I-CHEM
have VBP VBP O
been VBN VBN O
studied VBN VBN O
for IN IN O
a DT DT O
variety NN NN O
of IN IN O
indications NNS NNS O
for IN IN O
which WDT WDT O
they PRP PRP O
may MD MD O
offer VB VB O
advantages NNS NNS O
over IN IN O
current JJ JJ O
therapy NN NN O
. . . O

Once RB RB O
or CC CC O
twice RB RB O
daily JJ JJ O
dosage NN NN O
possible JJ JJ O
with IN IN O
nitrendipine NN NN B-CHEM
and CC CC O
nisoldipine NN NN B-CHEM
offers VBZ VBZ O
a DT DT O
convenient JJ JJ O
administration NN NN O
schedule NN NN O
, , , O
which WDT WDT O
encourages VBZ VBZ O
patient NN NN O
compliance NN NN O
in IN IN O
long JJ JJ O
- - - O
term NN NN O
therapy NN NN O
of IN IN O
hypertension NN NN O
. . . O

The DT DT O
coronary JJ JJ O
vasodilating NN NN O
properties NNS NNS O
of IN IN O
nisoldipine NN NN B-CHEM
have VBP VBP O
led VBN VBN O
to TO TO O
the DT DT O
investigation NN NN O
of IN IN O
this DT DT O
agent NN NN O
for IN IN O
use NN NN O
in IN IN O
angina NN NN O
. . . O

Selectivity NNP NNP O
for IN IN O
the DT DT O
cerebrovascular NN NN O
bed NN NN O
makes VBZ VBZ O
nimodipine NN NN B-CHEM
potentially RB RB O
useful JJ JJ O
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
subarachnoid NN NN O
hemorrhage NN NN O
, , , O
migraine NN NN O
headache NN NN O
, , , O
dementia NN NN O
, , , O
and CC CC O
stroke NN NN O
. . . O

In IN IN O
general JJ JJ O
, , , O
the DT DT O
dihydropyridine NN NN B-CHEM
calcium NN NN B-CHEM
channel NN NN I-CHEM
blockers NNS NNS I-CHEM
are VBP VBP O
usually RB RB O
well RB RB O
tolerated VBD VBD O
, , , O
with IN IN O
headache NN NN O
, , , O
facial JJ JJ O
flushing NN NN O
, , , O
palpitations NNS NNS O
, , , O
edema NN NN O
, , , O
nausea NN NN O
, , , O
anorexia NN NN O
, , , O
and CC CC O
dizziness NN NN O
being VBG VBG O
the DT DT O
more RBR RBR O
common JJ JJ O
adverse NN NN O
effects NNS NNS O
. . . O

The DT DT O
enhancement NN NN O
of IN IN O
aminonucleoside NN NN B-CHEM
nephrosis NNS NNS O
by IN IN O
the DT DT O
co NN NN O
- - - O
administration NN NN O
of IN IN O
protamine NN NN O
. . . O

An DT DT O
experimental JJ JJ O
model NN NN O
of IN IN O
focal JJ JJ O
segmental NN NN O
glomerular NN NN O
sclerosis NN NN O
( ( ( O
FSGS NNP NNP O
) ) ) O
was VBD VBD O
developed VBN VBN O
in IN IN O
rats NNS NNS O
by IN IN O
the DT DT O
combined JJ JJ O
administration NN NN O
of IN IN O
puromycin NN NN B-CHEM
- - - I-CHEM
aminonucleoside NN NN I-CHEM
( ( ( O
AMNS NNP NNP B-CHEM
) ) ) O
and CC CC O
protamine NN NN B-CHEM
sulfate NN NN I-CHEM
( ( ( O
PS NNP NNP B-CHEM
) ) ) O
. . . O

Male NNP NNP O
Sprague NNP NNP O
- : : O
Dawley NNP NNP O
rats NNS NNS O
, , , O
uninephrectomized JJ JJ O
three CD CD O
weeks NNS NNS O
before IN IN O
, , , O
received VBD VBD O
daily JJ JJ O
injections NNS NNS O
of IN IN O
subcutaneous JJ JJ O
AMNS NNP NNP B-CHEM
( ( ( O
1 CD CD O
mg NN NN O
/ NN NN O
100 CD CD O
g SYM SYM O
body NN NN O
wt NN NN O
) ) ) O
and CC CC O
intravenous JJ JJ O
PS NNP NNP B-CHEM
( ( ( O
2 CD CD O
separated JJ JJ O
doses NNS NNS O
of IN IN O
2 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
100 CD CD O
g SYM SYM O
body NN NN O
wt NN NN O
) ) ) O
for IN IN O
four CD CD O
days NNS NNS O
. . . O

The DT DT O
series NN NN O
of IN IN O
injections NNS NNS O
were VBD VBD O
repeated VBN VBN O
another DT DT O
three CD CD O
times NNS NNS O
at IN IN O
10 CD CD O
day NN NN O
intervals NNS NNS O
. . . O

The DT DT O
animals NNS NNS O
were VBD VBD O
sacrificed VBN VBN O
on IN IN O
days NNS NNS O
24 CD CD O
, , , O
52 CD CD O
, , , O
and CC CC O
80 CD CD O
. . . O

They PRP PRP O
developed VBD VBD O
nephrotic JJ JJ O
syndrome NN NN O
and CC CC O
finally RB RB O
renal JJ JJ O
failure NN NN O
. . . O

The DT DT O
time NN NN O
- - - O
course NN NN O
curve NN NN O
of IN IN O
creatinine NN NN B-CHEM
clearance NN NN O
dropped VBD VBD O
and CC CC O
showed VBD VBD O
significant JJ JJ O
difference NN NN O
( ( ( O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
from IN IN O
that DT DT O
of IN IN O
each DT DT O
control NN NN O
group NN NN O
, , , O
such JJ JJ O
as IN IN O
, , , O
AMNS NNP NNP B-CHEM
alone RB RB O
, , , O
PS NNP NNP B-CHEM
alone RB RB O
or CC CC O
saline NN NN O
injected VBN VBN O
. . . O

Their PRP$ PRP$ O
glomeruli NN NN O
showed VBD VBD O
changes NNS NNS O
of IN IN O
progressive JJ JJ O
FSGS NNP NNP O
. . . O

The DT DT O
ultrastructural JJ JJ O
studies NNS NNS O
in IN IN O
the DT DT O
initial JJ JJ O
stage NN NN O
revealed VBD VBD O
significant JJ JJ O
lack NN NN O
of IN IN O
particles NNS NNS O
of IN IN O
perfused JJ JJ O
ruthenium NN NN B-CHEM
red JJ JJ O
on IN IN O
the DT DT O
lamina NN NN O
rara NN NN O
externa NN NN O
and CC CC O
marked VBD VBD O
changes NNS NNS O
in IN IN O
epithelial NN NN O
cell NN NN O
cytoplasm NN NN O
. . . O

Therefore RB RB O
, , , O
it PRP PRP O
is VBZ VBZ O
suggested VBN VBN O
that IN IN O
the DT DT O
administration NN NN O
of IN IN O
PS NNP NNP B-CHEM
enhances VBZ VBZ O
the DT DT O
toxicity NN NN O
of IN IN O
AMNS NNP NNP B-CHEM
on IN IN O
the DT DT O
glomerulus NN NN O
and CC CC O
readily RB RB O
produces VBZ VBZ O
progressive JJ JJ O
FSGS NNP NNP O
in IN IN O
rats NNS NNS O
resulting VBG VBG O
in IN IN O
the DT DT O
end NN NN O
- : : O
stage NN NN O
renal NN NN O
disease NN NN O
. . . O

Theophylline NNP NNP B-CHEM
neurotoxicity NN NN O
in IN IN O
pregnant JJ JJ O
rats NNS NNS O
. . . O

The DT DT O
purpose NN NN O
of IN IN O
this DT DT O
investigation NN NN O
was VBD VBD O
to TO TO O
determine VB VB O
whether IN IN O
the DT DT O
neurotoxicity NN NN O
of IN IN O
theophylline NN NN B-CHEM
is VBZ VBZ O
altered VBN VBN O
in IN IN O
advanced JJ JJ O
pregnancy NN NN O
. . . O

Sprague NNP NNP O
- : : O
Dawley NNP NNP O
rats NNS NNS O
that WDT WDT O
were VBD VBD O
20 CD CD O
days NNS NNS O
pregnant JJ JJ O
and CC CC O
nonpregnant JJ JJ O
rats NNS NNS O
of IN IN O
the DT DT O
same JJ JJ O
age NN NN O
and CC CC O
strain NN NN O
received VBD VBD O
infusions NNS NNS O
of IN IN O
aminophylline NN NN B-CHEM
until IN IN O
onset NN NN O
of IN IN O
maximal NN NN O
seizures NNS NNS O
which WDT WDT O
occurred VBD VBD O
after IN IN O
28 CD CD O
and CC CC O
30 CD CD O
minutes NNS NNS O
respectively RB RB O
. . . O

Theophylline NNP NNP B-CHEM
concentrations NNS NNS O
at IN IN O
this DT DT O
endpoint NN NN O
in IN IN O
serum NN NN O
( ( ( O
total JJ JJ O
) ) ) O
and CC CC O
CSF NNP NNP O
were VBD VBD O
similar JJ JJ O
but CC CC O
serum NN NN O
( ( ( O
free JJ JJ O
) ) ) O
and CC CC O
brain NN NN O
concentrations NNS NNS O
were VBD VBD O
slightly RB RB O
different JJ JJ O
in IN IN O
pregnant JJ JJ O
rats NNS NNS O
. . . O

Theophylline NNP NNP B-CHEM
serum NN NN O
protein NN NN O
binding JJ JJ O
determined VBN VBN O
by IN IN O
equilibrium NN NN O
dialysis NN NN O
was VBD VBD O
lower JJR JJR O
in IN IN O
pregnant JJ JJ O
rats NNS NNS O
. . . O

Fetal NNP NNP O
serum NN NN O
concentrations NNS NNS O
at IN IN O
onset NN NN O
of IN IN O
seizures NNS NNS O
in IN IN O
the DT DT O
mother NN NN O
were VBD VBD O
similar JJ JJ O
to TO TO O
maternal JJ JJ O
brain NN NN O
and CC CC O
CSF NNP NNP O
concentrations NNS NNS O
and CC CC O
correlated VBD VBD O
significantly RB RB O
with IN IN O
the DT DT O
former JJ JJ O
. . . O

It PRP PRP O
is VBZ VBZ O
concluded VBN VBN O
that IN IN O
advanced JJ JJ O
pregnancy NN NN O
has VBZ VBZ O
a DT DT O
negligible JJ JJ O
effect NN NN O
on IN IN O
the DT DT O
neurotoxic JJ JJ O
response NN NN O
to TO TO O
theophylline VB VB B-CHEM
in IN IN O
rats NNS NNS O
. . . O

Hyperkalemia NNP NNP O
induced VBN VBN O
by IN IN O
indomethacin NN NN B-CHEM
and CC CC O
naproxen NN NN B-CHEM
and CC CC O
reversed VBN VBN O
by IN IN O
fludrocortisone NN NN B-CHEM
. . . O

We PRP PRP O
have VBP VBP O
described VBN VBN O
a DT DT O
patient NN NN O
with IN IN O
severe JJ JJ O
rheumatoid NN NN O
arthritis NN NN O
and CC CC O
a DT DT O
history NN NN O
of IN IN O
mefenamic JJ JJ B-CHEM
acid NN NN I-CHEM
nephropathy NN NN O
in IN IN O
whom WP WP O
hyperkalemia NN NN O
and CC CC O
inappropriate JJ JJ O
hypoaldosteronism NN NN O
were VBD VBD O
caused VBN VBN O
by IN IN O
both DT DT O
indomethacin NN NN B-CHEM
and CC CC O
naproxen NN NN B-CHEM
, , , O
without IN IN O
major JJ JJ O
decline NN NN O
in IN IN O
renal JJ JJ O
function NN NN O
. . . O

It PRP PRP O
is VBZ VBZ O
likely JJ JJ O
that IN IN O
preexisting VBG VBG O
renal JJ JJ O
disease NN NN O
predisposed VBD VBD O
this DT DT O
patient NN NN O
to TO TO O
type NN NN O
IV NNP NNP O
renal NN NN O
tubular NN NN O
acidosis NN NN O
with IN IN O
prostaglandin NN NN B-CHEM
synthetase NN NN O
inhibitors NNS NNS O
. . . O

Because IN IN O
he PRP PRP O
was VBD VBD O
unable JJ JJ O
to TO TO O
discontinue VB VB O
nonsteroidal NN NN O
anti JJ JJ O
- : : O
inflammatory JJ JJ O
drug NN NN O
therapy NN NN O
, , , O
fludrocortisone NN NN B-CHEM
was VBD VBD O
added VBN VBN O
, , , O
correcting VBG VBG O
the DT DT O
hyperkalemia NN NN O
and CC CC O
allowing VBG VBG O
indomethacin NN NN B-CHEM
therapy NN NN O
to TO TO O
be VB VB O
continued VBN VBN O
safely RB RB O
. . . O

Hypotension NNP NNP O
as IN IN O
a DT DT O
manifestation NN NN O
of IN IN O
cardiotoxicity NN NN O
in IN IN O
three CD CD O
patients NNS NNS O
receiving VBG VBG O
cisplatin NN NN B-CHEM
and CC CC O
5 CD CD B-CHEM
- : : I-CHEM
fluorouracil NN NN I-CHEM
. . . O

Cardiac NNP NNP O
symptoms NNS NNS O
, , , O
including VBG VBG O
hypotension NN NN O
, , , O
developed VBN VBN O
in IN IN O
three CD CD O
patients NNS NNS O
with IN IN O
advanced JJ JJ O
colorectal NN NN O
carcinoma NN NN O
while IN IN O
being VBG VBG O
treated VBN VBN O
with IN IN O
cisplatin NN NN B-CHEM
( ( ( O
CDDP NNP NNP B-CHEM
) ) ) O
and CC CC O
5 CD CD B-CHEM
- : : I-CHEM
fluorouracil NN NN I-CHEM
( ( ( O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
) ) ) O
. . . O

In IN IN O
two CD CD O
patients NNS NNS O
, , , O
hypotension NN NN O
was VBD VBD O
associated VBN VBN O
with IN IN O
severe RB RB O
left VBN VBN O
ventricular NN NN O
dysfunction NN NN O
. . . O

All DT DT O
three CD CD O
patients NNS NNS O
required VBN VBN O
therapy NN NN O
discontinuation NN NN O
. . . O

Cardiac NNP NNP O
enzymes NNS NNS O
remained VBD VBD O
normal JJ JJ O
despite IN IN O
transient NN NN O
electrocardiographic JJ JJ O
( ( ( O
EKG NNP NNP O
) ) ) O
changes NNS NNS O
. . . O

The DT DT O
presentation NN NN O
and CC CC O
cardiac JJ JJ O
evaluation NN NN O
( ( ( O
hemodynamic JJ JJ O
, , , O
echocardiographic JJ JJ O
, , , O
and CC CC O
scintigraphic JJ JJ O
) ) ) O
of IN IN O
these DT DT O
patients NNS NNS O
suggest VBP VBP O
new JJ JJ O
manifestations NNS NNS O
of IN IN O
5 CD CD B-CHEM
- : : I-CHEM
FU NNP NNP I-CHEM
cardiotoxicity NN NN O
that WDT WDT O
may MD MD O
be VB VB O
influenced VBN VBN O
by IN IN O
CDDP NNP NNP B-CHEM
. . . O

The DT DT O
possible JJ JJ O
pathophysiologic JJ JJ O
mechanisms NNS NNS O
are VBP VBP O
discussed VBN VBN O
. . . O

Fatal NNP NNP O
aplastic JJ JJ O
anemia NN NN O
in IN IN O
a DT DT O
patient NN NN O
treated VBN VBN O
with IN IN O
carbamazepine NN NN B-CHEM
. . . O

A DT DT O
case NN NN O
of IN IN O
fatal JJ JJ O
aplastic JJ JJ O
anemia NN NN O
due JJ JJ O
to TO TO O
carbamazepine VB VB B-CHEM
treatment NN NN O
in IN IN O
an DT DT O
epileptic JJ JJ O
woman NN NN O
is VBZ VBZ O
reported VBN VBN O
. . . O

Despite IN IN O
concerns NNS NNS O
of IN IN O
fatal JJ JJ O
bone NN NN O
marrow NN NN O
toxicity NN NN O
due JJ JJ O
to TO TO O
carbamazepine VB VB B-CHEM
, , , O
this DT DT O
is VBZ VBZ O
only RB RB O
the DT DT O
fourth JJ JJ O
documented VBN VBN O
and CC CC O
published VBN VBN O
report NN NN O
. . . O

Carbamazepine NNP NNP B-CHEM
is VBZ VBZ O
a DT DT O
safe JJ JJ O
drug NN NN O
, , , O
but CC CC O
physicians NNS NNS O
and CC CC O
patients NNS NNS O
should MD MD O
be VB VB O
aware JJ JJ O
of IN IN O
the DT DT O
exceedingly RB RB O
rare JJ JJ O
but CC CC O
potentially RB RB O
fatal JJ JJ O
side NN NN O
effects NNS NNS O
, , , O
better RBR RBR O
prevented VBN VBN O
by IN IN O
clinical JJ JJ O
than IN IN O
by IN IN O
laboratory NN NN O
monitoring NN NN O
. . . O

Participation NNP NNP O
of IN IN O
a DT DT O
bulbospinal JJ JJ O
serotonergic JJ JJ O
pathway NN NN O
in IN IN O
the DT DT O
rat NN NN O
brain NN NN O
in IN IN O
clonidine NN NN B-CHEM
- - - O
induced JJ JJ O
hypotension NN NN O
and CC CC O
bradycardia NN NN O
. . . O

The DT DT O
effects NNS NNS O
of IN IN O
microinjection NN NN O
of IN IN O
clonidine NN NN B-CHEM
( ( ( O
1 CD CD O
- : : O
10 CD CD O
micrograms NNS NNS O
in IN IN O
1 CD CD O
microliter NN NN O
) ) ) O
into IN IN O
a DT DT O
region NN NN O
adjacent JJ JJ O
to TO TO O
the DT DT O
ventrolateral JJ JJ O
surface NN NN O
of IN IN O
the DT DT O
medulla NN NN O
oblongata NN NN O
on IN IN O
cardiovascular JJ JJ O
function NN NN O
were VBD VBD O
assessed VBN VBN O
in IN IN O
urethane JJ JJ B-CHEM
- - - O
anesthetized JJ JJ O
rats NNS NNS O
. . . O

Intramedullary NNP NNP O
administration NN NN O
of IN IN O
clonidine NN NN B-CHEM
, , , O
but CC CC O
not RB RB O
saline VB VB O
vehicle NN NN O
, , , O
caused VBD VBD O
a DT DT O
dose NN NN O
- - - O
dependent JJ JJ O
decrease NN NN O
in IN IN O
both DT DT O
the DT DT O
mean NN NN O
arterial JJ JJ O
pressure NN NN O
and CC CC O
the DT DT O
heart NN NN O
rate NN NN O
. . . O

The DT DT O
clonidine NN NN B-CHEM
- - - O
induced JJ JJ O
hypotension NN NN O
was VBD VBD O
antagonized VBN VBN O
by IN IN O
prior RB RB O
spinal JJ JJ O
transection NN NN O
, , , O
but CC CC O
not RB RB O
bilateral JJ JJ O
vagotomy NN NN O
. . . O

On IN IN O
the DT DT O
other JJ JJ O
hand NN NN O
, , , O
the DT DT O
clonidine NN NN B-CHEM
- - - O
induced JJ JJ O
bradycardia NN NN O
was VBD VBD O
antagonized VBN VBN O
by IN IN O
prior RB RB O
bilateral JJ JJ O
vagotomy NN NN O
, , , O
but CC CC O
not RB RB O
spinal JJ JJ O
transection NN NN O
. . . O

Furthermore RB RB O
, , , O
selective JJ JJ O
destruction NN NN O
of IN IN O
the DT DT O
spinal JJ JJ O
5 CD CD B-CHEM
- : : I-CHEM
HT NNP NNP I-CHEM
nerves NNS NNS O
, , , O
produced VBN VBN O
by IN IN O
bilateral JJ JJ O
spinal JJ JJ O
injection NN NN O
of IN IN O
5 CD CD B-CHEM
, , , I-CHEM
7 CD CD I-CHEM
- : : I-CHEM
dihydroxytryptamine NN NN I-CHEM
, , , O
reduced VBD VBD O
the DT DT O
magnitude NN NN O
of IN IN O
the DT DT O
vasodepressor NN NN O
or CC CC O
the DT DT O
bradycardiac NN NN O
responses NNS NNS O
to TO TO O
clonidine VB VB B-CHEM
microinjected VBN VBN O
into IN IN O
the DT DT O
area NN NN O
near IN IN O
the DT DT O
ventrolateral JJ JJ O
surface NN NN O
of IN IN O
the DT DT O
medulla NN NN O
oblongata NN NN O
in IN IN O
rats NNS NNS O
. . . O

The DT DT O
data NNS NNS O
indicate VBP VBP O
that IN IN O
a DT DT O
bulbospinal JJ JJ O
serotonergic JJ JJ O
pathway NN NN O
is VBZ VBZ O
involved VBN VBN O
in IN IN O
development NN NN O
of IN IN O
clonidine NN NN B-CHEM
- - - O
induced JJ JJ O
hypotension NN NN O
and CC CC O
bradycardia NN NN O
. . . O

The DT DT O
induced JJ JJ O
hypotension NN NN O
is VBZ VBZ O
brought VBN VBN O
about IN IN O
by IN IN O
a DT DT O
decrease NN NN O
in IN IN O
sympathetic JJ JJ O
efferent NN NN O
activity NN NN O
, , , O
whereas IN IN O
the DT DT O
induced JJ JJ O
bradycardia NN NN O
was VBD VBD O
due JJ JJ O
to TO TO O
an DT DT O
increase NN NN O
in IN IN O
vagal NN NN O
efferent NN NN O
activity NN NN O
. . . O

Hypertension NNP NNP O
in IN IN O
neuroblastoma NN NN O
induced VBN VBN O
by IN IN O
imipramine NN NN B-CHEM
. . . O

Hypertension NNP NNP O
is VBZ VBZ O
a DT DT O
well RB RB O
- - - O
known VBN VBN O
finding NN NN O
in IN IN O
some DT DT O
patients NNS NNS O
with IN IN O
neuroblastoma NN NN O
. . . O

However RB RB O
, , , O
it PRP PRP O
has VBZ VBZ O
not RB RB O
previously RB RB O
been VBN VBN O
described VBN VBN O
in IN IN O
association NN NN O
with IN IN O
the DT DT O
use NN NN O
of IN IN O
Imipramine NNP NNP B-CHEM
. . . O

We PRP PRP O
report VBP VBP O
the DT DT O
occurrence NN NN O
of IN IN O
severe JJ JJ O
hypertension NN NN O
( ( ( O
blood NN NN O
pressure NN NN O
190 CD CD O
/ NN NN O
160 CD CD O
) ) ) O
in IN IN O
a DT DT O
4 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
girl NN NN O
with IN IN O
neuroblastoma NN NN O
who WP WP O
was VBD VBD O
given VBN VBN O
Imipramine NNP NNP B-CHEM
to TO TO O
control VB VB O
a DT DT O
behavior NN NN O
disorder NN NN O
. . . O

It PRP PRP O
was VBD VBD O
determined VBN VBN O
later RB RB O
that IN IN O
this DT DT O
patient NN NN O
' '' '' O
s VBZ VBZ O
tumor NN NN O
was VBD VBD O
recurring VBG VBG O
at IN IN O
the DT DT O
time NN NN O
of IN IN O
her PRP$ PRP$ O
hypertensive JJ JJ O
episode NN NN O
. . . O

Since IN IN O
she PRP PRP O
had VBD VBD O
no DT DT O
blood NN NN O
pressure NN NN O
elevation NN NN O
at IN IN O
initial JJ JJ O
diagnosis NN NN O
and CC CC O
none NN NN O
following VBG VBG O
discontinuation NN NN O
of IN IN O
the DT DT O
Imipramine NNP NNP B-CHEM
( ( ( O
when WRB WRB O
she PRP PRP O
was VBD VBD O
in IN IN O
florid JJ JJ O
relapse NN NN O
) ) ) O
, , , O
we PRP PRP O
believe VBP VBP O
that IN IN O
this DT DT O
drug NN NN O
rather RB RB O
than IN IN O
her PRP$ PRP$ O
underlying VBG VBG O
disease NN NN O
alone RB RB O
caused VBD VBD O
her PRP$ PRP$ O
hypertension NN NN O
. . . O

The DT DT O
mechanism NN NN O
for IN IN O
this DT DT O
reaction NN NN O
is VBZ VBZ O
believed VBN VBN O
to TO TO O
be VB VB O
increased VBN VBN O
levels NNS NNS O
of IN IN O
vasoactive JJ JJ O
catecholamines NNS NNS B-CHEM
due JJ JJ O
to TO TO O
interference NN NN O
of IN IN O
their PRP$ PRP$ O
physiologic JJ JJ O
inactivation NN NN O
by IN IN O
Imipramine NNP NNP B-CHEM
. . . O

From IN IN O
this DT DT O
experience NN NN O
, , , O
we PRP PRP O
urge VBP VBP O
extreme JJ JJ O
caution NN NN O
in IN IN O
the DT DT O
use NN NN O
of IN IN O
tricyclic JJ JJ O
antidepressants NNS NNS O
in IN IN O
children NNS NNS O
with IN IN O
active JJ JJ O
neuroblastoma NN NN O
. . . O

Rechallenge NNP NNP O
of IN IN O
patients NNS NNS O
who WP WP O
developed VBD VBD O
oral JJ JJ O
candidiasis NNS NNS O
or CC CC O
hoarseness NN NN O
with IN IN O
beclomethasone NN NN B-CHEM
dipropionate NN NN I-CHEM
. . . O

Of IN IN O
158 CD CD O
asthmatic JJ JJ O
patients NNS NNS O
who WP WP O
were VBD VBD O
placed VBN VBN O
on IN IN O
inhaled JJ JJ O
beclomethasone NN NN B-CHEM
, , , O
15 CD CD O
( ( ( O
9 CD CD O
. . . O
5 CD CD O
% NN NN O
) ) ) O
developed VBD VBD O
either CC CC O
hoarseness JJ JJ O
( ( ( O
8 CD CD O
) ) ) O
, , , O
oral JJ JJ O
thrush NN NN O
( ( ( O
6 CD CD O
) ) ) O
, , , O
or CC CC O
both DT DT O
( ( ( O
1 CD CD O
) ) ) O
. . . O

When WRB WRB O
their PRP$ PRP$ O
adverse NN NN O
reactions NNS NNS O
subsided VBD VBD O
, , , O
seven CD CD O
of IN IN O
these DT DT O
15 CD CD O
patients NNS NNS O
were VBD VBD O
rechallenged VBN VBN O
with IN IN O
inhaled JJ JJ O
beclomethasone NN NN B-CHEM
. . . O

These DT DT O
included VBD VBD O
five CD CD O
cases NNS NNS O
who WP WP O
developed JJ JJ O
hoarseness NNS NNS O
and CC CC O
three CD CD O
who WP WP O
developed VBD VBD O
Candidiasis NNP NNP O
. . . O

One CD CD O
patient NN NN O
had VBD VBD O
both DT DT O
. . . O

Oral NNP NNP O
thrush NN NN O
did VBD VBD O
not RB RB O
recur VB VB O
, , , O
but CC CC O
60 CD CD O
% NN NN O
( ( ( O
3 CD CD O
/ NN NN O
5 CD CD O
) ) ) O
of IN IN O
patients NNS NNS O
with IN IN O
hoarseness NN NN O
had VBD VBD O
recurrence NN NN O
. . . O

We PRP PRP O
conclude VBP VBP O
that IN IN O
patients NNS NNS O
may MD MD O
be VB VB O
restarted VBN VBN O
on IN IN O
inhaled JJ JJ O
beclomethasone NN NN B-CHEM
when WRB WRB O
clinically RB RB O
indicated VBD VBD O
; : : O
however RB RB O
, , , O
because IN IN O
of IN IN O
the DT DT O
high JJ JJ O
recurrence NN NN O
rate NN NN O
, , , O
patients NNS NNS O
who WP WP O
develop VBP VBP O
hoarseness NN NN O
should MD MD O
not RB RB O
be VB VB O
re NN NN O
- - - O
challenged JJ JJ O
. . . O

Concomitant NNP NNP O
use NN NN O
of IN IN O
oral JJ JJ O
prednisone NN NN B-CHEM
and CC CC O
topical JJ JJ O
beclomethasone NN NN B-CHEM
may MD MD O
increase VB VB O
the DT DT O
risk NN NN O
of IN IN O
developing VBG VBG O
hoarseness NN NN O
or CC CC O
candidiasis NN NN O
. . . O

Cyclophosphamide NNP NNP B-CHEM
cardiotoxicity NN NN O
: : : O
an DT DT O
analysis NN NN O
of IN IN O
dosing VBG VBG O
as IN IN O
a DT DT O
risk NN NN O
factor NN NN O
. . . O

Patients NNS NNS O
who WP WP O
undergo VBP VBP O
bone NN NN O
marrow NN NN O
transplantation NN NN O
are VBP VBP O
generally RB RB O
immunosuppressed VBN VBN O
with IN IN O
a DT DT O
dose NN NN O
of IN IN O
cyclophosphamide NN NN B-CHEM
( ( ( O
CYA NNP NNP B-CHEM
) ) ) O
which WDT WDT O
is VBZ VBZ O
usually RB RB O
calculated VBN VBN O
based VBN VBN O
on IN IN O
the DT DT O
patient NN NN O
' '' '' O
s VBZ VBZ O
weight NN NN O
. . . O

At IN IN O
these DT DT O
high JJ JJ O
doses NNS NNS O
of IN IN O
CYA NNP NNP B-CHEM
, , , O
serious JJ JJ O
cardiotoxicity NN NN O
may MD MD O
occur VB VB O
, , , O
but CC CC O
definitive JJ JJ O
risk NN NN O
factors NNS NNS O
for IN IN O
the DT DT O
development NN NN O
of IN IN O
such JJ JJ O
cardiotoxicity NN NN O
have VBP VBP O
not RB RB O
been VBN VBN O
described VBN VBN O
. . . O

Since IN IN O
chemotherapeutic JJ JJ O
agent NN NN O
toxicity NN NN O
generally RB RB O
correlates NNS NNS O
with IN IN O
dose NN NN O
per IN IN O
body NN NN O
surface NN NN O
area NN NN O
, , , O
we PRP PRP O
retrospectively RB RB O
calculated VBD VBD O
the DT DT O
dose NN NN O
of IN IN O
CYA NNP NNP B-CHEM
in IN IN O
patients NNS NNS O
transplanted VBN VBN O
at IN IN O
our PRP$ PRP$ O
institution NN NN O
to TO TO O
determine VB VB O
whether IN IN O
the DT DT O
incidence NN NN O
of IN IN O
CYA NNP NNP B-CHEM
cardiotoxicity NN NN O
correlated JJ JJ O
with IN IN O
the DT DT O
dose NN NN O
per IN IN O
body NN NN O
surface NN NN O
area NN NN O
. . . O

Eighty NNP NNP O
patients NNS NNS O
who WP WP O
were VBD VBD O
to TO TO O
receive VB VB O
CYA NNP NNP B-CHEM
50 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
d SYM SYM O
for IN IN O
four CD CD O
days NNS NNS O
as IN IN O
preparation NN NN O
for IN IN O
marrow NN NN O
grafting VBG VBG O
underwent NN NN O
a DT DT O
total NN NN O
of IN IN O
84 CD CD O
transplants NNS NNS O
for IN IN O
aplastic JJ JJ O
anemia NN NN O
, , , O
Wiskott NNP NNP O
- : : O
Aldrich NNP NNP O
syndrome NN NN O
, , , O
or CC CC O
severe RB RB O
combined VBN VBN O
immunodeficiency NN NN O
syndrome NN NN O
. . . O

Fourteen CD CD O
of IN IN O
84 CD CD O
( ( ( O
17 CD CD O
% NN NN O
) ) ) O
patients NNS NNS O
had VBD VBD O
symptoms NNS NNS O
and CC CC O
signs NNS NNS O
consistent JJ JJ O
with IN IN O
CYA NNP NNP B-CHEM
cardiotoxicity NN NN O
within IN IN O
ten CD CD O
days NNS NNS O
of IN IN O
receiving VBG VBG O
1 CD CD O
to TO TO O
4 CD CD O
doses NNS NNS O
of IN IN O
CYA NNP NNP B-CHEM
. . . O

Six CD CD O
of IN IN O
the DT DT O
14 CD CD O
patients NNS NNS O
died VBD VBD O
with IN IN O
congestive JJ JJ O
heart NN NN O
failure NN NN O
. . . O

The DT DT O
dose NN NN O
of IN IN O
CYA NNP NNP B-CHEM
per IN IN O
body NN NN O
surface NN NN O
area NN NN O
was VBD VBD O
calculated VBN VBN O
for IN IN O
all DT DT O
patients NNS NNS O
and CC CC O
the DT DT O
patients NNS NNS O
were VBD VBD O
divided VBN VBN O
into IN IN O
two CD CD O
groups NNS NNS O
based VBN VBN O
on IN IN O
daily JJ JJ O
CYA NNP NNP B-CHEM
dose NN NN O
: : : O
Group NNP NNP O
1 CD CD O
, , , O
CYA NNP NNP B-CHEM
less JJR JJR O
than IN IN O
or CC CC O
equal JJ JJ O
to TO TO O
1 CD CD O
. . . O
55 CD CD O
g SYM SYM O
/ NN NN O
m2 NN NN O
/ NN NN O
d SYM SYM O
; : : O
Group NNP NNP O
2 CD CD O
, , , O
CYA NNP NNP B-CHEM
greater JJR JJR O
than IN IN O
1 CD CD O
. . . O
55 CD CD O
g SYM SYM O
/ NN NN O
m2 NN NN O
/ NN NN O
d SYM SYM O
. . . O

Cardiotoxicity NNP NNP O
that WDT WDT O
was VBD VBD O
thought VBN VBN O
to TO TO O
be VB VB O
related VBN VBN O
to TO TO O
CYA NNP NNP B-CHEM
occurred VBD VBD O
in IN IN O
1 CD CD O
/ NN NN O
32 CD CD O
( ( ( O
3 CD CD O
% NN NN O
) ) ) O
of IN IN O
patients NNS NNS O
in IN IN O
Group NNP NNP O
1 CD CD O
and CC CC O
in IN IN O
13 CD CD O
/ NN NN O
52 CD CD O
( ( ( O
25 CD CD O
% NN NN O
) ) ) O
patients NNS NNS O
in IN IN O
Group NNP NNP O
2 CD CD O
( ( ( O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
025 CD CD O
) ) ) O
. . . O

Congestive NNP NNP O
heart NN NN O
failure NN NN O
caused VBD VBD O
or CC CC O
contributed VBD VBD O
to TO TO O
death NN NN O
in IN IN O
0 CD CD O
/ NN NN O
32 CD CD O
patients NNS NNS O
in IN IN O
Group NNP NNP O
1 CD CD O
v NN NN O
6 CD CD O
/ NN NN O
52 CD CD O
( ( ( O
12 CD CD O
% NN NN O
) ) ) O
of IN IN O
patients NNS NNS O
in IN IN O
Group NNP NNP O
2 CD CD O
( ( ( O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
25 CD CD O
) ) ) O
. . . O

There EX EX O
was VBD VBD O
no DT DT O
difference NN NN O
in IN IN O
the DT DT O
rate NN NN O
of IN IN O
engraftment NN NN O
of IN IN O
evaluable JJ JJ O
patients NNS NNS O
in IN IN O
the DT DT O
two CD CD O
groups NNS NNS O
( ( ( O
P NN NN O
greater JJR JJR O
than IN IN O
0 CD CD O
. . . O
5 CD CD O
) ) ) O
. . . O

We PRP PRP O
conclude VBP VBP O
that IN IN O
the DT DT O
CYA NNP NNP B-CHEM
cardiotoxicity NN NN O
correlates NNS NNS O
with IN IN O
CYA NNP NNP B-CHEM
dosage NN NN O
as IN IN O
calculated VBN VBN O
by IN IN O
body NN NN O
surface NN NN O
area NN NN O
, , , O
and CC CC O
that IN IN O
patients NNS NNS O
with IN IN O
aplastic JJ JJ O
anemia NN NN O
and CC CC O
immunodeficiencies NNS NNS O
can MD MD O
be VB VB O
effectively RB RB O
prepared VBN VBN O
for IN IN O
bone NN NN O
marrow NN NN O
grafting VBG VBG O
at IN IN O
a DT DT O
CYA NNP NNP B-CHEM
dose NN NN O
of IN IN O
1 CD CD O
. . . O
55 CD CD O
g SYM SYM O
/ NN NN O
m2 NN NN O
/ NN NN O
d SYM SYM O
for IN IN O
four CD CD O
days NNS NNS O
with IN IN O
a DT DT O
lower JJR JJR O
incidence NN NN O
of IN IN O
cardiotoxicity NN NN O
than IN IN O
patients NNS NNS O
whose WP$ WP$ O
CYA NNP NNP B-CHEM
dosage NN NN O
is VBZ VBZ O
calculated VBN VBN O
based VBN VBN O
on IN IN O
weight NN NN O
. . . O

This DT DT O
study NN NN O
reaffirms VBZ VBZ O
the DT DT O
principle NN NN O
that IN IN O
drug NN NN O
toxicity NN NN O
correlates NNS NNS O
with IN IN O
dose NN NN O
per IN IN O
body NN NN O
surface NN NN O
area NN NN O
. . . O

Studies NNS NNS O
of IN IN O
risk NN NN O
factors NNS NNS O
for IN IN O
aminoglycoside NN NN B-CHEM
nephrotoxicity NN NN O
. . . O

The DT DT O
epidemiology NN NN O
of IN IN O
aminoglycoside NN NN B-CHEM
- - - O
induced JJ JJ O
nephrotoxicity NN NN O
is VBZ VBZ O
not RB RB O
fully RB RB O
understood VBN VBN O
. . . O

Experimental NNP NNP O
studies NNS NNS O
in IN IN O
healthy JJ JJ O
human JJ JJ O
volunteers NNS NNS O
indicate VBP VBP O
aminoglycosides NNS NNS B-CHEM
cause VBP VBP O
proximal NN NN O
tubular NN NN O
damage NN NN O
in IN IN O
most JJS JJS O
patients NNS NNS O
, , , O
but CC CC O
rarely RB RB O
, , , O
if IN IN O
ever RB RB O
, , , O
cause NN NN O
glomerular NN NN O
or CC CC O
tubular JJ JJ O
dysfunction NN NN O
. . . O

Clinical NNP NNP O
trials NNS NNS O
of IN IN O
aminoglycosides NNS NNS B-CHEM
in IN IN O
seriously RB RB O
ill JJ JJ O
patients NNS NNS O
indicate VBP VBP O
that IN IN O
the DT DT O
relative JJ JJ O
risk NN NN O
for IN IN O
developing VBG VBG O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
during IN IN O
therapy NN NN O
ranges NNS NNS O
from IN IN O
8 CD CD O
to TO TO O
10 CD CD O
and CC CC O
that IN IN O
the DT DT O
attributable JJ JJ O
risk NN NN O
is VBZ VBZ O
70 CD CD O
% NN NN O
to TO TO O
80 CD CD O
% NN NN O
. . . O

Further RB RB O
analysis NN NN O
of IN IN O
these DT DT O
data NNS NNS O
suggests VBZ VBZ O
that IN IN O
the DT DT O
duration NN NN O
of IN IN O
therapy NN NN O
, , , O
plasma NN NN O
aminoglycoside IN IN B-CHEM
levels NNS NNS O
, , , O
liver NN NN O
disease NN NN O
, , , O
advanced JJ JJ O
age NN NN O
, , , O
high JJ JJ O
initial JJ JJ O
estimated VBN VBN O
creatinine NN NN B-CHEM
clearance NN NN O
and CC CC O
, , , O
possibly RB RB O
, , , O
female JJ JJ O
gender NN NN O
all DT DT O
increase NN NN O
the DT DT O
risk NN NN O
for IN IN O
nephrotoxicity NN NN O
. . . O

Other JJ JJ O
causes NNS NNS O
of IN IN O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
, , , O
such JJ JJ O
as IN IN O
shock NN NN O
, , , O
appear VB VB O
to TO TO O
have VB VB O
an DT DT O
additive JJ JJ O
effect NN NN O
. . . O

Predictive NNP NNP O
models NNS NNS O
have VBP VBP O
been VBN VBN O
developed VBN VBN O
from IN IN O
these DT DT O
analyses NNS NNS O
that WDT WDT O
should MD MD O
be VB VB O
useful JJ JJ O
for IN IN O
identifying VBG VBG O
patients NNS NNS O
at IN IN O
high JJ JJ O
risk NN NN O
. . . O

These DT DT O
models NNS NNS O
may MD MD O
also RB RB O
be VB VB O
useful JJ JJ O
in IN IN O
developing VBG VBG O
insights NNS NNS O
into IN IN O
the DT DT O
pathophysiology NN NN O
of IN IN O
aminoglycoside NN NN B-CHEM
- - - O
induced JJ JJ O
nephrotoxicity NN NN O
. . . O

Central NNP NNP O
action NN NN O
of IN IN O
narcotic JJ JJ O
analgesics NNS NNS O
. . . O

Part NN NN O
IV NNP NNP O
. . . O

Noradrenergic NNP NNP O
influences VBZ VBZ O
on IN IN O
the DT DT O
activity NN NN O
of IN IN O
analgesics NNS NNS O
in IN IN O
rats NNS NNS O
. . . O

The DT DT O
effect NN NN O
of IN IN O
clonidine NN NN B-CHEM
, , , O
naphazoline NN NN B-CHEM
and CC CC O
xylometazoline NN NN B-CHEM
on IN IN O
analgesia NN NN O
induced VBN VBN O
by IN IN O
morphine NN NN B-CHEM
, , , O
codeine NN NN B-CHEM
, , , O
fentanyl NN NN B-CHEM
and CC CC O
pentazocine NN NN B-CHEM
, , , O
and CC CC O
on IN IN O
cataleptic JJ JJ O
effect NN NN O
of IN IN O
morphine NN NN B-CHEM
, , , O
codine NN NN B-CHEM
and CC CC O
fentanyl NN NN B-CHEM
was VBD VBD O
studied VBN VBN O
in IN IN O
rats NNS NNS O
. . . O

The DT DT O
biochemical JJ JJ O
assays NNS NNS O
on IN IN O
the DT DT O
influence NN NN O
of IN IN O
four CD CD O
analgesics NNS NNS O
on IN IN O
the DT DT O
brain NN NN O
concentration NN NN O
and CC CC O
turnover NN NN O
of IN IN O
noradrenaline NN NN B-CHEM
( ( ( O
NA NNP NNP B-CHEM
) ) ) O
were VBD VBD O
also RB RB O
performed VBN VBN O
. . . O

It PRP PRP O
was VBD VBD O
found VBN VBN O
that IN IN O
three CD CD O
drugs NNS NNS O
stimulating VBG VBG O
central JJ JJ O
NA NNP NNP B-CHEM
receptors NNS NNS O
failed VBD VBD O
to TO TO O
affect VB VB O
the DT DT O
analgesic JJ JJ O
ED50 NNP NNP O
of IN IN O
all DT DT O
antinociceptive JJ JJ O
agents NNS NNS O
and CC CC O
they PRP PRP O
enhanced VBD VBD O
catalepsy NN NN O
induced VBN VBN O
by IN IN O
morphine NN NN B-CHEM
and CC CC O
fentanyl NN NN B-CHEM
. . . O

Codeine NNP NNP B-CHEM
catalepsy NN NN O
was VBD VBD O
increased VBN VBN O
by IN IN O
clonidine NN NN B-CHEM
and CC CC O
decreased VBN VBN O
by IN IN O
naphazoline NN NN B-CHEM
and CC CC O
xylometazoline NN NN B-CHEM
. . . O

The DT DT O
brain NN NN O
concentration NN NN O
of IN IN O
NA NNP NNP B-CHEM
was VBD VBD O
not RB RB O
changed VBN VBN O
by IN IN O
morphine NN NN B-CHEM
and CC CC O
fentanyl NN NN B-CHEM
, , , O
but CC CC O
one CD CD O
of IN IN O
the DT DT O
doses NNS NNS O
of IN IN O
codeine NN NN B-CHEM
( ( ( O
45 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
slightly RB RB O
enhanced VBD VBD O
it PRP PRP O
. . . O

Pentazocine NNP NNP B-CHEM
dose NN NN O
- : : O
dependently RB RB O
decreased VBD VBD O
the DT DT O
brain NN NN O
level NN NN O
of IN IN O
NA NNP NNP B-CHEM
. . . O

The DT DT O
rate NN NN O
of IN IN O
NA NNP NNP B-CHEM
turnover NN NN O
was VBD VBD O
not RB RB O
altered VBN VBN O
by IN IN O
analgesics NNS NNS O
except IN IN O
for IN IN O
the DT DT O
higher JJR JJR O
dose NN NN O
of IN IN O
fentanyl NN NN B-CHEM
( ( ( O
0 CD CD O
. . . O
2 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
following VBG VBG O
which WDT WDT O
the DT DT O
disappearance NN NN O
of IN IN O
NA NNP NNP B-CHEM
from IN IN O
the DT DT O
brain NN NN O
was VBD VBD O
diminished VBN VBN O
. . . O

The DT DT O
results NNS NNS O
are VBP VBP O
discussed VBN VBN O
in IN IN O
the DT DT O
light NN NN O
of IN IN O
various JJ JJ O
and CC CC O
non NN NN O
- - - O
uniform NN NN O
data NNS NNS O
from IN IN O
the DT DT O
literature NN NN O
. . . O

It PRP PRP O
is VBZ VBZ O
suggested VBN VBN O
that IN IN O
in IN IN O
rats NNS NNS O
the DT DT O
brain NN NN O
NA NNP NNP B-CHEM
plays VBZ VBZ O
a DT DT O
less RBR RBR O
important JJ JJ O
function NN NN O
than IN IN O
the DT DT O
other JJ JJ O
monoamines NNS NNS B-CHEM
in IN IN O
the DT DT O
behavioural NN NN O
activity NN NN O
of IN IN O
potent JJ JJ O
analgesics NNS NNS O
. . . O

Flurothyl NNP NNP B-CHEM
seizure NN NN O
thresholds NNS NNS O
in IN IN O
mice NNS NNS O
treated VBN VBN O
neonatally RB RB O
with IN IN O
a DT DT O
single JJ JJ O
injection NN NN O
of IN IN O
monosodium NN NN B-CHEM
glutamate NN NN I-CHEM
( ( ( O
MSG NNP NNP B-CHEM
) ) ) O
: : : O
evaluation NN NN O
of IN IN O
experimental JJ JJ O
parameters NNS NNS O
in IN IN O
flurothyl NN NN B-CHEM
seizure NN NN O
testing NN NN O
. . . O

Monosodium NNP NNP B-CHEM
glutamate NN NN I-CHEM
( ( ( O
MSG NNP NNP B-CHEM
) ) ) O
administration NN NN O
to TO TO O
neonatal JJ JJ O
rodents NNS NNS O
produces VBZ VBZ O
convulsions NNS NNS O
and CC CC O
results NNS NNS O
in IN IN O
numerous JJ JJ O
biochemical JJ JJ O
and CC CC O
behavioral JJ JJ O
deficits NNS NNS O
. . . O

These DT DT O
studies NNS NNS O
were VBD VBD O
undertaken VBN VBN O
to TO TO O
determine VB VB O
if IN IN O
neonatal JJ JJ O
administration NN NN O
of IN IN O
MSG NNP NNP B-CHEM
produced VBD VBD O
permanent JJ JJ O
alterations NNS NNS O
in IN IN O
seizure NN NN O
susceptibility NN NN O
, , , O
since IN IN O
previous JJ JJ O
investigations NNS NNS O
were VBD VBD O
inconclusive JJ JJ O
. . . O

A DT DT O
flurothyl NN NN B-CHEM
ether NN NN B-CHEM
seizure NN NN O
screening VBG VBG O
technique NN NN O
was VBD VBD O
used VBN VBN O
to TO TO O
evaluate VB VB O
seizure NN NN O
susceptibility NN NN O
in IN IN O
adult NN NN O
mice NN NN O
that WDT WDT O
received VBD VBD O
neonatal JJ JJ O
injections NNS NNS O
of IN IN O
MSG NNP NNP B-CHEM
( ( ( O
4 CD CD O
mg NN NN O
/ NN NN O
g SYM SYM O
and CC CC O
1 CD CD O
mg NN NN O
/ NN NN O
g SYM SYM O
) ) ) O
. . . O

MSG NNP NNP B-CHEM
treatment NN NN O
resulted VBD VBD O
in IN IN O
significant JJ JJ O
reductions NNS NNS O
in IN IN O
whole JJ JJ O
brain NN NN O
weight NN NN O
but CC CC O
did VBD VBD O
not RB RB O
alter VB VB O
seizure NN NN O
threshold NN NN O
. . . O

A DT DT O
naloxone NN NN B-CHEM
( ( ( O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
challenge NN NN O
was VBD VBD O
also RB RB O
ineffective JJ JJ O
in IN IN O
altering VBG VBG O
the DT DT O
seizure NN NN O
thresholds NNS NNS O
of IN IN O
either DT DT O
control NN NN O
of IN IN O
MSG NNP NNP B-CHEM
- - - O
treated JJ JJ O
mice NN NN O
. . . O

Flurothyl NNP NNP B-CHEM
ether NN NN B-CHEM
produced VBD VBD O
hypothermia NN NN O
which WDT WDT O
was VBD VBD O
correlated VBN VBN O
with IN IN O
the DT DT O
duration NN NN O
of IN IN O
flurothyl JJ JJ B-CHEM
exposure NN NN O
; : : O
however RB RB O
, , , O
the DT DT O
relationship NN NN O
of IN IN O
hypothermia NN NN O
to TO TO O
seizure VB VB O
induction NN NN O
was VBD VBD O
unclear JJ JJ O
. . . O

Flurothyl NNP NNP B-CHEM
seizure NN NN O
testing NN NN O
proved VBD VBD O
to TO TO O
be VB VB O
a DT DT O
rapid JJ JJ O
and CC CC O
reliable JJ JJ O
technique NN NN O
with IN IN O
which WDT WDT O
to TO TO O
evaluate VB VB O
seizure NN NN O
susceptibility NN NN O
. . . O

Susceptibility NNP NNP O
to TO TO O
seizures NNS NNS O
produced VBN VBN O
by IN IN O
pilocarpine NN NN B-CHEM
in IN IN O
rats NNS NNS O
after IN IN O
microinjection NN NN O
of IN IN O
isoniazid NN NN B-CHEM
or CC CC O
gamma NN NN B-CHEM
- - - I-CHEM
vinyl NN NN I-CHEM
- - - I-CHEM
GABA NNP NNP I-CHEM
into IN IN O
the DT DT O
substantia NN NN O
nigra NN NN O
. . . O

Pilocarpine NNP NNP B-CHEM
, , , O
given VBN VBN O
intraperitoneally RB RB O
to TO TO O
rats NNS NNS O
, , , O
reproduces NNS NNS O
the DT DT O
neuropathological JJ JJ O
sequelae NN NN O
of IN IN O
temporal JJ JJ O
lobe NN NN O
epilepsy NN NN O
and CC CC O
provides VBZ VBZ O
a DT DT O
relevant JJ JJ O
animal NN NN O
model NN NN O
for IN IN O
studying VBG VBG O
mechanisms NNS NNS O
of IN IN O
buildup NN NN O
of IN IN O
convulsive JJ JJ O
activity NN NN O
and CC CC O
pathways NNS NNS O
operative JJ JJ O
in IN IN O
the DT DT O
generalization NN NN O
and CC CC O
propagation NN NN O
of IN IN O
seizures NNS NNS O
within IN IN O
the DT DT O
forebrain NN NN O
. . . O

In IN IN O
the DT DT O
present JJ JJ O
study NN NN O
, , , O
the DT DT O
effects NNS NNS O
of IN IN O
manipulating VBG VBG O
the DT DT O
activity NN NN O
of IN IN O
the DT DT O
gamma NN NN B-CHEM
- - - I-CHEM
aminobutyric JJ JJ I-CHEM
acid NN NN I-CHEM
( ( ( O
GABA NNP NNP B-CHEM
) ) ) O
- : : O
mediated JJ JJ O
synaptic JJ JJ O
inhibition NN NN O
within IN IN O
the DT DT O
substantia NN NN O
nigra NN NN O
on IN IN O
seizures NNS NNS O
produced VBN VBN O
by IN IN O
pilocarpine NN NN B-CHEM
in IN IN O
rats NNS NNS O
, , , O
were VBD VBD O
investigated VBN VBN O
. . . O

In IN IN O
animals NNS NNS O
pretreated VBN VBN O
with IN IN O
microinjections NNS NNS O
of IN IN O
isoniazid NN NN B-CHEM
, , , O
150 CD CD O
micrograms NNS NNS O
, , , O
an DT DT O
inhibitor NN NN O
of IN IN O
activity NN NN O
of IN IN O
the DT DT O
GABA NNP NNP B-CHEM
- : : O
synthesizing VBG VBG O
enzyme NN NN O
, , , O
L NNP NNP B-CHEM
- : : I-CHEM
glutamic JJ JJ I-CHEM
acid NN NN I-CHEM
decarboxylase NN NN O
, , , O
into IN IN O
the DT DT O
substantia NN NN O
nigra NN NN O
pars NNS NNS O
reticulata NN NN O
( ( ( O
SNR NNP NNP O
) ) ) O
, , , O
bilaterally RB RB O
, , , O
non NN NN O
- - - O
convulsant JJ JJ O
doses NNS NNS O
of IN IN O
pilocarpine NN NN B-CHEM
, , , O
100 CD CD O
and CC CC O
200 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
resulted VBD VBD O
in IN IN O
severe JJ JJ O
motor NN NN O
limbic NN NN O
seizures NNS NNS O
and CC CC O
status NN NN O
epilepticus NN NN O
. . . O

Electroencephalographic NNP NNP O
and CC CC O
behavioral JJ JJ O
monitoring NN NN O
revealed VBD VBD O
a DT DT O
profound JJ JJ O
reduction NN NN O
of IN IN O
the DT DT O
threshold NN NN O
for IN IN O
pilocarpine NN NN B-CHEM
- - - O
induced JJ JJ O
convulsions NNS NNS O
. . . O

Morphological NNP NNP O
analysis NN NN O
of IN IN O
frontal JJ JJ O
forebrain NN NN O
sections NNS NNS O
with IN IN O
light JJ JJ O
microscopy NN NN O
revealed VBN VBN O
seizure NN NN O
- - - O
related VBN VBN O
damage NN NN O
to TO TO O
the DT DT O
hippocampal JJ JJ O
formation NN NN O
, , , O
thalamus NN NN O
, , , O
amygdala NN NN O
, , , O
olfactory NN NN O
cortex NN NN O
, , , O
substantia NN NN O
nigra NN NN O
and CC CC O
neocortex NN NN O
, , , O
which WDT WDT O
is VBZ VBZ O
typically RB RB O
observed VBN VBN O
with IN IN O
pilocarpine NN NN B-CHEM
in IN IN O
doses NNS NNS O
exceeding VBG VBG O
350 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
. . . O

Bilateral NNP NNP O
intrastriatal JJ JJ O
injections NNS NNS O
of IN IN O
isoniazid NN NN B-CHEM
did VBD VBD O
not RB RB O
augment JJ JJ O
seizures NNS NNS O
produced VBN VBN O
by IN IN O
pilocarpine NN NN B-CHEM
, , , O
200 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
. . . O

Application NNP NNP O
of IN IN O
an DT DT O
irreversible JJ JJ O
inhibitor NN NN O
of IN IN O
GABA NNP NNP B-CHEM
transaminase NN NN O
, , , O
gamma NN NN B-CHEM
- - - I-CHEM
vinyl NN NN I-CHEM
- - - I-CHEM
GABA NNP NNP I-CHEM
( ( ( O
D NNP NNP B-CHEM
, , , I-CHEM
L NNP NNP I-CHEM
- : : I-CHEM
4 CD CD I-CHEM
- : : I-CHEM
amino JJ JJ I-CHEM
- - - I-CHEM
hex NN NN I-CHEM
- - - I-CHEM
5 CD CD I-CHEM
- : : I-CHEM
enoic JJ JJ I-CHEM
acid NN NN I-CHEM
) ) ) O
, , , O
5 CD CD O
micrograms NNS NNS O
, , , O
into IN IN O
the DT DT O
SNR NNP NNP O
, , , O
bilaterally RB RB O
, , , O
suppressed VBD VBD O
the DT DT O
appearance NN NN O
of IN IN O
electrographic JJ JJ O
and CC CC O
behavioral JJ JJ O
seizures NNS NNS O
produced VBN VBN O
by IN IN O
pilocarpine NN NN B-CHEM
, , , O
380 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
. . . O

This DT DT O
treatment NN NN O
was VBD VBD O
also RB RB O
sufficient JJ JJ O
to TO TO O
protect VB VB O
animals NNS NNS O
from IN IN O
the DT DT O
occurrence NN NN O
of IN IN O
brain NN NN O
damage NN NN O
. . . O

Microinjections NNP NNP O
of IN IN O
gamma NN NN B-CHEM
- - - I-CHEM
vinyl NN NN I-CHEM
- - - I-CHEM
GABA NNP NNP I-CHEM
, , , O
5 CD CD O
micrograms NNS NNS O
, , , O
into IN IN O
the DT DT O
dorsal NN NN O
striatum NN NN O
, , , O
bilaterally RB RB O
, , , O
failed VBD VBD O
to TO TO O
prevent VB VB O
the DT DT O
development NN NN O
of IN IN O
convulsions NNS NNS O
produced VBN VBN O
by IN IN O
pilocarpine NN NN B-CHEM
, , , O
380 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
. . . O

The DT DT O
results NNS NNS O
demonstrate VBP VBP O
that IN IN O
the DT DT O
threshold NN NN O
for IN IN O
pilocarpine NN NN B-CHEM
- - - O
induced JJ JJ O
seizures NNS NNS O
in IN IN O
rats NNS NNS O
is VBZ VBZ O
subjected VBN VBN O
to TO TO O
the DT DT O
regulation NN NN O
of IN IN O
the DT DT O
GABA NNP NNP B-CHEM
- - - O
mediated JJ JJ O
synaptic JJ JJ O
inhibition NN NN O
within IN IN O
the DT DT O
substantia NN NN O
nigra NN NN O
. . . O

Human NNP NNP O
and CC CC O
canine NN NN O
ventricular NN NN O
vasoactive JJ JJ O
intestinal NN NN O
polypeptide NN NN O
: : : O
decrease NN NN O
with IN IN O
heart NN NN O
failure NN NN O
. . . O

Vasoactive NNP NNP O
intestinal JJ JJ O
polypeptide NN NN O
( ( ( O
VIP NNP NNP O
) ) ) O
is VBZ VBZ O
a DT DT O
systemic JJ JJ O
and CC CC O
coronary JJ JJ O
vasodilator NN NN O
that WDT WDT O
may MD MD O
have VB VB O
positive JJ JJ O
inotropic NN NN O
properties NNS NNS O
. . . O

Myocardial NNP NNP O
levels NNS NNS O
of IN IN O
VIP NNP NNP O
were VBD VBD O
assayed VBN VBN O
before IN IN O
and CC CC O
after IN IN O
the DT DT O
development NN NN O
of IN IN O
heart NN NN O
failure NN NN O
in IN IN O
two CD CD O
canine NN NN O
models NNS NNS O
. . . O

In IN IN O
the DT DT O
first JJ JJ O
, , , O
cobalt NN NN B-CHEM
cardiomyopathy NN NN O
was VBD VBD O
induced VBN VBN O
in IN IN O
eight CD CD O
dogs NNS NNS O
; : : O
VIP NNP NNP O
( ( ( O
by IN IN O
radioimmunoassay NN NN O
) ) ) O
decreased VBD VBD O
from IN IN O
35 CD CD O
+ NN NN O
/ NN NN O
- : : O
11 CD CD O
pg NN NN O
/ NN NN O
mg NN NN O
protein NN NN O
( ( ( O
mean NN NN O
+ NN NN O
/ NN NN O
- - - O
SD NNP NNP O
) ) ) O
to TO TO O
5 CD CD O
+ NN NN O
/ NN NN O
- : : O
4 CD CD O
pg NN NN O
/ NN NN O
mg NN NN O
protein NN NN O
( ( ( O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

In IN IN O
six CD CD O
dogs NNS NNS O
with IN IN O
doxorubicin NN NN B-CHEM
- - - O
induced JJ JJ O
heart NN NN O
failure NN NN O
, , , O
VIP NNP NNP O
decreased VBD VBD O
from IN IN O
31 CD CD O
+ NN NN O
/ NN NN O
- : : O
7 CD CD O
to TO TO O
11 CD CD O
+ NN NN O
/ NN NN O
- : : O
4 CD CD O
pg NN NN O
/ NN NN O
mg NN NN O
protein NN NN O
( ( ( O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

In IN IN O
addition NN NN O
, , , O
VIP NNP NNP O
content NN NN O
of IN IN O
left VBD VBD O
ventricular JJ JJ O
muscle NN NN O
of IN IN O
resected VBN VBN O
failing VBG VBG O
hearts NNS NNS O
in IN IN O
10 CD CD O
patients NNS NNS O
receiving VBG VBG O
a DT DT O
heart NN NN O
transplant NN NN O
was VBD VBD O
compared VBN VBN O
with IN IN O
the DT DT O
papillary JJ JJ O
muscles NNS NNS O
in IN IN O
14 CD CD O
patients NNS NNS O
( ( ( O
five CD CD O
with IN IN O
rheumatic JJ JJ O
disease NN NN O
, , , O
nine CD CD O
with IN IN O
myxomatous JJ JJ O
degeneration NN NN O
) ) ) O
receiving VBG VBG O
mitral JJ JJ O
valve NN NN O
prostheses NNS NNS O
. . . O

The DT DT O
lowest JJS JJS O
myocardial NN NN O
VIP NNP NNP O
concentration NN NN O
was VBD VBD O
found VBN VBN O
in IN IN O
the DT DT O
hearts NNS NNS O
of IN IN O
patients NNS NNS O
with IN IN O
coronary JJ JJ O
disease NN NN O
( ( ( O
one CD CD O
patient NN NN O
receiving VBG VBG O
a DT DT O
transplant NN NN O
and CC CC O
three CD CD O
receiving VBG VBG O
mitral JJ JJ O
prostheses NNS NNS O
) ) ) O
( ( ( O
6 CD CD O
. . . O
3 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
9 CD CD O
pg NN NN O
/ NN NN O
mg NN NN O
protein NN NN O
) ) ) O
. . . O

The DT DT O
other JJ JJ O
patients NNS NNS O
undergoing VBG VBG O
transplantation NN NN O
had VBD VBD O
an DT DT O
average JJ JJ O
ejection NN NN O
fraction NN NN O
of IN IN O
17 CD CD O
% NN NN O
+ NN NN O
/ NN NN O
- : : O
6 CD CD O
% NN NN O
and CC CC O
a DT DT O
VIP NNP NNP O
level NN NN O
of IN IN O
8 CD CD O
. . . O
8 CD CD O
+ NN NN O
/ NN NN O
- : : O
3 CD CD O
. . . O
9 CD CD O
pg NN NN O
/ NN NN O
mg NN NN O
protein NN NN O
. . . O

The DT DT O
hearts NNS NNS O
without IN IN O
coronary JJ JJ O
artery NN NN O
disease NN NN O
( ( ( O
average JJ JJ O
ejection NN NN O
fraction NN NN O
of IN IN O
this DT DT O
group NN NN O
62 CD CD O
% NN NN O
+ NN NN O
/ NN NN O
- : : O
10 CD CD O
% NN NN O
) ) ) O
had VBD VBD O
a DT DT O
VIP NNP NNP O
concentration NN NN O
of IN IN O
14 CD CD O
. . . O
1 CD CD O
+ NN NN O
/ NN NN O
- : : O
7 CD CD O
. . . O
9 CD CD O
pg NN NN O
/ NN NN O
mg NN NN O
protein NN NN O
, , , O
and CC CC O
this DT DT O
was VBD VBD O
greater JJR JJR O
than IN IN O
in IN IN O
hearts NNS NNS O
of IN IN O
the DT DT O
patients NNS NNS O
with IN IN O
coronary JJ JJ O
disease NN NN O
and CC CC O
the DT DT O
hearts NNS NNS O
of IN IN O
patients NNS NNS O
receiving VBG VBG O
a DT DT O
transplant NN NN O
( ( ( O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

Myocardial NNP NNP O
catecholamines NNS NNS B-CHEM
were VBD VBD O
also RB RB O
determined VBN VBN O
in IN IN O
14 CD CD O
subjects NNS NNS O
; : : O
a DT DT O
weak JJ JJ O
correlation NN NN O
( ( ( O
r LS LS O
= SYM SYM O
0 CD CD O
. . . O
57 CD CD O
, , , O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
between IN IN O
the DT DT O
tissue NN NN O
concentrations NNS NNS O
of IN IN O
VIP NNP NNP O
and CC CC O
norepinephrine NN NN B-CHEM
was VBD VBD O
noted VBN VBN O
. . . O
( ( ( O
ABSTRACT NNP NNP O
TRUNCATED NNP NNP O
AT IN IN O
250 CD CD O
WORDS NNP NNP O
) ) ) O

Non NNP NNP O
- : : O
invasive JJ JJ O
detection NN NN O
of IN IN O
coronary JJ JJ O
artery NN NN O
disease NN NN O
by IN IN O
body NN NN O
surface NN NN O
electrocardiographic JJ JJ O
mapping NN NN O
after IN IN O
dipyridamole NN NN B-CHEM
infusion NN NN O
. . . O

Electrocardiographic NNP NNP O
changes NNS NNS O
after IN IN O
dipyridamole NN NN B-CHEM
infusion NN NN O
( ( ( O
0 CD CD O
. . . O
568 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
4 CD CD O
min NN NN O
) ) ) O
were VBD VBD O
studied VBN VBN O
in IN IN O
41 CD CD O
patients NNS NNS O
with IN IN O
coronary JJ JJ O
artery NN NN O
disease NN NN O
and CC CC O
compared VBN VBN O
with IN IN O
those DT DT O
after IN IN O
submaximal NN NN O
treadmill NN NN O
exercise NN NN O
by IN IN O
use NN NN O
of IN IN O
the DT DT O
body NN NN O
surface NN NN O
mapping NN NN O
technique NN NN O
. . . O

Patients NNS NNS O
were VBD VBD O
divided VBN VBN O
into IN IN O
three CD CD O
groups NNS NNS O
; : : O
19 CD CD O
patients NNS NNS O
without IN IN O
myocardial NN NN O
infarction NN NN O
( ( ( O
non NN NN O
- - - O
MI NNP NNP O
group NN NN O
) ) ) O
, , , O
14 CD CD O
with IN IN O
anterior NN NN O
infarction NN NN O
( ( ( O
ANT NNP NNP O
- - - O
MI NNP NNP O
) ) ) O
and CC CC O
eight CD CD O
with IN IN O
inferior JJ JJ O
infarction NN NN O
( ( ( O
INF NNP NNP O
- - - O
MI NNP NNP O
) ) ) O
. . . O

Eighty NNP NNP O
- : : O
seven CD CD O
unipolar JJ JJ O
electrocardiograms NNS NNS O
( ( ( O
ECGs NNP NNP O
) ) ) O
distributed VBN VBN O
over IN IN O
the DT DT O
entire JJ JJ O
thoracic NN NN O
surface NN NN O
were VBD VBD O
simultaneously RB RB O
recorded VBN VBN O
. . . O

After IN IN O
dipyridamole NN NN B-CHEM
, , , O
ischemic JJ JJ O
ST NNP NNP O
- : : O
segment NN NN O
depression NN NN O
( ( ( O
0 CD CD O
. . . O
05 CD CD O
mV NN NN O
or CC CC O
more JJR JJR O
) ) ) O
was VBD VBD O
observed VBN VBN O
in IN IN O
84 CD CD O
% NN NN O
of IN IN O
the DT DT O
non NN NN O
- - - O
MI NNP NNP O
group NN NN O
, , , O
29 CD CD O
% NN NN O
of IN IN O
the DT DT O
ANT NNP NNP O
- : : O
MI NNP NNP O
group NN NN O
, , , O
63 CD CD O
% NN NN O
of IN IN O
the DT DT O
INF NNP NNP O
- - - O
MI NNP NNP O
group NN NN O
and CC CC O
61 CD CD O
% NN NN O
of IN IN O
the DT DT O
total JJ JJ O
population NN NN O
. . . O

Exercise NNP NNP O
- : : O
induced JJ JJ O
ST NNP NNP O
depression NN NN O
was VBD VBD O
observed VBN VBN O
in IN IN O
84 CD CD O
% NN NN O
of IN IN O
the DT DT O
non NN NN O
- - - O
MI NNP NNP O
group NN NN O
, , , O
43 CD CD O
% NN NN O
of IN IN O
the DT DT O
ANT NNP NNP O
- : : O
MI NNP NNP O
group NN NN O
, , , O
38 CD CD O
% NN NN O
of IN IN O
the DT DT O
INF NNP NNP O
- - - O
MI NNP NNP O
group NN NN O
and CC CC O
61 CD CD O
% NN NN O
of IN IN O
the DT DT O
total NN NN O
. . . O

For IN IN O
individual JJ JJ O
patients NNS NNS O
, , , O
there EX EX O
were VBD VBD O
no DT DT O
obvious JJ JJ O
differences NNS NNS O
between IN IN O
the DT DT O
body NN NN O
surface NN NN O
distribution NN NN O
of IN IN O
ST NNP NNP O
depression NN NN O
in IN IN O
both DT DT O
tests NNS NNS O
. . . O

The DT DT O
increase NN NN O
in IN IN O
pressure NN NN O
rate NN NN O
product NN NN O
after IN IN O
dipyridamole NN NN B-CHEM
was VBD VBD O
significantly RB RB O
less JJR JJR O
than IN IN O
that DT DT O
during IN IN O
the DT DT O
treadmill NN NN O
exercise NN NN O
. . . O

The DT DT O
data NNS NNS O
suggest VBP VBP O
that IN IN O
the DT DT O
dipyridamole NN NN B-CHEM
- - - O
induced JJ JJ O
myocardial NN NN O
ischemia NN NN O
is VBZ VBZ O
caused VBN VBN O
by IN IN O
the DT DT O
inhomogenous JJ JJ O
distribution NN NN O
of IN IN O
myocardial NN NN O
blood NN NN O
flow NN NN O
. . . O

We PRP PRP O
conclude VBP VBP O
that IN IN O
the DT DT O
dipyridamole NN NN B-CHEM
ECG NNP NNP O
test NN NN O
is VBZ VBZ O
as RB RB O
useful JJ JJ O
as IN IN O
the DT DT O
exercise NN NN O
ECG NNP NNP O
test NN NN O
for IN IN O
the DT DT O
assessment NN NN O
of IN IN O
coronary JJ JJ O
artery NN NN O
disease NN NN O
. . . O

Bradycardia NNP NNP O
after IN IN O
high JJ JJ O
- - - O
dose NN NN O
intravenous JJ JJ O
methylprednisolone NN NN B-CHEM
therapy NN NN O
. . . O

In IN IN O
5 CD CD O
consecutive JJ JJ O
patients NNS NNS O
with IN IN O
rheumatoid NN NN O
arthritis NN NN O
who WP WP O
received VBD VBD O
intravenous JJ JJ O
high JJ JJ O
- - - O
dose NN NN O
methylprednisolone NN NN B-CHEM
( ( ( O
MP NNP NNP B-CHEM
) ) ) O
therapy NN NN O
( ( ( O
1 CD CD O
g SYM SYM O
daily NN NN O
for IN IN O
2 CD CD O
or CC CC O
3 CD CD O
consecutive JJ JJ O
days NNS NNS O
) ) ) O
, , , O
a DT DT O
decline NN NN O
in IN IN O
pulse NN NN O
rate NN NN O
was VBD VBD O
observed VBN VBN O
, , , O
most JJS JJS O
pronounced VBN VBN O
on IN IN O
day NN NN O
4 CD CD O
. . . O

In IN IN O
one CD CD O
of IN IN O
the DT DT O
5 CD CD O
patients NNS NNS O
the DT DT O
bradycardia NN NN O
was VBD VBD O
associated VBN VBN O
with IN IN O
complaints NNS NNS O
of IN IN O
substernal JJ JJ O
pressure NN NN O
. . . O

Reversal NNP NNP O
to TO TO O
normal JJ JJ O
heart NN NN O
rate NN NN O
was VBD VBD O
found VBN VBN O
on IN IN O
day NN NN O
7 CD CD O
. . . O

Electrocardiographic NNP NNP O
registrations NNS NNS O
showed VBD VBD O
sinus CC CC O
bradycardia NNS NNS O
in IN IN O
all DT DT O
cases NNS NNS O
. . . O

No DT DT O
significant JJ JJ O
changes NNS NNS O
in IN IN O
plasma NN NN O
concentrations NNS NNS O
of IN IN O
electrolytes NNS NNS O
were VBD VBD O
found VBN VBN O
. . . O

Careful NNP NNP O
observation NN NN O
of IN IN O
patients NNS NNS O
receiving VBG VBG O
high JJ JJ O
- - - O
dose NN NN O
MP NNP NNP B-CHEM
is VBZ VBZ O
recommended VBN VBN O
. . . O

High NNP NNP O
- - - O
dose NN NN O
MP NNP NNP B-CHEM
may MD MD O
be VB VB O
contraindicated VBN VBN O
in IN IN O
patients NNS NNS O
with IN IN O
known VBN VBN O
heart NN NN O
disease NN NN O
. . . O

Two CD CD O
cases NNS NNS O
of IN IN O
downbeat NN NN O
nystagmus NN NN O
and CC CC O
oscillopsia NN NN O
associated VBN VBN O
with IN IN O
carbamazepine NN NN B-CHEM
. . . O

Downbeat NNP NNP O
nystagmus NN NN O
is VBZ VBZ O
often RB RB O
associated VBN VBN O
with IN IN O
structural JJ JJ O
lesions NNS NNS O
at IN IN O
the DT DT O
craniocervical JJ JJ O
junction NN NN O
, , , O
but CC CC O
has VBZ VBZ O
occasionally RB RB O
been VBN VBN O
reported VBN VBN O
as IN IN O
a DT DT O
manifestation NN NN O
of IN IN O
metabolic JJ JJ O
imbalance NN NN O
or CC CC O
drug NN NN O
intoxication NN NN O
. . . O

We PRP PRP O
recorded VBD VBD O
the DT DT O
eye NN NN O
movements NNS NNS O
of IN IN O
two CD CD O
patients NNS NNS O
with IN IN O
reversible JJ JJ O
downbeat NN NN O
nystagmus NN NN O
related VBN VBN O
to TO TO O
carbamazepine NN NN B-CHEM
therapy NN NN O
. . . O

The DT DT O
nystagmus NN NN O
of IN IN O
both DT DT O
patients NNS NNS O
resolved VBD VBD O
after IN IN O
reduction NN NN O
of IN IN O
the DT DT O
serum NN NN O
carbamazepine NN NN B-CHEM
levels NNS NNS O
. . . O

Neuroradiologic NNP NNP O
investigations NNS NNS O
including VBG VBG O
magnetic JJ JJ O
resonance NN NN O
imaging VBG VBG O
scans NNS NNS O
in IN IN O
both DT DT O
patients NNS NNS O
showed VBD VBD O
no DT DT O
evidence NN NN O
of IN IN O
intracranial JJ JJ O
abnormality NN NN O
. . . O

In IN IN O
patients NNS NNS O
with IN IN O
downbeat NN NN O
nystagmus NN NN O
who WP WP O
are VBP VBP O
taking VBG VBG O
anticonvulsant JJ JJ O
medications NNS NNS O
, , , O
consideration NN NN O
should MD MD O
be VB VB O
given VBN VBN O
to TO TO O
reduction NN NN O
in IN IN O
dose NN NN O
before IN IN O
further JJ JJ O
investigation NN NN O
is VBZ VBZ O
undertaken VBN VBN O
. . . O

Improvement NNP NNP O
by IN IN O
denopamine NN NN B-CHEM
( ( ( O
TA NNP NNP B-CHEM
- - - I-CHEM
064 CD CD I-CHEM
) ) ) O
of IN IN O
pentobarbital JJ JJ B-CHEM
- - - O
induced JJ JJ O
cardiac NN NN O
failure NN NN O
in IN IN O
the DT DT O
dog NN NN O
heart NN NN O
- : : O
lung NN NN O
preparation NN NN O
. . . O

The DT DT O
efficacy NN NN O
of IN IN O
denopamine NN NN B-CHEM
, , , O
an DT DT O
orally RB RB O
active JJ JJ O
beta NN NN O
1 CD CD O
- : : O
adrenoceptor NN NN O
agonist NN NN O
, , , O
in IN IN O
improving VBG VBG O
cardiac NN NN O
failure NN NN O
was VBD VBD O
assessed VBN VBN O
in IN IN O
dog NN NN O
heart NN NN O
- : : O
lung NN NN O
preparations NNS NNS O
. . . O

Cardiac NNP NNP O
functions NNS NNS O
depressed VBN VBN O
by IN IN O
pentobarbital NN NN B-CHEM
( ( ( O
118 CD CD O
+ NN NN O
/ NN NN O
- : : O
28 CD CD O
mg NN NN O
; : : O
mean NN NN O
value NN NN O
+ NN NN O
/ NN NN O
- - - O
SD NNP NNP O
) ) ) O
such JJ JJ O
that IN IN O
cardiac JJ JJ O
output NN NN O
and CC CC O
maximum NN NN O
rate NN NN O
of IN IN O
rise NN NN O
of IN IN O
left VBD VBD O
ventricular NN NN O
pressure NN NN O
( ( ( O
LV NNP NNP O
dP NN NN O
/ NN NN O
dt NN NN O
max NN NN O
) ) ) O
had VBD VBD O
been VBN VBN O
reduced VBN VBN O
by IN IN O
about IN IN O
35 CD CD O
% NN NN O
and CC CC O
26 CD CD O
% NN NN O
of IN IN O
the DT DT O
respective JJ JJ O
controls NNS NNS O
were VBD VBD O
improved VBN VBN O
by IN IN O
denopamine NN NN B-CHEM
( ( ( O
10 CD CD O
- : : O
300 CD CD O
micrograms NNS NNS O
) ) ) O
in IN IN O
a DT DT O
dose NN NN O
- - - O
dependent JJ JJ O
manner NN NN O
. . . O

With IN IN O
100 CD CD O
micrograms NNS NNS O
denopamine NN NN B-CHEM
, , , O
almost RB RB O
complete JJ JJ O
restoration NN NN O
of IN IN O
cardiac JJ JJ O
performance NN NN O
was VBD VBD O
attained VBN VBN O
, , , O
associated VBN VBN O
with IN IN O
a DT DT O
slight JJ JJ O
increase NN NN O
in IN IN O
heart NN NN O
rate NN NN O
. . . O

No DT DT O
arrhythmias NNS NNS O
were VBD VBD O
induced VBN VBN O
by IN IN O
these DT DT O
doses NNS NNS O
of IN IN O
denopamine NN NN B-CHEM
. . . O

The DT DT O
results NNS NNS O
warrant VBP VBP O
clinical JJ JJ O
trials NNS NNS O
of IN IN O
denopamine NN NN B-CHEM
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
cardiac JJ JJ O
failure NN NN O
. . . O

Clonazepam NNP NNP B-CHEM
monotherapy NN NN O
for IN IN O
epilepsy NN NN O
in IN IN O
childhood NN NN O
. . . O

Sixty NNP NNP O
patients NNS NNS O
( ( ( O
age NN NN O
- - - O
range NN NN O
one CD CD O
month NN NN O
to TO TO O
14 CD CD O
years NNS NNS O
) ) ) O
with IN IN O
other JJ JJ O
types NNS NNS O
of IN IN O
epilepsy NN NN O
than IN IN O
infantile NN NN O
spasms NNS NNS O
were VBD VBD O
treated VBN VBN O
with IN IN O
clonazepam NN NN B-CHEM
. . . O

Disappearance NNP NNP O
of IN IN O
seizures NNS NNS O
and CC CC O
normalization NN NN O
of IN IN O
abnormal JJ JJ O
EEG NNP NNP O
with IN IN O
disappearance NN NN O
of IN IN O
seizures NNS NNS O
were VBD VBD O
recognized VBN VBN O
in IN IN O
77 CD CD O
% NN NN O
and CC CC O
50 CD CD O
% NN NN O
, , , O
respectively RB RB O
. . . O

Seizures NNP NNP O
disappeared VBD VBD O
in IN IN O
71 CD CD O
% NN NN O
of IN IN O
the DT DT O
patients NNS NNS O
with IN IN O
generalized JJ JJ O
seizures NNS NNS O
and CC CC O
89 CD CD O
% NN NN O
of IN IN O
partial JJ JJ O
seizures NNS NNS O
. . . O

Improvement NNP NNP O
of IN IN O
abnormal JJ JJ O
EEG NNP NNP O
was VBD VBD O
noticed VBN VBN O
in IN IN O
76 CD CD O
% NN NN O
of IN IN O
diffuse NN NN O
paroxysms NNS NNS O
and CC CC O
in IN IN O
67 CD CD O
% NN NN O
of IN IN O
focal JJ JJ O
paroxysms NNS NNS O
. . . O

In IN IN O
excellent JJ JJ O
cases NNS NNS O
, , , O
mean VB VB O
effective JJ JJ O
dosages NNS NNS O
were VBD VBD O
0 CD CD O
. . . O
086 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
021 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
in IN IN O
infants NNS NNS O
and CC CC O
0 CD CD O
. . . O
057 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
022 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
day NN NN O
in IN IN O
schoolchildren NN NN O
, , , O
this DT DT O
difference NN NN O
was VBD VBD O
statistically RB RB O
significant JJ JJ O
( ( ( O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
005 CD CD O
) ) ) O
. . . O

The DT DT O
incidence NN NN O
of IN IN O
side NN NN O
effects NNS NNS O
such JJ JJ O
as IN IN O
drowsiness NN NN O
and CC CC O
ataxia NN NN O
was VBD VBD O
only RB RB O
5 CD CD O
% NN NN O
. . . O

Postmarketing NNP NNP O
study NN NN O
of IN IN O
timolol NN NN B-CHEM
- - - O
hydrochlorothiazide NN NN B-CHEM
antihypertensive JJ JJ O
therapy NN NN O
. . . O

A DT DT O
postmarketing VBG VBG O
surveillance NN NN O
study NN NN O
was VBD VBD O
conducted VBN VBN O
to TO TO O
determine VB VB O
the DT DT O
safety NN NN O
and CC CC O
efficacy NN NN O
of IN IN O
a DT DT O
fixed JJ JJ O
- - - O
ratio NN NN O
combination NN NN O
containing VBG VBG O
10 CD CD O
mg NN NN O
of IN IN O
timolol NN NN B-CHEM
maleate NN NN I-CHEM
and CC CC O
25 CD CD O
mg NN NN O
of IN IN O
hydrochlorothiazide NN NN B-CHEM
, , , O
administered JJ JJ O
twice RB RB O
daily RB RB O
for IN IN O
one CD CD O
month NN NN O
to TO TO O
hypertensive VB VB O
patients NNS NNS O
. . . O

Data NNP NNP O
on IN IN O
9 CD CD O
, , , O
037 CD CD O
patients NNS NNS O
were VBD VBD O
collected VBN VBN O
by IN IN O
1 CD CD O
, , , O
455 CD CD O
participating VBG VBG O
physicians NNS NNS O
. . . O

Mean VB VB O
systolic JJ JJ O
blood NN NN O
pressure NN NN O
decreased VBD VBD O
25 CD CD O
mmHg NN NN O
and CC CC O
mean VB VB O
diastolic JJ JJ O
blood NN NN O
pressure NN NN O
declined VBD VBD O
15 CD CD O
mmHg NN NN O
after IN IN O
one CD CD O
month NN NN O
of IN IN O
timolol NN NN B-CHEM
- - - O
hydrochlorothiazide NN NN B-CHEM
therapy NN NN O
( ( ( O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
01 CD CD O
, , , O
both DT DT O
comparisons NNS NNS O
) ) ) O
. . . O

Age NNP NNP O
, , , O
race NN NN O
, , , O
and CC CC O
sex NN NN O
appeared VBD VBD O
to TO TO O
have VB VB O
no DT DT O
influence NN NN O
on IN IN O
the DT DT O
decrease NN NN O
in IN IN O
blood NN NN O
pressure NN NN O
. . . O

The DT DT O
antihypertensive JJ JJ O
effect NN NN O
of IN IN O
the DT DT O
drug NN NN O
was VBD VBD O
greater JJR JJR O
in IN IN O
patients NNS NNS O
with IN IN O
more JJR JJR O
severe JJ JJ O
hypertension NN NN O
. . . O

Overall NNP NNP O
, , , O
1 CD CD O
, , , O
453 CD CD O
patients NNS NNS O
experienced VBD VBD O
a DT DT O
total NN NN O
of IN IN O
2 CD CD O
, , , O
658 CD CD O
adverse JJ JJ O
events NNS NNS O
, , , O
the DT DT O
most RBS RBS O
common JJ JJ O
being NN NN O
fatigue NN NN O
, , , O
dizziness NN NN O
, , , O
and CC CC O
weakness NN NN O
. . . O

Treatment NN NN O
in IN IN O
590 CD CD O
patients NNS NNS O
was VBD VBD O
discontinued VBN VBN O
because IN IN O
of IN IN O
adverse JJ JJ O
events NNS NNS O
. . . O

Salicylate NNP NNP B-CHEM
nephropathy NN NN O
in IN IN O
the DT DT O
Gunn NNP NNP O
rat NN NN O
: : : O
potential JJ JJ O
role NN NN O
of IN IN O
prostaglandins NNS NNS B-CHEM
. . . O

We PRP PRP O
examined VBD VBD O
the DT DT O
potential JJ JJ O
role NN NN O
of IN IN O
prostaglandins NNS NNS B-CHEM
in IN IN O
the DT DT O
development NN NN O
of IN IN O
analgesic JJ JJ O
nephropathy NN NN O
in IN IN O
the DT DT O
Gunn NNP NNP O
strain NN NN O
of IN IN O
rat NN NN O
. . . O

The DT DT O
homozygous JJ JJ O
Gunn NNP NNP O
rats NNS NNS O
have VBP VBP O
unconjugated JJ JJ O
hyperbilirubinemia NN NN O
due JJ JJ O
to TO TO O
the DT DT O
absence NN NN O
of IN IN O
glucuronyl NN NN B-CHEM
transferase NN NN O
, , , O
leading VBG VBG O
to TO TO O
marked VBN VBN O
bilirubin NN NN B-CHEM
deposition NN NN O
in IN IN O
renal JJ JJ O
medulla NN NN O
and CC CC O
papilla NN NN O
. . . O

These DT DT O
rats NNS NNS O
are VBP VBP O
also RB RB O
highly RB RB O
susceptible JJ JJ O
to TO TO O
develop VB VB O
papillary JJ JJ O
necrosis NNS NNS O
with IN IN O
analgesic JJ JJ O
administration NN NN O
. . . O

We PRP PRP O
used VBD VBD O
homozygous JJ JJ O
( ( ( O
jj NN NN O
) ) ) O
and CC CC O
phenotypically RB RB O
normal JJ JJ O
heterozygous JJ JJ O
( ( ( O
jJ NN NN O
) ) ) O
animals NNS NNS O
. . . O

Four CD CD O
groups NNS NNS O
of IN IN O
rats NNS NNS O
( ( ( O
n NN NN O
= SYM SYM O
7 CD CD O
) ) ) O
were VBD VBD O
studied VBN VBN O
: : : O
jj NN NN O
and CC CC O
jJ NN NN O
rats NNS NNS O
treated VBN VBN O
either CC CC O
with IN IN O
aspirin NN NN B-CHEM
300 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
every DT DT O
other JJ JJ O
day NN NN O
or CC CC O
sham NN NN O
- - - O
treated VBN VBN O
. . . O

After IN IN O
one CD CD O
week NN NN O
, , , O
slices NNS NNS O
of IN IN O
cortex NN NN O
, , , O
outer NN NN O
and CC CC O
inner JJ JJ O
medulla NN NN O
from IN IN O
one CD CD O
kidney NN NN O
were VBD VBD O
incubated JJ JJ O
in IN IN O
buffer NN NN O
and CC CC O
prostaglandin NN NN B-CHEM
synthesis NN NN O
was VBD VBD O
determined VBN VBN O
by IN IN O
radioimmunoassay NN NN O
. . . O

The DT DT O
other JJ JJ O
kidney NN NN O
was VBD VBD O
examined VBN VBN O
histologically RB RB O
. . . O

A DT DT O
marked JJ JJ O
corticomedullary JJ JJ O
gradient NN NN O
of IN IN O
prostaglandin NN NN B-CHEM
synthesis NN NN O
was VBD VBD O
observed VBN VBN O
in IN IN O
all DT DT O
groups NNS NNS O
. . . O

PGE2 NNP NNP B-CHEM
synthesis NN NN O
was VBD VBD O
significantly RB RB O
higher JJR JJR O
in IN IN O
outer JJ JJ O
medulla NN NN O
, , , O
but CC CC O
not RB RB O
cortex NN NN O
or CC CC O
inner JJ JJ O
medulla NN NN O
, , , O
of IN IN O
jj NN NN O
( ( ( O
38 CD CD O
+ NN NN O
/ NN NN O
- : : O
6 CD CD O
ng NN NN O
/ NN NN O
mg NN NN O
prot NN NN O
) ) ) O
than IN IN O
jJ NN NN O
rats NNS NNS O
( ( ( O
15 CD CD O
+ NN NN O
/ NN NN O
- : : O
3 CD CD O
) ) ) O
( ( ( O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
. . . O

Aspirin NNP NNP B-CHEM
treatment NN NN O
reduced VBD VBD O
PGE2 NNP NNP B-CHEM
synthesis NN NN O
in IN IN O
all DT DT O
regions NNS NNS O
, , , O
but CC CC O
outer JJ JJ O
medullary JJ JJ O
PGE2 NNP NNP B-CHEM
remained VBD VBD O
higher JJR JJR O
in IN IN O
jj NN NN O
( ( ( O
18 CD CD O
+ NN NN O
/ NN NN O
- : : O
3 CD CD O
) ) ) O
than IN IN O
jJ NN NN O
rats NNS NNS O
( ( ( O
9 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
) ) ) O
( ( ( O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

PGF2 NNP NNP B-CHEM
alpha NN NN I-CHEM
was VBD VBD O
also RB RB O
significantly RB RB O
higher JJR JJR O
in IN IN O
the DT DT O
outer JJ JJ O
medulla NN NN O
of IN IN O
jj NN NN O
rats NNS NNS O
with IN IN O
and CC CC O
without IN IN O
aspirin NN NN B-CHEM
administration NN NN O
( ( ( O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

The DT DT O
changes NNS NNS O
in IN IN O
renal NN NN O
prostaglandin NN NN B-CHEM
synthesis NN NN O
were VBD VBD O
accompanied VBN VBN O
by IN IN O
evidence NN NN O
of IN IN O
renal JJ JJ O
damage NN NN O
in IN IN O
aspirin NN NN B-CHEM
- - - O
treated VBN VBN O
jj NN NN O
but CC CC O
not RB RB O
jJ JJ JJ O
rats NNS NNS O
as IN IN O
evidenced VBN VBN O
by IN IN O
: : : O
increased VBN VBN O
incidence NN NN O
and CC CC O
severity NN NN O
of IN IN O
hematuria NN NN O
( ( ( O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
; : : O
increased VBN VBN O
serum NN NN O
creatinine NN NN B-CHEM
( ( ( O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
; : : O
and CC CC O
increase VB VB O
in IN IN O
outer NN NN O
medullary JJ JJ O
histopathologic NN NN O
lesions NNS NNS O
( ( ( O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
005 CD CD O
compared VBN VBN O
to TO TO O
either CC CC O
sham NN NN O
- - - O
treated VBN VBN O
jj NN NN O
or CC CC O
aspirin NN NN B-CHEM
- - - O
treated VBN VBN O
jJ NN NN O
) ) ) O
. . . O

These DT DT O
results NNS NNS O
suggest VBP VBP O
that IN IN O
enhanced JJ JJ O
prostaglandin NN NN B-CHEM
synthesis NN NN O
contributes VBZ VBZ O
to TO TO O
maintenance NN NN O
of IN IN O
renal JJ JJ O
function NN NN O
and CC CC O
morphological JJ JJ O
integrity NN NN O
, , , O
and CC CC O
that DT DT O
inhibition NN NN O
of IN IN O
prostaglandin NN NN B-CHEM
synthesis NN NN O
may MD MD O
lead VB VB O
to TO TO O
pathological JJ JJ O
renal JJ JJ O
medullary JJ JJ O
lesions NNS NNS O
and CC CC O
deterioration NN NN O
of IN IN O
renal JJ JJ O
function NN NN O
. . . O

Prophylactic NNP NNP O
lidocaine NN NN B-CHEM
in IN IN O
the DT DT O
early JJ JJ O
phase NN NN O
of IN IN O
suspected VBN VBN O
myocardial NN NN O
infarction NN NN O
. . . O

Four CD CD O
hundred CD CD O
two CD CD O
patients NNS NNS O
with IN IN O
suspected VBD VBD O
myocardial NN NN O
infarction NN NN O
seen VBN VBN O
within IN IN O
6 CD CD O
hours NNS NNS O
of IN IN O
the DT DT O
onset NN NN O
of IN IN O
symptoms NNS NNS O
entered VBD VBD O
a DT DT O
double JJ JJ O
- - - O
blind JJ JJ O
randomized JJ JJ O
trial NN NN O
of IN IN O
lidocaine NN NN B-CHEM
vs NNS NNS O
placebo NN NN O
. . . O

During IN IN O
the DT DT O
1 CD CD O
hour NN NN O
after IN IN O
administration NN NN O
of IN IN O
the DT DT O
drug NN NN O
the DT DT O
incidence NN NN O
of IN IN O
ventricular NN NN O
fibrillation NN NN O
or CC CC O
sustained VBD VBD O
ventricular JJ JJ O
tachycardia NN NN O
among IN IN O
the DT DT O
204 CD CD O
patients NNS NNS O
with IN IN O
acute JJ JJ O
myocardial NN NN O
infarction NN NN O
was VBD VBD O
low JJ JJ O
, , , O
1 CD CD O
. . . O
5 CD CD O
% NN NN O
. . . O

Lidocaine NNP NNP B-CHEM
, , , O
given VBN VBN O
in IN IN O
a DT DT O
300 CD CD O
mg NN NN O
dose NN NN O
intramuscularly RB RB O
followed VBN VBN O
by IN IN O
100 CD CD O
mg NN NN O
intravenously RB RB O
, , , O
did VBD VBD O
not RB RB O
prevent VB VB O
sustained JJ JJ O
ventricular NN NN O
tachycardia NNS NNS O
, , , O
although IN IN O
there EX EX O
was VBD VBD O
a DT DT O
significant JJ JJ O
reduction NN NN O
in IN IN O
the DT DT O
number NN NN O
of IN IN O
patients NNS NNS O
with IN IN O
warning NN NN O
arrhythmias NNS NNS O
between IN IN O
15 CD CD O
and CC CC O
45 CD CD O
minutes NNS NNS O
after IN IN O
the DT DT O
administration NN NN O
of IN IN O
lidocaine NN NN B-CHEM
( ( ( O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

The DT DT O
average JJ JJ O
plasma NN NN O
lidocaine NN NN B-CHEM
level NN NN O
10 CD CD O
minutes NNS NNS O
after IN IN O
administration NN NN O
for IN IN O
patients NNS NNS O
without IN IN O
a DT DT O
myocardial NN NN O
infarction NN NN O
was VBD VBD O
significantly RB RB O
higher JJR JJR O
than IN IN O
that DT DT O
for IN IN O
patients NNS NNS O
with IN IN O
an DT DT O
acute JJ JJ O
infarction NN NN O
. . . O

The DT DT O
mean NN NN O
plasma NN NN O
lidocaine NN NN B-CHEM
level NN NN O
of IN IN O
patients NNS NNS O
on IN IN O
beta NN NN O
- : : O
blocking VBG VBG O
agents NNS NNS O
was VBD VBD O
no DT DT O
different JJ JJ O
from IN IN O
that DT DT O
in IN IN O
patients NNS NNS O
not RB RB O
on IN IN O
beta NN NN O
blocking VBG VBG O
agents NNS NNS O
. . . O

During IN IN O
the DT DT O
1 CD CD O
- : : O
hour NN NN O
study NN NN O
period NN NN O
, , , O
the DT DT O
incidence NN NN O
of IN IN O
central JJ JJ O
nervous JJ JJ O
system NN NN O
side NN NN O
effects NNS NNS O
was VBD VBD O
significantly RB RB O
greater JJR JJR O
in IN IN O
the DT DT O
lidocaine NN NN B-CHEM
group NN NN O
, , , O
hypotension NN NN O
occurred VBD VBD O
in IN IN O
11 CD CD O
patients NNS NNS O
, , , O
nine CD CD O
of IN IN O
whom WP WP O
had VBD VBD O
received VBN VBN O
lidocaine NN NN B-CHEM
, , , O
and CC CC O
four CD CD O
patients NNS NNS O
died VBD VBD O
from IN IN O
asystole NN NN O
, , , O
three CD CD O
of IN IN O
whom WP WP O
had VBD VBD O
had VBN VBN O
lidocaine NN NN B-CHEM
. . . O

We PRP PRP O
cannot NN NN O
advocate NN NN O
the DT DT O
administration NN NN O
of IN IN O
lidocaine NN NN B-CHEM
prophylactically RB RB O
in IN IN O
the DT DT O
early JJ JJ O
hours NNS NNS O
of IN IN O
suspected VBN VBN O
myocardial NN NN O
infarction NN NN O
. . . O

Evidence NN NN O
for IN IN O
a DT DT O
cholinergic JJ JJ O
role NN NN O
in IN IN O
haloperidol NN NN B-CHEM
- - - O
induced JJ JJ O
catalepsy NN NN O
. . . O

Experiments NNS NNS O
in IN IN O
mice NN NN O
tested VBD VBD O
previous JJ JJ O
evidence NN NN O
that DT DT O
activation NN NN O
of IN IN O
cholinergic JJ JJ O
systems NNS NNS O
promotes NNS NNS O
catalepsy NN NN O
and CC CC O
that IN IN O
cholinergic JJ JJ O
mechanisms NNS NNS O
need VBP VBP O
to TO TO O
be VB VB O
intact JJ JJ O
for IN IN O
full JJ JJ O
expression NN NN O
of IN IN O
neuroleptic JJ JJ B-CHEM
- - - O
induced JJ JJ O
catalepsy NN NN O
. . . O

Large JJ JJ O
doses NNS NNS O
of IN IN O
the DT DT O
cholinomimetic JJ JJ O
, , , O
pilocarpine NN NN B-CHEM
, , , O
could MD MD O
induce VB VB O
catalepsy NN NN O
when WRB WRB O
peripheral JJ JJ O
cholinergic JJ JJ O
receptors NNS NNS O
were VBD VBD O
blocked VBN VBN O
. . . O

Low NNP NNP O
doses NNS NNS O
of IN IN O
pilocarpine NN NN B-CHEM
caused VBD VBD O
a DT DT O
pronounced JJ JJ O
enhancement NN NN O
of IN IN O
the DT DT O
catalepsy NN NN O
that WDT WDT O
was VBD VBD O
induced VBN VBN O
by IN IN O
the DT DT O
dopaminergic JJ JJ O
blocker NN NN O
, , , O
haloperidol NN NN B-CHEM
. . . O

A DT DT O
muscarinic JJ JJ O
receptor NN NN O
blocker NN NN O
, , , O
atropine NN NN B-CHEM
, , , O
disrupted VBN VBN O
haloperidol NN NN B-CHEM
- - - O
induced JJ JJ O
catalepsy NN NN O
. . . O

Intracranial NNP NNP O
injection NN NN O
of IN IN O
an DT DT O
acetylcholine NN NN B-CHEM
- - - O
synthesis NN NN O
inhibitor NN NN O
, , , O
hemicholinium NN NN B-CHEM
, , , O
prevented VBD VBD O
the DT DT O
catalepsy NN NN O
that WDT WDT O
is VBZ VBZ O
usually RB RB O
induced VBN VBN O
by IN IN O
haloperidol NN NN B-CHEM
. . . O

These DT DT O
findings NNS NNS O
suggest VBP VBP O
the DT DT O
hypothesis NNS NNS O
that IN IN O
the DT DT O
catalepsy NN NN O
that WDT WDT O
is VBZ VBZ O
produced VBN VBN O
by IN IN O
neuroleptics NNS NNS B-CHEM
such JJ JJ O
as IN IN O
haloperidol NN NN B-CHEM
is VBZ VBZ O
actually RB RB O
mediated VBN VBN O
by IN IN O
intrinsic JJ JJ O
central JJ JJ O
cholinergic JJ JJ O
systems NNS NNS O
. . . O

Alternatively RB RB O
, , , O
activation NN NN O
of IN IN O
central JJ JJ O
cholinergic JJ JJ O
systems NNS NNS O
could MD MD O
promote VB VB O
catalepsy NN NN O
by IN IN O
suppression NN NN O
of IN IN O
dopaminergic JJ JJ O
systems NNS NNS O
. . . O

Cardiovascular NNP NNP O
dysfunction NN NN O
and CC CC O
hypersensitivity NN NN O
to TO TO O
sodium VB VB B-CHEM
pentobarbital NN NN I-CHEM
induced VBN VBN O
by IN IN O
chronic JJ JJ O
barium NN NN B-CHEM
chloride NN NN I-CHEM
ingestion NN NN O
. . . O

Barium NNP NNP B-CHEM
- : : O
supplemented JJ JJ O
Long NNP NNP O
- : : O
Evans NNP NNP O
hooded VBD VBD O
rats NNS NNS O
were VBD VBD O
characterized VBN VBN O
by IN IN O
a DT DT O
persistent JJ JJ O
hypertension NN NN O
that WDT WDT O
was VBD VBD O
evident JJ JJ O
after IN IN O
1 CD CD O
month NN NN O
of IN IN O
barium NN NN B-CHEM
( ( ( O
100 CD CD O
micrograms NNS NNS O
/ NN NN O
ml NN NN O
mineral NN NN O
fortified VBN VBN O
water NN NN O
) ) ) O
treatment NN NN O
. . . O

Analysis NNP NNP O
of IN IN O
in IN IN O
vivo NN NN O
myocardial NN NN O
excitability NN NN O
, , , O
contractility NN NN O
, , , O
and CC CC O
metabolic JJ JJ O
characteristics NNS NNS O
at IN IN O
16 CD CD O
months NNS NNS O
revealed VBD VBD O
other JJ JJ O
significant JJ JJ O
barium NN NN B-CHEM
- - - O
induced JJ JJ O
disturbances NNS NNS O
within IN IN O
the DT DT O
cardiovascular JJ JJ O
system NN NN O
. . . O

The DT DT O
most RBS RBS O
distinctive JJ JJ O
aspect NN NN O
of IN IN O
the DT DT O
barium NN NN B-CHEM
effect NN NN O
was VBD VBD O
a DT DT O
demonstrated JJ JJ O
hypersensitivity NN NN O
of IN IN O
the DT DT O
cardiovascular JJ JJ O
system NN NN O
to TO TO O
sodium VB VB B-CHEM
pentobarbital NN NN I-CHEM
. . . O

Under IN IN O
barbiturate JJ JJ B-CHEM
anesthesia NN NN O
, , , O
virtually RB RB O
all DT DT O
of IN IN O
the DT DT O
myocardial NN NN O
contractile NN NN O
indices NNS NNS O
were VBD VBD O
depressed VBN VBN O
significantly RB RB O
in IN IN O
barium NN NN B-CHEM
- - - O
exposed VBN VBN O
rats NNS NNS O
relative JJ JJ O
to TO TO O
the DT DT O
corresponding JJ JJ O
control NN NN O
- - - O
fed VBN VBN O
rats NNS NNS O
. . . O

The DT DT O
lack NN NN O
of IN IN O
a DT DT O
similar JJ JJ O
response NN NN O
to TO TO O
ketamine VB VB B-CHEM
and CC CC O
xylazine VB VB B-CHEM
anesthesia RB RB O
revealed VBN VBN O
that IN IN O
the DT DT O
cardiovascular JJ JJ O
actions NNS NNS O
of IN IN O
sodium NN NN B-CHEM
pentobarbital NN NN I-CHEM
in IN IN O
barium NN NN B-CHEM
- - - O
treated VBN VBN O
rats NNS NNS O
were VBD VBD O
linked VBN VBN O
specifically RB RB O
to TO TO O
this DT DT O
anesthetic JJ JJ O
, , , O
and CC CC O
were VBD VBD O
not RB RB O
representative NN NN O
of IN IN O
a DT DT O
generalized JJ JJ O
anesthetic JJ JJ O
response NN NN O
. . . O

Other JJ JJ O
myocardial JJ JJ O
pathophysiologic NN NN O
and CC CC O
metabolic JJ JJ O
changes NNS NNS O
induced VBN VBN O
by IN IN O
barium NN NN B-CHEM
were VBD VBD O
manifest RBS RBS O
, , , O
irrespective JJ JJ O
of IN IN O
the DT DT O
anesthetic JJ JJ O
employed NN NN O
. . . O

The DT DT O
contractile NN NN O
element NN NN O
shortening VBG VBG O
velocity NN NN O
of IN IN O
the DT DT O
cardiac JJ JJ O
muscle NN NN O
fibers NNS NNS O
was VBD VBD O
significantly RB RB O
slower JJR JJR O
in IN IN O
both DT DT O
groups NNS NNS O
of IN IN O
barium NN NN B-CHEM
- - - O
treated VBN VBN O
rats NNS NNS O
relative JJ JJ O
to TO TO O
the DT DT O
control NN NN O
groups NNS NNS O
, , , O
irrespective JJ JJ O
of IN IN O
the DT DT O
anesthetic JJ JJ O
regimen NN NN O
. . . O

Similarly RB RB O
, , , O
significant JJ JJ O
disturbances NNS NNS O
in IN IN O
myocardial NN NN O
energy NN NN O
metabolism NN NN O
were VBD VBD O
detected VBN VBN O
in IN IN O
the DT DT O
barium NN NN B-CHEM
- - - O
exposed VBN VBN O
rats NNS NNS O
which WDT WDT O
were VBD VBD O
consistent JJ JJ O
with IN IN O
the DT DT O
reduced JJ JJ O
contractile NN NN O
element NN NN O
shortening VBG VBG O
velocity NN NN O
. . . O

In IN IN O
addition NN NN O
, , , O
the DT DT O
excitability NN NN O
of IN IN O
the DT DT O
cardiac JJ JJ O
conduction NN NN O
system NN NN O
was VBD VBD O
depressed VBN VBN O
preferentially RB RB O
in IN IN O
the DT DT O
atrioventricular NN NN O
nodal JJ JJ O
region NN NN O
of IN IN O
hearts NNS NNS O
from IN IN O
barium NN NN B-CHEM
- - - O
exposed VBN VBN O
rats NNS NNS O
. . . O

Overall RB RB O
, , , O
the DT DT O
altered JJ JJ O
cardiac NN NN O
contractility NN NN O
and CC CC O
excitability NN NN O
characteristics NNS NNS O
, , , O
the DT DT O
myocardial JJ JJ O
metabolic JJ JJ O
disturbances NNS NNS O
, , , O
and CC CC O
the DT DT O
hypersensitivity NN NN O
of IN IN O
the DT DT O
cardiovascular JJ JJ O
system NN NN O
to TO TO O
sodium VB VB B-CHEM
pentobarbital JJ JJ I-CHEM
suggest NN NN O
the DT DT O
existence NN NN O
of IN IN O
a DT DT O
heretofore NN NN O
undescribed JJ JJ O
cardiomyopathic JJ JJ O
disorder NN NN O
induced VBN VBN O
by IN IN O
chronic JJ JJ O
barium NN NN B-CHEM
exposure NN NN O
. . . O

These DT DT O
experimental JJ JJ O
findings NNS NNS O
represent VBP VBP O
the DT DT O
first JJ JJ O
indication NN NN O
that IN IN O
life NN NN O
- : : O
long RB RB O
barium NN NN B-CHEM
ingestion NN NN O
may MD MD O
have VB VB O
significant JJ JJ O
adverse JJ JJ O
effects NNS NNS O
on IN IN O
the DT DT O
mammalian NN NN O
cardiovascular JJ JJ O
system NN NN O
. . . O

Propranolol NNP NNP B-CHEM
antagonism NN NN O
of IN IN O
phenylpropanolamine NN NN B-CHEM
- - - O
induced JJ JJ O
hypertension NN NN O
. . . O

Phenylpropanolamine NNP NNP B-CHEM
( ( ( O
PPA NNP NNP B-CHEM
) ) ) O
overdose NN NN O
can MD MD O
cause VB VB O
severe JJ JJ O
hypertension NN NN O
, , , O
intracerebral JJ JJ O
hemorrhage NN NN O
, , , O
and CC CC O
death NN NN O
. . . O

We PRP PRP O
studied VBD VBD O
the DT DT O
efficacy NN NN O
and CC CC O
safety NN NN O
of IN IN O
propranolol NN NN B-CHEM
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
PPA NNP NNP B-CHEM
- : : O
induced JJ JJ O
hypertension NN NN O
. . . O

Subjects NNP NNP O
received VBD VBD O
propranolol NN NN B-CHEM
either CC CC O
by IN IN O
mouth NN NN O
for IN IN O
48 CD CD O
hours NNS NNS O
before IN IN O
PPA NNP NNP B-CHEM
or CC CC O
as IN IN O
a DT DT O
rapid JJ JJ O
intravenous JJ JJ O
infusion NN NN O
after IN IN O
PPA NNP NNP B-CHEM
. . . O

PPA NNP NNP B-CHEM
, , , O
75 CD CD O
mg NN NN O
alone RB RB O
, , , O
increased VBN VBN O
blood NN NN O
pressure NN NN O
( ( ( O
31 CD CD O
+ NN NN O
/ NN NN O
- : : O
14 CD CD O
mm NN NN O
Hg NNP NNP O
systolic JJ JJ O
, , , O
20 CD CD O
+ NN NN O
/ NN NN O
- : : O
5 CD CD O
mm NN NN O
Hg NNP NNP O
diastolic JJ JJ O
) ) ) O
, , , O
and CC CC O
propranolol NN NN B-CHEM
pretreatment NN NN O
antagonized VBD VBD O
this DT DT O
increase NN NN O
( ( ( O
12 CD CD O
+ NN NN O
/ NN NN O
- : : O
10 CD CD O
mm NN NN O
Hg NNP NNP O
systolic JJ JJ O
, , , O
10 CD CD O
+ NN NN O
/ NN NN O
- : : O
7 CD CD O
mm NN NN O
Hg NNP NNP O
diastolic JJ JJ O
) ) ) O
. . . O

Intravenous NNP NNP O
propranolol NN NN B-CHEM
after IN IN O
PPA NNP NNP B-CHEM
also RB RB O
decreased VBD VBD O
blood NN NN O
pressure NN NN O
. . . O

Left NNP NNP O
ventricular NN NN O
function NN NN O
( ( ( O
assessed VBN VBN O
by IN IN O
echocardiography NN NN O
) ) ) O
showed VBD VBD O
that IN IN O
PPA NNP NNP B-CHEM
increased VBD VBD O
the DT DT O
stroke NN NN O
volume NN NN O
30 CD CD O
% NN NN O
( ( ( O
from IN IN O
62 CD CD O
. . . O
5 CD CD O
+ NN NN O
/ NN NN O
- : : O
20 CD CD O
. . . O
9 CD CD O
to TO TO O
80 CD CD O
. . . O
8 CD CD O
+ NN NN O
/ NN NN O
- : : O
22 CD CD O
. . . O
4 CD CD O
ml NN NN O
) ) ) O
, , , O
the DT DT O
ejection NN NN O
fraction NN NN O
9 CD CD O
% NN NN O
( ( ( O
from IN IN O
64 CD CD O
% NN NN O
+ NN NN O
/ NN NN O
- : : O
10 CD CD O
% NN NN O
to TO TO O
70 CD CD O
% NN NN O
+ NN NN O
/ NN NN O
- : : O
7 CD CD O
% NN NN O
) ) ) O
, , , O
and CC CC O
cardiac NN NN O
output NN NN O
14 CD CD O
% NN NN O
( ( ( O
from IN IN O
3 CD CD O
. . . O
6 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
6 CD CD O
to TO TO O
4 CD CD O
. . . O
1 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
0 CD CD O
L NNP NNP O
/ NN NN O
min NN NN O
) ) ) O
. . . O

Intravenous NNP NNP O
propranolol NN NN B-CHEM
reversed VBD VBD O
these DT DT O
effects NNS NNS O
. . . O

Systemic NNP NNP O
vascular NN NN O
resistance NN NN O
was VBD VBD O
increased VBN VBN O
by IN IN O
PPA NNP NNP B-CHEM
28 CD CD O
% NN NN O
( ( ( O
from IN IN O
1710 CD CD O
+ NN NN O
/ NN NN O
- : : O
200 CD CD O
to TO TO O
2190 CD CD O
+ NN NN O
/ NN NN O
- : : O
700 CD CD O
dyne NN NN O
X NNP NNP O
sec NN NN O
/ NN NN O
cm5 NN NN O
) ) ) O
and CC CC O
was VBD VBD O
further RB RB O
increased VBN VBN O
by IN IN O
propranolol NN NN B-CHEM
22 CD CD O
% NN NN O
( ( ( O
to TO TO O
2660 CD CD O
+ NN NN O
/ NN NN O
- : : O
1200 CD CD O
dyne NN NN O
X NNP NNP O
sec NN NN O
/ NN NN O
cm5 NN NN O
) ) ) O
. . . O

We PRP PRP O
conclude VBP VBP O
that IN IN O
PPA NNP NNP B-CHEM
increases NNS NNS O
blood NN NN O
pressure NN NN O
by IN IN O
increasing VBG VBG O
systemic JJ JJ O
vascular NN NN O
resistance NN NN O
and CC CC O
cardiac JJ JJ O
output NN NN O
, , , O
and CC CC O
that IN IN O
propranolol NN NN B-CHEM
antagonizes VBZ VBZ O
this DT DT O
increase NN NN O
by IN IN O
reversing VBG VBG O
the DT DT O
effect NN NN O
of IN IN O
PPA NNP NNP B-CHEM
on IN IN O
cardiac JJ JJ O
output NN NN O
. . . O

That DT DT O
propranolol NN NN B-CHEM
antagonizes VBZ VBZ O
the DT DT O
pressor NN NN O
effect NN NN O
of IN IN O
PPA NNP NNP B-CHEM
is VBZ VBZ O
in IN IN O
contrast NN NN O
to TO TO O
the DT DT O
interaction NN NN O
in IN IN O
which WDT WDT O
propranolol NN NN B-CHEM
enhances VBZ VBZ O
the DT DT O
pressor NN NN O
effect NN NN O
of IN IN O
norepinephrine NN NN B-CHEM
. . . O

This DT DT O
is VBZ VBZ O
probably RB RB O
because IN IN O
PPA NNP NNP B-CHEM
has VBZ VBZ O
less JJR JJR O
beta NN NN O
2 CD CD O
activity NN NN O
than IN IN O
does VBZ VBZ O
norepinephrine NN NN B-CHEM
. . . O

Mesangial NNP NNP O
function NN NN O
and CC CC O
glomerular NN NN O
sclerosis NN NN O
in IN IN O
rats NNS NNS O
with IN IN O
aminonucleoside NN NN B-CHEM
nephrosis NN NN O
. . . O

The DT DT O
possible JJ JJ O
relationship NN NN O
between IN IN O
mesangial JJ JJ O
dysfunction NN NN O
and CC CC O
development NN NN O
of IN IN O
glomerular NN NN O
sclerosis NN NN O
was VBD VBD O
studied VBN VBN O
in IN IN O
the DT DT O
puromycin NN NN B-CHEM
aminonucleoside NN NN I-CHEM
( ( ( O
PAN NNP NNP B-CHEM
) ) ) O
model NN NN O
. . . O

Five CD CD O
male JJ JJ O
Wistar NNP NNP O
rats NNS NNS O
received VBD VBD O
repeated VBN VBN O
subcutaneous JJ JJ O
PAN NNP NNP B-CHEM
injections NNS NNS O
; : : O
five CD CD O
controls NNS NNS O
received VBD VBD O
saline NN NN O
only RB RB O
. . . O

After IN IN O
4 CD CD O
weeks NNS NNS O
the DT DT O
PAN NNP NNP B-CHEM
rats NNS NNS O
were VBD VBD O
severely RB RB O
proteinuric JJ JJ O
( ( ( O
190 CD CD O
+ NN NN O
/ NN NN O
- : : O
80 CD CD O
mg NN NN O
/ NN NN O
24 CD CD O
hr NN NN O
) ) ) O
, , , O
and CC CC O
all DT DT O
rats NNS NNS O
were VBD VBD O
given VBN VBN O
colloidal NN NN O
carbon NN NN B-CHEM
( ( ( O
CC NNP NNP O
) ) ) O
intravenously RB RB O
. . . O

At IN IN O
5 CD CD O
months NNS NNS O
glomerular JJ JJ O
sclerosis NN NN O
was VBD VBD O
found VBN VBN O
in IN IN O
7 CD CD O
. . . O
6 CD CD O
+ NN NN O
/ NN NN O
- : : O
3 CD CD O
. . . O
4 CD CD O
% NN NN O
of IN IN O
the DT DT O
glomeruli NN NN O
of IN IN O
PAN NNP NNP B-CHEM
rats NNS NNS O
; : : O
glomeruli NN NN O
of IN IN O
the DT DT O
controls NNS NNS O
were VBD VBD O
normal JJ JJ O
. . . O

Glomeruli NNP NNP O
of IN IN O
PAN NNP NNP B-CHEM
rats NNS NNS O
contained VBD VBD O
significantly RB RB O
more RBR RBR O
CC NNP NNP O
than IN IN O
glomeruli NN NN O
of IN IN O
controls NNS NNS O
. . . O

Glomeruli NNP NNP O
with IN IN O
sclerosis NNS NNS O
contained VBD VBD O
significantly RB RB O
more RBR RBR O
CC NNP NNP O
than IN IN O
non NN NN O
- - - O
sclerotic JJ JJ O
glomeruli NN NN O
in IN IN O
the DT DT O
same JJ JJ O
kidneys NNS NNS O
. . . O

CC NNP NNP O
was VBD VBD O
preferentially RB RB O
localized JJ JJ O
within IN IN O
the DT DT O
sclerotic JJ JJ O
areas NNS NNS O
of IN IN O
the DT DT O
affected VBN VBN O
glomeruli NN NN O
. . . O

Since IN IN O
mesangial NN NN O
CC NNP NNP O
clearance NN NN O
from IN IN O
the DT DT O
mesangium NN NN O
did VBD VBD O
not RB RB O
change VB VB O
during IN IN O
chronic JJ JJ O
PAN NNP NNP B-CHEM
treatment NN NN O
, , , O
we PRP PRP O
conclude VBP VBP O
that IN IN O
this DT DT O
preferential NN NN O
CC NNP NNP O
localization NN NN O
within IN IN O
the DT DT O
lesions NNS NNS O
is VBZ VBZ O
caused VBN VBN O
by IN IN O
an DT DT O
increased JJ JJ O
CC NNP NNP O
uptake NN NN O
shortly RB RB O
after IN IN O
injection NN NN O
in IN IN O
apparent JJ JJ O
vulnerable JJ JJ O
areas NNS NNS O
where WRB WRB O
sclerosis NNS NNS O
will MD MD O
develop VB VB O
subsequently RB RB O
. . . O

Cluster NNP NNP O
analysis NN NN O
showed VBD VBD O
a DT DT O
random JJ JJ O
distribution NN NN O
of IN IN O
lesions NNS NNS O
in IN IN O
the DT DT O
PAN NNP NNP B-CHEM
glomeruli NN NN O
in IN IN O
concordance NN NN O
with IN IN O
the DT DT O
random JJ JJ O
localization NN NN O
of IN IN O
mesangial JJ JJ O
areas NNS NNS O
with IN IN O
dysfunction NN NN O
in IN IN O
this DT DT O
model NN NN O
. . . O

Similar JJ JJ O
to TO TO O
the DT DT O
remnant NN NN O
kidney NN NN O
model NN NN O
in IN IN O
PAN NNP NNP B-CHEM
nephrosis NN NN O
the DT DT O
development NN NN O
of IN IN O
glomerular NN NN O
sclerosis NN NN O
may MD MD O
be VB VB O
related VBN VBN O
to TO TO O
" '' '' O
mesangial JJ JJ O
overloading NN NN O
. . . O
" '' '' O

Relationship NNP NNP O
between IN IN O
nicotine NN NN B-CHEM
- - - O
induced JJ JJ O
seizures NNS NNS O
and CC CC O
hippocampal JJ JJ O
nicotinic JJ JJ O
receptors NNS NNS O
. . . O

A DT DT O
controversy NN NN O
has VBZ VBZ O
existed VBN VBN O
for IN IN O
several JJ JJ O
years NNS NNS O
concerning VBG VBG O
the DT DT O
physiological JJ JJ O
relevance NN NN O
of IN IN O
the DT DT O
nicotinic JJ JJ O
receptor NN NN O
measured VBN VBN O
by IN IN O
alpha NN NN O
- - - O
bungarotoxin NN NN O
binding JJ JJ O
. . . O

Using VBG VBG O
mice NN NN O
derived VBD VBD O
from IN IN O
a DT DT O
classical JJ JJ O
F2 NNP NNP O
and CC CC O
backcross NN NN O
genetic JJ JJ O
design NN NN O
, , , O
a DT DT O
relationship NN NN O
between IN IN O
nicotine NN NN B-CHEM
- - - O
induced JJ JJ O
seizures NNS NNS O
and CC CC O
alpha NN NN O
- - - O
bungarotoxin NN NN O
nicotinic JJ JJ O
receptor NN NN O
concentration NN NN O
was VBD VBD O
found VBN VBN O
. . . O

Mice NNP NNP O
sensitive JJ JJ O
to TO TO O
the DT DT O
convulsant JJ JJ O
effects NNS NNS O
of IN IN O
nicotine NN NN B-CHEM
had VBD VBD O
greater JJR JJR O
alpha NN NN O
- - - O
bungarotoxin NN NN O
binding JJ JJ O
in IN IN O
the DT DT O
hippocampus NN NN O
than IN IN O
seizure NN NN O
insensitive JJ JJ O
mice NN NN O
. . . O

The DT DT O
binding JJ JJ O
sites NNS NNS O
from IN IN O
seizure NN NN O
sensitive JJ JJ O
and CC CC O
resistant JJ JJ O
mice NN NN O
were VBD VBD O
equally RB RB O
affected VBN VBN O
by IN IN O
treatment NN NN O
with IN IN O
dithiothreitol NN NN B-CHEM
, , , O
trypsin NN NN O
or CC CC O
heat NN NN O
. . . O

Thus RB RB O
it PRP PRP O
appears VBZ VBZ O
that IN IN O
the DT DT O
difference NN NN O
between IN IN O
seizure NN NN O
sensitive JJ JJ O
and CC CC O
insensitive JJ JJ O
animals NNS NNS O
may MD MD O
be VB VB O
due JJ JJ O
to TO TO O
a DT DT O
difference NN NN O
in IN IN O
hippocampal NN NN O
nicotinic JJ JJ O
receptor NN NN O
concentration NN NN O
as IN IN O
measured VBN VBN O
with IN IN O
alpha NN NN O
- - - O
bungarotoxin NN NN O
binding JJ JJ O
. . . O

The DT DT O
role NN NN O
of IN IN O
p NN NN B-CHEM
- - - I-CHEM
aminophenol NN NN I-CHEM
in IN IN O
acetaminophen NN NN B-CHEM
- - - O
induced JJ JJ O
nephrotoxicity NN NN O
: : : O
effect NN NN O
of IN IN O
bis NN NN B-CHEM
( ( ( I-CHEM
p NN NN I-CHEM
- - - I-CHEM
nitrophenyl NN NN I-CHEM
) ) ) I-CHEM
phosphate NN NN I-CHEM
on IN IN O
acetaminophen NN NN B-CHEM
and CC CC O
p NN NN B-CHEM
- - - I-CHEM
aminophenol NN NN I-CHEM
nephrotoxicity NN NN O
and CC CC O
metabolism NN NN O
in IN IN O
Fischer NNP NNP O
344 CD CD O
rats NNS NNS O
. . . O

Acetaminophen NNP NNP B-CHEM
( ( ( O
APAP NNP NNP B-CHEM
) ) ) O
produces VBZ VBZ O
proximal NN NN O
tubular JJ JJ O
necrosis NN NN O
in IN IN O
Fischer NNP NNP O
344 CD CD O
( ( ( O
F344 NNP NNP O
) ) ) O
rats NNS NNS O
. . . O

Recently RB RB O
, , , O
p NN NN B-CHEM
- - - I-CHEM
aminophenol NN NN I-CHEM
( ( ( O
PAP NNP NNP B-CHEM
) ) ) O
, , , O
a DT DT O
known VBN VBN O
potent NN NN O
nephrotoxicant NN NN O
, , , O
was VBD VBD O
identified VBN VBN O
as IN IN O
a DT DT O
metabolite NN NN O
of IN IN O
APAP NNP NNP B-CHEM
in IN IN O
F344 NNP NNP O
rats NNS NNS O
. . . O

The DT DT O
purpose NN NN O
of IN IN O
this DT DT O
study NN NN O
was VBD VBD O
to TO TO O
determine VB VB O
if IN IN O
PAP NNP NNP B-CHEM
formation NN NN O
is VBZ VBZ O
a DT DT O
requisite NN NN O
step NN NN O
in IN IN O
APAP NNP NNP B-CHEM
- : : O
induced JJ JJ O
nephrotoxicity NN NN O
. . . O

Therefore RB RB O
, , , O
the DT DT O
effect NN NN O
of IN IN O
bis NN NN B-CHEM
( ( ( I-CHEM
p NN NN I-CHEM
- - - I-CHEM
nitrophenyl NN NN I-CHEM
) ) ) I-CHEM
phosphate NN NN I-CHEM
( ( ( O
BNPP NNP NNP B-CHEM
) ) ) O
, , , O
an DT DT O
acylamidase NN NN O
inhibitor NN NN O
, , , O
on IN IN O
APAP NNP NNP B-CHEM
and CC CC O
PAP NNP NNP B-CHEM
nephrotoxicity NN NN O
and CC CC O
metabolism NN NN O
was VBD VBD O
determined VBN VBN O
. . . O

BNPP NNP NNP B-CHEM
( ( ( O
1 CD CD O
to TO TO O
8 CD CD O
mM NN NN O
) ) ) O
reduced VBD VBD O
APAP NNP NNP B-CHEM
deacetylation NN NN O
and CC CC O
covalent NN NN O
binding JJ JJ O
in IN IN O
F344 NNP NNP O
renal JJ JJ O
cortical JJ JJ O
homogenates NNS NNS O
in IN IN O
a DT DT O
concentration NN NN O
- - - O
dependent JJ JJ O
manner NN NN O
. . . O

Pretreatment NNP NNP O
of IN IN O
animals NNS NNS O
with IN IN O
BNPP NNP NNP B-CHEM
prior RB RB O
to TO TO O
APAP NNP NNP B-CHEM
or CC CC O
PAP NNP NNP B-CHEM
administration NN NN O
resulted VBD VBD O
in IN IN O
marked JJ JJ O
reduction NN NN O
of IN IN O
APAP NNP NNP B-CHEM
( ( ( O
900 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
nephrotoxicity NN NN O
but CC CC O
not RB RB O
PAP NNP NNP B-CHEM
nephrotoxicity NN NN O
. . . O

This DT DT O
result NN NN O
was VBD VBD O
not RB RB O
due JJ JJ O
to TO TO O
altered VBN VBN O
disposition NN NN O
of IN IN O
either DT DT O
APAP NNP NNP B-CHEM
or CC CC O
acetylated VBN VBN O
metabolites NNS NNS O
in IN IN O
plasma NN NN O
or CC CC O
renal JJ JJ O
cortical JJ JJ O
and CC CC O
hepatic JJ JJ O
tissue NN NN O
. . . O

Rather RB RB O
, , , O
BNPP NNP NNP B-CHEM
pretreatment NN NN O
reduced VBD VBD O
the DT DT O
fraction NN NN O
of IN IN O
APAP NNP NNP B-CHEM
excreted VBD VBD O
as IN IN O
PAP NNP NNP B-CHEM
by IN IN O
64 CD CD O
and CC CC O
75 CD CD O
% NN NN O
after IN IN O
APAP NNP NNP B-CHEM
doses NNS NNS O
of IN IN O
750 CD CD O
and CC CC O
900 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
. . . O

BNPP NNP NNP B-CHEM
did VBD VBD O
not RB RB O
alter VB VB O
the DT DT O
excretion NN NN O
of IN IN O
APAP NNP NNP B-CHEM
or CC CC O
any DT DT O
of IN IN O
its PRP$ PRP$ O
non NN NN O
- - - O
deacetylated JJ JJ O
metabolites NNS NNS O
nor CC CC O
did VBD VBD O
BNPP NNP NNP B-CHEM
alter VB VB O
excretion NN NN O
of IN IN O
PAP NNP NNP B-CHEM
or CC CC O
its PRP$ PRP$ O
metabolites NNS NNS O
after IN IN O
PAP NNP NNP B-CHEM
doses NNS NNS O
of IN IN O
150 CD CD O
and CC CC O
300 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
. . . O

Therefore RB RB O
, , , O
the DT DT O
BNPP NNP NNP B-CHEM
- - - O
induced JJ JJ O
reduction NN NN O
in IN IN O
APAP NNP NNP B-CHEM
- : : O
induced JJ JJ O
nephrotoxicity NN NN O
appears VBZ VBZ O
to TO TO O
be VB VB O
due JJ JJ O
to TO TO O
inhibition NN NN O
of IN IN O
APAP NNP NNP B-CHEM
deacetylation NN NN O
. . . O

It PRP PRP O
is VBZ VBZ O
concluded VBN VBN O
that IN IN O
PAP NNP NNP B-CHEM
formation NN NN O
, , , O
in IN IN O
vivo NN NN O
, , , O
accounts NNS NNS O
, , , O
at IN IN O
least JJS JJS O
in IN IN O
part NN NN O
, , , O
for IN IN O
APAP NNP NNP B-CHEM
- : : O
induced JJ JJ O
renal NN NN O
tubular NN NN O
necrosis NN NN O
. . . O

Morphine NNP NNP B-CHEM
- : : O
induced JJ JJ O
seizures NNS NNS O
in IN IN O
newborn JJ JJ O
infants NNS NNS O
. . . O

Two CD CD O
neonates NNS NNS O
suffered VBD VBD O
from IN IN O
generalized JJ JJ O
seizures NNS NNS O
during IN IN O
the DT DT O
course NN NN O
of IN IN O
intravenous JJ JJ O
morphine NN NN B-CHEM
sulfate NN NN I-CHEM
for IN IN O
post NN NN O
- - - O
operative JJ JJ O
analgesia NN NN O
. . . O

They PRP PRP O
received VBD VBD O
morphine NN NN B-CHEM
in IN IN O
doses NNS NNS O
of IN IN O
32 CD CD O
micrograms NNS NNS O
/ NN NN O
kg NN NN O
/ NN NN O
hr NN NN O
and CC CC O
40 CD CD O
micrograms NNS NNS O
/ NN NN O
kg NN NN O
/ NN NN O
hr NN NN O
larger JJR JJR O
than IN IN O
a DT DT O
group NN NN O
of IN IN O
10 CD CD O
neonates NNS NNS O
who WP WP O
received VBD VBD O
6 CD CD O
- : : O
24 CD CD O
micrograms NNS NNS O
/ NN NN O
kg NN NN O
/ NN NN O
hr NN NN O
and CC CC O
had VBD VBD O
no DT DT O
seizures NNS NNS O
. . . O

Plasma NNP NNP O
concentrations NNS NNS O
of IN IN O
morphine NN NN B-CHEM
in IN IN O
these DT DT O
neonates NNS NNS O
was VBD VBD O
excessive JJ JJ O
( ( ( O
60 CD CD O
and CC CC O
90 CD CD O
mg NN NN O
/ NN NN O
ml NN NN O
) ) ) O
. . . O

Other JJ JJ O
known VBN VBN O
reasons NNS NNS O
for IN IN O
seizures NNS NNS O
were VBD VBD O
ruled VBN VBN O
out IN IN O
and CC CC O
the DT DT O
convulsions NNS NNS O
stopped VBD VBD O
a DT DT O
few JJ JJ O
hours NNS NNS O
after IN IN O
cessation NN NN O
of IN IN O
morphine NN NN B-CHEM
and CC CC O
did VBD VBD O
not RB RB O
reoccur VB VB O
in IN IN O
the DT DT O
subsequent JJ JJ O
8 CD CD O
months NNS NNS O
. . . O

It PRP PRP O
is VBZ VBZ O
suggested VBN VBN O
that IN IN O
post NN NN O
- : : O
operative JJ JJ O
intravenous JJ JJ O
morphine NN NN B-CHEM
should MD MD O
not RB RB O
exceed VB VB O
20 CD CD O
micrograms NNS NNS O
/ NN NN O
kg NN NN O
/ NN NN O
ml NN NN O
in IN IN O
neonates NNS NNS O
. . . O

Indomethacin NNP NNP B-CHEM
induced JJ JJ O
hypotension NN NN O
in IN IN O
sodium NN NN B-CHEM
and CC CC O
volume NN NN O
depleted JJ JJ O
rats NNS NNS O
. . . O

After IN IN O
a DT DT O
single JJ JJ O
oral JJ JJ O
dose NN NN O
of IN IN O
4 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
indomethacin NN NN B-CHEM
( ( ( O
IDM NNP NNP B-CHEM
) ) ) O
to TO TO O
sodium NN NN B-CHEM
and CC CC O
volume NN NN O
depleted VBD VBD O
rats NNS NNS O
plasma NN NN O
renin NN NN O
activity NN NN O
( ( ( O
PRA NNP NNP O
) ) ) O
and CC CC O
systolic JJ JJ O
blood NN NN O
pressure NN NN O
fell VBD VBD O
significantly RB RB O
within IN IN O
four CD CD O
hours NNS NNS O
. . . O

In IN IN O
sodium NN NN B-CHEM
repleted JJ JJ O
animals NNS NNS O
indomethacin NN NN B-CHEM
did VBD VBD O
not RB RB O
change VB VB O
systolic JJ JJ O
blood NN NN O
pressure NN NN O
( ( ( O
BP NNP NNP O
) ) ) O
although IN IN O
plasma NN NN O
renin NN NN O
activity NN NN O
was VBD VBD O
decreased VBN VBN O
. . . O

Thus RB RB O
, , , O
indomethacin NN NN B-CHEM
by IN IN O
inhibition NN NN O
of IN IN O
prostaglandin NN NN B-CHEM
synthesis NN NN O
may MD MD O
diminish VB VB O
the DT DT O
blood NN NN O
pressure NN NN O
maintaining VBG VBG O
effect NN NN O
of IN IN O
the DT DT O
stimulated VBN VBN O
renin NN NN O
- - - O
angiotensin NN NN B-CHEM
system NN NN O
in IN IN O
sodium NN NN B-CHEM
and CC CC O
volume NN NN O
depletion NN NN O
. . . O

On IN IN O
the DT DT O
antiarrhythmic JJ JJ O
activity NN NN O
of IN IN O
one CD CD O
N NNP NNP O
- - - O
substituted JJ JJ O
piperazine NN NN B-CHEM
derivative NN NN O
of IN IN O
trans NNS NNS B-CHEM
- : : I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
amino JJ JJ I-CHEM
- - - I-CHEM
3 CD CD I-CHEM
- - - I-CHEM
hydroxy NN NN I-CHEM
- - - I-CHEM
1 CD CD I-CHEM
, , , I-CHEM
2 CD CD I-CHEM
, , , I-CHEM
3 CD CD I-CHEM
, , , I-CHEM
4 CD CD I-CHEM
- : : I-CHEM
tetrahydroanaphthalene NN NN I-CHEM
. . . O

The DT DT O
antiarrhythmic JJ JJ O
activity NN NN O
of IN IN O
the DT DT O
compound NN NN O
N NNP NNP B-CHEM
- : : I-CHEM
( ( ( I-CHEM
trans NNS NNS I-CHEM
- : : I-CHEM
3 CD CD I-CHEM
- : : I-CHEM
hydroxy NN NN I-CHEM
- : : I-CHEM
1 CD CD I-CHEM
, , , I-CHEM
2 CD CD I-CHEM
, , , I-CHEM
3 CD CD I-CHEM
, , , I-CHEM
4 CD CD I-CHEM
- : : I-CHEM
tetrahydro NN NN I-CHEM
- : : I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
naphthyl NN NN I-CHEM
) ) ) I-CHEM
- : : I-CHEM
N NNP NNP I-CHEM
- : : I-CHEM
( ( ( I-CHEM
3 CD CD I-CHEM
- : : I-CHEM
oxo NN NN I-CHEM
- : : I-CHEM
3 CD CD I-CHEM
- : : I-CHEM
phenyl NN NN I-CHEM
- : : I-CHEM
2 CD CD I-CHEM
- : : I-CHEM
methylpropyl NN NN I-CHEM
) ) ) I-CHEM
- : : I-CHEM
piperazine NN NN I-CHEM
hydrochloride NN NN I-CHEM
, , , O
referred VBD VBD O
to TO TO O
as IN IN O
P11 NNP NNP B-CHEM
, , , O
is VBZ VBZ O
studied VBN VBN O
on IN IN O
anaesthesized JJ JJ O
cats NNS NNS O
and CC CC O
Wistar NNP NNP O
albino NN NN O
rats NNS NNS O
, , , O
as RB RB O
well RB RB O
as IN IN O
on IN IN O
non NN NN O
- : : O
anaesthesized JJ JJ O
rabbits NNS NNS O
. . . O

Four CD CD O
types NNS NNS O
of IN IN O
experimental JJ JJ O
arrhythmia NN NN O
are VBP VBP O
used VBN VBN O
- - - O
- - - O
with IN IN O
BaCl2 NNP NNP B-CHEM
, , , O
with IN IN O
chloroform NN NN B-CHEM
- - - O
adrenaline NN NN B-CHEM
, , , O
with IN IN O
strophantine NN NN B-CHEM
G NNP NNP I-CHEM
and CC CC O
with IN IN O
aconitine NN NN B-CHEM
. . . O

The DT DT O
compound NN NN O
P11 NNP NNP B-CHEM
is VBZ VBZ O
introduced VBN VBN O
in IN IN O
doses NNS NNS O
of IN IN O
0 CD CD O
. . . O
25 CD CD O
and CC CC O
0 CD CD O
. . . O
50 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
intravenously RB RB O
and CC CC O
10 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
orally RB RB O
. . . O

The DT DT O
compound NN NN O
manifests NNS NNS O
antiarrhythmic JJ JJ O
activity NN NN O
in IN IN O
all DT DT O
models NNS NNS O
of IN IN O
experimental JJ JJ O
arrhythmia NN NN O
used VBN VBN O
, , , O
causing VBG VBG O
greatest JJS JJS O
inhibition NN NN O
on IN IN O
the DT DT O
arrhythmia NN NN O
induced VBN VBN O
by IN IN O
chloroform NN NN B-CHEM
- - - O
adrenaline NN NN B-CHEM
( ( ( O
in IN IN O
90 CD CD O
per IN IN O
cent NN NN O
) ) ) O
and CC CC O
with IN IN O
BaCl2 NNP NNP B-CHEM
( ( ( O
in IN IN O
84 CD CD O
per IN IN O
cent NN NN O
) ) ) O
. . . O

The DT DT O
results NNS NNS O
obtained VBD VBD O
are VBP VBP O
associated VBN VBN O
with IN IN O
the DT DT O
beta NN NN O
- - - O
adrenoblocking VBG VBG O
and CC CC O
with IN IN O
the DT DT O
membrane NN NN O
- - - O
stabilizing JJ JJ O
action NN NN O
of IN IN O
the DT DT O
compound NN NN O
. . . O

Recurrent NNP NNP O
subarachnoid NN NN O
hemorrhage NN NN O
associated VBN VBN O
with IN IN O
aminocaproic JJ JJ B-CHEM
acid NN NN I-CHEM
therapy NN NN O
and CC CC O
acute JJ JJ O
renal JJ JJ O
artery NN NN O
thrombosis NN NN O
. . . O

Case NN NN O
report NN NN O
. . . O

Epsilon NNP NNP B-CHEM
aminocaproic JJ JJ I-CHEM
acid NN NN I-CHEM
( ( ( O
EACA NNP NNP B-CHEM
) ) ) O
has VBZ VBZ O
been VBN VBN O
used VBN VBN O
to TO TO O
prevent VB VB O
rebleeding VBG VBG O
in IN IN O
patients NNS NNS O
with IN IN O
subarachnoid NN NN O
hemorrhage NN NN O
( ( ( O
SAH NNP NNP O
) ) ) O
. . . O

Although IN IN O
this DT DT O
agent NN NN O
does VBZ VBZ O
decrease VB VB O
the DT DT O
frequency NN NN O
of IN IN O
rebleeding VBG VBG O
, , , O
several JJ JJ O
reports NNS NNS O
have VBP VBP O
described VBN VBN O
thrombotic JJ JJ O
complications NNS NNS O
of IN IN O
EACA NNP NNP B-CHEM
therapy NN NN O
. . . O

These DT DT O
complications NNS NNS O
have VBP VBP O
included VBN VBN O
clinical JJ JJ O
deterioration NN NN O
and CC CC O
intracranial JJ JJ O
vascular NN NN O
thrombosis NNS NNS O
in IN IN O
patients NNS NNS O
with IN IN O
SAH NNP NNP O
, , , O
arteriolar NN NN O
and CC CC O
capillary JJ JJ O
fibrin NN NN O
thrombi NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
fibrinolytic JJ JJ O
syndromes NNS NNS O
treated VBN VBN O
with IN IN O
EACA NNP NNP B-CHEM
, , , O
or CC CC O
other JJ JJ O
thromboembolic JJ JJ O
phenomena NN NN O
. . . O

Since IN IN O
intravascular JJ JJ O
fibrin NN NN O
thrombi NN NN O
are VBP VBP O
often RB RB O
observed VBN VBN O
in IN IN O
patients NNS NNS O
with IN IN O
fibrinolytic JJ JJ O
disorders NNS NNS O
, , , O
EACA NNP NNP B-CHEM
should MD MD O
not RB RB O
be VB VB O
implicated VBN VBN O
in IN IN O
the DT DT O
pathogenesis NNS NNS O
of IN IN O
fibrin NN NN O
thrombi NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
disseminated VBN VBN O
intravascular JJ JJ O
coagulation NN NN O
or CC CC O
other JJ JJ O
" '' '' O
consumption NN NN O
coagulopathies NNS NNS O
. . . O
" '' '' O
This DT DT O
report NN NN O
describes VBZ VBZ O
subtotal JJ JJ O
infarction NN NN O
of IN IN O
the DT DT O
kidney NN NN O
due JJ JJ O
to TO TO O
thrombosis NNS NNS O
of IN IN O
a DT DT O
normal JJ JJ O
renal NN NN O
artery NN NN O
. . . O

This DT DT O
occlusion NN NN O
occurred VBD VBD O
after IN IN O
EACA NNP NNP B-CHEM
therapy NN NN O
in IN IN O
a DT DT O
patient NN NN O
with IN IN O
SAH NNP NNP O
and CC CC O
histopathological JJ JJ O
documentation NN NN O
of IN IN O
recurrent JJ JJ O
SAH NNP NNP O
. . . O

The DT DT O
corresponding JJ JJ O
clinical JJ JJ O
event NN NN O
was VBD VBD O
characterized VBN VBN O
by IN IN O
marked JJ JJ O
hypertension NN NN O
and CC CC O
abrupt JJ JJ O
neurological JJ JJ O
deterioration NN NN O
. . . O

Effect NN NN O
of IN IN O
vincristine NN NN B-CHEM
sulfate NN NN I-CHEM
on IN IN O
Pseudomonas NNP NNP O
infections NNS NNS O
in IN IN O
monkeys NNS NNS O
. . . O

In IN IN O
rhesus JJ JJ O
monkeys NNS NNS O
, , , O
intravenous JJ JJ O
challenge NN NN O
with IN IN O
0 CD CD O
. . . O
6 CD CD O
x SYM SYM O
10 CD CD O
( ( ( O
10 CD CD O
) ) ) O
to TO TO O
2 CD CD O
. . . O
2 CD CD O
x SYM SYM O
10 CD CD O
( ( ( O
10 CD CD O
) ) ) O
Pseudomonas NNP NNP O
aeruginosa NN NN O
organisms NNS NNS O
caused VBD VBD O
acute JJ JJ O
illness NN NN O
of IN IN O
4 CD CD O
to TO TO O
5 CD CD O
days NNS NNS O
' POS POS O
duration NN NN O
with IN IN O
spontaneous JJ JJ O
recovery NN NN O
in IN IN O
13 CD CD O
of IN IN O
15 CD CD O
monkeys NNS NNS O
; : : O
blood NN NN O
cultures NNS NNS O
became VBD VBD O
negative JJ JJ O
3 CD CD O
to TO TO O
17 CD CD O
days NNS NNS O
after IN IN O
challenge NN NN O
. . . O

Leukocytosis NNP NNP O
was VBD VBD O
observed VBN VBN O
in IN IN O
all DT DT O
monkeys NNS NNS O
. . . O

Intravenous NNP NNP O
or CC CC O
intratracheal JJ JJ O
inoculation NN NN O
of IN IN O
2 CD CD O
. . . O
0 CD CD O
to TO TO O
2 CD CD O
. . . O
5 CD CD O
mg NN NN O
of IN IN O
vincristine NN NN B-CHEM
sulfate NN NN I-CHEM
was VBD VBD O
followed VBN VBN O
by IN IN O
leukopenia NN NN O
in IN IN O
4 CD CD O
to TO TO O
5 CD CD O
days NNS NNS O
. . . O

Intravenous NNP NNP O
inoculation NN NN O
of IN IN O
4 CD CD O
. . . O
2 CD CD O
x SYM SYM O
10 CD CD O
( ( ( O
10 CD CD O
) ) ) O
to TO TO O
7 CD CD O
. . . O
8 CD CD O
x SYM SYM O
10 CD CD O
( ( ( O
10 CD CD O
) ) ) O
pyocin NN NN O
type NN NN O
6 CD CD O
Pseudomonas NNP NNP O
organisms NNS NNS O
in IN IN O
monkeys NNS NNS O
given VBN VBN O
vincristine NN NN B-CHEM
sulfate NN NN I-CHEM
4 CD CD O
days NNS NNS O
previously RB RB O
resulted VBD VBD O
in IN IN O
fatal JJ JJ O
infection NN NN O
in IN IN O
11 CD CD O
of IN IN O
14 CD CD O
monkeys NNS NNS O
, , , O
whereas IN IN O
none NN NN O
of IN IN O
four CD CD O
receiving VBG VBG O
Pseudomonas NNP NNP O
alone RB RB O
died VBD VBD O
. . . O

These DT DT O
studies NNS NNS O
suggest VBP VBP O
that IN IN O
an DT DT O
antimetabolite NN NN O
- - - O
induced JJ JJ O
leukopenia NN NN O
predisposes NNS NNS O
to TO TO O
severe JJ JJ O
Pseudomonas NNP NNP O
sepsis NN NN O
and CC CC O
that IN IN O
such JJ JJ O
monkeys NNS NNS O
may MD MD O
serve VB VB O
as IN IN O
a DT DT O
biological JJ JJ O
model NN NN O
for IN IN O
study NN NN O
of IN IN O
comparative JJ JJ O
efficacy NN NN O
of IN IN O
antimicrobial JJ JJ O
agents NNS NNS O
. . . O

Modification NNP NNP O
by IN IN O
propranolol NN NN B-CHEM
of IN IN O
cardiovascular JJ JJ O
effects NNS NNS O
of IN IN O
induced JJ JJ O
hypoglycaemia NN NN O
. . . O

The DT DT O
cardiovascular JJ JJ O
effects NNS NNS O
of IN IN O
hypoglycaemia NN NN O
, , , O
with IN IN O
and CC CC O
without IN IN O
beta NN NN O
- - - O
blockade NN NN O
, , , O
were VBD VBD O
compared VBN VBN O
in IN IN O
fourteen NN NN O
healthy JJ JJ O
men NNS NNS O
. . . O

Eight CD CD O
received VBN VBN O
insulin NN NN O
alone RB RB O
, , , O
and CC CC O
eight CD CD O
, , , O
including VBG VBG O
two CD CD O
of IN IN O
the DT DT O
original JJ JJ O
insulin NN NN O
- - - O
only RB RB O
group NN NN O
, , , O
were VBD VBD O
given VBN VBN O
propranolol NN NN B-CHEM
and CC CC O
insulin NN NN O
. . . O

In IN IN O
the DT DT O
insulin NN NN O
- - - O
group NN NN O
the DT DT O
period NN NN O
of IN IN O
hypoglycaemia NN NN O
was VBD VBD O
associated VBN VBN O
with IN IN O
an DT DT O
increase NN NN O
in IN IN O
heart NN NN O
- - - O
rate NN NN O
and CC CC O
a DT DT O
fall NN NN O
in IN IN O
diastolic JJ JJ O
blood NN NN O
- - - O
pressure NN NN O
. . . O

In IN IN O
the DT DT O
propranolol NN NN B-CHEM
- - - O
insulin NN NN O
group NN NN O
there EX EX O
was VBD VBD O
a DT DT O
significant JJ JJ O
fall NN NN O
in IN IN O
heart NN NN O
- - - O
rate NN NN O
in IN IN O
most JJS JJS O
subjects NNS NNS O
and CC CC O
an DT DT O
increase NN NN O
in IN IN O
diastolic JJ JJ O
pressure NN NN O
. . . O

Typical NNP NNP O
S NNP NNP O
- : : O
T NN NN O
/ NN NN O
T NN NN O
changes NNS NNS O
occurred VBD VBD O
in IN IN O
the DT DT O
insulin NN NN O
- - - O
group NN NN O
but CC CC O
in IN IN O
none NN NN O
of IN IN O
the DT DT O
propranolol NN NN B-CHEM
- - - O
insulin NN NN O
group NN NN O
. . . O

Hypertension NNP NNP O
in IN IN O
diabetics NNS NNS O
prone NN NN O
to TO TO O
hypoglycaemia NN NN O
attacks NNS NNS O
should MD MD O
not RB RB O
be VB VB O
treated VBN VBN O
with IN IN O
beta NN NN O
- - - O
blockers NNS NNS O
because IN IN O
these DT DT O
drugs NNS NNS O
may MD MD O
cause VB VB O
a DT DT O
sharp JJ JJ O
rise NN NN O
in IN IN O
blood NN NN O
- - - O
pressure NN NN O
in IN IN O
such JJ JJ O
patients NNS NNS O
. . . O

Long JJ JJ O
- - - O
term NN NN O
propranolol NN NN B-CHEM
therapy NN NN O
in IN IN O
pregnancy NN NN O
: : : O
maternal JJ JJ O
and CC CC O
fetal JJ JJ O
outcome NN NN O
. . . O

Propranolol NNP NNP B-CHEM
, , , O
a DT DT O
beta NN NN O
- - - O
adrenergic JJ JJ O
blocking VBG VBG O
agent NN NN O
, , , O
has VBZ VBZ O
found VBN VBN O
an DT DT O
important JJ JJ O
position NN NN O
in IN IN O
the DT DT O
practice NN NN O
of IN IN O
medicine NN NN O
. . . O

Its PRP$ PRP$ O
use NN NN O
in IN IN O
pregnancy NN NN O
, , , O
however RB RB O
, , , O
is VBZ VBZ O
an DT DT O
open JJ JJ O
question NN NN O
as IN IN O
a DT DT O
number NN NN O
of IN IN O
detrimental JJ JJ O
side NN NN O
effects NNS NNS O
have VBP VBP O
been VBN VBN O
reported VBN VBN O
in IN IN O
the DT DT O
fetus NN NN O
and CC CC O
neonate NN NN O
. . . O

Ten CD CD O
patients NNS NNS O
and CC CC O
12 CD CD O
pregnancies NNS NNS O
are VBP VBP O
reported VBN VBN O
where WRB WRB O
chronic JJ JJ O
propranolol NN NN B-CHEM
has VBZ VBZ O
been VBN VBN O
administered VBN VBN O
. . . O

Five CD CD O
patients NNS NNS O
with IN IN O
serial NN NN O
pregnancies NNS NNS O
with IN IN O
and CC CC O
without IN IN O
propranolol NN NN B-CHEM
therapy NN NN O
are VBP VBP O
also RB RB O
examined VBN VBN O
. . . O

Maternal NNP NNP O
, , , O
fetal JJ JJ O
, , , O
and CC CC O
neonatal JJ JJ O
complications NNS NNS O
are VBP VBP O
examined VBN VBN O
. . . O

An DT DT O
attempt NN NN O
is VBZ VBZ O
made VBN VBN O
to TO TO O
differentiate VB VB O
drug NN NN O
- - - O
related VBN VBN O
complications NNS NNS O
from IN IN O
maternal JJ JJ O
disease NN NN O
- - - O
- - - O
related VBN VBN O
complications NNS NNS O
. . . O

We PRP PRP O
conclude VBP VBP O
that IN IN O
previously RB RB O
reported VBD VBD O
hypoglycemia NN NN O
, , , O
hyperbilirubinemia NN NN O
, , , O
polycythemia NN NN O
, , , O
neonatal JJ JJ O
apnea NN NN O
, , , O
and CC CC O
bradycardia NNS NNS O
are VBP VBP O
not RB RB O
invariable JJ JJ O
and CC CC O
cannot NN NN O
be VB VB O
statistically RB RB O
correlated JJ JJ O
with IN IN O
chronic JJ JJ O
propranolol NN NN B-CHEM
therapy NN NN O
. . . O

Growth NN NN O
retardation NN NN O
, , , O
however RB RB O
, , , O
appears VBZ VBZ O
to TO TO O
be VB VB O
significant JJ JJ O
in IN IN O
both DT DT O
of IN IN O
our PRP$ PRP$ O
series NN NN O
. . . O

Central NNP NNP O
excitatory NN NN O
actions NNS NNS O
of IN IN O
flurazepam NN NN B-CHEM
. . . O

Toxic NNP NNP O
actions NNS NNS O
of IN IN O
flurazepam NN NN B-CHEM
( ( ( O
FZP NNP NNP B-CHEM
) ) ) O
were VBD VBD O
studied VBN VBN O
in IN IN O
cats NNS NNS O
, , , O
mice NN NN O
and CC CC O
rats NNS NNS O
. . . O

High NNP NNP O
doses NNS NNS O
caused VBD VBD O
an DT DT O
apparent JJ JJ O
central JJ JJ O
excitation NN NN O
, , , O
most RBS RBS O
clearly RB RB O
seen VBN VBN O
as IN IN O
clonic JJ JJ O
convulsions NNS NNS O
, , , O
superimposed VBN VBN O
on IN IN O
general JJ JJ O
depression NN NN O
. . . O

Following VBG VBG O
a DT DT O
lethal NN NN O
dose NN NN O
, , , O
death NN NN O
was VBD VBD O
always RB RB O
associated VBN VBN O
with IN IN O
convulsions NNS NNS O
. . . O

Comparing VBG VBG O
the DT DT O
relative JJ JJ O
sensitivity NN NN O
to TO TO O
central JJ JJ O
depression NN NN O
and CC CC O
excitation NN NN O
revealed VBD VBD O
that IN IN O
rats NNS NNS O
were VBD VBD O
least JJS JJS O
likely JJ JJ O
to TO TO O
have VB VB O
convulsions NNS NNS O
at IN IN O
doses NNS NNS O
that WDT WDT O
did VBD VBD O
not RB RB O
first JJ JJ O
cause NN NN O
loss NN NN O
of IN IN O
consciousness NN NN O
, , , O
while IN IN O
cats NNS NNS O
most RBS RBS O
clearly RB RB O
showed VBN VBN O
marked VBN VBN O
central JJ JJ O
excitatory NN NN O
actions NNS NNS O
. . . O

Signs NNS NNS O
of IN IN O
FZP NNP NNP B-CHEM
toxocity NN NN O
in IN IN O
cats NNS NNS O
included VBD VBD O
excessive JJ JJ O
salivation NN NN O
, , , O
extreme NN NN O
apprehensive JJ JJ O
behavior NN NN O
, , , O
retching VBG VBG O
, , , O
muscle NN NN O
tremors NNS NNS O
and CC CC O
convulsions NNS NNS O
. . . O

An DT DT O
interaction NN NN O
between IN IN O
FZP NNP NNP B-CHEM
and CC CC O
pentylenetetrazol NN NN B-CHEM
( ( ( O
PTZ NNP NNP B-CHEM
) ) ) O
was VBD VBD O
shown VBN VBN O
by IN IN O
pretreating VBG VBG O
mice NN NN O
with IN IN O
FZP NNP NNP B-CHEM
before IN IN O
PTZ NNP NNP B-CHEM
challenge NN NN O
. . . O

As IN IN O
a DT DT O
function NN NN O
of IN IN O
dose NN NN O
, , , O
FZP NNP NNP B-CHEM
first JJ JJ O
protected JJ JJ O
against IN IN O
convulsions NNS NNS O
and CC CC O
death NN NN O
. . . O

At IN IN O
higher JJR JJR O
doses NNS NNS O
, , , O
however RB RB O
, , , O
convulsions NNS NNS O
again RB RB O
emerged VBN VBN O
. . . O

These DT DT O
doses NNS NNS O
of IN IN O
FZP NNP NNP B-CHEM
were VBD VBD O
lower JJR JJR O
than IN IN O
those DT DT O
that WDT WDT O
would MD MD O
alone RB RB O
cause VB VB O
convulsions NNS NNS O
. . . O

These DT DT O
results NNS NNS O
may MD MD O
be VB VB O
relevant JJ JJ O
to TO TO O
the DT DT O
use NN NN O
of IN IN O
FZP NNP NNP B-CHEM
in IN IN O
clinical JJ JJ O
situations NNS NNS O
in IN IN O
which WDT WDT O
there EX EX O
is VBZ VBZ O
increased VBN VBN O
neural JJ JJ O
excitability NN NN O
, , , O
such JJ JJ O
as IN IN O
epilepsy NN NN O
or CC CC O
sedative JJ JJ O
- : : O
hypnotic JJ JJ O
drug NN NN O
withdrawal NN NN O
. . . O

Use NN NN O
of IN IN O
propranolol NN NN B-CHEM
in IN IN O
the DT DT O
treatment NN NN O
of IN IN O
idiopathic JJ JJ O
orthostatic JJ JJ O
hypotension NN NN O
. . . O

Five CD CD O
patients NNS NNS O
with IN IN O
idiopathic JJ JJ O
orthostatic JJ JJ O
hypotension NN NN O
who WP WP O
had VBD VBD O
physiologic JJ JJ O
and CC CC O
biochemical JJ JJ O
evidence NN NN O
of IN IN O
severe JJ JJ O
autonomic JJ JJ O
dysfunction NN NN O
were VBD VBD O
included VBN VBN O
in IN IN O
the DT DT O
study NN NN O
. . . O

They PRP PRP O
all DT DT O
exhibited VBD VBD O
markedly RB RB O
reduced VBN VBN O
plasma NN NN O
catecholamines NNS NNS B-CHEM
and CC CC O
plasma NN NN O
renin NN NN O
activity NN NN O
in IN IN O
both DT DT O
recumbent NN NN O
and CC CC O
upright JJ JJ O
positions NNS NNS O
and CC CC O
had VBD VBD O
marked VBN VBN O
hypersensitivity NN NN O
to TO TO O
the DT DT O
pressor NN NN O
effects NNS NNS O
of IN IN O
infused JJ JJ O
norepinephrine NN NN B-CHEM
. . . O

Treatment NN NN O
with IN IN O
propanolol NN NN B-CHEM
administered VBD VBD O
intravenously RB RB O
( ( ( O
1 CD CD O
- : : O
5 CD CD O
mg NN NN O
) ) ) O
produced VBD VBD O
increases NNS NNS O
in IN IN O
supine NN NN O
and CC CC O
upright JJ JJ O
blood NN NN O
pressure NN NN O
in IN IN O
4 CD CD O
of IN IN O
the DT DT O
5 CD CD O
individuals NNS NNS O
with IN IN O
rises NNS NNS O
ranging VBG VBG O
from IN IN O
11 CD CD O
/ NN NN O
6 CD CD O
to TO TO O
22 CD CD O
/ NN NN O
11 CD CD O
mmHg NN NN O
. . . O

Chronic NNP NNP O
oral JJ JJ O
administration NN NN O
of IN IN O
propranolol NN NN B-CHEM
( ( ( O
40 CD CD O
- : : O
160 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
) ) ) O
also RB RB O
elevated VBD VBD O
the DT DT O
blood NN NN O
pressures NNS NNS O
of IN IN O
these DT DT O
individuals NNS NNS O
with IN IN O
increases NNS NNS O
in IN IN O
the DT DT O
order NN NN O
of IN IN O
20 CD CD O
- : : O
35 CD CD O
/ NN NN O
15 CD CD O
- : : O
25 CD CD O
mmg NN NN O
being VBG VBG O
observed VBN VBN O
. . . O

In IN IN O
1 CD CD O
patient NN NN O
, , , O
marked VBD VBD O
hypertension NN NN O
was VBD VBD O
induced VBN VBN O
by IN IN O
propranolol NN NN B-CHEM
and CC CC O
the DT DT O
drug NN NN O
had VBD VBD O
to TO TO O
be VB VB O
withdrawn VBN VBN O
. . . O

It PRP PRP O
otherwise RB RB O
was VBD VBD O
well RB RB O
tolerated VBN VBN O
and CC CC O
no DT DT O
important JJ JJ O
side NN NN O
effects NNS NNS O
were VBD VBD O
observed VBN VBN O
. . . O

Treatment NN NN O
has VBZ VBZ O
been VBN VBN O
continued VBN VBN O
in IN IN O
3 CD CD O
individuals NNS NNS O
for IN IN O
6 CD CD O
- : : O
13 CD CD O
months NNS NNS O
with IN IN O
persistence NN NN O
of IN IN O
the DT DT O
pressor NN NN O
effect NN NN O
, , , O
although IN IN O
there EX EX O
appears VBZ VBZ O
to TO TO O
have VB VB O
been VBN VBN O
some DT DT O
decrease NN NN O
in IN IN O
the DT DT O
degree NN NN O
of IN IN O
response NN NN O
with IN IN O
time NN NN O
. . . O

Hemodynamic NNP NNP O
measurements NNS NNS O
in IN IN O
1 CD CD O
of IN IN O
the DT DT O
patients NNS NNS O
demonstrated VBD VBD O
an DT DT O
increase NN NN O
in IN IN O
total JJ JJ O
peripheral JJ JJ O
resistance NN NN O
and CC CC O
essentially RB RB O
no DT DT O
change NN NN O
in IN IN O
cardiac JJ JJ O
output NN NN O
following VBG VBG O
propranolol NN NN B-CHEM
therapy NN NN O
. . . O

The DT DT O
studies NNS NNS O
suggest VBP VBP O
that IN IN O
propranolol NN NN B-CHEM
is VBZ VBZ O
a DT DT O
useful JJ JJ O
drug NN NN O
in IN IN O
selected VBN VBN O
patients NNS NNS O
with IN IN O
severe JJ JJ O
idiopathic JJ JJ O
orthostatic JJ JJ O
hypotension NN NN O
. . . O

Total NNP NNP O
intravenous JJ JJ O
anesthesia NN NN O
with IN IN O
etomidate NN NN B-CHEM
. . . O

III NNP NNP O
. . . O

Some DT DT O
observations NNS NNS O
in IN IN O
adults NNS NNS O
. . . O

An DT DT O
investigation NN NN O
was VBD VBD O
undertaken VBN VBN O
to TO TO O
determine VB VB O
the DT DT O
dosage NN NN O
of IN IN O
etomidate NN NN B-CHEM
required VBN VBN O
to TO TO O
maintain VB VB O
sleep NN NN O
in IN IN O
adults NNS NNS O
undergoing VBG VBG O
surgery NN NN O
under IN IN O
regional JJ JJ O
local JJ JJ O
anesthesia NN NN O
. . . O

Premedication NNP NNP O
of IN IN O
diazepam NN NN B-CHEM
10 CD CD O
mg NN NN O
and CC CC O
atropine NN NN B-CHEM
0 CD CD O
. . . O
5 CD CD O
mg NN NN O
was VBD VBD O
given VBN VBN O
, , , O
and CC CC O
sleep VB VB O
was VBD VBD O
induced VBN VBN O
and CC CC O
maintained VBN VBN O
by IN IN O
intermittent JJ JJ O
intravenous JJ JJ O
injections NNS NNS O
of IN IN O
etomidate NN NN B-CHEM
0 CD CD O
. . . O
1 CD CD O
/ NN NN O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
given VBN VBN O
whenever WRB WRB O
the DT DT O
patient NN NN O
would MD MD O
open VB VB O
his PRP$ PRP$ O
eyes NNS NNS O
on IN IN O
request NN NN O
. . . O

A DT DT O
mean NN NN O
overall JJ JJ O
dose NN NN O
of IN IN O
etomidate NN NN B-CHEM
17 CD CD O
. . . O
4 CD CD O
microgram NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
. . . O
was VBD VBD O
required VBN VBN O
to TO TO O
maintain VB VB O
sleep NN NN O
, , , O
but CC CC O
great JJ JJ O
individual JJ JJ O
variation NN NN O
occurred VBD VBD O
, , , O
with IN IN O
older JJR JJR O
patients NNS NNS O
requiring VBG VBG O
less JJR JJR O
drug NN NN O
. . . O

The DT DT O
investigation NN NN O
was VBD VBD O
discontinued VBN VBN O
after IN IN O
18 CD CD O
patients NNS NNS O
because IN IN O
of IN IN O
the DT DT O
frequency NN NN O
and CC CC O
intensity NN NN O
of IN IN O
side NN NN O
- - - O
effects NNS NNS O
, , , O
particularly RB RB O
pain NN NN O
and CC CC O
myoclonia NN NN O
, , , O
which WDT WDT O
caused VBD VBD O
the DT DT O
technique NN NN O
to TO TO O
be VB VB O
abandoned VBN VBN O
in IN IN O
two CD CD O
cases NNS NNS O
. . . O

It PRP PRP O
is VBZ VBZ O
considered VBN VBN O
unlikely RB RB O
that DT DT O
etomidate NN NN B-CHEM
will MD MD O
prove VB VB O
to TO TO O
be VB VB O
the DT DT O
hypnotic JJ JJ O
of IN IN O
choice NN NN O
for IN IN O
a DT DT O
totally RB RB O
intravenous JJ JJ O
anesthetic JJ JJ O
technique NN NN O
in IN IN O
adults NNS NNS O
because IN IN O
of IN IN O
the DT DT O
high JJ JJ O
incidence NN NN O
of IN IN O
myoclonia NN NN O
after IN IN O
prolonged JJ JJ O
administration NN NN O
. . . O

In IN IN O
several JJ JJ O
patients NNS NNS O
uncontrollable JJ JJ O
muscle NN NN O
movements NNS NNS O
persisted VBD VBD O
for IN IN O
many JJ JJ O
minutes NNS NNS O
after IN IN O
complete JJ JJ O
recovery NN NN O
of IN IN O
consciousness NN NN O
. . . O

Evidence NN NN O
for IN IN O
cardiac JJ JJ O
beta NN NN O
2 CD CD O
- : : O
adrenoceptors NNS NNS O
in IN IN O
man NN NN O
. . . O

We PRP PRP O
compared VBD VBD O
the DT DT O
effects NNS NNS O
of IN IN O
single JJ JJ O
doses NNS NNS O
of IN IN O
50 CD CD O
mg NN NN O
atenolol NN NN B-CHEM
( ( ( O
cardioselective JJ JJ O
) ) ) O
, , , O
40 CD CD O
mg NN NN O
propranolol NN NN B-CHEM
( ( ( O
nonselective JJ JJ O
) ) ) O
, , , O
and CC CC O
placebo NN NN O
on IN IN O
both DT DT O
exercise NN NN O
- - - O
and CC CC O
isoproterenol NN NN B-CHEM
- - - O
induced JJ JJ O
tachycardia NN NN O
in IN IN O
two CD CD O
experiments NNS NNS O
involving VBG VBG O
nine CD CD O
normal JJ JJ O
subjects NNS NNS O
. . . O

Maximal NNP NNP O
exercise NN NN O
heart NN NN O
rate NN NN O
was VBD VBD O
reduced VBN VBN O
from IN IN O
187 CD CD O
+ NN NN O
/ NN NN O
- : : O
4 CD CD O
( ( ( O
SEM NNP NNP O
) ) ) O
after IN IN O
placebo NN NN O
to TO TO O
146 CD CD O
+ NN NN O
/ NN NN O
- : : O
7 CD CD O
bpm NN NN O
after IN IN O
atenolol NN NN B-CHEM
and CC CC O
138 CD CD O
+ NN NN O
/ NN NN O
- : : O
6 CD CD O
bpm NN NN O
after IN IN O
propranolol NN NN B-CHEM
, , , O
but CC CC O
there EX EX O
were VBD VBD O
no DT DT O
differences NNS NNS O
between IN IN O
the DT DT O
drugs NNS NNS O
. . . O

The DT DT O
effects NNS NNS O
on IN IN O
isoproterenol JJ JJ B-CHEM
tachycardia NNS NNS O
were VBD VBD O
determined VBN VBN O
before IN IN O
and CC CC O
after IN IN O
atropine NN NN B-CHEM
( ( ( O
0 CD CD O
. . . O
04 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
IV NNP NNP O
) ) ) O
. . . O

Isoproterenol NNP NNP B-CHEM
sensitivity NN NN O
was VBD VBD O
determined VBN VBN O
as IN IN O
the DT DT O
intravenous JJ JJ O
dose NN NN O
that WDT WDT O
increased VBD VBD O
heart NN NN O
rate NN NN O
by IN IN O
25 CD CD O
bpm NN NN O
( ( ( O
CD25 NNP NNP O
) ) ) O
and CC CC O
this DT DT O
was VBD VBD O
increased VBN VBN O
from IN IN O
1 CD CD O
. . . O
8 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
3 CD CD O
micrograms NNS NNS O
after IN IN O
placebo NN NN O
to TO TO O
38 CD CD O
. . . O
9 CD CD O
+ NN NN O
/ NN NN O
- : : O
8 CD CD O
. . . O
3 CD CD O
micrograms NNS NNS O
after IN IN O
propranolol NN NN B-CHEM
and CC CC O
8 CD CD O
. . . O
3 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
7 CD CD O
micrograms NNS NNS O
after IN IN O
atenolol NN NN B-CHEM
. . . O

The DT DT O
difference NN NN O
in IN IN O
the DT DT O
effects NNS NNS O
of IN IN O
the DT DT O
two CD CD O
was VBD VBD O
significant JJ JJ O
. . . O

After IN IN O
atropine NN NN B-CHEM
the DT DT O
CD25 NNP NNP O
was VBD VBD O
unchanged JJ JJ O
after IN IN O
placebo NN NN O
( ( ( O
2 CD CD O
. . . O
3 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
3 CD CD O
micrograms NNS NNS O
) ) ) O
and CC CC O
atenolol NN NN B-CHEM
( ( ( O
7 CD CD O
. . . O
7 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
3 CD CD O
micrograms NNS NNS O
) ) ) O
; : : O
it PRP PRP O
was VBD VBD O
reduced VBN VBN O
after IN IN O
propranolol NN NN B-CHEM
( ( ( O
24 CD CD O
. . . O
8 CD CD O
+ NN NN O
/ NN NN O
- : : O
5 CD CD O
. . . O
0 CD CD O
micrograms NNS NNS O
) ) ) O
, , , O
but CC CC O
remained VBD VBD O
different JJ JJ O
from IN IN O
atenolol NN NN B-CHEM
. . . O

This DT DT O
change NN NN O
with IN IN O
propranolol NN NN B-CHEM
sensitivity NN NN O
was VBD VBD O
calculated VBN VBN O
as IN IN O
the DT DT O
apparent JJ JJ O
Ka NNP NNP O
, , , O
this DT DT O
was VBD VBD O
unchanged JJ JJ O
by IN IN O
atropine NN NN B-CHEM
( ( ( O
11 CD CD O
. . . O
7 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
. . . O
1 CD CD O
and CC CC O
10 CD CD O
. . . O
1 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
. . . O
5 CD CD O
ml NN NN O
/ NN NN O
ng NN NN O
) ) ) O
. . . O

These DT DT O
data NNS NNS O
are VBP VBP O
consistent JJ JJ O
with IN IN O
the DT DT O
hypothesis NNS NNS O
that WDT WDT O
exercise NN NN O
- - - O
induced JJ JJ O
tachycardia NN NN O
results NNS NNS O
largely RB RB O
from IN IN O
beta NN NN O
1 CD CD O
- : : O
receptor NN NN O
activation NN NN O
that WDT WDT O
is VBZ VBZ O
blocked VBN VBN O
by IN IN O
both DT DT O
cardioselective JJ JJ O
and CC CC O
nonselective JJ JJ O
drugs NNS NNS O
, , , O
whereas IN IN O
isoproterenol JJ JJ B-CHEM
activates NNS NNS O
both DT DT O
beta NN NN O
1 CD CD O
- : : O
and CC CC O
beta NN NN O
2 CD CD O
- : : O
receptors NNS NNS O
so IN IN O
that IN IN O
after IN IN O
cardioselective JJ JJ O
blockade NN NN O
there EX EX O
remains VBZ VBZ O
a DT DT O
beta NN NN O
2 CD CD O
- : : O
component NN NN O
that WDT WDT O
can MD MD O
be VB VB O
blocked VBN VBN O
with IN IN O
a DT DT O
nonselective JJ JJ O
drug NN NN O
. . . O

While IN IN O
there EX EX O
appear VB VB O
to TO TO O
be VB VB O
beta NN NN O
2 CD CD O
- : : O
receptors NNS NNS O
in IN IN O
the DT DT O
human JJ JJ O
heart NN NN O
, , , O
their PRP$ PRP$ O
physiologic JJ JJ O
or CC CC O
pathologic JJ JJ O
roles NNS NNS O
remain VBP VBP O
to TO TO O
be VB VB O
defined VBN VBN O
. . . O

Hormones NNP NNP O
and CC CC O
risk NN NN O
of IN IN O
breast NN NN O
cancer NN NN O
. . . O

This DT DT O
paper NN NN O
reports NNS NNS O
the DT DT O
results NNS NNS O
of IN IN O
a DT DT O
study NN NN O
of IN IN O
50 CD CD O
menopausal NN NN O
women NNS NNS O
receiving VBG VBG O
hormonal NN NN O
replacement NN NN O
therapy NN NN O
. . . O

The DT DT O
majority NN NN O
( ( ( O
29 CD CD O
) ) ) O
had VBD VBD O
surgical JJ JJ O
menopause NN NN O
; : : O
their PRP$ PRP$ O
mean JJ JJ O
age NN NN O
was VBD VBD O
45 CD CD O
. . . O
7 CD CD O
years NNS NNS O
. . . O

It PRP PRP O
was VBD VBD O
hypothesized VBN VBN O
that IN IN O
progestins NNS NNS B-CHEM
could MD MD O
equilibrate VB VB O
the DT DT O
effects NNS NNS O
of IN IN O
the DT DT O
estrogenic JJ JJ O
stimulation NN NN O
on IN IN O
the DT DT O
mammary JJ JJ O
and CC CC O
endometrial JJ JJ O
target NN NN O
tissues NNS NNS O
of IN IN O
women NNS NNS O
on IN IN O
hormonal NN NN O
replacement NN NN O
therapy NN NN O
. . . O

The DT DT O
treatment NN NN O
schedule NN NN O
consisted VBN VBN O
of IN IN O
conjugated JJ JJ B-CHEM
estrogens NNS NNS I-CHEM
( ( ( O
Premarin NNP NNP B-CHEM
) ) ) O
1 CD CD O
. . . O
25 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
for IN IN O
21 CD CD O
days NNS NNS O
and CC CC O
Medroxyprogesterone NNP NNP B-CHEM
acetate NN NN I-CHEM
10 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
for IN IN O
10 CD CD O
days NNS NNS O
in IN IN O
each DT DT O
month NN NN O
. . . O

The DT DT O
mean JJ JJ O
treatment NN NN O
period NN NN O
was VBD VBD O
18 CD CD O
months NNS NNS O
. . . O

During IN IN O
the DT DT O
follow VB VB O
- - - O
up RP RP O
period NN NN O
, , , O
attention NN NN O
was VBD VBD O
paid VBN VBN O
to TO TO O
breast NN NN O
modifications NNS NNS O
as IN IN O
evidenced VBN VBN O
by IN IN O
symptomatology NN NN O
, , , O
physical JJ JJ O
examination NN NN O
, , , O
and CC CC O
plate NN NN O
thermography NN NN O
. . . O

Mastodynia NNP NNP O
was VBD VBD O
reported VBN VBN O
by IN IN O
21 CD CD O
patients NNS NNS O
, , , O
and CC CC O
physical JJ JJ O
examination NN NN O
revealed VBD VBD O
a DT DT O
light JJ JJ O
increase NN NN O
in IN IN O
breast NN NN O
firmness NN NN O
in IN IN O
12 CD CD O
women NNS NNS O
and CC CC O
a DT DT O
moderate JJ JJ O
increase NN NN O
in IN IN O
breast NN NN O
nodularity NN NN O
in IN IN O
2 CD CD O
women NNS NNS O
. . . O

Themography NNP NNP O
confirmed VBD VBD O
the DT DT O
existence NN NN O
of IN IN O
an DT DT O
excessive JJ JJ O
breast NN NN O
stimulation NN NN O
in IN IN O
1 CD CD O
women NNS NNS O
who WP WP O
complained VBD VBD O
of IN IN O
moderate NN NN O
mastodynia NN NN O
and CC CC O
in IN IN O
5 CD CD O
of IN IN O
the DT DT O
7 CD CD O
women NNS NNS O
who WP WP O
complained VBD VBD O
of IN IN O
severe JJ JJ O
mastodynia NN NN O
. . . O

Normalization NNP NNP O
was VBD VBD O
obtained VBN VBN O
by IN IN O
halving VBG VBG O
the DT DT O
estrogen NN NN B-CHEM
dose NN NN O
. . . O

These DT DT O
results NNS NNS O
suggest VBP VBP O
that IN IN O
hormonal JJ JJ O
replacement NN NN O
therapy NN NN O
can MD MD O
be VB VB O
safely RB RB O
prescribed VBN VBN O
if IN IN O
the DT DT O
following VBG VBG O
criteria NNS NNS O
are VBP VBP O
satisfied VBN VBN O
: : : O
1 CD CD O
) ) ) O
preliminary JJ JJ O
evaluation NN NN O
of IN IN O
patients NNS NNS O
from IN IN O
a DT DT O
clinical JJ JJ O
, , , O
metabolic JJ JJ O
, , , O
cytologic JJ JJ O
, , , O
and CC CC O
mammographic JJ JJ O
perspective NN NN O
; : : O
2 CD CD O
) ) ) O
cyclic JJ JJ O
treatment NN NN O
schedule NN NN O
, , , O
with IN IN O
a DT DT O
progestative JJ JJ O
phase NN NN O
of IN IN O
10 CD CD O
days NNS NNS O
; : : O
and CC CC O
3 CD CD O
) ) ) O
periodic JJ JJ O
complete JJ JJ O
follow VB VB O
- - - O
up RP RP O
, , , O
with IN IN O
accurate JJ JJ O
thermographic JJ JJ O
evaluation NN NN O
of IN IN O
the DT DT O
breast NN NN O
target NN NN O
tissues NNS NNS O
. . . O

Early RB RB O
infections NNS NNS O
in IN IN O
kidney NN NN O
, , , O
heart NN NN O
, , , O
and CC CC O
liver NN NN O
transplant NN NN O
recipients NNS NNS O
on IN IN O
cyclosporine NN NN B-CHEM
. . . O

Eighty NNP NNP O
- : : O
one CD CD O
renal JJ JJ O
, , , O
seventeen JJ JJ O
heart NN NN O
, , , O
and CC CC O
twenty CD CD O
- - - O
four CD CD O
liver NN NN O
transplant NN NN O
patients NNS NNS O
were VBD VBD O
followed VBN VBN O
for IN IN O
infection NN NN O
. . . O

Seventeen NNP NNP O
renal JJ JJ O
patients NNS NNS O
received VBD VBD O
azathioprine NN NN B-CHEM
( ( ( O
Aza NNP NNP B-CHEM
) ) ) O
and CC CC O
prednisone NN NN B-CHEM
as IN IN O
part NN NN O
of IN IN O
a DT DT O
randomized JJ JJ O
trial NN NN O
of IN IN O
immunosuppression NN NN O
with IN IN O
21 CD CD O
cyclosporine NN NN B-CHEM
- : : O
and CC CC O
- : : O
prednisone NN NN B-CHEM
- - - O
treated VBN VBN O
renal JJ JJ O
transplant NN NN O
patients NNS NNS O
. . . O

All DT DT O
others NNS NNS O
received VBD VBD O
cyclosporine NN NN B-CHEM
and CC CC O
prednisone NN NN B-CHEM
. . . O

The DT DT O
randomized JJ JJ O
Aza NNP NNP B-CHEM
patients NNS NNS O
had VBD VBD O
more JJR JJR O
overall JJ JJ O
infections NNS NNS O
( ( ( O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
and CC CC O
more JJR JJR O
nonviral JJ JJ O
infections NNS NNS O
( ( ( O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
02 CD CD O
) ) ) O
than IN IN O
the DT DT O
randomized JJ JJ O
cyclosporine NN NN B-CHEM
patients NNS NNS O
. . . O

Heart NNP NNP O
and CC CC O
liver NN NN O
patients NNS NNS O
had VBD VBD O
more JJR JJR O
infections NNS NNS O
than IN IN O
cyclosporine NN NN B-CHEM
renal NN NN O
patients NNS NNS O
but CC CC O
fewer JJR JJR O
infections NNS NNS O
than IN IN O
the DT DT O
Aza NNP NNP B-CHEM
renal JJ JJ O
patients NNS NNS O
. . . O

There EX EX O
were VBD VBD O
no DT DT O
infectious JJ JJ O
deaths NNS NNS O
in IN IN O
renal JJ JJ O
transplant NN NN O
patients NNS NNS O
on IN IN O
cyclosporine NN NN B-CHEM
or CC CC O
Aza NNP NNP B-CHEM
, , , O
but CC CC O
infection NN NN O
played VBD VBD O
a DT DT O
major JJ JJ O
role NN NN O
in IN IN O
3 CD CD O
out IN IN O
of IN IN O
6 CD CD O
cardiac NN NN O
transplant NN NN O
deaths NNS NNS O
and CC CC O
in IN IN O
8 CD CD O
out IN IN O
of IN IN O
9 CD CD O
liver NN NN O
transplant NN NN O
deaths NNS NNS O
. . . O

Renal NNP NNP O
patients NNS NNS O
on IN IN O
cyclosporine NN NN B-CHEM
had VBD VBD O
the DT DT O
fewest JJS JJS O
bacteremias NN NN O
. . . O

Analysis NNP NNP O
of IN IN O
site NN NN O
of IN IN O
infection NN NN O
showed VBD VBD O
a DT DT O
preponderance NN NN O
of IN IN O
abdominal JJ JJ O
infections NNS NNS O
in IN IN O
liver NN NN O
patients NNS NNS O
, , , O
intrathoracic NN NN O
infections NNS NNS O
in IN IN O
heart NN NN O
patients NNS NNS O
, , , O
and CC CC O
urinary JJ JJ O
tract NN NN O
infections NNS NNS O
in IN IN O
renal JJ JJ O
patients NNS NNS O
. . . O

Pulmonary NNP NNP O
infections NNS NNS O
were VBD VBD O
less RBR RBR O
common JJ JJ O
in IN IN O
cyclosporine NN NN B-CHEM
- - - O
treated VBN VBN O
renal NN NN O
patients NNS NNS O
than IN IN O
in IN IN O
Aza NNP NNP B-CHEM
- - - O
treated JJ JJ O
patients NNS NNS O
( ( ( O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

Aza NNP NNP B-CHEM
patients NNS NNS O
had VBD VBD O
significantly RB RB O
more JJR JJR O
staphylococcal JJ JJ O
infections NNS NNS O
than IN IN O
all DT DT O
other JJ JJ O
transplant NN NN O
groups NNS NNS O
( ( ( O
P NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
005 CD CD O
) ) ) O
, , , O
and CC CC O
systemic JJ JJ O
fungal JJ JJ O
infections NNS NNS O
occurred VBD VBD O
only RB RB O
in IN IN O
the DT DT O
liver NN NN O
transplant NN NN O
group NN NN O
. . . O

Cytomegalovirus NNP NNP O
( ( ( O
CMV NNP NNP O
) ) ) O
shedding VBG VBG O
or CC CC O
serological JJ JJ O
rises VBZ VBZ O
in IN IN O
antibody NN NN O
titer NN NN O
, , , O
or CC CC O
both DT DT O
occurred VBN VBN O
in IN IN O
78 CD CD O
% NN NN O
of IN IN O
cyclosporine NN NN B-CHEM
patients NNS NNS O
and CC CC O
76 CD CD O
% NN NN O
of IN IN O
Aza NNP NNP B-CHEM
patients NNS NNS O
. . . O

Of IN IN O
the DT DT O
cyclosporine NN NN B-CHEM
patients NNS NNS O
, , , O
15 CD CD O
% NN NN O
had VBD VBD O
symptoms NNS NNS O
related VBN VBN O
to TO TO O
CMV NNP NNP O
infection NN NN O
. . . O

Serological NNP NNP O
evidence NN NN O
for IN IN O
Epstein NNP NNP O
Barr NNP NNP O
Virus NNP NNP O
infection NN NN O
was VBD VBD O
found VBN VBN O
in IN IN O
20 CD CD O
% NN NN O
of IN IN O
65 CD CD O
cyclosporine NN NN B-CHEM
patients NNS NNS O
studied VBN VBN O
. . . O

Three CD CD O
had VBD VBD O
associated VBN VBN O
symptoms NNS NNS O
, , , O
and CC CC O
one CD CD O
developed VBD VBD O
a DT DT O
lymphoma NN NN O
. . . O

Structure NNP NNP O
- : : O
activity NN NN O
and CC CC O
dose VB VB O
- : : O
effect NN NN O
relationships NNS NNS O
of IN IN O
the DT DT O
antagonism NN NN O
of IN IN O
picrotoxin NN NN B-CHEM
- - - O
induced JJ JJ O
seizures NNS NNS O
by IN IN O
cholecystokinin NN NN B-CHEM
, , , O
fragments NNS NNS O
and CC CC O
analogues NNS NNS O
of IN IN O
cholecystokinin NN NN B-CHEM
in IN IN O
mice NN NN O
. . . O

Intraperitoneal NNP NNP O
administration NN NN O
of IN IN O
cholecystokinin NN NN B-CHEM
octapeptide NN NN I-CHEM
sulphate NN NN O
ester NN NN O
( ( ( O
CCK NNP NNP B-CHEM
- : : I-CHEM
8 CD CD I-CHEM
- : : O
SE NNP NNP O
) ) ) O
and CC CC O
nonsulphated JJ JJ O
cholecystokinin NN NN B-CHEM
octapeptide NN NN I-CHEM
( ( ( O
CCK NNP NNP B-CHEM
- : : I-CHEM
8 CD CD I-CHEM
- : : O
NS NNP NNP O
) ) ) O
enhanced VBD VBD O
the DT DT O
latency NN NN O
of IN IN O
seizures NNS NNS O
induced VBN VBN O
by IN IN O
picrotoxin NN NN B-CHEM
in IN IN O
mice NN NN O
. . . O

Experiments NNS NNS O
with IN IN O
N NNP NNP O
- : : O
and CC CC O
C NNP NNP O
- : : O
terminal NN NN O
fragments NNS NNS O
revealed VBD VBD O
that IN IN O
the DT DT O
C NNP NNP O
- - - O
terminal NN NN O
tetrapeptide NN NN O
( ( ( O
CCK NNP NNP O
- : : O
5 CD CD O
- : : O
8 CD CD O
) ) ) O
was VBD VBD O
the DT DT O
active JJ JJ O
centre NN NN O
of IN IN O
the DT DT O
CCK NNP NNP O
octapeptide NN NN O
molecule NN NN O
. . . O

The DT DT O
analogues NNS NNS O
CCK NNP NNP B-CHEM
- : : I-CHEM
8 CD CD I-CHEM
- : : O
SE NNP NNP O
and CC CC O
CCK NNP NNP B-CHEM
- : : I-CHEM
8 CD CD I-CHEM
- : : O
NS NNP NNP O
( ( ( O
dose NN NN O
range NN NN O
0 CD CD O
. . . O
2 CD CD O
- : : O
6 CD CD O
. . . O
4 CD CD O
mumol NN NN O
/ NN NN O
kg NN NN O
) ) ) O
and CC CC O
caerulein NN NN B-CHEM
dose NN NN O
range NN NN O
0 CD CD O
. . . O
1 CD CD O
- : : O
0 CD CD O
. . . O
8 CD CD O
mumol NN NN O
/ NN NN O
kg NN NN O
) ) ) O
showed VBD VBD O
bell NN NN O
- : : O
shaped VBN VBN O
dose VB VB O
- - - O
effect NN NN O
curves NNS NNS O
, , , O
with IN IN O
the DT DT O
greatest JJS JJS O
maximum NN NN O
inhibition NN NN O
for IN IN O
CCK NNP NNP B-CHEM
- : : I-CHEM
8 CD CD I-CHEM
- : : O
NS NNP NNP O
. . . O

The DT DT O
peptide NN NN O
CCK NNP NNP O
- : : O
5 CD CD O
- : : O
8 CD CD O
had VBD VBD O
weak JJ JJ O
anticonvulsant NN NN O
activity NN NN O
in IN IN O
comparison NN NN O
to TO TO O
the DT DT O
octapeptides NNS NNS O
, , , O
3 CD CD O
. . . O
2 CD CD O
mumol NN NN O
/ NN NN O
kg NN NN O
and CC CC O
larger JJR JJR O
doses NNS NNS O
of IN IN O
the DT DT O
reference NN NN O
drug NN NN O
, , , O
diazepam NN NN B-CHEM
, , , O
totally RB RB O
prevented VBN VBN O
picrotoxin NN NN B-CHEM
- - - O
induced JJ JJ O
seizures NNS NNS O
and CC CC O
mortality NN NN O
. . . O

The DT DT O
maximum NN NN O
effect NN NN O
of IN IN O
the DT DT O
peptides NNS NNS O
tested VBN VBN O
was VBD VBD O
less JJR JJR O
than IN IN O
that DT DT O
of IN IN O
diazepam NN NN B-CHEM
. . . O

Experiments NNS NNS O
with IN IN O
analogues NNS NNS O
and CC CC O
derivatives NNS NNS O
of IN IN O
CCK NNP NNP O
- : : O
5 CD CD O
- : : O
8 CD CD O
demonstrated VBN VBN O
that IN IN O
the DT DT O
effectiveness NN NN O
of IN IN O
the DT DT O
beta NN NN O
- - - O
alanyl NN NN O
derivatives NNS NNS O
of IN IN O
CCK NNP NNP O
- : : O
5 CD CD O
- : : O
8 CD CD O
were VBD VBD O
enhanced VBN VBN O
and CC CC O
that IN IN O
they PRP PRP O
were VBD VBD O
equipotent JJ JJ O
with IN IN O
CCK NNP NNP B-CHEM
- : : I-CHEM
8 CD CD I-CHEM
- : : O
SE NNP NNP O
. . . O

Of IN IN O
the DT DT O
CCK NNP NNP O
- - - O
2 CD CD O
- : : O
8 CD CD O
analogues NNS NNS O
, , , O
Ser NNP NNP O
( ( ( O
SO3H NNP NNP O
) ) ) O
7 CD CD O
- : : O
Ac NNP NNP O
- - - O
CCK NNP NNP O
- : : O
2 CD CD O
- : : O
8 CD CD O
- : : O
SE NNP NNP O
and CC CC O
Thr NNP NNP O
( ( ( O
SO3H NNP NNP O
) ) ) O
7 CD CD O
- : : O
Ac NNP NNP O
- - - O
CCK NNP NNP O
- : : O
2 CD CD O
- : : O
8 CD CD O
- : : O
SE NNP NNP O
and CC CC O
Hyp NNP NNP O
( ( ( O
SO3H NNP NNP O
) ) ) O
- : : O
Ac NNP NNP O
- - - O
CCK NNP NNP O
- : : O
2 CD CD O
- : : O
8 CD CD O
- : : O
SE NNP NNP O
were VBD VBD O
slightly RB RB O
more RBR RBR O
active JJ JJ O
than IN IN O
CCK NNP NNP B-CHEM
- : : I-CHEM
8 CD CD I-CHEM
- : : O
SE NNP NNP O
. . . O

Vasopressin NNP NNP B-CHEM
as IN IN O
a DT DT O
possible JJ JJ O
contributor NN NN O
to TO TO O
hypertension NN NN O
. . . O

The DT DT O
role NN NN O
of IN IN O
vasopressin NN NN B-CHEM
as IN IN O
a DT DT O
pressor NN NN O
agent NN NN O
to TO TO O
the DT DT O
hypertensive JJ JJ O
process NN NN O
was VBD VBD O
examined VBN VBN O
. . . O

Vasopressin NNP NNP B-CHEM
plays VBZ VBZ O
a DT DT O
major JJ JJ O
role NN NN O
in IN IN O
the DT DT O
pathogenesis NNS NNS O
of IN IN O
DOCA NNP NNP B-CHEM
- : : O
salt NN NN O
hypertension NN NN O
, , , O
since IN IN O
the DT DT O
elevation NN NN O
of IN IN O
blood NN NN O
pressure NN NN O
was VBD VBD O
not RB RB O
substantial JJ JJ O
in IN IN O
the DT DT O
rats NNS NNS O
with IN IN O
lithium NN NN B-CHEM
- - - O
treated JJ JJ O
diabetes NNS NNS O
insipidus NN NN O
after IN IN O
DOCA NNP NNP B-CHEM
- : : O
salt NN NN O
treatment NN NN O
. . . O

Administration NNP NNP O
of IN IN O
DDAVP NNP NNP B-CHEM
which WDT WDT O
has VBZ VBZ O
antidiuretic JJ JJ O
action NN NN O
but CC CC O
minimal JJ JJ O
vasopressor NN NN O
effect NN NN O
failed VBD VBD O
to TO TO O
increase VB VB O
blood NN NN O
pressure NN NN O
to TO TO O
the DT DT O
levels NNS NNS O
observed VBD VBD O
after IN IN O
administration NN NN O
of IN IN O
AVP NNP NNP O
. . . O

Furthermore RB RB O
, , , O
the DT DT O
pressor NN NN O
action NN NN O
of IN IN O
vasopressin NN NN B-CHEM
appears VBZ VBZ O
to TO TO O
be VB VB O
important JJ JJ O
in IN IN O
the DT DT O
development NN NN O
of IN IN O
this DT DT O
model NN NN O
of IN IN O
hypertension NN NN O
, , , O
since IN IN O
the DT DT O
enhanced JJ JJ O
pressor NN NN O
responsiveness NN NN O
to TO TO O
the DT DT O
hormone NN NN O
was VBD VBD O
observed VBN VBN O
in IN IN O
the DT DT O
initial JJ JJ O
stage NN NN O
of IN IN O
hypertension NN NN O
. . . O

Increased NNP NNP O
secretion NN NN O
of IN IN O
vasopressin NN NN B-CHEM
from IN IN O
neurohypophysis NN NN O
also RB RB O
promotes VBZ VBZ O
the DT DT O
function NN NN O
of IN IN O
the DT DT O
hormone NN NN O
as IN IN O
a DT DT O
pathogenetic JJ JJ O
factor NN NN O
in IN IN O
hypertension NN NN O
. . . O

An DT DT O
unproportional JJ JJ O
release NN NN O
of IN IN O
vasopressin NN NN B-CHEM
compared VBN VBN O
to TO TO O
plasma VB VB O
osmolality NN NN O
may MD MD O
be VB VB O
induced VBN VBN O
by IN IN O
the DT DT O
absence NN NN O
of IN IN O
an DT DT O
adjusting VBG VBG O
control NN NN O
of IN IN O
angiotensin NN NN B-CHEM
II NNP NNP O
forming VBG VBG O
and CC CC O
receptor NN NN O
binding JJ JJ O
capacity NN NN O
for IN IN O
sodium NN NN B-CHEM
balance NN NN O
in IN IN O
the DT DT O
brain NN NN O
. . . O

However RB RB O
, , , O
the DT DT O
role NN NN O
of IN IN O
vasopressin NN NN B-CHEM
remains NNS NNS O
to TO TO O
be VB VB O
determined VBN VBN O
in IN IN O
human JJ JJ O
essential JJ JJ O
hypertension NN NN O
. . . O

Toxic NNP NNP O
hepatitis NN NN O
induced VBN VBN O
by IN IN O
disulfiram NN NN B-CHEM
in IN IN O
a DT DT O
non NN NN O
- - - O
alcoholic JJ JJ O
. . . O

A DT DT O
reversible JJ JJ O
toxic JJ JJ O
liver NN NN O
damage NN NN O
was VBD VBD O
observed VBN VBN O
in IN IN O
a DT DT O
non NN NN O
- - - O
alcoholic JJ JJ O
woman NN NN O
treated VBN VBN O
with IN IN O
disulfiram NN NN B-CHEM
. . . O

The DT DT O
causative JJ JJ O
relationship NN NN O
was VBD VBD O
proven VBN VBN O
by IN IN O
challenge NN NN O
. . . O

Atrial NNP NNP O
thrombosis NN NN O
involving VBG VBG O
the DT DT O
heart NN NN O
of IN IN O
F NN NN O
- - - O
344 CD CD O
rats NNS NNS O
ingesting VBG VBG O
quinacrine NN NN B-CHEM
hydrochloride NN NN I-CHEM
. . . O

Quinacrine NNP NNP B-CHEM
hydrochloride NN NN I-CHEM
is VBZ VBZ O
toxic JJ JJ O
for IN IN O
the DT DT O
heart NN NN O
of IN IN O
F NN NN O
- - - O
344 CD CD O
rats NNS NNS O
. . . O

Rats NNP NNP O
treated VBN VBN O
with IN IN O
500 CD CD O
ppm NN NN O
quinacrine NN NN B-CHEM
hydrochloride NN NN I-CHEM
in IN IN O
the DT DT O
diet NN NN O
all DT DT O
developed VBD VBD O
a DT DT O
high JJ JJ O
incidence NN NN O
of IN IN O
left VBD VBD O
atrial JJ JJ O
thrombosis NN NN O
. . . O

The DT DT O
lesion NN NN O
was VBD VBD O
associated VBN VBN O
with IN IN O
cardiac JJ JJ O
hypertrophy NN NN O
and CC CC O
dilatation NN NN O
and CC CC O
focal JJ JJ O
myocardial NN NN O
degeneration NN NN O
. . . O

Rats NNP NNP O
died VBD VBD O
from IN IN O
cardiac JJ JJ O
hypertrophy NN NN O
with IN IN O
severe JJ JJ O
acute JJ JJ O
and CC CC O
chronic JJ JJ O
congestion NN NN O
of IN IN O
the DT DT O
lungs NNS NNS O
, , , O
liver NN NN O
, , , O
and CC CC O
other JJ JJ O
organs NNS NNS O
. . . O

Seventy CD CD O
percent NN NN O
of IN IN O
rats NNS NNS O
given VBN VBN O
250 CD CD O
ppm NN NN O
quinacrine NN NN B-CHEM
hydrochloride NN NN I-CHEM
and CC CC O
1 CD CD O
, , , O
000 CD CD O
ppm NN NN O
sodium NN NN B-CHEM
nitrite NN NN I-CHEM
simultaneously RB RB O
in IN IN O
the DT DT O
diet NN NN O
had VBD VBD O
thrombosis NNS NNS O
of IN IN O
the DT DT O
atria NN NN O
of IN IN O
the DT DT O
heart NN NN O
, , , O
while IN IN O
untreated JJ JJ O
control NN NN O
rats NNS NNS O
in IN IN O
this DT DT O
laboratory NN NN O
did VBD VBD O
not RB RB O
have VB VB O
atrial JJ JJ O
thrombosis NNS NNS O
. . . O

Sodium NNP NNP B-CHEM
nitrite NN NN I-CHEM
in IN IN O
combination NN NN O
with IN IN O
quinacrine NN NN B-CHEM
hydrochloride NN NN I-CHEM
appeared VBD VBD O
to TO TO O
have VB VB O
no DT DT O
additional JJ JJ O
effect NN NN O
. . . O

Alternating NNP NNP O
sinus CC CC O
rhythm NN NN O
and CC CC O
intermittent JJ JJ O
sinoatrial JJ JJ O
block NN NN O
induced VBN VBN O
by IN IN O
propranolol NN NN B-CHEM
. . . O

Alternating NNP NNP O
sinus CC CC O
rhythm NN NN O
and CC CC O
intermittent JJ JJ O
sinoatrial NN NN O
( ( ( O
S NNP NNP O
- - - O
A DT DT O
) ) ) O
block NN NN O
was VBD VBD O
observed VBN VBN O
in IN IN O
a DT DT O
57 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
woman NN NN O
, , , O
under IN IN O
treatment NN NN O
for IN IN O
angina NN NN O
with IN IN O
80 CD CD O
mg NN NN O
propranolol NN NN B-CHEM
daily JJ JJ O
. . . O

The DT DT O
electrocardiogram NN NN O
showed VBD VBD O
alternation NN NN O
of IN IN O
long JJ JJ O
and CC CC O
short JJ JJ O
P NN NN O
- - - O
P NN NN O
intervals NNS NNS O
and CC CC O
occasional JJ JJ O
pauses NNS NNS O
. . . O

These DT DT O
pauses NNS NNS O
were VBD VBD O
always RB RB O
preceded VBN VBN O
by IN IN O
the DT DT O
short JJ JJ O
P NN NN O
- - - O
P NN NN O
intervals NNS NNS O
and CC CC O
were VBD VBD O
usually RB RB O
followed VBN VBN O
by IN IN O
one CD CD O
or CC CC O
two CD CD O
P NN NN O
- : : O
P NN NN O
intervals NNS NNS O
of IN IN O
0 CD CD O
. . . O
92 CD CD O
- : : O
0 CD CD O
. . . O
95 CD CD O
s VBZ VBZ O
representing VBG VBG O
the DT DT O
basic JJ JJ O
sinus NN NN O
cycle NN NN O
. . . O

Following VBG VBG O
these DT DT O
basic JJ JJ O
sinus NN NN O
cycles NNS NNS O
, , , O
alternating VBG VBG O
rhythm NN NN O
started VBD VBD O
with IN IN O
the DT DT O
longer JJR JJR O
P NN NN O
- - - O
P NN NN O
interval NN NN O
. . . O

The DT DT O
long JJ JJ O
P NN NN O
- - - O
P NN NN O
intervals NNS NNS O
ranged VBD VBD O
between IN IN O
1 CD CD O
. . . O
04 CD CD O
- : : O
1 CD CD O
. . . O
12 CD CD O
s VBZ VBZ O
and CC CC O
the DT DT O
short JJ JJ O
P NN NN O
- - - O
P NN NN O
intervals NNS NNS O
between IN IN O
0 CD CD O
. . . O
80 CD CD O
- : : O
0 CD CD O
. . . O
84 CD CD O
s VBZ VBZ O
, , , O
respectively RB RB O
. . . O

The DT DT O
duration NN NN O
of IN IN O
the DT DT O
pauses NNS NNS O
were VBD VBD O
equal JJ JJ O
or CC CC O
almost RB RB O
equal JJ JJ O
to TO TO O
one CD CD O
short JJ JJ O
plus CC CC O
one CD CD O
long JJ JJ O
P NN NN O
- - - O
P NN NN O
interval NN NN O
or CC CC O
to TO TO O
twice RB RB O
the DT DT O
basic JJ JJ O
sinus NN NN O
cycle NN NN O
. . . O

In IN IN O
one CD CD O
recording VBG VBG O
a DT DT O
short JJ JJ O
period NN NN O
of IN IN O
regular JJ JJ O
sinus NN NN O
rhythm NN NN O
with IN IN O
intermittent NN NN O
2 CD CD O
/ NN NN O
1 CD CD O
S NNP NNP O
- : : O
A DT DT O
block NN NN O
was VBD VBD O
observed VBN VBN O
. . . O

This DT DT O
short JJ JJ O
period NN NN O
of IN IN O
sinus NN NN O
rhythm NN NN O
was VBD VBD O
interrupted VBN VBN O
by IN IN O
sudden JJ JJ O
prolongation NN NN O
of IN IN O
the DT DT O
P NN NN O
- - - O
P NN NN O
interval NN NN O
starting VBG VBG O
the DT DT O
alternative JJ JJ O
rhythm NN NN O
. . . O

There EX EX O
were VBD VBD O
small JJ JJ O
changes NNS NNS O
in IN IN O
the DT DT O
shape NN NN O
of IN IN O
the DT DT O
P NN NN O
waves NNS NNS O
and CC CC O
P NN NN O
- - - O
R NN NN O
intervals NNS NNS O
. . . O

S NNP NNP O
- : : O
A DT DT O
conduction NN NN O
through IN IN O
two CD CD O
pathways NNS NNS O
, , , O
the DT DT O
first JJ JJ O
with IN IN O
2 CD CD O
/ NN NN O
1 CD CD O
block NN NN O
the DT DT O
second JJ JJ O
having VBG VBG O
0 CD CD O
. . . O
12 CD CD O
- : : O
0 CD CD O
. . . O
14 CD CD O
s VBZ VBZ O
longer RBR RBR O
conduction NN NN O
time NN NN O
and CC CC O
with IN IN O
occasional JJ JJ O
2 CD CD O
/ NN NN O
1 CD CD O
block NN NN O
was VBD VBD O
proposed VBN VBN O
for IN IN O
the DT DT O
explanation NN NN O
of IN IN O
the DT DT O
alternating VBG VBG O
P NN NN O
- - - O
P NN NN O
interval NN NN O
and CC CC O
other JJ JJ O
electrocardiographic JJ JJ O
features NNS NNS O
seen VBN VBN O
. . . O

Atropine NNP NNP B-CHEM
1 CD CD O
mg NN NN O
given VBN VBN O
intravenously RB RB O
resulted VBN VBN O
in IN IN O
shortening NN NN O
of IN IN O
all DT DT O
P NN NN O
- - - O
P NN NN O
intervals NNS NNS O
without IN IN O
changing VBG VBG O
the DT DT O
rhythm NN NN O
. . . O

The DT DT O
abnormal JJ JJ O
rhythm NN NN O
disappeared VBD VBD O
with IN IN O
the DT DT O
withdrawal NN NN O
of IN IN O
propranolol NN NN B-CHEM
and CC CC O
when WRB WRB O
the DT DT O
drug NN NN O
was VBD VBD O
restarted VBN VBN O
a DT DT O
2 CD CD O
/ NN NN O
1 CD CD O
S NNP NNP O
- : : O
A DT DT O
block NN NN O
was VBD VBD O
seen VBN VBN O
. . . O

This DT DT O
was VBD VBD O
accepted VBN VBN O
as IN IN O
evidence NN NN O
for IN IN O
propranolol NN NN B-CHEM
being VBG VBG O
the DT DT O
cause NN NN O
of IN IN O
this DT DT O
conduction NN NN O
disorder NN NN O
. . . O

Antitumor NNP NNP O
effect NN NN O
, , , O
cardiotoxicity NN NN O
, , , O
and CC CC O
nephrotoxicity NN NN O
of IN IN O
doxorubicin NN NN B-CHEM
in IN IN O
the DT DT O
IgM NNP NNP O
solid JJ JJ O
immunocytoma NN NN O
- - - O
bearing VBG VBG O
LOU NNP NNP O
/ NN NN O
M NNP NNP O
/ NN NN O
WSL NNP NNP O
rat NN NN O
. . . O

Antitumor NNP NNP O
activity NN NN O
, , , O
cardiotoxicity NN NN O
, , , O
and CC CC O
nephrotoxicity NN NN O
induced VBN VBN O
by IN IN O
doxorubicin NN NN B-CHEM
were VBD VBD O
studied VBN VBN O
in IN IN O
LOU NNP NNP O
/ NN NN O
M NNP NNP O
/ NN NN O
WSL NNP NNP O
inbred JJ JJ O
rats NNS NNS O
each DT DT O
bearing VBG VBG O
a DT DT O
transplantable JJ JJ O
solid JJ JJ O
IgM NNP NNP O
immunocytoma NN NN O
. . . O

Animals NNS NNS O
with IN IN O
a DT DT O
tumor NN NN O
( ( ( O
diameter NN NN O
, , , O
15 CD CD O
. . . O
8 CD CD O
+ NN NN O
/ NN NN O
- : : O
3 CD CD O
. . . O
3 CD CD O
mm NN NN O
) ) ) O
were VBD VBD O
treated VBN VBN O
with IN IN O
iv JJ JJ O
injections NNS NNS O
of IN IN O
doxorubicin NN NN B-CHEM
on IN IN O
5 CD CD O
consecutive JJ JJ O
days NNS NNS O
, , , O
followed VBN VBN O
by IN IN O
1 CD CD O
weekly JJ JJ O
injection NN NN O
for IN IN O
7 CD CD O
weeks NNS NNS O
( ( ( O
dose NN NN O
range NN NN O
, , , O
0 CD CD O
. . . O
015 CD CD O
- : : O
4 CD CD O
. . . O
0 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
body NN NN O
wt NN NN O
) ) ) O
. . . O

Tumor NNP NNP O
regression NN NN O
was VBD VBD O
observed VBN VBN O
with IN IN O
0 CD CD O
. . . O
5 CD CD O
mg NN NN O
doxorubicin NN NN B-CHEM
/ NN NN O
kg NN NN O
. . . O

Complete JJ JJ O
disappearance NN NN O
of IN IN O
the DT DT O
tumor NN NN O
was VBD VBD O
induced VBN VBN O
with IN IN O
1 CD CD O
. . . O
0 CD CD O
mg NN NN O
doxorubicin NN NN B-CHEM
/ NN NN O
kg NN NN O
. . . O

Histologic NNP NNP O
evidence NN NN O
of IN IN O
cardiotoxicity NN NN O
scored VBD VBD O
as IN IN O
grade NN NN O
III NNP NNP O
was VBD VBD O
only RB RB O
observed VBN VBN O
at IN IN O
a DT DT O
dose NN NN O
of IN IN O
1 CD CD O
. . . O
0 CD CD O
mg NN NN O
doxorubicin NN NN B-CHEM
/ NN NN O
kg NN NN O
. . . O

Light NNP NNP O
microscopic JJ JJ O
evidence NN NN O
of IN IN O
renal JJ JJ O
damage NN NN O
was VBD VBD O
seen VBN VBN O
above IN IN O
a DT DT O
dose NN NN O
of IN IN O
0 CD CD O
. . . O
5 CD CD O
mg NN NN O
doxorubicin NN NN B-CHEM
/ NN NN O
kg NN NN O
, , , O
which WDT WDT O
resulted VBD VBD O
in IN IN O
albuminuria NN NN O
and CC CC O
very RB RB O
low JJ JJ O
serum NN NN O
albumin NN NN O
levels NNS NNS O
. . . O

In IN IN O
the DT DT O
group NN NN O
that WDT WDT O
received VBD VBD O
1 CD CD O
. . . O
0 CD CD O
mg NN NN O
doxorubicin NN NN B-CHEM
/ NN NN O
kg NN NN O
, , , O
the DT DT O
serum NN NN O
albumin NN NN O
level NN NN O
decreased VBD VBD O
from IN IN O
33 CD CD O
. . . O
6 CD CD O
+ NN NN O
/ NN NN O
- : : O
4 CD CD O
. . . O
1 CD CD O
to TO TO O
1 CD CD O
. . . O
5 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
5 CD CD O
g SYM SYM O
/ NN NN O
liter NN NN O
. . . O

Ascites NNP NNP O
and CC CC O
hydrothorax NN NN O
were VBD VBD O
observed VBN VBN O
simultaneously RB RB O
. . . O

The DT DT O
same JJ JJ O
experiments NNS NNS O
were VBD VBD O
performed VBN VBN O
with IN IN O
non NN NN O
- - - O
tumor NN NN O
- - - O
bearing NN NN O
rats NNS NNS O
, , , O
in IN IN O
which WDT WDT O
no DT DT O
major JJ JJ O
differences NNS NNS O
were VBD VBD O
observed VBN VBN O
. . . O

In IN IN O
conclusion NN NN O
, , , O
antitumor NN NN O
activity NN NN O
, , , O
cardiotoxicity NN NN O
, , , O
and CC CC O
nephrotoxicity NN NN O
were VBD VBD O
studied VBN VBN O
simultaneously RB RB O
in IN IN O
the DT DT O
same JJ JJ O
LOU NNP NNP O
/ NN NN O
M NNP NNP O
/ NN NN O
WSL NNP NNP O
rat NN NN O
. . . O

Albuminuria NNP NNP O
due JJ JJ O
to TO TO O
renal JJ JJ O
damage NN NN O
led VBN VBN O
to TO TO O
extremely RB RB O
low JJ JJ O
serum NN NN O
albumin NN NN O
levels NNS NNS O
, , , O
so RB RB O
ascites NNS NNS O
and CC CC O
hydrothorax NN NN O
were VBD VBD O
not RB RB O
necessarily RB RB O
a DT DT O
consequence NN NN O
of IN IN O
the DT DT O
observed VBN VBN O
cardiomyopathy NN NN O
. . . O

Intraoperative NNP NNP O
bradycardia NN NN O
and CC CC O
hypotension NN NN O
associated VBN VBN O
with IN IN O
timolol NN NN B-CHEM
and CC CC O
pilocarpine NN NN B-CHEM
eye NN NN O
drops NNS NNS O
. . . O

A DT DT O
69 CD CD O
- : : O
yr NN NN O
- - - O
old JJ JJ O
man NN NN O
, , , O
who WP WP O
was VBD VBD O
concurrently RB RB O
being VBG VBG O
treated VBN VBN O
with IN IN O
pilocarpine NN NN B-CHEM
nitrate NN NN I-CHEM
and CC CC O
timolol NN NN B-CHEM
maleate NN NN I-CHEM
eye NN NN O
drops NNS NNS O
, , , O
developed VBN VBN O
a DT DT O
bradycardia NN NN O
and CC CC O
became VBD VBD O
hypotensive JJ JJ O
during IN IN O
halothane NN NN B-CHEM
anaesthesia NN NN O
. . . O

Both DT DT O
timolol NN NN B-CHEM
and CC CC O
pilocarpine NN NN B-CHEM
were VBD VBD O
subsequently RB RB O
identified VBN VBN O
in IN IN O
a DT DT O
24 CD CD O
- : : O
h NN NN O
collection NN NN O
of IN IN O
urine NN NN O
. . . O

Timolol NNP NNP B-CHEM
( ( ( O
but CC CC O
not RB RB O
pilocarpine NN NN B-CHEM
) ) ) O
was VBD VBD O
detected VBN VBN O
in IN IN O
a DT DT O
sample NN NN O
of IN IN O
plasma NN NN O
removed VBD VBD O
during IN IN O
surgery NN NN O
; : : O
the DT DT O
plasma NN NN O
concentration NN NN O
of IN IN O
timolol NN NN B-CHEM
( ( ( O
2 CD CD O
. . . O
6 CD CD O
ng NN NN O
ml NN NN O
- : : O
1 CD CD O
) ) ) O
was VBD VBD O
consistent JJ JJ O
with IN IN O
partial JJ JJ O
beta NN NN O
- - - O
adrenoceptor NN NN O
blockade NN NN O
. . . O

It PRP PRP O
is VBZ VBZ O
postulated VBN VBN O
that IN IN O
this DT DT O
action NN NN O
may MD MD O
have VB VB O
been VBN VBN O
enhanced VBN VBN O
during IN IN O
halothane NN NN B-CHEM
anaesthesia NN NN O
with IN IN O
resultant JJ JJ O
bradycardia NNS NNS O
and CC CC O
hypotension NN NN O
. . . O

Pilocarpine NNP NNP B-CHEM
may MD MD O
have VB VB O
had VBN VBN O
a DT DT O
contributory NN NN O
effect NN NN O
. . . O

Succinylcholine NNP NNP B-CHEM
apnoea NN NN O
: : : O
attempted VBD VBD O
reversal NN NN O
with IN IN O
anticholinesterases NNS NNS O
. . . O

Anticholinesterases NNP NNP O
were VBD VBD O
administered VBN VBN O
in IN IN O
an DT DT O
attempt NN NN O
to TO TO O
antagonize VB VB O
prolonged JJ JJ O
neuromuscular NN NN O
blockade NN NN O
following VBG VBG O
the DT DT O
administration NN NN O
of IN IN O
succinylcholine NN NN B-CHEM
in IN IN O
a DT DT O
patient NN NN O
later RB RB O
found VBD VBD O
to TO TO O
be VB VB O
homozygous JJ JJ O
for IN IN O
atypical JJ JJ O
plasma NN NN O
cholinesterase NN NN O
. . . O

Edrophonium NNP NNP B-CHEM
10 CD CD O
mg NN NN O
, , , O
given VBN VBN O
74 CD CD O
min NN NN O
after IN IN O
succinylcholine NN NN B-CHEM
, , , O
when WRB WRB O
train NN NN O
- - - O
of IN IN O
- - - O
four CD CD O
stimulation NN NN O
was VBD VBD O
characteristic JJ JJ O
of IN IN O
phase NN NN O
II NNP NNP O
block NN NN O
, , , O
produced VBN VBN O
partial JJ JJ O
antagonism NN NN O
which WDT WDT O
was VBD VBD O
not RB RB O
sustained VBN VBN O
. . . O

Repeated NNP NNP O
doses NNS NNS O
of IN IN O
edrophonium NN NN B-CHEM
to TO TO O
70 CD CD O
mg NN NN O
and CC CC O
neostigmine NN NN B-CHEM
to TO TO O
2 CD CD O
. . . O
5 CD CD O
mg NN NN O
did VBD VBD O
not RB RB O
antagonize VB VB O
or CC CC O
augment VB VB O
the DT DT O
block NN NN O
. . . O

Spontaneous NNP NNP O
respiration NN NN O
recommenced VBD VBD O
200 CD CD O
min NN NN O
after IN IN O
succinylcholine NN NN B-CHEM
administration NN NN O
. . . O

It PRP PRP O
is VBZ VBZ O
concluded VBN VBN O
that IN IN O
anticholinesterases NNS NNS O
are VBP VBP O
only RB RB O
partially RB RB O
effective JJ JJ O
in IN IN O
restoring VBG VBG O
neuromuscular JJ JJ O
function NN NN O
in IN IN O
succinylcholine NN NN B-CHEM
apnoea NN NN O
despite IN IN O
muscle NN NN O
twitch NN NN O
activity NN NN O
typical JJ JJ O
of IN IN O
phase NN NN O
II NNP NNP O
block NN NN O
. . . O

Effect NN NN O
of IN IN O
doxorubicin NN NN B-CHEM
on IN IN O
[ NN NN B-CHEM
omega JJ JJ I-CHEM
- : : I-CHEM
I PRP PRP I-CHEM
- : : I-CHEM
131 CD CD I-CHEM
] NN NN I-CHEM
heptadecanoic JJ JJ I-CHEM
acid NN NN I-CHEM
myocardial NN NN O
scintigraphy NN NN O
and CC CC O
echocardiography NN NN O
in IN IN O
dogs NNS NNS O
. . . O

The DT DT O
effects NNS NNS O
of IN IN O
serial JJ JJ O
treatment NN NN O
with IN IN O
doxorubicin NN NN B-CHEM
on IN IN O
dynamic JJ JJ O
myocardial NN NN O
scintigraphy NN NN O
with IN IN O
[ NN NN B-CHEM
omega JJ JJ I-CHEM
- : : I-CHEM
I PRP PRP I-CHEM
- : : I-CHEM
131 CD CD I-CHEM
] NN NN I-CHEM
heptadecanoic JJ JJ I-CHEM
acid NN NN I-CHEM
( ( ( O
I NN NN B-CHEM
- : : I-CHEM
131 CD CD I-CHEM
HA NNP NNP I-CHEM
) ) ) O
, , , O
and CC CC O
on IN IN O
global JJ JJ O
left JJ JJ O
- - - O
ventricular NN NN O
function NN NN O
determined VBN VBN O
echocardiographically RB RB O
, , , O
were VBD VBD O
studied VBN VBN O
in IN IN O
a DT DT O
group NN NN O
of IN IN O
nine CD CD O
mongrel NN NN O
dogs NNS NNS O
. . . O

Total NNP NNP O
extractable JJ JJ O
myocardial NN NN O
lipid NN NN O
was VBD VBD O
compared VBN VBN O
postmortem NN NN O
between IN IN O
a DT DT O
group NN NN O
of IN IN O
control NN NN O
dogs NNS NNS O
and CC CC O
doxorubicin NN NN B-CHEM
- - - O
treated VBN VBN O
dogs NNS NNS O
. . . O

A DT DT O
significant JJ JJ O
and CC CC O
then RB RB O
progressive JJ JJ O
fall NN NN O
in IN IN O
global JJ JJ O
LV NNP NNP O
function NN NN O
was VBD VBD O
observed VBN VBN O
at IN IN O
a DT DT O
cumulative JJ JJ O
doxorubicin NN NN B-CHEM
dose NN NN O
of IN IN O
4 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
. . . O

A DT DT O
significant JJ JJ O
increase NN NN O
in IN IN O
the DT DT O
myocardial NN NN O
t1 NN NN O
/ NN NN O
2 CD CD O
of IN IN O
the DT DT O
I PRP PRP B-CHEM
- - - I-CHEM
131 CD CD I-CHEM
HA NNP NNP I-CHEM
was VBD VBD O
observed VBN VBN O
only RB RB O
at IN IN O
a DT DT O
higher JJR JJR O
cumulative JJ JJ O
dose NN NN O
, , , O
10 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
. . . O

No DT DT O
significant JJ JJ O
alteration NN NN O
in IN IN O
total JJ JJ O
extractable JJ JJ O
myocardial NN NN O
lipids NNS NNS O
was VBD VBD O
observed VBN VBN O
between IN IN O
control NN NN O
dogs NNS NNS O
and CC CC O
those DT DT O
treated VBN VBN O
with IN IN O
doxorubicin NN NN B-CHEM
. . . O

Our PRP$ PRP$ O
findings NNS NNS O
suggest VBP VBP O
that IN IN O
the DT DT O
changes NNS NNS O
leading VBG VBG O
to TO TO O
an DT DT O
alteration NN NN O
of IN IN O
myocardial JJ JJ O
dynamic JJ JJ O
imaging NN NN O
with IN IN O
I PRP PRP B-CHEM
- : : I-CHEM
131 CD CD I-CHEM
HA NNP NNP I-CHEM
are VBP VBP O
not RB RB O
the DT DT O
initiating VBG VBG O
factor NN NN O
in IN IN O
doxorubicin NN NN B-CHEM
cardiotoxicity NN NN O
. . . O

Hemodynamics NNP NNP O
and CC CC O
myocardial NN NN O
metabolism NN NN O
under IN IN O
deliberate JJ JJ O
hypotension NN NN O
. . . O

An DT DT O
experimental JJ JJ O
study NN NN O
in IN IN O
dogs NNS NNS O
. . . O

Coronary JJ JJ O
blood NN NN O
flow NN NN O
, , , O
cardiac JJ JJ O
work NN NN O
and CC CC O
metabolism NN NN O
were VBD VBD O
studied VBN VBN O
in IN IN O
dogs NNS NNS O
under IN IN O
sodium NN NN B-CHEM
nitroprusside NN NN I-CHEM
( ( ( O
SNP NNP NNP B-CHEM
) ) ) O
and CC CC O
trimetaphan JJ JJ B-CHEM
( ( ( O
TMP NNP NNP B-CHEM
) ) ) O
deliberate JJ JJ O
hypotension NN NN O
( ( ( O
20 CD CD O
% NN NN O
and CC CC O
40 CD CD O
% NN NN O
mean VB VB O
pressure NN NN O
decrease VB VB O
from IN IN O
baseline NN NN O
) ) ) O
. . . O

Regarding VBG VBG O
the DT DT O
effects NNS NNS O
of IN IN O
drug NN NN O
- - - O
induced JJ JJ O
hypotension NN NN O
on IN IN O
coronary JJ JJ O
blood NN NN O
flow NN NN O
, , , O
aortic JJ JJ O
and CC CC O
coronary JJ JJ O
sinus NNS NNS O
metabolic JJ JJ O
data NNS NNS O
( ( ( O
pH NN NN O
, , , O
pO2 NN NN O
, , , O
pCO2 NN NN O
) ) ) O
we PRP PRP O
could MD MD O
confirm VB VB O
that IN IN O
nitroprusside NN NN B-CHEM
hypotension NN NN O
could MD MD O
be VB VB O
safely RB RB O
used VBN VBN O
to TO TO O
30 CD CD O
% NN NN O
mean NN NN O
blood NN NN O
pressure NN NN O
decrease NN NN O
from IN IN O
control NN NN O
, , , O
trimetaphan JJ JJ B-CHEM
hypotension NN NN O
to TO TO O
20 CD CD O
% NN NN O
mean NN NN O
blood NN NN O
pressure NN NN O
decrease NN NN O
. . . O

Cardiac NNP NNP O
work NN NN O
was VBD VBD O
significantly RB RB O
reduced VBN VBN O
during IN IN O
SNP NNP NNP B-CHEM
hypotension NN NN O
. . . O

Myocardial NNP NNP O
O2 NNP NNP B-CHEM
consumption NN NN O
and CC CC O
O2 NNP NNP B-CHEM
availability NN NN O
were VBD VBD O
directly RB RB O
dependent JJ JJ O
on IN IN O
the DT DT O
coronary JJ JJ O
perfusion NN NN O
. . . O

Careful NNP NNP O
invasive JJ JJ O
monitoring NN NN O
of IN IN O
the DT DT O
blood NN NN O
pressure NN NN O
, , , O
blood NN NN O
gases NNS NNS O
and CC CC O
of IN IN O
the DT DT O
ECG NNP NNP O
ST NNP NNP O
- : : O
T NN NN O
segment NN NN O
is VBZ VBZ O
mandatory JJ JJ O
. . . O

Evidence NN NN O
for IN IN O
a DT DT O
selective JJ JJ O
brain NN NN O
noradrenergic JJ JJ O
involvement NN NN O
in IN IN O
the DT DT O
locomotor NN NN O
stimulant JJ JJ O
effects NNS NNS O
of IN IN O
amphetamine NN NN B-CHEM
in IN IN O
the DT DT O
rat NN NN O
. . . O

Male NNP NNP O
rats NNS NNS O
received VBD VBD O
the DT DT O
noradrenaline NN NN B-CHEM
neurotoxin NN NN O
DSP4 NNP NNP B-CHEM
( ( ( O
50 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
7 CD CD O
days NNS NNS O
prior RB RB O
to TO TO O
injection NN NN O
of IN IN O
D NNP NNP B-CHEM
- : : I-CHEM
amphetamine NN NN I-CHEM
( ( ( O
10 CD CD O
or CC CC O
40 CD CD O
mumol NN NN O
/ NN NN O
kg NN NN O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
. . . O

The DT DT O
hyperactivity NN NN O
induced VBN VBN O
by IN IN O
D NNP NNP B-CHEM
- : : I-CHEM
amphetamine NN NN I-CHEM
( ( ( O
10 CD CD O
mumol NN NN O
/ NN NN O
kg NN NN O
) ) ) O
was VBD VBD O
significantly RB RB O
reduced VBN VBN O
by IN IN O
DSP4 NNP NNP B-CHEM
pretreatment NN NN O
. . . O

However RB RB O
, , , O
the DT DT O
increased JJ JJ O
rearings NNS NNS O
and CC CC O
the DT DT O
amphetamine NN NN B-CHEM
- - - O
induced JJ JJ O
stereotypies NNS NNS O
were VBD VBD O
not RB RB O
blocked VBN VBN O
by IN IN O
pretreatment NN NN O
with IN IN O
DSP4 NNP NNP B-CHEM
. . . O

The DT DT O
reduction NN NN O
of IN IN O
amphetamine NN NN B-CHEM
hyperactivity NN NN O
induced VBN VBN O
by IN IN O
DSP4 NNP NNP B-CHEM
was VBD VBD O
blocked VBN VBN O
by IN IN O
pretreatment NN NN O
with IN IN O
the DT DT O
noradrenaline NN NN B-CHEM
- - - O
uptake JJ JJ O
blocking NN NN O
agent NN NN O
, , , O
desipramine NN NN B-CHEM
, , , O
which WDT WDT O
prevents VBZ VBZ O
the DT DT O
neurotoxic JJ JJ O
action NN NN O
of IN IN O
DSP4 NNP NNP B-CHEM
. . . O

The DT DT O
present NN NN O
results NNS NNS O
suggest VBP VBP O
a DT DT O
selective JJ JJ O
involvement NN NN O
of IN IN O
central JJ JJ O
noradrenergic JJ JJ O
neurones NNS NNS O
in IN IN O
the DT DT O
locomotor NN NN O
stimulant JJ JJ O
effect NN NN O
of IN IN O
amphetamine NN NN B-CHEM
in IN IN O
the DT DT O
rat NN NN O
. . . O

Accelerated NNP NNP O
junctional JJ JJ O
rhythms NNS NNS O
during IN IN O
oral JJ JJ O
verapamil NN NN B-CHEM
therapy NN NN O
. . . O

This DT DT O
study NN NN O
examined VBD VBD O
the DT DT O
frequency NN NN O
of IN IN O
atrioventricular NN NN O
( ( ( O
AV NNP NNP O
) ) ) O
dissociation NN NN O
and CC CC O
accelerated VBD VBD O
junctional JJ JJ O
rhythms NNS NNS O
in IN IN O
59 CD CD O
patients NNS NNS O
receiving VBG VBG O
oral JJ JJ O
verapamil NN NN B-CHEM
. . . O

Accelerated NNP NNP O
junctional JJ JJ O
rhythms NNS NNS O
and CC CC O
AV NNP NNP O
dissociation NN NN O
were VBD VBD O
frequent JJ JJ O
in IN IN O
patients NNS NNS O
with IN IN O
supraventricular JJ JJ O
tachyarrhythmias NNS NNS O
, , , O
particularly RB RB O
AV NNP NNP O
nodal NN NN O
reentry NN NN O
. . . O

Verapamil NNP NNP B-CHEM
administration NN NN O
to TO TO O
these DT DT O
patients NNS NNS O
led VBN VBN O
to TO TO O
an DT DT O
asymptomatic JJ JJ O
increase NN NN O
in IN IN O
activity NN NN O
of IN IN O
these DT DT O
junctional JJ JJ O
pacemakers NNS NNS O
. . . O

In IN IN O
patients NNS NNS O
with IN IN O
various JJ JJ O
chest NN NN O
pain NN NN O
syndromes NNS NNS O
, , , O
verapamil NN NN B-CHEM
neither DT DT O
increased VBN VBN O
the DT DT O
frequency NN NN O
of IN IN O
junctional JJ JJ O
rhythms NNS NNS O
nor CC CC O
suppressed VBD VBD O
their PRP$ PRP$ O
role NN NN O
as IN IN O
escape NN NN O
rhythms NNS NNS O
under IN IN O
physiologically RB RB O
appropriate JJ JJ O
circumstances NNS NNS O
. . . O

Interstrain NNP NNP O
variation NN NN O
in IN IN O
acute JJ JJ O
toxic JJ JJ O
response NN NN O
to TO TO O
caffeine NN NN B-CHEM
among IN IN O
inbred JJ JJ O
mice NNS NNS O
. . . O

Acute JJ JJ O
toxic JJ JJ O
dosage NN NN O
- - - O
dependent JJ JJ O
behavioral JJ JJ O
effects NNS NNS O
of IN IN O
caffeine NN NN B-CHEM
were VBD VBD O
compared VBN VBN O
in IN IN O
adult NN NN O
males NNS NNS O
from IN IN O
seven CD CD O
inbred JJ JJ O
mouse NN NN O
strains NNS NNS O
( ( ( O
A DT DT O
/ NN NN O
J NNP NNP O
, , , O
BALB NNP NNP O
/ NN NN O
cJ NN NN O
, , , O
CBA NNP NNP O
/ NN NN O
J NNP NNP O
, , , O
C3H NNP NNP O
/ NN NN O
HeJ NNP NNP O
, , , O
C57BL NNP NNP O
/ NN NN O
6J CD CD O
, , , O
DBA NNP NNP O
/ NN NN O
2J CD CD O
, , , O
SWR NNP NNP O
/ NN NN O
J NNP NNP O
) ) ) O
. . . O

C57BL NNP NNP O
/ NN NN O
6J CD CD O
, , , O
chosen NN NN O
as IN IN O
a DT DT O
" '' '' O
prototypic NN NN O
" '' '' O
mouse NN NN O
strain NN NN O
, , , O
was VBD VBD O
used VBN VBN O
to TO TO O
determine VB VB O
behavioral JJ JJ O
responses NNS NNS O
to TO TO O
a DT DT O
broad JJ JJ O
range NN NN O
( ( ( O
5 CD CD O
- : : O
500 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
of IN IN O
caffeine NN NN B-CHEM
doses NNS NNS O
. . . O

Five CD CD O
phenotypic JJ JJ O
characteristics NNS NNS O
- - - O
- - - O
locomotor NN NN O
activity NN NN O
, , , O
righting VBG VBG O
ability NN NN O
, , , O
clonic JJ JJ O
seizure NN NN O
induction NN NN O
, , , O
stress NN NN O
- - - O
induced JJ JJ O
lethality NN NN O
, , , O
death NN NN O
without IN IN O
external JJ JJ O
stress NN NN O
- - - O
- - - O
were VBD VBD O
scored VBN VBN O
at IN IN O
various JJ JJ O
caffeine NN NN B-CHEM
doses NNS NNS O
in IN IN O
drug NN NN O
- - - O
naive JJ JJ O
animals NNS NNS O
under IN IN O
empirically RB RB O
optimized JJ JJ O
, , , O
rigidly RB RB O
constant JJ JJ O
experimental JJ JJ O
conditions NNS NNS O
. . . O

Mice NNP NNP O
( ( ( O
n NN NN O
= SYM SYM O
12 CD CD O
for IN IN O
each DT DT O
point NN NN O
) ) ) O
received VBD VBD O
single JJ JJ O
IP NNP NNP O
injections NNS NNS O
of IN IN O
a DT DT O
fixed JJ JJ O
volume NN NN O
/ NN NN O
g SYM SYM O
body NN NN O
weight NN NN O
of IN IN O
physiological JJ JJ O
saline NN NN O
carrier NN NN O
with IN IN O
or CC CC O
without IN IN O
caffeine NN NN B-CHEM
in IN IN O
doses NNS NNS O
ranging VBG VBG O
from IN IN O
125 CD CD O
- : : O
500 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
. . . O

Loss NN NN O
of IN IN O
righting VBG VBG O
ability NN NN O
was VBD VBD O
scored VBN VBN O
at IN IN O
1 CD CD O
, , , O
3 CD CD O
, , , O
5 CD CD O
min NN NN O
post NN NN O
dosing NN NN O
and CC CC O
at IN IN O
5 CD CD O
min NN NN O
intervals NNS NNS O
thereafter RB RB O
for IN IN O
20 CD CD O
min NN NN O
. . . O

In IN IN O
the DT DT O
same JJ JJ O
animals NNS NNS O
the DT DT O
occurrence NN NN O
of IN IN O
clonic JJ JJ O
seizures NNS NNS O
was VBD VBD O
scored VBN VBN O
as IN IN O
to TO TO O
time NN NN O
of IN IN O
onset NN NN O
and CC CC O
severity NN NN O
for IN IN O
20 CD CD O
min NN NN O
after IN IN O
drug NN NN O
administration NN NN O
. . . O

When WRB WRB O
these DT DT O
proceeded VBD VBD O
to TO TO O
tonic JJ JJ O
seizures NNS NNS O
, , , O
death NN NN O
occurred VBD VBD O
in IN IN O
less JJR JJR O
than IN IN O
20 CD CD O
min NN NN O
. . . O

Animals NNS NNS O
surviving VBG VBG O
for IN IN O
20 CD CD O
min NN NN O
were VBD VBD O
immediately RB RB O
stressed VBN VBN O
by IN IN O
a DT DT O
swim VBP VBP O
test NN NN O
in IN IN O
25 CD CD O
degrees NNS NNS O
C NNP NNP O
water NN NN O
, , , O
and CC CC O
death NN NN O
- - - O
producing VBG VBG O
tonic JJ JJ O
seizures NNS NNS O
were VBD VBD O
scored VBN VBN O
for IN IN O
2 CD CD O
min NN NN O
. . . O

In IN IN O
other JJ JJ O
animals NNS NNS O
locomotor NN NN O
activity NN NN O
was VBD VBD O
measured VBN VBN O
15 CD CD O
or CC CC O
60 CD CD O
min NN NN O
after IN IN O
caffeine NN NN B-CHEM
administration NN NN O
. . . O

By IN IN O
any DT DT O
single JJ JJ O
behavioral JJ JJ O
criterion NN NN O
or CC CC O
a DT DT O
combination NN NN O
of IN IN O
these DT DT O
criteria NNS NNS O
, , , O
marked VBN VBN O
differences NNS NNS O
in IN IN O
response NN NN O
to TO TO O
toxic JJ JJ O
caffeine NN NN B-CHEM
doses NNS NNS O
were VBD VBD O
observed VBN VBN O
between IN IN O
strains NNS NNS O
. . . O

These DT DT O
results NNS NNS O
indicate VBP VBP O
that IN IN O
behavioral JJ JJ O
toxicity NN NN O
testing NN NN O
of IN IN O
alkylxanthines NNS NNS B-CHEM
in IN IN O
a DT DT O
single JJ JJ O
mouse NN NN O
strain NN NN O
may MD MD O
be VB VB O
misleading JJ JJ O
and CC CC O
suggest VB VB O
that IN IN O
toxic JJ JJ O
responses NNS NNS O
of IN IN O
the DT DT O
central JJ JJ O
nervous JJ JJ O
system NN NN O
to TO TO O
this DT DT O
class NN NN O
of IN IN O
compounds NNS NNS O
are VBP VBP O
genetically RB RB O
influenced VBN VBN O
in IN IN O
mammals NNS NNS O
. . . O

Treatment NN NN O
of IN IN O
ovarian JJ JJ O
cancer NN NN O
with IN IN O
a DT DT O
combination NN NN O
of IN IN O
cis NN NN B-CHEM
- - - I-CHEM
platinum NN NN I-CHEM
, , , O
adriamycin NN NN B-CHEM
, , , O
cyclophosphamide NN NN B-CHEM
and CC CC O
hexamethylmelamine NN NN B-CHEM
. . . O

During IN IN O
the DT DT O
last JJ JJ O
2 CD CD O
1 CD CD O
/ NN NN O
2 CD CD O
years NNS NNS O
, , , O
38 CD CD O
patients NNS NNS O
with IN IN O
ovarian JJ JJ O
cancer NN NN O
were VBD VBD O
treated VBN VBN O
with IN IN O
a DT DT O
combination NN NN O
of IN IN O
cisplatinum NN NN B-CHEM
( ( ( O
CPDD NNP NNP B-CHEM
) ) ) O
, , , O
50 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
, , , O
adriamycin NN NN B-CHEM
, , , O
30 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
, , , O
cyclophosphamide NN NN B-CHEM
, , , O
300 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
, , , O
on IN IN O
day NN NN O
1 CD CD O
; : : O
and CC CC O
hexamethylmelamine NN NN B-CHEM
( ( ( O
HMM NNP NNP B-CHEM
) ) ) O
, , , O
6 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
daily JJ JJ O
, , , O
for IN IN O
14 CD CD O
days NNS NNS O
. . . O

Each DT DT O
course NN NN O
was VBD VBD O
repeated VBN VBN O
monthly RB RB O
. . . O

2 CD CD O
patients NNS NNS O
had VBD VBD O
stage NN NN O
II NNP NNP O
, , , O
14 CD CD O
stage NN NN O
III NNP NNP O
and CC CC O
22 CD CD O
stage NN NN O
IV NNP NNP O
disease NN NN O
. . . O

14 CD CD O
of IN IN O
the DT DT O
38 CD CD O
patients NNS NNS O
were VBD VBD O
previously RB RB O
treated VBN VBN O
with IN IN O
chemotherapy NN NN O
, , , O
1 CD CD O
with IN IN O
radiation NN NN O
, , , O
6 CD CD O
with IN IN O
both DT DT O
chemotherapy NN NN O
and CC CC O
radiation NN NN O
, , , O
and CC CC O
17 CD CD O
did VBD VBD O
not RB RB O
have VB VB O
any DT DT O
treatment NN NN O
before IN IN O
CPDD NNP NNP B-CHEM
combination NN NN O
. . . O

31 CD CD O
of IN IN O
the DT DT O
38 CD CD O
cases NNS NNS O
( ( ( O
81 CD CD O
. . . O
5 CD CD O
% NN NN O
) ) ) O
demonstrated VBD VBD O
objective NN NN O
responses NNS NNS O
lasting VBG VBG O
for IN IN O
2 CD CD O
months NNS NNS O
or CC CC O
more JJR JJR O
. . . O

These DT DT O
responses NNS NNS O
were VBD VBD O
partial JJ JJ O
in IN IN O
19 CD CD O
and CC CC O
complete VB VB O
in IN IN O
12 CD CD O
cases NNS NNS O
. . . O

Hematologic NNP NNP O
toxicity NN NN O
was VBD VBD O
moderate JJ JJ O
and CC CC O
with IN IN O
reversible JJ JJ O
anemia NN NN O
developing VBG VBG O
in IN IN O
71 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
. . . O

Gastrointestinal NNP NNP O
side NN NN O
effects NNS NNS O
from IN IN O
CPDD NNP NNP B-CHEM
were VBD VBD O
universal JJ JJ O
. . . O

HMM NNP NNP B-CHEM
gastrointestinal JJ JJ O
toxicity NN NN O
necessitated JJ JJ O
discontinuation NN NN O
of IN IN O
the DT DT O
drug NN NN O
in IN IN O
5 CD CD O
patients NNS NNS O
. . . O

Severe NNP NNP O
nephrotoxicity NN NN O
was VBD VBD O
observed VBN VBN O
in IN IN O
2 CD CD O
patients NNS NNS O
but CC CC O
was VBD VBD O
reversible JJ JJ O
. . . O

There EX EX O
were VBD VBD O
no DT DT O
drug NN NN O
- - - O
related VBN VBN O
deaths NNS NNS O
. . . O

Nontraumatic NNP NNP O
dissecting VBG VBG O
aneurysm NN NN O
of IN IN O
the DT DT O
basilar NN NN O
artery NN NN O
. . . O

A DT DT O
case NN NN O
of IN IN O
nontraumatic JJ JJ O
dissecting NN NN O
aneurysm NN NN O
of IN IN O
the DT DT O
basilar NN NN O
artery NN NN O
in IN IN O
association NN NN O
with IN IN O
hypertension NN NN O
, , , O
smoke NN NN O
, , , O
and CC CC O
oral JJ JJ B-CHEM
contraceptives NNS NNS I-CHEM
is VBZ VBZ O
reported VBN VBN O
in IN IN O
a DT DT O
young JJ JJ O
female JJ JJ O
patient NN NN O
with IN IN O
a DT DT O
locked JJ JJ O
- - - O
in IN IN O
syndrome NN NN O
. . . O

A DT DT O
method NN NN O
for IN IN O
the DT DT O
measurement NN NN O
of IN IN O
tremor NN NN O
, , , O
and CC CC O
a DT DT O
comparison NN NN O
of IN IN O
the DT DT O
effects NNS NNS O
of IN IN O
tocolytic JJ JJ O
beta NN NN O
- - - O
mimetics NNS NNS O
. . . O

A DT DT O
method NN NN O
permitting VBG VBG O
measurement NN NN O
of IN IN O
finger NN NN O
tremor NN NN O
as IN IN O
a DT DT O
displacement NN NN O
- - - O
time NN NN O
curve NN NN O
is VBZ VBZ O
described VBN VBN O
, , , O
using VBG VBG O
a DT DT O
test NN NN O
system NN NN O
with IN IN O
simple JJ JJ O
amplitude NN NN O
calibration NN NN O
. . . O

The DT DT O
coordinates NNS NNS O
of IN IN O
the DT DT O
inversion NN NN O
points NNS NNS O
of IN IN O
the DT DT O
displacement NN NN O
- - - O
time NN NN O
curves NNS NNS O
were VBD VBD O
transferred VBN VBN O
through IN IN O
graphical JJ JJ O
input NN NN O
equipment NN NN O
to TO TO O
punched VB VB O
tape NN NN O
. . . O

By IN IN O
means NNS NNS O
of IN IN O
a DT DT O
computer NN NN O
program NN NN O
, , , O
periods NNS NNS O
and CC CC O
amplitudes NNS NNS O
of IN IN O
tremor NN NN O
oscillations NNS NNS O
were VBD VBD O
calculated VBN VBN O
and CC CC O
classified VBN VBN O
. . . O

The DT DT O
event NN NN O
frequency NN NN O
for IN IN O
each DT DT O
class NN NN O
of IN IN O
periods NNS NNS O
and CC CC O
amplitudes NNS NNS O
was VBD VBD O
determined VBN VBN O
. . . O

The DT DT O
actions NNS NNS O
of IN IN O
fenoterol NN NN B-CHEM
- - - I-CHEM
hydrobromide NN NN I-CHEM
, , , O
ritodrin NN NN B-CHEM
- - - I-CHEM
HCl NNP NNP I-CHEM
and CC CC O
placebo NN NN O
given VBN VBN O
to TO TO O
10 CD CD O
healthy JJ JJ O
subjects NNS NNS O
by IN IN O
intravenous JJ JJ O
infusion NN NN O
in IN IN O
a DT DT O
double JJ JJ O
- - - O
blind JJ JJ O
crossover NN NN O
study NN NN O
were VBD VBD O
tested VBN VBN O
by IN IN O
this DT DT O
method NN NN O
. . . O

At IN IN O
therapeutic JJ JJ O
doses NNS NNS O
both DT DT O
substances NNS NNS O
raised VBD VBD O
the DT DT O
mean NN NN O
tremor NN NN O
amplitude NN NN O
to TO TO O
about IN IN O
three CD CD O
times NNS NNS O
the DT DT O
control NN NN O
level NN NN O
. . . O

At IN IN O
the DT DT O
same JJ JJ O
time NN NN O
, , , O
the DT DT O
mean NN NN O
period NN NN O
within IN IN O
each DT DT O
class NN NN O
of IN IN O
amplitudes NNS NNS O
shortened VBN VBN O
by IN IN O
10 CD CD O
- : : O
- : : O
20 CD CD O
ms NN NN O
, , , O
whereas IN IN O
the DT DT O
mean NN NN O
periods NNS NNS O
calculated VBN VBN O
from IN IN O
all DT DT O
oscillations NNS NNS O
together RB RB O
did VBD VBD O
not RB RB O
change VB VB O
significantly RB RB O
. . . O

After IN IN O
the DT DT O
end NN NN O
of IN IN O
fenoterol NN NN B-CHEM
- - - I-CHEM
hydrobromide NN NN I-CHEM
infusion NN NN O
, , , O
tremor NN NN O
amplitudes NNS NNS O
decreased VBN VBN O
significantly RB RB O
faster RBR RBR O
than IN IN O
those DT DT O
following VBG VBG O
ritodrin NN NN B-CHEM
- - - I-CHEM
HCl NNP NNP I-CHEM
infusion NN NN O
. . . O

Propylthiouracil NNP NNP B-CHEM
- : : O
induced JJ JJ O
hepatic JJ JJ O
damage NN NN O
. . . O

Two CD CD O
cases NNS NNS O
of IN IN O
propylthiouracil NN NN B-CHEM
- - - O
induced JJ JJ O
liver NN NN O
damage NN NN O
have VBP VBP O
been VBN VBN O
observed VBN VBN O
. . . O

The DT DT O
first JJ JJ O
case NN NN O
is VBZ VBZ O
of IN IN O
an DT DT O
acute JJ JJ O
type NN NN O
of IN IN O
damage NN NN O
, , , O
proven VBN VBN O
by IN IN O
rechallenge NN NN O
; : : O
the DT DT O
second JJ JJ O
presents VBZ VBZ O
a DT DT O
clinical JJ JJ O
and CC CC O
histologic JJ JJ O
picture NN NN O
resembling VBG VBG O
chronic JJ JJ O
active JJ JJ O
hepatitis NN NN O
, , , O
with IN IN O
spontaneous JJ JJ O
remission NN NN O
. . . O

Studies NNS NNS O
on IN IN O
the DT DT O
bradycardia NN NN O
induced VBN VBN O
by IN IN O
bepridil NN NN B-CHEM
. . . O

Bepridil NNP NNP B-CHEM
, , , O
a DT DT O
novel NN NN O
active JJ JJ O
compound NN NN O
for IN IN O
prophylactic JJ JJ O
treatment NN NN O
of IN IN O
anginal JJ JJ O
attacks NNS NNS O
, , , O
induced JJ JJ O
persistent JJ JJ O
bradycardia NNS NNS O
and CC CC O
a DT DT O
non NN NN O
- - - O
specific JJ JJ O
anti NN NN O
- : : O
tachycardial JJ JJ O
effect NN NN O
, , , O
the DT DT O
mechanisms NNS NNS O
of IN IN O
which WDT WDT O
were VBD VBD O
investigated VBN VBN O
in IN IN O
vitro NN NN O
and CC CC O
in IN IN O
vivo NN NN O
. . . O

In IN IN O
vitro NN NN O
perfusion NN NN O
of IN IN O
bepridil NN NN B-CHEM
in IN IN O
the DT DT O
life NN NN O
- - - O
support NN NN O
medium NN NN O
for IN IN O
isolated VBN VBN O
sino NN NN O
- - - O
atrial JJ JJ O
tissue NN NN O
from IN IN O
rabbit NN NN O
heart NN NN O
, , , O
caused VBD VBD O
a DT DT O
reduction NN NN O
in IN IN O
action NN NN O
potential JJ JJ O
( ( ( O
AP NNP NNP O
) ) ) O
spike NN NN O
frequency NN NN O
( ( ( O
recorded VBN VBN O
by IN IN O
KCl NNP NNP B-CHEM
microelectrodes NNS NNS O
) ) ) O
starting VBG VBG O
at IN IN O
doses NNS NNS O
of IN IN O
5 CD CD O
X NNP NNP O
10 CD CD O
( ( ( O
- : : O
6 CD CD O
) ) ) O
M NNP NNP O
. . . O

This DT DT O
effect NN NN O
was VBD VBD O
dose JJ JJ O
- : : O
dependent JJ JJ O
up RB RB O
to TO TO O
concentrations NNS NNS O
of IN IN O
5 CD CD O
X NNP NNP O
10 CD CD O
( ( ( O
- : : O
5 CD CD O
) ) ) O
M NNP NNP O
, , , O
whereupon JJ JJ O
blockade NN NN O
of IN IN O
sinus NN NN O
activity NN NN O
set VBN VBN O
in IN IN O
. . . O

Bepridil NNP NNP B-CHEM
at IN IN O
a DT DT O
dose NN NN O
of IN IN O
5 CD CD O
X NNP NNP O
10 CD CD O
( ( ( O
- : : O
6 CD CD O
) ) ) O
M NNP NNP O
, , , O
induced VBD VBD O
a DT DT O
concomitant JJ JJ O
reduction NN NN O
in IN IN O
AP NNP NNP O
amplitude NN NN O
( ( ( O
falling VBG VBG O
from IN IN O
71 CD CD O
+ NN NN O
/ NN NN O
- : : O
8 CD CD O
mV NN NN O
to TO TO O
47 CD CD O
+ NN NN O
/ NN NN O
- : : O
6 CD CD O
mV NN NN O
) ) ) O
, , , O
maximum NN NN O
systolic JJ JJ O
depolarization NN NN O
velocity NN NN O
( ( ( O
phase NN NN O
0 CD CD O
) ) ) O
which WDT WDT O
fell VBD VBD O
from IN IN O
1 CD CD O
. . . O
85 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
35 CD CD O
V NNP NNP O
/ NN NN O
s VBZ VBZ O
to TO TO O
0 CD CD O
. . . O
84 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
28 CD CD O
V NNP NNP O
/ NN NN O
s VBZ VBZ O
, , , O
together RB RB O
with IN IN O
maximum NN NN O
diastolic JJ JJ O
depolarization NN NN O
velocity NN NN O
( ( ( O
phase NN NN O
4 CD CD O
) ) ) O
which WDT WDT O
fell VBD VBD O
from IN IN O
38 CD CD O
+ NN NN O
/ NN NN O
- : : O
3 CD CD O
mV NN NN O
/ NN NN O
s VBZ VBZ O
to TO TO O
24 CD CD O
+ NN NN O
/ NN NN O
- : : O
5 CD CD O
mV NN NN O
/ NN NN O
s VBZ VBZ O
. . . O

In IN IN O
vivo NN NN O
injection NN NN O
of IN IN O
bepridil NN NN B-CHEM
at IN IN O
a DT DT O
dose NN NN O
of IN IN O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
( ( ( O
i NNP NNP O
. . . O
v NN NN O
. . . O
) ) ) O
into IN IN O
6 CD CD O
anaesthetized VBD VBD O
dogs NNS NNS O
which WDT WDT O
had VBD VBD O
undergone JJ JJ O
ablation NN NN O
of IN IN O
all PDT PDT O
the DT DT O
extrinsic JJ JJ O
cardiac NN NN O
afferent NN NN O
nerve NN NN O
supply NN NN O
, , , O
together RB RB O
with IN IN O
a DT DT O
bilateral JJ JJ O
medullo NN NN O
- - - O
adrenalectomy NN NN O
, , , O
caused VBD VBD O
a DT DT O
marked JJ JJ O
reduction NN NN O
in IN IN O
heart NN NN O
rate NN NN O
which WDT WDT O
fell VBD VBD O
from IN IN O
98 CD CD O
. . . O
7 CD CD O
+ NN NN O
/ NN NN O
- : : O
4 CD CD O
. . . O
2 CD CD O
beats NNS NNS O
/ NN NN O
min NN NN O
to TO TO O
76 CD CD O
+ NN NN O
/ NN NN O
- : : O
5 CD CD O
. . . O
3 CD CD O
beats NNS NNS O
/ NN NN O
min NN NN O
sustained VBN VBN O
for IN IN O
more JJR JJR O
than IN IN O
45 CD CD O
min NN NN O
. . . O

It PRP PRP O
is VBZ VBZ O
concluded VBN VBN O
that IN IN O
bepridil NN NN B-CHEM
reduces VBZ VBZ O
heart NN NN O
rate NN NN O
by IN IN O
acting VBG VBG O
directly RB RB O
on IN IN O
the DT DT O
sinus NN NN O
node NN NN O
. . . O

This DT DT O
effect NN NN O
, , , O
which WDT WDT O
results NNS NNS O
in IN IN O
a DT DT O
flattening NN NN O
of IN IN O
the DT DT O
phase NN NN O
0 CD CD O
and CC CC O
phase NN NN O
4 CD CD O
slope NN NN O
, , , O
together RB RB O
with IN IN O
a DT DT O
longer RB RB O
AP NNP NNP O
duration NN NN O
, , , O
may MD MD O
be VB VB O
due JJ JJ O
to TO TO O
an DT DT O
increase NN NN O
in IN IN O
the DT DT O
time NN NN O
constants NNS NNS O
of IN IN O
slow JJ JJ O
inward NN NN O
ionic JJ JJ O
currents NNS NNS O
( ( ( O
already RB RB O
demonstrated VBN VBN O
elsewhere RB RB O
) ) ) O
, , , O
but CC CC O
also RB RB O
to TO TO O
an DT DT O
increased JJ JJ O
time NN NN O
constant JJ JJ O
for IN IN O
deactivation NN NN O
of IN IN O
the DT DT O
outward JJ JJ O
potassium NN NN B-CHEM
current JJ JJ O
( ( ( O
Ip NNP NNP O
) ) ) O
. . . O

Hepatitis NNP NNP O
and CC CC O
renal JJ JJ O
tubular NN NN O
acidosis NN NN O
after IN IN O
anesthesia NN NN O
with IN IN O
methoxyflurane NN NN B-CHEM
. . . O

A DT DT O
69 NN NN O
- - - O
year NN NN O
- - - O
old JJ JJ O
man NN NN O
operated VBN VBN O
for IN IN O
acute JJ JJ O
cholecystitis NNS NNS O
under IN IN O
methoxyflurane NN NN B-CHEM
anesthesia NN NN O
developed VBN VBN O
postoperatively RB RB O
a DT DT O
hepatic JJ JJ O
insufficiency NN NN O
syndrome NN NN O
and CC CC O
renal JJ JJ O
tubular NN NN O
acidosis NN NN O
. . . O

Massive JJ JJ O
bleeding NN NN O
appeared VBD VBD O
during IN IN O
surgery NN NN O
which WDT WDT O
lasted VBD VBD O
for IN IN O
six CD CD O
hours NNS NNS O
. . . O

Postoperative NNP NNP O
evolution NN NN O
under IN IN O
supportive JJ JJ O
therapy NN NN O
was VBD VBD O
favourable JJ JJ O
. . . O

Complete JJ JJ O
recovery NN NN O
was VBD VBD O
confirmed VBN VBN O
by IN IN O
repeated VBN VBN O
controls NNS NNS O
performed VBN VBN O
over IN IN O
a DT DT O
period NN NN O
of IN IN O
one CD CD O
year NN NN O
after IN IN O
surgery NN NN O
. . . O

Pituitary NNP NNP O
response NN NN O
to TO TO O
luteinizing VBG VBG O
hormone NN NN O
- - - O
releasing VBG VBG O
hormone NN NN O
during IN IN O
haloperidol NN NN B-CHEM
- - - O
induced JJ JJ O
hyperprolactinemia NN NN O
. . . O

The DT DT O
effects NNS NNS O
of IN IN O
a DT DT O
6 CD CD O
- : : O
hour NN NN O
infusion NN NN O
with IN IN O
haloperidol NN NN B-CHEM
on IN IN O
serum NN NN O
prolactin NN NN O
and CC CC O
luteinizing VBG VBG O
hormone NN NN O
( ( ( O
LH NNP NNP O
) ) ) O
levels NNS NNS O
was VBD VBD O
studied VBN VBN O
in IN IN O
a DT DT O
group NN NN O
of IN IN O
male JJ JJ O
subjects NNS NNS O
. . . O

Five CD CD O
hours NNS NNS O
after IN IN O
starting VBG VBG O
the DT DT O
infusions NNS NNS O
, , , O
a DT DT O
study NN NN O
of IN IN O
the DT DT O
pituitary JJ JJ O
responses NNS NNS O
to TO TO O
LH NNP NNP O
- : : O
releasing VBG VBG O
hormone NN NN O
( ( ( O
LH NNP NNP O
- - - O
RH NNP NNP O
) ) ) O
was VBD VBD O
carried VBN VBN O
out IN IN O
. . . O

Control NNP NNP O
patients NNS NNS O
received VBD VBD O
infusions NNS NNS O
of IN IN O
0 CD CD O
. . . O
9 CD CD O
% NN NN O
NaCl NNP NNP B-CHEM
solution NN NN O
. . . O

During IN IN O
the DT DT O
course NN NN O
of IN IN O
haloperidol NN NN B-CHEM
infusions NNS NNS O
, , , O
significant JJ JJ O
hyperprolactinemia NN NN O
was VBD VBD O
found VBN VBN O
, , , O
together RB RB O
with IN IN O
an DT DT O
abolished JJ JJ O
pituitary JJ JJ O
response NN NN O
to TO TO O
LH NNP NNP O
- : : O
RH NNP NNP O
, , , O
as IN IN O
compared VBN VBN O
with IN IN O
responses NNS NNS O
of IN IN O
control NN NN O
subjects NNS NNS O
. . . O

Antirifampicin NNP NNP O
antibodies NNS NNS O
in IN IN O
acute JJ JJ O
rifampicin NN NN B-CHEM
- - - O
associated VBN VBN O
renal JJ JJ O
failure NN NN O
. . . O

5 CD CD O
patients NNS NNS O
with IN IN O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
( ( ( O
3 CD CD O
with IN IN O
thrombopenia NN NN O
and CC CC O
hemolysis NN NN O
) ) ) O
induced VBN VBN O
by IN IN O
the DT DT O
reintroduction NN NN O
of IN IN O
rifampicin NN NN B-CHEM
are VBP VBP O
described VBN VBN O
. . . O

No DT DT O
correlation NN NN O
was VBD VBD O
found VBN VBN O
between IN IN O
the DT DT O
severity NN NN O
of IN IN O
clinical JJ JJ O
manifestations NNS NNS O
and CC CC O
the DT DT O
total NN NN O
dose NN NN O
taken VBN VBN O
by IN IN O
the DT DT O
patients NNS NNS O
. . . O

In IN IN O
all DT DT O
but CC CC O
1 CD CD O
patient NN NN O
, , , O
antirifampicin NN NN O
antibodies NNS NNS O
were VBD VBD O
detected VBN VBN O
. . . O

Antibodies NNP NNP O
suggested VBD VBD O
to TO TO O
be VB VB O
of IN IN O
the DT DT O
IgM NNP NNP O
class NN NN O
were VBD VBD O
detected VBN VBN O
in IN IN O
all DT DT O
3 CD CD O
patients NNS NNS O
with IN IN O
hematological JJ JJ O
disorders NNS NNS O
. . . O

The DT DT O
pattern NN NN O
of IN IN O
non NN NN O
- - - O
specific JJ JJ O
acute JJ JJ O
tubular JJ JJ O
necrosis NN NN O
found VBD VBD O
in IN IN O
the DT DT O
2 CD CD O
biopsied VBN VBN O
patients NNS NNS O
, , , O
indistinguishable JJ JJ O
from IN IN O
that DT DT O
of IN IN O
ischemic JJ JJ O
origin NN NN O
, , , O
raised VBD VBD O
the DT DT O
possibility NN NN O
of IN IN O
a DT DT O
vascular NN NN O
- - - O
mediated JJ JJ O
damage NN NN O
. . . O

In IN IN O
3 CD CD O
patients NNS NNS O
, , , O
the DT DT O
possibility NN NN O
of IN IN O
a DT DT O
triggering VBG VBG O
immunoallergic JJ JJ O
mechanism NN NN O
is VBZ VBZ O
discussed VBN VBN O
. . . O

Cardiovascular NNP NNP O
effects NNS NNS O
of IN IN O
hypotension NN NN O
induced VBN VBN O
by IN IN O
adenosine NN NN B-CHEM
triphosphate NN NN I-CHEM
and CC CC O
sodium NN NN B-CHEM
nitroprusside NN NN I-CHEM
on IN IN O
dogs NNS NNS O
with IN IN O
denervated JJ JJ O
hearts NNS NNS O
. . . O

Adenosine NNP NNP B-CHEM
triphosphate NN NN I-CHEM
( ( ( O
ATP NNP NNP B-CHEM
) ) ) O
and CC CC O
sodium NN NN B-CHEM
nitroprusside NN NN I-CHEM
( ( ( O
SNP NNP NNP B-CHEM
) ) ) O
are VBP VBP O
administered VBN VBN O
to TO TO O
patients NNS NNS O
to TO TO O
induce VB VB O
and CC CC O
control NN NN O
hypotension NN NN O
during IN IN O
anesthesia NN NN O
. . . O

SNP NNP NNP B-CHEM
is VBZ VBZ O
authorized VBN VBN O
for IN IN O
clinical JJ JJ O
use NN NN O
in IN IN O
USA NNP NNP O
and CC CC O
UK NNP NNP O
, , , O
and CC CC O
ATP NNP NNP B-CHEM
is VBZ VBZ O
clinically RB RB O
used VBN VBN O
in IN IN O
other JJ JJ O
countries NNS NNS O
such JJ JJ O
as IN IN O
Japan NNP NNP O
. . . O

We PRP PRP O
investigated VBD VBD O
how WRB WRB O
these DT DT O
two CD CD O
drugs NNS NNS O
act VBP VBP O
on IN IN O
the DT DT O
cardiovascular JJ JJ O
systems NNS NNS O
of IN IN O
20 CD CD O
dogs NNS NNS O
whose WP$ WP$ O
hearts NNS NNS O
had VBD VBD O
been VBN VBN O
denervated VBN VBN O
by IN IN O
a DT DT O
procedure NN NN O
we PRP PRP O
had VBD VBD O
devised VBN VBN O
. . . O

ATP NNP NNP B-CHEM
( ( ( O
10 CD CD O
dogs NNS NNS O
) ) ) O
or CC CC O
SNP NNP NNP B-CHEM
( ( ( O
10 CD CD O
dogs NNS NNS O
) ) ) O
was VBD VBD O
administered VBN VBN O
to TO TO O
reduce VB VB O
mean NN NN O
arterial JJ JJ O
pressure NN NN O
by IN IN O
30 CD CD O
% NN NN O
to TO TO O
70 CD CD O
% NN NN O
of IN IN O
control NN NN O
. . . O

Before IN IN O
, , , O
during IN IN O
and CC CC O
after IN IN O
induced JJ JJ O
hypotension NN NN O
, , , O
we PRP PRP O
measured VBD VBD O
major JJ JJ O
cardiovascular JJ JJ O
parameters NNS NNS O
. . . O

Hypotension NNP NNP O
induced VBN VBN O
by IN IN O
ATP NNP NNP B-CHEM
was VBD VBD O
accompanied VBN VBN O
by IN IN O
significant JJ JJ O
decreases NNS NNS O
in IN IN O
mean NN NN O
pulmonary JJ JJ O
arterial JJ JJ O
pressure NN NN O
( ( ( O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
, , , O
central JJ JJ O
venous JJ JJ O
pressure NN NN O
( ( ( O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
, , , O
left VBD VBD O
ventricular JJ JJ O
end NN NN O
- : : O
diastolic JJ JJ O
pressure NN NN O
( ( ( O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
, , , O
total JJ JJ O
peripheral JJ JJ O
resistance NN NN O
( ( ( O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
, , , O
rate NN NN O
pressure NN NN O
product NN NN O
( ( ( O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
, , , O
total JJ JJ O
body NN NN O
oxygen NN NN B-CHEM
consumption NN NN O
( ( ( O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
, , , O
and CC CC O
heart NN NN O
rate NN NN O
( ( ( O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
; : : O
all PDT PDT O
these DT DT O
variables NNS NNS O
returned VBD VBD O
normal JJ JJ O
within IN IN O
30 CD CD O
min NN NN O
after IN IN O
ATP NNP NNP B-CHEM
was VBD VBD O
stopped VBN VBN O
. . . O

Cardiac NNP NNP O
output NN NN O
did VBD VBD O
not RB RB O
change VB VB O
. . . O

During IN IN O
hypotension NN NN O
produced VBN VBN O
by IN IN O
SNP NNP NNP B-CHEM
similar JJ JJ O
decreases NNS NNS O
were VBD VBD O
observed VBN VBN O
in IN IN O
mean NN NN O
pulmonary JJ JJ O
arterial JJ JJ O
pressure NN NN O
( ( ( O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
, , , O
central JJ JJ O
venous JJ JJ O
pressure NN NN O
( ( ( O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
, , , O
left VBD VBD O
ventricular JJ JJ O
end NN NN O
- : : O
diastolic JJ JJ O
pressure NN NN O
( ( ( O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
, , , O
total JJ JJ O
peripheral JJ JJ O
resistance NN NN O
( ( ( O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
, , , O
rate NN NN O
pressure NN NN O
product NN NN O
( ( ( O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
, , , O
and CC CC O
oxygen NN NN B-CHEM
content NN NN O
difference NN NN O
between IN IN O
arterial NN NN O
and CC CC O
mixed JJ JJ O
venous JJ JJ O
blood NN NN O
( ( ( O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
, , , O
while IN IN O
heart NN NN O
rate NN NN O
( ( ( O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
001 CD CD O
) ) ) O
and CC CC O
cardiac JJ JJ O
output NN NN O
( ( ( O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
were VBD VBD O
increased VBN VBN O
. . . O

Recoveries NNP NNP O
of IN IN O
heart NN NN O
rate NN NN O
and CC CC O
left VBD VBD O
ventricular JJ JJ O
end NN NN O
- : : O
diastolic JJ JJ O
pressure NN NN O
were VBD VBD O
not RB RB O
shown VBN VBN O
within IN IN O
60 CD CD O
min NN NN O
after IN IN O
SNP NNP NNP B-CHEM
had VBD VBD O
been VBN VBN O
stopped VBN VBN O
. . . O

Both DT DT O
ATP NNP NNP B-CHEM
and CC CC O
SNP NNP NNP B-CHEM
should MD MD O
act VB VB O
on IN IN O
the DT DT O
pacemaker NN NN O
tissue NN NN O
of IN IN O
the DT DT O
heart NN NN O
. . . O

Comparative NNP NNP O
study NN NN O
: : : O
Endografine NNP NNP B-CHEM
( ( ( O
diatrizoate NN NN B-CHEM
) ) ) O
, , , O
Vasurix NNP NNP B-CHEM
polyvidone NN NN I-CHEM
( ( ( O
acetrizoate NN NN B-CHEM
) ) ) O
, , , O
Dimer NNP NNP B-CHEM
- : : I-CHEM
X NNP NNP I-CHEM
( ( ( O
iocarmate NN NN B-CHEM
) ) ) O
and CC CC O
Hexabrix NNP NNP B-CHEM
( ( ( O
ioxaglate NN NN B-CHEM
) ) ) O
in IN IN O
hysterosalpingography NN NN O
. . . O

Side NNP NNP O
effects NNS NNS O
of IN IN O
hysterosalpingography NN NN O
with IN IN O
Dimer NNP NNP B-CHEM
- : : I-CHEM
X NNP NNP I-CHEM
, , , O
Hexabrix NNP NNP B-CHEM
, , , O
Vasurix NNP NNP B-CHEM
polyvidone NN NN I-CHEM
and CC CC O
Endografine NNP NNP B-CHEM
in IN IN O
142 CD CD O
consecutive JJ JJ O
patients NNS NNS O
, , , O
receiving VBG VBG O
one CD CD O
of IN IN O
the DT DT O
four CD CD O
tested JJ JJ O
media NNS NNS O
were VBD VBD O
evaluated VBN VBN O
from IN IN O
replies NNS NNS O
to TO TO O
postal JJ JJ O
questionnaires NNS NNS O
. . . O

The DT DT O
Dimer NNP NNP B-CHEM
- - - I-CHEM
X NNP NNP I-CHEM
group NN NN O
had VBD VBD O
a DT DT O
higher JJR JJR O
incidence NN NN O
of IN IN O
nausea NN NN O
and CC CC O
dizziness NN NN O
. . . O

The DT DT O
Endografine NNP NNP B-CHEM
group NN NN O
had VBD VBD O
a DT DT O
higher JJR JJR O
incidence NN NN O
of IN IN O
abdominal JJ JJ O
pain NN NN O
. . . O

These DT DT O
differences NNS NNS O
occur VBP VBP O
especially RB RB O
in IN IN O
the DT DT O
age NN NN O
groups NNS NNS O
under IN IN O
30 CD CD O
years NNS NNS O
. . . O

Hexabrix NNP NNP B-CHEM
and CC CC O
Vasurix NNP NNP B-CHEM
polyvidone NN NN I-CHEM
are VBP VBP O
considered VBN VBN O
the DT DT O
best JJS JJS O
contrast NN NN B-CHEM
media NNS NNS I-CHEM
for IN IN O
hysterosalpingography NN NN O
and CC CC O
perhaps RB RB O
because IN IN O
of IN IN O
its PRP$ PRP$ O
low JJ JJ O
toxicity NN NN O
Hexabrix NNP NNP B-CHEM
should MD MD O
be VB VB O
preferred VBN VBN O
. . . O

Post NNP NNP O
- : : O
suxamethonium NN NN B-CHEM
pains NNS NNS O
in IN IN O
Nigerian NNP NNP O
surgical JJ JJ O
patients NNS NNS O
. . . O

Contrary NNP NNP O
to TO TO O
an DT DT O
earlier JJR JJR O
report NN NN O
by IN IN O
Coxon NNP NNP O
, , , O
scoline NN NN B-CHEM
pain NN NN O
occurs VBZ VBZ O
in IN IN O
African NNP NNP O
negroes NNS NNS O
. . . O

Its PRP$ PRP$ O
incidence NN NN O
was VBD VBD O
determined VBN VBN O
in IN IN O
a DT DT O
prospective JJ JJ O
study NN NN O
involving VBG VBG O
a DT DT O
total NN NN O
of IN IN O
100 CD CD O
Nigerian NNP NNP O
patients NNS NNS O
( ( ( O
50 CD CD O
out IN IN O
- : : O
patients NNS NNS O
and CC CC O
50 CD CD O
in IN IN O
- - - O
patients NNS NNS O
) ) ) O
. . . O

About IN IN O
62 CD CD O
% NN NN O
of IN IN O
the DT DT O
out IN IN O
- - - O
patients NNS NNS O
developed VBD VBD O
scoline NN NN B-CHEM
pain NN NN O
as IN IN O
compared VBN VBN O
with IN IN O
about IN IN O
26 CD CD O
% NN NN O
among IN IN O
the DT DT O
in IN IN O
- - - O
patients NNS NNS O
. . . O

The DT DT O
abolition NN NN O
of IN IN O
muscle NN NN O
fasciculations NNS NNS O
( ( ( O
by IN IN O
0 CD CD O
. . . O
075mg CD CD O
/ NN NN O
kg NN NN O
dose NN NN O
of IN IN O
Fazadinium NNP NNP B-CHEM
) ) ) O
did VBD VBD O
not RB RB O
influence VB VB O
the DT DT O
occurrence NN NN O
of IN IN O
scoline NN NN B-CHEM
pain NN NN O
. . . O

Neither DT DT O
the DT DT O
type NN NN O
of IN IN O
induction NN NN O
agent NN NN O
( ( ( O
Althesin NNP NNP B-CHEM
or CC CC O
Thiopentone NNP NNP B-CHEM
) ) ) O
nor CC CC O
the DT DT O
salt NN NN O
preparation NN NN O
of IN IN O
suxamethonium NN NN B-CHEM
used VBN VBN O
( ( ( O
chloride NN NN B-CHEM
or CC CC O
bromide NN NN B-CHEM
) ) ) O
, , , O
affected VBD VBD O
the DT DT O
incidence NN NN O
of IN IN O
scoline NN NN B-CHEM
pain NN NN O
. . . O

Invasive NNP NNP O
carcinoma NN NN O
of IN IN O
the DT DT O
renal JJ JJ O
pelvis NN NN O
following VBG VBG O
cyclophosphamide NN NN B-CHEM
therapy NN NN O
for IN IN O
nonmalignant NN NN O
disease NN NN O
. . . O

A DT DT O
47 JJ JJ O
- - - O
year NN NN O
- - - O
old JJ JJ O
woman NN NN O
with IN IN O
right NN NN O
hydroureteronephrosis NN NN O
due JJ JJ O
to TO TO O
ureterovesical JJ JJ O
junction NN NN O
obstruction NN NN O
had VBD VBD O
gross JJ JJ O
hematuria NN NN O
after IN IN O
being VBG VBG O
treated VBN VBN O
for IN IN O
five CD CD O
years NNS NNS O
wtih NN NN O
cyclophosphamide NN NN B-CHEM
for IN IN O
cerebral JJ JJ O
vasculitis NNS NNS O
. . . O

A DT DT O
right JJ JJ O
nephroureterectomy NN NN O
was VBD VBD O
required VBN VBN O
for IN IN O
control NN NN O
of IN IN O
bleeding VBG VBG O
. . . O

The DT DT O
pathology NN NN O
specimen NNS NNS O
contained VBD VBD O
clinically RB RB O
occult JJ JJ O
invasive JJ JJ O
carcinoma NN NN O
of IN IN O
the DT DT O
renal JJ JJ O
pelvis NN NN O
. . . O

Although IN IN O
the DT DT O
ability NN NN O
of IN IN O
cyclophosphamide NN NN B-CHEM
to TO TO O
cause VB VB O
hemorrhagic JJ JJ O
cystitis NNS NNS O
and CC CC O
urine JJ JJ O
cytologic JJ JJ O
abnormalities NNS NNS O
indistinguishable JJ JJ O
from IN IN O
high JJ JJ O
grade NN NN O
carcinoma NN NN O
is VBZ VBZ O
well RB RB O
known VBN VBN O
, , , O
it PRP PRP O
is VBZ VBZ O
less RBR RBR O
widely RB RB O
appreciated VBN VBN O
that IN IN O
it PRP PRP O
is VBZ VBZ O
also RB RB O
associated VBN VBN O
with IN IN O
carcinoma NN NN O
of IN IN O
the DT DT O
urinary JJ JJ O
tract NN NN O
. . . O

Twenty NNP NNP O
carcinomas NN NN O
of IN IN O
the DT DT O
urinary JJ JJ O
bladder NN NN O
and CC CC O
one CD CD O
carcinoma NN NN O
of IN IN O
the DT DT O
prostate NN NN O
have VBP VBP O
been VBN VBN O
reported VBN VBN O
in IN IN O
association NN NN O
with IN IN O
its PRP$ PRP$ O
use NN NN O
. . . O

The DT DT O
present JJ JJ O
case NN NN O
is VBZ VBZ O
the DT DT O
first JJ JJ O
carcinoma NN NN O
of IN IN O
the DT DT O
renal JJ JJ O
pelvis NN NN O
reported VBD VBD O
in IN IN O
association NN NN O
with IN IN O
cyclophosphamide NN NN B-CHEM
treatment NN NN O
. . . O

It PRP PRP O
is VBZ VBZ O
the DT DT O
third JJ JJ O
urinary JJ JJ O
tract NN NN O
cancer NN NN O
reported VBD VBD O
in IN IN O
association NN NN O
with IN IN O
cyclophosphamide NN NN B-CHEM
treatment NN NN O
for IN IN O
nonmalignant NN NN O
disease NN NN O
. . . O

The DT DT O
association NN NN O
of IN IN O
the DT DT O
tumor NN NN O
with IN IN O
preexisting VBG VBG O
hydroureteronephrosis NN NN O
suggests VBZ VBZ O
that IN IN O
stasis NNS NNS O
prolonged JJ JJ O
and CC CC O
intensified JJ JJ O
exposure NN NN O
of IN IN O
upper JJ JJ O
urinary JJ JJ O
tract NN NN O
epithelium NN NN O
to TO TO O
cyclophosphamide VB VB B-CHEM
. . . O

Patients NNS NNS O
who WP WP O
are VBP VBP O
candidates NNS NNS O
for IN IN O
long JJ JJ O
- - - O
term NN NN O
cyclophosphamide NN NN B-CHEM
treatment NN NN O
should MD MD O
be VB VB O
routinely RB RB O
evaluated VBN VBN O
for IN IN O
obstructive JJ JJ O
uropathy NN NN O
. . . O

Medial NNP NNP O
changes NNS NNS O
in IN IN O
arterial JJ JJ O
spasm NN NN O
induced VBN VBN O
by IN IN O
L NNP NNP B-CHEM
- : : I-CHEM
norepinephrine NN NN I-CHEM
. . . O

In IN IN O
normal JJ JJ O
rats NNS NNS O
, , , O
the DT DT O
media NNS NNS O
of IN IN O
small JJ JJ O
arteries NNS NNS O
( ( ( O
0 CD CD O
. . . O
4 CD CD O
- : : O
- : : O
0 CD CD O
. . . O
2 CD CD O
mm NN NN O
in IN IN O
diameter NN NN O
) ) ) O
previously RB RB O
was VBD VBD O
shown VBN VBN O
to TO TO O
contain VB VB O
intracellular JJ JJ O
vacuoles NNS NNS O
, , , O
identified VBN VBN O
ultrastructurally RB RB O
as IN IN O
herniations NNS NNS O
of IN IN O
one CD CD O
smooth JJ JJ O
muscle NN NN O
cell NN NN O
into IN IN O
another DT DT O
. . . O

The DT DT O
hypothesis NNS NNS O
that WDT WDT O
intense JJ JJ O
vasoconstriction NN NN O
would MD MD O
increase VB VB O
the DT DT O
number NN NN O
of IN IN O
such JJ JJ O
vacuoles NNS NNS O
has VBZ VBZ O
been VBN VBN O
tested VBN VBN O
. . . O

In IN IN O
the DT DT O
media NNS NNS O
of IN IN O
the DT DT O
saphenous JJ JJ O
artery NN NN O
and CC CC O
its PRP$ PRP$ O
distal JJ JJ O
branch NN NN O
, , , O
vasoconstriction NN NN O
induced VBN VBN O
by IN IN O
L NNP NNP B-CHEM
- : : I-CHEM
norepinephrine NN NN I-CHEM
produced VBD VBD O
many JJ JJ O
cell NN NN O
- - - O
to TO TO O
- - - O
cell NN NN O
hernias NN NN O
within IN IN O
15 CD CD O
minutes NNS NNS O
. . . O

At IN IN O
1 CD CD O
day NN NN O
their PRP$ PRP$ O
number NN NN O
was VBD VBD O
reduced VBN VBN O
to TO TO O
about IN IN O
1 CD CD O
/ NN NN O
10 CD CD O
of IN IN O
the DT DT O
original JJ JJ O
number NN NN O
. . . O

By IN IN O
7 CD CD O
days NNS NNS O
the DT DT O
vessel NN NN O
was VBD VBD O
almost RB RB O
restored VBN VBN O
to TO TO O
normal JJ JJ O
. . . O

Triple NNP NNP O
stimulation NN NN O
over IN IN O
1 CD CD O
day NN NN O
induced VBD VBD O
more JJR JJR O
severe JJ JJ O
changes NNS NNS O
in IN IN O
the DT DT O
media NNS NNS O
. . . O

These DT DT O
findings NNS NNS O
suggest VBP VBP O
that IN IN O
smooth JJ JJ O
muscle NN NN O
cells NNS NNS O
are VBP VBP O
susceptible JJ JJ O
to TO TO O
damage VB VB O
in IN IN O
the DT DT O
course NN NN O
of IN IN O
their PRP$ PRP$ O
specific JJ JJ O
function NN NN O
. . . O

The DT DT O
experimental JJ JJ O
data NNS NNS O
are VBP VBP O
discussed VBN VBN O
in IN IN O
relation NN NN O
to TO TO O
medial JJ JJ O
changes NNS NNS O
observed VBD VBD O
in IN IN O
other JJ JJ O
instances NNS NNS O
of IN IN O
arterial JJ JJ O
spasm NN NN O
. . . O

Endothelial NNP NNP O
changes NNS NNS O
that WDT WDT O
developed VBD VBD O
in IN IN O
the DT DT O
same JJ JJ O
experimental JJ JJ O
model NN NN O
were VBD VBD O
described VBN VBN O
in IN IN O
a DT DT O
previous JJ JJ O
paper NN NN O
. . . O

Bilateral NNP NNP O
retinal JJ JJ O
artery NN NN O
and CC CC O
choriocapillaris NN NN O
occlusion NN NN O
following VBG VBG O
the DT DT O
injection NN NN O
of IN IN O
long JJ JJ O
- - - O
acting VBG VBG O
corticosteroid NN NN B-CHEM
suspensions NNS NNS O
in IN IN O
combination NN NN O
with IN IN O
other JJ JJ O
drugs NNS NNS O
: : : O
I PRP PRP O
. . . O

Clinical NNP NNP O
studies NNS NNS O
. . . O

Two CD CD O
well RB RB O
- - - O
documented JJ JJ O
cases NNS NNS O
of IN IN O
bilateral JJ JJ O
retinal NN NN O
artery NN NN O
and CC CC O
choriocapillaris NN NN O
occlusions NNS NNS O
with IN IN O
blindness NN NN O
following VBG VBG O
head NN NN O
and CC CC O
neck NN NN O
soft JJ JJ O
- : : O
tissue NN NN O
injection NN NN O
with IN IN O
methylprednisolone NN NN B-CHEM
acetate NN NN I-CHEM
in IN IN O
combination NN NN O
with IN IN O
lidocaine NN NN B-CHEM
, , , O
epinephrine NN NN B-CHEM
, , , O
or CC CC O
penicillin NN NN B-CHEM
are VBP VBP O
reported VBN VBN O
. . . O

One CD CD O
case NN NN O
had VBD VBD O
only RB RB O
a DT DT O
unilateral JJ JJ O
injection NN NN O
. . . O

The DT DT O
acute JJ JJ O
observations NNS NNS O
included VBD VBD O
hazy JJ JJ O
sensorium NN NN O
, , , O
superior JJ JJ O
gaze VBP VBP O
palsy NN NN O
, , , O
pupillary JJ JJ O
abnormalities NNS NNS O
, , , O
and CC CC O
conjunctival NN NN O
hemorrhages NNS NNS O
with IN IN O
edema NN NN O
. . . O

Follow VB VB O
- - - O
up RP RP O
changes NNS NNS O
showed VBD VBD O
marked VBN VBN O
visual JJ JJ O
loss NN NN O
, , , O
constricted VBN VBN O
visual JJ JJ O
fields NNS NNS O
, , , O
optic JJ JJ O
nerve NN NN O
pallor NN NN O
, , , O
vascular JJ JJ O
attenuation NN NN O
, , , O
and CC CC O
chorioretinal JJ JJ O
atrophy NN NN O
. . . O

The DT DT O
literature NN NN O
is VBZ VBZ O
reviewed VBN VBN O
, , , O
and CC CC O
possible JJ JJ O
causes NNS NNS O
are VBP VBP O
discussed VBN VBN O
. . . O

Abnormalities NNP NNP O
of IN IN O
the DT DT O
pupil NN NN O
and CC CC O
visual JJ JJ O
- - - O
evoked JJ JJ O
potential JJ JJ O
in IN IN O
quinine NN NN B-CHEM
amblyopia NN NN O
. . . O

Total JJ JJ O
blindness NN NN O
with IN IN O
a DT DT O
transient NN NN O
tonic NN NN O
pupillary JJ JJ O
response NN NN O
, , , O
denervation NN NN O
supersensitivity NN NN O
, , , O
and CC CC O
abnormal JJ JJ O
visual JJ JJ O
- - - O
evoked JJ JJ O
potentials NNS NNS O
developed VBN VBN O
in IN IN O
a DT DT O
54 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
man NN NN O
after IN IN O
the DT DT O
use NN NN O
of IN IN O
quinine NN NN B-CHEM
sulfate NN NN I-CHEM
for IN IN O
leg NN NN O
cramps NNS NNS O
. . . O

He PRP PRP O
later RB RB O
recovered VBD VBD O
normal JJ JJ O
visual JJ JJ O
acuity NN NN O
. . . O

A DT DT O
transient NN NN O
tonic NN NN O
pupillary JJ JJ O
response NN NN O
, , , O
denervation NN NN O
supersensitivity NN NN O
, , , O
and CC CC O
abnormal JJ JJ O
visual JJ JJ O
- - - O
evoked JJ JJ O
potentials NNS NNS O
in IN IN O
quinine NN NN B-CHEM
toxicity NN NN O
, , , O
to TO TO O
our PRP$ PRP$ O
knowledge NN NN O
, , , O
have VBP VBP O
not RB RB O
been VBN VBN O
previously RB RB O
reported VBN VBN O
. . . O

Suxamethonium NNP NNP B-CHEM
- : : O
induced JJ JJ O
jaw NN NN O
stiffness NN NN O
and CC CC O
myalgia NN NN O
associated VBN VBN O
with IN IN O
atypical JJ JJ O
cholinesterase NN NN O
: : : O
case NN NN O
report NN NN O
. . . O

An DT DT O
11 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
boy NN NN O
was VBD VBD O
given VBN VBN O
halothane NN NN B-CHEM
, , , O
nitrous JJ JJ B-CHEM
oxide NN NN I-CHEM
and CC CC O
oxygen NN NN B-CHEM
, , , O
pancuronium NN NN B-CHEM
0 CD CD O
. . . O
4 CD CD O
mg NN NN O
and CC CC O
suxamethonium NN NN B-CHEM
100 CD CD O
mg NN NN O
for IN IN O
induction NN NN O
of IN IN O
anaesthesia NN NN O
. . . O

In IN IN O
response NN NN O
to TO TO O
this DT DT O
a DT DT O
marked JJ JJ O
jaw NN NN O
stiffness NNS NNS O
occurred VBD VBD O
which WDT WDT O
lasted VBD VBD O
for IN IN O
two CD CD O
minutes NNS NNS O
and CC CC O
the DT DT O
anaesthesia NN NN O
were VBD VBD O
terminated VBN VBN O
. . . O

Four CD CD O
hours NNS NNS O
of IN IN O
apnoea NN NN O
ensued VBD VBD O
and CC CC O
he PRP PRP O
suffered VBD VBD O
generalized JJ JJ O
severe JJ JJ O
myalgia NN NN O
lasting VBG VBG O
for IN IN O
one CD CD O
week NN NN O
. . . O

He PRP PRP O
was VBD VBD O
found VBN VBN O
to TO TO O
have VB VB O
atypical JJ JJ O
plasma NN NN O
cholinesterase NN NN O
with IN IN O
a DT DT O
dibucaine JJ JJ B-CHEM
number NN NN O
of IN IN O
12 CD CD O
, , , O
indicating VBG VBG O
homozygocity NN NN O
. . . O

This DT DT O
was VBD VBD O
verified VBN VBN O
by IN IN O
study NN NN O
of IN IN O
the DT DT O
family NN NN O
. . . O

The DT DT O
case NN NN O
shows VBZ VBZ O
that IN IN O
prolonged JJ JJ O
jaw NN NN O
rigidity NN NN O
and CC CC O
myalgia NN NN O
may MD MD O
occur VB VB O
after IN IN O
suxamethonium NN NN B-CHEM
in IN IN O
patients NNS NNS O
with IN IN O
atypical JJ JJ O
cholinesterase NN NN O
despite IN IN O
pretreatment NN NN O
with IN IN O
pancuronium NN NN B-CHEM
. . . O

Indomethacin NNP NNP B-CHEM
- : : O
induced JJ JJ O
hyperkalemia NN NN O
in IN IN O
three CD CD O
patients NNS NNS O
with IN IN O
gouty NN NN O
arthritis NN NN O
. . . O

We PRP PRP O
describe VBP VBP O
three CD CD O
patients NNS NNS O
in IN IN O
whom WP WP O
severe JJ JJ O
, , , O
life NN NN O
- - - O
threatening VBG VBG O
hyperkalemia NN NN O
and CC CC O
renal JJ JJ O
insufficiency NN NN O
developed VBN VBN O
after IN IN O
treatment NN NN O
of IN IN O
acute JJ JJ O
gouty NN NN O
arthritis NN NN O
with IN IN O
indomethacin NN NN B-CHEM
. . . O

This DT DT O
complication NN NN O
may MD MD O
result VB VB O
from IN IN O
an DT DT O
inhibition NN NN O
of IN IN O
prostaglandin NN NN B-CHEM
synthesis NN NN O
and CC CC O
consequent JJ JJ O
hyporeninemic JJ JJ O
hypoaidosteronism NN NN O
. . . O

Careful NNP NNP O
attention NN NN O
to TO TO O
renal JJ JJ O
function NN NN O
and CC CC O
potassium NN NN B-CHEM
balance NN NN O
in IN IN O
patients NNS NNS O
receiving VBG VBG O
indomethacin NN NN B-CHEM
or CC CC O
other JJ JJ O
nonsteroidal NN NN O
anti NN NN O
- : : O
inflammatory JJ JJ O
agents NNS NNS O
, , , O
particularly RB RB O
in IN IN O
those DT DT O
patients NNS NNS O
with IN IN O
diabetes NN NN O
mellitus NN NN O
or CC CC O
preexisting VBG VBG O
renal JJ JJ O
disease NN NN O
, , , O
will MD MD O
help VB VB O
prevent VB VB O
this DT DT O
potentially RB RB O
serious JJ JJ O
complication NN NN O
. . . O

Etomidate NNP NNP B-CHEM
: : : O
a DT DT O
foreshortened JJ JJ O
clinical JJ JJ O
trial NN NN O
. . . O

A DT DT O
clinical JJ JJ O
evaluation NN NN O
of IN IN O
etomidate NN NN B-CHEM
for IN IN O
outpatient JJ JJ O
cystoscopy NN NN O
was VBD VBD O
embarked VBN VBN O
upon IN IN O
. . . O

Unpremedicated NNP NNP O
patients NNS NNS O
were VBD VBD O
given VBN VBN O
fentanyl NN NN B-CHEM
1 CD CD O
microgram NN NN O
/ NN NN O
kg NN NN O
followed VBN VBN O
by IN IN O
etomidate NN NN B-CHEM
0 CD CD O
. . . O
3 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
. . . O

Anaesthesia NNP NNP O
was VBD VBD O
maintained VBN VBN O
with IN IN O
intermittent JJ JJ O
etomidate NN NN B-CHEM
in IN IN O
2 CD CD O
- : : O
4 CD CD O
mg NN NN O
doses NNS NNS O
. . . O

Patients NNS NNS O
were VBD VBD O
interviewed VBN VBN O
personally RB RB O
later RB RB O
the DT DT O
same JJ JJ O
day NN NN O
, , , O
and CC CC O
by IN IN O
questionnaire NN NN O
three CD CD O
to TO TO O
four CD CD O
weeks NNS NNS O
later RB RB O
. . . O

The DT DT O
trial NN NN O
was VBD VBD O
discontinued VBN VBN O
after IN IN O
20 CD CD O
cases NNS NNS O
because IN IN O
of IN IN O
an DT DT O
unacceptable JJ JJ O
incidence NN NN O
of IN IN O
side NN NN O
effects NNS NNS O
. . . O

Venous NNP NNP O
pain NN NN O
occurred VBD VBD O
in IN IN O
68 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
and CC CC O
50 CD CD O
% NN NN O
had VBD VBD O
redness JJ JJ O
, , , O
pain NN NN O
or CC CC O
swelling VBG VBG O
related VBN VBN O
to TO TO O
the DT DT O
injection NN NN O
site NN NN O
, , , O
in IN IN O
some DT DT O
cases NNS NNS O
lasting VBG VBG O
up RP RP O
to TO TO O
three CD CD O
weeks NNS NNS O
after IN IN O
anaesthesia NN NN O
. . . O

Skeletal NNP NNP O
movements NNS NNS O
occurred VBD VBD O
in IN IN O
50 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
; : : O
30 CD CD O
% NN NN O
experienced VBN VBN O
respiratory JJ JJ O
upset NN NN O
, , , O
one CD CD O
sufficiently RB RB O
severe JJ JJ O
to TO TO O
necessitate VB VB O
abandoning VBG VBG O
the DT DT O
technique NN NN O
. . . O

Nausea NNP NNP O
and CC CC O
vomiting VBG VBG O
occurred VBN VBN O
in IN IN O
40 CD CD O
% NN NN O
and CC CC O
25 CD CD O
% NN NN O
had VBD VBD O
disturbing VBG VBG O
emergence NN NN O
psychoses NNS NNS O
. . . O

Levodopa NNP NNP B-CHEM
- : : O
induced JJ JJ O
dyskinesias NNS NNS O
are VBP VBP O
improved VBN VBN O
by IN IN O
fluoxetine NN NN B-CHEM
. . . O

We PRP PRP O
evaluated VBD VBD O
the DT DT O
severity NN NN O
of IN IN O
motor NN NN O
disability NN NN O
and CC CC O
dyskinesias NN NN O
in IN IN O
seven CD CD O
levodopa NN NN B-CHEM
- : : O
responsive JJ JJ O
patients NNS NNS O
with IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
after IN IN O
an DT DT O
acute JJ JJ O
challenge NN NN O
with IN IN O
the DT DT O
mixed JJ JJ O
dopamine NN NN B-CHEM
agonist NN NN O
, , , O
apomorphine NN NN B-CHEM
, , , O
before IN IN O
and CC CC O
after IN IN O
the DT DT O
administration NN NN O
of IN IN O
fluoxetine NN NN B-CHEM
( ( ( O
20 CD CD O
mg NN NN O
twice RB RB O
per IN IN O
day NN NN O
) ) ) O
for IN IN O
11 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
days NNS NNS O
. . . O

After IN IN O
fluoxetine NN NN B-CHEM
treatment NN NN O
, , , O
there EX EX O
was VBD VBD O
a DT DT O
significant JJ JJ O
47 CD CD O
% NN NN O
improvement NN NN O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
of IN IN O
apomorphine NN NN B-CHEM
- - - O
induced JJ JJ O
dyskinesias NN NN O
without IN IN O
modification NN NN O
of IN IN O
parkinsonian JJ JJ O
motor NN NN O
disability NN NN O
. . . O

The DT DT O
dyskinesias NN NN O
were VBD VBD O
reduced VBN VBN O
predominantly RB RB O
in IN IN O
the DT DT O
lower JJR JJR O
limbs NNS NNS O
during IN IN O
the DT DT O
onset NN NN O
and CC CC O
disappearance NN NN O
of IN IN O
dystonic JJ JJ O
dyskinesias NNS NNS O
( ( ( O
onset NN NN O
- : : O
and CC CC O
end VB VB O
- : : O
of IN IN O
- - - O
dose NN NN O
dyskinesias NN NN O
) ) ) O
and CC CC O
in IN IN O
the DT DT O
upper JJ JJ O
limbs NNS NNS O
during IN IN O
choreic NN NN O
mid JJ JJ O
- : : O
dose NN NN O
dyskinesias NN NN O
. . . O

The DT DT O
results NNS NNS O
suggest VBP VBP O
that IN IN O
increased VBN VBN O
brain NN NN O
serotoninergic JJ JJ O
transmission NN NN O
with IN IN O
fluoxetine NN NN B-CHEM
may MD MD O
reduce VB VB O
levodopa NN NN B-CHEM
- : : O
or CC CC O
dopamine NN NN B-CHEM
agonist NN NN O
- : : O
induced JJ JJ O
dyskinesias NN NN O
without IN IN O
aggravating VBG VBG O
parkinsonian NN NN O
motor NN NN O
disability NN NN O
. . . O

A DT DT O
large JJ JJ O
population NN NN O
- - - O
based JJ JJ O
follow VB VB O
- - - O
up RP RP O
study NN NN O
of IN IN O
trimethoprim NN NN B-CHEM
- - - I-CHEM
sulfamethoxazole NN NN I-CHEM
, , , O
trimethoprim VB VB B-CHEM
, , , O
and CC CC O
cephalexin NN NN B-CHEM
for IN IN O
uncommon JJ JJ O
serious JJ JJ O
drug NN NN O
toxicity NN NN O
. . . O

We PRP PRP O
conducted VBD VBD O
a DT DT O
population NN NN O
- - - O
based JJ JJ O
45 CD CD O
- : : O
day NN NN O
follow VB VB O
- : : O
up RP RP O
study NN NN O
of IN IN O
232 CD CD O
, , , O
390 CD CD O
people NNS NNS O
who WP WP O
were VBD VBD O
prescribed VBN VBN O
trimethoprim JJ JJ B-CHEM
- : : I-CHEM
sulfamethoxazole NN NN I-CHEM
( ( ( O
TMP NNP NNP B-CHEM
- - - I-CHEM
SMZ NNP NNP I-CHEM
) ) ) O
, , , O
266 CD CD O
, , , O
951 CD CD O
prescribed VBN VBN O
trimethoprim VB VB B-CHEM
alone RB RB O
, , , O
and CC CC O
196 CD CD O
, , , O
397 CD CD O
prescribed VBN VBN O
cephalexin NN NN B-CHEM
, , , O
to TO TO O
estimate VB VB O
the DT DT O
risk NN NN O
of IN IN O
serious JJ JJ O
liver NN NN O
, , , O
blood NN NN O
, , , O
skin NN NN O
, , , O
and CC CC O
renal JJ JJ O
disorders NNS NNS O
resulting VBG VBG O
in IN IN O
referral NN NN O
or CC CC O
hospitalization NN NN O
associated VBN VBN O
with IN IN O
these DT DT O
drugs NNS NNS O
. . . O

The DT DT O
results NNS NNS O
were VBD VBD O
based VBN VBN O
on IN IN O
information NN NN O
recorded VBN VBN O
on IN IN O
office NN NN O
computers NNS NNS O
by IN IN O
selected JJ JJ O
general JJ JJ O
practitioners NNS NNS O
in IN IN O
the DT DT O
United NNP NNP O
Kingdom NNP NNP O
, , , O
together RB RB O
with IN IN O
a DT DT O
review NN NN O
of IN IN O
clinical JJ JJ O
records NNS NNS O
. . . O

The DT DT O
risk NN NN O
of IN IN O
clinically RB RB O
important JJ JJ O
idiopathic JJ JJ O
liver NN NN O
disease NN NN O
was VBD VBD O
similar JJ JJ O
for IN IN O
persons NNS NNS O
prescribed VBN VBN O
TMP NNP NNP B-CHEM
- : : I-CHEM
SMZ NNP NNP I-CHEM
( ( ( O
5 CD CD O
. . . O
2 CD CD O
/ NN NN O
100 CD CD O
, , , O
000 CD CD O
) ) ) O
and CC CC O
those DT DT O
prescribed VBN VBN O
trimethoprim VB VB B-CHEM
alone RB RB O
( ( ( O
3 CD CD O
. . . O
8 CD CD O
/ NN NN O
100 CD CD O
, , , O
000 CD CD O
) ) ) O
. . . O

The DT DT O
risk NN NN O
for IN IN O
those DT DT O
prescribed VBN VBN O
cephalexin NN NN B-CHEM
was VBD VBD O
somewhat RB RB O
lower JJR JJR O
( ( ( O
2 CD CD O
. . . O
0 CD CD O
/ NN NN O
100 CD CD O
, , , O
000 CD CD O
) ) ) O
. . . O

Only RB RB O
five CD CD O
patients NNS NNS O
experienced VBD VBD O
blood NN NN O
disorders NNS NNS O
, , , O
one CD CD O
of IN IN O
whom WP WP O
was VBD VBD O
exposed VBN VBN O
to TO TO O
TMP NNP NNP B-CHEM
- : : I-CHEM
SMZ NNP NNP I-CHEM
; : : O
of IN IN O
seven CD CD O
with IN IN O
erythema NN NN O
multiforme NN NN O
and CC CC O
Stevens NNP NNP O
- : : O
Johnson NNP NNP O
syndrome NN NN O
, , , O
four CD CD O
were VBD VBD O
exposed VBN VBN O
to TO TO O
TMP NNP NNP B-CHEM
- : : I-CHEM
SMZ NNP NNP I-CHEM
. . . O

The DT DT O
one CD CD O
case NN NN O
of IN IN O
toxic JJ JJ O
epidermal JJ JJ O
necrolysis NN NN O
occurred VBD VBD O
in IN IN O
a DT DT O
patient NN NN O
who WP WP O
took VBD VBD O
cephalexin NN NN B-CHEM
. . . O

Finally RB RB O
, , , O
only RB RB O
five CD CD O
cases NNS NNS O
of IN IN O
acute JJ JJ O
parenchymal NN NN O
renal NN NN O
disease NN NN O
occurred VBD VBD O
, , , O
none NN NN O
likely JJ JJ O
to TO TO O
be VB VB O
caused VBN VBN O
by IN IN O
a DT DT O
study NN NN O
drug NN NN O
. . . O

We PRP PRP O
conclude VBP VBP O
that IN IN O
the DT DT O
risk NN NN O
of IN IN O
the DT DT O
serious JJ JJ O
diseases NNS NNS O
studied VBN VBN O
is VBZ VBZ O
small JJ JJ O
for IN IN O
the DT DT O
three CD CD O
agents NNS NNS O
, , , O
and CC CC O
compares NNS NNS O
reasonably RB RB O
with IN IN O
the DT DT O
risk NN NN O
for IN IN O
many JJ JJ O
other JJ JJ O
antibiotics NNS NNS O
. . . O

Clinical NNP NNP O
safety NN NN O
of IN IN O
lidocaine NN NN B-CHEM
in IN IN O
patients NNS NNS O
with IN IN O
cocaine NN NN B-CHEM
- - - O
associated VBN VBN O
myocardial NN NN O
infarction NN NN O
. . . O

STUDY NNP NNP O
OBJECTIVE NNP NNP O
: : : O
To TO TO O
evaluate VB VB O
the DT DT O
safety NN NN O
of IN IN O
lidocaine NN NN B-CHEM
in IN IN O
the DT DT O
setting VBG VBG O
of IN IN O
cocaine NN NN B-CHEM
- - - O
induced JJ JJ O
myocardial NN NN O
infarction NN NN O
( ( ( O
MI NNP NNP O
) ) ) O
. . . O

DESIGN NNP NNP O
: : : O
A DT DT O
retrospective NN NN O
, , , O
multicenter NN NN O
study NN NN O
. . . O

SETTING NNP NNP O
: : : O
Twenty CD CD O
- - - O
nine CD CD O
university NN NN O
, , , O
university NN NN O
- - - O
affiliated JJ JJ O
, , , O
or CC CC O
community NN NN O
hospitals NNS NNS O
during IN IN O
a DT DT O
6 CD CD O
- : : O
year NN NN O
period NN NN O
( ( ( O
total NN NN O
of IN IN O
117 CD CD O
cumulative JJ JJ O
hospital NN NN O
- - - O
years NNS NNS O
) ) ) O
. . . O

PARTICIPANTS NNS NNS O
: : : O
Patients NNS NNS O
with IN IN O
cocaine NN NN B-CHEM
- - - O
associated VBN VBN O
MI NNP NNP O
who WP WP O
received VBD VBD O
lidocaine NN NN B-CHEM
in IN IN O
the DT DT O
emergency NN NN O
department NN NN O
. . . O

RESULTS NNS NNS O
: : : O
Of IN IN O
29 CD CD O
patients NNS NNS O
who WP WP O
received VBD VBD O
lidocaine NN NN B-CHEM
in IN IN O
the DT DT O
setting VBG VBG O
of IN IN O
cocaine NN NN B-CHEM
- - - O
associated VBN VBN O
MI NNP NNP O
, , , O
no DT DT O
patient NN NN O
died VBD VBD O
; : : O
exhibited VBN VBN O
bradydysrhythmias NNS NNS O
, , , O
ventricular NN NN O
tachycardia NNS NNS O
, , , O
or CC CC O
ventricular JJ JJ O
fibrillation NN NN O
; : : O
or CC CC O
experienced VBN VBN O
seizures NNS NNS O
after IN IN O
administration NN NN O
of IN IN O
lidocaine NN NN B-CHEM
( ( ( O
95 CD CD O
% NN NN O
confidence NN NN O
interval NN NN O
, , , O
0 CD CD O
% NN NN O
to TO TO O
11 CD CD O
% NN NN O
) ) ) O
. . . O

CONCLUSION NNP NNP O
: : : O
Despite IN IN O
theoretical JJ JJ O
concerns NNS NNS O
that WDT WDT O
lidocaine VBP VBP B-CHEM
may MD MD O
enhance VB VB O
cocaine JJ JJ B-CHEM
toxicity NN NN O
, , , O
the DT DT O
use NN NN O
of IN IN O
lidocaine NN NN B-CHEM
in IN IN O
patients NNS NNS O
with IN IN O
cocaine NN NN B-CHEM
- - - O
associated VBN VBN O
MI NNP NNP O
was VBD VBD O
not RB RB O
associated VBN VBN O
with IN IN O
significant JJ JJ O
cardiovascular NN NN O
or CC CC O
central JJ JJ O
nervous JJ JJ O
system NN NN O
toxicity NN NN O
. . . O

Experimental NNP NNP O
progressive JJ JJ O
muscular NN NN O
dystrophy NN NN O
and CC CC O
its PRP$ PRP$ O
treatment NN NN O
with IN IN O
high JJ JJ O
doses NNS NNS O
anabolizing VBG VBG O
agents NNS NNS O
. . . O

We PRP PRP O
are VBP VBP O
still RB RB O
a DT DT O
long JJ JJ O
way NN NN O
from IN IN O
discovering VBG VBG O
an DT DT O
unequivocal JJ JJ O
pathogenetic JJ JJ O
interpretation NN NN O
of IN IN O
progressive JJ JJ O
muscular NN NN O
dystrophy NN NN O
in IN IN O
man NN NN O
. . . O

Noteworthy NNP NNP O
efforts NNS NNS O
have VBP VBP O
been VBN VBN O
made VBN VBN O
in IN IN O
the DT DT O
experimental JJ JJ O
field NN NN O
; : : O
a DT DT O
recessive JJ JJ O
autosomic JJ JJ O
form NN NN O
found VBD VBD O
in IN IN O
the DT DT O
mouse NN NN O
seems VBZ VBZ O
to TO TO O
bear VB VB O
the DT DT O
closest JJS JJS O
resemblance NN NN O
to TO TO O
the DT DT O
human JJ JJ O
form NN NN O
from IN IN O
the DT DT O
genetic JJ JJ O
point NN NN O
of IN IN O
view NN NN O
. . . O

Myopathy NNP NNP O
due JJ JJ O
to TO TO O
lack NN NN O
of IN IN O
vitamin NN NN B-CHEM
E NNP NNP I-CHEM
and CC CC O
myopathy NN NN O
induced VBN VBN O
by IN IN O
certain JJ JJ O
viruses NNS NNS O
have VBP VBP O
much RB RB O
in IN IN O
common JJ JJ O
anatomically RB RB O
and CC CC O
pathologically RB RB O
with IN IN O
the DT DT O
human JJ JJ O
form NN NN O
. . . O

The DT DT O
authors NNS NNS O
induced VBD VBD O
myodystrophy NN NN O
in IN IN O
the DT DT O
rat NN NN O
by IN IN O
giving VBG VBG O
it PRP PRP O
a DT DT O
diet NN NN O
lacking VBG VBG O
in IN IN O
vitamin NN NN B-CHEM
E NNP NNP I-CHEM
. . . O

The DT DT O
pharmacological JJ JJ O
characteristics NNS NNS O
of IN IN O
vitamin NN NN B-CHEM
E NNP NNP I-CHEM
and CC CC O
the DT DT O
degenerative JJ JJ O
changes NNS NNS O
brought VBN VBN O
about IN IN O
by IN IN O
its PRP$ PRP$ O
deficiency NN NN O
, , , O
especially RB RB O
in IN IN O
the DT DT O
muscles NNS NNS O
, , , O
are VBP VBP O
illustrated VBN VBN O
. . . O

It PRP PRP O
is VBZ VBZ O
thus RB RB O
confirmed VBN VBN O
that IN IN O
the DT DT O
histological JJ JJ O
characteristics NNS NNS O
of IN IN O
myopathic JJ JJ O
rat NN NN O
muscle NN NN O
induced VBN VBN O
experimentally RB RB O
are VBP VBP O
extraordinarily RB RB O
similar JJ JJ O
to TO TO O
those DT DT O
of IN IN O
human JJ JJ O
myopathy NN NN O
as IN IN O
confirmed VBN VBN O
during IN IN O
biopsies NNS NNS O
performed VBN VBN O
at IN IN O
the DT DT O
Orthopaedic NNP NNP O
Traumatological NNP NNP O
Centre NNP NNP O
, , , O
Florence NNP NNP O
. . . O

The DT DT O
encouraging NN NN O
results NNS NNS O
obtained VBN VBN O
in IN IN O
various JJ JJ O
authoratative JJ JJ O
departments NNS NNS O
in IN IN O
myopathic JJ JJ O
patients NNS NNS O
by IN IN O
using VBG VBG O
anabolizing VBG VBG O
steroids NNS NNS B-CHEM
have VBP VBP O
encouraged VBN VBN O
the DT DT O
authors NNS NNS O
to TO TO O
investigate VB VB O
the DT DT O
beneficial JJ JJ O
effects NNS NNS O
of IN IN O
one CD CD O
anabolizing VBG VBG O
agent NN NN O
( ( ( O
Dianabol NNP NNP B-CHEM
, , , O
CIBA NNP NNP B-CHEM
) ) ) O
at IN IN O
high JJ JJ O
doses NNS NNS O
in IN IN O
rats NNS NNS O
rendered VBN VBN O
myopathic JJ JJ O
by IN IN O
a DT DT O
diet JJ JJ O
deficient NN NN O
in IN IN O
vitamin NN NN B-CHEM
E NNP NNP I-CHEM
. . . O

In IN IN O
this DT DT O
way NN NN O
they PRP PRP O
obtained VBD VBD O
appreciable JJ JJ O
changes NNS NNS O
in IN IN O
body NN NN O
weight NN NN O
( ( ( O
increased VBN VBN O
from IN IN O
50 CD CD O
to TO TO O
70 CD CD O
g SYM SYM O
after IN IN O
forty NN NN O
days NNS NNS O
at IN IN O
a DT DT O
dose NN NN O
of IN IN O
5 CD CD O
mg NN NN O
per IN IN O
day NN NN O
of IN IN O
anabolizing VBG VBG O
agent NN NN O
) ) ) O
, , , O
but CC CC O
most JJS JJS O
of IN IN O
all DT DT O
they PRP PRP O
found VBD VBD O
histological JJ JJ O
changes NNS NNS O
due JJ JJ O
to TO TO O
" '' '' O
regenerative JJ JJ O
" '' '' O
changes NNS NNS O
in IN IN O
the DT DT O
muscle NN NN O
tissue NN NN O
, , , O
which WDT WDT O
however RB RB O
maintained VBD VBD O
its PRP$ PRP$ O
myopathic JJ JJ O
characteristics NNS NNS O
in IN IN O
the DT DT O
control NN NN O
animals NNS NNS O
that WDT WDT O
were VBD VBD O
not RB RB O
treated VBN VBN O
with IN IN O
the DT DT O
anabolizing VBG VBG O
agent NN NN O
. . . O

The DT DT O
authors NNS NNS O
conclude VBP VBP O
by IN IN O
affirming VBG VBG O
the DT DT O
undoubted JJ JJ O
efficacy NN NN O
of IN IN O
the DT DT O
anabolizing VBG VBG O
steroids NNS NNS B-CHEM
in IN IN O
experimental JJ JJ O
myopathic JJ JJ O
disease NN NN O
, , , O
but CC CC O
they PRP PRP O
have VBP VBP O
reservations NNS NNS O
as IN IN O
to TO TO O
the DT DT O
transfer NN NN O
of IN IN O
the DT DT O
results NNS NNS O
into IN IN O
the DT DT O
human JJ JJ O
field NN NN O
, , , O
where WRB WRB O
high JJ JJ O
dosage NN NN O
cannot NN NN O
be VB VB O
carried VBN VBN O
out IN IN O
continuously RB RB O
because IN IN O
of IN IN O
the DT DT O
effects NNS NNS O
of IN IN O
the DT DT O
drug NN NN O
on IN IN O
virility NN NN O
; : : O
because IN IN O
the DT DT O
tissue NN NN O
injury NN NN O
too RB RB O
often RB RB O
occurs VBZ VBZ O
at IN IN O
an DT DT O
irreversible JJ JJ O
stage NN NN O
vis NN NN O
- : : O
a DT DT O
- - - O
vis NN NN O
the DT DT O
" '' '' O
regeneration NN NN O
" '' '' O
of IN IN O
the DT DT O
muscle NN NN O
tissue NN NN O
; : : O
and CC CC O
finally RB RB O
because IN IN O
the DT DT O
dystrophic JJ JJ O
injurious JJ JJ O
agent NN NN O
is VBZ VBZ O
certainly RB RB O
not RB RB O
the DT DT O
lack NN NN O
of IN IN O
vitamin NN NN B-CHEM
E NNP NNP I-CHEM
but CC CC O
something NN NN O
as IN IN O
yet RB RB O
unknown JJ JJ O
. . . O

Paclitaxel NNP NNP B-CHEM
3 CD CD O
- : : O
hour NN NN O
infusion NN NN O
given VBN VBN O
alone RB RB O
and CC CC O
combined VBN VBN O
with IN IN O
carboplatin NN NN B-CHEM
: : : O
preliminary JJ JJ O
results NNS NNS O
of IN IN O
dose NN NN O
- - - O
escalation NN NN O
trials NNS NNS O
. . . O

Paclitaxel NNP NNP B-CHEM
( ( ( O
Taxol NNP NNP B-CHEM
; : : O
Bristol NNP NNP O
- : : O
Myers NNP NNP O
Squibb NNP NNP O
Company NNP NNP O
, , , O
Princeton NNP NNP O
, , , O
NJ NNP NNP O
) ) ) O
by IN IN O
3 CD CD O
- : : O
hour NN NN O
infusion NN NN O
was VBD VBD O
combined VBN VBN O
with IN IN O
carboplatin NN NN B-CHEM
in IN IN O
a DT DT O
phase NN NN O
I PRP PRP O
/ NN NN O
II NNP NNP O
study NN NN O
directed VBD VBD O
to TO TO O
patients NNS NNS O
with IN IN O
non NN NN O
- - - O
small JJ JJ O
cell NN NN O
lung NN NN O
cancer NN NN O
. . . O

Carboplatin NNP NNP B-CHEM
was VBD VBD O
given VBN VBN O
at IN IN O
a DT DT O
fixed VBN VBN O
target NN NN O
area NN NN O
under IN IN O
the DT DT O
concentration NN NN O
- - - O
time NN NN O
curve NN NN O
of IN IN O
6 CD CD O
. . . O
0 CD CD O
by IN IN O
the DT DT O
Calvert NNP NNP O
formula NN NN O
, , , O
whereas IN IN O
paclitaxel NN NN B-CHEM
was VBD VBD O
escalated VBN VBN O
in IN IN O
patient NN NN O
cohorts NNS NNS O
from IN IN O
150 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
( ( ( O
dose NN NN O
level NN NN O
I PRP PRP O
) ) ) O
to TO TO O
175 CD CD O
, , , O
200 CD CD O
, , , O
225 CD CD O
, , , O
and CC CC O
250 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
. . . O

The DT DT O
225 NN NN O
mg NN NN O
/ NN NN O
m2 NN NN O
level NN NN O
was VBD VBD O
expanded VBN VBN O
for IN IN O
the DT DT O
phase NN NN O
II NNP NNP O
study NN NN O
since IN IN O
the DT DT O
highest JJS JJS O
level NN NN O
achieved VBN VBN O
( ( ( O
250 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
) ) ) O
required VBN VBN O
modification NN NN O
because IN IN O
of IN IN O
nonhematologic JJ JJ O
toxicities NNS NNS O
( ( ( O
arthralgia NN NN O
and CC CC O
sensory JJ JJ O
neuropathy NN NN O
) ) ) O
. . . O

Therapeutic NNP NNP O
effects NNS NNS O
were VBD VBD O
noted VBN VBN O
at IN IN O
all DT DT O
dose NN NN O
levels NNS NNS O
, , , O
with IN IN O
objective NN NN O
responses NNS NNS O
in IN IN O
17 CD CD O
( ( ( O
two CD CD O
complete JJ JJ O
and CC CC O
15 CD CD O
partial JJ JJ O
regressions NNS NNS O
) ) ) O
of IN IN O
41 CD CD O
previously RB RB O
untreated VBD VBD O
patients NNS NNS O
. . . O

Toxicities NNP NNP O
were VBD VBD O
compared VBN VBN O
with IN IN O
a DT DT O
cohort NN NN O
of IN IN O
patients NNS NNS O
in IN IN O
a DT DT O
phase NN NN O
I PRP PRP O
trial NN NN O
of IN IN O
paclitaxel NN NN B-CHEM
alone RB RB O
at IN IN O
identical JJ JJ O
dose NN NN O
levels NNS NNS O
. . . O

Carboplatin NNP NNP B-CHEM
did VBD VBD O
not RB RB O
appear VB VB O
to TO TO O
add VB VB O
to TO TO O
the DT DT O
hematologic JJ JJ O
toxicities NNS NNS O
observed VBD VBD O
, , , O
and CC CC O
the DT DT O
paclitaxel NN NN B-CHEM
/ NN NN O
carboplatin NN NN B-CHEM
combination NN NN O
could MD MD O
be VB VB O
dosed VBN VBN O
every DT DT O
3 CD CD O
weeks NNS NNS O
. . . O

The DT DT O
dose NN NN O
- - - O
dependent JJ JJ O
effect NN NN O
of IN IN O
misoprostol NN NN B-CHEM
on IN IN O
indomethacin NN NN B-CHEM
- : : O
induced JJ JJ O
renal JJ JJ O
dysfunction NN NN O
in IN IN O
well RB RB O
compensated VBD VBD O
cirrhosis NNS NNS O
. . . O

Misoprostol NNP NNP B-CHEM
( ( ( O
200 CD CD O
micrograms NNS NNS O
) ) ) O
has VBZ VBZ O
been VBN VBN O
shown VBN VBN O
to TO TO O
acutely RB RB O
counteract VB VB O
the DT DT O
indomethacin NN NN B-CHEM
- - - O
induced JJ JJ O
renal NN NN O
dysfunction NN NN O
in IN IN O
well RB RB O
compensated VBD VBD O
cirrhotic JJ JJ O
patients NNS NNS O
. . . O

The DT DT O
aim NN NN O
of IN IN O
this DT DT O
study NN NN O
was VBD VBD O
to TO TO O
determine VB VB O
if IN IN O
the DT DT O
prophylactic JJ JJ O
value NN NN O
of IN IN O
misoprostol NN NN B-CHEM
was VBD VBD O
dose JJ JJ O
- - - O
dependent NN NN O
. . . O

Parameters NNP NNP O
of IN IN O
renal JJ JJ O
hemodynamics NNS NNS O
and CC CC O
tubular JJ JJ O
sodium NN NN B-CHEM
and CC CC O
water NN NN O
handling VBG VBG O
were VBD VBD O
assessed VBN VBN O
by IN IN O
clearance NN NN O
techniques NNS NNS O
in IN IN O
26 CD CD O
well RB RB O
compensated VBD VBD O
cirrhotic JJ JJ O
patients NNS NNS O
before IN IN O
and CC CC O
after IN IN O
an DT DT O
oral JJ JJ O
combination NN NN O
of IN IN O
50 CD CD O
mg NN NN O
of IN IN O
indomethacin NN NN B-CHEM
and CC CC O
various JJ JJ O
doses NNS NNS O
of IN IN O
misoprostol NN NN B-CHEM
. . . O

The DT DT O
200 CD CD O
- : : O
micrograms NNS NNS O
dose NN NN O
was VBD VBD O
able JJ JJ O
to TO TO O
totally RB RB O
abolish VB VB O
the DT DT O
deleterious JJ JJ O
renal JJ JJ O
effects NNS NNS O
of IN IN O
indomethacin NN NN B-CHEM
, , , O
whereas IN IN O
the DT DT O
800 CD CD O
- : : O
micrograms NNS NNS O
dose NN NN O
resulted VBD VBD O
in IN IN O
significant JJ JJ O
worsening NN NN O
of IN IN O
renal JJ JJ O
hemodynamics NNS NNS O
and CC CC O
sodium NN NN B-CHEM
retention NN NN O
. . . O

These DT DT O
changes NNS NNS O
were VBD VBD O
maximal NN NN O
in IN IN O
the DT DT O
hour NN NN O
immediately RB RB O
after IN IN O
medications NNS NNS O
and CC CC O
slowly RB RB O
returned VBD VBD O
toward IN IN O
base NN NN O
- - - O
line NN NN O
levels NNS NNS O
thereafter RB RB O
. . . O

These DT DT O
results NNS NNS O
suggest VBP VBP O
that IN IN O
the DT DT O
renal NN NN O
protective JJ JJ O
effects NNS NNS O
of IN IN O
misoprostol NN NN B-CHEM
is VBZ VBZ O
dose JJ JJ O
- - - O
dependent NN NN O
. . . O

However RB RB O
, , , O
until IN IN O
this DT DT O
apparent JJ JJ O
ability NN NN O
of IN IN O
200 CD CD O
micrograms NNS NNS O
of IN IN O
misoprostol NN NN B-CHEM
to TO TO O
prevent VB VB O
the DT DT O
adverse JJ JJ O
effects NNS NNS O
of IN IN O
indomethacin NN NN B-CHEM
on IN IN O
renal JJ JJ O
function NN NN O
is VBZ VBZ O
confirmed VBN VBN O
with IN IN O
chronic JJ JJ O
frequent JJ JJ O
dosing NN NN O
, , , O
it PRP PRP O
would MD MD O
be VB VB O
prudent JJ JJ O
to TO TO O
avoid VB VB O
nonsteroidal NN NN O
anti JJ JJ O
- : : O
inflammatory JJ JJ O
therapy NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
cirrhosis NNS NNS O
. . . O

Increased VBN VBN O
frequency NN NN O
and CC CC O
severity NN NN O
of IN IN O
angio NN NN O
- - - O
oedema NN NN O
related VBN VBN O
to TO TO O
long JJ JJ O
- - - O
term NN NN O
therapy NN NN O
with IN IN O
angiotensin NN NN B-CHEM
- - - I-CHEM
converting VBG VBG I-CHEM
enzyme NN NN I-CHEM
inhibitor NN NN I-CHEM
in IN IN O
two CD CD O
patients NNS NNS O
. . . O

Adverse NNP NNP O
reactions NNS NNS O
to TO TO O
drugs NNS NNS O
are VBP VBP O
well RB RB O
recognized VBN VBN O
as IN IN O
a DT DT O
cause NN NN O
of IN IN O
acute JJ JJ O
or CC CC O
chronic JJ JJ O
urticaria NNS NNS O
, , , O
and CC CC O
angio NN NN O
- - - O
oedema NN NN O
. . . O

Angiotensin NNP NNP B-CHEM
- : : I-CHEM
converting VBG VBG I-CHEM
enzyme NN NN I-CHEM
( ( ( I-CHEM
ACE NNP NNP I-CHEM
) ) ) I-CHEM
inhibitors NNS NNS I-CHEM
, , , O
used VBN VBN O
to TO TO O
treat VB VB O
hypertension NN NN O
and CC CC O
congestive JJ JJ O
heart NN NN O
failure NN NN O
, , , O
were VBD VBD O
introduced VBN VBN O
in IN IN O
Europe NNP NNP O
in IN IN O
the DT DT O
middle NN NN O
of IN IN O
the DT DT O
eighties NNS NNS O
, , , O
and CC CC O
the DT DT O
use NN NN O
of IN IN O
these DT DT O
drugs NNS NNS O
has VBZ VBZ O
increased VBN VBN O
progressively RB RB O
. . . O

Soon RB RB O
after IN IN O
the DT DT O
introduction NN NN O
of IN IN O
ACE NNP NNP B-CHEM
inhibitors NNS NNS I-CHEM
, , , O
acute JJ JJ O
bouts NNS NNS O
of IN IN O
angio NN NN O
- - - O
oedema NN NN O
were VBD VBD O
reported VBN VBN O
in IN IN O
association NN NN O
with IN IN O
the DT DT O
use NN NN O
of IN IN O
these DT DT O
drugs NNS NNS O
. . . O

We PRP PRP O
wish VBP VBP O
to TO TO O
draw VB VB O
attention NN NN O
to TO TO O
the DT DT O
possibility NN NN O
of IN IN O
adverse JJ JJ O
reactions NNS NNS O
to TO TO O
ACE NNP NNP B-CHEM
inhibitors NNS NNS I-CHEM
after IN IN O
long JJ JJ O
- - - O
term NN NN O
use NN NN O
and CC CC O
in IN IN O
patients NNS NNS O
with IN IN O
pre NN NN O
- - - O
existing VBG VBG O
angio NN NN O
- - - O
oedema NN NN O
. . . O

Myoclonus NNP NNP O
associated VBN VBN O
with IN IN O
lorazepam NN NN B-CHEM
therapy NN NN O
in IN IN O
very RB RB O
- - - O
low JJ JJ O
- - - O
birth NN NN O
- - - O
weight NN NN O
infants NNS NNS O
. . . O

Lorazepam NNP NNP B-CHEM
is VBZ VBZ O
being VBG VBG O
used VBN VBN O
with IN IN O
increasing VBG VBG O
frequency NN NN O
as IN IN O
a DT DT O
sedative JJ JJ O
in IN IN O
the DT DT O
newborn NN NN O
and CC CC O
the DT DT O
young JJ JJ O
infant NN NN O
. . . O

Concern NNP NNP O
has VBZ VBZ O
been VBN VBN O
raised VBN VBN O
with IN IN O
regard NN NN O
to TO TO O
the DT DT O
safety NN NN O
of IN IN O
lorazepam NN NN B-CHEM
in IN IN O
this DT DT O
age NN NN O
group NN NN O
, , , O
especially RB RB O
in IN IN O
very RB RB O
- - - O
low JJ JJ O
- - - O
birth NN NN O
- - - O
weight NN NN O
( ( ( O
VLBW NNP NNP O
; : : O
< NN NN O
1 CD CD O
, , , O
500 CD CD O
g SYM SYM O
) ) ) O
infants NNS NNS O
. . . O

Three CD CD O
young JJ JJ O
infants NNS NNS O
, , , O
all DT DT O
of IN IN O
birth NN NN O
weight NN NN O
< NN NN O
1 CD CD O
, , , O
500 CD CD O
g SYM SYM O
, , , O
experienced VBN VBN O
myoclonus NN NN O
following VBG VBG O
the DT DT O
intravenous JJ JJ O
administration NN NN O
of IN IN O
lorazepam NN NN B-CHEM
. . . O

The DT DT O
potential JJ JJ O
neurotoxic NN NN O
effects NNS NNS O
of IN IN O
the DT DT O
drug NN NN O
( ( ( O
and CC CC O
its PRP$ PRP$ O
vehicle NN NN O
) ) ) O
in IN IN O
this DT DT O
population NN NN O
are VBP VBP O
discussed VBN VBN O
. . . O

Injectable NNP NNP O
lorazepam NN NN B-CHEM
should MD MD O
be VB VB O
used VBN VBN O
with IN IN O
caution NN NN O
in IN IN O
VLBW NNP NNP O
infants NNS NNS O
. . . O

Transvenous NNP NNP O
right NN NN O
ventricular NN NN O
pacing VBG VBG O
during IN IN O
cardiopulmonary JJ JJ O
resuscitation NN NN O
of IN IN O
pediatric JJ JJ O
patients NNS NNS O
with IN IN O
acute JJ JJ O
cardiomyopathy NN NN O
. . . O

We PRP PRP O
describe VBP VBP O
the DT DT O
cardiopulmonary JJ JJ O
resuscitation NN NN O
efforts NNS NNS O
on IN IN O
five CD CD O
patients NNS NNS O
who WP WP O
presented VBD VBD O
in IN IN O
acute JJ JJ O
circulatory NN NN O
failure NN NN O
from IN IN O
myocardial NN NN O
dysfunction NN NN O
. . . O

Three CD CD O
patients NNS NNS O
had VBD VBD O
acute JJ JJ O
viral JJ JJ O
myocarditis NN NN O
, , , O
one CD CD O
had VBD VBD O
a DT DT O
carbamazepine NN NN B-CHEM
- - - O
induced JJ JJ O
acute JJ JJ O
eosinophilic JJ JJ O
myocarditis NN NN O
, , , O
and CC CC O
one CD CD O
had VBD VBD O
cardiac JJ JJ O
hemosiderosis NN NN O
resulting VBG VBG O
in IN IN O
acute JJ JJ O
cardiogenic JJ JJ O
shock NN NN O
. . . O

All DT DT O
patients NNS NNS O
were VBD VBD O
continuously RB RB O
monitored VBN VBN O
with IN IN O
central JJ JJ O
venous JJ JJ O
and CC CC O
arterial JJ JJ O
catheters NNS NNS O
in IN IN O
addition NN NN O
to TO TO O
routine VB VB O
noninvasive JJ JJ O
monitoring NN NN O
. . . O

An DT DT O
introducer NN NN O
sheath NN NN O
, , , O
a DT DT O
pacemaker NN NN O
, , , O
and CC CC O
sterile JJ JJ O
pacing NN NN O
wires NNS NNS O
were VBD VBD O
made VBN VBN O
readily RB RB O
available JJ JJ O
for IN IN O
the DT DT O
patients NNS NNS O
, , , O
should MD MD O
the DT DT O
need NN NN O
arise VB VB O
to TO TO O
terminate VB VB O
resistant JJ JJ O
cardiac JJ JJ O
dysrhythmias NN NN O
. . . O

All DT DT O
patients NNS NNS O
developed VBN VBN O
cardiocirculatory NN NN O
arrest NN NN O
associated VBN VBN O
with IN IN O
extreme JJ JJ O
hypotension NN NN O
and CC CC O
dysrhythmias NN NN O
within IN IN O
the DT DT O
first JJ JJ O
48 CD CD O
hours NNS NNS O
of IN IN O
their PRP$ PRP$ O
admission NN NN O
to TO TO O
the DT DT O
pediatric JJ JJ O
intensive JJ JJ O
care NN NN O
unit NN NN O
( ( ( O
PICU NNP NNP O
) ) ) O
. . . O

Right RB RB O
ventricular NN NN O
pacemaker NN NN O
wires NNS NNS O
were VBD VBD O
inserted VBN VBN O
in IN IN O
all DT DT O
of IN IN O
them PRP PRP O
during IN IN O
cardiopulmonary JJ JJ O
resuscitation NN NN O
( ( ( O
CPR NNP NNP O
) ) ) O
. . . O

In IN IN O
four CD CD O
patients NNS NNS O
, , , O
cardiac NN NN O
pacing NN NN O
was VBD VBD O
used VBN VBN O
, , , O
resulting VBG VBG O
in IN IN O
a DT DT O
temporary JJ JJ O
captured VBN VBN O
rhythm NN NN O
and CC CC O
restoration NN NN O
of IN IN O
their PRP$ PRP$ O
cardiac NN NN O
output NN NN O
. . . O

These DT DT O
patients NNS NNS O
had VBD VBD O
a DT DT O
second JJ JJ O
event NN NN O
of IN IN O
cardiac JJ JJ O
arrest NN NN O
, , , O
resulting VBG VBG O
in IN IN O
death NN NN O
, , , O
within IN IN O
10 CD CD O
to TO TO O
60 CD CD O
minutes NNS NNS O
. . . O

In IN IN O
one CD CD O
patient NN NN O
, , , O
cardiac NN NN O
pacing NN NN O
was VBD VBD O
not RB RB O
used VBN VBN O
, , , O
because IN IN O
he PRP PRP O
converted VBD VBD O
to TO TO O
normal JJ JJ O
sinus NN NN O
rhythm NN NN O
by IN IN O
electrical JJ JJ O
defibrillation NN NN O
within IN IN O
three CD CD O
minutes NNS NNS O
of IN IN O
initiating VBG VBG O
CPR NNP NNP O
. . . O

We PRP PRP O
conclude VBP VBP O
that IN IN O
cardiac JJ JJ O
pacing NN NN O
during IN IN O
resuscitative JJ JJ O
efforts NNS NNS O
in IN IN O
pediatric NN NN O
patients NNS NNS O
suffering VBG VBG O
from IN IN O
acute JJ JJ O
myocardial NN NN O
dysfunction NN NN O
may MD MD O
not RB RB O
have VB VB O
long JJ JJ O
- - - O
term NN NN O
value NN NN O
in IN IN O
and CC CC O
of IN IN O
itself PRP PRP O
; : : O
however RB RB O
, , , O
if IN IN O
temporary JJ JJ O
hemodynamic JJ JJ O
stability NN NN O
is VBZ VBZ O
achieved VBN VBN O
by IN IN O
this DT DT O
procedure NN NN O
, , , O
it PRP PRP O
may MD MD O
provide VB VB O
additional JJ JJ O
time NN NN O
needed VBD VBD O
to TO TO O
institute VB VB O
other JJ JJ O
therapeutic JJ JJ O
modalities NNS NNS O
. . . O

Efficacy NNP NNP O
and CC CC O
safety NN NN O
of IN IN O
granisetron NN NN B-CHEM
, , , O
a DT DT O
selective JJ JJ O
5 CD CD B-CHEM
- : : I-CHEM
hydroxytryptamine NN NN I-CHEM
- : : O
3 CD CD O
receptor NN NN O
antagonist NN NN O
, , , O
in IN IN O
the DT DT O
prevention NN NN O
of IN IN O
nausea NN NN O
and CC CC O
vomiting VBG VBG O
induced VBN VBN O
by IN IN O
high JJ JJ O
- - - O
dose NN NN O
cisplatin NN NN B-CHEM
. . . O

PURPOSE NNP NNP O
: : : O
To TO TO O
assess VB VB O
the DT DT O
antiemetic JJ JJ O
effects NNS NNS O
and CC CC O
safety NN NN O
profile NN NN O
of IN IN O
four CD CD O
different JJ JJ O
doses NNS NNS O
of IN IN O
granisetron NN NN B-CHEM
( ( ( O
Kytril NNP NNP B-CHEM
; : : O
SmithKline NNP NNP O
Beecham NNP NNP O
Pharmaceuticals NNP NNP O
, , , O
Philadelphia NNP NNP O
, , , O
PA NNP NNP O
) ) ) O
when WRB WRB O
administered VBN VBN O
as IN IN O
a DT DT O
single JJ JJ O
intravenous JJ JJ O
( ( ( O
IV NNP NNP O
) ) ) O
dose NN NN O
for IN IN O
prophylaxis NN NN O
of IN IN O
cisplatin NN NN B-CHEM
- - - O
induced JJ JJ O
nausea NN NN O
and CC CC O
vomiting VBG VBG O
. . . O

PATIENTS NNS NNS O
AND CC CC O
METHODS NNP NNP O
: : : O
One CD CD O
hundred CD CD O
eighty NN NN O
- : : O
four CD CD O
chemotherapy NN NN O
- : : O
naive JJ JJ O
patients NNS NNS O
receiving VBG VBG O
high JJ JJ O
- - - O
dose NN NN O
cisplatin NN NN B-CHEM
( ( ( O
81 CD CD O
to TO TO O
120 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
) ) ) O
were VBD VBD O
randomized VBN VBN O
to TO TO O
receive VB VB O
one CD CD O
of IN IN O
four CD CD O
granisetron NN NN B-CHEM
doses NNS NNS O
( ( ( O
5 CD CD O
, , , O
10 CD CD O
, , , O
20 CD CD O
, , , O
or CC CC O
40 CD CD O
micrograms NNS NNS O
/ NN NN O
kg NN NN O
) ) ) O
administered VBD VBD O
before IN IN O
chemotherapy NN NN O
. . . O

Patients NNS NNS O
were VBD VBD O
observed VBN VBN O
on IN IN O
an DT DT O
inpatient NN NN O
basis NN NN O
for IN IN O
18 CD CD O
to TO TO O
24 CD CD O
hours NNS NNS O
, , , O
and CC CC O
vital JJ JJ O
signs NNS NNS O
, , , O
nausea NN NN O
, , , O
vomiting VBG VBG O
, , , O
retching VBG VBG O
, , , O
and CC CC O
appetite NN NN O
were VBD VBD O
assessed VBN VBN O
. . . O

Safety NNP NNP O
analyses NNS NNS O
included VBD VBD O
incidence NN NN O
of IN IN O
adverse JJ JJ O
experiences NNS NNS O
and CC CC O
laboratory NN NN O
parameter NN NN O
changes NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
After IN IN O
granisetron NN NN B-CHEM
doses NNS NNS O
of IN IN O
5 CD CD O
, , , O
10 CD CD O
, , , O
20 CD CD O
, , , O
and CC CC O
40 CD CD O
micrograms NNS NNS O
/ NN NN O
kg NN NN O
, , , O
a DT DT O
major JJ JJ O
response NN NN O
( ( ( O
< NN NN O
or CC CC O
= SYM SYM O
two CD CD O
vomiting VBG VBG O
or CC CC O
retching VBG VBG O
episodes NNS NNS O
, , , O
and CC CC O
no DT DT O
antiemetic JJ JJ O
rescue NN NN O
) ) ) O
was VBD VBD O
recorded VBN VBN O
in IN IN O
23 CD CD O
% NN NN O
, , , O
57 CD CD O
% NN NN O
, , , O
58 CD CD O
% NN NN O
, , , O
and CC CC O
60 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
, , , O
respectively RB RB O
, , , O
and CC CC O
a DT DT O
complete JJ JJ O
response NN NN O
( ( ( O
no DT DT O
vomiting VBG VBG O
or CC CC O
retching VBG VBG O
, , , O
and CC CC O
no DT DT O
antiemetic JJ JJ O
rescue NN NN O
) ) ) O
in IN IN O
18 CD CD O
% NN NN O
, , , O
41 CD CD O
% NN NN O
, , , O
40 CD CD O
% NN NN O
, , , O
and CC CC O
47 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
, , , O
respectively RB RB O
. . . O

There EX EX O
was VBD VBD O
a DT DT O
statistically RB RB O
longer JJR JJR O
time NN NN O
to TO TO O
first JJ JJ O
episode NN NN O
of IN IN O
nausea NN NN O
( ( ( O
P NN NN O
= SYM SYM O
. . . O
0015 CD CD O
) ) ) O
and CC CC O
vomiting VBG VBG O
( ( ( O
P NN NN O
= SYM SYM O
. . . O
0001 CD CD O
) ) ) O
, , , O
and CC CC O
fewer JJR JJR O
patients NNS NNS O
were VBD VBD O
administered VBN VBN O
additional JJ JJ O
antiemetic JJ JJ O
medication NN NN O
in IN IN O
the DT DT O
10 CD CD O
- : : O
micrograms NNS NNS O
/ NN NN O
kg NN NN O
dosing VBG VBG O
groups NNS NNS O
than IN IN O
in IN IN O
the DT DT O
5 CD CD O
- : : O
micrograms NNS NNS O
/ NN NN O
kg NN NN O
dosing VBG VBG O
group NN NN O
. . . O

As IN IN O
granisetron NN NN B-CHEM
dose NN NN O
increased VBN VBN O
, , , O
appetite NN NN O
return NN NN O
increased VBN VBN O
( ( ( O
P NN NN O
= SYM SYM O
. . . O
040 CD CD O
) ) ) O
. . . O

Headache NNP NNP O
was VBD VBD O
the DT DT O
most RBS RBS O
frequently RB RB O
reported VBN VBN O
adverse JJ JJ O
event NN NN O
( ( ( O
20 CD CD O
% NN NN O
) ) ) O
. . . O

CONCLUSION NNP NNP O
: : : O
A DT DT O
single JJ JJ O
10 CD CD O
- : : O
, , , O
20 CD CD O
- : : O
, , , O
or CC CC O
40 CD CD O
- : : O
micrograms NNS NNS O
/ NN NN O
kg NN NN O
dose NN NN O
of IN IN O
granisetron NN NN B-CHEM
was VBD VBD O
effective JJ JJ O
in IN IN O
controlling VBG VBG O
vomiting VBG VBG O
in IN IN O
57 CD CD O
% NN NN O
to TO TO O
60 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
who WP WP O
received VBD VBD O
cisplatin NN NN B-CHEM
at IN IN O
doses NNS NNS O
greater JJR JJR O
than IN IN O
81 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
and CC CC O
totally RB RB O
prevented JJ JJ O
vomiting VBG VBG O
in IN IN O
40 CD CD O
% NN NN O
to TO TO O
47 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
. . . O

There EX EX O
were VBD VBD O
no DT DT O
statistically RB RB O
significant JJ JJ O
differences NNS NNS O
in IN IN O
efficacy NN NN O
between IN IN O
the DT DT O
10 CD CD O
- : : O
micrograms NNS NNS O
/ NN NN O
kg NN NN O
dose NN NN O
and CC CC O
the DT DT O
20 CD CD O
- : : O
and CC CC O
40 CD CD O
- : : O
micrograms NNS NNS O
/ NN NN O
kg NN NN O
doses NNS NNS O
. . . O

Granisetron NNP NNP B-CHEM
was VBD VBD O
well RB RB O
tolerated VBN VBN O
at IN IN O
all DT DT O
doses NNS NNS O
. . . O

Adverse NNP NNP O
interaction NN NN O
between IN IN O
clonidine NN NN B-CHEM
and CC CC O
verapamil NN NN B-CHEM
. . . O

OBJECTIVE NNP NNP O
: : : O
To TO TO O
report VB VB O
two CD CD O
cases NNS NNS O
of IN IN O
a DT DT O
possible JJ JJ O
adverse JJ JJ O
interaction NN NN O
between IN IN O
clonidine NN NN B-CHEM
and CC CC O
verapamil NN NN B-CHEM
resulting VBG VBG O
in IN IN O
atrioventricular NN NN O
( ( ( O
AV NNP NNP O
) ) ) O
block NN NN O
in IN IN O
both DT DT O
patients NNS NNS O
and CC CC O
severe JJ JJ O
hypotension NN NN O
in IN IN O
one CD CD O
patient NN NN O
. . . O

CASE NN NN O
SUMMARIES NNP NNP O
: : : O
A DT DT O
54 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
woman NN NN O
with IN IN O
hyperaldosteronism NN NN O
was VBD VBD O
treated VBN VBN O
with IN IN O
verapamil NN NN B-CHEM
480 CD CD O
mg NN NN O
/ NN NN O
d SYM SYM O
and CC CC O
spironolactone NN NN B-CHEM
100 CD CD O
mg NN NN O
/ NN NN O
d SYM SYM O
. . . O

After IN IN O
the DT DT O
addition NN NN O
of IN IN O
a DT DT O
minimal JJ JJ O
dose NN NN O
of IN IN O
clonidine NN NN B-CHEM
( ( ( O
0 CD CD O
. . . O
15 CD CD O
mg NN NN O
bid NN NN O
) ) ) O
, , , O
she PRP PRP O
developed VBD VBD O
complete JJ JJ O
AV NNP NNP O
block NN NN O
and CC CC O
severe JJ JJ O
hypotension NN NN O
, , , O
which WDT WDT O
resolved VBD VBD O
upon IN IN O
cessation NN NN O
of IN IN O
all DT DT O
medications NNS NNS O
. . . O

A DT DT O
65 NN NN O
- - - O
year NN NN O
- - - O
old JJ JJ O
woman NN NN O
was VBD VBD O
treated VBN VBN O
with IN IN O
extended JJ JJ O
- - - O
release NN NN O
verapamil NN NN B-CHEM
240 CD CD O
mg NN NN O
/ NN NN O
d SYM SYM O
. . . O

After IN IN O
the DT DT O
addition NN NN O
of IN IN O
clonidine NN NN B-CHEM
0 CD CD O
. . . O
15 CD CD O
mg NN NN O
bid NN NN O
she PRP PRP O
developed VBD VBD O
complete JJ JJ O
AV NNP NNP O
block NN NN O
, , , O
which WDT WDT O
resolved VBD VBD O
after IN IN O
all DT DT O
therapy NN NN O
was VBD VBD O
stopped VBN VBN O
. . . O

DISCUSSION NNP NNP O
: : : O
An DT DT O
adverse JJ JJ O
interaction NN NN O
between IN IN O
clonidine NN NN B-CHEM
and CC CC O
verapamil NN NN B-CHEM
has VBZ VBZ O
not RB RB O
been VBN VBN O
reported VBN VBN O
previously RB RB O
. . . O

We PRP PRP O
describe VBP VBP O
two CD CD O
such JJ JJ O
cases NNS NNS O
and CC CC O
discuss VB VB O
the DT DT O
various JJ JJ O
mechanisms NNS NNS O
that WDT WDT O
might MD MD O
cause VB VB O
such JJ JJ O
an DT DT O
interaction NN NN O
. . . O

Clinicians NNP NNP O
should MD MD O
be VB VB O
acquainted VBN VBN O
with IN IN O
this DT DT O
possibly RB RB O
fatal JJ JJ O
interaction NN NN O
between IN IN O
two CD CD O
commonly RB RB O
used VBD VBD O
antihypertensive JJ JJ O
drugs NNS NNS O
. . . O

CONCLUSIONS NNP NNP O
: : : O
Caution NNP NNP O
is VBZ VBZ O
recommended VBN VBN O
in IN IN O
combining VBG VBG O
clonidine NN NN B-CHEM
and CC CC O
verapamil NN NN B-CHEM
therapy NN NN O
, , , O
even RB RB O
in IN IN O
patients NNS NNS O
who WP WP O
do VBP VBP O
not RB RB O
have VB VB O
sinus NN NN O
or CC CC O
AV NNP NNP O
node NN NN O
dysfunction NN NN O
. . . O

The DT DT O
two CD CD O
drugs NNS NNS O
may MD MD O
act VB VB O
synergistically RB RB O
on IN IN O
both DT DT O
the DT DT O
AV NNP NNP O
node NN NN O
and CC CC O
the DT DT O
peripheral JJ JJ O
circulation NN NN O
. . . O

Pharmacological NNP NNP O
studies NNS NNS O
on IN IN O
a DT DT O
new JJ JJ O
dihydrothienopyridine NN NN B-CHEM
calcium NN NN I-CHEM
antagonist NN NN O
, , , O
S NNP NNP B-CHEM
- : : I-CHEM
312 CD CD I-CHEM
- : : I-CHEM
d SYM SYM I-CHEM
. . . O

5th CD CD O
communication NN NN O
: : : O
anticonvulsant JJ JJ O
effects NNS NNS O
in IN IN O
mice NN NN O
. . . O

S NNP NNP B-CHEM
- : : I-CHEM
312 CD CD I-CHEM
, , , O
S NNP NNP B-CHEM
- : : I-CHEM
312 CD CD I-CHEM
- : : I-CHEM
d SYM SYM I-CHEM
, , , O
but CC CC O
not RB RB O
S NNP NNP B-CHEM
- : : I-CHEM
312 CD CD I-CHEM
- : : I-CHEM
l NN NN I-CHEM
, , , O
L NNP NNP O
- : : O
type NN NN O
calcium NN NN B-CHEM
channel NN NN O
antagonists NNS NNS O
, , , O
showed VBD VBD O
anticonvulsant JJ JJ O
effects NNS NNS O
on IN IN O
the DT DT O
audiogenic JJ JJ O
tonic JJ JJ O
convulsions NNS NNS O
in IN IN O
DBA NNP NNP O
/ NN NN O
2 CD CD O
mice NN NN O
; : : O
and CC CC O
their PRP$ PRP$ O
ED50 NNP NNP O
values NNS NNS O
were VBD VBD O
18 CD CD O
. . . O
4 CD CD O
( ( ( O
12 CD CD O
. . . O
8 CD CD O
- : : O
27 CD CD O
. . . O
1 CD CD O
) ) ) O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
p NN NN O
. . . O
o NN NN O
. . . O
and CC CC O
15 CD CD O
. . . O
0 CD CD O
( ( ( O
10 CD CD O
. . . O
2 CD CD O
- : : O
23 CD CD O
. . . O
7 CD CD O
) ) ) O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
p NN NN O
. . . O
o NN NN O
. . . O
, , , O
respectively RB RB O
, , , O
while IN IN O
that DT DT O
of IN IN O
flunarizine NN NN B-CHEM
was VBD VBD O
34 CD CD O
. . . O
0 CD CD O
( ( ( O
26 CD CD O
. . . O
0 CD CD O
- : : O
44 CD CD O
. . . O
8 CD CD O
) ) ) O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
p NN NN O
. . . O
o NN NN O
. . . O

Although IN IN O
moderate JJ JJ O
anticonvulsant JJ JJ O
effects NNS NNS O
of IN IN O
S NNP NNP B-CHEM
- - - I-CHEM
312 CD CD I-CHEM
- : : I-CHEM
d SYM SYM I-CHEM
in IN IN O
higher JJR JJR O
doses NNS NNS O
were VBD VBD O
observed VBN VBN O
against IN IN O
the DT DT O
clonic JJ JJ O
convulsions NNS NNS O
induced VBN VBN O
by IN IN O
pentylenetetrazole NN NN B-CHEM
( ( ( O
85 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
s VBZ VBZ O
. . . O
c SYM SYM O
. . . O
) ) ) O
or CC CC O
bemegride NN NN B-CHEM
( ( ( O
40 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
s VBZ VBZ O
. . . O
c SYM SYM O
. . . O
) ) ) O
, , , O
no DT DT O
effects NNS NNS O
were VBD VBD O
observed VBN VBN O
in IN IN O
convulsions NNS NNS O
induced VBN VBN O
by IN IN O
N NNP NNP B-CHEM
- : : I-CHEM
methyl NN NN I-CHEM
- : : I-CHEM
D NNP NNP I-CHEM
- : : I-CHEM
aspartate NN NN I-CHEM
, , , O
picrotoxin NN NN B-CHEM
, , , O
or CC CC O
electroshock NN NN O
in IN IN O
Slc NNP NNP O
: : : O
ddY NN NN O
mice NN NN O
. . . O

S NNP NNP B-CHEM
- : : I-CHEM
312 CD CD I-CHEM
- : : I-CHEM
d SYM SYM I-CHEM
may MD MD O
be VB VB O
useful JJ JJ O
in IN IN O
the DT DT O
therapy NN NN O
of IN IN O
certain JJ JJ O
types NNS NNS O
of IN IN O
human JJ JJ O
epilepsy NN NN O
. . . O

Transmural NNP NNP O
myocardial NN NN O
infarction NN NN O
with IN IN O
sumatriptan NN NN B-CHEM
. . . O

For IN IN O
sumatriptan NN NN B-CHEM
, , , O
tightness NN NN O
in IN IN O
the DT DT O
chest NN NN O
caused VBN VBN O
by IN IN O
an DT DT O
unknown JJ JJ O
mechanism NN NN O
has VBZ VBZ O
been VBN VBN O
reported VBN VBN O
in IN IN O
3 CD CD O
- : : O
5 CD CD O
% NN NN O
of IN IN O
users NNS NNS O
. . . O

We PRP PRP O
describe VBP VBP O
a DT DT O
47 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
woman NN NN O
with IN IN O
an DT DT O
acute JJ JJ O
myocardial NN NN O
infarction NN NN O
after IN IN O
administration NN NN O
of IN IN O
sumatriptan NN NN B-CHEM
6 CD CD O
mg NN NN O
subcutaneously NN NN O
for IN IN O
cluster NN NN O
headache NN NN O
. . . O

The DT DT O
patient NN NN O
had VBD VBD O
no DT DT O
history NN NN O
of IN IN O
underlying VBG VBG O
ischaemic JJ JJ O
heart NN NN O
disease NN NN O
or CC CC O
Prinzmetal NNP NNP O
' POS POS O
s VBZ VBZ O
angina NN NN O
. . . O

She PRP PRP O
recovered VBD VBD O
without IN IN O
complications NNS NNS O
. . . O

Flumazenil NNP NNP B-CHEM
induces NNS NNS O
seizures NNS NNS O
and CC CC O
death NN NN O
in IN IN O
mixed JJ JJ O
cocaine NN NN B-CHEM
- - - O
diazepam NN NN B-CHEM
intoxications NNS NNS O
. . . O

STUDY NNP NNP O
HYPOTHESIS NNP NNP O
: : : O
Administration NNP NNP O
of IN IN O
the DT DT O
benzodiazepine NN NN B-CHEM
antagonist NN NN O
flumazenil NN NN B-CHEM
may MD MD O
unmask VB VB O
seizures NNS NNS O
in IN IN O
mixed JJ JJ O
cocaine NN NN B-CHEM
- - - O
benzodiazepine NN NN B-CHEM
intoxication NN NN O
. . . O

DESIGN NNP NNP O
: : : O
Male NNP NNP O
Sprague NNP NNP O
- : : O
Dawley NNP NNP O
rats NNS NNS O
received VBD VBD O
100 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
cocaine NN NN B-CHEM
IP NNP NNP O
alone RB RB O
, , , O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
diazepam NN NN B-CHEM
alone RB RB O
, , , O
or CC CC O
a DT DT O
combination NN NN O
of IN IN O
diazepam NN NN B-CHEM
and CC CC O
cocaine NN NN B-CHEM
. . . O

Three CD CD O
minutes NNS NNS O
later RB RB O
, , , O
groups NNS NNS O
were VBD VBD O
challenged VBN VBN O
with IN IN O
vehicle NN NN O
or CC CC O
flumazenil NN NN B-CHEM
5 CD CD O
or CC CC O
10 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
IP NNP NNP O
. . . O

Animal NNP NNP O
behavior NN NN O
, , , O
seizures NNS NNS O
( ( ( O
time NN NN O
to TO TO O
and CC CC O
incidence NN NN O
) ) ) O
, , , O
death NN NN O
( ( ( O
time NN NN O
to TO TO O
and CC CC O
incidence NN NN O
) ) ) O
, , , O
and CC CC O
cortical JJ JJ O
EEG NNP NNP O
tracings NNS NNS O
were VBD VBD O
recorded VBN VBN O
. . . O

INTERVENTIONS NNP NNP O
: : : O
Administration NNP NNP O
of IN IN O
flumazenil NN NN B-CHEM
to TO TO O
animals NNS NNS O
after IN IN O
they PRP PRP O
had VBD VBD O
received VBN VBN O
a DT DT O
combination NN NN O
dose NN NN O
of IN IN O
cocaine NN NN B-CHEM
and CC CC O
diazepam NN NN B-CHEM
. . . O

RESULTS NNS NNS O
: : : O
In IN IN O
group NN NN O
1 CD CD O
, , , O
animals NNS NNS O
received VBD VBD O
cocaine NN NN B-CHEM
followed VBN VBN O
by IN IN O
vehicle NN NN O
. . . O

This DT DT O
resulted VBD VBD O
in IN IN O
100 CD CD O
% NN NN O
developing VBG VBG O
seizures NNS NNS O
and CC CC O
death NN NN O
. . . O

Group NNP NNP O
2 CD CD O
received VBD VBD O
diazepam NN NN B-CHEM
alone RB RB O
followed VBN VBN O
by IN IN O
vehicle NN NN O
. . . O

Animals NNS NNS O
became VBD VBD O
somnolent NN NN O
and CC CC O
none NN NN O
died VBD VBD O
. . . O

Group NNP NNP O
3 CD CD O
received VBD VBD O
diazepam NN NN B-CHEM
followed VBN VBN O
by IN IN O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
flumazenil NN NN B-CHEM
. . . O

Animals NNS NNS O
became VBD VBD O
somnolent NN NN O
after IN IN O
diazepam NN NN B-CHEM
and CC CC O
then RB RB O
active JJ JJ O
after IN IN O
flumazenil NN NN B-CHEM
administration NN NN O
. . . O

In IN IN O
group NN NN O
4 CD CD O
, , , O
a DT DT O
combination NN NN O
of IN IN O
cocaine NN NN B-CHEM
and CC CC O
diazepam NN NN B-CHEM
was VBD VBD O
administered VBN VBN O
simultaneously RB RB O
. . . O

This DT DT O
resulted VBD VBD O
in IN IN O
no DT DT O
overt NN NN O
or CC CC O
EEG NNP NNP O
- : : O
detectable JJ JJ O
seizures NNS NNS O
and CC CC O
a DT DT O
50 CD CD O
% NN NN O
incidence NN NN O
of IN IN O
death NN NN O
. . . O

Group NNP NNP O
5 CD CD O
received VBD VBD O
a DT DT O
similar JJ JJ O
combination NN NN O
of IN IN O
cocaine NN NN B-CHEM
and CC CC O
diazepam NN NN B-CHEM
, , , O
followed VBD VBD O
later RB RB O
by IN IN O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
flumazenil NN NN B-CHEM
. . . O

This DT DT O
resulted VBD VBD O
in IN IN O
an DT DT O
increased JJ JJ O
incidence NN NN O
of IN IN O
seizures NNS NNS O
, , , O
90 CD CD O
% NN NN O
( ( ( O
P NN NN O
< NN NN O
. . . O
01 CD CD O
) ) ) O
, , , O
and CC CC O
death NN NN O
, , , O
100 CD CD O
% NN NN O
( ( ( O
P NN NN O
< NN NN O
or CC CC O
= SYM SYM O
. . . O
01 CD CD O
) ) ) O
, , , O
compared VBN VBN O
with IN IN O
group NN NN O
4 CD CD O
. . . O

Group NNP NNP O
6 CD CD O
received VBD VBD O
cocaine NN NN B-CHEM
and CC CC O
diazepam NN NN B-CHEM
followed VBN VBN O
by IN IN O
10 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
flumazenil NN NN B-CHEM
. . . O

This DT DT O
also RB RB O
resulted VBN VBN O
in IN IN O
an DT DT O
increased JJ JJ O
incidence NN NN O
of IN IN O
seizures NNS NNS O
, , , O
90 CD CD O
% NN NN O
( ( ( O
P NN NN O
< NN NN O
or CC CC O
= SYM SYM O
. . . O
01 CD CD O
) ) ) O
, , , O
and CC CC O
death NN NN O
, , , O
90 CD CD O
% NN NN O
( ( ( O
P NN NN O
< NN NN O
or CC CC O
= SYM SYM O
. . . O
05 CD CD O
) ) ) O
, , , O
compared VBN VBN O
with IN IN O
group NN NN O
4 CD CD O
. . . O

CONCLUSION NNP NNP O
: : : O
Flumazenil NNP NNP B-CHEM
can MD MD O
unmask VB VB O
seizures NNS NNS O
and CC CC O
increase VB VB O
the DT DT O
incidence NN NN O
of IN IN O
death NN NN O
in IN IN O
a DT DT O
model NN NN O
of IN IN O
combined VBN VBN O
cocaine NN NN B-CHEM
- - - O
diazepam NN NN B-CHEM
intoxications NNS NNS O
. . . O

Mechanisms NNP NNP O
for IN IN O
protective JJ JJ O
effects NNS NNS O
of IN IN O
free JJ JJ O
radical JJ JJ O
scavengers NNS NNS O
on IN IN O
gentamicin NN NN B-CHEM
- - - O
mediated JJ JJ O
nephropathy NN NN O
in IN IN O
rats NNS NNS O
. . . O

Studies NNS NNS O
were VBD VBD O
performed VBN VBN O
to TO TO O
examine VB VB O
the DT DT O
mechanisms NNS NNS O
for IN IN O
the DT DT O
protective JJ JJ O
effects NNS NNS O
of IN IN O
free JJ JJ O
radical JJ JJ O
scavengers NNS NNS O
on IN IN O
gentamicin NN NN B-CHEM
( ( ( O
GM NNP NNP B-CHEM
) ) ) O
- : : O
mediated JJ JJ O
nephropathy NN NN O
. . . O

Administration NNP NNP O
of IN IN O
GM NNP NNP B-CHEM
at IN IN O
40 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
sc NN NN O
for IN IN O
13 CD CD O
days NNS NNS O
to TO TO O
rats NNS NNS O
induced VBD VBD O
a DT DT O
significant JJ JJ O
reduction NN NN O
in IN IN O
renal JJ JJ O
blood NN NN O
flow NN NN O
( ( ( O
RBF NNP NNP O
) ) ) O
and CC CC O
inulin NN NN O
clearance NN NN O
( ( ( O
CIn NNP NNP O
) ) ) O
as RB RB O
well RB RB O
as IN IN O
marked VBN VBN O
tubular NN NN O
damage NN NN O
. . . O

A DT DT O
significant JJ JJ O
reduction NN NN O
in IN IN O
urinary JJ JJ O
guanosine NN NN B-CHEM
3 CD CD I-CHEM
' POS POS I-CHEM
, , , I-CHEM
5 CD CD I-CHEM
' POS POS I-CHEM
- : : I-CHEM
cyclic JJ JJ I-CHEM
monophosphate NN NN I-CHEM
( ( ( O
cGMP NN NN B-CHEM
) ) ) O
excretion NN NN O
and CC CC O
a DT DT O
significant JJ JJ O
increase NN NN O
in IN IN O
renal JJ JJ O
cortical JJ JJ O
renin NN NN O
and CC CC O
endothelin NN NN O
- - - O
1 CD CD O
contents NNS NNS O
were VBD VBD O
also RB RB O
observed VBN VBN O
in IN IN O
GM NNP NNP B-CHEM
- - - O
mediated JJ JJ O
nephropathy NN NN O
. . . O

Superoxide NNP NNP B-CHEM
dismutase NN NN O
( ( ( O
SOD NNP NNP O
) ) ) O
or CC CC O
dimethylthiourea NN NN B-CHEM
( ( ( O
DMTU NNP NNP B-CHEM
) ) ) O
significantly RB RB O
lessened VBD VBD O
the DT DT O
GM NNP NNP B-CHEM
- - - O
induced JJ JJ O
decrement NN NN O
in IN IN O
CIn NNP NNP O
. . . O

The DT DT O
SOD NNP NNP O
- - - O
induced JJ JJ O
increase NN NN O
in IN IN O
glomerular NN NN O
filtration NN NN O
rate NN NN O
was VBD VBD O
associated VBN VBN O
with IN IN O
a DT DT O
marked JJ JJ O
improvement NN NN O
in IN IN O
RBF NNP NNP O
, , , O
an DT DT O
increase NN NN O
in IN IN O
urinary JJ JJ O
cGMP NN NN B-CHEM
excretion NN NN O
, , , O
and CC CC O
a DT DT O
decrease NN NN O
in IN IN O
renal JJ JJ O
renin NN NN O
and CC CC O
endothelin NN NN O
- - - O
1 CD CD O
content NN NN O
. . . O

SOD NNP NNP O
did VBD VBD O
not RB RB O
attenuate VB VB O
the DT DT O
tubular NN NN O
damage NN NN O
. . . O

In IN IN O
contrast NN NN O
, , , O
DMTU NNP NNP B-CHEM
significantly RB RB O
reduced VBD VBD O
the DT DT O
tubular NN NN O
damage NN NN O
and CC CC O
lipid JJ JJ O
peroxidation NN NN O
, , , O
but CC CC O
it PRP PRP O
did VBD VBD O
not RB RB O
affect VB VB O
renal JJ JJ O
hemodynamics NNS NNS O
and CC CC O
vasoactive JJ JJ O
substances NNS NNS O
. . . O

Neither DT DT O
SOD NNP NNP O
nor CC CC O
DMTU NNP NNP B-CHEM
affected VBD VBD O
the DT DT O
renal JJ JJ O
cortical JJ JJ O
GM NNP NNP B-CHEM
content NN NN O
in IN IN O
GM NNP NNP B-CHEM
- - - O
treated JJ JJ O
rats NNS NNS O
. . . O

These DT DT O
results NNS NNS O
suggest VBP VBP O
that IN IN O
1 CD CD O
) ) ) O
both DT DT O
SOD NNP NNP O
and CC CC O
DMTU NNP NNP B-CHEM
have VBP VBP O
protective JJ JJ O
effects NNS NNS O
on IN IN O
GM NNP NNP B-CHEM
- : : O
mediated JJ JJ O
nephropathy NN NN O
, , , O
2 CD CD O
) ) ) O
the DT DT O
mechanisms NNS NNS O
for IN IN O
the DT DT O
protective JJ JJ O
effects NNS NNS O
differ VBP VBP O
for IN IN O
SOD NNP NNP O
and CC CC O
DMTU NNP NNP B-CHEM
, , , O
and CC CC O
3 CD CD O
) ) ) O
superoxide NN NN B-CHEM
anions NNS NNS O
play VBP VBP O
a DT DT O
critical JJ JJ O
role NN NN O
in IN IN O
GM NNP NNP B-CHEM
- : : O
induced JJ JJ O
renal JJ JJ O
vasoconstriction NN NN O
. . . O

Cephalothin NNP NNP B-CHEM
- : : O
induced JJ JJ O
immune JJ JJ O
hemolytic JJ JJ O
anemia NN NN O
. . . O

A DT DT O
patient NN NN O
with IN IN O
renal JJ JJ O
disease NN NN O
developed VBN VBN O
Coombs NNP NNP O
- : : O
positive JJ JJ O
hemolytic NN NN O
anemia NN NN O
while IN IN O
receiving VBG VBG O
cephalothin NN NN B-CHEM
therapy NN NN O
. . . O

An DT DT O
anti JJ JJ O
- : : O
cephalothin NN NN B-CHEM
IgG NNP NNP O
antibody NN NN O
was VBD VBD O
detected VBN VBN O
in IN IN O
the DT DT O
patient NN NN O
' '' '' O
s VBZ VBZ O
serum NN NN O
and CC CC O
in IN IN O
the DT DT O
eluates NNS NNS O
from IN IN O
her PRP$ PRP$ O
erythrocytes NNS NNS O
. . . O

In IN IN O
addition NN NN O
, , , O
nonimmunologic JJ JJ O
binding JJ JJ O
of IN IN O
normal JJ JJ O
and CC CC O
patient NN NN O
' POS POS O
s VBZ VBZ O
serum NN NN O
proteins NNS NNS O
to TO TO O
her PRP$ PRP$ O
own JJ JJ O
and CC CC O
cephalothin JJ JJ B-CHEM
- - - O
coated JJ JJ O
normal JJ JJ O
red JJ JJ O
cells NNS NNS O
was VBD VBD O
demonstrated VBN VBN O
. . . O

Skin NNP NNP O
tests NNS NNS O
and CC CC O
in IN IN O
vitro NN NN O
lymphocyte NN NN O
stimulation NN NN O
revealed VBD VBD O
that IN IN O
the DT DT O
patient NN NN O
was VBD VBD O
sensitized VBN VBN O
to TO TO O
cephalothin VB VB B-CHEM
and CC CC O
also RB RB O
to TO TO O
ampicillin VB VB B-CHEM
. . . O

Careful NNP NNP O
investigation NN NN O
of IN IN O
drug NN NN O
- - - O
induced JJ JJ O
hemolytic JJ JJ O
anemias NN NN O
reveals VBZ VBZ O
the DT DT O
complexity NN NN O
of IN IN O
the DT DT O
immune JJ JJ O
mechanisms NNS NNS O
involved VBN VBN O
. . . O

Assessment NNP NNP O
of IN IN O
cardiomyocyte NN NN O
DNA NNP NNP O
synthesis NN NN O
during IN IN O
hypertrophy NN NN O
in IN IN O
adult NN NN O
mice NN NN O
. . . O

The DT DT O
ability NN NN O
of IN IN O
cardiomyocytes NNS NNS O
to TO TO O
synthesize VB VB O
DNA NNP NNP O
in IN IN O
response NN NN O
to TO TO O
experimentally RB RB O
induced VBN VBN O
cardiac JJ JJ O
hypertrophy NN NN O
was VBD VBD O
assessed VBN VBN O
in IN IN O
adult NN NN O
mice NN NN O
. . . O

Isoproterenol NNP NNP B-CHEM
delivered VBN VBN O
by IN IN O
osmotic JJ JJ O
minipump NN NN O
implantation NN NN O
in IN IN O
adult NN NN O
C3Heb NNP NNP O
/ NN NN O
FeJ NNP NNP O
mice NN NN O
resulted VBD VBD O
in IN IN O
a DT DT O
46 CD CD O
% NN NN O
increase NN NN O
in IN IN O
heart NN NN O
weight NN NN O
and CC CC O
a DT DT O
19 CD CD O
. . . O
3 CD CD O
% NN NN O
increase NN NN O
in IN IN O
cardiomyocyte NN NN O
area NN NN O
. . . O

No DT DT O
DNA NNP NNP O
synthesis NN NN O
, , , O
as IN IN O
assessed VBN VBN O
by IN IN O
autoradiographic JJ JJ O
analysis NN NN O
of IN IN O
isolated JJ JJ O
cardiomyocytes NNS NNS O
, , , O
was VBD VBD O
observed VBN VBN O
in IN IN O
control NN NN O
or CC CC O
hypertrophic JJ JJ O
hearts NNS NNS O
. . . O

A DT DT O
survey NN NN O
of IN IN O
15 CD CD O
independent JJ JJ O
inbred VBN VBN O
strains NNS NNS O
of IN IN O
mice NNS NNS O
revealed VBD VBD O
that IN IN O
ventricular NN NN O
cardiomyocyte NN NN O
nuclear JJ JJ O
number NN NN O
ranged VBN VBN O
from IN IN O
3 CD CD O
to TO TO O
13 CD CD O
% NN NN O
mononucleate NN NN O
, , , O
suggesting VBG VBG O
that IN IN O
cardiomyocyte NN NN O
terminal NN NN O
differentiation NN NN O
is VBZ VBZ O
influenced VBN VBN O
directly RB RB O
or CC CC O
indirectly RB RB O
by IN IN O
genetic JJ JJ O
background NN NN O
. . . O

To TO TO O
determine VB VB O
whether IN IN O
the DT DT O
capacity NN NN O
for IN IN O
reactive JJ JJ O
DNA NNP NNP O
synthesis NN NN O
was VBD VBD O
also RB RB O
subject JJ JJ O
to TO TO O
genetic JJ JJ O
regulation NN NN O
, , , O
cardiac JJ JJ O
hypertrophy NN NN O
was VBD VBD O
induced VBN VBN O
in IN IN O
the DT DT O
strains NNS NNS O
of IN IN O
mice NNS NNS O
comprising VBG VBG O
the DT DT O
extremes NNS NNS O
of IN IN O
the DT DT O
nuclear JJ JJ O
number NN NN O
survey NN NN O
. . . O

These DT DT O
data NNS NNS O
indicate VBP VBP O
that IN IN O
adult NN NN O
mouse NN NN O
atrial NN NN O
and CC CC O
ventricular JJ JJ O
cardiomyocytes NNS NNS O
do VBP VBP O
not RB RB O
synthesize VB VB O
DNA NNP NNP O
in IN IN O
response NN NN O
to TO TO O
isoproterenol VB VB B-CHEM
- - - O
induced JJ JJ O
cardiac NN NN O
hypertrophy NN NN O
. . . O

Central NNP NNP O
cardiovascular JJ JJ O
effects NNS NNS O
of IN IN O
AVP NNP NNP B-CHEM
and CC CC O
ANP NNP NNP O
in IN IN O
normotensive JJ JJ O
and CC CC O
spontaneously RB RB O
hypertensive JJ JJ O
rats NNS NNS O
. . . O

The DT DT O
purpose NN NN O
of IN IN O
the DT DT O
present JJ JJ O
study NN NN O
was VBD VBD O
to TO TO O
compare VB VB O
influence NN NN O
of IN IN O
central JJ JJ O
arginine NN NN B-CHEM
vasopressin NN NN I-CHEM
( ( ( O
AVP NNP NNP B-CHEM
) ) ) O
and CC CC O
of IN IN O
atrial JJ JJ O
natriuretic JJ JJ O
peptide NN NN O
( ( ( O
ANP NNP NNP O
) ) ) O
on IN IN O
control NN NN O
of IN IN O
arterial JJ JJ O
blood NN NN O
pressure NN NN O
( ( ( O
MAP NNP NNP O
) ) ) O
and CC CC O
heart NN NN O
rate NN NN O
( ( ( O
HR NNP NNP O
) ) ) O
in IN IN O
normotensive JJ JJ O
( ( ( O
WKY NNP NNP O
) ) ) O
and CC CC O
spontaneously RB RB O
hypertensive JJ JJ O
( ( ( O
SHR NNP NNP O
) ) ) O
rats NNS NNS O
. . . O

Three CD CD O
series NNS NNS O
of IN IN O
experiments NNS NNS O
were VBD VBD O
performed VBN VBN O
on IN IN O
30 CD CD O
WKY NNP NNP O
and CC CC O
30 CD CD O
SHR NNP NNP O
, , , O
chronically RB RB O
instrumented VBN VBN O
with IN IN O
guide NN NN O
tubes NNS NNS O
in IN IN O
the DT DT O
lateral NN NN O
ventricle NN NN O
( ( ( O
LV NNP NNP O
) ) ) O
and CC CC O
arterial JJ JJ O
and CC CC O
venous JJ JJ O
catheters NNS NNS O
. . . O

MAP NNP NNP O
and CC CC O
HR NNP NNP O
were VBD VBD O
monitored VBN VBN O
before IN IN O
and CC CC O
after IN IN O
i NNP NNP O
. . . O
v NN NN O
. . . O
injections NNS NNS O
of IN IN O
either DT DT O
vehicle NN NN O
or CC CC O
1 CD CD O
, , , O
10 CD CD O
and CC CC O
50 CD CD O
ng NN NN O
of IN IN O
AVP NNP NNP B-CHEM
and CC CC O
25 CD CD O
, , , O
125 CD CD O
and CC CC O
500 CD CD O
ng NN NN O
of IN IN O
ANP NNP NNP O
. . . O

Sensitivity NNP NNP O
of IN IN O
cardiac JJ JJ O
component NN NN O
of IN IN O
baroreflex NN NN O
( ( ( O
CCB NNP NNP O
) ) ) O
, , , O
expressed VBD VBD O
as IN IN O
a DT DT O
slope NN NN O
of IN IN O
the DT DT O
regression NN NN O
line NN NN O
was VBD VBD O
determined VBN VBN O
from IN IN O
relationships NNS NNS O
between IN IN O
systolic JJ JJ O
arterial NN NN O
pressure NN NN O
( ( ( O
SAP NNP NNP O
) ) ) O
and CC CC O
HR NNP NNP O
period NN NN O
( ( ( O
HRp NNP NNP O
) ) ) O
during IN IN O
phenylephrine NN NN B-CHEM
( ( ( O
Phe NNP NNP B-CHEM
) ) ) O
- : : O
induced JJ JJ O
hypertension NN NN O
and CC CC O
sodium NN NN B-CHEM
nitroprusside NN NN I-CHEM
( ( ( O
SN NNP NNP B-CHEM
) ) ) O
- : : O
induced JJ JJ O
hypotension NN NN O
. . . O

CCB NNP NNP O
was VBD VBD O
measured VBN VBN O
before IN IN O
and CC CC O
after IN IN O
administration NN NN O
of IN IN O
either DT DT O
vehicle NN NN O
, , , O
AVP NNP NNP B-CHEM
, , , O
ANP NNP NNP O
, , , O
or CC CC O
both DT DT O
peptides NNS NNS O
together RB RB O
. . . O

Increases NNP NNP O
of IN IN O
MAP NNP NNP O
occurred VBD VBD O
after IN IN O
LV NNP NNP O
administration NN NN O
of IN IN O
1 CD CD O
, , , O
10 CD CD O
and CC CC O
50 CD CD O
ng NN NN O
of IN IN O
AVP NNP NNP B-CHEM
in IN IN O
WKY NNP NNP O
and CC CC O
of IN IN O
10 CD CD O
and CC CC O
50 CD CD O
ng NN NN O
in IN IN O
SHR NNP NNP O
. . . O

ANP NNP NNP O
did VBD VBD O
not RB RB O
cause VB VB O
significant JJ JJ O
changes NNS NNS O
in IN IN O
MAP NNP NNP O
in IN IN O
both DT DT O
strains NNS NNS O
as IN IN O
compared VBN VBN O
to TO TO O
vehicle NN NN O
, , , O
but CC CC O
it PRP PRP O
abolished VBD VBD O
AVP NNP NNP B-CHEM
- : : O
induced VBN VBN O
MAP NNP NNP O
increase NN NN O
in IN IN O
WKY NNP NNP O
and CC CC O
SHR NNP NNP O
. . . O

CCB NNP NNP O
was VBD VBD O
reduced VBN VBN O
in IN IN O
WKY NNP NNP O
and CC CC O
SHR NNP NNP O
after IN IN O
LV NNP NNP O
administration NN NN O
of IN IN O
AVP NNP NNP B-CHEM
during IN IN O
SN NNP NNP B-CHEM
- : : O
induced JJ JJ O
hypotension NN NN O
. . . O

In IN IN O
SHR NNP NNP O
but CC CC O
not RB RB O
in IN IN O
WKY NNP NNP O
administration NN NN O
of IN IN O
ANP NNP NNP O
, , , O
AVP NNP NNP B-CHEM
and CC CC O
ANP NNP NNP O
+ NN NN O
AVP NNP NNP B-CHEM
decreased VBD VBD O
CCB NNP NNP O
during IN IN O
Phe NNP NNP B-CHEM
- : : O
induced VBN VBN O
MAP NNP NNP O
elevation NN NN O
. . . O

The DT DT O
results NNS NNS O
indicate VBP VBP O
that IN IN O
centrally RB RB O
applied VBN VBN O
AVP NNP NNP B-CHEM
and CC CC O
ANP NNP NNP O
exert NN NN O
differential JJ JJ O
effects NNS NNS O
on IN IN O
blood NN NN O
pressure NN NN O
and CC CC O
baroreflex JJ JJ O
control NN NN O
of IN IN O
heart NN NN O
rate NN NN O
in IN IN O
WKY NNP NNP O
and CC CC O
SHR NNP NNP O
and CC CC O
suggest JJS JJS O
interaction NN NN O
of IN IN O
these DT DT O
two CD CD O
peptides NNS NNS O
in IN IN O
blood NN NN O
pressure NN NN O
regulation NN NN O
at IN IN O
the DT DT O
level NN NN O
of IN IN O
central JJ JJ O
nervous JJ JJ O
system NN NN O
. . . O

Cutaneous NNP NNP O
exposure NN NN O
to TO TO O
warfarin NN NN B-CHEM
- - - O
like IN IN O
anticoagulant NN NN O
causing VBG VBG O
an DT DT O
intracerebral JJ JJ O
hemorrhage NN NN O
: : : O
a DT DT O
case NN NN O
report NN NN O
. . . O

A DT DT O
case NN NN O
of IN IN O
intercerebral JJ JJ O
hematoma NN NN O
due JJ JJ O
to TO TO O
warfarin VB VB B-CHEM
- - - O
induced JJ JJ O
coagulopathy NN NN O
is VBZ VBZ O
presented VBN VBN O
. . . O

The DT DT O
39 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
woman NN NN O
had VBD VBD O
spread VBN VBN O
a DT DT O
warfarin NN NN B-CHEM
- - - O
type NN NN O
rat NN NN O
poison NN NN O
around IN IN O
her PRP$ PRP$ O
house NN NN O
weekly NN NN O
using VBG VBG O
her PRP$ PRP$ O
bare JJ JJ O
hands NNS NNS O
, , , O
with IN IN O
no DT DT O
washing VBG VBG O
post NN NN O
application NN NN O
. . . O

Percutaneous NNP NNP O
absorption NN NN O
of IN IN O
warfarin NN NN B-CHEM
causing VBG VBG O
coagulopathy NN NN O
, , , O
reported VBD VBD O
three CD CD O
times NNS NNS O
in IN IN O
the DT DT O
past JJ JJ O
, , , O
is VBZ VBZ O
a DT DT O
significant JJ JJ O
risk NN NN O
if IN IN O
protective JJ JJ O
measures NNS NNS O
, , , O
such JJ JJ O
as IN IN O
gloves NNS NNS O
, , , O
are VBP VBP O
not RB RB O
used VBN VBN O
. . . O

An DT DT O
adverse JJ JJ O
drug NN NN O
interaction NN NN O
with IN IN O
piroxicam NN NN B-CHEM
, , , O
which WDT WDT O
she PRP PRP O
took VBD VBD O
occasionally RB RB O
, , , O
may MD MD O
have VB VB O
exacerbated VBN VBN O
the DT DT O
coagulopathy NN NN O
. . . O

Pediatric NNP NNP O
heart NN NN O
transplantation NN NN O
without IN IN O
chronic JJ JJ O
maintenance NN NN O
steroids NNS NNS B-CHEM
. . . O

From IN IN O
1986 CD CD O
to TO TO O
February NNP NNP O
1993 CD CD O
, , , O
40 CD CD O
children NNS NNS O
aged VBN VBN O
2 CD CD O
months NNS NNS O
to TO TO O
18 CD CD O
years NNS NNS O
( ( ( O
average JJ JJ O
age NN NN O
10 CD CD O
. . . O
4 CD CD O
+ NN NN O
/ NN NN O
- : : O
5 CD CD O
. . . O
8 CD CD O
years NNS NNS O
) ) ) O
underwent JJ JJ O
heart NN NN O
transplantation NN NN O
. . . O

Indications NNP NNP O
for IN IN O
transplantation NN NN O
were VBD VBD O
idiopathic JJ JJ O
cardiomyopathy NN NN O
( ( ( O
52 CD CD O
% NN NN O
) ) ) O
, , , O
congenital JJ JJ O
heart NN NN O
disease NN NN O
( ( ( O
35 CD CD O
% NN NN O
) ) ) O
with IN IN O
and CC CC O
without IN IN O
prior RB RB O
repair NN NN O
( ( ( O
71 CD CD O
% NN NN O
and CC CC O
29 CD CD O
% NN NN O
, , , O
respectively RB RB O
) ) ) O
, , , O
hypertrophic JJ JJ O
cardiomyopathy NN NN O
( ( ( O
5 CD CD O
% NN NN O
) ) ) O
, , , O
valvular JJ JJ O
heart NN NN O
disease NN NN O
( ( ( O
3 CD CD O
% NN NN O
) ) ) O
, , , O
and CC CC O
doxorubicin NN NN B-CHEM
cardiomyopathy NN NN O
( ( ( O
5 CD CD O
% NN NN O
) ) ) O
. . . O

Patients NNS NNS O
were VBD VBD O
managed VBN VBN O
with IN IN O
cyclosporine NN NN B-CHEM
and CC CC O
azathioprine NN NN B-CHEM
. . . O

No DT DT O
prophylaxis NN NN O
with IN IN O
antilymphocyte NN NN O
globulin NN NN O
was VBD VBD O
used VBN VBN O
. . . O

Steroids NNP NNP B-CHEM
were VBD VBD O
given VBN VBN O
to TO TO O
39 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
for IN IN O
refractory NN NN O
rejection NN NN O
, , , O
but CC CC O
weaning VBG VBG O
was VBD VBD O
always RB RB O
attempted VBN VBN O
and CC CC O
generally RB RB O
successful JJ JJ O
( ( ( O
64 CD CD O
% NN NN O
) ) ) O
. . . O

Five CD CD O
patients NNS NNS O
( ( ( O
14 CD CD O
% NN NN O
) ) ) O
received VBD VBD O
maintenance NN NN O
steroids NNS NNS B-CHEM
. . . O

Four CD CD O
patients NNS NNS O
died VBD VBD O
in IN IN O
the DT DT O
perioperative JJ JJ O
period NN NN O
and CC CC O
one CD CD O
died VBD VBD O
4 CD CD O
months NNS NNS O
later RB RB O
. . . O

There EX EX O
have VBP VBP O
been VBN VBN O
no DT DT O
deaths NNS NNS O
related VBN VBN O
to TO TO O
rejection NN NN O
or CC CC O
infection NN NN O
. . . O

Average NNP NNP O
follow VB VB O
- - - O
up RP RP O
was VBD VBD O
36 CD CD O
+ NN NN O
/ NN NN O
- : : O
19 CD CD O
months NNS NNS O
( ( ( O
range NN NN O
1 CD CD O
to TO TO O
65 CD CD O
months NNS NNS O
) ) ) O
. . . O

Cumulative NNP NNP O
survival NN NN O
is VBZ VBZ O
88 CD CD O
% NN NN O
at IN IN O
5 CD CD O
years NNS NNS O
. . . O

In IN IN O
patients NNS NNS O
less JJR JJR O
than IN IN O
7 CD CD O
years NNS NNS O
of IN IN O
age NN NN O
, , , O
rejection NN NN O
was VBD VBD O
monitored VBN VBN O
noninvasively RB RB O
. . . O

In IN IN O
the DT DT O
first JJ JJ O
postoperative JJ JJ O
month NN NN O
, , , O
89 CD CD O
% NN NN O
of IN IN O
patients NNS NNS O
were VBD VBD O
treated VBN VBN O
for IN IN O
rejection NN NN O
. . . O

Freedom NNP NNP O
from IN IN O
serious JJ JJ O
infections NNS NNS O
was VBD VBD O
83 CD CD O
% NN NN O
at IN IN O
1 CD CD O
month NN NN O
and CC CC O
65 CD CD O
% NN NN O
at IN IN O
1 CD CD O
year NN NN O
. . . O

Cytomegalovirus NNP NNP O
infections NNS NNS O
were VBD VBD O
treated VBN VBN O
successfully RB RB O
with IN IN O
ganciclovir NN NN B-CHEM
in IN IN O
11 CD CD O
patients NNS NNS O
. . . O

No DT DT O
impairment NN NN O
of IN IN O
growth NN NN O
was VBD VBD O
observed VBN VBN O
in IN IN O
children NNS NNS O
who WP WP O
underwent JJ JJ O
transplantation NN NN O
compared VBN VBN O
with IN IN O
a DT DT O
control NN NN O
population NN NN O
. . . O

Twenty CD CD O
- : : O
one CD CD O
patients NNS NNS O
( ( ( O
60 CD CD O
% NN NN O
) ) ) O
have VBP VBP O
undergone VBN VBN O
annual JJ JJ O
catheterizations NNS NNS O
and CC CC O
no DT DT O
sign NN NN O
of IN IN O
graft NN NN O
atherosclerosis NN NN O
has VBZ VBZ O
been VBN VBN O
observed VBN VBN O
. . . O

Seizures NNP NNP O
occurred VBD VBD O
in IN IN O
five CD CD O
patients NNS NNS O
( ( ( O
14 CD CD O
% NN NN O
) ) ) O
and CC CC O
hypertension NN NN O
was VBD VBD O
treated VBN VBN O
in IN IN O
10 CD CD O
patients NNS NNS O
( ( ( O
28 CD CD O
% NN NN O
) ) ) O
. . . O

No DT DT O
patient NN NN O
was VBD VBD O
disabled JJ JJ O
and CC CC O
no DT DT O
lymphoproliferative JJ JJ O
disorder NN NN O
was VBD VBD O
observed VBN VBN O
. . . O
( ( ( O
ABSTRACT NNP NNP O
TRUNCATED NNP NNP O
AT IN IN O
250 CD CD O
WORDS NNP NNP O
) ) ) O

Delirium NNP NNP O
during IN IN O
fluoxetine NN NN B-CHEM
treatment NN NN O
. . . O

A DT DT O
case NN NN O
report NN NN O
. . . O

The DT DT O
correlation NN NN O
between IN IN O
high JJ JJ O
serum NN NN O
tricyclic JJ JJ O
antidepressant NN NN O
concentrations NNS NNS O
and CC CC O
central JJ JJ O
nervous JJ JJ O
system NN NN O
side NN NN O
effects NNS NNS O
has VBZ VBZ O
been VBN VBN O
well RB RB O
established VBN VBN O
. . . O

Only RB RB O
a DT DT O
few JJ JJ O
reports NNS NNS O
exist VBP VBP O
, , , O
however RB RB O
, , , O
on IN IN O
the DT DT O
relationship NN NN O
between IN IN O
the DT DT O
serum NN NN O
concentrations NNS NNS O
of IN IN O
selective JJ JJ O
serotonin NN NN B-CHEM
reuptake NN NN O
inhibitors NNS NNS O
( ( ( O
SSRIs NNP NNP O
) ) ) O
and CC CC O
their PRP$ PRP$ O
toxic JJ JJ O
effects NNS NNS O
. . . O

In IN IN O
some DT DT O
cases NNS NNS O
, , , O
a DT DT O
high JJ JJ O
serum NN NN O
concentration NN NN O
of IN IN O
citalopram NN NN B-CHEM
( ( ( O
> NN NN O
600 CD CD O
nmol NN NN O
/ NN NN O
L NNP NNP O
) ) ) O
in IN IN O
elderly JJ JJ O
patients NNS NNS O
has VBZ VBZ O
been VBN VBN O
associated VBN VBN O
with IN IN O
increased VBN VBN O
somnolence NN NN O
and CC CC O
movement NN NN O
difficulties NNS NNS O
. . . O

Widespread NNP NNP O
cognitive JJ JJ O
disorders NNS NNS O
, , , O
such JJ JJ O
as IN IN O
delirium NN NN O
, , , O
have VBP VBP O
not RB RB O
been VBN VBN O
previously RB RB O
linked VBN VBN O
with IN IN O
high JJ JJ O
blood NN NN O
levels NNS NNS O
of IN IN O
SSRIs NNP NNP O
. . . O

In IN IN O
this DT DT O
report NN NN O
, , , O
we PRP PRP O
describe VBP VBP O
a DT DT O
patient NN NN O
with IN IN O
acute JJ JJ O
hyperkinetic JJ JJ O
delirium NN NN O
connected VBN VBN O
with IN IN O
a DT DT O
high JJ JJ O
serum NN NN O
total JJ JJ O
fluoxetine NN NN B-CHEM
( ( ( O
fluoxetine NN NN B-CHEM
plus CC CC O
desmethylfluoxetine NN NN B-CHEM
) ) ) O
concentration NN NN O
. . . O

Pulmonary NNP NNP O
edema NN NN O
and CC CC O
shock NN NN O
after IN IN O
high JJ JJ O
- - - O
dose NN NN O
aracytine NN NN B-CHEM
- : : I-CHEM
C NNP NNP I-CHEM
for IN IN O
lymphoma NN NN O
; : : O
possible JJ JJ O
role NN NN O
of IN IN O
TNF NNP NNP O
- : : O
alpha NN NN O
and CC CC O
PAF NNP NNP O
. . . O

Four CD CD O
out IN IN O
of IN IN O
23 CD CD O
consecutive JJ JJ O
patients NNS NNS O
treated VBN VBN O
with IN IN O
high JJ JJ O
- - - O
dose NN NN O
Ara NNP NNP B-CHEM
- : : I-CHEM
C NNP NNP I-CHEM
for IN IN O
lymphomas NN NN O
in IN IN O
our PRP$ PRP$ O
institution NN NN O
developed VBN VBN O
a DT DT O
strikingly RB RB O
similar JJ JJ O
syndrome NN NN O
during IN IN O
the DT DT O
perfusion NN NN O
. . . O

It PRP PRP O
was VBD VBD O
characterized VBN VBN O
by IN IN O
the DT DT O
onset NN NN O
of IN IN O
fever NN NN O
, , , O
diarrhea NN NN O
, , , O
shock NN NN O
, , , O
pulmonary JJ JJ O
edema NN NN O
, , , O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
, , , O
metabolic JJ JJ O
acidosis NN NN O
, , , O
weight NN NN O
gain NN NN O
and CC CC O
leukocytosis NN NN O
. . . O

Thorough NNP NNP O
bacteriological JJ JJ O
screening VBG VBG O
failed VBN VBN O
to TO TO O
provide VB VB O
evidence NN NN O
of IN IN O
infection NN NN O
. . . O

Sequential NNP NNP O
biological JJ JJ O
assays NNS NNS O
of IN IN O
IL NNP NNP O
- : : O
1 CD CD O
, , , O
IL NNP NNP O
- : : O
2 CD CD O
, , , O
TNF NNP NNP O
and CC CC O
PAF NNP NNP O
were VBD VBD O
performed VBN VBN O
during IN IN O
Ara NNP NNP B-CHEM
- : : I-CHEM
C NNP NNP I-CHEM
infusion NN NN O
to TO TO O
ten CD CD O
patients NNS NNS O
, , , O
including VBG VBG O
the DT DT O
four CD CD O
who WP WP O
developed VBD VBD O
the DT DT O
syndrome NN NN O
. . . O

TNF NNP NNP O
and CC CC O
PAF NNP NNP O
activity NN NN O
was VBD VBD O
found VBN VBN O
in IN IN O
the DT DT O
serum NN NN O
of IN IN O
respectively RB RB O
two CD CD O
and CC CC O
four CD CD O
of IN IN O
the DT DT O
cases NNS NNS O
, , , O
but CC CC O
not RB RB O
in IN IN O
the DT DT O
six CD CD O
controls NNS NNS O
. . . O

As IN IN O
TNF NNP NNP O
and CC CC O
PAF NNP NNP O
are VBP VBP O
thought VBN VBN O
to TO TO O
be VB VB O
involved VBN VBN O
in IN IN O
the DT DT O
development NN NN O
of IN IN O
septic JJ JJ O
shock NN NN O
and CC CC O
adult NN NN O
respiratory JJ JJ O
distress NN NN O
syndrome NN NN O
, , , O
we PRP PRP O
hypothesize NN NN O
that IN IN O
high JJ JJ O
- - - O
dose NN NN O
Ara NNP NNP B-CHEM
- : : I-CHEM
C NNP NNP I-CHEM
may MD MD O
be VB VB O
associated VBN VBN O
with IN IN O
cytokine NN NN O
release NN NN O
. . . O

Protective JJ JJ O
effect NN NN O
of IN IN O
clentiazem NN NN B-CHEM
against IN IN O
epinephrine NN NN B-CHEM
- - - O
induced JJ JJ O
cardiac JJ JJ O
injury NN NN O
in IN IN O
rats NNS NNS O
. . . O

We PRP PRP O
investigated VBD VBD O
the DT DT O
effects NNS NNS O
of IN IN O
clentiazem NN NN B-CHEM
, , , O
a DT DT O
1 CD CD B-CHEM
, , , I-CHEM
5 CD CD I-CHEM
- : : I-CHEM
benzothiazepine NN NN I-CHEM
calcium NN NN B-CHEM
antagonist NN NN O
, , , O
on IN IN O
epinephrine NN NN B-CHEM
- : : O
induced JJ JJ O
cardiomyopathy NN NN O
in IN IN O
rats NNS NNS O
. . . O

With IN IN O
2 CD CD O
- : : O
week NN NN O
chronic JJ JJ O
epinephrine NN NN B-CHEM
infusion NN NN O
, , , O
16 CD CD O
of IN IN O
30 CD CD O
rats NNS NNS O
died VBD VBD O
within IN IN O
4 CD CD O
days NNS NNS O
, , , O
and CC CC O
severe JJ JJ O
ischemic JJ JJ O
lesions NNS NNS O
and CC CC O
fibrosis NNS NNS O
of IN IN O
the DT DT O
left NN NN O
ventricles NNS NNS O
were VBD VBD O
observed VBN VBN O
. . . O

In IN IN O
epinephrine NN NN B-CHEM
- - - O
treated VBN VBN O
rats NNS NNS O
, , , O
left VBD VBD O
atrial NN NN O
and CC CC O
left VBD VBD O
ventricular NN NN O
papillary JJ JJ O
muscle NN NN O
contractile NN NN O
responses NNS NNS O
to TO TO O
isoproterenol VB VB B-CHEM
were VBD VBD O
reduced VBN VBN O
, , , O
but CC CC O
responses NNS NNS O
to TO TO O
calcium NN NN B-CHEM
were VBD VBD O
normal JJ JJ O
or CC CC O
enhanced VBN VBN O
compared VBN VBN O
to TO TO O
controls NNS NNS O
. . . O

Left NNP NNP O
ventricular NN NN O
alpha NN NN O
and CC CC O
beta NN NN O
adrenoceptor NN NN O
densities NNS NNS O
were VBD VBD O
also RB RB O
reduced VBN VBN O
compared VBN VBN O
to TO TO O
controls NNS NNS O
. . . O

Treatment NN NN O
with IN IN O
clentiazem NN NN B-CHEM
prevented VBN VBN O
epinephrine NN NN B-CHEM
- - - O
induced JJ JJ O
death NN NN O
( ( ( O
P NN NN O
< NN NN O
. . . O
05 CD CD O
) ) ) O
, , , O
and CC CC O
attenuated VBD VBD O
the DT DT O
ventricular JJ JJ O
ischemic JJ JJ O
lesions NNS NNS O
and CC CC O
fibrosis NNS NNS O
, , , O
in IN IN O
a DT DT O
dose NN NN O
- - - O
dependent JJ JJ O
manner NN NN O
. . . O

Left NNP NNP O
atrial NN NN O
and CC CC O
left VBD VBD O
ventricular NN NN O
papillary JJ JJ O
muscle NN NN O
contractile NN NN O
responses NNS NNS O
to TO TO O
isoproterenol VB VB B-CHEM
were VBD VBD O
reduced VBN VBN O
compared VBN VBN O
to TO TO O
controls NNS NNS O
in IN IN O
groups NNS NNS O
treated VBN VBN O
with IN IN O
clentiazem NN NN B-CHEM
alone RB RB O
, , , O
but CC CC O
combined VBD VBD O
with IN IN O
epinephrine NN NN B-CHEM
, , , O
clentiazem NN NN B-CHEM
restored VBN VBN O
left VBD VBD O
atrial NN NN O
responses NNS NNS O
and CC CC O
enhanced VBN VBN O
left VBD VBD O
ventricular NN NN O
papillary JJ JJ O
responses NNS NNS O
to TO TO O
isoproterenol VB VB B-CHEM
. . . O

On IN IN O
the DT DT O
other JJ JJ O
hand NN NN O
clentiazem NN NN B-CHEM
did VBD VBD O
not RB RB O
prevent VB VB O
epinephrine NN NN B-CHEM
- : : O
induced VBN VBN O
down RB RB O
- - - O
regulation NN NN O
of IN IN O
alpha NN NN O
and CC CC O
beta NN NN O
adrenoceptors NNS NNS O
. . . O

Interestingly RB RB O
, , , O
clentiazem NN NN B-CHEM
, , , O
infused VBN VBN O
alone RB RB O
, , , O
resulted VBD VBD O
in IN IN O
decreased VBD VBD O
adrenergic JJ JJ O
receptor NN NN O
densities NNS NNS O
in IN IN O
the DT DT O
left NN NN O
ventricle NN NN O
. . . O

Clentiazem NNP NNP B-CHEM
also RB RB O
did VBD VBD O
not RB RB O
prevent VB VB O
the DT DT O
enhanced JJ JJ O
responses NNS NNS O
to TO TO O
calcium VB VB B-CHEM
seen VBN VBN O
in IN IN O
the DT DT O
epinephrine NN NN B-CHEM
- - - O
treated JJ JJ O
animals NNS NNS O
, , , O
although IN IN O
the DT DT O
high JJ JJ O
dose NN NN O
of IN IN O
clentiazem NN NN B-CHEM
partially RB RB O
attenuated VBD VBD O
the DT DT O
maximal NN NN O
response NN NN O
to TO TO O
calcium NN NN B-CHEM
compared VBN VBN O
to TO TO O
epinephrine VB VB B-CHEM
- - - O
treated JJ JJ O
animals NNS NNS O
. . . O

In IN IN O
conclusion NN NN O
, , , O
clentiazem NN NN B-CHEM
attenuated VBN VBN O
epinephrine NN NN B-CHEM
- - - O
induced JJ JJ O
cardiac JJ JJ O
injury NN NN O
, , , O
possibly RB RB O
through IN IN O
its PRP$ PRP$ O
effect NN NN O
on IN IN O
the DT DT O
adrenergic JJ JJ O
pathway NN NN O
. . . O

Kaliuretic NNP NNP O
effect NN NN O
of IN IN O
L NNP NNP B-CHEM
- : : I-CHEM
dopa NN NN I-CHEM
treatment NN NN O
in IN IN O
parkinsonian NN NN O
patients NNS NNS O
. . . O

Hypokalemia NNP NNP O
, , , O
sometimes RB RB O
severe JJ JJ O
, , , O
was VBD VBD O
observed VBN VBN O
in IN IN O
some DT DT O
L NNP NNP B-CHEM
- - - I-CHEM
dopa NN NN I-CHEM
- - - O
treated JJ JJ O
parkinsonian NN NN O
patients NNS NNS O
. . . O

The DT DT O
influence NN NN O
of IN IN O
L NNP NNP B-CHEM
- - - I-CHEM
dopa NN NN I-CHEM
on IN IN O
the DT DT O
renal JJ JJ O
excretion NN NN O
of IN IN O
potassium NN NN B-CHEM
was VBD VBD O
studied VBN VBN O
in IN IN O
3 CD CD O
patients NNS NNS O
with IN IN O
hypokalemia NN NN O
and CC CC O
in IN IN O
5 CD CD O
normokalemic JJ JJ O
patients NNS NNS O
by IN IN O
determination NN NN O
of IN IN O
renal JJ JJ O
plasma NN NN O
flow NN NN O
, , , O
glomerular JJ JJ O
filtration NN NN O
rate NN NN O
, , , O
plasma NN NN O
concentration NN NN O
of IN IN O
potassium NN NN B-CHEM
and CC CC O
sodium NN NN B-CHEM
as RB RB O
well RB RB O
as IN IN O
urinary JJ JJ O
excretion NN NN O
of IN IN O
potassium NN NN B-CHEM
, , , O
sodium NN NN B-CHEM
and CC CC O
aldosterone NN NN B-CHEM
. . . O

L NNP NNP B-CHEM
- : : I-CHEM
Dopa NNP NNP I-CHEM
intake NN NN O
was VBD VBD O
found VBN VBN O
to TO TO O
cause VB VB O
an DT DT O
increased JJ JJ O
excretion NN NN O
of IN IN O
potassium NN NN B-CHEM
, , , O
and CC CC O
sometimes RB RB O
also RB RB O
of IN IN O
sodium NN NN B-CHEM
, , , O
in IN IN O
the DT DT O
hypokalemic JJ JJ O
but CC CC O
not RB RB O
in IN IN O
the DT DT O
normokalemic JJ JJ O
patients NNS NNS O
. . . O

This DT DT O
effect NN NN O
on IN IN O
the DT DT O
renal JJ JJ O
function NN NN O
could MD MD O
be VB VB O
prohibited VBN VBN O
by IN IN O
the DT DT O
administration NN NN O
of IN IN O
a DT DT O
peripheral JJ JJ O
dopa NN NN O
decarbodylase NN NN O
inhibitor NN NN O
. . . O

It PRP PRP O
is VBZ VBZ O
not RB RB O
known VBN VBN O
why WRB WRB O
this DT DT O
effect NN NN O
occurred VBD VBD O
in IN IN O
some DT DT O
individuals NNS NNS O
but CC CC O
not RB RB O
in IN IN O
others NNS NNS O
, , , O
but CC CC O
our PRP$ PRP$ O
results NNS NNS O
indicate VBP VBP O
a DT DT O
correlation NN NN O
between IN IN O
aldosterone NN NN B-CHEM
production NN NN O
and CC CC O
this DT DT O
renal JJ JJ O
effect NN NN O
of IN IN O
L NNP NNP B-CHEM
- - - I-CHEM
dopa NN NN I-CHEM
. . . O

Cocaine NNP NNP B-CHEM
induced VBD VBD O
myocardial NN NN O
ischemia NN NN O
. . . O

We PRP PRP O
report VBP VBP O
a DT DT O
case NN NN O
of IN IN O
myocardial NN NN O
ischemia NN NN O
induced VBN VBN O
by IN IN O
cocaine NN NN B-CHEM
. . . O

The DT DT O
ischemia NN NN O
probably RB RB O
induced JJ JJ O
by IN IN O
coronary JJ JJ O
artery NN NN O
spasm NN NN O
was VBD VBD O
reversed VBN VBN O
by IN IN O
nitroglycerin NN NN B-CHEM
and CC CC O
calcium NN NN B-CHEM
blocking VBG VBG O
agents NNS NNS O
. . . O

Doxorubicin NNP NNP B-CHEM
- : : O
induced JJ JJ O
cardiotoxicity NN NN O
monitored VBN VBN O
by IN IN O
ECG NNP NNP O
in IN IN O
freely RB RB O
moving VBG VBG O
mice NN NN O
. . . O

A DT DT O
new JJ JJ O
model NN NN O
to TO TO O
test VB VB O
potential JJ JJ O
protectors NNS NNS O
. . . O

In IN IN O
laboratory NN NN O
animals NNS NNS O
, , , O
histology NN NN O
is VBZ VBZ O
most RBS RBS O
commonly RB RB O
used VBN VBN O
to TO TO O
study VB VB O
doxorubicin NN NN B-CHEM
- : : O
induced JJ JJ O
cardiotoxicity NN NN O
. . . O

However RB RB O
, , , O
for IN IN O
monitoring VBG VBG O
during IN IN O
treatment NN NN O
, , , O
large JJ JJ O
numbers NNS NNS O
of IN IN O
animals NNS NNS O
are VBP VBP O
needed VBN VBN O
. . . O

Recently RB RB O
we PRP PRP O
developed VBD VBD O
a DT DT O
new JJ JJ O
method NN NN O
to TO TO O
measure VB VB O
ECG NNP NNP O
values NNS NNS O
in IN IN O
freely RB RB O
moving VBG VBG O
mice NNS NNS O
by IN IN O
telemetry NN NN O
. . . O

With IN IN O
this DT DT O
model NN NN O
we PRP PRP O
investigated VBD VBD O
the DT DT O
effect NN NN O
of IN IN O
chronic JJ JJ O
doxorubicin NN NN B-CHEM
administration NN NN O
on IN IN O
the DT DT O
ECG NNP NNP O
of IN IN O
freely RB RB O
moving VBG VBG O
BALB NNP NNP O
/ NN NN O
c SYM SYM O
mice NN NN O
and CC CC O
the DT DT O
efficacy NN NN O
of IN IN O
ICRF NNP NNP B-CHEM
- : : I-CHEM
187 CD CD I-CHEM
as IN IN O
a DT DT O
protective JJ JJ O
agent NN NN O
. . . O

The DT DT O
ST NNP NNP O
interval NN NN O
significantly RB RB O
widened VBD VBD O
from IN IN O
15 CD CD O
. . . O
0 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
5 CD CD O
to TO TO O
56 CD CD O
. . . O
8 CD CD O
+ NN NN O
/ NN NN O
- : : O
11 CD CD O
. . . O
8 CD CD O
ms NN NN O
in IN IN O
week NN NN O
10 CD CD O
( ( ( O
7 CD CD O
weekly JJ JJ O
doses NNS NNS O
of IN IN O
4 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
doxorubicin NN NN B-CHEM
given VBN VBN O
i NNP NNP O
. . . O
v NN NN O
. . . O
plus CC CC O
3 CD CD O
weeks NNS NNS O
of IN IN O
observation NN NN O
) ) ) O
. . . O

The DT DT O
ECG NNP NNP O
of IN IN O
the DT DT O
control NN NN O
animals NNS NNS O
did VBD VBD O
not RB RB O
change VB VB O
during IN IN O
the DT DT O
entire JJ JJ O
study NN NN O
. . . O

After IN IN O
sacrifice NN NN O
the DT DT O
hearts NNS NNS O
of IN IN O
doxorubicin NN NN B-CHEM
- - - O
treated JJ JJ O
animals NNS NNS O
were VBD VBD O
enlarged VBN VBN O
and CC CC O
the DT DT O
atria NN NN O
were VBD VBD O
hypertrophic JJ JJ O
. . . O

As IN IN O
this DT DT O
schedule NN NN O
exerted VBN VBN O
more JJR JJR O
toxicity NN NN O
than IN IN O
needed VBN VBN O
to TO TO O
investigate VB VB O
protective JJ JJ O
agents NNS NNS O
, , , O
the DT DT O
protection NN NN O
of IN IN O
ICRF NNP NNP B-CHEM
- : : I-CHEM
187 CD CD I-CHEM
was VBD VBD O
determined VBN VBN O
using VBG VBG O
a DT DT O
dose NN NN O
schedule NN NN O
with IN IN O
lower JJR JJR O
general NN NN O
toxicity NN NN O
( ( ( O
6 CD CD O
weekly JJ JJ O
doses NNS NNS O
of IN IN O
4 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
doxorubicin NN NN B-CHEM
given VBN VBN O
i NNP NNP O
. . . O
v NN NN O
. . . O
plus CC CC O
2 CD CD O
weeks NNS NNS O
of IN IN O
observation NN NN O
) ) ) O
. . . O

On IN IN O
this DT DT O
schedule NN NN O
, , , O
the DT DT O
animals NNS NNS O
' POS POS O
hearts NNS NNS O
appeared VBD VBD O
normal JJ JJ O
after IN IN O
sacrifice NN NN O
and CC CC O
ICRF NNP NNP B-CHEM
- : : I-CHEM
187 CD CD I-CHEM
( ( ( O
50 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
given VBN VBN O
i NNP NNP O
. . . O
p NN NN O
. . . O
1 CD CD O
h NN NN O
before IN IN O
doxorubicin NN NN B-CHEM
) ) ) O
provided VBD VBD O
almost RB RB O
full JJ JJ O
protection NN NN O
. . . O

These DT DT O
data NNS NNS O
were VBD VBD O
confirmed VBN VBN O
by IN IN O
histology NN NN O
. . . O

The DT DT O
results NNS NNS O
indicate VBP VBP O
that IN IN O
this DT DT O
new JJ JJ O
model NN NN O
is VBZ VBZ O
very RB RB O
sensitive JJ JJ O
and CC CC O
enables VBZ VBZ O
monitoring VBG VBG O
of IN IN O
the DT DT O
development NN NN O
of IN IN O
cardiotoxicity NN NN O
with IN IN O
time NN NN O
. . . O

These DT DT O
findings NNS NNS O
result NN NN O
in IN IN O
a DT DT O
model NN NN O
that WDT WDT O
allows VBZ VBZ O
the DT DT O
testing NN NN O
of IN IN O
protectors NNS NNS O
against IN IN O
doxorubicin NN NN B-CHEM
- - - O
induced JJ JJ O
cardiotoxicity NN NN O
as IN IN O
demonstrated VBN VBN O
by IN IN O
the DT DT O
protection NN NN O
provided VBN VBN O
by IN IN O
ICRF NNP NNP B-CHEM
- : : I-CHEM
187 CD CD I-CHEM
. . . O

Epinephrine NNP NNP B-CHEM
dysrhythmogenicity NN NN O
is VBZ VBZ O
not RB RB O
enhanced VBN VBN O
by IN IN O
subtoxic JJ JJ O
bupivacaine NN NN B-CHEM
in IN IN O
dogs NNS NNS O
. . . O

Since IN IN O
bupivacaine NN NN B-CHEM
and CC CC O
epinephrine NN NN B-CHEM
may MD MD O
both DT DT O
precipitate VB VB O
dysrhythmias NN NN O
, , , O
circulating VBG VBG O
bupivacaine NN NN B-CHEM
during IN IN O
regional JJ JJ O
anesthesia NN NN O
could MD MD O
potentiate VB VB O
dysrhythmogenic JJ JJ O
effects NNS NNS O
of IN IN O
epinephrine NN NN B-CHEM
. . . O

We PRP PRP O
therefore RB RB O
examined VBD VBD O
whether IN IN O
bupivacaine NN NN B-CHEM
alters NNS NNS O
the DT DT O
dysrhythmogenicity NN NN O
of IN IN O
subsequent JJ JJ O
administration NN NN O
of IN IN O
epinephrine NN NN B-CHEM
in IN IN O
conscious JJ JJ O
, , , O
healthy JJ JJ O
dogs NNS NNS O
and CC CC O
in IN IN O
anesthetized JJ JJ O
dogs NNS NNS O
with IN IN O
myocardial NN NN O
infarction NN NN O
. . . O

Forty CD CD O
- : : O
one CD CD O
conscious JJ JJ O
dogs NNS NNS O
received VBD VBD O
10 CD CD O
micrograms NNS NNS O
. . . O
kg NN NN O
- : : O
1 CD CD O
. . . O
min NN NN O
- : : O
1 CD CD O
epinephrine NN NN B-CHEM
. . . O

Seventeen NNP NNP O
animals NNS NNS O
responded VBD VBD O
with IN IN O
ventricular NN NN O
tachycardia NNS NNS O
( ( ( O
VT NNP NNP O
) ) ) O
within IN IN O
3 CD CD O
min NN NN O
. . . O

After IN IN O
3 CD CD O
h NN NN O
, , , O
these DT DT O
responders NNS NNS O
randomly RB RB O
received VBD VBD O
1 CD CD O
or CC CC O
2 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
bupivacaine NN NN B-CHEM
or CC CC O
saline NN NN O
over IN IN O
5 CD CD O
min NN NN O
, , , O
followed VBN VBN O
by IN IN O
10 CD CD O
micrograms NNS NNS O
. . . O
kg NN NN O
- : : O
1 CD CD O
. . . O
min NN NN O
- : : O
1 CD CD O
epinephrine NN NN B-CHEM
. . . O

In IN IN O
the DT DT O
bupivacaine NN NN B-CHEM
groups NNS NNS O
, , , O
epinephrine NN NN B-CHEM
caused VBD VBD O
fewer JJR JJR O
prodysrhythmic JJ JJ O
effects NNS NNS O
than IN IN O
without IN IN O
bupivacaine NN NN B-CHEM
. . . O

VT NNP NNP O
appeared VBD VBD O
in IN IN O
fewer NN NN O
dogs NNS NNS O
and CC CC O
at IN IN O
a DT DT O
later JJ JJ O
time NN NN O
, , , O
and CC CC O
there EX EX O
were VBD VBD O
more JJR JJR O
sinoatrial JJ JJ O
beats NNS NNS O
and CC CC O
less JJR JJR O
ectopies NNS NNS O
. . . O

Epinephrine NNP NNP B-CHEM
shortened VBD VBD O
QT NNP NNP O
less JJR JJR O
after IN IN O
bupivacaine NN NN B-CHEM
than IN IN O
in IN IN O
control NN NN O
animals NNS NNS O
. . . O

One CD CD O
day NN NN O
after IN IN O
experimental JJ JJ O
myocardial NN NN O
infarction NN NN O
, , , O
six CD CD O
additional JJ JJ O
halothane NN NN B-CHEM
- : : O
anesthetized JJ JJ O
dogs NNS NNS O
received VBD VBD O
4 CD CD O
micrograms NNS NNS O
. . . O
kg NN NN O
- : : O
1 CD CD O
. . . O
min NN NN O
- : : O
1 CD CD O
epinephrine NN NN B-CHEM
until IN IN O
VT NNP NNP O
appeared VBD VBD O
. . . O

After IN IN O
45 CD CD O
min NN NN O
, , , O
1 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
bupivacaine NN NN B-CHEM
was VBD VBD O
injected VBN VBN O
over IN IN O
5 CD CD O
min NN NN O
, , , O
again RB RB O
followed VBN VBN O
by IN IN O
4 CD CD O
micrograms NNS NNS O
. . . O
kg NN NN O
- : : O
1 CD CD O
. . . O
min NN NN O
- : : O
1 CD CD O
epinephrine NN NN B-CHEM
. . . O

In IN IN O
these DT DT O
dogs NNS NNS O
, , , O
the DT DT O
prodysrhythmic JJ JJ O
response NN NN O
to TO TO O
epinephrine NN NN B-CHEM
was VBD VBD O
also RB RB O
mitigated VBN VBN O
by IN IN O
preceding VBG VBG O
bupivacaine NN NN B-CHEM
. . . O

Bupivacaine NNP NNP B-CHEM
antagonizes NNS NNS O
epinephrine NN NN B-CHEM
dysrhythmogenicity NN NN O
in IN IN O
conscious JJ JJ O
dogs NNS NNS O
susceptible JJ JJ O
to TO TO O
VT NNP NNP O
and CC CC O
in IN IN O
anesthetized JJ JJ O
dogs NNS NNS O
with IN IN O
spontaneous JJ JJ O
postinfarct NN NN O
dysrhythmias NN NN O
. . . O

There EX EX O
is VBZ VBZ O
no DT DT O
evidence NN NN O
that IN IN O
systemic JJ JJ O
subtoxic NN NN O
bupivacaine NN NN B-CHEM
administration NN NN O
enhances VBZ VBZ O
the DT DT O
dysrhythmogenicity NN NN O
of IN IN O
subsequent JJ JJ O
epinephrine NN NN B-CHEM
. . . O

Milk NNP NNP O
- : : O
alkali NN NN O
syndrome NN NN O
induced VBN VBN O
by IN IN O
1 CD CD B-CHEM
, , , I-CHEM
25 CD CD I-CHEM
( ( ( I-CHEM
OH UH UH I-CHEM
) ) ) I-CHEM
2D CD CD I-CHEM
in IN IN O
a DT DT O
patient NN NN O
with IN IN O
hypoparathyroidism NN NN O
. . . O

Milk NNP NNP O
- : : O
alkali NN NN O
syndrome NN NN O
was VBD VBD O
first RB RB O
described VBD VBD O
70 CD CD O
years NNS NNS O
ago RB RB O
in IN IN O
the DT DT O
context NN NN O
of IN IN O
the DT DT O
treatment NN NN O
of IN IN O
peptic JJ JJ O
ulcer NN NN O
disease NN NN O
with IN IN O
large JJ JJ O
amounts NNS NNS O
of IN IN O
calcium NN NN B-CHEM
and CC CC O
alkali NN NN B-CHEM
. . . O

Although IN IN O
with IN IN O
current JJ JJ O
ulcer NN NN O
therapy NN NN O
( ( ( O
H NNP NNP O
- : : O
2 CD CD O
blockers NNS NNS O
, , , O
omeprazole NN NN B-CHEM
, , , O
and CC CC O
sucralfate NN NN B-CHEM
) ) ) O
, , , O
the DT DT O
frequency NN NN O
of IN IN O
milk NN NN O
- - - O
alkali NN NN O
syndrome NN NN O
has VBZ VBZ O
decreased VBN VBN O
significantly RB RB O
, , , O
the DT DT O
classic JJ JJ O
triad NN NN O
of IN IN O
hypercalcemia NN NN O
, , , O
alkalosis NN NN O
, , , O
and CC CC O
renal JJ JJ O
impairment NN NN O
remains VBZ VBZ O
the DT DT O
hallmark NN NN O
of IN IN O
the DT DT O
syndrome NN NN O
. . . O

Milk NNP NNP O
- : : O
alkali NN NN O
syndrome NN NN O
can MD MD O
present VB VB O
serious JJ JJ O
and CC CC O
occasionally RB RB O
life NN NN O
- : : O
threatening VBG VBG O
illness NN NN O
unless IN IN O
diagnosed VBN VBN O
and CC CC O
treated VBN VBN O
appropriately RB RB O
. . . O

This DT DT O
article NN NN O
presents VBZ VBZ O
a DT DT O
patient NN NN O
with IN IN O
hypoparathyroidism NN NN O
who WP WP O
was VBD VBD O
treated VBN VBN O
with IN IN O
calcium NN NN B-CHEM
carbonate NN NN I-CHEM
and CC CC O
calcitriol NN NN B-CHEM
resulting VBG VBG O
in IN IN O
two CD CD O
admissions NNS NNS O
to TO TO O
the DT DT O
hospital NN NN O
for IN IN O
milk NN NN O
- - - O
alkali NN NN O
syndrome NN NN O
. . . O

The DT DT O
patient NN NN O
was VBD VBD O
successfully RB RB O
treated VBN VBN O
with IN IN O
intravenous JJ JJ O
pamidronate NN NN B-CHEM
on IN IN O
his PRP$ PRP$ O
first JJ JJ O
admission NN NN O
and CC CC O
with IN IN O
hydrocortisone NN NN B-CHEM
on IN IN O
the DT DT O
second JJ JJ O
. . . O

This DT DT O
illustrates VBZ VBZ O
intravenous JJ JJ O
pamidronate NN NN B-CHEM
as IN IN O
a DT DT O
valuable JJ JJ O
therapeutic JJ JJ O
tool NN NN O
when WRB WRB O
milk NN NN O
- - - O
alkali NN NN O
syndrome NN NN O
presents VBZ VBZ O
as IN IN O
hypercalcemic JJ JJ O
emergency NN NN O
. . . O

Famotidine NNP NNP B-CHEM
- - - O
associated VBN VBN O
delirium NN NN O
. . . O

A DT DT O
series NN NN O
of IN IN O
six CD CD O
cases NNS NNS O
. . . O

Famotidine NNP NNP B-CHEM
is VBZ VBZ O
a DT DT O
histamine NN NN O
H2 NNP NNP O
- : : O
receptor NN NN O
antagonist NN NN O
used VBN VBN O
in IN IN O
inpatient NN NN O
settings NNS NNS O
for IN IN O
prevention NN NN O
of IN IN O
stress NN NN O
ulcers NNS NNS O
and CC CC O
is VBZ VBZ O
showing VBG VBG O
increasing VBG VBG O
popularity NN NN O
because IN IN O
of IN IN O
its PRP$ PRP$ O
low JJ JJ O
cost NN NN O
. . . O

Although IN IN O
all DT DT O
of IN IN O
the DT DT O
currently RB RB O
available JJ JJ O
H2 NNP NNP O
- : : O
receptor NN NN O
antagonists NNS NNS O
have VBP VBP O
shown VBN VBN O
the DT DT O
propensity NN NN O
to TO TO O
cause VB VB O
delirium NN NN O
, , , O
only RB RB O
two CD CD O
previously RB RB O
reported VBD VBD O
cases NNS NNS O
have VBP VBP O
been VBN VBN O
associated VBN VBN O
with IN IN O
famotidine NN NN B-CHEM
. . . O

The DT DT O
authors NNS NNS O
report VBP VBP O
on IN IN O
six CD CD O
cases NNS NNS O
of IN IN O
famotidine NN NN B-CHEM
- - - O
associated VBN VBN O
delirium NN NN O
in IN IN O
hospitalized VBN VBN O
patients NNS NNS O
who WP WP O
cleared VBD VBD O
completely RB RB O
upon IN IN O
removal NN NN O
of IN IN O
famotidine NN NN B-CHEM
. . . O

The DT DT O
pharmacokinetics NNS NNS O
of IN IN O
famotidine NN NN B-CHEM
are VBP VBP O
reviewed VBN VBN O
, , , O
with IN IN O
no DT DT O
change NN NN O
in IN IN O
its PRP$ PRP$ O
metabolism NN NN O
in IN IN O
the DT DT O
elderly JJ JJ O
population NN NN O
seen VBN VBN O
. . . O

The DT DT O
implications NNS NNS O
of IN IN O
using VBG VBG O
famotidine NN NN B-CHEM
in IN IN O
elderly JJ JJ O
persons NNS NNS O
are VBP VBP O
discussed VBN VBN O
. . . O

Encephalopathy NNP NNP O
during IN IN O
amitriptyline NN NN B-CHEM
therapy NN NN O
: : : O
are VBP VBP O
neuroleptic JJ JJ O
malignant NN NN O
syndrome NN NN O
and CC CC O
serotonin NN NN O
syndrome NN NN O
spectrum NN NN O
disorders NNS NNS O
? . . O

This DT DT O
report NN NN O
describes VBZ VBZ O
a DT DT O
case NN NN O
of IN IN O
encephalopathy JJ JJ O
developed VBN VBN O
in IN IN O
the DT DT O
course NN NN O
of IN IN O
amitriptyline NN NN B-CHEM
therapy NN NN O
, , , O
during IN IN O
a DT DT O
remission NN NN O
of IN IN O
unipolar JJ JJ O
depression NN NN O
. . . O

This DT DT O
patient NN NN O
could MD MD O
have VB VB O
been VBN VBN O
diagnosed VBN VBN O
as IN IN O
having VBG VBG O
either CC CC O
neuroleptic JJ JJ O
malignant JJ JJ O
syndrome NN NN O
( ( ( O
NMS NNP NNP O
) ) ) O
or CC CC O
serotonin NN NN O
syndrome NN NN O
( ( ( O
SS NNP NNP O
) ) ) O
. . . O

The DT DT O
major JJ JJ O
determinant NN NN O
of IN IN O
the DT DT O
symptoms NNS NNS O
may MD MD O
have VB VB O
been VBN VBN O
dopamine NN NN B-CHEM
/ NN NN O
serotonin NN NN B-CHEM
imbalance NN NN O
in IN IN O
the DT DT O
central JJ JJ O
nervous JJ JJ O
system NN NN O
. . . O

The DT DT O
NMS NNP NNP O
- - - O
like IN IN O
encephalopathy NN NN O
that IN IN O
develops NNS NNS O
in IN IN O
association NN NN O
with IN IN O
the DT DT O
use NN NN O
of IN IN O
antidepressants NNS NNS O
indicates VBZ VBZ O
that IN IN O
NMS NNP NNP O
and CC CC O
SS NNP NNP O
are VBP VBP O
spectrum NN NN O
disorders NNS NNS O
induced VBN VBN O
by IN IN O
drugs NNS NNS O
with IN IN O
both DT DT O
antidopaminergic JJ JJ O
and CC CC O
serotonergic JJ JJ O
effects NNS NNS O
. . . O

Genetic NNP NNP O
separation NN NN O
of IN IN O
tumor NN NN O
growth NN NN O
and CC CC O
hemorrhagic JJ JJ O
phenotypes NNS NNS O
in IN IN O
an DT DT O
estrogen NN NN B-CHEM
- - - O
induced JJ JJ O
tumor NN NN O
. . . O

Chronic NNP NNP O
administration NN NN O
of IN IN O
estrogen NN NN B-CHEM
to TO TO O
the DT DT O
Fischer NNP NNP O
344 CD CD O
( ( ( O
F344 NNP NNP O
) ) ) O
rat NN NN O
induces NNS NNS O
growth NN NN O
of IN IN O
large JJ JJ O
, , , O
hemorrhagic JJ JJ O
pituitary JJ JJ O
tumors NNS NNS O
. . . O

Ten CD CD O
weeks NNS NNS O
of IN IN O
diethylstilbestrol NN NN B-CHEM
( ( ( O
DES NNP NNP B-CHEM
) ) ) O
treatment NN NN O
caused VBD VBD O
female JJ JJ O
F344 NNP NNP O
rat NN NN O
pituitaries NNS NNS O
to TO TO O
grow VB VB O
to TO TO O
an DT DT O
average NN NN O
of IN IN O
109 CD CD O
. . . O
2 CD CD O
+ NN NN O
/ NN NN O
- : : O
6 CD CD O
. . . O
3 CD CD O
mg NN NN O
( ( ( O
mean NN NN O
+ NN NN O
/ NN NN O
- - - O
SE NNP NNP O
) ) ) O
versus CC CC O
11 CD CD O
. . . O
3 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
4 CD CD O
mg NN NN O
for IN IN O
untreated JJ JJ O
rats NNS NNS O
, , , O
and CC CC O
to TO TO O
become VB VB O
highly RB RB O
hemorrhagic JJ JJ O
. . . O

The DT DT O
same JJ JJ O
DES NNP NNP B-CHEM
treatment NN NN O
produced VBD VBD O
no DT DT O
significant JJ JJ O
growth NN NN O
( ( ( O
8 CD CD O
. . . O
9 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
5 CD CD O
mg NN NN O
for IN IN O
treated VBN VBN O
females NNS NNS O
versus CC CC O
8 CD CD O
. . . O
7 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
1 CD CD O
for IN IN O
untreated JJ JJ O
females NNS NNS O
) ) ) O
or CC CC O
morphological JJ JJ O
changes NNS NNS O
in IN IN O
Brown NNP NNP O
Norway NNP NNP O
( ( ( O
BN NNP NNP O
) ) ) O
rat NN NN O
pituitaries NNS NNS O
. . . O

An DT DT O
F1 NNP NNP O
hybrid NN NN O
of IN IN O
F344 NNP NNP O
and CC CC O
BN NNP NNP O
exhibited VBD VBD O
significant JJ JJ O
pituitary JJ JJ O
growth NN NN O
after IN IN O
10 CD CD O
weeks NNS NNS O
of IN IN O
DES NNP NNP B-CHEM
treatment NN NN O
with IN IN O
an DT DT O
average JJ JJ O
mass NN NN O
of IN IN O
26 CD CD O
. . . O
3 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
7 CD CD O
mg NN NN O
compared VBN VBN O
with IN IN O
8 CD CD O
. . . O
6 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
9 CD CD O
mg NN NN O
for IN IN O
untreated JJ JJ O
rats NNS NNS O
. . . O

Surprisingly RB RB O
, , , O
the DT DT O
F1 NNP NNP O
hybrid JJ JJ O
tumors NNS NNS O
were VBD VBD O
not RB RB O
hemorrhagic JJ JJ O
and CC CC O
had VBD VBD O
hemoglobin NN NN O
content NN NN O
and CC CC O
outward RB RB O
appearance NN NN O
identical JJ JJ O
to TO TO O
that DT DT O
of IN IN O
BN NNP NNP O
. . . O

Expression NNP NNP O
of IN IN O
both DT DT O
growth NN NN O
and CC CC O
morphological JJ JJ O
changes NNS NNS O
is VBZ VBZ O
due JJ JJ O
to TO TO O
multiple JJ JJ O
genes NNS NNS O
. . . O

However RB RB O
, , , O
while IN IN O
DES NNP NNP B-CHEM
- : : O
induced JJ JJ O
pituitary JJ JJ O
growth NN NN O
exhibited VBD VBD O
quantitative JJ JJ O
, , , O
additive JJ JJ O
inheritance NN NN O
, , , O
the DT DT O
hemorrhagic JJ JJ O
phenotype NN NN O
exhibited VBD VBD O
recessive JJ JJ O
, , , O
epistatic JJ JJ O
inheritance NN NN O
. . . O

Only RB RB O
5 CD CD O
of IN IN O
the DT DT O
160 CD CD O
F2 NNP NNP O
pituitaries NNS NNS O
exhibited VBD VBD O
the DT DT O
hemorrhagic JJ JJ O
phenotype NN NN O
; : : O
36 CD CD O
of IN IN O
the DT DT O
160 CD CD O
F2 NNP NNP O
pituitaries NNS NNS O
were VBD VBD O
in IN IN O
the DT DT O
F344 NNP NNP O
range NN NN O
of IN IN O
mass NN NN O
, , , O
but CC CC O
31 CD CD O
of IN IN O
these DT DT O
were VBD VBD O
not RB RB O
hemorrhagic JJ JJ O
, , , O
indicating VBG VBG O
that IN IN O
the DT DT O
hemorrhagic JJ JJ O
phenotype NN NN O
is VBZ VBZ O
not RB RB O
merely RB RB O
a DT DT O
consequence NN NN O
of IN IN O
extensive JJ JJ O
growth NN NN O
. . . O

The DT DT O
hemorrhagic JJ JJ O
F2 NNP NNP O
pituitaries NNS NNS O
were VBD VBD O
all DT DT O
among IN IN O
the DT DT O
most RBS RBS O
massive JJ JJ O
, , , O
indicating VBG VBG O
that IN IN O
some DT DT O
of IN IN O
the DT DT O
genes NNS NNS O
regulate VBP VBP O
both DT DT O
phenotypes NNS NNS O
. . . O

Increased NNP NNP O
expression NN NN O
of IN IN O
neuronal NN NN O
nitric JJ JJ B-CHEM
oxide NN NN I-CHEM
synthase NN NN O
in IN IN O
bladder NN NN O
afferent NN NN O
pathways NNS NNS O
following VBG VBG O
chronic JJ JJ O
bladder NN NN O
irritation NN NN O
. . . O

Immunocytochemical NNP NNP O
techniques NNS NNS O
were VBD VBD O
used VBN VBN O
to TO TO O
examine VB VB O
alterations NNS NNS O
in IN IN O
the DT DT O
expression NN NN O
of IN IN O
neuronal NN NN O
nitric JJ JJ B-CHEM
oxide NN NN I-CHEM
synthase NN NN O
( ( ( O
NOS NNP NNP O
) ) ) O
in IN IN O
bladder NN NN O
pathways NNS NNS O
following VBG VBG O
acute JJ JJ O
and CC CC O
chronic JJ JJ O
irritation NN NN O
of IN IN O
the DT DT O
urinary JJ JJ O
tract NN NN O
of IN IN O
the DT DT O
rat NN NN O
. . . O

Chemical NNP NNP O
cystitis NNS NNS O
was VBD VBD O
induced VBN VBN O
by IN IN O
cyclophosphamide NN NN B-CHEM
( ( ( O
CYP NNP NNP B-CHEM
) ) ) O
which WDT WDT O
is VBZ VBZ O
metabolized VBN VBN O
to TO TO O
acrolein VB VB B-CHEM
, , , O
an DT DT O
irritant NN NN O
eliminated VBN VBN O
in IN IN O
the DT DT O
urine NN NN O
. . . O

Injection NNP NNP O
of IN IN O
CYP NNP NNP B-CHEM
( ( ( O
n NN NN O
= SYM SYM O
10 CD CD O
, , , O
75 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
i NNP NNP O
. . . O
p NN NN O
. . . O
) ) ) O
2 CD CD O
hours NNS NNS O
prior RB RB O
to TO TO O
perfusion NN NN O
( ( ( O
acute JJ JJ O
treatment NN NN O
) ) ) O
of IN IN O
the DT DT O
animals NNS NNS O
increased VBN VBN O
Fos NNP NNP O
- : : O
immunoreactivity NN NN O
( ( ( O
IR NNP NNP O
) ) ) O
in IN IN O
neurons NNS NNS O
in IN IN O
the DT DT O
dorsal NN NN O
commissure NN NN O
, , , O
dorsal NN NN O
horn NN NN O
, , , O
and CC CC O
autonomic JJ JJ O
regions NNS NNS O
of IN IN O
spinal JJ JJ O
segments NNS NNS O
( ( ( O
L1 NNP NNP O
- : : O
L2 NNP NNP O
and CC CC O
L6 NNP NNP O
- : : O
S1 NNP NNP O
) ) ) O
which WDT WDT O
receive VBP VBP O
afferent NN NN O
inputs NNS NNS O
from IN IN O
the DT DT O
bladder NN NN O
, , , O
urethra NN NN O
, , , O
and CC CC O
ureter NN NN O
. . . O

Fos NNP NNP O
- : : O
IR NNP NNP O
in IN IN O
the DT DT O
spinal JJ JJ O
cord NN NN O
was VBD VBD O
not RB RB O
changed VBN VBN O
in IN IN O
rats NNS NNS O
receiving VBG VBG O
chronic JJ JJ O
CYP NNP NNP B-CHEM
treatment NN NN O
( ( ( O
n NN NN O
= SYM SYM O
15 CD CD O
, , , O
75 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
i NNP NNP O
. . . O
p NN NN O
. . . O
, , , O
every DT DT O
3rd CD CD O
day NN NN O
for IN IN O
2 CD CD O
weeks NNS NNS O
) ) ) O
. . . O

In IN IN O
control NN NN O
animals NNS NNS O
and CC CC O
in IN IN O
animals NNS NNS O
treated VBN VBN O
acutely RB RB O
with IN IN O
CYP NNP NNP B-CHEM
, , , O
only RB RB O
small JJ JJ O
numbers NNS NNS O
of IN IN O
NOS NNP NNP O
- : : O
IR NNP NNP O
cells NNS NNS O
( ( ( O
0 CD CD O
. . . O
5 CD CD O
- : : O
0 CD CD O
. . . O
7 CD CD O
cell NN NN O
profiles NNS NNS O
/ NN NN O
sections NNS NNS O
) ) ) O
were VBD VBD O
detected VBN VBN O
in IN IN O
the DT DT O
L6 NNP NNP O
- - - O
S1 NNP NNP O
dorsal NN NN O
root NN NN O
ganglia NN NN O
( ( ( O
DRG NNP NNP O
) ) ) O
. . . O

Chronic NNP NNP O
CYP NNP NNP B-CHEM
administration NN NN O
significantly RB RB O
( ( ( O
P NN NN O
< NN NN O
or CC CC O
= SYM SYM O
. . . O
002 CD CD O
) ) ) O
increased VBN VBN O
bladder NN NN O
weight NN NN O
by IN IN O
60 CD CD O
% NN NN O
and CC CC O
increased VBN VBN O
( ( ( O
7 CD CD O
- : : O
to TO TO O
11 CD CD O
- : : O
fold NN NN O
) ) ) O
the DT DT O
numbers NNS NNS O
of IN IN O
NOS NNP NNP O
- : : O
immunoreactive JJ JJ O
( ( ( O
IR NNP NNP O
) ) ) O
afferent NN NN O
neurons NNS NNS O
in IN IN O
the DT DT O
L6 NNP NNP O
- - - O
S1 NNP NNP O
DRG NNP NNP O
. . . O

A DT DT O
small JJ JJ O
increase NN NN O
( ( ( O
1 CD CD O
. . . O
5 CD CD O
- : : O
fold NN NN O
) ) ) O
also RB RB O
occurred VBD VBD O
in IN IN O
the DT DT O
L1 NNP NNP O
DRG NNP NNP O
, , , O
but CC CC O
no DT DT O
change NN NN O
was VBD VBD O
detected VBN VBN O
in IN IN O
the DT DT O
L2 NNP NNP O
and CC CC O
L5 NNP NNP O
DRG NNP NNP O
. . . O

Bladder NNP NNP O
afferent NN NN O
cells NNS NNS O
in IN IN O
the DT DT O
L6 NNP NNP O
- - - O
S1 NNP NNP O
DRG NNP NNP O
labeled VBN VBN O
by IN IN O
Fluorogold NNP NNP O
( ( ( O
40 CD CD O
microliters NNS NNS O
) ) ) O
injected VBN VBN O
into IN IN O
the DT DT O
bladder NN NN O
wall NN NN O
did VBD VBD O
not RB RB O
exhibit NN NN O
NOS NNP NNP O
- : : O
IR NNP NNP O
in IN IN O
control NN NN O
animals NNS NNS O
; : : O
however RB RB O
, , , O
following VBG VBG O
chronic JJ JJ O
CYP NNP NNP B-CHEM
administration NN NN O
, , , O
a DT DT O
significant JJ JJ O
percentage NN NN O
of IN IN O
bladder NN NN O
afferent JJ JJ O
neurons NNS NNS O
were VBD VBD O
NOS NNP NNP O
- : : O
IR NNP NNP O
: : : O
L6 NNP NNP O
( ( ( O
19 CD CD O
. . . O
8 CD CD O
+ NN NN O
/ NN NN O
- : : O
4 CD CD O
. . . O
6 CD CD O
% NN NN O
) ) ) O
and CC CC O
S1 NNP NNP O
( ( ( O
25 CD CD O
. . . O
3 CD CD O
+ NN NN O
/ NN NN O
- : : O
2 CD CD O
. . . O
9 CD CD O
% NN NN O
) ) ) O
. . . O

These DT DT O
results NNS NNS O
indicate VBP VBP O
that IN IN O
neuronal JJ JJ O
gene NN NN O
expression NN NN O
in IN IN O
visceral JJ JJ O
sensory NN NN O
pathways NNS NNS O
can MD MD O
be VB VB O
upregulated JJ JJ O
by IN IN O
chemical NN NN O
irritation NN NN O
of IN IN O
afferent NN NN O
receptors NNS NNS O
in IN IN O
the DT DT O
urinary JJ JJ O
tract NN NN O
and CC CC O
/ NN NN O
or CC CC O
that DT DT O
pathological JJ JJ O
changes NNS NNS O
in IN IN O
the DT DT O
urinary JJ JJ O
tract NN NN O
can MD MD O
initiate VB VB O
chemical NN NN O
signals NNS NNS O
that WDT WDT O
alter VBP VBP O
the DT DT O
chemical NN NN O
properties NNS NNS O
of IN IN O
visceral JJ JJ O
afferent NN NN O
neurons NNS NNS O
. . . O

Effects NNP NNP O
of IN IN O
a DT DT O
new JJ JJ O
calcium NN NN B-CHEM
antagonist NN NN O
, , , O
CD NNP NNP B-CHEM
- : : I-CHEM
832 CD CD I-CHEM
, , , O
on IN IN O
isoproterenol NN NN B-CHEM
- : : O
induced JJ JJ O
myocardial NN NN O
ischemia NN NN O
in IN IN O
dogs NNS NNS O
with IN IN O
partial JJ JJ O
coronary JJ JJ O
stenosis NN NN O
. . . O

Effects NNP NNP O
of IN IN O
CD NNP NNP B-CHEM
- - - I-CHEM
832 CD CD I-CHEM
on IN IN O
isoproterenol NN NN B-CHEM
( ( ( O
ISO NNP NNP B-CHEM
) ) ) O
- : : O
induced JJ JJ O
myocardial NN NN O
ischemia NN NN O
were VBD VBD O
studied VBN VBN O
in IN IN O
dogs NNS NNS O
with IN IN O
partial JJ JJ O
coronary JJ JJ O
stenosis NN NN O
of IN IN O
the DT DT O
left NN NN O
circumflex NN NN O
coronary JJ JJ O
artery NN NN O
and CC CC O
findings NNS NNS O
were VBD VBD O
compared VBN VBN O
with IN IN O
those DT DT O
for IN IN O
nifedipine NN NN B-CHEM
or CC CC O
diltiazem NN NN B-CHEM
. . . O

In IN IN O
the DT DT O
presence NN NN O
of IN IN O
coronary JJ JJ O
artery NN NN O
stenosis NN NN O
, , , O
3 CD CD O
- : : O
min NN NN O
periods NNS NNS O
of IN IN O
intracoronary JJ JJ O
ISO NNP NNP B-CHEM
infusion NN NN O
( ( ( O
10 CD CD O
ng NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
) ) ) O
increased VBN VBN O
heart NN NN O
rate NN NN O
and CC CC O
maximal NN NN O
rate NN NN O
of IN IN O
left VBD VBD O
ventricular NN NN O
pressure NN NN O
rise NN NN O
, , , O
which WDT WDT O
resulted VBD VBD O
in IN IN O
a DT DT O
decrease NN NN O
in IN IN O
percentage NN NN O
segmental NN NN O
shortening VBG VBG O
and CC CC O
ST NNP NNP O
- : : O
segment NN NN O
elevation NN NN O
of IN IN O
the DT DT O
epicardial JJ JJ O
electrocardiogram NN NN O
. . . O

After IN IN O
the DT DT O
control NN NN O
ISO NNP NNP B-CHEM
infusion NN NN O
with IN IN O
stenosis NN NN O
was VBD VBD O
performed VBN VBN O
, , , O
equihypotensive JJ JJ O
doses NNS NNS O
of IN IN O
CD NNP NNP B-CHEM
- : : I-CHEM
832 CD CD I-CHEM
( ( ( O
3 CD CD O
and CC CC O
10 CD CD O
micrograms NNS NNS O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
, , , O
n NN NN O
= SYM SYM O
7 CD CD O
) ) ) O
, , , O
nifedipine NN NN B-CHEM
( ( ( O
1 CD CD O
and CC CC O
3 CD CD O
micrograms NNS NNS O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
, , , O
n NN NN O
= SYM SYM O
9 CD CD O
) ) ) O
or CC CC O
diltiazem NN NN B-CHEM
( ( ( O
10 CD CD O
and CC CC O
30 CD CD O
micrograms NNS NNS O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
, , , O
n NN NN O
= SYM SYM O
7 CD CD O
) ) ) O
were VBD VBD O
infused VBN VBN O
5 CD CD O
min NN NN O
before IN IN O
and CC CC O
during IN IN O
the DT DT O
second JJ JJ O
and CC CC O
third JJ JJ O
ISO NNP NNP B-CHEM
infusion NN NN O
. . . O

Both DT DT O
CD NNP NNP B-CHEM
- : : I-CHEM
832 CD CD I-CHEM
and CC CC O
diltiazem NN NN B-CHEM
, , , O
but CC CC O
not RB RB O
nifedipine NN NN B-CHEM
, , , O
significantly RB RB O
reduced VBD VBD O
the DT DT O
increase NN NN O
in IN IN O
heart NN NN O
rate NN NN O
induced VBN VBN O
by IN IN O
ISO NNP NNP B-CHEM
infusion NN NN O
. . . O

In IN IN O
contrast NN NN O
to TO TO O
nifedipine NN NN B-CHEM
, , , O
CD NNP NNP B-CHEM
- : : I-CHEM
832 CD CD I-CHEM
( ( ( O
10 CD CD O
micrograms NNS NNS O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
) ) ) O
prevented VBD VBD O
the DT DT O
decrease NN NN O
in IN IN O
percentage NN NN O
segmental NN NN O
shortening VBG VBG O
from IN IN O
32 CD CD O
+ NN NN O
/ NN NN O
- : : O
12 CD CD O
% NN NN O
to TO TO O
115 CD CD O
+ NN NN O
/ NN NN O
- : : O
26 CD CD O
% NN NN O
of IN IN O
the DT DT O
control NN NN O
value NN NN O
( ( ( O
P NN NN O
< NN NN O
. . . O
01 CD CD O
) ) ) O
and CC CC O
ST NNP NNP O
- : : O
segment NN NN O
elevation NN NN O
from IN IN O
5 CD CD O
. . . O
6 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
0 CD CD O
mV NN NN O
to TO TO O
1 CD CD O
. . . O
6 CD CD O
+ NN NN O
/ NN NN O
- : : O
1 CD CD O
. . . O
3 CD CD O
mV NN NN O
( ( ( O
P NN NN O
< NN NN O
. . . O
01 CD CD O
) ) ) O
at IN IN O
3 CD CD O
min NN NN O
after IN IN O
ISO NNP NNP B-CHEM
infusion NN NN O
with IN IN O
stenosis NN NN O
. . . O

Diltiazem NNP NNP B-CHEM
( ( ( O
30 CD CD O
micrograms NNS NNS O
/ NN NN O
kg NN NN O
/ NN NN O
min NN NN O
) ) ) O
also RB RB O
prevented VBD VBD O
the DT DT O
decrease NN NN O
in IN IN O
percentage NN NN O
segmental NN NN O
shortening VBG VBG O
from IN IN O
34 CD CD O
+ NN NN O
/ NN NN O
- : : O
14 CD CD O
% NN NN O
to TO TO O
63 CD CD O
+ NN NN O
/ NN NN O
- : : O
18 CD CD O
% NN NN O
of IN IN O
the DT DT O
control NN NN O
value NN NN O
( ( ( O
P NN NN O
< NN NN O
. . . O
05 CD CD O
) ) ) O
and CC CC O
ST NNP NNP O
- : : O
segment NN NN O
elevation NN NN O
from IN IN O
4 CD CD O
. . . O
7 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
7 CD CD O
mV NN NN O
to TO TO O
2 CD CD O
. . . O
1 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
7 CD CD O
mV NN NN O
( ( ( O
P NN NN O
< NN NN O
. . . O
01 CD CD O
) ) ) O
at IN IN O
3 CD CD O
min NN NN O
after IN IN O
ISO NNP NNP B-CHEM
infusion NN NN O
with IN IN O
stenosis NN NN O
. . . O

These DT DT O
data NNS NNS O
show VBP VBP O
that IN IN O
CD NNP NNP B-CHEM
- : : I-CHEM
832 CD CD I-CHEM
improves VBZ VBZ O
myocardial NN NN O
ischemia NN NN O
during IN IN O
ISO NNP NNP B-CHEM
infusion NN NN O
with IN IN O
stenosis NN NN O
and CC CC O
suggest VB VB O
that IN IN O
the DT DT O
negative JJ JJ O
chronotropic NN NN O
property NN NN O
of IN IN O
CD NN NN B-CHEM
- - - I-CHEM
832 CD CD I-CHEM
plays VBZ VBZ O
a DT DT O
major JJ JJ O
role NN NN O
in IN IN O
the DT DT O
beneficial JJ JJ O
effects NNS NNS O
of IN IN O
CD NNP NNP B-CHEM
- - - I-CHEM
832 CD CD I-CHEM
. . . O

The DT DT O
effect NN NN O
of IN IN O
recombinant JJ JJ O
human JJ JJ O
insulin NN NN O
- - - O
like IN IN O
growth NN NN O
factor NN NN O
- : : O
I PRP PRP O
on IN IN O
chronic JJ JJ O
puromycin NN NN B-CHEM
aminonucleoside NN NN I-CHEM
nephropathy NN NN O
in IN IN O
rats NNS NNS O
. . . O

We PRP PRP O
recently RB RB O
demonstrated VBD VBD O
that IN IN O
recombinant NN NN O
hGH NN NN O
exacerbates NNS NNS O
renal JJ JJ O
functional JJ JJ O
and CC CC O
structural JJ JJ O
injury NN NN O
in IN IN O
chronic JJ JJ O
puromycin NN NN B-CHEM
aminonucleoside NN NN I-CHEM
( ( ( O
PAN NNP NNP B-CHEM
) ) ) O
nephropathy NN NN O
, , , O
an DT DT O
experimental JJ JJ O
model NN NN O
of IN IN O
glomerular NN NN O
disease NN NN O
. . . O

Therefore RB RB O
, , , O
we PRP PRP O
examined VBD VBD O
whether IN IN O
recombinant JJ JJ O
human JJ JJ O
( ( ( O
rh NN NN O
) ) ) O
IGF NNP NNP O
- : : O
I PRP PRP O
is VBZ VBZ O
a DT DT O
safer NN NN O
alternative NN NN O
for IN IN O
the DT DT O
treatment NN NN O
of IN IN O
growth NN NN O
failure NN NN O
in IN IN O
rats NNS NNS O
with IN IN O
chronic JJ JJ O
PAN NNP NNP B-CHEM
nephropathy NN NN O
. . . O

The DT DT O
glomerulopathy NN NN O
was VBD VBD O
induced VBN VBN O
by IN IN O
seven CD CD O
serial JJ JJ O
injections NNS NNS O
of IN IN O
PAN NNP NNP B-CHEM
over IN IN O
12 CD CD O
wk NN NN O
. . . O

Experimental NNP NNP O
animals NNS NNS O
( ( ( O
n NN NN O
= SYM SYM O
6 CD CD O
) ) ) O
received VBD VBD O
rhIGF NN NN O
- : : O
I PRP PRP O
, , , O
400 CD CD O
micrograms NNS NNS O
/ NN NN O
d SYM SYM O
, , , O
whereas IN IN O
control NN NN O
rats NNS NNS O
( ( ( O
n NN NN O
= SYM SYM O
6 CD CD O
) ) ) O
received VBD VBD O
the DT DT O
vehicle NN NN O
. . . O

rhIGF NN NN O
- : : O
I PRP PRP O
improved VBD VBD O
weight NN NN O
gain NN NN O
by IN IN O
14 CD CD O
% NN NN O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
, , , O
without IN IN O
altering VBG VBG O
hematocrit NN NN O
or CC CC O
blood NN NN O
pressure NN NN O
in IN IN O
rats NNS NNS O
with IN IN O
renal JJ JJ O
disease NN NN O
. . . O

Urinary NNP NNP O
protein NN NN O
excretion NN NN O
was VBD VBD O
unaltered VBN VBN O
by IN IN O
rhIGF NN NN O
- : : O
I PRP PRP O
treatment NN NN O
in IN IN O
rats NNS NNS O
with IN IN O
chronic JJ JJ O
PAN NNP NNP B-CHEM
nephropathy NN NN O
. . . O

After IN IN O
12 CD CD O
wk NN NN O
, , , O
the DT DT O
inulin NN NN O
clearance NN NN O
was VBD VBD O
higher JJR JJR O
in IN IN O
rhIGF NN NN O
- - - O
I PRP PRP O
- - - O
treated VBN VBN O
rats NNS NNS O
, , , O
0 CD CD O
. . . O
48 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
08 CD CD O
versus CC CC O
0 CD CD O
. . . O
24 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
06 CD CD O
mL NN NN O
/ NN NN O
min NN NN O
/ NN NN O
100 CD CD O
g SYM SYM O
of IN IN O
body NN NN O
weight NN NN O
in IN IN O
untreated JJ JJ O
PAN NNP NNP B-CHEM
nephropathy JJ JJ O
animals NNS NNS O
, , , O
p NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
. . . O

The DT DT O
improvement NN NN O
in IN IN O
GFR NNP NNP O
was VBD VBD O
not RB RB O
associated VBN VBN O
with IN IN O
enhanced JJ JJ O
glomerular NN NN O
hypertrophy NN NN O
or CC CC O
increased VBN VBN O
segmental JJ JJ O
glomerulosclerosis NN NN O
, , , O
tubulointerstitial JJ JJ O
injury NN NN O
, , , O
or CC CC O
renal JJ JJ O
cortical JJ JJ O
malondialdehyde NN NN B-CHEM
content NN NN O
. . . O

In IN IN O
rats NNS NNS O
with IN IN O
PAN NNP NNP B-CHEM
nephropathy NN NN O
, , , O
administration NN NN O
of IN IN O
rhIGF NN NN O
- - - O
I PRP PRP O
increased VBD VBD O
IGF NNP NNP O
- : : O
I PRP PRP O
and CC CC O
GH NNP NNP O
receptor NN NN O
gene NN NN O
expression NN NN O
, , , O
without IN IN O
altering VBG VBG O
the DT DT O
steady JJ JJ O
state NN NN O
level NN NN O
of IN IN O
IGF NNP NNP O
- : : O
I PRP PRP O
receptor NN NN O
mRNA NN NN O
. . . O

In IN IN O
normal JJ JJ O
rats NNS NNS O
with IN IN O
intact JJ JJ O
kidneys NNS NNS O
, , , O
rhIGF NN NN O
- : : O
I PRP PRP O
administration NN NN O
( ( ( O
n NN NN O
= SYM SYM O
4 CD CD O
) ) ) O
did VBD VBD O
not RB RB O
alter VB VB O
weight NN NN O
gain NN NN O
, , , O
blood NN NN O
pressure NN NN O
, , , O
proteinuria NN NN O
, , , O
GFR NNP NNP O
, , , O
glomerular NN NN O
planar NN NN O
area NN NN O
, , , O
renal JJ JJ O
cortical JJ JJ O
malondialdehyde NN NN B-CHEM
content NN NN O
, , , O
or CC CC O
glomerular NN NN O
or CC CC O
tubulointerstitial JJ JJ O
damage NN NN O
, , , O
compared VBN VBN O
with IN IN O
untreated JJ JJ O
animals NNS NNS O
( ( ( O
n NN NN O
= SYM SYM O
4 CD CD O
) ) ) O
. . . O

rhIGF NN NN O
- : : O
I PRP PRP O
treatment NN NN O
reduced VBD VBD O
the DT DT O
steady JJ JJ O
state NN NN O
renal NN NN O
IGF NNP NNP O
- : : O
I PRP PRP O
mRNA NN NN O
level NN NN O
but CC CC O
did VBD VBD O
not RB RB O
modify VB VB O
gene NN NN O
expression NN NN O
of IN IN O
the DT DT O
IGF NNP NNP O
- : : O
I PRP PRP O
or CC CC O
GH NNP NNP O
receptors NNS NNS O
. . . O

We PRP PRP O
conclude VBP VBP O
that IN IN O
: : : O
1 CD CD O
) ) ) O
administration NN NN O
of IN IN O
rhIGF NN NN O
- - - O
I PRP PRP O
improves NNS NNS O
growth NN NN O
and CC CC O
GFR NNP NNP O
in IN IN O
rats NNS NNS O
with IN IN O
chronic JJ JJ O
PAN NNP NNP B-CHEM
nephropathy NN NN O
and CC CC O
2 CD CD O
) ) ) O
unlike IN IN O
rhGH NN NN O
, , , O
long JJ JJ O
- - - O
term NN NN O
use NN NN O
of IN IN O
rhIGF NN NN O
- - - O
I PRP PRP O
does VBZ VBZ O
not RB RB O
worsen VB VB O
renal JJ JJ O
functional JJ JJ O
and CC CC O
structural JJ JJ O
injury NN NN O
in IN IN O
this DT DT O
disease NN NN O
model NN NN O
. . . O

Nefiracetam NNP NNP B-CHEM
( ( ( O
DM NNP NNP B-CHEM
- : : I-CHEM
9384 CD CD I-CHEM
) ) ) O
reverses VBZ VBZ O
apomorphine NN NN B-CHEM
- - - O
induced JJ JJ O
amnesia NN NN O
of IN IN O
a DT DT O
passive JJ JJ O
avoidance NN NN O
response NN NN O
: : : O
delayed JJ JJ O
emergence NN NN O
of IN IN O
the DT DT O
memory NN NN O
retention NN NN O
effects NNS NNS O
. . . O

Nefiracetam NNP NNP B-CHEM
is VBZ VBZ O
a DT DT O
novel NN NN O
pyrrolidone NN NN B-CHEM
derivative JJ JJ O
which WDT WDT O
attenuates VBZ VBZ O
scopolamine NN NN B-CHEM
- - - O
induced JJ JJ O
learning NN NN O
and CC CC O
post NN NN O
- - - O
training NN NN O
consolidation NN NN O
deficits NNS NNS O
. . . O

Given VBN VBN O
that DT DT O
apomorphine NN NN B-CHEM
inhibits NNS NNS O
passive JJ JJ O
avoidance NN NN O
retention NN NN O
when WRB WRB O
given VBN VBN O
during IN IN O
training NN NN O
or CC CC O
in IN IN O
a DT DT O
defined VBN VBN O
10 CD CD O
- : : O
12h CD CD O
post NN NN O
- : : O
training NN NN O
period NN NN O
, , , O
we PRP PRP O
evaluated VBD VBD O
the DT DT O
ability NN NN O
of IN IN O
nefiracetam NN NN B-CHEM
to TO TO O
attenuate VB VB O
amnesia NN NN O
induced VBN VBN O
by IN IN O
dopaminergic JJ JJ O
agonism NN NN O
. . . O

A DT DT O
step NN NN O
- - - O
down RB RB O
passive JJ JJ O
avoidance NN NN O
paradigm NN NN O
was VBD VBD O
employed VBN VBN O
and CC CC O
nefiracetam NN NN B-CHEM
( ( ( O
3 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
and CC CC O
apomorphine NN NN B-CHEM
( ( ( O
0 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
were VBD VBD O
given VBN VBN O
alone RB RB O
or CC CC O
in IN IN O
combination NN NN O
during IN IN O
training NN NN O
and CC CC O
at IN IN O
the DT DT O
10 CD CD O
- : : O
12h CD CD O
post NN NN O
- : : O
training NN NN O
period NN NN O
of IN IN O
consolidation NN NN O
. . . O

Co NNP NNP O
- : : O
administration NN NN O
of IN IN O
nefiracetam NN NN B-CHEM
and CC CC O
apomorphine NN NN B-CHEM
during IN IN O
training NN NN O
or CC CC O
10h CD CD O
thereafter RB RB O
produced VBD VBD O
no DT DT O
significant JJ JJ O
anti JJ JJ O
- : : O
amnesic JJ JJ O
effect NN NN O
. . . O

However RB RB O
, , , O
administration NN NN O
of IN IN O
nefiracetam NN NN B-CHEM
during IN IN O
training NN NN O
completely RB RB O
reversed VBD VBD O
the DT DT O
amnesia NN NN O
induced VBN VBN O
by IN IN O
apomorphine NN NN B-CHEM
at IN IN O
the DT DT O
10h CD CD O
post NN NN O
- : : O
training NN NN O
time NN NN O
and CC CC O
the DT DT O
converse NN NN O
was VBD VBD O
also RB RB O
true JJ JJ O
. . . O

These DT DT O
effects NNS NNS O
were VBD VBD O
not RB RB O
mediated VBN VBN O
by IN IN O
a DT DT O
dopaminergic JJ JJ O
mechanism NN NN O
as IN IN O
nefiracetam NN NN B-CHEM
, , , O
at IN IN O
millimolar JJ JJ O
concentrations NNS NNS O
, , , O
failed VBD VBD O
to TO TO O
displace VB VB O
either CC CC O
[ NN NN O
3H CD CD O
] NN NN O
SCH NNP NNP B-CHEM
23390 CD CD I-CHEM
or CC CC O
[ NN NN O
3H CD CD O
] NN NN O
spiperone NN NN B-CHEM
binding JJ JJ O
from IN IN O
D1 NN NN O
or CC CC O
D2 NN NN O
dopamine NN NN B-CHEM
receptor NN NN O
subtypes NNS NNS O
, , , O
respectively RB RB O
. . . O

It PRP PRP O
is VBZ VBZ O
suggested VBN VBN O
that IN IN O
nefiracetam NN NN B-CHEM
augments NNS NNS O
molecular JJ JJ O
processes NNS NNS O
in IN IN O
the DT DT O
early JJ JJ O
stages NNS NNS O
of IN IN O
events NNS NNS O
which WDT WDT O
ultimately RB RB O
lead VB VB O
to TO TO O
consolidation NN NN O
of IN IN O
memory NN NN O
. . . O

Phenytoin NNP NNP B-CHEM
encephalopathy NN NN O
as IN IN O
probable JJ JJ O
idiosyncratic JJ JJ O
reaction NN NN O
: : : O
case NN NN O
report NN NN O
. . . O

A DT DT O
case NN NN O
of IN IN O
phenytoin NN NN B-CHEM
( ( ( O
DPH NNP NNP B-CHEM
) ) ) O
encephalopathy NN NN O
with IN IN O
increasing VBG VBG O
seizures NNS NNS O
and CC CC O
EEG NNP NNP O
and CC CC O
mental JJ JJ O
changes NNS NNS O
is VBZ VBZ O
described VBN VBN O
. . . O

Despite IN IN O
adequate JJ JJ O
oral JJ JJ O
dosage NN NN O
of IN IN O
DPH NNP NNP B-CHEM
( ( ( O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
/ NN NN O
daily JJ JJ O
) ) ) O
the DT DT O
plasma NN NN O
level NN NN O
was VBD VBD O
very RB RB O
low JJ JJ O
( ( ( O
2 CD CD O
. . . O
8 CD CD O
microgramg NN NN O
/ NN NN O
ml NN NN O
) ) ) O
. . . O

The DT DT O
encephalopathy NN NN O
was VBD VBD O
probably RB RB O
an DT DT O
idiosyncratic JJ JJ O
and CC CC O
not RB RB O
toxic JJ JJ O
or CC CC O
allergic JJ JJ O
reaction NN NN O
. . . O

In IN IN O
fact NN NN O
the DT DT O
concentration NN NN O
of IN IN O
free JJ JJ O
DPH NNP NNP B-CHEM
was VBD VBD O
normal JJ JJ O
, , , O
the DT DT O
patient NN NN O
presented VBD VBD O
a DT DT O
retarded JJ JJ O
morbilliform NN NN O
rash NN NN O
during IN IN O
DPH NNP NNP B-CHEM
treatment NN NN O
, , , O
the DT DT O
protidogram NN NN O
was VBD VBD O
normal JJ JJ O
, , , O
and CC CC O
an DT DT O
intradermic JJ JJ O
DPH NNP NNP B-CHEM
injection NN NN O
had VBD VBD O
no DT DT O
local JJ JJ O
effect NN NN O
. . . O

The DT DT O
authors NNS NNS O
conclude VBP VBP O
that IN IN O
in IN IN O
a DT DT O
patient NN NN O
starting VBG VBG O
DPH NNP NNP B-CHEM
treatment NN NN O
an DT DT O
unexpected JJ JJ O
increase NN NN O
in IN IN O
seizures NNS NNS O
, , , O
with IN IN O
EEG NNP NNP O
and CC CC O
mental JJ JJ O
changes NNS NNS O
occurring VBG VBG O
simultaneously RB RB O
, , , O
should MD MD O
alert VB VB O
the DT DT O
physician NN NN O
to TO TO O
the DT DT O
possible JJ JJ O
need VBP VBP O
for IN IN O
eliminating VBG VBG O
DPH NNP NNP B-CHEM
from IN IN O
the DT DT O
therapeutic JJ JJ O
regimen NNS NNS O
, , , O
even RB RB O
if IN IN O
plasma NN NN O
concentrations NNS NNS O
are VBP VBP O
low JJ JJ O
. . . O

Prevention NNP NNP O
and CC CC O
treatment NN NN O
of IN IN O
endometrial JJ JJ O
disease NN NN O
in IN IN O
climacteric JJ JJ O
women NNS NNS O
receiving VBG VBG O
oestrogen NN NN B-CHEM
therapy NN NN O
. . . O

The DT DT O
treatment NN NN O
regimens NNS NNS O
are VBP VBP O
described VBN VBN O
in IN IN O
74 CD CD O
patients NNS NNS O
with IN IN O
endometrial JJ JJ O
disease NN NN O
among IN IN O
850 CD CD O
climacteric JJ JJ O
women NNS NNS O
receiving VBG VBG O
oestrogen NN NN B-CHEM
therapy NN NN O
. . . O

Cystic NNP NNP O
hyperplasia NN NN O
was VBD VBD O
associated VBN VBN O
with IN IN O
unopposed JJ JJ O
oestrogen NN NN B-CHEM
therapy NN NN O
without IN IN O
progestagen NN NN B-CHEM
. . . O

Two CD CD O
courses NNS NNS O
of IN IN O
21 CD CD O
days NNS NNS O
of IN IN O
5 CD CD O
mg NN NN O
norethisterone NN NN B-CHEM
daily RB RB O
caused VBD VBD O
reversion NN NN O
to TO TO O
normal JJ JJ O
in IN IN O
all DT DT O
57 CD CD O
cases NNS NNS O
of IN IN O
cystic JJ JJ O
hyperplasia NN NN O
and CC CC O
6 CD CD O
of IN IN O
the DT DT O
8 CD CD O
cases NNS NNS O
of IN IN O
atypical JJ JJ O
hyperplasia NN NN O
. . . O

4 CD CD O
cases NNS NNS O
of IN IN O
endometrial JJ JJ O
carcinoma NN NN O
referred VBD VBD O
from IN IN O
elsewhere RB RB O
demonstrated VBN VBN O
the DT DT O
problems NNS NNS O
of IN IN O
inappropriate JJ JJ O
and CC CC O
unsupervised JJ JJ O
unopposed JJ JJ O
oestrogen NN NN B-CHEM
therapy NN NN O
and CC CC O
the DT DT O
difficulty NN NN O
in IN IN O
distinguishing VBG VBG O
severe JJ JJ O
hyperplasia NN NN O
from IN IN O
malignancy NN NN O
. . . O

Cyclical NNP NNP O
low JJ JJ O
- - - O
dose NN NN O
oestrogen NN NN B-CHEM
therapy NN NN O
with IN IN O
7 CD CD O
- : : O
- : : O
13 CD CD O
days NNS NNS O
of IN IN O
progestagen NN NN B-CHEM
does VBZ VBZ O
not RB RB O
seem VB VB O
to TO TO O
increase VB VB O
the DT DT O
risk NN NN O
of IN IN O
endometrial JJ JJ O
hyperplasia NN NN O
or CC CC O
carcinoma NN NN O
. . . O

Effects NNP NNP O
of IN IN O
exercise NN NN O
on IN IN O
the DT DT O
severity NN NN O
of IN IN O
isoproterenol NN NN B-CHEM
- - - O
induced JJ JJ O
myocardial NN NN O
infarction NN NN O
. . . O

The DT DT O
effect NN NN O
of IN IN O
exercise NN NN O
on IN IN O
the DT DT O
severity NN NN O
of IN IN O
isoproterenol NN NN B-CHEM
- - - O
induced JJ JJ O
myocardial NN NN O
infarction NN NN O
was VBD VBD O
studied VBN VBN O
in IN IN O
male JJ JJ O
rats NNS NNS O
. . . O

Ninety CD CD O
- - - O
three CD CD O
rats NNS NNS O
were VBD VBD O
randomly RB RB O
divided VBN VBN O
into IN IN O
three CD CD O
groups NNS NNS O
. . . O

The DT DT O
exercise NN NN O
- - - O
isoproterenol NN NN B-CHEM
( ( ( O
E NNP NNP O
- - - O
1 CD CD O
) ) ) O
and CC CC O
exercise NN NN O
control NN NN O
( ( ( O
EC NNP NNP O
) ) ) O
groups NNS NNS O
exercised VBD VBD O
daily JJ JJ O
for IN IN O
thirty CD CD O
days NNS NNS O
on IN IN O
a DT DT O
treadmill NN NN O
at IN IN O
1 CD CD O
mph NN NN O
, , , O
2 CD CD O
% NN NN O
grade NN NN O
while IN IN O
animals NNS NNS O
of IN IN O
the DT DT O
sedentary JJ JJ O
- - - O
isoproterenol NN NN B-CHEM
( ( ( O
S NNP NNP O
- - - O
I PRP PRP O
) ) ) O
group NN NN O
remained VBD VBD O
sedentary JJ JJ O
. . . O

Eight CD CD O
animals NNS NNS O
were VBD VBD O
assigned VBN VBN O
to TO TO O
the DT DT O
sedentary JJ JJ O
control NN NN O
( ( ( O
SC NNP NNP O
) ) ) O
group NN NN O
which WDT WDT O
remained VBD VBD O
sedentary JJ JJ O
throughout IN IN O
the DT DT O
experimental JJ JJ O
period NN NN O
. . . O

Forty CD CD O
- : : O
eight CD CD O
hours NNS NNS O
after IN IN O
the DT DT O
final JJ JJ O
exercise NN NN O
period NN NN O
, , , O
S NNP NNP O
- : : O
I PRP PRP O
and CC CC O
E NNP NNP O
- : : O
I PRP PRP O
animals NNS NNS O
received VBD VBD O
a DT DT O
single JJ JJ O
subcutaneous JJ JJ O
injection NN NN O
of IN IN O
isoproterenol NN NN B-CHEM
( ( ( O
250 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
body NN NN O
weight NN NN O
) ) ) O
. . . O

Animals NNS NNS O
of IN IN O
the DT DT O
S NNP NNP O
- : : O
I PRP PRP O
group NN NN O
exhibited VBN VBN O
significantly RB RB O
( ( ( O
Pp NNP NNP O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
greater JJR JJR O
mortality NN NN O
from IN IN O
the DT DT O
effects NNS NNS O
of IN IN O
isoproterenol NN NN B-CHEM
than IN IN O
animals NNS NNS O
of IN IN O
the DT DT O
E NNP NNP O
- : : O
I PRP PRP O
group NN NN O
. . . O

Serum NNP NNP O
CPK NNP NNP O
activity NN NN O
for IN IN O
E NNP NNP O
- : : O
I PRP PRP O
animals NNS NNS O
was VBD VBD O
significantly RB RB O
( ( ( O
p NN NN O
less JJR JJR O
than IN IN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
greater JJR JJR O
than IN IN O
for IN IN O
animals NNS NNS O
in IN IN O
the DT DT O
S NNP NNP O
- : : O
I PRP PRP O
and CC CC O
EC NNP NNP O
groups NNS NNS O
twenty CD CD O
hours NNS NNS O
following VBG VBG O
isoproterenol NN NN B-CHEM
injection NN NN O
. . . O

No DT DT O
statistically RB RB O
significant JJ JJ O
differences NNS NNS O
were VBD VBD O
observed VBN VBN O
between IN IN O
the DT DT O
two CD CD O
isoproterenol NN NN B-CHEM
treated VBD VBD O
groups NNS NNS O
for IN IN O
severity NN NN O
of IN IN O
the DT DT O
induced JJ JJ O
lesions NNS NNS O
, , , O
changes NNS NNS O
in IN IN O
heart NN NN O
weight NN NN O
, , , O
or CC CC O
heart NN NN O
weight NN NN O
to TO TO O
body NN NN O
weight NN NN O
ratios NN NN O
. . . O

The DT DT O
results NNS NNS O
indicated VBD VBD O
that IN IN O
exercise NN NN O
reduced VBD VBD O
the DT DT O
mortality NN NN O
associated VBN VBN O
with IN IN O
the DT DT O
effects NNS NNS O
of IN IN O
large JJ JJ O
dosages NNS NNS O
of IN IN O
isoproterenol NN NN B-CHEM
but CC CC O
had VBD VBD O
little JJ JJ O
on IN IN O
the DT DT O
severity NN NN O
of IN IN O
the DT DT O
infarction NN NN O
. . . O

Human NNP NNP O
corticotropin NN NN B-CHEM
- : : O
releasing VBG VBG O
hormone NN NN O
and CC CC O
thyrotropin NN NN B-CHEM
- - - O
releasing VBG VBG O
hormone NN NN O
modulate NN NN O
the DT DT O
hypercapnic JJ JJ O
ventilatory NN NN O
response NN NN O
in IN IN O
humans NNS NNS O
. . . O

Human NNP NNP O
corticotropin NN NN B-CHEM
- : : O
releasing VBG VBG O
hormone NN NN O
( ( ( O
hCRH NN NN O
) ) ) O
and CC CC O
thyrotropin JJ JJ B-CHEM
- : : O
releasing VBG VBG O
hormone NN NN O
( ( ( O
TRH NNP NNP O
) ) ) O
are VBP VBP O
known VBN VBN O
to TO TO O
stimulate VB VB O
ventilation NN NN O
after IN IN O
i NNP NNP O
. . . O
v NN NN O
. . . O
administration NN NN O
in IN IN O
humans NNS NNS O
. . . O

In IN IN O
a DT DT O
placebo NN NN O
- - - O
controlled JJ JJ O
, , , O
single JJ JJ O
- - - O
blind JJ JJ O
study NN NN O
we PRP PRP O
aimed VBD VBD O
to TO TO O
clarify VB VB O
if IN IN O
both DT DT O
peptides NNS NNS O
act VBP VBP O
by IN IN O
altering VBG VBG O
central JJ JJ O
chemosensitivity NN NN O
. . . O

Two CD CD O
subsequent JJ JJ O
CO2 NNP NNP B-CHEM
- : : O
rebreathing NN NN O
tests NNS NNS O
were VBD VBD O
performed VBN VBN O
in IN IN O
healthy JJ JJ O
young JJ JJ O
volunteers NNS NNS O
. . . O

During IN IN O
the DT DT O
first JJ JJ O
test NN NN O
0 CD CD O
. . . O
9 CD CD O
% NN NN O
NaCl NNP NNP B-CHEM
was VBD VBD O
given VBN VBN O
i NNP NNP O
. . . O
v NN NN O
. . . O
; : : O
during IN IN O
the DT DT O
second JJ JJ O
test NN NN O
200 CD CD O
micrograms NNS NNS O
of IN IN O
hCRH NN NN O
( ( ( O
n NN NN O
= SYM SYM O
12 CD CD O
) ) ) O
or CC CC O
400 CD CD O
micrograms NNS NNS O
of IN IN O
TRH NNP NNP O
( ( ( O
n NN NN O
= SYM SYM O
6 CD CD O
) ) ) O
was VBD VBD O
administered VBN VBN O
i NNP NNP O
. . . O
v NN NN O
. . . O
Nine CD CD O
subjects NNS NNS O
received VBD VBD O
0 CD CD O
. . . O
9 CD CD O
% NN NN O
NaCl NNP NNP B-CHEM
i NNP NNP O
. . . O
v NN NN O
. . . O
during IN IN O
both DT DT O
rebreathing VBG VBG O
manoeuvres NNS NNS O
. . . O

The DT DT O
CO2 NNP NNP B-CHEM
- - - O
response NN NN O
curves NNS NNS O
for IN IN O
the DT DT O
two CD CD O
tests NNS NNS O
were VBD VBD O
compared VBN VBN O
within IN IN O
the DT DT O
same JJ JJ O
subject NN NN O
. . . O

In IN IN O
the DT DT O
hCRH NN NN O
group NN NN O
a DT DT O
marked VBN VBN O
parallel JJ JJ O
shift NN NN O
of IN IN O
the DT DT O
CO2 NNP NNP B-CHEM
- - - O
response NN NN O
curve NN NN O
to TO TO O
the DT DT O
left NN NN O
was VBD VBD O
observed VBN VBN O
after IN IN O
hCRH NN NN O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
. . . O

The DT DT O
same JJ JJ O
effect NN NN O
occurred VBD VBD O
following VBG VBG O
TRH NNP NNP O
but CC CC O
was VBD VBD O
less RBR RBR O
striking JJ JJ O
( ( ( O
P NN NN O
= SYM SYM O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

hCRH NN NN O
and CC CC O
TRH NNP NNP O
caused VBD VBD O
a DT DT O
reduction NN NN O
in IN IN O
the DT DT O
CO2 NNP NNP B-CHEM
threshold NN NN O
. . . O

The DT DT O
CO2 NNP NNP B-CHEM
- - - O
response NN NN O
curves NNS NNS O
in IN IN O
the DT DT O
control NN NN O
group NN NN O
were VBD VBD O
nearly RB RB O
identical JJ JJ O
. . . O

The DT DT O
results NNS NNS O
indicate VBP VBP O
an DT DT O
additive JJ JJ O
effect NN NN O
of IN IN O
both DT DT O
releasing VBG VBG O
hormones NNS NNS O
on IN IN O
the DT DT O
hypercapnic JJ JJ O
ventilatory NN NN O
response NN NN O
in IN IN O
humans NNS NNS O
, , , O
presumably RB RB O
independent JJ JJ O
of IN IN O
central JJ JJ O
chemosensitivity NN NN O
. . . O

Lamivudine NNP NNP B-CHEM
is VBZ VBZ O
effective JJ JJ O
in IN IN O
suppressing VBG VBG O
hepatitis NN NN O
B NNP NNP O
virus NN NN O
DNA NNP NNP O
in IN IN O
Chinese JJ JJ O
hepatitis NN NN B-CHEM
B NNP NNP I-CHEM
surface NN NN I-CHEM
antigen NN NN I-CHEM
carriers NNS NNS O
: : : O
a DT DT O
placebo NN NN O
- - - O
controlled JJ JJ O
trial NN NN O
. . . O

Lamivudine NNP NNP B-CHEM
is VBZ VBZ O
a DT DT O
novel NN NN O
2 CD CD B-CHEM
' POS POS I-CHEM
, , , I-CHEM
3 CD CD I-CHEM
' POS POS I-CHEM
- : : I-CHEM
dideoxy NN NN I-CHEM
cytosine NN NN I-CHEM
analogue NN NN O
that WDT WDT O
has VBZ VBZ O
potent JJ JJ O
inhibitory NN NN O
effects NNS NNS O
on IN IN O
hepatitis NNP NNP O
B NNP NNP O
virus NN NN O
replication NN NN O
in IN IN O
vitro NN NN O
and CC CC O
in IN IN O
vivo NN NN O
. . . O

We PRP PRP O
performed VBD VBD O
a DT DT O
single JJ JJ O
- - - O
blind JJ JJ O
, , , O
placebo NN NN O
- - - O
controlled JJ JJ O
study NN NN O
to TO TO O
assess VB VB O
its PRP$ PRP$ O
effectiveness NN NN O
and CC CC O
safety NN NN O
in IN IN O
Chinese JJ JJ O
hepatitis NN NN B-CHEM
B NNP NNP I-CHEM
surface NN NN I-CHEM
antigen NN NN I-CHEM
( ( ( O
HBsAg NNP NNP B-CHEM
) ) ) O
carriers NNS NNS O
. . . O

Forty CD CD O
- : : O
two CD CD O
Chinese JJ JJ O
HBsAg NNP NNP B-CHEM
carriers NNS NNS O
were VBD VBD O
randomized VBN VBN O
to TO TO O
receive VB VB O
placebo NN NN O
( ( ( O
6 CD CD O
patients NNS NNS O
) ) ) O
or CC CC O
lamivudine NN NN B-CHEM
orally RB RB O
in IN IN O
dosages NNS NNS O
of IN IN O
25 CD CD O
mg NN NN O
, , , O
100 CD CD O
mg NN NN O
, , , O
or CC CC O
300 CD CD O
mg NN NN O
daily JJ JJ O
( ( ( O
12 CD CD O
patients NNS NNS O
for IN IN O
each DT DT O
dosage NN NN O
) ) ) O
. . . O

The DT DT O
drug NN NN O
was VBD VBD O
given VBN VBN O
for IN IN O
4 CD CD O
weeks NNS NNS O
. . . O

The DT DT O
patients NNS NNS O
were VBD VBD O
closely RB RB O
monitored VBN VBN O
clinically RB RB O
, , , O
biochemically RB RB O
, , , O
and CC CC O
serologically RB RB O
up IN IN O
to TO TO O
4 CD CD O
weeks NNS NNS O
after IN IN O
drug NN NN O
treatment NN NN O
. . . O

All DT DT O
36 CD CD O
patients NNS NNS O
receiving VBG VBG O
lamivudine NN NN B-CHEM
had VBD VBD O
a DT DT O
decrease NN NN O
in IN IN O
hepatitis NNP NNP O
B NNP NNP O
virus NN NN O
( ( ( O
HBV NNP NNP O
) ) ) O
DNA NNP NNP O
values NNS NNS O
of IN IN O
> NN NN O
90 CD CD O
% NN NN O
( ( ( O
P NN NN O
< NN NN O
. . . O
001 CD CD O
compared VBN VBN O
with IN IN O
placebo NN NN O
) ) ) O
. . . O

Although IN IN O
25 CD CD O
mg NN NN O
of IN IN O
lamivudine NN NN B-CHEM
was VBD VBD O
slightly RB RB O
less RBR RBR O
effective JJ JJ O
than IN IN O
100 CD CD O
mg NN NN O
( ( ( O
P NN NN O
= SYM SYM O
. . . O
011 CD CD O
) ) ) O
and CC CC O
300 CD CD O
mg NN NN O
( ( ( O
P NN NN O
= SYM SYM O
. . . O
005 CD CD O
) ) ) O
, , , O
it PRP PRP O
still RB RB O
induced VBD VBD O
94 CD CD O
% NN NN O
suppression NN NN O
of IN IN O
HBV NNP NNP O
DNA NNP NNP O
after IN IN O
the DT DT O
fourth JJ JJ O
week NN NN O
of IN IN O
therapy NN NN O
. . . O

HBV NNP NNP O
DNA NNP NNP O
values NNS NNS O
returned VBD VBD O
to TO TO O
pretreatment NN NN O
levels NNS NNS O
within IN IN O
4 CD CD O
weeks NNS NNS O
of IN IN O
cessation NN NN O
of IN IN O
therapy NN NN O
. . . O

There EX EX O
was VBD VBD O
no DT DT O
change NN NN O
in IN IN O
the DT DT O
hepatitis NN NN O
B NNP NNP O
e SYM SYM O
antigen NN NN O
status NN NN O
or CC CC O
in IN IN O
aminotransferase NN NN O
levels NNS NNS O
. . . O

No DT DT O
serious JJ JJ O
adverse JJ JJ O
events NNS NNS O
were VBD VBD O
observed VBN VBN O
. . . O

In IN IN O
conclusion NN NN O
, , , O
a DT DT O
4 CD CD O
- : : O
week NN NN O
course NN NN O
of IN IN O
lamivudine NN NN B-CHEM
was VBD VBD O
safe JJ JJ O
and CC CC O
effective JJ JJ O
in IN IN O
suppression NN NN O
of IN IN O
HBV NNP NNP O
DNA NNP NNP O
in IN IN O
Chinese JJ JJ O
HBsAg NNP NNP B-CHEM
carriers NNS NNS O
. . . O

The DT DT O
suppression NN NN O
was VBD VBD O
> NN NN O
90 CD CD O
% NN NN O
but CC CC O
reversible JJ JJ O
. . . O

Studies NNS NNS O
with IN IN O
long JJ JJ O
- - - O
term NN NN O
lamivudine NN NN B-CHEM
administration NN NN O
should MD MD O
be VB VB O
performed VBN VBN O
to TO TO O
determine VB VB O
if IN IN O
prolonged JJ JJ O
suppression NN NN O
of IN IN O
HBV NNP NNP O
DNA NNP NNP O
can MD MD O
be VB VB O
achieved VBN VBN O
. . . O

Population NN NN O
- - - O
based JJ JJ O
study NN NN O
of IN IN O
risk NN NN O
of IN IN O
venous JJ JJ O
thromboembolism NN NN O
associated VBN VBN O
with IN IN O
various JJ JJ O
oral JJ JJ B-CHEM
contraceptives NNS NNS I-CHEM
. . . O

BACKGROUND NNP NNP O
: : : O
Four CD CD O
studies NNS NNS O
published VBN VBN O
since IN IN O
December NNP NNP O
, , , O
1995 CD CD O
, , , O
reported VBD VBD O
that IN IN O
the DT DT O
incidence NN NN O
of IN IN O
venous JJ JJ O
thromboembolism NN NN O
( ( ( O
VTE NNP NNP O
) ) ) O
was VBD VBD O
higher JJR JJR O
in IN IN O
women NNS NNS O
who WP WP O
used VBD VBD O
oral JJ JJ B-CHEM
contraceptives NNS NNS I-CHEM
( ( ( O
OCs NNP NNP B-CHEM
) ) ) O
containing VBG VBG O
the DT DT O
third JJ JJ O
- - - O
generation NN NN O
progestagens NNS NNS B-CHEM
gestodene NN NN B-CHEM
or CC CC O
desogestrel NN NN B-CHEM
than IN IN O
in IN IN O
users NNS NNS O
of IN IN O
OCs NNP NNP B-CHEM
containing VBG VBG O
second JJ JJ O
- - - O
generation NN NN O
progestagens NNS NNS B-CHEM
. . . O

However RB RB O
, , , O
confounding VBG VBG O
and CC CC O
bias NN NN O
in IN IN O
the DT DT O
design NN NN O
of IN IN O
these DT DT O
studies NNS NNS O
may MD MD O
have VB VB O
affected VBN VBN O
the DT DT O
findings NNS NNS O
. . . O

The DT DT O
aim NN NN O
of IN IN O
our PRP$ PRP$ O
study NN NN O
was VBD VBD O
to TO TO O
re VB VB O
- - - O
examine VB VB O
the DT DT O
association NN NN O
between IN IN O
risk NN NN O
of IN IN O
VTE NNP NNP O
and CC CC O
OC NNP NNP B-CHEM
use NN NN O
with IN IN O
a DT DT O
different JJ JJ O
study NN NN O
design NN NN O
and CC CC O
analysis NN NN O
to TO TO O
avoid VB VB O
some DT DT O
of IN IN O
the DT DT O
bias NN NN O
and CC CC O
confounding VBG VBG O
of IN IN O
the DT DT O
earlier JJR JJR O
studies NNS NNS O
. . . O

METHODS NNP NNP O
: : : O
We PRP PRP O
used VBD VBD O
computer NN NN O
records NNS NNS O
of IN IN O
patients NNS NNS O
from IN IN O
143 CD CD O
general JJ JJ O
practices NNS NNS O
in IN IN O
the DT DT O
UK NNP NNP O
. . . O

The DT DT O
study NN NN O
was VBD VBD O
based VBN VBN O
on IN IN O
the DT DT O
medical JJ JJ O
records NNS NNS O
of IN IN O
about IN IN O
540 CD CD O
, , , O
000 CD CD O
women NNS NNS O
born VBN VBN O
between IN IN O
1941 CD CD O
and CC CC O
1981 CD CD O
. . . O

All DT DT O
women NNS NNS O
who WP WP O
had VBD VBD O
a DT DT O
recorded JJ JJ O
diagnosis NN NN O
of IN IN O
deep JJ JJ O
- - - O
vein NN NN O
thrombosis NN NN O
, , , O
venous JJ JJ O
thrombosis NN NN O
not RB RB O
otherwise RB RB O
specified VBD VBD O
, , , O
or CC CC O
pulmonary JJ JJ O
embolus CC CC O
during IN IN O
the DT DT O
study NN NN O
period NN NN O
, , , O
and CC CC O
who WP WP O
had VBD VBD O
been VBN VBN O
treated VBN VBN O
with IN IN O
an DT DT O
anticoagulant NN NN O
were VBD VBD O
identified VBN VBN O
as IN IN O
potential JJ JJ O
cases NNS NNS O
of IN IN O
VTE NNP NNP O
. . . O

We PRP PRP O
did VBD VBD O
a DT DT O
cohort NN NN O
analysis NN NN O
to TO TO O
estimate VB VB O
and CC CC O
compare VB VB O
incidence NN NN O
of IN IN O
VTE NNP NNP O
in IN IN O
users NNS NNS O
of IN IN O
the DT DT O
main JJ JJ O
OC NNP NNP B-CHEM
preparations NNS NNS O
, , , O
and CC CC O
a DT DT O
nested JJ JJ O
case NN NN O
- - - O
control NN NN O
study NN NN O
to TO TO O
calculate VB VB O
the DT DT O
odds NNS NNS O
ratios NN NN O
of IN IN O
VTE NNP NNP O
associated VBN VBN O
with IN IN O
use NN NN O
of IN IN O
different JJ JJ O
types NNS NNS O
of IN IN O
OC NNP NNP B-CHEM
, , , O
after IN IN O
adjustment NN NN O
for IN IN O
potential JJ JJ O
confounding NN NN O
factors NNS NNS O
. . . O

In IN IN O
the DT DT O
case NN NN O
- - - O
control NN NN O
study NN NN O
, , , O
we PRP PRP O
matched VBD VBD O
cases NNS NNS O
to TO TO O
controls NNS NNS O
by IN IN O
exact JJ JJ O
year NN NN O
of IN IN O
birth NN NN O
, , , O
practice NN NN O
, , , O
and CC CC O
current JJ JJ O
use NN NN O
of IN IN O
OCs NNP NNP B-CHEM
. . . O

We PRP PRP O
used VBD VBD O
a DT DT O
multiple JJ JJ O
logistic JJ JJ O
regression NN NN O
model NN NN O
that WDT WDT O
included VBD VBD O
body NN NN O
- : : O
mass NN NN O
index NN NN O
, , , O
number NN NN O
of IN IN O
cycles NNS NNS O
, , , O
change NN NN O
in IN IN O
type NN NN O
of IN IN O
OC NNP NNP B-CHEM
prescribed VBN VBN O
within IN IN O
3 CD CD O
months NNS NNS O
of IN IN O
the DT DT O
event NN NN O
, , , O
previous JJ JJ O
pregnancy NN NN O
, , , O
and CC CC O
concurrent NN NN O
disease NN NN O
. . . O

FINDINGS NNS NNS O
: : : O
85 CD CD O
women NNS NNS O
met VBD VBD O
the DT DT O
inclusion NN NN O
criteria NNS NNS O
for IN IN O
VTE NNP NNP O
, , , O
two CD CD O
of IN IN O
whom WP WP O
were VBD VBD O
users NNS NNS O
of IN IN O
progestagen NN NN B-CHEM
- - - O
only RB RB O
OCs NNP NNP B-CHEM
. . . O

Of IN IN O
the DT DT O
83 CD CD O
cases NNS NNS O
of IN IN O
VTE NNP NNP O
associated VBN VBN O
with IN IN O
use NN NN O
of IN IN O
combined VBN VBN O
OCs NNP NNP B-CHEM
, , , O
43 CD CD O
were VBD VBD O
recorded VBN VBN O
as IN IN O
deep JJ JJ O
- - - O
vein NN NN O
thrombosis NN NN O
, , , O
35 CD CD O
as IN IN O
pulmonary JJ JJ O
thrombosis NNS NNS O
, , , O
and CC CC O
five CD CD O
as IN IN O
venous JJ JJ O
thrombosis NN NN O
not RB RB O
otherwise RB RB O
specified VBN VBN O
. . . O

The DT DT O
crude NN NN O
rate NN NN O
of IN IN O
VTE NNP NNP O
per IN IN O
10 CD CD O
, , , O
000 CD CD O
woman NN NN O
- : : O
years NNS NNS O
was VBD VBD O
4 CD CD O
. . . O
10 CD CD O
in IN IN O
current JJ JJ O
users NNS NNS O
of IN IN O
any DT DT O
OC NNP NNP B-CHEM
, , , O
3 CD CD O
. . . O
10 CD CD O
in IN IN O
users NNS NNS O
of IN IN O
second JJ JJ O
- - - O
generation NN NN O
OCs NNP NNP B-CHEM
, , , O
and CC CC O
4 CD CD O
. . . O
96 CD CD O
in IN IN O
users NNS NNS O
of IN IN O
third JJ JJ O
- - - O
generation NN NN O
preparations NNS NNS O
. . . O

After IN IN O
adjustment NN NN O
for IN IN O
age NN NN O
, , , O
the DT DT O
rate NN NN O
ratio NN NN O
of IN IN O
VTE NNP NNP O
in IN IN O
users NNS NNS O
of IN IN O
third JJ JJ O
- - - O
generation NN NN O
relative JJ JJ O
to TO TO O
second JJ JJ O
- - - O
generation NN NN O
OCs NNP NNP B-CHEM
was VBD VBD O
1 CD CD O
. . . O
68 CD CD O
( ( ( O
95 CD CD O
% NN NN O
CI NNP NNP O
1 CD CD O
. . . O
04 CD CD O
- : : O
2 CD CD O
. . . O
75 CD CD O
) ) ) O
. . . O

Logistic NNP NNP O
regression NN NN O
showed VBD VBD O
no DT DT O
significant JJ JJ O
difference NN NN O
in IN IN O
the DT DT O
risk NN NN O
of IN IN O
VTE NNP NNP O
between IN IN O
users NNS NNS O
of IN IN O
third JJ JJ O
- - - O
generation NN NN O
and CC CC O
second JJ JJ O
- - - O
generation NN NN O
OCs NNP NNP B-CHEM
. . . O

Among IN IN O
users NNS NNS O
of IN IN O
third JJ JJ O
- - - O
generation NN NN O
progestagens NNS NNS B-CHEM
, , , O
the DT DT O
risk NN NN O
of IN IN O
VTE NNP NNP O
was VBD VBD O
higher JJR JJR O
in IN IN O
users NNS NNS O
of IN IN O
desogestrel NN NN B-CHEM
with IN IN O
20 CD CD O
g SYM SYM O
ethinyloestradiol NN NN B-CHEM
than IN IN O
in IN IN O
users NNS NNS O
of IN IN O
gestodene NN NN B-CHEM
or CC CC O
desogestrel NN NN B-CHEM
with IN IN O
30 CD CD O
g SYM SYM O
ethinyloestradiol NN NN B-CHEM
. . . O

With IN IN O
all DT DT O
second JJ JJ O
- - - O
generation NN NN O
OCs NNP NNP B-CHEM
as IN IN O
the DT DT O
reference NN NN O
, , , O
the DT DT O
odds NNS NNS O
ratios NN NN O
for IN IN O
VTE NNP NNP O
were VBD VBD O
3 CD CD O
. . . O
49 CD CD O
( ( ( O
1 CD CD O
. . . O
21 CD CD O
- : : O
10 CD CD O
. . . O
12 CD CD O
) ) ) O
for IN IN O
desogestrel NN NN B-CHEM
plus CC CC O
20 CD CD O
g SYM SYM O
ethinyloestradiol NN NN B-CHEM
and CC CC O
1 CD CD O
. . . O
18 CD CD O
( ( ( O
0 CD CD O
. . . O
66 CD CD O
- : : O
2 CD CD O
. . . O
17 CD CD O
) ) ) O
for IN IN O
the DT DT O
other JJ JJ O
third JJ JJ O
- - - O
generation NN NN O
progestagens NNS NNS B-CHEM
. . . O

INTERPRETATION NN NN O
: : : O
The DT DT O
previously RB RB O
reported VBD VBD O
increase NN NN O
in IN IN O
odds NNS NNS O
ratio NN NN O
associated VBN VBN O
with IN IN O
third JJ JJ O
- - - O
generation NN NN O
OCs NNP NNP B-CHEM
when WRB WRB O
compared VBN VBN O
with IN IN O
second JJ JJ O
- - - O
generation NN NN O
products NNS NNS O
is VBZ VBZ O
likely JJ JJ O
to TO TO O
have VB VB O
been VBN VBN O
the DT DT O
result NN NN O
of IN IN O
residual JJ JJ O
confounding NN NN O
by IN IN O
age NN NN O
. . . O

The DT DT O
increased VBN VBN O
odds NNS NNS O
ratio NN NN O
associated VBN VBN O
with IN IN O
products NNS NNS O
containing VBG VBG O
20 CD CD O
micrograms NNS NNS O
ethinyloestradiol NN NN B-CHEM
and CC CC O
desogestrel VB VB B-CHEM
compared VBN VBN O
with IN IN O
the DT DT O
30 CD CD O
micrograms NNS NNS O
product NN NN O
is VBZ VBZ O
biologically RB RB O
implausible JJ JJ O
, , , O
and CC CC O
is VBZ VBZ O
likely JJ JJ O
to TO TO O
be VB VB O
the DT DT O
result NN NN O
of IN IN O
preferential JJ JJ O
prescribing NN NN O
and CC CC O
, , , O
thus RB RB O
, , , O
confounding VBG VBG O
. . . O

MK NNP NNP B-CHEM
- : : I-CHEM
801 CD CD I-CHEM
augments NNS NNS O
pilocarpine NN NN B-CHEM
- : : O
induced JJ JJ O
electrographic JJ JJ O
seizure NN NN O
but CC CC O
protects VBZ VBZ O
against IN IN O
brain NN NN O
damage NN NN O
in IN IN O
rats NNS NNS O
. . . O

1 CD CD O
. . . O

The DT DT O
authors NNS NNS O
examined VBD VBD O
the DT DT O
anticonvulsant JJ JJ O
effects NNS NNS O
of IN IN O
MK NNP NNP B-CHEM
- : : I-CHEM
801 CD CD I-CHEM
on IN IN O
the DT DT O
pilocarpine NN NN B-CHEM
- - - O
induced JJ JJ O
seizure NN NN O
model NN NN O
. . . O

Intraperitoneal NNP NNP O
injection NN NN O
of IN IN O
pilocarpine NN NN B-CHEM
( ( ( O
400 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
induced JJ JJ O
tonic NN NN O
and CC CC O
clonic JJ JJ O
seizure NN NN O
. . . O

Scopolamine NNP NNP B-CHEM
( ( ( O
10 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
and CC CC O
pentobarbital JJ JJ B-CHEM
( ( ( O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
prevented VBD VBD O
development NN NN O
of IN IN O
pilocarpine NN NN B-CHEM
- - - O
induced JJ JJ O
behavioral JJ JJ O
seizure NN NN O
but CC CC O
MK NNP NNP B-CHEM
- : : I-CHEM
801 CD CD I-CHEM
( ( ( O
0 CD CD O
. . . O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
) ) ) O
did VBD VBD O
not RB RB O
. . . O

2 CD CD O
. . . O

An DT DT O
electrical JJ JJ O
seizure NN NN O
measured VBN VBN O
with IN IN O
hippocampal NN NN O
EEG NNP NNP O
appeared VBD VBD O
in IN IN O
the DT DT O
pilocarpine NN NN B-CHEM
- - - O
treated JJ JJ O
group NN NN O
. . . O

Scopolamine NNP NNP B-CHEM
and CC CC O
pentobarbital NN NN B-CHEM
blocked VBD VBD O
the DT DT O
pilocarpine NN NN B-CHEM
- - - O
induced JJ JJ O
electrographic JJ JJ O
seizure NN NN O
, , , O
MK NNP NNP B-CHEM
- : : I-CHEM
801 CD CD I-CHEM
treatment NN NN O
augmented VBD VBD O
the DT DT O
electrographic JJ JJ O
seizure NN NN O
induced VBN VBN O
by IN IN O
pilocarpine NN NN B-CHEM
. . . O

3 CD CD O
. . . O

Brain NNP NNP O
damage NN NN O
was VBD VBD O
assessed VBN VBN O
by IN IN O
examining VBG VBG O
the DT DT O
hippocampus NN NN O
microscopically RB RB O
. . . O

Pilocarpine NNP NNP B-CHEM
produced VBD VBD O
neuronal JJ JJ O
death NN NN O
in IN IN O
the DT DT O
hippocampus NN NN O
, , , O
which WDT WDT O
showed VBD VBD O
pyknotic JJ JJ O
changes NNS NNS O
. . . O

Pentobarbital NNP NNP B-CHEM
, , , O
scopolamine NN NN B-CHEM
and CC CC O
MK NNP NNP B-CHEM
- : : I-CHEM
801 CD CD I-CHEM
protected VBD VBD O
the DT DT O
brain NN NN O
damage NN NN O
by IN IN O
pilocarpine NN NN B-CHEM
, , , O
though IN IN O
in IN IN O
the DT DT O
MK NNP NNP B-CHEM
- - - I-CHEM
801 CD CD I-CHEM
- - - O
treated JJ JJ O
group NN NN O
, , , O
the DT DT O
pyramidal NN NN O
cells NNS NNS O
of IN IN O
hippocampus NN NN O
appeared VBD VBD O
darker JJR JJR O
than IN IN O
normal JJ JJ O
. . . O

In IN IN O
all DT DT O
treatments NNS NNS O
, , , O
granule NN NN O
cells NNS NNS O
of IN IN O
the DT DT O
dentate NN NN O
gyrus NN NN O
were VBD VBD O
not RB RB O
affected VBN VBN O
. . . O

4 CD CD O
. . . O

These DT DT O
results NNS NNS O
indicate VBP VBP O
that IN IN O
status NN NN O
epilepticus NN NN O
induced VBN VBN O
by IN IN O
pilocarpine NN NN B-CHEM
is VBZ VBZ O
initiated VBN VBN O
by IN IN O
cholinergic JJ JJ O
overstimulation NN NN O
and CC CC O
propagated VBN VBN O
by IN IN O
glutamatergic JJ JJ O
transmission NN NN O
, , , O
the DT DT O
elevation NN NN O
of IN IN O
which WDT WDT O
may MD MD O
cause VB VB O
brain NN NN O
damage NN NN O
through IN IN O
an DT DT O
excitatory NN NN O
NMDA NNP NNP B-CHEM
receptor NN NN O
- - - O
mediated JJ JJ O
mechanism NN NN O
. . . O

Paclitaxel NNP NNP B-CHEM
, , , O
5 CD CD B-CHEM
- : : I-CHEM
fluorouracil NN NN I-CHEM
, , , O
and CC CC O
folinic JJ JJ B-CHEM
acid NN NN I-CHEM
in IN IN O
metastatic JJ JJ O
breast NN NN O
cancer NN NN O
: : : O
BRE NNP NNP O
- - - O
26 CD CD O
, , , O
a DT DT O
phase NN NN O
II NNP NNP O
trial NN NN O
. . . O

5 CD CD B-CHEM
- : : I-CHEM
Fluorouracil NNP NNP I-CHEM
plus CC CC O
folinic JJ JJ B-CHEM
acid NN NN I-CHEM
and CC CC O
paclitaxel NN NN B-CHEM
( ( ( O
Taxol NNP NNP B-CHEM
; : : O
Bristol NNP NNP O
- : : O
Myers NNP NNP O
Squibb NNP NNP O
Company NNP NNP O
, , , O
Princeton NNP NNP O
, , , O
NJ NNP NNP O
) ) ) O
are VBP VBP O
effective JJ JJ O
salvage NN NN O
therapies NNS NNS O
for IN IN O
metastatic JJ JJ O
breast NN NN O
cancer NN NN O
patients NNS NNS O
. . . O

Paclitaxel NNP NNP B-CHEM
and CC CC O
5 CD CD B-CHEM
- : : I-CHEM
fluorouracil NN NN I-CHEM
have VBP VBP O
additive JJ JJ O
cytotoxicity NN NN O
in IN IN O
MCF NNP NNP O
- : : O
7 CD CD O
cell NN NN O
lines NNS NNS O
. . . O

We PRP PRP O
performed VBD VBD O
a DT DT O
phase NN NN O
II NNP NNP O
trial NN NN O
of IN IN O
paclitaxel NN NN B-CHEM
175 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
over IN IN O
3 CD CD O
hours NNS NNS O
on IN IN O
day NN NN O
I PRP PRP O
followed VBD VBD O
by IN IN O
folinic JJ JJ B-CHEM
acid NN NN I-CHEM
300 CD CD O
mg NN NN O
over IN IN O
1 CD CD O
hour NN NN O
before IN IN O
5 CD CD B-CHEM
- : : I-CHEM
fluorouracil NN NN I-CHEM
350 CD CD O
mg NN NN O
/ NN NN O
m2 NN NN O
on IN IN O
days NNS NNS O
1 CD CD O
to TO TO O
3 CD CD O
every DT DT O
28 CD CD O
days NNS NNS O
( ( ( O
TFL NNP NNP O
) ) ) O
in IN IN O
women NNS NNS O
with IN IN O
metastatic JJ JJ O
breast NN NN O
cancer NN NN O
. . . O

Analysis NNP NNP O
is VBZ VBZ O
reported VBN VBN O
on IN IN O
37 CD CD O
patients NNS NNS O
with IN IN O
a DT DT O
minimum NN NN O
of IN IN O
6 CD CD O
months NNS NNS O
follow VB VB O
- - - O
up RP RP O
who WP WP O
received VBD VBD O
a DT DT O
total NN NN O
of IN IN O
192 CD CD O
cycles NNS NNS O
of IN IN O
TFL NNP NNP O
: : : O
nine CD CD O
cycles NNS NNS O
( ( ( O
5 CD CD O
% NN NN O
) ) ) O
were VBD VBD O
associated VBN VBN O
with IN IN O
grade NN NN O
3 CD CD O
/ NN NN O
4 CD CD O
neutropenia NN NN O
requiring VBG VBG O
hospitalization NN NN O
; : : O
seven CD CD O
( ( ( O
4 CD CD O
% NN NN O
) ) ) O
cycles NNS NNS O
in IN IN O
two CD CD O
patients NNS NNS O
required VBN VBN O
granulocyte NN NN B-CHEM
colony NN NN I-CHEM
- : : I-CHEM
stimulating VBG VBG I-CHEM
factor NN NN I-CHEM
due JJ JJ O
to TO TO O
neutropenia NN NN O
; : : O
no DT DT O
patient NN NN O
required VBN VBN O
platelet NN NN O
transfusions NNS NNS O
. . . O

Grade NNP NNP O
3 CD CD O
/ NN NN O
4 CD CD O
nonhematologic JJ JJ O
toxicities NNS NNS O
were VBD VBD O
uncommon JJ JJ O
. . . O

Among IN IN O
the DT DT O
34 CD CD O
patients NNS NNS O
evaluable JJ JJ O
for IN IN O
response NN NN O
, , , O
there EX EX O
were VBD VBD O
three CD CD O
complete JJ JJ O
responses NNS NNS O
( ( ( O
9 CD CD O
% NN NN O
) ) ) O
and CC CC O
18 CD CD O
partial JJ JJ O
responses NNS NNS O
( ( ( O
53 CD CD O
% NN NN O
) ) ) O
for IN IN O
an DT DT O
overall JJ JJ O
response NN NN O
rate NN NN O
of IN IN O
62 CD CD O
% NN NN O
. . . O

Of IN IN O
the DT DT O
19 CD CD O
evaluable JJ JJ O
patients NNS NNS O
with IN IN O
prior RB RB O
doxorubicin NN NN B-CHEM
exposure NN NN O
, , , O
11 CD CD O
( ( ( O
58 CD CD O
% NN NN O
) ) ) O
responded VBD VBD O
compared VBN VBN O
with IN IN O
nine CD CD O
of IN IN O
15 CD CD O
( ( ( O
60 CD CD O
% NN NN O
) ) ) O
without IN IN O
prior RB RB O
doxorubicin NN NN B-CHEM
. . . O

Plasma NNP NNP O
paclitaxel NN NN B-CHEM
concentrations NNS NNS O
were VBD VBD O
measured VBN VBN O
at IN IN O
the DT DT O
completion NN NN O
of IN IN O
paclitaxel NN NN B-CHEM
infusion NN NN O
and CC CC O
at IN IN O
24 CD CD O
hours NNS NNS O
in IN IN O
19 CD CD O
patients NNS NNS O
. . . O

TFL NNP NNP O
is VBZ VBZ O
an DT DT O
active JJ JJ O
, , , O
well RB RB O
- - - O
tolerated JJ JJ O
regimen NNS NNS O
in IN IN O
metastatic JJ JJ O
breast NN NN O
cancer NN NN O
. . . O

Efficacy NNP NNP O
and CC CC O
proarrhythmia NN NN O
with IN IN O
the DT DT O
use NN NN O
of IN IN O
d SYM SYM B-CHEM
, , , I-CHEM
l NN NN I-CHEM
- - - I-CHEM
sotalol NN NN I-CHEM
for IN IN O
sustained JJ JJ O
ventricular NN NN O
tachyarrhythmias NNS NNS O
. . . O

This DT DT O
study NN NN O
prospectively RB RB O
evaluated VBD VBD O
the DT DT O
clinical JJ JJ O
efficacy NN NN O
, , , O
the DT DT O
incidence NN NN O
of IN IN O
torsades NNS NNS O
de IN IN O
pointes NNS NNS O
, , , O
and CC CC O
the DT DT O
presumable JJ JJ O
risk NN NN O
factors NNS NNS O
for IN IN O
torsades NNS NNS O
de IN IN O
pointes NNS NNS O
in IN IN O
patients NNS NNS O
treated VBN VBN O
with IN IN O
d SYM SYM B-CHEM
, , , I-CHEM
l NN NN I-CHEM
- - - I-CHEM
sotalol NN NN I-CHEM
for IN IN O
sustained JJ JJ O
ventricular NN NN O
tachyarrhythmias NNS NNS O
. . . O

Eighty NNP NNP O
- : : O
one CD CD O
consecutive JJ JJ O
patients NNS NNS O
( ( ( O
54 CD CD O
with IN IN O
coronary JJ JJ O
artery NN NN O
disease NN NN O
, , , O
and CC CC O
20 CD CD O
with IN IN O
dilated JJ JJ O
cardiomyopathy NN NN O
) ) ) O
with IN IN O
inducible JJ JJ O
sustained JJ JJ O
ventricular NN NN O
tachycardia NNS NNS O
or CC CC O
ventricular NN NN O
fibrillation NN NN O
received VBD VBD O
oral JJ JJ O
d SYM SYM B-CHEM
, , , I-CHEM
l NN NN I-CHEM
- - - I-CHEM
sotalol NN NN I-CHEM
to TO TO O
prevent VB VB O
induction NN NN O
of IN IN O
the DT DT O
ventricular NN NN O
tachyarrhythmia NN NN O
. . . O

During IN IN O
oral JJ JJ O
loading NN NN O
with IN IN O
d SYM SYM B-CHEM
, , , I-CHEM
l NN NN I-CHEM
- - - I-CHEM
sotalol NN NN I-CHEM
, , , O
continuous JJ JJ O
electrocardiographic JJ JJ O
( ( ( O
ECG NNP NNP O
) ) ) O
monitoring VBG VBG O
was VBD VBD O
performed VBN VBN O
. . . O

Those DT DT O
patients NNS NNS O
in IN IN O
whom WP WP O
d SYM SYM B-CHEM
, , , I-CHEM
l NN NN I-CHEM
- - - I-CHEM
sotalol NN NN I-CHEM
prevented VBN VBN O
induction NN NN O
of IN IN O
ventricular NN NN O
tachycardia NNS NNS O
or CC CC O
ventricular JJ JJ O
fibrillation NN NN O
were VBD VBD O
discharged VBN VBN O
with IN IN O
the DT DT O
drug NN NN O
and CC CC O
followed VBD VBD O
up RB RB O
on IN IN O
an DT DT O
outpatient JJ JJ O
basis NN NN O
for IN IN O
21 CD CD O
+ NN NN O
/ NN NN O
- : : O
18 CD CD O
months NNS NNS O
. . . O

Induction NNP NNP O
of IN IN O
the DT DT O
ventricular NN NN O
tachyarrhythmia NN NN O
was VBD VBD O
prevented VBN VBN O
by IN IN O
oral JJ JJ O
d SYM SYM B-CHEM
, , , I-CHEM
l NN NN I-CHEM
- - - I-CHEM
sotalol NN NN I-CHEM
in IN IN O
35 CD CD O
( ( ( O
43 CD CD O
% NN NN O
) ) ) O
patients NNS NNS O
; : : O
the DT DT O
ventricular NN NN O
tachyarrhythmia NN NN O
remained VBD VBD O
inducible JJ JJ O
in IN IN O
40 CD CD O
( ( ( O
49 CD CD O
% NN NN O
) ) ) O
patients NNS NNS O
; : : O
and CC CC O
two CD CD O
( ( ( O
2 CD CD O
. . . O
5 CD CD O
% NN NN O
) ) ) O
patients NNS NNS O
did VBD VBD O
not RB RB O
tolerate VB VB O
even RB RB O
40 CD CD O
mg NN NN O
of IN IN O
d SYM SYM B-CHEM
, , , I-CHEM
l NN NN I-CHEM
- - - I-CHEM
sotalol NN NN I-CHEM
once RB RB O
daily JJ JJ O
. . . O

Four CD CD O
( ( ( O
5 CD CD O
% NN NN O
) ) ) O
patients NNS NNS O
had VBD VBD O
from IN IN O
torsades NNS NNS O
de IN IN O
pointes NNS NNS O
during IN IN O
the DT DT O
initial JJ JJ O
oral JJ JJ O
treatment NN NN O
with IN IN O
d SYM SYM B-CHEM
, , , I-CHEM
l NN NN I-CHEM
- - - I-CHEM
sotalol NN NN I-CHEM
. . . O

Neither DT DT O
ECG NNP NNP O
[ NN NN O
sinus JJ JJ O
- : : O
cycle NN NN O
length NN NN O
( ( ( O
SCL NNP NNP O
) ) ) O
, , , O
QT NNP NNP O
or CC CC O
QTc NNP NNP O
interval NN NN O
, , , O
or CC CC O
U NNP NNP O
wave NN NN O
] NN NN O
nor CC CC O
clinical JJ JJ O
parameters NNS NNS O
identified VBN VBN O
patients NNS NNS O
at IN IN O
risk NN NN O
for IN IN O
torsades NNS NNS O
de IN IN O
pointes NNS NNS O
. . . O

However RB RB O
, , , O
the DT DT O
oral JJ JJ O
dose NN NN O
of IN IN O
d SYM SYM B-CHEM
, , , I-CHEM
l NN NN I-CHEM
- - - I-CHEM
sotalol NN NN I-CHEM
was VBD VBD O
significantly RB RB O
lower JJR JJR O
in IN IN O
patients NNS NNS O
with IN IN O
torsades NNS NNS O
de IN IN O
pointes NNS NNS O
( ( ( O
200 CD CD O
+ NN NN O
/ NN NN O
- : : O
46 CD CD O
vs NNS NNS O
. . . O
328 CD CD O
+ NN NN O
/ NN NN O
- : : O
53 CD CD O
mg NN NN O
/ NN NN O
day NN NN O
; : : O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
0017 CD CD O
) ) ) O
. . . O

Risk NN NN O
factors NNS NNS O
associated VBN VBN O
with IN IN O
the DT DT O
development NN NN O
of IN IN O
torsades NNS NNS O
de IN IN O
pointes NNS NNS O
were VBD VBD O
the DT DT O
appearance NN NN O
of IN IN O
an DT DT O
U NNP NNP O
wave NN NN O
( ( ( O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
049 CD CD O
) ) ) O
, , , O
female JJ JJ O
gender NN NN O
( ( ( O
p NN NN O
= SYM SYM O
0 CD CD O
. . . O
015 CD CD O
) ) ) O
, , , O
and CC CC O
significant JJ JJ O
dose NN NN O
- - - O
corrected JJ JJ O
changes NNS NNS O
of IN IN O
SCL NNP NNP O
, , , O
QT NNP NNP O
interval NN NN O
, , , O
and CC CC O
QTc NNP NNP O
interval NN NN O
( ( ( O
p NN NN O
< NN NN O
0 CD CD O
. . . O
05 CD CD O
) ) ) O
. . . O

During IN IN O
follow VB VB O
- - - O
up RP RP O
, , , O
seven CD CD O
( ( ( O
20 CD CD O
% NN NN O
) ) ) O
patients NNS NNS O
had VBD VBD O
a DT DT O
nonfatal NN NN O
ventricular NN NN O
tachycardia NNS NNS O
recurrence NN NN O
, , , O
and CC CC O
two CD CD O
( ( ( O
6 CD CD O
% NN NN O
) ) ) O
patients NNS NNS O
died VBD VBD O
suddenly RB RB O
. . . O

One CD CD O
female JJ JJ O
patient NN NN O
with IN IN O
stable JJ JJ O
cardiac NN NN O
disease NN NN O
had VBD VBD O
recurrent JJ JJ O
torsades NNS NNS O
de IN IN O
pointes NNS NNS O
after IN IN O
2 CD CD O
years NNS NNS O
of IN IN O
successful JJ JJ O
treatment NN NN O
with IN IN O
d SYM SYM B-CHEM
, , , I-CHEM
l NN NN I-CHEM
- - - I-CHEM
sotalol NN NN I-CHEM
. . . O

Torsades NNP NNP O
de IN IN O
pointes NNS NNS O
occurred VBD VBD O
early RB RB O
during IN IN O
treatment NN NN O
even RB RB O
with IN IN O
low JJ JJ O
doses NNS NNS O
of IN IN O
oral JJ JJ O
d SYM SYM B-CHEM
, , , I-CHEM
l NN NN I-CHEM
- - - I-CHEM
sotalol NN NN I-CHEM
. . . O

Pronounced NNP NNP O
changes NNS NNS O
in IN IN O
the DT DT O
surface NN NN O
ECG NNP NNP O
( ( ( O
cycle NN NN O
length NN NN O
, , , O
QT NNP NNP O
, , , O
and CC CC O
QTc NNP NNP O
) ) ) O
in IN IN O
relation NN NN O
to TO TO O
the DT DT O
dose NN NN O
of IN IN O
oral JJ JJ O
d SYM SYM B-CHEM
, , , I-CHEM
l NN NN I-CHEM
- - - I-CHEM
sotalol NN NN I-CHEM
might MD MD O
identify VB VB O
a DT DT O
subgroup NN NN O
of IN IN O
patients NNS NNS O
with IN IN O
an DT DT O
increased JJ JJ O
risk NN NN O
for IN IN O
torsades NNS NNS O
de IN IN O
pointes NNS NNS O
. . . O

Other JJ JJ O
ECG NNP NNP O
parameters NNS NNS O
before IN IN O
the DT DT O
application NN NN O
of IN IN O
d SYM SYM B-CHEM
, , , I-CHEM
l NN NN I-CHEM
- - - I-CHEM
sotalol NN NN I-CHEM
did VBD VBD O
not RB RB O
identify VB VB O
patients NNS NNS O
at IN IN O
increased VBN VBN O
risk NN NN O
for IN IN O
torsades NNS NNS O
de IN IN O
pointes NNS NNS O
. . . O

Recurrence NNP NNP O
rates NNS NNS O
of IN IN O
ventricular NN NN O
tachyarrhythmias NNS NNS O
are VBP VBP O
high JJ JJ O
despite IN IN O
complete JJ JJ O
suppression NN NN O
of IN IN O
the DT DT O
arrhythmia NN NN O
during IN IN O
programmed VBN VBN O
stimulation NN NN O
. . . O

Therefore RB RB O
programmed JJ JJ O
electrical JJ JJ O
stimulation NN NN O
in IN IN O
the DT DT O
case NN NN O
of IN IN O
d SYM SYM B-CHEM
, , , I-CHEM
l NN NN I-CHEM
- - - I-CHEM
sotalol NN NN I-CHEM
seems VBZ VBZ O
to TO TO O
be VB VB O
of IN IN O
limited JJ JJ O
prognostic JJ JJ O
value NN NN O
. . . O

Chronic NNP NNP O
hyperprolactinemia NN NN O
and CC CC O
changes NNS NNS O
in IN IN O
dopamine NN NN B-CHEM
neurons NNS NNS O
. . . O

The DT DT O
tuberoinfundibular JJ JJ O
dopaminergic NN NN O
( ( ( O
TIDA NNP NNP O
) ) ) O
system NN NN O
is VBZ VBZ O
known VBN VBN O
to TO TO O
inhibit NN NN O
prolactin NN NN O
( ( ( O
PRL NNP NNP O
) ) ) O
secretion NN NN O
. . . O

In IN IN O
young JJ JJ O
animals NNS NNS O
this DT DT O
system NN NN O
responds VBZ VBZ O
to TO TO O
acute JJ JJ O
elevations NNS NNS O
in IN IN O
serum NN NN O
PRL NNP NNP O
by IN IN O
increasing VBG VBG O
its PRP$ PRP$ O
activity NN NN O
. . . O

However RB RB O
, , , O
this DT DT O
responsiveness NN NN O
is VBZ VBZ O
lost VBN VBN O
in IN IN O
aging VBG VBG O
rats NNS NNS O
with IN IN O
chronically RB RB O
high JJ JJ O
serum NN NN O
PRL NNP NNP O
levels NNS NNS O
. . . O

The DT DT O
purpose NN NN O
of IN IN O
this DT DT O
study NN NN O
was VBD VBD O
to TO TO O
induce VB VB O
hyperprolactinemia NN NN O
in IN IN O
rats NNS NNS O
for IN IN O
extended VBN VBN O
periods NNS NNS O
of IN IN O
time NN NN O
and CC CC O
examine VB VB O
its PRP$ PRP$ O
effects NNS NNS O
on IN IN O
dopaminergic JJ JJ O
systems NNS NNS O
in IN IN O
the DT DT O
brain NN NN O
. . . O

Hyperprolactinemia NNP NNP O
was VBD VBD O
induced VBN VBN O
by IN IN O
treatment NN NN O
with IN IN O
haloperidol NN NN B-CHEM
, , , O
a DT DT O
dopamine NN NN B-CHEM
receptor NN NN O
antagonist NN NN O
, , , O
and CC CC O
Palkovits NNP NNP O
' POS POS O
microdissection NN NN O
technique NN NN O
in IN IN O
combination NN NN O
with IN IN O
high JJ JJ O
- - - O
performance NN NN O
liquid NN NN O
chromatography NN NN O
was VBD VBD O
used VBN VBN O
to TO TO O
measure VB VB O
neurotransmitter NN NN O
concentrations NNS NNS O
in IN IN O
several JJ JJ O
areas NNS NNS O
of IN IN O
the DT DT O
brain NN NN O
. . . O

After IN IN O
6 CD CD O
months NNS NNS O
of IN IN O
hyperprolactinemia NN NN O
, , , O
dopamine NN NN B-CHEM
( ( ( O
DA NNP NNP B-CHEM
) ) ) O
concentrations NNS NNS O
in IN IN O
the DT DT O
median NN NN O
eminence NN NN O
( ( ( O
ME PRP PRP O
) ) ) O
increased VBN VBN O
by IN IN O
84 CD CD O
% NN NN O
over IN IN O
the DT DT O
control NN NN O
group NN NN O
. . . O

Nine CD CD O
months NNS NNS O
of IN IN O
hyperprolactinemia NN NN O
produced VBD VBD O
a DT DT O
50 CD CD O
% NN NN O
increase NN NN O
in IN IN O
DA NNP NNP B-CHEM
concentrations NNS NNS O
in IN IN O
the DT DT O
ME PRP PRP O
over IN IN O
the DT DT O
control NN NN O
group NN NN O
. . . O

However RB RB O
, , , O
DA NNP NNP B-CHEM
response NN NN O
was VBD VBD O
lost VBN VBN O
if IN IN O
a DT DT O
9 CD CD O
- : : O
month NN NN O
long JJ JJ O
haloperidol NN NN B-CHEM
- - - O
induced JJ JJ O
hyperprolactinemia NN NN O
was VBD VBD O
followed VBN VBN O
by IN IN O
a DT DT O
1 CD CD O
1 CD CD O
/ NN NN O
2 CD CD O
month NN NN O
- : : O
long RB RB O
extremely RB RB O
high JJ JJ O
increase NN NN O
in IN IN O
serum NN NN O
PRL NNP NNP O
levels NNS NNS O
produced VBN VBN O
by IN IN O
implantation NN NN O
of IN IN O
MMQ NNP NNP O
cells NNS NNS O
under IN IN O
the DT DT O
kidney NN NN O
capsule NN NN O
. . . O

There EX EX O
was VBD VBD O
no DT DT O
change NN NN O
in IN IN O
the DT DT O
levels NNS NNS O
of IN IN O
DA NNP NNP B-CHEM
, , , O
norepinephrine NN NN B-CHEM
( ( ( O
NE NNP NNP B-CHEM
) ) ) O
, , , O
serotonin NN NN B-CHEM
( ( ( O
5 CD CD B-CHEM
- : : I-CHEM
HT NNP NNP I-CHEM
) ) ) O
, , , O
or CC CC O
their PRP$ PRP$ O
metabolites NNS NNS O
in IN IN O
the DT DT O
arcuate NN NN O
nucleus NN NN O
( ( ( O
AN DT DT O
) ) ) O
, , , O
medial JJ JJ O
preoptic JJ JJ O
area NN NN O
( ( ( O
MPA NNP NNP O
) ) ) O
, , , O
caudate JJ JJ O
putamen NNS NNS O
( ( ( O
CP NNP NNP O
) ) ) O
, , , O
substantia NN NN O
nigra NN NN O
( ( ( O
SN NNP NNP O
) ) ) O
, , , O
and CC CC O
zona NN NN O
incerta NN NN O
( ( ( O
ZI NNP NNP O
) ) ) O
, , , O
except IN IN O
for IN IN O
a DT DT O
decrease NN NN O
in IN IN O
5 CD CD B-CHEM
- : : I-CHEM
hydroxyindoleacetic JJ JJ I-CHEM
acid NN NN I-CHEM
( ( ( O
5 CD CD B-CHEM
- : : I-CHEM
HIAA NNP NNP I-CHEM
) ) ) O
in IN IN O
the DT DT O
AN DT DT O
after IN IN O
6 CD CD O
- : : O
months NNS NNS O
of IN IN O
hyperprolactinemia NN NN O
and CC CC O
an DT DT O
increase NN NN O
in IN IN O
DA NNP NNP B-CHEM
concentrations NNS NNS O
in IN IN O
the DT DT O
AN DT DT O
after IN IN O
9 CD CD O
- : : O
months NNS NNS O
of IN IN O
hyperprolactinemia NN NN O
. . . O

These DT DT O
results NNS NNS O
demonstrate VBP VBP O
that IN IN O
hyperprolactinemia NN NN O
specifically RB RB O
affects VBZ VBZ O
TIDA NNP NNP O
neurons NNS NNS O
and CC CC O
these DT DT O
effects NNS NNS O
vary VBP VBP O
, , , O
depending VBG VBG O
on IN IN O
the DT DT O
duration NN NN O
and CC CC O
intensity NN NN O
of IN IN O
hyperprolactinemia NN NN O
. . . O

The DT DT O
age NN NN O
- - - O
related VBN VBN O
decrease NN NN O
in IN IN O
hypothalamic JJ JJ O
dopamine NN NN B-CHEM
function NN NN O
may MD MD O
be VB VB O
associated VBN VBN O
with IN IN O
increases NNS NNS O
in IN IN O
PRL NNP NNP O
secretion NN NN O
. . . O

Treatment NN NN O
- - - O
related VBN VBN O
disseminated VBN VBN O
necrotizing VBG VBG O
leukoencephalopathy NN NN O
with IN IN O
characteristic JJ JJ O
contrast NN NN O
enhancement NN NN O
of IN IN O
the DT DT O
white JJ JJ O
matter NN NN O
. . . O

This DT DT O
report NN NN O
describes VBZ VBZ O
unique JJ JJ O
contrast NN NN O
enhancement NN NN O
of IN IN O
the DT DT O
white JJ JJ O
matter NN NN O
on IN IN O
T1 NNP NNP O
- : : O
weighted JJ JJ O
magnetic JJ JJ O
resonance NN NN O
images NNS NNS O
of IN IN O
two CD CD O
patients NNS NNS O
with IN IN O
disseminated VBD VBD O
necrotizing VBG VBG O
leukoencephalopathy NN NN O
, , , O
which WDT WDT O
developed VBD VBD O
from IN IN O
acute JJ JJ O
lymphoblastic JJ JJ O
leukemia NN NN O
treated VBN VBN O
with IN IN O
high JJ JJ O
- - - O
dose NN NN O
methotrexate NN NN B-CHEM
. . . O

In IN IN O
both DT DT O
patients NNS NNS O
, , , O
the DT DT O
enhancement NN NN O
was VBD VBD O
more RBR RBR O
pronounced VBN VBN O
near IN IN O
the DT DT O
base NN NN O
of IN IN O
the DT DT O
brain NN NN O
than IN IN O
at IN IN O
the DT DT O
vertex NN NN O
. . . O

Necropsy NNP NNP O
of IN IN O
the DT DT O
first JJ JJ O
case NN NN O
revealed VBD VBD O
loss NN NN O
of IN IN O
myelination NN NN O
and CC CC O
necrosis NN NN O
of IN IN O
the DT DT O
white JJ JJ O
matter NN NN O
. . . O

Possible JJ JJ O
mechanisms NNS NNS O
causing VBG VBG O
such JJ JJ O
a DT DT O
leukoencephalopathy JJ JJ O
are VBP VBP O
discussed VBN VBN O
. . . O

Thrombotic NNP NNP O
complications NNS NNS O
in IN IN O
acute JJ JJ O
promyelocytic JJ JJ O
leukemia NN NN O
during IN IN O
all DT DT B-CHEM
- - - I-CHEM
trans NNS NNS I-CHEM
- : : I-CHEM
retinoic JJ JJ I-CHEM
acid NN NN I-CHEM
therapy NN NN O
. . . O

A DT DT O
case NN NN O
of IN IN O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
, , , O
due JJ JJ O
to TO TO O
occlusion NN NN O
of IN IN O
renal JJ JJ O
vessels NNS NNS O
in IN IN O
a DT DT O
patient NN NN O
with IN IN O
acute JJ JJ O
promyelocytic JJ JJ O
leukemia NN NN O
( ( ( O
APL NNP NNP O
) ) ) O
treated VBN VBN O
with IN IN O
all DT DT B-CHEM
- - - I-CHEM
trans NNS NNS I-CHEM
- : : I-CHEM
retinoic JJ JJ I-CHEM
acid NN NN I-CHEM
( ( ( O
ATRA NNP NNP B-CHEM
) ) ) O
and CC CC O
tranexamic JJ JJ B-CHEM
acid NN NN I-CHEM
has VBZ VBZ O
been VBN VBN O
described VBN VBN O
recently RB RB O
. . . O

We PRP PRP O
report VBP VBP O
a DT DT O
case NN NN O
of IN IN O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
in IN IN O
an DT DT O
APL NNP NNP O
patient NN NN O
treated VBN VBN O
with IN IN O
ATRA NNP NNP B-CHEM
alone RB RB O
. . . O

This DT DT O
case NN NN O
further RB RB O
supports VBZ VBZ O
the DT DT O
concern NN NN O
about IN IN O
thromboembolic JJ JJ O
complications NNS NNS O
associated VBN VBN O
with IN IN O
ATRA NNP NNP B-CHEM
therapy NN NN O
in IN IN O
APL NNP NNP O
patients NNS NNS O
. . . O

The DT DT O
patients NNS NNS O
, , , O
a DT DT O
43 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
man NN NN O
, , , O
presented VBN VBN O
all PDT PDT O
the DT DT O
signs NNS NNS O
and CC CC O
symptoms NNS NNS O
of IN IN O
APL NNP NNP O
and CC CC O
was VBD VBD O
included VBN VBN O
in IN IN O
a DT DT O
treatment NN NN O
protocol NN NN O
with IN IN O
ATRA NNP NNP B-CHEM
. . . O

After IN IN O
10 CD CD O
days NNS NNS O
of IN IN O
treatment NN NN O
, , , O
he PRP PRP O
developed VBD VBD O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
that WDT WDT O
was VBD VBD O
completely RB RB O
reversible JJ JJ O
after IN IN O
complete JJ JJ O
remission NN NN O
of IN IN O
APL NNP NNP O
was VBD VBD O
achieved VBN VBN O
and CC CC O
therapy NN NN O
discontinued VBD VBD O
. . . O

We PRP PRP O
conclude VBP VBP O
that IN IN O
ATRA NNP NNP B-CHEM
is VBZ VBZ O
a DT DT O
valid JJ JJ O
therapeutic JJ JJ O
choice NN NN O
for IN IN O
patients NNS NNS O
with IN IN O
APL NNP NNP O
, , , O
although IN IN O
the DT DT O
procoagulant JJ JJ O
tendency NN NN O
is VBZ VBZ O
not RB RB O
completely RB RB O
corrected VBN VBN O
. . . O

Thrombotic NNP NNP O
events NNS NNS O
, , , O
however RB RB O
, , , O
could MD MD O
be VB VB O
avoided VBN VBN O
by IN IN O
using VBG VBG O
low JJ JJ O
- - - O
dose NN NN O
heparin NN NN B-CHEM
. . . O

Pupillary NNP NNP O
changes NNS NNS O
associated VBN VBN O
with IN IN O
the DT DT O
development NN NN O
of IN IN O
stimulant JJ JJ O
- - - O
induced JJ JJ O
mania NN NN O
: : : O
a DT DT O
case NN NN O
report NN NN O
. . . O

A DT DT O
30 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
cocaine NN NN B-CHEM
- - - O
dependent JJ JJ O
man NN NN O
who WP WP O
was VBD VBD O
a DT DT O
subject NN NN O
in IN IN O
a DT DT O
study NN NN O
evaluating VBG VBG O
the DT DT O
anticraving VBG VBG O
efficacy NN NN O
of IN IN O
the DT DT O
stimulant JJ JJ O
medication NN NN O
diethylpropion NN NN B-CHEM
( ( ( O
DEP NNP NNP B-CHEM
) ) ) O
became VBD VBD O
manic JJ JJ O
during IN IN O
his PRP$ PRP$ O
second JJ JJ O
week NN NN O
on IN IN O
the DT DT O
study NN NN O
drug NN NN O
. . . O

Pupillometric NNP NNP O
changes NNS NNS O
while IN IN O
on IN IN O
DEP NNP NNP B-CHEM
, , , O
especially RB RB O
changes NNS NNS O
in IN IN O
the DT DT O
total JJ JJ O
power NN NN O
of IN IN O
pupillary JJ JJ O
oscillation NN NN O
, , , O
were VBD VBD O
dramatically RB RB O
different JJ JJ O
than IN IN O
those DT DT O
observed VBN VBN O
in IN IN O
the DT DT O
eight CD CD O
other JJ JJ O
study NN NN O
subjects NNS NNS O
who WP WP O
did VBD VBD O
not RB RB O
become VB VB O
manic JJ JJ O
. . . O

The DT DT O
large JJ JJ O
changes NNS NNS O
in IN IN O
total JJ JJ O
power NN NN O
of IN IN O
pupillary JJ JJ O
oscillation NN NN O
occurred VBD VBD O
a DT DT O
few JJ JJ O
days NNS NNS O
before IN IN O
the DT DT O
patient NN NN O
became VBD VBD O
fully RB RB O
manic JJ JJ O
. . . O

Such JJ JJ O
medication NN NN O
- - - O
associated VBN VBN O
changes NNS NNS O
in IN IN O
the DT DT O
total JJ JJ O
power NN NN O
of IN IN O
pupillary JJ JJ O
oscillation NN NN O
might MD MD O
be VB VB O
of IN IN O
utility NN NN O
in IN IN O
identifying VBG VBG O
persons NNS NNS O
at IN IN O
risk NN NN O
for IN IN O
manic JJ JJ O
- - - O
like IN IN O
adverse JJ JJ O
effects NNS NNS O
during IN IN O
the DT DT O
medical JJ JJ O
use NN NN O
of IN IN O
psychomotor NN NN O
stimulants NNS NNS O
or CC CC O
sympathomimetic JJ JJ O
agents NNS NNS O
. . . O

Fetal NNP NNP O
risks NNS NNS O
due JJ JJ O
to TO TO O
warfarin NN NN B-CHEM
therapy NN NN O
during IN IN O
pregnancy NN NN O
. . . O

Two CD CD O
mothers NNS NNS O
with IN IN O
heart NN NN O
valve NN NN O
prosthesis NN NN O
were VBD VBD O
treated VBN VBN O
with IN IN O
warfarin NN NN B-CHEM
during IN IN O
pregnancy NN NN O
. . . O

In IN IN O
the DT DT O
first JJ JJ O
case NN NN O
a DT DT O
caesarean JJ JJ O
section NN NN O
was VBD VBD O
done VBN VBN O
one CD CD O
week NN NN O
after IN IN O
replacement NN NN O
of IN IN O
warfarin NN NN B-CHEM
with IN IN O
heparin NN NN B-CHEM
. . . O

The DT DT O
baby NN NN O
died VBD VBD O
of IN IN O
cerebral JJ JJ O
and CC CC O
pulmonary JJ JJ O
hemorrhage NN NN O
. . . O

The DT DT O
second JJ JJ O
mother NN NN O
had VBD VBD O
a DT DT O
male JJ JJ O
infant NN NN O
by IN IN O
caesarean JJ JJ O
section NN NN O
. . . O

The DT DT O
baby NN NN O
showed VBD VBD O
warfarin NN NN B-CHEM
- : : O
induced JJ JJ O
embryopathy NN NN O
with IN IN O
nasal NN NN O
hypoplasia NN NN O
and CC CC O
stippled VBD VBD O
epiphyses NNS NNS O
( ( ( O
chondrodysplasia NN NN O
punctata NN NN O
) ) ) O
. . . O

Nasal NNP NNP O
hypoplasia NN NN O
with IN IN O
or CC CC O
without IN IN O
stippled JJ JJ O
epiphyses NNS NNS O
has VBZ VBZ O
now RB RB O
been VBN VBN O
reported VBN VBN O
in IN IN O
11 CD CD O
infants NNS NNS O
born VBN VBN O
to TO TO O
mothers NNS NNS O
treated VBN VBN O
with IN IN O
warfarin NN NN B-CHEM
during IN IN O
the DT DT O
first JJ JJ O
trimester NN NN O
, , , O
and CC CC O
a DT DT O
causal NN NN O
association NN NN O
is VBZ VBZ O
probable JJ JJ O
. . . O

In IN IN O
view NN NN O
of IN IN O
the DT DT O
risks NNS NNS O
to TO TO O
both DT DT O
mother NN NN O
and CC CC O
fetus NN NN O
in IN IN O
women NNS NNS O
with IN IN O
prosthetic JJ JJ O
cardiac NN NN O
valves NNS NNS O
it PRP PRP O
is VBZ VBZ O
recommended VBN VBN O
that IN IN O
therapeutic JJ JJ O
abortion NN NN O
be VB VB O
advised VBN VBN O
as IN IN O
the DT DT O
first JJ JJ O
alternative NN NN O
. . . O

The DT DT O
negative JJ JJ O
mucosal NN NN O
potential JJ JJ O
: : : O
separating VBG VBG O
central JJ JJ O
and CC CC O
peripheral JJ JJ O
effects NNS NNS O
of IN IN O
NSAIDs NNP NNP O
in IN IN O
man NN NN O
. . . O

OBJECTIVE NNP NNP O
: : : O
We PRP PRP O
wanted VBD VBD O
to TO TO O
test VB VB O
whether IN IN O
assessment NN NN O
of IN IN O
both DT DT O
a DT DT O
central JJ JJ O
pain NN NN O
- - - O
related VBN VBN O
signal NN NN O
( ( ( O
chemo NN NN O
- - - O
somatosensory NN NN O
evoked VBD VBD O
potential JJ JJ O
, , , O
CSSEP NNP NNP O
) ) ) O
and CC CC O
a DT DT O
concomitantly RB RB O
recorded VBN VBN O
peripheral JJ JJ O
signal NN NN O
( ( ( O
negative JJ JJ O
mucosal NN NN O
potential JJ JJ O
, , , O
NMP NNP NNP O
) ) ) O
allows VBZ VBZ O
for IN IN O
separation NN NN O
of IN IN O
central JJ JJ O
and CC CC O
peripheral JJ JJ O
effects NNS NNS O
of IN IN O
NSAIDs NNP NNP O
. . . O

For IN IN O
this DT DT O
purpose NN NN O
, , , O
experimental JJ JJ O
conditions NNS NNS O
were VBD VBD O
created VBN VBN O
in IN IN O
which WDT WDT O
NSAIDs NNP NNP O
had VBD VBD O
previously RB RB O
been VBN VBN O
observed VBN VBN O
to TO TO O
produce VB VB O
effects NNS NNS O
on IN IN O
phasic NN NN O
and CC CC O
tonic JJ JJ O
pain NN NN O
by IN IN O
either DT DT O
central JJ JJ O
or CC CC O
peripheral JJ JJ O
mechanisms NNS NNS O
. . . O

METHODS NNP NNP O
: : : O
According VBG VBG O
to TO TO O
a DT DT O
double JJ JJ O
- - - O
blind JJ JJ O
, , , O
randomised VBN VBN O
, , , O
controlled VBN VBN O
, , , O
threefold JJ JJ O
cross NN NN O
- - - O
over IN IN O
design NN NN O
, , , O
18 CD CD O
healthy JJ JJ O
subjects NNS NNS O
( ( ( O
11 CD CD O
males NNS NNS O
, , , O
7 CD CD O
females NNS NNS O
; : : O
mean VB VB O
age NN NN O
26 CD CD O
years NNS NNS O
) ) ) O
received VBD VBD O
either CC CC O
placebo NN NN O
, , , O
400 CD CD O
mg NN NN O
ibuprofen NN NN B-CHEM
, , , O
or CC CC O
800 CD CD O
mg NN NN O
ibuprofen NN NN B-CHEM
. . . O

Phasic NNP NNP O
pain NN NN O
was VBD VBD O
applied VBN VBN O
by IN IN O
means NNS NNS O
of IN IN O
short JJ JJ O
pulses NNS NNS O
of IN IN O
CO2 NNP NNP B-CHEM
to TO TO O
the DT DT O
nasal NN NN O
mucosa NN NN O
( ( ( O
stimulus NN NN O
duration NN NN O
500 CD CD O
ms NN NN O
, , , O
interval NN NN O
approximately RB RB O
60 CD CD O
s VBZ VBZ O
) ) ) O
, , , O
and CC CC O
tonic JJ JJ O
pain NN NN O
was VBD VBD O
induced VBN VBN O
in IN IN O
the DT DT O
nasal NN NN O
cavity NN NN O
by IN IN O
means NNS NNS O
of IN IN O
dry JJ JJ O
air NN NN O
of IN IN O
controlled JJ JJ O
temperature NN NN O
, , , O
humidity NN NN O
and CC CC O
flow NN NN O
rate NN NN O
( ( ( O
22 CD CD O
degrees NNS NNS O
C NNP NNP O
, , , O
0 CD CD O
% NN NN O
relative JJ JJ O
humidity NN NN O
, , , O
145 CD CD O
ml NN NN O
. . . O
s VBZ VBZ O
- - - O
1 CD CD O
) ) ) O
. . . O

Both DT DT O
CSSEPs NNP NNP O
as IN IN O
central JJ JJ O
and CC CC O
NMPs NNP NNP O
as IN IN O
peripheral JJ JJ O
correlates NNS NNS O
of IN IN O
pain NN NN O
were VBD VBD O
obtained VBN VBN O
in IN IN O
response NN NN O
to TO TO O
the DT DT O
CO2 NNP NNP B-CHEM
stimuli NN NN O
. . . O

Additionally RB RB O
, , , O
the DT DT O
subjects NNS NNS O
rated VBD VBD O
the DT DT O
intensity NN NN O
of IN IN O
both DT DT O
phasic NN NN O
and CC CC O
tonic JJ JJ O
pain NN NN O
by IN IN O
means NNS NNS O
of IN IN O
visual JJ JJ O
analogue NN NN O
scales NNS NNS O
. . . O

RESULTS NNS NNS O
: : : O
As IN IN O
described VBN VBN O
earlier RBR RBR O
, , , O
administration NN NN O
of IN IN O
ibuprofen NN NN B-CHEM
was VBD VBD O
followed VBN VBN O
by IN IN O
a DT DT O
decrease NN NN O
in IN IN O
tonic JJ JJ O
pain NN NN O
but CC CC O
- - - O
relative JJ JJ O
to TO TO O
placebo NN NN O
- - - O
an DT DT O
increase NN NN O
in IN IN O
correlates NNS NNS O
of IN IN O
phasic JJ JJ O
pain NN NN O
, , , O
indicating VBG VBG O
a DT DT O
specific JJ JJ O
effect NN NN O
of IN IN O
ibuprofen NN NN B-CHEM
on IN IN O
the DT DT O
interaction NN NN O
between IN IN O
the DT DT O
pain NN NN O
stimuli NN NN O
under IN IN O
these DT DT O
special JJ JJ O
experimental JJ JJ O
conditions NNS NNS O
. . . O

Based VBN VBN O
on IN IN O
the DT DT O
similar JJ JJ O
behaviour NN NN O
of IN IN O
CSSEP NNP NNP O
and CC CC O
NMP NNP NNP O
, , , O
it PRP PRP O
was VBD VBD O
concluded VBN VBN O
that IN IN O
the DT DT O
pharmacological JJ JJ O
process NN NN O
underlying VBG VBG O
this DT DT O
phenomenon NN NN O
was VBD VBD O
localised VBN VBN O
in IN IN O
the DT DT O
periphery NN NN O
. . . O

By IN IN O
means NNS NNS O
of IN IN O
the DT DT O
simultaneous JJ JJ O
recording NN NN O
of IN IN O
interrelated VBN VBN O
peripheral NN NN O
and CC CC O
central JJ JJ O
electrophysiologic JJ JJ O
correlates NNS NNS O
of IN IN O
nociception NN NN O
, , , O
it PRP PRP O
was VBD VBD O
possible JJ JJ O
to TO TO O
separate VB VB O
central JJ JJ O
and CC CC O
peripheral JJ JJ O
effects NNS NNS O
of IN IN O
an DT DT O
NSAID NNP NNP O
. . . O

The DT DT O
major JJ JJ O
advantage NN NN O
of IN IN O
this DT DT O
pain NN NN O
model NN NN O
is VBZ VBZ O
the DT DT O
possibility NN NN O
of IN IN O
obtaining VBG VBG O
peripheral JJ JJ O
pain NN NN O
- - - O
related VBN VBN O
activity NN NN O
directly RB RB O
using VBG VBG O
a DT DT O
non NN NN O
- - - O
invasive JJ JJ O
technique NN NN O
in IN IN O
humans NNS NNS O
. . . O

Effect NN NN O
of IN IN O
D NNP NNP B-CHEM
- - - I-CHEM
Glucarates NNP NNP I-CHEM
on IN IN O
basic JJ JJ O
antibiotic JJ JJ O
- - - O
induced JJ JJ O
renal NN NN O
damage NN NN O
in IN IN O
rats NNS NNS O
. . . O

Dehydrated NNP NNP O
rats NNS NNS O
regularly RB RB O
develop VBP VBP O
acute JJ JJ O
renal JJ JJ O
failure NN NN O
following VBG VBG O
single JJ JJ O
injection NN NN O
of IN IN O
aminoglycoside NN NN B-CHEM
antibiotics NNS NNS O
combined VBN VBN O
with IN IN O
dextran NN NN O
or CC CC O
of IN IN O
antibiotics NNS NNS O
only RB RB O
. . . O

Oral NNP NNP O
administration NN NN O
of IN IN O
2 CD CD B-CHEM
, , , I-CHEM
5 CD CD I-CHEM
- : : I-CHEM
di NN NN I-CHEM
- - - I-CHEM
O NNP NNP I-CHEM
- : : I-CHEM
acetyl NN NN I-CHEM
- : : I-CHEM
D NNP NNP I-CHEM
- - - I-CHEM
glucaro NN NN I-CHEM
- - - I-CHEM
1 CD CD I-CHEM
, , , I-CHEM
4 CD CD I-CHEM
- : : I-CHEM
6 CD CD I-CHEM
, , , I-CHEM
3 CD CD I-CHEM
- : : I-CHEM
dilactone NN NN I-CHEM
protected VBD VBD O
rats NNS NNS O
against IN IN O
renal JJ JJ O
failure NN NN O
induced VBN VBN O
by IN IN O
kanamycin NN NN B-CHEM
- - - O
dextran NN NN O
. . . O

The DT DT O
protective JJ JJ O
effect NN NN O
was VBD VBD O
prevalent JJ JJ O
among IN IN O
D NNP NNP B-CHEM
- : : I-CHEM
glucarates NNS NNS I-CHEM
, , , O
and CC CC O
also RB RB O
to TO TO O
other JJ JJ O
saccharic JJ JJ B-CHEM
acid NN NN I-CHEM
, , , O
hexauronic JJ JJ B-CHEM
acids NNS NNS I-CHEM
and CC CC O
hexaaldonic JJ JJ B-CHEM
acids NNS NNS I-CHEM
, , , O
although IN IN O
to TO TO O
a DT DT O
lesser NN NN O
degree NN NN O
, , , O
but CC CC O
not RB RB O
to TO TO O
a DT DT O
hexaaldose NN NN O
, , , O
sugar NN NN B-CHEM
alcohols NNS NNS I-CHEM
, , , O
substances NNS NNS O
inthe NN NN O
TCA NNP NNP B-CHEM
cycle NN NN O
and CC CC O
other JJ JJ O
acidic JJ JJ O
compounds NNS NNS O
. . . O

D NNP NNP B-CHEM
- : : I-CHEM
Glucarates NNP NNP I-CHEM
were VBD VBD O
effective JJ JJ O
against IN IN O
renal JJ JJ O
damage NN NN O
induced VBN VBN O
by IN IN O
peptide NN NN O
antibiotics NNS NNS O
as RB RB O
well RB RB O
as IN IN O
various JJ JJ O
aminoglycoside NN NN B-CHEM
antibitocis NN NN O
. . . O

Dose NNP NNP O
- : : O
responses NNS NNS O
were VBD VBD O
observed VBN VBN O
in IN IN O
the DT DT O
protective JJ JJ O
effect NN NN O
of IN IN O
D NNP NNP B-CHEM
- - - I-CHEM
Glucarates NNP NNP I-CHEM
. . . O

With IN IN O
a DT DT O
D NNP NNP B-CHEM
- : : I-CHEM
glucarate NN NN I-CHEM
of IN IN O
a DT DT O
fixed JJ JJ O
size NN NN O
of IN IN O
dose NN NN O
, , , O
approximately RB RB O
the DT DT O
same JJ JJ O
degree NN NN O
of IN IN O
protection NN NN O
was VBD VBD O
obtained VBN VBN O
against IN IN O
renal JJ JJ O
damages NNS NNS O
induced VBN VBN O
by IN IN O
different JJ JJ O
basic JJ JJ O
antibiotics NNS NNS O
despite IN IN O
large JJ JJ O
disparities NNS NNS O
in IN IN O
administration NN NN O
doses NNS NNS O
of IN IN O
different JJ JJ O
antibiotics NNS NNS O
. . . O

D NNP NNP B-CHEM
- : : I-CHEM
Glucarates NNP NNP I-CHEM
had VBD VBD O
the DT DT O
ability NN NN O
to TO TO O
prevent VB VB O
renal JJ JJ O
damage NN NN O
but CC CC O
not RB RB O
to TO TO O
cure VB VB O
it PRP PRP O
. . . O

Rats NNP NNP O
excreted VBD VBD O
acidic JJ JJ O
urine NN NN O
when WRB WRB O
they PRP PRP O
were VBD VBD O
spared VBN VBN O
from IN IN O
renal JJ JJ O
lesions NNS NNS O
by IN IN O
monosaccharides NNS NNS B-CHEM
. . . O

The DT DT O
reduction NN NN O
effect NN NN O
of IN IN O
D NNP NNP B-CHEM
- : : I-CHEM
glucarates NNS NNS I-CHEM
against IN IN O
nephrotoxicity NN NN O
of IN IN O
basic JJ JJ O
antibiotics NNS NNS O
was VBD VBD O
discussed VBN VBN O
. . . O

Acute JJ JJ O
severe JJ JJ O
depression NN NN O
following VBG VBG O
peri NN NN O
- - - O
operative JJ JJ O
ondansetron NN NN B-CHEM
. . . O

A DT DT O
41 JJ JJ O
- - - O
year NN NN O
- - - O
old JJ JJ O
woman NN NN O
with IN IN O
a DT DT O
strong JJ JJ O
history NN NN O
of IN IN O
postoperative JJ JJ O
nausea NN NN O
and CC CC O
vomiting VBG VBG O
presented VBN VBN O
for IN IN O
abdominal JJ JJ O
hysterectomy NN NN O
3 CD CD O
months NNS NNS O
after IN IN O
a DT DT O
previous JJ JJ O
anaesthetic JJ JJ O
where WRB WRB O
ondansetron NN NN B-CHEM
prophylaxis NNS NNS O
had VBD VBD O
been VBN VBN O
used VBN VBN O
. . . O

She PRP PRP O
had VBD VBD O
developed VBN VBN O
a DT DT O
severe JJ JJ O
acute JJ JJ O
major JJ JJ O
depression NN NN O
disorder NN NN O
almost RB RB O
immediately RB RB O
thereafter RB RB O
, , , O
possibly RB RB O
related VBN VBN O
to TO TO O
the DT DT O
use NN NN O
of IN IN O
a DT DT O
serotonin NN NN B-CHEM
antagonist NN NN O
. . . O

Nine CD CD O
years NNS NNS O
before IN IN O
she PRP PRP O
had VBD VBD O
experienced VBN VBN O
a DT DT O
self NN NN O
- - - O
limited JJ JJ O
puerperal NN NN O
depressive JJ JJ O
episode NN NN O
. . . O

Anaesthesia NNP NNP O
with IN IN O
a DT DT O
propofol NN NN B-CHEM
infusion NN NN O
and CC CC O
avoidance NN NN O
of IN IN O
serotonin NN NN B-CHEM
antagonists NNS NNS O
provided VBD VBD O
a DT DT O
nausea NN NN O
- - - O
free JJ JJ O
postoperative JJ JJ O
course NN NN O
without IN IN O
exacerbation NN NN O
of IN IN O
the DT DT O
depression NN NN O
disorder NN NN O
. . . O

Hypertensive NNP NNP O
response NN NN O
during IN IN O
dobutamine NN NN B-CHEM
stress NN NN O
echocardiography NN NN O
. . . O

Among IN IN O
3 CD CD O
, , , O
129 CD CD O
dobutamine NN NN B-CHEM
stress NN NN O
echocardiographic JJ JJ O
studies NNS NNS O
, , , O
a DT DT O
hypertensive JJ JJ O
response NN NN O
, , , O
defined VBN VBN O
as IN IN O
systolic JJ JJ O
blood NN NN O
pressure NN NN O
( ( ( O
BP NNP NNP O
) ) ) O
> NN NN O
or CC CC O
= SYM SYM O
220 CD CD O
mm NN NN O
Hg NNP NNP O
and CC CC O
/ NN NN O
or CC CC O
diastolic JJ JJ O
BP NNP NNP O
> NN NN O
or CC CC O
= SYM SYM O
110 CD CD O
mm NN NN O
Hg NNP NNP O
, , , O
occurred VBD VBD O
in IN IN O
30 CD CD O
patients NNS NNS O
( ( ( O
1 CD CD O
% NN NN O
) ) ) O
. . . O

Patients NNS NNS O
with IN IN O
this DT DT O
response NN NN O
more RBR RBR O
often RB RB O
had VBD VBD O
a DT DT O
history NN NN O
of IN IN O
hypertension NN NN O
and CC CC O
had VBD VBD O
higher JJR JJR O
resting VBG VBG O
systolic JJ JJ O
and CC CC O
diastolic JJ JJ O
BP NNP NNP O
before IN IN O
dobutamine NN NN B-CHEM
infusion NN NN O
. . . O

Continuously NNP NNP O
nebulized VBD VBD O
albuterol NN NN B-CHEM
in IN IN O
severe JJ JJ O
exacerbations NNS NNS O
of IN IN O
asthma NN NN O
in IN IN O
adults NNS NNS O
: : : O
a DT DT O
case NN NN O
- - - O
controlled JJ JJ O
study NN NN O
. . . O

A DT DT O
retrospective NN NN O
, , , O
case NN NN O
- - - O
controlled JJ JJ O
analysis NN NN O
comparing VBG VBG O
patients NNS NNS O
admitted VBN VBN O
to TO TO O
a DT DT O
medical JJ JJ O
intensive JJ JJ O
care NN NN O
unit NN NN O
with IN IN O
severe JJ JJ O
exacerbations NNS NNS O
of IN IN O
asthma NN NN O
who WP WP O
received VBD VBD O
continuously RB RB O
nebulized JJ JJ O
albuterol NN NN B-CHEM
( ( ( O
CNA NNP NNP O
) ) ) O
versus CC CC O
intermittent JJ JJ O
albuterol NN NN B-CHEM
( ( ( O
INA NNP NNP O
) ) ) O
treatments NNS NNS O
is VBZ VBZ O
reported VBN VBN O
. . . O

Forty CD CD O
matched VBN VBN O
pairs NNS NNS O
of IN IN O
patients NNS NNS O
with IN IN O
asthma NN NN O
are VBP VBP O
compared VBN VBN O
. . . O

CNA NNP NNP O
was VBD VBD O
administered VBN VBN O
for IN IN O
a DT DT O
mean NN NN O
of IN IN O
11 CD CD O
+ NN NN O
/ NN NN O
- : : O
10 CD CD O
hr NN NN O
. . . O

The DT DT O
incidence NN NN O
of IN IN O
cardiac JJ JJ O
dysrhythmias NN NN O
was VBD VBD O
similar JJ JJ O
between IN IN O
groups NNS NNS O
. . . O

Symptomatic NNP NNP O
hypokalemia NN NN O
did VBD VBD O
not RB RB O
occur VB VB O
. . . O

CNA NNP NNP O
patients NNS NNS O
had VBD VBD O
higher JJR JJR O
heart NN NN O
rates NNS NNS O
during IN IN O
treatment NN NN O
, , , O
which WDT WDT O
may MD MD O
reflect VB VB O
severity NN NN O
of IN IN O
illness NN NN O
. . . O

The DT DT O
incidence NN NN O
of IN IN O
intubation NN NN O
was VBD VBD O
similar JJ JJ O
. . . O

We PRP PRP O
conclude VBP VBP O
that IN IN O
CNA NNP NNP O
and CC CC O
INA NNP NNP O
demonstrated VBD VBD O
similar JJ JJ O
profiles NNS NNS O
with IN IN O
regard NN NN O
to TO TO O
safety NN NN O
, , , O
morbidity NN NN O
, , , O
and CC CC O
mortality NN NN O
. . . O

Paraplegia NNP NNP O
following VBG VBG O
intrathecal JJ JJ O
methotrexate NN NN B-CHEM
: : : O
report NN NN O
of IN IN O
a DT DT O
case NN NN O
and CC CC O
review NN NN O
of IN IN O
the DT DT O
literature NN NN O
. . . O

A DT DT O
patient NN NN O
who WP WP O
developed VBD VBD O
paraplegia NN NN O
following VBG VBG O
the DT DT O
intrathecal JJ JJ O
instillation NN NN O
of IN IN O
methotrexate NN NN B-CHEM
is VBZ VBZ O
discribed VBN VBN O
. . . O

The DT DT O
ten CD CD O
previously RB RB O
reported VBD VBD O
cases NNS NNS O
of IN IN O
this DT DT O
unusual JJ JJ O
complication NN NN O
are VBP VBP O
reviewed VBN VBN O
. . . O

The DT DT O
following VBG VBG O
factors NNS NNS O
appear VBP VBP O
to TO TO O
predispose VB VB O
to TO TO O
the DT DT O
development NN NN O
of IN IN O
this DT DT O
complication NN NN O
: : : O
abnormal JJ JJ O
cerebrospinal NN NN O
dynamics NNS NNS O
related VBN VBN O
to TO TO O
the DT DT O
presence NN NN O
of IN IN O
central JJ JJ O
nervous JJ JJ O
system NN NN O
leukemia NN NN O
, , , O
and CC CC O
epidural JJ JJ O
cerebrospinal JJ JJ O
leakage NN NN O
; : : O
elevated VBD VBD O
cerebrospinal JJ JJ O
fluid JJ JJ O
methothexate NN NN B-CHEM
concentration NN NN O
related VBN VBN O
to TO TO O
abnormal JJ JJ O
cerebrospinal JJ JJ O
fluid JJ JJ O
dynamics NNS NNS O
and CC CC O
to TO TO O
inappropriately RB RB O
high JJ JJ O
methotrexate NN NN B-CHEM
doses NNS NNS O
based VBN VBN O
on IN IN O
body NN NN O
surface NN NN O
area NN NN O
calculations NNS NNS O
in IN IN O
older JJR JJR O
children NNS NNS O
and CC CC O
adults NNS NNS O
; : : O
the DT DT O
presence NN NN O
of IN IN O
neurotoxic JJ JJ O
preservatives NNS NNS O
in IN IN O
commercially RB RB O
available JJ JJ O
methotrexate NN NN B-CHEM
preparations NNS NNS O
and CC CC O
diluents NNS NNS O
; : : O
and CC CC O
the DT DT O
use NN NN O
of IN IN O
methotrexate JJ JJ B-CHEM
diluents NNS NNS O
of IN IN O
unphysiologic JJ JJ O
pH NN NN O
, , , O
ionic JJ JJ O
content NN NN O
and CC CC O
osmolarity NN NN O
. . . O

The DT DT O
role NN NN O
of IN IN O
methotrexate NN NN B-CHEM
contaminants NNS NNS O
, , , O
local JJ JJ O
folate NN NN O
deficiency NN NN O
, , , O
and CC CC O
cranial JJ JJ O
irradiation NN NN O
in IN IN O
the DT DT O
pathogenesis NNS NNS O
of IN IN O
intrathecal JJ JJ O
methotrexate NN NN B-CHEM
toxicity NN NN O
is VBZ VBZ O
unclear JJ JJ O
. . . O

The DT DT O
incidence NN NN O
of IN IN O
neurotoxicity NN NN O
may MD MD O
be VB VB O
reduced VBN VBN O
by IN IN O
employing VBG VBG O
lower JJR JJR O
doses NNS NNS O
of IN IN O
methotrexate NN NN B-CHEM
in IN IN O
the DT DT O
presence NN NN O
of IN IN O
central JJ JJ O
nervous JJ JJ O
system NN NN O
leukemia NN NN O
, , , O
in IN IN O
older JJR JJR O
children NNS NNS O
and CC CC O
adults NNS NNS O
, , , O
and CC CC O
in IN IN O
the DT DT O
presence NN NN O
of IN IN O
epidural JJ JJ O
leakage NN NN O
. . . O

Only RB RB O
preservative JJ JJ O
- - - O
free JJ JJ O
methotrexate NN NN B-CHEM
in IN IN O
Elliott NNP NNP O
' POS POS O
s VBZ VBZ O
B NNP NNP O
Solution NN NN O
at IN IN O
a DT DT O
concentration NN NN O
of IN IN O
not RB RB O
more JJR JJR O
than IN IN O
1 CD CD O
mg NN NN O
/ NN NN O
ml NN NN O
should MD MD O
be VB VB O
used VBN VBN O
for IN IN O
intrathecal JJ JJ O
administration NN NN O
. . . O

Periodic NNP NNP O
monitoring NN NN O
of IN IN O
cerebruspinal JJ JJ O
fluid JJ JJ O
methotrexate NN NN B-CHEM
levels NNS NNS O
may MD MD O
be VB VB O
predictive JJ JJ O
of IN IN O
the DT DT O
development NN NN O
of IN IN O
serious JJ JJ O
neurotoxicity NN NN O
. . . O

Hyperosmolar NNP NNP O
nonketotic JJ JJ O
coma NN NN O
precipitated VBN VBN O
by IN IN O
lithium NN NN B-CHEM
- - - O
induced JJ JJ O
nephrogenic JJ JJ O
diabetes NNS NNS O
insipidus NN NN O
. . . O

A DT DT O
45 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
man NN NN O
, , , O
with IN IN O
a DT DT O
10 CD CD O
- : : O
year NN NN O
history NN NN O
of IN IN O
manic JJ JJ O
depression NN NN O
treated VBN VBN O
with IN IN O
lithium NN NN B-CHEM
, , , O
was VBD VBD O
admitted VBN VBN O
with IN IN O
hyperosmolar NN NN O
, , , O
nonketotic JJ JJ O
coma NN NN O
. . . O

He PRP PRP O
gave VBD VBD O
a DT DT O
five CD CD O
- - - O
year NN NN O
history NN NN O
of IN IN O
polyuria NN NN O
and CC CC O
polydipsia NN NN O
, , , O
during IN IN O
which WDT WDT O
time NN NN O
urinalysis NNS NNS O
had VBD VBD O
been VBN VBN O
negative JJ JJ O
for IN IN O
glucose NN NN B-CHEM
. . . O

After IN IN O
recovery NN NN O
from IN IN O
hyperglycaemia NN NN O
, , , O
he PRP PRP O
remained VBD VBD O
polyuric JJ JJ O
despite IN IN O
normal JJ JJ O
blood NN NN O
glucose NN NN B-CHEM
concentrations NNS NNS O
; : : O
water NN NN O
deprivation NN NN O
testing NN NN O
indicated VBD VBD O
nephrogenic JJ JJ O
diabetes NNS NNS O
insipidus NN NN O
, , , O
likely JJ JJ O
to TO TO O
be VB VB O
lithium NN NN B-CHEM
- - - O
induced JJ JJ O
. . . O

We PRP PRP O
hypothesize NN NN O
that IN IN O
when WRB WRB O
this DT DT O
man NN NN O
developed VBN VBN O
type NN NN O
2 CD CD O
diabetes NN NN O
, , , O
chronic JJ JJ O
polyuria NNS NNS O
due JJ JJ O
to TO TO O
nephrogenic JJ JJ O
diabetes NN NN O
insipidus NN NN O
was VBD VBD O
sufficient JJ JJ O
to TO TO O
precipitate NN NN O
hyperosmolar NN NN O
dehydration NN NN O
. . . O

Effects NNP NNP O
of IN IN O
the DT DT O
intracoronary JJ JJ O
infusion NN NN O
of IN IN O
cocaine NN NN B-CHEM
on IN IN O
left VBD VBD O
ventricular NN NN O
systolic JJ JJ O
and CC CC O
diastolic JJ JJ O
function NN NN O
in IN IN O
humans NNS NNS O
. . . O

BACKGROUND NNP NNP O
: : : O
In IN IN O
dogs NNS NNS O
, , , O
a DT DT O
large JJ JJ O
amount NN NN O
of IN IN O
intravenous JJ JJ O
cocaine NN NN B-CHEM
causes NNS NNS O
a DT DT O
profound JJ JJ O
deterioration NN NN O
of IN IN O
left VBD VBD O
ventricular NN NN O
( ( ( O
LV NNP NNP O
) ) ) O
systolic JJ JJ O
function NN NN O
and CC CC O
an DT DT O
increase NN NN O
in IN IN O
LV NNP NNP O
end NN NN O
- : : O
diastolic JJ JJ O
pressure NN NN O
. . . O

This DT DT O
study NN NN O
was VBD VBD O
done VBN VBN O
to TO TO O
assess VB VB O
the DT DT O
influence NN NN O
of IN IN O
a DT DT O
high JJ JJ O
intracoronary JJ JJ O
cocaine NN NN B-CHEM
concentration NN NN O
on IN IN O
LV NNP NNP O
systolic JJ JJ O
and CC CC O
diastolic JJ JJ O
function NN NN O
in IN IN O
humans NNS NNS O
. . . O

METHODS NNP NNP O
AND CC CC O
RESULTS NNS NNS O
: : : O
In IN IN O
20 CD CD O
patients NNS NNS O
( ( ( O
14 CD CD O
men NNS NNS O
and CC CC O
6 CD CD O
women NNS NNS O
aged VBD VBD O
39 CD CD O
to TO TO O
72 CD CD O
years NNS NNS O
) ) ) O
referred VBN VBN O
for IN IN O
cardiac JJ JJ O
catheterization NN NN O
for IN IN O
the DT DT O
evaluation NN NN O
of IN IN O
chest NN NN O
pain NN NN O
, , , O
we PRP PRP O
measured VBD VBD O
heart NN NN O
rate NN NN O
, , , O
systemic JJ JJ O
arterial JJ JJ O
pressure NN NN O
, , , O
LV NNP NNP O
pressure NN NN O
and CC CC O
its PRP$ PRP$ O
first JJ JJ O
derivative JJ JJ O
( ( ( O
dP NN NN O
/ NN NN O
dt NN NN O
) ) ) O
, , , O
and CC CC O
LV NNP NNP O
volumes NNS NNS O
and CC CC O
ejection NN NN O
fraction NN NN O
before IN IN O
and CC CC O
during IN IN O
the DT DT O
final JJ JJ O
2 CD CD O
to TO TO O
3 CD CD O
minutes NNS NNS O
of IN IN O
a DT DT O
15 CD CD O
- : : O
minute NN NN O
intracoronary JJ JJ O
infusion NN NN O
of IN IN O
saline NN NN O
( ( ( O
n NN NN O
= SYM SYM O
10 CD CD O
, , , O
control NN NN O
subjects NNS NNS O
) ) ) O
or CC CC O
cocaine NN NN B-CHEM
hydrochloride NN NN I-CHEM
1 CD CD O
mg NN NN O
/ NN NN O
min NN NN O
( ( ( O
n NN NN O
= SYM SYM O
10 CD CD O
) ) ) O
. . . O

No DT DT O
variable JJ JJ O
changed VBN VBN O
with IN IN O
saline NN NN O
. . . O

With IN IN O
cocaine NN NN B-CHEM
, , , O
the DT DT O
drug NN NN O
concentration NN NN O
in IN IN O
blood NN NN O
obtained VBD VBD O
from IN IN O
the DT DT O
coronary JJ JJ O
sinus NN NN O
was VBD VBD O
3 CD CD O
. . . O
0 CD CD O
+ NN NN O
/ NN NN O
- : : O
0 CD CD O
. . . O
4 CD CD O
( ( ( O
mean NN NN O
+ NN NN O
/ NN NN O
- - - O
SD NNP NNP O
) ) ) O
mg NN NN O
/ NN NN O
L NNP NNP O
, , , O
similar JJ JJ O
in IN IN O
magnitude NN NN O
to TO TO O
the DT DT O
blood NN NN O
cocaine NN NN B-CHEM
concentration NN NN O
reported VBD VBD O
in IN IN O
abusers NNS NNS O
dying VBG VBG O
of IN IN O
cocaine NN NN B-CHEM
intoxication NN NN O
. . . O

Cocaine NNP NNP B-CHEM
induced VBD VBD O
no DT DT O
significant JJ JJ O
change NN NN O
in IN IN O
heart NN NN O
rate NN NN O
, , , O
LV NNP NNP O
dP NN NN O
/ NN NN O
dt NN NN O
( ( ( O
positive JJ JJ O
or CC CC O
negative JJ JJ O
) ) ) O
, , , O
or CC CC O
LV NNP NNP O
end NN NN O
- : : O
diastolic JJ JJ O
volume NN NN O
, , , O
but CC CC O
it PRP PRP O
caused VBD VBD O
an DT DT O
increase NN NN O
in IN IN O
systolic JJ JJ O
and CC CC O
mean VB VB O
arterial JJ JJ O
pressures NNS NNS O
, , , O
LV NNP NNP O
end NN NN O
- : : O
diastolic JJ JJ O
pressure NN NN O
, , , O
and CC CC O
LV NNP NNP O
end NN NN O
- : : O
systolic JJ JJ O
volume NN NN O
, , , O
as RB RB O
well RB RB O
as IN IN O
a DT DT O
decrease NN NN O
in IN IN O
LV NNP NNP O
ejection NN NN O
fraction NN NN O
. . . O

CONCLUSIONS NNP NNP O
: : : O
In IN IN O
humans NNS NNS O
, , , O
the DT DT O
intracoronary JJ JJ O
infusion NN NN O
of IN IN O
cocaine NN NN B-CHEM
sufficient JJ JJ O
in IN IN O
amount NN NN O
to TO TO O
achieve VB VB O
a DT DT O
high JJ JJ O
drug NN NN O
concentration NN NN O
in IN IN O
coronary JJ JJ O
sinus NN NN O
blood NN NN O
causes NNS NNS O
a DT DT O
deterioration NN NN O
of IN IN O
LV NNP NNP O
systolic JJ JJ O
and CC CC O
diastolic JJ JJ O
performance NN NN O
. . . O

Ascending NNP NNP O
dose NN NN O
tolerance NN NN O
study NN NN O
of IN IN O
intramuscular JJ JJ O
carbetocin NN NN B-CHEM
administered VBD VBD O
after IN IN O
normal JJ JJ O
vaginal JJ JJ O
birth NN NN O
. . . O

OBJECTIVE NNP NNP O
: : : O
To TO TO O
determine VB VB O
the DT DT O
maximum NN NN O
tolerated VBD VBD O
dose NN NN O
( ( ( O
MTD NNP NNP O
) ) ) O
of IN IN O
carbetocin NN NN B-CHEM
( ( ( O
a DT DT O
long JJ JJ O
- - - O
acting VBG VBG O
synthetic JJ JJ O
analogue NN NN O
of IN IN O
oxytocin NN NN B-CHEM
) ) ) O
, , , O
when WRB WRB O
administered VBD VBD O
immediately RB RB O
after IN IN O
vaginal JJ JJ O
delivery NN NN O
at IN IN O
term NN NN O
. . . O

MATERIALS NNS NNS O
AND CC CC O
METHODS NNP NNP O
: : : O
Carbetocin NNP NNP B-CHEM
was VBD VBD O
given VBN VBN O
as IN IN O
an DT DT O
intramuscular JJ JJ O
injection NN NN O
immediately RB RB O
after IN IN O
the DT DT O
birth NN NN O
of IN IN O
the DT DT O
infant NN NN O
in IN IN O
45 CD CD O
healthy JJ JJ O
women NNS NNS O
with IN IN O
normal JJ JJ O
singleton NN NN O
pregnancies NNS NNS O
who WP WP O
delivered VBD VBD O
vaginally RB RB O
at IN IN O
term NN NN O
. . . O

Dosage NNP NNP O
groups NNS NNS O
of IN IN O
15 CD CD O
, , , O
30 CD CD O
, , , O
50 CD CD O
, , , O
75 CD CD O
, , , O
100 CD CD O
, , , O
125 CD CD O
, , , O
150 CD CD O
, , , O
175 CD CD O
or CC CC O
200 CD CD O
microg NN NN O
carbetocin NN NN B-CHEM
were VBD VBD O
assigned VBN VBN O
to TO TO O
blocks NNS NNS O
of IN IN O
three CD CD O
women NNS NNS O
according VBG VBG O
to TO TO O
the DT DT O
continual JJ JJ O
reassessment NN NN O
method NN NN O
( ( ( O
CRM NNP NNP O
) ) ) O
. . . O

RESULTS NNS NNS O
: : : O
All DT DT O
dosage NN NN O
groups NNS NNS O
consisted VBD VBD O
of IN IN O
three CD CD O
women NNS NNS O
, , , O
except IN IN O
those DT DT O
with IN IN O
100 CD CD O
microg NN NN O
( ( ( O
n NN NN O
= SYM SYM O
6 CD CD O
) ) ) O
and CC CC O
200 CD CD O
microg NN NN O
( ( ( O
n NN NN O
= SYM SYM O
18 CD CD O
) ) ) O
. . . O

Recorded NNP NNP O
were VBD VBD O
dose JJ JJ O
- : : O
limiting VBG VBG O
adverse JJ JJ O
events NNS NNS O
: : : O
hyper NN NN O
- - - O
or CC CC O
hypotension NN NN O
( ( ( O
three CD CD O
) ) ) O
, , , O
severe JJ JJ O
abdominal JJ JJ O
pain NN NN O
( ( ( O
0 CD CD O
) ) ) O
, , , O
vomiting VBG VBG O
( ( ( O
0 CD CD O
) ) ) O
and CC CC O
retained VBD VBD O
placenta NN NN O
( ( ( O
four CD CD O
) ) ) O
. . . O

Serious JJ JJ O
adverse JJ JJ O
events NNS NNS O
occurred VBD VBD O
in IN IN O
seven CD CD O
women NNS NNS O
: : : O
six CD CD O
cases NNS NNS O
with IN IN O
blood NN NN O
loss NN NN O
> NN NN O
or CC CC O
= SYM SYM O
1000 CD CD O
ml NN NN O
, , , O
four CD CD O
cases NNS NNS O
of IN IN O
manual JJ JJ O
placenta NN NN O
removal NN NN O
, , , O
five CD CD O
cases NNS NNS O
of IN IN O
additional JJ JJ O
oxytocics NNS NNS O
administration NN NN O
and CC CC O
five CD CD O
cases NNS NNS O
of IN IN O
blood NN NN O
transfusion NN NN O
. . . O

Maximum NNP NNP O
blood NN NN O
loss NN NN O
was VBD VBD O
greatest JJS JJS O
at IN IN O
the DT DT O
upper JJ JJ O
and CC CC O
lower JJR JJR O
dose NN NN O
levels NNS NNS O
, , , O
and CC CC O
lowest JJS JJS O
in IN IN O
the DT DT O
70 CD CD O
- : : O
125 CD CD O
microg NN NN O
dose NN NN O
range NN NN O
. . . O

Four CD CD O
out IN IN O
of IN IN O
six CD CD O
cases NNS NNS O
with IN IN O
blood NN NN O
loss NN NN O
> NN NN O
or CC CC O
= SYM SYM O
1000 CD CD O
ml NN NN O
occurred VBD VBD O
in IN IN O
the DT DT O
200 CD CD O
microg NN NN O
group NN NN O
. . . O

The DT DT O
majority NN NN O
of IN IN O
additional JJ JJ O
administration NN NN O
of IN IN O
oxytocics NNS NNS O
( ( ( O
4 CD CD O
/ NN NN O
5 CD CD O
) ) ) O
and CC CC O
blood NN NN O
transfusion NN NN O
( ( ( O
3 CD CD O
/ NN NN O
5 CD CD O
) ) ) O
occurred VBD VBD O
in IN IN O
the DT DT O
dose NN NN O
groups NNS NNS O
of IN IN O
200 CD CD O
microg NN NN O
. . . O

All DT DT O
retained VBD VBD O
placentae NN NN O
were VBD VBD O
found VBN VBN O
in IN IN O
the DT DT O
group NN NN O
of IN IN O
200 CD CD O
microg NN NN O
. . . O

CONCLUSION NNP NNP O
: : : O
The DT DT O
MTD NNP NNP O
was VBD VBD O
calculated VBN VBN O
to TO TO O
be VB VB O
at IN IN O
200 CD CD O
microg NN NN O
carbetocin NN NN B-CHEM
. . . O

Heparin NNP NNP B-CHEM
- : : O
induced JJ JJ O
thrombocytopenia NN NN O
, , , O
paradoxical JJ JJ O
thromboembolism NN NN O
, , , O
and CC CC O
other JJ JJ O
side NN NN O
effects NNS NNS O
of IN IN O
heparin NN NN B-CHEM
therapy NN NN O
. . . O

Although IN IN O
several JJ JJ O
new JJ JJ O
anticoagulant JJ JJ O
drugs NNS NNS O
are VBP VBP O
in IN IN O
development NN NN O
, , , O
heparin NN NN B-CHEM
remains VBZ VBZ O
the DT DT O
drug NN NN O
of IN IN O
choice NN NN O
for IN IN O
most JJS JJS O
anticoagulation NN NN O
needs NNS NNS O
. . . O

The DT DT O
clinical JJ JJ O
effects NNS NNS O
of IN IN O
heparin NN NN B-CHEM
are VBP VBP O
meritorious JJ JJ O
, , , O
but CC CC O
side NN NN O
effects NNS NNS O
do VBP VBP O
exist VB VB O
. . . O

Important NNP NNP O
untoward JJ JJ O
effects NNS NNS O
of IN IN O
heparin NN NN B-CHEM
therapy NN NN O
including VBG VBG O
heparin NN NN B-CHEM
- - - O
induced JJ JJ O
thrombocytopenia NN NN O
, , , O
heparin NN NN B-CHEM
- - - O
associated VBN VBN O
osteoporosis NN NN O
, , , O
eosinophilia NN NN O
, , , O
skin NN NN O
reactions NNS NNS O
, , , O
allergic JJ JJ O
reactions NNS NNS O
other JJ JJ O
than IN IN O
thrombocytopenia NN NN O
and CC CC O
alopecia NN NN O
will MD MD O
be VB VB O
discussed VBN VBN O
in IN IN O
this DT DT O
article NN NN O
. . . O

Nonopaque NNP NNP O
crystal NN NN O
deposition NN NN O
causing VBG VBG O
ureteric JJ JJ O
obstruction NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
HIV NNP NNP O
undergoing VBG VBG O
indinavir NN NN B-CHEM
therapy NN NN O
. . . O

OBJECTIVE NNP NNP O
: : : O
We PRP PRP O
describe VBP VBP O
the DT DT O
unique JJ JJ O
CT NNP NNP O
features NNS NNS O
of IN IN O
ureteric JJ JJ O
calculi NN NN O
in IN IN O
six CD CD O
HIV NNP NNP O
- : : O
infected JJ JJ O
patients NNS NNS O
receiving VBG VBG O
indinavir NN NN B-CHEM
, , , O
the DT DT O
most RBS RBS O
commonly RB RB O
used VBN VBN O
HIV NNP NNP O
protease NN NN O
inhibitor NN NN O
, , , O
which WDT WDT O
is VBZ VBZ O
associated VBN VBN O
with IN IN O
an DT DT O
increased JJ JJ O
incidence NN NN O
of IN IN O
urolithiasis NN NN O
. . . O

CONCLUSION NNP NNP O
: : : O
Ureteric NNP NNP O
obstruction NN NN O
caused VBN VBN O
by IN IN O
precipitated JJ JJ O
indinavir NN NN B-CHEM
crystals NNS NNS O
may MD MD O
be VB VB O
difficult JJ JJ O
to TO TO O
diagnose VB VB O
with IN IN O
unenhanced JJ JJ O
CT NNP NNP O
. . . O

The DT DT O
calculi NN NN O
are VBP VBP O
not RB RB O
opaque JJ JJ O
, , , O
and CC CC O
secondary JJ JJ O
signs NNS NNS O
of IN IN O
obstruction NN NN O
may MD MD O
be VB VB O
absent JJ JJ O
or CC CC O
minimal JJ JJ O
and CC CC O
should MD MD O
be VB VB O
sought VBN VBN O
carefully RB RB O
. . . O

Images NNP NNP O
may MD MD O
need VB VB O
to TO TO O
be VB VB O
obtained VBN VBN O
using VBG VBG O
i NNP NNP O
. . . O
v NN NN O
. . . O
contrast NN NN O
material NN NN O
to TO TO O
enable JJ JJ O
diagnosis NN NN O
of IN IN O
ureteric JJ JJ O
stones NNS NNS O
or CC CC O
obstruction NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
HIV NNP NNP O
infection NN NN O
who WP WP O
receive VBP VBP O
indinavir NN NN B-CHEM
therapy NN NN O
. . . O

Ischemic NNP NNP O
colitis NN NN O
and CC CC O
sumatriptan JJ JJ B-CHEM
use NN NN O
. . . O

Sumatriptan NNP NNP B-CHEM
succinate NN NN I-CHEM
, , , O
a DT DT O
serotonin NN NN B-CHEM
- - - O
1 CD CD O
( ( ( O
5 CD CD B-CHEM
- : : I-CHEM
hydroxytryptamine NN NN I-CHEM
- : : O
1 CD CD O
) ) ) O
receptor NN NN O
agonist NN NN O
, , , O
is VBZ VBZ O
an DT DT O
antimigraine NN NN O
drug NN NN O
that WDT WDT O
is VBZ VBZ O
reported VBN VBN O
to TO TO O
act VB VB O
by IN IN O
selectively RB RB O
constricting VBG VBG O
intracranial JJ JJ O
arteries NNS NNS O
. . . O

Recently RB RB O
, , , O
vasopressor NN NN O
responses NNS NNS O
that WDT WDT O
are VBP VBP O
distinct JJ JJ O
from IN IN O
the DT DT O
cranial JJ JJ O
circulation NN NN O
have VBP VBP O
been VBN VBN O
demonstrated VBN VBN O
to TO TO O
occur VB VB O
in IN IN O
the DT DT O
systemic JJ JJ O
, , , O
pulmonary JJ JJ O
, , , O
and CC CC O
coronary JJ JJ O
circulations NNS NNS O
. . . O

Cases NNS NNS O
have VBP VBP O
been VBN VBN O
published VBN VBN O
of IN IN O
coronary JJ JJ O
vasospasm NN NN O
, , , O
myocardial NN NN O
ischemia NN NN O
, , , O
and CC CC O
myocardial NN NN O
infarction NN NN O
occurring VBG VBG O
after IN IN O
sumatriptan JJ JJ B-CHEM
use NN NN O
. . . O

We PRP PRP O
report VBP VBP O
on IN IN O
the DT DT O
development NN NN O
of IN IN O
8 CD CD O
serious JJ JJ O
cases NNS NNS O
of IN IN O
ischemic JJ JJ O
colitis NNS NNS O
in IN IN O
patients NNS NNS O
with IN IN O
migraine NN NN O
treated VBN VBN O
with IN IN O
sumatriptan NN NN B-CHEM
. . . O

Pallidotomy NNP NNP O
with IN IN O
the DT DT O
gamma NN NN O
knife NN NN O
: : : O
a DT DT O
positive JJ JJ O
experience NN NN O
. . . O

51 CD CD O
patients NNS NNS O
with IN IN O
medically RB RB O
refractory JJ JJ O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
underwent JJ JJ O
stereotactic JJ JJ O
posteromedial JJ JJ O
pallidotomy NN NN O
between IN IN O
August NNP NNP O
1993 CD CD O
and CC CC O
February NNP NNP O
1997 CD CD O
for IN IN O
treatment NN NN O
of IN IN O
bradykinesia NN NN O
, , , O
rigidity NN NN O
, , , O
and CC CC O
L NNP NNP B-CHEM
- : : I-CHEM
DOPA NNP NNP I-CHEM
- : : O
induced JJ JJ O
dyskinesias NN NN O
. . . O

In IN IN O
29 CD CD O
patients NNS NNS O
, , , O
the DT DT O
pallidotomies NNS NNS O
were VBD VBD O
performed VBN VBN O
with IN IN O
the DT DT O
Leksell NNP NNP O
Gamma NNP NNP O
Knife NN NN O
and CC CC O
in IN IN O
22 CD CD O
they PRP PRP O
were VBD VBD O
performed VBN VBN O
with IN IN O
the DT DT O
standard JJ JJ O
radiofrequency NN NN O
( ( ( O
RF NNP NNP O
) ) ) O
method NN NN O
. . . O

Clinical NNP NNP O
assessment NN NN O
as RB RB O
well RB RB O
as IN IN O
blinded JJ JJ O
ratings NNS NNS O
of IN IN O
Unified NNP NNP O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
Disease NNP NNP O
Rating NNP NNP O
Scale NNP NNP O
( ( ( O
UPDRS NNP NNP O
) ) ) O
scores NNS NNS O
were VBD VBD O
carried VBN VBN O
out IN IN O
pre NN NN O
- - - O
and CC CC O
postoperatively RB RB O
. . . O

Mean VB VB O
follow VB VB O
- - - O
up RP RP O
time NN NN O
is VBZ VBZ O
20 CD CD O
. . . O
6 CD CD O
months NNS NNS O
( ( ( O
range NN NN O
6 CD CD O
- : : O
48 CD CD O
) ) ) O
and CC CC O
all DT DT O
except IN IN O
4 CD CD O
patients NNS NNS O
have VBP VBP O
been VBN VBN O
followed VBN VBN O
more JJR JJR O
than IN IN O
one CD CD O
year NN NN O
. . . O

85 CD CD O
percent NN NN O
of IN IN O
patients NNS NNS O
with IN IN O
dyskinesias NN NN O
were VBD VBD O
relieved VBN VBN O
of IN IN O
symptoms NNS NNS O
, , , O
regardless RB RB O
of IN IN O
whether IN IN O
the DT DT O
pallidotomies NNS NNS O
were VBD VBD O
performed VBN VBN O
with IN IN O
the DT DT O
Gamma NNP NNP O
Knife NN NN O
or CC CC O
radiofrequency NN NN O
methods NNS NNS O
. . . O

About IN IN O
2 CD CD O
/ NN NN O
3 CD CD O
of IN IN O
the DT DT O
patients NNS NNS O
in IN IN O
both DT DT O
Gamma NNP NNP O
Knife NN NN O
and CC CC O
radiofrequency NN NN O
groups NNS NNS O
showed VBD VBD O
improvements NNS NNS O
in IN IN O
bradykinesia NN NN O
and CC CC O
rigidity NN NN O
, , , O
although IN IN O
when WRB WRB O
considered VBN VBN O
as IN IN O
a DT DT O
group NN NN O
neither DT DT O
the DT DT O
Gamma NNP NNP O
Knife NN NN O
nor CC CC O
the DT DT O
radiofrequency NN NN O
group NN NN O
showed VBD VBD O
statistically RB RB O
significant JJ JJ O
improvements NNS NNS O
in IN IN O
UPDRS NNP NNP O
scores NNS NNS O
. . . O

One CD CD O
patient NN NN O
in IN IN O
the DT DT O
Gamma NNP NNP O
Knife NN NN O
group NN NN O
( ( ( O
3 CD CD O
. . . O
4 CD CD O
% NN NN O
) ) ) O
developed VBD VBD O
a DT DT O
homonymous JJ JJ O
hemianopsia NN NN O
9 CD CD O
months NNS NNS O
following VBG VBG O
treatment NN NN O
and CC CC O
5 CD CD O
patients NNS NNS O
( ( ( O
27 CD CD O
. . . O
7 CD CD O
% NN NN O
) ) ) O
in IN IN O
the DT DT O
radiofrequency NN NN O
group NN NN O
became VBD VBD O
transiently RB RB O
confused VBN VBN O
postoperatively RB RB O
. . . O

No DT DT O
other JJ JJ O
complications NNS NNS O
were VBD VBD O
seen VBN VBN O
. . . O

Gamma NNP NNP O
Knife NN NN O
pallidotomy NN NN O
is VBZ VBZ O
as RB RB O
effective JJ JJ O
as IN IN O
radiofrequency NN NN O
pallidotomy NN NN O
in IN IN O
controlling VBG VBG O
certain JJ JJ O
of IN IN O
the DT DT O
symptoms NNS NNS O
of IN IN O
Parkinson NNP NNP O
' POS POS O
s VBZ VBZ O
disease NN NN O
. . . O

It PRP PRP O
may MD MD O
be VB VB O
the DT DT O
only JJ JJ O
practical JJ JJ O
technique NN NN O
available JJ JJ O
in IN IN O
certain JJ JJ O
patients NNS NNS O
, , , O
such JJ JJ O
as IN IN O
those DT DT O
who WP WP O
take VBP VBP O
anticoagulants NNS NNS O
, , , O
have VBP VBP O
bleeding VBG VBG O
diatheses NNS NNS O
or CC CC O
serious JJ JJ O
systemic JJ JJ O
medical JJ JJ O
illnesses NNS NNS O
. . . O

It PRP PRP O
is VBZ VBZ O
a DT DT O
viable JJ JJ O
option NN NN O
for IN IN O
other JJ JJ O
patients NNS NNS O
as RB RB O
well RB RB O
. . . O

Centrally NNP NNP O
mediated JJ JJ O
cardiovascular JJ JJ O
effects NNS NNS O
of IN IN O
intracisternal JJ JJ O
application NN NN O
of IN IN O
carbachol NN NN B-CHEM
in IN IN O
anesthetized JJ JJ O
rats NNS NNS O
. . . O

The DT DT O
pressor NN NN O
response NN NN O
to TO TO O
the DT DT O
intracisternal JJ JJ O
( ( ( O
i NNP NNP O
. . . O
c SYM SYM O
. . . O
) ) ) O
injection NN NN O
of IN IN O
carbachol NN NN B-CHEM
( ( ( O
1 CD CD O
mug NN NN O
) ) ) O
in IN IN O
anesthetized JJ JJ O
rats NNS NNS O
was VBD VBD O
analyzed VBN VBN O
. . . O

This DT DT O
response NN NN O
was VBD VBD O
significantly RB RB O
reduced VBN VBN O
by IN IN O
the DT DT O
intravenous JJ JJ O
( ( ( O
i NNP NNP O
. . . O
v NN NN O
. . . O
) ) ) O
injection NN NN O
of IN IN O
guanethidine NN NN B-CHEM
( ( ( O
5 CD CD O
mg NN NN O
) ) ) O
, , , O
hexamethonium NN NN B-CHEM
( ( ( O
10 CD CD O
mg NN NN O
) ) ) O
or CC CC O
phentolamine NN NN B-CHEM
( ( ( O
5 CD CD O
mg NN NN O
) ) ) O
, , , O
and CC CC O
conversely RB RB O
, , , O
potentiated JJ JJ O
by IN IN O
i NNP NNP O
. . . O
v NN NN O
. . . O
desmethylimipramine NN NN B-CHEM
( ( ( O
0 CD CD O
. . . O
3 CD CD O
mg NN NN O
) ) ) O
, , , O
while IN IN O
propranolol NN NN B-CHEM
( ( ( O
0 CD CD O
. . . O
5 CD CD O
mg NN NN O
) ) ) O
i NNP NNP O
. . . O
v NN NN O
. . . O
selectively RB RB O
inhibited VBN VBN O
the DT DT O
enlargement NN NN O
of IN IN O
pulse NN NN O
pressure NN NN O
and CC CC O
the DT DT O
tachycardia NN NN O
following NN NN O
i NNP NNP O
. . . O
c SYM SYM O
. . . O
carbachol NN NN B-CHEM
( ( ( O
1 CD CD O
mug NN NN O
) ) ) O
. . . O

On IN IN O
the DT DT O
other JJ JJ O
hand NN NN O
, , , O
the DT DT O
pressor NN NN O
response NN NN O
to TO TO O
i NNP NNP O
. . . O
c SYM SYM O
. . . O
carbachol NN NN B-CHEM
( ( ( O
1 CD CD O
mug NN NN O
) ) ) O
was VBD VBD O
almost RB RB O
completely RB RB O
blocked VBN VBN O
by IN IN O
i NNP NNP O
. . . O
c SYM SYM O
. . . O
atropine NN NN B-CHEM
( ( ( O
3 CD CD O
mug NN NN O
) ) ) O
or CC CC O
hexamethonium NN NN B-CHEM
( ( ( O
500 CD CD O
mug NN NN O
) ) ) O
, , , O
and CC CC O
significantly RB RB O
reduced VBN VBN O
by IN IN O
i NNP NNP O
. . . O
c SYM SYM O
. . . O
chlorpromazine NN NN B-CHEM
( ( ( O
50 CD CD O
mug NN NN O
) ) ) O
but CC CC O
significantly RB RB O
potentiated VBN VBN O
by IN IN O
i NNP NNP O
. . . O
c SYM SYM O
. . . O
desmethylimipramine NN NN B-CHEM
( ( ( O
30 CD CD O
mug NN NN O
) ) ) O
. . . O

The DT DT O
pressor NN NN O
response NN NN O
to TO TO O
i NNP NNP O
. . . O
c SYM SYM O
. . . O
carbachol NN NN B-CHEM
( ( ( O
1 CD CD O
mug NN NN O
) ) ) O
remained VBD VBD O
unchanged JJ JJ O
after IN IN O
sectioning VBG VBG O
of IN IN O
the DT DT O
bilateral JJ JJ O
cervical JJ JJ O
vagal NN NN O
nerves NNS NNS O
but CC CC O
disappeared VBD VBD O
after IN IN O
sectioning VBG VBG O
of IN IN O
the DT DT O
spinal JJ JJ O
cord NN NN O
( ( ( O
C7 NNP NNP O
- - - O
C8 NNP NNP O
) ) ) O
. . . O

From IN IN O
the DT DT O
above JJ JJ O
result NN NN O
it PRP PRP O
is VBZ VBZ O
suggested VBN VBN O
that IN IN O
the DT DT O
pressor NN NN O
response NN NN O
to TO TO O
i NNP NNP O
. . . O
c SYM SYM O
. . . O
carbachol NN NN B-CHEM
ortral JJ JJ O
and CC CC O
peripheral JJ JJ O
adrenergic JJ JJ O
mechanisms NNS NNS O
, , , O
and CC CC O
that IN IN O
the DT DT O
sympathetic JJ JJ O
trunk NN NN O
is VBZ VBZ O
the DT DT O
main JJ JJ O
pathway NN NN O
. . . O

Neuroleptic NNP NNP O
malignant NN NN O
syndrome NN NN O
and CC CC O
methylphenidate NN NN B-CHEM
. . . O

A DT DT O
1 CD CD O
- : : O
year NN NN O
- - - O
old JJ JJ O
female NN NN O
presented VBN VBN O
with IN IN O
neuroleptic JJ JJ O
malignant NN NN O
syndrome NN NN O
probably RB RB O
caused VBN VBN O
by IN IN O
methylphenidate NN NN B-CHEM
. . . O

She PRP PRP O
had VBD VBD O
defects NNS NNS O
in IN IN O
the DT DT O
supratentorial JJ JJ O
brain NN NN O
including VBG VBG O
the DT DT O
basal NN NN O
ganglia NN NN O
and CC CC O
the DT DT O
striatum NN NN O
( ( ( O
multicystic JJ JJ O
encephalomalacia NN NN O
) ) ) O
due JJ JJ O
to TO TO O
severe JJ JJ O
perinatal JJ JJ O
hypoxic NN NN O
- - - O
ischemic JJ JJ O
encephalopathy NN NN O
, , , O
which WDT WDT O
was VBD VBD O
considered VBN VBN O
to TO TO O
be VB VB O
a DT DT O
possible JJ JJ O
predisposing VBG VBG O
factor NN NN O
causing VBG VBG O
neuroleptic JJ JJ O
malignant NN NN O
syndrome NN NN O
. . . O

A DT DT O
dopaminergic JJ JJ O
blockade NN NN O
mechanism NN NN O
generally RB RB O
is VBZ VBZ O
accepted VBN VBN O
as IN IN O
the DT DT O
pathogenesis NNS NNS O
of IN IN O
this DT DT O
syndrome NN NN O
. . . O

However RB RB O
, , , O
methylphenidate NN NN B-CHEM
is VBZ VBZ O
a DT DT O
dopamine NN NN B-CHEM
agonist NN NN O
via IN IN O
the DT DT O
inhibition NN NN O
of IN IN O
uptake NN NN O
of IN IN O
dopamine NN NN B-CHEM
, , , O
and CC CC O
therefore RB RB O
dopaminergic JJ JJ O
systems NNS NNS O
in IN IN O
the DT DT O
brainstem NN NN O
( ( ( O
mainly RB RB O
the DT DT O
midbrain NN NN O
) ) ) O
and CC CC O
the DT DT O
spinal JJ JJ O
cord NN NN O
were VBD VBD O
unlikely JJ JJ O
to TO TO O
participate VB VB O
in IN IN O
the DT DT O
onset NN NN O
of IN IN O
this DT DT O
syndrome NN NN O
. . . O

A DT DT O
relative JJ JJ O
gamma NN NN B-CHEM
- - - I-CHEM
aminobutyric JJ JJ I-CHEM
acid NN NN I-CHEM
- - - O
ergic JJ JJ O
deficiency NN NN O
might MD MD O
occur VB VB O
because IN IN O
diazepam NN NN B-CHEM
, , , O
a DT DT O
gamma NN NN B-CHEM
- - - I-CHEM
aminobutyric JJ JJ I-CHEM
acid NN NN I-CHEM
- - - O
mimetic JJ JJ O
agent NN NN O
, , , O
was VBD VBD O
strikingly RB RB O
effective JJ JJ O
. . . O

This DT DT O
is VBZ VBZ O
the DT DT O
first JJ JJ O
reported VBD VBD O
patient NN NN O
with IN IN O
neuroleptic JJ JJ O
malignant NN NN O
syndrome NN NN O
probably RB RB O
caused VBN VBN O
by IN IN O
methylphenidate NN NN B-CHEM
. . . O

Differential NNP NNP O
effects NNS NNS O
of IN IN O
17alpha CD CD B-CHEM
- : : I-CHEM
ethinylestradiol NN NN I-CHEM
on IN IN O
the DT DT O
neutral JJ JJ O
and CC CC O
acidic JJ JJ O
pathways NNS NNS O
of IN IN O
bile NN NN B-CHEM
salt NN NN I-CHEM
synthesis NN NN O
in IN IN O
the DT DT O
rat NN NN O
. . . O

Effects NNP NNP O
of IN IN O
17alpha CD CD B-CHEM
- : : I-CHEM
ethinylestradiol NN NN I-CHEM
( ( ( O
EE NNP NNP B-CHEM
) ) ) O
on IN IN O
the DT DT O
neutral JJ JJ O
and CC CC O
acidic JJ JJ O
biosynthetic JJ JJ O
pathways NNS NNS O
of IN IN O
bile NN NN B-CHEM
salt NN NN I-CHEM
( ( ( O
BS NNP NNP B-CHEM
) ) ) O
synthesis NN NN O
were VBD VBD O
evaluated VBN VBN O
in IN IN O
rats NNS NNS O
with IN IN O
an DT DT O
intact JJ JJ O
enterohepatic JJ JJ O
circulation NN NN O
and CC CC O
in IN IN O
rats NNS NNS O
with IN IN O
long JJ JJ O
- - - O
term NN NN O
bile NN NN O
diversion NN NN O
to TO TO O
induce VB VB O
BS NNP NNP B-CHEM
synthesis NN NN O
. . . O

For IN IN O
this DT DT O
purpose NN NN O
, , , O
bile NN NN B-CHEM
salt NN NN I-CHEM
pool NN NN O
composition NN NN O
, , , O
synthesis NN NN O
of IN IN O
individual JJ JJ O
BS NNP NNP B-CHEM
in IN IN O
vivo NN NN O
, , , O
hepatic JJ JJ O
activities NNS NNS O
, , , O
and CC CC O
expression NN NN O
levels NNS NNS O
of IN IN O
cholesterol NN NN B-CHEM
7alpha CD CD O
- : : O
hydroxylase NN NN O
( ( ( O
CYP7A NNP NNP O
) ) ) O
, , , O
and CC CC O
sterol NN NN B-CHEM
27 CD CD O
- : : O
hydroxylase NN NN O
( ( ( O
CYP27 NNP NNP O
) ) ) O
, , , O
as RB RB O
well RB RB O
as IN IN O
of IN IN O
other JJ JJ O
enzymes NNS NNS O
involved VBN VBN O
in IN IN O
BS NNP NNP B-CHEM
synthesis NN NN O
, , , O
were VBD VBD O
analyzed VBN VBN O
in IN IN O
rats NNS NNS O
treated VBN VBN O
with IN IN O
EE NNP NNP B-CHEM
( ( ( O
5 CD CD O
mg NN NN O
/ NN NN O
kg NN NN O
, , , O
3 CD CD O
days NNS NNS O
) ) ) O
or CC CC O
its PRP$ PRP$ O
vehicle NN NN O
. . . O

BS NNP NNP B-CHEM
pool NN NN O
size NN NN O
was VBD VBD O
decreased VBN VBN O
by IN IN O
27 CD CD O
% NN NN O
but CC CC O
total JJ JJ O
BS NNP NNP B-CHEM
synthesis NN NN O
was VBD VBD O
not RB RB O
affected VBN VBN O
by IN IN O
EE NNP NNP B-CHEM
in IN IN O
intact JJ JJ O
rats NNS NNS O
. . . O

Synthesis NNP NNP O
of IN IN O
cholate NN NN B-CHEM
was VBD VBD O
reduced VBN VBN O
by IN IN O
68 CD CD O
% NN NN O
in IN IN O
EE NNP NNP B-CHEM
- - - O
treated JJ JJ O
rats NNS NNS O
, , , O
while IN IN O
that DT DT O
of IN IN O
chenodeoxycholate NN NN B-CHEM
was VBD VBD O
increased VBN VBN O
by IN IN O
60 CD CD O
% NN NN O
. . . O

The DT DT O
recently RB RB O
identified VBN VBN O
Delta22 NNP NNP O
- : : O
isomer NN NN O
of IN IN O
beta NN NN O
- - - O
muricholate NN NN O
contributed VBD VBD O
for IN IN O
5 CD CD O
. . . O
4 CD CD O
% NN NN O
and CC CC O
18 CD CD O
. . . O
3 CD CD O
% NN NN O
( ( ( O
P NN NN O
< NN NN O
0 CD CD O
. . . O
01 CD CD O
) ) ) O
to TO TO O
the DT DT O
pool NN NN O
in IN IN O
control NN NN O
and CC CC O
EE NNP NNP B-CHEM
- : : O
treated VBN VBN O
rats NNS NNS O
, , , O
respectively RB RB O
, , , O
but CC CC O
could MD MD O
not RB RB O
be VB VB O
detected VBN VBN O
in IN IN O
bile NN NN O
after IN IN O
exhaustion NN NN O
of IN IN O
the DT DT O
pool NN NN O
. . . O

A DT DT O
clear JJ JJ O
reduction NN NN O
of IN IN O
BS NNP NNP B-CHEM
synthesis NN NN O
was VBD VBD O
found VBN VBN O
in IN IN O
bile NN NN O
- - - O
diverted JJ JJ O
rats NNS NNS O
treated VBN VBN O
with IN IN O
EE NNP NNP B-CHEM
, , , O
yet RB RB O
biliary JJ JJ O
BS NNP NNP B-CHEM
composition NN NN O
was VBD VBD O
only RB RB O
minimally RB RB O
affected VBN VBN O
. . . O

Activity NN NN O
of IN IN O
CYP7A NNP NNP O
was VBD VBD O
decreased VBN VBN O
by IN IN O
EE NNP NNP B-CHEM
in IN IN O
both DT DT O
intact JJ JJ O
and CC CC O
bile JJ JJ O
- - - O
diverted JJ JJ O
rats NNS NNS O
, , , O
whereas IN IN O
the DT DT O
activity NN NN O
of IN IN O
the DT DT O
CYP27 NNP NNP O
was VBD VBD O
not RB RB O
affected VBN VBN O
. . . O

Hepatic NNP NNP O
mRNA NN NN O
levels NNS NNS O
of IN IN O
CYP7A NNP NNP O
were VBD VBD O
significantly RB RB O
reduced VBN VBN O
by IN IN O
EE NNP NNP B-CHEM
in IN IN O
bile NN NN O
- - - O
diverted JJ JJ O
rats NNS NNS O
only RB RB O
; : : O
CYP27 NNP NNP O
mRNA NN NN O
levels NNS NNS O
were VBD VBD O
not RB RB O
affected VBN VBN O
by IN IN O
EE NNP NNP B-CHEM
. . . O

In IN IN O
addition NN NN O
, , , O
mRNA NN NN O
levels NNS NNS O
of IN IN O
sterol NN NN B-CHEM
12alpha CD CD O
- : : O
hydroxylase NN NN O
and CC CC O
lithocholate NN NN O
6beta CD CD O
- : : O
hydroxylase NN NN O
were VBD VBD O
increased VBN VBN O
by IN IN O
bile JJ JJ O
diversion NN NN O
and CC CC O
suppressed VBN VBN O
by IN IN O
EE NNP NNP B-CHEM
. . . O

This DT DT O
study NN NN O
shows VBZ VBZ O
that IN IN O
17alpha CD CD B-CHEM
- : : I-CHEM
ethinylestradiol NN NN I-CHEM
( ( ( O
EE NNP NNP B-CHEM
) ) ) O
- : : O
induced JJ JJ O
intrahepatic JJ JJ O
cholestasis NN NN O
in IN IN O
rats NNS NNS O
is VBZ VBZ O
associated VBN VBN O
with IN IN O
selective JJ JJ O
inhibition NN NN O
of IN IN O
the DT DT O
neutral JJ JJ O
pathway NN NN O
of IN IN O
bile NN NN B-CHEM
salt NN NN I-CHEM
( ( ( O
BS NNP NNP B-CHEM
) ) ) O
synthesis NN NN O
. . . O

Simultaneous NNP NNP O
impairment NN NN O
of IN IN O
other JJ JJ O
enzymes NNS NNS O
in IN IN O
the DT DT O
BS NNP NNP B-CHEM
biosynthetic JJ JJ O
pathways NNS NNS O
may MD MD O
contribute VB VB O
to TO TO O
overall JJ JJ O
effects NNS NNS O
of IN IN O
EE NNP NNP B-CHEM
on IN IN O
BS NNP NNP B-CHEM
synthesis NN NN O
. . . O

Glibenclamide NNP NNP B-CHEM
- - - O
sensitive JJ JJ O
hypotension NN NN O
produced VBN VBN O
by IN IN O
helodermin NN NN B-CHEM
assessed VBN VBN O
in IN IN O
the DT DT O
rat NN NN O
. . . O

The DT DT O
effects NNS NNS O
of IN IN O
helodermin NN NN B-CHEM
, , , O
a DT DT O
basic JJ JJ O
35 CD CD O
- : : O
amino JJ JJ B-CHEM
acid NN NN I-CHEM
peptide NN NN O
isolated VBN VBN O
from IN IN O
the DT DT O
venom NN NN O
of IN IN O
a DT DT O
lizard NN NN O
salivary JJ JJ O
gland NN NN O
, , , O
on IN IN O
arterial JJ JJ O
blood NN NN O
pressure NN NN O
and CC CC O
heart NN NN O
rate NN NN O
were VBD VBD O
examined VBN VBN O
in IN IN O
the DT DT O
rat NN NN O
, , , O
focusing VBG VBG O
on IN IN O
the DT DT O
possibility NN NN O
that DT DT O
activation NN NN O
of IN IN O
ATP NNP NNP B-CHEM
sensitive JJ JJ O
K NNP NNP B-CHEM
+ NN NN O
( ( ( O
K NNP NNP B-CHEM
( ( ( O
ATP NNP NNP B-CHEM
) ) ) O
) ) ) O
channels NNS NNS O
is VBZ VBZ O
involved VBN VBN O
in IN IN O
the DT DT O
responses NNS NNS O
. . . O

The DT DT O
results NNS NNS O
were VBD VBD O
also RB RB O
compared VBN VBN O
with IN IN O
those DT DT O
of IN IN O
vasoactive JJ JJ O
intestinal JJ JJ O
polypeptide NN NN O
( ( ( O
VIP NNP NNP O
) ) ) O
. . . O

Helodermin NNP NNP B-CHEM
produced VBD VBD O
hypotension NN NN O
in IN IN O
a DT DT O
dose NN NN O
- - - O
dependent JJ JJ O
manner NN NN O
with IN IN O
approximately RB RB O
similar JJ JJ O
potency NN NN O
and CC CC O
duration NN NN O
to TO TO O
VIP NNP NNP O
. . . O

Hypotension NNP NNP O
induced VBN VBN O
by IN IN O
both DT DT O
peptides NNS NNS O
was VBD VBD O
significantly RB RB O
attenuated VBN VBN O
by IN IN O
glibenclamide NN NN B-CHEM
, , , O
which WDT WDT O
abolished VBD VBD O
a DT DT O
levcromakalim NN NN B-CHEM
- - - O
produced VBN VBN O
decrease NN NN O
in IN IN O
arterial JJ JJ O
blood NN NN O
pressure NN NN O
. . . O

Oxyhemoglobin NNP NNP O
did VBD VBD O
not RB RB O
affect VB VB O
helodermin NN NN B-CHEM
- : : O
induced JJ JJ O
hypotension NN NN O
, , , O
whereas IN IN O
it PRP PRP O
shortened VBD VBD O
the DT DT O
duration NN NN O
of IN IN O
acetylcholine NN NN B-CHEM
( ( ( O
ACh NNP NNP B-CHEM
) ) ) O
- : : O
produced VBN VBN O
hypotension NN NN O
. . . O

These DT DT O
findings NNS NNS O
suggest VBP VBP O
that IN IN O
helodermin NN NN B-CHEM
- : : O
produced VBN VBN O
hypotension NN NN O
is VBZ VBZ O
partly RB RB O
attributable JJ JJ O
to TO TO O
the DT DT O
activation NN NN O
of IN IN O
glibenclamide NN NN B-CHEM
- - - O
sensitive JJ JJ O
K NNP NNP B-CHEM
+ NN NN O
channels NNS NNS O
( ( ( O
K NNP NNP B-CHEM
( ( ( O
ATP NNP NNP B-CHEM
) ) ) O
channels NNS NNS O
) ) ) O
, , , O
which WDT WDT O
presumably RB RB O
exist VB VB O
on IN IN O
arterial NN NN O
smooth JJ JJ O
muscle NN NN O
cells NNS NNS O
. . . O

EDRF NNP NNP O
( ( ( O
endothelium NN NN O
- - - O
derived VBN VBN O
relaxing VBG VBG O
factor NN NN O
) ) ) O
/ NN NN O
nitric NN NN B-CHEM
oxide NN NN I-CHEM
does VBZ VBZ O
not RB RB O
seem VB VB O
to TO TO O
play VB VB O
an DT DT O
important JJ JJ O
role NN NN O
in IN IN O
the DT DT O
peptide NN NN O
- - - O
produced JJ JJ O
hypotension NN NN O
. . . O

Long JJ JJ O
- - - O
term NN NN O
efficacy NN NN O
and CC CC O
adverse JJ JJ O
event NN NN O
of IN IN O
nifedipine NN NN B-CHEM
sustained VBD VBD O
- : : O
release NN NN O
tablets NNS NNS O
for IN IN O
cyclosporin NN NN B-CHEM
A DT DT I-CHEM
- - - O
induced JJ JJ O
hypertension NN NN O
in IN IN O
patients NNS NNS O
with IN IN O
psoriasis NN NN O
. . . O

Thirteen NNP NNP O
psoriatic JJ JJ O
patients NNS NNS O
with IN IN O
hypertension NN NN O
during IN IN O
the DT DT O
course NN NN O
of IN IN O
cyclosporin NN NN B-CHEM
A DT DT I-CHEM
therapy NN NN O
were VBD VBD O
treated VBN VBN O
for IN IN O
25 CD CD O
months NNS NNS O
with IN IN O
a DT DT O
calcium NN NN B-CHEM
channel NN NN O
blocker NN NN O
, , , O
sustained JJ JJ O
- - - O
release NN NN O
nifedipine NN NN B-CHEM
, , , O
to TO TO O
study VB VB O
the DT DT O
clinical JJ JJ O
antihypertensive JJ JJ O
effects NNS NNS O
and CC CC O
adverse JJ JJ O
events NNS NNS O
during IN IN O
treatment NN NN O
with IN IN O
both DT DT O
drugs NNS NNS O
. . . O

Seven CD CD O
of IN IN O
the DT DT O
13 CD CD O
patients NNS NNS O
had VBD VBD O
exhibited VBN VBN O
a DT DT O
subclinical JJ JJ O
hypertensive JJ JJ O
state NN NN O
before IN IN O
cyclosporin NN NN B-CHEM
A DT DT I-CHEM
therapy NN NN O
. . . O

Both DT DT O
systolic JJ JJ O
and CC CC O
diastolic JJ JJ O
blood NN NN O
pressures NNS NNS O
of IN IN O
these DT DT O
13 CD CD O
patients NNS NNS O
were VBD VBD O
decreased VBN VBN O
significantly RB RB O
after IN IN O
4 CD CD O
weeks NNS NNS O
of IN IN O
nifedipine NN NN B-CHEM
therapy NN NN O
, , , O
and CC CC O
blood NN NN O
pressure NN NN O
was VBD VBD O
maintained VBN VBN O
within IN IN O
the DT DT O
normal JJ JJ O
range NN NN O
thereafter NN NN O
for IN IN O
25 CD CD O
months NNS NNS O
. . . O

The DT DT O
adverse JJ JJ O
events NNS NNS O
during IN IN O
combined VBN VBN O
therapy NN NN O
with IN IN O
cyclosporin NN NN B-CHEM
A DT DT I-CHEM
and CC CC O
nifedipine NN NN B-CHEM
included VBD VBD O
an DT DT O
increase NN NN O
in IN IN O
blood NN NN B-CHEM
urea JJ JJ I-CHEM
nitrogen NN NN I-CHEM
levels NNS NNS O
in IN IN O
9 CD CD O
of IN IN O
the DT DT O
13 CD CD O
patients NNS NNS O
and CC CC O
development NN NN O
of IN IN O
gingival NN NN O
hyperplasia NN NN O
in IN IN O
2 CD CD O
of IN IN O
the DT DT O
13 CD CD O
patients NNS NNS O
. . . O

Our PRP$ PRP$ O
findings NNS NNS O
indicate VBP VBP O
that IN IN O
sustained JJ JJ O
- : : O
release NN NN O
nifedipine NN NN B-CHEM
is VBZ VBZ O
useful JJ JJ O
for IN IN O
hypertensive JJ JJ O
psoriatic JJ JJ O
patients NNS NNS O
under IN IN O
long JJ JJ O
- - - O
term NN NN O
treatment NN NN O
with IN IN O
cyclosporin NN NN B-CHEM
A DT DT I-CHEM
, , , O
but CC CC O
that IN IN O
these DT DT O
patients NNS NNS O
should MD MD O
be VB VB O
monitored VBN VBN O
for IN IN O
gingival NN NN O
hyperplasia NN NN O
. . . O


